

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat

Breast Care

11, 385-390

DOI: 10.1159/000453569

Citation Report

#	ARTICLE	IF	CITATIONS
1	Facilitation of \hat{I}^2 Selection and Modification of Positive Selection in the Thymus of Pd-1â€“Deficient Mice. <i>Journal of Experimental Medicine</i> , 2000, 191, 891-898.	4.2	177
2	Cardiac Myosin and the TH1/TH2 Paradigm in Autoimmune Myocarditis. <i>American Journal of Pathology</i> , 2001, 159, 5-12.	1.9	54
3	Maintenance and loss of self-tolerance in B cells. <i>Seminars in Immunopathology</i> , 2001, 23, 351-366.	4.0	3
4	Regulatory function of in vivo energized CD4+ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 8738-8743.	3.3	60
5	Genetic remodeling of protein glycosylation in vivo induces autoimmune disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 1142-1147.	3.3	193
6	PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 13866-13871.	3.3	732
7	Genetic Modifiers of Systemic Lupus Erythematosus in Fc \hat{I}^3 RIBâˆ“/âˆ“ Mice. <i>Journal of Experimental Medicine</i> , 2002, 195, 1167-1174.	4.2	238
8	Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12293-12297.	3.3	2,563
9	Sustained Activation of Lyn Tyrosine Kinase In Vivo Leads to Autoimmunity. <i>Journal of Experimental Medicine</i> , 2002, 196, 1593-1604.	4.2	153
10	Susceptibility genes in the pathogenesis of murine lupus. <i>Arthritis Research</i> , 2002, 4, S255.	2.0	49
11	Interaction of B7RP-1 with ICOS negatively regulates antigen presentation by B cells. <i>Inflammation</i> , 2003, 27, 191-200.	1.7	3
12	Immunology of B7-H1 and Its Roles in Human Diseases. <i>International Journal of Hematology</i> , 2003, 78, 321-328.	0.7	34
13	Therapeutic vaccination with tumor cells that engage CD137. <i>Journal of Molecular Medicine</i> , 2003, 81, 71-86.	1.7	26
14	B7-H1 pathway and its role in the evasion of tumor immunity. <i>Journal of Molecular Medicine</i> , 2003, 81, 281-287.	1.7	249
15	T-Helper Cell Tolerance to Ubiquitous Nuclear Antigens. <i>Scandinavian Journal of Immunology</i> , 2003, 58, 478-492.	1.3	6
16	B cell inhibitory receptors and autoimmunity. <i>Immunology</i> , 2003, 108, 263-273.	2.0	93
17	Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T-cell receptor Vbeta repertoire. <i>Immunology</i> , 2003, 110, 304-312.	2.0	47
18	The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice. <i>Journal of Experimental Medicine</i> , 2003, 198, 63-69.	4.2	697

#	ARTICLE	IF	CITATIONS
19	B7DC/PDL2 Promotes Tumor Immunity by a PD-1-independent Mechanism. <i>Journal of Experimental Medicine</i> , 2003, 197, 1721-1730.	4.2	130
20	A Role for Complement in Feedback Enhancement of Antibody Responses by IgG3. <i>Journal of Experimental Medicine</i> , 2003, 197, 1183-1190.	4.2	66
21	Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction. <i>Journal of Experimental Medicine</i> , 2003, 197, 1083-1091.	4.2	259
22	PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 5336-5341.	3.3	536
23	Costimulatory signals controlling regulatory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15292-15293.	3.3	29
24	Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor. <i>Journal of Experimental Medicine</i> , 2003, 198, 31-38.	4.2	144
25	Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis. <i>Journal of Experimental Medicine</i> , 2003, 198, 71-78.	4.2	461
26	PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver. <i>Journal of Experimental Medicine</i> , 2003, 198, 39-50.	4.2	353
27	Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IAA ⁺ knockout NOD mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 13447-13452.	3.3	64
28	T Cell Costimulatory Molecules in Anti-Viral Immunity: Potential Role in Immunotherapeutic Vaccines. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2003, 14, 221-229.	0.3	5
29	Bruton's Tyrosine Kinase Is Essential for Human B Cell Tolerance. <i>Journal of Experimental Medicine</i> , 2004, 200, 927-934.	4.2	131
30	Gene-Targeted Mice Lacking the Trex1 (DNase III) 3'5' DNA Exonuclease Develop Inflammatory Myocarditis. <i>Molecular and Cellular Biology</i> , 2004, 24, 6719-6727.	1.1	316
31	PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10691-10696.	3.3	556
32	The candidate gene approach: have murine models informed the study of human SLE?. <i>Clinical and Experimental Immunology</i> , 2004, 137, 1-7.	1.1	12
33	A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 236-247.	1.4	59
34	Role of an intronic polymorphism in the PDCD1 gene with the risk of sporadic systemic lupus erythematosus and the occurrence of antiphospholipid antibodies. <i>Human Genetics</i> , 2004, 115, 393-8.	1.8	37
35	The role of ICOS and other costimulatory molecules in allergy and asthma. <i>Seminars in Immunopathology</i> , 2004, 25, 349-359.	4.0	53
36	Current advances in the human lupus genetics. <i>Current Rheumatology Reports</i> , 2004, 6, 391-398.	2.1	35

#	ARTICLE	IF	CITATIONS
37	Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells. <i>Journal of Experimental Medicine</i> , 2004, 199, 1567-1575.	4.2	960
38	Reciprocal Changes in Tumor Antigenicity and Antigen-specific T Cell Function during Tumor Progression. <i>Journal of Experimental Medicine</i> , 2004, 200, 1581-1592.	4.2	96
39	A Deficiency in Drak2 Results in a T Cell Hypersensitivity and an Unexpected Resistance to Autoimmunity. <i>Immunity</i> , 2004, 21, 781-791.	6.6	67
40	CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2. <i>Journal of Immunotherapy</i> , 2005, 28, 120-128.	1.2	199
41	Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma. <i>Journal of Immunotherapy</i> , 2005, 28, 582-592.	1.2	270
42	Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. <i>Current Opinion in Immunology</i> , 2005, 17, 195-201.	2.4	101
43	CD25 ⁺ CD4 ⁺ Regulatory T-Cells in Cancer. <i>Immunologic Research</i> , 2005, 32, 155-168.	1.3	101
44	Interferon- β and Cancer Immunoediting. <i>Immunologic Research</i> , 2005, 32, 231-246.	1.3	123
45	Circulating and thymic CD4+ CD25+ T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. <i>Immunology</i> , 2005, 116, 134-141.	2.0	116
46	Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. <i>British Journal of Cancer</i> , 2005, 92, 913-920.	2.9	234
47	Embryonic reversions and lineage infidelities in tumour cells: genome-based models and role of genetic instability. <i>International Journal of Experimental Pathology</i> , 2005, 86, 67-79.	0.6	13
48	Dendritic cell-mediated T cell polarization. <i>Seminars in Immunopathology</i> , 2005, 26, 289-307.	4.0	296
49	Immunological ignorance of solid tumors. <i>Seminars in Immunopathology</i> , 2005, 27, 19-35.	4.0	44
50	The balance of immune responses: costimulation verse coinhibition. <i>Journal of Molecular Medicine</i> , 2005, 83, 193-202.	1.7	69
51	T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens. <i>Journal of Molecular Medicine</i> , 2005, 83, 267-278.	1.7	30
53	Costimulation: critical pathways in the immunologic regulation of asthma. <i>Current Allergy and Asthma Reports</i> , 2005, 5, 149-154.	2.4	19
54	Immunotherapy for melanoma: The good, the bad, and the future. <i>Current Oncology Reports</i> , 2005, 7, 383-392.	1.8	8
55	Fc Receptors and Their Role in Immune Regulation and Autoimmunity. <i>Journal of Clinical Immunology</i> , 2005, 25, 1-18.	2.0	197

#	ARTICLE	IF	CITATIONS
56	Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti-“Cytotoxic T-Lymphocyte Antigen-4. <i>Journal of Clinical Oncology</i> , 2005, 23, 6043-6053.	0.8	989
57	Mucosal FOXP3-Expressing CD4+ CD25high Regulatory T Cells in Helicobacter pylori-Infected Patients. <i>Infection and Immunity</i> , 2005, 73, 523-531.	1.0	246
58	Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 9253-9257.	3.3	102
59	Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. <i>Journal of Experimental Medicine</i> , 2005, 201, 779-791.	4.2	395
60	CD4 + regulatory cells as a potential immunotherapy. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2005, 360, 1647-1661.	1.8	26
61	Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2005, 360, 1747-1767.	1.8	56
62	Chronic Stress and Susceptibility to Skin Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1760-1767.	3.0	170
63	Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS. <i>Journal of Neuroscience</i> , 2005, 25, 2537-2546.	1.7	150
64	Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells. <i>Journal of Immunology</i> , 2005, 175, 4583-4592.	0.4	297
65	Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 11823-11828.	3.3	380
66	Programmed Death-1 (PD-1):PD-Ligand 1 Interactions Inhibit TCR-Mediated Positive Selection of Thymocytes. <i>Journal of Immunology</i> , 2005, 175, 7372-7379.	0.4	122
67	The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. <i>Journal of Experimental Medicine</i> , 2005, 201, 567-577.	4.2	212
68	Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b ^{+/+} /Pdcd1 ^{+/+} mice. <i>Journal of Experimental Medicine</i> , 2005, 202, 1643-1648.	4.2	47
69	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-“12” dependent manner. <i>Journal of Experimental Medicine</i> , 2005, 202, 1075-1085.	4.2	806
70	Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. <i>British Journal of Cancer</i> , 2005, 93, 1372-1381.	2.9	136
71	Tumor cells convert immature myeloid dendritic cells into TGF-“12” secreting cells inducing CD4+CD25+ regulatory T cell proliferation. <i>Journal of Experimental Medicine</i> , 2005, 202, 919-929.	4.2	676
72	Interleukin-7-Dependent Expansion and Persistence of Melanoma-Specific T Cells in Lymphodepleted Mice Lead to Tumor Regression and Editing. <i>Cancer Research</i> , 2005, 65, 10569-10577.	0.4	81
73	Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. <i>Trends in Immunology</i> , 2005, 26, 111-117.	2.9	410

#	ARTICLE	IF	CITATIONS
74	The Immunomodulatory Proteins B7-DC, B7-H2, and B7-H3 Are Differentially Expressed across Gestation in the Human Placenta. <i>American Journal of Pathology</i> , 2005, 167, 465-473.	1.9	77
75	Dietary exposure to soy or whey proteins alters colonic global gene expression profiles during rat colon tumorigenesis. <i>Molecular Cancer</i> , 2005, 4, 1.	7.9	150
76	Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-Free Survival in Breast Cancer. <i>PLoS Medicine</i> , 2005, 2, e284.	3.9	182
77	Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway. <i>Breast Cancer Research</i> , 2005, 7, 212-4.	2.2	23
78	Tumor microenvironments, the immune system and cancer survival. <i>Genome Biology</i> , 2005, 6, 211.	13.9	25
79	Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. <i>Arthritis Research and Therapy</i> , 2006, 8, R163.	1.6	70
80	Mutation of the PIK3CA oncogene in human cancers. <i>British Journal of Cancer</i> , 2006, 94, 455-459.	2.9	444
81	Checkpoint Blockade in Cancer Immunotherapy. <i>Advances in Immunology</i> , 2006, 90, 297-339.	1.1	498
82	PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 1441-1446.	3.2	197
83	Microarray Analysis of Mercury-Induced Changes in Gene Expression in Human Liver Carcinoma (HepG2) Cells: Importance in Immune Responses. <i>International Journal of Environmental Research and Public Health</i> , 2006, 3, 141-173.	1.2	35
84	Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. <i>Journal of Clinical Investigation</i> , 2006, 116, 2423-2433.	3.9	425
85	EGF-induced activation of Akt results in mTOR-dependent p70S6 kinase phosphorylation and inhibition of HC11 cell lactogenic differentiation. <i>BMC Cell Biology</i> , 2006, 7, 34.	3.0	55
86	Activation, coactivation, and costimulation of resting human natural killer cells. <i>Immunological Reviews</i> , 2006, 214, 73-91.	2.8	531
87	From pharmacology to immunopharmacology. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 379-382.	1.1	7
88	Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. <i>Immunology</i> , 2006, 117, 433-442.	2.0	594
89	The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. <i>British Journal of Cancer</i> , 2006, 95, 1202-1211.	2.9	39
90	Activating and inhibitory Fcγ3Rs in autoimmune disorders. <i>Seminars in Immunopathology</i> , 2006, 28, 305-319.	4.0	53
91	MUC1 in Endometriosis and Ovarian Cancer. <i>Immunologic Research</i> , 2006, 36, 229-236.	1.3	25

#	ARTICLE	IF	CITATIONS
92	Programmed Death-1 Gene Polymorphisms in Patients With Systemic Lupus Erythematosus in Taiwan. <i>Journal of Clinical Immunology</i> , 2006, 26, 506-511.	2.0	49
93	The mTOR Pathway in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2006, 11, 53-61.	1.0	42
94	Exploiting Our Knowledge of NF- κ B Signaling for the Treatment of Mammary Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2006, 11, 63-73.	1.0	40
95	Modification of accessory molecule signaling. <i>Seminars in Immunopathology</i> , 2006, 27, 409-424.	4.0	31
96	Regulatory T cells and innate immune regulation in tumor immunity. <i>Seminars in Immunopathology</i> , 2006, 28, 17-23.	4.0	45
97	Genetics of SLE in mice. <i>Seminars in Immunopathology</i> , 2006, 28, 83-96.	4.0	76
98	The genetics of systemic lupus erythematosus: understanding how SNPs confer disease susceptibility. <i>Seminars in Immunopathology</i> , 2006, 28, 109-117.	4.0	12
99	Unraveling the genetics of systemic lupus erythematosus. <i>Seminars in Immunopathology</i> , 2006, 28, 119-130.	4.0	127
100	Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. <i>Journal of Molecular Medicine</i> , 2006, 84, 887-899.	1.7	24
101	Putting T cells to sleep: A new paradigm for immune evasion by persistent viruses. <i>Journal of Biosciences</i> , 2006, 31, 497-501.	0.5	2
102	Mutations in PIK3CA are infrequent in neuroblastoma. <i>BMC Cancer</i> , 2006, 6, 177.	1.1	29
103	Biomarkers for the Development of Cancer Vaccines. <i>Molecular Diagnosis and Therapy</i> , 2006, 10, 337-343.	1.6	15
104	Generation and Characterization of B7-H4/B7S1/B7x-Deficient Mice. <i>Molecular and Cellular Biology</i> , 2006, 26, 6403-6411.	1.1	72
105	Random migration precedes stable target cell interactions of tumor-infiltrating T cells. <i>Journal of Experimental Medicine</i> , 2006, 203, 2749-2761.	4.2	201
106	Cancer-specific mutations in PIK3CA are oncogenic in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 1475-1479.	3.3	388
107	Regulation of T cell activation and tolerance by PDL2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 11695-11700.	3.3	151
108	Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion. <i>Journal of Immunology</i> , 2006, 177, 6527-6539.	0.4	116
109	BTNL2, a Butyrophilin-Like Molecule That Functions to Inhibit T Cell Activation. <i>Journal of Immunology</i> , 2006, 176, 7354-7360.	0.4	168

#	ARTICLE	IF	CITATIONS
110	Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18066-18071.	3.3	32
111	An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme1. Neuro-Oncology, 2006, 8, 234-243.	0.6	253
112	The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses1. Neuro-Oncology, 2006, 8, 261-279.	0.6	516
113	Insulin-induced remission in new-onset NOD mice is maintained by the PD-1/PD-L1 pathway. Journal of Experimental Medicine, 2006, 203, 2737-2747.	4.2	280
114	Immunization with a Circumsporozoite Epitope Fused to Bordetella pertussis Adenylate Cyclase in Conjunction with Cytotoxic T-Lymphocyte-Associated Antigen 4 Blockade Confers Protection against Plasmodium berghei Liver-Stage Malaria. Infection and Immunity, 2006, 74, 2277-2285.	1.0	31
115	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3360-3365.	3.3	1,308
116	Rare cancer-specific mutations in PIK3CA show gain of function. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5569-5574.	3.3	345
117	Programmed death-1 (PD-1) defines a transient and dysfunctional oligoclonal T cell population in acute homeostatic proliferation. Journal of Experimental Medicine, 2007, 204, 2321-2333.	4.2	57
118	Novel Exosome-Targeted CD4+ T Cell Vaccine Counteracting CD4+25+ Regulatory T Cell-Mediated Immune Suppression and Stimulating Efficient Central Memory CD8+ CTL Responses. Journal of Immunology, 2007, 179, 2731-2740.	0.4	51
119	Increase in circulating Foxp3+CD4+CD25high regulatory T cells in nasopharyngeal carcinoma patients. British Journal of Cancer, 2007, 96, 617-622.	2.9	128
120	NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. British Journal of Cancer, 2007, 97, 105-111.	2.9	69
121	Down-Regulation of the Interferon Signaling Pathway in T Lymphocytes from Patients with Metastatic Melanoma. PLoS Medicine, 2007, 4, e176.	3.9	124
122	Ectopic Expression of Vascular Cell Adhesion Molecule-1 as a New Mechanism for Tumor Immune Evasion. Cancer Research, 2007, 67, 1832-1841.	0.4	81
123	Distinct Cytokine-Driven Responses of Activated Blood T ^H 1 T Cells: Insights into Unconventional T Cell Pleiotropy. Journal of Immunology, 2007, 178, 4304-4314.	0.4	128
124	Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. Journal of Experimental Medicine, 2007, 204, 1181-1191.	4.2	41
125	Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA. Molecular and Cellular Biology, 2007, 27, 662-677.	1.1	147
126	Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7564-7569.	3.3	445
127	<i>In vivo</i> imaging of T cell delivery to tumors after adoptive transfer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12457-12461.	3.3	113

#	ARTICLE	IF	CITATIONS
128	Activation of naturally occurring lung CD4 ⁺ CD25 ⁺ regulatory T cells requires CD8 and MHC I interaction. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15057-15062.	3.3	20
129	Molecular basis for checkpoints in the CD8 T cell response: Tolerance versus activation. Seminars in Immunology, 2007, 19, 153-161.	2.7	38
130	Melanoma Induces Immunosuppression by Up-Regulating FOXP3+ Regulatory T Cells. Journal of Surgical Research, 2007, 141, 72-77.	0.8	66
131	Immunosuppressive Strategies that are Mediated by Tumor Cells. Annual Review of Immunology, 2007, 25, 267-296.	9.5	1,466
132	Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Research, 2007, 9, 212.	2.2	584
133	Impairment of organ-specific T cell negative selection by diabetes susceptibility genes: genomic analysis by mRNA profiling. Genome Biology, 2007, 8, R12.	13.9	37
134	Prognostic Significance of Immunoreactive Neutrophil Elastase in Human Breast Cancer: Long-Term Follow-Up Results in 313 Patients. Neoplasia, 2007, 9, 260-264.	2.3	53
135	Current state of immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2007, 6, 196-211.	1.3	150
136	Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. Translational Lung Cancer Research, 2007, 6, 178-185.	1.3	21
137	Immune surveillance of tumors. Journal of Clinical Investigation, 2007, 117, 1137-1146.	3.9	1,198
138	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. Translational Lung Cancer Research, 2007, 6, 169-177.	1.3	4
139	Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. Translational Lung Cancer Research, 2007, 6, 186-195.	1.3	13
140	Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2007, 6, 220-229.	1.3	10
141	Immunotherapy and radiation therapy for malignant pleural mesothelioma. Translational Lung Cancer Research, 2007, 6, 212-219.	1.3	31
142	Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. Translational Lung Cancer Research, 2007, 6, 113-118.	1.3	13
143	Special topics in immunotherapy and radiation therapy: reirradiation and palliation. Translational Lung Cancer Research, 2007, 6, 119-130.	1.3	11
144	HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. European Journal of Immunology, 2007, 37, 675-685.	1.6	92
145	Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene, 2007, 26, 6577-6592.	2.6	170

#	ARTICLE	IF	CITATIONS
146	Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort. <i>Genes and Immunity</i> , 2007, 8, 279-287.	2.2	76
147	Expression of interferon- γ in human adrenal gland and kidney tumours. <i>British Journal of Cancer</i> , 2007, 97, 420-425.	2.9	5
148	Cancer immunoediting from immune surveillance to immune escape. <i>Immunology</i> , 2007, 121, 1-14.	2.0	863
149	Protection against polyoma virus-induced tumors is perforin-independent. <i>Virology</i> , 2007, 358, 485-492.	1.1	10
150	Inhibitory costimulation and anti-tumor immunity. <i>Seminars in Cancer Biology</i> , 2007, 17, 288-298.	4.3	27
151	The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma. <i>Journal of Neuroimmunology</i> , 2007, 185, 75-86.	1.1	63
152	Immunotherapeutic Strategies for High-Risk Bladder Cancer. <i>Seminars in Oncology</i> , 2007, 34, 165-172.	0.8	29
153	Increases in circulating T lymphocytes expressing HLA-DR and CD40 ligand in patients with dilated cardiomyopathy. <i>Heart and Vessels</i> , 2007, 22, 316-321.	0.5	17
154	Potent Systemic Antitumor Immunity Induced by Vaccination with Chemotactic-Prostate Tumor Associated Antigen Gene-Modified Tumor Cell and Blockade of B7-H1. <i>Journal of Clinical Immunology</i> , 2007, 27, 117-130.	2.0	12
155	Polymorphisms of Genes for Programmed Cell Death 1 Ligands in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Immunology</i> , 2007, 27, 563-567.	2.0	15
156	PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children. <i>Human Genetics</i> , 2007, 121, 223-232.	1.8	63
157	Autoimmunological features in inflammatory cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2007, 96, 469-480.	1.5	51
158	Failure to confirm association between PDCD1 polymorphisms and rheumatoid arthritis in a Japanese population. <i>Journal of Human Genetics</i> , 2007, 52, 557-560.	1.1	27
159	PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T cell responses in EAE. <i>European Journal of Immunology</i> , 2008, 38, 2706-2717.	1.6	103
160	Strategies and challenges in eliciting immunity to melanoma. <i>Immunological Reviews</i> , 2008, 222, 28-42.	2.8	19
161	The tumor microenvironment and its role in promoting tumor growth. <i>Oncogene</i> , 2008, 27, 5904-5912.	2.6	1,869
162	HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. <i>Oncogene</i> , 2008, 27, 5869-5885.	2.6	356
163	Mage-b vaccine delivered by recombinant <i>Listeria monocytogenes</i> is highly effective against breast cancer metastases. <i>British Journal of Cancer</i> , 2008, 99, 741-749.	2.9	72

#	ARTICLE	IF	CITATIONS
164	Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. <i>British Journal of Cancer</i> , 2008, 99, 1704-1711.	2.9	261
165	Special regulatory T cell review: The resurgence of the concept of contrasuppression in immunoregulation. <i>Immunology</i> , 2008, 123, 40-44.	2.0	68
166	Adjuvant therapy of melanoma with interferon: lessons of the past decade. <i>Journal of Translational Medicine</i> , 2008, 6, 62.	1.8	64
167	Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. <i>Breast Cancer Research</i> , 2008, 10, 214.	2.2	20
168	The complex role of B7 molecules in tumor immunology. <i>Trends in Molecular Medicine</i> , 2008, 14, 550-559.	3.5	84
169	Prospects and challenges of building a cancer vaccine targeting telomerase. <i>Biochimie</i> , 2008, 90, 173-180.	1.3	50
170	Insulin-like Growth Factor-1 Binding Protein-2 Is a Target for the Immunomodulation of Breast Cancer. <i>Cancer Research</i> , 2008, 68, 8400-8409.	0.4	55
171	NFATc1 Regulates PD-1 Expression upon T Cell Activation. <i>Journal of Immunology</i> , 2008, 181, 4832-4839.	0.4	311
172	Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 652-656.	3.3	270
173	Generation and regulation of human CD4 ⁺ IL-17-producing T cells in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 15505-15510.	3.3	259
174	Imatinib Mesylate Inhibits CD4 ⁺ CD25 ⁺ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL ⁺ Tumors. <i>Journal of Immunology</i> , 2008, 181, 6955-6963.	0.4	140
175	Intrarenal Antigens Activate CD4 ⁺ Cells via Co-stimulatory Signals from Dendritic Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 515-526.	3.0	28
176	Identification of Cardiac Troponin I Sequence Motifs Leading to Heart Failure by Induction of Myocardial Inflammation and Fibrosis. <i>Circulation</i> , 2008, 118, 2063-2072.	1.6	97
177	Tumorigenesis and anti-tumor immune responses in <i>Xenopus</i> . <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 167.	3.0	35
178	Dysregulation of CD8 ⁺ lymphocyte apoptosis, chronic disease, and immune regulation. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 3771.	3.0	55
179	3-Phosphoinositide-Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma. <i>Cancer Research</i> , 2009, 69, 6299-6306.	0.4	126
180	Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer. <i>Cancer Research</i> , 2009, 69, 4192-4201.	0.4	164
181	Deletion of PTEN Promotes Tumorigenic Signaling, Resistance to Anoikis, and Altered Response to Chemotherapeutic Agents in Human Mammary Epithelial Cells. <i>Cancer Research</i> , 2009, 69, 8275-8283.	0.4	79

#	ARTICLE	IF	CITATIONS
182	Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition. <i>Cancer Research</i> , 2009, 69, 565-572.	0.4	340
183	Follicular lymphoma B cells induce the conversion of conventional CD4 ⁺ T cells to T _H 17 regulatory cells. <i>International Journal of Cancer</i> , 2009, 124, 239-244.	2.3	70
184	DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 567-580.	1.2	3
185	Fish oil targets PTEN to regulate NF κ B for downregulation of anti-apoptotic genes in breast tumor growth. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 213-228.	1.1	92
186	PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations. <i>Proteins: Structure, Function and Bioinformatics</i> , 2009, 75, 499-508.	1.5	21
187	Does chemotherapy modify the immune surveillance of hematological malignancies?. <i>Leukemia</i> , 2009, 23, 53-58.	3.3	39
188	Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1585-1595.	1.2	183
189	Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1745-1754.	1.2	85
190	A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. <i>Clinical Proteomics</i> , 2010, 6, 129-151.	1.1	203
191	N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine. <i>Cell Stress and Chaperones</i> , 2010, 15, 631-638.	1.2	8
192	Phase I Study of Single-Agent Anti α Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. <i>Journal of Clinical Oncology</i> , 2010, 28, 3167-3175.	0.8	2,667
193	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor α positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10208-10213.	3.3	324
194	Tumor-Associated Lymphocytes and Increased FoxP3+ Regulatory T Cell Frequency Correlate with More Aggressive Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2325-2333.	1.8	133
195	Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-12.	3.0	41
196	Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art. <i>Seminars in Immunology</i> , 2010, 22, 105-112.	2.7	44
197	Glucose Metabolism Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography Is Independent of PTEN/AKT Status in Human Colon Carcinoma Cells. <i>Translational Oncology</i> , 2011, 4, 241-248.	1.7	21
198	The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants. <i>Immunobiology</i> , 2011, 216, 918-924.	0.8	15
199	Costimulatory pathways in transplantation. <i>Seminars in Immunology</i> , 2011, 23, 293-303.	2.7	80

#	ARTICLE	IF	CITATIONS
200	Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. <i>Immunological Reviews</i> , 2011, 241, 104-118.	2.8	229
201	A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. <i>Investigational New Drugs</i> , 2011, 29, 489-498.	1.2	285
202	Cancer Immunotherapy and Nanomedicine. <i>Pharmaceutical Research</i> , 2011, 28, 200-214.	1.7	75
203	Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. <i>Seminars in Immunopathology</i> , 2011, 33, 369-383.	2.8	265
204	Contribution of the immune system to the chemotherapeutic response. <i>Seminars in Immunopathology</i> , 2011, 33, 353-367.	2.8	30
205	Analysis of the T-Cell Receptor Repertoires of Tumor-Infiltrating Conventional and Regulatory T Cells Reveals No Evidence for Conversion in Carcinogen-Induced Tumors. <i>Cancer Research</i> , 2011, 71, 736-746.	0.4	112
206	Advances in Breast Cancer – Looking Back over the Year. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 1117-1129.	0.8	17
207	Role of the PD-1 Pathway in the Immune Response. <i>American Journal of Transplantation</i> , 2012, 12, 2575-2587.	2.6	348
208	Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death. <i>International Journal of Molecular Sciences</i> , 2012, 13, 9545-9571.	1.8	228
209	Overcoming implementation challenges of personalized cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 542-548.	12.5	115
210	Recognition of self and altered self by T cells in autoimmunity and allergy. <i>Protein and Cell</i> , 2013, 4, 8-16.	4.8	36
211	Emerging Concepts in Breast Cancer Risk Prediction. <i>Current Obstetrics and Gynecology Reports</i> , 2013, 2, 43-52.	0.3	8
212	Therapeutic Cancer Vaccines. <i>Advances in Cancer Research</i> , 2013, 119, 421-475.	1.9	450
213	Novel Immunotherapies in GI Malignancies. <i>Current Oncology Reports</i> , 2013, 15, 224-231.	1.8	5
214	Personal genomes, quantitative dynamic omics and personalized medicine. <i>Quantitative Biology</i> , 2013, 1, 71-90.	0.3	29
215	KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. <i>Modern Pathology</i> , 2013, 26, 1307-1319.	2.9	102
216	Does a reasonable treatment approach beyond second-line exist?. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 169-171.	2.2	0
217	Individualising treatment choices in a crowded treatment algorithm. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 160-168.	2.2	2

#	ARTICLE	IF	CITATIONS
218	Metastatic melanoma: New paradigms of treatment and new toxicities. European Journal of Cancer, Supplement, 2013, 11, 278-280.	2.2	1
219	A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Investigational New Drugs, 2013, 31, 707-713.	1.2	86
220	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	2.2	320
221	Tumour heterogeneity and cancer cell plasticity. Nature, 2013, 501, 328-337.	13.7	2,043
222	The FGF/FGF receptor axis as a therapeutic target in breast cancer. Expert Review of Endocrinology and Metabolism, 2013, 8, 391-402.	1.2	56
223	New drugs, new knowledge, new targets. Nature Reviews Clinical Oncology, 2013, 10, 75-76.	12.5	9
224	Immunotherapy of melanoma. European Journal of Cancer, Supplement, 2013, 11, 97-105.	2.2	53
225	Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. European Journal of Cancer, Supplement, 2013, 11, 3-22.	2.2	6
226	The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of Advanced Breast Cancer. Current Oncology Reports, 2013, 15, 14-23.	1.8	20
227	Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management. Heart Failure Reviews, 2013, 18, 715-732.	1.7	91
228	Mutations in components of antiviral or microbial defense as a basis for breast cancer. Functional and Integrative Genomics, 2013, 13, 411-424.	1.4	9
229	Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. European Respiratory Review, 2013, 22, 565-576.	3.0	23
230	Immunotherapy treatments for small-cell lung cancer: past, present and future. Lung Cancer Management, 2013, 2, 517-525.	1.5	1
231	PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production. Mucosal Immunology, 2013, 6, 728-739.	2.7	40
232	Significance Analysis of Prognostic Signatures. PLoS Computational Biology, 2013, 9, e1002875.	1.5	27
233	Locally Advanced Lung Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 247-262.	1.0	19
234	Human Plasmacytoid Dendritic Cells: From Molecules to Intercellular Communication Network. Frontiers in Immunology, 2013, 4, 372.	2.2	93
235	Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design. ImmunoTargets and Therapy, 2013, 3, 1.	2.7	4

#	ARTICLE	IF	CITATIONS
236	Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis. <i>Cancer Research</i> , 2013, 73, 3285-3296.	0.4	251
237	The delicate balance of melanoma immunotherapy. <i>Clinical and Translational Immunology</i> , 2013, 2, e5.	1.7	22
238	TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e105.	2.3	371
239	Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. <i>British Journal of Cancer</i> , 2013, 108, 1560-1565.	2.9	139
240	Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes. <i>Haematologica</i> , 2013, 98, 1689-1696.	1.7	10
241	Update on the challenges and recent advances in cancer immunotherapy. <i>ImmunoTargets and Therapy</i> , 2013, 2, 39.	2.7	8
242	Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. <i>ImmunoTargets and Therapy</i> , 2013, 2, 73.	2.7	28
243	T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management. <i>ImmunoTargets and Therapy</i> , 2013, 2, 135.	2.7	5
244	The Combination of a Low-Dose Chemotherapeutic Agent, 5-Fluorouracil, and an Adenoviral Tumor Vaccine Has a Synergistic Benefit on Survival in a Tumor Model System. <i>PLoS ONE</i> , 2013, 8, e67904.	1.1	47
245	Cancer testis antigen and immunotherapy. <i>ImmunoTargets and Therapy</i> , 2013, 2, 11.	2.7	43
246	Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 329.	0.4	19
247	Therapeutic cancer vaccines and combination immunotherapies involving vaccination. <i>ImmunoTargets and Therapy</i> , 2014, 3, 135.	2.7	9
248	The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e115103.	1.1	182
249	⁶⁴ Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues. <i>PLoS ONE</i> , 2014, 9, e109866.	1.1	97
250	Increased CD112 Expression in Methylcholanthrene-Induced Tumors in CD155-Deficient Mice. <i>PLoS ONE</i> , 2014, 9, e112415.	1.1	21
251	Somatic Mutations Favorable to Patient Survival Are Predominant in Ovarian Carcinomas. <i>PLoS ONE</i> , 2014, 9, e112561.	1.1	3
252	Characterization of X Chromosome Inactivation Using Integrated Analysis of Whole-Exome and mRNA Sequencing. <i>PLoS ONE</i> , 2014, 9, e113036.	1.1	24
253	Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. <i>PLoS ONE</i> , 2014, 9, e114900.	1.1	77

#	ARTICLE	IF	CITATIONS
254	Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 357.	0.4	60
255	Nanocarrier-based immunotherapy in cancer management and research. <i>ImmunoTargets and Therapy</i> , 2014, 3, 121.	2.7	18
256	Interleukin-17 and type 17 helper T cells in cancer management and research. <i>ImmunoTargets and Therapy</i> , 2014, 3, 39.	2.7	18
257	Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy. <i>Current Medicinal Chemistry</i> , 2014, 22, 264-289.	1.2	178
258	Malignant Melanoma. <i>Healthcare (Switzerland)</i> , 2014, 2, 1-19.	1.0	39
259	Dermatology: Where are We Coming from and Where are We Going to?. <i>Frontiers in Medicine</i> , 2014, 1, 40.	1.2	0
260	APC licensing and CD4+T cell help in liver-stage malaria. <i>Frontiers in Microbiology</i> , 2014, 5, 617.	1.5	10
261	RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells. <i>ELife</i> , 2014, 3, e03881.	2.8	91
262	Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. <i>Journal of Personalized Medicine</i> , 2014, 4, 386-401.	1.1	13
263	Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification. <i>Vaccines</i> , 2014, 2, 549-562.	2.1	8
264	Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. <i>World Journal of Clinical Oncology</i> , 2014, 5, 990.	0.9	87
265	Regulation of T-cell Tolerance by Lymphatic Endothelial Cells. <i>Journal of Clinical & Cellular Immunology</i> , 2014, 05, .	1.5	40
266	365 days: Nature's 10. <i>Nature</i> , 2014, 516, 311-319.	18.7	9
267	The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. <i>Immune Network</i> , 2014, 14, 265.	1.6	78
268	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
269	Managing Multi-center Flow Cytometry Data for Immune Monitoring. <i>Cancer Informatics</i> , 2014, 13s7, CIN.S16346.	0.9	9
270	Emerging options for the treatment of melanoma – focus on ipilimumab. <i>ImmunoTargets and Therapy</i> , 2014, 3, 67.	2.7	2
271	Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. <i>ImmunoTargets and Therapy</i> , 2014, 3, 151.	2.7	12

#	ARTICLE	IF	CITATIONS
272	Assessment of Subnetwork Detection Methods for Breast Cancer. <i>Cancer Informatics</i> , 2014, 13s6, CIN.S17641.	0.9	8
273	Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tt 5	0.4	23
274	Tumor Infiltrating Lymphocytes â€œ The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2014, 05, .	0.3	3
275	MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 398-412.	3.9	348
276	Cooperative interactions between p53 and NFÎ±B enhance cell plasticity. <i>Oncotarget</i> , 2014, 5, 12111-12125.	0.8	28
277	Epithelial ovarian cancer: An overview. <i>World Journal of Translational Medicine</i> , 2014, 3, 1.	3.5	109
278	miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. <i>ELife</i> , 2014, 3, .	2.8	153
279	IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. <i>Oncotarget</i> , 2014, 5, 11064-11080.	0.8	103
280	Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art. <i>Critical Reviews in Immunology</i> , 2014, 34, 399-432.	1.0	13
281	Awareness and understanding of cancer immunotherapy in Europe. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1828-1835.	1.4	6
282	Regulatory considerations for clinical development of cancer vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3409-3414.	1.4	5
283	Adding fuel to the fire: Immunogenic intensification. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3306-3312.	1.4	4
284	IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3179-3189.	1.4	44
285	Tumor cell lysates as immunogenic sources for cancer vaccine design. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3261-3269.	1.4	126
286	PD-1 and PD-L1 antibodies for melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3111-3116.	1.4	54
287	Biomarkers in melanoma: where are we now?. <i>Melanoma Management</i> , 2014, 1, 139-150.	0.1	1
288	Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3125-3131.	1.4	62
289	TroVax in colorectal cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3196-3200.	1.4	19

#	ARTICLE	IF	CITATIONS
290	Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3415-3424.	1.4	39
291	Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3354-3368.	1.4	85
292	Vaccines versus immunotherapy: Overview of approaches in deciding between options. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3369-3374.	1.4	11
293	BSSV: Bayesian based somatic structural variation identification with whole genome DNA-seq data. , 2014, 2014, 3937-40.		2
294	Cancer vaccines: What do we need to measure in clinical trials?. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3236-3240.	1.4	10
295	Antigen-specific vaccines for cancer treatment. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3332-3346.	1.4	124
296	Past, present and future targets for immunotherapy in ovarian cancer. <i>Immunotherapy</i> , 2014, 6, 1279-1293.	1.0	34
297	Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax [®] , as a therapeutic strategy for metastatic breast cancer. <i>Journal of Translational Medicine</i> , 2014, 12, 322.	1.8	30
298	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. , 2014, 2, 40.		50
299	Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 488.	2.2	197
300	L1CAM is expressed in triple-negative breast cancers and is inversely correlated with Androgen receptor. <i>BMC Cancer</i> , 2014, 14, 958.	1.1	38
301	Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities. , 2014, 2, 38.		33
302	Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?. <i>Breast Cancer Research</i> , 2014, 16, 457.	2.2	2
303	MAGE-specific T cells detected directly <i>ex-vivo</i> correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy. , 2014, 2, 32.		7
304	Pre-operative prognostic nutritional index predicts the outcomes for triple-negative breast cancer. <i>Tumor Biology</i> , 2014, 35, 12165-12171.	0.8	43
305	Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. <i>Breast Cancer Research</i> , 2014, 16, 489.	2.2	54
306	Characterization of age signatures of DNA methylation in normal and cancer tissues from multiple studies. <i>BMC Genomics</i> , 2014, 15, 997.	1.2	20
307	New antibody approaches to lymphoma therapy. <i>Journal of Hematology and Oncology</i> , 2014, 7, 58.	6.9	50

#	ARTICLE	IF	CITATIONS
308	Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 501-510.	1.1	9
309	Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma. <i>Journal of Hematology and Oncology</i> , 2014, 7, 91.	6.9	22
310	Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. <i>Arthritis Research and Therapy</i> , 2014, 16, 469.	1.6	55
311	Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 511-523.	1.1	34
312	Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor. <i>Cancer Cell International</i> , 2014, 14, 115.	1.8	38
314	Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. , 2014, 2, 41.		80
315	Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. <i>Cell Death and Disease</i> , 2014, 5, e1568-e1568.	2.7	42
316	Current advances in T-cell-based cancer immunotherapy. <i>Immunotherapy</i> , 2014, 6, 1265-1278.	1.0	119
317	Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. <i>Modern Pathology</i> , 2014, 27, 1193-1202.	2.9	18
318	A Cancer Theory Kerfuffle Can Lead to New Lines of Research. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju405-dju405.	3.0	66
319	Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e190.	2.3	17
320	Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy. <i>Oncogenesis</i> , 2014, 3, e133-e133.	2.1	18
321	Effects of Epithelial to Mesenchymal Transition on T Cell Targeting of Melanoma Cells. <i>Frontiers in Oncology</i> , 2014, 4, 367.	1.3	29
322	Characterization of the Usage of the Serine Metabolic Network in Human Cancer. <i>Cell Reports</i> , 2014, 9, 1507-1519.	2.9	136
323	Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 320.	1.3	5
324	Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 351.	1.3	15
325	Experiences and Expectations for Glioma Immunotherapeutic Approaches. <i>Frontiers in Oncology</i> , 2014, 4, 355.	1.3	1
326	The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. <i>Frontiers in Pharmacology</i> , 2014, 5, 235.	1.6	280

#	ARTICLE	IF	CITATIONS
327	Suppression of Invasion and Metastasis of Triple-Negative Breast Cancer Lines by Pharmacological or Genetic Inhibition of Slug Activity. <i>Neoplasia</i> , 2014, 16, 1047-1058.	2.3	78
328	Is vaccine research still relevant for metastatic melanoma?. <i>Melanoma Management</i> , 2014, 1, 91-94.	0.1	5
329	Membrane domain formation is a key factor for targeted intracellular drug delivery. <i>Frontiers in Physiology</i> , 2014, 5, 462.	1.3	3
330	Immunotherapy for Lung Cancer: Has it Finally Arrived?. <i>Frontiers in Oncology</i> , 2014, 4, 288.	1.3	32
331	Human Cytomegalovirus Antigens in Malignant Gliomas as Targets for Adoptive Cellular Therapy. <i>Frontiers in Oncology</i> , 2014, 4, 338.	1.3	10
332	Histological Analysis of CD8 ⁺ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas. <i>Frontiers in Immunology</i> , 2014, 5, 632.	2.2	29
333	Microenvironment of Tumor-Draining Lymph Nodes: Opportunities for Liposome-Based Targeted Therapy. <i>International Journal of Molecular Sciences</i> , 2014, 15, 20209-20239.	1.8	65
334	Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?. <i>Laboratory Investigation</i> , 2014, 94, 13-30.	1.7	63
335	Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. <i>Frontiers in Pharmacology</i> , 2014, 5, 252.	1.6	34
336	Combinations of Immunotherapy and Radiation in Cancer Therapy. <i>Frontiers in Oncology</i> , 2014, 4, 325.	1.3	205
337	CD8 ⁺ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2014, 5, 575.	2.2	57
338	Emerging Understanding of Multiscale Tumor Heterogeneity. <i>Frontiers in Oncology</i> , 2014, 4, 366.	1.3	90
339	New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. <i>European Respiratory Review</i> , 2014, 23, 367-378.	3.0	78
340	High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. <i>Melanoma Management</i> , 2014, 1, 7-10.	0.1	1
342	Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?. <i>Immunotherapy</i> , 2014, 6, 1017-1020.	1.0	10
343	Targeting SH2 domains in breast cancer. <i>Future Medicinal Chemistry</i> , 2014, 6, 1909-1926.	1.1	57
344	The Oncogenic STP Axis Promotes Triple-Negative Breast Cancer via Degradation of the REST Tumor Suppressor. <i>Cell Reports</i> , 2014, 9, 1318-1332.	2.9	24
345	Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2014, 74, 1016-1022.	0.8	12

#	ARTICLE	IF	CITATIONS
346	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. <i>Nature Communications</i> , 2014, 5, 5712.	5.8	503
347	Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. <i>Cancer Cell</i> , 2014, 26, 623-637.	7.7	751
348	To affinity and beyond: Harnessing the T Cell receptor for cancer immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3313-3321.	1.4	29
349	Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response. <i>MAbs</i> , 2014, 6, 1124-1132.	2.6	4
350	Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer. <i>Medical Oncology</i> , 2014, 31, 323.	1.2	39
351	Somatic Mutations and Immunotherapy Outcome with CTLA-4 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 2230-2232.	13.9	43
352	Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5964-5975.	3.2	70
353	Demethylation of the TSDR Is a Marker of Squamous Cell Carcinoma in Transplant Recipients. <i>American Journal of Transplantation</i> , 2014, 14, 2617-2622.	2.6	17
354	Integration of Genomic Data Enables Selective Discovery of Breast Cancer Drivers. <i>Cell</i> , 2014, 159, 1461-1475.	13.5	77
355	Immune regulation of bone metastasis. <i>BoneKey Reports</i> , 2014, 3, 600.	2.7	28
356	Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. <i>Lancet Oncology</i> , The, 2014, 15, e625-e634.	5.1	186
357	Stromal Expression of miR-21 Identifies High-Risk Group in Triple-Negative Breast Cancer. <i>American Journal of Pathology</i> , 2014, 184, 3217-3225.	1.9	44
358	Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer. <i>Cancer Discovery</i> , 2014, 4, 1377-1386.	7.7	76
359	PD-1 blockade induces responses by inhibiting adaptive immune resistance. <i>Nature</i> , 2014, 515, 568-571.	13.7	5,429
360	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. <i>Nature</i> , 2014, 515, 558-562.	13.7	2,109
361	Antitumour immunity gets a boost. <i>Nature</i> , 2014, 515, 496-498.	13.7	90
362	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <i>Nature</i> , 2014, 515, 563-567.	13.7	4,342
363	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , 2014, 515, 577-581.	13.7	1,705

#	ARTICLE	IF	CITATIONS
364	Oncogenic activity of the regulatory subunit p85 β of phosphatidylinositol 3-kinase (PI3K). Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16826-16829.	3.3	36
365	IgE-based immunotherapy of cancer: challenges and chances. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 137-149.	2.7	29
366	The Immunological Synapse. Cancer Immunology Research, 2014, 2, 1023-1033.	1.6	330
367	Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Annals of Oncology, 2014, 25, 2277-2284.	0.6	119
368	Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5429-38.	3.3	419
369	Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations. British Journal of Cancer, 2014, 111, 2351-2360.	2.9	22
370	PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond. Cancer Immunology Research, 2014, 2, 1132-1141.	1.6	42
371	DNA barcoding reveals diverse growth kinetics of human breast tumour subclones in serially passaged xenografts. Nature Communications, 2014, 5, 5871.	5.8	86
372	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications, 2014, 5, 5241.	5.8	780
373	Harnessing the PD-1 Pathway in Renal Cell Carcinoma: Current Evidence and Future Directions. BioDrugs, 2014, 28, 513-526.	2.2	7
374	DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes. Genome Medicine, 2014, 6, 44.	3.6	25
375	Humanization of the mouse mammary gland by replacement of the luminal layer with genetically-engineered preneoplastic human cells. Breast Cancer Research, 2014, 16, 504.	2.2	13
376	Mutational profiling of kinases in glioblastoma. BMC Cancer, 2014, 14, 718.	1.1	50
377	Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer. BMC Cancer, 2014, 14, 871.	1.1	4
378	MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer, 2014, 14, 957.	1.1	66
379	Combining functional genomics strategies identifies modular heterogeneity of breast cancer intrinsic subtypes. BioData Mining, 2014, 7, 27.	2.2	2
380	Semi-automated literature mining to identify putative biomarkers of disease from multiple biofluids. Journal of Clinical Bioinformatics, 2014, 4, 13.	1.2	6
381	Integrative network analysis of TCGA data for ovarian cancer. BMC Systems Biology, 2014, 8, 1338.	3.0	95

#	ARTICLE	IF	CITATIONS
382	Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel. <i>BMC Medical Genomics</i> , 2014, 7, 62.	0.7	25
383	Onco-STIS: a web-based laboratory information management system for sample and analysis tracking in oncogenomic experiments. <i>Source Code for Biology and Medicine</i> , 2014, 9, 25.	1.7	3
384	DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival. <i>Breast Cancer Research</i> , 2014, 16, 450.	2.2	76
385	New concepts in breast cancer genomics and genetics. <i>Breast Cancer Research</i> , 2014, 16, 460.	2.2	28
386	Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 464.	2.2	40
387	Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 466.	2.2	35
388	Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. <i>Breast Cancer Research</i> , 2014, 16, 491.	2.2	27
389	Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. <i>Breast Cancer Research</i> , 2014, 16, 3417.	2.2	21
390	Toca-1 is suppressed by p53 to limit breast cancer cell invasion and tumor metastasis. <i>Breast Cancer Research</i> , 2014, 16, 3413.	2.2	18
391	Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. <i>Genome Medicine</i> , 2014, 6, 80.	3.6	44
392	Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches. <i>EJNMMI Research</i> , 2014, 4, 34.	1.1	9
393	Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. , 2014, 2, 42.		186
394	Potential for immunotherapy in soft tissue sarcoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3117-3124.	1.4	26
395	The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. <i>National Science Review</i> , 2014, 1, 396-412.	4.6	72
396	Where to start with systemic melanoma therapy?. <i>Melanoma Management</i> , 2014, 1, 15-18.	0.1	0
397	Dendritic Cell Cancer Vaccines: From the Bench to the Bedside. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0024.	0.4	11
398	Distinct cytokine mRNA expression pattern in immunoglobulin G4-related kidney disease associated with renal cell carcinoma. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 269-274.	1.4	7
399	NCI Workshop Report: Clinical and Computational Requirements for Correlating Imaging Phenotypes with Genomics Signatures. <i>Translational Oncology</i> , 2014, 7, 556-569.	1.7	69

#	ARTICLE	IF	CITATIONS
400	Structure and Cancer Immunotherapy of the B7 Family Member B7x. <i>Cell Reports</i> , 2014, 9, 1089-1098.	2.9	58
401	Drug development: A chance of survival. <i>Nature</i> , 2014, 515, S118-S120.	13.7	8
402	Evaluating biomarkers in melanoma. <i>Frontiers in Oncology</i> , 2014, 4, 383.	1.3	38
403	Genetic risk signatures of opioid-induced respiratory depression following pediatric tonsillectomy. <i>Pharmacogenomics</i> , 2014, 15, 1749-1762.	0.6	26
404	Adoptive Immunotherapy for Hematological Malignancies Using T Cells Gene-Modified to Express Tumor Antigen-Specific Receptors. <i>Pharmaceuticals</i> , 2014, 7, 1049-1068.	1.7	21
405	Mining genome sequencing data to identify the genomic features linked to breast cancer histopathology. <i>Journal of Pathology Informatics</i> , 2014, 5, 3.	0.8	22
406	A Novel Subset of Human tumors that Simultaneously Overexpress Multiple E2F-responsive Genes Found in Breast, Ovarian, and Prostate Cancers. <i>Cancer Informatics</i> , 2014, 13s5, CIN.S14062.	0.9	17
407	A Role for Naturally Occurring Alleles of Endoplasmic Reticulum Aminopeptidases in Tumor Immunity and Cancer Pre-Disposition. <i>Frontiers in Oncology</i> , 2014, 4, 363.	1.3	56
408	Immunotherapy of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2014, 1, 433-446.	4.2	5
409	Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers. <i>Nucleic Acids Research</i> , 2014, 42, 12973-12983.	6.5	5
410	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. <i>Cancer Cell</i> , 2014, 25, 91-101.	7.7	847
411	Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. <i>Nature Genetics</i> , 2014, 46, 613-617.	9.4	211
412	Programmed death ligand-1 expression in non-small cell lung cancer. <i>Laboratory Investigation</i> , 2014, 94, 107-116.	1.7	697
413	Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E384-93.	3.3	165
414	Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. <i>Clinical and Translational Immunology</i> , 2014, 3, e22.	1.7	64
415	Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases. <i>Neuron</i> , 2014, 84, 594-607.	3.8	51
416	SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer. <i>Molecular Cell</i> , 2014, 56, 595-607.	4.5	133
417	STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors. <i>Immunity</i> , 2014, 41, 830-842.	6.6	1,325

#	ARTICLE	IF	CITATIONS
418	The melanoma revolution: From UV carcinogenesis to a new era in therapeutics. <i>Science</i> , 2014, 346, 945-949.	6.0	328
419	Renal cell carcinoma. <i>BMJ, The</i> , 2014, 349, g4797-g4797.	3.0	509
420	Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. <i>Nature</i> , 2014, 515, 130-133.	13.7	556
421	Tumor Antigen-Specific Monoclonal Antibodies and Induction of T-Cell Immunity. <i>Seminars in Oncology</i> , 2014, 41, 678-684.	0.8	15
422	Specificity Delivers: Therapeutic Role of Tumor Antigen-Specific Antibodies in Pancreatic Cancer. <i>Seminars in Oncology</i> , 2014, 41, 559-575.	0.8	3
423	Pan-cancer patterns of DNA methylation. <i>Genome Medicine</i> , 2014, 6, 66.	3.6	149
424	Novel agents in development for advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 240-253.	1.4	33
425	Immune approaches to the treatment of breast cancer, around the corner?. <i>Breast Cancer Research</i> , 2014, 16, 204.	2.2	38
426	CARM1 and BAF155: an example of how chromatin remodeling factors can be relocalized and contribute to cancer. <i>Breast Cancer Research</i> , 2014, 16, 307.	2.2	1
427	Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy. <i>Nature Communications</i> , 2014, 5, 5476.	5.8	39
428	Biology of breast cancer in young women. <i>Breast Cancer Research</i> , 2014, 16, 427.	2.2	296
429	Breast cancer intra-tumor heterogeneity. <i>Breast Cancer Research</i> , 2014, 16, 210.	2.2	256
430	RNF43 is frequently mutated in colorectal and endometrial cancers. <i>Nature Genetics</i> , 2014, 46, 1264-1266.	9.4	388
431	Antibody-Cytokine Fusion Proteins for Treatment of Cancer: Engineering Cytokines for Improved Efficacy and Safety. <i>Seminars in Oncology</i> , 2014, 41, 623-636.	0.8	56
432	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2014, 11, 400-410.	1.9	267
433	A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. , 2014, 2, 30.		27
434	Male breast cancer: a rare disease that might uncover underlying pathways of breast cancer. <i>Nature Reviews Cancer</i> , 2014, 14, 643-644.	12.8	36
435	Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma. , 2014, 2, 9.		14

#	ARTICLE	IF	CITATIONS
436	VSIG4 expression on macrophages facilitates lung cancer development. <i>Laboratory Investigation</i> , 2014, 94, 706-715.	1.7	65
437	Molecular Heterogeneity of Triple-Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 154-158.	0.5	58
438	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2014, 32, 1020-1030.	0.8	2,015
439	Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma. <i>Cancer Discovery</i> , 2014, 4, 1154-1167.	7.7	123
440	Bioactive compounds or metabolites from black raspberries modulate T lymphocyte proliferation, myeloid cell differentiation and Jak/STAT signaling. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 889-900.	2.0	42
441	Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. <i>Frontiers in Chemistry</i> , 2014, 2, 105.	1.8	147
442	Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer. <i>Cancer Management and Research</i> , 2014, 6, 389.	0.9	15
443	High-Throughput Analysis of Plasma Hybrid Markers for Early Detection of Cancers. <i>Proteomes</i> , 2014, 2, 1-17.	1.7	11
444	An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e116054.	1.1	28
445	Characterizing Cancer-Specific Networks by Integrating TCGA Data. <i>Cancer Informatics</i> , 2014, 13s2, CIN.S13776.	0.9	5
446	Multivariate Boosting for Integrative Analysis of High-Dimensional Cancer Genomic Data. <i>Cancer Informatics</i> , 2014, 13s7, CIN.S16353.	0.9	2
447	Subcutaneous metastases from melanoma: a discussion of clinical experience. <i>Melanoma Management</i> , 2014, 1, 31-40.	0.1	2
448	The role of chemotherapy in the modern management of melanoma. <i>Melanoma Management</i> , 2014, 1, 173-184.	0.1	8
449	Potential of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14004.	2.0	33
450	UNSUPERVISED FEATURE CONSTRUCTION AND KNOWLEDGE EXTRACTION FROM GENOME-WIDE ASSAYS OF BREAST CANCER WITH DENOISING AUTOENCODERS. , 2014, , .		79
451	Normalized ImQCM: An Algorithm for Detecting Weak Quasi-Cliques in Weighted Graph with Applications in Gene Co-Expression Module Discovery in Cancers. <i>Cancer Informatics</i> , 2014, 13s3, CIN.S14021.	0.9	47
452	<sc>eEF</sc>2Kâ€”a new target in breast cancers with combined inactivation of p53 and PTEN. <i>EMBO Molecular Medicine</i> , 2014, 6, 1512-1514.	3.3	7
453	Normal Cell-Type Epigenetics and Breast Cancer Classification: A Case Study of Cell Mixtureâ€”Adjusted Analysis of DNA Methylation Data from Tumors. <i>Cancer Informatics</i> , 2014, 13s4, CIN.S13980.	0.9	16

#	ARTICLE	IF	CITATIONS
454	A Comprehensive Comparison of Normalization Methods for Loading Control and Variance Stabilization of Reverse-Phase Protein Array Data. <i>Cancer Informatics</i> , 2014, 13, CIN.S13329.	0.9	19
455	Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas. <i>BMC Medical Genomics</i> , 2014, 7, S2.	0.7	13
456	The biological and clinical challenge of liver cancer heterogeneity. <i>Hepatic Oncology</i> , 2014, 1, 349-353.	4.2	34
457	Combination therapies in advanced melanoma. <i>Melanoma Management</i> , 2014, 1, 47-56.	0.1	2
458	How anti-PD1 treatments are changing the management of melanoma. <i>Melanoma Management</i> , 2014, 1, 165-172.	0.1	5
459	Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non-Small Cell Lung Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 541-549.	0.6	171
460	Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses. <i>Stem Cell Reports</i> , 2015, 5, 392-404.	2.3	63
461	ALK alteration is a frequent event in aggressive breast cancers. <i>Breast Cancer Research</i> , 2015, 17, 127.	2.2	29
462	Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer. <i>BMC Clinical Pathology</i> , 2015, 15, 20.	1.8	61
463	The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer. <i>Genome Research</i> , 2015, 25, 488-503.	2.4	106
464	Predicting the outcome of melanoma: can we tell the future of a patient's melanoma?. <i>Melanoma Management</i> , 2015, 2, 217-224.	0.1	5
465	Classic Ras Proteins Promote Proliferation and Survival via Distinct Phosphoproteome Alterations in Neurofibromin-Null Malignant Peripheral Nerve Sheath Tumor Cells. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 568-586.	0.9	14
466	Integration and comparison of different genomic data for outcome prediction in cancer. <i>BioData Mining</i> , 2015, 8, 32.	2.2	14
467	Modern reproductive patterns associated with estrogen receptor positive but not negative breast cancer susceptibility. <i>Evolution, Medicine and Public Health</i> , 2015, 2015, 52-74.	1.1	30
468	Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon- β on the murine Renca renal cell carcinoma cell line in vitro and in vivo. <i>Molecular Medicine Reports</i> , 2015, 12, 6727-6737.	1.1	30
469	Targeting immune checkpoints in melanoma: an update. <i>Melanoma Management</i> , 2015, 2, 339-352.	0.1	2
470	T Cell Intrinsic USP15 Deficiency Promotes Excessive IFN- γ Production and an Immunosuppressive Tumor Microenvironment in MCA-Induced Fibrosarcoma. <i>Cell Reports</i> , 2015, 13, 2470-2479.	2.9	41
471	A multi-omic analysis of human naïve CD4+ T cells. <i>BMC Systems Biology</i> , 2015, 9, 75.	3.0	43

#	ARTICLE	IF	CITATIONS
472	Expression of immune checkpoint molecules in endometrial carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1947-1952.	0.8	30
473	Gene therapy: progress and predictions. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2015, 282, 20143003.	1.2	108
474	Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery. <i>Oncology Letters</i> , 2015, 10, 1079-1086.	0.8	14
475	Combination immunotherapy with $\hat{\pm}$ -CTLA-4 and $\hat{\pm}$ -PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. , 2015, 3, 21.		157
476	A sequence-specific DNA binding small molecule triggers the release of immunogenic signals and phagocytosis in a model of B-cell lymphoma. <i>Quarterly Reviews of Biophysics</i> , 2015, 48, 453-464.	2.4	12
477	Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. <i>Journal of Translational Medicine</i> , 2015, 13, 214.	1.8	84
478	The Emerging Role of ABL Kinases in Solid Tumors. <i>Trends in Cancer</i> , 2015, 1, 110-123.	3.8	61
479	Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2015, 17, 80.	2.2	5
480	The prognostic influence of tumor infiltrating Foxp3+CD4+, CD4+ and CD8+ T cells in resected non-small cell lung cancer. <i>Journal of Inflammation</i> , 2015, 12, 63.	1.5	46
481	MEK and PI3K inhibition in solid tumors: rationale and evidence to date. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 170-180.	1.4	105
482	ABCB5 Identifies Immunoregulatory Dermal Cells. <i>Cell Reports</i> , 2015, 12, 1564-1574.	2.9	51
483	Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. <i>International Journal of Oncology</i> , 2015, 46, 28-36.	1.4	69
484	Analysis of different $\langle \text{sc} \rangle \text{HER} \langle / \text{sc} \rangle \hat{\epsilon} 2$ mutations in breast cancer progression and drug resistance. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 2691-2701.	1.6	42
485	A phase $\langle \text{sc} \rangle 2 \langle / \text{sc} \rangle$, multicenter, open $\hat{\epsilon}$ label study of sepantronium bromide ($\langle \text{sc} \rangle \text{YM} \langle / \text{sc} \rangle 155$) plus docetaxel in patients with stage $\langle \text{sc} \rangle \text{III} \langle / \text{sc} \rangle$ (unresectable) or stage $\langle \text{sc} \rangle \text{IV} \langle / \text{sc} \rangle$ melanoma. <i>Cancer Medicine</i> , 2015, 4, 643-650.	1.3	36
486	$\langle \text{sc} \rangle \text{HER} 2 \langle / \text{sc} \rangle$ as a target in invasive urothelial carcinoma. <i>Cancer Medicine</i> , 2015, 4, 844-852.	1.3	41
487	Molecular portrait of breast cancer in $\langle \text{sc} \rangle \text{C} \langle / \text{sc} \rangle \text{hina}$ reveals comprehensive transcriptomic likeness to $\langle \text{sc} \rangle \text{C} \langle / \text{sc} \rangle \text{aucasian}$ breast cancer and low prevalence of luminal A subtype. <i>Cancer Medicine</i> , 2015, 4, 1016-1030.	1.3	31
488	Identifying Etiologically Distinct Sub $\hat{\epsilon}$ types of Cancer: A Demonstration Project Involving Breast Cancer. <i>Cancer Medicine</i> , 2015, 4, 1432-1439.	1.3	15
489	Single $\hat{\epsilon}$ fraction radiation therapy in patients with metastatic Merkel cell carcinoma. <i>Cancer Medicine</i> , 2015, 4, 1161-1170.	1.3	59

#	ARTICLE	IF	CITATIONS
490	Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10. <i>European Journal of Immunology</i> , 2015, 45, 999-1009.	1.6	74
491	Identification of several potential chromatin binding sites of HOXB7 and its downstream target genes in breast cancer. <i>International Journal of Cancer</i> , 2015, 137, 2374-2383.	2.3	28
492	Inherited <i>CHST11/MIR3922</i> deletion is associated with a novel recessive syndrome presenting with skeletal malformation and malignant lymphoproliferative disease. <i>Molecular Genetics & Genomic Medicine</i> , 2015, 3, 413-423.	0.6	11
493	Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses. <i>Cancer Science</i> , 2015, 106, 505-511.	1.7	40
494	Low programmed cell death-1 (PD-1) expression in peripheral CD4 ⁺ T cells in Japanese patients with autoimmune type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2015, 180, 452-457.	1.1	88
495	New clinical advances in immunotherapy for the treatment of solid tumours. <i>Immunology</i> , 2015, 145, 182-201.	2.0	35
496	Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. <i>Pathology International</i> , 2015, 65, 644-651.	0.6	33
497	Noncoding RNAs and chronic inflammation: Micro-managing the fire within. <i>BioEssays</i> , 2015, 37, 1005-1015.	1.2	33
498	Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00158.	1.1	12
499	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. <i>Cancer Science</i> , 2015, 106, 945-950.	1.7	78
500	Anterior gradient 2 is a binding stabilizer of hypoxia inducible factor-1 α that enhances CoCl ₂ -induced doxorubicin resistance in breast cancer cells. <i>Cancer Science</i> , 2015, 106, 1041-1049.	1.7	34
501	Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus. <i>Immunology</i> , 2015, 146, 497-507.	2.0	31
502	Phosphoproteomic profiling of tumor tissues identifies HSP27 Ser82 phosphorylation as a robust marker of early ischemia. <i>Scientific Reports</i> , 2015, 5, 13660.	1.6	11
503	Divergent Synthesis of Chondroitin Sulfate Disaccharides and Identification of Sulfate Motifs that Inhibit Triple Negative Breast Cancer. <i>Scientific Reports</i> , 2015, 5, 14355.	1.6	35
504	Suppression of established hepatocarcinoma in adjuvant only immunotherapy: alum triggers anti-tumor CD8 ⁺ T cell response. <i>Scientific Reports</i> , 2015, 5, 17695.	1.6	11
505	Highly informative marker sets consisting of genes with low individual degree of differential expression. <i>Scientific Reports</i> , 2015, 5, 14967.	1.6	24
506	Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. <i>Cancer Medicine</i> , 2015, 4, 1289-1293.	1.3	7
507	Inhibition of focal adhesion kinase induces apoptosis in bladder cancer cells via Src and the phosphatidylinositol 3-kinase/Akt pathway. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1725-1731.	0.8	38

#	ARTICLE	IF	CITATIONS
508	Long-term Outcomes of Helper Peptide Vaccination for Metastatic Melanoma. <i>Annals of Surgery</i> , 2015, 262, 456-464.	2.1	26
509	PKC ζ Promotes Breast Cancer Invasion by Regulating Expression of E-cadherin and Zonula Occludens-1 (ZO-1) via NF κ B-p65. <i>Scientific Reports</i> , 2015, 5, 12520.	1.6	28
510	Developmental genes significantly afflicted by aberrant promoter methylation and somatic mutation predict overall survival of late-stage colorectal cancer. <i>Scientific Reports</i> , 2015, 5, 18616.	1.6	13
511	Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Oncologist</i> , 2015, 20, 1247-1252.	1.9	28
512	Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2015, 5, 13110.	1.6	310
513	Development of 1-N-11C-Methyl-L- and -D-Tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-Methyl-Tryptophan. <i>Scientific Reports</i> , 2015, 5, 16417.	1.6	15
514	Novel genes associated with lymph node metastasis in triple negative breast cancer. <i>Scientific Reports</i> , 2015, 5, 15832.	1.6	48
515	Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. <i>Blood</i> , 2015, 126, 2475-2478.	0.6	108
516	Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 974-984.	0.5	127
517	Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis. <i>BMJ Open</i> , 2015, 5, e006321-e006321.	0.8	6
518	NLR5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients. <i>Oncology Letters</i> , 2015, 10, 1533-1540.	0.8	22
519	Ethnicity-Dependent and -Independent Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization. <i>Scientific Reports</i> , 2015, 5, 13526.	1.6	45
520	ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8 ⁺ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy. <i>EMBO Molecular Medicine</i> , 2015, 7, 754-769.	3.3	41
521	Immune Checkpoint Blockade in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015, 4, 201-207.	4.2	40
522	A high-throughput RNAi screen for detection of immune checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. <i>EMBO Molecular Medicine</i> , 2015, 7, 450-463.	3.3	39
523	PIK3CA rs7640662 (C/G) single nucleotide polymorphism lacks association with breast cancer cases in Persians. <i>Interventional Medicine & Applied Science</i> , 2015, 7, 3-8.	0.2	1
524	Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients. , 2015, 3, 45.		9
525	Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. <i>Scientific Reports</i> , 2014, 4, 6566.	1.6	61

#	ARTICLE	IF	CITATIONS
526	A standardized and reproducible protocol for serum-free monolayer culturing of primary paediatric brain tumours to be utilized for therapeutic assays. <i>Scientific Reports</i> , 2015, 5, 12218.	1.6	17
527	Increased survival time of a patient with metastatic malignant melanoma following immunotherapy: A case report and literature review. <i>Oncology Letters</i> , 2015, 10, 883-886.	0.8	4
528	Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. <i>Scientific Reports</i> , 2015, 5, 12298.	1.6	63
529	A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients. <i>Scientific Reports</i> , 2015, 5, 16553.	1.6	99
530	TIGIT-positive circulating follicular helper T cells and sickle cell alloimmunization. <i>Haematologica</i> , 2015, 100, 1371-1373.	1.7	3
531	Deciphering Genomic Underpinnings of Quantitative MRI-based Radiomic Phenotypes of Invasive Breast Carcinoma. <i>Scientific Reports</i> , 2015, 5, 17787.	1.6	134
532	Identifying ultrasound and clinical features of breast cancer molecular subtypes by ensemble decision. <i>Scientific Reports</i> , 2015, 5, 11085.	1.6	61
533	Characterization of DNA variants in the human kinome in breast cancer. <i>Scientific Reports</i> , 2015, 5, 14736.	1.6	2
534	Cancer type-dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types. <i>Molecular Systems Biology</i> , 2015, 11, 824.	3.2	54
535	Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. <i>EMBO Journal</i> , 2015, 34, 2042-2058.	3.5	100
536	T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in lymphoid mice. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1401-12.	1.2	7
537	Combined Mapping of Multiple Clustering Algorithms (COMMUNAL): A Robust Method for Selection of Cluster Number, K. <i>Scientific Reports</i> , 2015, 5, 16971.	1.6	16
538	Systematically Prioritizing Functional Differentially Methylated Regions (fDMRs) by Integrating Multi-omics Data in Colorectal Cancer. <i>Scientific Reports</i> , 2015, 5, 12789.	1.6	6
539	MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer. <i>Scientific Reports</i> , 2015, 5, 11471.	1.6	19
540	FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. <i>Cell Death Discovery</i> , 2015, 1, 15049.	2.0	37
541	Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2015, 5, 15179.	1.6	706
542	Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma. <i>Oncology Letters</i> , 2015, 10, 1063-1068.	0.8	12
543	TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays. <i>Scientific Reports</i> , 2015, 5, 17879.	1.6	11

#	ARTICLE	IF	CITATIONS
544	Leveraging a Multi-Omics Strategy for Prioritizing Personalized Candidate Mutation-Driver Genes: A Proof-of-Concept Study. <i>Scientific Reports</i> , 2015, 5, 17564.	1.6	13
545	HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1061-1064.	2.3	70
546	The influence of cancer tissue sampling on the identification of cancer characteristics. <i>Scientific Reports</i> , 2015, 5, 15474.	1.6	33
547	The wound inflammatory response exacerbates growth of preneoplastic cells and progression to cancer. <i>EMBO Journal</i> , 2015, 34, 2219-2236.	3.5	210
548	Implementation of <i>In Vitro</i> Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms. <i>Journal of Visualized Experiments</i> , 2015, , e52879.	0.2	2
549	A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9s2, BCBCR.S29425.	0.6	4
550	Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. <i>Biomarkers in Cancer</i> , 2015, 7s2, BIC.S29325.	3.6	51
551	Targeting Breast Cancer Metastasis. <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9s1, BCBCR.S25460.	0.6	145
552	Advanced Applications of RNA Sequencing and Challenges. <i>Bioinformatics and Biology Insights</i> , 2015, 9s1, BBI.S28991.	1.0	178
553	Current and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Control</i> , 2015, 22, 109-120.	0.7	41
554	Reference-free inference of tumor phylogenies from single-cell sequencing data. <i>BMC Genomics</i> , 2015, 16, S7.	1.2	10
555	An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. <i>BMC Genomics</i> , 2015, 16, S2.	1.2	12
556	Enhancing cancer clonality analysis with integrative genomics. <i>BMC Bioinformatics</i> , 2015, 16, S7.	1.2	6
557	Novel melanoma therapy. <i>Experimental Hematology and Oncology</i> , 2015, 5, 23.	2.0	8
558	Somatic mutations in leukocytes infiltrating primary breast cancers. <i>Npj Breast Cancer</i> , 2015, 1, 15005.	2.3	30
559	Regulation rewiring analysis reveals mutual regulation between STAT1 and miR-155-5p in tumor immunosurveillance in seven major cancers. <i>Scientific Reports</i> , 2015, 5, 12063.	1.6	19
560	No association between HPV positive breast cancer and expression of human papilloma viral transcripts. <i>Scientific Reports</i> , 2015, 5, 18081.	1.6	21
561	SEOM guidelines for the management of Malignant Melanoma 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 1030-1035.	1.2	11

#	ARTICLE	IF	CITATIONS
562	Mammary Stem Cell Self-Renewal Is Regulated by Slit2/Robo1 Signaling through SNAI1 and mINSC. Cell Reports, 2015, 13, 290-301.	2.9	54
563	Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib. Oncology Reports, 2015, 33, 526-532.	1.2	16
564	Context-Specific Effects of TGF- β 2/SMAD3 in Cancer Are Modulated by the Epigenome. Cell Reports, 2015, 13, 2480-2490.	2.9	43
565	PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagnostic Pathology, 2015, 10, 189.	0.9	76
567	A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles. BMC Genomics, 2015, 16, S6.	1.2	12
568	Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer. BMC Genomics, 2015, 16, S5.	1.2	29
569	Computational methods and resources for the interpretation of genomic variants in cancer. BMC Genomics, 2015, 16, S7.	1.2	18
570	Leveraging global gene expression patterns to predict expression of unmeasured genes. BMC Genomics, 2015, 16, 1065.	1.2	3
571	Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. Journal of Translational Medicine, 2015, 13, 319.	1.8	27
572	Nivolumab plus ipilimumab in the treatment of advanced melanoma. Journal of Hematology and Oncology, 2015, 8, 123.	6.9	42
573	Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?. Journal of Hematology and Oncology, 2015, 8, 124.	6.9	25
574	PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2+ breast cancer cells by inducing Bim. Breast Cancer Research, 2015, 17, 86.	2.2	40
575	Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model. EJNMMI Research, 2015, 5, 47.	1.1	1
576	Cancer classification in the genomic era: five contemporary problems. Human Genomics, 2015, 9, 27.	1.4	48
577	NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. , 2015, 3, 18.		51
578	Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study. , 2015, 3, 27.		17
579	Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: whatâ€™s new and whatâ€™s enough. Chinese Journal of Cancer, 2015, 34, 310-9.	4.9	13
580	Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein. BMC Cancer, 2015, 15, 905.	1.1	33

#	ARTICLE	IF	CITATIONS
581	TGF β 2 isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications. <i>BMC Cancer</i> , 2015, 15, 1010.	1.1	25
582	Principles of immunology and its nuances in the central nervous system: Fig. 1.. <i>Neuro-Oncology</i> , 2015, 17, vii3-vii8.	0.6	28
583	Shared kernel Bayesian screening. <i>Biometrika</i> , 2015, 102, 829-842.	1.3	10
584	Ectopic expression of RNF168 and 53BP1 increases mutagenic but not physiological non-homologous end joining. <i>Nucleic Acids Research</i> , 2015, 43, 4950-4961.	6.5	26
586	Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases. <i>BMC Cancer</i> , 2015, 15, 699.	1.1	16
587	High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers. <i>BMC Cancer</i> , 2015, 15, 986.	1.1	19
588	Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy. <i>BMC Cancer</i> , 2015, 15, 1027.	1.1	49
589	Primary pulmonary melanoma: a report of two cases. <i>World Journal of Surgical Oncology</i> , 2015, 13, 274.	0.8	9
590	Chromatin interaction analysis reveals changes in small chromosome and telomere clustering between epithelial and breast cancer cells. <i>Genome Biology</i> , 2015, 16, 214.	3.8	206
591	Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer. <i>Biology Direct</i> , 2015, 10, 57.	1.9	64
592	The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain. <i>Clinical Epigenetics</i> , 2015, 7, 57.	1.8	75
593	Understanding drugs in breast cancer through drug sensitivity screening. <i>SpringerPlus</i> , 2015, 4, 611.	1.2	11
594	JITC launches a new section: commentary and editorials. , 2015, 3, 28.		0
595	Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. , 2015, 3, 47.		119
596	Comprehensive data resources and analytical tools for pathological association of aminoacyl tRNA synthetases with cancer. <i>Database: the Journal of Biological Databases and Curation</i> , 2015, 2015, bav022-bav022.	1.4	4
597	Present and future therapies of hepatitis B: From discovery to cure. <i>Hepatology</i> , 2015, 62, 1893-1908.	3.6	269
598	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. <i>Journal of Pathology</i> , 2015, 237, 166-178.	2.1	53
599	Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. <i>The Cochrane Library</i> , 2015, 2015, CD010341.	1.5	32

#	ARTICLE	IF	CITATIONS
600	Ipilimumab for the treatment of melanoma. <i>Melanoma Management</i> , 2015, 2, 33-39.	0.1	2
601	From personalized to patient-specific treatment of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 193-197.	0.1	0
602	Integrative network-based approach identifies key genetic elements in breast invasive carcinoma. <i>BMC Genomics</i> , 2015, 16, S2.	1.2	30
603	Detection of miRNA regulatory effect on triple negative breast cancer transcriptome. <i>BMC Genomics</i> , 2015, 16, S4.	1.2	12
604	Evolutionary history of phosphatidylinositol-3-kinases: ancestral origin in eukaryotes and complex duplication patterns. <i>BMC Evolutionary Biology</i> , 2015, 15, 226.	3.2	16
605	Gene expression and splicing alterations analyzed by high throughput RNA sequencing of chronic lymphocytic leukemia specimens. <i>BMC Cancer</i> , 2015, 15, 714.	1.1	17
606	Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. <i>BMC Cancer</i> , 2015, 15, 727.	1.1	51
607	Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. <i>BMC Cancer</i> , 2015, 15, 697.	1.1	3
608	Partial PTEN deletion is linked to poor prognosis in breast cancer. <i>BMC Cancer</i> , 2015, 15, 963.	1.1	30
609	Can Peto's paradox be used as the null hypothesis to identify the role of evolution in natural resistance to cancer? A critical review. <i>BMC Cancer</i> , 2015, 15, 792.	1.1	17
610	The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype. <i>BMC Cancer</i> , 2015, 15, 791.	1.1	29
611	The treatment patterns, efficacy, and safety of nab-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. <i>BMC Cancer</i> , 2015, 15, 1019.	1.1	22
612	Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma. <i>BMC Veterinary Research</i> , 2015, 11, 132.	0.7	9
613	Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential. <i>BMC Systems Biology</i> , 2015, 9, 62.	3.0	40
614	DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. <i>BMC Medical Genomics</i> , 2015, 8, 73.	0.7	29
615	Gene-expression signature functional annotation of breast cancer tumours in function of age. <i>BMC Medical Genomics</i> , 2015, 8, 80.	0.7	6
616	A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 102.	1.8	221
617	The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 168.	1.8	40

#	ARTICLE	IF	CITATIONS
618	What's new in melanoma? Combination!. Journal of Translational Medicine, 2015, 13, 213.	1.8	38
619	Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. Journal of Translational Medicine, 2015, 13, 247.	1.8	57
620	The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome. Journal of Translational Medicine, 2015, 13, 295.	1.8	25
621	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. Journal of Translational Medicine, 2015, 13, 351.	1.8	56
623	Assessing breast cancer cell lines as tumour models by comparison of mRNA expression profiles. Breast Cancer Research, 2015, 17, 114.	2.2	60
624	Multipotent luminal mammary cancer stem cells model tumor heterogeneity. Breast Cancer Research, 2015, 17, 137.	2.2	41
625	Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Research, 2015, 17, 124.	2.2	210
626	New metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research, 2015, 17, 150.	2.2	33
627	Fast and scalable inference of multi-sample cancer lineages. Genome Biology, 2015, 16, 91.	3.8	180
628	CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. Genome Biology, 2015, 16, 160.	3.8	182
629	Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia. Genome Medicine, 2015, 7, 28.	3.6	17
630	Integrating tumor microenvironment with cancer molecular classifications. Genome Medicine, 2015, 7, 115.	3.6	2
631	Tools for translational epigenetic studies involving formalin-fixed paraffin-embedded human tissue: applying the Infinium HumanMethylation450 Beadchip assay to large population-based studies. BMC Research Notes, 2015, 8, 543.	0.6	15
632	DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer. Clinical Epigenetics, 2015, 7, 75.	1.8	49
633	Transgelin gene is frequently downregulated by promoter DNA hypermethylation in breast cancer. Clinical Epigenetics, 2015, 7, 104.	1.8	34
634	The integrative epigenomic-transcriptomic landscape of ER positive breast cancer. Clinical Epigenetics, 2015, 7, 126.	1.8	24
635	Repeated episodes of spontaneous regression/progression of cervical adenocarcinoma after adjuvant chemoradiation therapy: a case report. Journal of Medical Case Reports, 2015, 9, 114.	0.4	0
636	Spontaneous regression of non-small cell lung cancer after biopsy of a mediastinal lymph node metastasis: a case report. Journal of Medical Case Reports, 2015, 9, 217.	0.4	23

#	ARTICLE	IF	CITATIONS
637	Two state model for a constant disease hazard in paratuberculosis (and other bovine diseases). <i>Veterinary Research</i> , 2015, 46, 67.	1.1	3
638	A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma. <i>SpringerPlus</i> , 2015, 4, 186.	1.2	8
639	GATA family transcriptional factors: emerging suspects in hematologic disorders. <i>Experimental Hematology and Oncology</i> , 2015, 4, 28.	2.0	57
640	Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. <i>Experimental Hematology and Oncology</i> , 2015, 4, 34.	2.0	21
641	Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer. <i>Human Genomics</i> , 2015, 9, 34.	1.4	32
642	Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. , 2015, 3, 26.		206
643	Update on checkpoint blockade therapy for lymphoma. , 2015, 3, 33.		11
644	Baseline circulating IL-17 predicts toxicity while TGF- β 1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. , 2015, 3, 39.		302
645	Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+ $\hat{\text{a}}$ %HLA-DR $\hat{\text{o}}$ /neg) found in aggressive pediatric sarcoma patients. , 2015, 3, 35.		45
646	A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial. , 2015, 3, 48.		26
647	Immunotherapy in endometrial cancer - an evolving therapeutic paradigm. <i>Gynecologic Oncology Research and Practice</i> , 2015, 2, 11.	3.6	46
648	Inhibitory receptors as targets for cancer immunotherapy. <i>European Journal of Immunology</i> , 2015, 45, 1892-1905.	1.6	116
649	Breast cancer subtype intertumor heterogeneity: MRI $\hat{\text{a}}$ -based features predict results of a genomic assay. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1398-1406.	1.9	119
650	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. <i>Histopathology</i> , 2015, 67, 529-537.	1.6	37
651	Converting biology into clinical benefit: lessons learned from BRAF inhibitors. <i>Melanoma Management</i> , 2015, 2, 241-254.	0.1	10
652	Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial. <i>Melanoma Management</i> , 2015, 2, 209-215.	0.1	7
653	Immune Checkpoint Inhibitor Therapy Associated Hypophysitis. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2015, 8, CMED.S22469.	1.0	38
654	Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC following Chemotherapy. <i>Clinical Medicine Insights: Oncology</i> , 2015, 9, CMO.S23252.	0.6	27

#	ARTICLE	IF	CITATIONS
655	Cancer therapeutic potential of combinatorial immuno- and vasomodulatory interventions. <i>Journal of the Royal Society Interface</i> , 2015, 12, 20150439.	1.5	16
656	Pembrolizumab in the management of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 315-325.	0.1	4
657	Impact of allele-specific peptides in proteome quantification. <i>Proteomics - Clinical Applications</i> , 2015, 9, 432-436.	0.8	4
658	Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. <i>Small</i> , 2015, 11, 5483-5496.	5.2	103
659	Runx1 is associated with breast cancer progression in MMTV- <i>PyMT</i> transgenic mice and its depletion in vitro inhibits migration and invasion. <i>Journal of Cellular Physiology</i> , 2015, 230, 2522-2532.	2.0	63
660	Beyond peptides and mAbs—current status and future perspectives for biotherapeutics with novel constructs. <i>Journal of Clinical Pharmacology</i> , 2015, 55, S4-20.	1.0	55
661	RAC1 P29S regulates PD-L1 expression in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 590-598.	1.5	69
662	Human IgG4: a structural perspective. <i>Immunological Reviews</i> , 2015, 268, 139-159.	2.8	119
663	Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer. <i>Medicine (United States)</i> , 2015, 94, e1911.	0.4	22
664	Associations Between Elastography Findings and Clinicopathological Factors in Breast Cancer. <i>Medicine (United States)</i> , 2015, 94, e2290.	0.4	18
665	Liver resection and ablation for metastatic melanoma: A single center experience. <i>Journal of Surgical Oncology</i> , 2015, 111, 962-968.	0.8	19
666	MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer. <i>Drug Development Research</i> , 2015, 76, 328-342.	1.4	9
667	Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy. <i>Assay and Drug Development Technologies</i> , 2015, 13, 623-627.	0.6	3
668	CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials. <i>Clinical Cancer Research</i> , 2015, 21, 4027-4029.	3.2	4
669	The end of the beginning: PD-1 inhibition as the new standard of care first-line immunotherapy in metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 305-309.	0.1	1
670	Pathology to Enhance Precision Medicine in Oncology. <i>Advances in Anatomic Pathology</i> , 2015, 22, 267-272.	2.4	30
671	The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation. <i>Journal of Cellular Physiology</i> , 2015, 230, 2683-2694.	2.0	58
672	Immunotherapies for bladder cancer. <i>Current Opinion in Urology</i> , 2015, 25, 586-596.	0.9	17

#	ARTICLE	IF	CITATIONS
673	Myeloid Cells as Targets for Therapy in Solid Tumors. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 343-350.	1.0	32
674	The Evolution of Therapies in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2015, 7, 1815-1846.	1.7	107
675	Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. <i>Oncotarget</i> , 2015, 6, 28716-28730.	0.8	14
676	Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. <i>Oncotarget</i> , 2015, 6, 34221-34227.	0.8	198
677	Increased Treatment-Related Toxicity Subsequent to an Anti-PD-1 Agent. <i>Current Oncology</i> , 2015, 22, 320-322.	0.9	6
678	Prognostic and predictive value of PDL1 expression in breast cancer. <i>Oncotarget</i> , 2015, 6, 5449-5464.	0.8	424
679	Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. <i>Oncotarget</i> , 2015, 6, 8261-8270.	0.8	54
680	Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. <i>Journal of Clinical Investigation</i> , 2015, 125, 3384-3391.	3.9	1,112
681	Targeting PD-1/PD-L1 in lung cancer: current perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2015, 6, 55.	1.3	10
682	Lymphoma: Immune Evasion Strategies. <i>Cancers</i> , 2015, 7, 736-762.	1.7	35
683	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. <i>Oncotarget</i> , 2015, 6, 42008-42018.	0.8	278
684	New and emerging factors in tumorigenesis: an overview. <i>Cancer Management and Research</i> , 2015, 7, 225.	0.9	27
685	Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?. <i>Cancer Management and Research</i> , 2015, 7, 93.	0.9	10
686	Reverse phase protein arrays in signaling pathways: a data integration perspective. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3519.	2.0	40
687	PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4631.	2.0	6
688	PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells. <i>Journal of Cancer</i> , 2015, 6, 1320-1330.	1.2	6
689	Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2015, 6, 1306-1319.	1.2	18
690	Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma. <i>Journal of Clinical & Cellular Immunology</i> , 2015, 06, .	1.5	19

#	ARTICLE	IF	CITATIONS
691	Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas. <i>Oncotarget</i> , 2015, 6, 43653-43666.	0.8	14
692	Adoptive T Cell Immunotherapy For Cancer. <i>Rambam Maimonides Medical Journal</i> , 2015, 6, e0004.	0.4	187
693	Tumor neoantigens: building a framework for personalized cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2015, 125, 3413-3421.	3.9	502
694	Comparative genomic analysis reveals bilateral breast cancers are genetically independent. <i>Oncotarget</i> , 2015, 6, 31820-31829.	0.8	20
695	Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2015, 7, 321.	1.0	14
696	Cancer stem cell plasticity and tumor hierarchy. <i>World Journal of Stem Cells</i> , 2015, 7, 27.	1.3	202
697	Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells. <i>Immune Network</i> , 2015, 15, 58.	1.6	11
698	Cancer immunotherapy: harnessing the immune system to battle cancer. <i>Journal of Clinical Investigation</i> , 2015, 125, 3335-3337.	3.9	1,016
699	Targeting SOD1 induces synthetic lethal killing in BLM- and CHEK2-deficient colorectal cancer cells. <i>Oncotarget</i> , 2015, 6, 27907-27922.	0.8	34
700	Nivolumab in the treatment of malignant melanoma: review of the literature. <i>OncoTargets and Therapy</i> , 2015, 8, 2045.	1.0	21
701	The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastro­intestinal tract cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2015, 8, 2617.	1.0	28
702	Nonsurgical Management of Cervical Cancer: Locally Advanced, Recurrent, and Metastatic Disease, Survivorship, and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e299-e309.	1.8	21
703	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. <i>OncoTargets and Therapy</i> , 2015, 8, 1149.	1.0	5
704	Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. <i>Pharmacogenomics and Personalized Medicine</i> , 2015, 8, 63.	0.4	24
705	The role of regulatory T cells in cancer immunology. <i>ImmunoTargets and Therapy</i> , 2015, 4, 159.	2.7	96
706	PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRP1 α axis in HPV negative head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 42067-42080.	0.8	95
707	Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5215.	2.0	19
708	Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. <i>OncoTargets and Therapy</i> , 2015, 8, 3323.	1.0	42

#	ARTICLE	IF	CITATIONS
709	Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy. <i>Oncolytic Virotherapy</i> , 2015, 4, 75.	6.0	15
710	Immunotherapy and Radiation – A New Combined Treatment Approach for Bladder Cancer?. <i>Bladder Cancer</i> , 2015, 1, 15-27.	0.2	19
711	Review Computational characterisation of cancer molecular profiles derived using next generation sequencing. <i>Wspolczesna Onkologia</i> , 2015, 1A, 78-91.	0.7	4
712	New developments in the management of advanced melanoma – role of pembrolizumab. <i>OncoTargets and Therapy</i> , 2015, 8, 2535.	1.0	16
713	Whole-Exome Sequencing Identifies Novel Somatic Mutations in Chinese Breast Cancer Patients. <i>Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research</i> , 2015, 09, .	0.1	22
714	Therapeutic cancer vaccines. <i>Journal of Clinical Investigation</i> , 2015, 125, 3401-3412.	3.9	640
715	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. <i>Cancers</i> , 2015, 7, 2397-2414.	1.7	61
716	Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. <i>Oncotarget</i> , 2015, 6, 37117-37134.	0.8	80
717	Identification of Copy Number Aberrations in Breast Cancer Subtypes Using Persistence Topology. <i>Microarrays (Basel, Switzerland)</i> , 2015, 4, 339-369.	1.4	18
718	New and Promising Strategies in the Management of Bladder Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 105-112.	1.8	20
719	Drug Development for Metastasis Prevention. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 449-473.	0.2	48
720	Anti-HBV Drugs: Progress, Unmet Needs, and New Hope. <i>Viruses</i> , 2015, 7, 4960-4977.	1.5	38
721	Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles. <i>Viruses</i> , 2015, 7, 5780-5791.	1.5	24
722	Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. <i>Viruses</i> , 2015, 7, 6009-6042.	1.5	67
723	Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?. <i>Viruses</i> , 2015, 7, 6291-6312.	1.5	48
724	Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy. <i>Vaccines</i> , 2015, 3, 420-428.	2.1	14
725	Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages. <i>Vaccines</i> , 2015, 3, 448-466.	2.1	19
726	The Promise of Preventive Cancer Vaccines. <i>Vaccines</i> , 2015, 3, 467-489.	2.1	38

#	ARTICLE	IF	CITATIONS
727	Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. <i>Vaccines</i> , 2015, 3, 490-502.	2.1	43
728	Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State. <i>Vaccines</i> , 2015, 3, 597-619.	2.1	46
729	Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms's Tumor 1 in Patients with Advanced Colorectal Cancer. <i>Vaccines</i> , 2015, 3, 1004-1018.	2.1	34
730	Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure. <i>Veterinary Sciences</i> , 2015, 2, 363-387.	0.6	24
731	Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. <i>Vaccines</i> , 2015, 3, 662-685.	2.1	225
732	PI3K and AKT: Unfaithful Partners in Cancer. <i>International Journal of Molecular Sciences</i> , 2015, 16, 21138-21152.	1.8	208
733	Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine's Tool Box. <i>Molecules</i> , 2015, 20, 16852-16891.	1.7	471
734	Age and the means of bypassing stasis influence the intrinsic subtype of immortalized human mammary epithelial cells. <i>Frontiers in Cell and Developmental Biology</i> , 2015, 3, 13.	1.8	25
735	A top-down view of the tumor microenvironment: structure, cells and signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2015, 3, 33.	1.8	70
736	Effects of Age on the Detection and Management of Breast Cancer. <i>Cancers</i> , 2015, 7, 908-929.	1.7	263
737	Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. <i>International Journal of Molecular Sciences</i> , 2015, 16, 19447-19457.	1.8	3
738	Application of Metabolomics in Drug Resistant Breast Cancer Research. <i>Metabolites</i> , 2015, 5, 100-118.	1.3	50
739	Analysis of Reverse Phase Protein Array Data: From Experimental Design towards Targeted Biomarker Discovery. <i>Microarrays (Basel, Switzerland)</i> , 2015, 4, 520-539.	1.4	14
740	Chemoprevention of Breast Cancer by Dietary Polyphenols. <i>Molecules</i> , 2015, 20, 22578-22620.	1.7	91
741	Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing. <i>Sensors</i> , 2015, 15, 16281-16313.	2.1	140
742	Mutant p53's Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival. <i>Frontiers in Endocrinology</i> , 2015, 6, 53.	1.5	28
743	Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. <i>Frontiers in Endocrinology</i> , 2015, 6, 59.	1.5	152
744	Estrogen-Related Receptors in Breast Cancer and Prostate Cancer. <i>Frontiers in Endocrinology</i> , 2015, 6, 83.	1.5	56

#	ARTICLE	IF	CITATIONS
745	Establishing the pig as a large animal model for vaccine development against human cancer. <i>Frontiers in Genetics</i> , 2015, 6, 286.	1.1	24
746	A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity. <i>Frontiers in Genetics</i> , 2015, 6, 341.	1.1	9
747	Editorial: T Cell Regulation by the Environment. <i>Frontiers in Immunology</i> , 2015, 6, 229.	2.2	1
748	Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?. <i>Frontiers in Immunology</i> , 2015, 6, 258.	2.2	16
749	Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 271.	2.2	36
750	Inhibitory Receptors Beyond T Cell Exhaustion. <i>Frontiers in Immunology</i> , 2015, 6, 310.	2.2	188
751	Targeting C-Type Lectin Receptors for Cancer Immunity. <i>Frontiers in Immunology</i> , 2015, 6, 408.	2.2	80
752	Novel Immune Check-Point Regulators in Tolerance Maintenance. <i>Frontiers in Immunology</i> , 2015, 6, 421.	2.2	37
753	Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics. <i>Frontiers in Immunology</i> , 2015, 6, 424.	2.2	12
754	Real-Time Imaging of Resident T Cells in Human Lung and Ovarian Carcinomas Reveals How Different Tumor Microenvironments Control T Lymphocyte Migration. <i>Frontiers in Immunology</i> , 2015, 6, 500.	2.2	118
755	Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications. <i>Frontiers in Immunology</i> , 2015, 6, 505.	2.2	86
756	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 516.	2.2	79
757	Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. <i>Frontiers in Immunology</i> , 2015, 6, 582.	2.2	73
758	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	2.2	317
759	The Role of Chemokines in Shaping the Balance Between CD4+ T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer Diseases. <i>Frontiers in Immunology</i> , 2015, 6, 609.	2.2	46
760	Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells. <i>Frontiers in Immunology</i> , 2015, 6, 633.	2.2	12
761	4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. <i>Frontiers in Oncology</i> , 2015, 5, 117.	1.3	211
762	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. <i>Frontiers in Oncology</i> , 2015, 5, 152.	1.3	26

#	ARTICLE	IF	CITATIONS
763	Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. <i>Frontiers in Oncology</i> , 2015, 5, 153.	1.3	129
764	Immunotherapy of Childhood Sarcomas. <i>Frontiers in Oncology</i> , 2015, 5, 181.	1.3	54
765	Putative Breast Cancer Driver Mutations in TBX3 Cause Impaired Transcriptional Repression. <i>Frontiers in Oncology</i> , 2015, 5, 244.	1.3	18
766	Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 249.	1.3	80
767	ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW. <i>Fukushima Journal of Medical Sciences</i> , 2015, 61, 13-22.	0.1	20
768	Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15048.	1.8	7
769	Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. <i>Oncotarget</i> , 2015, 6, 32317-32338.	0.8	35
770	Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy. <i>Viruses</i> , 2015, 7, 6506-6525.	1.5	30
771	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. <i>Oncotarget</i> , 2015, 6, 14209-14219.	0.8	209
772	Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. <i>OncoTargets and Therapy</i> , 2015, 8, 929.	1.0	27
773	Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ib1–IIa cervical cancer patients who undergo radical surgery. <i>OncoTargets and Therapy</i> , 2015, 8, 1355.	1.0	33
774	Update on use of aldesleukin for treatment of high-risk metastatic melanoma. <i>ImmunoTargets and Therapy</i> , 2015, 4, 79.	2.7	21
775	Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. <i>Viruses</i> , 2015, 7, 5889-5901.	1.5	19
776	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. <i>Oncotarget</i> , 2015, 6, 4704-4716.	0.8	127
777	Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. <i>Oncotarget</i> , 2015, 6, 4569-4584.	0.8	401
778	Profile of neratinib and its potential in the treatment of breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2015, 7, 147.	1.0	44
779	TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. <i>Journal of Clinical Investigation</i> , 2015, 125, 2046-2058.	3.9	603
780	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2015, 6, 7-17.	0.1	82

#	ARTICLE	IF	CITATIONS
781	Ganetespi: research and clinical development. <i>OncoTargets and Therapy</i> , 2015, 8, 1849.	1.0	62
782	Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity. <i>Vaccines</i> , 2015, 3, 771-802.	2.1	11
783	Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma. <i>OncoTargets and Therapy</i> , 2015, 8, 1451.	1.0	37
784	Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma. <i>PLoS ONE</i> , 2015, 10, e0118564.	1.1	197
785	Phase II Study of <i>Pseudomonas aeruginosa</i> -Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2â€“Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane. <i>PLoS ONE</i> , 2015, 10, e0118607.	1.1	11
786	Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment. <i>PLoS ONE</i> , 2015, 10, e0119483.	1.1	35
787	Anaplastic Lymphoma Kinase Gene Copy Number Gain in Inflammatory Breast Cancer (IBC): Prevalence, Clinicopathologic Features and Prognostic Implication. <i>PLoS ONE</i> , 2015, 10, e0120320.	1.1	12
788	Correlation between Activation of PI3K/AKT/mTOR Pathway and Prognosis of Breast Cancer in Chinese Women. <i>PLoS ONE</i> , 2015, 10, e0120511.	1.1	37
789	The Invadopodia Scaffold Protein Tks5 Is Required for the Growth of Human Breast Cancer Cells In Vitro and In Vivo. <i>PLoS ONE</i> , 2015, 10, e0121003.	1.1	54
790	AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection. <i>PLoS ONE</i> , 2015, 10, e0122106.	1.1	43
791	Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF- κ B. <i>PLoS ONE</i> , 2015, 10, e0123410.	1.1	181
792	Bone Marrow Stromal Antigen 2 (BST-2) DNA Is Demethylated in Breast Tumors and Breast Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0123931.	1.1	20
793	Development and Validation of a Novel Platform-Independent Metastasis Signature in Human Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0126631.	1.1	12
794	Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues. <i>PLoS ONE</i> , 2015, 10, e0126762.	1.1	18
795	Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0127028.	1.1	116
796	Network-Based Integration of Disparate Omic Data To Identify "Silent Players" in Cancer. <i>PLoS Computational Biology</i> , 2015, 11, e1004595.	1.5	60
797	Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. <i>Wspolczesna Onkologia</i> , 2015, 1A, 68-77.	0.7	2,410
798	Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers. <i>PLoS ONE</i> , 2015, 10, e0137885.	1.1	20

#	ARTICLE	IF	CITATIONS
799	Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers. PLoS ONE, 2015, 10, e0142433.	1.1	14
800	High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS ONE, 2015, 10, e0142656.	1.1	176
801	A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces. PLoS Computational Biology, 2015, 11, e1004518.	1.5	122
802	Identification of High-Impact cis-Regulatory Mutations Using Transcription Factor Specific Random Forest Models. PLoS Computational Biology, 2015, 11, e1004590.	1.5	21
803	Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling. PLoS ONE, 2015, 10, e0127678.	1.1	34
804	Methylcholanthrene-Induced Sarcomas Develop Independently from NOX2-Derived ROS. PLoS ONE, 2015, 10, e0129786.	1.1	11
805	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS ONE, 2015, 10, e0130142.	1.1	390
806	Lymphangioliomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness. PLoS ONE, 2015, 10, e0132546.	1.1	15
807	Pathway Relevance Ranking for Tumor Samples through Network-Based Data Integration. PLoS ONE, 2015, 10, e0133503.	1.1	24
808	Single-Cell Genetic Analysis Using Automated Microfluidics to Resolve Somatic Mosaicism. PLoS ONE, 2015, 10, e0135007.	1.1	41
809	B7H1 Expression and Epithelial-To-Mesenchymal Transition Phenotypes on Colorectal Cancer Stem-Like Cells. PLoS ONE, 2015, 10, e0135528.	1.1	57
810	PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS ONE, 2015, 10, e0136023.	1.1	202
811	The Prognostic Value of Forkhead Box P3 Expression in Operable Breast Cancer: A Large-Scale Meta-Analysis. PLoS ONE, 2015, 10, e0136374.	1.1	15
812	PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. PLoS ONE, 2015, 10, e0136476.	1.1	59
813	Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer. PLoS ONE, 2015, 10, e0136688.	1.1	56
814	Cancer-Testis Antigen Expression in Serous Endometrial Cancer with Loss of X Chromosome Inactivation. PLoS ONE, 2015, 10, e0137476.	1.1	12
815	Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma. PLoS ONE, 2015, 10, e0139073.	1.1	101
816	Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. PLoS ONE, 2015, 10, e0140293.	1.1	29

#	ARTICLE	IF	CITATIONS
817	Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer. PLoS ONE, 2015, 10, e0141763.	1.1	77
818	Profiling of Discrete Gynecological Cancers Reveals Novel Transcriptional Modules and Common Features Shared by Other Cancer Types and Embryonic Stem Cells. PLoS ONE, 2015, 10, e0142229.	1.1	52
819	Intra-Genome DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers. PLoS ONE, 2015, 10, e0143178.	1.1	14
820	Altered T Lymphocyte Proliferation upon Lipopolysaccharide Challenge Ex Vivo. PLoS ONE, 2015, 10, e0144375.	1.1	25
821	Mutation Screening of 1,237 Cancer Genes across Six Model Cell Lines of Basal-Like Breast Cancer. PLoS ONE, 2015, 10, e0144528.	1.1	6
822	Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression. PLoS ONE, 2015, 10, e0144767.	1.1	16
823	TIGIT predominantly regulates the immune response via regulatory T cells. Journal of Clinical Investigation, 2015, 125, 4053-4062.	3.9	470
824	A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. Oncotarget, 2015, 6, 44781-44793.	0.8	94
825	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. OncoTargets and Therapy, 2015, 8, 2949.	1.0	7
826	Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets. Current Genomics, 2015, 17, 33-61.	0.7	3
827	Bladder cancer in the elderly patient: challenges and solutions. Clinical Interventions in Aging, 2015, 10, 939.	1.3	44
828	Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Design, Development and Therapy, 2015, 9, 901.	2.0	150
829	Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy. Oncolytic Virotherapy, 2015, 4, 157.	6.0	14
830	Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. Journal of Immunology Research, 2015, 2015, 1-16.	0.9	54
831	Molecular Imaging-Guided Interventional Hyperthermia in Treatment of Breast Cancer. BioMed Research International, 2015, 2015, 1-11.	0.9	5
832	PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.2	74
833	Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. BioMed Research International, 2015, 2015, 1-16.	0.9	111
834	Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma. Sarcoma, 2015, 2015, 1-9.	0.7	48

#	ARTICLE	IF	CITATIONS
835	The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. BioMed Research International, 2015, 2015, 1-12.	0.9	25
836	Deciphering the Correlation between Breast Tumor Samples and Cell Lines by Integrating Copy Number Changes and Gene Expression Profiles. BioMed Research International, 2015, 2015, 1-11.	0.9	11
837	Immunotherapy for Bone and Soft Tissue Sarcomas. BioMed Research International, 2015, 2015, 1-11.	0.9	16
838	Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. Journal of Immunology Research, 2015, 2015, 1-7.	0.9	49
839	Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. Journal of Immunology Research, 2015, 2015, 1-14.	0.9	30
840	Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma. BioMed Research International, 2015, 2015, 1-5.	0.9	6
841	Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. Journal of Immunology Research, 2015, 2015, 1-11.	0.9	12
842	Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive Microenvironment. BioMed Research International, 2015, 2015, 1-12.	0.9	59
843	Anticytotoxic T-Lymphocyte Antigen-4 Induced Autoimmune Hypophysitis: A Case Report and Literature Review. Case Reports in Endocrinology, 2015, 2015, 1-6.	0.2	7
844	Clinical Development of Immune Checkpoint Inhibitors. BioMed Research International, 2015, 2015, 1-12.	0.9	51
845	Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?. BioMed Research International, 2015, 2015, 1-9.	0.9	19
846	Spaced Seed Data Structures for De Novo Assembly. International Journal of Genomics, 2015, 2015, 1-8.	0.8	6
847	Sepsis: From Pathophysiology to Individualized Patient Care. Journal of Immunology Research, 2015, 2015, 1-13.	0.9	64
848	Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. BioMed Research International, 2015, 2015, 1-8.	0.9	43
849	Immunotherapy in Tumors. Deutsches Ärztblatt International, 2015, 112, 809-15.	0.6	31
850	Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. BioMed Research International, 2015, 2015, 1-17.	0.9	47
851	Adverse Events of Monoclonal Antibodies Used for Cancer Therapy. BioMed Research International, 2015, 2015, 1-13.	0.9	59
852	Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. Journal of Immunology Research, 2015, 2015, 1-6.	0.9	27

#	ARTICLE	IF	CITATIONS
853	IL-21: A Pleiotropic Cytokine with Potential Applications in Oncology. <i>Journal of Immunology Research</i> , 2015, 2015, 1-15.	0.9	78
854	Immunomodulatory Effects of the <i>Agaricus blazei</i> Murrill-Based Mushroom Extract AndoSan in Patients with Multiple Myeloma Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation: A Randomized, Double Blinded Clinical Study. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	44
855	Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes. <i>Scientifica</i> , 2015, 2015, 1-8.	0.6	4
856	RNA-Based Vaccines in Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	0.9	169
857	Whole Exome- and mRNA-Sequencing of an AT/RT Case Reveals Few Somatic Mutations and Several Deregulated Signalling Pathways in the Context of SMARCB1 Deficiency. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	6
858	Human Tumor Antigens and Cancer Immunotherapy. <i>BioMed Research International</i> , 2015, 2015, 1-17.	0.9	173
859	From mice to humans: developments in cancer immunoeediting. <i>Journal of Clinical Investigation</i> , 2015, 125, 3338-3346.	3.9	271
860	Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study. <i>Oncotarget</i> , 2015, 6, 22985-22995.	0.8	16
861	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. , 2015, 34, 313-321.		31
862	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. <i>Oncotarget</i> , 2015, 6, 12890-12908.	0.8	92
863	Making Sense of Current and Emerging Therapies in Pancreatic Cancer: Balancing Benefit and Value. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e222-e227.	1.8	1
864	Biomarkers of cancer angioprevention for clinical studies. <i>Ecancermedicalscience</i> , 2015, 9, 600.	0.6	6
865	Personalized targeted therapy for esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 7648.	1.4	43
866	<i>PDL1</i> expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. <i>Oncotarget</i> , 2015, 6, 13506-13519.	0.8	105
867	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. <i>Journal of Clinical Investigation</i> , 2015, 125, 3981-3991.	3.9	328
868	Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. <i>Oncotarget</i> , 2015, 6, 33961-33971.	0.8	113
869	Oncogenic cancer/testis antigens: prime candidates for immunotherapy. <i>Oncotarget</i> , 2015, 6, 15772-15787.	0.8	265
870	Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. <i>World Journal of Hepatology</i> , 2015, 7, 2449.	0.8	32

#	ARTICLE	IF	CITATIONS
871	High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. <i>Oncotarget</i> , 2015, 6, 33972-33981.	0.8	159
872	Going viral: a review of replication-selective oncolytic adenoviruses. <i>Oncotarget</i> , 2015, 6, 19976-19989.	0.8	110
873	Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis. <i>Oncotarget</i> , 2015, 6, 22890-22904.	0.8	37
874	Cyr61 as mediator of Src signaling in triple negative breast cancer cells. <i>Oncotarget</i> , 2015, 6, 13520-13538.	0.8	24
875	Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. <i>Oncotarget</i> , 2015, 6, 36041-36052.	0.8	103
876	LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. <i>Oncotarget</i> , 2015, 6, 27359-27377.	0.8	242
877	Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. <i>Oncotarget</i> , 2015, 6, 2496-2508.	0.8	16
878	Managing breast cancer in younger women: challenges and solutions. <i>Breast Cancer: Targets and Therapy</i> , 2016, 8, 1.	1.0	20
879	WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results. <i>Ecanermedicalscience</i> , 2015, 9, 604.	0.6	11
880	Association between Chemotherapy-Response Assays and Subsets of Tumor-Infiltrating Lymphocytes in Gastric Cancer: A Pilot Study. <i>Journal of Gastric Cancer</i> , 2015, 15, 223.	0.9	11
881	Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy. <i>Oncotarget</i> , 2015, 6, 7040-7052.	0.8	14
882	Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. <i>Cancers</i> , 2015, 7, 1959-1982.	1.7	32
883	Triple negative breast cancer: looking for the missing link between biology and treatments. <i>Oncotarget</i> , 2015, 6, 26560-26574.	0.8	133
884	Novel immunological strategies for HIV-1 eradication. <i>Journal of Virus Eradication</i> , 2015, 1, 232-236.	0.3	6
885	Identifying core gene modules in glioblastoma based on multilayer factor-mediated dysfunctional regulatory networks through integrating multi-dimensional genomic data. <i>Nucleic Acids Research</i> , 2015, 43, 1997-2007.	6.5	31
886	Genomic profiling of breast cancers. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 34-39.	0.9	19
887	T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?. <i>Photochemical and Photobiological Sciences</i> , 2015, 14, 1492-1509.	1.6	76
888	Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine. <i>RSC Advances</i> , 2015, 5, 25105-25114.	1.7	34

#	ARTICLE	IF	CITATIONS
889	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 372, 2509-2520.	13.9	7,696
890	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 123-135.	13.9	7,261
891	A RING to rule them all? Insights into the Map3k1 PHD motif provide a new mechanistic understanding into the diverse roles of Map3k1. <i>Cell Death and Differentiation</i> , 2015, 22, 540-548.	5.0	28
892	Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy's smart bombs. <i>Cancer Gene Therapy</i> , 2015, 22, 63-63.	2.2	5
893	Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. <i>Nature Communications</i> , 2015, 6, 6683.	5.8	365
894	Inhibition of BMP signaling suppresses metastasis in mammary cancer. <i>Oncogene</i> , 2015, 34, 2437-2449.	2.6	86
895	Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. <i>Journal of Experimental Medicine</i> , 2015, 212, 1125-1137.	4.2	368
896	Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. <i>Science Translational Medicine</i> , 2015, 7, 275ra22.	5.8	369
897	Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3113-3120.	3.2	109
898	Myeloid-Derived Suppressor Cells Impair Alveolar Macrophages through PD-1 Receptor Ligation during <i>Pneumocystis Pneumonia</i> . <i>Infection and Immunity</i> , 2015, 83, 572-582.	1.0	37
899	Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors. <i>Journal of Translational Medicine</i> , 2015, 13, 161.	1.8	24
900	Triple-negative breast cancer: new perspectives for targeted therapies. <i>OncoTargets and Therapy</i> , 2015, 8, 177.	1.0	109
901	Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. <i>EMBO Molecular Medicine</i> , 2015, 7, 1034-1047.	3.3	380
902	Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 487-498.	21.5	203
903	Recent advances in the field of anti-cancer immunotherapy. <i>BBA Clinical</i> , 2015, 3, 280-288.	4.1	72
904	Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 15-29.	2.5	13
905	Advances and Applications of Single-Cell Sequencing Technologies. <i>Molecular Cell</i> , 2015, 58, 598-609.	4.5	485
906	TFmiR: a web server for constructing and analyzing disease-specific transcription factor and miRNA co-regulatory networks. <i>Nucleic Acids Research</i> , 2015, 43, W283-W288.	6.5	48

#	ARTICLE	IF	CITATIONS
907	Rethinking Clinical Response and Outcome Assessment in a Biologic Age. <i>Current Oncology Reports</i> , 2015, 17, 27.	1.8	3
908	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. , 2015, 3, 3.		76
909	Frequency and distribution of Notch mutations in tumor cell lines. <i>BMC Cancer</i> , 2015, 15, 311.	1.1	15
910	Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment. <i>Advances in Cancer Research</i> , 2015, 128, 197-233.	1.9	45
911	Single-cell transcriptogenomics reveals transcriptional exclusion of ENU-mutated alleles. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2015, 772, 55-62.	0.4	27
912	Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax[®] platform in the treatment of glioblastoma multiforme. <i>CNS Oncology</i> , 2015, 4, 63-69.	1.2	40
913	Monoclonal antibodies specific to human Î²42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. <i>MAbs</i> , 2015, 7, 620-629.	2.6	6
914	High-resolution genomic analysis: the tumor-immune interface comes into focus. <i>Genome Biology</i> , 2015, 16, 65.	3.8	4
915	SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	30
916	Emerging Treatment Paradigms in Radiation Oncology. <i>Clinical Cancer Research</i> , 2015, 21, 3393-3401.	3.2	33
917	Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer. <i>Immunologic Research</i> , 2015, 62, 316-324.	1.3	20
918	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 541-552.	12.5	121
919	IRF5: a rheostat for tumorâ€infiltrating lymphocyte trafficking in breast cancer?. <i>Immunology and Cell Biology</i> , 2015, 93, 425-426.	1.0	9
920	Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: â€What does not kill me strengthens meâ€™. <i>British Journal of Cancer</i> , 2015, 112, 1725-1732.	2.9	252
921	Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. <i>British Journal of Cancer</i> , 2015, 112, 1904-1910.	2.9	191
922	Severe Acute Orthopnea: Ipilimumab-Induced Bilateral Phrenic Nerve Neuropathy. <i>Lung</i> , 2015, 193, 611-613.	1.4	16
923	Stereotactic Radiosurgery for Melanoma Brainâ€Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 368-375.	0.4	334
924	Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. <i>British Journal of Cancer</i> , 2015, 112, 1895-1903.	2.9	52

#	ARTICLE	IF	CITATIONS
925	The Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer. <i>Molecular Cell</i> , 2015, 58, 690-698.	4.5	117
926	Building better monoclonal antibody-based therapeutics. <i>Nature Reviews Cancer</i> , 2015, 15, 361-370.	12.8	558
927	From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 153, 45-53.	1.2	47
928	Combinatorial Strategies for the Induction of Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 187.	2.2	289
929	Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e237.	2.3	106
930	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 408-424.	12.5	456
931	Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate $\hat{1}^3\hat{1}$ -Low T Cells. <i>Journal of Immunology</i> , 2015, 195, 421-425.	0.4	62
932	Cell Surface CD74 \hat{a} €MIF Interactions Drive Melanoma Survival in Response to Interferon- $\hat{1}^3$. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2775-2784.	0.3	64
933	Programmed death-1 checkpoint blockade in acute myeloid leukemia. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1191-1203.	1.4	75
934	TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3771-3782.	3.2	152
935	A Gender Factor in Shaping T-Cell Immunity to Melanoma. <i>Frontiers in Oncology</i> , 2015, 5, 8.	1.3	13
936	PD-1/PD-L1 inhibitors. <i>Current Opinion in Pharmacology</i> , 2015, 23, 32-38.	1.7	483
937	Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer. <i>Journal of Biomedical Informatics</i> , 2015, 56, 220-228.	2.5	32
938	Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes. <i>Frontiers in Genetics</i> , 2015, 6, 215.	1.1	70
939	Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 107-121.	1.4	8
940	Cell Fusion Connects Oncogenesis with Tumor Evolution. <i>American Journal of Pathology</i> , 2015, 185, 2049-2060.	1.9	53
941	Type I interferons in anticancer immunity. <i>Nature Reviews Immunology</i> , 2015, 15, 405-414.	10.6	929
942	Stereotactic Radiation Therapy Augments Antigen-Specific PD-1 \hat{a} €Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. <i>Cancer Immunology Research</i> , 2015, 3, 345-355.	1.6	520

#	ARTICLE	IF	CITATIONS
943	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	13.9	6,773
944	Porous Silicon Microparticle Potentiates Anti-Tumor Immunity by Enhancing Cross-Presentation and Inducing Type I Interferon Response. <i>Cell Reports</i> , 2015, 11, 957-966.	2.9	90
945	Differential control of CD4 ⁺ T _H 1 cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma. <i>European Journal of Immunology</i> , 2015, 45, 1019-1029.	1.6	62
946	Application of quantitative proteomics to the integrated analysis of the ubiquitylated and global proteomes of xenograft tumor tissues. <i>Clinical Proteomics</i> , 2015, 12, 14.	1.1	7
947	Toward Localized <i>In Vivo</i> Biomarker Concentration Measurements. <i>IEEE Transactions on Magnetics</i> , 2015, 51, 1-4.	1.2	37
948	Prognostic value of CD45RO(+) tumor-infiltrating lymphocytes for locally advanced rectal cancer following 30Gy/10f neoadjuvant radiotherapy. <i>International Journal of Colorectal Disease</i> , 2015, 30, 753-760.	1.0	16
949	Genome-wide analysis of alternative transcripts in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 295-307.	1.1	26
950	Targeting CD151 by lentivirus-mediated RNA interference inhibits luminal and basal-like breast cancer cell growth and invasion. <i>Molecular and Cellular Biochemistry</i> , 2015, 407, 111-121.	1.4	8
951	Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. <i>Journal of Neuro-Oncology</i> , 2015, 123, 75-84.	1.4	8
952	Dendritic cell immunotherapy for brain tumors. <i>Journal of Neuro-Oncology</i> , 2015, 123, 425-432.	1.4	10
953	Renal Toxicities of Targeted Therapies. <i>Targeted Oncology</i> , 2015, 10, 487-499.	1.7	66
954	Novel Immunologic Approaches in Lymphoma: Unleashing the Brakes on the Immune System. <i>Current Oncology Reports</i> , 2015, 17, 30.	1.8	9
955	Pitfalls in RECIST Data Extraction for Clinical Trials. <i>Academic Radiology</i> , 2015, 22, 779-786.	1.3	31
956	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. <i>Clinical Therapeutics</i> , 2015, 37, 764-782.	1.1	469
957	Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 29-39.	1.1	52
958	Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 158.	1.8	20
959	Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1-3.	1.1	19
960	Immune play: defending the liver. <i>Hepatic Oncology</i> , 2015, 2, 15-18.	4.2	0

#	ARTICLE	IF	CITATIONS
961	SomlnaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering. <i>BMC Bioinformatics</i> , 2015, 16, 125.	1.2	36
962	Identification of sample-specific regulations using integrative network level analysis. <i>BMC Cancer</i> , 2015, 15, 319.	1.1	11
963	Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles. <i>Breast Cancer Research</i> , 2015, 17, 48.	2.2	17
964	C-Reactive Protein As a Marker of Melanoma Progression. <i>Journal of Clinical Oncology</i> , 2015, 33, 1389-1396.	0.8	71
965	Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses. <i>Journal of Clinical Oncology</i> , 2015, 33, 1008-1014.	0.8	179
966	The Impact of DNA Input Amount and DNA Source on the Performance of Whole-Exome Sequencing in Cancer Epidemiology. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1207-1213.	1.1	26
967	Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study. <i>Clinical Cancer Research</i> , 2015, 21, 749-755.	3.2	223
968	Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 712-720.	3.2	225
969	Lung Cancer in the Era of Precision Medicine. <i>Clinical Cancer Research</i> , 2015, 21, 2213-2220.	3.2	148
970	Does It Make a Difference? Understanding Immune Effects of Targeted Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3102-3104.	3.2	27
971	PD-1 Restrains Radiotherapy-Induced Abscopal Effect. <i>Cancer Immunology Research</i> , 2015, 3, 610-619.	1.6	327
972	PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 620-630.	1.6	84
973	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 1158-1164.	1.6	237
974	ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels. <i>British Journal of Cancer</i> , 2015, 112, 1059-1066.	2.9	45
975	Tumor-Associated and Disease-Associated Autoantibody Repertoires in Healthy Colostrum and Maternal and Newborn Cord Sera. <i>Journal of Immunology</i> , 2015, 194, 5272-5281.	0.4	23
976	Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. <i>Annals of Oncology</i> , 2015, 26, 1698-1704.	0.6	244
977	INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia. <i>Leukemia</i> , 2015, 29, 1485-1495.	3.3	45
978	Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. <i>JAMA Oncology</i> , 2015, 1, 359.	3.4	164

#	ARTICLE	IF	CITATIONS
979	Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1083-1093.	2.0	44
980	Programmed Death-1 Controls T Cell Survival by Regulating Oxidative Metabolism. <i>Journal of Immunology</i> , 2015, 194, 5789-5800.	0.4	104
981	Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 986-991.	1.6	21
982	Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3050-7.	3.3	64
983	Transcriptional repression of IFN γ by ATF2 confers melanoma resistance to therapy. <i>Oncogene</i> , 2015, 34, 5739-5748.	2.6	23
984	The fate of chemoresistance in triple negative breast cancer (TNBC). <i>BBA Clinical</i> , 2015, 3, 257-275.	4.1	293
985	BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1680-1692.	1.9	32
986	Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity. <i>Vaccine</i> , 2015, 33, B21-B28.	1.7	28
987	Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1095-1108.	2.0	19
988	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1148-1157.	1.6	391
989	The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2464-2474.	0.3	90
990	Cancer and the Immune System: Basic Concepts and Targets for Intervention. <i>Seminars in Oncology</i> , 2015, 42, 523-538.	0.8	220
991	CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. <i>Frontiers in Oncology</i> , 2014, 4, 385.	1.3	175
992	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. <i>Cancer Immunology Research</i> , 2015, 3, 855-863.	1.6	60
993	Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy – Detecting Illusive Disease, Defining Response. <i>Frontiers in Neurology</i> , 2015, 6, 33.	1.1	139
994	Immunotherapeutic Advancements for Glioblastoma. <i>Frontiers in Oncology</i> , 2015, 5, 12.	1.3	37
995	Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. <i>Journal of Breast Health</i> , 2015, 11, 59-66.	0.9	177
996	Immunotherapy for malignant glioma. , 2015, 6, 68.		36

#	ARTICLE	IF	CITATIONS
997	Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?. <i>Cancer Biology and Therapy</i> , 2015, 16, 1704-1709.	1.5	7
999	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1bâ€² dose-escalation study. <i>Lancet Haematology</i> , 2015, 2, e516-e527.	2.2	140
1000	Progress of cancer genomics. <i>Thoracic Cancer</i> , 2015, 6, 557-560.	0.8	1
1001	The RUNX complex: reaching beyond haematopoiesis into immunity. <i>Immunology</i> , 2015, 146, 523-536.	2.0	73
1002	Feasibility of implementing molecularâ€­guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. <i>Cancer Medicine</i> , 2015, 4, 871-886.	1.3	26
1003	A Permutation Approach for Selecting the Penalty Parameter in Penalized Model Selection. <i>Biometrics</i> , 2015, 71, 1185-1194.	0.8	18
1004	Epidermal growth factor receptor and <i>AKT1</i> gene copy numbers by multiâ€­gene fluorescence <i>in situ</i> hybridization impact on prognosis in breast cancer. <i>Cancer Science</i> , 2015, 106, 642-649.	1.7	17
1005	Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 501-519.	1.5	3
1006	Pseudoprogression and Immune-Related Response in Solid Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3541-3543.	0.8	720
1007	Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. <i>British Journal of Cancer</i> , 2015, 113, 1677-1686.	2.9	64
1008	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1308-1315.	1.6	114
1009	Photodynamic Therapy of Nonâ€­Small Cell Lung Cancer. Narrative Review and Future Directions. <i>Annals of the American Thoracic Society</i> , 2016, 13, 265-275.	1.5	103
1010	Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14325-14330.	3.3	206
1011	Therapeutic targeting of casein kinase 1Î´ in breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 318ra202.	5.8	61
1012	Global transcription network incorporating distal regulator binding reveals selective cooperation of cancer drivers and risk genes. <i>Nucleic Acids Research</i> , 2015, 43, 5716-5729.	6.5	6
1013	Cardio-Oncology. <i>Circulation</i> , 2015, 132, 2248-2258.	1.6	99
1014	Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. <i>Breast Cancer Research</i> , 2015, 17, 134.	2.2	58
1015	Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers. <i>Breast Cancer Research</i> , 2015, 17, 148.	2.2	17

#	ARTICLE	IF	CITATIONS
1016	Developmental Insights into Breast Cancer Intratumoral Heterogeneity. Trends in Cancer, 2015, 1, 242-251.	3.8	16
1017	Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1.. Gastroenterology Report, 2015, 3, gov052.	0.6	21
1018	Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus Science and Medicine, 2015, 2, e000112-e000112.	1.1	38
1019	Identification of Variant-Specific Functions of <i>PIK3CA</i> by Rapid Phenotyping of Rare Mutations. Cancer Research, 2015, 75, 5341-5354.	0.4	130
1020	Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer and Metastasis Reviews, 2015, 34, 823-842.	2.7	39
1021	Systematic pan-cancer analysis of tumour purity. Nature Communications, 2015, 6, 8971.	5.8	937
1022	Plasma Autoantibodies Associated with Basal-like Breast Cancers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1332-1340.	1.1	42
1023	The Antigenic Repertoire of Premalignant and High-Risk Lesions. Cancer Prevention Research, 2015, 8, 266-270.	0.7	14
1024	Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma. Cancer Immunology Research, 2015, 3, 1165-1174.	1.6	61
1026	The immortality two-step. Cell Cycle, 2015, 14, 798-798.	1.3	1
1027	The potential complementary role of targeted alpha therapy in the management of metastatic melanoma. Melanoma Management, 2015, 2, 353-366.	0.1	1
1028	A new paradigm for tumor immune escape: β -catenin-driven immune exclusion. , 2015, 3, 43.		114
1029	Overcoming Antigen Escape with CAR T-cell Therapy. Cancer Discovery, 2015, 5, 1238-1240.	7.7	69
1030	Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Medicine, 2015, 13, 211.	2.3	570
1031	Advances in the treatment of newly diagnosed glioblastoma. BMC Medicine, 2015, 13, 293.	2.3	36
1032	Tumor-Infiltrating Immune Cells Are Associated With Prognosis of Gastric Cancer. Medicine (United Tj ETQq1 1 0.784314 rgBT /Over 0,4 95	0.4	
1033	Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report. Cellular Oncology (Dordrecht), 2015, 38, 485-491.	2.1	23
1034	Evolution of the immune system in humans from infancy to old age. Proceedings of the Royal Society B: Biological Sciences, 2015, 282, 20143085.	1.2	1,054

#	ARTICLE	IF	CITATIONS
1035	Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment. , 2015, 3, 53.		50
1036	Patterns and functional implications of rare germline variants across 12 cancer types. Nature Communications, 2015, 6, 10086.	5.8	243
1037	T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. Journal of Hematology and Oncology, 2015, 8, 93.	6.9	127
1038	Intratumoral talimogene laherparepvec therapy in melanoma. Melanoma Management, 2015, 2, 297-300.	0.1	2
1039	ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. Journal of Hematology and Oncology, 2015, 8, 129.	6.9	223
1040	Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Breast Care, 2015, 10, 168-172.	0.8	19
1041	Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Therapeutic Advances in Medical Oncology, 2015, 7, 181-191.	1.4	20
1042	Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecologic Oncology, 2015, 138, 656-662.	0.6	57
1043	TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. Haematologica, 2015, 100, 1415-1425.	1.7	73
1044	Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2015, 76, 969-975.	1.1	38
1045	Beyond the one-locus-one-miRNA paradigm: microRNA isoforms enable deeper insights into breast cancer heterogeneity. Nucleic Acids Research, 2015, 43, 9158-9175.	6.5	134
1046	Pathological conditions re-shape physiological Tregs into pathological Tregs. Burns and Trauma, 2015, 3, .	2.3	74
1047	Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Journal of Physical Education and Sports Management, 2015, 1, a000570.	0.5	92
1048	Granulomatous interstitial nephritis: a chameleon in a globalized world. CKJ: Clinical Kidney Journal, 2015, 8, 511-515.	1.4	8
1049	Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spreadâ€”Identification of a Promising Novel therapeutic target. Translational Oncology, 2015, 8, 295-307.	1.7	30
1050	Transformation of enriched mammary cell populations with polyomavirus middle T antigen influences tumor subtype and metastatic potential. Breast Cancer Research, 2015, 17, 132.	2.2	10
1051	Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. Therapeutic Advances in Hematology, 2015, 6, 295-307.	1.1	16
1052	Curcumin and tumor immune-editing: resurrecting the immune system. Cell Division, 2015, 10, 6.	1.1	105

#	ARTICLE	IF	CITATIONS
1053	Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. <i>Arthritis Research and Therapy</i> , 2015, 17, 340.	1.6	80
1054	Widespread intron retention diversifies most cancer transcriptomes. <i>Genome Medicine</i> , 2015, 7, 45.	3.6	283
1055	Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations. , 2015, 3, 58.		26
1056	Second-line combination therapies in nonsmall cell lung cancer without known driver mutations. <i>European Respiratory Review</i> , 2015, 24, 582-593.	3.0	22
1057	HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. <i>Breast Cancer Research</i> , 2015, 17, 149.	2.2	42
1058	The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 69-79.	1.1	15
1059	Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis. <i>Cell Adhesion and Migration</i> , 2015, 9, 265-276.	1.1	62
1060	Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 851-856.	3.3	321
1061	Detection of <i>BRCA1</i> and <i>BRCA2</i> germline mutations in Japanese population using next-generation sequencing. <i>Molecular Genetics & Genomic Medicine</i> , 2015, 3, 121-129.	0.6	59
1062	Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 435-441.	1.1	13
1063	Intrinsic Subtypes, <i>PIK3CA</i> Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1340-1347.	0.8	105
1064	Developing biomarker-specific end points in lung cancer clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 135-146.	12.5	43
1065	Therapeutic targeting of tumor suppressor genes. <i>Cancer</i> , 2015, 121, 1357-1368.	2.0	132
1066	Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?. <i>Medical Microbiology and Immunology</i> , 2015, 204, 121-129.	2.6	23
1067	PD-1/PD-L1 axis: efficient checkpoint blockade against cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 63-63.	12.5	58
1068	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 326-332.	1.6	310
1069	Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. <i>British Journal of Cancer</i> , 2015, 112, 103-111.	2.9	98
1070	Checkpoint inhibitors in immunotherapy of ovarian cancer. <i>Tumor Biology</i> , 2015, 36, 33-39.	0.8	19

#	ARTICLE	IF	CITATIONS
1071	Targeted Therapies in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 347-358.	0.6	6
1072	Novel and emerging targeted-based cancer therapy agents and methods. <i>Tumor Biology</i> , 2015, 36, 543-556.	0.8	28
1073	PTEN Loss Is Associated with Worse Outcome in <i>HER2</i> -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. <i>Clinical Cancer Research</i> , 2015, 21, 2065-2074.	3.2	59
1074	Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis. <i>Molecular Cancer Research</i> , 2015, 13, 743-754.	1.5	32
1075	Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction. <i>Cell Cycle</i> , 2015, 14, 744-754.	1.3	9
1076	Signaling-Mediated Regulation of MicroRNA Processing. <i>Cancer Research</i> , 2015, 75, 783-791.	0.4	46
1077	Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 9-18.	1.1	61
1078	Patient-derived xenograft models of breast cancer and their predictive power. <i>Breast Cancer Research</i> , 2015, 17, 17.	2.2	225
1079	Triple-negative breast cancer in African-American women: disparities versus biology. <i>Nature Reviews Cancer</i> , 2015, 15, 248-254.	12.8	342
1080	Three Steps to Breaking Immune Tolerance to Lymphoma: A Microparticle Approach. <i>Cancer Immunology Research</i> , 2015, 3, 389-398.	1.6	13
1081	The role of CD95 and CD95 ligand in cancer. <i>Cell Death and Differentiation</i> , 2015, 22, 549-559.	5.0	243
1082	Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 304-311.	0.8	521
1083	Cancer genomics: why rare is valuable. <i>Journal of Molecular Medicine</i> , 2015, 93, 369-381.	1.7	8
1084	Glioblastoma stem cells and stem cell-targeting immunotherapies. <i>Journal of Neuro-Oncology</i> , 2015, 123, 449-457.	1.4	25
1085	Loss of the Notch effector RBPJ promotes tumorigenesis. <i>Journal of Experimental Medicine</i> , 2015, 212, 37-52.	4.2	52
1086	Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells. <i>Cancer Immunology Research</i> , 2015, 3, 116-124.	1.6	32
1087	<i>PIK3CA</i> Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor Targeted Therapies in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1334-1339.	0.8	201
1088	Immune Checkpoint Blockade and Interferon- γ in Melanoma. <i>Seminars in Oncology</i> , 2015, 42, 436-447.	0.8	34

#	ARTICLE	IF	CITATIONS
1089	Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. <i>Clinical Chemistry</i> , 2015, 61, 544-553.	1.5	85
1090	Immunotherapy for the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2015, 17, 5.	1.8	59
1091	Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. <i>Gut</i> , 2015, 64, 842-848.	6.1	155
1092	Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study. <i>International Journal of Cancer</i> , 2015, 137, 949-958.	2.3	17
1093	Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer. <i>British Journal of Cancer</i> , 2015, 112, 755-764.	2.9	62
1095	Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 701-708.	0.8	171
1096	CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. <i>Cancer Medicine</i> , 2015, 4, 661-672.	1.3	100
1097	Omics Pipe: a community-based framework for reproducible multi-omics data analysis. <i>Bioinformatics</i> , 2015, 31, 1724-1728.	1.8	66
1098	ASSIGN: context-specific genomic profiling of multiple heterogeneous biological pathways. <i>Bioinformatics</i> , 2015, 31, 1745-1753.	1.8	28
1099	Targeting drivers of melanoma with synthetic small molecules and phytochemicals. <i>Cancer Letters</i> , 2015, 359, 20-35.	3.2	67
1100	Overexpression of Programmed Death Ligands in Naturally Occurring Postweaning Multisystemic Wasting Syndrome. <i>Viral Immunology</i> , 2015, 28, 101-106.	0.6	9
1101	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. <i>Gut</i> , 2015, 64, 1721-1731.	6.1	197
1102	The chemistry and pharmacology of privileged pyrroloquinazolines. <i>MedChemComm</i> , 2015, 6, 510-520.	3.5	11
1103	Comparison of circulating and intratumoral regulatory T cells in patients with renal cell carcinoma. <i>Tumor Biology</i> , 2015, 36, 3727-3734.	0.8	11
1104	Immune-mediated antitumor effect by type 2 diabetes drug, metformin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1809-1814.	3.3	450
1105	Inferring biological tasks using Pareto analysis of high-dimensional data. <i>Nature Methods</i> , 2015, 12, 233-235.	9.0	145
1106	The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 587-596.	1.1	36
1107	Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 687-692.	3.2	801

#	ARTICLE	IF	CITATIONS
1108	Markers for the identification of late breast cancer recurrence. <i>Breast Cancer Research</i> , 2015, 17, 10.	2.2	60
1109	Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated With Estrogen Receptor-Negative Subtypes and Poor Prognosis. <i>EBioMedicine</i> , 2015, 2, 255-263.	2.7	95
1110	New perspectives on type I IFNs in cancer. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 175-178.	3.2	50
1111	Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage. <i>Cancer Immunology Research</i> , 2015, 3, 557-566.	1.6	44
1112	Metabolic signatures of human breast cancer. <i>Molecular and Cellular Oncology</i> , 2015, 2, e992217.	0.3	56
1113	BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. <i>Tumor Biology</i> , 2015, 36, 4243-4252.	0.8	29
1114	S100 proteins in cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 96-109.	12.8	622
1115	VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. <i>Journal of Experimental Medicine</i> , 2015, 212, 139-148.	4.2	836
1116	Immune Checkpoint Blockade in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 1974-1982.	0.8	2,220
1117	Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. <i>Journal of Medical Genetics</i> , 2015, 52, 231-239.	1.5	17
1118	Homologous-recombination-deficient tumours are dependent on PolÎ±-mediated repair. <i>Nature</i> , 2015, 518, 258-262.	13.7	671
1119	Gain of HIF-1Î± under Normoxia in Cancer Mediates Immune Adaptation through the AKT/ERK and VEGFA Axes. <i>Clinical Cancer Research</i> , 2015, 21, 1438-1446.	3.2	46
1120	Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. <i>Genome Research</i> , 2015, 25, 316-327.	2.4	343
1121	T-cell-associated cellular immunotherapy for lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1249-1258.	1.2	14
1122	Intrinsic cancer subtypes-next steps into personalized medicine. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 3-16.	2.1	24
1123	Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity. <i>Cell</i> , 2015, 160, 48-61.	13.5	2,948
1124	The future of breast cancer systemic therapy: the next 10Âyears. <i>Journal of Molecular Medicine</i> , 2015, 93, 119-125.	1.7	19
1125	Cancer immunotherapy meets biomaterials. <i>Nature Biotechnology</i> , 2015, 33, 44-45.	9.4	48

#	ARTICLE	IF	CITATIONS
1126	Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 12-21.	1.4	22
1127	Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma. <i>Medical Oncology</i> , 2015, 32, 275.	1.2	32
1128	The butterfly effect in cancer: A single base mutation can remodel the cell. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1131-1136.	3.3	62
1129	Hypoxia-inducible factor 1 and breast cancer metastasis. <i>Journal of Zhejiang University: Science B</i> , 2015, 16, 32-43.	1.3	171
1130	RAGE Mediates S100A7-Induced Breast Cancer Growth and Metastasis by Modulating the Tumor Microenvironment. <i>Cancer Research</i> , 2015, 75, 974-985.	0.4	112
1131	Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 298-306.	1.9	14
1132	Targeting T cell metabolism for therapy. <i>Trends in Immunology</i> , 2015, 36, 71-80.	2.9	204
1133	The Osteogenic Niche Promotes Early-Stage Bone Colonization of Disseminated Breast Cancer Cells. <i>Cancer Cell</i> , 2015, 27, 193-210.	7.7	308
1134	Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis. <i>Cell Cycle</i> , 2015, 14, 146-156.	1.3	45
1135	RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer. <i>Cell Cycle</i> , 2015, 14, 109-122.	1.3	33
1136	TAp73 suppresses tumor angiogenesis through repression of proangiogenic cytokines and HIF-1 α activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 220-225.	3.3	66
1137	A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1 α -Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. <i>Clinical Cancer Research</i> , 2015, 21, 1019-1027.	3.2	677
1138	Combination Therapy with Anti α -CTLA-4 and Anti α -PD-1 Leads to Distinct Immunologic Changes In Vivo. <i>Journal of Immunology</i> , 2015, 194, 950-959.	0.4	362
1139	Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 425-437.	1.1	29
1140	HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E166-75.	3.3	150
1141	Current challenges in designing GBM trials for immunotherapy. <i>Journal of Neuro-Oncology</i> , 2015, 123, 331-337.	1.4	34
1142	Anaplastic Thyroid Cancer: Outcome and the Mutation/Expression Profiles of Potential Targets. <i>Pathology and Oncology Research</i> , 2015, 21, 695-701.	0.9	32
1143	Multiple checkpoints on the long road towards cancer immunotherapy. <i>Immunology and Cell Biology</i> , 2015, 93, 323-325.	1.0	9

#	ARTICLE	IF	CITATIONS
1144	The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression. <i>Molecular and Cellular Oncology</i> , 2015, 2, e970955.	0.3	31
1145	Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer. <i>Nucleic Acids Research</i> , 2015, 43, 1345-1356.	6.5	157
1146	Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. <i>Modern Pathology</i> , 2015, 28, 766-777.	2.9	117
1147	IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. <i>Cancer Research</i> , 2015, 75, 1635-1644.	0.4	145
1148	<i>APOBEC3B</i> expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2841-2846.	3.3	118
1149	Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage. <i>Cancer Research</i> , 2015, 75, 1311-1321.	0.4	83
1150	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. <i>Cancer Immunology Research</i> , 2015, 3, 288-295.	1.6	145
1151	Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. <i>British Journal of Cancer</i> , 2015, 112, 1411-1420.	2.9	51
1152	Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. , 2015, 3, 2.		93
1153	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2015, 16, 257-265.	5.1	1,269
1154	Both PD-1 Ligands Protect the Kidney from Ischemia Reperfusion Injury. <i>Journal of Immunology</i> , 2015, 194, 325-333.	0.4	70
1155	Requirement for Innate Immunity and CD90+ NK1.1 ^{hi} Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy. <i>Cancer Immunology Research</i> , 2015, 3, 296-304.	1.6	25
1156	Can oncology recapitulate paleontology? Lessons from species extinctions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 273-285.	12.5	31
1157	Role of epigenetic modifications in luminal breast cancer. <i>Epigenomics</i> , 2015, 7, 847-862.	1.0	41
1158	Hypoxia-induced nitric oxide release by luminal cells stimulates proliferation and uPA secretion of myoepithelial cells in a bicellular murine mammary tumor. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1727-1738.	1.2	2
1159	Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. <i>Clinical Cancer Research</i> , 2015, 21, 3619-3630.	3.2	115
1160	Targeting a cell state common to triple-negative breast cancers. <i>Molecular Systems Biology</i> , 2015, 11, 789.	3.2	21
1161	Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 2644-2651.	3.2	70

#	ARTICLE	IF	CITATIONS
1162	The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer. <i>Molecular Therapy</i> , 2015, 23, 717-727.	3.7	218
1163	The origin of breast tumor heterogeneity. <i>Oncogene</i> , 2015, 34, 5309-5316.	2.6	125
1164	PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. <i>Journal of Translational Medicine</i> , 2015, 13, 5.	1.8	73
1165	Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. <i>Tumor Biology</i> , 2015, 36, 5865-5871.	0.8	17
1169	Multigene prognostic tests in breast cancer: past, present, future. <i>Breast Cancer Research</i> , 2015, 17, 11.	2.2	209
1170	Biomarkers for glioma immunotherapy: the next generation. <i>Journal of Neuro-Oncology</i> , 2015, 123, 359-372.	1.4	23
1171	The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy. <i>Cell Cycle</i> , 2015, 14, 3812-3819.	1.3	42
1172	Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. <i>Oncogene</i> , 2015, 34, 5411-5417.	2.6	48
1173	TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. <i>Cancer Research</i> , 2015, 75, 1908-1921.	0.4	56
1174	Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments. <i>Current Oncology Reports</i> , 2015, 17, 15.	1.8	29
1175	Nivolumab in NSCLC: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 85-96.	1.4	196
1176	The interaction of anticancer therapies with tumor-associated macrophages. <i>Journal of Experimental Medicine</i> , 2015, 212, 435-445.	4.2	507
1177	Concepts in solid tumor evolution. <i>Trends in Genetics</i> , 2015, 31, 208-214.	2.9	51
1178	Engineering control into medicine. <i>Journal of Critical Care</i> , 2015, 30, 652.e1-652.e7.	1.0	10
1179	Renal effects of targeted anticancer therapies. <i>Nature Reviews Nephrology</i> , 2015, 11, 354-370.	4.1	95
1180	NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2015, 13, 32.	1.8	81
1182	Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. <i>Medical Oncology</i> , 2015, 32, 86.	1.2	104
1183	Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 9.	1.8	54

#	ARTICLE	IF	CITATIONS
1184	Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations. <i>Genome Medicine</i> , 2015, 7, 6.	3.6	6
1185	Immunotherapy for Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 317.	1.3	23
1186	Cases of Spontaneous Tumor Regression in Hepatobiliary Cancers: Implications for Immunotherapy?. <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 161-165.	0.6	13
1187	ATM gene mutations in sporadic breast cancer patients from Brazil. <i>SpringerPlus</i> , 2015, 4, 23.	1.2	14
1188	Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer. <i>Oncogene</i> , 2015, 34, 5427-5435.	2.6	71
1189	Nivolumab in melanoma: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 97-106.	1.4	124
1190	The immune response in cancer: from immunology to pathology to immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 127-135.	1.4	51
1191	Association between PDCD1 Gene Polymorphisms and Risk of Systemic Lupus Erythematosus in Three Main Ethnic Groups of the Malaysian Population. <i>International Journal of Molecular Sciences</i> , 2015, 16, 9794-9803.	1.8	20
1192	Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States. <i>Journal of Clinical Oncology</i> , 2015, 33, 2376-2383.	0.8	266
1193	Nivolumab and Olaparib. <i>Hospital Pharmacy</i> , 2015, 50, 356-366.	0.4	4
1194	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	13.5	2,562
1195	Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents. <i>Frontiers in Immunology</i> , 2015, 6, 29.	2.2	139
1196	Spotlight on pembrolizumab in the treatment of advanced melanoma. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2883.	2.0	7
1197	Intra-tumor Genetic Heterogeneity and Mortality in Head and Neck Cancer: Analysis of Data from The Cancer Genome Atlas. <i>PLoS Medicine</i> , 2015, 12, e1001786.	3.9	244
1198	Hsp90, the Concertmaster: Tuning Transcription. <i>Frontiers in Oncology</i> , 2015, 5, 100.	1.3	52
1199	The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594). <i>Oncolytic Virotherapy</i> , 2015, 4, 25.	6.0	45
1200	Evolving Concepts: Immunity in Oncology from Targets to Treatments. <i>Journal of Oncology</i> , 2015, 2015, 1-15.	0.6	23
1201	Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions. <i>Frontiers in Oncology</i> , 2015, 4, 378.	1.3	4

#	ARTICLE	IF	CITATIONS
1202	The future of high-grade glioma: Where we are and where are we going. , 2015, 6, 9.		29
1203	Personalized Medicine for Gliomas. , 2015, 6, 89.		31
1204	Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. <i>Frontiers in Immunology</i> , 2015, 6, 67.	2.2	122
1205	Tim-3 and Tim-4 as the potential targets for antitumor therapy. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2458-2462.	1.4	44
1206	Atlas of Cancer Signalling Network: a systems biology resource for integrative analysis of cancer data with Google Maps. <i>Oncogenesis</i> , 2015, 4, e160-e160.	2.1	129
1207	Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. <i>Advances in Cancer Research</i> , 2015, 128, 263-307.	1.9	123
1208	Combination cancer immunotherapy and new immunomodulatory targets. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 561-584.	21.5	1,058
1209	Big opportunities for small molecules in immuno-oncology. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 603-622.	21.5	369
1210	Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm. <i>Scientific Reports</i> , 2015, 5, 11966.	1.6	93
1211	Chemotherapy triggers HIF-1 α -dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4600-9.	3.3	205
1212	A Molecular Portrait of High-Grade Ductal Carcinoma <i>in Situ</i> . <i>Cancer Research</i> , 2015, 75, 3980-3990.	0.4	122
1213	The Evolution of T-cell Therapies for Solid Malignancies. <i>Clinical Cancer Research</i> , 2015, 21, 3384-3392.	3.2	71
1214	Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. <i>Cancer Immunology Research</i> , 2015, 3, 464-469.	1.6	91
1215	CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells. <i>Journal of Immunology</i> , 2015, 195, 1054-1063.	0.4	34
1216	ErbB3 α -ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. <i>Cancer Research</i> , 2015, 75, 3554-3567.	0.4	18
1217	Update in Lung Cancer 2014. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 283-294.	2.5	36
1218	Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 125-140.	1.0	27
1219	Targeted Therapies in Melanoma: Translational Research at Its Finest. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1929-1933.	0.3	12

#	ARTICLE	IF	CITATIONS
1221	Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 479-496.	2.7	101
1222	Metabolomic profiling of hormone-dependent cancers: a bird's eye view. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 477-485.	3.1	42
1223	CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma. <i>Human Gene Therapy</i> , 2015, 26, 498-505.	1.4	56
1224	PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. <i>Blood Cancer Journal</i> , 2015, 5, e330-e330.	2.8	124
1225	Revealing Missing Human Protein Isoforms Based on Ab Initio Prediction, RNA-seq and Proteomics. <i>Scientific Reports</i> , 2015, 5, 10940.	1.6	51
1226	Inhibition of the autocrine IL-6/JAK2/STAT3/calprotectin axis as targeted therapy for HR ⁺ /HER2 ⁺ breast cancers. <i>Genes and Development</i> , 2015, 29, 1631-1648.	2.7	94
1227	Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. <i>JAMA Dermatology</i> , 2015, 151, 1206.	2.0	385
1228	Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. <i>Oncogene</i> , 2015, 34, 373-383.	2.6	42
1229	Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 1017-1029.	1.6	159
1230	Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma. <i>Molecular Therapy</i> , 2015, 23, 1444-1455.	3.7	18
1231	An Integrative Multi-scale Analysis of the Dynamic DNA Methylation Landscape in Aging. <i>PLoS Genetics</i> , 2015, 11, e1004996.	1.5	132
1232	Cancer immunotherapy: exploiting neoepitopes. <i>Cell Research</i> , 2015, 25, 887-888.	5.7	25
1233	Shp2 signaling suppresses senescence in <i>PyMT</i> -induced mammary gland cancer in mice. <i>EMBO Journal</i> , 2015, 34, 1493-1508.	3.5	31
1234	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. <i>Clinical Cancer Research</i> , 2015, 21, 3969-3976.	3.2	205
1235	PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. <i>Cancer Immunology Research</i> , 2015, 3, 946-955.	1.6	66
1236	CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 1257-1268.	1.6	241
1237	BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. <i>OncoTargets and Therapy</i> , 2015, 8, 157.	1.0	134
1238	In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. <i>Vaccine</i> , 2015, 33, 7415-7422.	1.7	142

#	ARTICLE	IF	CITATIONS
1239	Synthetic Nanoparticles for Vaccines and Immunotherapy. <i>Chemical Reviews</i> , 2015, 115, 11109-11146.	23.0	623
1240	Advanced Proteogenomic Analysis Reveals Multiple Peptide Mutations and Complex Immunoglobulin Peptides in Colon Cancer. <i>Journal of Proteome Research</i> , 2015, 14, 3555-3567.	1.8	36
1241	New immunotherapies targeting the PD-1 pathway. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 587-595.	4.0	158
1242	The center for causal discovery of biomedical knowledge from big data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 1132-1136.	2.2	30
1243	Blinatumomab and Pembrolizumab. <i>Hospital Pharmacy</i> , 2015, 50, 269-273.	0.4	4
1244	Clonality and Evolutionary History of Rhabdomyosarcoma. <i>PLoS Genetics</i> , 2015, 11, e1005075.	1.5	58
1245	T-cell exhaustion in the tumor microenvironment. <i>Cell Death and Disease</i> , 2015, 6, e1792-e1792.	2.7	743
1246	Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. <i>Clinical and Translational Immunology</i> , 2015, 4, e30.	1.7	39
1247	The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. <i>Nature Reviews Cancer</i> , 2015, 15, 409-425.	12.8	1,474
1248	Combined immunotherapyâ€”a new standard in metastatic melanoma?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 439-440.	12.5	8
1249	Evaluation and integration of cancer gene classifiers: identification and ranking of plausible drivers. <i>Scientific Reports</i> , 2015, 5, 10204.	1.6	18
1250	Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. <i>Scientific Reports</i> , 2015, 5, 11198.	1.6	150
1251	A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. <i>Clinical Cancer Research</i> , 2015, 21, 4903-4912.	3.2	73
1252	Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. <i>Ecancermedalscience</i> , 2015, 9, 518.	0.6	50
1253	Tryptophan-Degrading Enzymes in Tumoral Immune Resistance. <i>Frontiers in Immunology</i> , 2015, 6, 34.	2.2	201
1254	Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. <i>Frontiers in Immunology</i> , 2015, 6, 127.	2.2	51
1255	Modulation of Immune Cell Functions by the E3 Ligase Cbl-b. <i>Frontiers in Oncology</i> , 2015, 5, 58.	1.3	64
1256	Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer. <i>Current Oncology</i> , 2015, 22, 33-48.	0.9	95

#	ARTICLE	IF	CITATIONS
1257	Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. <i>Molecular and Clinical Oncology</i> , 2015, 3, 232-236.	0.4	42
1258	Phospho-PRAS40Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer. <i>Oncology Letters</i> , 2015, 9, 785-789.	0.8	12
1259	CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function. <i>Cell Reports</i> , 2015, 12, 244-257.	2.9	287
1260	Engineering CART cells: Design concepts. <i>Trends in Immunology</i> , 2015, 36, 494-502.	2.9	354
1261	TGF β -Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis. <i>BoneKey Reports</i> , 2015, 4, 719.	2.7	17
1262	Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2266-2272.	0.3	7
1263	Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. <i>Oncogene</i> , 2015, 34, 5960-5970.	2.6	67
1264	Antigen-specific T cell therapies for cancer: Figure 1.. <i>Human Molecular Genetics</i> , 2015, 24, R67-R73.	1.4	32
1265	Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv156.	3.0	62
1266	Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1193-1203.	2.0	18
1267	Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes. <i>Scientific Reports</i> , 2015, 5, 12133.	1.6	36
1268	Treatment of Liver Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021535.	2.9	241
1269	Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 5543-5551.	3.2	119
1270	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4607-4618.	3.2	271
1271	The prognostic landscape of genes and infiltrating immune cells across human cancers. <i>Nature Medicine</i> , 2015, 21, 938-945.	15.2	2,505
1272	Cancer in the parasitic protozoans <i>Trypanosoma brucei</i> and <i>Toxoplasma gondii</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8835-8842.	3.3	42
1273	Innate and Adaptive Cellular Immune Responses to <i>Mycobacterium tuberculosis</i> Infection. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a018424.	2.9	116
1274	Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. <i>Modern Pathology</i> , 2015, 28, 1154-1166.	2.9	143

#	ARTICLE	IF	CITATIONS
1275	Precision medicine for metastatic breast cancer—limitations and solutions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 693-704.	12.5	272
1276	Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective. <i>Insights Into Imaging</i> , 2015, 6, 479-487.	1.6	27
1277	Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. <i>Immunotherapy</i> , 2015, 7, 611-619.	1.0	141
1278	Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. <i>Cell Reports</i> , 2015, 12, 511-524.	2.9	39
1279	Evolving synergistic combinations of targeted immunotherapies to combat cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 457-472.	12.8	576
1280	Molecular and cellular insights into T cell exhaustion. <i>Nature Reviews Immunology</i> , 2015, 15, 486-499.	10.6	3,159
1281	Age-associated inflammation connects RAS-induced senescence to stem cell dysfunction and epidermal malignancy. <i>Cell Death and Differentiation</i> , 2015, 22, 1764-1774.	5.0	56
1282	Phytochemicals potently inhibit migration of metastatic breast cancer cells. <i>Integrative Biology (United Kingdom)</i> , 2015, 7, 792-800.	0.6	40
1283	Fundamental Principles of Cancer Biology: Does It Have Relevance to the Perioperative Period?. <i>Current Anesthesiology Reports</i> , 2015, 5, 250-256.	0.9	7
1284	MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy. <i>Cell Reports</i> , 2015, 11, 1358-1366.	2.9	40
1285	Engineered materials for cancer immunotherapy. <i>Nano Today</i> , 2015, 10, 511-531.	6.2	96
1286	Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	96
1287	Immune Targeting of Tumor Epithelial–Mesenchymal Transition via Brachyury-Based Vaccines. <i>Advances in Cancer Research</i> , 2015, 128, 69-93.	1.9	12
1288	Subclonal diversification of primary breast cancer revealed by multiregion sequencing. <i>Nature Medicine</i> , 2015, 21, 751-759.	15.2	711
1289	Concepts of immunotherapy for glioma. <i>Journal of Neuro-Oncology</i> , 2015, 123, 323-330.	1.4	12
1290	Determination of HER2 and p53 Mutations by Sequence Analysis Method and EGFR/Chromosome 7 Gene Status by Fluorescence in Situ Hybridization for the Predilection of Targeted Therapy Modalities in Immunohistochemically Triple Negative Breast Carcinomas in Turkish Population. <i>Pathology and Oncology Research</i> . 2015. 21. 1223-1227.	0.9	3
1291	Publisher's Note: Abstraction for data integration: Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction. <i>Computational Biology and Chemistry</i> , 2015, 58, 104-119.	1.1	4
1292	Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. <i>Current Opinion in Virology</i> , 2015, 13, 81-85.	2.6	40

#	ARTICLE	IF	CITATIONS
1293	Synthetic biology in cell-based cancer immunotherapy. <i>Trends in Biotechnology</i> , 2015, 33, 449-461.	4.9	61
1294	Development of individualized anti-metastasis strategies by engineering nanomedicines. <i>Chemical Society Reviews</i> , 2015, 44, 6258-6286.	18.7	115
1295	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. <i>Seminars in Oncology</i> , 2015, 42, 601-616.	0.8	139
1296	Immune Modulation in Hematologic Malignancies. <i>Seminars in Oncology</i> , 2015, 42, 617-625.	0.8	22
1297	Human ortholog of <i>Drosophila</i> Melted impedes SMAD2 release from TGF- β 2 receptor I to inhibit TGF- β 2 signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3000-9.	3.3	20
1298	Identifying genes that mediate anthracycline toxicity in immune cells. <i>Frontiers in Pharmacology</i> , 2015, 6, 62.	1.6	4
1299	The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2015, 7, 439-449.	1.7	2
1300	Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 1123-1129.	1.6	127
1301	Primary malignant melanoma of the trachea: A case report. <i>Oncology Letters</i> , 2015, 9, 657-660.	0.8	6
1302	PI3K mutations in breast cancer: prognostic and therapeutic implications. <i>Breast Cancer: Targets and Therapy</i> , 2015, 7, 111.	1.0	113
1303	In-situ tumor vaccination: Bringing the fight to the tumor. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1901-1909.	1.4	60
1304	Reconstruction of clonal trees and tumor composition from multi-sample sequencing data. <i>Bioinformatics</i> , 2015, 31, i62-i70.	1.8	194
1305	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 908-918.	5.1	1,419
1306	2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond. <i>EBioMedicine</i> , 2015, 2, 92-93.	2.7	51
1307	Safety and diagnostic accuracy of tumor biopsies in children with cancer. <i>Cancer</i> , 2015, 121, 1098-1107.	2.0	15
1308	Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 631-638.	0.4	102
1309	The emerging role of resident memory T cells in protective immunity and inflammatory disease. <i>Nature Medicine</i> , 2015, 21, 688-697.	15.2	455
1310	Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3816-25.	3.3	295

#	ARTICLE	IF	CITATIONS
1311	OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. <i>Frontiers in Oncology</i> , 2015, 5, 34.	1.3	193
1312	Accurate Computation of Survival Statistics in Genome-Wide Studies. <i>PLoS Computational Biology</i> , 2015, 11, e1004071.	1.5	24
1313	Within-Host Stochastic Emergence Dynamics of Immune-Escape Mutants. <i>PLoS Computational Biology</i> , 2015, 11, e1004149.	1.5	10
1314	The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. <i>Oncologist</i> , 2015, 20, 812-822.	1.9	198
1315	Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. <i>Molecular Therapy</i> , 2015, 23, 1630-1640.	3.7	165
1316	Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. <i>Nature Communications</i> , 2015, 6, 7458.	5.8	383
1317	IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. <i>Nature Medicine</i> , 2015, 21, 719-729.	15.2	658
1318	Inflammation and cancer: advances and new agents. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 584-596.	12.5	901
1319	The pharmacology of second-generation chimeric antigen receptors. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 499-509.	21.5	411
1320	Antagonists of PD-1 and PD-L1 in Cancer Treatment. <i>Seminars in Oncology</i> , 2015, 42, 587-600.	0.8	259
1321	Perturbation-Expression Analysis Identifies RUNX1 as a Regulator of Human Mammary Stem Cell Differentiation. <i>PLoS Computational Biology</i> , 2015, 11, e1004161.	1.5	22
1322	Are Macrophages in Tumors Good Targets for Novel Therapeutic Approaches?. <i>Molecules and Cells</i> , 2015, 38, 95-104.	1.0	9
1323	The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. <i>Oncologist</i> , 2015, 20, 1058-1068.	1.9	56
1324	Targeting the Innate Immune System as Immunotherapy for Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2015, 5, 83.	1.3	33
1325	Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines. <i>Current Oncology</i> , 2015, 22, 29-42.	0.9	18
1326	ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics. <i>Frontiers in Genetics</i> , 2015, 6, 17.	1.1	32
1327	Mechanisms and Applications of Interleukins in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 1691-1710.	1.8	66
1328	T Cells. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2050-2064.	2.2	59

#	ARTICLE	IF	CITATIONS
1329	Clinical significance of high expression of circulating serum lncRNA RP11-445H22.4 in breast cancer patients: a Chinese population-based study. <i>Tumor Biology</i> , 2015, 36, 7659-7665.	0.8	65
1330	Tumor infiltrating lymphocytes in ovarian cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 807-820.	1.5	257
1331	Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6140-6145.	3.3	498
1332	Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. <i>Cancer Biology and Therapy</i> , 2015, 16, 662-670.	1.5	27
1333	A pooling-based approach to mapping genetic variants associated with DNA methylation. <i>Genome Research</i> , 2015, 25, 907-917.	2.4	30
1334	Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma. <i>Urology</i> , 2015, 85, 703.e1-703.e6.	0.5	122
1335	Identification of Novel Genetic Markers of Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	56
1336	Mechanisms of action of therapeutic antibodies for cancer. <i>Molecular Immunology</i> , 2015, 67, 28-45.	1.0	136
1337	Mechanisms of aromatase inhibitor resistance. <i>Nature Reviews Cancer</i> , 2015, 15, 261-275.	12.8	319
1338	Designing vaccines to prevent breast cancer recurrence or invasive disease. <i>Immunotherapy</i> , 2015, 7, 69-72.	1.0	12
1339	Examining the utility of patient-derived xenograft mouse models. <i>Nature Reviews Cancer</i> , 2015, 15, 311-316.	12.8	300
1340	Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 5708-5713.	3.3	105
1341	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. <i>Nature</i> , 2015, 521, 94-98.	18.7	451
1342	The Proteomic Landscape of Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2015, 11, 630-644.	2.9	179
1343	Immune Checkpoint Inhibitors in Cancer Treatment: A Review. <i>Pharmaceuticals</i> , 2015, 8, 40-61.	1.7	50
1344	A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2015, 51, 376-382.	0.8	50
1345	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. <i>Human Pathology</i> , 2015, 46, 357-365.	1.1	252
1346	Toxicities of Immunotherapy for the Practitioner. <i>Journal of Clinical Oncology</i> , 2015, 33, 2092-2099.	0.8	521

#	ARTICLE	IF	CITATIONS
1347	Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2015, 27, 36-48.	0.4	8
1348	Tumour and patient factors in renal cell carcinoma towards personalized therapy. <i>Nature Reviews Urology</i> , 2015, 12, 253-262.	1.9	22
1349	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015, 33, 2013-2020.	0.8	385
1350	Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function. <i>RNA Biology</i> , 2015, 12, 628-642.	1.5	85
1351	Cancer prevention and therapy through the modulation of the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2015, 35, S199-S223.	4.3	285
1352	Cell signaling events differentiate ER-negative subtypes from ER-positive breast cancer. <i>Medical Oncology</i> , 2015, 32, 142.	1.2	7
1353	Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer. <i>BioDrugs</i> , 2015, 29, 75-89.	2.2	57
1354	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. <i>Nature Medicine</i> , 2015, 21, 530-536.	15.2	118
1355	Adoptive cell transfer as personalized immunotherapy for human cancer. <i>Science</i> , 2015, 348, 62-68.	6.0	1,911
1356	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. <i>Nature Medicine</i> , 2015, 21, 449-456.	15.2	1,592
1357	Therapies for triple negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 983-998.	0.9	85
1358	Clinical management of breast cancer heterogeneity. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 381-394.	12.5	400
1359	T cell metabolic fitness in antitumor immunity. <i>Trends in Immunology</i> , 2015, 36, 257-264.	2.9	237
1360	Investigations of Interferon-Lambda for the Treatment of Cancer. <i>Journal of Innate Immunity</i> , 2015, 7, 243-250.	1.8	33
1361	Mutant MHC class II epitopes drive therapeutic immune responses to cancer. <i>Nature</i> , 2015, 520, 692-696.	13.7	1,030
1364	Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 386-396.	3.3	130
1365	Broadening the repertoire of melanoma-associated T-cell epitopes. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 609-620.	2.0	8
1366	A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1669-1678.	1.2	9

#	ARTICLE	IF	CITATIONS
1367	Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 487-499.	1.1	20
1368	Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2015, 33, 621-631.	1.2	63
1369	Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. <i>Investigational New Drugs</i> , 2015, 33, 664-670.	1.2	3
1370	The role of checkpoints in the treatment of GBM. <i>Journal of Neuro-Oncology</i> , 2015, 123, 413-423.	1.4	15
1371	Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. <i>Journal of Neuro-Oncology</i> , 2015, 123, 339-346.	1.4	10
1372	The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound Î ² -glucan. <i>Journal of Natural Medicines</i> , 2015, 69, 198-208.	1.1	13
1373	Immunoprofiling for Prognostic Assessment of Colon Cancer: a Novel Complement to Ultrastaging. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 999-1006.	0.9	17
1374	Treatment of NRAS-Mutant Melanoma. <i>Current Treatment Options in Oncology</i> , 2015, 16, 15.	1.3	110
1375	Breast Cancer Under Age 40: a Different Approach. <i>Current Treatment Options in Oncology</i> , 2015, 16, 16.	1.3	67
1376	Immunotherapy in Upper GI Malignancies. <i>Current Treatment Options in Oncology</i> , 2015, 16, 20.	1.3	9
1377	Immunotherapy in Prostate Cancer. <i>Current Urology Reports</i> , 2015, 16, 34.	1.0	8
1378	Lymphovascular invasion and histologic grade are associated with specific genomic profiles in invasive carcinomas of the breast. <i>Tumor Biology</i> , 2015, 36, 1835-1848.	0.8	21
1379	Immunotherapy for lung cancer: for whom the bell tolls?. <i>Tumor Biology</i> , 2015, 36, 1411-1422.	0.8	17
1380	Targeting cancer-specific mutations by T cell receptor gene therapy. <i>Current Opinion in Immunology</i> , 2015, 33, 112-119.	2.4	82
1381	Tumor Intrinsic Subtype Is Reflected in Cancer-Adjacent Tissue. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 406-414.	1.1	72
1382	Safety and Survival With GVAX Pancreas Prime and <i>Listeria Monocytogenes</i> Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1325-1333.	0.8	490
1383	Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 647-664.	1.5	40
1384	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2006-2017.	13.9	2,489

#	ARTICLE	IF	CITATIONS
1385	Combinatorial code governing cellular responses to complex stimuli. <i>Nature Communications</i> , 2015, 6, 6847.	5.8	32
1386	New horizons in tumor microenvironment biology: challenges and opportunities. <i>BMC Medicine</i> , 2015, 13, 45.	2.3	535
1387	Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. <i>BMC Medicine</i> , 2015, 13, 46.	2.3	27
1388	Identification of rare germline copy number variations over-represented in five human cancer types. <i>Molecular Cancer</i> , 2015, 14, 25.	7.9	32
1389	A conserved region within interferon regulatory factor 5 controls breast cancer cell migration through a cytoplasmic and transcription-independent mechanism. <i>Molecular Cancer</i> , 2015, 14, 32.	7.9	8
1390	Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. <i>Cell Communication and Signaling</i> , 2015, 13, 14.	2.7	45
1391	Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. <i>Retrovirology</i> , 2015, 12, 14.	0.9	119
1392	Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 8.	2.2	82
1393	MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 13.	2.2	69
1394	Invasive lobular carcinoma of the breast: morphology, biomarkers and â€^{TM} omics. <i>Breast Cancer Research</i> , 2015, 17, 12.	2.2	256
1395	Molecular subtyping for clinically defined breast cancer subgroups. <i>Breast Cancer Research</i> , 2015, 17, 29.	2.2	51
1396	Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. <i>Breast Cancer Research</i> , 2015, 17, 43.	2.2	248
1397	Targeting PTEN-defined breast cancers with a one-two punch. <i>Breast Cancer Research</i> , 2015, 17, 51.	2.2	4
1398	PhyloWGS: Reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. <i>Genome Biology</i> , 2015, 16, 35.	3.8	351
1399	Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. <i>Genome Biology</i> , 2015, 16, 45.	3.8	145
1400	Denosing perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer. <i>Genome Biology</i> , 2015, 16, 61.	3.8	5
1401	Variant interpretation through Bayesian fusion of frequency and genomic knowledge. <i>Genome Medicine</i> , 2015, 7, 4.	3.6	1
1402	TET proteins and the control of cytosine demethylation in cancer. <i>Genome Medicine</i> , 2015, 7, 9.	3.6	176

#	ARTICLE	IF	CITATIONS
1403	Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. <i>Genome Medicine</i> , 2015, 7, 21.	3.6	34
1404	Multiplex bisulfite PCR resequencing of clinical FFPE DNA. <i>Clinical Epigenetics</i> , 2015, 7, 28.	1.8	26
1405	Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells. <i>Cell and Bioscience</i> , 2015, 5, 10.	2.1	9
1406	Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing. <i>Human Genomics</i> , 2015, 9, 2.	1.4	36
1407	Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. <i>Acta Neuropathologica Communications</i> , 2015, 3, 4.	2.4	100
1408	Response of Head and Neck Squamous Cell Carcinoma Cells Carrying PIK3CA Mutations to Selected Targeted Therapies. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 543.	1.2	25
1409	The next steps in next-gen sequencing of cancer genomes. <i>Journal of Clinical Investigation</i> , 2015, 125, 462-468.	3.9	34
1410	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. <i>Drugs</i> , 2015, 75, 563-575.	4.9	18
1411	Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches. <i>Stem Cells</i> , 2015, 33, 2085-2092.	1.4	131
1412	IFN- β from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. <i>British Journal of Cancer</i> , 2015, 112, 1501-1509.	2.9	533
1413	Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages. <i>Gastroenterology</i> , 2015, 149, 201-210.	0.6	233
1414	Pembrolizumab "is the writing on the wall for cancer?". <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 371-371.	12.5	0
1415	Transplanted Tumor Growth and the Incidence of T-Lymphocyte Populations in the Spleen of Newcastle Virus-Treated Mice. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 182-186.	0.7	2
1416	From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. <i>Experimental Biology and Medicine</i> , 2015, 240, 1087-1098.	1.1	52
1417	Tailoring therapies "improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449
1418	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 399-411.	1.6	387
1419	Clinically feasible approaches to potentiating cancer cell-based immunotherapies. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 851-869.	1.4	67
1420	Refining the treatment of NSCLC according to histological and molecular subtypes. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 511-526.	12.5	247

#	ARTICLE	IF	CITATIONS
1421	Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. <i>Cancer Discovery</i> , 2015, 5, 488-505.	7.7	97
1422	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
1423	Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. <i>Cell</i> , 2015, 161, 1035-1045.	13.5	228
1424	Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. <i>Nature Communications</i> , 2015, 6, 7114.	5.8	139
1425	Pugh et al. reply. <i>Nature</i> , 2015, 520, E12-E14.	13.7	8
1426	Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma. <i>BMC Veterinary Research</i> , 2015, 11, 107.	0.7	14
1427	Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines. <i>Cell Communication and Signaling</i> , 2015, 13, 26.	2.7	47
1428	New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing. <i>BMC Medical Genomics</i> , 2015, 8, 19.	0.7	34
1429	Presence of circulating Her2-reactive CD8 ⁺ T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. <i>Breast Cancer Research</i> , 2015, 17, 34.	2.2	63
1430	Circulating CD14 ⁺ HLA-DR ^{low} myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC. <i>Tumor Biology</i> , 2015, 36, 7987-7996.	0.8	30
1431	FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	80
1432	Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 101.	1.1	93
1433	Classifying Cancers Based on T-cell Infiltration and PD-L1. <i>Cancer Research</i> , 2015, 75, 2139-2145.	0.4	1,167
1434	The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies. <i>Cancer Immunology Research</i> , 2015, 3, 436-443.	1.6	631
1435	Coordinated epigenetic remodelling of transcriptional networks occurs during early breast carcinogenesis. <i>Clinical Epigenetics</i> , 2015, 7, 52.	1.8	26
1436	Immunotherapeutic Approaches to Sarcoma. <i>Current Treatment Options in Oncology</i> , 2015, 16, 26.	1.3	48
1437	A microfluidic device for label-free, physical capture of circulating tumor cell clusters. <i>Nature Methods</i> , 2015, 12, 685-691.	9.0	628
1438	Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 195.	1.1	101

#	ARTICLE	IF	CITATIONS
1439	Molecular characterization and targeted therapeutic approaches in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 60.	2.2	132
1440	Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2015, 33, 881-889.	1.2	46
1441	Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. , 2015, 3, 11.		274
1442	Zodiac: A Comprehensive Depiction of Genetic Interactions in Cancer by Integrating TCGA Data. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	27
1443	Mutational landscape determines sensitivity to PD-1 blockade in non-“small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	6.0	6,756
1444	Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics. <i>Clinical Cancer Research</i> , 2015, 21, 2236-2243.	3.2	147
1445	Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?. <i>Clinical Cancer Research</i> , 2015, 21, 2244-2255.	3.2	179
1446	Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in <i>BRAF</i> ^{V600E} melanoma. <i>Science Translational Medicine</i> , 2015, 7, 279ra41.	5.8	470
1447	Overcoming T cell exhaustion in infection and cancer. <i>Trends in Immunology</i> , 2015, 36, 265-276.	2.9	856
1448	Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. <i>Cancer Letters</i> , 2015, 360, 302-309.	3.2	119
1449	TLR5 Ligand-“Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. <i>Cancer Research</i> , 2015, 75, 1959-1971.	0.4	33
1450	How Treatment Monitoring Is Influencing Treatment Decisions in Glioblastomas. <i>Current Treatment Options in Neurology</i> , 2015, 17, 343.	0.7	13
1451	The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 459-465.	2.0	34
1452	Emerging Therapeutic Targets of Sepsis-Associated Acute Kidney Injury. <i>Seminars in Nephrology</i> , 2015, 35, 38-54.	0.6	36
1453	Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 237-51.	1.2	154
1454	Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. <i>Nature Medicine</i> , 2015, 21, 327-334.	15.2	129
1455	Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1220-9.	3.3	72
1456	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. <i>Nature</i> , 2015, 520, 373-377.	13.7	1,955

#	ARTICLE	IF	CITATIONS
1457	Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. <i>Clinical Cancer Research</i> , 2015, 21, 3052-3060.	3.2	198
1458	Haematological malignancies: at the forefront of immunotherapeutic innovation. <i>Nature Reviews Cancer</i> , 2015, 15, 201-215.	12.8	63
1459	DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. <i>Oncogene</i> , 2015, 34, 5869-5878.	2.6	195
1460	Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 410-420.	0.9	17
1461	PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. <i>Leukemia</i> , 2015, 29, 2110-2113.	3.3	170
1462	Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1000-1007.	0.8	206
1463	Breast cancer risk associated with gene expression and genotype polymorphisms of the folate-metabolizing MTHFR gene: a case-control study in a high altitude Ecuadorian mestizo population. <i>Tumor Biology</i> , 2015, 36, 6451-6461.	0.8	31
1464	Î±-Tubulin Acetylation Elevated in Metastatic and Basal-like Breast Cancer Cells Promotes Microtentacle Formation, Adhesion, and Invasive Migration. <i>Cancer Research</i> , 2015, 75, 203-215.	0.4	160
1465	Immunological mechanisms of the antitumor effects of supplemental oxygenation. <i>Science Translational Medicine</i> , 2015, 7, 277ra30.	5.8	458
1466	Intertwined regulation of angiogenesis and immunity by myeloid cells. <i>Trends in Immunology</i> , 2015, 36, 240-249.	2.9	122
1467	Interleukin-35: Expanding Its Job Profile. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 499-512.	0.5	83
1468	The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 561-568.	3.2	133
1469	Repurposing Drugs in Oncology (ReDO) "clarithromycin as an anti-cancer agent. <i>Ecancermedalscience</i> , 2015, 9, 513.	0.6	62
1470	Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8 + T-cell Activation Against Tumors. <i>Molecular Therapy</i> , 2015, 23, 1092-1102.	3.7	6
1471	Melanoma-intrinsic Î²-catenin signalling prevents anti-tumour immunity. <i>Nature</i> , 2015, 523, 231-235.	13.7	2,130
1472	Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. <i>Annals of Oncology</i> , 2015, 26, 1791-1798.	0.6	68
1473	Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. <i>Clinical Cancer Research</i> , 2015, 21, 2359-2366.	3.2	125
1474	IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 2167-2176.	3.2	16

#	ARTICLE	IF	CITATIONS
1475	4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. <i>Nature Medicine</i> , 2015, 21, 581-590.	15.2	1,304
1476	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2015, 33, 278-284.	0.8	102
1477	Targeting precision medicine toxicity: recent developments. <i>Therapeutic Advances in Drug Safety</i> , 2015, 6, 4-14.	1.0	4
1478	Methylation of cell-free circulating DNA in the diagnosis of cancer. <i>Frontiers in Molecular Biosciences</i> , 2015, 2, 13.	1.6	159
1479	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. <i>Journal of Clinical Investigation</i> , 2015, 125, 2077-2089.	3.9	111
1480	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB / Clinical Oncology, 2015, 33, 2004-2012.	0.8	1,035
1481	Molecular Biology and Immunology of Head and Neck Cancer. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 397-407.	0.6	32
1482	Ipilimumab-induced hypophysitis: review of the literature. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 1159-1166.	1.8	56
1483	The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. , 2015, 3, 15.		57
1484	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. <i>Molecular Therapy</i> , 2015, 23, 1380-1390.	3.7	88
1485	Exploiting replicative stress to treat cancer. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 405-423.	21.5	243
1486	Translational value of mouse models in oncology drug development. <i>Nature Medicine</i> , 2015, 21, 431-439.	15.2	242
1487	Phosphotyrosine Signaling Analysis in Human Tumors Is Confounded by Systemic Ischemia-Driven Artifacts and Intra-Specimen Heterogeneity. <i>Cancer Research</i> , 2015, 75, 1495-1503.	0.4	42
1488	The phosphoinositide 3-kinase pathway and therapy resistance in cancer. <i>F1000prime Reports</i> , 2015, 7, 13.	5.9	91
1489	PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors. <i>Journal of Immunotherapy</i> , 2015, 38, 1-11.	1.2	333
1490	Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2015, 38, 80-84.	1.2	79
1491	Peripheral Neuropathy Associated With Ipilimumab. <i>Journal of Immunotherapy</i> , 2015, 38, 77-79.	1.2	53
1492	Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2015, 10, 500-508.	0.5	129

#	ARTICLE	IF	CITATIONS
1493	Stress, Metabolism and Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 97-103.	1.0	34
1494	Effect of Surgery on Pancreatic Tumor-Dependent Lymphocyte Asset. <i>Pancreas</i> , 2015, 44, 386-393.	0.5	33
1495	Molecular Classification of Gastric Adenocarcinoma: Translating New Insights from The Cancer Genome Atlas Research Network. <i>Current Treatment Options in Oncology</i> , 2015, 16, 17.	1.3	53
1496	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1889-1894.	0.8	1,809
1497	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 319-334.	12.5	489
1498	Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies. <i>Journal of Neuro-Oncology</i> , 2015, 123, 373-383.	1.4	14
1499	The STING pathway and the T cell-inflamed tumor microenvironment. <i>Trends in Immunology</i> , 2015, 36, 250-256.	2.9	190
1500	Immunomodulatory spherical nucleic acids. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 3892-3897.	3.3	205
1501	Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer. <i>Journal of the Royal Society Interface</i> , 2015, 12, 20141153.	1.5	82
1502	CMPD: cancer mutant proteome database. <i>Nucleic Acids Research</i> , 2015, 43, D849-D855.	6.5	13
1503	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1191-1196.	0.8	445
1504	Objective Measurement and Clinical Significance of TILs in Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	325
1505	Effect of minichromosome maintenance protein 2 deficiency on the locations of DNA replication origins. <i>Genome Research</i> , 2015, 25, 558-569.	2.4	22
1506	Genotype/Phenotype Correlations in Patients with Hereditary Breast Cancer. <i>Breast Care</i> , 2015, 10, 22-26.	0.8	17
1507	Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis. <i>Journal of Immunology</i> , 2015, 194, 2985-2991.	0.4	369
1508	Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 457-466.	1.1	7
1509	siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8+ T cells in NOD/SCID/IL2Rg(null) mice. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 645-654.	2.0	42
1510	Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions. <i>Journal of Immunotherapy</i> , 2015, 38, 96-106.	1.2	171

#	ARTICLE	IF	CITATIONS
1511	Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. <i>Oncogene</i> , 2015, 34, 5997-6006.	2.6	100
1512	Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2. <i>Neoplasia</i> , 2015, 17, 279-288.	2.3	56
1513	Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. <i>Clinical Cancer Research</i> , 2015, 21, 3178-3186.	3.2	34
1514	Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2 ⁺ Breast Cancer. <i>Advanced Functional Materials</i> , 2015, 25, 2646-2659.	7.8	155
1515	Changes in BAI1 and Nestin Expression Are Prognostic Indicators for Survival and Metastases in Breast Cancer and Provide Opportunities for Dual Targeted Therapies. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 307-314.	1.9	26
1516	Novel molecular targets for urothelial carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 515-525.	1.5	7
1517	Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 485-493.	1.1	14
1518	Optimal Drug Prediction From Personal Genomics Profiles. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2015, 19, 1264-1270.	3.9	43
1519	Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. <i>British Journal of Cancer</i> , 2015, 112, 1421-1427.	2.9	215
1520	Racial Variation in Breast Tumor Promoter Methylation in the Carolina Breast Cancer Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 921-930.	1.1	41
1521	Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases. <i>Clinical Cancer Research</i> , 2015, 21, 3149-3159.	3.2	324
1522	Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. <i>European Journal of Radiology</i> , 2015, 84, 1259-1268.	1.2	105
1523	Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. <i>Cancer Cell</i> , 2015, 27, 450-461.	7.7	3,266
1524	Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. <i>Cell</i> , 2015, 161, 205-214.	13.5	1,872
1525	A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2015, 13, 265-272.	1.9	188
1526	NF- κ B Regulates PD-1 Expression in Macrophages. <i>Journal of Immunology</i> , 2015, 194, 4545-4554.	0.4	134
1527	When are signal transduction targeted therapies acting as immunotherapy?. <i>Cancer Biology and Therapy</i> , 2015, 16, 645-647.	1.5	1
1528	Oncolytic Virus Immunotherapy for Melanoma. <i>Current Treatment Options in Oncology</i> , 2015, 16, 326.	1.3	40

#	ARTICLE	IF	CITATIONS
1529	PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 569-579.	1.1	17
1530	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1902-1909.	0.8	351
1531	TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10. <i>International Journal of Cancer</i> , 2015, 137, 1386-1396.	2.3	25
1532	Mutant Allele Tumor Heterogeneity (MATH) and Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2015, 9, 1-5.	1.3	43
1533	Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. <i>Bone Marrow Transplantation</i> , 2015, 50, 770-780.	1.3	9
1534	TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2722-2729.	3.2	57
1535	Something in the Air: Hyperoxic Conditioning of the Tumor Microenvironment for Enhanced Immunotherapy. <i>Cancer Cell</i> , 2015, 27, 435-436.	7.7	32
1536	Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints. <i>Current Opinion in Virology</i> , 2015, 13, 33-39.	2.6	45
1537	Macrophages and Therapeutic Resistance in Cancer. <i>Cancer Cell</i> , 2015, 27, 462-472.	7.7	1,130
1538	TGF β 2 Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. <i>Cancer Research</i> , 2015, 75, 2232-2242.	0.4	429
1539	Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1287-1293.	2.0	18
1540	Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 41-50.	0.8	75
1541	Combination approaches and anti-PD1 therapies: the focus of new research at ESMO and SMR. <i>Melanoma Management</i> , 2015, 2, 9-14.	0.1	3
1542	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. <i>Cancer Cell</i> , 2015, 28, 515-528.	7.7	426
1543	The first five years of single-cell cancer genomics and beyond. <i>Genome Research</i> , 2015, 25, 1499-1507.	2.4	324
1544	Biomaterial Strategies for Immunomodulation. <i>Annual Review of Biomedical Engineering</i> , 2015, 17, 317-349.	5.7	132
1545	Early detection of breast cancer using total biochemical analysis of peripheral blood components: a preliminary study. <i>BMC Cancer</i> , 2015, 15, 408.	1.1	50
1546	Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1315-1327.	2.0	134

#	ARTICLE	IF	CITATIONS
1547	Adiposity is associated with p53 gene mutations in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 635-645.	1.1	4
1548	4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 647-658.	1.1	51
1549	CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. <i>Cell</i> , 2015, 163, 174-186.	13.5	346
1550	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639.	13.9	7,973
1551	The changing role of ER in endocrine resistance. <i>Breast</i> , 2015, 24, S60-S66.	0.9	97
1552	Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. <i>Modern Pathology</i> , 2015, 28, 1594-1602.	2.9	228
1553	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. <i>Modern Pathology</i> , 2015, 28, 1535-1544.	2.9	76
1554	How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)?. <i>Current Opinion in Virology</i> , 2015, 14, 93-100.	2.6	78
1555	A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. <i>Annals of Oncology</i> , 2015, 26, 2267-2274.	0.6	67
1556	Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. <i>Annals of Oncology</i> , 2015, 26, 2375-2391.	0.6	1,136
1557	Predictive biomarkers in precision medicine and drug development against lung cancer. <i>Chinese Journal of Cancer</i> , 2015, 34, 295-309.	4.9	34
1558	Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3096-3104.	0.8	26
1559	Nivolumab in combination with ipilimumab for the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1135-1141.	1.1	22
1560	Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2021, 22, 513-526.	1.5	24
1561	Signatures of post-zygotic structural genetic aberrations in the cells of histologically normal breast tissue that can predispose to sporadic breast cancer. <i>Genome Research</i> , 2015, 25, 1521-1535.	2.4	25
1562	PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation. <i>Cancer Immunology Research</i> , 2015, 3, 110-115.	1.6	45
1563	CD8 + T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis. <i>BMC Systems Biology</i> , 2015, 9, 27.	3.0	16
1564	Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance. <i>Trends in Immunology</i> , 2015, 36, 665-667.	2.9	2

#	ARTICLE	IF	CITATIONS
1565	Genomic landscapes of breast fibroepithelial tumors. <i>Nature Genetics</i> , 2015, 47, 1341-1345.	9.4	167
1566	Intron retention is a widespread mechanism of tumor-suppressor inactivation. <i>Nature Genetics</i> , 2015, 47, 1242-1248.	9.4	322
1567	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. <i>Oncologist</i> , 2015, 20, 648-652.	1.9	38
1568	Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells. <i>Journal of Immunology</i> , 2015, 195, 4028-4037.	0.4	26
1569	Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 445-454.	1.1	25
1570	Predictors of clinical response to immunotherapy with or without radiotherapy. <i>Journal of Radiation Oncology</i> , 2015, 4, 339-345.	0.7	17
1571	Transcriptome analysis of basal and luminal tumor-initiating cells in ErbB2-driven breast cancer. <i>Genomics Data</i> , 2015, 4, 119-122.	1.3	4
1572	Five-Year Risk for Interval-Invasive Second Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	31
1573	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. <i>JAMA Oncology</i> , 2015, 1, 448.	3.4	482
1574	The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma. <i>Dermatology and Therapy</i> , 2015, 5, 151-169.	1.4	19
1575	Targeting LKB1 in cancer – exposing and exploiting vulnerabilities. <i>British Journal of Cancer</i> , 2015, 113, 574-584.	2.9	81
1576	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1803-1813.	13.9	4,889
1577	Immune checkpoints and immunotherapy for colorectal cancer. <i>Gastroenterology Report</i> , 2015, 3, gov053.	0.6	80
1578	Immunosuppressive mechanisms in glioblastoma: Fig. 1.. <i>Neuro-Oncology</i> , 2015, 17, vii9-vii14.	0.6	275
1579	Immunomodulation: checkpoint blockade etc.: Fig. 1.. <i>Neuro-Oncology</i> , 2015, 17, vii26-vii31.	0.6	26
1580	Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data. <i>Journal of Medical Imaging</i> , 2015, 2, 041007.	0.8	126
1581	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	5.1	582
1582	Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology. <i>Translational Oncology</i> , 2015, 8, 407-416.	1.7	43

#	ARTICLE	IF	CITATIONS
1583	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. <i>BMC Medicine</i> , 2015, 13, 177.	2.3	45
1584	Relevance of tumor-infiltrating lymphocytes in breast cancer. <i>BMC Medicine</i> , 2015, 13, 202.	2.3	177
1585	Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 997-1004.	1.1	58
1586	Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 737-745.	0.4	42
1587	<i>HER2</i> missense mutations have distinct effects on oncogenic signaling and migration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6205-14.	3.3	69
1588	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in <i>MET</i> -Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2015, 5, 1271-1281.	7.7	162
1589	Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma—challenges in management. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1595-1602.	1.0	5
1590	ATM rs189037 (G>A) polymorphism and risk of lung cancer and head and neck cancer: A meta-analysis. <i>Meta Gene</i> , 2015, 6, 42-48.	0.3	12
1591	Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 538-545.	0.8	14
1592	Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. <i>Clinical Epigenetics</i> , 2015, 7, 59.	1.8	49
1593	MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. <i>Nature Communications</i> , 2015, 6, 8755.	5.8	175
1594	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. <i>Neuro-Oncology</i> , 2015, 17, vii32-vii40.	0.6	21
1595	Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti-PD-L1 efficacy. <i>Science</i> , 2015, 350, 1084-1089.	6.0	2,782
1596	DeDaL: Cytoscape 3 app for producing and morphing data-driven and structure-driven network layouts. <i>BMC Systems Biology</i> , 2015, 9, 46.	3.0	17
1597	High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 701-709.	1.4	25
1598	Interferons and the Immunogenic Effects of Cancer Therapy. <i>Trends in Immunology</i> , 2015, 36, 725-737.	2.9	107
1599	Potential of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2850-2863.	1.9	33
1600	Optimal management of hormone receptor positive metastatic breast cancer in 2016. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 304-320.	1.4	104

#	ARTICLE	IF	CITATIONS
1601	Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems. <i>BMC Medical Genomics</i> , 2015, 8, 25.	0.7	58
1603	Pin1 inhibits PP2A-mediated Rb dephosphorylation in regulation of cell cycle and S-phase DNA damage. <i>Cell Death and Disease</i> , 2015, 6, e1640-e1640.	2.7	29
1604	Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. <i>Nature</i> , 2015, 527, 249-253.	13.7	897
1605	Post-transplantation malignancies: here today, gone tomorrow?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 705-717.	12.5	53
1606	New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies. <i>Clinical Cancer Research</i> , 2015, 21, 5191-5197.	3.2	29
1608	Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1109-1121.	2.0	11
1609	Clinical significance of the integrin $\alpha 6 \beta 4$ in human malignancies. <i>Laboratory Investigation</i> , 2015, 95, 976-986.	1.7	166
1610	Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer. <i>Drugs</i> , 2015, 75, 1925-1934.	4.9	23
1611	The path to routine use of genomic biomarkers in the cancer clinic. <i>Genome Research</i> , 2015, 25, 1508-1513.	2.4	35
1612	T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2015, 28, 638-652.	7.7	168
1613	HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6215-23.	3.3	299
1614	Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade. <i>Cancer Immunology Research</i> , 2015, 3, 1269-1278.	1.6	84
1615	Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells. <i>Molecular Cancer</i> , 2015, 14, 149.	7.9	209
1616	Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. <i>Structure</i> , 2015, 23, 2341-2348.	1.6	399
1617	Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 5427-5433.	3.2	254
1618	Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. <i>Cancer Immunology Research</i> , 2015, 3, 1185-1192.	1.6	227
1619	A Gene Regulatory Program in Human Breast Cancer. <i>Genetics</i> , 2015, 201, 1341-1348.	1.2	14
1620	A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients. <i>Genome Medicine</i> , 2015, 7, 104.	3.6	65

#	ARTICLE	IF	CITATIONS
1621	Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1962-1971.	1.9	25
1622	Targeted therapies for ER+/HER2- metastatic breast cancer. <i>BMC Medicine</i> , 2015, 13, 137.	2.3	59
1623	Nivolumab: A Review in Advanced Melanoma. <i>Drugs</i> , 2015, 75, 1413-1424.	4.9	44
1624	Genomic spectra of biliary tract cancer. <i>Nature Genetics</i> , 2015, 47, 1003-1010.	9.4	907
1625	Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry. <i>Nature Protocols</i> , 2015, 10, 1308-1318.	5.5	67
1626	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	4.9	307
1627	Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 347-356.	1.1	38
1628	Next-generation sequencing to guide cancer therapy. <i>Genome Medicine</i> , 2015, 7, 80.	3.6	251
1629	Pan-cancer stratification of solid human epithelial tumors and cancer cell lines reveals commonalities and tissue-specific features of the CpG island methylator phenotype. <i>Epigenetics and Chromatin</i> , 2015, 8, 14.	1.8	42
1630	Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. <i>Cancer Immunology Research</i> , 2015, 3, 1082-1095.	1.6	147
1631	Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. <i>Drugs</i> , 2015, 75, 1311-1321.	4.9	5
1632	8p deletion is strongly linked to poor prognosis in breast cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 1080-1087.	1.5	26
1633	Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma: Table 1. <i>Neuro-Oncology</i> , 2015, 17, 1043-1045.	0.6	24
1634	Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. <i>Nature</i> , 2015, 525, 119-123.	13.7	284
1635	PIK3CAH1047R induces multipotency and multi-lineage mammary tumours. <i>Nature</i> , 2015, 525, 114-118.	13.7	260
1636	Injectable cryogel-based whole-cell cancer vaccines. <i>Nature Communications</i> , 2015, 6, 7556.	5.8	312
1637	The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. <i>Seminars in Oncology</i> , 2015, 42, 663-671.	0.8	388
1638	Academically led clinical trials: challenges and opportunities. <i>Annals of Oncology</i> , 2015, 26, 2010-2011.	0.6	1

#	ARTICLE	IF	CITATIONS
1639	Clinical implications of molecular heterogeneity in triple negative breast cancer. <i>Breast</i> , 2015, 24, S36-S40.	0.9	108
1640	Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4410-7.	3.3	283
1641	CSN6 positively regulates c-Jun in a MEK1-dependent manner. <i>Cell Cycle</i> , 2015, 14, 3079-3087.	1.3	10
1642	Why has active immunotherapy not worked in lung cancer?. <i>Annals of Oncology</i> , 2015, 26, 2213-2220.	0.6	35
1643	Frequent PD-L1 expression in testicular germ cell tumors. <i>British Journal of Cancer</i> , 2015, 113, 411-413.	2.9	126
1644	Targeting Signaling Transduction Pathways in Bladder Cancer. <i>Current Oncology Reports</i> , 2015, 17, 58.	1.8	37
1645	AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. <i>Journal of Hematology and Oncology</i> , 2015, 8, 96.	6.9	84
1646	Global gene expression profiling reveals a suppressed immune response pathway associated with 3q amplification in squamous carcinoma of the lung. <i>Genomics Data</i> , 2015, 5, 272-274.	1.3	6
1647	The burgeoning family of unconventional T cells. <i>Nature Immunology</i> , 2015, 16, 1114-1123.	7.0	655
1648	Immunological landscape and immunotherapy of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 681-700.	8.2	478
1649	Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. <i>Annals of Oncology</i> , 2015, 26, 2367-2374.	0.6	40
1650	APC selectively mediates response to chemotherapeutic agents in breast cancer. <i>BMC Cancer</i> , 2015, 15, 457.	1.1	36
1651	Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 139.	1.8	36
1652	Circulating $PD-L1$ in NSCLC patients and the correlation between the level of $PD-L1$ expression and the clinical characteristics. <i>Thoracic Cancer</i> , 2015, 6, 534-538.	0.8	107
1653	Immunological evaluation of peptide vaccination for cancer patients with the HLA $A26$ allele. <i>Cancer Science</i> , 2015, 106, 1257-1263.	1.7	7
1654	$PD-1$ expression on $CD4+$ T cells and myeloid DC s correlates with the immune pathogenesis of atrial fibrillation. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 1223-1233.	1.6	23
1655	Classical pathology and mutational load of breast cancer – integration of two worlds. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 225-238.	1.3	91
1656	Epigenetic and Immune Regulation of Colorectal Cancer Stem Cells. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 414-421.	1.0	5

#	ARTICLE	IF	CITATIONS
1657	Pharmacologic Management of Advanced Cervical Cancer: Antiangiogenesis Therapy and Immunotherapeutic Considerations. <i>Drugs</i> , 2015, 75, 1853-1865.	4.9	11
1658	Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. <i>British Journal of Cancer</i> , 2015, 113, 1343-1349.	2.9	54
1659	Immunotherapy in Sarcoma: Future Horizons. <i>Current Oncology Reports</i> , 2015, 17, 52.	1.8	16
1660	Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab. <i>International Journal of Hematology</i> , 2015, 102, 493-497.	0.7	12
1661	Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 487-495.	1.2	53
1662	Early phase clinical trials—are dose expansion cohorts needed?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 626-628.	12.5	34
1663	Breast Cancer Update 2014 — Focus on the Patient and the Tumour. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 170-182.	0.8	9
1664	Unique potential of 4-1BB agonist antibody to promote durable regression of HPV ⁺ tumors when combined with an E6/E7 peptide vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5290-9.	3.3	79
1665	Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas. <i>BMC Cancer</i> , 2015, 15, 524.	1.1	20
1666	Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2687-2699.	1.9	15
1667	Limited evidence that cancer susceptibility regions are preferential targets for somatic mutation. <i>Genome Biology</i> , 2015, 16, 193.	3.8	19
1668	Modelling breast cancer requires identification and correction of a critical cell lineage-dependent transduction bias. <i>Nature Communications</i> , 2015, 6, 6927.	5.8	20
1669	Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked. <i>Experimental Hematology and Oncology</i> , 2015, 4, 1.	2.0	8
1670	The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Oncologist</i> , 2015, 20, 1253-1260.	1.9	40
1671	An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. <i>Current Treatment Options in Oncology</i> , 2015, 16, 54.	1.3	44
1672	The role of B-1 cells in inflammation. <i>Immunologic Research</i> , 2015, 63, 153-166.	1.3	91
1673	Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. <i>Blood Cancer Journal</i> , 2015, 5, e285-e285.	2.8	82
1674	Immunological hallmarks of stromal cells in the tumour microenvironment. <i>Nature Reviews Immunology</i> , 2015, 15, 669-682.	10.6	850

#	ARTICLE	IF	CITATIONS
1675	Adoptive T-Cell Immunotherapy. <i>Current Topics in Microbiology and Immunology</i> , 2015, 391, 427-454.	0.7	48
1676	A basal stem cell signature identifies aggressive prostate cancer phenotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6544-52.	3.3	168
1677	Next-Generation Sequencing to Guide Clinical Trials. <i>Clinical Cancer Research</i> , 2015, 21, 4536-4544.	3.2	59
1678	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. <i>Drugs and Aging</i> , 2015, 32, 821-834.	1.3	12
1679	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <i>Cell</i> , 2015, 163, 506-519.	13.5	1,485
1680	Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors. <i>Seminars in Oncology</i> , 2015, 42, 713-723.	0.8	11
1681	The growth threshold conjecture: a theoretical framework for understanding T-cell tolerance. <i>Royal Society Open Science</i> , 2015, 2, 150016.	1.1	22
1682	Genetic instability in the tumor microenvironment: a new look at an old neighbor. <i>Molecular Cancer</i> , 2015, 14, 145.	7.9	48
1683	Inferring pathway dysregulation in cancers from multiple types of omic data. <i>Genome Medicine</i> , 2015, 7, 61.	3.6	13
1684	Resimmune, an anti-CD3 β recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. <i>Haematologica</i> , 2015, 100, 794-800.	1.7	46
1685	Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. <i>Trends in Cancer</i> , 2015, 1, 66-75.	3.8	101
1686	Muscle-invasive urothelial bladder cancer: an update on systemic therapy. <i>Therapeutic Advances in Urology</i> , 2015, 7, 312-330.	0.9	34
1687	A seven-gene CpG-island methylation panel predicts breast cancer progression. <i>BMC Cancer</i> , 2015, 15, 417.	1.1	30
1688	Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. <i>Carcinogenesis</i> , 2015, 36, S111-S127.	1.3	43
1689	Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. <i>Molecular Cancer</i> , 2015, 14, 119.	7.9	50
1690	Patterns of Chromosomal Aberrations in Solid Tumors. <i>Recent Results in Cancer Research</i> , 2015, 200, 115-142.	1.8	44
1691	MicroRNA letâ€b regulates genomic balance by targeting Aurora B kinase. <i>Molecular Oncology</i> , 2015, 9, 1056-1070.	2.1	21
1692	Local sequence assembly reveals a high-resolution profile of somatic structural variations in 97 cancer genomes. <i>Nucleic Acids Research</i> , 2015, 43, 8146-8156.	6.5	22

#	ARTICLE	IF	CITATIONS
1693	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. <i>Cancer Immunology Research</i> , 2015, 3, 1375-1385.	1.6	342
1694	The mammary stem cell hierarchy: a looking glass into heterogeneous breast cancer landscapes. <i>Endocrine-Related Cancer</i> , 2015, 22, T161-T176.	1.6	45
1695	Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 886-893.	2.9	136
1696	The Dynamics of Interactions Among Immune and Glioblastoma Cells. <i>NeuroMolecular Medicine</i> , 2015, 17, 335-352.	1.8	30
1697	Manipulating the in vivo immune response by targeted gene knockdown. <i>Current Opinion in Immunology</i> , 2015, 35, 63-72.	2.4	7
1698	Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 496.e11-496.e16.	0.8	35
1699	The Possible Interaction between Receptor Activator of Nuclear Factor Kappa-B Ligand Expressed by Extramammary Paget Cells and its Ligand on Dermal Macrophages. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2547-2550.	0.3	37
1700	Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. <i>Laboratory Investigation</i> , 2015, 95, 385-396.	1.7	71
1701	In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. <i>Nature Genetics</i> , 2015, 47, 1212-1219.	9.4	139
1702	Molecular portraits: the evolution of the concept of transcriptome-based cancer signatures. <i>Briefings in Bioinformatics</i> , 2015, 16, 1000-1007.	3.2	9
1703	The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib. <i>International Journal of Hematology</i> , 2015, 102, 426-433.	0.7	5
1704	Lung cancer: Biology and treatment options. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 189-210.	3.3	526
1705	Melanoma Risk and Survival among Organ Transplant Recipients. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2657-2665.	0.3	108
1706	LINE-1 expression and retrotransposition in Barrett's esophagus and esophageal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4894-900.	3.3	127
1707	Strategies for combining immunotherapy with radiation for anticancer therapy. <i>Immunotherapy</i> , 2015, 7, 967-980.	1.0	83
1708	Histopathological Evidence of Lymph Node Metastasis in Papillary Thyroid Carcinoma. <i>Endocrine Pathology</i> , 2015, 26, 218-228.	5.2	12
1709	Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 325-332.	2.0	149
1710	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2015, 33, 3488-3515.	0.8	606

#	ARTICLE	IF	CITATIONS
1711	IL-36 β Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. <i>Cancer Cell</i> , 2015, 28, 296-306.	7.7	93
1712	Oncolytic viruses: a new class of immunotherapy drugs. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 642-662.	21.5	1,055
1713	Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant Women. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1170-1177.	0.5	1
1714	Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. <i>JAMA Oncology</i> , 2015, 1, 1340.	3.4	63
1715	Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer. <i>Drug Discovery Today</i> , 2015, 20, 1391-1397.	3.2	74
1716	Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. <i>Translational Research</i> , 2015, 166, 412-424.	2.2	65
1717	Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology. <i>Laboratory Investigation</i> , 2015, 95, 377-384.	1.7	180
1718	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>Journal of Clinical Oncology</i> , 2015, 33, 3193-3198.	0.8	892
1719	Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. <i>Genome Biology</i> , 2015, 16, 107.	3.8	109
1720	Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. <i>New England Journal of Medicine</i> , 2015, 373, 288-290.	13.9	339
1721	Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 187-194.	0.7	20
1722	Integrating Immunotherapies in Prostate Cancer. <i>Current Oncology Reports</i> , 2015, 17, 45.	1.8	3
1723	Activating Mutations in <i>PIK3CA</i> Lead to Widespread Modulation of the Tyrosine Phosphoproteome. <i>Journal of Proteome Research</i> , 2015, 14, 3882-3891.	1.8	7
1724	Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells. <i>Leukemia</i> , 2015, 29, 1781-1785.	3.3	26
1725	Adaptive Immune Resistance: How Cancer Protects from Immune Attack. <i>Cancer Discovery</i> , 2015, 5, 915-919.	7.7	495
1726	Are Cancer Outcomes Worse in the Presence of HIV Infection?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1165-1166.	1.1	4
1727	Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response. <i>Cancer Immunology Research</i> , 2015, 3, 827-835.	1.6	66
1728	Pembrolizumab. , 2015, 3, 36.		171

#	ARTICLE	IF	CITATIONS
1729	Adoptive cell therapy for sarcoma. <i>Immunotherapy</i> , 2015, 7, 21-35.	1.0	12
1730	Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. <i>Connective Tissue Research</i> , 2015, 56, 414-425.	1.1	123
1731	Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1201-1208.	1.4	11
1732	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. <i>Cell</i> , 2015, 162, 974-986.	13.5	1,408
1733	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. <i>Cell</i> , 2015, 162, 1229-1241.	13.5	2,158
1734	Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2790-2795.	1.4	54
1735	Management of Dermatologic Complications of Lung Cancer Therapies. <i>Current Treatment Options in Oncology</i> , 2015, 16, 50.	1.3	13
1736	Immunology and Immunotherapy of Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3293-3304.	0.8	566
1737	Immune checkpoint inhibitors in melanoma. <i>Melanoma Management</i> , 2015, 2, 267-284.	0.1	6
1738	Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results. <i>Drugs</i> , 2015, 75, 1757-1771.	4.9	11
1739	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. <i>Cell</i> , 2015, 162, 1242-1256.	13.5	507
1740	Nutrient Competition: A New Axis of Tumor Immunosuppression. <i>Cell</i> , 2015, 162, 1206-1208.	13.5	102
1741	An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. <i>Cancer Gene Therapy</i> , 2015, 22, 454-462.	2.2	62
1742	Emerging cytokine networks in colorectal cancer. <i>Nature Reviews Immunology</i> , 2015, 15, 615-629.	10.6	306
1743	Inferred miRNA activity identifies miRNA-mediated regulatory networks underlying multiple cancers. <i>Bioinformatics</i> , 2016, 32, 96-105.	1.8	31
1744	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , 2015, 350, 207-211.	6.0	2,275
1745	Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. <i>European Journal of Cancer</i> , 2015, 51, 2689-2697.	1.3	69
1746	Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. <i>Neuro-Oncology</i> , 2015, 17, 1312-1321.	0.6	57

#	ARTICLE	IF	CITATIONS
1747	Regulatory T lymphocytes and transforming growth factor beta in epithelial ovarian tumors-prognostic significance. <i>Journal of Ovarian Research</i> , 2015, 8, 39.	1.3	17
1748	An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer. <i>Genome Biology</i> , 2015, 16, 140.	3.8	60
1749	Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. <i>Journal of Clinical Oncology</i> , 2015, 33, 3621-3627.	0.8	172
1750	Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 41-50.	0.1	7
1751	Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation. <i>Modern Pathology</i> , 2015, 28, 1415-1427.	2.9	36
1752	Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. <i>Nature Biotechnology</i> , 2015, 33, 1152-1158.	9.4	573
1753	Emerging strategies for cancer immunoprevention. <i>Oncogene</i> , 2015, 34, 6029-6039.	2.6	39
1754	Strategies to Prevent "Bad Luck" in Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv213.	3.0	30
1755	Quantitative Radiology Reporting in Oncology: Survey of Oncologists and Radiologists. <i>American Journal of Roentgenology</i> , 2015, 205, W233-W243.	1.0	29
1756	Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 395-404.	1.2	13
1757	Extracutaneous melanomas: a primer for the radiologist. <i>Insights Into Imaging</i> , 2015, 6, 707-717.	1.6	23
1758	Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction. <i>Nature Communications</i> , 2015, 6, 6771.	5.8	138
1759	Multiplying therapies and reducing toxicity in metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2015, 16, 1014-1018.	1.5	9
1760	A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma. <i>Tumor Microenvironment and Therapy</i> , 2015, 2, 14-18.	1.2	3
1761	CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation. <i>Nature Immunology</i> , 2015, 16, 1060-1068.	7.0	110
1762	KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?. <i>British Journal of Cancer</i> , 2015, 113, 914-920.	2.9	7
1763	Perspectives on Human Variation through the Lens of Diversity and Race: Figure 1.. <i>Cold Spring Harbor Perspectives in Biology</i> , 2015, 7, a023358.	2.3	16
1764	Antibody-based immunotherapy of solid cancers: progress and possibilities. <i>Immunotherapy</i> , 2015, 7, 923-939.	1.0	24

#	ARTICLE	IF	CITATIONS
1765	Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. <i>Seminars in Oncology</i> , 2015, 42, 562-572.	0.8	30
1766	Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing. <i>Breast Cancer Research</i> , 2015, 17, 102.	2.2	30
1767	Copy number analysis of ductal carcinoma in situ with and without recurrence. <i>Modern Pathology</i> , 2015, 28, 1174-1184.	2.9	40
1768	PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. <i>Cancer Immunology Research</i> , 2015, 3, 1303-1307.	1.6	135
1769	Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv256.	3.0	90
1770	Associations between sociodemographic and clinicopathological factors and breast cancer subtypes in a population-based study. <i>Cancer Causes and Control</i> , 2015, 26, 1737-1750.	0.8	18
1771	Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples. <i>Journal of Proteome Research</i> , 2015, 14, 4394-4401.	1.8	18
1772	The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 441-453.	1.1	63
1773	Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 141.	3.5	186
1774	Engineering opportunities in cancer immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14467-14472.	3.3	111
1775	Management of melanoma brain metastases. <i>Melanoma Management</i> , 2015, 2, 225-239.	0.1	2
1776	Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15444-15449.	3.3	36
1777	Obesity and cancer immunotherapy toxicity. <i>Immunotherapy</i> , 2015, 7, 319-322.	1.0	20
1778	Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. <i>Meta Gene</i> , 2015, 4, 129-141.	0.3	17
1779	Multiple breast cancer risk variants are associated with differential transcript isoform expression in tumors. <i>Human Molecular Genetics</i> , 2015, 24, 7421-7431.	1.4	24
1780	Landscape of Tumor Antigens in T Cell Immunotherapy. <i>Journal of Immunology</i> , 2015, 195, 5117-5122.	0.4	124
1781	Comprehensive functional characterization of cancer-associated testis antigens defines obligate participation in multiple hallmarks of cancer. <i>Nature Communications</i> , 2015, 6, 8840.	5.8	94
1782	The mathematics of cancer: integrating quantitative models. <i>Nature Reviews Cancer</i> , 2015, 15, 730-745.	12.8	539

#	ARTICLE	IF	CITATIONS
1783	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. <i>Immunotherapy</i> , 2015, 7, 1169-1186.	1.0	45
1784	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1319-1327.	0.5	138
1785	Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015, 7, 365-377.	0.9	103
1786	Immune profiling in human breast cancer using high-sensitivity detection and analysis techniques. <i>JRSM Open</i> , 2015, 6, 205427041560390.	0.2	14
1787	Overview of current immunotherapeutic strategies for glioma. <i>Immunotherapy</i> , 2015, 7, 1073-1104.	1.0	40
1788	STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15408-15413.	3.3	404
1789	Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 104.	6.9	139
1790	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. <i>Molecular Oncology</i> , 2015, 9, 1936-1965.	2.1	64
1791	CAR T cell immunotherapy: The path from the byâ€œroad toâ€œthe freeway?. <i>Molecular Oncology</i> , 2015, 9, 1994-2018.	2.1	43
1792	Genetics: Big hopes for big data. <i>Nature</i> , 2015, 527, S108-S109.	13.7	40
1793	Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis. <i>Journal of Ovarian Research</i> , 2015, 8, 38.	1.3	28
1794	Promoter methylation of TRIM9 as a marker for detection of circulating tumor DNA in breast cancer patients. <i>SpringerPlus</i> , 2015, 4, 635.	1.2	22
1795	Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6506-14.	3.3	299
1796	Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits. <i>Breast Cancer Research</i> , 2015, 17, 85.	2.2	29
1797	Microenvironmental regulation of therapeutic response in cancer. <i>Trends in Cell Biology</i> , 2015, 25, 198-213.	3.6	604
1798	Feedback Suppression of PI3K \pm Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3K β . <i>Cancer Cell</i> , 2015, 27, 109-122.	7.7	203
1799	Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	37
1800	Splicing mutation analysis reveals previously unrecognized pathways in lymph node-invasive breast cancer. <i>Scientific Reports</i> , 2014, 4, 7063.	1.6	41

#	ARTICLE	IF	CITATIONS
1801	Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. <i>Nature Genetics</i> , 2015, 47, 106-114.	9.4	830
1802	Golden age of melanoma therapy. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 1-1.	12.5	24
1803	Immunoprevention of Human Papillomavirus-associated Malignancies. <i>Cancer Prevention Research</i> , 2015, 8, 95-104.	0.7	25
1804	Linking Tumor Mutations to Drug Responses via a Quantitative Chemical-Genetic Interaction Map. <i>Cancer Discovery</i> , 2015, 5, 154-167.	7.7	57
1805	Development of a robust classifier for quality control of reverse-phase protein arrays. <i>Bioinformatics</i> , 2015, 31, 912-918.	1.8	43
1806	Novel immunotherapies for hematologic malignancies. <i>Immunological Reviews</i> , 2015, 263, 90-105.	2.8	44
1807	Inhibitor of differentiation 4 (ID4): From development to cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 92-103.	3.3	50
1808	Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge. <i>Cancer Research</i> , 2015, 75, 5-10.	0.4	261
1809	Clinical blockade of PD1 and LAG3 - potential mechanisms of action. <i>Nature Reviews Immunology</i> , 2015, 15, 45-56.	10.6	524
1810	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1430-1437.	0.8	914
1811	PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 311-319.	13.9	3,099
1812	PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment. <i>Cancer Research</i> , 2015, 75, 508-518.	0.4	184
1813	B7H1/CD80 Interaction Augments PD-1-dependent T Cell Apoptosis and Ameliorates Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2015, 194, 560-574.	0.4	61
1814	Immunotherapy in prostate cancer: review of the current evidence. <i>Clinical and Translational Oncology</i> , 2015, 17, 339-357.	1.2	25
1815	miRNA - Therapeutic tool in breast cancer? Where are we now?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2015, 20, 79-86.	0.3	10
1816	Checkpoint parley. <i>Nature Reviews Cancer</i> , 2015, 15, 3-3.	12.8	25
1817	Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015, 17, 11-23.	1.2	8
1818	Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans. <i>Clinical Cancer Research</i> , 2015, 21, 534-543.	3.2	47

#	ARTICLE	IF	CITATIONS
1819	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. <i>Trends in Molecular Medicine</i> , 2015, 21, 24-33.	3.5	628
1820	Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer. <i>Modern Pathology</i> , 2015, 28, 677-685.	2.9	28
1821	Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+ T and NK Cells. <i>Journal of Immunology</i> , 2015, 194, 438-445.	0.4	185
1822	Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews. <i>Genetics in Medicine</i> , 2015, 17, 519-532.	1.1	26
1823	Checkpoint parley. <i>Nature Reviews Immunology</i> , 2015, 15, 5-5.	10.6	9
1824	Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. <i>Nature</i> , 2015, 518, 422-426.	13.7	545
1825	TRAF2 is an NF- κ B-activating oncogene in epithelial cancers. <i>Oncogene</i> , 2015, 34, 209-216.	2.6	54
1826	Posttranslational modifications of RUNX1 as potential anticancer targets. <i>Oncogene</i> , 2015, 34, 3483-3492.	2.6	47
1827	ER β decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway. <i>Oncogene</i> , 2015, 34, 4130-4141.	2.6	45
1828	SAMNetWeb: identifying condition-specific networks linking signaling and transcription. <i>Bioinformatics</i> , 2015, 31, 1124-1126.	1.8	14
1829	The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. <i>Cancer Discovery</i> , 2015, 5, 43-51.	7.7	1,180
1830	Association between a PD-1 gene polymorphism and antisperm antibody-related infertility in Iranian men. <i>Journal of Assisted Reproduction and Genetics</i> , 2015, 32, 103-106.	1.2	16
1831	Emerging biomarkers in head and neck cancer in the era of genomics. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 11-26.	12.5	264
1832	NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation. <i>Oncogene</i> , 2015, 34, 3780-3790.	2.6	40
1833	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. <i>Modern Pathology</i> , 2015, 28, 505-514.	2.9	180
1834	Chemotherapy benefit for ER^+ breast cancer and contamination of Nonluminal subtypes—waiting for TAILORx and RxPONDER. <i>Annals of Oncology</i> , 2015, 26, 70-74.	0.6	11
1835	Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. <i>Oncogene</i> , 2015, 34, 3215-3225.	2.6	130
1836	Linking form to function: Biophysical aspects of artificial antigen presenting cell design. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 781-790.	1.9	44

#	ARTICLE	IF	CITATIONS
1837	Cancer Evolution: Mathematical Models and Computational Inference. <i>Systematic Biology</i> , 2015, 64, e1-e25.	2.7	292
1838	Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA. <i>Briefings in Bioinformatics</i> , 2015, 16, 291-303.	3.2	122
1839	RECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch. <i>Oncogene</i> , 2015, 34, 2189-2203.	2.6	34
1840	Systems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-1± protein levels and activity. <i>Oncogene</i> , 2015, 34, 154-164.	2.6	24
1841	Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. <i>Oncogene</i> , 2015, 34, 3617-3626.	2.6	211
1842	Bulky scalp melanoma with metastasis responding completely to ipilimumab. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216204.	0.2	1
1843	Battling regional (stage III) lung cancer: bumpy road of a cancer survivor in the immunotherapy age. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215304.	0.2	2
1844	PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. <i>JCI Insight</i> , 2016, 1, .	2.3	60
1845	Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance. <i>Chinese Medical Journal</i> , 2016, 129, 879-880.	0.9	4
1846	Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216426.	0.2	20
1847	Challenges in the use of immunotherapy in metastatic melanoma. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216681.	0.2	1
1848	Vedolizumab: a novel treatment for ipilimumab-induced colitis. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216641.	0.2	39
1849	Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches. <i>Journal of Thoracic Disease</i> , 2016, 8, E1348-E1350.	0.6	6
1850	Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors. <i>Oncotarget</i> , 2016, 7, 81341-81356.	0.8	66
1851	Genomic characterization of high-risk non-muscle invasive bladder cancer. <i>Oncotarget</i> , 2016, 7, 75176-75184.	0.8	64
1852	Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. <i>Oncotarget</i> , 2016, 7, 33498-33511.	0.8	85
1853	MicroRNA-124 enhances response to radiotherapy in human epidermal growth factor receptor 2-positive breast cancer cells by targeting signal transducer and activator of transcription 3. <i>Croatian Medical Journal</i> , 2016, 57, 457-464.	0.2	18
1854	The steady progress of targeted therapies, promising advances for lung cancer. <i>Ecanermedscience</i> , 2016, 10, 638.	0.6	6

#	ARTICLE	IF	CITATIONS
1855	Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 56233-56240.	0.8	48
1856	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. <i>Oncotarget</i> , 2016, 7, 32731-32753.	0.8	30
1857	Neoantigen-based cancer immunotherapy. <i>Annals of Translational Medicine</i> , 2016, 4, 262-262.	0.7	63
1858	Checkpoint Inhibitors for Advanced Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 473-474.	0.2	2
1859	Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 73618-73637.	0.8	77
1860	Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. <i>Oncotarget</i> , 2016, 7, 10557-10567.	0.8	154
1861	Repulsive guidance molecule B inhibits metastasis and is associated with decreased mortality in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 15678-15689.	0.8	16
1862	Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6075-6082.	1.0	47
1863	A retrospective evaluation of associations between chronic obstructive pulmonary disease, smoking, and efficacy of chemotherapy and selected laboratory parameters in patients with advanced non-small cell lung cancer. <i>Wspolczesna Onkologia</i> , 2016, 5, 407-413.	0.7	2
1864	Immuno-oncology combinations: raising the tail of the survival curve. <i>Cancer Biology and Medicine</i> , 2016, 13, 171-193.	1.4	98
1865	Current advances in biomarkers for targeted therapy in triple-negative breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2016, Volume 8, 183-197.	1.0	30
1866	PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. <i>Oncotarget</i> , 2016, 7, 24269-24283.	0.8	251
1867	Increased Infiltration of CD8 ⁺ T Cells by Dacarbazine in a Patient with Mucosal Penile Melanoma Refractory to Nivolumab. <i>Annals of Dermatology</i> , 2016, 28, 486.	0.3	7
1868	Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 6323-6334.	0.8	21
1869	Tumour progression and metastasis. <i>Ecancermedicalsecience</i> , 2016, 10, 617.	0.6	57
1870	Contemporary treatment of metastatic renal cell carcinoma. <i>Oncology Reviews</i> , 2016, 10, 295.	0.8	32
1871	The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. <i>Oncotarget</i> , 2016, 7, 3477-3488.	0.8	73
1872	IL-15 superagonist/IL-15R α Sushi-Fc fusion complex (IL-15SA/IL-15R α Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. <i>Oncotarget</i> , 2016, 7, 16130-16145.	0.8	138

#	ARTICLE	IF	CITATIONS
1873	New generation of breast cancer clinical trials implementing molecular profiling. <i>Cancer Biology and Medicine</i> , 2016, 13, 226-235.	1.4	5
1874	Predictive Value of Molecular Subtyping for Locoregional Recurrence in Early-Stage Breast Cancer with N1 without Postmastectomy Radiotherapy. <i>Journal of Breast Cancer</i> , 2016, 19, 176.	0.8	11
1875	Clinical significance of <i>PD-L1</i> and <i>PD-L2</i> copy number gains in non-small-cell lung cancer. <i>Oncotarget</i> , 2016, 7, 32113-32128.	0.8	100
1876	Immune checkpoint inhibition in patients with brain metastases. <i>Annals of Translational Medicine</i> , 2016, 4, S9-S9.	0.7	29
1877	Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel. <i>Journal of Cancer</i> , 2016, 7, 947-956.	1.2	9
1878	Importance of tumor infiltrating lymphocytes in non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2016, 4, 142-142.	0.7	6
1879	Molecular biology of breast tumors and prognosis. <i>F1000Research</i> , 2016, 5, 711.	0.8	6
1880	PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression. <i>Translational Cancer Research</i> , 2016, 5, S1396-S1399.	0.4	8
1881	Evaluation and consequences of heterogeneity in the circulating tumor cell compartment. <i>Oncotarget</i> , 2016, 7, 48625-48643.	0.8	53
1882	Fundamental effects of PD-1 antibody on the body: a brief report. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4137-4141.	1.0	4
1883	A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5781-5789.	1.0	2
1884	Tremelimumab: research and clinical development. <i>OncoTargets and Therapy</i> , 2016, 9, 1767.	1.0	51
1885	WISP3 is highly expressed in a subset of colorectal carcinomas with a better prognosis. <i>OncoTargets and Therapy</i> , 2016, 9, 287.	1.0	5
1886	Identifying candidate agents for lung adenocarcinoma by walking the human interactome. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5439-5450.	1.0	3
1887	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5855-5866.	1.0	11
1888	CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas. <i>Cancers</i> , 2016, 8, 71.	1.7	8
1889	Targeting Oncogenes into a Defined Subset of Mammary Cells Demonstrates That the Initiating Oncogenic Mutation Defines the Resulting Tumor Phenotype. <i>International Journal of Biological Sciences</i> , 2016, 12, 381-388.	2.6	9
1890	Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine. <i>Cancer Management and Research</i> , 2016, 8, 57.	0.9	20

#	ARTICLE	IF	CITATIONS
1891	Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories. <i>International Journal of Molecular Sciences</i> , 2016, 17, 651.	1.8	20
1892	Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2149.	1.8	2
1893	New advances in targeted gastric cancer treatment. <i>World Journal of Gastroenterology</i> , 2016, 22, 6776.	1.4	74
1894	Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. <i>Oncoscience</i> , 2016, 3, 164-172.	0.9	34
1895	Insight to drug delivery aspects for colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 582.	1.4	101
1896	Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7081-7093.	1.0	83
1897	Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). <i>Oncotarget</i> , 2016, 7, 30323-30335.	0.8	297
1898	A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7275-7283.	1.0	49
1899	Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis. <i>OncoTargets and Therapy</i> , 2016, 9, 431.	1.0	50
1900	Immune checkpoint inhibitors and prostate cancer: a new frontier?. <i>Oncology Reviews</i> , 2016, 10, 293.	0.8	47
1901	Association of <i>Fusobacterium nucleatum</i> with immunity and molecular alterations in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 557.	1.4	278
1902	Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3447-3452.	3.9	439
1903	A prognostic index for locoregional recurrence after neoadjuvant chemotherapy. <i>Ecancermedalscience</i> , 2016, 10, 647.	0.6	1
1904	Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis. <i>Journal of Thoracic Disease</i> , 2016, 8, 3197-3204.	0.6	39
1905	Chronic Inflammation in Skin Malignancies. <i>Journal of Molecular Signaling</i> , 2016, 11, 2.	0.5	41
1906	Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?. <i>Cancer Biology and Medicine</i> , 2016, 13, 157-170.	1.4	86
1907	Targeted therapies and immunotherapy in non-small-cell lung cancer. <i>Ecancermedalscience</i> , 2016, 10, 648.	0.6	29
1908	<nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 101-112.	1.0	60

#	ARTICLE	IF	CITATIONS
1909	Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists. <i>Oncotarget</i> , 2016, 7, 42919-42942.	0.8	21
1910	Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells. <i>Oncotarget</i> , 2016, 7, 27158-27175.	0.8	49
1911	Novel therapeutic strategies for patients with triple-negative breast cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6519-6528.	1.0	26
1912	Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 3187.	1.0	11
1913	The neutrophil-to-lymphocyte ratio: a narrative review. <i>Ecancermedalscience</i> , 2016, 10, 702.	0.6	202
1914	Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2016, Volume 3, 31-36.	1.8	32
1915	Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. <i>Journal of Cancer</i> , 2016, 7, 1095-1104.	1.2	73
1916	The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review. <i>Journal of Immunology Research</i> , 2016, 2016, 1-11.	0.9	20
1917	High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients. <i>Oncotarget</i> , 2016, 7, 33035-33045.	0.8	46
1918	Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 22.	1.2	17
1919	New targeted treatments for non-small-cell lung cancer – role of nivolumab. <i>Biologics: Targets and Therapy</i> , 2016, Volume 10, 103-117.	3.0	23
1920	PD-1 marks dysfunctional regulatory T cells in malignant gliomas. <i>JCI Insight</i> , 2016, 1, .	2.3	182
1921	Lung cancer in Brazil: epidemiology and treatment challenges. <i>Lung Cancer: Targets and Therapy</i> , 2016, Volume 7, 141-148.	1.3	16
1922	Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2016, 19, 261.	0.8	21
1923	Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy. <i>Immune Network</i> , 2016, 16, 134.	1.6	8
1924	Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. <i>Ecancermedalscience</i> , 2016, 10, 609.	0.6	30
1925	<i>CXCL12</i> promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients. <i>Oncotarget</i> , 2016, 7, 53309-53320.	0.8	37
1927	T cell Bim levels reflect responses to anti-â€œPD-1 cancer therapy. <i>JCI Insight</i> , 2016, 1, .	2.3	68

#	ARTICLE	IF	CITATIONS
1928	Immunological battlefield in gastric cancer and role of immunotherapies. <i>World Journal of Gastroenterology</i> , 2016, 22, 6373.	1.4	33
1929	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 771-788.	0.6	84
1930	Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast. <i>Oncotarget</i> , 2016, 7, 1707-1716.	0.8	25
1931	Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer. <i>Oncotarget</i> , 2016, 7, 79494-79502.	0.8	15
1932	Improving the clinical impact of biomaterials in cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 15421-15443.	0.8	56
1933	The Prognostic Yield of Biomarkers Harvested in Chemotherapy-Naive stage II Colon Cancer: Can We Separate the Wheat from the Chaff?. <i>Molecular Medicine</i> , 2016, 22, 271-273.	1.9	3
1934	On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer. <i>Oncotarget</i> , 2016, 7, 67626-67649.	0.8	42
1935	Tandem CAR T cells targeting HER2 and IL13R α 2 mitigate tumor antigen escape. <i>Journal of Clinical Investigation</i> , 2016, 126, 3036-3052.	3.9	515
1936	Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 20282-20292.	0.8	28
1937	From the era of ineffective tumor vaccines to a future with effective immunotherapy. <i>Journal of Thoracic Disease</i> , 2016, 8, 1916-1917.	0.6	0
1938	Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 1338-1350.	1.3	56
1939	Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis. <i>Oncotarget</i> , 2016, 7, 44288-44298.	0.8	88
1940	A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 10133-10152.	0.8	92
1941	Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer. <i>Oncotarget</i> , 2016, 7, 53230-53244.	0.8	30
1942	The head and neck cancer immune landscape and its immunotherapeutic implications. <i>JCI Insight</i> , 2016, 1, e89829.	2.3	569
1943	Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. <i>Oncotarget</i> , 2016, 7, 3403-3415.	0.8	306
1944	Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. <i>Oncotarget</i> , 2016, 7, 32925-32932.	0.8	248
1945	Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy. <i>Journal of Oncology Practice</i> , 2016, 12, 649-650.	2.5	8

#	ARTICLE	IF	CITATIONS
1946	CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. <i>Journal of Clinical Investigation</i> , 2016, 126, 2610-2620.	3.9	336
1947	New players in non-alcoholic fatty liver disease induced carcinogenesis: lipid dysregulation impairs liver immune surveillance. <i>Hepatobiliary Surgery and Nutrition</i> , 2016, 5, 511-514.	0.7	0
1948	Immunoproteasomes and immunotherapy—a smoking gun for lung cancer?. <i>Journal of Thoracic Disease</i> , 2016, 8, E558-E563.	0.6	7
1949	Immunoproteasome deficiency in non-small cell lung cancer and its relevance to immunotherapy. <i>Journal of Thoracic Disease</i> , 2016, 8, E1082-E1086.	0.6	4
1950	PD-L1 expression in lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 3053-3055.	0.6	2
1951	Immunotherapy in urothelial carcinoma: fade or future standard?. <i>Translational Andrology and Urology</i> , 2016, 5, 662-667.	0.6	2
1952	Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence. <i>Translational Gastroenterology and Hepatology</i> , 2016, 1, 25-25.	1.5	18
1953	Targeting angiogenesis in gastrointestinal tumors: current challenges. <i>Translational Gastroenterology and Hepatology</i> , 2016, 1, 67-67.	1.5	15
1954	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?—current evidence and future perspectives. <i>Translational Lung Cancer Research</i> , 2016, 5, 628-636.	1.3	15
1955	Pembrolizumab as first-line treatment for non-small cell lung cancer—a game changer?. <i>Translational Lung Cancer Research</i> , 2016, 5, 538-542.	1.3	4
1956	Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. <i>Translational Lung Cancer Research</i> , 2016, 5, 720-726.	1.3	32
1957	Genomic landscape of DNA repair genes in cancer. <i>Oncotarget</i> , 2016, 7, 23312-23321.	0.8	153
1958	Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. <i>Stem Cell Investigation</i> , 2016, 3, 70-70.	1.3	39
1959	Tumor lymphocytic infiltration in non-small cell lung cancer: the ultimate prognostic marker?. <i>Translational Lung Cancer Research</i> , 2016, 5, 370-372.	1.3	6
1960	Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 487-494.	0.6	40
1961	DMBA induced mouse mammary tumors display high incidence of activating <i>Pik3caH1047</i> and loss of function <i>Pten</i> mutations. <i>Oncotarget</i> , 2016, 7, 64289-64299.	0.8	51
1962	Beyond RAS and BRAF: a target rich disease that is ripe for picking. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 705-712.	0.6	2
1963	Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases. <i>Journal of Thoracic Disease</i> , 2016, 8, E535-E537.	0.6	21

#	ARTICLE	IF	CITATIONS
1964	Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. <i>Translational Lung Cancer Research</i> , 2016, 5, 301-321.	1.3	37
1965	The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. <i>Oncotarget</i> , 2016, 7, 37331-37346.	0.8	73
1966	Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 479-486.	0.6	21
1967	Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. <i>JCI Insight</i> , 2016, 1, e87415.	2.3	125
1968	Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. <i>Oncotarget</i> , 2016, 7, 32318-32328.	0.8	141
1969	The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression. <i>Oncotarget</i> , 2016, 7, 7913-7924.	0.8	107
1970	Dendritic cell-based vaccine for pancreatic cancer in Japan. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 133.	0.6	22
1971	Dabrafenib in metastatic melanoma: a monocentric "real life" experience. <i>Ecancermedicalscience</i> , 2016, 10, 624.	0.6	4
1972	Mutations of Chromatin Structure Regulating Genes in Human Malignancies. <i>Current Protein and Peptide Science</i> , 2016, 17, 411-437.	0.7	25
1973	ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. <i>Oncotarget</i> , 2016, 7, 66020-66031.	0.8	75
1974	Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. <i>Oncotarget</i> , 2016, 7, 77404-77415.	0.8	139
1975	LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis. <i>Oncotarget</i> , 2016, 7, 65837-65848.	0.8	35
1976	Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. <i>Oncotarget</i> , 2016, 7, 10051-10063.	0.8	247
1977	The PI3K inhibitor taselelisib overcomes letrozole resistance in a breast cancer model expressing aromatase. <i>Genes and Cancer</i> , 2016, 7, 73-85.	0.6	17
1978	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. <i>Oncotarget</i> , 2016, 7, 76565-76576.	0.8	100
1979	Aptamers: A Feasible Technology in Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2016, 2016, 1-12.	0.9	26
1980	PPAR γ as a Metabolic Initiator of Mammary Neoplasia and Immune Tolerance. <i>PPAR Research</i> , 2016, 2016, 1-7.	1.1	6
1981	NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?. <i>Journal of Immunology Research</i> , 2016, 2016, 1-13.	0.9	65

#	ARTICLE	IF	CITATIONS
1982	Current Immunotherapies for Sarcoma: Clinical Trials and Rationale. <i>Sarcoma</i> , 2016, 2016, 1-6.	0.7	20
1983	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. <i>BioMed Research International</i> , 2016, 2016, 1-12.	0.9	19
1984	A Case of Non-Small Cell Lung Cancer with Possible "Disease Flare" on Nivolumab Treatment. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-3.	0.2	28
1985	Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. <i>Journal of Immunology Research</i> , 2016, 2016, 1-11.	0.9	32
1986	The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. <i>Journal of Immunology Research</i> , 2016, 2016, 1-13.	0.9	153
1987	Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination. <i>Mediators of Inflammation</i> , 2016, 2016, 1-12.	1.4	25
1988	The Role of Forkhead Box Protein M1 in Breast Cancer Progression and Resistance to Therapy. <i>International Journal of Breast Cancer</i> , 2016, 2016, 1-8.	0.6	47
1989	Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data. <i>Journal of Immunology Research</i> , 2016, 2016, 1-12.	0.9	17
1990	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. <i>Journal of Immunology Research</i> , 2016, 2016, 1-14.	0.9	36
1991	Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells. <i>Mediators of Inflammation</i> , 2016, 2016, 1-11.	1.4	29
1992	Bacteria in Cancer Therapy: Renaissance of an Old Concept. <i>International Journal of Microbiology</i> , 2016, 2016, 1-14.	0.9	117
1993	Effector, Memory, and Dysfunctional CD8 ⁺ T Cell Fates in the Antitumor Immune Response. <i>Journal of Immunology Research</i> , 2016, 2016, 1-14.	0.9	186
1994	The RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB. <i>ELife</i> , 2016, 5, .	2.8	48
1995	META2: Intercellular DNA Methylation Pairwise Annotation and Integrative Analysis. <i>BioMed Research International</i> , 2016, 2016, 1-10.	0.9	0
1996	Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer. <i>Disease Markers</i> , 2016, 2016, 1-12.	0.6	26
1997	Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. <i>Journal of Immunology Research</i> , 2016, 2016, 1-25.	0.9	49
1998	A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-5.	0.2	9
1999	Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease. <i>Mediators of Inflammation</i> , 2016, 2016, 1-17.	1.4	28

#	ARTICLE	IF	CITATIONS
2000	PD-L1 Expression Is Associated with Tumor FOXP3 ⁺ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. <i>Journal of Cancer</i> , 2016, 7, 784-793.	1.2	125
2001	PD-1 blockade enhances the vaccination-induced immune response in glioma. <i>JCI Insight</i> , 2016, 1, .	2.3	128
2002	Therapy of solid tumors using probiotic Symbioflor-2 - restraints and potential. <i>Oncotarget</i> , 2016, 7, 22605-22622.	0.8	35
2003	Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone-receptor-negative breast cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4653-4660.	1.0	38
2004	The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5567-5575.	1.0	113
2005	Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. <i>Cancers</i> , 2016, 8, 81.	1.7	61
2006	AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells. <i>Journal of Cancer</i> , 2016, 7, 1579-1586.	1.2	90
2007	Enhanced Anti-Tumor Efficacy through a Combination of Integrin $\alpha_6\beta_1$ -Targeted Photodynamic Therapy and Immune Checkpoint Inhibition. <i>Theranostics</i> , 2016, 6, 627-637.	4.6	92
2008	Toxicity management of immunotherapy for patients with metastatic melanoma. <i>Annals of Translational Medicine</i> , 2016, 4, 272-272.	0.7	92
2009	Elevated preoperative neutrophil-to-lymphocyte ratio is associated with poor prognosis in gastrointestinal stromal tumor patients. <i>OncoTargets and Therapy</i> , 2016, 9, 877.	1.0	14
2010	Potential role of immunotherapy in advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 21-30.	1.0	46
2011	Targeted Therapies for Brain Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1543.	1.8	67
2012	Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e51.	1.0	99
2013	Inducible Mouse Models for Cancer Drug Target Validation. <i>Journal of Cancer Prevention</i> , 2016, 21, 243-248.	0.8	10
2014	Restraint and Social Isolation Stressors Differentially Regulate Adaptive Immunity and Tumor Angiogenesis in a Breast Cancer Mouse Model. <i>Cancer and Clinical Oncology</i> , 2016, 6, 12.	0.2	27
2015	Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers. <i>Journal of Cancer</i> , 2016, 7, 1599-1604.	1.2	8
2016	The multifaceted role of autophagy in tumor evasion from immune surveillance. <i>Oncotarget</i> , 2016, 7, 17591-17607.	0.8	53
2017	Optimal delivery of follow-up care following pulmonary lobectomy for lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2016, 7, 29.	1.3	4

#	ARTICLE	IF	CITATIONS
2018	Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. <i>Oncotarget</i> , 2016, 7, 34341-34355.	0.8	258
2019	Administration of polysaccharide from <i>Panax notoginseng</i> prolonged the survival of H22 tumor-bearing mice. <i>OncoTargets and Therapy</i> , 2016, 9, 3433.	1.0	25
2020	Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer. <i>Journal of Breast Cancer</i> , 2016, 19, 242.	0.8	65
2021	High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. <i>Theranostics</i> , 2016, 6, 1629-1640.	4.6	167
2022	Versatile roles of extracellular vesicles in cancer. <i>Journal of Clinical Investigation</i> , 2016, 126, 1163-1172.	3.9	261
2023	An update on clinical oncology for the non-oncologist. <i>Einstein (Sao Paulo, Brazil)</i> , 2016, 14, 294-299.	0.3	2
2024	Dendritic-Tumor Fusion Cell-Based Cancer Vaccines. <i>International Journal of Molecular Sciences</i> , 2016, 17, 828.	1.8	56
2025	Targeting signal transduction pathways of cancer stem cells for therapeutic opportunities of metastasis. <i>Oncotarget</i> , 2016, 7, 76337-76353.	0.8	37
2026	Clinical utility of nivolumab in the treatment of advanced melanoma. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 313.	0.9	16
2027	Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 892.	1.2	43
2028	New Strategies for the Treatment of Solid Tumors with CAR-T Cells. <i>International Journal of Biological Sciences</i> , 2016, 12, 718-729.	2.6	67
2029	Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence. <i>Oncotarget</i> , 2016, 7, 52517-52529.	0.8	309
2030	The emerging role of immunotherapy in colorectal cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 305-305.	0.7	63
2031	In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform. <i>Frontiers in Bioengineering and Biotechnology</i> , 2016, 4, 12.	2.0	531
2032	Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 27.	1.8	107
2033	Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. <i>Viruses</i> , 2016, 8, 9.	1.5	79
2034	Monitoring of the Immune Dysfunction in Cancer Patients. <i>Vaccines</i> , 2016, 4, 29.	2.1	15
2035	Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. <i>Vaccines</i> , 2016, 4, 37.	2.1	63

#	ARTICLE	IF	CITATIONS
2036	Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment. <i>Vaccines</i> , 2016, 4, 41.	2.1	44
2037	The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy. <i>Vaccines</i> , 2016, 4, 43.	2.1	35
2038	Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity. <i>Vaccines</i> , 2016, 4, 46.	2.1	87
2039	Human plasma metabolomics for identifying differential metabolites and predicting molecular subtypes of breast cancer. <i>Oncotarget</i> , 2016, 7, 9925-9938.	0.8	90
2040	Non-small cell lung cancer: current treatment and future advances. <i>Translational Lung Cancer Research</i> , 2016, 5, 288-300.	1.3	1,256
2041	Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance. <i>Canadian Urological Association Journal</i> , 2016, 10, 383.	0.3	22
2042	Long non-coding RNAs as prognostic markers in human breast cancer. <i>Oncotarget</i> , 2016, 7, 20584-20596.	0.8	133
2043	Harnessing the immune system to improve cancer therapy. <i>Annals of Translational Medicine</i> , 2016, 4, 261-261.	0.7	225
2044	Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-11.	0.7	79
2045	Exosomes and tumor-mediated immune suppression. <i>Journal of Clinical Investigation</i> , 2016, 126, 1216-1223.	3.9	439
2046	Histidine phosphorylation relieves copper inhibition in the mammalian potassium channel KCa3.1. <i>ELife</i> , 2016, 5, .	2.8	46
2047	Estrogen Receptor $\hat{1}^2$ in Melanoma: From Molecular Insights to Potential Clinical Utility. <i>Frontiers in Endocrinology</i> , 2016, 7, 140.	1.5	57
2048	Strategies for Integrated Analysis of Genetic, Epigenetic, and Gene Expression Variation in Cancer: Addressing the Challenges. <i>Frontiers in Genetics</i> , 2016, 7, 2.	1.1	23
2049	Exosomes: The Link between GPCR Activation and Metastatic Potential?. <i>Frontiers in Genetics</i> , 2016, 7, 56.	1.1	21
2050	Integrated Systems for NGS Data Management and Analysis: Open Issues and Available Solutions. <i>Frontiers in Genetics</i> , 2016, 7, 75.	1.1	45
2051	Engineered Swine Models of Cancer. <i>Frontiers in Genetics</i> , 2016, 7, 78.	1.1	56
2052	Gene Coexpression Analyses Differentiate Networks Associated with Diverse Cancers Harboring TP53 Missense or Null Mutations. <i>Frontiers in Genetics</i> , 2016, 7, 137.	1.1	23
2053	Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b. <i>Frontiers in Genetics</i> , 2016, 7, 143.	1.1	20

#	ARTICLE	IF	CITATIONS
2054	Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition. <i>Frontiers in Immunology</i> , 2016, 7, 24.	2.2	44
2055	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. <i>Frontiers in Immunology</i> , 2016, 7, 94.	2.2	26
2056	Marrow-Infiltrating Lymphocytes – Role in Biology and Cancer Therapy. <i>Frontiers in Immunology</i> , 2016, 7, 112.	2.2	22
2057	Regulation of Natural Killer Cell Function by STAT3. <i>Frontiers in Immunology</i> , 2016, 7, 128.	2.2	64
2058	Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4+ and CD8+ T Cells. <i>Frontiers in Immunology</i> , 2016, 7, 221.	2.2	20
2059	Tertiary Lymphoid Organs in Cancer Tissues. <i>Frontiers in Immunology</i> , 2016, 7, 244.	2.2	74
2060	Features of Memory-Like and PD-1+ Human NK Cell Subsets. <i>Frontiers in Immunology</i> , 2016, 7, 351.	2.2	107
2061	T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2016, 7, 353.	2.2	77
2062	Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. <i>Frontiers in Immunology</i> , 2016, 7, 407.	2.2	238
2063	IL-1 β , But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Immunology</i> , 2016, 7, 465.	2.2	16
2064	Improved Antitumor Activity of a Therapeutic Melanoma Vaccine through the Use of the Dual COX-2/5-LO Inhibitor Licofelone. <i>Frontiers in Immunology</i> , 2016, 7, 537.	2.2	9
2065	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. <i>Frontiers in Immunology</i> , 2016, 7, 550.	2.2	409
2066	Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients. <i>Frontiers in Immunology</i> , 2016, 7, 573.	2.2	73
2067	PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN- γ and Can Be Expressed in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016, 7, 581.	2.2	41
2068	Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells. <i>Frontiers in Immunology</i> , 2016, 7, 610.	2.2	111
2069	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016, 7, 621.	2.2	132
2070	Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC. <i>Frontiers in Medicine</i> , 2016, 3, 65.	1.2	8
2071	Focus on Nivolumab in NSCLC. <i>Frontiers in Medicine</i> , 2016, 3, 67.	1.2	7

#	ARTICLE	IF	CITATIONS
2072	Murine Model Imitating Chronic Wound Infections for Evaluation of Antimicrobial Photodynamic Therapy Efficacy. <i>Frontiers in Microbiology</i> , 2016, 7, 1258.	1.5	37
2073	Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents. <i>Frontiers in Oncology</i> , 2015, 5, 300.	1.3	32
2074	Systemic Immunotherapy for the Treatment of Brain Metastases. <i>Frontiers in Oncology</i> , 2016, 6, 49.	1.3	66
2075	Enrichment of Inflammatory IL-17 and TNF- α Secreting CD4+ T Cells within Colorectal Tumors despite the Presence of Elevated CD39+ T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1. <i>Frontiers in Oncology</i> , 2016, 6, 50.	1.3	26
2076	The Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer Progression. <i>Frontiers in Oncology</i> , 2016, 6, 54.	1.3	46
2077	HZE Radiation Non-Targeted Effects on the Microenvironment That Mediate Mammary Carcinogenesis. <i>Frontiers in Oncology</i> , 2016, 6, 57.	1.3	29
2078	Cytokine-Induced Modulation of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 96.	1.3	181
2079	Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention. <i>Frontiers in Oncology</i> , 2016, 6, 108.	1.3	57
2080	Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 109.	1.3	108
2081	Hypothesis: The Intratumoral Immune Response against a Cancer Progenitor Cell Impacts the Development of Well-Differentiated versus Dedifferentiated Disease in Liposarcoma. <i>Frontiers in Oncology</i> , 2016, 6, 134.	1.3	2
2082	Translational Research to Improve the Efficacy of Carbon Ion Radiotherapy: Experience of Gunma University. <i>Frontiers in Oncology</i> , 2016, 6, 139.	1.3	20
2083	Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 165.	1.3	9
2084	Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. <i>Frontiers in Oncology</i> , 2016, 6, 212.	1.3	35
2085	Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 233.	1.3	148
2086	Recent Advances in Immunotherapy in Metastatic NSCLC. <i>Frontiers in Oncology</i> , 2016, 6, 239.	1.3	29
2087	Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women. <i>Frontiers in Oncology</i> , 2016, 6, 241.	1.3	23
2088	Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report. <i>Frontiers in Oncology</i> , 2016, 6, 250.	1.3	17
2089	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. <i>Frontiers in Oncology</i> , 2016, 6, 256.	1.3	39

#	ARTICLE	IF	CITATIONS
2090	Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 713-720.	0.6	45
2091	Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?. <i>Antibodies</i> , 2016, 5, 1.	1.2	34
2092	The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation. <i>Biomolecules</i> , 2016, 6, 45.	1.8	22
2093	Direct Lymph Node Vaccination of Lentivector/Prostate-Specific Antigen is Safe and Generates Tissue-Specific Responses in Rhesus Macaques. <i>Biomedicines</i> , 2016, 4, 6.	1.4	2
2094	Innate Lymphoid Cells in Tumor Immunity. <i>Biomedicines</i> , 2016, 4, 7.	1.4	26
2095	Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies. <i>Biomedicines</i> , 2016, 4, 21.	1.4	11
2096	Updates in Therapy for Advanced Melanoma. <i>Cancers</i> , 2016, 8, 17.	1.7	37
2097	A Perspective of Immunotherapy for Prostate Cancer. <i>Cancers</i> , 2016, 8, 64.	1.7	28
2098	Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2016, 8, 87.	1.7	30
2099	The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy. <i>Cancers</i> , 2016, 8, 97.	1.7	97
2100	Advances in Cancer Immunotherapy in Solid Tumors. <i>Cancers</i> , 2016, 8, 106.	1.7	131
2101	Androgen Receptor: A Complex Therapeutic Target for Breast Cancer. <i>Cancers</i> , 2016, 8, 108.	1.7	49
2102	Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma. <i>Cancers</i> , 2016, 8, 110.	1.7	43
2103	First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma—An Update on Patient Selection and Response Evaluation. <i>Diagnostics</i> , 2016, 6, 44.	1.3	11
2104	The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2016, 17, 286.	1.8	7
2105	Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. <i>International Journal of Molecular Sciences</i> , 2016, 17, 714.	1.8	69
2106	A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 759.	1.8	38
2107	Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. <i>International Journal of Molecular Sciences</i> , 2016, 17, 790.	1.8	32

#	ARTICLE	IF	CITATIONS
2108	The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment. International Journal of Molecular Sciences, 2016, 17, 1030.	1.8	33
2109	PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of Tissue Micro Arrays. International Journal of Molecular Sciences, 2016, 17, 1046.	1.8	20
2110	A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. International Journal of Molecular Sciences, 2016, 17, 1151.	1.8	134
2111	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. International Journal of Molecular Sciences, 2016, 17, 1169.	1.8	53
2112	Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. International Journal of Molecular Sciences, 2016, 17, 1468.	1.8	45
2113	Pre-Analytical Considerations for Successful Next-Generation Sequencing (NGS): Challenges and Opportunities for Formalin-Fixed and Paraffin-Embedded Tumor Tissue (FFPE) Samples. International Journal of Molecular Sciences, 2016, 17, 1579.	1.8	64
2114	Immunotherapy for Gastroesophageal Cancer. Journal of Clinical Medicine, 2016, 5, 84.	1.0	41
2115	The Changing Landscape of Breast Cancer: How Biology Drives Therapy. Medicines (Basel, Switzerland), 2016, 3, 2.	0.7	11
2116	Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases. Medical Sciences (Basel, Switzerland), 2016, 4, 8.	1.3	7
2117	Immunoregulation in Fungal Diseases. Microorganisms, 2016, 4, 47.	1.6	14
2118	Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future. Pharmaceuticals, 2016, 9, 28.	1.7	7
2119	Analysing multiple types of molecular profiles simultaneously: connecting the needles in the haystack. BMC Bioinformatics, 2016, 17, 77.	1.2	2
2120	p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading. BMC Cancer, 2016, 16, 649.	1.1	25
2121	Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients. BMC Cancer, 2016, 16, 821.	1.1	22
2122	Impact of prognostic nutritional index on long-term outcomes in patients with breast cancer. World Journal of Surgical Oncology, 2016, 14, 170.	0.8	79
2123	Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. Journal of Translational Medicine, 2016, 14, 299.	1.8	26
2124	Immune checkpoint inhibitors and response analysis: a tough challenge. A case report. BMC Research Notes, 2016, 9, 349.	0.6	9
2125	Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors – an autopsy study. , 2016, 4, 13.		162

#	ARTICLE	IF	CITATIONS
2126	The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma. <i>Bladder Cancer</i> , 2016, 2, 425-432.	0.2	23
2127	A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab. <i>Drug Target Insights</i> , 2016, 10, DTI.S31565.	0.9	26
2128	Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model. <i>PLoS ONE</i> , 2016, 11, e0151832.	1.1	64
2129	MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice. <i>PLoS ONE</i> , 2016, 11, e0145920.	1.1	31
2130	Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. <i>PLoS ONE</i> , 2016, 11, e0163138.	1.1	8
2131	Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies. <i>PLoS ONE</i> , 2016, 11, e0152448.	1.1	35
2132	Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. <i>PLoS ONE</i> , 2016, 11, e0157368.	1.1	975
2133	Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy. <i>PLoS ONE</i> , 2016, 11, e0165102.	1.1	20
2134	PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. <i>PLoS Pathogens</i> , 2016, 12, e1005642.	2.1	87
2135	PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0160485.	1.1	33
2136	The Circadian Rhythm Gene <i>Arntl2</i> Is a Metastasis Susceptibility Gene for Estrogen Receptor-Negative Breast Cancer. <i>PLoS Genetics</i> , 2016, 12, e1006267.	1.5	57
2137	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. <i>PLoS Medicine</i> , 2016, 13, e1002201.	3.9	300
2138	Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4. <i>PLoS ONE</i> , 2016, 11, e0146370.	1.1	61
2139	Inhibition of Cellular Adhesion by Immunological Targeting of Osteopontin Neoepitopes Generated through Matrix Metalloproteinase and Thrombin Cleavage. <i>PLoS ONE</i> , 2016, 11, e0148333.	1.1	7
2140	Identifying Cancer Subtypes from miRNA-TF-mRNA Regulatory Networks and Expression Data. <i>PLoS ONE</i> , 2016, 11, e0152792.	1.1	59
2141	PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. <i>PLoS ONE</i> , 2016, 11, e0153954.	1.1	73
2142	Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. <i>PLoS ONE</i> , 2016, 11, e0155189.	1.1	112
2143	Cutaneous Melanoma with Brain Metastasis: Report of 193 Patients with New Observations. <i>PLoS ONE</i> , 2016, 11, e0156115.	1.1	13

#	ARTICLE	IF	CITATIONS
2144	Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis. PLoS ONE, 2016, 11, e0156323.	1.1	44
2145	Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization. PLoS ONE, 2016, 11, e0157670.	1.1	8
2146	Loss of Dickkopf 3 Promotes the Tumorigenesis of Basal Breast Cancer. PLoS ONE, 2016, 11, e0160077.	1.1	28
2147	RNAseq Analyses Identify Tumor Necrosis Factor-Mediated Inflammation as a Major Abnormality in ALS Spinal Cord. PLoS ONE, 2016, 11, e0160520.	1.1	59
2148	Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS ONE, 2016, 11, e0161779.	1.1	172
2149	A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer. PLoS ONE, 2016, 11, e0162407.	1.1	74
2150	CA153 in Breast Secretions as a Potential Molecular Marker for Diagnosing Breast Cancer: A Meta Analysis. PLoS ONE, 2016, 11, e0163030.	1.1	16
2151	Consensus Analysis of Whole Transcriptome Profiles from Two Breast Cancer Patient Cohorts Reveals Long Non-Coding RNAs Associated with Intrinsic Subtype and the Tumour Microenvironment. PLoS ONE, 2016, 11, e0163238.	1.1	21
2152	Language-Agnostic Reproducible Data Analysis Using Literate Programming. PLoS ONE, 2016, 11, e0164023.	1.1	1
2153	Impact of the Choice of Normalization Method on Molecular Cancer Class Discovery Using Nonnegative Matrix Factorization. PLoS ONE, 2016, 11, e0164880.	1.1	7
2154	TCGA Expedition: A Data Acquisition and Management System for TCGA Data. PLoS ONE, 2016, 11, e0165395.	1.1	62
2155	Improving Gene-Set Enrichment Analysis of RNA-Seq Data with Small Replicates. PLoS ONE, 2016, 11, e0165919.	1.1	16
2156	The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer. PLoS ONE, 2016, 11, e0166680.	1.1	54
2157	A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways. PLoS ONE, 2016, 11, e0167397.	1.1	9
2158	Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors. Oncotarget, 2016, 7, 23282-23299.	0.8	81
2159	Tumor infiltrating lymphocytes in lung cancer: a new prognostic parameter. Journal of Thoracic Disease, 2016, 8, E833-E835.	0.6	26
2160	Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Design, Development and Therapy, 2016, Volume 10, 3153-3161.	2.0	29
2161	The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials. OncoTargets and Therapy, 2016, Volume 9, 5867-5874.	1.0	22

#	ARTICLE	IF	CITATIONS
2162	The highly expressed 5â€™isomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR-140 by reducing breast cancer proliferation and migration. BMC Genomics, 2016, 17, 566.	1.2	85
2163	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. Journal of Cancer, 2016, 7, 484-489.	1.2	106
2164	PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets and Therapy, 2016, Volume 9, 5023-5039.	1.0	558
2165	Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines, 2016, 4, 28.	2.1	372
2166	Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial. Theranostics, 2016, 6, 418-427.	4.6	134
2167	Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention. Frontiers in Pharmacology, 2016, 7, 356.	1.6	35
2168	Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Frontiers in Pharmacology, 2016, 7, 395.	1.6	131
2169	Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment. Frontiers in Pharmacology, 2016, 7, 405.	1.6	42
2170	Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications. Frontiers in Surgery, 2016, 3, 40.	0.6	70
2171	Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment. OncoTargets and Therapy, 2016, Volume 9, 5101-5116.	1.0	27
2172	Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Breast Cancer, 2016, 19, 385.	0.8	2
2173	Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response. Journal of Gastric Cancer, 2016, 16, 1.	0.9	66
2174	<i>Xist</i> reduction in breast cancer upregulates AKT phosphorylation via HDAC3-mediated repression of PHLPP1 expression. Oncotarget, 2016, 7, 43256-43266.	0.8	97
2175	Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. OncoTargets and Therapy, 2016, 9, 3711.	1.0	98
2176	Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer: Targets and Therapy, 2016, 8, 93.	1.0	201
2177	Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients. OncoTargets and Therapy, 2016, Volume 9, 4805-4813.	1.0	42
2178	High-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-κB signaling pathway in non-small cell lung cancer cells. OncoTargets and Therapy, 2016, Volume 9, 6511-6518.	1.0	13
2179	PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. OncoTargets and Therapy, 2016, 9, 489.	1.0	43

#	ARTICLE	IF	CITATIONS
2180	<i>PD-L1</i> promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. <i>Oncotarget</i> , 2016, 7, 79943-79955.	0.8	73
2181	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 15-25.	0.2	29
2182	Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. <i>Journal of Cancer</i> , 2016, 7, 1281-1294.	1.2	300
2183	The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. <i>Oncotarget</i> , 2016, 7, 74350-74361.	0.8	35
2184	Comprehensive landscape of subtype-specific coding and non-coding RNA transcripts in breast cancer. <i>Oncotarget</i> , 2016, 7, 68851-68863.	0.8	19
2185	The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials. <i>OncoTargets and Therapy</i> , 2016, 9, 1571.	1.0	7
2186	A dried blood spot mass spectrometry metabolomic approach for rapid breast cancer detection. <i>OncoTargets and Therapy</i> , 2016, 9, 1389.	1.0	56
2187	The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0161731.	1.1	15
2188	LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer. <i>Oncotarget</i> , 2016, 7, 13047-13059.	0.8	79
2189	Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival. <i>Oncotarget</i> , 2016, 7, 57633-57650.	0.8	88
2190	The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. <i>Annals of Translational Medicine</i> , 2016, 4, 173-173.	0.7	84
2191	The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 215-215.	0.7	13
2192	Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. <i>Annals of Translational Medicine</i> , 2016, 4, 268-268.	0.7	16
2193	The Role of the Transcription Factor Ets1 in Lupus and Other Autoimmune Diseases. <i>Critical Reviews in Immunology</i> , 2016, 36, 485-510.	1.0	36
2194	Computational selection of antibody-drug conjugate targets for breast cancer. <i>Oncotarget</i> , 2016, 7, 2555-2571.	0.8	15
2195	Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. <i>Oncotarget</i> , 2016, 7, 75379-75393.	0.8	27
2196	Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. <i>Oncotarget</i> , 2016, 7, 17194-17211.	0.8	80
2197	Long noncoding RNA LINP1: scaffolding non-homologous end joining. <i>Cell Death Discovery</i> , 2016, 2, 16059.	2.0	12

#	ARTICLE	IF	CITATIONS
2198	Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216228.	0.2	61
2199	Prognostic significance of PLIN1 expression in human breast cancer. <i>Oncotarget</i> , 2016, 7, 54488-54502.	0.8	38
2200	A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. <i>Oncotarget</i> , 2016, 7, 10215-10227.	0.8	158
2201	The challenge of developmental therapeutics for adrenocortical carcinoma. <i>Oncotarget</i> , 2016, 7, 46734-46749.	0.8	17
2202	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. <i>Oncotarget</i> , 2016, 7, 73068-73079.	0.8	76
2203	Current and emerging therapies in unresectable and recurrent gastric cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 4812.	1.4	45
2204	Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: A systemic review and meta-analysis. <i>Oncotarget</i> , 2016, 7, 34217-34228.	0.8	146
2205	Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues. <i>Pancreas</i> , 2016, 45, 613-619.	0.5	1
2206	Bayesian Inference for Latent Biologic Structure With Determinantal Point Processes (DPP). <i>Biometrics</i> , 2016, 72, 955-964.	0.8	18
2207	Expression of <i>FOXM1</i> and related proteins in breast cancer molecular subtypes. <i>International Journal of Experimental Pathology</i> , 2016, 97, 170-177.	0.6	43
2208	Residual inflammation and viral reservoirs. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 234-241.	1.5	107
2209	Proportions of blood-borne $\text{V}\alpha 1+$ and $\text{V}\alpha 2+$ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2016, 64, 116-126.	1.3	54
2210	Pembrolizumab (Keytruda). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2777-2789.	1.4	237
2211	Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 974-980.	1.9	64
2212	Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. <i>Immunotherapy</i> , 2016, 8, 809-819.	1.0	44
2213	Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. <i>Immunotherapy</i> , 2016, 8, 821-837.	1.0	139
2214	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. <i>Immunotherapy</i> , 2016, 8, 907-921.	1.0	20
2215	Role of cellular events in the pathophysiology of sepsis. <i>Inflammation Research</i> , 2016, 65, 853-868.	1.6	54

#	ARTICLE	IF	CITATIONS
2216	Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration. <i>MABs</i> , 2016, 8, 1371-1385.	2.6	7
2217	Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 442-453.	0.5	19
2218	Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (<i>Lsl-Kras^{G12D/+};Lsl-Trp53^{R172H/+};Pdx1-Cre</i>), Its Variants, and Their Application in Immunology and Oncology Drug Discovery. <i>Current Protocols in Pharmacology</i> , 2016, 73, 14.39.1-14.39.20.	4.0	141
2219	MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases. <i>Journal of Immunotherapy</i> , 2016, 39, 181-187.	1.2	54
2220	Future directions in the treatment of osteosarcoma. <i>Current Opinion in Pediatrics</i> , 2016, 28, 26-33.	1.0	228
2221	Immune Checkpoint Therapy and the Search for Predictive Biomarkers. <i>Cancer Journal (Sudbury, Mass)</i> 2016, 22, 138-146.	1.0	36
2222	Phenotypic characterization of breast invasive carcinoma via transferable tissue morphometric patterns learned from glioblastoma multiforme. , 2016, 2016, 1025-1028.		0
2223	Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. <i>Therapeutic Advances in Urology</i> , 2016, 8, 319-326.	0.9	25
2224	Targeting microRNAs as key modulators of tumor immune response. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 103.	3.5	160
2225	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. <i>Cancer Immunology Research</i> , 2016, 4, 569-573.	1.6	20
2226	Multispectral Imaging of T and B Cells in Murine Spleen and Tumor. <i>Journal of Immunology</i> , 2016, 196, 3943-3950.	0.4	63
2227	Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile. <i>Histopathology</i> , 2016, 68, 1030-1039.	1.6	31
2228	Single-cell approaches for molecular classification of endocrine tumors. <i>Current Opinion in Oncology</i> , 2016, 28, 43-49.	1.1	5
2229	Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1). <i>American Journal of Surgical Pathology</i> , 2016, 40, 1133-1142.	2.1	85
2230	Targeted Therapies Combined With Immune Checkpoint Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 138-146.	1.0	36
2231	Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 596-603.	1.2	43
2232	Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. <i>Journal of Neuro-Oncology</i> , 2016, 129, 453-460.	1.4	82
2233	Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma. <i>Cancer</i> , 2016, 122, 1017-1028.	2.0	106

#	ARTICLE	IF	CITATIONS
2234	Fully Automated RNAscope In Situ Hybridization Assays for Formalinâ€Fixed Paraffinâ€Embedded Cells and Tissues. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2201-2208.	1.2	89
2235	Laser Directâ€Write Onto Live Tissues: A Novel Model for Studying Cancer Cell Migration. <i>Journal of Cellular Physiology</i> , 2016, 231, 2333-2338.	2.0	34
2236	A case of fatal Guillainâ€Barre syndrome from anti-PD1 monoclonal antibody use. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1869-1870.	1.2	29
2237	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 323-331.	1.1	100
2238	Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 219-232.	1.1	40
2239	Oncolytic Virus-Mediated Targeting of PGE 2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy. <i>Cancer Cell</i> , 2016, 30, 108-119.	7.7	95
2240	Kataegis Expression Signature in Breast Cancer Is Associated with Late Onset, Better Prognosis, and Higher HER2 Levels. <i>Cell Reports</i> , 2016, 16, 672-683.	2.9	33
2241	High-throughput genomic profiling of tumor-infiltrating leukocytes. <i>Current Opinion in Immunology</i> , 2016, 41, 77-84.	2.4	43
2242	BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells. <i>Molecular Cell</i> , 2016, 63, 277-292.	4.5	61
2243	Computational genomics tools for dissecting tumourâ€immune cell interactions. <i>Nature Reviews Genetics</i> , 2016, 17, 441-458.	7.7	233
2244	Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphenylprone to immune checkpoint inhibitor treatment. <i>Experimental Dermatology</i> , 2016, 25, 553-554.	1.4	17
2245	Microglandular adenosis associated with tripleâ€negative breast cancer is a neoplastic lesion of tripleâ€negative phenotype harbouring <i><sc>TP53</sc></i> somatic mutations. <i>Journal of Pathology</i> , 2016, 238, 677-688.	2.1	52
2246	Neutrophilâ€toâ€lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1068-74.	0.9	115
2247	Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2454-2463.	1.2	8
2248	Breast cancer molecular subtype classifier that incorporates MRI features. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 122-129.	1.9	114
2249	Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 1074-1084.	0.9	259
2250	Precision Oncology Medicine: The Clinical Relevance of Patientâ€Specific Biomarkers Used to Optimize Cancer Treatment. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1484-1499.	1.0	75
2251	The case for immuneâ€based approaches in biliary tract carcinoma. <i>Hepatology</i> , 2016, 64, 1785-1791.	3.6	25

#	ARTICLE	IF	CITATIONS
2252	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	2.9	230
2253	Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer. <i>Molecular Carcinogenesis</i> , 2016, 55, 977-990.	1.3	40
2254	Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers. <i>Proteomics - Clinical Applications</i> , 2016, 10, 720-731.	0.8	26
2255	The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. <i>Haematologica</i> , 2016, 101, 794-802.	1.7	94
2256	Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. <i>Journal of Immunology</i> , 2016, 197, 1477-1488.	0.4	42
2257	Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2969-2979.	0.8	397
2258	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2980-2987.	0.8	444
2259	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. <i>Modern Pathology</i> , 2016, 29, 1165-1172.	2.9	340
2260	Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 289-300.	1.4	8
2261	Harnessing shared antigens and T-cell receptors in cancer: Opportunities and challenges. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 7944-7945.	3.3	8
2262	Precision medicine for advanced prostate cancer. <i>Current Opinion in Urology</i> , 2016, 26, 231-239.	0.9	23
2263	Immune Checkpoint Therapies in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 117-120.	1.0	46
2264	The current status of checkpoint inhibitors in metastatic bladder cancer. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 629-635.	1.7	11
2265	A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2016, 36, 313-320.	1.0	4
2266	Oncolytic Viruses: Therapeutics With an Identity Crisis. <i>EBioMedicine</i> , 2016, 9, 31-36.	2.7	82
2267	Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. , 2016, 166, 30-39.		102
2268	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. <i>British Journal of Cancer</i> , 2016, 115, 252-260.	2.9	66
2269	Biomarker development in the precision medicine era: lung cancer as a case study. <i>Nature Reviews Cancer</i> , 2016, 16, 525-537.	12.8	406

#	ARTICLE	IF	CITATIONS
2270	Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 8490-8495.	3.3	140
2271	Long-range regulators of the lncRNA <i>HOTAIR</i> enhance its prognostic potential in breast cancer. <i>Human Molecular Genetics</i> , 2016, 25, 3269-3283.	1.4	58
2272	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. <i>Neuro-Oncology</i> , 2016, 18, 1357-1366.	0.6	116
2273	Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a000620.	0.5	5
2274	Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2403-2411.	2.9	36
2275	The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 212-214.	2.3	20
2276	Self-Assembly Protein Nanogels for Safer Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2016, 5, 1413-1419.	3.9	48
2277	Estimating DNA Methylation Levels by Joint Modeling of Multiple Methylation Profiles From Microarray Data. <i>Biometrics</i> , 2016, 72, 354-363.	0.8	7
2278	Are physicians prepared for whole genome sequencing? a qualitative analysis. <i>Clinical Genetics</i> , 2016, 89, 228-234.	1.0	108
2279	Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site. <i>Immunological Reviews</i> , 2016, 270, 178-192.	2.8	30
2280	Immunotherapy for uveal melanoma. <i>Melanoma Management</i> , 2016, 3, 125-135.	0.1	3
2281	Reply to A. Wong et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1562-1563.	0.8	1
2282	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 255-264.	2.3	335
2283	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1213-1224.	2.3	93
2284	PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells. <i>Breast Cancer Research</i> , 2016, 18, 95.	2.2	30
2285	Distinct mutation accumulation rates among tissues determine the variation in cancer risk. <i>Scientific Reports</i> , 2016, 6, 19458.	1.6	22
2286	Changing the Paradigm of Cancer Screening, Prevention, and Treatment. <i>Dose-Response</i> , 2016, 14, 155932581668053.	0.7	10
2287	PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. <i>SpringerPlus</i> , 2016, 5, 805.	1.2	61

#	ARTICLE	IF	CITATIONS
2288	Pathway Oriented Therapy in Breast Cancer - a Light at the End of the Tunnel!. Breast Care, 2016, 11, 382-383.	0.8	0
2289	A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 8-17.	2.3	21
2290	Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells. BMC Cancer, 2016, 16, 551.	1.1	31
2291	Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. Journal of the American Chemical Society, 2016, 138, 16686-16695.	6.6	384
2292	What does PD-L1 positive or negative mean?. Journal of Experimental Medicine, 2016, 213, 2835-2840.	4.2	263
2293	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I "pre-analytical and analytical validation. ", 2016, 4, 76.		155
2294	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Research, 2016, 76, 7012-7023.	0.4	47
2295	The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecologic Oncology Research and Practice, 2016, 3, 11.	3.6	118
2296	The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer and Metastasis Reviews, 2016, 35, 575-588.	2.7	237
2297	A Translational Perspective of a Deubiquitinase Inhibitor in Antitumor Immunity. EBioMedicine, 2016, 13, 7-8.	2.7	1
2298	Rapid cloning, expression, and functional characterization of paired α 2 and β 3 T-cell receptor chains from single-cell analysis. Molecular Therapy - Methods and Clinical Development, 2016, 3, 15054.	1.8	45
2299	Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. Npj Genomic Medicine, 2016, 1, .	1.7	103
2300	Interferon- β and Tumor Necrosis Factor- α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype. Scientific Reports, 2016, 6, 26345.	1.6	69
2301	Responses to immune checkpoint inhibitors in nonagenarians. OncoImmunology, 2016, 5, e1234572.	2.1	24
2302	High expression of CD39 in gastric cancer reduces patient outcome following radical resection. Oncology Letters, 2016, 12, 4080-4086.	0.8	42
2303	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell, 2016, 167, 1540-1554.e12.	13.5	830
2304	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncology, The, 2016, 17, e542-e551.	5.1	1,274
2305	Big Data Bioinformatics. Methods, 2016, 111, 1-2.	1.9	13

#	ARTICLE	IF	CITATIONS
2306	The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients. <i>Scientific Reports</i> , 2016, 6, 37933.	1.6	112
2307	The Disappearance of Lymph Node Metastasis from Neuroendocrine Carcinoma after Endoscopic Ultrasound-guided Fine Needle Aspiration. <i>Internal Medicine</i> , 2016, 55, 2805-2809.	0.3	0
2308	Cancer Immunotherapy for Gliomas: Overview and Future Directions. <i>Neurologia Medico-Chirurgica</i> , 2016, 56, 355-360.	1.0	5
2309	HER2-encoded mir-4728 forms a receptor-independent circuit with miR-21-5p through the non-canonical poly(A) polymerase PABPC1. <i>Scientific Reports</i> , 2016, 6, 35664.	1.6	17
2310	Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. , 2016, 4, 58.		35
2311	The space of enzyme regulation in HeLa cells can be inferred from its intracellular metabolome. <i>Scientific Reports</i> , 2016, 6, 28415.	1.6	15
2312	The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. <i>Scientific Reports</i> , 2016, 6, 19740.	1.6	157
2313	Interpretable per case weighted ensemble method for cancer associations. <i>BMC Genomics</i> , 2016, 17, 501.	1.2	5
2314	Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 227.	1.8	56
2315	The cost and value of cancer drugs “are new innovations outpacing our ability to pay?”. <i>Israel Journal of Health Policy Research</i> , 2016, 5, 40.	1.4	18
2316	Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2016, 4, 232470961667431.	0.3	40
2317	Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. <i>BMC Cancer</i> , 2016, 16, 850.	1.1	22
2318	Luminal B breast cancer subtype displays a dicotomic epigenetic pattern. <i>SpringerPlus</i> , 2016, 5, 623.	1.2	11
2319	Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report. <i>Journal of Hematology and Oncology</i> , 2016, 9, 81.	6.9	62
2320	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. , 2016, 4, 92.		31
2321	PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. <i>Breast Care</i> , 2016, 11, 385-390.	0.8	20,872
2322	Clonal relationships between lobular carcinoma in situ and other breast malignancies. <i>Breast Cancer Research</i> , 2016, 18, 66.	2.2	32
2323	Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. , 2016, 4, 94.		91

#	ARTICLE	IF	CITATIONS
2324	Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53 deficient mammary cancers. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 749-57.	1.2	25
2325	AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. <i>BMC Cancer</i> , 2016, 16, 622.	1.1	65
2326	Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. <i>Scientific Reports</i> , 2016, 6, 20090.	1.6	138
2327	An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER ⁺ /PR ⁺ /Her2 ⁻ Human Breast Cancer Cells. <i>Molecular Pharmacology</i> , 2016, 90, 674-688.	1.0	124
2328	TCR diversity – a universal cancer immunotherapy biomarker?. , 2016, 4, 69.		18
2329	Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors. <i>Radiology and Oncology</i> , 2016, 50, 274-279.	0.6	24
2330	Cancer immunotherapy trials: leading a paradigm shift in drug development. , 2016, 4, 42.		35
2331	Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups. <i>Breast Cancer Research</i> , 2016, 18, 74.	2.2	75
2332	Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 129.	2.2	85
2333	A cloud-based workflow to quantify transcript-expression levels in public cancer compendia. <i>Scientific Reports</i> , 2016, 6, 39259.	1.6	76
2334	High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer. <i>Oncology Letters</i> , 2016, 12, 1422-1428.	0.8	12
2335	Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. , 2016, 4, 44.		54
2336	DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. <i>Npj Breast Cancer</i> , 2016, 2, 16007.	2.3	33
2337	Canine cancer immunotherapy studies: linking mouse and human. , 2016, 4, 97.		86
2338	A New VISTA on combination therapy for negative checkpoint regulator blockade. , 2016, 4, 86.		36
2339	Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders. , 2016, 4, 95.		18
2340	Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. <i>Scientific Reports</i> , 2016, 6, 20254.	1.6	260
2341	PD-1/PD-L pathway inhibits M.tb-specific CD4+ T-cell functions and phagocytosis of macrophages in active tuberculosis. <i>Scientific Reports</i> , 2016, 6, 38362.	1.6	103

#	ARTICLE	IF	CITATIONS
2342	The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. <i>Science Immunology</i> , 2016, 1, .	5.6	415
2343	Regulation of effector function of CNS autoreactive CD4 T cells through inhibitory receptors and IL-7R α . <i>Journal of Neuroinflammation</i> , 2016, 13, 302.	3.1	8
2344	Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing. <i>Genome Biology</i> , 2016, 17, 250.	3.8	68
2345	Relational Network for Knowledge Discovery through Heterogeneous Biomedical and Clinical Features. <i>Scientific Reports</i> , 2016, 6, 29915.	1.6	10
2346	Immune checkpoint inhibitors for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016, 3, 201-211.	4.2	5
2347	Differential network analysis reveals the genome-wide landscape of estrogen receptor modulation in hormonal cancers. <i>Scientific Reports</i> , 2016, 6, 23035.	1.6	31
2348	The effect of activated M α 1 on α 1T cell-mediated killing of gastric cancer cells in vitro. <i>Oncology Letters</i> , 2016, 12, 3368-3372.	0.8	1
2349	Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib. <i>Scientific Reports</i> , 2016, 6, 39598.	1.6	6
2350	Nivolumab-associated acute glomerulonephritis: a case report and literature review. <i>BMC Nephrology</i> , 2016, 17, 188.	0.8	91
2351	PD-L1 is upregulated by EBV-driven LMP1 through NF- α B pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 109.	6.9	217
2352	Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. <i>Genome Medicine</i> , 2016, 8, 136.	3.6	64
2353	Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis. <i>BMC Cancer</i> , 2016, 16, 687.	1.1	104
2354	Reprogramming the immunological microenvironment through radiation and targeting Axl. <i>Nature Communications</i> , 2016, 7, 13898.	5.8	150
2355	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
2356	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 547-573.	2.7	189
2357	PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment. <i>Scientific Reports</i> , 2016, 6, 39296.	1.6	74
2358	Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease. <i>Clinical and Translational Immunology</i> , 2016, 5, e109.	1.7	26
2359	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2016, 2, 16002.	2.3	31

#	ARTICLE	IF	CITATIONS
2360	The PD-1/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats. <i>Scientific Reports</i> , 2016, 6, 27683.	1.6	69
2361	The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy. <i>Clinical and Translational Science</i> , 2016, 9, 283-292.	1.5	36
2362	The adhesion molecule PECAM-1 enhances the TGF- β -mediated inhibition of T cell function. <i>Science Signaling</i> , 2016, 9, ra27.	1.6	19
2363	CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma. <i>Scientific Reports</i> , 2016, 6, 29032.	1.6	51
2364	Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. <i>Scientific Reports</i> , 2016, 6, 31726.	1.6	232
2365	An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. <i>Breast Cancer Research</i> , 2016, 18, 121.	2.2	89
2366	IL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skin. <i>Nature Communications</i> , 2016, 7, 12080.	5.8	64
2367	Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. <i>Science Advances</i> , 2016, 2, e1501924.	4.7	100
2368	Emerging therapeutic agents for lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 138.	6.9	77
2369	Advancements in unresectable melanoma: a multidisciplinary perspective. <i>Melanoma Management</i> , 2016, 3, 171-175.	0.1	0
2370	Dendritic cell vaccines for melanoma: past, present and future. <i>Melanoma Management</i> , 2016, 3, 273-289.	0.1	20
2371	Advances in the development of intralesional therapies for melanoma. <i>Melanoma Management</i> , 2016, 3, 259-266.	0.1	5
2372	A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e397.	2.3	114
2373	Identification of cancer-driver genes in focal genomic alterations from whole genome sequencing data. <i>Scientific Reports</i> , 2016, 6, 25582.	1.6	4
2374	A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 379-385.	0.4	5
2375	B Lymphocytes and Cancer: A Love-Hate Relationship. <i>Trends in Cancer</i> , 2016, 2, 747-757.	3.8	284
2376	Integrative modelling of tumour DNA methylation quantifies the contribution of metabolism. <i>Nature Communications</i> , 2016, 7, 13666.	5.8	37
2377	Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients. <i>Scientific Reports</i> , 2016, 6, 39247.	1.6	74

#	ARTICLE	IF	CITATIONS
2378	Cancer Prevention: Lessons Learned and Future Directions. <i>Trends in Cancer</i> , 2016, 2, 713-722.	3.8	15
2379	Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. <i>Nature Communications</i> , 2016, 7, 12258.	5.8	76
2380	The SDF-1 rs1801157 Polymorphism is Associated with Cancer Risk: An Update Pooled Analysis and FPRP Test of 17,876 Participants. <i>Scientific Reports</i> , 2016, 6, 27466.	1.6	14
2381	Endogenous programmed death ligand-1 restrains the development and onset of Sjögren's syndrome in non-obese diabetic mice. <i>Scientific Reports</i> , 2016, 6, 39105.	1.6	27
2382	SePIA: RNA and small RNA sequence processing, integration, and analysis. <i>BioData Mining</i> , 2016, 9, 20.	2.2	25
2383	BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine. <i>Scientific Reports</i> , 2016, 6, 28217.	1.6	23
2384	Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. <i>Journal of Translational Medicine</i> , 2016, 14, 173.	1.8	103
2385	Dynamic Changes in Chromatin Accessibility Occur in CD8 + T Cells Responding to Viral Infection. <i>Immunity</i> , 2016, 45, 1327-1340.	6.6	231
2386	Diversity and collaboration for effective immunotherapy. <i>Nature Medicine</i> , 2016, 22, 1390-1391.	15.2	8
2387	PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. <i>Scientific Reports</i> , 2016, 6, 25952.	1.6	36
2388	Prioritizing cancer-related microRNAs by integrating microRNA and mRNA datasets. <i>Scientific Reports</i> , 2016, 6, 35350.	1.6	12
2389	<i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. <i>Cancer Research</i> , 2016, 76, 7118-7129.	0.4	99
2390	Checkpoint inhibition in myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 528-533.	0.9	10
2391	Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery. <i>Journal of Neurosurgery</i> , 2016, 125, 31-39.	0.9	13
2392	Oestrogen receptor negativity in breast cancer: a cause or consequence?. <i>Bioscience Reports</i> , 2016, 36, .	1.1	13
2393	T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 2255-2262.	13.9	1,033
2394	Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. <i>Science Translational Medicine</i> , 2016, 8, 368ra171.	5.8	140
2395	Novel agents in follicular lymphoma: choosing the best target. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 284-292.	0.9	3

#	ARTICLE	IF	CITATIONS
2396	Immunotherapy in genitourinary malignancies. <i>Current Opinion in Urology</i> , 2016, 26, 501-507.	0.9	6
2397	A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. <i>Medicine (United States)</i> , 2016, 95, e5539.	0.4	37
2398	Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-Cell Lung Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 392-397.	0.6	261
2399	Impact of Immune-Modulatory Drugs on Regulatory T Cell. <i>Transplantation</i> , 2016, 100, 2288-2300.	0.5	99
2400	A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 604-608.	0.6	17
2401	Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab. <i>Journal of Immunotherapy</i> , 2016, 39, 373-378.	1.2	19
2402	The Importance of Biopsy in the Era of Molecular Medicine. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 418-422.	1.0	32
2403	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , 2016, 16, 434.	1.1	124
2404	Challenges in the Delivery of Therapies to Melanoma Brain Metastases. <i>Current Pharmacology Reports</i> , 2016, 2, 309-325.	1.5	18
2405	SNooPer: a machine learning-based method for somatic variant identification from low-pass next-generation sequencing. <i>BMC Genomics</i> , 2016, 17, 912.	1.2	50
2406	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. , 2016, 4, 81.		79
2407	Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneity. <i>BMC Medicine</i> , 2016, 14, 201.	2.3	3
2408	Ipilimumab-Induced Neutropenia in Melanoma. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2016, 4, 232470961666183.	0.3	22
2409	Immune Therapy for Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 334-341.	1.0	16
2410	Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. , 2016, 4, 84.		94
2411	Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol. <i>BMJ Open</i> , 2016, 6, e013904.	0.8	63
2412	Programmed death-ligand 1 expression in rectal cancer. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2016, 48, 352-356.	0.3	15
2413	Immune-related endocrine disorders in novel immune checkpoint inhibition therapy. <i>Genes and Diseases</i> , 2016, 3, 252-256.	1.5	17

#	ARTICLE	IF	CITATIONS
2414	miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer. <i>Scientific Reports</i> , 2016, 6, 32541.	1.6	53
2415	An integrative and comparative study of pan-cancer transcriptomes reveals distinct cancer common and specific signatures. <i>Scientific Reports</i> , 2016, 6, 33398.	1.6	31
2416	Immune DNA signature of T-cell infiltration in breast tumor exomes. <i>Scientific Reports</i> , 2016, 6, 30064.	1.6	30
2417	A Synthetic Dosage Lethal Genetic Interaction Between <i>CKS1B</i> and <i>PLK1</i> Is Conserved in Yeast and Human Cancer Cells. <i>Genetics</i> , 2016, 204, 807-819.	1.2	27
2418	Relationship between the inflammatory infiltrate and the degree of differentiation of the canine cutaneous squamous cell carcinoma. <i>Veterinary and Animal Science</i> , 2016, 1-2, 4-8.	0.6	3
2419	Data integration to prioritize drugs using genomics and curated data. <i>BioData Mining</i> , 2016, 9, 21.	2.2	14
2420	Subtype-specific CpG island shore methylation and mutation patterns in 30 breast cancer cell lines. <i>BMC Systems Biology</i> , 2016, 10, 116.	3.0	12
2421	Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. <i>Journal of Translational Medicine</i> , 2016, 14, 232.	1.8	27
2422	Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy—a report of two cases. , 2016, 4, 80.		80
2423	GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells <i>in vitro</i> . <i>Clinical and Translational Immunology</i> , 2016, 5, e119.	1.7	30
2424	Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. <i>Oncolmmunology</i> , 2016, 5, e1240857.	2.1	56
2425	Reference-free deconvolution of DNA methylation data and mediation by cell composition effects. <i>BMC Bioinformatics</i> , 2016, 17, 259.	1.2	202
2426	Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3+)/activated cytotoxic T lymphocyte (granzyme B+) ratio on resected left-sided pancreatic cancer. <i>Oncology Letters</i> , 2016, 12, 4477-4484.	0.8	30
2427	Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2016, 151, 97-109.e4.	0.6	120
2428	GPU-Powered Shotgun Stochastic Search for Dirichlet Process Mixtures of Gaussian Graphical Models. <i>Journal of Computational and Graphical Statistics</i> , 2016, 25, 762-788.	0.9	7
2429	A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 681-691.	2.2	46
2430	Overexpression of Ran GTPase Components Regulating Nuclear Export, but not Mitotic Spindle Assembly, Marks Chromosome Instability and Poor Prognosis in Breast Cancer. <i>Targeted Oncology</i> , 2016, 11, 677-686.	1.7	35
2431	GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. <i>Molecular Therapy</i> , 2016, 24, 1135-1149.	3.7	281

#	ARTICLE	IF	CITATIONS
2432	Treating cancer with selective CDK4/6 inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 417-430.	12.5	806
2433	Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2659-2667.	3.2	39
2434	Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 347-354.	1.2	57
2435	From immunotoxicity to carcinogenicity: the effects of carbamate pesticides on the immune system. <i>Environmental Science and Pollution Research</i> , 2016, 23, 9448-9458.	2.7	59
2436	Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016, 33, 44.	1.2	40
2437	Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. <i>Clinical Breast Cancer</i> , 2016, 16, 256-261.	1.1	19
2438	A liquid biopsy for cancer immunotherapy. <i>Nature Medicine</i> , 2016, 22, 340-341.	15.2	21
2439	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2016, 76, 2301-2313.	0.4	509
2440	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 895-901.	1.4	20
2441	The ever-expanding role of HIF in tumour and stromal biology. <i>Nature Cell Biology</i> , 2016, 18, 356-365.	4.6	337
2442	Reporter nanoparticle that monitors its anticancer efficacy in real time. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E2104-13.	3.3	73
2443	Monitoring immune responses in the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2016, 41, 23-31.	2.4	96
2444	Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5864-5875.	3.2	99
2445	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 47.	6.9	271
2446	Neoadjuvant treatment for melanoma: current challenges and future perspectives. <i>Melanoma Management</i> , 2016, 3, 149-159.	0.1	1
2447	Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy. <i>Melanoma Management</i> , 2016, 3, 137-147.	0.1	1
2448	Repeat courses of SRS in patients initially treated with SRS alone for brain-metastatic melanoma. <i>Melanoma Management</i> , 2016, 3, 97-104.	0.1	5
2449	Emerging immunotherapies for glioblastoma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 133-145.	1.0	34

#	ARTICLE	IF	CITATIONS
2450	Targeting neoantigens for cancer immunotherapy: Table 1.. International Immunology, 2016, 28, 365-370.	1.8	42
2451	Selected summary for the 2015 Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE). Hepatic Oncology, 2016, 3, 5-8.	4.2	0
2452	Intralesional treatment for advanced melanoma: what's on the horizon?. Melanoma Management, 2016, 3, 113-123.	0.1	0
2453	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. Drugs, 2016, 76, 925-945.	4.9	123
2454	Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis. Genomics, 2016, 107, 223-230.	1.3	57
2455	Proteogenomics connects somatic mutations to signalling in breast cancer. Nature, 2016, 534, 55-62.	13.7	1,384
2456	<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clinical Cancer Research, 2016, 22, 4585-4593.	3.2	977
2457	Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2016, 34, 2389-2397.	0.8	293
2458	CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. Journal of Immunology, 2016, 197, 179-187.	0.4	48
2459	Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. Cancer and Metastasis Reviews, 2016, 35, 413-426.	2.7	44
2460	Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy. BMC Cancer, 2016, 16, 329.	1.1	26
2461	GATA3-dependent cellular reprogramming requires activation-domain dependent recruitment of a chromatin remodeler. Genome Biology, 2016, 17, 36.	3.8	121
2462	Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. Cancer Research, 2016, 76, 4850-4860.	0.4	33
2463	Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. British Journal of Cancer, 2016, 115, 25-33.	2.9	129
2464	Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Annals of Oncology, 2016, 27, 1706-1712.	0.6	113
2465	PDL1: The Illusion of an Ideal Biomarker. European Urology Focus, 2016, 1, 269-271.	1.6	11
2466	Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated $\gamma\delta$ Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells. Stem Cell Reports, 2016, 6, 213-227.	2.3	66
2467	A fully human IgG1 anti-PD-L1 MAb in an <i>in vitro</i> assay enhances antigen-specific T cell responses. Clinical and Translational Immunology, 2016, 5, e83.	1.7	52

#	ARTICLE	IF	CITATIONS
2468	Emerging molecular classifications and therapeutic implications for gastric cancer. Chinese Journal of Cancer, 2016, 35, 49.	4.9	35
2469	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. Current Treatment Options in Oncology, 2016, 17, 31.	1.3	57
2470	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Current Oncology Reports, 2016, 18, 42.	1.8	54
2471	Identification of genes responsible for RelA-dependent proliferation arrest in human mammary epithelial cells conditionally expressing RelA. Genomics Data, 2016, 7, 92-93.	1.3	2
2472	PD-L1 Expression in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 964-975.	0.5	329
2473	The emerging role of GATA transcription factors in development and disease. Expert Reviews in Molecular Medicine, 2016, 18, e3.	1.6	172
2474	Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Cancer Immunology, Immunotherapy, 2016, 65, 753-763.	2.0	32
2475	Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nature Cell Biology, 2016, 18, 632-644.	4.6	174
2476	Investigational new drugs for brain cancer. Expert Opinion on Investigational Drugs, 2016, 25, 937-956.	1.9	16
2477	Therapeutic Application of Pharmacogenomics in Oncology. AAPS Journal, 2016, 18, 819-829.	2.2	7
2479	Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer. Drugs, 2016, 76, 969-978.	4.9	34
2480	PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion. Immunity, 2016, 44, 1190-1203.	6.6	116
2481	Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity, 2016, 44, 1034-1051.	6.6	232
2482	Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity, 2016, 44, 1052-1068.	6.6	213
2483	Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity, 2016, 44, 989-1004.	6.6	1,538
2484	First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. British Journal of Cancer, 2016, 114, 1199-1205.	2.9	30
2485	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature Reviews Clinical Oncology, 2016, 13, 674-690.	12.5	1,938
2486	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. Targeted Oncology, 2016, 11, 593-603.	1.7	14

#	ARTICLE	IF	CITATIONS
2487	Eradication Strategies for Chronic Hepatitis B Infection. <i>Clinical Infectious Diseases</i> , 2016, 62, S318-S325.	2.9	13
2488	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. <i>Clinical Cancer Research</i> , 2016, 22, 5068-5078.	3.2	38
2489	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016, 22, 5487-5496.	3.2	480
2490	Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 563-568.	1.6	293
2491	Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. <i>Immunotherapy</i> , 2016, 8, 705-719.	1.0	61
2492	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2016, 2, 1179.	3.4	154
2493	PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. <i>Modern Pathology</i> , 2016, 29, 1104-1112.	2.9	210
2494	Oncolytic virotherapy for urological cancers. <i>Nature Reviews Urology</i> , 2016, 13, 334-352.	1.9	18
2495	Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases. <i>Modern Pathology</i> , 2016, 29, 824-831.	2.9	68
2496	Epigenetic Determinants of Cancer. <i>Cold Spring Harbor Perspectives in Biology</i> , 2016, 8, a019505.	2.3	834
2497	Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. <i>Cancer Research</i> , 2016, 76, 3767-3772.	0.4	124
2498	Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 3425-3431.	3.2	368
2499	Phase I study to evaluate toxicity and feasibility of intratumoral injection of Î±-gal glycolipids in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 897-907.	2.0	11
2500	Phase 1 Study of Intravenous Oncolytic Poxvirus (vDD) in Patients With Advanced Solid Cancers. <i>Molecular Therapy</i> , 2016, 24, 1492-1501.	3.7	110
2501	Aberrant PD-L1 expression through 3'UTR disruption in multiple cancers. <i>Nature</i> , 2016, 534, 402-406.	13.7	536
2502	CIS is a potent checkpoint in NK cell-mediated tumor immunity. <i>Nature Immunology</i> , 2016, 17, 816-824.	7.0	289
2503	Pembrolizumab for the treatment of advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 867-873.	0.5	10
2504	Naringenin prevents TGF-Î²1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation. <i>Breast Cancer Research</i> , 2016, 18, 38.	2.2	91

#	ARTICLE	IF	CITATIONS
2505	Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1091-1108.	1.3	9
2506	FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. <i>Oncologist</i> , 2016, 21, 643-650.	1.9	302
2507	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. <i>Science</i> , 2016, 352, 189-196.	6.0	3,421
2508	The Face of the Next Generation in China. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1090-1091.	2.5	4
2509	Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. <i>Cancer Treatment Reviews</i> , 2016, 45, 19-29.	3.4	21
2510	PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. <i>Translational Oncology</i> , 2016, 9, 64-69.	1.7	77
2511	The acetyltransferase Tip60 contributes to mammary tumorigenesis by modulating DNA repair. <i>Cell Death and Differentiation</i> , 2016, 23, 1198-1208.	5.0	62
2512	Presentation of hepatocellular antigens. <i>Cellular and Molecular Immunology</i> , 2016, 13, 293-300.	4.8	34
2513	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. <i>Modern Pathology</i> , 2016, 29, 476-488.	2.9	95
2514	<i>MYC</i> and <i>PVT1</i> synergize to regulate <i>RSPO1</i> levels in breast cancer. <i>Cell Cycle</i> , 2016, 15, 881-885.	1.3	27
2515	PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. <i>Clinical Cancer Research</i> , 2016, 22, 1173-1184.	3.2	207
2516	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016, 4, 383-389.	1.6	247
2517	<i>KRAS</i> oncogene in lung cancer: focus on molecularly driven clinical trials. <i>European Respiratory Review</i> , 2016, 25, 71-76.	3.0	72
2518	Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1559-1564.	3.2	28
2519	Analysis of functional germline variants in <i>APOBEC3</i> and driver genes on breast cancer risk in Moroccan study population. <i>BMC Cancer</i> , 2016, 16, 165.	1.1	20
2520	Into the Clinic With Nivolumab and Pembrolizumab. <i>Oncologist</i> , 2016, 21, 527-528.	1.9	17
2521	The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer. <i>Hormones and Cancer</i> , 2016, 7, 219-228.	4.9	42
2522	Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade. <i>Seminars in Oncology</i> , 2016, 43, 222-232.	0.8	23

#	ARTICLE	IF	CITATIONS
2523	The tandem duplicator phenotype as a distinct genomic configuration in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2373-82.	3.3	103
2524	ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models. Molecular Cancer, 2016, 15, 26.	7.9	147
2525	Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Research, 2016, 76, 3156-3165.	0.4	224
2526	Limitations of the Driver/Passenger Model in Cancer Prevention. Cancer Prevention Research, 2016, 9, 335-338.	0.7	7
2527	Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1369-1376.	1.2	13
2528	Tumor-Derived Exosomes and Their Role in Cancer Progression. Advances in Clinical Chemistry, 2016, 74, 103-141.	1.8	549
2529	Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab. Targeted Oncology, 2016, 11, 553-556.	1.7	32
2530	NLRX1 Sequesters STING to Negatively Regulate the Interferon Response, Thereby Facilitating the Replication of HIV-1 and DNA Viruses. Cell Host and Microbe, 2016, 19, 515-528.	5.1	130
2531	Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. Genome Research, 2016, 26, 732-744.	2.4	225
2532	Adenosine-mediated immunosuppression in patients with squamous cell carcinoma of the head and neck. Hno, 2016, 64, 303-309.	0.4	6
2533	Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1792-1801.	3.3	17
2534	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer, 2016, 16, 275-287.	12.8	2,133
2535	Epigenetic and genetic burden measures are associated with tumor characteristics in invasive breast carcinoma. Epigenetics, 2016, 11, 344-353.	1.3	14
2536	Characterization of alanine to valine sequence variants in the Fc region of nivolumab biosimilar produced in Chinese hamster ovary cells. MAbs, 2016, 8, 951-960.	2.6	12
2537	The role of neoantigens in response to immune checkpoint blockade. International Immunology, 2016, 28, 411-419.	1.8	148
2538	MicroRNAs provide a novel pathway toward combinatorial immune checkpoint blockade. Neuro-Oncology, 2016, 18, 601-602.	0.6	2
2539	Epithelial to Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?. Clinical Cancer Research, 2016, 22, 3422-3424.	3.2	65
2540	CCR9 in cancer: oncogenic role and therapeutic targeting. Journal of Hematology and Oncology, 2016, 9, 10.	6.9	59

#	ARTICLE	IF	CITATIONS
2541	Aromatase expression and regulation in breast and endometrial cancer. <i>Journal of Molecular Endocrinology</i> , 2016, 57, R19-R33.	1.1	148
2542	Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies. <i>Cell Reports</i> , 2016, 15, 264-273.	2.9	28
2543	Practicability of detecting somatic point mutation from RNA high throughput sequencing data. <i>Genomics</i> , 2016, 107, 163-169.	1.3	30
2544	Carcinogenic potential of high aspect ratio carbon nanomaterials. <i>Environmental Science: Nano</i> , 2016, 3, 483-493.	2.2	24
2545	P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance. <i>Journal of Cell Biology</i> , 2016, 213, 81-95.	2.3	57
2546	Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1 α . <i>Cancer Research</i> , 2016, 76, 2231-2242.	0.4	107
2547	Emerging Opportunities and Challenges in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1845-1855.	3.2	242
2548	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. <i>Tumor Biology</i> , 2016, 37, 7507-7514.	0.8	40
2549	The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma. <i>Medicine (United States)</i> , 2016, 95, e3134.	0.4	13
2550	Advances in immunotherapy for melanoma. <i>BMC Medicine</i> , 2016, 14, 20.	2.3	111
2551	Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 117-131.	1.1	18
2552	Intratumoral Heterogeneity of the Epigenome. <i>Cancer Cell</i> , 2016, 29, 440-451.	7.7	172
2553	Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. <i>European Journal of Cancer</i> , 2016, 60, 12-25.	1.3	321
2554	Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. <i>Annals of Oncology</i> , 2016, 27, 1286-1291.	0.6	92
2555	Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. <i>Nature Cell Biology</i> , 2016, 18, 572-578.	4.6	197
2556	Durable antitumor responses to CD47 blockade require adaptive immune stimulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E2646-54.	3.3	272
2557	Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw028.	3.0	20
2558	Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 35-43.	1.4	26

#	ARTICLE	IF	CITATIONS
2559	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. <i>Oncologist</i> , 2016, 21, 634-642.	1.9	379
2560	Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: Validation of the cut-off value of the Ki67 labeling index as a predictive factor. <i>Molecular and Clinical Oncology</i> , 2016, 4, 648-654.	0.4	24
2561	Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 25.	1.3	15
2562	Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. <i>Modern Pathology</i> , 2016, 29, 753-763.	2.9	230
2563	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 2542-2552.	13.9	1,048
2564	Reversing T-cell Dysfunction and Exhaustion in Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1856-1864.	3.2	317
2565	Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors—implications for therapeutic potential. <i>Tumor Biology</i> , 2016, 37, 11909-11916.	0.8	3
2566	Dose Expansion Cohorts in Phase I Trials. <i>Statistics in Biopharmaceutical Research</i> , 2016, 8, 161-170.	0.6	33
2567	Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 51-59.	1.4	13
2568	A new molecular signature method for prediction of driver cancer pathways from transcriptional data. <i>Nucleic Acids Research</i> , 2016, 44, e110-e110.	6.5	15
2569	Cancer-associated oxidoreductase ERO1- β drives the production of VEGF via oxidative protein folding and regulating the mRNA level. <i>British Journal of Cancer</i> , 2016, 114, 1227-1234.	2.9	40
2570	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4623-4633.	3.2	153
2571	Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. <i>Immunity</i> , 2016, 44, 924-938.	6.6	857
2572	Myeloid-derived suppressor cells enhance the expression of melanoma-associated antigen A4 in a Lewis lung cancer murine model. <i>Oncology Letters</i> , 2016, 11, 809-816.	0.8	11
2573	The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival. <i>British Journal of Cancer</i> , 2016, 114, 1145-1151.	2.9	25
2574	Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. <i>Annals of Oncology</i> , 2016, 27, 1304-1311.	0.6	66
2575	Nature Biotechnology's academic spinouts of 2015. <i>Nature Biotechnology</i> , 2016, 34, 484-492.	9.4	5
2576	Emerging nanotechnologies for cancer immunotherapy. <i>Experimental Biology and Medicine</i> , 2016, 241, 1116-1126.	1.1	26

#	ARTICLE	IF	CITATIONS
2577	Tree inference for single-cell data. <i>Genome Biology</i> , 2016, 17, 86.	3.8	257
2578	Systems immune monitoring in cancer therapy. <i>European Journal of Cancer</i> , 2016, 61, 77-84.	1.3	38
2579	Cancer immunotherapy: the beginning of the end of cancer?. <i>BMC Medicine</i> , 2016, 14, 73.	2.3	908
2580	Chordoma: The Quest for Better Treatment Options. <i>Oncology and Therapy</i> , 2016, 4, 35-51.	1.0	34
2581	Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences. <i>Cancer Gene Therapy</i> , 2016, 23, 178-187.	2.2	21
2582	Learning from PD-1 Resistance: New Combination Strategies. <i>Trends in Molecular Medicine</i> , 2016, 22, 448-451.	3.5	61
2583	OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer. <i>Clinical and Translational Immunology</i> , 2016, 5, e70.	1.7	102
2584	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. <i>Nature Genetics</i> , 2016, 48, 607-616.	9.4	933
2585	Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14. <i>MBio</i> , 2016, 7, .	1.8	88
2586	Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. <i>Cancer Immunology Research</i> , 2016, 4, 600-610.	1.6	86
2587	Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. <i>Breast Cancer Research</i> , 2016, 18, 43.	2.2	90
2588	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Resistant Refractory Metastatic Melanoma. <i>JAMA Oncology</i> , 2016, 2, 1056.	3.4	41
2589	Increased Proportion of Variance Explained and Prediction Accuracy of Survival of Breast Cancer Patients with Use of Whole-Genome Multiomic Profiles. <i>Genetics</i> , 2016, 203, 1425-1438.	1.2	49
2590	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. <i>Haematologica</i> , 2016, 101, 531-540.	1.7	75
2591	Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2016, 114, 1084-1089.	2.9	113
2592	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2460-2467.	0.8	1,185
2593	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 2602-2609.	0.8	101
2594	Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. <i>Oncology Letters</i> , 2016, 11, 1581-1585.	0.8	34

#	ARTICLE	IF	CITATIONS
2595	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 473-486.	12.5	831
2596	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2219-2231.	1.4	49
2597	Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker. <i>Clinical Cancer Research</i> , 2016, 22, 2114-2120.	3.2	6
2598	Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer. <i>Breast Care</i> , 2016, 11, 96-100.	0.8	33
2599	The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 361-370.	1.1	11
2600	Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016, 27, 1291-1298.	0.6	129
2602	MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays. <i>Radiology</i> , 2016, 281, 382-391.	3.6	387
2603	Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. <i>American Journal of Pathology</i> , 2016, 186, 1537-1546.	1.9	31
2604	A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 741-749.	2.2	13
2605	Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2016, 51, 1268-1270.	1.3	68
2606	Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 522-530.	3.6	231
2607	Targeting lymphoma with precision using semisynthetic anti-idiotypic peptibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5376-5381.	3.3	22
2608	Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 703-713.	7.7	92
2609	Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival. <i>BMC Cancer</i> , 2016, 16, 219.	1.1	17
2610	Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity. <i>BMC Systems Biology</i> , 2016, 10, 16.	3.0	24
2611	Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. , 2016, 4, 26.		10
2612	Adapting Cancer Immunotherapy Models for the Real World. <i>Trends in Immunology</i> , 2016, 37, 354-363.	2.9	77
2613	State-of-the-art of regulatory dendritic cells in cancer. , 2016, 164, 97-104.		43

#	ARTICLE	IF	CITATIONS
2614	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. <i>International Immunology</i> , 2016, 28, 373-382.	1.8	143
2615	Roles of regulatory T cells in cancer immunity. <i>International Immunology</i> , 2016, 28, 401-409.	1.8	412
2616	Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5553-5563.	3.2	96
2617	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. <i>Medical Oncology</i> , 2016, 33, 59.	1.2	22
2618	Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. <i>Molecular Cancer</i> , 2016, 15, 34.	7.9	57
2619	Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. <i>Journal of Immunology</i> , 2016, 196, 4793-4804.	0.4	10
2620	A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy. <i>American Journal of Ophthalmology Case Reports</i> , 2016, 2, 23-25.	0.4	28
2621	Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients. <i>Cancer Cell</i> , 2016, 29, 711-722.	7.7	242
2622	Phosphatidylinositol-3 kinase-dependent translational regulation of Id1 involves the PPM1G phosphatase. <i>Oncogene</i> , 2016, 35, 5807-5816.	2.6	13
2623	In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis. <i>Oncogene</i> , 2016, 35, 5446-5455.	2.6	51
2624	Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. <i>Clinical Cancer Research</i> , 2016, 22, 4827-4836.	3.2	24
2626	ARACNe-AP: gene network reverse engineering through adaptive partitioning inference of mutual information. <i>Bioinformatics</i> , 2016, 32, 2233-2235.	1.8	305
2627	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5461-5471.	3.2	234
2628	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 4848-4858.	3.2	146
2629	Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. <i>Acta Radiologica</i> , 2016, 57, 1149-1155.	0.5	23
2630	CoINclDE: A framework for discovery of patient subtypes across multiple datasets. <i>Genome Medicine</i> , 2016, 8, 27.	3.6	29
2631	Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2863-2873.	1.8	137
2632	Biology and treatment of BRAF mutant metastatic melanoma. <i>Melanoma Management</i> , 2016, 3, 33-45.	0.1	28

#	ARTICLE	IF	CITATIONS
2633	Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology. <i>Diagnostic Cytopathology</i> , 2016, 44, 1000-1009.	0.5	55
2634	The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2016, 18, 66.	1.8	6
2635	NETs in cancer. <i>Tumor Biology</i> , 2016, 37, 14355-14361.	0.8	52
2636	Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 845-857.	1.6	110
2637	PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. , 2016, 4, 48.		178
2638	Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, 783-796.	1.6	31
2639	Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1462-1464.	0.6	65
2640	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 587-600.	1.3	30
2641	Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. <i>Oncologist</i> , 2016, 21, 1315-1325.	1.9	64
2642	Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. <i>Journal of Virology</i> , 2016, 90, 8934-8946.	1.5	69
2643	Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 581-590.	1.4	71
2644	Treatment of malignant melanoma with nivolumab and vemurafenib combined with hypofractionated radiation therapy. <i>International Cancer Conference Journal</i> , 2016, 5, 214-218.	0.2	1
2645	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1374-1385.	5.1	1,034
2646	A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment. <i>Journal of Biomedical Science</i> , 2016, 23, 64.	2.6	21
2647	MicroRNA expression and gene regulation drive breast cancer progression and metastasis in PyMT mice. <i>Breast Cancer Research</i> , 2016, 18, 75.	2.2	14
2648	CRISPR-mediated genome editing and human diseases. <i>Genes and Diseases</i> , 2016, 3, 244-251.	1.5	70
2649	Adoptive immunotherapy against ovarian cancer. <i>Journal of Ovarian Research</i> , 2016, 9, 30.	1.3	33
2650	Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3717-3718.	0.8	13

#	ARTICLE	IF	CITATIONS
2652	Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation. <i>Journal of Neuro-Oncology</i> , 2016, 130, 397-411.	1.4	11
2653	Molecular switch of EZH2 in hypoxia. <i>Cell Cycle</i> , 2016, 15, 3007-3008.	1.3	6
2654	A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. <i>British Journal of Cancer</i> , 2016, 115, 784-788.	2.9	18
2655	Restoring anti-oncogene Th1 responses with dendritic cell vaccines in HER2-positive breast cancer: progress and potential. <i>Immunotherapy</i> , 2016, 8, 1219-1232.	1.0	22
2656	Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. <i>Annals of Oncology</i> , 2016, 27, 1940-1946.	0.6	94
2657	Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?. <i>Asian Journal of Urology</i> , 2016, 3, 195-202.	0.5	12
2658	Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis. <i>Cell Reports</i> , 2016, 16, 472-486.	2.9	95
2659	Mammary Tumor-Associated RNAs Impact Tumor Cell Proliferation, Invasion, and Migration. <i>Cell Reports</i> , 2016, 17, 261-274.	2.9	51
2660	Spontaneous breast cancer remission: A case report. <i>International Journal of Surgery Case Reports</i> , 2016, 25, 132-136.	0.2	3
2661	Radiotherapy: Changing the Game in Immunotherapy. <i>Trends in Cancer</i> , 2016, 2, 286-294.	3.8	270
2662	Intergenerically Spliced Chimeric RNAs in Cancer. <i>Trends in Cancer</i> , 2016, 2, 475-484.	3.8	76
2663	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1590-1598.	5.1	594
2664	Advances in PET Detection of the Antitumor T Cell Response. <i>Advances in Immunology</i> , 2016, 131, 187-231.	1.1	39
2665	Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. <i>Asian Journal of Urology</i> , 2016, 3, 268-277.	0.5	4
2666	Intrinsic subtypes and bladder cancer metastasis. <i>Asian Journal of Urology</i> , 2016, 3, 260-267.	0.5	31
2667	Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. <i>Nature Genetics</i> , 2016, 48, 1327-1329.	9.4	115
2668	Emerging roles of p53 and other tumour-suppressor genes in immune regulation. <i>Nature Reviews Immunology</i> , 2016, 16, 741-750.	10.6	262
2669	Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. <i>Cancer Research</i> , 2016, 76, 6964-6974.	0.4	294

#	ARTICLE	IF	CITATIONS
2670	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. <i>Cancer Immunology Research</i> , 2016, 4, 959-967.	1.6	428
2671	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. <i>Journal of Clinical Oncology</i> , 2016, 34, 3838-3845.	0.8	715
2672	A saltationist theory of cancer evolution. <i>Nature Genetics</i> , 2016, 48, 1102-1103.	9.4	18
2673	Systemic chromosome instability in Shugoshin-1 mice resulted in compromised glutathione pathway, activation of Wnt signaling and defects in immune system in the lung. <i>Oncogenesis</i> , 2016, 5, e256-e256.	2.1	13
2674	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. <i>Cancer Immunology Research</i> , 2016, 4, 936-947.	1.6	132
2675	Mouse models in oncoimmunology. <i>Nature Reviews Cancer</i> , 2016, 16, 759-773.	12.8	267
2676	Current clinical trials testing the combination of immunotherapy with radiotherapy. , 2016, 4, 51.		317
2677	Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4431-4439.	1.8	187
2678	Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies. <i>Cell Death and Disease</i> , 2016, 7, e2380-e2380.	2.7	38
2679	Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline <i>POLE</i> Deficiency Treated with Checkpoint Blockade Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 1230-1236.	7.7	242
2680	CloneCNA: detecting subclonal somatic copy number alterations in heterogeneous tumor samples from whole-exome sequencing data. <i>BMC Bioinformatics</i> , 2016, 17, 310.	1.2	27
2681	The Relationship Between Dormant Cancer Cells and Their Microenvironment. <i>Advances in Cancer Research</i> , 2016, 132, 45-71.	1.9	125
2682	Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?. <i>Respiratory Medicine Case Reports</i> , 2016, 19, 118-120.	0.2	10
2683	Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6107-E6116.	3.3	51
2684	TGF β 1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. <i>Cancer Discovery</i> , 2016, 6, 1366-1381.	7.7	196
2685	Gemcitabine reduces MDSCs, tregs and TGF β 1 while restoring the teff/treg ratio in patients with pancreatic cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 282.	1.8	152
2686	Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 100.	6.9	93
2687	Trends and advances in tumor immunology and lung cancer immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 157.	3.5	50

#	ARTICLE	IF	CITATIONS
2689	Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1511-1522.	2.0	17
2690	Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 163-172.	1.1	50
2691	A unified analytic framework for prioritization of non-coding variants of uncertain significance in heritable breast and ovarian cancer. <i>BMC Medical Genomics</i> , 2016, 9, 19.	0.7	28
2692	Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. <i>Haematologica</i> , 2016, 101, 1144-1158.	1.7	6
2693	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncology</i> , 2016, 17, 1497-1508.	5.1	1,279
2694	Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. <i>BMC Cancer</i> , 2016, 16, 744.	1.1	94
2695	Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms. <i>Tumor Biology</i> , 2016, 37, 15411-15431.	0.8	27
2696	The Long and Winding Road. <i>Advances in Pharmacology</i> , 2016, 76, 147-173.	1.2	2
2697	PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?. <i>Medical Oncology</i> , 2016, 33, 120.	1.2	23
2698	Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. <i>British Journal of Cancer</i> , 2016, 115, 1186-1192.	2.9	50
2699	Genomic Approaches to Understanding Response and Resistance to Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 5642-5650.	3.2	134
2700	Identifying candidate drivers of drug response in heterogeneous cancer by mining high throughput genomics data. <i>BMC Genomics</i> , 2016, 17, 638.	1.2	8
2701	Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment. , 2016, 4, 30.		44
2702	Drug repurposing for glioblastoma based on molecular subtypes. <i>Journal of Biomedical Informatics</i> , 2016, 64, 131-138.	2.5	29
2703	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. <i>Genome Medicine</i> , 2016, 8, 79.	3.6	151
2704	Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. <i>British Journal of Cancer</i> , 2016, 115, 1280-1284.	2.9	36
2705	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11919-11924.	3.3	197
2706	FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6600-E6609.	3.3	119

#	ARTICLE	IF	CITATIONS
2707	Mutational landscape of <i>EGFR</i> , <i>MYC</i> , and <i>Kras</i> driven genetically engineered mouse models of lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6409-E6417.	3.3	158
2708	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2016, 65, 1533-1544.	2.0	89
2709	Enzyme-Instructed Self-Assembly for Spatiotemporal Profiling of the Activities of Alkaline Phosphatases on Live Cells. Chem, 2016, 1, 246-263.	5.8	143
2710	Novel therapeutic options in Acute Myeloid Leukemia. Leukemia Research Reports, 2016, 6, 39-49.	0.2	30
2711	Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagnostic Pathology, 2016, 11, 95.	0.9	149
2712	Mammary-Stem-Cell-Based Somatic Mouse Models Reveal Breast Cancer Drivers Causing Cell Fate Dysregulation. Cell Reports, 2016, 16, 3146-3156.	2.9	48
2713	Simul-seq: combined DNA and RNA sequencing for whole-genome and transcriptome profiling. Nature Methods, 2016, 13, 953-958.	9.0	34
2714	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. Journal of Clinical Oncology, 2016, 34, 4102-4109.	0.8	528
2715	ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance. Oncogenesis, 2016, 5, e259-e259.	2.1	37
2716	BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling. Cancer Research, 2016, 76, 6555-6567.	0.4	107
2718	Novel anti-EPHA2 antibody, DS-8895a for cancer treatment. Cancer Biology and Therapy, 2016, 17, 1158-1167.	1.5	32
2719	Genomic insights into head and neck cancer. Cancers of the Head & Neck, 2016, 1, .	6.2	65
2720	Mena ^{INV} mediates synergistic cross-talk between signaling pathways driving chemotaxis and haptotaxis. Molecular Biology of the Cell, 2016, 27, 3085-3094.	0.9	12
2721	Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. , 2016, 4, 53.		278
2722	Immunotherapy as a Potential Treatment for Chordoma: a Review. Current Oncology Reports, 2016, 18, 55.	1.8	16
2723	Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8 ⁺ T cells. Human Vaccines and Immunotherapeutics, 2016, 12, 2519-2522.	1.4	6
2724	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 3638-3647.	0.8	140
2725	Molecular Imaging of Immunotherapy Targets in Cancer. Journal of Nuclear Medicine, 2016, 57, 1487-1492.	2.8	77

#	ARTICLE	IF	CITATIONS
2726	Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 79-87.	0.9	108
2727	Anti-androgen therapy in triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 305-308.	1.4	21
2728	CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 787-798.	1.7	29
2729	Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma. <i>Tumor Biology</i> , 2016, 37, 13855-13870.	0.8	19
2730	Metastatic melanoma and immunotherapy. <i>Clinical Immunology</i> , 2016, 172, 105-110.	1.4	43
2731	Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 444-454.	1.0	26
2732	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2016, 18, 59.	1.8	35
2733	Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. <i>Cell</i> , 2016, 166, 1041-1054.	13.5	206
2734	Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies. <i>Cancer Research</i> , 2016, 76, 5415-5422.	0.4	43
2735	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 755-765.	1.6	36
2736	Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. <i>Haematologica</i> , 2016, 101, 976-984.	1.7	70
2737	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. <i>Modern Pathology</i> , 2016, 29, 1292-1305.	2.9	68
2738	Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. <i>Seminars in Oncology</i> , 2016, 43, 476-483.	0.8	55
2739	Oncolytic viruses as immunotherapeutics on the rise. <i>Journal of Molecular Medicine</i> , 2016, 94, 979-991.	1.7	43
2740	Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer. <i>Cell Reports</i> , 2016, 16, 2032-2046.	2.9	36
2741	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. <i>Oral Oncology</i> , 2016, 61, 152-158.	0.8	48
2742	Immunotherapy of advanced renal cell carcinoma: Current and future therapies. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2997-3004.	1.4	12
2743	Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance. <i>Cancer Immunology Research</i> , 2016, 4, 799-811.	1.6	25

#	ARTICLE	IF	CITATIONS
2744	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. <i>Investigational New Drugs</i> , 2016, 34, 677-684.	1.2	30
2745	Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1247-1253.	1.5	50
2746	Therapeutic targets and new directions for antibodies developed for ovarian cancer. <i>MAbs</i> , 2016, 8, 1437-1455.	2.6	15
2747	The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Clinical Infectious Diseases</i> , 2016, 63, 1490-1493.	2.9	226
2748	Spatial Heterogeneity in the Tumor Microenvironment. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026583.	2.9	194
2749	The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 910-921.	1.9	58
2750	Sticking It to Cancer with Molecular Glue for SHP2. <i>Cancer Cell</i> , 2016, 30, 194-196.	7.7	72
2751	Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. <i>Immunity</i> , 2016, 45, 389-401.	6.6	496
2752	Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. <i>Oncologist</i> , 2016, 21, 1063-1078.	1.9	41
2753	Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects. <i>Pituitary</i> , 2016, 19, 625-642.	1.6	94
2754	Socializing Individualized T-Cell Cancer Immunotherapy. <i>Molecular Therapy</i> , 2016, 24, 1170-1173.	3.7	1
2755	The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026930.	2.9	309
2757	Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1927-1939.	0.5	63
2758	Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. <i>Oncologist</i> , 2016, 21, 1230-1240.	1.9	212
2759	Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1461-1464.	0.8	71
2760	The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 48.	1.3	36
2761	Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1. <i>Molecular and Cellular Biology</i> , 2016, 36, 2384-2395.	1.1	25
2762	JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships. <i>Microbiology and Molecular Biology Reviews</i> , 2016, 80, 793-835.	2.9	348

#	ARTICLE	IF	CITATIONS
2763	PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?. <i>Clinical Cancer Research</i> , 2016, 22, 4539-4541.	3.2	39
2764	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. <i>Cancer</i> , 2016, 122, 1836-1843.	2.0	39
2765	Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. <i>International Journal of Cancer</i> , 2016, 138, 187-194.	2.3	83
2766	A phase I, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 316-323.	1.0	4
2767	Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing. <i>Molecular Genetics & Genomic Medicine</i> , 2016, 4, 262-272.	0.6	11
2768	Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression. <i>Pharmacological Research</i> , 2016, 111, 688-702.	3.1	113
2769	An investigation of the association of genetic susceptibility risk with somatic mutation burden in breast cancer. <i>British Journal of Cancer</i> , 2016, 115, 752-760.	2.9	16
2770	Chemotherapy remains an essential element of personalized care for persons with lung cancers. <i>Annals of Oncology</i> , 2016, 27, 1829-1835.	0.6	83
2771	Pembrolizumab in classical Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2016, 97, 219-227.	1.1	22
2772	Therapeutic implications of melanoma heterogeneity. <i>Experimental Dermatology</i> , 2016, 25, 497-500.	1.4	28
2773	Translating cancer genomes and transcriptomes for precision oncology. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 75-88.	157.7	133
2774	PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. <i>Pharmacotherapy</i> , 2016, 36, 317-334.	1.2	82
2775	High affinity nanobodies against human epidermal growth factor receptor selected on cells by $E. coli$ display. <i>MAbs</i> , 2016, 8, 1286-1301.	2.6	28
2776	Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors. <i>Thoracic Cancer</i> , 2016, 7, 161-166.	0.8	16
2777	PenPC: A Two-Step Approach to Estimate the Skeletons of High-Dimensional Directed Acyclic Graphs. <i>Biometrics</i> , 2016, 72, 146-155.	0.8	19
2778	Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2370-2377.	1.9	30
2779	Evolving Immunotherapy Approaches for Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2016, 18, 57.	1.8	24
2780	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. <i>Clinical Cancer Research</i> , 2016, 22, 5729-5737.	3.2	175

#	ARTICLE	IF	CITATIONS
2781	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2016, 4, 726-733.	1.6	133
2782	Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. <i>Visceral Medicine</i> , 2016, 32, 178-183.	0.5	32
2783	Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review. <i>Melanoma Management</i> , 2016, 3, 231-243.	0.1	4
2784	Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. <i>Investigational New Drugs</i> , 2016, 34, 794-796.	1.2	17
2785	Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. <i>Nature Biotechnology</i> , 2016, 34, 1037-1045.	9.4	279
2786	Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth. <i>Oncogenesis</i> , 2016, 5, e255-e255.	2.1	12
2787	Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. <i>Breast Care</i> , 2016, 11, 167-173.	0.8	92
2788	Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. <i>BMC Genomics</i> , 2016, 17, 525.	1.2	172
2789	Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. , 2016, 4, 50.		413
2790	Chlorin-Based Nanoscale Metal-Organic Framework Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy. <i>Journal of the American Chemical Society</i> , 2016, 138, 12502-12510.	6.6	429
2791	Analogies Between Cancer-Derived Extracellular Vesicles and Enveloped Viruses with an Emphasis on Human Breast Cancer. <i>Current Pathobiology Reports</i> , 2016, 4, 169-179.	1.6	1
2792	Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. <i>Annals of Oncology</i> , 2016, 27, 1966-1969.	0.6	22
2793	Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways. <i>Cancer Research</i> , 2016, 76, 6424-6435.	0.4	77
2794	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. <i>Cancer Immunology Research</i> , 2016, 4, 820-822.	1.6	63
2795	Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. , 2016, 4, 36.		90
2796	Tumorigenic potential is restored during differentiation in fusion-reprogrammed cancer cells. <i>Cell Death and Disease</i> , 2016, 7, e2314-e2314.	2.7	6
2797	Cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases. <i>Immunology and Cell Biology</i> , 2016, 94, 935-942.	1.0	29
2798	Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. <i>Cancer Research</i> , 2016, 76, 6153-6158.	0.4	189

#	ARTICLE	IF	CITATIONS
2799	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 835-844.	1.6	138
2800	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. <i>Molecular Cancer</i> , 2016, 15, 55.	7.9	212
2801	The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms. <i>Clinics in Colon and Rectal Surgery</i> , 2016, 29, 232-238.	0.5	17
2802	Tandem duplications contribute to not one but two distinct phenotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5257-8.	3.3	8
2803	Current Progress in Immunotherapy for the Treatment of Biliary Cancers. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 351-357.	0.6	8
2804	Mathematical models of breast and ovarian cancers. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2016, 8, 337-362.	6.6	19
2805	A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 578-588.	0.4	190
2806	New insights in melanoma biomarkers: long-noncoding RNAs. <i>Melanoma Management</i> , 2016, 3, 195-205.	0.1	0
2807	Engineered T cells: the promise and challenges of cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2016, 16, 566-581.	12.8	876
2808	Precision glycoalyx editing as a strategy for cancer immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10304-10309.	3.3	328
2809	Targeted Programming of the Lymph Node Environment Causes Evolution of Local and Systemic Immunity. <i>Cellular and Molecular Bioengineering</i> , 2016, 9, 418-432.	1.0	13
2810	Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harboring Targetable Oncogenic Driver Mutations. <i>Drugs</i> , 2016, 76, 1321-1336.	4.9	17
2811	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1387-1396.	0.5	6
2812	Development of the Theta Comparative Cell Scoring Method to Quantify Diverse Phenotypic Responses Between Distinct Cell Types. <i>Assay and Drug Development Technologies</i> , 2016, 14, 395-406.	0.6	17
2813	Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. <i>BMC Cancer</i> , 2016, 16, 587.	1.1	26
2814	Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. <i>Genome Biology</i> , 2016, 17, 174.	3.8	1,768
2815	Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody. <i>Advanced Materials</i> , 2016, 28, 8912-8920.	11.1	286
2816	Multi-organ Mapping of Cancer Risk. <i>Cell</i> , 2016, 166, 1132-1146.e7.	13.5	128

#	ARTICLE	IF	CITATIONS
2817	Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer. <i>Oral Oncology</i> , 2016, 61, 159-165.	0.8	60
2818	The broken "off-switch" in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. <i>BBA Clinical</i> , 2016, 6, 87-99.	4.1	133
2819	PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome. <i>Modern Pathology</i> , 2016, 29, 1552-1564.	2.9	25
2820	Influence maximization in time bounded network identifies transcription factors regulating perturbed pathways. <i>Bioinformatics</i> , 2016, 32, i128-i136.	1.8	11
2821	Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?. <i>British Journal of Radiology</i> , 2016, 89, 20160472.	1.0	32
2822	Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. <i>Journal of Pathology</i> , 2016, 240, 315-328.	2.1	35
2823	Data on affected cancer-related genes in pediatric t(12;21)-positive acute lymphoblastic leukemia patients harboring unbalanced der(6)t(X;6) translocations. <i>Data in Brief</i> , 2016, 8, 894-903.	0.5	0
2824	Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia. <i>Journal of Immunology</i> , 2016, 197, 2532-2540.	0.4	110
2825	Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ. <i>Journal of Immunology</i> , 2016, 197, 2509-2521.	0.4	25
2826	Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. <i>Nature Genetics</i> , 2016, 48, 1119-1130.	9.4	396
2827	Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 3562-3569.	0.8	175
2828	Sequencing of New and Old Therapies for Metastatic Melanoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 52.	1.3	7
2829	Regulatory circuits of T cell function in cancer. <i>Nature Reviews Immunology</i> , 2016, 16, 599-611.	10.6	445
2830	Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. <i>Annals of Oncology</i> , 2016, 27, 1953-1958.	0.6	289
2831	Interleukin-2 reverses CD8+ T cell exhaustion in clinical malignant pleural effusion of lung cancer. <i>Clinical and Experimental Immunology</i> , 2016, 186, 106-114.	1.1	26
2832	Multiple Expressed Endogenous Glioma Epitopes as Novel Vaccines for Gliomas. <i>Clinical Cancer Research</i> , 2016, 22, 4760-4762.	3.2	3
2833	Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2598-2608.	1.9	52
2834	Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 54.	1.3	18

#	ARTICLE	IF	CITATIONS
2835	CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2016, 76, 5671-5682.	0.4	454
2836	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	2.0	288
2837	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016, 122, 3354-3362.	2.0	236
2838	Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1201-1212.	2.0	36
2839	EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1901-1911.	0.5	14
2840	In search of a target: PD-1 and PD-L1 profiling across glioma types. <i>Neuro-Oncology</i> , 2016, 18, 1331-1332.	0.6	18
2841	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. <i>Clinical Cancer Research</i> , 2016, 22, 6051-6060.	3.2	393
2842	Immunotherapy in Lung Cancer. <i>Cancer Treatment and Research</i> , 2016, 170, 203-223.	0.2	8
2843	Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis. <i>European Urology</i> , 2016, 70, 1082-1083.	0.9	38
2844	A new correlation clustering method for cancer mutation analysis. <i>Bioinformatics</i> , 2016, 32, 3717-3728.	1.8	15
2845	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 360-374.	1.4	37
2846	L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo. <i>BMC Cancer</i> , 2016, 16, 343.	1.1	78
2847	Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression. <i>Lung Cancer Management</i> , 2016, 5, 119-122.	1.5	5
2848	IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation. <i>Nature Communications</i> , 2016, 7, 13567.	5.8	54
2849	The calcium pump plasma membrane Ca ²⁺ -ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin. <i>Scientific Reports</i> , 2016, 6, 25505.	1.6	53
2850	SMARCE1 regulates metastatic potential of breast cancer cells through the HIF1A/PTK2 pathway. <i>Breast Cancer Research</i> , 2016, 18, 81.	2.2	37
2851	Looking beyond the cancer cell for effective drug combinations. <i>Genome Medicine</i> , 2016, 8, 125.	3.6	31
2852	Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. , 2016, 4, 72.		156

#	ARTICLE	IF	CITATIONS
2853	A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16007.	2.0	34
2854	Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. <i>Nature Communications</i> , 2016, 7, 13404.	5.8	613
2855	Promising Novel Agents for Aggressive B-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1229-1237.	0.9	9
2856	CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT. <i>Nature Communications</i> , 2016, 7, 13362.	5.8	53
2857	The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. <i>Npj Breast Cancer</i> , 2016, 2, 16022.	2.3	21
2858	Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression. <i>Scientific Reports</i> , 2016, 6, 37558.	1.6	28
2859	Validation of biomarkers to predict response to immunotherapy in cancer: Volume II – clinical validation and regulatory considerations. , 2016, 4, 77.		87
2860	Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. <i>Oncologist</i> , 2016, 21, 1326-1336.	1.9	49
2861	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. <i>Nature Communications</i> , 2016, 7, 12632.	5.8	648
2862	B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells. <i>Scientific Reports</i> , 2016, 6, 36722.	1.6	36
2864	New potential beneficial effects of actein, a triterpene glycoside isolated from <i>Cimicifuga</i> species, in breast cancer treatment. <i>Scientific Reports</i> , 2016, 6, 35263.	1.6	50
2865	In-depth comparison of somatic point mutation callers based on different tumor next-generation sequencing depth data. <i>Scientific Reports</i> , 2016, 6, 36540.	1.6	99
2866	High-content molecular profiling of T-cell therapy in oncology. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16009.	2.0	6
2867	Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. <i>Npj Breast Cancer</i> , 2016, 2, .	2.3	266
2868	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. <i>Npj Breast Cancer</i> , 2016, 2, 16036.	2.3	127
2869	National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3346-3348.	0.8	6
2870	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1558-1568.	5.1	827
2871	Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. <i>Carcinogenesis</i> , 2016, 37, bgw097.	1.3	22

#	ARTICLE	IF	CITATIONS
2872	Varicella-Zoster Virus Downregulates Programmed Death Ligand 1 and Major Histocompatibility Complex Class I in Human Brain Vascular Adventitial Fibroblasts, Perineurial Cells, and Lung Fibroblasts. <i>Journal of Virology</i> , 2016, 90, 10527-10534.	1.5	21
2873	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. <i>Cancer Discovery</i> , 2016, 6, 1134-1147.	7.7	106
2874	Role of Metabolism in the Immunobiology of Regulatory T Cells. <i>Journal of Immunology</i> , 2016, 197, 2567-2575.	0.4	103
2875	Update in Lung Cancer 2015. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 661-671.	2.5	13
2876	Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1477-1489.	2.0	50
2877	Heralding a new paradigm in 3D tumor modeling. <i>Biomaterials</i> , 2016, 108, 197-213.	5.7	127
2878	Decoding the usefulness of non-coding RNAs as breast cancer markers. <i>Journal of Translational Medicine</i> , 2016, 14, 265.	1.8	58
2879	Immunotherapy for prostate cancer: False promises or true hope?. <i>Cancer</i> , 2016, 122, 3598-3607.	2.0	22
2880	Cutaneous Complications of Targeted Melanoma Therapy. <i>Current Treatment Options in Oncology</i> , 2016, 17, 57.	1.3	62
2881	Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications. <i>Tumor Biology</i> , 2016, 37, 14479-14499.	0.8	13
2882	Integrative Modeling Reveals Annexin A2-mediated Epigenetic Control of Mesenchymal Glioblastoma. <i>EBioMedicine</i> , 2016, 12, 72-85.	2.7	21
2884	Rapid bone repair in a patient with lung cancer metastases to the spine using a novel herbal medicine: A case report. <i>Oncology Letters</i> , 2016, 12, 2023-2027.	0.8	4
2885	CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions. <i>Nucleic Acids Research</i> , 2016, 44, 10588-10602.	6.5	53
2886	Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. <i>BMC Cancer</i> , 2016, 16, 734.	1.1	126
2887	Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 78.	2.2	75
2888	Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. <i>Oncologist</i> , 2016, 21, 1200-1211.	1.9	211
2889	Occupational and environmental exposure to pesticides and cytokine pathways in chronic diseases (Review). <i>International Journal of Molecular Medicine</i> , 2016, 38, 1012-1020.	1.8	133
2890	Addition of the p110 α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer. <i>Tumor Biology</i> , 2016, 37, 14831-14839.	0.8	6

#	ARTICLE	IF	CITATIONS
2891	Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. <i>Nature Genetics</i> , 2016, 48, 1330-1338.	9.4	161
2892	Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. <i>Annals of Oncology</i> , 2016, 27, 2288-2294.	0.6	117
2893	Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors. <i>Cancer Immunology Research</i> , 2016, 4, 903-909.	1.6	45
2894	MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy. <i>BMC Cancer</i> , 2016, 16, 695.	1.1	4
2895	Lymphocyte-mediated Immune Regulation in Health and Disease: The Treg and $\gamma\delta$ T Cell Co-conspiracy. <i>Immunological Investigations</i> , 2016, 45, 767-775.	1.0	14
2896	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 627-642.	1.5	102
2897	Checkpoint inhibitors in lung cancer: latest developments and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 460-473.	1.4	30
2898	First-line immunotherapy in lung cancer – taking the first step. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 595-596.	12.5	5
2899	Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 3803-3815.	0.8	336
2900	PD-L1 in melanoma: facts and myths. <i>Melanoma Management</i> , 2016, 3, 187-194.	0.1	11
2901	Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 543-552.	1.4	90
2902	Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma. <i>Cell Death and Disease</i> , 2016, 7, e2358-e2358.	2.7	20
2903	Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. <i>JAMA Dermatology</i> , 2016, 152, 1128.	2.0	188
2904	PD-L1 expression is associated with advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2016, 12, 921-927.	0.8	18
2905	Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. <i>Oncology Letters</i> , 2016, 12, 944-950.	0.8	75
2906	Advances in immunotherapy for melanoma management. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2501-2511.	1.4	15
2907	Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. <i>Clinical and Translational Science</i> , 2016, 9, 89-104.	1.5	144
2908	Surgical immune interventions for solid malignancies. <i>American Journal of Surgery</i> , 2016, 212, 682-690.e5.	0.9	9

#	ARTICLE	IF	CITATIONS
2909	Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. <i>Human Pathology</i> , 2016, 57, 116-125.	1.1	71
2910	Peripheral tolerance can be modified by altering KLF2-regulated Treg migration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E4662-70.	3.3	37
2911	Concepts and targets in triple-negative breast cancer: recent results and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 351-359.	1.4	24
2912	MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. <i>Human Mutation</i> , 2016, 37, 1004-1012.	1.1	6
2913	Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2016, 11, 753-761.	1.7	73
2914	Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. <i>Immunotherapy</i> , 2016, 8, 785-798.	1.0	7
2915	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). <i>Journal of Neuro-Oncology</i> , 2016, 130, 19-29.	1.4	107
2916	CDK4/6 inhibition in luminal breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 76-81.	0.3	8
2917	Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers. <i>British Journal of Cancer</i> , 2016, 115, 490-496.	2.9	88
2918	Small-molecule binding sites to explore protein-protein interactions in the cancer proteome. <i>Molecular BioSystems</i> , 2016, 12, 3067-3087.	2.9	15
2919	Cellular immunotherapy for malignant gliomas. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1265-1275.	1.4	37
2920	Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. <i>Science</i> , 2016, 353, 399-403.	6.0	259
2921	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. <i>Modern Pathology</i> , 2016, 29, 1433-1442.	2.9	144
2922	Drug discovery in advanced prostate cancer: translating biology into therapy. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 699-718.	21.5	111
2923	The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies. <i>Tumor Biology</i> , 2016, 37, 11711-11721.	0.8	35
2924	MicroRNA-497 downregulation contributes to cell proliferation, migration, and invasion of estrogen receptor alpha negative breast cancer by targeting estrogen-related receptor alpha. <i>Tumor Biology</i> , 2016, 37, 13205-13214.	0.8	31
2925	CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations. <i>Molecular Cell</i> , 2016, 63, 526-538.	4.5	58
2926	Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2016, 375, 819-829.	13.9	2,430

#	ARTICLE	IF	CITATIONS
2927	IFN- γ cancer immunotherapy: new kid on the block. <i>Immunotherapy</i> , 2016, 8, 877-888.	1.0	30
2928	Long Non-coding RNAs and Their Roles in Non-small-cell Lung Cancer. <i>Genomics, Proteomics and Bioinformatics</i> , 2016, 14, 280-288.	3.0	100
2929	Recent advances and future of immunotherapy for glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1245-1264.	1.4	57
2930	Biology and Management of Patients With Triple-Negative Breast Cancer. <i>Oncologist</i> , 2016, 21, 1050-1062.	1.9	220
2931	Systemic therapy for bladder cancer finally comes into a new age. <i>Future Oncology</i> , 2016, 12, 2227-2242.	1.1	6
2932	p120-Catenin Is Critical for the Development of Invasive Lobular Carcinoma in Mice. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2016, 21, 81-88.	1.0	12
2933	Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2016, 9, 184-190.	0.4	31
2934	Atezolizumab: First Global Approval. <i>Drugs</i> , 2016, 76, 1227-1232.	4.9	91
2935	Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab. <i>Oral Oncology</i> , 2016, 63, e1-e3.	0.8	11
2936	Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk. <i>Nature Communications</i> , 2016, 7, 11672.	5.8	38
2937	Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. <i>Nature Genetics</i> , 2016, 48, 1500-1507.	9.4	217
2938	Cryo-thermal therapy elicits potent anti-tumor immunity by inducing extracellular Hsp70-dependent MDSC differentiation. <i>Scientific Reports</i> , 2016, 6, 27136.	1.6	46
2939	Gene Expression Profiling of Breast Cancer Brain Metastasis. <i>Scientific Reports</i> , 2016, 6, 28623.	1.6	51
2940	EGFR and SYNE2 are associated with p21 expression and SYNE2 variants predict post-operative clinical outcomes in HBV-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2016, 6, 31237.	1.6	17
2941	The role of deubiquitinases in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 589-600.	2.7	40
2942	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. <i>Scientific Reports</i> , 2016, 6, 36956.	1.6	196
2943	Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7749-E7758.	3.3	48
2944	Posterior Contraction Rates of the Phylogenetic Indian Buffet Processes. <i>Bayesian Analysis</i> , 2016, 11, 477-497.	1.6	6

#	ARTICLE	IF	CITATIONS
2945	Deubiquitination and Stabilization of PD-L1 by CSN5. <i>Cancer Cell</i> , 2016, 30, 925-939.	7.7	538
2946	Epigenomic Deconvolution of Breast Tumors Reveals Metabolic Coupling between Constituent Cell Types. <i>Cell Reports</i> , 2016, 17, 2075-2086.	2.9	84
2947	Pan-cancer transcriptomic analysis associates long non-coding RNAs with key mutational driver events. <i>Nature Communications</i> , 2016, 7, 13197.	5.8	54
2948	Intrinsic cellular signaling mechanisms determine the sensitivity of cancer cells to virus-induced apoptosis. <i>Scientific Reports</i> , 2016, 6, 37213.	1.6	4
2949	Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. <i>Science Immunology</i> , 2016, 1, .	5.6	169
2950	PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors. <i>Cancer Immunology Research</i> , 2016, 4, 1027-1037.	1.6	18
2951	Talimogene laherparepvec: overview, combination therapy and current practices. <i>Melanoma Management</i> , 2016, 3, 267-272.	0.1	8
2953	One microenvironment does not fit all: heterogeneity beyond cancer cells. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 601-629.	2.7	58
2954	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016, 7, 10582.	5.8	412
2955	The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis. <i>Nature Communications</i> , 2016, 7, 12160.	5.8	43
2956	A microscopic landscape of the invasive breast cancer genome. <i>Scientific Reports</i> , 2016, 6, 27545.	1.6	33
2957	Interactions between immune challenges and cancer cells proliferation: timing does matter!. <i>Evolution, Medicine and Public Health</i> , 2016, 2016, 299-311.	1.1	7
2958	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <i>Genome Biology</i> , 2016, 17, 231.	3.8	746
2959	FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. <i>World Journal of Surgical Oncology</i> , 2016, 14, 238.	0.8	25
2960	Magneto-nanosensor platform for probing low-affinity protein-protein interactions and identification of a low-affinity PD-L1/PD-L2 interaction. <i>Nature Communications</i> , 2016, 7, 12220.	5.8	29
2961	Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. <i>Cell Reports</i> , 2016, 17, 957-965.	2.9	22
2962	Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. <i>Scientific Reports</i> , 2016, 6, 35056.	1.6	116
2963	Acute interstitial nephritis related to immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 2016, 115, 1457-1461.	2.9	88

#	ARTICLE	IF	CITATIONS
2964	Systematic analysis of mutation distribution in three dimensional protein structures identifies cancer driver genes. <i>Scientific Reports</i> , 2016, 6, 26483.	1.6	20
2965	Density of immunogenic antigens does not explain the presence or absence of the T-cellâ€inflamed tumor microenvironment in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7759-E7768.	3.3	328
2966	Application of RNAi-induced gene expression profiles for prognostic prediction in breast cancer. <i>Genome Medicine</i> , 2016, 8, 114.	3.6	3
2967	Combination approaches in NSCLC involving immune checkpoint inhibitors. <i>Lung Cancer Management</i> , 2016, 5, 163-171.	1.5	1
2968	Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications. <i>CNS Drugs</i> , 2016, 30, 1149-1168.	2.7	3
2969	Correlation of Apobec Mrna Expression with overall Survival and pd-1 Expression in Urothelial Carcinoma. <i>Scientific Reports</i> , 2016, 6, 27702.	1.6	46
2970	Tracking Cancer Genetic Evolution using OncoTrack. <i>Scientific Reports</i> , 2016, 6, 29647.	1.6	5
2971	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7769-E7777.	3.3	145
2972	Emerging role of immunotherapy in urothelial carcinomaâ€”Immunobiology/biomarkers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 556-565.	0.8	23
2973	Making urothelial carcinomas less immune to immunotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 534-537.	0.8	2
2974	Programmed Death-1 Culls Peripheral Accumulation of High-Affinity Autoreactive CD4ÂT Cells to Protect against Autoimmunity. <i>Cell Reports</i> , 2016, 17, 1783-1794.	2.9	35
2975	NKG2D ligand expression in pediatric brain tumors. <i>Cancer Biology and Therapy</i> , 2016, 17, 1253-1265.	1.5	26
2976	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. <i>Science Translational Medicine</i> , 2016, 8, 328rv4.	5.8	1,844
2978	Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 457-474.	1.1	13
2979	Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3 + T-regulatory Cell Function and Promotes Antitumor Immunity. <i>EBioMedicine</i> , 2016, 13, 99-112.	2.7	86
2980	Dendritic Cells and Cancer Immunity. <i>Trends in Immunology</i> , 2016, 37, 855-865.	2.9	624
2981	PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. <i>Nature Medicine</i> , 2016, 22, 1321-1329.	15.2	138
2982	Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy. <i>Scientific Reports</i> , 2016, 6, 30934.	1.6	29

#	ARTICLE	IF	CITATIONS
2983	High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1. <i>Scientific Reports</i> , 2016, 6, 35297.	1.6	77
2984	Portraying breast cancers with long noncoding RNAs. <i>Science Advances</i> , 2016, 2, e1600220.	4.7	102
2985	Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells. <i>Science Signaling</i> , 2016, 9, ra94.	1.6	18
2986	Alternative Polyadenylation in Triple-Negative Breast Tumors Allows NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation. <i>Cancer Research</i> , 2016, 76, 7231-7241.	0.4	47
2988	Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. , 2016, 4, 68.		27
2989	Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. <i>Cell Death Discovery</i> , 2016, 2, 16025.	2.0	68
2990	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
2991	Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. <i>Nature Communications</i> , 2016, 7, 12624.	5.8	550
2992	Aryl Hydrocarbon Receptor Activates NDRG1 Transcription under Hypoxia in Breast Cancer Cells. <i>Scientific Reports</i> , 2016, 6, 20808.	1.6	19
2993	Integrating Multi-omics Data to Dissect Mechanisms of DNA repair Dysregulation in Breast Cancer. <i>Scientific Reports</i> , 2016, 6, 34000.	1.6	8
2994	PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer. <i>Scientific Reports</i> , 2016, 6, 35651.	1.6	71
2995	Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with <i>PDL1</i> amplification. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001180.	0.5	57
2996	The immune system's role in sepsis progression, resolution, and long-term outcome. <i>Immunological Reviews</i> , 2016, 274, 330-353.	2.8	495
2997	The epigenetic landscape of T cell exhaustion. <i>Science</i> , 2016, 354, 1165-1169.	6.0	694
2998	The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications. <i>Science Immunology</i> , 2016, 1, .	5.6	149
2999	Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. <i>Science Translational Medicine</i> , 2016, 8, 334ra53.	5.8	105
3000	Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations. <i>Cancer Research</i> , 2016, 76, 6785-6794.	0.4	3
3001	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , 2016, 14, 168.	2.3	106

#	ARTICLE	IF	CITATIONS
3002	Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 96.	6.9	21
3003	Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?. <i>Genome Medicine</i> , 2016, 8, 111.	3.6	59
3004	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. , 2016, 4, 60.		60
3005	Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. , 2016, 4, 64.		75
3006	An Open-Label, Dose- Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 5204-5210.	3.2	19
3007	Adenovirus vector carrying REIC/DKK-3 gene: neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy. <i>Cancer Gene Therapy</i> , 2016, 23, 400-409.	2.2	28
3008	Interdependent IL-7 and IFN- γ signalling in T-cell controls tumour eradication by combined CTLA-4+PD-1 therapy. <i>Nature Communications</i> , 2016, 7, 12335.	5.8	93
3009	Genetic variation in the insulin, insulin-like growth factor, growth hormone, and leptin pathways in relation to breast cancer in African-American women: the AMBER consortium. <i>Npj Breast Cancer</i> , 2016, 2, .	2.3	10
3010	The alternatively-included 11a sequence modifies the effects of Mena on actin cytoskeletal organization and cell behavior. <i>Scientific Reports</i> , 2016, 6, 35298.	1.6	22
3011	Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. <i>Trends in Molecular Medicine</i> , 2016, 22, 1000-1011.	3.5	60
3012	Palmitoylation: a protein S-acylation with implications for breast cancer. <i>Npj Breast Cancer</i> , 2016, 2, 16028.	2.3	34
3013	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). <i>Scientific Reports</i> , 2016, 6, 32512.	1.6	19
3014	SSA-ME Detection of cancer driver genes using mutual exclusivity by small subnetwork analysis. <i>Scientific Reports</i> , 2016, 6, 36257.	1.6	12
3015	The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2016, 6, 32020.	1.6	18
3016	Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells. <i>Protein and Cell</i> , 2016, 7, 538-543.	4.8	10
3017	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. <i>Protein and Cell</i> , 2016, 7, 866-877.	4.8	44
3018	Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma. <i>Oncology and Therapy</i> , 2016, 4, 239-256.	1.0	8
3019	A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells. <i>Scientific Reports</i> , 2016, 6, 19772.	1.6	46

#	ARTICLE	IF	CITATIONS
3020	Na ⁺ ve CD8+ T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF- β 2 immunosuppression in the tumor microenvironment. <i>Scientific Reports</i> , 2016, 6, 28208.	1.6	36
3021	Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 1450-1460.	1.9	101
3022	PD-L1 testing, fit for routine evaluation? From a pathologist's point of view. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 201-206.	0.3	38
3023	An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. <i>Nature Communications</i> , 2016, 7, 13443.	5.8	156
3024	Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score. <i>Scientific Reports</i> , 2016, 6, 36231.	1.6	27
3025	The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. <i>BMC Genomics</i> , 2016, 17, 442.	1.2	25
3026	Effect of surgical wound fluids after intraoperative electron radiotherapy on the cancer stem cell phenotype in a panel of human breast cancer cell lines. <i>Oncology Letters</i> , 2016, 12, 3707-3714.	0.8	15
3027	Induction of IL-25 secretion from tumour-associated fibroblasts suppresses mammary tumour metastasis. <i>Nature Communications</i> , 2016, 7, 11311.	5.8	32
3028	miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. <i>Nature Communications</i> , 2016, 7, 11406.	5.8	245
3029	SURVIV for survival analysis of mRNA isoform variation. <i>Nature Communications</i> , 2016, 7, 11548.	5.8	85
3030	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. <i>Nature Communications</i> , 2016, 7, 12791.	5.8	196
3031	Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response. <i>Scientific Reports</i> , 2016, 6, 19049.	1.6	179
3032	Crizotinib resistance: implications for therapeutic strategies. <i>Annals of Oncology</i> , 2016, 27, iii42-iii50.	0.6	109
3033	Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade. <i>American Journal of Pathology</i> , 2016, 186, 3225-3235.	1.9	299
3034	Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. <i>Nature Communications</i> , 2016, 7, 12499.	5.8	625
3035	Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer. <i>Scientific Reports</i> , 2016, 6, 19435.	1.6	102
3036	CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. <i>Scientific Reports</i> , 2016, 6, 20070.	1.6	237
3037	Glycosyltransferase Gene Expression Profiles Classify Cancer Types and Propose Prognostic Subtypes. <i>Scientific Reports</i> , 2016, 6, 26451.	1.6	63

#	ARTICLE	IF	CITATIONS
3038	Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. <i>Scientific Reports</i> , 2016, 6, 31745.	1.6	22
3039	Clinical significance of tumor-infiltrating lymphocytes in breast cancer. , 2016, 4, 59.		530
3040	From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 59.	1.3	3
3041	Whole-exome sequencing identifies recurrent <i>AKT1</i> mutations in sclerosing hemangioma of lung. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10672-10677.	3.3	42
3042	53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. <i>BMC Cancer</i> , 2016, 16, 725.	1.1	28
3043	Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. <i>BMC Medicine</i> , 2016, 14, 89.	2.3	57
3044	Drug Combinations as the New Standard for Melanoma Treatment. <i>Current Treatment Options in Oncology</i> , 2016, 17, 61.	1.3	16
3045	Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. <i>Nature Communications</i> , 2016, 7, 13193.	5.8	1,270
3046	Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. <i>Annals of Oncology</i> , 2016, 27, 2242-2250.	0.6	84
3047	Cancer driver gene discovery through an integrative genomics approach in a non-parametric Bayesian framework. <i>Bioinformatics</i> , 2017, 33, 483-490.	1.8	22
3048	In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. <i>Science Immunology</i> , 2016, 1, aaf6925.	5.6	142
3049	Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 853-860.	1.4	13
3050	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016, 102, 21-27.	0.9	11
3051	Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. <i>Nature Communications</i> , 2016, 7, 12498.	5.8	69
3052	Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. <i>Nature Communications</i> , 2016, 7, 13354.	5.8	224
3053	Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. <i>Oncogenesis</i> , 2016, 5, e267-e267.	2.1	28
3054	Transcriptome sequencing uncovers a threeâ€“long noncoding RNA signature in predicting breast cancer survival. <i>Scientific Reports</i> , 2016, 6, 27931.	1.6	68
3055	Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8 ⁺ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7240-E7249.	3.3	187

#	ARTICLE	IF	CITATIONS
3056	The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. <i>Science Advances</i> , 2016, 2, e1601737.	4.7	175
3057	Approaches to modernize the combination drug development paradigm. <i>Genome Medicine</i> , 2016, 8, 115.	3.6	64
3058	Systematic Quality Control Analysis of LINCS Data. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 588-598.	1.3	15
3059	“Big Data” for breast cancer: where to look and what you will find. <i>Npj Breast Cancer</i> , 2016, 2, .	2.3	21
3060	Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. <i>Scientific Reports</i> , 2016, 6, 30093.	1.6	213
3061	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2016, 375, 1749-1755.	13.9	1,668
3062	Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. <i>New England Journal of Medicine</i> , 2016, 375, 1767-1778.	13.9	1,025
3063	Eph Receptor Tyrosine Kinases in Tumor Immunity. <i>Cancer Research</i> , 2016, 76, 6452-6457.	0.4	55
3064	Successful Treatment of a Patient with Glioblastoma and a Germline <i>POLE</i> Mutation: Where Next?. <i>Cancer Discovery</i> , 2016, 6, 1210-1211.	7.7	14
3065	Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. <i>Cancer Immunology Research</i> , 2016, 4, 1007-1015.	1.6	84
3066	Primary breast cancer cell culture yields intra-tumor heterogeneous subpopulations expressing exclusive patterns of receptor tyrosine kinases. <i>BMC Cancer</i> , 2016, 16, 740.	1.1	12
3067	Lung Cancer Subtypes Generate Unique Immune Responses. <i>Journal of Immunology</i> , 2016, 197, 4493-4503.	0.4	115
3068	Generation of T cell effectors using tumor cell-loaded dendritic cells for adoptive T cell therapy. <i>Medical Oncology</i> , 2016, 33, 136.	1.2	6
3069	Immune checkpoint therapy and type 1 diabetes. <i>Diabetology International</i> , 2016, 7, 221-227.	0.7	12
3070	Bioinformatic Studies to Predict MicroRNAs with the Potential of Uncoupling RECK Expression from epithelial “mesenchymal Transition in Cancer Cells. <i>Cancer Informatics</i> , 2016, 15, CIN.S34141.	0.9	2
3071	Imaging Biomarkers in Immunotherapy. <i>Biomarkers in Cancer</i> , 2016, 8s2, BIC.S31805.	3.6	31
3072	Upregulation of Cyclooxygenase-2/Prostaglandin E ₂ (COX-2/PGE ₂) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S38529.	0.6	35
3073	Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S39384.	0.6	32

#	ARTICLE	IF	CITATIONS
3074	The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. <i>Biomarkers in Cancer</i> , 2016, 8s2, BIC.S31802.	3.6	70
3075	Flow Cytometry-based Assay for the Monitoring of NK Cell Functions. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	11
3076	Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel. <i>Oncology Letters</i> , 2016, 12, 4493-4504.	0.8	26
3077	Mice lacking Programmed cell death-1 show a role for CD8+ T cells in long-term immunity against blood-stage malaria. <i>Scientific Reports</i> , 2016, 6, 26210.	1.6	25
3078	Large molecular systems landscape uncovers T cell trapping in human skin cancer. <i>Scientific Reports</i> , 2016, 6, 19012.	1.6	12
3079	Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S34540.	0.6	121
3080	Selective Cell Elimination from Mixed 3D Culture Using a Near Infrared Photoimmunotherapy Technique. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	14
3081	Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. <i>Biomarkers in Cancer</i> , 2016, 8s1, BIC.S34417.	3.6	27
3082	KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S40182.	0.6	18
3083	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S34535.	0.6	34
3084	A novel non-Hodgkin lymphoma murine model closer to the standard clinical scenario. <i>Journal of Translational Medicine</i> , 2016, 14, 323.	1.8	15
3085	Acute visual loss after ipilimumab treatment for metastatic melanoma. , 2016, 4, 66.		59
3086	Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. , 2016, 4, 37.		1
3087	Itâ€™s TIME for a biomarker-driven approach to cancer immunotherapy. , 2016, 4, 43.		6
3088	Groverâ€™s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. , 2016, 4, 47.		27
3089	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. , 2016, 4, 52.		37
3090	Molecular profiles to biology and pathways: a systems biology approach. <i>Chinese Journal of Cancer</i> , 2016, 35, 53.	4.9	6
3091	Imaging in Advanced Nonâ€™Small Cell Lung Cancer. <i>Journal of Thoracic Imaging</i> , 2016, 31, 238-242.	0.8	3

#	ARTICLE	IF	CITATIONS
3092	On the inconsistency of $\hat{\alpha}$, "1-penalised sparse precision matrix estimation. BMC Bioinformatics, 2016, 17, 448.	1.2	6
3093	Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient. BMC Cancer, 2016, 16, 591.	1.1	25
3094	Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer, 2016, 16, 868.	1.1	15
3095	Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials. BMC Cancer, 2016, 16, 889.	1.1	2
3096	Conservation of immune gene signatures in solid tumors and prognostic implications. BMC Cancer, 2016, 16, 911.	1.1	70
3097	PureCN: copy number calling and SNV classification using targeted short read sequencing. Source Code for Biology and Medicine, 2016, 11, 13.	1.7	101
3098	High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. Journal of Hematology and Oncology, 2016, 9, 132.	6.9	39
3099	Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. Breast Cancer Research, 2016, 18, 56.	2.2	42
3100	WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Breast Cancer Research, 2016, 18, 92.	2.2	56
3101	A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. , 2016, 4, 85.		18
3102	Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. , 2016, 4, 89.		81
3103	Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma. Melanoma Research, 2016, 26, 429-441.	0.6	53
3104	Integrative analysis of somatic mutations and transcriptomic data to functionally stratify breast cancer patients. BMC Genomics, 2016, 17, 513.	1.2	15
3105	XMRF: an R package to fit Markov Networks to high-throughput genetics data. BMC Systems Biology, 2016, 10, 69.	3.0	15
3106	Long range personalized cancer treatment strategies incorporating evolutionary dynamics. Biology Direct, 2016, 11, 56.	1.9	16
3107	In epithelial cancers, aberrant COL17A1 promoter methylation predicts its misexpression and increased invasion. Clinical Epigenetics, 2016, 8, 120.	1.8	76
3108	Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. Cancer & Metabolism, 2016, 4, 12.	2.4	57
3109	Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases. , 2016, 4, 78.		56

#	ARTICLE	IF	CITATIONS
3110	Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 10.	3.6	1
3111	Genomically personalized therapy in head and neck cancer. <i>Cancers of the Head & Neck</i> , 2016, 1, 2.	6.2	22
3112	Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. <i>RMD Open</i> , 2016, 2, e000321.	1.8	37
3113	Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 267-273.	1.0	9
3114	Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials. <i>Medicine (United States)</i> , 2016, 95, e3997.	0.4	12
3115	Undifferentiated Carcinoma With Osteoclastic Giant Cells of the Pancreas. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1203-1216.	2.1	100
3116	Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 257-266.	1.0	38
3117	Rational Design of Peptide Vaccines against Multiple Types of Human Papillomavirus. <i>Cancer Informatics</i> , 2016, 15s1, CIN.S39071.	0.9	19
3118	Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S34537.	0.6	105
3119	Drug Monographs: Atezolizumab and Everolimus. <i>Hospital Pharmacy</i> , 2016, 51, 810-814.	0.4	3
3120	Identifying causal networks linking cancer processes and anti-tumor immunity using Bayesian network inference and metagene constructs. <i>Biotechnology Progress</i> , 2016, 32, 470-479.	1.3	30
3121	Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies. <i>Head and Neck</i> , 2016, 38, 1176-1186.	0.9	17
3122	Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. <i>Head and Neck</i> , 2016, 38, 1008-1016.	0.9	14
3123	Mutated Pathways as a Guide to Adjuvant Therapy Treatments for Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 184-189.	1.9	2
3124	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2698-2704.	0.8	868
3125	Immunological Mechanisms in Breast Cancer - from Bench to Bedside. <i>Breast Care</i> , 2016, 11, 93-94.	0.8	0
3127	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1954-1961.	3.3	122
3128	Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 191-201.	1.4	12

#	ARTICLE	IF	CITATIONS
3129	Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1727-1738.	1.2	73
3130	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. <i>Kidney International</i> , 2016, 90, 638-647.	2.6	524
3131	Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration. <i>BMC Cancer</i> , 2016, 16, 204.	1.1	35
3132	Local iron homeostasis in the breast ductal carcinoma microenvironment. <i>BMC Cancer</i> , 2016, 16, 187.	1.1	68
3133	Effects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma. <i>BMC Urology</i> , 2016, 16, 2.	0.6	3
3134	Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. <i>Journal of Hematology and Oncology</i> , 2016, 9, 29.	6.9	21
3135	Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. <i>Critical Care</i> , 2016, 20, 124.	2.5	118
3136	DNA methylation and hormone receptor status in breast cancer. <i>Clinical Epigenetics</i> , 2016, 8, 17.	1.8	48
3137	Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers. , 2016, 4, 17.		155
3138	Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 58.	2.2	98
3139	Prediction of outcome in breast cancer patients using test parameters from complete blood count. <i>Molecular and Clinical Oncology</i> , 2016, 4, 918-924.	0.4	16
3140	Multiple Inhibitory Pathways Contribute to Lung CD8+ T Cell Impairment and Protect against Immunopathology during Acute Viral Respiratory Infection. <i>Journal of Immunology</i> , 2016, 197, 233-243.	0.4	26
3141	Assessment of Brain Tumor Response: RANO and Its Offspring. <i>Current Treatment Options in Oncology</i> , 2016, 17, 35.	1.3	65
3142	Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 994-1003.	5.1	194
3144	Merkel Cell Carcinoma Therapeutic Update. <i>Current Treatment Options in Oncology</i> , 2016, 17, 36.	1.3	88
3145	Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside. <i>Current Treatment Options in Oncology</i> , 2016, 17, 33.	1.3	51
3146	Delivery strategies and potential targets for siRNA in major cancer types. <i>Advanced Drug Delivery Reviews</i> , 2016, 104, 2-15.	6.6	100
3147	FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair. <i>Cell Reports</i> , 2016, 15, 2488-2499.	2.9	147

#	ARTICLE	IF	CITATIONS
3148	Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 691-705.	12.5	47
3149	RNA splicing factors as oncoproteins and tumour suppressors. <i>Nature Reviews Cancer</i> , 2016, 16, 413-430.	12.8	549
3150	Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 811-826.	1.5	41
3151	Precision medicine informatics. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 668-670.	2.2	31
3152	Uncoupling protein 2 regulates metabolic reprogramming and fate of antigen-stimulated CD8+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 869-874.	2.0	19
3153	High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. <i>Carcinogenesis</i> , 2016, 37, 669-676.	1.3	39
3154	Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 411-417.	1.4	98
3155	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. <i>Cancer Immunology Research</i> , 2016, 4, 669-678.	1.6	117
3156	Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma. <i>Molecular and Clinical Oncology</i> , 2016, 4, 903-908.	0.4	4
3157	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. <i>Nature Medicine</i> , 2016, 22, 792-799.	15.2	322
3158	Current and Evolving Methods to Visualize Biological Data in Cancer Research. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw031.	3.0	18
3159	Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. <i>Modern Pathology</i> , 2016, 29, 1028-1037.	2.9	84
3160	Acid-induced aggregation propensity of nivolumab is dependent on the Fc. <i>MAbs</i> , 2016, 8, 1107-1117.	2.6	41
3161	A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient. <i>Case Reports in Oncology</i> , 2016, 9, 112-118.	0.3	4
3162	Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 1601-1610.	0.8	7
3163	Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. <i>Current Treatment Options in Oncology</i> , 2016, 17, 40.	1.3	34
3164	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3119-3125.	0.8	755
3165	Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. <i>Oncologist</i> , 2016, 21, 804-816.	1.9	208

#	ARTICLE	IF	CITATIONS
3166	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). <i>Medical Oncology</i> , 2016, 33, 80.	1.2	32
3167	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. <i>Nature Reviews Urology</i> , 2016, 13, 420-431.	1.9	78
3168	Survivin: a unique target for tumor therapy. <i>Cancer Cell International</i> , 2016, 16, 49.	1.8	328
3169	Recent results of immunotherapy and perspectives for advanced NSCLC. <i>Lung Cancer Management</i> , 2016, 5, 57-60.	1.5	0
3170	Neoantigen landscape dynamics during human melanomaâ€T cell interactions. <i>Nature</i> , 2016, 536, 91-95.	13.7	387
3171	Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 41.	1.3	33
3172	Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma. <i>Melanoma Research</i> , 2016, 26, 125-137.	0.6	18
3173	Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. <i>Molecular Cancer Research</i> , 2016, 14, 589-598.	1.5	29
3174	Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2523-2528.	1.4	15
3175	Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw144.	3.0	271
3176	Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026211.	2.9	105
3177	The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expressionâ€Based Meta-Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 6039-6050.	3.2	48
3178	Genomic and Epigenomic Alterations in Cancer. <i>American Journal of Pathology</i> , 2016, 186, 1724-1735.	1.9	130
3179	The role of myeloid cells in cancer therapies. <i>Nature Reviews Cancer</i> , 2016, 16, 447-462.	12.8	570
3180	Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. <i>Annals of Oncology</i> , 2016, 27, 1532-1538.	0.6	103
3181	Combinatorial approach to cancer immunotherapy: strength in numbers. <i>Journal of Leukocyte Biology</i> , 2016, 100, 275-290.	1.5	90
3182	Landscape of tumor-infiltrating T cell repertoire of human cancers. <i>Nature Genetics</i> , 2016, 48, 725-732.	9.4	288
3183	Metronomic Chemotherapy for Metastatic Breast Cancer â€ a Systematic Review of the Literature. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 525-534.	0.8	27

#	ARTICLE	IF	CITATIONS
3184	Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. <i>Journal of Experimental Medicine</i> , 2016, 213, 1133-1139.	4.2	78
3185	Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. <i>Breast Care</i> , 2016, 11, 102-107.	0.8	35
3186	Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N. <i>Diagnostic Pathology</i> , 2016, 11, 44.	0.9	64
3187	Immunotherapy in glioblastoma: emerging options in precision medicine. <i>CNS Oncology</i> , 2016, 5, 175-186.	1.2	11
3188	Major histocompatibility complex I upregulation in clear cell renal cell carcinoma is associated with increased survival. <i>Asian Journal of Urology</i> , 2016, 3, 75-81.	0.5	4
3189	The PD-1:PD-L1 immune inhibitory checkpoint in <i>Helicobacter pylori</i> infection and gastric cancer: a comprehensive review and future perspectives. <i>Porto Biomedical Journal</i> , 2016, 1, 4-11.	0.4	22
3190	RANKL/RANK control Brca1 mutation-driven mammary tumors. <i>Cell Research</i> , 2016, 26, 761-774.	5.7	128
3191	Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. <i>International Journal of Clinical Oncology</i> , 2016, 21, 946-952.	1.0	42
3192	Study of breast cancer incidence in patients of lymphangioliomyomatosis. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 195-201.	1.1	9
3193	Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 1-9.	1.1	45
3194	Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. <i>Clinical and Translational Oncology</i> , 2016, 18, 653-659.	1.2	8
3195	Exudative Polymorphous Vitelliform Retinopathy: Importance of Early Recognition of the Condition in Patients with Metastatic Melanoma. <i>Ophthalmology and Therapy</i> , 2016, 5, 121-127.	1.0	6
3196	Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. <i>Oncology and Therapy</i> , 2016, 4, 17-33.	1.0	19
3197	Immunotherapy for Head and Neck Squamous Cell Carcinoma. <i>Current Oral Health Reports</i> , 2016, 3, 74-81.	0.5	6
3198	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 976-983.	5.1	846
3199	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 943-955.	5.1	293
3200	FTY720 (Gilenya) treatment prevents spontaneous autoimmune myocarditis and dilated cardiomyopathy in transgenic HLA-DQ8-BALB/c mice. <i>Cardiovascular Pathology</i> , 2016, 25, 353-361.	0.7	4
3201	Translational and clinical implications of the genetic landscape of prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 597-610.	12.5	63

#	ARTICLE	IF	CITATIONS
3202	Checkpoint Inhibitors and Their Application in Breast Cancer. <i>Breast Care</i> , 2016, 11, 108-115.	0.8	45
3203	Peripheral Blood Regulatory T-Cell and Type 1 Helper T-Cell Population Decrease after Hepatic Artery Embolization. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1561-1568.	0.2	23
3204	When Genome Maintenance Goes Badly Awry. <i>Molecular Cell</i> , 2016, 62, 777-787.	4.5	64
3205	Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. <i>Translational Oncology</i> , 2016, 9, 114-123.	1.7	27
3206	Nintedanib in NSCLC: evidence to date and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 188-197.	1.4	19
3207	Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1607-1611.	2.8	105
3208	RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , 2016, 62, 138-145.	1.3	211
3209	ESR1 mutations: Pièce de résistance. <i>Genes and Diseases</i> , 2016, 3, 124-129.	1.5	3
3210	The Utility of Exercise Testing in Patients with Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1397-1410.	0.5	62
3211	The oncolytic virus Î”PK has multimodal anti-tumor activity. <i>Pathogens and Disease</i> , 2016, 74, ftw050.	0.8	9
3212	Coley’s Lessons Remembered. <i>Integrative Cancer Therapies</i> , 2016, 15, 502-511.	0.8	36
3213	Epigenetic therapy in gastrointestinal cancer: the right combination. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 560-579.	1.4	81
3214	Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2016, 6, 14.	1.2	44
3215	Identification of mRNA isoform switching in breast cancer. <i>BMC Genomics</i> , 2016, 17, 181.	1.2	27
3216	Predicting analysis times in randomized clinical trials with cancer immunotherapy. <i>BMC Medical Research Methodology</i> , 2016, 16, 12.	1.4	17
3217	Identification of stromal ColX±1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer. <i>BMC Cancer</i> , 2016, 16, 274.	1.1	42
3218	The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark. <i>BMC Cancer</i> , 2016, 16, 295.	1.1	2
3219	Integrating mutation and gene expression cross-sectional data to infer cancer progression. <i>BMC Systems Biology</i> , 2016, 10, 12.	3.0	24

#	ARTICLE	IF	CITATIONS
3220	Effects of the lifestyle habits in breast cancer transcriptional regulation. <i>Cancer Cell International</i> , 2016, 16, 7.	1.8	20
3221	The voltage gated Ca ²⁺ -channel Cav3.2 and therapeutic responses in breast cancer. <i>Cancer Cell International</i> , 2016, 16, 24.	1.8	34
3222	Safety of targeting tumor endothelial cell antigens. <i>Journal of Translational Medicine</i> , 2016, 14, 90.	1.8	5
3223	Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. <i>Journal of Translational Medicine</i> , 2016, 14, 95.	1.8	117
3224	Toward precision medicine of breast cancer. <i>Theoretical Biology and Medical Modelling</i> , 2016, 13, 7.	2.1	48
3225	An exact algorithm for finding cancer driver somatic genome alterations: the weighted mutually exclusive maximum set cover problem. <i>Algorithms for Molecular Biology</i> , 2016, 11, 11.	0.3	4
3226	Second- and third-generation ALK inhibitors for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 19.	6.9	116
3227	ELF5 isoform expression is tissue-specific and significantly altered in cancer. <i>Breast Cancer Research</i> , 2016, 18, 4.	2.2	37
3228	Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 9.	2.2	20
3229	p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 13.	2.2	41
3230	An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells. <i>Breast Cancer Research</i> , 2016, 18, 27.	2.2	67
3231	Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. <i>Breast Cancer Research</i> , 2016, 18, 50.	2.2	56
3232	Determining breast cancer histological grade from RNA-sequencing data. <i>Breast Cancer Research</i> , 2016, 18, 48.	2.2	34
3233	A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 124.	0.7	17
3234	A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors. <i>Clinical and Translational Medicine</i> , 2016, 5, 3.	1.7	65
3235	Increased expression of A Proliferation-inducing Ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: a possible link between COPD and lung cancer?. <i>Multidisciplinary Respiratory Medicine</i> , 2016, 11, 17.	0.6	10
3236	Metabolic communication in tumors: a new layer of immunoregulation for immune evasion. , 2016, 4, 4.		105
3237	Mismatch in epitope specificities between IFN γ 3 inflamed and uninfamed conditions leads to escape from T lymphocyte killing in melanoma. , 2016, 4, 10.		35

#	ARTICLE	IF	CITATIONS
3238	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15.		67
3239	From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. , 2016, 4, 14.		101
3240	Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid. , 2016, 4, 20.		32
3241	Targetless T cells in cancer immunotherapy. , 2016, 4, 23.		26
3242	T-Cell Therapy Using Interleukin-21â€œPrimed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. Journal of Clinical Oncology, 2016, 34, 3787-3795.	0.8	98
3243	Immune Checkpoint Inhibitors in Older Adults. Current Oncology Reports, 2016, 18, 47.	1.8	49
3244	PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Reports, 2016, 15, 2692-2704.	2.9	92
3245	Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8272-8277.	3.3	56
3246	Phosphatidylinositol 3-Kinase. Pancreas, 2016, 45, 21-31.	0.5	11
3247	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837.	7.7	785
3248	Suppression of microRNA activity amplifies IFN- γ -induced macrophage activation and promotes anti-tumour immunity. Nature Cell Biology, 2016, 18, 790-802.	4.6	214
3249	The Chromatin Remodeling Component <i>Arid1a</i> Is a Suppressor of Spontaneous Mammary Tumors in Mice. Genetics, 2016, 203, 1601-1611.	1.2	8
3250	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. Oncologist, 2016, 21, 848-854.	1.9	154
3251	CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Reports, 2016, 15, 2719-2732.	2.9	217
3252	Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer. British Journal of Cancer, 2016, 114, 1412-1420.	2.9	8
3253	MINTbase: a framework for the interactive exploration of mitochondrial and nuclear tRNA fragments. Bioinformatics, 2016, 32, 2481-2489.	1.8	89
3254	Metabolomics in epidemiology: from metabolite concentrations to integrative reaction networks. International Journal of Epidemiology, 2016, 45, 1319-1328.	0.9	40
3255	RJIVE for exploration of multi-source molecular data. Bioinformatics, 2016, 32, 2877-2879.	1.8	54

#	ARTICLE	IF	CITATIONS
3256	EPiG-Seq: extracting patterns and identifying co-expressed genes from RNA-Seq data. BMC Genomics, 2016, 17, 255.	1.2	16
3257	Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. Journal of Hematology and Oncology, 2016, 9, 48.	6.9	28
3258	Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients. Medical Oncology, 2016, 33, 74.	1.2	17
3259	Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression. Cancer Discovery, 2016, 6, 1022-1035.	7.7	116
3260	Genetic screens to study the immune system in cancer. Current Opinion in Immunology, 2016, 41, 55-61.	2.4	15
3261	Modified breast cancer model for preclinical immunotherapy studies. Journal of Surgical Research, 2016, 204, 467-474.	0.8	22
3262	Molecular and genetic inflammation networks in major human diseases. Molecular BioSystems, 2016, 12, 2318-2341.	2.9	49
3263	HIF1 α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3735-44.	3.3	62
3264	Uterine adenocarcinomas are mesenchymal neoplasms. Journal of Pathology, 2016, 238, 381-388.	2.1	94
3265	Novel personalized pathway-based metabolomics models reveal key metabolic pathways for breast cancer diagnosis. Genome Medicine, 2016, 8, 34.	3.6	122
3266	Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. Journal of Translational Medicine, 2016, 14, 188.	1.8	72
3267	Inflammation as a driver and vulnerability of KRAS mediated oncogenesis. Seminars in Cell and Developmental Biology, 2016, 58, 127-135.	2.3	73
3268	Network-based pathway enrichment analysis with incomplete network information. Bioinformatics, 2016, 32, 3165-3174.	1.8	46
3269	A lectin-based approach to detecting carcinogenesis in breast tissue. Oncology Letters, 2016, 11, 3889-3895.	0.8	15
3270	Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1775-1780.	1.2	14
3271	Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. Journal of Thoracic Oncology, 2016, 11, 1511-1521.	0.5	95
3272	Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal of Cancer, 2016, 115, 303-311.	2.9	27
3273	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. Journal of Clinical Oncology, 2016, 34, 3733-3739.	0.8	586

#	ARTICLE	IF	CITATIONS
3274	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. <i>Annals of Surgical Oncology</i> , 2016, 23, 4169-4177.	0.7	236
3275	Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?. <i>Surgery Today</i> , 2016, 46, 139-148.	0.7	13
3276	Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. <i>Oncogene</i> , 2016, 35, 691-701.	2.6	40
3277	IL-15 temporally reorients IL-10 biased B-1a cells toward IL-12 expression. <i>Cellular and Molecular Immunology</i> , 2016, 13, 229-239.	4.8	7
3278	IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG. <i>Oncogene</i> , 2016, 35, 1111-1121.	2.6	51
3279	Genome-wide DNA methylation profiling in triple-negative breast cancer reveals epigenetic signatures with important clinical value. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1038424.	0.3	24
3280	Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1048929.	0.3	31
3281	Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. <i>Oncogene</i> , 2016, 35, 1250-1260.	2.6	189
3282	Metastatic melanoma of the gallbladder: report of two cases and a review of the literature. <i>Clinical and Experimental Medicine</i> , 2016, 16, 295-300.	1.9	25
3283	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183
3284	Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2016, 114, 256-261.	2.9	256
3285	Bt2a2, a T cell immunomodulatory molecule coregulated with MHC class II genes. <i>Journal of Experimental Medicine</i> , 2016, 213, 177-187.	4.2	49
3286	Colorectal clinical trials: what is on the horizon?. <i>Future Oncology</i> , 2016, 12, 525-531.	1.1	1
3287	Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 1569-1589.	2.4	100
3288	Co-occurrence of MYC amplification and TP53 mutations in human cancer. <i>Nature Genetics</i> , 2016, 48, 104-106.	9.4	42
3289	Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2855-2864.	3.2	80
3290	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2016, 11, 143-148.	1.7	152
3291	Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types. <i>Nature Communications</i> , 2016, 7, 10499.	5.8	124

#	ARTICLE	IF	CITATIONS
3292	184AA3: a xenograft model of ER+ breast adenocarcinoma. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 37-52.	1.1	8
3293	Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression. <i>Cancer Discovery</i> , 2016, 6, 516-531.	7.7	164
3294	Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. <i>Tumor Biology</i> , 2016, 37, 4251-4261.	0.8	78
3295	Clonal Abundance of Tumor-Specific CD4+ T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion. <i>Immunity</i> , 2016, 44, 179-193.	6.6	39
3296	Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence. <i>Nucleic Acids Research</i> , 2016, 44, 4105-4122.	6.5	38
3297	Molecular basis of antibody binding to mucin glycopeptides in lung cancer. <i>International Journal of Oncology</i> , 2016, 48, 587-594.	1.4	13
3298	Cancer immunoprevention. <i>Current Opinion in Immunology</i> , 2016, 39, 52-58.	2.4	50
3299	Synthetic RORÎt Agonists Enhance Protective Immunity. <i>ACS Chemical Biology</i> , 2016, 11, 1012-1018.	1.6	48
3300	Immune-checkpoint blockade " durable cancer control. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 77-78.	12.5	71
3301	Strategies and developments of immunotherapies in osteosarcoma. <i>Oncology Letters</i> , 2016, 11, 511-520.	0.8	43
3302	Yeast-Derived Particulate Î²-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer. <i>Journal of Immunology</i> , 2016, 196, 2167-2180.	0.4	86
3303	X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. <i>Cell Death and Disease</i> , 2016, 7, e2073-e2073.	2.7	44
3304	A panoply of errors: polymerase proofreading domain mutations in cancer. <i>Nature Reviews Cancer</i> , 2016, 16, 71-81.	12.8	292
3305	Acquired resistance to immunotherapy and future challenges. <i>Nature Reviews Cancer</i> , 2016, 16, 121-126.	12.8	353
3306	Reply: Co-occurrence of MYC amplification and TP53 mutations in human cancer. <i>Nature Genetics</i> , 2016, 48, 106-108.	9.4	2
3307	Synergistic COX2 Induction by IFNÎ³ and TNFÎ± Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2016, 4, 303-311.	1.6	53
3308	Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer. <i>International Journal of Clinical Oncology</i> , 2016, 21, 548-556.	1.0	29
3309	Prognostic Factors for Breast Cancer: an Immunomorphological Update. <i>Pathology and Oncology Research</i> , 2016, 22, 449-452.	0.9	17

#	ARTICLE	IF	CITATIONS
3310	Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. <i>Cancer Research</i> , 2016, 76, 1381-1390.	0.4	451
3311	The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 235-251.	1.1	18
3312	Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 223-234.	1.1	3
3313	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. <i>Cell</i> , 2016, 164, 293-309.	13.5	399
3314	Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent. <i>Medical Oncology</i> , 2016, 33, 13.	1.2	12
3315	The immune microenvironment of breast ductal carcinoma in situ. <i>Modern Pathology</i> , 2016, 29, 249-258.	2.9	119
3316	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 2908-2918.	3.2	459
3317	A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2650-2658.	3.2	63
3318	PD-1 Blockade Expands Intratumoral Memory T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 194-203.	1.6	321
3319	Epigenetic Therapeutics: A New Weapon in the War Against Cancer. <i>Annual Review of Medicine</i> , 2016, 67, 73-89.	5.0	285
3320	EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. <i>Cancer Research</i> , 2016, 76, 1284-1296.	0.4	190
3321	PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease. <i>Nature Medicine</i> , 2016, 22, 135-137.	15.2	286
3322	BRCAness revisited. <i>Nature Reviews Cancer</i> , 2016, 16, 110-120.	12.8	976
3323	CrossHub: a tool for multi-way analysis of The Cancer Genome Atlas (TCGA) in the context of gene expression regulation mechanisms. <i>Nucleic Acids Research</i> , 2016, 44, e62-e62.	6.5	41
3324	Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2177-2182.	3.2	119
3325	The increase of circulating PD-L1-expressing CD68+ macrophage in ovarian cancer. <i>Tumor Biology</i> , 2016, 37, 5031-5037.	0.8	55
3326	Regulatory T cells in the immunotherapy of melanoma. <i>Tumor Biology</i> , 2016, 37, 77-85.	0.8	17
3327	Pharmacogenomics. <i>Urologic Clinics of North America</i> , 2016, 43, 77-86.	0.8	9

#	ARTICLE	IF	CITATIONS
3328	Large-scale profiling of microRNAs for The Cancer Genome Atlas. <i>Nucleic Acids Research</i> , 2016, 44, e3-e3.	6.5	125
3329	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 46.	3.4	693
3330	Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients. <i>Tumor Biology</i> , 2016, 37, 6581-6588.	0.8	80
3331	Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 571-579.	0.4	172
3332	Systematic discovery of complex insertions and deletions in human cancers. <i>Nature Medicine</i> , 2016, 22, 97-104.	15.2	93
3333	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 228-241.	12.5	679
3334	Mir-138 exerts anti-glioma efficacy by targeting immune checkpoints. <i>Neuro-Oncology</i> , 2016, 18, 639-648.	0.6	161
3335	A brief review on long noncoding RNAs: a new paradigm in breast cancer pathogenesis, diagnosis and therapy. <i>Tumor Biology</i> , 2016, 37, 1479-1485.	0.8	52
3336	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. <i>Human Pathology</i> , 2016, 47, 52-63.	1.1	284
3337	Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and Tj ETQq1 1 0.784314 rgBT/Overlock 10 Tf 50	1.1	10
3338	AKT signaling in ERBB2-amplified breast cancer. , 2016, 158, 63-70.		49
3339	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	7.7	1,158
3340	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1583-1591.	3.2	86
3341	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv362.	3.0	71
3342	Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 51-67.	1.2	42
3343	Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. <i>Oncologist</i> , 2016, 21, 84-94.	1.9	20
3344	Immunomonitoring in glioma immunotherapy: current status and future perspectives. <i>Journal of Neuro-Oncology</i> , 2016, 127, 1-13.	1.4	20
3345	PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. <i>Oncogene</i> , 2016, 35, 2961-2970.	2.6	30

#	ARTICLE	IF	CITATIONS
3346	Recognizing that the microbiome is part of the human immune system will advance treatment of both cancer and infections. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 772-774.	0.6	5
3347	A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. <i>Cancer Research</i> , 2016, 76, 1578-1590.	0.4	411
3348	Monocyte and interferon based therapy for the treatment of ovarian cancer. <i>Cytokine and Growth Factor Reviews</i> , 2016, 29, 109-115.	3.2	27
3349	CTLA-4 and PD-1 Pathways. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 98-106.	0.6	1,644
3350	TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 289-300.	0.9	89
3351	Tracking metastatic breast cancer: the future of biology in biosensors. <i>Medical Oncology</i> , 2016, 33, 36.	1.2	6
3352	Prognostic implications of securin expression and sub-cellular localization in human breast cancer. <i>Cellular Oncology (Dordrecht)</i> , 2016, 39, 319-331.	2.1	7
3353	Personalised cancer care: promises and challenges of targeted therapy. <i>Journal of the Royal Society of Medicine</i> , 2016, 109, 98-105.	1.1	13
3354	Killers on sterols. <i>Nature</i> , 2016, 531, 583-584.	13.7	15
3355	Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung. <i>Oncologist</i> , 2016, 21, 205-213.	1.9	22
3356	How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. <i>Oncologist</i> , 2016, 21, 233-243.	1.9	71
3357	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cell</i> , 2016, 165, 35-44.	13.5	2,437
3358	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. <i>Autophagy</i> , 2016, 12, 864-875.	4.3	90
3359	Integrating multidimensional omics data for cancer outcome. <i>Biostatistics</i> , 2016, 17, 605-618.	0.9	32
3360	Combining Epigenetic and Immunotherapy to Combat Cancer. <i>Cancer Research</i> , 2016, 76, 1683-1689.	0.4	251
3361	Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. <i>Clinical Cancer Research</i> , 2016, 22, 4328-4340.	3.2	94
3362	Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2016, 4, 390-399.	1.6	112
3363	Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer. <i>Genome Biology</i> , 2016, 17, 11.	3.8	184

#	ARTICLE	IF	CITATIONS
3364	Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum. <i>Advances in Experimental Medicine and Biology</i> , 2016, 882, 33-68.	0.8	34
3365	Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. <i>Investigational New Drugs</i> , 2016, 34, 355-363.	1.2	58
3366	B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway. <i>Tumor Biology</i> , 2016, 37, 9465-9472.	0.8	29
3367	Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e47-e63.	4.6	265
3368	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. <i>Oncologist</i> , 2016, 21, 283-291.	1.9	45
3369	Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 601-611.	2.0	13
3370	Cobimetinib Plus Vemurafenib: A Review in BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma. <i>Drugs</i> , 2016, 76, 605-615.	4.9	16
3371	Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. <i>International Immunology</i> , 2016, 28, 383-391.	1.8	223
3372	Pan-Cancer Analyses Reveal Long Intergenic Non-Coding RNAs Relevant to Tumor Diagnosis, Subtyping and Prognosis. <i>EBioMedicine</i> , 2016, 7, 62-72.	2.7	33
3373	Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. <i>Gynecologic Oncology</i> , 2016, 141, 86-94.	0.6	26
3374	Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. <i>Gynecologic Oncology</i> , 2016, 141, 65-71.	0.6	11
3375	Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 141, 57-64.	0.6	33
3376	The importance of p53 pathway genetics in inherited and somatic cancer genomes. <i>Nature Reviews Cancer</i> , 2016, 16, 251-265.	12.8	131
3377	Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. <i>British Journal of Haematology</i> , 2016, 172, 111-121.	1.2	16
3378	Immunotherapy for head and neck cancer: latest developments and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 168-175.	1.4	18
3379	Thermodynamic measures of cancer: Gibbs free energy and entropy of protein-protein interactions. <i>Journal of Biological Physics</i> , 2016, 42, 339-350.	0.7	42
3380	Molecular profiling of head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1625-38.	0.9	79
3381	A novel approach for next-generation sequencing of circulating tumor cells. <i>Molecular Genetics & Genomic Medicine</i> , 2016, 4, 395-406.	0.6	21

#	ARTICLE	IF	CITATIONS
3383	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <i>Advances in Immunology</i> , 2016, 130, 25-74.	1.1	181
3384	Emerging therapeutic targets in metastatic progression: A focus on breast cancer. , 2016, 161, 79-96.		53
3385	Reply to: "Subverting misconceptions about radiation therapy". <i>Nature Immunology</i> , 2016, 17, 345-346.	7.0	0
3386	Driving CAR T-cells forward. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 370-383.	12.5	492
3387	The role of tumor microenvironment in melanoma therapy resistance. <i>Melanoma Management</i> , 2016, 3, 23-32.	0.1	18
3388	Advances of Molecular Targeted Therapy in Gastric Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 125-134.	0.6	15
3390	Basics of PD-1 in self-tolerance, infection, and cancer immunity. <i>International Journal of Clinical Oncology</i> , 2016, 21, 448-455.	1.0	74
3391	High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. <i>Familial Cancer</i> , 2016, 15, 405-412.	0.9	105
3392	Combination Therapies for Melanoma: A New Standard of Care?. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 99-105.	3.3	23
3393	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. <i>Cancer Research</i> , 2016, 76, 999-1008.	0.4	451
3394	Comparison of CT volumetric measurement with RECIST response in patients with lung cancer. <i>European Journal of Radiology</i> , 2016, 85, 524-533.	1.2	51
3395	CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1. <i>Clinical Cancer Research</i> , 2016, 22, 3571-3581.	3.2	177
3396	Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma. <i>Oncology Letters</i> , 2016, 11, 1829-1834.	0.8	74
3397	Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. <i>Cell Death and Differentiation</i> , 2016, 23, 938-951.	5.0	104
3398	Optimizing mouse models for precision cancer prevention. <i>Nature Reviews Cancer</i> , 2016, 16, 187-196.	12.8	59
3399	<i>NRAS</i> mutant melanoma: an overview for the clinician for melanoma management. <i>Melanoma Management</i> , 2016, 3, 47-59.	0.1	12
3400	mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. <i>Science</i> , 2016, 351, 728-733.	6.0	585
3401	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 655-674.	1.4	21

#	ARTICLE	IF	CITATIONS
3402	Clostridium novyi-NT in cancer therapy. <i>Genes and Diseases</i> , 2016, 3, 144-152.	1.5	73
3403	Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. <i>British Journal of Cancer</i> , 2016, 114, 562-570.	2.9	59
3404	Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. <i>Modern Pathology</i> , 2016, 29, 347-358.	2.9	43
3405	Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. <i>Seminars in Oncology</i> , 2016, 43, 291-299.	0.8	13
3406	The Herpes Simplex Virus Latency-Associated Transcript Gene Is Associated with a Broader Repertoire of Virus-Specific Exhausted CD8 ⁺ T Cells Retained within the Trigeminal Ganglia of Latently Infected HLA Transgenic Rabbits. <i>Journal of Virology</i> , 2016, 90, 3913-3928.	1.5	32
3408	Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. <i>Seminars in Immunology</i> , 2016, 28, 73-80.	2.7	56
3409	Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease. <i>Clinical Cancer Research</i> , 2016, 22, 3606-3617.	3.2	73
3410	Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction Intervals. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1495-1504.	3.0	91
3411	Expression of ROR1 has prognostic significance in triple negative breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 589-595.	1.4	63
3412	Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. <i>Cancer Letters</i> , 2016, 382, 118-126.	3.2	15
3413	Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data. <i>European Journal of Cancer</i> , 2016, 55, 147-157.	1.3	28
3414	New Strategies in Breast Cancer: Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 2105-2110.	3.2	124
3415	Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. <i>Cancer Immunology Research</i> , 2016, 4, 345-353.	1.6	214
3416	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2170-2175.	3.3	102
3417	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. <i>Targeted Oncology</i> , 2016, 11, 469-477.	1.7	34
3418	Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 175-181.	1.6	30
3419	Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8 ⁺ Cytolytic T Cell Responses. <i>Immunity</i> , 2016, 44, 274-286.	6.6	144
3420	STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population. <i>Medical Oncology</i> , 2016, 33, 24.	1.2	9

#	ARTICLE	IF	CITATIONS
3421	APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma. <i>Medical Oncology</i> , 2016, 33, 26.	1.2	20
3422	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. <i>Nature Communications</i> , 2016, 7, 10501.	5.8	1,163
3423	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016, 48, 356-358.	9.4	143
3424	Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1092-1101.	1.4	37
3425	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.	0.8	141
3426	New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer. <i>Tumor Biology</i> , 2016, 37, 11017-11024.	0.8	20
3427	Pembrolizumab: A Review in Advanced Melanoma. <i>Drugs</i> , 2016, 76, 375-386.	4.9	39
3428	Targeting the tumour microenvironment in ovarian cancer. <i>European Journal of Cancer</i> , 2016, 56, 131-143.	1.3	84
3429	Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities. <i>Trends in Cancer</i> , 2016, 2, 95-109.	3.8	177
3430	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3630-3642.	3.2	353
3431	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 1134-1150.	0.8	683
3432	Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1. <i>Journal of Immunology</i> , 2016, 196, 2870-2878.	0.4	19
3433	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. <i>Immunity</i> , 2016, 44, 343-354.	6.6	767
3434	Biomarkers of residual disease after neoadjuvant therapy for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 487-503.	12.5	43
3435	A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1. <i>Genome Research</i> , 2016, 26, 541-553.	2.4	45
3436	Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report. <i>Targeted Oncology</i> , 2016, 11, 557-563.	1.7	16
3437	Interleukin-35 Limits Anti-Tumor Immunity. <i>Immunity</i> , 2016, 44, 316-329.	6.6	230
3438	The Lymphatic System in Disease Processes and Cancer Progression. <i>Annual Review of Biomedical Engineering</i> , 2016, 18, 125-158.	5.7	172

#	ARTICLE	IF	CITATIONS
3440	Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen. <i>Immunology and Cell Biology</i> , 2016, 94, 593-603.	1.0	34
3441	Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1223-1230.	0.8	300
3442	Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. <i>Nature Communications</i> , 2016, 7, 10391.	5.8	784
3443	Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8 ⁺ T-cell axis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E874-83.	3.3	86
3444	Expanding the antimalarial toolkit: Targeting host-parasite interactions. <i>Journal of Experimental Medicine</i> , 2016, 213, 143-153.	4.2	22
3445	Adjuvant therapy for pancreas cancer in an era of value based cancer care. <i>Cancer Treatment Reviews</i> , 2016, 42, 10-17.	3.4	16
3446	DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. <i>Nature Communications</i> , 2016, 7, 10478.	5.8	195
3447	Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment. <i>Nature Medicine</i> , 2016, 22, 122-124.	15.2	15
3448	Genetic variants in the mTOR pathway and breast cancer risk in African American women. <i>Carcinogenesis</i> , 2016, 37, 49-55.	1.3	10
3449	ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling. <i>Science Signaling</i> , 2016, 9, ra12.	1.6	46
3450	Immunotherapy for pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1795-1805.	1.2	27
3451	Immunotherapy and Oncogenic Pathways: The PTEN Connection. <i>Cancer Discovery</i> , 2016, 6, 128-129.	7.7	17
3452	The Length Distribution of Class II-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference. <i>Journal of Immunology</i> , 2016, 196, 1480-1487.	0.4	192
3453	Duality at the gate: Skin dendritic cells as mediators of vaccine immunity and tolerance. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 104-116.	1.4	9
3454	A cancer treatment based on synergy between anti-angiogenic and immune cell therapies. <i>Journal of Theoretical Biology</i> , 2016, 394, 197-211.	0.8	22
3455	Microfluidics: A New Tool for Modeling Cancer-Immune Interactions. <i>Trends in Cancer</i> , 2016, 2, 6-19.	3.8	163
3456	ALKR1275Q perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN. <i>Oncogene</i> , 2016, 35, 4447-4458.	2.6	19
3457	The Genomic Landscape of Male Breast Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 4045-4056.	3.2	119

#	ARTICLE	IF	CITATIONS
3458	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-like Small Cell Carcinoma-like Subsets. <i>Clinical Cancer Research</i> , 2016, 22, 3618-3629.	3.2	342
3459	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3764-3773.	3.2	733
3460	PD-1/PD-L1 blockage in cancer treatment—from basic research to clinical application. <i>International Journal of Clinical Oncology</i> , 2016, 21, 447-447.	1.0	10
3461	Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 211-226.	1.1	80
3462	Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. <i>Cancer Causes and Control</i> , 2016, 27, 459-472.	0.8	63
3463	Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 141-150.	2.7	25
3464	The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 18.	1.3	18
3465	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. <i>Cancer Cell</i> , 2016, 29, 285-296.	7.7	349
3466	Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. <i>Translational Oncology</i> , 2016, 9, 32-40.	1.7	17
3467	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. <i>International Journal of Clinical Oncology</i> , 2016, 21, 462-473.	1.0	255
3468	The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian but not endometrial cancer. <i>Tumor Biology</i> , 2016, 37, 10697-10702.	0.8	20
3469	Antitumour actions of interferons: implications for cancer therapy. <i>Nature Reviews Cancer</i> , 2016, 16, 131-144.	12.8	688
3470	Leukaemia 'firsts' in cancer research and treatment. <i>Nature Reviews Cancer</i> , 2016, 16, 163-172.	12.8	67
3471	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 511-525.	1.4	212
3472	Targeted therapies in gastric cancer treatment: where we are and where we are going. <i>Investigational New Drugs</i> , 2016, 34, 378-393.	1.2	16
3473	High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 813-819.	2.0	53
3474	Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2132-2139.	1.1	17
3475	Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer. <i>Tumor Biology</i> , 2016, 37, 8159-8168.	0.8	62

#	ARTICLE	IF	CITATIONS
3476	The thioredoxin system in breast cancer cell invasion and migration. <i>Redox Biology</i> , 2016, 8, 68-78.	3.9	141
3477	Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016, 76, 1653-1663.	0.4	41
3478	An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer. <i>Surgery Today</i> , 2016, 46, 1341-1347.	0.7	34
3479	Digital image analysis outperforms manual biomarker assessment in breast cancer. <i>Modern Pathology</i> , 2016, 29, 318-329.	2.9	144
3480	Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria. <i>Neuro-Oncology Practice</i> , 2016, 3, 59-67.	1.0	24
3481	Metformin attenuates transforming growth factor beta (TGF- β) mediated oncogenesis in mesenchymal stem-like/clinically low triple negative breast cancer. <i>Cell Cycle</i> , 2016, 15, 1046-1059.	1.3	60
3482	Eavesdropping on altered cell-to-cell signaling in cancer by secretome profiling. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1029061.	0.3	6
3483	Loss of miR-203 regulates cell shape and matrix adhesion through ROBO1/Rac/FAK in response to stiffness. <i>Journal of Cell Biology</i> , 2016, 212, 707-719.	2.3	38
3484	Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. <i>Cancer Immunology Research</i> , 2016, 4, 419-430.	1.6	247
3485	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1460-1468.	0.8	413
3486	Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications. <i>Oncologist</i> , 2016, 21, 220-232.	1.9	35
3487	Microfluidics: Rapid Diagnosis for Breast Cancer. <i>Nano-Micro Letters</i> , 2016, 8, 204-220.	14.4	21
3488	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 273-290.	12.5	909
3489	Cutting Edge: Engineering Active IKK β in T Cells Drives Tumor Rejection. <i>Journal of Immunology</i> , 2016, 196, 2933-2938.	0.4	18
3490	Dipeptide-Based Metabolic Labeling of Bacterial Cells for Endogenous Antibody Recruitment. <i>ACS Infectious Diseases</i> , 2016, 2, 302-309.	1.8	30
3491	Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. <i>MAbs</i> , 2016, 8, 593-603.	2.6	156
3492	Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. <i>Cancer Immunology Research</i> , 2016, 4, 452-462.	1.6	76
3493	Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. <i>Journal of Molecular Medicine</i> , 2016, 94, 535-543.	1.7	81

#	ARTICLE	IF	CITATIONS
3494	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2016, 18, 21.	1.8	39
3495	Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. <i>Neuro-Oncology</i> , 2016, 18, 1137-1145.	0.6	126
3496	Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2016, 22, 2885-2896.	3.2	45
3497	Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer. <i>Tumor Biology</i> , 2016, 37, 7033-7045.	0.8	49
3498	Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 171-181.	0.8	38
3499	The tumor microenvironment in esophageal cancer. <i>Oncogene</i> , 2016, 35, 5337-5349.	2.6	234
3500	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1909-1920.	6.3	3,077
3501	Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. <i>Advances in Immunology</i> , 2016, 130, 75-93.	1.1	74
3502	MEGSA: A Powerful and Flexible Framework for Analyzing Mutual Exclusivity of Tumor Mutations. <i>American Journal of Human Genetics</i> , 2016, 98, 442-455.	2.6	40
3503	GEMINI: a computationally-efficient search engine for large gene expression datasets. <i>BMC Bioinformatics</i> , 2016, 17, 102.	1.2	13
3504	Genetic and Epigenetic Regulation of PD-1 Expression. <i>Journal of Immunology</i> , 2016, 196, 2431-2437.	0.4	181
3505	Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 976-988.	0.5	197
3506	Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. <i>Nature Medicine</i> , 2016, 22, 427-432.	15.2	381
3507	Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 289-293.	1.6	135
3508	Pituitary Medicine From Discovery to Patient-Focused Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 769-777.	1.8	40
3509	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517.	0.8	627
3511	A high number of IgG4-positive cells in gastric cancer tissue is associated with tumor progression and poor prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 549-557.	1.4	22
3512	A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. <i>Cellular Oncology (Dordrecht)</i> , 2016, 39, 265-277.	2.1	70

#	ARTICLE	IF	CITATIONS
3513	The Impact of Genomic Profiling for Novel Cancer Therapy – Recent Progress in Non-Small Cell Lung Cancer. <i>Journal of Genetics and Genomics</i> , 2016, 43, 3-10.	1.7	8
3514	Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , 2016, 70, e75-e76.	0.9	0
3515	Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 516-524.	12.5	288
3516	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 1364-1370.	3.2	251
3517	In Search of a Cure for Sepsis: Taming the Monster in Critical Care Medicine. <i>Journal of Innate Immunity</i> , 2016, 8, 156-170.	1.8	20
3518	Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. <i>Breast Cancer Research</i> , 2016, 18, 26.	2.2	25
3519	Disentangling the aneuploidy and senescence paradoxes: a study of triploid breast cancers non-responsive to neoadjuvant therapy. <i>Histochemistry and Cell Biology</i> , 2016, 145, 497-508.	0.8	36
3520	Adoptive T-Cell Therapy for Cancer. <i>Advances in Immunology</i> , 2016, 130, 279-294.	1.1	168
3521	The Basis of Oncoimmunology. <i>Cell</i> , 2016, 164, 1233-1247.	13.5	671
3522	Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. <i>EBioMedicine</i> , 2016, 6, 50-58.	2.7	113
3523	Development of immuno-oncology drugs – from CTLA4 to PD1 to the next generations. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 235-247.	21.5	503
3524	Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. <i>Clinical Cancer Research</i> , 2016, 22, 2102-2104.	3.2	31
3525	Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 183-193.	1.0	112
3526	Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. <i>Modern Pathology</i> , 2016, 29, 528-541.	2.9	60
3527	Vaccines for established cancer: overcoming the challenges posed by immune evasion. <i>Nature Reviews Cancer</i> , 2016, 16, 219-233.	12.8	580
3528	PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. <i>Cancer Biology and Therapy</i> , 2016, 17, 407-413.	1.5	113
3529	Tumor-associated macrophages and anti-tumor therapies: complex links. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 2411-2424.	2.4	99
3530	HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 4119-4132.	3.2	266

#	ARTICLE	IF	CITATIONS
3531	Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 474-480.	1.6	17
3532	Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. <i>International Journal of Clinical Oncology</i> , 2016, 21, 456-461.	1.0	29
3533	Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 157-167.	0.6	27
3534	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 4-31.	1.4	40
3535	Family History of Cancer in Relation to Breast Cancer Subtypes in African American Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 366-373.	1.1	18
3536	The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography. <i>Tumor Biology</i> , 2016, 37, 7327-7332.	0.8	9
3537	Bypassing checkpoints, overcoming resistance, and honing in on new targets. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 75-76.	12.5	9
3538	The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNF α /IL17 Dependent. <i>Clinical Cancer Research</i> , 2016, 22, 2207-2216.	3.2	22
3540	Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. <i>British Journal of Cancer</i> , 2016, 114, 298-304.	2.9	7
3541	Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 220-230.	4.0	188
3542	In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. <i>Nature Nanotechnology</i> , 2016, 11, 295-303.	15.6	392
3543	A vaccine from plant virus proteins. <i>Nature Nanotechnology</i> , 2016, 11, 214-215.	15.6	21
3544	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 793-801.	3.2	60
3545	Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. <i>Clinical Cancer Research</i> , 2016, 22, 1592-1602.	3.2	108
3546	Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. <i>Nature Reviews Cancer</i> , 2016, 16, 56-66.	12.8	341
3547	Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN γ That Induce PD-L1 Expression in Head and Neck Cancer. <i>Cancer Research</i> , 2016, 76, 1031-1043.	0.4	265
3548	Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model. <i>Immunologic Research</i> , 2016, 64, 160-170.	1.3	48
3549	Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles. <i>Nature Communications</i> , 2016, 7, 10248.	5.8	34

#	ARTICLE	IF	CITATIONS
3550	Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. <i>Current Oncology Reports</i> , 2016, 18, 6.	1.8	26
3551	MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells. <i>Tumor Biology</i> , 2016, 37, 8825-8839.	0.8	41
3552	New Method for Joint Network Analysis Reveals Common and Different Coexpression Patterns among Genes and Proteins in Breast Cancer. <i>Journal of Proteome Research</i> , 2016, 15, 743-754.	1.8	23
3553	Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication. <i>Cancer Immunology Research</i> , 2016, 4, 95-100.	1.6	124
3554	The LINK-A lncRNA activates normoxic HIF1 α signalling in triple-negative breast cancer. <i>Nature Cell Biology</i> , 2016, 18, 213-224.	4.6	444
3555	SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 638-643.	3.3	66
3556	Proteomic maps of breast cancer subtypes. <i>Nature Communications</i> , 2016, 7, 10259.	5.8	256
3557	Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E328-37.	3.3	41
3558	Germline PARP4 mutations in patients with primary thyroid and breast cancers. <i>Endocrine-Related Cancer</i> , 2016, 23, 171-179.	1.6	39
3559	Cancer immunotherapy targeting neoantigens. <i>Seminars in Immunology</i> , 2016, 28, 22-27.	2.7	199
3560	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2565-2574.	3.2	80
3561	Current progress in immunotherapy for pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 244-251.	3.2	149
3562	Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. <i>Clinical Cancer Research</i> , 2016, 22, 2734-2743.	3.2	68
3563	Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. <i>Cancer Research</i> , 2016, 76, 440-452.	0.4	93
3564	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. <i>Cancer Immunology Research</i> , 2016, 4, 204-214.	1.6	175
3565	Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. <i>Nucleic Acids Research</i> , 2016, 44, e30-e30.	6.5	109
3566	Immunosuppressive cells in tumor immune escape and metastasis. <i>Journal of Molecular Medicine</i> , 2016, 94, 509-522.	1.7	270
3567	Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 389-397.	1.1	14

#	ARTICLE	IF	CITATIONS
3568	TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. <i>Nucleic Acids Research</i> , 2016, 44, e71-e71.	6.5	2,519
3569	DriverDBv2: a database for human cancer driver gene research. <i>Nucleic Acids Research</i> , 2016, 44, D975-D979.	6.5	102
3570	Take two: Combining immunotherapy with epigenetic drugs to tackle cancer. <i>Nature Medicine</i> , 2016, 22, 8-10.	15.2	57
3571	Highly multiplexed targeted DNA sequencing from single nuclei. <i>Nature Protocols</i> , 2016, 11, 214-235.	5.5	49
3572	Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2250-2260.	3.2	29
3573	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. <i>Trends in Immunology</i> , 2016, 37, 141-153.	2.9	24
3574	Identification of an Immunogenic Subset of Metastatic Uveal Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 2237-2249.	3.2	71
3575	Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 482-488.	3.3	37
3576	Small Molecule Inhibitors of Ca ²⁺ -S100B Reveal Two Protein Conformations. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 592-608.	2.9	13
3577	iWAS – A novel approach to analyzing Next Generation Sequence data for immunology. <i>Cellular Immunology</i> , 2016, 299, 6-13.	1.4	8
3578	The changing landscape of phase I trials in oncology. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 106-117.	12.5	84
3579	Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. <i>Cancer Research</i> , 2016, 76, 472-479.	0.4	140
3580	INTEGRATE: gene fusion discovery using whole genome and transcriptome data. <i>Genome Research</i> , 2016, 26, 108-118.	2.4	120
3581	Immune suppressive mechanisms in the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2016, 39, 1-6.	2.4	407
3582	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. <i>Targeted Oncology</i> , 2016, 11, 345-351.	1.7	56
3583	Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. <i>Pediatric Research</i> , 2016, 79, 371-377.	1.1	12
3584	Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 1104-1110.	0.7	116
3585	Senescence and cancer: An evolving inflammatory paradox. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 14-22.	3.3	35

#	ARTICLE	IF	CITATIONS
3586	Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	7
3587	PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF- κ B. <i>Cancer Research</i> , 2016, 76, 239-250.	0.4	84
3588	The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. <i>European Radiology</i> , 2016, 26, 2798-2807.	2.3	33
3589	Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis. <i>Pathology and Oncology Research</i> , 2016, 22, 331-339.	0.9	13
3590	Combination cancer immunotherapies tailored to the tumour microenvironment. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 143-158.	12.5	753
3591	GeneFu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. <i>Bioinformatics</i> , 2016, 32, 1097-1099.	1.8	255
3592	PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. <i>Cancer Research</i> , 2016, 76, 275-282.	0.4	204
3593	Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 13-20.	1.1	81
3594	Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway. <i>Tumor Biology</i> , 2016, 37, 5107-5115.	0.8	22
3595	PDL1 Regulation by p53 via miR-34. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	475
3596	The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. <i>Neuro-Oncology</i> , 2016, 18, 153-159.	0.6	86
3597	Immunotherapy for cancer in the central nervous system: Current and future directions. <i>OncImmunology</i> , 2016, 5, e1082027.	2.1	72
3598	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 582-595.	3.2	88
3599	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 1499-1509.	3.2	428
3600	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 135-145.	13.9	1,040
3601	PTEN is required to maintain luminal epithelial homeostasis and integrity in the adult mammary gland. <i>Developmental Biology</i> , 2016, 409, 202-217.	0.9	12
3602	PI3K-p110 α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. <i>Oncogene</i> , 2016, 35, 3607-3612.	2.6	38
3603	Immune checkpoint inhibitors: a new frontier in bladder cancer. <i>World Journal of Urology</i> , 2016, 34, 49-55.	1.2	15

#	ARTICLE	IF	CITATIONS
3604	Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, 1324-1333.	0.6	33
3605	Novel immunotherapies in lymphoid malignancies. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 25-40.	12.5	224
3606	ccmGDB: a database for cancer cell metabolism genes. <i>Nucleic Acids Research</i> , 2016, 44, D959-D968.	6.5	41
3607	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426.	0.8	203
3608	Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 17-22.	2.0	16
3609	Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer. <i>Tumor Biology</i> , 2016, 37, 4135-4142.	0.8	34
3610	Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. <i>Clinical Cancer Research</i> , 2016, 22, 886-894.	3.2	705
3611	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. <i>Clinical Cancer Research</i> , 2016, 22, 1161-1172.	3.2	57
3612	Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 58-71.	3.3	49
3613	Immunotherapy and tumor microenvironment. <i>Cancer Letters</i> , 2016, 370, 85-90.	3.2	242
3614	Intellectual property issues of immune checkpoint inhibitors. <i>MAbs</i> , 2016, 8, 10-26.	2.6	12
3615	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 470-478.	3.2	168
3616	Quantum dot-based in situ simultaneous molecular imaging and quantitative analysis of EGFR and collagen IV and identification of their prognostic value in triple-negative breast cancer. <i>Tumor Biology</i> , 2016, 37, 2509-2518.	0.8	9
3617	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. <i>Gastroenterology</i> , 2016, 150, 48-63.	0.6	90
3618	NF- κ B2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2. <i>Oncogene</i> , 2016, 35, 2735-2745.	2.6	49
3619	RING finger protein 31 promotes p53 degradation in breast cancer cells. <i>Oncogene</i> , 2016, 35, 1955-1964.	2.6	58
3621	Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 368-378.	0.6	31
3622	PD-L1 expression and prognostic impact in glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 195-205.	0.6	463

#	ARTICLE	IF	CITATIONS
3623	Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. <i>Molecular Therapy</i> , 2016, 24, 166-174.	3.7	161
3624	The Immunotherapy Roadmap. <i>Clinical Cancer Research</i> , 2016, 22, 275-276.	3.2	2
3625	MicroRNA <i>MIR21</i> and T Cells in Colorectal Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 33-40.	1.6	29
3626	Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. <i>Clinical and Translational Oncology</i> , 2016, 18, 497-506.	1.2	98
3627	PTEN and NEDD4 in Human Breast Carcinoma. <i>Pathology and Oncology Research</i> , 2016, 22, 41-47.	0.9	19
3628	Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation. <i>Tumor Biology</i> , 2016, 37, 2603-2611.	0.8	9
3629	Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world. <i>World Journal of Urology</i> , 2016, 34, 163-171.	1.2	20
3630	Systematic integration of molecular profiles identifies miR-22 as a regulator of lipid and folate metabolism in breast cancer cells. <i>Oncogene</i> , 2016, 35, 2766-2776.	2.6	62
3631	Cripto-1 modulates macrophage cytokine secretion and phagocytic activity via NF- κ B signaling. <i>Immunologic Research</i> , 2016, 64, 104-114.	1.3	17
3632	Comprehensive profiling of biological processes reveals two major prognostic subtypes in breast cancer. <i>Tumor Biology</i> , 2016, 37, 3365-3370.	0.8	0
3633	SUMOylation regulates p27 ^{Kip1} stability and localization in response to TGF β 2. <i>Journal of Molecular Cell Biology</i> , 2016, 8, 17-30.	1.5	11
3634	Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients. <i>European Radiology</i> , 2016, 26, 286-295.	2.3	24
3635	Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. <i>Gastric Cancer</i> , 2016, 19, 466-471.	2.7	124
3636	JRK is a positive regulator of β -catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer. <i>Oncogene</i> , 2016, 35, 2834-2841.	2.6	20
3637	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 56.	3.4	183
3638	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i> , 2016, 26, 1-133.	2.4	10,674
3639	Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. <i>Oncogene</i> , 2016, 35, 2166-2177.	2.6	49
3640	<i>In silico</i> tumor control induced via alternating immunostimulating and immunosuppressive phases. <i>Virulence</i> , 2016, 7, 174-186.	1.8	15

#	ARTICLE	IF	CITATIONS
3641	Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 421-430.	1.4	18
3642	Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. <i>Oncogene</i> , 2016, 35, 2413-2427.	2.6	426
3643	Key mechanisms involved in ionizing radiation-induced systemic effects. A current review. <i>Toxicology Research</i> , 2016, 5, 12-33.	0.9	71
3644	Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes. <i>Briefings in Bioinformatics</i> , 2016, 17, 642-656.	3.2	120
3645	Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. <i>Leukemia</i> , 2016, 30, 484-491.	3.3	201
3646	Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors. <i>Journal of Molecular Medicine</i> , 2016, 94, 83-93.	1.7	65
3647	Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. <i>Clinical Cancer Research</i> , 2016, 22, 436-447.	3.2	107
3648	CAR-T Cell Therapy for Lymphoma. <i>Annual Review of Medicine</i> , 2016, 67, 165-183.	5.0	123
3649	Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs. <i>Oncogene</i> , 2016, 35, 1743-1749.	2.6	13
3650	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. <i>Genetics in Medicine</i> , 2016, 18, 128-136.	1.1	83
3651	The hypoxic tumor microenvironment: A driving force for breast cancer progression. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 382-391.	1.9	418
3652	The associations between PD-1, CTLA-4 gene polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis and systemic review. <i>Rheumatology International</i> , 2016, 36, 33-44.	1.5	17
3653	Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data. <i>Briefings in Bioinformatics</i> , 2016, 17, 224-232.	3.2	29
3654	Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. <i>Pituitary</i> , 2016, 19, 82-92.	1.6	259
3655	Luminal epithelial cells within the mammary gland can produce basal cells upon oncogenic stress. <i>Oncogene</i> , 2016, 35, 1461-1467.	2.6	30
3656	Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. <i>Oncogene</i> , 2016, 35, 1996-2002.	2.6	142
3657	Emerging strategies to effectively target autophagy in cancer. <i>Oncogene</i> , 2016, 35, 1-11.	2.6	226
3658	Lectin microarray technology identifies specific lectins related to lymph node metastasis of advanced gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 531-542.	2.7	33

#	ARTICLE	IF	CITATIONS
3659	Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 164-174.	2.7	13
3660	Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. <i>Gut</i> , 2017, 66, 794-801.	6.1	377
3661	CD4+ regulatory T cells in gastric cancer mucosa are proliferating and express high levels of IL-10 but little TGF- β 2. <i>Gastric Cancer</i> , 2017, 20, 116-125.	2.7	72
3662	Precision oncology: A new era of cancer clinical trials. <i>Cancer Letters</i> , 2017, 387, 121-126.	3.2	53
3663	CTLA-4 Limits Anti-CD20-Mediated Tumor Regression. <i>Clinical Cancer Research</i> , 2017, 23, 193-203.	3.2	35
3664	Integration of multiple OMIC-biomarkers: A precision medicine strategy for lung cancer. <i>Lung Cancer</i> , 2017, 107, 50-58.	0.9	45
3665	Fuzheng Qingjie Granules Inhibit Growth of Hepatoma Cells via Inducing Mitochondria-Mediated Apoptosis and Enhancing Immune Function. <i>Integrative Cancer Therapies</i> , 2017, 16, 329-338.	0.8	16
3666	Translational aspects in targeting the stromal tumour microenvironment: From bench to bedside. <i>European Journal of Molecular and Clinical Medicine</i> , 2017, 3, 9.	0.5	18
3667	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 115-128.	12.5	95
3668	Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. <i>Breast Cancer</i> , 2017, 24, 111-120.	1.3	21
3669	Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. <i>Clinical and Translational Oncology</i> , 2017, 19, 119-124.	1.2	23
3670	Liver transplantation for hepatobiliary malignancies: a new era of Transplant Oncology has begun. <i>Surgery Today</i> , 2017, 47, 403-415.	0.7	48
3671	Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2 ⁻ and ER+HER2+) breast cancers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 170, 65-74.	1.2	26
3672	Function of PD-L1 in antitumor immunity of glioma cells. <i>Saudi Journal of Biological Sciences</i> , 2017, 24, 803-807.	1.8	33
3673	Designing therapeutic cancer vaccines by mimicking viral infections. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 203-213.	2.0	36
3674	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. <i>World Journal of Urology</i> , 2017, 35, 121-130.	1.2	37
3675	Principles of Kinase Inhibitor Therapy for Solid Tumors. <i>Annals of Surgery</i> , 2017, 265, 311-319.	2.1	10
3676	Sequential monitoring of Phase I dose expansion cohorts. <i>Statistics in Medicine</i> , 2017, 36, 204-214.	0.8	12

#	ARTICLE	IF	CITATIONS
3677	Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026740.	2.9	25
3678	Elements of cancer immunity and the cancer’s immune set point. <i>Nature</i> , 2017, 541, 321-330.	13.7	3,558
3679	Utilizing somatic mutation data from numerous studies for cancer research: proof of concept and applications. <i>Oncogene</i> , 2017, 36, 3375-3383.	2.6	14
3680	Targeting the PI3K/AKT pathway via G11 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells. <i>Scientific Reports</i> , 2017, 7, 40361.	1.6	41
3681	COX2/mPGES1/PGE ₂ pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1117-1122.	3.3	378
3682	Tumor evolution: Linear, branching, neutral or punctuated?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1867, 151-161.	3.3	239
3683	Systemic Immunity Is Required for Effective Cancer Immunotherapy. <i>Cell</i> , 2017, 168, 487-502.e15.	13.5	708
3684	Modification of host dendritic cells by microchimerism-derived extracellular vesicles generates split tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1099-1104.	3.3	55
3685	Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. <i>Science</i> , 2017, 355, .	6.0	988
3686	Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. <i>Gut</i> , 2017, 66, 1463-1473.	6.1	173
3687	Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?. <i>Seminars in Immunopathology</i> , 2017, 39, 327-331.	2.8	22
3688	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. <i>British Journal of Cancer</i> , 2017, 116, 432-440.	2.9	59
3689	±3 Chains of type V collagen regulate breast tumour growth via glypican-1. <i>Nature Communications</i> , 2017, 8, 14351.	5.8	48
3690	Interrogating open issues in cancer precision medicine with patient-derived xenografts. <i>Nature Reviews Cancer</i> , 2017, 17, 254-268.	12.8	527
3691	Cancer immunotherapy’s immune checkpoint blockade and associated endocrinopathies. <i>Nature Reviews Endocrinology</i> , 2017, 13, 195-207.	4.3	515
3692	Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy. <i>Annals of Thoracic Surgery</i> , 2017, 103, e123-e125.	0.7	4
3693	Strategies to overcome therapeutic resistance in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 102-110.	0.8	35
3694	Integrated genomic and molecular characterization of cervical cancer. <i>Nature</i> , 2017, 543, 378-384.	13.7	1,158

#	ARTICLE	IF	CITATIONS
3695	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER± metastatic breast cancer. <i>Nature Genetics</i> , 2017, 49, 444-450.	9.4	77
3696	Tumour-associated macrophages as treatment targets in oncology. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 399-416.	12.5	2,667
3697	Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E970-E979.	3.3	172
3698	Inverse lichenoid drug eruption associated with nivolumab. <i>JAAD Case Reports</i> , 2017, 3, 7-9.	0.4	13
3699	SHARPIN Facilitates p53 Degradation in Breast Cancer Cells. <i>Neoplasia</i> , 2017, 19, 84-92.	2.3	36
3700	The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. <i>NeuroImage: Clinical</i> , 2017, 13, 386-394.	1.4	101
3701	Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 221-232.	2.3	12
3702	Aptamers for CD Antigens: From Cell Profiling to Activity Modulation. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 29-44.	2.3	33
3703	Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade. <i>Molecular Therapy - Oncolytics</i> , 2017, 4, 41-54.	2.0	74
3704	A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 1.	6.9	216
3705	A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet. <i>Clinical and Translational Medicine</i> , 2017, 6, 3.	1.7	58
3706	Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. <i>Modern Pathology</i> , 2017, 30, 530-538.	2.9	92
3707	Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. <i>Modern Pathology</i> , 2017, 30, 577-586.	2.9	132
3708	Death receptor 6 contributes to autoimmunity in lupus-prone mice. <i>Nature Communications</i> , 2017, 8, 13957.	5.8	38
3709	Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer. <i>Cell Cycle</i> , 2017, 16, 312-318.	1.3	18
3710	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 100-105.	1.6	46
3711	Molecular chess? Hallmarks of anti-cancer drug resistance. <i>BMC Cancer</i> , 2017, 17, 10.	1.1	221
3712	Angiopoietin pathway gene expression associated with poor breast cancer survival. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 191-198.	1.1	51

#	ARTICLE	IF	CITATIONS
3713	A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 406-412.	1.0	16
3714	Clinical Impact of Frequent Surveillance Imaging in the First Year Following Chemoradiation for Locally Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 410-414.	1.1	7
3715	Renal complications of immune checkpoint blockade. <i>Current Problems in Cancer</i> , 2017, 41, 100-110.	1.0	81
3716	Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival. <i>Scientific Reports</i> , 2017, 7, 40177.	1.6	12
3717	Immunosuppressive Myeloid Cells Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. <i>Molecular Therapy</i> , 2017, 25, 232-248.	3.7	130
3718	TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation. <i>Oncogene</i> , 2017, 36, 2991-3001.	2.6	48
3719	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-235.	0.8	458
3720	A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer. <i>Medical Oncology</i> , 2017, 34, 20.	1.2	10
3721	Catch my drift? Making sense of genomic intra-tumour heterogeneity. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1867, 95-100.	3.3	23
3722	The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma. <i>Nature Communications</i> , 2017, 8, 13930.	5.8	56
3723	The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer. <i>Oncogene</i> , 2017, 36, 3490-3503.	2.6	33
3724	Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics. <i>Annual Review of Immunology</i> , 2017, 35, 337-370.	9.5	69
3725	Differentiated State of Initiating Tumor Cells Is Key to Distinctive Immune Responses Seen in H-RasG12V-Induced Squamous Tumors. <i>Cancer Immunology Research</i> , 2017, 5, 198-210.	1.6	7
3726	The development of dendritic cell vaccine-based immunotherapies for glioblastoma. <i>Seminars in Immunopathology</i> , 2017, 39, 225-239.	2.8	42
3728	Sustained epidermal powder drug delivery via skin microchannels. <i>Journal of Controlled Release</i> , 2017, 249, 94-102.	4.8	26
3729	Neutrophils dominate the immune cell composition in non-small cell lung cancer. <i>Nature Communications</i> , 2017, 8, 14381.	5.8	304
3730	Mouse Models of Breast Cancer Share Amplification and Deletion Events with Human Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2017, 22, 71-84.	1.0	17
3731	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3610-3618.	3.2	225

#	ARTICLE	IF	CITATIONS
3732	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. <i>Cancer Discovery</i> , 2017, 7, 302-321.	7.7	128
3733	Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity. <i>Molecular Medicine Reports</i> , 2017, 15, 1063-1070.	1.1	91
3734	The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 417-427.	1.9	16
3735	Epigenetics in cancer stem cells. <i>Molecular Cancer</i> , 2017, 16, 29.	7.9	296
3736	Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. <i>Genetics in Medicine</i> , 2017, 19, 989-997.	1.1	90
3737	Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 428-439.	1.9	25
3738	Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determined by multiparametric single cell mass cytometry analysis. <i>BMC Immunology</i> , 2017, 18, 6.	0.9	31
3739	Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer. <i>Molecular Cancer</i> , 2017, 16, 32.	7.9	39
3740	Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. <i>Leukemia</i> , 2017, 31, 829-836.	3.3	74
3741	Integrative Comparison of mRNA Expression Patterns in Breast Cancers from Caucasian and Asian Americans with Implications for Precision Medicine. <i>Cancer Research</i> , 2017, 77, 423-433.	0.4	20
3742	Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. <i>Clinical and Translational Oncology</i> , 2017, 19, 761-768.	1.2	12
3743	Insertions and Deletions Target Lineage-Defining Genes in Human Cancers. <i>Cell</i> , 2017, 168, 460-472.e14.	13.5	106
3744	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. <i>Cancer Immunology Research</i> , 2017, 5, 106-117.	1.6	236
3745	Imaging Surveillance After Primary Breast Cancer Treatment. <i>American Journal of Roentgenology</i> , 2017, 208, 676-686.	1.0	59
3746	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. <i>World Journal of Urology</i> , 2017, 35, 1401-1407.	1.2	29
3747	Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>Modern Pathology</i> , 2017, 30, 509-518.	2.9	32
3748	MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation. <i>Modern Pathology</i> , 2017, 30, 682-697.	2.9	59
3749	SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression. <i>Scientific Reports</i> , 2017, 7, 40585.	1.6	17

#	ARTICLE	IF	CITATIONS
3750	Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation. <i>Cancer Research</i> , 2017, 77, 1310-1321.	0.4	32
3751	Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000163.	1.2	7
3752	Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication. <i>Cancer Immunology Research</i> , 2017, 5, 127-136.	1.6	17
3753	Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review. <i>Chinese Journal of Cancer</i> , 2017, 36, 10.	4.9	38
3754	Is immunotherapy here to stay in multiple myeloma?. <i>Haematologica</i> , 2017, 102, 423-432.	1.7	42
3755	Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy. <i>Targeted Oncology</i> , 2017, 12, 211-218.	1.7	17
3756	PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. <i>Drugs</i> , 2017, 77, 113-130.	4.9	44
3757	Precision oncology for acute myeloid leukemia using a knowledge bank approach. <i>Nature Genetics</i> , 2017, 49, 332-340.	9.4	229
3758	Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. <i>Oncogene</i> , 2017, 36, 3334-3345.	2.6	83
3759	iGC—an integrated analysis package of gene expression and copy number alteration. <i>BMC Bioinformatics</i> , 2017, 18, 35.	1.2	16
3760	Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma. <i>Neuroradiology</i> , 2017, 59, 135-145.	1.1	57
3761	Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and PD-L1 Expression in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 878-883.	0.5	109
3762	Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2017, 451, 24-30.	1.6	18
3763	Radiotherapy and immunotherapy: a beneficial liaison?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 365-379.	12.5	760
3764	Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now287.	0.6	128
3765	Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?. <i>Journal of Translational Medicine</i> , 2017, 15, 17.	1.8	40
3766	Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. <i>Current Gastroenterology Reports</i> , 2017, 19, 3.	1.1	141
3767	Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. <i>Leukemia</i> , 2017, 31, 2181-2190.	3.3	188

#	ARTICLE	IF	CITATIONS
3768	Large-scale analysis of branchpoint usage across species and cell lines. <i>Genome Research</i> , 2017, 27, 639-649.	2.4	97
3769	Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment. <i>Cancer Research</i> , 2017, 77, 1271-1282.	0.4	134
3770	Targeting ALK: Precision Medicine Takes on Drug Resistance. <i>Cancer Discovery</i> , 2017, 7, 137-155.	7.7	405
3771	Prognostic significance of Ki67 in Chinese women diagnosed with ER+/HER2- breast cancers by the 2015 St. Gallen consensus classification. <i>BMC Cancer</i> , 2017, 17, 28.	1.1	6
3772	PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. <i>Journal of Hematology and Oncology</i> , 2017, 10, 34.	6.9	82
3773	Insights from Global Analyses of Long Noncoding RNAs in Breast Cancer. <i>Current Pathobiology Reports</i> , 2017, 5, 23-34.	1.6	15
3774	Redirecting the focus of cancer immunotherapy to premalignant conditions. <i>Cancer Letters</i> , 2017, 391, 83-88.	3.2	24
3775	New strategies for cancer immunotherapy: targeting regulatory T cells. <i>Genome Medicine</i> , 2017, 9, 10.	3.6	62
3776	Medication-associated gastrointestinal tract injury. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 245-266.	1.4	22
3777	Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 581-592.	2.0	189
3778	A Dynamic Model of Immune Responses to Antigen Presentation Predicts Different Regions of Tumor or Pathogen Elimination. <i>Cell Systems</i> , 2017, 4, 231-241.e11.	2.9	59
3779	Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells. <i>Molecular Oncology</i> , 2017, 11, 358-372.	2.1	43
3780	Cardiovascular Toxicities Associated with Cancer Immunotherapies. <i>Current Cardiology Reports</i> , 2017, 19, 21.	1.3	126
3781	A first reported case of metastatic anorectal amelanotic melanoma with a marked response to anti-PD-1 antibody nivolumab: A case report. <i>International Journal of Surgery Case Reports</i> , 2017, 31, 188-192.	0.2	21
3782	Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. <i>Nature Communications</i> , 2017, 8, 14572.	5.8	279
3783	Carcinogenesis and therapeutics: the microbiota perspective. <i>Nature Microbiology</i> , 2017, 2, 17008.	5.9	108
3784	Pathway-wide association study identifies five shared pathways associated with schizophrenia in three ancestral distinct populations. <i>Translational Psychiatry</i> , 2017, 7, e1037-e1037.	2.4	21
3785	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 4270-4279.	3.2	117

#	ARTICLE	IF	CITATIONS
3786	Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition. <i>Cells Tissues Organs</i> , 2017, 203, 128-138.	1.3	20
3787	Emerging role of checkpoint blockade therapy in lymphoma. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 81-90.	1.1	32
3788	State of the art in anti-cancer mAbs. <i>Journal of Biomedical Science</i> , 2017, 24, 15.	2.6	64
3789	Cost-Effectiveness of Immune Checkpoint Inhibition in <i>BRAF</i> Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1194-1202.	0.8	89
3790	Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 593-603.	2.0	19
3791	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2017, 25, 1713-1739.	1.0	125
3792	The biology of uveal melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 109-140.	2.7	160
3793	INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC. <i>Molecular Cancer Research</i> , 2017, 15, 765-775.	1.5	26
3794	Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2516-2527.	1.2	15
3795	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. <i>Immunity</i> , 2017, 46, 197-204.	6.6	400
3796	Targeting neoantigens to augment antitumour immunity. <i>Nature Reviews Cancer</i> , 2017, 17, 209-222.	12.8	724
3797	Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. , 2017, 5, 1.		68
3798	Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3575-3584.	3.2	78
3799	Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3168-3180.	3.2	67
3800	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, R123-R144.	1.6	64
3801	Oncogenic growth factor signaling mediating tumor escape from cellular immunity. <i>Current Opinion in Immunology</i> , 2017, 45, 52-59.	2.4	19
3802	Enrichment of circulating head and neck tumour cells using spiral microfluidic technology. <i>Scientific Reports</i> , 2017, 7, 42517.	1.6	69
3803	Cancer cells exhibit clonal diversity in phenotypic plasticity. <i>Open Biology</i> , 2017, 7, 160283.	1.5	30

#	ARTICLE	IF	CITATIONS
3804	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. <i>Molecular Systems Biology</i> , 2017, 13, 914.	3.2	73
3805	Inflammatory cytokines IL-17 and TNF- α up-regulate PD-L1 expression in human prostate and colon cancer cells. <i>Immunology Letters</i> , 2017, 184, 7-14.	1.1	241
3806	Developing Cures: Targeting Ontogenesis in Cancer. <i>Trends in Cancer</i> , 2017, 3, 126-136.	3.8	11
3807	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 1015-1026.	13.9	2,677
3808	Tumor Microenvironment and Differential Responses to Therapy. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026781.	2.9	278
3809	T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. <i>Gut</i> , 2017, 66, 454-463.	6.1	48
3810	Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 7.	1.3	46
3811	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 446-453.	5.1	322
3812	Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors. <i>Scientific Reports</i> , 2017, 7, 41921.	1.6	28
3813	The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2017, 7, 42913.	1.6	33
3814	Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 783-791.	1.2	36
3815	A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. <i>Clinical Cancer Research</i> , 2017, 23, 4035-4045.	3.2	104
3816	Immune Microenvironment in Microsatellite-Unstable Endometrial Cancers: Hereditary or Sporadic Origin Matters. <i>Clinical Cancer Research</i> , 2017, 23, 4473-4481.	3.2	96
3817	PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. <i>Scientific Reports</i> , 2017, 7, 44173.	1.6	70
3818	Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3127-3132.	3.3	92
3819	Standard of care in immunotherapy trials: Challenges and considerations. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2164-2178.	1.4	4
3820	An Acquired <i>HER2</i> T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with <i>HER2</i> Mutant-Driven Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 575-585.	7.7	85
3821	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1051.	3.4	658

#	ARTICLE	IF	CITATIONS
3822	Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 219-230.	1.1	40
3823	Precision medicine driven by cancer systems biology. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 91-108.	2.7	38
3824	Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer. <i>Cell Reports</i> , 2017, 18, 2359-2372.	2.9	59
3825	Towards a better cancer precision medicine: Systems biology meets immunotherapy. <i>Current Opinion in Systems Biology</i> , 2017, 2, 67-73.	1.3	7
3826	Expanding the B Cell-Centric View of Systemic Lupus Erythematosus. <i>Trends in Immunology</i> , 2017, 38, 373-382.	2.9	40
3827	Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 463-479.	1.9	44
3828	T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. <i>Science</i> , 2017, 355, 1428-1433.	6.0	1,229
3829	Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. <i>Oncologist</i> , 2017, 22, 470-479.	1.9	244
3830	Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. <i>Modern Pathology</i> , 2017, 30, 826-833.	2.9	101
3831	Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis Emergence. <i>Scientific Reports</i> , 2017, 7, 43813.	1.6	24
3832	Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 651-660.	1.1	76
3833	The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose. <i>Molecular Therapy</i> , 2017, 25, 880-891.	3.7	50
3834	Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. <i>Cell Discovery</i> , 2017, 3, 17004.	3.1	147
3835	Prediction of years of life after diagnosis of breast cancer using omics and omic-by-treatment interactions. <i>European Journal of Human Genetics</i> , 2017, 25, 538-544.	1.4	28
3836	Exhaustion-associated regulatory regions in CD8 ⁺ tumor-infiltrating T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E2776-E2785.	3.3	242
3837	Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. <i>EBioMedicine</i> , 2017, 17, 30-44.	2.7	52
3838	Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies. <i>Molecular Therapy</i> , 2017, 25, 523-533.	3.7	103
3839	ITIH5 mediates epigenetic reprogramming of breast cancer cells. <i>Molecular Cancer</i> , 2017, 16, 44.	7.9	29

#	ARTICLE	IF	CITATIONS
3840	Immune checkpoint inhibitors in challenging populations. <i>Cancer</i> , 2017, 123, 1904-1911.	2.0	266
3841	Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 683-695.	2.0	53
3842	Immune modulation by dendritic-cell-based cancer vaccines. <i>Journal of Biosciences</i> , 2017, 42, 161-173.	0.5	15
3843	Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. <i>Clinical and Experimental Immunology</i> , 2017, 188, 455-466.	1.1	55
3844	Tracking the fate and origin of clinically relevant adoptively transferred CD8 ⁺ T cells in vivo. <i>Science Immunology</i> , 2017, 2, .	5.6	68
3845	Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. <i>Science Signaling</i> , 2017, 10, .	1.6	43
3846	Armed Oncolytic Adenovirus Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. <i>Cancer Research</i> , 2017, 77, 2040-2051.	0.4	170
3847	Combination immunotherapy: a road map. , 2017, 5, 16.		325
3848	Targeting the programmed death-1 pathway in lymphoid neoplasms. <i>Cancer Treatment Reviews</i> , 2017, 54, 99-109.	3.4	27
3849	Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance. <i>Laboratory Investigation</i> , 2017, 97, 657-668.	1.7	70
3850	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	689
3851	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. <i>Cancer Immunology Research</i> , 2017, 5, 312-318.	1.6	354
3852	MINT: a multivariate integrative method to identify reproducible molecular signatures across independent experiments and platforms. <i>BMC Bioinformatics</i> , 2017, 18, 128.	1.2	83
3853	Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities. <i>Oncologist</i> , 2017, 22, 304-310.	1.9	8
3854	Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 793.	3.4	74
3855	Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 321-330.	1.1	34
3856	An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. <i>Nature Communications</i> , 2017, 8, 14369.	5.8	192
3857	Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. <i>Nature Medicine</i> , 2017, 23, 376-385.	15.2	111

#	ARTICLE	IF	CITATIONS
3858	The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. <i>Journal of Experimental Medicine</i> , 2017, 214, 381-400.	4.2	154
3859	Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. <i>Journal of Clinical Pathology</i> , 2017, 70, 255-259.	1.0	97
3860	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. <i>Clinical Cancer Research</i> , 2017, 23, 3859-3870.	3.2	129
3861	Reactivation of dormant anti-tumor immunity â€” a clinical perspective of therapeutic immune checkpoint modulation. <i>Cell Communication and Signaling</i> , 2017, 15, 5.	2.7	34
3862	Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles. <i>Endocrine-Related Cancer</i> , 2017, 24, R81-R97.	1.6	21
3863	Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 44-50.	1.2	12
3864	DNA vaccines for prostate cancer. , 2017, 174, 27-42.		36
3865	Metastatic disease from uveal melanoma: treatment options and future prospects. <i>British Journal of Ophthalmology</i> , 2017, 101, 38-44.	2.1	287
3866	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. <i>Clinical Cancer Research</i> , 2017, 23, 3711-3720.	3.2	710
3867	Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 947-951.	0.7	26
3868	Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. <i>British Journal of Cancer</i> , 2017, 116, 802-810.	2.9	124
3869	PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer. <i>Scientific Reports</i> , 2017, 7, 42319.	1.6	23
3870	Precision medicine in immune checkpoint blockade therapy for nonâ€”small cell lung cancer. <i>Clinical and Translational Medicine</i> , 2017, 6, 7.	1.7	41
3871	Genetically engineered mouse models in oncology research and cancer medicine. <i>EMBO Molecular Medicine</i> , 2017, 9, 137-153.	3.3	356
3872	Applications of Immunogenomics to Cancer. <i>Cell</i> , 2017, 168, 600-612.	13.5	198
3873	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. <i>Cell</i> , 2017, 168, 707-723.	13.5	3,483
3874	Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. <i>Scientific Reports</i> , 2017, 7, 41960.	1.6	73
3875	The PP2A-B56 Phosphatase Opposes Cyclin E Autocatalytic Degradation via Site-Specific Dephosphorylation. <i>Molecular and Cellular Biology</i> , 2017, 37, .	1.1	10

#	ARTICLE	IF	CITATIONS
3876	Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice. <i>Current Oncology Reports</i> , 2017, 19, 5.	1.8	0
3877	Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence. <i>Medical Oncology</i> , 2017, 34, 34.	1.2	25
3878	CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure. <i>Current Breast Cancer Reports</i> , 2017, 9, 26-33.	0.5	55
3879	Tumor regulation of the tissue environment in the liver. , 2017, 173, 47-57.		68
3880	Interplay between Immune Checkpoint Proteins and Cellular Metabolism. <i>Cancer Research</i> , 2017, 77, 1245-1249.	0.4	82
3881	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2213-2221.	0.4	168
3882	Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. <i>Journal of Hematology and Oncology</i> , 2017, 10, 64.	6.9	30
3884	Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 381-389.	1.4	31
3885	Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1123-1131.	1.2	42
3886	The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. <i>Current Oncology Reports</i> , 2017, 19, 17.	1.8	30
3887	Tissue-specific tumorigenesis: context matters. <i>Nature Reviews Cancer</i> , 2017, 17, 239-253.	12.8	234
3888	Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma. <i>Scientific Reports</i> , 2017, 7, 42980.	1.6	27
3889	Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017, 23, 4290-4300.	3.2	192
3890	Immunotherapy-associated autoimmune hemolytic anemia. , 2017, 5, 15.		56
3891	In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells. <i>Oncology Reports</i> , 2017, 37, 1367-1378.	1.2	5
3892	Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. <i>Molecular Imaging and Biology</i> , 2017, 19, 903-914.	1.3	91
3893	Tim β 3 and its role in regulating anti-tumor immunity. <i>Immunological Reviews</i> , 2017, 276, 97-111.	2.8	599
3894	<sc>TAM</sc> receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. <i>Immunological Reviews</i> , 2017, 276, 165-177.	2.8	125

#	ARTICLE	IF	CITATIONS
3895	Advances in targeting coâ€inhibitory and coâ€stimulatory pathways in transplantation settings: the Yin to the Yang ofÂcancer immunotherapy. <i>Immunological Reviews</i> , 2017, 276, 192-212.	2.8	44
3896	Introduction to checkpoint inhibitors and cancer immunotherapy. <i>Immunological Reviews</i> , 2017, 276, 5-8.	2.8	151
3897	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. <i>Neurotherapeutics</i> , 2017, 14, 1049-1065.	2.1	20
3898	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. <i>Cell Reports</i> , 2017, 18, 2162-2174.	2.9	244
3899	<i>ZNF50</i> 3/ <i>Zpo2</i> drives aggressive breast cancer progression by down-regulation of GATA3 expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3169-3174.	3.3	32
3900	<sc>LAG</sc>3 (<sc>CD</sc>223) as a cancer immunotherapy target. <i>Immunological Reviews</i> , 2017, 276, 80-96.	2.8	664
3901	The third group of the B7â€<sc>CD</sc>28 immune checkpoint family: <sc>HHLA</sc>2, <sc>TMIGD</sc>2, B7x, and B7â€H3. <i>Immunological Reviews</i> , 2017, 276, 26-39.	2.8	185
3902	Immunoregulatory functions of <sc>VISTA</sc>. <i>Immunological Reviews</i> , 2017, 276, 66-79.	2.8	154
3903	Coâ€inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. <i>Immunological Reviews</i> , 2017, 276, 9-25.	2.8	13
3904	Potential targeting of B7â€H4 for the treatment of cancer. <i>Immunological Reviews</i> , 2017, 276, 40-51.	2.8	103
3905	Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature. <i>Targeted Oncology</i> , 2017, 12, 235-241.	1.7	40
3906	Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 142-148.	0.8	16
3907	INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 486-491.	1.3	235
3908	PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load. <i>Scientific Reports</i> , 2017, 7, 43627.	1.6	52
3909	Debugging the Black Box. <i>Cancer Discovery</i> , 2017, 7, 250-251.	7.7	0
3910	Immunotherapy in pancreatic cancer treatment: a new frontier. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 168-194.	1.4	73
3911	A population genetics perspective on the determinants of intra-tumor heterogeneity. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1867, 109-126.	3.3	37
3912	Highly specific imaging of mRNA in single cells by target RNA-initiated rolling circle amplification. <i>Chemical Science</i> , 2017, 8, 3668-3675.	3.7	134

#	ARTICLE	IF	CITATIONS
3913	A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. <i>Journal of Translational Medicine</i> , 2017, 15, 21.	1.8	21
3914	Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. <i>Targeted Oncology</i> , 2017, 12, 153-161.	1.7	31
3915	Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2 ⁺ advanced breast cancer: results from BOLERO-2. <i>British Journal of Cancer</i> , 2017, 116, 726-730.	2.9	112
3916	Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 479-488.	1.1	14
3917	Future strategies for the discovery of therapeutic aptamers. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 317-319.	2.5	8
3918	Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients. <i>Journal of Ovarian Research</i> , 2017, 10, 8.	1.3	21
3919	Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF- α . <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 523-535.	2.0	76
3920	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017, 73, 61-70.	1.3	88
3921	Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2 ⁺ breast cancer that had progressed during or after prior endocrine therapy. <i>Breast Cancer Research</i> , 2017, 19, 18.	2.2	87
3922	The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 6.	1.3	44
3923	Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. <i>Cancer Cell</i> , 2017, 31, 194-207.	7.7	179
3924	Interferon- γ -inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity. <i>Scientific Reports</i> , 2017, 7, 42145.	1.6	12
3925	Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 439-450.	1.1	47
3926	Advances in understanding tumour evolution through single-cell sequencing. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1867, 127-138.	3.3	95
3927	MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. <i>British Journal of Cancer</i> , 2017, 116, 742-751.	2.9	13
3928	'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. <i>Nature Immunology</i> , 2017, 18, 255-262.	7.0	361
3929	Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF- κ B Pathway in Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 4831-4842.	3.2	33
3930	Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 81.	6.9	114

#	ARTICLE	IF	CITATIONS
3931	Designing and building oncolytic viruses. <i>Future Virology</i> , 2017, 12, 193-213.	0.9	109
3932	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. <i>EBioMedicine</i> , 2017, 18, 56-61.	2.7	83
3933	The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1069-1077.	0.4	58
3934	The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective. <i>Cancer Gene Therapy</i> , 2017, 24, 89-99.	2.2	31
3935	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. <i>Nature</i> , 2017, 545, 60-65.	13.7	1,280
3936	Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. <i>Npj Breast Cancer</i> , 2017, 3, 9.	2.3	47
3937	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. <i>Cancer Research</i> , 2017, 77, 3280-3292.	0.4	76
3938	Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2017, 5, 357-362.	1.6	40
3939	Patient perspectives on ipilimumab across the melanoma treatment trajectory. <i>Supportive Care in Cancer</i> , 2017, 25, 2155-2167.	1.0	14
3940	Immunologic approaches for the treatment of multiple myeloma. <i>Cancer Treatment Reviews</i> , 2017, 55, 190-199.	3.4	46
3941	Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy. <i>Nature Biotechnology</i> , 2017, 35, 297-298.	9.4	14
3942	Papilloma-pseudovirus eradicates intestinal tumours and triples the lifespan of ApcMin/+ mice. <i>Nature Communications</i> , 2017, 8, 15004.	5.8	8
3943	Aberrant low expression of p85 in stromal fibroblasts promotes breast cancer cell metastasis through exosome-mediated paracrine Wnt10b. <i>Oncogene</i> , 2017, 36, 4692-4705.	2.6	100
3944	Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line. <i>Scientific Reports</i> , 2017, 7, 46079.	1.6	23
3945	Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients. <i>Arthritis Research and Therapy</i> , 2017, 19, 52.	1.6	25
3946	Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 41-54.	3.3	55
3947	Resistance to immunotherapy: clouds in a bright sky. <i>Investigational New Drugs</i> , 2017, 35, 649-654.	1.2	8
3948	No association between prediagnosis exercise and survival in patients with high-risk primary melanoma: A population-based study. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 424-427.	1.5	8

#	ARTICLE	IF	CITATIONS
3949	Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	541
3950	Survival Deficit for HIV-Infected Lymphoma Patients in the National Cancer Database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 289-290.	1.1	2
3951	A statistical framework for data integration through graphical models with application to cancer genomics. <i>Annals of Applied Statistics</i> , 2017, 11, 161-184.	0.5	19
3952	End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma. <i>Future Oncology</i> , 2017, 13, 1181-1193.	1.1	25
3953	Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. <i>Investigational New Drugs</i> , 2017, 35, 436-441.	1.2	73
3954	Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma. <i>Medical Oncology</i> , 2017, 34, 94.	1.2	52
3955	Selective blockade of B7-3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 2199-2210.	1.6	43
3956	Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. <i>Science</i> , 2017, 356, 200-205.	6.0	327
3957	Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 852-867.	7.7	132
3958	Immune Checkpoint Inhibitors for Brain Metastases. <i>Current Oncology Reports</i> , 2017, 19, 38.	1.8	18
3959	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet, The</i> , 2017, 389, 2492-2502.	6.3	3,224
3960	NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 420-425.	0.6	61
3961	Integrative epigenetic and genetic pan-cancer somatic alteration portraits. <i>Epigenetics</i> , 2017, 12, 561-574.	1.3	18
3962	Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas. <i>Cancer Research</i> , 2017, 77, 3982-3989.	0.4	294
3963	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. <i>Clinical Cancer Research</i> , 2017, 23, 4938-4944.	3.2	120
3964	Very low expression of PD-L1 in medullary thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2017, 24, L35-L38.	1.6	34
3965	Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. <i>CNS Oncology</i> , 2017, 6, 139-151.	1.2	12
3966	Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 271-280.	1.4	15

#	ARTICLE	IF	CITATIONS
3967	Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1701-1712.	1.2	40
3968	Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2017, 22, 690-697.	1.0	20
3969	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. <i>Genome Medicine</i> , 2017, 9, 34.	3.6	2,480
3970	Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. <i>Protein and Cell</i> , 2017, 8, 573-589.	4.8	67
3971	Network-aided Bi-Clustering for discovering cancer subtypes. <i>Scientific Reports</i> , 2017, 7, 1046.	1.6	17
3972	Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes. <i>Annals of Oncology</i> , 2017, 28, 1678-1679.	0.6	27
3973	Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2698-2706.	0.7	24
3974	Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. <i>Annals of Oncology</i> , 2017, 28, 1658-1666.	0.6	26
3975	Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. <i>RMD Open</i> , 2017, 3, e000412.	1.8	161
3976	Nivolumab induced myxedema crisis. , 2017, 5, 13.		48
3977	Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 131-137.	1.0	10
3978	History and current state of immunotherapy in glioma and brain metastasis. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 347-368.	1.4	59
3979	New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. <i>Critical Care</i> , 2017, 21, 89.	2.5	340
3980	Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. <i>Oncologist</i> , 2017, 22, 700-708.	1.9	11
3981	Association Study Confirmed Three Breast Cancer-Specific Molecular Subtype-Associated Susceptibility Loci in Chinese Han Women. <i>Oncologist</i> , 2017, 22, 890-894.	1.9	14
3982	Indicators of responsiveness to immune checkpoint inhibitors. <i>Scientific Reports</i> , 2017, 7, 807.	1.6	70
3983	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , 2017, 5, 417-424.	1.6	400
3984	WNT Signaling and Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 101-110.	1.0	222

#	ARTICLE	IF	CITATIONS
3985	Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. <i>Annals of Oncology</i> , 2017, 28, 1388-1398.	0.6	70
3986	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. <i>Cancer Journal (Sudbury, Tj ETQq1 1 0,784314 rgBT /Ove</i>	1.0	8
3987	miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. <i>Genes and Development</i> , 2017, 31, 553-566.	2.7	87
3988	Extracellular Regulation of the Mitotic Spindle and Fate Determinants Driving Asymmetric Cell Division. <i>Results and Problems in Cell Differentiation</i> , 2017, 61, 351-373.	0.2	10
3989	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. <i>Lung Cancer</i> , 2017, 109, 1-8.	0.9	27
3990	Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy. <i>Cellular and Molecular Immunology</i> , 2017, 14, 809-818.	4.8	52
3991	Dramatic response of metaplastic breast cancer to chemo-immunotherapy. <i>Npj Breast Cancer</i> , 2017, 3, 8.	2.3	60
3992	Applied Cancer Immunogenomics. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 125-130.	1.0	16
3993	Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer. <i>Oncology Reports</i> , 2017, 37, 2603-2610.	1.2	38
3994	Adjuvant Therapy for Melanoma. <i>Current Oncology Reports</i> , 2017, 19, 36.	1.8	26
3995	Ribociclib: First Global Approval. <i>Drugs</i> , 2017, 77, 799-807.	4.9	69
3996	Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. <i>Annals of Oncology</i> , 2017, 28, 874-881.	0.6	197
3997	Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 32 TCGA cancer types. <i>Nucleic Acids Research</i> , 2017, 45, 2973-2985.	6.5	158
3998	Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e464-e469.	1.3	62
3999	A murine preclinical syngeneic transplantation model for breast cancer precision medicine. <i>Science Advances</i> , 2017, 3, e1600957.	4.7	10
4000	CLImAT-HET: detecting subclonal copy number alterations and loss of heterozygosity in heterogeneous tumor samples from whole-genome sequencing data. <i>BMC Medical Genomics</i> , 2017, 10, 15.	0.7	19
4001	Current status of research and treatment for non-small cell lung cancer in never-smoking females. <i>Cancer Biology and Therapy</i> , 2017, 18, 359-368.	1.5	66
4002	Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery. <i>Cancer Discovery</i> , 2017, 7, 561-574.	7.7	33

#	ARTICLE	IF	CITATIONS
4003	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	3.4	219
4004	Post-chemotherapy PD-L1 expression correlates with clinical outcomes in Japanese bladder cancer patients treated with total cystectomy. <i>Medical Oncology</i> , 2017, 34, 117.	1.2	7
4005	Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis. <i>Cell Death and Disease</i> , 2017, 8, e2779-e2779.	2.7	114
4006	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017, 13, 363-374.	4.9	125
4007	Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. <i>Cancer Biology and Therapy</i> , 2017, 18, 369-378.	1.5	31
4008	PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 253-267.	1.4	78
4009	Mechanisms of Immune Tolerance in Leukemia and Lymphoma. <i>Trends in Immunology</i> , 2017, 38, 513-525.	2.9	86
4010	Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients. <i>Cancer Gene Therapy</i> , 2017, 24, 277-281.	2.2	18
4011	Immunotherapy is different: Implications for vaccine clinical trial design. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2179-2184.	1.4	1
4012	Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 105.	6.9	129
4013	IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1049-1058.	2.0	32
4014	Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 627-638.	1.1	21
4015	Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. <i>Journal of Neuro-Oncology</i> , 2017, 133, 561-569.	1.4	43
4016	Pretreatment neutrophil-to-lymphocyte ratio predicts worse survival outcomes and advanced tumor staging in patients undergoing radical cystectomy for bladder cancer. <i>Asian Journal of Urology</i> , 2017, 4, 239-246.	0.5	14
4017	Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance. <i>Oncology Reports</i> , 2017, 37, 1989-1997.	1.2	8
4018	Immunotherapy for metastatic renal cell carcinoma. <i>The Cochrane Library</i> , 2017, 2017, CD011673.	1.5	31
4019	Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment. <i>Nature Communications</i> , 2017, 8, 15365.	5.8	41
4020	In vivo photolabeling of tumor-infiltrating cells reveals highly regulated egress of T-cell subsets from tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 5677-5682.	3.3	62

#	ARTICLE	IF	CITATIONS
4021	Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State. <i>Cancer Research</i> , 2017, 77, 2564-2569.	0.4	87
4022	What We Know About Stage II and III Colon Cancer: It's Still Not Enough. <i>Targeted Oncology</i> , 2017, 12, 265-275.	1.7	25
4023	Checkpoint inhibition and melanoma: Considerations in treating the older adult. <i>Journal of Geriatric Oncology</i> , 2017, 8, 237-241.	0.5	27
4024	Focus on cutaneous and uveal melanoma specificities. <i>Genes and Development</i> , 2017, 31, 724-743.	2.7	75
4025	Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 287-298.	1.4	4
4026	Immunotherapy in hematologic malignancies: past, present, and future. <i>Journal of Hematology and Oncology</i> , 2017, 10, 94.	6.9	76
4027	Emerging therapies for breast cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 98.	6.9	60
4028	Statistical controversies in clinical research: building the bridge to phase II efficacy estimation in dose-expansion cohorts. <i>Annals of Oncology</i> , 2017, 28, 1427-1435.	0.6	6
4029	Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2713-2722.	3.2	91
4030	The transcription factor GATA3 is required for homologous recombination repair by regulating CtIP expression. <i>Oncogene</i> , 2017, 36, 5168-5176.	2.6	13
4031	p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes. <i>Molecular Cancer Research</i> , 2017, 15, 1051-1062.	1.5	51
4032	Progress in the application and mechanism of metformin in treating non-small cell lung cancer. <i>Oncology Letters</i> , 2017, 13, 2873-2880.	0.8	18
4033	Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1268-1279.	0.5	152
4034	Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4223-E4232.	3.3	121
4035	A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. <i>Cancer Immunology Research</i> , 2017, 5, 468-479.	1.6	117
4036	Expression and function of MutT homolog 1 in distinct subtypes of breast cancer. <i>Oncology Letters</i> , 2017, 13, 2161-2168.	0.8	20
4037	Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. <i>Journal of Molecular Biology</i> , 2017, 429, 1767-1786.	2.0	14
4038	Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN- γ -induced immunologic dormancy of tumor-repopulating cells. <i>Nature Communications</i> , 2017, 8, 15207.	5.8	147

#	ARTICLE	IF	CITATIONS
4039	The RBâ€“IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity. <i>Oncogene</i> , 2017, 36, 5145-5157.	2.6	35
4040	A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1765-1767.	1.4	3
4041	Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. <i>Neuro-Oncology</i> , 2017, 19, 1481-1493.	0.6	32
4042	In vivo imaging reveals a tumor-associated macrophageâ€“mediated resistance pathway in antiâ€“PD-1 therapy. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	466
4043	Checkpoint inhibitors in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2017, 10, 103.	6.9	106
4044	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1113-1121.	2.0	29
4045	The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Gliomaâ€“Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 50.	2.0	10
4046	Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. <i>Cell Reports</i> , 2017, 19, 1189-1201.	2.9	1,256
4047	Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 281-292.	2.1	10
4048	Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. <i>Nature Nanotechnology</i> , 2017, 12, 763-769.	15.6	136
4049	<i>AJRCCM</i> : 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1150-1160.	2.5	75
4050	Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer. <i>Oncology Letters</i> , 2017, 13, 2015-2020.	0.8	3
4051	Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries. <i>Current Opinion in Immunology</i> , 2017, 46, 38-44.	2.4	40
4052	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. <i>Cancer Research</i> , 2017, 77, 2318-2327.	0.4	235
4053	Human Tumor Antigens Yesterday, Today, and Tomorrow. <i>Cancer Immunology Research</i> , 2017, 5, 347-354.	1.6	94
4054	Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. <i>Journal of Hematology and Oncology</i> , 2017, 10, 86.	6.9	64
4055	Immunotherapy in genitourinary malignancies. <i>Journal of Hematology and Oncology</i> , 2017, 10, 95.	6.9	32
4056	Tâ€“cell infiltration and clonality correlate with programmed cell death protein 1 and programmed deathâ€“ligand 1 expression in patients with soft tissue sarcomas. <i>Cancer</i> , 2017, 123, 3291-3304.	2.0	202

#	ARTICLE	IF	CITATIONS
4057	Programmed cell death ligand 1 as a biomarker in head and neck cancer. <i>Cancer Cytopathology</i> , 2017, 125, 529-533.	1.4	1
4058	Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. <i>Journal of Neuro-Oncology</i> , 2017, 133, 331-338.	1.4	107
4059	Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. <i>Cell</i> , 2017, 169, 750-765.e17.	13.5	937
4060	Clinical value of R-spondins in triple-negative and metaplastic breast cancers. <i>British Journal of Cancer</i> , 2017, 116, 1595-1603.	2.9	31
4061	Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity. <i>Npj Breast Cancer</i> , 2017, 3, 14.	2.3	115
4062	Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. <i>Scientific Reports</i> , 2017, 7, 1089.	1.6	19
4063	Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. <i>Journal of Experimental Medicine</i> , 2017, 214, 1679-1690.	4.2	41
4064	Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, 1725-1733.	1.9	196
4065	MiSTIC, an integrated platform for the analysis of heterogeneity in large tumour transcriptome datasets. <i>Nucleic Acids Research</i> , 2017, 45, e122-e122.	6.5	14
4066	CXCL10/CXCR3-Dependent Mobilization of Herpes Simplex Virus-Specific CD8 + T EM and CD8 + T RM Cells within Infected Tissues Allows Efficient Protection against Recurrent Herpesvirus Infection and Disease. <i>Journal of Virology</i> , 2017, 91, .	1.5	40
4067	Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. <i>Clinical Cancer Research</i> , 2017, 23, 4556-4568.	3.2	149
4068	4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. <i>Cancer Immunology Research</i> , 2017, 5, 439-445.	1.6	45
4069	Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer. <i>Molecular Medicine Reports</i> , 2017, 15, 2957-2968.	1.1	9
4070	Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. <i>Nature Communications</i> , 2017, 8, 15081.	5.8	743
4071	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <i>Cancer</i> , 2017, 123, 3285-3290.	2.0	170
4072	A novel molecular diagnostics platform for somatic and germline precision oncology. <i>Molecular Genetics & Genomic Medicine</i> , 2017, 5, 336-359.	0.6	12
4073	The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. <i>Current Treatment Options in Oncology</i> , 2017, 18, 27.	1.3	25
4074	Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 33-42.	6.6	81

#	ARTICLE	IF	CITATIONS
4075	Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. <i>British Journal of Cancer</i> , 2017, 116, 1425-1435.	2.9	76
4076	Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E3766-E3775.	3.3	27
4077	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4993-4998.	3.3	614
4078	NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. <i>Journal of Experimental Medicine</i> , 2017, 214, 1711-1724.	4.2	176
4079	Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	107
4080	Signaling by Antibodies: Recent Progress. <i>Annual Review of Immunology</i> , 2017, 35, 285-311.	9.5	167
4081	Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management. <i>Cancer Research</i> , 2017, 77, 3666-3671.	0.4	93
4082	Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4919-4928.	3.2	74
4083	The use of immunotherapy in the treatment of melanoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 88.	6.9	89
4085	Beyond Correlations, Sensitivities, and Specificities. <i>Academic Radiology</i> , 2017, 24, 1027-1035.	1.3	6
4086	Measurements of metastatic renal cell tumours as determined by diffusion weighted imaging or computed tomography are in close agreement, a pilot study. <i>European Journal of Radiology Open</i> , 2017, 4, 45-49.	0.7	2
4087	Orphan CpG islands define a novel class of highly active enhancers. <i>Epigenetics</i> , 2017, 12, 449-464.	1.3	38
4088	Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations. <i>Annals of Oncology</i> , 2017, 28, 1005-1014.	0.6	71
4089	Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1139-1145.	1.1	63
4090	Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. <i>Journal of Neuro-Oncology</i> , 2017, 133, 277-285.	1.4	39
4091	Genome variation across cancers scales with tissue stiffness - An invasion-mutation mechanism and implications for immune cell infiltration. <i>Current Opinion in Systems Biology</i> , 2017, 2, 103-114.	1.3	50
4092	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49+ Tumor-Initiating Population. <i>Stem Cell Reports</i> , 2017, 8, 1392-1407.	2.3	62
4093	KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1175-1187.	2.0	211

#	ARTICLE	IF	CITATIONS
4094	Phenotypic characterisation of breast cancer: the role of CDC42. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 317-325.	1.1	22
4095	Progress and challenges in the treatment of small cell lung cancer. <i>Medical Oncology</i> , 2017, 34, 110.	1.2	25
4096	Dysfunctional T cell metabolism in the tumor microenvironment. <i>Cytokine and Growth Factor Reviews</i> , 2017, 35, 7-14.	3.2	101
4097	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. <i>Cancer Discovery</i> , 2017, 7, 832-851.	7.7	49
4098	The next generation of immunotherapy: keeping lung cancer in check. <i>Journal of Hematology and Oncology</i> , 2017, 10, 87.	6.9	84
4099	Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 29-39.	1.3	66
4100	Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma. <i>Leukemia</i> , 2017, 31, 1695-1705.	3.3	94
4101	Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory. <i>Journal of Immunology</i> , 2017, 198, 205-217.	0.4	24
4102	Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT. <i>Translational Oncology</i> , 2017, 10, 1-9.	1.7	46
4103	Immunosuppression in liver tumors: opening the portal to effective immunotherapy. <i>Cancer Gene Therapy</i> , 2017, 24, 114-120.	2.2	15
4104	Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations. <i>Cancer Discovery</i> , 2017, 7, 188-201.	7.7	997
4105	CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 185-196.	1.4	71
4106	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. <i>Clinical Cancer Research</i> , 2017, 23, 3035-3044.	3.2	28
4107	Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies. <i>International Journal of Cancer</i> , 2017, 140, 1609-1619.	2.3	16
4108	Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 491-499.	1.1	59
4109	Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia. <i>International Journal of Hematology</i> , 2017, 105, 453-464.	0.7	23
4110	Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. <i>Lancet Oncology</i> , The, 2017, 18, 42-51.	5.1	412
4111	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <i>Lancet Oncology</i> , The, 2017, 18, 31-41.	5.1	845

#	ARTICLE	IF	CITATIONS
4112	Evasion of host immune defenses by human papillomavirus. <i>Virus Research</i> , 2017, 231, 21-33.	1.1	142
4113	Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway. <i>Oncogene</i> , 2017, 36, 2680-2692.	2.6	75
4114	Identification of MYST3 as a novel epigenetic activator of ER α frequently amplified in breast cancer. <i>Oncogene</i> , 2017, 36, 2910-2918.	2.6	44
4115	Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy. <i>DNA Repair</i> , 2017, 56, 16-25.	1.3	84
4116	DNA repair and systemic lupus erythematosus. <i>DNA Repair</i> , 2017, 56, 174-182.	1.3	24
4117	Insufficient antibody validation challenges oestrogen receptor beta research. <i>Nature Communications</i> , 2017, 8, 15840.	5.8	170
4118	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, 911-919.	1.9	95
4119	The interplay between metabolic remodeling and immune regulation in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 1308-1315.	0.6	46
4120	Cancer therapies in HIV cure research. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 96-104.	1.5	19
4121	Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 516-523.	1.6	74
4122	Transcriptional and epigenetic regulation of T cell hyporesponsiveness. <i>Journal of Leukocyte Biology</i> , 2017, 102, 601-615.	1.5	39
4123	Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials. <i>JAMA Oncology</i> , 2017, 3, e171029.	3.4	70
4124	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1977-1984.	1.2	14
4125	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017, 77, 1313-1336.	4.9	39
4126	Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. <i>Journal of Immunotherapy</i> , 2017, 40, 31-35.	1.2	85
4127	PD-L1 Assessment for Targeted Therapy Testing in Cancer: Urgent Need For Realistic Economic and Practice Expectations. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 1-3.	0.6	9
4128	Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. <i>Modern Pathology</i> , 2017, 30, 1204-1212.	2.9	81
4129	Novel therapeutic strategies in the treatment of triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 493-511.	1.4	58

#	ARTICLE	IF	CITATIONS
4130	Secretory pathway Ca ²⁺ -ATPases promote in vitro microcalcifications in breast cancer cells. <i>Molecular Carcinogenesis</i> , 2017, 56, 2474-2485.	1.3	28
4131	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , 2017, 11, 317-370.	1.9	1,537
4132	Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lung. <i>International Cancer Conference Journal</i> , 2017, 6, 131-134.	0.2	3
4133	PSIP1/p75 promotes tumorigenicity in breast cancer cells by promoting the transcription of cell cycle genes. <i>Carcinogenesis</i> , 2017, 38, 966-975.	1.3	25
4134	The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw283.	3.0	182
4135	PD-L1 Expression in Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw304.	3.0	43
4136	Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes. <i>Immunology</i> , 2017, 152, 175-184.	2.0	82
4137	A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1359-1366.	2.0	29
4138	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. <i>Targeted Oncology</i> , 2017, 12, 563-569.	1.7	71
4139	Antibody blood-brain barrier efflux is modulated by glycan modification. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 2228-2239.	1.1	17
4140	B cell regulation in cancer and anti-tumor immunity. <i>Cellular and Molecular Immunology</i> , 2017, 14, 662-674.	4.8	427
4141	Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. <i>Current Oncology Reports</i> , 2017, 19, 45.	1.8	70
4142	Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. <i>Immunologic Research</i> , 2017, 65, 880-887.	1.3	55
4143	Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon?. <i>EPMA Journal</i> , 2017, 8, 119-127.	3.3	47
4144	Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 823-834.	2.8	65
4145	Chromatin states define tumour-specific T cell dysfunction and reprogramming. <i>Nature</i> , 2017, 545, 452-456.	13.7	643
4146	RNA-Seq based genome-wide analysis reveals loss of inter-chromosomal regulation in breast cancer. <i>Scientific Reports</i> , 2017, 7, 1760.	1.6	69
4147	Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. <i>Oncologist</i> , 2017, 22, 680-693.	1.9	23

#	ARTICLE	IF	CITATIONS
4148	Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. <i>Oncologist</i> , 2017, 22, 709-718.	1.9	221
4149	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. <i>Cancer Cell</i> , 2017, 31, 820-832.e3.	7.7	433
4150	Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. <i>Cancer Biology and Therapy</i> , 2017, 18, 451-469.	1.5	35
4151	Enhancing identification of cancer types via lowly-expressed microRNAs. <i>Nucleic Acids Research</i> , 2017, 45, 5048-5060.	6.5	14
4152	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. <i>Oncologist</i> , 2017, 22, 963-971.	1.9	145
4153	Enabling a genetically informed approach to cancer medicine: evaluation of the impact of comprehensive tumor sequencing. <i>Personalized Medicine</i> , 2017, 14, 189-192.	0.8	0
4154	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. <i>British Journal of Cancer</i> , 2017, 116, 1558-1563.	2.9	91
4155	Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. <i>Oncolimmunology</i> , 2017, 6, e1329071.	2.1	85
4156	Assessment of nivolumab benefitâ€“risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. <i>Annals of Oncology</i> , 2017, 28, 2002-2008.	0.6	152
4157	Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers. <i>Oncology Letters</i> , 2017, 13, 4708-4712.	0.8	40
4158	Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial. <i>Annals of Oncology</i> , 2017, 28, 1832-1835.	0.6	36
4159	Dynamics of the cell-mediated immune response to tumour growth. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2017, 375, 20160291.	1.6	20
4160	Integrated Theory-and Data-Driven Feature Selection in Gene Expression Data Analysis. , 2017, 2017, 1525-1532.		20
4161	Evaluation of dosing strategy for pembrolizumab for oncology indications. , 2017, 5, 43.		189
4162	The BRG1 ATPase of human SWI/SNF chromatin remodeling enzymes as a driver of cancer. <i>Epigenomics</i> , 2017, 9, 919-931.	1.0	108
4163	Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1560-1566.	2.8	73
4164	Immunogenomics: using genomics to personalize cancer immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 209-219.	1.4	7
4165	Hallmarks of response to immune checkpoint blockade. <i>British Journal of Cancer</i> , 2017, 117, 1-7.	2.9	194

#	ARTICLE	IF	CITATIONS
4166	Anticancer effects of the microbiome and its products. <i>Nature Reviews Microbiology</i> , 2017, 15, 465-478.	13.6	399
4167	Advancing Immunotherapy in Metastatic Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 35.	1.3	13
4168	Delivering safer immunotherapies for cancer. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 79-101.	6.6	233
4169	Combinatorial drug delivery approaches for immunomodulation. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 161-174.	6.6	42
4170	PI3K-p110 α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85 β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7095-7100.	3.3	75
4171	Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer. <i>Medicine (United States)</i> , 2017, 96, e5582.	0.4	13
4172	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2770-2780.	1.8	210
4173	Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma. <i>Oncologist</i> , 2017, 22, 749-753.	1.9	38
4174	Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and) T ₁₋₂ N ₀₋₁ M ₀ Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1082-1089.	1.9	82
4175	Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. <i>Oncologist</i> , 2017, 22, 1086-1093.	1.9	77
4176	Clinical analysis of bevacizumab targeting therapy in treating early colorectal carcinoma after operation. <i>Oncology Letters</i> , 2017, 13, 4675-4678.	0.8	2
4177	CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients. <i>British Journal of Cancer</i> , 2017, 117, 385-397.	2.9	77
4178	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2415-2426.	13.9	2,145
4179	Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001677.	0.5	14
4180	DNA Damage and Repair Biomarkers of Immunotherapy Response. <i>Cancer Discovery</i> , 2017, 7, 675-693.	7.7	519
4181	Molecular genetics complexity impeding research progress in breast and ovarian cancers. <i>Molecular and Clinical Oncology</i> , 2017, 7, 3-14.	0.4	12
4182	Targeting the duality of cancer. <i>Npj Precision Oncology</i> , 2017, 1, .	2.3	39
4183	Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8 ⁺ T Cells. <i>Cancer Immunology Research</i> , 2017, 5, 630-641.	1.6	50

#	ARTICLE	IF	CITATIONS
4184	Allelic imbalance of somatic mutations in cancer genomes and transcriptomes. <i>Scientific Reports</i> , 2017, 7, 1653.	1.6	31
4185	PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 882-889.	0.6	105
4186	Immunotherapy for Breast Cancer: What Are We Missing?. <i>Clinical Cancer Research</i> , 2017, 23, 2640-2646.	3.2	176
4187	LincIN, a novel NF90-binding long non-coding RNA, is overexpressed in advanced breast tumors and involved in metastasis. <i>Breast Cancer Research</i> , 2017, 19, 62.	2.2	36
4188	Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. <i>Targeted Oncology</i> , 2017, 12, 301-308.	1.7	66
4189	Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. <i>Clinical and Translational Oncology</i> , 2017, 19, 1478-1488.	1.2	46
4190	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 863-873.	5.1	561
4191	Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. <i>Cancer Treatment Reviews</i> , 2017, 58, 22-33.	3.4	76
4192	A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. <i>Neoplasia</i> , 2017, 19, 530-536.	2.3	71
4193	Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. <i>Molecular Therapy</i> , 2017, 25, 1917-1932.	3.7	50
4194	A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). <i>British Journal of Cancer</i> , 2017, 117, 33-40.	2.9	104
4195	Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. <i>British Journal of Cancer</i> , 2017, 117, 203-209.	2.9	38
4196	A molecular portrait of microsatellite instability across multiple cancers. <i>Nature Communications</i> , 2017, 8, 15180.	5.8	480
4197	GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis. <i>Oncogene</i> , 2017, 36, 5567-5575.	2.6	40
4198	An engineering design approach to systems biology. <i>Integrative Biology (United Kingdom)</i> , 2017, 9, 574-583.	0.6	22
4199	Treatment strategies for DNA repair-deficient prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 889-898.	1.3	26
4200	Correlation of immune phenotype with IDH mutation in diffuse glioma. <i>Neuro-Oncology</i> , 2017, 19, 1460-1468.	0.6	213
4201	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	6.0	4,945

#	ARTICLE	IF	CITATIONS
4202	Combined immune checkpoint blockade as a therapeutic strategy for <i>BRCA1</i> -mutated breast cancer. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	227
4203	Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. <i>Clinical Cancer Research</i> , 2017, 23, 4671-4679.	3.2	110
4204	Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth <i>In Vitro</i> and <i>In Vivo</i> By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1470-1486.	1.9	53
4205	Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated ¹⁸ F-Fluorodeoxyglucose (¹⁸ F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study. <i>BMC Cancer</i> , 2017, 17, 392.	1.1	14
4206	Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets. <i>Journal of Biomedical Science</i> , 2017, 24, 35.	2.6	88
4207	Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. <i>Molecular Cancer</i> , 2017, 16, 99.	7.9	129
4208	Molecular characterization of breast cancer cell lines through multiple omic approaches. <i>Breast Cancer Research</i> , 2017, 19, 65.	2.2	67
4209	Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 66.	2.2	32
4210	Precision medicine for hepatocellular carcinoma using molecular pattern diagnostics: results from a preclinical pilot study. <i>Cell Death and Disease</i> , 2017, 8, e2867-e2867.	2.7	8
4211	Autophagy in natural and therapy-driven anticancer immunosurveillance. <i>Autophagy</i> , 2017, 13, 2163-2170.	4.3	52
4212	Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. , 2017, 5, 23.		118
4213	Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 9.	3.6	30
4214	The Transcriptional Landscape of p53 Signalling Pathway. <i>EBioMedicine</i> , 2017, 20, 109-119.	2.7	47
4215	A novel combination strategy for effectively targeting cancer stem-like cells. <i>Immunology and Cell Biology</i> , 2017, 95, 573-574.	1.0	3
4216	A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. <i>Nature Methods</i> , 2017, 14, 737-742.	9.0	105
4217	PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. <i>Nature Neuroscience</i> , 2017, 20, 917-926.	7.1	148
4218	Unravelling the biology of SCLC: implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 549-561.	12.5	336
4219	Wnt/beta-catenin pathway: modulating anticancer immune response. <i>Journal of Hematology and Oncology</i> , 2017, 10, 101.	6.9	448

#	ARTICLE	IF	CITATIONS
4220	Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. Current Treatment Options in Oncology, 2017, 18, 33.	1.3	13
4221	Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 2017, 18, 36.	1.3	14
4222	A case of cystitis after administration of nivolumab. International Cancer Conference Journal, 2017, 6, 164-166.	0.2	22
4223	Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncology, The, 2017, 18, 895-903.	5.1	872
4224	Therapeutic T cell engineering. Nature, 2017, 545, 423-431.	13.7	622
4225	B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clinical Cancer Research, 2017, 23, 5202-5209.	3.2	99
4226	Going beyond genetics to discover cancer targets. Genome Biology, 2017, 18, 95.	3.8	2
4227	The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nature Communications, 2017, 8, 15129.	5.8	271
4228	A Joint Bayesian Model for Integrating Microarray and RNA Sequencing Transcriptomic Data. Journal of Computational Biology, 2017, 24, 647-662.	0.8	23
4229	Molecular heterogeneity at the network level: high-dimensional testing, clustering and a TCGA case study. Bioinformatics, 2017, 33, 2890-2896.	1.8	13
4230	Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Research, 2017, 27, 358-368.	0.6	20
4231	Clinical applications of PD-L1 bioassays for cancer immunotherapy. Journal of Hematology and Oncology, 2017, 10, 110.	6.9	66
4232	Myeloid-derived suppressor cells—a new therapeutic target to overcome resistance to cancer immunotherapy. Journal of Leukocyte Biology, 2017, 102, 727-740.	1.5	88
4233	Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer, 2017, 123, 2143-2153.	2.0	119
4234	Interaction of molecular alterations with immune response in melanoma. Cancer, 2017, 123, 2130-2142.	2.0	24
4235	Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. Modern Pathology, 2017, 30, 1086-1099.	2.9	63
4236	Combining radiotherapy with immunotherapy: the past, the present and the future. British Journal of Radiology, 2017, 90, 20170157.	1.0	99
4237	Gender-related prognostic value and genomic pattern of intra-tumor heterogeneity in colorectal cancer. Carcinogenesis, 2017, 38, 837-846.	1.3	30

#	ARTICLE	IF	CITATIONS
4238	Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies. <i>Journal of Leukocyte Biology</i> , 2017, 102, 393-406.	1.5	55
4239	Centrosome amplification: a suspect in breast cancer and racial disparities. <i>Endocrine-Related Cancer</i> , 2017, 24, T47-T64.	1.6	15
4240	Clinical application of a cancer genomic profiling assay to guide precision medicine decisions. <i>Personalized Medicine</i> , 2017, 14, 309-325.	0.8	22
4241	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1705-1717.	2.5	56
4242	Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. <i>Oncologist</i> , 2017, 22, 631-637.	1.9	91
4243	Genomic landscape of high-grade meningiomas. <i>Npj Genomic Medicine</i> , 2017, 2, .	1.7	130
4244	Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models. <i>Scientific Reports</i> , 2017, 7, 2396.	1.6	62
4245	Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. <i>Scientific Reports</i> , 2017, 7, 2452.	1.6	70
4246	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 904-916.	5.1	427
4247	Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma. <i>Translational Oncology</i> , 2017, 10, 511-517.	1.7	47
4248	Acquired IFN γ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. <i>Nature Communications</i> , 2017, 8, 15440.	5.8	195
4249	Clinical utility of gene-expression signatures in early stage breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 595-610.	12.5	197
4250	Personalized peptide vaccines and their relation to other therapies in urological cancer. <i>Nature Reviews Urology</i> , 2017, 14, 501-510.	1.9	30
4251	Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. <i>Cancer Research</i> , 2017, 77, 3894-3907.	0.4	152
4252	High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. <i>ERJ Open Research</i> , 2017, 3, 00110-2016.	1.1	20
4253	Immunological characterization of a rigid $\hat{I}\pm$ -Tn mimetic on murine iNKT and human NK cells. <i>Glycoconjugate Journal</i> , 2017, 34, 553-562.	1.4	4
4254	Immunotherapy and radiation in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 134, 531-539.	1.4	29
4255	Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. <i>Medical Oncology</i> , 2017, 34, 121.	1.2	12

#	ARTICLE	IF	CITATIONS
4256	Function of the vitamin D endocrine system in mammary gland and breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2017, 453, 88-95.	1.6	51
4257	The Boosting Potential of Bacteria in Cancer Immunotherapy. <i>Trends in Molecular Medicine</i> , 2017, 23, 580-582.	3.5	10
4258	Integrative analysis on histopathological image for identifying cellular heterogeneity. , 2017, 10140, .		0
4259	Mutational Signatures in Breast Cancer: The Problem at the DNA Level. <i>Clinical Cancer Research</i> , 2017, 23, 2617-2629.	3.2	102
4260	AACR Project GENIE: Powering Precision Medicine through an International Consortium. <i>Cancer Discovery</i> , 2017, 7, 818-831.	7.7	1,235
4261	Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 403-414.	0.8	103
4262	Primary malignant melanoma of esophagus following chemoradiotherapy for esophageal squamous cell carcinoma: report of a case. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 336-341.	0.4	8
4263	Targeting the programmed cell death-1 pathway in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2017, 16, 767-773.	2.5	16
4264	Role of Aspirin in Breast Cancer Survival. <i>Current Oncology Reports</i> , 2017, 19, 48.	1.8	62
4265	DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. <i>Nature Genetics</i> , 2017, 49, 1052-1060.	9.4	235
4266	STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC. <i>Journal of Dental Research</i> , 2017, 96, 1027-1034.	2.5	147
4267	A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data. <i>Breast Cancer Research</i> , 2017, 19, 63.	2.2	3
4268	Glioblastoma targeted therapy: updated approaches from recent biological insights. <i>Annals of Oncology</i> , 2017, 28, 1457-1472.	0.6	314
4269	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2017, 28, 1988-1995.	0.6	326
4270	CloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens. <i>Bioinformatics</i> , 2017, 33, 3110-3112.	1.8	51
4271	Pembrolizumab-induced pneumonitis. <i>ERJ Open Research</i> , 2017, 3, 00081-2016.	1.1	35
4272	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. <i>Oncologist</i> , 2017, 22, 627-630.	1.9	74
4273	Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	49

#	ARTICLE	IF	CITATIONS
4274	Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an <i>STK11</i> variant. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a000778.	0.5	20
4275	Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5561-5572.	3.2	198
4276	Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 431-439.	1.4	73
4277	New insights into the role of <i>EMT</i> in tumor immune escape. <i>Molecular Oncology</i> , 2017, 11, 824-846.	2.1	332
4278	PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation. <i>International Journal of Cancer</i> , 2017, 141, 1402-1412.	2.3	175
4279	Advancing Immune and Cell-Based Therapies Through Imaging. <i>Molecular Imaging and Biology</i> , 2017, 19, 379-384.	1.3	20
4280	Immunotherapy for Esophageal Squamous Cell Carcinoma. <i>Current Oncology Reports</i> , 2017, 19, 33.	1.8	53
4281	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , 2017, 18, 599-610.	5.1	257
4282	Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. <i>European Urology</i> , 2017, 72, 354-365.	0.9	195
4283	Wnt signaling in triple-negative breast cancer. <i>Oncogenesis</i> , 2017, 6, e310-e310.	2.1	217
4284	Immunotherapy resistance: the answers lie ahead “not in front” of us. , 2017, 5, 10.		13
4285	Targeted Therapies for Melanoma Brain Metastases. <i>Current Treatment Options in Neurology</i> , 2017, 19, 13.	0.7	28
4286	Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 463-482.	12.5	945
4287	CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. <i>Nucleic Acids Research</i> , 2017, 45, 6698-6716.	6.5	114
4288	Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. <i>Neuro-Oncology</i> , 2017, 19, 1047-1057.	0.6	325
4289	Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment. <i>Thoracic Cancer</i> , 2017, 8, 275-277.	0.8	17
4290	Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014. <i>JAMA Surgery</i> , 2017, 152, 672.	2.2	57
4292	Breast cancer in Asian Americans in California, 1988–2013: increasing incidence trends and recent data on breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 139-147.	1.1	77

#	ARTICLE	IF	CITATIONS
4293	Milestones in the systemic treatment of lung cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 22-26.	0.3	8
4294	Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies. Drugs, 2017, 77, 843-857.	4.9	40
4295	Quantitative magnetic resonance imaging biomarkers in oncological clinical trials: Current techniques and standardization challenges. Chronic Diseases and Translational Medicine, 2017, 3, 8-20.	0.9	9
4296	Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. Cell Reports, 2017, 19, 203-217.	2.9	454
4297	Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 559-564.	1.1	12
4298	Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation. Clinical and Translational Radiation Oncology, 2017, 2, 29-35.	0.9	27
4299	The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas. European Urology Focus, 2017, 3, 584-589.	1.6	17
4300	Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report. Respiratory Medicine Case Reports, 2017, 20, 95-97.	0.2	11
4301	Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. Journal of Experimental Medicine, 2017, 214, 1029-1047.	4.2	39
4302	Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 575-582.	1.4	20
4303	Diagnosis and Treatment of Kaposi Sarcoma. American Journal of Clinical Dermatology, 2017, 18, 529-539.	3.3	98
4304	Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacological Research, 2017, 120, 1-9.	3.1	46
4305	Emerging and investigational therapies for neuroblastoma. Expert Opinion on Orphan Drugs, 2017, 5, 355-368.	0.5	27
4306	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery, 2017, 7, 596-609.	7.7	490
4307	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. BMC Medicine, 2017, 15, 55.	2.3	65
4308	Development of CAR T cells designed to improve antitumor efficacy and safety. , 2017, 178, 83-91.		90
4309	Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries. British Journal of Cancer, 2017, 116, 1088-1091.	2.9	7
4310	Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. Scientific Reports, 2017, 7, 45124.	1.6	72

#	ARTICLE	IF	CITATIONS
4311	Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. <i>BMC Cancer</i> , 2017, 17, 210.	1.1	59
4312	Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. , 2017, 5, 3.		44
4313	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
4314	Detecting gene signature activation in breast cancer in an absolute, single-patient manner. <i>Breast Cancer Research</i> , 2017, 19, 32.	2.2	8
4315	A key to the backdoor into the castle: The clinical ramifications of immunoediting driven by antigenic competition. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1579-1585.	1.4	0
4316	Immunotherapy in malignant melanoma: recent approaches and new perspectives. <i>Melanoma Management</i> , 2017, 4, 39-48.	0.1	7
4317	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. <i>British Journal of Cancer</i> , 2017, 116, 1141-1147.	2.9	112
4318	T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. <i>Laboratory Investigation</i> , 2017, 97, 669-697.	1.7	167
4319	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. <i>Modern Pathology</i> , 2017, 30, 952-963.	2.9	50
4320	A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. <i>Nature Communications</i> , 2017, 8, 14802.	5.8	168
4321	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017, 28, 1436-1447.	0.6	249
4322	Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. <i>Neuro-Oncology</i> , 2017, 19, 1058-1067.	0.6	38
4323	CD8 T cell regulation by T regulatory cells and the programmed cell death protein 1 pathway. <i>Immunology</i> , 2017, 151, 146-153.	2.0	12
4324	Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4347-4353.	3.2	26
4325	HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. <i>Clinical Cancer Research</i> , 2017, 23, 4323-4334.	3.2	64
4326	Cancer immunotherapies targeting the PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2017, 24, 26.	2.6	501
4327	Biomarkers to predict prognosis and response to checkpoint inhibitors. <i>International Journal of Clinical Oncology</i> , 2017, 22, 629-634.	1.0	57
4328	Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 792-802.	5.1	203

#	ARTICLE	IF	CITATIONS
4329	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. <i>Annals of Oncology</i> , 2017, 28, 1036-1041.	0.6	207
4330	<sc>UV</sc>-induced somatic mutations elicit a functional T cell response in the <sc>YUMMER</sc> 1.7 mouse melanoma model. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 428-435.	1.5	143
4331	Renal cell carcinoma: new insights and challenges for a clinician scientist. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F145-F154.	1.3	46
4332	<i>In vivo</i> models in breast cancer research: progress, challenges and future directions. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 359-371.	1.2	131
4333	Emerging molecular therapeutic targets for cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017, 67, 632-644.	1.8	150
4334	ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. <i>Molecular Pharmaceutics</i> , 2017, 14, 1782-1789.	2.3	84
4335	CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. <i>Scientific Reports</i> , 2017, 7, 737.	1.6	543
4336	PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer. <i>Scientific Reports</i> , 2017, 7, 46209.	1.6	41
4337	Computational approach for deriving cancer progression roadmaps from static sample data. <i>Nucleic Acids Research</i> , 2017, 45, gkx003.	6.5	13
4338	High number of kinase mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival. <i>International Journal of Cancer</i> , 2017, 141, 184-190.	2.3	14
4339	The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 67-77.	3.3	112
4340	Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. <i>Lung Cancer</i> , 2017, 108, 205-211.	0.9	42
4341	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	1.7	120
4342	Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. <i>Scientific Reports</i> , 2017, 7, 738.	1.6	12
4343	A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2017, 7, 45828.	1.6	21
4344	Immune checkpoint dysfunction in large and medium vessel vasculitis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 312, H1052-H1059.	1.5	85
4345	Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4493-4500.	3.2	15
4346	Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. <i>Clinical Cancer Research</i> , 2017, 23, 4429-4440.	3.2	142

#	ARTICLE	IF	CITATIONS
4347	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. <i>Drugs and Aging</i> , 2017, 34, 331-357.	1.3	7
4348	An Anti-Programmed Death-1 Antibody (Î±PD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional Î±PD-1 Nanoparticle. <i>Molecular Pharmaceutics</i> , 2017, 14, 1494-1500.	2.3	26
4349	Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. <i>Nature Communications</i> , 2017, 8, 14754.	5.8	268
4350	Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients. <i>Scientific Reports</i> , 2017, 7, 45283.	1.6	45
4351	Lipinâ€1 regulation of phospholipid synthesis maintains endoplasmic reticulum homeostasis and is critical for tripleâ€negative breast cancer cell survival. <i>FASEB Journal</i> , 2017, 31, 2893-2904.	0.2	44
4352	Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. <i>Clinical Cancer Research</i> , 2017, 23, 4242-4250.	3.2	704
4353	Nivolumab in renal cell carcinoma: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 171-181.	1.4	52
4354	Body mass and cancer: genetics, endocrinologyâ€ and more. <i>Future Science OA</i> , 2017, 3, FSO170.	0.9	0
4355	PD-L2: A prognostic marker in chromophobe renal cell carcinoma?. <i>Medical Oncology</i> , 2017, 34, 71.	1.2	17
4356	Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 1035-1046.	1.7	7
4357	Enhanced Degradation of Misfolded Proteins Promotes Tumorigenesis. <i>Cell Reports</i> , 2017, 18, 3143-3154.	2.9	83
4358	Radiobiology of stereotactic body radiation therapy (SBRT). <i>Reports of Practical Oncology and Radiotherapy</i> , 2017, 22, 86-95.	0.3	52
4359	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. <i>Nature Communications</i> , 2017, 8, 14864.	5.8	112
4360	Prognostic value of CA20, a score based on centrosome amplification-associated genes, in breast tumors. <i>Scientific Reports</i> , 2017, 7, 262.	1.6	32
4361	Cancer Immunotherapy: Whence and Whither. <i>Molecular Cancer Research</i> , 2017, 15, 635-650.	1.5	30
4362	A Bayesian semiparametric factor analysis model for subtype identification. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2017, 16, 145-158.	0.2	0
4363	Molecular genetic and immunotherapeutic targets in metastatic melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 281-293.	1.4	16
4364	Role of TIM-3 in ovarian cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 1079-1083.	1.2	20

#	ARTICLE	IF	CITATIONS
4365	Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone. <i>Human Gene Therapy</i> , 2017, 28, 493-509.	1.4	17
4366	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 4402-4415.	3.2	91
4367	Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 3251-3262.	3.2	175
4368	Chimeric antigen receptor T cells: a novel therapy for solid tumors. <i>Journal of Hematology and Oncology</i> , 2017, 10, 78.	6.9	232
4369	Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. <i>Breast Cancer Research</i> , 2017, 19, 44.	2.2	85
4370	Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. <i>Future Oncology</i> , 2017, 13, 1263-1279.	1.1	113
4371	Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point ¹⁸ F-FDG PET/CT Imaging in Patients with Advanced Melanoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1421-1428.	2.8	209
4372	A comprehensive analysis of cancer-driving mutations and genes in kidney cancer. <i>Oncology Letters</i> , 2017, 13, 2151-2160.	0.8	4
4373	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. <i>Angiogenesis</i> , 2017, 20, 185-204.	3.7	482
4374	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. <i>Lancet Oncology</i> , The, 2017, 18, 587-598.	5.1	261
4375	Phase I Escalating-Dose Trial of CART Therapy Targeting CEA+ Metastatic Colorectal Cancers. <i>Molecular Therapy</i> , 2017, 25, 1248-1258.	3.7	305
4376	DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. <i>Epigenetics</i> , 2017, 12, 416-432.	1.3	98
4377	An increased neutrophil-to-lymphocyte ratio predicts poorer survival following recurrence for patients with breast cancer. <i>Molecular and Clinical Oncology</i> , 2017, 6, 266-270.	0.4	42
4378	Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 55-66.	3.3	117
4379	Cancer immunotherapy: how low-level ionizing radiation can play a key role. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 819-832.	2.0	49
4380	A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. <i>European Radiology</i> , 2017, 27, 3991-4001.	2.3	92
4381	Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 349-361.	1.1	15
4382	The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities. <i>Targeted Oncology</i> , 2017, 12, 139-152.	1.7	31

#	ARTICLE	IF	CITATIONS
4383	Obstacles Posed by the Tumor Microenvironment to T ^A cell Activity: A Case for Synergistic Therapies. <i>Cancer Cell</i> , 2017, 31, 311-325.	7.7	502
4384	FOXC1: an emerging marker and therapeutic target for cancer. <i>Oncogene</i> , 2017, 36, 3957-3963.	2.6	110
4385	Targeting Lyn regulates Snail family shuttling and inhibits metastasis. <i>Oncogene</i> , 2017, 36, 3964-3975.	2.6	33
4386	Comparing available criteria for measuring brain metastasis response to immunotherapy. <i>Journal of Neuro-Oncology</i> , 2017, 132, 479-485.	1.4	39
4387	Treatment of Relapsed/Refractory Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , 2017, 18, 17.	1.3	179
4388	Glycoproteins in Claudin-Low Breast Cancer Cell Lines Have a Unique Expression Profile. <i>Journal of Proteome Research</i> , 2017, 16, 1391-1400.	1.8	7
4389	The high price of anticancer drugs: origins, implications, barriers, solutions. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 381-390.	12.5	289
4390	MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability. <i>Molecular Cancer</i> , 2017, 16, 55.	7.9	12
4391	Tumor Immunology Viewed from Alternative Animal Models—the Xenopus Story. <i>Current Pathobiology Reports</i> , 2017, 5, 49-56.	1.6	10
4392	Suppressive IL-17A ⁺ Foxp3 ⁺ and ex-Th17 IL-17A ^{neg} Foxp3 ⁺ Treg cells are a source of tumour-associated Treg cells. <i>Nature Communications</i> , 2017, 8, 14649.	5.8	128
4393	Genetics of primary sclerosing cholangitis and pathophysiological implications. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 279-295.	8.2	93
4394	Contemporary update on neoadjuvant therapy for bladder cancer. <i>Nature Reviews Urology</i> , 2017, 14, 348-358.	1.9	24
4395	Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion—A New Role for the AXL Receptor Tyrosine Kinase. <i>Clinical Cancer Research</i> , 2017, 23, 2928-2933.	3.2	59
4396	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. , 2017, 5, 8.		111
4397	Inhibitors of <sc>STAT</sc>3, β -catenin, and <sc>IGF</sc>1R sensitize mouse <sc>PIK</sc>3<sc>CA</sc>-mutant breast cancer to <sc>PI</sc>3K inhibitors. <i>Molecular Oncology</i> , 2017, 11, 552-566.	2.1	25
4398	Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer. <i>Cancer</i> , 2017, 123, 2535-2542.	2.0	33
4399	Immune checkpoint inhibition and its relationship with hypermutation phenotype as a potential treatment for Glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 359-372.	1.4	8
4400	PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. <i>Journal of Experimental Medicine</i> , 2017, 214, 895-904.	4.2	614

#	ARTICLE	IF	CITATIONS
4401	Biological Subtypes of Triple-Negative Breast Cancer. <i>Breast Care</i> , 2017, 12, 8-14.	0.8	85
4402	Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. <i>Journal of Pathology</i> , 2017, 242, 165-177.	2.1	43
4404	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. , 2017, 178, 31-47.		89
4405	NF- κ B-mutated melanoma tumors harbor distinct clinical and biological characteristics. <i>Molecular Oncology</i> , 2017, 11, 438-451.	2.1	112
4406	Immune Checkpoint Inhibitors in Gliomas. <i>Current Oncology Reports</i> , 2017, 19, 23.	1.8	27
4407	Genome-wide in vivo screen identifies host molecule in promoting cancer metastasis. <i>Protein and Cell</i> , 2017, 8, 398-400.	4.8	0
4408	Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. <i>Cancer Research</i> , 2017, 77, 2952-2963.	0.4	86
4409	Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer. <i>Current Opinion in Immunology</i> , 2017, 45, 82-88.	2.4	34
4410	Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 710-718.	2.8	38
4411	Effective combinatorial immunotherapy for castration-resistant prostate cancer. <i>Nature</i> , 2017, 543, 728-732.	13.7	403
4412	Compromised BRCA1-PALB2 interaction is associated with breast cancer risk. <i>Oncogene</i> , 2017, 36, 4161-4170.	2.6	71
4413	Germline Mutations in Triple-Negative Breast Cancer. <i>Breast Care</i> , 2017, 12, 15-19.	0.8	59
4414	Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1312-1318.	3.3	23
4415	PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining. <i>International Journal of Clinical Oncology</i> , 2017, 22, 726-733.	1.0	47
4416	Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitination. <i>Neoplasia</i> , 2017, 19, 346-353.	2.3	71
4417	In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis. <i>Scientific Reports</i> , 2017, 7, 43492.	1.6	23
4418	Heterogeneity assessment of functional T cell avidity. <i>Scientific Reports</i> , 2017, 7, 44320.	1.6	10
4419	Insights into the pathological mechanisms of p85 ^{T315I} mutations using a yeast-based phosphatidylinositol 3-kinase model. <i>Bioscience Reports</i> , 2017, 37, .	1.1	10

#	ARTICLE	IF	CITATIONS
4420	Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. <i>Onc Immunology</i> , 2017, 6, e1305535.	2.1	56
4421	Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia. <i>Cancer Immunology Research</i> , 2017, 5, 376-384.	1.6	106
4422	Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. <i>Biomarker Research</i> , 2017, 5, 12.	2.8	149
4423	Evolution of MHC-based technologies used for detection of antigen-responsive T cells. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 657-666.	2.0	65
4424	Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 529-536.	1.2	128
4425	Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2017, 76, 152-166.	1.3	82
4426	Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape. <i>Journal of Thoracic Oncology</i> , 2017, 12, 943-953.	0.5	136
4427	Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. <i>Nature</i> , 2017, 543, 723-727.	13.7	232
4428	Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 49-57.	1.3	121
4429	Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 180-188.	1.2	647
4430	MicroRNA-6826 and miR-6875 in plasma are valuable non-invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer. <i>Oncology Reports</i> , 2017, 37, 23-30.	1.2	42
4431	The genetic landscape of breast carcinomas with neuroendocrine differentiation. <i>Journal of Pathology</i> , 2017, 241, 405-419.	2.1	52
4432	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. <i>Lancet Oncology</i> , 2017, 18, 52-62.	5.1	225
4433	Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 173, 122-129.	1.2	62
4434	The emerging role of immune checkpoint inhibition in malignant lymphoma. <i>Haematologica</i> , 2017, 102, 30-42.	1.7	101
4436	The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumorigenesis. <i>Journal of Pathology</i> , 2017, 241, 501-510.	2.1	27
4437	Cornerstones of CRISPR-Cas in drug discovery and therapy. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 89-100.	21.5	370
4438	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 583-589.	0.6	510

#	ARTICLE	IF	CITATIONS
4439	Immuno-Oncology: The Third Paradigm in Early Drug Development. <i>Targeted Oncology</i> , 2017, 12, 125-138.	1.7	22
4440	Immunotherapy against cancer-related viruses. <i>Cell Research</i> , 2017, 27, 59-73.	5.7	101
4441	Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 451-460.	2.0	16
4442	Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 115-123.	1.6	8
4443	Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. <i>Annals of Oncology</i> , 2017, 28, 512-518.	0.6	171
4444	Designer vaccine nanodiscs for personalized cancer immunotherapy. <i>Nature Materials</i> , 2017, 16, 489-496.	13.3	817
4445	Driving gene-engineered T cell immunotherapy of cancer. <i>Cell Research</i> , 2017, 27, 38-58.	5.7	232
4446	Immune targets and neoantigens for cancer immunotherapy and precision medicine. <i>Cell Research</i> , 2017, 27, 11-37.	5.7	185
4447	Dendritic cell-based immunotherapy. <i>Cell Research</i> , 2017, 27, 74-95.	5.7	593
4448	Programmed cell death ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC). <i>Thoracic Cancer</i> , 2017, 8, 73-79.	0.8	17
4449	Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 40-48.	1.3	71
4450	Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. <i>Neuro-Oncology</i> , 2017, 19, i1-i24.	0.6	171
4451	Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a029587.	2.9	15
4452	The landscape of new drugs in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 335-346.	12.5	56
4453	Immune Toxicities Elicited by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. <i>Cancer Research</i> , 2017, 77, 1322-1330.	0.4	188
4454	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 264-276.	7.7	706
4455	Rapid PD-L1 detection in tumors with PET using a highly specific peptide. <i>Biochemical and Biophysical Research Communications</i> , 2017, 483, 258-263.	1.0	132
4456	SNP variants at the MAP3K1/SETD9 locus 5q11.2 associate with somatic PIK3CA variants in breast cancers. <i>European Journal of Human Genetics</i> , 2017, 25, 384-387.	1.4	7

#	ARTICLE	IF	CITATIONS
4457	TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)? Head and Neck Pathology, 2017, 11, 354-363.	1.3	67
4458	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical Cancer Research, 2017, 23, 2972-2980.	3.2	106
4459	Topological methods for genomics: Present and future directions. Current Opinion in Systems Biology, 2017, 1, 95-101.	1.3	46
4460	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). Clinical Lung Cancer, 2017, 18, 333-339.	1.1	47
4461	Molecular Pathways: The Necrosome—A Target for Cancer Therapy. Clinical Cancer Research, 2017, 23, 1132-1136.	3.2	35
4462	Nuclear Localized LSR: A Novel Regulator of Breast Cancer Behavior and Tumorigenesis. Molecular Cancer Research, 2017, 15, 165-178.	1.5	23
4463	Melanoma exosomes deliver a complex biological payload that upregulates PTPN 11 to suppress T lymphocyte function. Pigment Cell and Melanoma Research, 2017, 30, 203-218.	1.5	39
4464	Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Investigational New Drugs, 2017, 35, 207-216.	1.2	70
4465	Rapid and partial remission of primary lesion but complicated by secondary fibrosis after treatment with nivolumab in a lung squamous carcinoma. Therapeutic Advances in Respiratory Disease, 2017, 11, 129-132.	1.0	2
4466	Pharmacological and immunological targeting of tumor mesenchymalization. , 2017, 170, 212-225.		14
4467	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. Clinical Genitourinary Cancer, 2017, 15, 31-41.e4.	0.9	31
4468	Peptide vaccines in cancer — old concept revisited. Current Opinion in Immunology, 2017, 45, 1-7.	2.4	94
4469	Post-nano strategies for drug delivery: multistage porous silicon microvectors. Journal of Materials Chemistry B, 2017, 5, 207-219.	2.9	47
4470	Collateral damage: insights into bacterial mechanisms that predispose host cells to cancer. Nature Reviews Microbiology, 2017, 15, 109-128.	13.6	142
4471	Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 580-585.	3.3	296
4472	Immunization against HIF-1 α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells <i>In Vivo</i> . Clinical Cancer Research, 2017, 23, 3396-3404.	3.2	29
4473	Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma. Cancer Immunology Research, 2017, 5, 118-126.	1.6	56
4474	Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunology, Immunotherapy, 2017, 66, 427-440.	2.0	50

#	ARTICLE	IF	CITATIONS
4475	First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2017, 23, 3269-3276.	3.2	244
4476	Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. <i>Liver Cancer</i> , 2017, 6, 1-12.	4.2	60
4477	Immunoplasticity in cutaneous melanoma: beyond pure morphology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 357-369.	1.4	3
4478	Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. <i>British Journal of Cancer</i> , 2017, 116, 324-334.	2.9	35
4479	DNA sequencing technologies: 2006â€“2016. <i>Nature Protocols</i> , 2017, 12, 213-218.	5.5	266
4480	Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 264-272.	21.5	204
4481	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 43-50.	0.5	317
4482	Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion. <i>Clinical Cancer Research</i> , 2017, 23, 2817-2830.	3.2	32
4483	Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 538-546.	2.8	102
4484	Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 1-15.	3.3	215
4485	The Safety of available immunotherapy for the treatment of glioblastoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 277-287.	1.0	19
4486	Regulatory T cells in cancer immunotherapy. <i>Cell Research</i> , 2017, 27, 109-118.	5.7	1,212
4487	RECIST â€” learning from the past to build the future. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 187-192.	12.5	78
4488	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. <i>Oncogene</i> , 2017, 36, 2737-2749.	2.6	34
4489	Rheumatic and Musculoskeletal Immuneâ€“Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. <i>Arthritis Care and Research</i> , 2017, 69, 1751-1763.	1.5	292
4490	Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer. <i>Drugs</i> , 2017, 77, 17-28.	4.9	10
4491	Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. <i>Annals of Oncology</i> , 2017, 28, 673-675.	0.6	87
4492	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 17-28.	1.6	130

#	ARTICLE	IF	CITATIONS
4493	Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy. <i>Immunotherapy</i> , 2017, 9, 71-82.	1.0	5
4494	<scp>PD</scp> â€1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. <i>EMBO Molecular Medicine</i> , 2017, 9, 167-180.	3.3	172
4495	Cancer and inflammation. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2017, 9, e1370.	6.6	166
4496	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet, The</i> , 2017, 389, 255-265.	6.3	3,872
4497	Brain metastasis: Unique challenges and open opportunities. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1867, 49-57.	3.3	110
4498	Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. <i>British Journal of Dermatology</i> , 2017, 176, 1649-1652.	1.4	83
4499	Humanized Mouse Models of Clinical Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 187-215.	9.6	437
4500	The recurrent architecture of tumour initiation, progression and drug sensitivity. <i>Nature Reviews Cancer</i> , 2017, 17, 116-130.	12.8	170
4501	DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio: An Epigenetic Tool to Explore Cancer Inflammation and Outcomes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 328-338.	1.1	62
4502	Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. <i>International Journal of Oncology</i> , 2017, 50, 41-48.	1.4	65
4503	Innate immune signaling and regulation in cancer immunotherapy. <i>Cell Research</i> , 2017, 27, 96-108.	5.7	291
4504	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 84-91.	1.6	126
4505	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017, 8, 1136.	5.8	686
4506	De novo pathway-based biomarker identification. <i>Nucleic Acids Research</i> , 2017, 45, e151-e151.	6.5	48
4507	MHC-I Genotype Restricts the Oncogenic Mutational Landscape. <i>Cell</i> , 2017, 171, 1272-1283.e15.	13.5	307
4508	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. <i>Cell</i> , 2017, 171, 1259-1271.e11.	13.5	968
4509	Regression of an intramedullary spinal cord metastasis with a checkpoint inhibitor: a case report. <i>CNS Oncology</i> , 2017, 6, 275-280.	1.2	14
4510	Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells. <i>Oncology Letters</i> , 2017, 14, 5563-5568.	0.8	3

#	ARTICLE	IF	CITATIONS
4511	Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development. <i>Stem Cells Translational Medicine</i> , 2017, 6, 2115-2125.	1.6	232
4512	Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. <i>British Journal of Cancer</i> , 2017, 117, 1753-1760.	2.9	40
4513	Humanized mouse model supports development, function, and tissue residency of human natural killer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9626-E9634.	3.3	138
4514	T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. <i>Cancer Immunology Research</i> , 2017, 5, 978-991.	1.6	170
4515	Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy. <i>Transfusion Medicine and Hemotherapy</i> , 2017, 44, 337-350.	0.7	21
4516	Metastatic melanoma imaging using a novel Tc-99m-labeled lactam-cyclized alpha-MSH peptide. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4952-4955.	1.0	5
4517	Small-cell lung cancer: what we know, what we need to know and the path forward. <i>Nature Reviews Cancer</i> , 2017, 17, 725-737.	12.8	558
4518	Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma. <i>Scientific Reports</i> , 2017, 7, 14049.	1.6	37
4519	Antibody Isotypes for Tumor Immunotherapy. <i>Transfusion Medicine and Hemotherapy</i> , 2017, 44, 320-326.	0.7	45
4520	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 1133-1140.	1.6	114
4521	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. <i>Lung Cancer</i> , 2017, 111, 108-115.	0.9	11
4522	Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy. <i>Molecular Pharmaceutics</i> , 2017, 14, 4551-4559.	2.3	30
4523	Ipilimumab-Induced Enteritis without Colitis: A New Challenge. <i>Case Reports in Oncology</i> , 2017, 9, 705-713.	0.3	41
4524	<i>ALK</i> Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. <i>Oncologist</i> , 2017, 22, 1444-1450.	1.9	81
4525	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017, 18, e653-e706.	5.1	153
4526	Lunatic Fringe and p53 Cooperatively Suppress Mesenchymal Stem-Like Breast Cancer. <i>Neoplasia</i> , 2017, 19, 885-895.	2.3	10
4527	Modulation of antigen presenting cell functions during chronic HPV infection. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 4, 58-65.	4.5	48
4528	Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. <i>Seminars in Immunology</i> , 2017, 34, 114-122.	2.7	29

#	ARTICLE	IF	CITATIONS
4529	Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CART Cells against Metastatic Head and Neck Cancer. <i>Molecular Therapy</i> , 2017, 25, 2440-2451.	3.7	151
4530	Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach. <i>Bioconjugate Chemistry</i> , 2017, 28, 2756-2771.	1.8	36
4531	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. <i>Nature Communications</i> , 2017, 8, 707.	5.8	123
4532	Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7596-7607.	3.2	14
4533	Obstruction of BRAFV600E transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth. <i>Cancer Gene Therapy</i> , 2017, 24, 401-408.	2.2	1
4534	Impaired polyfunctionality of CD8+ T cells in severe sepsis patients with human cytomegalovirus reactivation. <i>Experimental and Molecular Medicine</i> , 2017, 49, e382-e382.	3.2	27
4535	PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung. <i>Radiology and Oncology</i> , 2017, 51, 357-362.	0.6	40
4536	A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry. <i>Future Science OA</i> , 2017, 3, FSO244.	0.9	24
4537	Vitamin D Receptor Signaling and Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, 1009-1038.	1.2	52
4538	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. <i>ESMO Open</i> , 2017, 2, e000236.	2.0	30
4539	Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 5729-5736.	3.2	172
4540	Correlation between Tumor-Infiltrating Lymphocytes and Pathological Response in Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy in H. Adam Malik General Hospital. <i>Case Reports in Oncology</i> , 2017, 10, 699-705.	0.3	2
4541	Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management (Review). <i>Oncology Letters</i> , 2017, 14, 5671-5680.	0.8	54
4542	In vivo Confocal Microscopy in Differentiating Ipilimumab-Induced Anterior Uveitis from Metastatic Uveal Melanoma. <i>Case Reports in Ophthalmology</i> , 2017, 7, 404-409.	0.3	16
4543	Unusually high levels of serum p53 antibody in recurrent gastric cancer. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 503-507.	0.4	1
4544	Radiomics: the bridge between medical imaging and personalized medicine. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 749-762.	12.5	3,216
4545	Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity. <i>Advanced Materials</i> , 2017, 29, 1703969.	11.1	392
4546	Combating subclonal evolution of resistant cancer phenotypes. <i>Nature Communications</i> , 2017, 8, 1231.	5.8	124

#	ARTICLE	IF	CITATIONS
4547	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. <i>Nature Communications</i> , 2017, 8, 1197.	5.8	77
4548	Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling. <i>Nature Communications</i> , 2017, 8, 1186.	5.8	78
4549	The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. <i>Science Advances</i> , 2017, 3, eaao5268.	4.7	38
4550	Current challenges in the management of follicular lymphoma. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 13-24.	0.7	1
4551	Mapping genomic and transcriptomic alterations spatially in epithelial cells adjacent to human breast carcinoma. <i>Nature Communications</i> , 2017, 8, 1245.	5.8	14
4552	Immune checkpoint inhibitors in renal cell carcinoma. <i>Clinical Science</i> , 2017, 131, 2627-2642.	1.8	62
4553	A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 6468-6477.	3.2	48
4554	Has the melanoma information tsunami become a maelstrom?. <i>Melanoma Management</i> , 2017, 4, 179-182.	0.1	0
4555	Triple-negative breast cancer and the potential for targeted therapy. <i>Pharmacogenomics</i> , 2017, 18, 1595-1609.	0.6	165
4556	Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion. <i>Oncology Letters</i> , 2017, 14, 6829-6832.	0.8	3
4557	Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth. <i>ACS Nano</i> , 2017, 11, 10135-10146.	7.3	84
4558	New perspectives for targeting RAF kinase in human cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 676-691.	12.8	285
4559	Fractional Laser Releases Tumor-Associated Antigens in Poorly Immunogenic Tumor and Induces Systemic Immunity. <i>Scientific Reports</i> , 2017, 7, 12751.	1.6	12
4560	The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy. <i>Lasers in Medical Science</i> , 2017, 32, 1935-1939.	1.0	2
4561	Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. <i>Cancer Cell</i> , 2017, 32, 506-519.e5.	7.7	240
4562	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017, 171, 540-556.e25.	13.5	1,742
4563	IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. <i>Cancer Research</i> , 2017, 77, 6667-6678.	0.4	126
4564	Guidelines for the use of flow cytometry and cell sorting in immunological studies [*] . <i>European Journal of Immunology</i> , 2017, 47, 1584-1797.	1.6	505

#	ARTICLE	IF	CITATIONS
4566	Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. <i>Cancer Research</i> , 2017, 77, 6415-6428.	0.4	206
4567	4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7263-7275.	3.2	41
4568	Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence. <i>Nature Medicine</i> , 2017, 23, 1319-1330.	15.2	116
4569	Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. <i>Cancer Research</i> , 2017, 77, 6119-6130.	0.4	92
4570	PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. <i>Cancer Research</i> , 2017, 77, 6365-6374.	0.4	77
4571	Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 424-431.	1.2	11
4572	Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence. <i>Scientific Reports</i> , 2017, 7, 7952.	1.6	71
4573	Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2892-2901.	1.9	35
4574	Nanomaterials for convection-enhanced delivery of agents to treat brain tumors. <i>Current Opinion in Biomedical Engineering</i> , 2017, 4, 1-12.	1.8	25
4575	MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin. <i>EBioMedicine</i> , 2017, 24, 34-42.	2.7	8
4576	When theory meets experiment: the PD-1 challenge. <i>Journal of Molecular Modeling</i> , 2017, 23, 308.	0.8	4
4577	Hollow MnO ₂ as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. <i>Nature Communications</i> , 2017, 8, 902.	5.8	1,124
4578	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 1420-1435.	7.7	507
4579	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. <i>Cell</i> , 2017, 171, 934-949.e16.	13.5	1,515
4581	Binding of PLD2-Generated Phosphatidic Acid to KIF5B Promotes MT1-MMP Surface Trafficking and Lung Metastasis of Mouse Breast Cancer Cells. <i>Developmental Cell</i> , 2017, 43, 186-197.e7.	3.1	63
4582	Immunotherapy for Breast Cancer: Current and Future Strategies. <i>Current Surgery Reports</i> , 2017, 5, 1.	0.4	31
4583	EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. <i>Nature Cell Biology</i> , 2017, 19, 1371-1378.	4.6	257
4584	PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions. <i>Cancer Prevention Research</i> , 2017, 10, 684-693.	0.7	53

#	ARTICLE	IF	CITATIONS
4585	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 472-492.	157.7	1,662
4586	Updated recommendation on molecular-targeted therapy for metastatic renal cell cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 591-594.	0.4	1
4587	Anti-PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice. <i>Journal of Immunology</i> , 2017, 199, 3535-3546.	0.4	40
4588	Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8+ T Cells in Chronic versus Acute Infection. <i>Immunity</i> , 2017, 47, 648-663.e8.	6.6	50
4589	Signatures of positive selection reveal a universal role of chromatin modifiers as cancer driver genes. <i>Scientific Reports</i> , 2017, 7, 13124.	1.6	20
4590	Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. <i>Journal of Immunotherapy</i> , 2017, 40, 334-340.	1.2	16
4591	Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes. <i>MBio</i> , 2017, 8, .	1.8	57
4592	Widespread Post-transcriptional Attenuation of Genomic Copy-Number Variation in Cancer. <i>Cell Systems</i> , 2017, 5, 386-398.e4.	2.9	102
4593	Tristetraprolin inhibits macrophage IL-27-induced activation of antitumour cytotoxic T cell responses. <i>Nature Communications</i> , 2017, 8, 867.	5.8	31
4594	Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model. <i>Oncology Letters</i> , 2017, 14, 4197-4205.	0.8	23
4595	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	3.4	260
4596	Sox2 Communicates with Tregs Through CCL1 to Promote the Stemness Property of Breast Cancer Cells. <i>Stem Cells</i> , 2017, 35, 2351-2365.	1.4	69
4598	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	13.5	596
4599	Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy. <i>Cell</i> , 2017, 171, 1138-1150.e15.	13.5	113
4600	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nature Communications</i> , 2017, 8, 1050.	5.8	115
4601	Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. <i>Scientific Reports</i> , 2017, 7, 13380.	1.6	208
4602	Adaptive Multiview Nonnegative Matrix Factorization Algorithm for Integration of Multimodal Biomedical Data. <i>Cancer Informatics</i> , 2017, 16, 117693511772572.	0.9	6
4603	Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy related intracranial effects. <i>British Journal of Radiology</i> , 2018, 91, 20170553.	1.0	3

#	ARTICLE	IF	CITATIONS
4604	Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy. <i>Human Pathology</i> , 2017, 70, 49-54.	1.1	38
4605	MAGT1-mediated disturbance of Mg ²⁺ homeostasis lead to exhausted of HBV-infected NK and CD8+ T cells. <i>Scientific Reports</i> , 2017, 7, 13594.	1.6	11
4606	Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 293-302.	1.1	19
4607	Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. <i>Current Pharmacology Reports</i> , 2017, 3, 360-373.	1.5	10
4608	Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors. <i>Scientific Reports</i> , 2017, 7, 13682.	1.6	37
4609	Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 805-814.	1.4	13
4610	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	13.7	1,099
4611	PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis. <i>Nature Cell Biology</i> , 2017, 19, 1358-1370.	4.6	212
4612	Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). <i>Annals of Oncology</i> , 2017, 28, 2698-2706.	0.6	77
4613	Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. <i>Annals of Oncology</i> , 2017, 28, 3044-3050.	0.6	198
4614	Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. <i>Annals of Oncology</i> , 2017, 28, 3015-3021.	0.6	79
4615	Breast Cancer: Multiple Subtypes within a Tumor?. <i>Trends in Cancer</i> , 2017, 3, 753-760.	3.8	253
4616	Comprehensive analysis of normal adjacent to tumor transcriptomes. <i>Nature Communications</i> , 2017, 8, 1077.	5.8	394
4617	BCL-XL directly modulates RAS signalling to favour cancer cell stemness. <i>Nature Communications</i> , 2017, 8, 1123.	5.8	43
4618	Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival. <i>Scientific Reports</i> , 2017, 7, 13902.	1.6	15
4619	A novel approach for data integration and disease subtyping. <i>Genome Research</i> , 2017, 27, 2025-2039.	2.4	139
4620	Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. <i>Cancer</i> , 2017, 123, 4823-4831.	2.0	79
4621	Checkpoint immunotherapy in head and neck cancers. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 475-489.	2.7	33

#	ARTICLE	IF	CITATIONS
4622	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. <i>Cell</i> , 2017, 170, 927-938.e20.	13.5	368
4623	Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. <i>Cell Death and Disease</i> , 2017, 8, e3004-e3004.	2.7	90
4624	Unravelling biology and shifting paradigms in cancer with single-cell sequencing. <i>Nature Reviews Cancer</i> , 2017, 17, 557-569.	12.8	280
4625	Evolutionary biology of high-risk multiple myeloma. <i>Nature Reviews Cancer</i> , 2017, 17, 543-556.	12.8	178
4626	Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis. <i>ESMO Open</i> , 2017, 2, e000222.	2.0	11
4627	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2598-2608.	1.9	1,779
4628	FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. <i>Oncologist</i> , 2017, 22, 1392-1399.	1.9	235
4629	The prognostic implications of growth-related gene product \hat{I}^2 in laryngeal squamous cell carcinoma. <i>Oncology Letters</i> , 2017, 14, 3337-3342.	0.8	1
4630	Immunotherapy in Gynecologic Cancers: Are We There Yet?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 59.	1.3	45
4631	Enlighting the Shadow for Advanced Hepatocellular Carcinoma: Immunotherapy with Immune Checkpoint Inhibitors. <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 288-290.	0.6	1
4632	Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors. <i>Annals of Thoracic Surgery</i> , 2017, 104, e217-e218.	0.7	69
4633	Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 937-949.	1.1	16
4634	Novel Immunotherapies for Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 344-357.	1.2	30
4635	Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma. <i>Drugs</i> , 2017, 77, 1645-1655.	4.9	5
4636	Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 353-373.	1.0	28
4638	mTOR co-targeting strategies for head and neck cancer therapy. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 491-502.	2.7	46
4639	Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 484-494.	1.2	4
4640	Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. <i>Science Signaling</i> , 2017, 10, .	1.6	25

#	ARTICLE	IF	CITATIONS
4642	A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. <i>Nature Genetics</i> , 2017, 49, 1476-1486.	9.4	427
4643	Pathways from senescence to melanoma: focus on MITF sumoylation. <i>Oncogene</i> , 2017, 36, 6659-6667.	2.6	31
4644	Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab. <i>Oncolimmunology</i> , 2017, 6, e1363138.	2.1	20
4645	Immunotherapy for metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 566-571.	0.9	18
4646	Optimizing tumor immune response through combination of radiation and immunotherapy. <i>Medical Oncology</i> , 2017, 34, 165.	1.2	14
4647	The potential and promise of IL-15 in immuno-oncogenic therapies. <i>Immunology Letters</i> , 2017, 190, 159-168.	1.1	152
4648	Immuno-targeting of <i>Staphylococcus aureus</i> via surface remodeling complexes. <i>Chemical Science</i> , 2017, 8, 6804-6809.	3.7	16
4649	Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting. <i>BMJ Open</i> , 2017, 7, e014880.	0.8	18
4650	Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. <i>Clinical Cancer Research</i> , 2017, 23, 6165-6177.	3.2	249
4651	Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients. <i>Cancer Immunology Research</i> , 2017, 5, 898-907.	1.6	184
4653	Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient. <i>Thoracic Cancer</i> , 2017, 8, 706-709.	0.8	8
4654	The colorectal cancer immune microenvironment and approach to immunotherapies. <i>Future Oncology</i> , 2017, 13, 1633-1647.	1.1	76
4655	Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings. <i>CEN Case Reports</i> , 2017, 6, 169-174.	0.5	17
4656	CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1609-1617.	2.0	76
4657	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. <i>British Journal of Cancer</i> , 2017, 117, 913-920.	2.9	145
4658	Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	61
4659	The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions. <i>Targeted Oncology</i> , 2017, 12, 709-718.	1.7	17
4660	Tumour radiosensitivity is associated with immune activation in solid tumours. <i>European Journal of Cancer</i> , 2017, 84, 304-314.	1.3	44

#	ARTICLE	IF	CITATIONS
4661	Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2561-2574.	1.4	91
4662	Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. <i>Clinical Cancer Research</i> , 2017, 23, 4950-4958.	3.2	46
4663	Classifying the evolutionary and ecological features of neoplasms. <i>Nature Reviews Cancer</i> , 2017, 17, 605-619.	12.8	303
4664	Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells. <i>Nature Communications</i> , 2017, 8, 562.	5.8	101
4665	A novel signature for stratifying the molecular heterogeneity of the tissue-infiltrating T-cell receptor repertoire reflects gastric cancer prognosis. <i>Scientific Reports</i> , 2017, 7, 7762.	1.6	25
4666	Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. <i>Scientific Reports</i> , 2017, 7, 11671.	1.6	57
4667	GOS2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer. <i>Cell Cycle</i> , 2017, 16, 2146-2155.	1.3	15
4668	Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. <i>Oncologist</i> , 2017, 22, 1478-1490.	1.9	176
4669	Immunotherapy of cancer: targeting cancer during active disease or during dormancy?. <i>Immunotherapy</i> , 2017, 9, 943-949.	1.0	6
4670	Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 902-910.e2.	0.6	56
4671	Nanomaterials for cancer immunotherapy. <i>Biomaterials</i> , 2017, 148, 16-30.	5.7	226
4672	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. <i>Nature Communications</i> , 2017, 8, 607.	5.8	109
4673	Predictors of responses to immune checkpoint blockade in advanced melanoma. <i>Nature Communications</i> , 2017, 8, 592.	5.8	166
4674	Bacterial outer membrane vesicles suppress tumor by interferon- γ -mediated antitumor response. <i>Nature Communications</i> , 2017, 8, 626.	5.8	329
4675	Immune cell profiling in cancer: molecular approaches to cell-specific identification. <i>Npj Precision Oncology</i> , 2017, 1, 26.	2.3	73
4676	Patent trend and competitive analysis of cancer immunotherapy in the United States. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2583-2593.	1.4	6
4677	Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis. <i>Translational Oncology</i> , 2017, 10, 854-866.	1.7	5
4678	Stochastic model of contact inhibition and the proliferation of melanoma in situ. <i>Scientific Reports</i> , 2017, 7, 8026.	1.6	13

#	ARTICLE	IF	CITATIONS
4679	Identification of a p53 target, CD137L, that mediates growth suppression and immune response of osteosarcoma cells. <i>Scientific Reports</i> , 2017, 7, 10739.	1.6	3
4680	Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2849-2861.	1.9	41
4681	Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. <i>Cancer Cell</i> , 2017, 32, 377-391.e9.	7.7	419
4682	De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. <i>Nature Immunology</i> , 2017, 18, 1207-1217.	7.0	190
4683	Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4. <i>Nature Medicine</i> , 2017, 23, 1220-1225.	15.2	107
4684	Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. <i>Nature Communications</i> , 2017, 8, 517.	5.8	319
4685	Network-based machine learning and graph theory algorithms for precision oncology. <i>Npj Precision Oncology</i> , 2017, 1, 25.	2.3	74
4686	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
4687	Neoantigen prediction and the need for validation. <i>Nature Biotechnology</i> , 2017, 35, 815-817.	9.4	69
4688	Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. <i>Scientific Reports</i> , 2017, 7, 7848.	1.6	43
4689	Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. <i>Radiographics</i> , 2017, 37, 1371-1387.	1.4	56
4690	Tim-3, Lag-3, and TIGIT. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 127-156.	0.7	109
4691	Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2017, 7, 11373.	1.6	70
4692	Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. <i>Pancreas</i> , 2017, 46, 1180-1187.	0.5	47
4693	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. <i>Science</i> , 2017, 357, 1156-1160.	6.0	1,059
4694	PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. <i>Cancer Research</i> , 2017, 77, 6353-6364.	0.4	161
4695	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , 2017, 7, 1394-1403.	7.7	701
4696	Immunotherapies for advanced melanoma: as promising as they are expensive?. <i>Journal of the Royal Society of Medicine</i> , 2017, 110, 395-399.	1.1	2

#	ARTICLE	IF	CITATIONS
4697	Relationship between PD-L1 expression and clinical characteristics in patients with breast invasive ductal carcinoma. <i>Open Medicine (Poland)</i> , 2017, 12, 288-292.	0.6	13
4698	A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. <i>Journal of the Royal Society Interface</i> , 2017, 14, 20170320.	1.5	118
4699	CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. <i>Immunotherapy</i> , 2017, 9, 929-941.	1.0	34
4700	New Opportunities and Challenges to Defeat Cancer Stem Cells. <i>Trends in Cancer</i> , 2017, 3, 780-796.	3.8	77
4701	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. <i>Nature Communications</i> , 2017, 8, 606.	5.8	89
4702	Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients. <i>Oncology Letters</i> , 2017, 14, 3379-3386.	0.8	3
4703	Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. <i>Medical Molecular Morphology</i> , 2017, 50, 185-194.	0.4	31
4704	Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells. <i>Oncology Letters</i> , 2017, 14, 3832-3838.	0.8	12
4705	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. <i>Pharmacoeconomics</i> , 2017, 35, 1195-1209.	1.7	16
4706	The Challenge for Development of Valuable Immuno-oncology Biomarkers. <i>Clinical Cancer Research</i> , 2017, 23, 4970-4979.	3.2	76
4707	Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease. <i>Molecular and Clinical Oncology</i> , 2017, 7, 604-608.	0.4	21
4708	Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer. <i>Medical Oncology</i> , 2017, 34, 170.	1.2	31
4709	A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. <i>Scientific Reports</i> , 2017, 7, 8951.	1.6	111
4710	A signal-based method for finding driver modules of breast cancer metastasis to the lung. <i>Scientific Reports</i> , 2017, 7, 10023.	1.6	5
4711	PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. <i>Scientific Reports</i> , 2017, 7, 10255.	1.6	160
4712	Immunobiology of the IL-15/IL-15R α complex as an antitumor and antiviral agent. <i>Cytokine and Growth Factor Reviews</i> , 2017, 38, 10-21.	3.2	108
4713	Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers. <i>Scientific Reports</i> , 2017, 7, 8606.	1.6	113
4714	Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status. <i>Scientific Reports</i> , 2017, 7, 10380.	1.6	20

#	ARTICLE	IF	CITATIONS
4715	Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies. <i>JAMA Neurology</i> , 2017, 74, 1216.	4.5	244
4716	Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1031-1036.	1.3	25
4717	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6823-6832.	3.2	66
4718	Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma. <i>Ocular Oncology and Pathology</i> , 2017, 3, 133-141.	0.5	44
4719	Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2607-2618.	1.2	43
4720	Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation. <i>Pharmacoeconomics</i> , 2017, 35, 1257-1270.	1.7	49
4721	Identifying DNase I hypersensitive sites as driver distal regulatory elements in breast cancer. <i>Nature Communications</i> , 2017, 8, 436.	5.8	22
4722	Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer. <i>Nature Communications</i> , 2017, 8, 228.	5.8	105
4723	Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. <i>Scientific Reports</i> , 2017, 7, 10735.	1.6	28
4724	Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 1512-1520.	2.8	56
4725	Copy number rather than epigenetic alterations are the major dictator of imprinted methylation in tumors. <i>Nature Communications</i> , 2017, 8, 467.	5.8	27
4726	The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment. <i>Scientific Reports</i> , 2017, 7, 10349.	1.6	29
4727	Case series of pleomorphic carcinomas of the lung treated with nivolumab. <i>Thoracic Cancer</i> , 2017, 8, 724-728.	0.8	39
4728	BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer. <i>Oncogene</i> , 2017, 36, 6235-6243.	2.6	73
4729	Atezolizumab for the treatment of non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 935-945.	1.3	34
4730	HIT ⁿ DRIVE: patient-specific multidriver gene prioritization for precision oncology. <i>Genome Research</i> , 2017, 27, 1573-1588.	2.4	78
4731	Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy. <i>Molecular Imaging</i> , 2017, 16, 153601211771845.	0.7	47
4732	Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers. <i>Oncologist</i> , 2017, 22, 1316-1324.	1.9	67

#	ARTICLE	IF	CITATIONS
4733	A perspective on the impact of radiation therapy on the immune rheostat. <i>British Journal of Radiology</i> , 2017, 90, 20170272.	1.0	9
4734	Identification of driver copy number alterations in diverse cancer types and application in drug repositioning. <i>Molecular Oncology</i> , 2017, 11, 1459-1474.	2.1	15
4735	PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 146-153.	0.9	145
4736	CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. <i>Cancer Research</i> , 2017, 77, 5118-5128.	0.4	34
4738	Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone. <i>Clinical Orthopaedics and Related Research</i> , 2017, 475, 3071-3081.	0.7	14
4739	PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. <i>Modern Pathology</i> , 2017, 30, 1551-1560.	2.9	35
4740	A mixed-effects model for incomplete data from labeling-based quantitative proteomics experiments. <i>Annals of Applied Statistics</i> , 2017, 11, 114-138.	0.5	9
4741	UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. <i>Neoplasia</i> , 2017, 19, 649-658.	2.3	4,166
4742	Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. <i>Nature Reviews Endocrinology</i> , 2017, 13, 644-660.	4.3	324
4743	Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer. <i>Radiology</i> , 2017, 285, 401-413.	3.6	92
4744	Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. <i>British Journal of Radiology</i> , 2017, 90, 20170257.	1.0	14
4745	Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. <i>Oncologist</i> , 2017, 22, 1039-1048.	1.9	115
4746	Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1017-1034.	1.5	67
4747	Lung cancer as a paradigm for precision oncology in solid tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 221-233.	1.4	14
4748	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017, 7, 1088-1097.	7.7	160
4749	The Spectrum of Triple-Negative Breast Disease. <i>American Journal of Pathology</i> , 2017, 187, 2139-2151.	1.9	118
4750	Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance. <i>Endocrine-Related Cancer</i> , 2017, 24, R349-R366.	1.6	47
4751	Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review. <i>Oncology Letters</i> , 2017, 14, 1568-1580.	0.8	18

#	ARTICLE	IF	CITATIONS
4752	The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. <i>Surgical Oncology</i> , 2017, 26, 368-376.	0.8	67
4753	Melanoma subtypes demonstrate distinct PD-L1 expression profiles. <i>Laboratory Investigation</i> , 2017, 97, 1063-1071.	1.7	156
4754	The immune contexture in cancer prognosis and treatment. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 717-734.	12.5	1,590
4755	PD-L1 induced by IFN- γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. <i>International Journal of Clinical Oncology</i> , 2017, 22, 1026-1033.	1.0	241
4756	Theranostic Gold Nanoantennas for Simultaneous Multiplexed Raman Imaging of Immunomarkers and Photothermal Therapy. <i>ACS Omega</i> , 2017, 2, 3583-3594.	1.6	29
4757	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: follow-up and post-hoc analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017, 178, 896-905.	1.2	120
4758	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1378.	3.4	300
4759	Modulating the Cellular Immune Response of Oligonucleotides by Brush Polymer-Assisted Compaction. <i>Small</i> , 2017, 13, 1701432.	5.2	26
4760	Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1249-1264.	2.0	56
4761	The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility. <i>Current Urology Reports</i> , 2017, 18, 65.	1.0	5
4762	Combined immunotherapy for advanced prostate cancer: Empowering the T cell army. <i>Asian Journal of Urology</i> , 2017, 4, 199-200.	0.5	0
4763	Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis. <i>Turkish Journal of Emergency Medicine</i> , 2017, 17, 157-159.	0.3	16
4764	Concordance of DNA methylation profiles between breast core biopsy and surgical excision specimens containing ductal carcinoma in situ (DCIS). <i>Experimental and Molecular Pathology</i> , 2017, 103, 78-83.	0.9	5
4765	Comparison of algorithms for the detection of cancer drivers at subgene resolution. <i>Nature Methods</i> , 2017, 14, 782-788.	9.0	72
4766	Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1300622.	0.3	2
4767	Tissue microenvironment dictates the fate and tumor-suppressive function of type 3 ILCs. <i>Journal of Experimental Medicine</i> , 2017, 214, 2331-2347.	4.2	78
4768	Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma. <i>Medicine (United States)</i> , 2017, 96, e7350.	0.4	44
4769	Adoptive transfer of murine T cells expressing a chimeric PD-1 δ ap10 receptor as an immunotherapy for lymphoma. <i>Immunology</i> , 2017, 152, 472-483.	2.0	19

#	ARTICLE	IF	CITATIONS
4770	Japanese Kampo medicine ninjin'yoeito synergistically enhances tumor vaccine effects mediated by CD8+ T cells. <i>Oncology Letters</i> , 2017, 13, 3471-3478.	0.8	13
4771	Precision Medicine and PET/Computed Tomography in Melanoma. <i>PET Clinics</i> , 2017, 12, 449-458.	1.5	11
4772	PD-L1 pitfalls: Emphasizing the importance of membranous localization and correlation with tumor cell and macrophage distributions. <i>Gynecologic Oncology Reports</i> , 2017, 20, 135-136.	0.3	1
4773	Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2017, 21, 78-80.	0.3	18
4774	A Novel Target Antigen for the Treatment of Acute Myeloid Leukemia by CAR T Cells. <i>Molecular Therapy</i> , 2017, 25, 1997-1998.	3.7	2
4776	Cancer Immunotherapies: Are They as Effective in the Elderly?. <i>Drugs and Aging</i> , 2017, 34, 567-581.	1.3	31
4777	Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC—a computational study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 124, 157-164.	0.2	8
4778	PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. <i>Oncology Letters</i> , 2017, 14, 250-256.	0.8	46
4779	Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, e172085.	3.4	37
4780	The new era of cancer immunotherapy: what can molecular imaging do to help?. <i>Clinical and Translational Imaging</i> , 2017, 5, 299-301.	1.1	8
4781	Is Disease-Specific Immunotherapy a Potential Reality for MDS?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S26-S30.	0.2	5
4782	Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing. <i>Journal of Surgical Research</i> , 2017, 220, 125-132.	0.8	45
4783	Immunotherapy. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 867-874.	0.5	4
4784	Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. <i>Modern Pathology</i> , 2017, 30, 1622-1632.	2.9	62
4785	Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification. <i>Modern Pathology</i> , 2017, 30, 1516-1526.	2.9	22
4786	Oesophageal cancer. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17048.	18.1	671
4787	The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 42, 1739-1754.	1.1	3,166
4788	Versican-Derived Matrikines Regulate Batf3—Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. <i>Journal of Immunology</i> , 2017, 199, 1933-1941.	0.4	82

#	ARTICLE	IF	CITATIONS
4789	Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. <i>Current Oncology Reports</i> , 2017, 19, 62.	1.8	20
4790	Genome-wide identification of inter-individually variable DNA methylation sites improves the efficacy of epigenetic association studies. <i>Npj Genomic Medicine</i> , 2017, 2, 11.	1.7	59
4791	Loss of p27kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells. <i>Scientific Reports</i> , 2017, 7, 595.	1.6	22
4792	Deregulated MITF sumoylation: A route to melanoma. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1331154.	0.3	1
4793	Shifting the balance of power? The combination of oncolytic virotherapy and immune checkpoint blockade for glioblastoma treatment. <i>Neuro-Oncology</i> , 2017, 19, 463-465.	0.6	2
4794	Tools to define the melanoma-associated immunopeptidome. <i>Immunology</i> , 2017, 152, 536-544.	2.0	14
4796	HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features. <i>Modern Pathology</i> , 2017, 30, 1561-1566.	2.9	24
4797	PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens. <i>Nature Communications</i> , 2017, 8, 105.	5.8	109
4798	Evasion of immunosurveillance by genomic alterations of PPAR β /RXR α in bladder cancer. <i>Nature Communications</i> , 2017, 8, 103.	5.8	107
4799	Pan-urolologic cancer genomic subtypes that transcend tissue of origin. <i>Nature Communications</i> , 2017, 8, 199.	5.8	49
4800	Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. <i>Scientific Reports</i> , 2017, 7, 5532.	1.6	166
4801	Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis. <i>Scientific Reports</i> , 2017, 7, 5995.	1.6	25
4802	Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis. <i>Scientific Reports</i> , 2017, 7, 6069.	1.6	66
4803	Machine Learning-Assisted Network Inference Approach to Identify a New Class of Genes that Coordinate the Functionality of Cancer Networks. <i>Scientific Reports</i> , 2017, 7, 6993.	1.6	37
4804	Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. <i>Annals of Oncology</i> , 2017, 28, 2472-2480.	0.6	45
4805	Accelerating high-dimensional clustering with lossless data reduction. <i>Bioinformatics</i> , 2017, 33, 2867-2872.	1.8	3
4806	Long-term outcomes after carbon-ion radiotherapy for oral mucosal malignant melanoma. <i>Journal of Radiation Research</i> , 2017, 58, 517-522.	0.8	27
4807	HER2-positive breast cancer is lost in translation: time for patient-centered research. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 669-681.	12.5	59

#	ARTICLE	IF	CITATIONS
4808	Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells. <i>Oncogene</i> , 2017, 36, 6490-6500.	2.6	69
4809	Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 651-659.	0.8	14
4810	Macrophage biology plays a central role during ionizing radiation-elicited tumor response. <i>Biomedical Journal</i> , 2017, 40, 200-211.	1.4	71
4811	Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations. <i>Molecular Therapy</i> , 2017, 25, 2533-2545.	3.7	8
4812	The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2017, 2, 99-103.	0.6	14
4813	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. <i>Annals of Oncology</i> , 2017, 28, 2581-2587.	0.6	201
4814	Clinical Relevance of microRNA Expressions in Breast Cancer Validated Using the Cancer Genome Atlas (TCGA). <i>Annals of Surgical Oncology</i> , 2017, 24, 2943-2949.	0.7	51
4815	Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer. <i>Oncology Letters</i> , 2017, 14, 2405-2409.	0.8	22
4816	Recent developments in the treatment of metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 551-564.	1.4	82
4817	Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients. <i>International Journal of Oncology</i> , 2017, 51, 781-790.	1.4	46
4819	MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells. <i>Cell Death and Disease</i> , 2017, 8, e2973-e2973.	2.7	80
4820	A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies. <i>Cancer Immunology Research</i> , 2017, 5, 790-803.	1.6	38
4821	An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1529-1544.	2.0	12
4822	Significance of Monocyte Counts at Recurrence on Survival Outcome of Women With Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 302-310.	1.2	19
4823	Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 100-109.	0.6	24
4824	Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab. <i>Medicine (United States)</i> , 2017, 96, e5951.	0.4	15
4825	Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches. <i>Frontiers of Medicine</i> , 2017, 11, 509-521.	1.5	19
4826	Identification of essential genes for cancer immunotherapy. <i>Nature</i> , 2017, 548, 537-542.	13.7	668

#	ARTICLE	IF	CITATIONS
4827	Lung cancer as a cardiotoxic state: a review. <i>Medical Oncology</i> , 2017, 34, 159.	1.2	12
4828	Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Molecular Cancer Research</i> , 2017, 15, 1542-1550.	1.5	59
4829	Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nursesâ€™ Health Study. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 613-622.	1.1	30
4830	Metalloprotease-dependent activation of EGFR modulates CD44+/CD24â€™ populations in triple negative breast cancer cells through the MEK/ERK pathway. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 421-433.	1.1	20
4831	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. <i>Cell</i> , 2017, 170, 1120-1133.e17.	13.5	960
4832	The PI3K Pathway in Human Disease. <i>Cell</i> , 2017, 170, 605-635.	13.5	1,702
4833	Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. <i>British Journal of Cancer</i> , 2017, 117, 921-924.	2.9	81
4834	Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics. <i>Current Oncology Reports</i> , 2017, 19, 66.	1.8	10
4835	Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. <i>Genomics, Proteomics and Bioinformatics</i> , 2017, 15, 220-235.	3.0	96
4836	Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. <i>ACS Nano</i> , 2017, 11, 8690-8706.	7.3	108
4837	Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. <i>Oncology</i> , 2017, 93, 249-258.	0.9	19
4838	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2310-2325.	3.3	46
4839	Recent Advances in Targeting ROS1 in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1611-1625.	0.5	194
4840	CDK4/6 inhibition triggers anti-tumour immunity. <i>Nature</i> , 2017, 548, 471-475.	13.7	998
4841	Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. <i>Nature</i> , 2017, 549, 106-110.	13.7	501
4842	Fighting tubulin-targeting anticancer drug toxicity and resistance. <i>Endocrine-Related Cancer</i> , 2017, 24, T107-T117.	1.6	42
4843	Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. <i>JAMA Oncology</i> , 2017, 3, e172411.	3.4	750
4844	Î²-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy. <i>Cancer Research</i> , 2017, 77, 5639-5651.	0.4	168

#	ARTICLE	IF	CITATIONS
4845	The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 767-777.	1.6	120
4846	Androgen deprivation and immunotherapy for the treatment of prostate cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, T297-T310.	1.6	96
4847	Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement. <i>Molecular and Clinical Oncology</i> , 2017, 7, 359-366.	0.4	13
4848	Novel landscape of HLA-EG isoforms expressed in clear cell renal cell carcinoma patients. <i>Molecular Oncology</i> , 2017, 11, 1561-1578.	2.1	67
4850	Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. <i>Targeted Oncology</i> , 2017, 12, 571-597.	1.7	135
4851	Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 75.	2.0	15
4852	Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1381-1389.	2.1	54
4853	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	91
4854	Huaier extract restrains the proliferative potential of endocrine-resistant breast cancer cells through increased ATM by suppressing miR-203. <i>Scientific Reports</i> , 2017, 7, 7313.	1.6	20
4855	Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. <i>Annals of Oncology</i> , 2017, 28, 2539-2546.	0.6	84
4856	Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 533-550.	1.4	74
4857	Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. <i>European Respiratory Journal</i> , 2017, 50, 1700050.	3.1	301
4858	BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. <i>Cell Death and Disease</i> , 2017, 8, e2982-e2982.	2.7	17
4859	Cell Dispersal Influences Tumor Heterogeneity and Introduces a Bias in NGS Data Interpretation. <i>Scientific Reports</i> , 2017, 7, 7358.	1.6	8
4860	Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of Function. <i>Molecular Cancer Research</i> , 2017, 15, 1598-1607.	1.5	16
4861	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. <i>Current Oncology Reports</i> , 2017, 19, 64.	1.8	106
4862	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 1168-1183.	7.7	58
4863	Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1527-1533.	1.0	28

#	ARTICLE	IF	CITATIONS
4864	A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice. <i>Molecular Therapy</i> , 2017, 25, 2280-2288.	3.7	40
4865	EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice. <i>European Respiratory Journal</i> , 2017, 50, 1700514.	3.1	20
4866	Genomic Evolution of Breast Cancer Metastasis and Relapse. <i>Cancer Cell</i> , 2017, 32, 169-184.e7.	7.7	534
4867	Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. <i>Cancer Cell</i> , 2017, 32, 253-267.e5.	7.7	430
4868	Pembrolizumab reactivates pulmonary granulomatosis. <i>Respiratory Medicine Case Reports</i> , 2017, 22, 126-129.	0.2	18
4869	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	530
4870	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
4871	Development of an intervention to support patients and clinicians with advanced lung cancer when considering systematic anticancer therapy: protocol for the PACT study. <i>BMJ Open</i> , 2017, 7, e015277.	0.8	4
4872	Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 7, 378-382.	0.4	24
4873	Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 51.	1.3	69
4874	Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2017, 18, 1360-1372.	5.1	377
4875	Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2017, 11, 117822341773156.	0.6	36
4876	NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma. <i>Scientific Reports</i> , 2017, 7, 17064.	1.6	67
4877	Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. <i>Clinical Trials</i> , 2017, 14, 611-620.	0.7	7
4878	Skin Delivery of Clec4a Small Hairpin RNA Elicited an Effective Antitumor Response by Enhancing CD8 + Immunity In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 9, 419-427.	2.3	9
4879	The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. <i>Future Oncology</i> , 2017, 13, 2583-2592.	1.1	113
4880	Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. <i>Cell</i> , 2017, 171, 1678-1691.e13.	13.5	467
4881	Identification of cancer genes that are independent of dominant proliferation and lineage programs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E11276-E11284.	3.3	20

#	ARTICLE	IF	CITATIONS
4882	Modulation of antitumor immunity with histone deacetylase inhibitors. <i>Immunotherapy</i> , 2017, 9, 1359-1372.	1.0	37
4883	Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. <i>Scientific Reports</i> , 2017, 7, 16517.	1.6	51
4884	How to evaluate the immune status of lung cancer patients before immunotherapy. <i>Breathe</i> , 2017, 13, 291-296.	0.6	11
4885	Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma. <i>Clinical and Translational Immunology</i> , 2017, 6, e161.	1.7	51
4886	Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo. <i>International Journal of Oncology</i> , 2018, 52, 127-138.	1.4	60
4887	Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. <i>Nature Communications</i> , 2017, 8, 1954.	5.8	237
4888	Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E10981-E10990.	3.3	217
4889	MELK Promotes Melanoma Growth by Stimulating the NF- κ B Pathway. <i>Cell Reports</i> , 2017, 21, 2829-2841.	2.9	61
4890	Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, 640.	2.8	19
4891	Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. <i>Nature Communications</i> , 2017, 8, 1811.	5.8	360
4892	Human CD26 ^{high} T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. <i>Nature Communications</i> , 2017, 8, 1961.	5.8	67
4893	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. <i>Npj Breast Cancer</i> , 2017, 3, 48.	2.3	63
4894	Comprehensive statistical inference of the clonal structure of cancer from multiple biopsies. <i>Scientific Reports</i> , 2017, 7, 16943.	1.6	1
4895	Multiplex three-dimensional optical mapping of tumor immune microenvironment. <i>Scientific Reports</i> , 2017, 7, 17031.	1.6	41
4896	QuPath: Open source software for digital pathology image analysis. <i>Scientific Reports</i> , 2017, 7, 16878.	1.6	3,854
4897	Detection of programmed death ligand 1 protein and CD8 ⁺ lymphocyte infiltration in plurihormonal pituitary adenomas. <i>Medicine (United States)</i> , 2017, 96, e9056.	0.4	13
4898	Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2017, 7, 16956.	1.6	29
4899	T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. <i>Nature Communications</i> , 2017, 8, 1747.	5.8	336

#	ARTICLE	IF	CITATIONS
4900	DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. <i>Nature Communications</i> , 2017, 8, 1751.	5.8	497
4901	Detection of Somatic Mutations in Exome Sequencing of Tumor-only Samples. <i>Scientific Reports</i> , 2017, 7, 15959.	1.6	13
4902	Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer. <i>Oncology Letters</i> , 2017, 14, 4135-4141.	0.8	35
4903	Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells. <i>Scientific Reports</i> , 2017, 7, 16345.	1.6	16
4904	Regulatory T cells control toxicity in a humanized model of IL-2 therapy. <i>Nature Communications</i> , 2017, 8, 1762.	5.8	40
4905	Functional germline variants as potential co-oncogenes. <i>Npj Breast Cancer</i> , 2017, 3, 46.	2.3	14
4906	Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer. <i>Breast Care</i> , 2017, 12, 296-302.	0.8	8
4907	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , 2017, 552, 116-120.	13.7	480
4908	PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma. <i>Cancer Biology and Therapy</i> , 2017, 18, 937-939.	1.5	17
4909	Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue. <i>Biomarker Insights</i> , 2017, 12, 117727191769985.	1.0	3
4910	Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. <i>Cell</i> , 2017, 171, 1284-1300.e21.	13.5	366
4911	Breast cancers with EGFR and HER2 amplification favor distant metastasis and poor clinical outcome. <i>Oncology Letters</i> , 2017, 14, 6562-6570.	0.8	19
4912	Towards Multiple Kernel Principal Component Analysis for Integrative Analysis of Tumor Samples. <i>Journal of Integrative Bioinformatics</i> , 2017, 14, .	1.0	4
4913	Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy. <i>Nano Letters</i> , 2017, 17, 7387-7393.	4.5	184
4914	T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E10409-E10417.	3.3	53
4915	Personalised medicine for nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2017, 26, 170066.	3.0	37
4916	Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?. <i>Oncologist</i> , 2017, 22, 1470-1477.	1.9	10
4917	Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer. <i>Developmental Cell</i> , 2017, 43, 418-435.e13.	3.1	62

#	ARTICLE	IF	CITATIONS
4918	PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells. <i>Npj Breast Cancer</i> , 2017, 3, 45.	2.3	21
4919	Role of epithelial to mesenchymal transition associated genes in mammary gland regeneration and breast tumorigenesis. <i>Nature Communications</i> , 2017, 8, 1669.	5.8	52
4920	Systematic Screening of Chemokines to Identify Candidates to Model and Create Ectopic Lymph Node Structures for Cancer Immunotherapy. <i>Scientific Reports</i> , 2017, 7, 15996.	1.6	19
4921	Actionable gene-based classification toward precision medicine in gastric cancer. <i>Genome Medicine</i> , 2017, 9, 93.	3.6	59
4922	Non-“small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. <i>Cancer</i> , 2017, 123, 4800-4807.	2.0	19
4923	Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy. <i>Melanoma Management</i> , 2017, 4, 61-68.	0.1	20
4924	Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma. <i>Respiratory Medicine Case Reports</i> , 2017, 22, 283-286.	0.2	19
4925	Implications of aging and the endoplasmic reticulum unfolded protein response on the molecular modality of breast cancer. <i>Experimental and Molecular Medicine</i> , 2017, 49, e389-e389.	3.2	30
4926	Combining immunotherapies for the treatment of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 694-700.	0.8	36
4927	Are We Ready to Use ESR1 Mutations in Clinical Practice. <i>Breast Care</i> , 2017, 12, 309-313.	0.8	17
4928	Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. <i>Nature Reviews Neurology</i> , 2017, 13, 755-763.	4.9	139
4929	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <i>Nature Communications</i> , 2017, 8, 1324.	5.8	584
4930	Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer. <i>Oncology Letters</i> , 2017, 14, 7225-7231.	0.8	26
4931	C-reactive protein/albumin and neutrophil/lymphocyte ratios and their combination predict overall survival in patients with gastric cancer. <i>Oncology Letters</i> , 2017, 14, 7417-7424.	0.8	29
4932	CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy. <i>Journal of Immunology</i> , 2017, 199, 4110-4123.	0.4	37
4933	Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-1 (CD274) expression: Possible roles of tumour micro environmental factors for CD274 expression. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 268-278.	1.3	18
4934	Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry. <i>Cancer Immunology Research</i> , 2017, 5, 1062-1073.	1.6	29
4935	Identification of Genetic and Epigenetic Variants Associated with Breast Cancer Prognosis by Integrative Bioinformatics Analysis. <i>Cancer Informatics</i> , 2017, 16, CIN.S39783.	0.9	36

#	ARTICLE	IF	CITATIONS
4936	Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells. <i>ChemMedChem</i> , 2017, 12, 2006-2013.	1.6	9
4937	Role of Platinum in Early-Stage Triple-Negative Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 68.	1.3	14
4938	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. <i>Nature</i> , 2017, 551, 517-520.	13.7	532
4939	Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression. <i>Convergent Science Physical Oncology</i> , 2017, 3, 034002.	2.6	114
4940	Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events. <i>Case Reports in Oncology</i> , 2017, 10, 296-300.	0.3	10
4941	Association between B7 α -H1 and cervical cancer: B7 α -H1 impairs the immune response in human cervical cancer cells. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 4125-4133.	0.8	5
4942	Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. <i>Nature Communications</i> , 2017, 8, 1404.	5.8	177
4943	ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 454-463.	0.7	5
4944	Brachial Plexus Neuritis Associated With Anti α -Programmed Cell Death-1 Antibodies: Report of 2 Cases. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2017, 1, 192-197.	1.2	22
4945	Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 9, 312-321.	2.3	36
4946	Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer. <i>Medicine (United States)</i> , 2017, 96, e8407.	0.4	8
4947	TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. <i>Cancer Research</i> , 2017, 77, e108-e110.	0.4	4,049
4948	Lowly methylated region analysis identifies EBF1 as a potential epigenetic modifier in breast cancer. <i>Epigenetics</i> , 2017, 12, 964-972.	1.3	16
4949	Two Cases of Sinusitis Induced by Immune Checkpoint Inhibition. <i>Journal of Immunotherapy</i> , 2017, 40, 312-314.	1.2	16
4950	Polyfunctional response by Imm α TAC α (αIMCαgp100) redirected αCDα8α and αCDα4α T cells. <i>Immunology</i> , 2017, 152, 425-438.	2.0	53
4951	Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope. <i>Current Oncology Reports</i> , 2017, 19, 49.	1.8	23
4952	Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy. <i>Bioconjugate Chemistry</i> , 2017, 28, 1993-2000.	1.8	46
4953	Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells. <i>Scientific Reports</i> , 2017, 7, 3763.	1.6	14

#	ARTICLE	IF	CITATIONS
4954	Revealing protein networks and gene-drug connectivity in cancer from direct information. <i>Scientific Reports</i> , 2017, 7, 3739.	1.6	14
4955	An abscopal effect in a case of concomitant treatment of locally and peritoneally recurrent gastric cancer using adoptive T cell immunotherapy and radiotherapy. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 380-384.	0.2	26
4956	The Expression of Connexins and SOX2 Reflects the Plasticity of Glioma Stem-Like Cells. <i>Translational Oncology</i> , 2017, 10, 555-569.	1.7	21
4957	New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 10-22.	1.0	45
4958	Genotranscriptomic meta-analysis of the <sc>CHD</sc> family chromatin remodelers in human cancers – initial evidence of an oncogenic role for <sc>CHD</sc>7. <i>Molecular Oncology</i> , 2017, 11, 1348-1360.	2.1	28
4959	Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1-3.	3.3	3
4960	Targeted therapies for renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2017, 13, 496-511.	4.1	185
4961	Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. <i>Oncogene</i> , 2017, 36, 6143-6153.	2.6	264
4962	Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival. <i>Biomaterials</i> , 2017, 141, 260-271.	5.7	46
4963	Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells. <i>Oncogene</i> , 2017, 36, 6074-6084.	2.6	26
4964	Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 5187-5201.	3.2	288
4965	Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer. <i>JAMA Dermatology</i> , 2017, 153, 1162.	2.0	69
4966	Somatic mutations in ZFHX4 gene are associated with poor overall survival of Chinese esophageal squamous cell carcinoma patients. <i>Scientific Reports</i> , 2017, 7, 4951.	1.6	46
4967	Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. <i>Pancreas</i> , 2017, 46, 994-1002.	0.5	21
4968	Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration. <i>Case Reports in Oncology</i> , 2017, 10, 368-371.	0.3	21
4969	Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma. <i>Neurology: Genetics</i> , 2017, 3, e164.	0.9	32
4970	Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. <i>Oncology Letters</i> , 2017, 14, 337-344.	0.8	33
4971	Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model. <i>Oncology Letters</i> , 2017, 14, 1162-1166.	0.8	1

#	ARTICLE	IF	CITATIONS
4972	Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition. <i>Immunogenetics</i> , 2017, 69, 547-556.	1.2	30
4973	Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. <i>Targeted Oncology</i> , 2017, 12, 475-485.	1.7	30
4974	HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. <i>British Journal of Cancer</i> , 2017, 117, 451-460.	2.9	321
4975	Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6157-E6165.	3.3	90
4976	Continuous immunotypes describe human immune variation and predict diverse responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6097-E6106.	3.3	104
4977	Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 697-708.	0.9	16
4978	The role for chemotherapy in the modern management of melanoma. <i>Melanoma Management</i> , 2017, 4, 125-136.	0.1	26
4979	Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. <i>Npj Systems Biology and Applications</i> , 2017, 3, 8.	1.4	55
4980	Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 685-694.	1.6	37
4981	Landmarks in the treatment of muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2017, 14, 565-574.	1.9	122
4982	Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 676-684.	1.6	130
4983	Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 593-600.	1.1	12
4984	Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. <i>Cell Metabolism</i> , 2017, 26, 94-109.	7.2	374
4985	An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature</i> , 2017, 547, 217-221.	13.7	2,112
4986	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. <i>Nature</i> , 2017, 547, 222-226.	13.7	1,806
4987	Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 831-840.	0.8	14
4988	A retrospective clinical analysis of 5 cases of vaginal melanoma. <i>Molecular and Clinical Oncology</i> , 2017, 6, 373-376.	0.4	10
4989	Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1529.	3.4	412

#	ARTICLE	IF	CITATIONS
4990	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. <i>Breast</i> , 2017, 34, S19-S26.	0.9	46
4991	A novel network regularized matrix decomposition method to detect mutated cancer genes in tumour samples with inter-patient heterogeneity. <i>Scientific Reports</i> , 2017, 7, 2855.	1.6	10
4992	Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5687-5695.	3.2	170
4993	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. <i>Clinical Cancer Research</i> , 2017, 23, 5737-5744.	3.2	69
4994	Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain A and B in cancer cells. <i>Oncology Reports</i> , 2017, 38, 693-702.	1.2	25
4995	Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. <i>CNS Drugs</i> , 2017, 31, 675-684.	2.7	24
4996	Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. <i>Cell Research</i> , 2017, 27, 1034-1045.	5.7	259
4997	Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics. <i>Clinical Cancer Research</i> , 2017, 23, 6363-6373.	3.2	12
4998	Endogenous Heat Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma. <i>Oncologist</i> , 2017, 22, 1026.	1.9	18
4999	Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. <i>Npj Breast Cancer</i> , 2017, 3, 24.	2.3	91
5000	Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 1410-1420.	1.5	27
5001	Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions. <i>Oncology and Therapy</i> , 2017, 5, 69-74.	1.0	5
5002	Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. <i>American Journal of Surgery</i> , 2017, 214, 666-671.	0.9	8
5003	Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days. <i>Respiratory Medicine Case Reports</i> , 2017, 22, 31-33.	0.2	6
5004	Recurrent and functional regulatory mutations in breast cancer. <i>Nature</i> , 2017, 547, 55-60.	13.7	269
5005	A checkpoint to pain. <i>Nature Neuroscience</i> , 2017, 20, 897-899.	7.1	7
5006	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 655-668.	12.5	787
5007	Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. <i>Npj Breast Cancer</i> , 2017, 3, 17.	2.3	41

#	ARTICLE	IF	CITATIONS
5008	DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis. <i>Cancer Biology and Therapy</i> , 2017, 18, 439-449.	1.5	21
5009	Assessing treatment efficacy in the subset of responders in a randomized clinical trial. <i>Annals of Oncology</i> , 2017, 28, 1640-1647.	0.6	7
5010	GRAPE: a pathway template method to characterize tissue-specific functionality from gene expression profiles. <i>BMC Bioinformatics</i> , 2017, 18, 317.	1.2	9
5011	A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. <i>Journal of Translational Medicine</i> , 2017, 15, 150.	1.8	26
5012	Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes. <i>Breast Cancer Research</i> , 2017, 19, 71.	2.2	65
5013	New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31st Annual Meeting of the Society for Immunotherapy of Cancer, 2016., 2017, 5, 50.		10
5014	Immune Escape in Breast Cancer During <i>In Situ</i> to Invasive Carcinoma Transition. <i>Cancer Discovery</i> , 2017, 7, 1098-1115.	7.7	185
5015	Revealing common disease mechanisms shared by tumors of different tissues of origin through semantic representation of genomic alterations and topic modeling. <i>BMC Genomics</i> , 2017, 18, 105.	1.2	2
5016	High-throughput validation of ceRNA regulatory networks. <i>BMC Genomics</i> , 2017, 18, 418.	1.2	46
5017	Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials. <i>BMC Medical Research Methodology</i> , 2017, 17, 83.	1.4	10
5018	Is cancer a pure growth curve or does it follow a kinetics of dynamical structural transformation?. <i>BMC Cancer</i> , 2017, 17, 174.	1.1	23
5019	Infections and cancer: the "fifty shades of immunity" hypothesis. <i>BMC Cancer</i> , 2017, 17, 257.	1.1	51
5020	Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. <i>BMC Cancer</i> , 2017, 17, 260.	1.1	27
5021	Emerging role of mutations in epigenetic regulators including MLL2 derived from The Cancer Genome Atlas for cervical cancer. <i>BMC Cancer</i> , 2017, 17, 252.	1.1	13
5022	The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients. <i>BMC Cancer</i> , 2017, 17, 306.	1.1	15
5023	Immunotherapy in head and neck cancer: aiming at EXTREME precision. <i>BMC Medicine</i> , 2017, 15, 110.	2.3	64
5024	Spotlight on landmark oncology trials: the latest evidence and novel trial designs. <i>BMC Medicine</i> , 2017, 15, 111.	2.3	3
5025	Human basigin up-regulates a cascade set of interferon-stimulated genes with anti-cancerous properties in a lung cancer model. <i>Cancer Cell International</i> , 2017, 17, 18.	1.8	6

#	ARTICLE	IF	CITATIONS
5026	HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells. <i>Molecular Cancer</i> , 2017, 16, 38.	7.9	39
5027	Precision medicine in breast cancer: reality or utopia?. <i>Journal of Translational Medicine</i> , 2017, 15, 139.	1.8	56
5028	Molecular imaging biomarkers for cell-based immunotherapies. <i>Journal of Translational Medicine</i> , 2017, 15, 140.	1.8	11
5029	The era of bioengineering: how will this affect the next generation of cancer immunotherapy?. <i>Journal of Translational Medicine</i> , 2017, 15, 142.	1.8	16
5030	Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. <i>Diagnostic Pathology</i> , 2017, 12, 45.	0.9	93
5031	Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs. <i>Journal of Hematology and Oncology</i> , 2017, 10, 89.	6.9	60
5032	Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 124.	6.9	42
5033	Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 36.	3.5	24
5034	AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 65.	3.5	58
5035	miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 72.	2.2	43
5036	SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling. <i>Genome Biology</i> , 2017, 18, 66.	3.8	26
5037	Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. <i>Clinical Epigenetics</i> , 2017, 9, 59.	1.8	118
5038	Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 73.	0.4	47
5039	The undifferentiated carcinoma that became a melanoma: Re-biopsy of a cancer of an unknown primary site: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 82.	0.4	13
5040	The NF1 somatic mutational landscape in sporadic human cancers. <i>Human Genomics</i> , 2017, 11, 13.	1.4	203
5041	Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma. <i>Biomarker Research</i> , 2017, 5, 6.	2.8	8
5042	Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. , 2017, 5, 22.		217
5043	Immunotherapy biomarkers 2016: overcoming the barriers. , 2017, 5, 29.		21

#	ARTICLE	IF	CITATIONS
5044	Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. , 2017, 5, 25.		35
5045	Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. , 2017, 5, 31.		45
5046	Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer. , 2017, 5, 39.		56
5047	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
5048	Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. , 2017, 5, 46.		64
5049	Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. , 2017, 5, 45.		20
5050	Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. , 2017, 5, 49.		29
5051	Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. , 2017, 5, 52.		42
5052	Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. <i>Oncologist</i> , 2017, 22, 1232-1237.	1.9	109
5053	MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer. <i>Oncology Letters</i> , 2017, 14, 958-964.	0.8	15
5054	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2017, 3, 1511.	3.4	131
5055	Herpesviral vectors and their application in oncolytic therapy, vaccination, and gene transfer. <i>Virus Genes</i> , 2017, 53, 741-748.	0.7	10
5056	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	1.3	76
5057	PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. <i>Modern Pathology</i> , 2017, 30, 1411-1421.	2.9	151
5058	Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7623-7628.	3.3	38
5059	Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity. <i>Journal of Experimental Medicine</i> , 2017, 214, 2231-2241.	4.2	100
5060	Radiotherapy and Immune Checkpoint Blockade for Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 32-39.	1.0	28
5061	Immunotherapy of Prostate Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2017, 23, 6764-6770.	3.2	173

#	ARTICLE	IF	CITATIONS
5062	PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF. <i>Cell Death and Differentiation</i> , 2017, 24, 1705-1716.	5.0	64
5063	A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma. <i>Cancer Biology and Therapy</i> , 2017, 18, 547-551.	1.5	36
5064	Immune checkpoints in chronic obstructive pulmonary disease. <i>European Respiratory Review</i> , 2017, 26, 170045.	3.0	27
5065	Protein network construction using reverse phase protein array data. <i>Methods</i> , 2017, 124, 89-99.	1.9	5
5066	Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001974.	0.5	54
5067	Modeling the Dichotomy of the Immune Response to Cancer: Cytotoxic Effects and Tumor-Promoting Inflammation. <i>Bulletin of Mathematical Biology</i> , 2017, 79, 1426-1448.	0.9	35
5068	Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 33-43.	2.0	30
5069	Myeloid-derived suppressor cells and tumor escape from immune surveillance. <i>Seminars in Immunopathology</i> , 2017, 39, 295-305.	2.8	63
5070	Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw207.	3.0	26
5071	Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study. <i>Chinese Journal of Integrative Medicine</i> , 2017, 23, 733-739.	0.7	17
5072	PD-1/PD-L1 immune-checkpoint blockade in B-cell lymphomas. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 203-220.	12.5	358
5073	Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 28-35.	2.0	120
5074	Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines. <i>Head and Neck Pathology</i> , 2017, 11, 203-211.	1.3	23
5075	Analysis of the interplay between methylation and expression reveals its potential role in cancer aetiology. <i>Functional and Integrative Genomics</i> , 2017, 17, 53-68.	1.4	14
5076	Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. <i>Oncologist</i> , 2017, 22, 3-11.	1.9	34
5077	Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. <i>Modern Pathology</i> , 2017, 30, 340-349.	2.9	138
5078	Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 843-853.	1.4	51
5079	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. <i>Cancer Research</i> , 2017, 77, 839-850.	0.4	195

#	ARTICLE	IF	CITATIONS
5080	Combinatorial immunotherapy for melanoma. <i>Cancer Gene Therapy</i> , 2017, 24, 141-147.	2.2	24
5081	The molecular basis of breast cancer pathological phenotypes. <i>Journal of Pathology</i> , 2017, 241, 375-391.	2.1	86
5082	Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b+Ly6G+ intratumor myeloid cells through the TICAM-1 signaling pathway. <i>Cell Death and Differentiation</i> , 2017, 24, 385-396.	5.0	28
5083	Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. <i>Annals of Oncology</i> , 2017, 28, 34-43.	0.6	198
5084	Distinct patterns of cytolytic T cell activation by different tumour cells revealed by Ca ²⁺ signalling and granule mobilization. <i>Immunology</i> , 2017, 150, 199-212.	2.0	3
5085	Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2017, 105, 383-386.	0.7	59
5086	Cancer immunotherapy in patients with preexisting autoimmune disorders. <i>Seminars in Immunopathology</i> , 2017, 39, 333-337.	2.8	31
5087	Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. <i>Journal of Gastroenterology</i> , 2017, 52, 265-275.	2.3	88
5088	Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw192.	3.0	296
5089	KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2017, 140, 930-937.	2.3	28
5090	Genome evolution in ductal carcinoma <i>in situ</i> : invasion of the clones. <i>Journal of Pathology</i> , 2017, 241, 208-218.	2.1	70
5091	Basis for molecular diagnostics and immunotherapy for esophageal cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 33-45.	1.1	23
5092	Genotype/immunotype™ correlations in resected NSCLC. <i>Annals of Oncology</i> , 2017, 28, 7-8.	0.6	7
5093	Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 11-20.	1.3	88
5094	Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 119-128.	2.0	89
5095	Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026054.	2.9	94
5096	TP53 Mutations in Breast and Ovarian Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026252.	2.9	116
5097	Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 161-170.	2.0	39

#	ARTICLE	IF	CITATIONS
5098	Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance. <i>Annals of Oncology</i> , 2017, 28, 457-467.	0.6	27
5099	Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1. <i>Head and Neck</i> , 2017, 39, E34-E39.	0.9	12
5100	Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 21-28.	1.3	85
5101	Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2017, 71, 169-176.	0.8	16
5102	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. <i>Annals of Oncology</i> , 2017, 28, 57-74.	0.6	45
5103	Analysis of genes involved in the PI3K/Akt pathway in radiation- and MNU-induced rat mammary carcinomas. <i>Journal of Radiation Research</i> , 2017, 58, 183-194.	0.8	9
5104	Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them. <i>Cancer Gene Therapy</i> , 2017, 24, 121-129.	2.2	21
5105	Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. <i>Bioengineered</i> , 2017, 8, 367-373.	1.4	7
5106	Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment. <i>Cancer Research</i> , 2017, 77, 520-531.	0.4	18
5107	An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi. <i>Cancer</i> , 2017, 123, 617-628.	2.0	86
5108	Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. <i>Laboratory Investigation</i> , 2017, 97, 176-186.	1.7	14
5109	Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non"small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 60-67.	1.1	6
5110	Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. <i>Modern Pathology</i> , 2017, 30, 278-285.	2.9	77
5111	Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 45-50.	2.0	55
5112	Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 528-532.	1.4	30
5113	Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1 β , IL8, CXCL5, and Mip-1 α . <i>Clinical Cancer Research</i> , 2017, 23, 2346-2355.	3.2	148
5114	MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 143-155.	1.9	31
5115	The challenges of tumor genetic diversity. <i>Cancer</i> , 2017, 123, 917-927.	2.0	67

#	ARTICLE	IF	CITATIONS
5116	Preclinical Pharmacokinetics and Biodistribution Studies of ⁸⁹ Zr-Labeled Pembrolizumab. <i>Journal of Nuclear Medicine</i> , 2017, 58, 162-168.	2.8	152
5117	DMAK: A curated pan-cancer DNA methylation annotation knowledgebase. <i>Bioengineered</i> , 2017, 8, 182-190.	1.4	4
5118	Genomic complexity of multiple myeloma and its clinical implications. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 100-113.	12.5	413
5119	A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. <i>JAMA Oncology</i> , 2017, 3, 256.	3.4	164
5120	Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. <i>Journal of Human Genetics</i> , 2017, 62, 15-24.	1.1	122
5121	The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia. <i>Leukemia</i> , 2017, 31, 470-478.	3.3	78
5122	Molecular mechanisms involved in dendritic cell dysfunction in cancer. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 761-776.	2.4	77
5123	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2017, 22, 81-88.	1.9	128
5124	Oral Squamous Carcinoma Cells Express B7-H1 and B7-DC Receptors in Vivo. <i>Pathology and Oncology Research</i> , 2017, 23, 99-110.	0.9	17
5125	HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status. <i>Clinical Cancer Research</i> , 2017, 23, 825-832.	3.2	78
5126	PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 454-465.	3.2	126
5127	Adaptive immunity programmes in breast cancer. <i>Immunology</i> , 2017, 150, 25-34.	2.0	43
5128	2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. <i>Supportive Care in Cancer</i> , 2017, 25, 297-301.	1.0	12
5129	DM-BLD: differential methylation detection using a hierarchical Bayesian model exploiting local dependency. <i>Bioinformatics</i> , 2017, 33, 161-168.	1.8	17
5130	Parkin and mitophagy in cancer. <i>Oncogene</i> , 2017, 36, 1315-1327.	2.6	201
5131	A novel regulatory network among LncRpa, CircRar1, MiR-671 and apoptotic genes promotes lead-induced neuronal cell apoptosis. <i>Archives of Toxicology</i> , 2017, 91, 1671-1684.	1.9	104
5132	PSSV: a novel pattern-based probabilistic approach for somatic structural variation identification. <i>Bioinformatics</i> , 2017, 33, 177-183.	1.8	5
5133	Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 176-189.	2.2	44

#	ARTICLE	IF	CITATIONS
5134	Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. <i>Journal of Neuro-Oncology</i> , 2017, 131, 105-115.	1.4	61
5135	Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 602-611.	2.7	76
5136	Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. <i>Oncogene</i> , 2017, 36, 1559-1572.	2.6	96
5137	Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. <i>Oncogene</i> , 2017, 36, 1339-1350.	2.6	39
5138	Local delivery of checkpoints antibodies. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 245-248.	1.4	16
5139	Anti-PD-L1 peptide improves survival in sepsis. <i>Journal of Surgical Research</i> , 2017, 208, 33-39.	0.8	92
5140	Anti-regulatory T cells. <i>Seminars in Immunopathology</i> , 2017, 39, 317-326.	2.8	35
5141	An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 85-93.	1.6	28
5142	Three-dimensional image-based mechanical modeling for predicting the response of breast cancer to neoadjuvant therapy. <i>Computer Methods in Applied Mechanics and Engineering</i> , 2017, 314, 494-512.	3.4	53
5143	Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. <i>Kidney International Reports</i> , 2017, 2, 108-123.	0.4	72
5144	Advances in immunotherapy for the treatment of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 1-9.	1.4	65
5145	Treatment of Multifocal Renal Cell Carcinoma in a Solitary Kidney With Nivolumab. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e165-e167.	0.9	2
5146	Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. <i>Annals of Oncology</i> , 2017, 28, 44-56.	0.6	43
5147	Global chemotherapy development for gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 92-101.	2.7	38
5148	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. <i>Modern Pathology</i> , 2017, 30, 69-84.	2.9	48
5149	Considerations for successful cancer immunotherapy in aged hosts. <i>Clinical and Experimental Immunology</i> , 2017, 187, 53-63.	1.1	56
5150	“Omic and Electronic Health Record Big Data Analytics for Precision Medicine. <i>IEEE Transactions on Biomedical Engineering</i> , 2017, 64, 263-273.	2.5	198
5151	Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. <i>Annals of Oncology</i> , 2017, 28, 83-89.	0.6	97

#	ARTICLE	IF	CITATIONS
5152	Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 5-7.	1.3	23
5153	Irreversible electroporation inhibits pro-cancer inflammatory signaling in triple negative breast cancer cells. <i>Bioelectrochemistry</i> , 2017, 113, 42-50.	2.4	23
5154	Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. <i>Annals of Oncology</i> , 2017, 28, 75-82.	0.6	159
5155	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. <i>Nature Reviews Urology</i> , 2017, 14, 15-25.	1.9	210
5156	Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. <i>Oncogene</i> , 2017, 36, 585-592.	2.6	15
5157	Personalized cancer vaccines: Targeting the cancer mutanome. <i>Vaccine</i> , 2017, 35, 1094-1100.	1.7	63
5158	Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. <i>Cell Research</i> , 2017, 27, 147-150.	5.7	111
5159	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. <i>JAMA Oncology</i> , 2017, 3, 244.	3.4	191
5160	PD-1/PD-L1 blockade in renal cell cancer. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 77-84.	1.3	27
5161	Inactivation of Capicua drives cancer metastasis. <i>Nature Genetics</i> , 2017, 49, 87-96.	9.4	130
5162	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3214-3222.	3.2	44
5163	Estimating Survival in Patients With Lung Cancer and Brain Metastases. <i>JAMA Oncology</i> , 2017, 3, 827.	3.4	543
5164	CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 81-90.	1.4	4
5165	PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 317-320.	1.3	81
5166	Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors. <i>Journal of Human Genetics</i> , 2017, 62, 397-405.	1.1	55
5167	Progress with palbociclib in breast cancer: latest evidence and clinical considerations. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 83-105.	1.4	45
5168	The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026112.	2.9	42
5170	The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sjögren's syndrome and systemic sclerosis. <i>Immunologic Research</i> , 2017, 65, 622-629.	1.3	16

#	ARTICLE	IF	CITATIONS
5171	Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 533-540.	1.2	41
5172	Next generation predictive biomarkers for immune checkpoint inhibition. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 179-190.	2.7	84
5173	Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. <i>Nano Letters</i> , 2017, 17, 1326-1335.	4.5	506
5174	Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 221-234.	12.5	89
5175	IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer. <i>Cancer Research</i> , 2017, 77, 1119-1126.	0.4	35
5176	Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling. <i>Oncogene</i> , 2017, 36, 4235-4242.	2.6	59
5177	Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors. <i>Neuroimaging Clinics of North America</i> , 2017, 27, 155-166.	0.5	8
5178	Immune-Related Adverse Effects of Cancer Immunotherapy—Implications for Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 65-78.	0.8	101
5179	Genomic Amplification of <i>CD274</i> (PD-L1) in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1220-1226.	3.2	92
5180	Clinicopathological features of programmed death ligand-1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. <i>Gastric Cancer</i> , 2017, 20, 407-415.	2.7	189
5181	ALK alterations and inhibition in lung cancer. <i>Seminars in Cancer Biology</i> , 2017, 42, 81-88.	4.3	33
5182	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 110-120.	0.5	108
5183	Circulating and disseminated tumour cells—mechanisms of immune surveillance and escape. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 155-167.	12.5	426
5184	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017, 23, 1388-1396.	3.2	261
5185	microRNAs with AAGUGC seed motif constitute an integral part of an oncogenic signaling network. <i>Oncogene</i> , 2017, 36, 731-745.	2.6	19
5186	A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. <i>CNS Oncology</i> , 2017, 6, 29-43.	1.2	34
5187	PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2. <i>Oncogene</i> , 2017, 36, 410-422.	2.6	33
5188	Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 135-141.	0.7	24

#	ARTICLE	IF	CITATIONS
5189	Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. <i>Oncologist</i> , 2017, 22, 70-80.	1.9	58
5190	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	139
5191	Are we entering the era of combination therapy for melanoma?. <i>Melanoma Management</i> , 2017, 4, 5-8.	0.1	0
5192	Tâ€cell immunoglobulin and mucin domainâ€containing proteinâ€3 and galectinâ€9 protein expression: Potential prognostic significance in esophageal squamous cell carcinoma for Chinese patients. <i>Oncology Letters</i> , 2017, 14, 8007-8013.	0.8	11
5193	A Case of Immune Thrombocytopenia as a Rare Side Effect of an Immunotherapy with PD1-Blocking Agents for Metastatic Melanoma. <i>Transfusion Medicine and Hemotherapy</i> , 2017, 44, 426-428.	0.7	35
5194	Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy. <i>Medicine (United States)</i> , 2017, 96, e9431.	0.4	36
5195	CoCl2 increases the expression of hypoxic markers HIFâ€1â, VEGF and CXCR4 in breast cancer MCFâ€7 cells. <i>Oncology Letters</i> , 2018, 15, 1119-1124.	0.8	27
5196	Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer. <i>Medicine (United States)</i> , 2017, 96, e9431.	0.4	36
5197	Optimal duration of adjuvant endocrine therapy: how to apply the newest data. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 679-692.	1.4	10
5198	Stromal and intraepithelial tumorâ€infiltrating lymphocytes in colorectal carcinoma. <i>Oncology Letters</i> , 2017, 14, 6421-6432.	0.8	27
5199	Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer. <i>Medicine (United States)</i> , 2017, 96, e9431.	0.4	36
5200	Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma. <i>Journal of the Endocrine Society</i> , 2017, 1, 646-649.	0.1	75
5201	Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents. <i>Cancer Growth and Metastasis</i> , 2017, 10, 117906441770928.	3.5	24
5202	Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients. <i>Medicine (United States)</i> , 2017, 96, e8931.	0.4	21
5203	Targeted therapy of brain metastases: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 781-796.	1.4	46
5204	Contribution of Adipose Tissue to Development of Cancer. , 2017, 8, 237-282.		139
5205	De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 457-465.	1.7	60
5206	PDâ€L1 expression is associated with p16INK4A expression in nonâ€oropharyngeal head and neck squamous cell carcinoma. <i>Oncology Letters</i> , 2017, 15, 2259-2265.	0.8	11

#	ARTICLE	IF	CITATIONS
5207	p16Ink4a and p21Cip1/Waf1 promote tumour growth by enhancing myeloid-derived suppressor cells chemotaxis. <i>Nature Communications</i> , 2017, 8, 2050.	5.8	47
5208	The Successful Treatment of Pulmonary Pleomorphic Carcinoma with Pembrolizumab: A Case Report. <i>Case Reports in Oncology</i> , 2017, 10, 752-757.	0.3	31
5209	Hypoxia modulates the stem cell population and induces EMT in the MCF-10A breast epithelial cell line. <i>Oncology Reports</i> , 2017, 39, 483-490.	1.2	13
5210	Genomic regression analysis of coordinated expression. <i>Nature Communications</i> , 2017, 8, 2187.	5.8	17
5211	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. <i>Nature Communications</i> , 2017, 8, 2193.	5.8	99
5212	Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer. <i>Journal of Bone Oncology</i> , 2017, 9, 59-64.	1.0	32
5213	Informatics for cancer immunotherapy. <i>Annals of Oncology</i> , 2017, 28, xii56-xii73.	0.6	19
5214	Immunotherapy in ovarian cancer. <i>Annals of Oncology</i> , 2017, 28, viii1-viii7.	0.6	276
5215	Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2017, 8, 310-314.	0.4	22
5216	Preclinical and clinical development of neoantigen vaccines. <i>Annals of Oncology</i> , 2017, 28, xii11-xii17.	0.6	160
5217	High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e612-e612.	2.8	132
5218	Biology and evolution of poorly differentiated neuroendocrine tumors. <i>Nature Medicine</i> , 2017, 23, 664-673.	15.2	192
5219	The role of MDM2 and MDM4 in breast cancer development and prevention. <i>Journal of Molecular Cell Biology</i> , 2017, 9, 53-61.	1.5	56
5220	Targeting Neoantigens in Glioblastoma. <i>Neurosurgery</i> , 2017, 64, 165-176.	0.6	24
5221	Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 769-779.	1.4	11
5222	Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 7, 988-990.	0.4	19
5223	Paradoxical response to osimertinib therapy in a patient with T790M-mutated lung adenocarcinoma. <i>Molecular and Clinical Oncology</i> , 2018, 8, 175-177.	0.4	3
5224	TNF α blockade overcomes resistance to anti-PD-1 in experimental melanoma. <i>Nature Communications</i> , 2017, 8, 2256.	5.8	284

#	ARTICLE	IF	CITATIONS
5225	Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 19-31.	0.8	212
5226	Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 91-104.	0.8	26
5227	Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab. <i>Scientific Reports</i> , 2017, 7, 18027.	1.6	21
5228	Case report on the role of radiofrequency-assisted spleen-preserving surgery for splenic metastasis in the era of check-point inhibitors. <i>Medicine (United States)</i> , 2017, 96, e9106.	0.4	7
5229	Immune checkpoint inhibitors in the treatment of advanced mucosal melanoma. <i>Melanoma Management</i> , 2017, 4, 161-167.	0.1	7
5230	Epigenetic and genetic deregulation in cancer target distinct signaling pathway domains. <i>Nucleic Acids Research</i> , 2017, 45, 583-596.	6.5	18
5231	Expression levels of UL16 binding protein 1 and natural killer group 2 member D affect overall survival in patients with gastric cancer following gastrectomy. <i>Oncology Letters</i> , 2017, 15, 747-754.	0.8	15
5232	Normal breast tissue DNA methylation differences at regulatory elements are associated with the cancer risk factor age. <i>Breast Cancer Research</i> , 2017, 19, 81.	2.2	66
5233	An update on the relevance of vaccine research for the treatment of metastatic melanoma. <i>Melanoma Management</i> , 2017, 4, 203-215.	0.1	8
5234	Interrelation of the Circulating and Tissue MicroRNA-21 with Tissue PDCD4 Expression and the Invasiveness of Iraqi Female Breast Tumors. <i>Indian Journal of Clinical Biochemistry</i> , 2017, 34, 26-38.	0.9	10
5235	Association between inflammation and cancer stem cell phenotype in breast cancer. <i>Oncology Letters</i> , 2018, 15, 2380-2386.	0.8	23
5236	Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3. <i>Oncogene</i> , 2017, 36, 5709-5721.	2.6	81
5237	Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2017, 57, 87-97.	0.3	26
5238	Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey. <i>Lung Cancer Management</i> , 2017, 6, 93-107.	1.5	5
5239	Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. <i>Chinese Journal of Cancer</i> , 2017, 36, 94.	4.9	47
5240	Precision Medicine in Oncology and Immuno-Oncology: Where We Stand and Where We're Headed. <i>Biomedicine Hub</i> , 2017, 2, 1-8.	0.4	1
5241	Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden. <i>BMC Cancer</i> , 2017, 17, 888.	1.1	46
5243	MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1. <i>BMC Cancer</i> , 2017, 17, 750.	1.1	23

#	ARTICLE	IF	CITATIONS
5244	Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report. <i>BMC Cancer</i> , 2017, 17, 778.	1.1	22
5245	A Retrospective Study, an Initial Lesion of Primary Malignant Melanoma of the Esophagus Revealed by Endoscopy. <i>Internal Medicine</i> , 2017, 56, 2133-2137.	0.3	6
5246	Why cure, why now?. <i>Journal of Medical Ethics</i> , 2017, 43, 67-70.	1.0	17
5247	Is Mastectomy Oncologically Safer than Breast-Conserving Treatment in Early Breast Cancer. <i>Breast Care</i> , 2017, 12, 385-390.	0.8	19
5248	The Regulation of Pathways of Inflammation and Resolution in Immune Cells and Cancer Stem Cells by Selenium. <i>Advances in Cancer Research</i> , 2017, 136, 153-172.	1.9	25
5249	Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances. <i>Bosnian Journal of Basic Medical Sciences</i> , 2017, 17, 274-275.	0.6	14
5250	Association of the long non-coding RNA MALAT1 with the polycomb repressive complex pathway in T and NK cell lymphoma. <i>Oncotarget</i> , 2017, 8, 31305-31317.	0.8	45
5251	Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma. <i>Medical Science Monitor</i> , 2017, 23, 4619-4632.	0.5	25
5252	HDAC10 promotes angiogenesis in endothelial cells through the PTPN22/ERK axis. <i>Oncotarget</i> , 2017, 8, 61338-61349.	0.8	26
5253	Lynch syndrome-related small intestinal adenocarcinomas. <i>Oncotarget</i> , 2017, 8, 21483-21500.	0.8	25
5254	Targeted therapies for gastric cancer: failures and hopes from clinical trials. <i>Oncotarget</i> , 2017, 8, 57654-57669.	0.8	99
5255	Fatty acid metabolism in breast cancer subtypes. <i>Oncotarget</i> , 2017, 8, 29487-29500.	0.8	150
5256	Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives. <i>Cureus</i> , 2017, 9, e1258.	0.2	6
5257	The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab. <i>Annals of Research Hospitals</i> , 2017, 1, 1-1.	0.0	1
5258	Genomic Profiling to Expand Management Options for Locally Advanced Esophagogastric Cancers: A Proof of Principle Case. <i>JCO Precision Oncology</i> , 2017, 1, 1-6.	1.5	1
5259	PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 58457-58468.	0.8	42
5260	A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma. <i>Oncotarget</i> , 2017, 8, 68291-68304.	0.8	71
5261	Decreased Serum Concentration of Total IgG Is Related to Tumor Progression in Gastric Cancer Patients. <i>Yonago Acta Medica</i> , 2017, 60, 119-125.	0.3	11

#	ARTICLE	IF	CITATIONS
5262	DNA methylation-based immune response signature improves patient diagnosis in multiple cancers. <i>Journal of Clinical Investigation</i> , 2017, 127, 3090-3102.	3.9	110
5263	Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance. <i>Oncotarget</i> , 2017, 8, 70982-71001.	0.8	42
5264	Meta-analysis of programmed cell death 1 polymorphisms with systemic lupus erythematosus risk. <i>Oncotarget</i> , 2017, 8, 36885-36897.	0.8	20
5265	Immunotherapeutic approaches for hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 33897-33910.	0.8	50
5266	Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis. <i>Oncotarget</i> , 2017, 8, 41334-41347.	0.8	22
5267	Protein tyrosine phosphatase receptor-type $\hat{\gamma}$ acts as a negative regulator suppressing breast cancer. <i>Oncotarget</i> , 2017, 8, 98798-98811.	0.8	11
5268	Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma. <i>Experimental Hematology and Oncology</i> , 2017, 6, 29.	2.0	12
5269	PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. <i>Oncotarget</i> , 2017, 8, 15894-15911.	0.8	84
5270	Developing T-cell therapies for lymphoma without receptor engineering. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 622-631.	0.9	2
5271	PD-L1 and c-MET expression and survival in patients with small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 53978-53988.	0.8	32
5272	Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy. <i>JCO Precision Oncology</i> , 2017, 1, 1-9.	1.5	3
5273	Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified. <i>Blood Advances</i> , 2017, 1, 486-493.	2.5	35
5274	Pseudoprogression in lung adenocarcinoma during treatment with nivolumab. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-219919.	0.2	11
5275	Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	1.5	3
5276	Programmed Cell Death-1/Programmed Death-ligand 1 Pathway. <i>Chinese Medical Journal</i> , 2017, 130, 986-992.	0.9	15
5277	Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease?. <i>ACG Case Reports Journal</i> , 2017, 4, e112.	0.2	35
5278	Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. <i>Blood Advances</i> , 2017, 1, 1884-1890.	2.5	40
5279	Developing T-cell therapies for lymphoma without receptor engineering. <i>Blood Advances</i> , 2017, 1, 2579-2590.	2.5	7

#	ARTICLE	IF	CITATIONS
5280	HDAC inhibition potentiates immunotherapy in triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 114156-114172.	0.8	139
5281	Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2017, Volume 10, 325-339.	0.8	52
5282	Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma. <i>Cancer Management and Research</i> , 2017, Volume 9, 741-750.	0.9	19
5283	ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4859-4867.	1.0	11
5284	Analysis of Class I Major Histocompatibility Complex Gene Transcription in Human Tumors Caused by Human Papillomavirus Infection. <i>Viruses</i> , 2017, 9, 252.	1.5	29
5285	Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 223-236.	0.9	16
5286	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. <i>Ecancermedalscience</i> , 2017, 11, 787.	0.6	34
5287	Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation. <i>Frontiers in Pharmacology</i> , 2017, 7, 515.	1.6	3
5288	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 49.	1.6	459
5289	Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting. <i>Frontiers in Pharmacology</i> , 2017, 8, 51.	1.6	59
5290	Immune Checkpoint in Glioblastoma: Promising and Challenging. <i>Frontiers in Pharmacology</i> , 2017, 8, 242.	1.6	133
5291	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2017, 8, 730.	1.6	350
5292	Cancer Immunoprevention and Public Health. <i>Frontiers in Public Health</i> , 2017, 5, 101.	1.3	10
5293	Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. <i>Journal of Cancer</i> , 2017, 8, 410-416.	1.2	176
5294	Targeting immune checkpoints in malignant glioma. <i>Oncotarget</i> , 2017, 8, 7157-7174.	0.8	42
5295	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1259-1271.	0.9	16
5296	Immunotherapy in Gastrointestinal Cancers. <i>BioMed Research International</i> , 2017, 2017, 1-17.	0.9	69
5297	Focal adhesion kinases crucially regulate TGF β -induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1783-1792.	1.0	35

#	ARTICLE	IF	CITATIONS
5298	Treating & EGFR mutation resistance in non-small cell lung cancer role of osimertinib. The Application of Clinical Genetics, 2017, Volume 10, 49-56.	1.4	25
5299	Immune Checkpoint Inhibitors in Melanoma and HIV Infection. Open AIDS Journal, 2017, 11, 91-100.	0.1	12
5300	Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers, 2017, 9, 13.	1.7	40
5301	Mutation Clusters from Cancer Exome. Genes, 2017, 8, 201.	1.0	1
5302	Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients. Journal of Breast Cancer, 2017, 20, 246.	0.8	17
5303	Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Advances, 2017, 1, 2643-2654.	2.5	91
5304	Bevacizumab in the treatment of NSCLC: patient selection and perspectives. Lung Cancer: Targets and Therapy, 2017, Volume 8, 259-269.	1.3	37
5305	New PD-L1 inhibitors in non-small cell lung cancer impact of atezolizumab. Lung Cancer: Targets and Therapy, 2017, Volume 8, 67-78.	1.3	27
5306	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. OncoTargets and Therapy, 2017, Volume 10, 3363-3372.	1.0	11
5307	Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. OncoTargets and Therapy, 2017, Volume 10, 2097-2106.	1.0	45
5308	Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. OncoTargets and Therapy, 2017, Volume 10, 2349-2363.	1.0	35
5309	Bilateral Uveitis and Keratitis Following Nivolumab Treatment for Metastatic Melanoma. Medical Case Reports (Wilmington, Del), 2017, 03, .	0.1	19
5310	Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful. Korean Journal of Radiology, 2017, 18, 54.	1.5	23
5311	Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles. Immune Network, 2017, 17, 378.	1.6	70
5312	Phase II Trial of Adjuvant Immunotherapy with Autologous Tumor-derived Gp96 Vaccination in Patients with Gastric Cancer. Journal of Cancer, 2017, 8, 1826-1832.	1.2	24
5313	The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer. Oncotarget, 2017, 8, 57826-57835.	0.8	24
5314	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. ImmunoTargets and Therapy, 2017, Volume 6, 51-71.	2.7	101
5315	Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Korean Journal of Radiology, 2017, 18, 42.	1.5	33

#	ARTICLE	IF	CITATIONS
5316	Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. Medical Sciences (Basel, Switzerland), 2017, 5, 28.	1.3	22
5317	Associations between gene expression profiles of invasive breast cancer and Breast Imaging Reporting and Data System MRI lexicon. Annals of Surgical Treatment and Research, 2017, 93, 18.	0.4	7
5318	Depletion of CTCF in Breast Cancer Cells Selectively Induces Cancer Cell Death via p53. Journal of Cancer, 2017, 8, 2124-2131.	1.2	14
5319	The prognostic value of long noncoding RNA HOTTIP on clinical outcomes in breast cancer. Oncotarget, 2017, 8, 6833-6844.	0.8	35
5320	The landscape of DNA methylation-mediated regulation of long non-coding RNAs in breast cancer. Oncotarget, 2017, 8, 51134-51150.	0.8	12
5321	A six-long non-coding RNAs signature as a potential prognostic marker for survival prediction of ER-positive breast cancer patients. Oncotarget, 2017, 8, 67861-67870.	0.8	19
5322	Epigenetic Silencing of <i>MORT1A</i> Is an Early Event in Cancer and Is Associated with Luminal, Receptor Positive Breast Tumor Subtypes. Journal of Breast Cancer, 2017, 20, 198.	0.8	19
5323	Prognostic Significance of Host-related Biomarkers for Survival in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Cancer, 2017, 8, 2974-2983.	1.2	26
5324	Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Lung Cancer: Targets and Therapy, 2017, Volume 8, 1-11.	1.3	6
5325	Molecular classification of esophagogastric junction carcinoma correlated with prognosis. OncoTargets and Therapy, 2017, Volume 10, 4765-4772.	1.0	5
5326	Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment. Patient Preference and Adherence, 2017, Volume 11, 1389-1399.	0.8	23
5327	Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer. Cancers, 2017, 9, 5.	1.7	99
5328	Immune Checkpoints as a Target for Colorectal Cancer Treatment. International Journal of Molecular Sciences, 2017, 18, 1324.	1.8	112
5329	Cancer immunology and melanoma immunotherapy. Anais Brasileiros De Dermatologia, 2017, 92, 830-835.	0.5	8
5330	<i>NRAS</i> -mutant melanoma: current challenges and future prospect. OncoTargets and Therapy, 2017, Volume 10, 3941-3947.	1.0	122
5331	HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles. Current Cancer Drug Targets, 2017, 17, 637-649.	0.8	65
5332	Cost analysis of adverse events associated with non-small cell lung cancer management in France. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 443-449.	0.7	9
5333	Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 2537-2549.	2.0	6

#	ARTICLE	IF	CITATIONS
5334	The new era of nanotechnology, an alternative to change cancer treatment. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2871-2890.	2.0	135
5335	Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade. <i>BioMed Research International</i> , 2017, 2017, 1-5.	0.9	49
5336	Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. <i>Oncotarget</i> , 2017, 8, 79809-79815.	0.8	27
5337	Prognostic immune-related gene models for breast cancer: a pooled analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4423-4433.	1.0	10
5338	Role of tumor microenvironment in tumorigenesis. <i>Journal of Cancer</i> , 2017, 8, 761-773.	1.2	1,048
5339	Targeting macrophage anti-tumor activity to suppress melanoma progression. <i>Oncotarget</i> , 2017, 8, 18486-18496.	0.8	18
5340	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2017, Volume 7, 1-11.	5.5	49
5341	Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 73-82.	2.7	121
5342	Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 919-926.	1.0	77
5343	The role and significance of VEGFR2⁺ regulatory T cells in tumor immunity. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4315-4319.	1.0	32
5344	HsigAtlas 1.0: a human immunosuppression gene database. <i>Database: the Journal of Biological Databases and Curation</i> , 2017, 2017, .	1.4	44
5345	Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1875.	1.8	26
5346	Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1936.	1.8	19
5347	Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2032.	1.8	27
5348	Control of NK Cell Activation by Immune Checkpoint Molecules. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2129.	1.8	64
5349	A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2134.	1.8	55
5350	Recent Advances in Comprehending the Signaling Pathways Involved in the Progression of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2321.	1.8	8
5351	Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2382.	1.8	8

#	ARTICLE	IF	CITATIONS
5352	Targeting Immune Cell Checkpoints during Sepsis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2413.	1.8	125
5353	The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2540.	1.8	96
5354	Immunotherapy for Prostate Cancer: Where We Are Headed. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2627.	1.8	47
5355	Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2642.	1.8	72
5356	Metabolic Portraits of Breast Cancer by HR MAS MR Spectroscopy of Intact Tissue Samples. <i>Metabolites</i> , 2017, 7, 18.	1.3	35
5357	PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer. <i>Molecules</i> , 2017, 22, 2277.	1.7	12
5358	RNA Biomarkers: Frontier of Precision Medicine for Cancer. <i>Non-coding RNA</i> , 2017, 3, 9.	1.3	106
5359	Detecting Disease Specific Pathway Substructures through an Integrated Systems Biology Approach. <i>Non-coding RNA</i> , 2017, 3, 20.	1.3	25
5360	Long Non-Coding RNA TUG1 Expression Is Associated with Different Subtypes in Human Breast Cancer. <i>Non-coding RNA</i> , 2017, 3, 26.	1.3	17
5361	Modulation of Ras/ERK and Phosphoinositide Signaling by Long-Chain n-3 PUFA in Breast Cancer and Their Potential Complementary Role in Combination with Targeted Drugs. <i>Nutrients</i> , 2017, 9, 185.	1.7	27
5362	Bacterial Toxins for Cancer Therapy. <i>Toxins</i> , 2017, 9, 236.	1.5	65
5363	Novel immunotherapy in metastatic renal cell carcinoma. <i>Investigative and Clinical Urology</i> , 2017, 58, 220.	1.0	16
5364	New Immunotherapy Strategies in Breast Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 68.	1.2	76
5365	Roles of Long Noncoding RNAs in Recurrence and Metastasis of Radiotherapy-Resistant Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1903.	1.8	66
5366	Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1517.	1.8	69
5367	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017, 23, 4675.	1.4	91
5368	Recent Advances in the Neoadjuvant Treatment of Breast Cancer. <i>Journal of Breast Cancer</i> , 2017, 20, 119.	0.8	55
5369	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIC 2-98 phase III trial. <i>International Journal of Oncology</i> , 2018, 52, 424-432.	1.4	9

#	ARTICLE	IF	CITATIONS
5370	Metabolomics Applications in Precision Medicine: An Oncological Perspective. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 2740-2751.	1.0	82
5371	EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1172.	1.8	73
5372	PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. <i>Frontiers in Pharmacology</i> , 2017, 8, 561.	1.6	1,276
5373	The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas. <i>Cancers</i> , 2017, 9, 134.	1.7	101
5374	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. <i>International Journal of Molecular Sciences</i> , 2017, 18, 645.	1.8	193
5375	Focused Ultrasound Immunotherapy for Central Nervous System Pathologies: Challenges and Opportunities. <i>Theranostics</i> , 2017, 7, 3608-3623.	4.6	93
5376	CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2017, 8, 269.	2.2	56
5377	Immunoregulatory Role of NK Cells in Tissue Inflammation and Regeneration. <i>Frontiers in Immunology</i> , 2017, 8, 301.	2.2	114
5378	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , 2017, 8, 1597.	2.2	225
5379	Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 332.	1.6	25
5380	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. <i>Theranostics</i> , 2017, 7, 3585-3594.	4.6	214
5381	An Efficient Electroporation Protocol for the Genetic Modification of Mammalian Cells. <i>Frontiers in Bioengineering and Biotechnology</i> , 2016, 4, 99.	2.0	45
5382	DGK-1±: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 16.	1.8	27
5383	A Comprehensive Infrastructure for Big Data in Cancer Research: Accelerating Cancer Research and Precision Medicine. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 83.	1.8	59
5384	The influence of radiation in the context of developing combination immunotherapies in cancer. , 2017, 5, 115-122.	1.4	12
5385	EMT and Treatment Resistance in Pancreatic Cancer. <i>Cancers</i> , 2017, 9, 122.	1.7	105
5386	PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	13
5387	Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 418-429.	0.6	20

#	ARTICLE	IF	CITATIONS
5388	The Consequences of Chromosome Segregation Errors in Mitosis and Meiosis. <i>Biology</i> , 2017, 6, 12.	1.3	118
5389	MYC-Driven Pathways in Breast Cancer Subtypes. <i>Biomolecules</i> , 2017, 7, 53.	1.8	152
5390	Viroimmunotherapy of Thoracic Cancers. <i>Biomedicines</i> , 2017, 5, 2.	1.4	11
5391	Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil". <i>Biomedicines</i> , 2017, 5, 8.	1.4	44
5392	Engineered Aptamers to Probe Molecular Interactions on the Cell Surface. <i>Biomedicines</i> , 2017, 5, 54.	1.4	17
5393	Immunotherapy for Pediatric Brain Tumors. <i>Brain Sciences</i> , 2017, 7, 137.	1.1	24
5394	Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer. <i>Cancers</i> , 2017, 9, 49.	1.7	53
5395	Immunotherapy for Colorectal Cancer. <i>Cancers</i> , 2017, 9, 50.	1.7	125
5396	Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment. <i>Cancers</i> , 2017, 9, 62.	1.7	9
5397	The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer. <i>Cancers</i> , 2017, 9, 81.	1.7	119
5398	Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review. <i>Cancers</i> , 2017, 9, 83.	1.7	44
5399	Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). <i>Cancers</i> , 2017, 9, 115.	1.7	26
5400	Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. <i>Cancers</i> , 2017, 9, 164.	1.7	26
5401	Ubiquitin Specific Peptidase 22 Regulates Histone H2B Mono-Ubiquitination and Exhibits Both Oncogenic and Tumor Suppressor Roles in Cancer. <i>Cancers</i> , 2017, 9, 167.	1.7	43
5402	Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer. <i>Cells</i> , 2017, 6, 12.	1.8	75
5403	Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives. <i>Diagnostics</i> , 2017, 7, 10.	1.3	38
5404	Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer. <i>Diseases (Basel)</i> , 2017, 5, 54.	1.0	54
5405	MYC Deregulation in Primary Human Cancers. <i>Genes</i> , 2017, 8, 151.	1.0	281

#	ARTICLE	IF	CITATIONS
5406	Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. <i>Genes</i> , 2017, 8, 217.	1.0	24
5407	Immuno-PET for Clinical Theranostic Approaches. <i>International Journal of Molecular Sciences</i> , 2017, 18, 57.	1.8	50
5408	Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 85.	1.8	25
5409	Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context. <i>International Journal of Molecular Sciences</i> , 2017, 18, 152.	1.8	20
5410	Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 194.	1.8	18
5411	Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. <i>International Journal of Molecular Sciences</i> , 2017, 18, 308.	1.8	353
5412	Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 459.	1.8	66
5413	Function and Clinical Implications of Long Non-Coding RNAs in Melanoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 715.	1.8	37
5414	Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 856.	1.8	20
5415	Epigenetic Strategies to Boost Cancer Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1108.	1.8	29
5416	Down-TM's Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1218.	1.8	7
5417	The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1374.	1.8	47
5418	Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1660.	1.8	33
5419	Cytokines in Male Fertility and Reproductive Pathologies: Immunoregulation and Beyond. <i>Frontiers in Endocrinology</i> , 2017, 8, 307.	1.5	146
5420	Cbl-b Deficiency Mediates Resistance to Programed Death-Ligand 1/Programed Death-1 Regulation. <i>Frontiers in Immunology</i> , 2017, 8, 42.	2.2	26
5421	High Endothelial Venules and Other Blood Vessels: Critical Regulators of Lymphoid Organ Development and Function. <i>Frontiers in Immunology</i> , 2017, 8, 45.	2.2	138
5422	Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation. <i>Frontiers in Immunology</i> , 2017, 8, 66.	2.2	102
5423	Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles. <i>Frontiers in Immunology</i> , 2017, 8, 69.	2.2	32

#	ARTICLE	IF	CITATIONS
5424	Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy. <i>Frontiers in Immunology</i> , 2017, 8, 71.	2.2	84
5425	Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity. <i>Frontiers in Immunology</i> , 2017, 8, 83.	2.2	38
5426	Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity. <i>Frontiers in Immunology</i> , 2017, 8, 86.	2.2	167
5427	The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 158.	2.2	20
5428	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. <i>Frontiers in Immunology</i> , 2017, 8, 267.	2.2	61
5429	Impact of Metabolism in on T-Cell Differentiation and Function and Cross Talk with Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2017, 8, 270.	2.2	103
5430	Inflammasomes in Inflammation-Induced Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 271.	2.2	76
5431	The Spontaneous Autoimmune Neuromyopathy in ICOSL ^{-/-} NOD Mice Is CD4 ⁺ T-Cell and Interferon- γ Dependent. <i>Frontiers in Immunology</i> , 2017, 8, 287.	2.2	6
5432	In Vivo Imaging Sheds Light on Immune Cell Migration and Function in Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 309.	2.2	21
5433	Role of Natural Killer Cells in HIV-Associated Malignancies. <i>Frontiers in Immunology</i> , 2017, 8, 315.	2.2	5
5434	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Frontiers in Immunology</i> , 2017, 8, 386.	2.2	27
5435	Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pneumonectomy. <i>Frontiers in Immunology</i> , 2017, 8, 456.	2.2	51
5436	Co-Inflammatory Roles of TGF β 1 in the Presence of TNF α Drive a Pro-inflammatory Fate in Mesenchymal Stem Cells. <i>Frontiers in Immunology</i> , 2017, 8, 479.	2.2	27
5437	Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. <i>Frontiers in Immunology</i> , 2017, 8, 555.	2.2	76
5438	Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential. <i>Frontiers in Immunology</i> , 2017, 8, 570.	2.2	34
5439	PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 572.	2.2	59
5440	Regulatory T Cell and Forkhead Box Protein 3 as Modulators of Immune Homeostasis. <i>Frontiers in Immunology</i> , 2017, 8, 605.	2.2	78
5441	Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness. <i>Frontiers in Immunology</i> , 2017, 8, 613.	2.2	60

#	ARTICLE	IF	CITATIONS
5442	Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 619.	2.2	69
5443	Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. <i>Frontiers in Immunology</i> , 2017, 8, 683.	2.2	10
5444	Tumor-Associated Tertiary Lymphoid Structures: Gene-Expression Profiling and Their Bioengineering. <i>Frontiers in Immunology</i> , 2017, 8, 767.	2.2	42
5445	Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 774.	2.2	102
5446	Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. <i>Frontiers in Immunology</i> , 2017, 8, 829.	2.2	159
5447	Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?. <i>Frontiers in Immunology</i> , 2017, 8, 830.	2.2	54
5448	Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?. <i>Frontiers in Immunology</i> , 2017, 8, 950.	2.2	11
5449	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. <i>Frontiers in Immunology</i> , 2017, 8, 961.	2.2	93
5450	Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1024.	2.2	29
5451	The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1113.	2.2	13
5452	Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF. <i>Frontiers in Immunology</i> , 2017, 8, 1150.	2.2	7
5453	Natural Killer T Cell-Targeted Immunotherapy Mediating Long-term Memory Responses and Strong Antitumor Activity. <i>Frontiers in Immunology</i> , 2017, 8, 1206.	2.2	16
5454	Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1215.	2.2	80
5455	PD-1 Controls Tonic Signaling and Lymphopenia-Induced Proliferation of T Lymphocytes. <i>Frontiers in Immunology</i> , 2017, 8, 1289.	2.2	20
5456	Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release. <i>Frontiers in Immunology</i> , 2017, 8, 1342.	2.2	22
5457	Two Distinct Myeloid Subsets at the Term Human Fetal-Maternal Interface. <i>Frontiers in Immunology</i> , 2017, 8, 1357.	2.2	12
5458	CCL3 Enhances Antitumor Immune Priming in the Lymph Node via IFN γ with Dependency on Natural Killer Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1390.	2.2	27
5459	Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1412.	2.2	80

#	ARTICLE	IF	CITATIONS
5460	Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. <i>Frontiers in Immunology</i> , 2017, 8, 1479.	2.2	121
5461	Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1482.	2.2	53
5462	Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis. <i>Frontiers in Immunology</i> , 2017, 8, 1492.	2.2	33
5463	Will a mAb-Based Immunotherapy Directed against Cancer Stem Cells Be Feasible?. <i>Frontiers in Immunology</i> , 2017, 8, 1509.	2.2	23
5464	Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives. <i>Frontiers in Immunology</i> , 2017, 8, 1526.	2.2	74
5465	B7-H1 Influences the Accumulation of Virus-Specific Tissue Resident Memory T Cells in the Central Nervous System. <i>Frontiers in Immunology</i> , 2017, 8, 1532.	2.2	18
5466	Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. <i>Frontiers in Immunology</i> , 2017, 8, 1547.	2.2	125
5467	An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes. <i>Frontiers in Immunology</i> , 2017, 8, 1566.	2.2	103
5468	Tregs: Where We Are and What Comes Next?. <i>Frontiers in Immunology</i> , 2017, 8, 1578.	2.2	142
5469	Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1594.	2.2	48
5470	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1617.	2.2	43
5471	The Future of Immunotherapy: A 20-Year Perspective. <i>Frontiers in Immunology</i> , 2017, 8, 1668.	2.2	76
5472	Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1679.	2.2	171
5473	Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients. <i>Frontiers in Immunology</i> , 2017, 8, 1702.	2.2	48
5474	The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1718.	2.2	36
5475	Strategies to Improve Vaccine Efficacy against Tuberculosis by Targeting Innate Immunity. <i>Frontiers in Immunology</i> , 2017, 8, 1755.	2.2	26
5476	Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?. <i>Frontiers in Immunology</i> , 2017, 8, 1830.	2.2	168
5477	Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?. <i>Frontiers in Immunology</i> , 2017, 8, 1848.	2.2	73

#	ARTICLE	IF	CITATIONS
5478	Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1897.	2.2	55
5479	The Different Functional Distribution of $\alpha\text{CD}4^{\text{hi}}$ Effector T Cells (Treg/Tnull) in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1900.	2.2	39
5480	Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 4.	1.2	27
5481	Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms. <i>Frontiers in Medicine</i> , 2017, 4, 9.	1.2	14
5482	Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib. <i>Frontiers in Medicine</i> , 2017, 4, 36.	1.2	11
5483	Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework. <i>Frontiers in Medicine</i> , 2017, 4, 182.	1.2	41
5484	Tumor Heterogeneity in Breast Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 227.	1.2	379
5485	The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies. <i>Frontiers in Molecular Biosciences</i> , 2017, 4, 52.	1.6	24
5486	Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 26.	1.3	79
5487	Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 38.	1.3	14
5488	Mammalian SWI/SNF Enzymes and the Epigenetics of Tumor Cell Metabolic Reprogramming. <i>Frontiers in Oncology</i> , 2017, 7, 49.	1.3	13
5489	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. <i>Frontiers in Oncology</i> , 2017, 7, 50.	1.3	30
5490	Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine. <i>Frontiers in Oncology</i> , 2017, 7, 52.	1.3	26
5491	Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by <i>Mycobacterium bovis</i> Bacille Calmette-Guérin. <i>Frontiers in Oncology</i> , 2017, 7, 61.	1.3	24
5492	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 67.	1.3	28
5493	Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2017, 7, 86.	1.3	1
5494	Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 94.	1.3	19
5495	Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery. <i>Frontiers in Oncology</i> , 2017, 7, 96.	1.3	61

#	ARTICLE	IF	CITATIONS
5496	Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy. <i>Frontiers in Oncology</i> , 2017, 7, 114.	1.3	22
5497	The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. <i>Frontiers in Oncology</i> , 2017, 7, 121.	1.3	48
5498	Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma. <i>Frontiers in Oncology</i> , 2017, 7, 141.	1.3	16
5499	Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases—Implications for Intraoperative Radiotherapy after Resection. <i>Frontiers in Oncology</i> , 2017, 7, 147.	1.3	24
5500	Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. <i>Frontiers in Oncology</i> , 2017, 7, 156.	1.3	87
5501	The OncoPig Cancer Model: An Innovative Large Animal Translational Oncology Platform. <i>Frontiers in Oncology</i> , 2017, 7, 190.	1.3	92
5502	Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. <i>Frontiers in Oncology</i> , 2017, 7, 193.	1.3	343
5503	Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. <i>Frontiers in Oncology</i> , 2017, 7, 197.	1.3	18
5504	Resources for Interpreting Variants in Precision Genomic Oncology Applications. <i>Frontiers in Oncology</i> , 2017, 7, 214.	1.3	18
5505	Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. <i>Frontiers in Oncology</i> , 2017, 7, 230.	1.3	43
5506	Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review. <i>Frontiers in Oncology</i> , 2017, 7, 233.	1.3	61
5507	Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis. <i>Frontiers in Oncology</i> , 2017, 7, 248.	1.3	88
5508	Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles. <i>Frontiers in Oncology</i> , 2017, 7, 253.	1.3	50
5509	A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma. <i>Journal of Immunology Research</i> , 2017, 2017, 1-9.	0.9	34
5510	Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs. <i>International Journal of Genomics</i> , 2017, 2017, 1-9.	0.8	40
5511	Metabolic Footprints and Molecular Subtypes in Breast Cancer. <i>Disease Markers</i> , 2017, 2017, 1-19.	0.6	52
5512	Defining the biological basis of radiomic phenotypes in lung cancer. <i>ELife</i> , 2017, 6, .	2.8	258
5513	Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future. <i>BioMed Research International</i> , 2017, 2017, 1-10.	0.9	6

#	ARTICLE	IF	CITATIONS
5514	Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2017, 2017, 1-9.	0.7	12
5515	Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications. <i>Stem Cells International</i> , 2017, 2017, 1-11.	1.2	132
5516	Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. <i>Journal of Immunology Research</i> , 2017, 2017, 1-7.	0.9	31
5517	Dual Roles of IL-27 in Cancer Biology and Immunotherapy. <i>Mediators of Inflammation</i> , 2017, 2017, 1-14.	1.4	90
5518	Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review. <i>Journal of Immunology Research</i> , 2017, 2017, 1-6.	0.9	45
5519	Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. <i>Stem Cells International</i> , 2017, 2017, 1-9.	1.2	11
5520	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	13
5521	Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	65
5522	Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells. <i>Journal of Immunology Research</i> , 2017, 2017, 1-14.	0.9	11
5523	Tumor Proteins D52 and D54 Have Opposite Effects on the Terminal Differentiation of Chondrocytes. <i>BioMed Research International</i> , 2017, 2017, 1-11.	0.9	4
5524	CD80 Expressed by CD8 ⁺ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8 ⁺ T Cells. <i>Journal of Immunology Research</i> , 2017, 2017, 1-6.	0.9	33
5525	Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. <i>BioMed Research International</i> , 2017, 2017, 1-18.	0.9	40
5526	Are PD-1 antibodies safe for use in metastatic uveal melanoma?. <i>Melanoma Management</i> , 2017, 4, 79-82.	0.1	0
5527	Management of the cutaneous adverse effects of antimelanoma therapy. <i>Melanoma Management</i> , 2017, 4, 187-202.	0.1	5
5528	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. <i>BioMed Research International</i> , 2017, 2017, 1-13.	0.9	10
5529	Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host. <i>Disease Markers</i> , 2017, 2017, 1-14.	0.6	24
5530	Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-4.	0.2	5
5531	Advances in Immunotherapy for Glioblastoma Multiforme. <i>Journal of Immunology Research</i> , 2017, 2017, 1-11.	0.9	73

#	ARTICLE	IF	CITATIONS
5532	Systemic Treatment of Metastatic Conjunctival Melanoma. Case Reports in Oncological Medicine, 2017, 2017, 1-3.	0.2	26
5533	MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives. Journal of Immunology Research, 2017, 2017, 1-16.	0.9	61
5534	Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells. Mediators of Inflammation, 2017, 2017, 1-9.	1.4	33
5535	Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma. Case Reports in Oncological Medicine, 2017, 2017, 1-4.	0.2	2
5536	Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN- γ in Chinese Resected Stage III Malignant Melanoma. Journal of Immunology Research, 2017, 2017, 1-8.	0.9	10
5537	The Role of Adjunctive Therapies in Septic Shock by Gram Negative MDR/XDR Infections. Canadian Journal of Infectious Diseases and Medical Microbiology, 2017, 2017, 1-6.	0.7	6
5538	A New Network-Based Strategy for Predicting the Potential miRNA-mRNA Interactions in Tumorigenesis. International Journal of Genomics, 2017, 2017, 1-11.	0.8	5
5539	PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?. BioMed Research International, 2017, 2017, 1-7.	0.9	49
5540	Interaction of MRE11 and Clinicopathologic Characteristics in Recurrence of Breast Cancer: Individual and Cumulated Receiver Operating Characteristic Analyses. BioMed Research International, 2017, 2017, 1-9.	0.9	3
5541	The Diagnostic Roles of Cytokines in Hepatobiliary Cancers. BioMed Research International, 2017, 2017, 1-5.	0.9	9
5542	Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy. Case Reports in Oncological Medicine, 2017, 2017, 1-4.	0.2	11
5543	Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies. Journal of Immunology Research, 2017, 2017, 1-13.	0.9	24
5544	<i>FOXP3</i> Allelic Variants and Haplotype Structures Are Associated with Aggressive Breast Cancer Subtypes. Disease Markers, 2017, 2017, 1-8.	0.6	12
5545	Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. BioMed Research International, 2017, 2017, 1-13.	0.9	239
5546	Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report. Neurologia Medico-Chirurgica, 2017, 57, 191-197.	1.0	18
5547	Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. Melanoma Management, 2017, 4, 175-178.	0.1	24
5548	RNA Sequencing Analysis Reveals Interactions between Breast Cancer or Melanoma Cells and the Tissue Microenvironment during Brain Metastasis. BioMed Research International, 2017, 2017, 1-10.	0.9	28
5549	A population of innate myelolymphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice. ELife, 2017, 6, .	2.8	5

#	ARTICLE	IF	CITATIONS
5550	Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 653-664.	0.5	61
5551	Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 655-668.	0.7	11
5552	Immunotherapy and gene therapy as novel treatments for cancer. , 2017, v48, 138-147.		22
5553	Role of Dietary Metabolites in Regulating the Host Immune Response in Gastrointestinal Disease. <i>Frontiers in Immunology</i> , 2017, 8, 51.	2.2	9
5554	Melanoma: tumor microenvironment and new treatments. <i>Anais Brasileiros De Dermatologia</i> , 2017, 92, 156-166.	0.5	35
5555	New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2513-2526.	1.0	33
5556	PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 52889-52900.	0.8	82
5557	Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer. <i>Oncotarget</i> , 2017, 8, 95620-95631.	0.8	38
5558	Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?. <i>Translational Andrology and Urology</i> , 2017, 6, 1067-1080.	0.6	19
5559	Role of poly(ε-caprolactone) lipid-core nanocapsules on melanoma–neutrophil crosstalk. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 7153-7163.	3.3	11
5560	Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2983-2992.	1.0	46
5561	High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab. <i>Oncology Letters</i> , 2018, 15, 3061-3067.	0.8	16
5562	Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer. <i>International Journal of Biological Sciences</i> , 2017, 13, 1163-1171.	2.6	39
5563	The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3557-3566.	1.0	16
5564	High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. <i>International Journal of Biological Sciences</i> , 2017, 13, 1172-1179.	2.6	45
5565	Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. <i>Journal of Cancer</i> , 2017, 8, 1460-1465.	1.2	13
5566	Acute Hyperglycemia Associated with Anti-Cancer Medication. <i>Endocrinology and Metabolism</i> , 2017, 32, 23.	1.3	48
5567	SIRPÎ±-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells. <i>Oncotarget</i> , 2017, 8, 11284-11301.	0.8	17

#	ARTICLE	IF	CITATIONS
5568	Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. <i>Cancer Management and Research</i> , 2017, Volume 9, 553-563.	0.9	14
5569	Role of afatinib in the treatment of advanced lung squamous cell carcinoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 147-157.	0.8	7
5570	A practical guide to the handling and administration of talimogene laherparepvec in Europe. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3867-3880.	1.0	33
5571	Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3485-3491.	1.0	12
5572	Induction of PD-L1 expression by epidermal growth factor receptor–mediated signaling in esophageal squamous cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 763-771.	1.0	39
5573	Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: a retrospective study. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1123-1129.	1.0	38
5574	Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 57-66.	1.3	5
5575	Increased risk of breast cancer in neurofibromatosis type 1: current insights. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 531-536.	1.0	31
5576	Challenging the standard of care in advanced melanoma: focus on pembrolizumab. <i>Cancer Management and Research</i> , 2017, Volume 9, 433-442.	0.9	15
5577	Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer. <i>Acta Dermato-Venereologica</i> , 2017, 97, 539-540.	0.6	18
5578	Update on immune checkpoint inhibitors in gynecological cancers. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e20.	1.0	49
5579	Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer. <i>Journal of Cancer</i> , 2017, 8, 1579-1585.	1.2	26
5580	Preclinical Melanoma Imaging with ⁶⁸ Ga-Labeled $\hat{\pm}$ Melanocyte-Stimulating Hormone Derivatives Using PET. <i>Theranostics</i> , 2017, 7, 805-813.	4.6	37
5581	Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs. <i>Theranostics</i> , 2017, 7, 3504-3516.	4.6	54
5582	A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/MTOR signaling pathway. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2115-2126.	1.0	55
5583	Novel Therapies in Platinum-refractory Metastatic Germ Cell Tumor: A Case Report with a Focus on a PD-1 Inhibitor. <i>Rare Tumors</i> , 2017, 9, 47-49.	0.3	14
5584	Response Evaluation of Chemotherapy for Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2017, 80, 136.	0.7	16
5585	Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX. <i>Theranostics</i> , 2017, 7, 4322-4339.	4.6	59

#	ARTICLE	IF	CITATIONS
5586	Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma. <i>Journal of Cancer</i> , 2017, 8, 3166-3172.	1.2	41
5587	Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200. <i>Cancer Management and Research</i> , 2017, Volume 9, 601-609.	0.9	21
5588	PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level. <i>Journal of Cancer</i> , 2017, 8, 3251-3260.	1.2	21
5589	Genome-wide identification of key modulators of gene-gene interaction networks in breast cancer. <i>BMC Genomics</i> , 2017, 18, 679.	1.2	4
5590	AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?. <i>Annals of Translational Medicine</i> , 2017, 5, S14-S14.	0.7	5
5591	Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 177-184.	2.0	21
5592	Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5745-5754.	1.0	14
5593	4-Thiazolidinone derivative Les-3833 effectively inhibits viability of human melanoma cells through activating apoptotic mechanisms. <i>Croatian Medical Journal</i> , 2017, 58, 129-139.	0.2	13
5594	Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. <i>Theranostics</i> , 2017, 7, 2111-2133.	4.6	12
5595	Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 34796-34810.	0.8	45
5596	Type I β phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF- κ B. <i>Oncotarget</i> , 2017, 8, 42414-42427.	0.8	26
5597	Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. <i>Cancer Management and Research</i> , 2017, Volume 9, 207-213.	0.9	128
5598	Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 8337-8351.	3.3	19
5599	The past and future of breast cancer treatment“from the papyrus to individualised treatment approaches. <i>Ecancermedalscience</i> , 2017, 11, 746.	0.6	35
5600	The Predictive and Prognostic Role of Stromal Tumor-infiltrating Lymphocytes in HER2-positive Breast Cancer with Trastuzumab-based Treatment: a Meta-analysis and Systematic Review. <i>Journal of Cancer</i> , 2017, 8, 3838-3848.	1.2	16
5601	Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab. <i>Case Reports in Oncology</i> , 2017, 10, 230-234.	0.3	35
5602	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1487-1502.	1.0	12
5603	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3697-3708.	1.0	6

#	ARTICLE	IF	CITATIONS
5604	Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. <i>Oncotarget</i> , 2017, 8, 48248-48252.	0.8	97
5605	Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 93149-93155.	0.8	58
5606	Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities. <i>Oncotarget</i> , 2017, 8, 90521-90531.	0.8	81
5607	Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. <i>Oncotarget</i> , 2017, 8, 66491-66503.	0.8	2
5608	A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes. <i>Journal of Thoracic Disease</i> , 2017, 9, 2560-2571.	0.6	25
5609	Targeted therapy for soft tissue sarcomas in adolescents and young adults. <i>Adolescent Health, Medicine and Therapeutics</i> , 2017, Volume 8, 41-55.	0.7	11
5610	Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer Cells. <i>PLoS ONE</i> , 2017, 12, e0168822.	1.1	50
5611	Soluble B and T Lymphocyte Attenuator Correlates to Disease Severity in Sepsis and High Levels Are Associated with an Increased Risk of Mortality. <i>PLoS ONE</i> , 2017, 12, e0169176.	1.1	37
5612	Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. <i>PLoS ONE</i> , 2017, 12, e0170634.	1.1	69
5613	p53 pathway determines the cellular response to alcohol-induced DNA damage in MCF-7 breast cancer cells. <i>PLoS ONE</i> , 2017, 12, e0175121.	1.1	20
5614	Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. <i>PLoS ONE</i> , 2017, 12, e0175563.	1.1	15
5615	Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients. <i>PLoS ONE</i> , 2017, 12, e0176045.	1.1	28
5616	Integrative clustering of multi-level omic data based on non-negative matrix factorization algorithm. <i>PLoS ONE</i> , 2017, 12, e0176278.	1.1	116
5617	HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss. <i>PLoS ONE</i> , 2017, 12, e0176778.	1.1	36
5618	The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer. <i>PLoS ONE</i> , 2017, 12, e0177019.	1.1	11
5619	Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. <i>PLoS ONE</i> , 2017, 12, e0177810.	1.1	23
5620	Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines. <i>PLoS ONE</i> , 2017, 12, e0177830.	1.1	17
5621	Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model. <i>PLoS ONE</i> , 2017, 12, e0178479.	1.1	112

#	ARTICLE	IF	CITATIONS
5622	Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses. PLoS ONE, 2017, 12, e0179201.	1.1	28
5623	Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme. PLoS ONE, 2017, 12, e0181538.	1.1	34
5624	Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression. PLoS ONE, 2017, 12, e0181598.	1.1	31
5625	PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0182692.	1.1	200
5626	Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling. PLoS ONE, 2017, 12, e0182786.	1.1	91
5627	Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS ONE, 2017, 12, e0183023.	1.1	73
5628	Analysis of the whole transcriptome from gingivo-buccal squamous cell carcinoma reveals deregulated immune landscape and suggests targets for immunotherapy. PLoS ONE, 2017, 12, e0183606.	1.1	10
5629	Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. PLoS ONE, 2017, 12, e0183639.	1.1	2
5630	Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells. PLoS ONE, 2017, 12, e0183976.	1.1	5
5631	A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express Î±-gal epitopes. PLoS ONE, 2017, 12, e0184901.	1.1	10
5632	Construction of miRNA-miRNA networks revealing the complexity of miRNA-mediated mechanisms in trastuzumab treated breast cancer cell lines. PLoS ONE, 2017, 12, e0185558.	1.1	28
5633	Forced expression of IL-7R promotes CD8 T cell cytotoxicity to self antigen. PLoS ONE, 2017, 12, e0188112.	1.1	8
5634	Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. PLoS ONE, 2017, 12, e0189697.	1.1	40
5635	Isolated Adrenocorticotrophic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer. Internal Medicine, 2017, 56, 2463-2469.	0.3	34
5636	Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. Hepatic Oncology, 2017, 4, 129-137.	4.2	16
5637	Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy. Melanoma Management, 2017, 4, 143-145.	0.1	8
5638	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology, 2017, 6, e1344805.	2.1	142
5639	Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer. PLoS ONE, 2017, 12, e0186192.	1.1	49

#	ARTICLE	IF	CITATIONS
5640	Unique Features of Germline Variation in Five Egyptian Familial Breast Cancer Families Revealed by Exome Sequencing. <i>PLoS ONE</i> , 2017, 12, e0167581.	1.1	17
5641	In vitro and in vivo antiviral activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection. <i>PLoS ONE</i> , 2017, 12, e0174916.	1.1	33
5642	Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. <i>PLoS ONE</i> , 2017, 12, e0188174.	1.1	85
5643	Epistasis in genomic and survival data of cancer patients. <i>PLoS Computational Biology</i> , 2017, 13, e1005626.	1.5	16
5644	Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency. <i>PLoS Genetics</i> , 2017, 13, e1006853.	1.5	39
5645	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. <i>PLoS Medicine</i> , 2017, 14, e1002309.	3.9	256
5646	Ultrasound-targeted microbubble destruction-mediated Foxp3 knockdown may suppress the tumor growth of HCC mice by relieving immunosuppressive Tregs function. <i>Experimental and Therapeutic Medicine</i> , 2017, 15, 31-38.	0.8	7
5647	Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?. <i>Melanoma Management</i> , 2017, 4, 151-155.	0.1	2
5648	Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. <i>Nature Communications</i> , 2017, 8, 1738.	5.8	310
5649	Addressing the challenges of applying precision oncology. <i>Npj Precision Oncology</i> , 2017, 1, 28.	2.3	43
5650	CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer. <i>BMC Cancer</i> , 2017, 17, 469.	1.1	35
5651	Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma. <i>BMC Cancer</i> , 2017, 17, 584.	1.1	11
5652	BRCA2 carriers with male breast cancer show elevated tumour methylation. <i>BMC Cancer</i> , 2017, 17, 641.	1.1	10
5653	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2017, 17, 618.	1.1	42
5654	Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. <i>BMC Cancer</i> , 2017, 17, 690.	1.1	41
5655	Robust expression of tumor suppressor miRNAs let-7 and miR-195 detected in plasma of Saudi female breast cancer patients. <i>BMC Cancer</i> , 2017, 17, 799.	1.1	56
5656	Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling. <i>BMC Cancer</i> , 2017, 17, 802.	1.1	10
5657	Comparative gene co-expression network analysis of epithelial to mesenchymal transition reveals lung cancer progression stages. <i>BMC Cancer</i> , 2017, 17, 830.	1.1	10

#	ARTICLE	IF	CITATIONS
5658	Bilateral uveitis and macular edema induced by Nivolumab: a case report. <i>BMC Ophthalmology</i> , 2017, 17, 227.	0.6	41
5659	Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies. <i>BMC Pulmonary Medicine</i> , 2017, 17, 175.	0.8	14
5660	Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital) Tj ETQqO O O rgBT /Overlock 10 TF 5	0.9	4
5661	Targeting protein quality control pathways in breast cancer. <i>BMC Biology</i> , 2017, 15, 109.	1.7	27
5662	Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model. <i>BMC Systems Biology</i> , 2017, 11, 70.	3.0	37
5663	Reconstructing cancer drug response networks using multitask learning. <i>BMC Systems Biology</i> , 2017, 11, 96.	3.0	5
5664	Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma. <i>Cancer Cell International</i> , 2017, 17, 105.	1.8	38
5665	Checkpoint inhibitors in melanoma and early phase development in solid tumors: whatâ€™s the future?. <i>Journal of Translational Medicine</i> , 2017, 15, 173.	1.8	36
5666	Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry. <i>Journal of Translational Medicine</i> , 2017, 15, 206.	1.8	26
5667	Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2017, 15, 244.	1.8	73
5668	Data integration from pathology slides for quantitative imaging of multiple cell types within the tumor immune cell infiltrate. <i>Diagnostic Pathology</i> , 2017, 12, 69.	0.9	25
5669	The emerging roles of CDK12 in tumorigenesis. <i>Cell Division</i> , 2017, 12, 7.	1.1	61
5670	Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 136.	6.9	42
5671	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 146.	6.9	77
5672	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 174.	6.9	92
5673	IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 140.	3.5	19
5674	Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research</i> , 2017, 19, 2.	2.2	457
5675	Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis. <i>Breast Cancer Research</i> , 2017, 19, 79.	2.2	20

#	ARTICLE	IF	CITATIONS
5676	AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 88.	2.2	25
5677	Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin. <i>Breast Cancer Research</i> , 2017, 19, 86.	2.2	44
5678	Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. <i>Breast Cancer Research</i> , 2017, 19, 91.	2.2	90
5679	Alcohol consumption and breast tumor gene expression. <i>Breast Cancer Research</i> , 2017, 19, 108.	2.2	23
5680	ReMixT: clone-specific genomic structure estimation in cancer. <i>Genome Biology</i> , 2017, 18, 140.	3.8	29
5681	Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. <i>Genome Medicine</i> , 2017, 9, 89.	3.6	39
5682	Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. <i>EJNMMI Research</i> , 2017, 7, 57.	1.1	35
5683	Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy. <i>Clinical Sarcoma Research</i> , 2017, 7, 14.	2.3	20
5684	Apigenin in cancer therapy: anti-cancer effects and mechanisms of action. <i>Cell and Bioscience</i> , 2017, 7, 50.	2.1	346
5685	Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. , 2017, 5, 53.		688
5686	Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment. , 2017, 5, 54.		30
5687	Regression of multifocal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab. , 2017, 5, 61.		5
5688	Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. , 2017, 5, 56.		9
5689	Acute interstitial nephritis after sequential ipilimumab - nivolumab therapy of metastatic melanoma. , 2017, 5, 57.		29
5690	Tumor-derived exosomes induce CD8+ T cell suppressors. , 2017, 5, 65.		133
5691	Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. , 2017, 5, 67.		28
5692	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. , 2017, 5, 66.		37
5693	Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. , 2017, 5, 72.		37

#	ARTICLE	IF	CITATIONS
5694	Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. , 2017, 5, 75.		52
5695	Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. , 2017, 5, 76.		96
5696	Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. , 2017, 5, 81.		33
5697	Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. , 2017, 5, 82.		77
5698	Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. , 2017, 5, 83.		46
5699	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
5700	Biomarkers for immunotherapy in bladder cancer: a moving target. , 2017, 5, 94.		144
5701	Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. , 2017, 5, 95.		1,460
5702	Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas. , 2017, 5, 99.		48
5703	A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. , 2017, 5, 103.		8
5704	Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. , 2017, 5, 102.		31
5705	Hereditary breast cancer associated with Cowden syndrome-related PTEN mutation with Lhermitte-Duclos disease. Surgical Case Reports, 2017, 3, 83.	0.2	8
5706	Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report. Surgical Case Reports, 2017, 3, 94.	0.2	14
5707	Interleukin-35 on B cell and T cell induction and regulation. Journal of Inflammation, 2017, 14, 16.	1.5	63
5708	Perspective on the dynamics of cancer. Theoretical Biology and Medical Modelling, 2017, 14, 18.	2.1	13
5709	Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors. Breast Cancer Research, 2017, 19, 112.	2.2	75
5710	Associations of two-pore domain potassium channels and triple negative breast cancer subtype in The Cancer Genome Atlas: systematic evaluation of gene expression and methylation. BMC Research Notes, 2017, 10, 475.	0.6	20
5711	Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. Chinese Journal of Cancer, 2017, 36, 61.	4.9	42

#	ARTICLE	IF	CITATIONS
5712	The 150 most important questions in cancer research and clinical oncology series: questions 50â€“56. Chinese Journal of Cancer, 2017, 36, 69.	4.9	6
5713	The 150 most important questions in cancer research and clinical oncology series: questions 57â€“66. Chinese Journal of Cancer, 2017, 36, 79.	4.9	6
5714	The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study. Chinese Journal of Cancer, 2017, 36, 84.	4.9	29
5715	Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya. Tropical Medicine and Health, 2017, 45, 19.	1.0	7
5716	Regulation of blood vascular permeability in the skin. Inflammation and Regeneration, 2017, 37, 11.	1.5	64
5717	A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer. Cancer Convergence, 2017, 1, 5.	8.0	50
5718	Breast MRI radiomics: comparison of computer- and human-extracted imaging phenotypes. European Radiology Experimental, 2017, 1, 22.	1.7	29
5719	Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets. BMC Rheumatology, 2017, 1, 2.	0.6	39
5720	Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy. Neurologia Medico-Chirurgica, 2017, 57, 321-330.	1.0	16
5721	Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients. Investigational New Drugs, 2017, 35, 842-847.	1.2	13
5722	Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer. Scientific Reports, 2017, 7, 15742.	1.6	9
5723	Using machine learning algorithms to identify genes essential for cell survival. BMC Bioinformatics, 2017, 18, 397.	1.2	5
5724	Interactive visual exploration and refinement of cluster assignments. BMC Bioinformatics, 2017, 18, 406.	1.2	17
5725	Analysis of breast cancer subtypes by AP-ISA biclustering. BMC Bioinformatics, 2017, 18, 481.	1.2	3
5726	ANAT 2.0: reconstructing functional protein subnetworks. BMC Bioinformatics, 2017, 18, 495.	1.2	12
5727	A comparison of graph- and kernel-based omics data integration algorithms for classifying complex traits. BMC Bioinformatics, 2017, 18, 539.	1.2	26
5728	Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. BMC Complementary and Alternative Medicine, 2017, 17, 534.	3.7	31
5729	Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?. , 2017, 5, 84.		5

#	ARTICLE	IF	CITATIONS
5730	Estrogen receptor- \pm promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer. <i>Oncology Letters</i> , 2017, 15, 2855-2862.	0.8	10
5731	Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP). <i>Internal Medicine</i> , 2017, 56, 2311-2315.	0.3	23
5732	Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer. <i>Case Reports in Oncology</i> , 2017, 10, 361-367.	0.3	9
5733	PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. <i>Oncotarget</i> , 2017, 8, 66293-66304.	0.8	11
5734	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. <i>Oncotarget</i> , 2017, 8, 90532-90544.	0.8	89
5735	Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2017, 6, S8-S20.	1.3	97
5736	Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2017, Volume 7, 1-7.	1.2	1
5737	High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. <i>Oncotarget</i> , 2017, 8, 18021-18030.	0.8	46
5738	Live, Learn, Pass It on. <i>Journal of Patient Experience</i> , 2017, 4, 162-168.	0.4	7
5739	Combining vasculature disrupting agent and toll-like receptor 7/8 agonist for cancer therapy. <i>Oncotarget</i> , 2017, 8, 5371-5381.	0.8	28
5740	The combination of checkpoint immunotherapy and targeted therapy in cancer. <i>Annals of Translational Medicine</i> , 2017, 5, 388-388.	0.7	54
5741	Severe Esophagitis and Gastritis from Nivolumab Therapy. <i>ACG Case Reports Journal</i> , 2017, 4, e57.	0.2	67
5742	On the origin of myeloid-derived suppressor cells. <i>Oncotarget</i> , 2017, 8, 3649-3665.	0.8	156
5743	PML promotes metastasis of triple-negative breast cancer through transcriptional regulation of HIF1A target genes. <i>JCI Insight</i> , 2017, 2, e87380.	2.3	36
5744	Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 8657-8669.	0.8	19
5745	Characterization of potential driver mutations involved in human breast cancer by computational approaches. <i>Oncotarget</i> , 2017, 8, 50252-50272.	0.8	50
5746	Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer. <i>Oncotarget</i> , 2017, 8, 51621-51629.	0.8	24
5747	Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>Ecancermedalscience</i> , 2017, 11, 759.	0.6	21

#	ARTICLE	IF	CITATIONS
5748	Atezolizumab in advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 3603-3606.	0.6	7
5749	Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. <i>Oncotarget</i> , 2017, 8, 61618-61625.	0.8	13
5750	Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. <i>Oncotarget</i> , 2017, 8, 33159-33171.	0.8	96
5751	Lung cancer prognosis: can histological patterns and morphological features have a role in the management of lung cancer patients?. <i>Annals of Translational Medicine</i> , 2017, 5, 353-353.	0.7	11
5752	Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. <i>Oncotarget</i> , 2017, 8, 46414-46424.	0.8	27
5753	Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 96649-96655.	0.8	22
5754	Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. <i>Oncotarget</i> , 2017, 8, 67094-67103.	0.8	47
5755	Cellular immunity augmentation in mainstream oncologic therapy. <i>Cancer Biology and Medicine</i> , 2017, 14, 121.	1.4	8
5756	Identification of lung adenocarcinoma specific dysregulated genes with diagnostic and prognostic value across 27 TCGA cancer types. <i>Oncotarget</i> , 2017, 8, 87292-87306.	0.8	16
5757	Improving Molecular Testing and Personalized Medicine in Non-Small-Cell Lung Cancer in Ontario. <i>Current Oncology</i> , 2017, 24, 103-110.	0.9	30
5758	Lippia origanoides extract induces cell cycle arrest and apoptosis and suppresses NF- κ B signaling in triple-negative breast cancer cells. <i>International Journal of Oncology</i> , 2017, 51, 1801-1808.	1.4	13
5759	Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities. <i>Case Reports in Oncology</i> , 2017, 9, 644-649.	0.3	13
5760	Distribution of circulating tumor DNA in lung cancer: analysis of the primary lung and bone marrow along with the pulmonary venous and peripheral blood. <i>Oncotarget</i> , 2017, 8, 59268-59281.	0.8	19
5761	Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward. <i>Kidney Cancer</i> , 2017, 1, 31-40.	0.2	10
5762	PD-L1 and intratumoral immune response in breast cancer. <i>Oncotarget</i> , 2017, 8, 51641-51651.	0.8	37
5763	EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. <i>Oncotarget</i> , 2017, 8, 63901-63910.	0.8	30
5764	IFN- γ -related mRNA profile predicts clinical response to PD-1 blockade. <i>Journal of Clinical Investigation</i> , 2017, 127, 2930-2940.	3.9	2,560
5765	Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion. <i>Oncotarget</i> , 2017, 8, 1884-1912.	0.8	59

#	ARTICLE	IF	CITATIONS
5766	Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2017, 1, 15-29.	0.2	4
5767	PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. <i>Oncotarget</i> , 2017, 8, 98524-98532.	0.8	40
5768	Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype. <i>Oncotarget</i> , 2017, 8, 73329-73344.	0.8	64
5769	Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. <i>Oncotarget</i> , 2017, 8, 57680-57692.	0.8	62
5770	Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review. <i>Kidney Cancer</i> , 2017, 1, 133-141.	0.2	9
5771	Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 8738-8751.	0.8	129
5772	Triple-negative breast cancer: is there a treatment on the horizon?. <i>Oncotarget</i> , 2017, 8, 1913-1924.	0.8	275
5773	PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2017, 9, E384-E386.	0.6	17
5774	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017, 28, 1700-1712.	0.6	844
5775	Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 179-190.	1.3	6
5776	PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis. <i>Journal of Cancer</i> , 2017, 8, 2018-2025.	1.2	80
5777	Response Assessment in Neuro-Oncology Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 2439-2449.	0.8	306
5778	PD1 signal transduction pathways in T cells. <i>Oncotarget</i> , 2017, 8, 51936-51945.	0.8	191
5779	The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3367-3376.	2.0	6
5780	Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2851-2860.	2.0	34
5781	Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1175-1182.	2.0	14
5782	Targeting the androgen receptor in triple-negative breast cancer: current perspectives. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4675-4685.	1.0	48
5783	Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2003-2007.	1.0	5

#	ARTICLE	IF	CITATIONS
5784	The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5491-5524.	1.0	56
5785	PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1331.	1.8	60
5786	The reverse Warburg effect is likely to be an Achilles' heel of cancer that can be exploited for cancer therapy. <i>Oncotarget</i> , 2017, 8, 57813-57825.	0.8	190
5787	Tumor location impacts immune response in mouse models of colon cancer. <i>Oncotarget</i> , 2017, 8, 54775-54787.	0.8	75
5788	Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1542.	1.8	25
5789	Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. <i>Oncotarget</i> , 2017, 8, 44960-44975.	0.8	82
5790	Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments. <i>Cancer Management and Research</i> , 2017, Volume 9, 19-27.	0.9	13
5791	Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. <i>Cancer Management and Research</i> , 2018, Volume 10, 1-11.	0.9	23
5792	Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. <i>Journal of Cancer</i> , 2017, 8, 332-344.	1.2	20
5793	ATM kinase sustains breast cancer stem-like cells by promoting ATG4C expression and autophagy. <i>Oncotarget</i> , 2017, 8, 21692-21709.	0.8	39
5794	Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. <i>Oncotarget</i> , 2017, 8, 90215-90224.	0.8	68
5795	Viroimmunotherapy for Colorectal Cancer: Clinical Studies. <i>Biomedicines</i> , 2017, 5, 11.	1.4	25
5796	Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3625-3634.	1.0	20
5797	Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. <i>Oncolytic Virotherapy</i> , 2017, Volume 6, 11-18.	6.0	32
5798	Advances on immunotherapy in genitourinary and renal cell carcinoma. <i>Translational Cancer Research</i> , 2017, 6, 17-29.	0.4	10
5799	An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma. <i>Vaccines</i> , 2017, 5, 38.	2.1	14
5800	The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy. <i>Molecular and Clinical Oncology</i> , 2017, 7, 1112-1118.	0.4	6
5801	Immune checkpoints, their control by immunotherapy and ovarian cancer. <i>Wspolczesna Onkologia</i> , 2017, 3, 189-196.	0.7	2

#	ARTICLE	IF	CITATIONS
5802	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. <i>Medical Science Monitor</i> , 2017, 23, 1208-1216.	0.5	49
5803	Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2017, 8, 8910-8920.	0.8	108
5804	Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges. <i>Kidney Cancer</i> , 2017, 1, 107-114.	0.2	8
5805	Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. <i>Biomedicines</i> , 2017, 5, 3.	1.4	29
5806	Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. <i>Oncotarget</i> , 2017, 8, 72167-72181.	0.8	221
5807	Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5077-5087.	1.0	1
5808	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence <i>in situ</i> hybridization (FISH) to select the optimal patients for matched therapy?. <i>Oncotarget</i> , 2017, 8, 100863-100898.	0.8	16
5809	Soluble cytotoxic T-lymphocyte antigen 4: a favorable predictor in malignant tumors after therapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2147-2154.	1.0	24
5810	Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non–small cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1101-1110.	1.0	13
5811	Evidence from a meta-analysis: is nivolumab neurotoxic in cancer patients?. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1335-1344.	1.0	3
5812	First-line treatment of metastatic melanoma: role of nivolumab. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 1-10.	2.7	26
5813	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. <i>Diagnostics</i> , 2017, 7, 23.	1.3	13
5814	Reasons for Lack of Referral to Medical Oncology for Systemic Therapy in Stage Iv Non-small-cell Lung Cancer: Comparison of 2003–2006 with 2010–2011. <i>Current Oncology</i> , 2017, 24, 486-493.	0.9	13
5815	Targeted therapies in breast cancer: New challenges to fight against resistance. <i>World Journal of Clinical Oncology</i> , 2017, 8, 120.	0.9	227
5816	Research progress in the treatment of small cell lung cancer. <i>Journal of Cancer</i> , 2017, 8, 29-38.	1.2	12
5817	Monitoring of <i>KRAS</i> -mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 38056-38060.	0.8	71
5818	Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 503-514.	1.0	18
5819	Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2017, 8, 124-130.	1.2	28

#	ARTICLE	IF	CITATIONS
5820	Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic. <i>Journal of Cancer</i> , 2017, 8, 513-522.	1.2	36
5821	Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in patients with breast cancer: a meta-analysis. <i>Journal of Cancer</i> , 2017, 8, 4098-4105.	1.2	45
5822	Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer. <i>Journal of Cancer</i> , 2017, 8, 4075-4082.	1.2	7
5823	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. <i>Oncotarget</i> , 2017, 8, 110693-110707.	0.8	115
5824	Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy. <i>Annals of Translational Medicine</i> , 2017, 5, 385-385.	0.7	50
5825	Prognostic value of histone chaperone FACT subunits expression in breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 301-311.	1.0	12
5826	Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer. <i>Oncotarget</i> , 2017, 8, 113345-113359.	0.8	61
5827	Pediatric hepatocellular carcinoma: challenges and solutions. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 15-21.	1.8	49
5828	The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer. <i>Oncology Reviews</i> , 2017, 11, 324.	0.8	28
5829	Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma. <i>Wspolczesna Onkologia</i> , 2017, 1, 1-5.	0.7	12
5830	Management of intracranial melanomas in the era of precision medicine. <i>Oncotarget</i> , 2017, 8, 89326-89347.	0.8	16
5831	>MTHFR C677T polymorphism and breast, ovarian cancer risk: a meta-analysis of 19,260 patients and 26,364 controls. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 227-238.	1.0	37
5832	Mental Health Services Use by Melanoma Patients Receiving Adjuvant Interferon: Association of Pre-treatment Mental Health Care with Early Discontinuation. <i>Current Oncology</i> , 2017, 24, 503-512.	0.9	2
5833	Chemotherapy resistance mechanisms in advanced skin cancer. <i>Oncology Reviews</i> , 2017, 11, 326.	0.8	83
5834	Systemic anticancer therapy (SACT) for lung cancer and its potential for interactions with other medicines. <i>Ecancermedalscience</i> , 2017, 11, 764.	0.6	2
5835	Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas. <i>Medical Science Monitor</i> , 2017, 23, 3593-3602.	0.5	20
5836	PD-1 and its ligands are important immune checkpoints in cancer. <i>Oncotarget</i> , 2017, 8, 2171-2186.	0.8	234
5837	Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 31347-31354.	0.8	147

#	ARTICLE	IF	CITATIONS
5838	Analysis of <i>ESR1</i> and <i>PIK3CA</i> mutations in plasma cell-free DNA from ER-positive breast cancer patients. <i>Oncotarget</i> , 2017, 8, 52142-52155.	0.8	48
5839	<i>PIK3CA</i> gene mutations in Northwest Chinese esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 2585.	1.4	9
5840	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 41641-41669.	0.8	15
5841	A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors. <i>Oncotarget</i> , 2017, 8, 16690-16703.	0.8	22
5842	Case Report. Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis. <i>The Journal of Critical Care Medicine</i> , 2017, 3, 84-88.	0.3	0
5843	Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis. <i>Oncotarget</i> , 2017, 8, 83637-83649.	0.8	7
5844	From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. <i>World Journal of Clinical Oncology</i> , 2017, 8, 37.	0.9	64
5845	Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. <i>JCI Insight</i> , 2017, 2, e90521.	2.3	83
5846	PD-1 inhibitors in endometrial cancer. <i>Oncotarget</i> , 2017, 8, 106169-106170.	0.8	15
5847	Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 93156-93167.	0.8	20
5848	Profile of the breast cancer susceptibility marker rs4245739 identifies a role for miRNAs. <i>Cancer Biology and Medicine</i> , 2017, 14, 387.	1.4	9
5849	Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues. <i>Oncotarget</i> , 2017, 8, 3355-3363.	0.8	15
5850	Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics. <i>Oncotarget</i> , 2017, 8, 19310-19322.	0.8	81
5851	Recent advances in the biology and therapy of medullary thyroid carcinoma. <i>F1000Research</i> , 2017, 6, 2184.	0.8	18
5852	PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes. <i>Oncotarget</i> , 2017, 8, 51210-51223.	0.8	37
5853	Phosphatidylinositol 3-kinase (PI3K \pm)/AKT axis blockade with tasisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. <i>Oncotarget</i> , 2017, 8, 76479-76491.	0.8	24
5854	Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. <i>Oncotarget</i> , 2017, 8, 91779-91794.	0.8	298
5855	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. <i>Oncotarget</i> , 2017, 8, 99223-99236.	0.8	9

#	ARTICLE	IF	CITATIONS
5856	Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. <i>Oncotarget</i> , 2017, 8, 8890-8899.	0.8	48
5857	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. <i>Oncotarget</i> , 2017, 8, 41932-41946.	0.8	95
5858	Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 92699-92714.	0.8	29
5859	Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. <i>Journal of Clinical Oncology</i> , 2017, 35, 3322-3329.	0.8	204
5860	Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction. <i>In Vivo</i> , 2017, 31, 1225-1228.	0.6	14
5861	PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2017, 8, 24644-24651.	0.8	146
5862	Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	1.5	35
5863	Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes. <i>JCO Precision Oncology</i> , 2017, 2017, 1-9.	1.5	6
5864	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3807-3814.	0.8	364
5865	Cell-Cycle Therapeutics Come of Age. <i>Journal of Clinical Oncology</i> , 2017, 35, 2949-2959.	0.8	269
5866	Hypermutation and microsatellite instability in gastrointestinal cancers. <i>Oncotarget</i> , 2017, 8, 112103-112115.	0.8	69
5867	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	0.8	348
5868	Next-Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients With Lymphoid Malignancies. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	1.5	18
5869	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	1.5	1,266
5870	Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	110
5871	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and) Tj ETQq1 1 0 784314 rgBT /Overl	0.8	95
5872	Microenvironmental regulation of the progression of oral potentially malignant disorders towards malignancy. <i>Oncotarget</i> , 2017, 8, 81617-81635.	0.8	17
5873	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1542-1549.	0.8	527

#	ARTICLE	IF	CITATIONS
5874	Landscape of Microsatellite Instability Across 39 Cancer Types. <i>JCO Precision Oncology</i> , 2017, 2017, 1-15.	1.5	796
5875	The concept of immune surveillance against tumors: The first theories. <i>Oncotarget</i> , 2017, 8, 7175-7180.	0.8	221
5876	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 75675-75686.	0.8	42
5877	Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2017, 35, 139-140.	0.8	22
5878	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2117-2124.	0.8	538
5879	Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. <i>Oncotarget</i> , 2017, 8, 12417-12432.	0.8	24
5880	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	1.5	44
5881	Novel Considerations in the Approach to Glioblastoma. <i>Journal of Oncology Practice</i> , 2017, 13, 639-640.	2.5	0
5882	The role of novel immunotherapies in non-Hodgkin lymphoma. <i>Translational Cancer Research</i> , 2017, 6, 93-103.	0.4	26
5883	Exceptional Chemotherapy Response in Metastatic Colorectal Cancer Associated With Hyper-Indel-Hypermutated Cancer Genome and Comutation of <i>POLD1</i> and <i>MLH1</i> . <i>JCO Precision Oncology</i> , 2017, 2017, 1-12.	1.5	3
5884	Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. <i>Oncotarget</i> , 2017, 8, 71371-71384.	0.8	85
5885	Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A. <i>Oncotarget</i> , 2017, 8, 40434-40453.	0.8	59
5886	Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma. <i>Journal of Global Oncology</i> , 2017, 3, 360-369.	0.5	34
5887	Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	1.5	17
5888	Risk of cumulative toxicity after complete melanoma response with pembrolizumab. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016218308.	0.2	5
5889	The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. <i>Oncotarget</i> , 2017, 8, 38850-38862.	0.8	36
5890	PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways. <i>Oncotarget</i> , 2017, 8, 99901-99912.	0.8	78
5891	Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer. <i>Oncotarget</i> , 2017, 8, 80443-80452.	0.8	78

#	ARTICLE	IF	CITATIONS
5892	Liquid biopsies in lung cancer—time to implement research technologies in routine care?. <i>Annals of Translational Medicine</i> , 2017, 5, 278-278.	0.7	27
5893	Review: Oncolytic virotherapy, updates and future directions. <i>Oncotarget</i> , 2017, 8, 102617-102639.	0.8	111
5894	EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 75712-75726.	0.8	119
5895	Genomic alterations of ERBB receptors in cancer: clinical implications. <i>Oncotarget</i> , 2017, 8, 114371-114392.	0.8	96
5896	Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer. <i>Oncotarget</i> , 2017, 8, 99372-99381.	0.8	22
5897	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. <i>Oncotarget</i> , 2017, 8, 106132-106142.	0.8	174
5898	Altered follicular helper T cell impaired antibody production in a murine model of myelodysplastic syndromes. <i>Oncotarget</i> , 2017, 8, 98270-98279.	0.8	5
5899	The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 16421-16429.	0.8	50
5900	Systemic treatment for hepatocellular carcinoma: Still unmet expectations. <i>World Journal of Hepatology</i> , 2017, 9, 80.	0.8	28
5901	Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab. <i>Journal of Blood Medicine</i> , 2017, Volume 8, 41-54.	0.7	5
5902	Identification of candidate genes related to pancreatic cancer based on analysis of gene co-expression and protein-protein interaction network. <i>Oncotarget</i> , 2017, 8, 71105-71116.	0.8	10
5903	Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 237-252.	0.7	109
5904	Increased PD-L1 expression in erlotinib-resistant NSCLC cells with <i>MET</i> gene amplification is reversed upon MET-TKI treatment. <i>Oncotarget</i> , 2017, 8, 68221-68229.	0.8	31
5905	Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 199-212.	0.6	26
5906	A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC. <i>Journal of Thoracic Disease</i> , 2017, 9, E292-E294.	0.6	0
5907	Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. <i>Journal of Thoracic Disease</i> , 2017, 9, 655-665.	0.6	15
5908	Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: what's next?. <i>Journal of Thoracic Disease</i> , 2017, 9, E519-E521.	0.6	3
5909	Role of CXC group chemokines in lung cancer development and progression. <i>Journal of Thoracic Disease</i> , 2017, 9, S164-S171.	0.6	53

#	ARTICLE	IF	CITATIONS
5910	PD-L1 protein expression in non-small cell lung cancer based on different immunohistochemical antibodies. <i>Journal of Thoracic Disease</i> , 2017, 9, E470-E473.	0.6	3
5911	Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, E540-E542.	0.6	28
5912	Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 1903-1910.	0.6	25
5913	Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy. <i>Journal of Thoracic Disease</i> , 2017, 9, 2142-2158.	0.6	92
5914	Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2579-2586.	0.6	51
5915	Anti-cancer activity of dose-fractioned mPE +/ã~ bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. <i>Journal of Thoracic Disease</i> , 2017, 9, 3123-3131.	0.6	18
5916	The role of an immune checkpoint score in resected non-small cell lung cancer patientsâ€™ prognosis. <i>Journal of Thoracic Disease</i> , 2017, 9, 3480-3482.	0.6	1
5917	KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 4187-4190.	0.6	4
5918	Tumor-associated macrophagesâ€™ additional effectors at anti-PD-1/PD-L1 therapy?. <i>Journal of Thoracic Disease</i> , 2017, 9, 4197-4200.	0.6	5
5919	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Translational Lung Cancer Research</i> , 2017, 6, 373-386.	1.3	45
5920	Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 570-587.	1.3	42
5921	Molecular diagnostics of lung cancer in the clinic. <i>Translational Lung Cancer Research</i> , 2017, 6, 560-569.	1.3	43
5922	Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study. <i>Translational Lung Cancer Research</i> , 2017, 6, S39-S40.	1.3	5
5923	Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway. <i>Oncotarget</i> , 2017, 8, 36246-36265.	0.8	22
5924	Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients. <i>Oncotarget</i> , 2017, 8, 61538-61550.	0.8	28
5925	Implementing liquid biopsies into clinical decision making for cancer immunotherapy. <i>Oncotarget</i> , 2017, 8, 48507-48520.	0.8	63
5926	Immunotherapy for malignant pleural mesothelioma: current status and future directions. <i>Translational Lung Cancer Research</i> , 2017, 6, 315-324.	1.3	30
5927	Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 83986-83994.	0.8	69

#	ARTICLE	IF	CITATIONS
5928	Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. <i>Oncotarget</i> , 2017, 8, 24031-24044.	0.8	77
5929	Genetic and immune features of resectable malignant brainstem gliomas. <i>Oncotarget</i> , 2017, 8, 82571-82582.	0.8	12
5930	Immune checkpoint blockade for hematologic malignancies: a review. <i>Stem Cell Investigation</i> , 2017, 4, 32-32.	1.3	59
5931	Potential Immunotherapeutics for Immunosuppression in Sepsis. <i>Biomolecules and Therapeutics</i> , 2017, 25, 569-577.	1.1	19
5932	Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, S1359-S1363.	0.6	3
5933	Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?. <i>Journal of Thoracic Disease</i> , 2017, 9, 2771-2773.	0.6	3
5934	Moving more potent and less toxic options to the frontline in the management of advanced lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2812-2818.	0.6	1
5935	Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed. <i>Journal of Thoracic Disease</i> , 2017, 9, 4821-4824.	0.6	13
5936	Locally advanced non-small cell lung cancer treatment: another step forward. <i>Journal of Thoracic Disease</i> , 2017, 9, 4908-4911.	0.6	4
5937	Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?. <i>Translational Lung Cancer Research</i> , 2017, 6, S78-S83.	1.3	9
5938	Small-cell lung cancer in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2017, 6, S67-S70.	1.3	5
5939	Reproducibility of PD-L1 assessment in non-small cell lung cancer—know your limits but never stop trying to exceed them. <i>Translational Lung Cancer Research</i> , 2017, 6, S51-S54.	1.3	12
5940	Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. <i>Blood Advances</i> , 2017, 1, 455-466.	2.5	54
5941	Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, S41-S43.	1.3	2
5942	Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling. <i>Oncotarget</i> , 2017, 8, 98215-98232.	0.8	30
5943	PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. <i>Oncotarget</i> , 2017, 8, 90123-90131.	0.8	89
5944	Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. <i>Oncotarget</i> , 2017, 8, 3197-3205.	0.8	53
5945	Improving radiotherapy in cancer treatment: Promises and challenges. <i>Oncotarget</i> , 2017, 8, 62742-62758.	0.8	186

#	ARTICLE	IF	CITATIONS
5946	Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. <i>Oncotarget</i> , 2017, 8, 58887-58902.	0.8	22
5947	Targeting Melanoma with Cancer-Killing Viruses. <i>The Open Virology Journal</i> , 2017, 11, 28-47.	1.8	8
5948	Isoform expression patterns of EPHA10 protein mediate breast cancer progression by regulating the E-Cadherin and β -catenin complex. <i>Oncotarget</i> , 2017, 8, 30344-30356.	0.8	15
5949	A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer. <i>Oncotarget</i> , 2017, 8, 29067-29079.	0.8	29
5950	High-affinity human PD-L1 variants attenuate the suppression of T cell activation. <i>Oncotarget</i> , 2017, 8, 88360-88375.	0.8	30
5951	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 77415-77423.	0.8	68
5952	Abscopal Effect after Radioembolization for Metastatic Breast Cancer in the Setting of Immunotherapy. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 432-433.	0.2	15
5953	Targeting complement-mediated immunoregulation for cancer immunotherapy. <i>Seminars in Immunology</i> , 2018, 37, 85-97.	2.7	44
5954	Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. <i>Translational Research</i> , 2018, 196, 62-70.	2.2	9
5955	Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. <i>British Journal of Cancer</i> , 2018, 118, 763-769.	2.9	28
5956	Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. <i>Cell Research</i> , 2018, 28, 433-447.	5.7	91
5957	miR-372 promotes breast cancer cell proliferation by directly targeting LATS2. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 2812-2817.	0.8	26
5958	Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 815-824.	1.4	53
5959	The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. <i>Esophagus</i> , 2018, 15, 103-108.	1.0	14
5960	Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. <i>Cancer Immunology Research</i> , 2018, 6, 389-401.	1.6	68
5961	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers. <i>JAMA Oncology</i> , 2018, 4, 522.	3.4	92
5963	Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF β enhance the efficacy of cancer immunotherapy. <i>Nature Communications</i> , 2018, 9, 741.	5.8	238
5964	Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 445-457.	2.5	19

#	ARTICLE	IF	CITATIONS
5965	PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation. <i>Investigational New Drugs</i> , 2018, 36, 763-772.	1.2	9
5966	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint) <i>Tj ETQq1 1 0.784314 rgBT /Overl</i>	2.8	96
5967	Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. <i>Nature Communications</i> , 2018, 9, 785.	5.8	29
5968	Immune Checkpoint Inhibition in Hodgkin Lymphoma. <i>HemaSphere</i> , 2018, 2, e20.	1.2	15
5969	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 730-749.	7.7	367
5970	Combined laparoscopic abdomino-endoscopic perineal total mesorectal excision for anorectal malignant melanoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2018, 44, 135-138.	0.2	4
5971	Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort. <i>Npj Breast Cancer</i> , 2018, 4, 5.	2.3	32
5972	Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002352.	0.5	11
5973	Higher than reported adolescent and young adult clinical trial enrollment during the "Golden Age" of melanoma clinical trials. <i>Cancer Medicine</i> , 2018, 7, 991-996.	1.3	12
5974	Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2018, 20, 24.	1.8	35
5975	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. <i>British Journal of Cancer</i> , 2018, 118, 820-824.	2.9	190
5976	A proteomic landscape of diffuse-type gastric cancer. <i>Nature Communications</i> , 2018, 9, 1012.	5.8	175
5977	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. <i>Science Advances</i> , 2018, 4, eaar2766.	4.7	416
5978	Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. <i>Cancer Medicine</i> , 2018, 7, 690-697.	1.3	90
5979	Cutaneous Manifestations of Reactions to Biologics. <i>Current Allergy and Asthma Reports</i> , 2018, 18, 12.	2.4	6
5980	Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2594-E2603.	3.3	23
5981	Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 768-776.	3.0	76
5982	Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. <i>Cancer Research</i> , 2018, 78, 2732-2746.	0.4	52

#	ARTICLE	IF	CITATIONS
5983	Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. <i>Future Oncology</i> , 2018, 14, 1869-1874.	1.1	31
5984	Discoidin domain receptor 1: New star in cancer-targeted therapy and its complex role in breast carcinoma (Review). <i>Oncology Letters</i> , 2018, 15, 3403-3408.	0.8	23
5985	PD-1 is required to maintain stem cell properties in human dental pulp stem cells. <i>Cell Death and Differentiation</i> , 2018, 25, 1350-1360.	5.0	31
5986	Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. <i>Journal of Internal Medicine</i> , 2018, 283, 568-577.	2.7	78
5987	Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 40-54.	4.2	24
5988	Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. <i>Cancer</i> , 2018, 124, 2010-2017.	2.0	81
5989	STAT3 regulates cytotoxicity of human CD57+ CD4+ T cells in blood and lymphoid follicles. <i>Scientific Reports</i> , 2018, 8, 3529.	1.6	29
5990	Focal Irradiation and Systemic TGF β 2 Blockade in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2493-2504.	3.2	201
5991	Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors. <i>Cancer Immunology Research</i> , 2018, 6, 434-447.	1.6	49
5992	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. <i>Breast Care</i> , 2018, 13, 8-14.	0.8	32
5993	T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology. <i>Toxicologic Pathology</i> , 2018, 46, 131-146.	0.9	12
5994	Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. <i>Molecular Cancer</i> , 2018, 17, 38.	7.9	489
5995	Engineering chimeric antigen receptor-T cells for cancer treatment. <i>Molecular Cancer</i> , 2018, 17, 32.	7.9	57
5996	Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. <i>Journal of Hematology and Oncology</i> , 2018, 11, 22.	6.9	176
5997	Analysis of middle- and long-term efficacy of thoracoscope-assisted segmental resection of the lung on non-small cell lung cancer in the early stage. <i>Oncology Letters</i> , 2018, 15, 3662-3668.	0.8	1
5998	Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions. <i>Breast Care</i> , 2018, 13, 27-31.	0.8	8
5999	Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1 ⁺ Tim-3 ⁺ CD8 ⁺ T Cells. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	14
6000	p63 isoforms in triple-negative breast cancer: γ p63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 351-359.	1.4	17

#	ARTICLE	IF	CITATIONS
6001	Systemic immune-inflammation index in germ-cell tumours. <i>British Journal of Cancer</i> , 2018, 118, 831-838.	2.9	70
6002	PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 345-359.	1.3	27
6003	Data-Driven Tree Transforms and Metrics. <i>IEEE Transactions on Signal and Information Processing Over Networks</i> , 2018, 4, 451-466.	1.6	11
6004	Imaging in neuro-oncology. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641875986.	1.5	41
6005	Targeting <sc>CDK</sc> 2 overcomes melanoma resistance against <sc>BRAF</sc> and Hsp90 inhibitors. <i>Molecular Systems Biology</i> , 2018, 14, e7858.	3.2	53
6006	Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. <i>International Journal of Clinical Oncology</i> , 2018, 23, 410-420.	1.0	50
6007	The association between copy number aberration, DNA methylation and gene expression in tumor samples. <i>Nucleic Acids Research</i> , 2018, 46, 3009-3018.	6.5	51
6008	Pulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report. <i>Case Reports in Oncology</i> , 2018, 10, 1070-1075.	0.3	27
6009	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491875907.	0.6	4
6010	Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 589-598.	1.4	21
6011	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. <i>Current Treatment Options in Oncology</i> , 2018, 19, 16.	1.3	5
6012	Metabolites, genome organization, and cellular differentiation gene programs. <i>Current Opinion in Immunology</i> , 2018, 51, 62-67.	2.4	7
6013	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , 2018, 16, 805-812.	1.5	169
6014	Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition. <i>Cancer Immunology Research</i> , 2018, 6, 617-627.	1.6	13
6015	Combination Cancer Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 20-27.	4.2	55
6016	The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1289-1296.	3.3	90
6017	Untargeted and stable isotope-assisted metabolomic analysis of MDA-MB-231 cells under hypoxia. <i>Metabolomics</i> , 2018, 14, 40.	1.4	14
6018	Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy. <i>Bioconjugate Chemistry</i> , 2018, 29, 771-775.	1.8	68

#	ARTICLE	IF	CITATIONS
6019	Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. <i>Nature</i> , 2018, 555, 371-376.	13.7	649
6020	Prostaglandin E ₂ Induction Suppresses the Th1 Immune Responses in Cattle with Johne's Disease. <i>Infection and Immunity</i> , 2018, 86, .	1.0	26
6021	Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 217-231.	157.7	117
6022	BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment. <i>Journal of Leukocyte Biology</i> , 2018, 104, 265-274.	1.5	29
6023	Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia</i> , 2018, 32, 1094-1105.	3.3	164
6024	Sarcoid-like reactions in patients receiving modern melanoma treatment. <i>Melanoma Research</i> , 2018, 28, 230-236.	0.6	67
6025	Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma. <i>Journal of Dental Research</i> , 2018, 97, 622-626.	2.5	16
6026	Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). <i>International Journal of Oncology</i> , 2018, 52, 1041-1056.	1.4	4
6027	Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. <i>Pituitary</i> , 2018, 21, 274-282.	1.6	25
6028	BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers. <i>Drugs</i> , 2018, 78, 549-566.	4.9	95
6029	The role of the mitochondria and the endoplasmic reticulum contact sites in the development of the immune responses. <i>Cell Death and Disease</i> , 2018, 9, 336.	2.7	58
6030	The gut microbiota and immune checkpoint inhibitors. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2178-2182.	1.4	28
6031	CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. <i>Neuro-Oncology</i> , 2018, 20, 1429-1438.	0.6	197
6032	Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer. <i>Oncologist</i> , 2018, 23, 660-669.	1.9	16
6033	Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand in $\tilde{\Delta}^{1/2}$ vitro. <i>Oncology Letters</i> , 2018, 15, 5345-5351.	0.8	10
6034	Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. <i>Neuro-Oncology</i> , 2018, 20, 1101-1112.	0.6	67
6035	Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report. <i>Thoracic Cancer</i> , 2018, 9, 646-651.	0.8	4
6036	Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 509-519.	1.0	93

#	ARTICLE	IF	CITATIONS
6037	Melanoma Immunotherapy in the Elderly. <i>Current Oncology Reports</i> , 2018, 20, 20.	1.8	16
6038	Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells. <i>Nature Communications</i> , 2018, 9, 914.	5.8	7
6039	Computationally-Guided Development of a Stromal Inflammation Histologic Biomarker in Lung Squamous Cell Carcinoma. <i>Scientific Reports</i> , 2018, 8, 3941.	1.6	11
6040	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , 2018, 24, 3366-3376.	3.2	73
6041	Immunotherapy for Head and Neck Squamous Cell Carcinoma. <i>Current Oncology Reports</i> , 2018, 20, 22.	1.8	131
6042	Data-Driven Methods for Advancing Precision Oncology. <i>Current Pharmacology Reports</i> , 2018, 4, 145-156.	1.5	6
6043	PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. <i>Journal of the American Society of Cytopathology</i> , 2018, 7, 133-141.	0.2	56
6044	B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3126-3131.	3.3	35
6045	Physiological function of phospholipase D2 in anti-tumor immunity: regulation of CD8+ T lymphocyte proliferation. <i>Scientific Reports</i> , 2018, 8, 6283.	1.6	10
6046	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. <i>Journal of Immunotherapy</i> , 2018, 41, 284-291.	1.2	11
6047	Specific breast cancer prognosis subtype distinctions based on DNA methylation patterns. <i>Molecular Oncology</i> , 2018, 12, 1047-1060.	2.1	68
6048	Analysis of PD-1 and Tim-3 expression on CD4+ T cells of patients with rheumatoid arthritis; negative association with DAS28. <i>Clinical Rheumatology</i> , 2018, 37, 2063-2071.	1.0	14
6049	Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. <i>Journal of Neuro-Oncology</i> , 2018, 139, 251-259.	1.4	16
6050	Pitfalls in the radiological response assessment of immunotherapy. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 138-143.	0.3	59
6051	Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. <i>Journal of Immunotherapy</i> , 2018, 41, 241-247.	1.2	40
6052	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. <i>Lung Cancer</i> , 2018, 120, 137-141.	0.9	29
6053	New Therapies in Head and Neck Cancer. <i>Trends in Cancer</i> , 2018, 4, 385-396.	3.8	50
6054	Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. <i>Nature Communications</i> , 2018, 9, 1591.	5.8	64

#	ARTICLE	IF	CITATIONS
6055	Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. <i>Nature Communications</i> , 2018, 9, 1595.	5.8	89
6056	Recent advances in precision oncology research. <i>Npj Precision Oncology</i> , 2018, 2, 11.	2.3	39
6057	Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report. <i>Case Reports in Oncology</i> , 2018, 11, 143-150.	0.3	20
6058	Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer. <i>Molecular Oncology</i> , 2018, 12, 925-935.	2.1	57
6059	A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy. <i>Advanced Materials</i> , 2018, 30, e1706098.	11.1	130
6060	The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy. <i>Journal of Neuro-Oncology</i> , 2018, 139, 89-95.	1.4	69
6061	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. <i>Nature Communications</i> , 2018, 9, 1614.	5.8	76
6062	EMUDRA: Ensemble of Multiple Drug Repositioning Approaches to improve prediction accuracy. <i>Bioinformatics</i> , 2018, 34, 3151-3159.	1.8	30
6063	Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 736-744.	0.8	31
6064	A defect in KCa3.1 channel activity limits the ability of CD8 ⁺ T cells from cancer patients to infiltrate an adenosine-rich microenvironment. <i>Science Signaling</i> , 2018, 11, .	1.6	48
6065	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. <i>ESMO Open</i> , 2018, 3, e000344.	2.0	105
6066	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	3.2	222
6067	Relapsed Myasthenia Gravis after Nivolumab Treatment. <i>Internal Medicine</i> , 2018, 57, 1893-1897.	0.3	32
6068	Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2018, 94, 153-160.	1.6	25
6069	Slow-Release Formulation of Cowpea Mosaic Virus for In Situ Vaccine Delivery to Treat Ovarian Cancer. <i>Advanced Science</i> , 2018, 5, 1700991.	5.6	54
6070	A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. <i>Cancer Cell</i> , 2018, 33, 817-828.e7.	7.7	172
6071	Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer. <i>Oncogene</i> , 2018, 37, 4013-4032.	2.6	40
6072	In Vivo Antitumor Effects of MK615 Led by PD-L1 Downregulation. <i>Integrative Cancer Therapies</i> , 2018, 17, 646-653.	0.8	12

#	ARTICLE	IF	CITATIONS
6073	Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1386-1392.	3.0	137
6074	IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 645-657.	1.6	31
6075	Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 86.	1.8	33
6076	PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. <i>Cancer</i> , 2018, 124, 2498-2506.	2.0	101
6077	Pembrolizumab for primary malignant melanoma of the central nervous system. <i>Journal of Neuro-Oncology</i> , 2018, 139, 225-227.	1.4	3
6078	Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 22.	1.3	60
6079	Emerging Systemic Therapies for Colorectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2018, 31, 179-191.	0.5	26
6080	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986.	13.9	1,495
6081	Tumor xenograft modeling identifies TCF4/ITF2 loss associated with breast cancer chemoresistance. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	15
6082	Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. <i>Gynecologic Oncology Reports</i> , 2018, 24, 1-5.	0.3	10
6083	Nanoscale Metal-Organic Framework Overcomes Hypoxia for Photodynamic Therapy Primed Cancer Immunotherapy. <i>Journal of the American Chemical Society</i> , 2018, 140, 5670-5673.	6.6	557
6084	Next generation antibody drugs: pursuit of the 'high-hanging fruit'. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 197-223.	21.5	595
6085	Morphology of Immunomodulation in Breast Cancer Tumor Draining Lymph Nodes Depends on Stage and Intrinsic Subtype. <i>Scientific Reports</i> , 2018, 8, 5321.	1.6	9
6086	A flexible MHC class I multimer loading system for large-scale detection of antigen-specific T cells. <i>Journal of Experimental Medicine</i> , 2018, 215, 1493-1504.	4.2	33
6087	Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876823.	1.4	78
6088	Implementing Keytruda/Pembrolizumab Testing in Clinical Practice. <i>Oncologist</i> , 2018, 23, 647-649.	1.9	7
6089	Melanoma: What do all the mutations mean?. <i>Cancer</i> , 2018, 124, 3490-3499.	2.0	131
6090	A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. <i>Nature Communications</i> , 2018, 9, 1532.	5.8	276

#	ARTICLE	IF	CITATIONS
6091	Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. <i>Science Advances</i> , 2018, 4, eaao1736.	4.7	269
6092	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876209.	1.4	102
6093	PD-L1 expression testing in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876349.	1.4	120
6094	Radiotherapy and checkpoint inhibitors: a winning new combination?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876824.	1.4	87
6095	Quo Vadis? Do Immunotherapies Have a Role in Glioblastoma?. <i>Current Treatment Options in Neurology</i> , 2018, 20, 14.	0.7	22
6096	Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. <i>Cell</i> , 2018, 173, 879-893.e13.	13.5	777
6097	Hypothesis: can the abscopal effect explain the impact of adjuvant radiotherapy on breast cancer mortality?. <i>Npj Breast Cancer</i> , 2018, 4, 8.	2.3	38
6098	Concordance measure and discriminatory accuracy in transformation cure models. <i>Biostatistics</i> , 2018, 19, 14-26.	0.9	20
6099	Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. <i>Cancer Research</i> , 2018, 78, 3112-3121.	0.4	57
6100	Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. <i>Nature Communications</i> , 2018, 9, 1317.	5.8	94
6101	Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 430-438.	0.5	2
6102	<i>PIK3CA</i> mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis. <i>Thoracic Cancer</i> , 2018, 9, 571-579.	0.8	20
6103	Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting <i>IDH2</i> and <i>PIK3CA</i> : a validation cohort. <i>Histopathology</i> , 2018, 73, 339-344.	1.6	44
6104	Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 3299-3308.	3.2	37
6105	Epigenetic alterations to Polycomb targets precede malignant transition in a mouse model of breast cancer. <i>Scientific Reports</i> , 2018, 8, 5535.	1.6	9
6106	Neth2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors. <i>Cancer Immunology Research</i> , 2018, 6, 636-644.	1.6	20
6107	Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. <i>Cancer</i> , 2018, 124, 2169-2173.	2.0	86
6108	Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2018, 23, 112-126.	2.9	58

#	ARTICLE	IF	CITATIONS
6109	Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. <i>Oncogene</i> , 2018, 37, 3686-3697.	2.6	45
6110	Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 695-705.	1.5	106
6111	Clinical assessment of immune-related adverse events. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876462.	1.4	101
6112	Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 89-105.	1.1	13
6113	Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876372.	1.4	3
6114	<i>Mbd2</i> enables tumorigenesis within the intestine while preventing tumour-promoting inflammation. <i>Journal of Pathology</i> , 2018, 245, 270-282.	2.1	24
6115	JAMI: fast computation of conditional mutual information for ceRNA network analysis. <i>Bioinformatics</i> , 2018, 34, 3050-3051.	1.8	13
6116	Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. <i>Gastric Cancer</i> , 2018, 21, 925-935.	2.7	13
6117	3D Imaging Detection of HER2 Based in the Use of Novel Affibody-Quantum Dots Probes and Ratiometric Analysis. <i>Translational Oncology</i> , 2018, 11, 672-685.	1.7	6
6118	Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1897-1910.	2.0	42
6119	Quantitative image analysis for evaluation of tumor response in clinical oncology. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 18-28.	0.9	16
6120	Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy. <i>Scientific Reports</i> , 2018, 8, 5466.	1.6	19
6121	Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E4041-E4050.	3.3	564
6122	Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3433-3446.	3.2	49
6123	MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells. <i>Oncology Letters</i> , 2018, 15, 4797-4804.	0.8	29
6124	Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. <i>Nature Communications</i> , 2018, 9, 1357.	5.8	100
6125	Programmed self-assembly of peptide-major histocompatibility complex for antigen-specific immune modulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E4032-E4040.	3.3	7
6126	T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	229

#	ARTICLE	IF	CITATIONS
6127	Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas. <i>International Journal of Cancer</i> , 2018, 143, 1379-1387.	2.3	8
6128	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	7.7	827
6129	Targeting the tumour stroma to improve cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 366-381.	12.5	719
6130	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 475-486.	1.3	83
6131	Whole Recombinant <i>Saccharomyces cerevisiae</i> Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial. <i>Journal of Immunotherapy</i> , 2018, 41, 141-150.	1.2	21
6132	Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. <i>ESMO Open</i> , 2018, 3, e000326.	2.0	52
6133	STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876374.	1.4	30
6134	Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management. <i>Current Oncology Reports</i> , 2018, 20, 44.	1.8	53
6135	Electrophysiologic Toxicity of Chemoradiation. <i>Current Oncology Reports</i> , 2018, 20, 45.	1.8	18
6136	In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 779-787.	1.4	30
6137	Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity. <i>Nanoscale</i> , 2018, 10, 9311-9319.	2.8	77
6138	Role of PD-1 during effector CD8 T cell differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4749-4754.	3.3	327
6139	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2018, 23, 1199-1209.	1.9	42
6140	Tumor cell-intrinsic Tim-3 promotes liver cancer via NF- κ B/IL-6/STAT3 axis. <i>Oncogene</i> , 2018, 37, 2456-2468.	2.6	54
6142	Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. <i>Trends in Cancer</i> , 2018, 4, 119-137.	3.8	247
6143	Organotropism: new insights into molecular mechanisms of breast cancer metastasis. <i>Npj Precision Oncology</i> , 2018, 2, 4.	2.3	211
6144	Trailblazing Precision Oncology for Rare Tumor Subtypes. <i>Oncologist</i> , 2018, 23, 143-144.	1.9	0
6145	CAR-T cells: the long and winding road to solid tumors. <i>Cell Death and Disease</i> , 2018, 9, 282.	2.7	312

#	ARTICLE	IF	CITATIONS
6146	The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity. <i>Journal of Neuro-Oncology</i> , 2018, 138, 299-306.	1.4	37
6147	Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway. <i>Cell Death and Disease</i> , 2018, 9, 260.	2.7	59
6148	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2467-2472.	3.3	131
6149	<i>Salmonella enterica</i> Serovar Typhimurium Increases Functional PD-L1 Synergistically with Gamma Interferon in Intestinal Epithelial Cells via <i>Salmonella</i> Pathogenicity Island 2. <i>Infection and Immunity</i> , 2018, 86, .	1.0	9
6150	Cloning and expansion of antigen-specific T cells using iPS cell technology: development of "off-the-shelf" T cells for the use in allogeneic transfusion settings. <i>International Journal of Hematology</i> , 2018, 107, 271-277.	0.7	21
6151	Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model. <i>Experimental Gerontology</i> , 2018, 105, 146-154.	1.2	26
6152	Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment. <i>Journal of Controlled Release</i> , 2018, 274, 24-34.	4.8	123
6153	Contraction of T cell richness in lung cancer brain metastases. <i>Scientific Reports</i> , 2018, 8, 2171.	1.6	74
6154	Challenges and Opportunities in Dose Finding in Oncology and Immunoncology. <i>Clinical and Translational Science</i> , 2018, 11, 345-351.	1.5	39
6155	Unleashing the tiger "iatrogenic autoimmunity from cancer immunotherapy drugs. <i>JRSM Open</i> , 2018, 9, 205427041774690.	0.2	3
6156	Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 3.	2.0	83
6157	Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents. <i>Drugs and Aging</i> , 2018, 35, 93-115.	1.3	6
6158	Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. <i>Journal of Bone Oncology</i> , 2018, 11, 27-32.	1.0	63
6159	Regulation of T cell proliferation with drug-responsive microRNA switches. <i>Nucleic Acids Research</i> , 2018, 46, 1541-1552.	6.5	31
6160	Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry. <i>Scientific Reports</i> , 2018, 8, 1840.	1.6	33
6161	Tumor Mutational Burden Guides Therapy in a Treatment Refractory PLEKHA7-Mutant Uterine Carcinosarcoma. <i>Oncologist</i> , 2018, 23, 518-523.	1.9	40
6162	Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 117, 73-79.	0.9	135
6163	Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 2020, 2020, CD011123.	1.5	136

#	ARTICLE	IF	CITATIONS
6164	Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 103-108.	0.8	20
6165	Cervical cancer – State of the science: From angiogenesis blockade to checkpoint inhibition. <i>Gynecologic Oncology</i> , 2018, 148, 609-621.	0.6	96
6166	Synthetic Immunobiotics: A Future Success Story in Small Molecule-Based Immunotherapy?. <i>ACS Infectious Diseases</i> , 2018, 4, 664-672.	1.8	7
6167	Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. <i>British Journal of Cancer</i> , 2018, 118, 679-697.	2.9	17
6168	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTERO302). <i>British Journal of Cancer</i> , 2018, 118, 654-661.	2.9	192
6169	TGF β 2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <i>Nature</i> , 2018, 554, 544-548.	13.7	3,359
6170	Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival. <i>Npj Genomic Medicine</i> , 2018, 3, 1.	1.7	79
6171	Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions. <i>Scientific Reports</i> , 2018, 8, 2233.	1.6	15
6172	Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). <i>Scientific Reports</i> , 2018, 8, 2918.	1.6	182
6173	Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. <i>Journal of Experimental Medicine</i> , 2018, 215, 859-876.	4.2	150
6174	Temozolomide-associated hypermutation in gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1300-1309.	0.6	130
6175	Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment. <i>Case Reports in Oncology</i> , 2018, 10, 1112-1115.	0.3	4
6176	Multiple Tumor Induction after Treatment of Temporal Arteritis with Prednisone. <i>Case Reports in Oncology</i> , 2018, 10, 1076-1084.	0.3	2
6177	Radiation therapy and immunotherapy: what is the optimal timing or sequencing?. <i>Immunotherapy</i> , 2018, 10, 299-316.	1.0	49
6178	Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. <i>International Journal of Cancer</i> , 2018, 143, 419-429.	2.3	8
6179	Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. <i>International Journal of Clinical Oncology</i> , 2018, 23, 634-640.	1.0	103
6180	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. <i>Targeted Oncology</i> , 2018, 13, 1-20.	1.7	31
6181	Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. <i>Medical Oncology</i> , 2018, 35, 37.	1.2	52

#	ARTICLE	IF	CITATIONS
6182	Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. <i>Oncogene</i> , 2018, 37, 2502-2514.	2.6	69
6183	IL-2 and Beyond in Cancer Immunotherapy. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 45-68.	0.5	83
6184	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , 2018, 3, e000299.	2.0	29
6185	A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 710-716.	1.9	25
6186	A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1 α -XBP1 Activation. <i>Molecular Cancer Research</i> , 2018, 16, 745-753.	1.5	8
6187	Immune gene expression and response to chemotherapy in advanced breast cancer. <i>British Journal of Cancer</i> , 2018, 118, 480-488.	2.9	37
6188	Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies. <i>Cell Death and Disease</i> , 2018, 9, 112.	2.7	94
6189	Cell death-based treatment of lung adenocarcinoma. <i>Cell Death and Disease</i> , 2018, 9, 117.	2.7	434
6190	Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. <i>ESMO Open</i> , 2018, 3, e000283.	2.0	45
6191	Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7 χ and HHLA2, in PD-L1 α -Negative Human Lung Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 1954-1964.	3.2	64
6192	Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. <i>Oncogenesis</i> , 2018, 7, 2.	2.1	68
6193	Clinical Development of PD-1 in Advanced Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 7-14.	1.0	37
6194	The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. <i>Cellular and Molecular Immunology</i> , 2018, 15, 438-446.	4.8	88
6195	Epigenetic control of CD8+ T cell differentiation. <i>Nature Reviews Immunology</i> , 2018, 18, 340-356.	10.6	334
6196	HER2 Overexpression Triggers an IL1 β Proinflammatory Circuit to Drive Tumorigenesis and Promote Chemotherapy Resistance. <i>Cancer Research</i> , 2018, 78, 2040-2051.	0.4	68
6197	The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. <i>Medical Oncology</i> , 2018, 35, 25.	1.2	124
6198	Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2018, 8, 1922.	1.6	108
6199	Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1570-E1577.	3.3	62

#	ARTICLE	IF	CITATIONS
6200	Regulatory T cells (Tregs): A major immune checkpoint to consider in combinatorial therapeutic HIV-1 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1432-1437.	1.4	5
6201	Mitotically-Associated lncRNA (MANCR) Affects Genomic Stability and Cell Division in Aggressive Breast Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 587-598.	1.5	62
6202	Radiation effects on antitumor immune responses: current perspectives and challenges. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774257.	1.4	185
6203	Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774604.	1.4	11
6204	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774974.	1.4	200
6205	Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401775012.	1.4	61
6206	Differential microRNA expression profiles in tamoxifen-resistant human breast cancer cell lines induced by two methods. <i>Oncology Letters</i> , 2018, 15, 3532-3539.	0.8	20
6207	Accuarcy: accurate tumor purity and ploidy inference from tumor-normal WGS data by jointly modelling somatic copy number alterations and heterozygous germline single-nucleotide-variants. <i>Bioinformatics</i> , 2018, 34, 2004-2011.	1.8	19
6208	Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. <i>Cancer Immunology Research</i> , 2018, 6, 288-294.	1.6	70
6209	Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401775163.	1.4	29
6210	Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. <i>ESMO Open</i> , 2018, 3, e000278.	2.0	197
6211	Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 2473-2481.	3.2	49
6212	Precision Oncology Decision Support: Current Approaches and Strategies for the Future. <i>Clinical Cancer Research</i> , 2018, 24, 2719-2731.	3.2	54
6213	Genome-Wide Gene Expression Changes in the Normal-Appearing Airway during the Evolution of Smoking-Associated Lung Adenocarcinoma. <i>Cancer Prevention Research</i> , 2018, 11, 237-248.	0.7	23
6214	Role of immune-checkpoint inhibitors in lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346581775007.	1.0	88
6215	A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis. <i>Journal of Leukocyte Biology</i> , 2018, 103, 1151-1164.	1.5	25
6216	Foxo-dependent Par-4 Upregulation Prevents Long-term Survival of Residual Cells Following PI3K/Akt Inhibition. <i>Molecular Cancer Research</i> , 2018, 16, 599-609.	1.5	13
6217	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. <i>European Journal of Heart Failure</i> , 2018, 20, 445-459.	2.9	118

#	ARTICLE	IF	CITATIONS
6218	Challenging Standard-of-Care Paradigms in the Precision Oncology Era. <i>Trends in Cancer</i> , 2018, 4, 101-109.	3.8	56
6219	Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 335-345.	1.5	19
6220	Percentages of PD-1 ⁺ CD4 ⁺ T cells and PD-L1 ⁺ DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 832-838.	1.4	15
6221	Anti-PD1 in the wonder-gut-land. <i>Cell Research</i> , 2018, 28, 263-264.	5.7	25
6222	DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. <i>Nature Communications</i> , 2018, 9, 248.	5.8	181
6223	Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition. <i>Nature Communications</i> , 2018, 9, 249.	5.8	124
6224	PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 373-380.	1.5	56
6225	Feature specific quantile normalization enables cross-platform classification of molecular subtypes using gene expression data. <i>Bioinformatics</i> , 2018, 34, 1868-1874.	1.8	53
6226	The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 4287-4292.	1.2	69
6227	Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. <i>Lancet Oncology</i> , The, 2018, 19, 229-239.	5.1	111
6228	TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic <i>Kras</i> -Mutant Mouse Lung Cancer Models. <i>Cancer Immunology Research</i> , 2018, 6, 163-177.	1.6	30
6229	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2018, 6, 189-200.	1.6	102
6230	Established, emerging and elusive molecular targets in the treatment of lung cancer. <i>Journal of Pathology</i> , 2018, 244, 565-577.	2.1	15
6231	Profiling Tumor Infiltrating Immune Cells with CIBERSORT. <i>Methods in Molecular Biology</i> , 2018, 1711, 243-259.	0.4	1,936
6232	Modeling of Interactions between Cancer Stem Cells and their Microenvironment: Predicting Clinical Response. <i>Methods in Molecular Biology</i> , 2018, 1711, 333-349.	0.4	8
6233	Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis. <i>Nature Communications</i> , 2018, 9, 503.	5.8	72
6234	Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. <i>Journal of Experimental Medicine</i> , 2018, 215, 895-910.	4.2	63
6235	Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. <i>Gut</i> , 2018, 67, 1168-1180.	6.1	139

#	ARTICLE	IF	CITATIONS
6236	The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. <i>Breast Care</i> , 2018, 13, 16-21.	0.8	135
6237	Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. <i>JAMA Oncology</i> , 2018, 4, 717.	3.4	229
6238	Emerging Biomarkers in Cutaneous Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 203-218.	1.6	35
6239	Decitabine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells. <i>Oncogene</i> , 2018, 37, 2302-2312.	2.6	57
6240	Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention. <i>Annual Review of Medicine</i> , 2018, 69, 97-111.	5.0	31
6241	Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 365-369.	1.8	88
6242	Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer. <i>JAMA Oncology</i> , 2018, 4, 537.	3.4	104
6243	Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 529-541.	3.3	11
6244	Talimogene laherparepvec: First in class oncolytic virotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 839-846.	1.4	247
6245	Tumor Hypoxia As an Enhancer of Inflammation-Mediated Metastasis: Emerging Therapeutic Strategies. <i>Targeted Oncology</i> , 2018, 13, 157-173.	1.7	22
6246	Mutational signatures and chromosome alteration profiles of squamous cell carcinomas of the vulva. <i>Experimental and Molecular Medicine</i> , 2018, 50, e442-e442.	3.2	43
6247	Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. <i>Nature Communications</i> , 2018, 9, 578.	5.8	60
6248	BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage. <i>Nature Communications</i> , 2018, 9, 537.	5.8	31
6249	Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies. <i>AAPS Journal</i> , 2018, 20, 28.	2.2	13
6250	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2018, 19, 405-415.	5.1	305
6251	Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. <i>Scientific Reports</i> , 2018, 8, 2592.	1.6	81
6252	Transcriptome analysis and prognosis of ALDH isoforms in human cancer. <i>Scientific Reports</i> , 2018, 8, 2713.	1.6	26
6253	The Integrated Genomic Landscape of Thymic Epithelial Tumors. <i>Cancer Cell</i> , 2018, 33, 244-258.e10.	7.7	270

#	ARTICLE	IF	CITATIONS
6254	Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. <i>Cancer Cell</i> , 2018, 33, 187-201.e10.	7.7	381
6255	DKK2 imparts tumor immunity evasion through β -catenin-independent suppression of cytotoxic immune-cell activation. <i>Nature Medicine</i> , 2018, 24, 262-270.	15.2	106
6256	Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. <i>American Journal of Clinical Pathology</i> , 2018, 149, 253-261.	0.4	22
6257	Microsatellite instability status determined by next-generation sequencing and compared with μ PD-L1 and tumor mutational burden in 11,348 patients. <i>Cancer Medicine</i> , 2018, 7, 746-756.	1.3	348
6258	Is There an Age Threshold for Holding Off on Testing Novel Therapies?. <i>Current Oncology Reports</i> , 2018, 20, 6.	1.8	2
6259	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology</i> , 2018, 19, 310-322.	5.1	486
6260	ER α -Mediated Nuclear Sequestration of RSK2 Is Required for ER+ Breast Cancer Tumorigenesis. <i>Cancer Research</i> , 2018, 78, 2014-2025.	0.4	17
6261	Immune Checkpoint Blockade for Breast Cancer. <i>Cancer Treatment and Research</i> , 2018, 173, 155-165.	0.2	69
6262	Hypermutated Tumors and Immune Checkpoint Inhibition. <i>Drugs</i> , 2018, 78, 155-162.	4.9	22
6263	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. <i>Lancet Oncology</i> , 2018, 19, 416-426.	5.1	517
6264	Increased diversity with reduced α -diversity evenness of tumor infiltrating T-cells for the successful cancer immunotherapy. <i>Scientific Reports</i> , 2018, 8, 1058.	1.6	51
6265	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. <i>ESMO Open</i> , 2018, 3, e000257.	2.0	62
6266	Hypermethylation of NF- κ B-Activating Protein-Like (NKAPL) Promoter in Hepatocellular Carcinoma Suppresses Its Expression and Predicts a Poor Prognosis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 676-686.	1.1	12
6267	Checkpoint Inhibitors, Palliative Care, or Hospice. <i>Current Oncology Reports</i> , 2018, 20, 2.	1.8	8
6268	Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. <i>Nature Protocols</i> , 2018, 13, 335-357.	5.5	32
6269	Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer. <i>Scientific Reports</i> , 2018, 8, 1023.	1.6	33
6270	Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. <i>Clinical Cancer Research</i> , 2018, 24, 3282-3291.	3.2	44
6271	Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. <i>Oncologist</i> , 2018, 23, 528-539.	1.9	102

#	ARTICLE	IF	CITATIONS
6272	Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. <i>CMAJ Open</i> , 2018, 6, E31-E38.	1.1	27
6273	Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. <i>British Journal of Surgery</i> , 2018, 105, e158-e168.	0.1	32
6274	Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. <i>Investigational New Drugs</i> , 2018, 36, 509-512.	1.2	24
6275	The differences in the assessments of side effects at an oncology outpatient clinic. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 386-393.	1.0	7
6276	Two Cases of Atezolizumab-Induced Hypophysitis. <i>Journal of the Endocrine Society</i> , 2018, 2, 91-95.	0.1	43
6277	eIF2 β phosphorylation is pathognomonic for immunogenic cell death. <i>Cell Death and Differentiation</i> , 2018, 25, 1375-1393.	5.0	162
6278	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 47-53.	1.0	287
6279	SALL4 α -KHDRBS3 network enhances stemness by modulating $CD44$ splicing in basal-like breast cancer. <i>Cancer Medicine</i> , 2018, 7, 454-462.	1.3	31
6280	Toxicities Associated With PD-1/PD-L1 Blockade. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 36-40.	1.0	72
6281	PD-1/PD-L1 Axis in Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 15-19.	1.0	61
6282	PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy. <i>Cancer Journal (Sudbury, Mass)</i> 1.0 90	1.0	90
6283	Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals. <i>Clinical and Experimental Medicine</i> , 2018, 18, 165-175.	1.9	41
6284	Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients. <i>Clinical and Translational Oncology</i> , 2018, 20, 1072-1079.	1.2	43
6285	Back from the dead: TIL apoptosis in cancer immune evasion. <i>British Journal of Cancer</i> , 2018, 118, 309-311.	2.9	8
6286	The biology and management of non-small cell lung cancer. <i>Nature</i> , 2018, 553, 446-454.	13.7	2,877
6287	Chemotherapy induces enrichment of CD47 ⁺ /CD73 ⁺ /PDL1 ⁺ immune evasive triple-negative breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1239-E1248.	3.3	238
6288	Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. <i>Journal of the National Cancer Institute</i> , 2018, 110, 787-790.	3.0	123
6289	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018, 24, 1326-1336.	3.2	281

#	ARTICLE	IF	CITATIONS
6290	Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 276-287.	1.6	69
6291	MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 205-215.	0.4	167
6292	Integrative network-based approach identifies central genetic and transcriptomic elements in triple-negative breast cancer. <i>Functional and Integrative Genomics</i> , 2018, 18, 113-124.	1.4	12
6293	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. <i>European Urology</i> , 2018, 73, 462-468.	0.9	36
6294	Protein biomarkers for subtyping breast cancer and implications for future research. <i>Expert Review of Proteomics</i> , 2018, 15, 131-152.	1.3	63
6295	Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Clinical and Translational Oncology</i> , 2018, 20, 815-826.	1.2	57
6296	Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. <i>Modern Pathology</i> , 2018, 31, 623-632.	2.9	102
6297	Shared cancer neoantigens: Making private matters public. <i>Journal of Experimental Medicine</i> , 2018, 215, 5-7.	4.2	46
6298	Mechanisms of Action and Clinical Development of Elotuzumab. <i>Clinical and Translational Science</i> , 2018, 11, 261-266.	1.5	23
6299	Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 601-612.	1.1	47
6300	Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. <i>Future Oncology</i> , 2018, 14, 907-917.	1.1	112
6301	Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review. <i>Clinical and Translational Radiation Oncology</i> , 2018, 9, 5-11.	0.9	76
6302	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 38-69.	2.0	134
6303	Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy. <i>JAAD Case Reports</i> , 2018, 4, 13-16.	0.4	13
6304	Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib. <i>JAAD Case Reports</i> , 2018, 4, 10-12.	0.4	18
6305	PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes. <i>Journal of Thoracic Oncology</i> , 2018, 13, 510-520.	0.5	77
6306	Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E468-E477.	3.3	72
6307	Abscopal effect of radiation on bone metastases of breast cancer: A case report. <i>Cancer Biology and Therapy</i> , 2018, 19, 20-24.	1.5	19

#	ARTICLE	IF	CITATIONS
6308	Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. <i>Case Reports in Oncology</i> , 2018, 10, 897-909.	0.3	57
6309	Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura. <i>Case Reports in Oncology</i> , 2018, 10, 998-1005.	0.3	10
6310	Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care. <i>JAMA Oncology</i> , 2018, 4, 326.	3.4	43
6311	Scavenger Receptor Type B1 and Lipoprotein Nanoparticle Inhibit Myeloid-Derived Suppressor Cells. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 686-697.	1.9	56
6312	Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. <i>Clinical Cancer Research</i> , 2018, 24, 1344-1354.	3.2	414
6313	Tumor-infiltrating lymphocytes are associated with β -catenin overexpression in breast cancer. <i>Cancer Biomarkers</i> , 2018, 21, 639-650.	0.8	9
6314	PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective. <i>Journal of Pathology</i> , 2018, 244, 512-524.	2.1	144
6315	Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 563-573.	2.0	50
6316	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. <i>Oncologist</i> , 2018, 23, 410-421.	1.9	23
6317	Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2018, 52, 125-134.	4.3	51
6318	Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database. <i>Acta Oncologica</i> , 2018, 57, 867-872.	0.8	33
6319	Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. <i>Gut</i> , 2018, 67, 179-193.	6.1	73
6320	Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer. <i>Radiology</i> , 2018, 287, 326-332.	3.6	24
6321	Immunotherapy in triple-negative breast cancer. <i>Medical Oncology</i> , 2018, 35, 13.	1.2	94
6322	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028837.	2.3	7
6323	SEOM-SERAM-SEMIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer. <i>Clinical and Translational Oncology</i> , 2018, 20, 837-852.	1.2	9
6324	Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. <i>Seminars in Cancer Biology</i> , 2018, 52, 26-38.	4.3	49
6325	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a033704.	2.3	10

#	ARTICLE	IF	CITATIONS
6326	The CARMA3-Bcl10-MALT1 Signalosome Drives NF- κ B Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2018, 78, 1225-1240.	0.4	65
6327	Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2018, 23, 155-e17.	1.9	21
6328	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 210.	3.4	437
6329	mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. <i>Molecular Therapy</i> , 2018, 26, 420-434.	3.7	132
6330	Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices. <i>Journal of Immunotherapy</i> , 2018, 41, 86-95.	1.2	28
6331	Impact of oncogenic pathways on evasion of antitumor immune responses. <i>Nature Reviews Cancer</i> , 2018, 18, 139-147.	12.8	506
6332	Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. <i>Scientific Reports</i> , 2018, 8, 208.	1.6	24
6333	Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases. <i>Human Gene Therapy</i> , 2018, 29, 971-996.	1.4	44
6334	Identification of topological features in renal tumor microenvironment associated with patient survival. <i>Bioinformatics</i> , 2018, 34, 1024-1030.	1.8	57
6335	JUNB governs a feed-forward network of TGF- β 2 signaling that aggravates breast cancer invasion. <i>Nucleic Acids Research</i> , 2018, 46, 1180-1195.	6.5	77
6336	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774501.	1.4	101
6337	Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval. <i>Oncologist</i> , 2018, 23, 328-336.	1.9	87
6338	Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1164-1176.	2.5	77
6339	Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2018, 24, 1872-1880.	3.2	319
6340	Evolving notions on immune response in colorectal cancer and their implications for biomarker development. <i>Inflammation Research</i> , 2018, 67, 375-389.	1.6	32
6341	Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. <i>Journal of Neuro-Oncology</i> , 2018, 137, 269-278.	1.4	42
6342	Thyroid dysfunctions secondary to cancer immunotherapy. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 625-638.	1.8	59
6343	Cell Membrane Bioconjugation and Membrane-Derived Nanomaterials for Immunotherapy. <i>Bioconjugate Chemistry</i> , 2018, 29, 624-634.	1.8	37

#	ARTICLE	IF	CITATIONS
6344	Improving immune-vascular crosstalk for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 195-203.	10.6	340
6345	Versatile and on-demand biologics co-production in yeast. <i>Nature Communications</i> , 2018, 9, 77.	5.8	28
6346	Dosimetry Prediction for Clinical Translation of ⁶⁴ Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression. <i>Scientific Reports</i> , 2018, 8, 633.	1.6	41
6347	Synergy of vaccination and agonist OX40 treatment toward a mechanism-driven combination of glioma immunotherapy. <i>Neuro-Oncology</i> , 2018, 20, 4-5.	0.6	4
6348	Population-dependent Intron Retention and DNA Methylation in Breast Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 461-469.	1.5	23
6349	Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014. <i>Oncologist</i> , 2018, 23, 481-488.	1.9	77
6350	Deregulated PP1 β phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. <i>Nature Communications</i> , 2018, 9, 159.	5.8	39
6351	Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects. <i>Journal of Neurosurgery</i> , 2018, 129, 1397-1406.	0.9	55
6352	Mechanisms of resistance to immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 2018, 118, 9-16.	2.9	944
6353	A poly(beta-amino ester) activates macrophages independent of NF- κ B signaling. <i>Acta Biomaterialia</i> , 2018, 68, 168-177.	4.1	28
6354	TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. <i>Cancer Cell</i> , 2018, 33, 60-74.e6.	7.7	270
6355	High macrophage PD-L1 expression not responsible for T cell suppression. <i>Cellular Immunology</i> , 2018, 324, 50-58.	1.4	5
6356	Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e563-e575.	0.9	72
6357	High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. <i>Nature Medicine</i> , 2018, 24, 144-153.	15.2	564
6358	Inhibitors of the PD-1 Pathway in Tumor Therapy. <i>Journal of Immunology</i> , 2018, 200, 375-383.	0.4	112
6359	Hitting the Target: How T Cells Detect and Eliminate Tumors. <i>Journal of Immunology</i> , 2018, 200, 392-399.	0.4	67
6360	The Role of Mass Spectrometry and Proteogenomics in the Advancement of HLA Epitope Prediction. <i>Proteomics</i> , 2018, 18, e1700259.	1.3	49
6361	Aggressive triple negative breast cancers have unique molecular signature on the basis of mitochondrial genetic and functional defects. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1060-1071.	1.8	57

#	ARTICLE	IF	CITATIONS
6362	The bone-marrow niche in MDS and MGUS: implications for AML and MM. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 219-233.	12.5	120
6363	Regulatory T Cells: From Discovery to Autoimmunity. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a029041.	2.9	49
6364	Molecular Biomarkers in the Clinical Management of Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030601.	2.9	11
6365	Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. <i>Journal of Immunology</i> , 2018, 200, 432-442.	0.4	153
6366	Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. <i>Clinical and Translational Oncology</i> , 2018, 20, 966-974.	1.2	31
6367	High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018, 553, 347-350.	13.7	269
6368	Precision oncology in the age of integrative genomics. <i>Nature Biotechnology</i> , 2018, 36, 46-60.	9.4	104
6369	Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in 18F-FDG PET in Squamous Cell Carcinoma of the Head and Neck. <i>Scientific Reports</i> , 2018, 8, 105.	1.6	47
6370	Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 472-483.	0.6	42
6371	Mycoplasma bovis-Induced Inhibition of Bovine Peripheral Blood Mononuclear Cell Proliferation Is Ameliorated after Blocking the Immune-Inhibitory Programmed Death 1 Receptor. <i>Infection and Immunity</i> , 2018, 86, .	1.0	19
6372	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 351.	3.4	599
6373	A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 605-613.	2.0	4
6374	Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. <i>Radiotherapy and Oncology</i> , 2018, 128, 154-160.	0.3	109
6375	Computational identification of micro-structural variations and their proteogenomic consequences in cancer. <i>Bioinformatics</i> , 2018, 34, 1672-1681.	1.8	8
6376	TCGA-assembler 2: software pipeline for retrieval and processing of TCGA/CPTAC data. <i>Bioinformatics</i> , 2018, 34, 1615-1617.	1.8	182
6377	Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 316-320.	3.0	171
6378	The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 777-786.	3.0	58
6379	Discovery of internalizing antibodies to basal breast cancer cells. <i>Protein Engineering, Design and Selection</i> , 2018, 31, 17-28.	1.0	4

#	ARTICLE	IF	CITATIONS
6380	BCScreen: A gene panel to test for breast carcinogenesis in chemical safety screening. <i>Computational Toxicology</i> , 2018, 5, 16-24.	1.8	10
6381	Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas. <i>Journal of Surgical Research</i> , 2018, 223, 207-214.	0.8	20
6382	Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing. <i>Cell</i> , 2018, 172, 205-217.e12.	13.5	324
6383	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.	6.0	898
6384	The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. <i>Science</i> , 2018, 359, 104-108.	6.0	2,027
6385	Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer. <i>Bioscience Reports</i> , 2018, 38, .	1.1	60
6386	Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. <i>Targeted Oncology</i> , 2018, 13, 125-140.	1.7	19
6387	Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. <i>Clinical Cancer Research</i> , 2018, 24, 1138-1151.	3.2	63
6388	Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 360, k793.	2.4	438
6389	Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 4529-4538.	3.2	82
6390	Exosomes: Definition, Role in Tumor Development and Clinical Implications. <i>Cancer Microenvironment</i> , 2018, 11, 13-21.	3.1	39
6391	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 853-861.e4.	7.7	725
6392	A protocol for custom CRISPR Cas9 donor vector construction to truncate genes in mammalian cells using pcDNA3 backbone. <i>BMC Molecular Biology</i> , 2018, 19, 3.	3.0	4
6393	Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report. <i>BMC Nephrology</i> , 2018, 19, 48.	0.8	66
6394	Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs). <i>BMC Cancer</i> , 2018, 18, 174.	1.1	22
6395	Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options. <i>BMC Cancer</i> , 2018, 18, 203.	1.1	38
6396	Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. <i>BMC Cancer</i> , 2018, 18, 225.	1.1	28
6397	Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report. <i>BMC Cancer</i> , 2018, 18, 302.	1.1	17

#	ARTICLE	IF	CITATIONS
6398	Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. <i>BMC Cancer</i> , 2018, 18, 395.	1.1	15
6399	Population-level distribution and putative immunogenicity of cancer neoepitopes. <i>BMC Cancer</i> , 2018, 18, 414.	1.1	32
6400	SALL1 functions as a tumor suppressor in breast cancer by regulating cancer cell senescence and metastasis through the NuRD complex. <i>Molecular Cancer</i> , 2018, 17, 78.	7.9	40
6401	Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. <i>Molecular Cancer</i> , 2018, 17, 81.	7.9	27
6402	Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: implications for differential diagnosis and immunotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 81.	1.8	28
6403	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 31.	6.9	256
6404	Next generation of immune checkpoint therapy in cancer: new developments and challenges. <i>Journal of Hematology and Oncology</i> , 2018, 11, 39.	6.9	597
6405	Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway. <i>Journal of Hematology and Oncology</i> , 2018, 11, 46.	6.9	53
6406	Gut microbiome modulates efficacy of immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 47.	6.9	138
6407	The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 72.	3.5	68
6408	The perfect personalized cancer therapy: cancer vaccines against neoantigens. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 86.	3.5	82
6409	Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. <i>Breast Cancer Research</i> , 2018, 20, 15.	2.2	71
6410	Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. <i>Breast Cancer Research</i> , 2018, 20, 28.	2.2	35
6411	SQUID: transcriptomic structural variation detection from RNA-seq. <i>Genome Biology</i> , 2018, 19, 52.	3.8	27
6412	CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 233.	0.7	41
6413	From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards. <i>Genome Medicine</i> , 2018, 10, 18.	3.6	36
6414	Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. <i>Clinical and Translational Medicine</i> , 2018, 7, 11.	1.7	337
6415	Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. , 2018, 6, 14.		118

#	ARTICLE	IF	CITATIONS
6416	Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model. , 2018, 6, 17.		81
6417	Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. , 2018, 6, 27.		17
6418	Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. , 2018, 6, 26.		150
6419	Precision medicine becomes realityâ€”tumor typeâ€”agnostic therapy. Cancer Communications, 2018, 38, 1-7.	3.7	99
6420	Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer. BMC Cancer, 2018, 18, 367.	1.1	72
6421	Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. Journal of Translational Medicine, 2018, 16, 87.	1.8	35
6422	PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagnostic Pathology, 2018, 13, 12.	0.9	175
6423	Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report. Journal of Medical Case Reports, 2018, 12, 48.	0.4	30
6424	The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective. , 2018, 6, 15.		22
6425	Immunotherapy for Merkel cell carcinoma: a turning point in patient care. , 2018, 6, 23.		34
6426	CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival. Acta Neuropathologica Communications, 2018, 6, 18.	2.4	26
6427	Pushing the limits of immune-related response: a case of â€œextreme pseudoprogressionâ€•. Cancer Immunology, Immunotherapy, 2018, 67, 1105-1111.	2.0	16
6428	PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population. Journal of Neuro-Oncology, 2018, 139, 281-291.	1.4	25
6429	Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro-Oncology, 2018, 20, 1566-1572.	0.6	166
6430	Targeted therapy according to next generation sequencing-based panel sequencing. Fukushima Journal of Medical Sciences, 2018, 64, 9-14.	0.1	17
6431	Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. Cancer, 2018, 124, 3819-3829.	2.0	39
6432	Review of diagnostic, prognostic, and predictive biomarkers in melanoma. Clinical and Experimental Metastasis, 2018, 35, 487-493.	1.7	26
6433	<i>N</i>-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome. Molecular Oncology, 2018, 12, 972-990.	2.1	24

#	ARTICLE	IF	CITATIONS
6434	The importance of greater speed in drug development for advanced malignancies. <i>Cancer Medicine</i> , 2018, 7, 1824-1836.	1.3	23
6435	The binding of an anti-PD-1 antibody to Fc γ R1 TM has a profound impact on its biological functions. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1079-1090.	2.0	162
6436	APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. <i>Oncogene</i> , 2018, 37, 3924-3936.	2.6	204
6437	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. <i>British Journal of Cancer</i> , 2018, 118, 1296-1301.	2.9	49
6438	Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. <i>British Journal of Cancer</i> , 2018, 118, 1329-1336.	2.9	75
6439	Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors. <i>Nature Communications</i> , 2018, 9, 1677.	5.8	96
6440	Noninvasive PET Imaging of T cells. <i>Trends in Cancer</i> , 2018, 4, 359-373.	3.8	88
6441	Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literature. <i>Supportive Care in Cancer</i> , 2018, 26, 2945-2953.	1.0	51
6442	Integrative Pharmacology: Advancing Development of Effective Immunotherapies. <i>AAPS Journal</i> , 2018, 20, 66.	2.2	10
6443	Checkpoint Inhibitors in the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2018, 20, 51.	1.8	10
6444	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 621-625.	1.0	44
6445	Mutation load estimation model as a predictor of the response to cancer immunotherapy. <i>Npj Genomic Medicine</i> , 2018, 3, 12.	1.7	55
6446	Short- and long-term evolution in our arms race with cancer: Why the war on cancer is winnable. <i>Evolutionary Applications</i> , 2018, 11, 845-852.	1.5	1
6447	Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 1310-1318.	1.9	40
6448	Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. <i>Future Oncology</i> , 2018, 14, 2293-2302.	1.1	25
6449	Recent advances in the management of lung cancer. <i>Clinical Medicine</i> , 2018, 18, s41-s46.	0.8	274
6450	The emerging clinical relevance of genomics in cancer medicine. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 353-365.	12.5	351
6451	Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. <i>Cancer Immunology Research</i> , 2018, 6, 605-616.	1.6	199

#	ARTICLE	IF	CITATIONS
6452	Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors. <i>Annals of Thoracic Surgery</i> , 2018, 106, 178-183.	0.7	96
6453	Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 831-839.	0.5	94
6454	Cancer CRISPR Screens In Vivo. <i>Trends in Cancer</i> , 2018, 4, 349-358.	3.8	70
6455	Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1324-1331.	1.9	65
6456	Harnessing and Optimizing the Interplay between Immunotherapy and Radiotherapy to Improve Survival Outcomes. <i>Molecular Cancer Research</i> , 2018, 16, 1209-1214.	1.5	7
6457	Combination nivolumab- and cabiralizumab-associated acute bilateral anterior and posterior scleritis and anterior uveitis. <i>American Journal of Ophthalmology Case Reports</i> , 2018, 10, 117-118.	0.4	13
6458	Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. <i>Gut</i> , 2018, 67, 1845-1854.	6.1	134
6459	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 3108-3118.	3.2	200
6460	Cutaneous melanoma: From pathogenesis to therapy (Review). <i>International Journal of Oncology</i> , 2018, 52, 1071-1080.	1.4	281
6461	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	3.4	1,350
6462	The human breast cancer-associated protein, the prolactin-inducible protein (PIP), regulates intracellular signaling events and cytokine production by macrophages. <i>Immunologic Research</i> , 2018, 66, 245-254.	1.3	10
6463	Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. <i>Trends in Cancer</i> , 2018, 4, 292-319.	3.8	389
6464	Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3193-3208.	2.9	9
6465	miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. <i>Oncogene</i> , 2018, 37, 3151-3165.	2.6	90
6466	Sensitive and frequent identification of high avidity neo-epitope-specific CD8 + T cells in immunotherapy-naive ovarian cancer. <i>Nature Communications</i> , 2018, 9, 1092.	5.8	122
6467	GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. <i>Nature Communications</i> , 2018, 9, 1059.	5.8	72
6468	Kernelized rank learning for personalized drug recommendation. <i>Bioinformatics</i> , 2018, 34, 2808-2816.	1.8	44
6469	Network-based integration of multi-omics data for prioritizing cancer genes. <i>Bioinformatics</i> , 2018, 34, 2441-2448.	1.8	130

#	ARTICLE	IF	CITATIONS
6470	Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. <i>Melanoma Research</i> , 2018, 28, 237-245.	0.6	35
6471	Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 3014-3025.	3.2	64
6472	Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641875961.	1.5	17
6473	Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. <i>Nature Medicine</i> , 2018, 24, 505-511.	15.2	47
6474	Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 246-259.	0.8	23
6475	Anti-CTLA-4 therapy requires an Fc domain for efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3912-3917.	3.3	121
6476	Armed oncolytic viruses: A kick-start for anti-tumor immunity. <i>Cytokine and Growth Factor Reviews</i> , 2018, 41, 28-39.	3.2	110
6477	Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3426-E3435.	3.3	74
6478	The multiforme of glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 437-438.	0.6	3
6479	Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments. <i>Annual Review of Chemical and Biomolecular Engineering</i> , 2018, 9, 105-127.	3.3	161
6480	A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	6
6481	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2851-2858.	3.2	65
6482	Tumor oxygenation and cancer therapy – then and now. <i>British Journal of Radiology</i> , 2019, 92, 20170955.	1.0	37
6483	Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 553-557.	1.6	119
6484	Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. <i>World Journal of Urology</i> , 2018, 36, 1703-1709.	1.2	71
6485	Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 1-7.	0.9	6
6486	Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. <i>Immunity</i> , 2018, 48, 417-433.	6.6	416
6487	TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy. <i>Cellular and Molecular Immunology</i> , 2018, 15, 428-437.	4.8	116

#	ARTICLE	IF	CITATIONS
6488	Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 126-136.	2.0	33
6489	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	13.9	3,334
6490	Autoimmune Polyendocrine Syndromes. <i>New England Journal of Medicine</i> , 2018, 378, 1132-1141.	13.9	311
6491	An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. <i>British Journal of Cancer</i> , 2018, 118, 1107-1114.	2.9	26
6492	Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer. <i>Scientific Reports</i> , 2018, 8, 4899.	1.6	91
6493	Cancer immunotherapy using checkpoint blockade. <i>Science</i> , 2018, 359, 1350-1355.	6.0	4,274
6494	Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381876449.	0.8	21
6495	Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model. <i>Oncology Letters</i> , 2018, 15, 5098-5104.	0.8	1
6496	Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1626-1635.	3.3	14
6497	Preclinical and clinical development of palbociclib and future perspectives. <i>Clinical and Translational Oncology</i> , 2018, 20, 1136-1144.	1.2	20
6498	Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. <i>International Review of Cell and Molecular Biology</i> , 2018, 336, 175-203.	1.6	204
6499	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. <i>American Journal of Pathology</i> , 2018, 188, 1478-1485.	1.9	119
6500	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. <i>Cancer Cell</i> , 2018, 33, 649-663.e4.	7.7	448
6501	Melanoma and Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2018, 20, 29.	1.8	54
6502	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. <i>Oncologist</i> , 2018, 23, 936-942.	1.9	69
6503	Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1123-1138.	1.1	9
6504	Single nucleotide variant profiles of viable single circulating tumour cells reveal CTC behaviours in breast cancer. <i>Oncology Reports</i> , 2018, 39, 2147-2159.	1.2	28
6505	The benefit and risk of nivolumab in non-small cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials. <i>Cancer Medicine</i> , 2018, 7, 1642-1659.	1.3	15

#	ARTICLE	IF	CITATIONS
6507	NF1 mutations in conjunctival melanoma. <i>British Journal of Cancer</i> , 2018, 118, 1243-1247.	2.9	59
6508	Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. <i>Melanoma Research</i> , 2018, 28, 250-255.	0.6	17
6509	A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 1035-1041.	2.9	77
6510	Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 925-933.	2.0	8
6511	Oncolytic viruses and immunity. <i>Current Opinion in Immunology</i> , 2018, 51, 83-90.	2.4	73
6512	Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. <i>Journal of the Endocrine Society</i> , 2018, 2, 241-251.	0.1	146
6513	Cancer vaccines: translation from mice to human clinical trials. <i>Current Opinion in Immunology</i> , 2018, 51, 111-122.	2.4	39
6514	Receptor Occupancy Imaging Studies in Oncology Drug Development. <i>AAPS Journal</i> , 2018, 20, 43.	2.2	12
6515	Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 1-7.	0.2	6
6516	The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. <i>European Journal of Health Economics</i> , 2018, 19, 1163-1172.	1.4	25
6517	The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 293-302.	1.1	16
6518	MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state. <i>Nature Communications</i> , 2018, 9, 1024.	5.8	114
6519	Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma. <i>Melanoma Research</i> , 2018, 28, 171-184.	0.6	18
6520	Immune-modified response criteria – an iterative learning process?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 267-268.	12.5	5
6521	From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation. <i>British Journal of Cancer</i> , 2018, 118, 933-935.	2.9	34
6522	A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. <i>Scientific Reports</i> , 2018, 8, 3737.	1.6	128
6523	FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 353-363.	1.5	119
6524	A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma. <i>Journal of Immunotherapy</i> , 2018, 41, 151-157.	1.2	9

#	ARTICLE	IF	CITATIONS
6525	Antibody-drug conjugates: recent advances in conjugation and linker chemistries. <i>Protein and Cell</i> , 2018, 9, 33-46.	4.8	494
6526	Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. <i>Clinical Immunology</i> , 2018, 189, 34-42.	1.4	37
6527	Selection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library. <i>Cellular and Molecular Immunology</i> , 2018, 15, 146-157.	4.8	10
6528	IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. <i>Gut</i> , 2018, 67, 320-332.	6.1	381
6529	Estimating the Probability of Clonal Relatedness of Pairs of Tumors in Cancer Patients. <i>Biometrics</i> , 2018, 74, 321-330.	0.8	8
6530	Selective expression of long non-coding RNAs in a breast cancer cell progression model. <i>Journal of Cellular Physiology</i> , 2018, 233, 1291-1299.	2.0	22
6531	The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 459-468.	0.8	8
6532	Optical spectroscopic imaging for cell therapy and tissue engineering. <i>Applied Spectroscopy Reviews</i> , 2018, 53, 360-375.	3.4	18
6533	Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated With Cytotoxic Neoadjuvant Chemotherapy. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 523-532.	0.6	47
6534	T-cell receptor-engineered T cells for cancer treatment: current status and future directions. <i>Protein and Cell</i> , 2018, 9, 254-266.	4.8	124
6535	Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas. <i>Developmental Dynamics</i> , 2018, 247, 555-564.	0.8	96
6536	A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. <i>British Journal of Dermatology</i> , 2018, 178, 265-269.	1.4	40
6537	CD103+ lung dendritic cells (LDCs) induce stronger Th1/Th17 immunity to a bacterial lung infection than CD11bhi LDCs. <i>Cellular and Molecular Immunology</i> , 2018, 15, 377-387.	4.8	33
6538	Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. <i>Surgery Today</i> , 2018, 48, 1-8.	0.7	88
6539	A Peroxidase Peroxiredoxin 1-Specific Redox Regulation of the Novel FOXO3 microRNA Target let-7. <i>Antioxidants and Redox Signaling</i> , 2018, 28, 62-77.	2.5	48
6540	Molecular classification of Crohn's disease reveals two clinically relevant subtypes. <i>Gut</i> , 2018, 67, 36-42.	6.1	89
6541	Biological predictors of radiosensitivity in head and neck squamous cell carcinoma. <i>Clinical Oral Investigations</i> , 2018, 22, 189-200.	1.4	29
6542	MerTK as a therapeutic target in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 92-102.	0.6	62

#	ARTICLE	IF	CITATIONS
6543	A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. <i>Investigational New Drugs</i> , 2018, 36, 144-146.	1.2	42
6544	PD-1 and cancer: molecular mechanisms and polymorphisms. <i>Immunogenetics</i> , 2018, 70, 73-86.	1.2	100
6545	Nanotherapeutic systems for local treatment of brain tumors. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2018, 10, e1479.	3.3	51
6546	The emerging role of immune checkpoint based approaches in AML and MDS. <i>Leukemia and Lymphoma</i> , 2018, 59, 790-802.	0.6	90
6547	Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan. <i>Clinical and Translational Oncology</i> , 2018, 20, 169-175.	1.2	15
6548	Immunohistochemical Analysis of Foxp3+, CD4+, CD8+ Cell Infiltrates and PD-L1 in Oral Squamous Cell Carcinoma. <i>Pathology and Oncology Research</i> , 2018, 24, 497-505.	0.9	46
6549	Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 225-235.	0.6	61
6550	Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 83-93.	0.6	124
6551	Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. <i>Clinical Immunology</i> , 2018, 189, 43-51.	1.4	27
6552	Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. <i>Protein and Cell</i> , 2018, 9, 838-847.	4.8	196
6553	Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028530.	2.3	94
6554	NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma. <i>Cancer</i> , 2018, 124, 537-545.	2.0	27
6555	Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 549-556.	1.8	39
6556	Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 11-30.	1.5	149
6557	Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 311-325.	2.0	40
6558	Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 250-255.	0.6	304
6559	Breast Cancer in Latinas: A Focus on Intrinsic Subtypes Distribution. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 3-10.	1.1	26
6560	The anti-PD-1 era – an opportunity to enhance radiotherapy for patients with bladder cancer. <i>Nature Reviews Urology</i> , 2018, 15, 251-259.	1.9	27

#	ARTICLE	IF	CITATIONS
6561	Cut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	6.0	3,126
6562	Checkpoint inhibitor-induced uveitis: a case series. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 187-191.	1.0	59
6563	Infiltration of β 2-microglobulin ⁺ T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer. <i>Cancer Biomarkers</i> , 2018, 20, 395-409.	0.8	22
6564	PFOS induces proliferation, cell-cycle progression, and malignant phenotype in human breast epithelial cells. <i>Archives of Toxicology</i> , 2018, 92, 705-716.	1.9	50
6565	Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer. <i>Case Reports in Oncology</i> , 2018, 10, 802-808.	0.3	5
6566	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. <i>Investigational New Drugs</i> , 2018, 36, 601-607.	1.2	90
6567	Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma. <i>Cancer Research</i> , 2018, 78, 326-337.	0.4	100
6568	Dampness-Heat Accelerates DMBA-Induced Mammary Tumors in Rats. <i>Chinese Journal of Integrative Medicine</i> , 2018, 24, 758-762.	0.7	4
6569	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 334-340.	3.2	323
6570	The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. <i>Seminars in Cancer Biology</i> , 2018, 52, 12-15.	4.3	12
6571	Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor- β 2 Pathway. <i>Gastroenterology</i> , 2018, 154, 195-210.	0.6	105
6572	Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 592-599.	3.2	75
6573	Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. <i>Cancer</i> , 2018, 124, 271-277.	2.0	265
6574	A Bayesian Phase I/II Trial Design for Immunotherapy. <i>Journal of the American Statistical Association</i> , 2018, 113, 1016-1027.	1.8	38
6575	In-vitro effect of pembrolizumab on different T regulatory cell subsets. <i>Clinical and Experimental Immunology</i> , 2018, 191, 189-197.	1.1	42
6576	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. <i>JAMA Oncology</i> , 2018, 4, 173.	3.4	753
6577	Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy. <i>JAMA Oncology</i> , 2018, 4, 253.	3.4	76
6578	Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 374.	3.4	735

#	ARTICLE	IF	CITATIONS
6579	Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. <i>Oncolmmunology</i> , 2018, 7, e1376156.	2.1	14
6580	Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. <i>Oncologist</i> , 2018, 23, 116-117.	1.9	3
6581	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 689-713.	2.4	351
6582	Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer. <i>Modern Pathology</i> , 2018, 31, 288-298.	2.9	38
6583	Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes. <i>Modern Pathology</i> , 2018, 31, 299-306.	2.9	17
6584	Primary central nervous system malignant melanoma with leptomeningeal melanomatosis: a case report and review of the literature. <i>Neurosurgical Review</i> , 2018, 41, 333-339.	1.2	27
6585	Granuloma annulare associated with immune checkpoint inhibitors. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e124-e126.	1.3	22
6586	The diverse functions of the PD1 inhibitory pathway. <i>Nature Reviews Immunology</i> , 2018, 18, 153-167.	10.6	1,210
6587	Immune checkpoint blockade in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 91-104.	10.6	407
6588	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. <i>Oncolmmunology</i> , 2018, 7, e1385689.	2.1	46
6589	Cholangiocarcinoma – evolving concepts and therapeutic strategies. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 95-111.	12.5	1,051
6590	Endocrinopathies with use of cancer immunotherapies. <i>Clinical Endocrinology</i> , 2018, 88, 327-332.	1.2	20
6591	Oncogenic RAS-induced CK1 β drives nuclear FOXO proteolysis. <i>Oncogene</i> , 2018, 37, 363-376.	2.6	22
6592	Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 13-30.	12.5	337
6593	Detection of ABCB5 tumour antigen-specific CD8+ T cells in melanoma patients and implications for immunotherapy. <i>Clinical and Experimental Immunology</i> , 2017, 191, 74-83.	1.1	5
6594	Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2018, 12, 221-229.	1.3	27
6595	Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 181-193.	3.3	18
6596	Inhibition of IL-6/JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels. <i>Molecular Oncology</i> , 2018, 12, 269-286.	2.1	92

#	ARTICLE	IF	CITATIONS
6597	Synthetic immune niches for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 212-219.	10.6	141
6598	Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. <i>Leukemia</i> , 2018, 32, 230-233.	3.3	49
6599	Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells. <i>Neuro-Oncology</i> , 2018, 20, 44-54.	0.6	51
6600	Immune Modulation Therapy and Imaging: Workshop Report. <i>Journal of Nuclear Medicine</i> , 2018, 59, 410-417.	2.8	23
6601	⁸⁹ Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 110-120.	3.3	100
6602	MicroRNA-132 suppresses cell proliferation in human breast cancer by directly targeting FOXA1. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 124-131.	2.8	32
6603	Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. <i>Abdominal Radiology</i> , 2018, 43, 218-230.	1.0	86
6604	¹⁸ F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 95-101.	3.3	46
6605	Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. <i>Clinical Cancer Research</i> , 2018, 24, 730-736.	3.2	16
6606	Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 325-336.	2.5	77
6607	Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. <i>Oncologist</i> , 2018, 23, 71-83.	1.9	45
6608	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. <i>Pathology and Oncology Research</i> , 2018, 24, 701-716.	0.9	17
6609	The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 466, 73-80.	1.6	63
6610	New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. <i>Advances in Anatomic Pathology</i> , 2018, 25, 131-142.	2.4	37
6611	Emerging biomarkers for cancer immunotherapy in melanoma. <i>Seminars in Cancer Biology</i> , 2018, 52, 207-215.	4.3	42
6612	Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 47-60.	2.0	29
6613	Contralateral breast cancers: Independent cancers or metastases?. <i>International Journal of Cancer</i> , 2018, 142, 347-356.	2.3	37
6614	Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA- ¹²⁵ I Gal and MVA-MUC1 (TG4010) in a murine tumor model. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 140-145.	1.4	25

#	ARTICLE	IF	CITATIONS
6615	Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. <i>Modern Pathology</i> , 2018, 31, 68-82.	2.9	58
6616	Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases. <i>Modern Pathology</i> , 2018, 31, 101-110.	2.9	38
6617	A system for detecting high impact-low frequency mutations in primary tumors and metastases. <i>Oncogene</i> , 2018, 37, 185-196.	2.6	21
6618	Cancer vaccines on the move. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 9-10.	12.5	127
6619	An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. <i>Molecular Therapy</i> , 2018, 26, 379-389.	3.7	78
6620	Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. <i>Cancer Immunology Research</i> , 2018, 6, 14-24.	1.6	129
6621	Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , 2018, 14, 417-430.	1.1	55
6622	Review of cancer treatment with immune checkpoint inhibitors. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 85-91.	1.0	102
6623	Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles. <i>Modern Pathology</i> , 2018, 31, 418-428.	2.9	75
6624	Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid Chondrosarcoma. <i>Oncologist</i> , 2018, 23, 118-120.	1.9	58
6625	Can checkpoint inhibitor therapy improve response to chemotherapy?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 183-185.	1.2	1
6626	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2 ⁺ advanced breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 127-134.	1.1	90
6627	Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2018, 28, 2-11.	1.0	23
6628	Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 63-70.	1.1	172
6629	Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 6-12.	0.6	25
6630	Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 4840-4848.	7.2	109
6631	Evolution of early phase clinical trials in oncology. <i>Journal of Molecular Medicine</i> , 2018, 96, 31-38.	1.7	13
6632	Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!. <i>Blood Reviews</i> , 2018, 32, 203-224.	2.8	21

#	ARTICLE	IF	CITATIONS
6633	Immune-related tumour response assessment criteria: a comprehensive review. <i>British Journal of Radiology</i> , 2018, 91, 20170457.	1.0	58
6634	Current status of cancer immunotherapy for esophageal squamous cell carcinoma. <i>Esophagus</i> , 2018, 15, 1-9.	1.0	19
6635	Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. <i>Current Problems in Cancer</i> , 2018, 42, 49-58.	1.0	25
6636	Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. <i>MAbs</i> , 2018, 10, 315-324.	2.6	72
6637	Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells. <i>Cancer Immunology Research</i> , 2018, 6, 139-150.	1.6	172
6638	Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 2045-2058.	2.4	103
6639	Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 337-348.	1.1	6
6640	Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 2035-2043.	3.2	75
6641	T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling. <i>Clinical Cancer Research</i> , 2018, 24, 870-881.	3.2	75
6642	Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy. <i>Clinical Breast Cancer</i> , 2018, 18, e237-e244.	1.1	39
6643	Towards personalized, tumour-specific, therapeutic vaccines for cancer. <i>Nature Reviews Immunology</i> , 2018, 18, 168-182.	10.6	736
6644	Multispectral imaging reveals hyper active TGF- β^2 signaling in colorectal cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 105-112.	1.5	28
6645	Coactivation of Estrogen Receptor and IKK β Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer. <i>Cancer Research</i> , 2018, 78, 974-984.	0.4	34
6646	Clinical role of breast MRI now and going forward. <i>Clinical Radiology</i> , 2018, 73, 700-714.	0.5	83
6647	Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review. <i>Neoplasia</i> , 2018, 20, 92-98.	2.3	24
6648	Emerging trends in the immunotherapy of pancreatic cancer. <i>Cancer Letters</i> , 2018, 417, 35-46.	3.2	77
6649	Statistical and integrative system-level analysis of DNA methylation data. <i>Nature Reviews Genetics</i> , 2018, 19, 129-147.	7.7	228
6650	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 55-70.	1.9	5

#	ARTICLE	IF	CITATIONS
6651	Kras and Tumor Immunity: Friend or Foe?. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031849.	2.9	62
6652	Race Disparities in the Contribution of miRNA Isoforms and tRNA-Derived Fragments to Triple-Negative Breast Cancer. Cancer Research, 2018, 78, 1140-1154.	0.4	90
6653	Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood, 2018, 131, 1183-1194.	0.6	276
6654	Metallic nanoparticles for cancer immunotherapy. Materials Today, 2018, 21, 673-685.	8.3	164
6655	Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Molecular Cancer Therapeutics, 2018, 17, 671-676.	1.9	33
6656	Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. Molecular Therapy, 2018, 26, 435-445.	3.7	39
6657	Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology, 2018, 31, 214-234.	2.9	278
6658	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treatment Reviews, 2018, 63, 48-60.	3.4	134
6659	PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective. Seminars in Cancer Biology, 2018, 52, 53-65.	4.3	58
6660	Product review on the Anti-PD-L1 antibody atezolizumab. Human Vaccines and Immunotherapeutics, 2018, 14, 269-276.	1.4	41
6661	Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer. Annual Review of Cancer Biology, 2018, 2, 313-336.	2.3	230
6662	Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers. Statistics in Medicine, 2018, 37, 687-709.	0.8	8
6663	CAR-T cells and combination therapies: What's next in the immunotherapy revolution?. Pharmacological Research, 2018, 129, 194-203.	3.1	33
6664	Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model. Prostate Cancer and Prostatic Diseases, 2018, 21, 113-125.	2.0	46
6665	A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. Clinical Cancer Research, 2018, 24, 1525-1535.	3.2	153
6666	Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. Cancer Discovery, 2018, 8, 354-369.	7.7	62
6667	Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma. JAMA Dermatology, 2018, 154, 82.	2.0	51
6668	Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Annals of Hematology, 2018, 97, 197-207.	0.8	162

#	ARTICLE	IF	CITATIONS
6669	Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. <i>Frontiers of Medicine</i> , 2018, 12, 229-235.	1.5	53
6670	Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 117-129.	0.9	28
6671	Drug development in the era of precision medicine. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 183-196.	21.5	294
6672	Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. <i>Nature Reviews Urology</i> , 2018, 15, 92-111.	1.9	139
6673	Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. <i>Nature Reviews Urology</i> , 2018, 15, 112-124.	1.9	73
6674	A suite of DNA methylation markers that can detect most common human cancers. <i>Epigenetics</i> , 2018, 13, 61-72.	1.3	48
6675	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> , 2018, 359, 582-587.	6.0	834
6676	Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 1785-1794.	3.2	42
6677	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1562-1573.	3.2	150
6678	PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2018, 200, 834-846.	0.4	23
6679	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018, 8, 216-233.	7.7	503
6680	BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 299-310.	2.0	48
6681	Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 671-686.	1.1	564
6682	CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 649-658.	1.1	5
6683	The inflammatory microenvironment and microbiome in prostate cancer development. <i>Nature Reviews Urology</i> , 2018, 15, 11-24.	1.9	311
6684	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 731-740.	1.1	71
6685	Targeting immuno-metabolism to improve anti-cancer therapies. <i>Cancer Letters</i> , 2018, 414, 127-135.	3.2	13
6686	CTLA-4: a moving target in immunotherapy. <i>Blood</i> , 2018, 131, 58-67.	0.6	704

#	ARTICLE	IF	CITATIONS
6687	Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. <i>JAMA Oncology</i> , 2018, 4, 126.	3.4	8
6688	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e173776.	3.4	116
6689	Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. <i>Leukemia</i> , 2018, 32, 252-262.	3.3	234
6690	Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. <i>Nature</i> , 2018, 553, 91-95.	13.7	660
6691	Optimizing Strategies for Immune Checkpoint Imaging with Immuno-PET in Preclinical Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 711.1-711.	2.8	5
6692	Cancer vaccine strategies: translation from mice to human clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1863-1869.	2.0	38
6693	Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 136, 453-461.	1.4	34
6694	Single-cell heterogeneity in ductal carcinoma in situ of breast. <i>Modern Pathology</i> , 2018, 31, 406-417.	2.9	41
6695	Targeting bromodomain and extraterminal proteins in breast cancer. <i>Pharmacological Research</i> , 2018, 129, 156-176.	3.1	38
6696	Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 201-234.	1.0	47
6697	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2018, 36, 638-646.	1.2	149
6698	PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 1-10.	1.6	139
6699	Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer. <i>Journal of Immunotherapy</i> , 2018, 41, 42-44.	1.2	17
6700	Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 376-383.	3.3	160
6701	Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 35-41.	1.1	7
6702	Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. <i>Cancer Causes and Control</i> , 2018, 29, 25-32.	0.8	9
6703	Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. <i>Investigational New Drugs</i> , 2018, 36, 96-102.	1.2	150
6704	SEOM clinical guideline for the management of malignant melanoma (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 69-74.	1.2	16

#	ARTICLE	IF	CITATIONS
6705	Imaging PD-L1 Expression with ImmunoPET. <i>Bioconjugate Chemistry</i> , 2018, 29, 96-103.	1.8	109
6706	Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. <i>British Journal of Cancer</i> , 2018, 118, 312-324.	2.9	184
6707	A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma. <i>Investigational New Drugs</i> , 2018, 36, 103-113.	1.2	19
6708	Pharmacotherapeutic Management of Pediatric Lymphoma. <i>Paediatric Drugs</i> , 2018, 20, 43-57.	1.3	10
6709	Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor- α -positive breast cancer. <i>FASEB Journal</i> , 2018, 32, 1222-1235.	0.2	22
6710	Ceritinib Enhances the Efficacy of Trametinib in <i>BRAF/NRAS</i> -Wild-Type Melanoma Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 73-83.	1.9	18
6711	Insights from structures of cancer-relevant pre-mRNA splicing factors. <i>Current Opinion in Genetics and Development</i> , 2018, 48, 57-66.	1.5	16
6712	Molecular Subtypes and Local-Regional Control of Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 95-120.	0.6	297
6713	Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis. <i>Clinical Cancer Research</i> , 2018, 24, 581-591.	3.2	21
6714	Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 7-24.	1.0	23
6715	Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 530-539.	0.6	2
6716	The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 133-143.	1.0	13
6717	Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 166-175.	3.0	122
6718	Ancient and modern: hints of a core post-transcriptional network driving chemotherapy resistance in ovarian cancer. <i>Wiley Interdisciplinary Reviews RNA</i> , 2018, 9, e1432.	3.2	10
6719	Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 851-860.	0.6	6
6720	Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 73-81.	1.5	25
6721	Breast Cancer Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 511-520.	3.2	567
6722	Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. <i>Gastric Cancer</i> , 2018, 21, 31-40.	2.7	75

#	ARTICLE	IF	CITATIONS
6723	<i>linc00673</i> (ERLR01) is a prognostic indicator of overall survival in breast cancer. <i>Transcription</i> , 2018, 9, 17-29.	1.7	22
6724	The role of vitamin D in hepatic metastases from colorectal cancer. <i>Clinical and Translational Oncology</i> , 2018, 20, 259-273.	1.2	3
6725	Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 221-227.	0.8	6
6726	T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	206
6727	BNIP3 modulates the interface between B16-F10 melanoma cells and immune cells. <i>Oncotarget</i> , 2018, 9, 17631-17644.	0.8	12
6728	Harnessing the immune system in the battle against breast cancer. <i>Drugs in Context</i> , 2018, 7, 1-21.	1.0	19
6729	Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma. <i>Medicine (United States)</i> , 2018, 97, e12937.	0.4	4
6730	Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. <i>Translational Lung Cancer Research</i> , 2018, 7, 404-415.	1.3	54
6731	Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	1.5	35
6732	Prognostic role of platelet to lymphocyte ratio in prostate cancer. <i>Medicine (United States)</i> , 2018, 97, e12504.	0.4	28
6733	Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma. <i>Aging</i> , 2018, 10, 973-987.	1.4	70
6734	Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study. <i>Oncotarget</i> , 2018, 9, 15542-15551.	0.8	80
6735	Analysis of <i>NTRK</i> Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. <i>JCO Precision Oncology</i> , 2018, 2018, 1-20.	1.5	201
6736	Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. <i>JCI Insight</i> , 2018, 3, .	2.3	49
6737	UBASH3B promotes tamoxifen resistance and could be negatively regulated by ESR1. <i>Oncotarget</i> , 2018, 9, 8326-8333.	0.8	4
6738	Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 1008-1018.	1.8	52
6739	ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors. <i>Journal of Oncology Practice</i> , 2018, 14, 72-76.	2.5	8
6740	Frameshift events predict anti-PD-1/L1 response in head and neck cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	190

#	ARTICLE	IF	CITATIONS
6741	HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape. <i>Oncotarget</i> , 2018, 9, 4120-4133.	0.8	66
6742	Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient. <i>Medicine (United States)</i> , 2018, 97, e12907.	0.4	20
6743	Spatial and phenotypic immune profiling of metastatic colon cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	73
6744	Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer. <i>Oncotarget</i> , 2018, 9, 15480-15497.	0.8	24
6745	Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab. <i>Cureus</i> , 2018, 10, e2238.	0.2	20
6746	Intratumor heterogeneity of <i>HMCN1</i> mutant alleles associated with poor prognosis in patients with breast cancer. <i>Oncotarget</i> , 2018, 9, 33337-33347.	0.8	18
6747	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 610-617.	0.6	192
6748	Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	1.5	0
6749	Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-12.	1.0	14
6750	Influence of <i>TP53</i> Mutation on Survival in Patients With Advanced <i>EGFR</i> -Mutant Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-29.	1.5	49
6751	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 391-398.	0.8	156
6752	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1428-1439.	0.8	551
6753	Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. <i>Journal of Clinical Oncology</i> , 2018, 36, 1905-1912.	0.8	268
6754	Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1419-1427.	0.8	477
6755	Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. <i>Journal of Global Oncology</i> , 2018, 4, 1-6.	0.5	24
6756	Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 737-744.	0.7	21
6757	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator-Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 383-390.	0.8	431
6758	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1714-1768.	0.8	2,691

#	ARTICLE	IF	CITATIONS
6759	Imaging Advances in the Management of Kidney Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3582-3590.	0.8	16
6760	SIK2 attenuates proliferation and survival of breast cancer cells with simultaneous perturbation of MAPK and PI3K/Akt pathways. <i>Oncotarget</i> , 2018, 9, 21876-21892.	0.8	24
6761	Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis. <i>Anti-Cancer Drugs</i> , 2018, 29, 904-910.	0.7	32
6762	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	0.8	1,109
6763	Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 1611-1618.	0.8	448
6764	Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). <i>Journal of Clinical Oncology</i> , 2018, 36, 1412-1418.	0.8	324
6765	Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2995-3006.	0.8	223
6766	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). <i>Journal of Clinical Oncology</i> , 2018, 36, 3223-3230.	0.8	267
6767	Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3450-3458.	0.8	55
6768	Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery. <i>Journal of Clinical Oncology</i> , 2018, 36, 3529-3532.	0.8	0
6769	Phosphatidylinositol 3-Kinase ï± Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1291-1299.	0.8	298
6770	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1658-1667.	0.8	483
6771	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 543-553.	0.8	162
6772	Global Challenges for Cancer Imaging. <i>Journal of Global Oncology</i> , 2018, 4, 1-10.	0.5	20
6773	Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky001.	0.3	5
6774	Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?. <i>Journal of Thoracic Disease</i> , 2018, 10, 1198-1200.	0.6	6
6775	A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 3575-3584.	0.6	36
6776	Neoadjuvant immunotherapy for non-small cell lung cancer: can early intervention result in durable clinical benefit?. <i>Journal of Thoracic Disease</i> , 2018, 10, S3203-S3206.	0.6	6

#	ARTICLE	IF	CITATIONS
6777	Broader indications for checkpoint inhibitors in NSCLC. <i>Journal of Thoracic Disease</i> , 2018, 10, 5190-5191.	0.6	0
6778	Lung cancer in never smokers—the East Asian experience. <i>Translational Lung Cancer Research</i> , 2018, 7, 450-463.	1.3	104
6779	Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. <i>Translational Lung Cancer Research</i> , 2018, 7, 668-677.	1.3	56
6780	Tumor mutational burden in non-small cell lung cancer—the pathologist's point of view. <i>Translational Lung Cancer Research</i> , 2018, 7, 716-721.	1.3	10
6781	PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs. <i>Cancer Biology and Medicine</i> , 2018, 15, 434.	1.4	19
6782	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 89-89.	1.5	30
6783	Cardio-toxicity of checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S4400-S4404.	0.6	19
6784	Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer—where are we?. <i>Translational Lung Cancer Research</i> , 2018, 7, 682-690.	1.3	29
6785	New horizons from immunotherapy in malignant pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2018, 10, S322-S332.	0.6	8
6786	Immunotherapy in treatment naïve advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S412-S421.	0.6	13
6787	Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 1124-1128.	0.6	50
6788	Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 1205-1206.	0.6	2
6789	Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?. <i>Journal of Thoracic Disease</i> , 2018, 10, S3162-S3165.	0.6	0
6790	Modern concepts in cardio-oncology. <i>Journal of Thoracic Disease</i> , 2018, 10, S4386-S4390.	0.6	13
6791	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, 647-660.	1.3	66
6792	Effects of mdig on proliferation and apoptosis of lung cancer cells. <i>Oncology Letters</i> , 2018, 16, 7146-7151.	0.8	0
6793	Gut microbiome: a key player in cancer immunotherapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 479-480.	0.7	10
6794	Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?. <i>Journal of Thoracic Disease</i> , 2018, 10, S3241-S3243.	0.6	2

#	ARTICLE	IF	CITATIONS
6795	PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S4034-S4037.	0.6	5
6796	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. <i>Translational Lung Cancer Research</i> , 2018, 7, 691-702.	1.3	8
6797	Role of immune checkpoint blockers in patients with EGFR mutation. <i>Translational Lung Cancer Research</i> , 2018, 7, S385-S387.	1.3	2
6798	Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer—driving down a precarious road in driver-mutated lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S377-S380.	1.3	3
6799	Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?. <i>Translational Lung Cancer Research</i> , 2018, 7, S370-S372.	1.3	2
6800	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). <i>Oncotarget</i> , 2018, 9, 17554-17563.	0.8	21
6801	Immunomodulation in hepatocellular cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 208-219.	0.6	22
6802	Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 225-230.	0.6	2
6803	Approach and management of checkpoint inhibitor-related immune hepatitis. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 220-224.	0.6	28
6804	Immune checkpoint inhibitors in gastrointestinal malignancies. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 390-403.	0.6	6
6805	Immune profiling of microsatellite instability-high and polymerase δ (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 404-415.	0.6	49
6806	Immunotherapy in pancreatic adenocarcinoma—overcoming barriers to response. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 143-159.	0.6	42
6807	Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 21-24.	0.6	1
6808	Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 25-29.	0.6	3
6809	A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 219-227.	0.6	6
6810	Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018, 10, S1516-S1533.	0.6	57
6811	Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1461-S1467.	0.6	25
6812	Immunotherapy in surgically resectable non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S404-S411.	0.6	53

#	ARTICLE	IF	CITATIONS
6813	Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S451-S459.	0.6	34
6814	Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 816-824.	0.6	9
6815	Combining radiation plus immunotherapy to improve systemic immune response. <i>Journal of Thoracic Disease</i> , 2018, 10, S468-S479.	0.6	46
6816	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1564-S1580.	0.6	58
6817	Immunotherapy in previously treated non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Disease</i> , 2018, 10, S422-S432.	0.6	9
6818	Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios. <i>Journal of Thoracic Disease</i> , 2018, 10, S1494-S1502.	0.6	12
6819	Oncogene-addicted non-small cell lung cancer and immunotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1547-S1555.	0.6	25
6820	Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time?. <i>Journal of Thoracic Disease</i> , 2018, 10, 1276-1279.	0.6	4
6821	Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma. <i>Journal of Thoracic Disease</i> , 2018, 10, 1891-1902.	0.6	23
6822	Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S995-S998.	0.6	1
6823	The evolving understanding of immunoediting and the clinical impact of immune escape. <i>Journal of Thoracic Disease</i> , 2018, 10, 1248-1252.	0.6	10
6824	Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S1534-S1546.	0.6	7
6825	Immunotherapy in the Asiatic population: any differences from Caucasian population?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1482-S1493.	0.6	42
6826	Efficacy and immune activation of ipilimumab in early-stage lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018, 10, S1945-S1948.	0.6	1
6827	Radiologic presentation of non-small cell lung cancer treated with anti-PD-1 therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S3930-S3932.	0.6	1
6828	Heart failure in cancer: role of checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S4323-S4334.	0.6	15
6829	Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?â€”the shifting paradigm of therapeutics. <i>Translational Lung Cancer Research</i> , 2018, 7, S39-S45.	1.3	11
6830	Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution. <i>Translational Lung Cancer Research</i> , 2018, 7, S91-S94.	1.3	16

#	ARTICLE	IF	CITATIONS
6831	Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. <i>Translational Lung Cancer Research</i> , 2018, 7, 50-68.	1.3	96
6832	Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 180-188.	1.3	28
6833	Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. <i>Translational Lung Cancer Research</i> , 2018, 7, 464-486.	1.3	11
6834	Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?. <i>Translational Lung Cancer Research</i> , 2018, 7, 631-638.	1.3	68
6835	Reirradiation for locoregionally recurrent non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S2522-S2536.	0.6	20
6836	Moving away (finally) from doublet therapy in lung cancer: immunotherapy and KEYNOTE-189. <i>Journal of Thoracic Disease</i> , 2018, 10, 5186-5189.	0.6	1
6837	Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis. <i>Journal of Thoracic Disease</i> , 2018, 10, 6254-6260.	0.6	6
6838	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. <i>Translational Lung Cancer Research</i> , 2018, 7, 703-715.	1.3	152
6839	Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort. <i>Current Oncology</i> , 2018, 25, 384-392.	0.9	48
6840	Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching. <i>Journal of Thoracic Disease</i> , 2018, 10, S2195-S2197.	0.6	3
6841	Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?. <i>Journal of Thoracic Disease</i> , 2018, 10, S3994-S3998.	0.6	17
6842	Immunotherapy in colorectal cancer: for the select few or all?. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 170-179.	0.6	51
6843	Thymic tumors and immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S1509-S1515.	0.6	30
6844	Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S433-S450.	0.6	15
6845	Insight into the regulatory mechanism of VEGFA isoforms in p53 mutant breast cancer: can it be substantiated with solely in vitro studies?. <i>Journal of Thoracic Disease</i> , 2018, 10, 567-569.	0.6	0
6846	Immune checkpoint inhibitors in small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S460-S467.	0.6	46
6847	Identifying and managing the adverse effects of immune checkpoint blockade. <i>Journal of Thoracic Disease</i> , 2018, 10, S480-S489.	0.6	78
6848	Advanced non-small cell lung cancer: the role of PD-L1 inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S1468-S1473.	0.6	11

#	ARTICLE	IF	CITATIONS
6849	Single nucleotide polymorphisms of casitas B-lineage lymphoma proto-oncogene-b predict outcomes of patients with advanced non-small cell lung cancer after first-line platinum based doublet chemotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 1635-1647.	0.6	2
6850	Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study. <i>Journal of Thoracic Disease</i> , 2018, 10, S1108-S1112.	0.6	15
6851	Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. <i>Journal of Thoracic Disease</i> , 2018, 10, S4282-S4295.	0.6	69
6852	VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 6378-6382.	0.6	13
6853	Nivolumab as first-line treatment in non-small cell lung cancer patientsâ€™key factors: tumor mutation burden and PD-L1 â‰¥50%. <i>Translational Lung Cancer Research</i> , 2018, 7, S28-S30.	1.3	11
6854	Putting the brakes on CTLA-4 inhibition in lung cancer?. <i>Translational Lung Cancer Research</i> , 2018, 7, S35-S38.	1.3	7
6855	Methods of measurement for tumor mutational burden in tumor tissue. <i>Translational Lung Cancer Research</i> , 2018, 7, 661-667.	1.3	166
6856	Immunotherapy efficacy and gender: discovery in precision medicine. <i>Translational Lung Cancer Research</i> , 2018, 7, S211-S213.	1.3	9
6857	Tumor mutational burden as predictive factor of response to immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, S358-S361.	1.3	8
6858	Approach to evaluating tumor mutational burden in routine clinical practice. <i>Translational Lung Cancer Research</i> , 2018, 7, 678-681.	1.3	23
6859	Three-dimensional tumor model mimics stromal - breast cancer cells signaling. <i>Oncotarget</i> , 2018, 9, 249-267.	0.8	44
6860	PD-L1 immunohistochemistry in patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S2127-S2129.	0.6	7
6861	Harmonization study of antibodies and platforms for programmed death ligand 1 immunostaining in non-small cell lung cancer: does shuffling couples settle the troubles?. <i>Journal of Thoracic Disease</i> , 2018, 10, S2124-S2126.	0.6	1
6862	Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2018, 10, 4433-4444.	0.6	24
6863	Atezolizumab in non-squamous non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S3155-S3159.	0.6	4
6864	Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, S221-S224.	1.3	2
6865	Analysis of Treg cell population in patients with breast cancer with respect to progesterone receptor status. <i>Wspolczesna Onkologia</i> , 2018, 22, 236-239.	0.7	5
6866	Understanding and quantifying the immune microenvironment in hepatocellular carcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 107-107.	1.5	1

#	ARTICLE	IF	CITATIONS
6867	The evolving toxicity profile of SBRT for lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 8, 48-57.	1.3	39
6868	Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 161-165.	0.6	12
6869	Identification of a novel therapeutic target in driver-negative non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S218-S220.	1.3	0
6870	Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 3583-3616.	1.4	118
6871	Development of biomarkers for real precision medicine. <i>Translational Lung Cancer Research</i> , 2018, 7, S228-S231.	1.3	0
6872	Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 1283-1299.	3.9	163
6873	Combining immunotherapy with radiation therapy in thoracic oncology. <i>Journal of Thoracic Disease</i> , 2018, 10, S2492-S2507.	0.6	16
6874	Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S4082-S4084.	0.6	1
6875	Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?. <i>Translational Lung Cancer Research</i> , 2018, 7, S198-S201.	1.3	8
6876	PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. <i>Translational Lung Cancer Research</i> , 2018, 7, S283-S286.	1.3	1
6877	Silencing of casein kinase 1 delta reduces migration and metastasis of triple negative breast cancer cells. <i>Oncotarget</i> , 2018, 9, 30821-30836.	0.8	19
6878	Intrathoracic core needle biopsy and repeat biopsy for PD-L1 evaluation in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S4031-S4033.	0.6	3
6879	Reversal of resistance to chemotherapy following anti-programmed cell death-1 immunotherapy in metastatic lung adenocarcinoma. <i>Medicine (United States)</i> , 2018, 97, e13427.	0.4	1
6880	Vaccination with induced pluripotent stem cells confers protection against cancer. <i>Stem Cell Investigation</i> , 2018, 5, 23-23.	1.3	3
6881	A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer. <i>Medicine (United States)</i> , 2018, 97, e13112.	0.4	14
6882	Chimeric Antigen Receptor T-Cell Therapy: A Beacon of Hope in the Fight Against Cancer. <i>Cureus</i> , 2018, 10, e3486.	0.2	8
6883	NIBIT-MESO-1: limitations and clinical perspectives in MPM treatment testing an immune checkpoint blockade combination in a single-arm study. <i>Journal of Thoracic Disease</i> , 2018, 10, S3878-S3881.	0.6	0
6884	High-throughput cancer hypothesis testing with an integrated PhysiCell-EMEWS workflow. <i>BMC Bioinformatics</i> , 2018, 19, 483.	1.2	54

#	ARTICLE	IF	CITATIONS
6885	Predictive factors of postoperative survival among patients with pulmonary neuroendocrine tumor. <i>Journal of Thoracic Disease</i> , 2018, 10, 6912-6920.	0.6	13
6886	Histology versus cytology: PD-L1 testing in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S225-S227.	1.3	7
6887	Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?. <i>Journal of Thoracic Disease</i> , 2018, 10, S4069-S4072.	0.6	3
6888	Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach. <i>Translational Lung Cancer Research</i> , 2018, 7, S265-S269.	1.3	1
6889	Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma. <i>Melanoma Management</i> , 2018, 5, MMT08.	0.1	2
6890	Quality of life for non-small cell lung cancer patients in the age of immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, S149-S152.	1.3	17
6891	Tumor Regression and Cure Depends on Sustained Th1 Responses. <i>Journal of Immunotherapy</i> , 2018, 41, 369-378.	1.2	26
6892	Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model. <i>Journal of Immunotherapy</i> , 2018, 41, 361-368.	1.2	51
6893	Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. <i>Medicine (United States)</i> , 2018, 97, e12344.	0.4	4
6894	Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer. <i>Medicine (United States)</i> , 2018, 97, e11435.	0.4	13
6895	The growing role of precision and personalized medicine for cancer treatment. <i>Technology</i> , 2018, 06, 79-100.	1.4	237
6896	Unravelling the Interplay between Extracellular Acidosis and Immune Cells. <i>Mediators of Inflammation</i> , 2018, 2018, 1-11.	1.4	154
6897	Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma. <i>Scientifica</i> , 2018, 2018, 1-7.	0.6	14
6898	Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. <i>JCI Insight</i> , 2018, 3, .	2.3	81
6899	Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. <i>Translational Lung Cancer Research</i> , 2018, 7, S290-S293.	1.3	2
6900	Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S95-S99.	1.3	7
6901	Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 224-234.	2.5	124
6902	The clinical utility of tumor mutational burden in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 639-646.	1.3	98

#	ARTICLE	IF	CITATIONS
6903	Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations. <i>Disease Markers</i> , 2018, 2018, 1-7.	0.6	13
6904	Role of indoleamine 2,3-dioxygenase in pathology of the gastrointestinal tract. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481881533.	1.4	27
6905	Jumonji ATâ€rich interactive domain 1B promotes the growth of pancreatic tumors via the phosphatase and tensin homolog/protein kinase B signaling pathway. <i>Oncology Letters</i> , 2018, 16, 267-275.	0.8	6
6906	Histological complete response with nivolumab for renal cell carcinoma with multiple metastases: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 10, 244-248.	0.4	15
6907	High PDâ€L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy. <i>Oncology Letters</i> , 2019, 17, 1626-1634.	0.8	14
6908	Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptorâ€positive/human epidermal growth factor receptor type 2 negative breast cancer. <i>Oncology Letters</i> , 2019, 17, 2177-2186.	0.8	20
6909	Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression. <i>Annals of Translational Medicine</i> , 2018, 6, 444-444.	0.7	5
6910	ATL. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1514-1519.	1.2	18
6911	Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies. <i>Lung Cancer Management</i> , 2018, 7, LMT07.	1.5	1
6912	ROS1â€rearranged highâ€PDâ€L1â€expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report. <i>Oncology Letters</i> , 2019, 17, 488-491.	0.8	2
6913	Using the Spleen as an <i>In Vivo</i> Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with \pm -PD-L1. <i>Sarcoma</i> , 2018, 2018, 1-13.	0.7	24
6914	Inactivation of DNA repairâ€prospects for boosting cancer immune surveillance. <i>Genome Medicine</i> , 2018, 10, 91.	3.6	8
6915	Combining immunotherapy and radiotherapy in lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S1447-S1460.	0.6	54
6916	LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers. <i>Oncotarget</i> , 2018, 9, 22586-22604.	0.8	21
6917	Tumor microenvironment classification based on Tâ€cell infiltration and PDâ€L1 in patients with mismatch repairâ€proficient and â€deficient colorectal cancer. <i>Oncology Letters</i> , 2018, 17, 2335-2343.	0.8	8
6918	Increased serum levels of Galectinâ€9 in patients with chronic lymphocytic leukemia. <i>Oncology Letters</i> , 2019, 17, 1019-1029.	0.8	10
6919	Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2018, 10, 398-407.	0.6	16
6920	Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-225937.	0.2	20

#	ARTICLE	IF	CITATIONS
6921	New drugs and new toxicities: pembrolizumab-induced myocarditis. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223252.	0.2	19
6922	A case of autoimmune haemolytic anaemia after 39 cycles of nivolumab. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224608.	0.2	14
6923	Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy. <i>Oncotarget</i> , 2018, 9, 2887-2894.	0.8	69
6924	Metastatic primary pulmonary melanoma successfully treated with checkpoint inhibitors. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223025.	0.2	1
6925	Delayed Presentation of Isolated Adrenocorticotropin Insufficiency after Nivolumab Therapy for Advanced Non-small-cell lung carcinoma (NSCLC). <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-225048.	0.2	14
6926	Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-16.	1.5	41
6927	Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2018, 23, 1388-1390.	1.9	17
6928	Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?. <i>Annals of Translational Medicine</i> , 2018, 6, S120-S120.	0.7	3
6929	Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens. <i>World Journal of Gastroenterology</i> , 2018, 24, 5418-5432.	1.4	77
6930	The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages. <i>Oncotarget</i> , 2018, 9, 7942-7948.	0.8	27
6931	The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 4239-4248.	0.8	14
6932	Immunomodulatory effect of statins on Regulatory T Lymphocytes in human colorectal cancer is determined by the stage of disease. <i>Oncotarget</i> , 2018, 9, 35752-35761.	0.8	9
6933	Coexisting genomic aberrations associated with lymph node metastasis in breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 2310-2324.	3.9	22
6934	Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	1.5	43
6935	Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. <i>Radiology and Oncology</i> , 2018, 52, 365-369.	0.6	36
6936	An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma. <i>BMB Reports</i> , 2018, 51, 572-577.	1.1	4
6937	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 4441-4453.	3.9	155
6938	Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. <i>Oncotarget</i> , 2018, 9, 20826-20837.	0.8	97

#	ARTICLE	IF	CITATIONS
6939	Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 157-172.	0.7	40
6940	Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clinical and Translational Medicine, 2018, 7, 32.	1.7	29
6941	Actionable Gene Alterations in an Asian Population With Triple-Negative Breast Cancer. JCO Precision Oncology, 2018, 2, 1-13.	1.5	3
6942	Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm. World Journal of Gastroenterology, 2018, 24, 5081-5094.	1.4	58
6943	Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight, 2018, 3, .	2.3	137
6944	The Adaptive Complexity of Cancer. BioMed Research International, 2018, 2018, 1-14.	0.9	17
6945	Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80. Frontiers in Immunology, 2018, 9, 3061.	2.2	28
6946	Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. Frontiers in Immunology, 2018, 9, 3081.	2.2	116
6947	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget, 2018, 9, 15001-15014.	0.8	33
6948	Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018. Ochsner Journal, 2018, 18, 370-376.	0.5	33
6949	Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature. Gastroenterology Research, 2018, 11, 174-188.	0.4	19
6950	Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model. Medical Science Monitor, 2018, 24, 5501-5508.	0.5	59
6951	Nivolumab therapy for lung cancer with tracheo-parenchymal fistula. Medicine (United States), 2018, 97, e13739.	0.4	6
6952	Correlation between Programmed Death-1 Ligand-1 and p53 in Patients with Lung Adenocarcinoma. Chinese Medical Journal, 2018, 131, 990-993.	0.9	8
6953	Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies. Melanoma Management, 2018, 5, MMT07.	0.1	15
6955	Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Current Urology Reports, 2018, 19, 109.	1.0	47
6956	Evaluation of immune repertoire inference methods from RNA-seq data. Nature Biotechnology, 2018, 36, 1034-1034.	9.4	7
6957	Single sample scoring of molecular phenotypes. BMC Bioinformatics, 2018, 19, 404.	1.2	286

#	ARTICLE	IF	CITATIONS
6958	TRIM59 promotes breast cancer motility by suppressing p62-selective autophagic degradation of PDCD10. <i>PLoS Biology</i> , 2018, 16, e3000051.	2.6	78
6959	Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States. <i>PLoS ONE</i> , 2018, 13, e0206370.	1.1	58
6960	Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3505.	1.8	69
6961	A DNA Methylation-Based Test for Breast Cancer Detection in Circulating Cell-Free DNA. <i>Journal of Clinical Medicine</i> , 2018, 7, 420.	1.0	46
6962	Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer. <i>Nature Communications</i> , 2018, 9, 4718.	5.8	44
6963	Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 363, k4226.	2.4	362
6964	Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy. <i>Targeted Oncology</i> , 2018, 13, 757-767.	1.7	15
6965	Pseudoprogression of Melanoma Brain Metastases. <i>Current Oncology Reports</i> , 2018, 20, 91.	1.8	14
6966	From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology. <i>High-Throughput</i> , 2018, 7, 33.	4.4	48
6967	Pathway-based subnetworks enable cross-disease biomarker discovery. <i>Nature Communications</i> , 2018, 9, 4746.	5.8	30
6968	Immune cells inhibit the tumor metastasis in the 4D cellular lung model by reducing the number of live circulating tumor cells. <i>Scientific Reports</i> , 2018, 8, 16569.	1.6	14
6969	Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer. <i>iScience</i> , 2018, 9, 258-277.	1.9	83
6970	<i>BRCA1/2</i> and <i>TP53</i> mutation status associates with <i>PD-1</i> and <i>PD-L1</i> expression in ovarian cancer. <i>Oncotarget</i> , 2018, 9, 17501-17511.	0.8	70
6971	Immune checkpoint inhibitors and radiotherapyâ€”concept and review of current literature. <i>Annals of Translational Medicine</i> , 2018, 6, 155-155.	0.7	16
6972	Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7423-7427.	1.0	32
6973	Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 2431.	2.2	85
6974	From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3584.	1.8	10
6975	Theranostics Applications of Nanoparticles in Cancer Immunotherapy. <i>Medical Sciences (Basel)</i> Tj ETQq1 1 0.784314 rgBT /Qverlock 10	1.3	7

#	ARTICLE	IF	CITATIONS
6976	Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880850.	1.4	30
6977	Perspective: cancer vaccines in the era of immune checkpoint blockade. <i>Mammalian Genome</i> , 2018, 29, 703-713.	1.0	20
6978	Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. <i>Cancer Research</i> , 2018, 78, 6349-6353.	0.4	183
6979	Bayesian variable selection for parametric survival model with applications to cancer omics data. <i>Human Genomics</i> , 2018, 12, 49.	1.4	11
6980	Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 513.	1.3	29
6981	The Role of Leukocytes in Diabetic Cardiomyopathy. <i>Frontiers in Physiology</i> , 2018, 9, 1547.	1.3	50
6982	HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3595.	1.8	78
6983	Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening. <i>Scientific Reports</i> , 2018, 8, 17366.	1.6	13
6984	Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. <i>Journal of Cancer</i> , 2018, 9, 4099-4107.	1.2	7
6985	The role of neoantigen in immune checkpoint blockade therapy. <i>Experimental Hematology and Oncology</i> , 2018, 7, 28.	2.0	99
6986	Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities. <i>Journal of Experimental Medicine</i> , 2018, 215, 3115-3135.	4.2	29
6987	Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 145.	2.2	18
6988	B2M, JAK2 and MET in the genetic landscape of immunotolerance in lung cancer. <i>Oncotarget</i> , 2018, 9, 35603-35604.	0.8	3
6989	Dissecting the Immune Landscape of Acute Myeloid Leukemia. <i>Biomedicines</i> , 2018, 6, 110.	1.4	32
6990	Translocation-Related Sarcomas. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3784.	1.8	37
6991	Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. , 2018, 6, 126.		40
6992	Cancer immunotherapy in routine cost-effective cancer care?. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	1
6993	Combatting mucosal melanoma: recent advances and future perspectives. <i>Melanoma Management</i> , 2018, 5, MMT11.	0.1	75

#	ARTICLE	IF	CITATIONS
6994	CAR T Cell Therapy for Neuroblastoma. <i>Frontiers in Immunology</i> , 2018, 9, 2380.	2.2	107
6995	Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV. <i>Frontiers in Immunology</i> , 2018, 9, 2447.	2.2	1
6996	PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28â€8 and E1L3N). <i>Diagnostic Pathology</i> , 2018, 13, 91.	0.9	48
6997	Kaposiâ€™s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab. , 2018, 6, 122.		6
6998	Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 7949-7960.	0.8	49
6999	Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. <i>Oncotarget</i> , 2018, 9, 11009-11019.	0.8	44
7000	The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7521-7527.	1.0	21
7001	Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7529-7542.	1.0	29
7002	A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7691-7697.	1.0	6
7003	Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8239-8250.	1.0	32
7004	Radiation Therapy and Immunotherapyâ€”A Potential Combination in Cancer Treatment. <i>Current Oncology</i> , 2018, 25, 454-460.	0.9	29
7005	Predictors of Immunotherapy-Induced Immune-Related Adverse Events. <i>Current Oncology</i> , 2018, 25, 403-410.	0.9	77
7006	Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Brief Review. <i>Current Oncology</i> , 2018, 25, 342-347.	0.9	98
7007	Upregulation of Ets1 expression by NFATc2 and NFKB1/RELA promotes breast cancer cell invasiveness. <i>Oncogenesis</i> , 2018, 7, 91.	2.1	41
7008	The multi-faceted role of Gata3 in developmental haematopoiesis. <i>Open Biology</i> , 2018, 8, 180152.	1.5	20
7009	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. <i>Oncotarget</i> , 2018, 9, 33762-33777.	0.8	17
7010	Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 177-194.	1.0	10
7011	Clinicopathological analysis of PD-L2 expression in colorectal cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7635-7642.	1.0	18

#	ARTICLE	IF	CITATIONS
7012	Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2481.	2.2	23
7013	V β 3V α 2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma. <i>Frontiers in Oncology</i> , 2018, 8, 508.	1.3	15
7014	Is There a Role for Adjuvant Therapy After Surgery in "High Risk for Recurrence" Kidney Cancer? an Update on Current Concepts. <i>Current Oncology</i> , 2018, 25, 444-453.	0.9	9
7015	A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. , 2018, 6, 128.		233
7016	Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. , 2018, 6, 129.		95
7017	Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. <i>Lung Cancer: Targets and Therapy</i> , 2018, Volume 9, 85-90.	1.3	20
7018	Lung cancer, elderly and immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S1474-S1481.	0.6	25
7019	Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 7079-7094.	3.3	44
7020	Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors. <i>Frontiers in Immunology</i> , 2018, 9, 2662.	2.2	8
7021	Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants. <i>Frontiers in Immunology</i> , 2018, 9, 2531.	2.2	32
7022	The Identification of Immunological Biomarkers in Kidney Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 456.	1.3	40
7023	Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 530.	1.3	27
7024	Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11701-E11710.	3.3	108
7025	New drug developments in metastatic gastric cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880807.	1.4	19
7026	Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. <i>BMC Cancer</i> , 2018, 18, 1137.	1.1	69
7027	Toward the precision breast cancer survival prediction utilizing combined whole genome-wide expression and somatic mutation analysis. <i>BMC Medical Genomics</i> , 2018, 11, 104.	0.7	10
7028	Botanical Therapeutics: Phytochemical Screening and Biological Assessment of Chamomile, Parsley and Celery Extracts against A375 Human Melanoma and Dendritic Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3624.	1.8	30
7029	Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint Inhibitors?. <i>Cureus</i> , 2018, 10, e3254.	0.2	9

#	ARTICLE	IF	CITATIONS
7030	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. <i>Lancet Oncology</i> , The, 2018, 19, 1579-1589.	5.1	742
7031	Immune and genomic signatures in oral (head and neck) cancer. <i>Heliyon</i> , 2018, 4, e00880.	1.4	19
7032	The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	26
7033	Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). <i>BMC Cancer</i> , 2018, 18, 1074.	1.1	12
7034	PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer. <i>BMC Urology</i> , 2018, 18, 97.	0.6	36
7035	Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 307.	1.8	16
7036	Association of specific gene mutations derived from machine learning with survival in lung adenocarcinoma. <i>PLoS ONE</i> , 2018, 13, e0207204.	1.1	42
7037	CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes. <i>Oncotarget</i> , 2018, 9, 5208-5215.	0.8	73
7038	Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 2759.	2.2	58
7039	Polyclonal Rabbit Anti-Cancer-Associated Fibroblasts Globulins Induce Cancer Cells Apoptosis and Inhibit Tumor Growth. <i>International Journal of Biological Sciences</i> , 2018, 14, 1621-1629.	2.6	5
7040	Immune regulation and anti-cancer activity by lipid inflammatory mediators. <i>International Immunopharmacology</i> , 2018, 65, 580-592.	1.7	29
7041	Single-cell reconstruction of the early maternal-fetal interface in humans. <i>Nature</i> , 2018, 563, 347-353.	13.7	1,547
7042	Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report. <i>BMC Cancer</i> , 2018, 18, 1105.	1.1	48
7043	Updates on immunotherapy for colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 160-169.	0.6	126
7044	The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7369-7383.	1.0	19
7045	The elevated glutaminolysis of bladder cancer and T cells in a simulated tumor microenvironment contributes to the up-regulation of PD-L1 expression by interferon- γ . <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7229-7243.	1.0	11
7046	Review of Immune Therapies Targeting Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 74.	1.3	48
7047	Radiotherapy induces responses of lung cancer to CTLA-4 blockade. <i>Nature Medicine</i> , 2018, 24, 1845-1851.	15.2	626

#	ARTICLE	IF	CITATIONS
7048	Mathematical modeling identifies Lck as a potential mediator for PD-1 induced inhibition of early TCR signaling. <i>PLoS ONE</i> , 2018, 13, e0206232.	1.1	22
7049	Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers. <i>Frontiers in Immunology</i> , 2018, 9, 2480.	2.2	57
7050	Epigenetic profiling for the molecular classification of metastatic brain tumors. <i>Nature Communications</i> , 2018, 9, 4627.	5.8	79
7051	β-catenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors. <i>BMC Cancer</i> , 2018, 18, 1062.	1.1	20
7052	Blocking-Free ELISA Using a Gold Nanoparticle Layer Coated Commercial Microwell Plate. <i>Sensors</i> , 2018, 18, 3537.	2.1	6
7053	Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges. <i>Current Oncology</i> , 2018, 25, 373-384.	0.9	109
7054	Surface CD200 and CD200R antigens on lymphocytes in advanced gastric cancer: a new potential target for immunotherapy. <i>Archives of Medical Science</i> , 2018, 14, 1271-1280.	0.4	7
7055	The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies. <i>Current Treatment Options in Oncology</i> , 2018, 19, 70.	1.3	17
7056	Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics. <i>Cell Reports</i> , 2018, 25, 1458-1468.e4.	2.9	315
7057	Integration of Tumor Genomic Data with Cell Lines Using Multi-dimensional Network Modules Improves Cancer Pharmacogenomics. <i>Cell Systems</i> , 2018, 7, 526-536.e6.	2.9	23
7058	Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice. <i>Journal of the American Chemical Society</i> , 2018, 140, 16596-16609.	6.6	68
7059	Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. <i>Nature Communications</i> , 2018, 9, 4664.	5.8	331
7060	Tumour-targeting bacteria engineered to fight cancer. <i>Nature Reviews Cancer</i> , 2018, 18, 727-743.	12.8	439
7061	⁶⁸ Ga-DOTA-GGNle-CycMSH _{hex} targets the melanocortin-1 receptor for melanoma imaging. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	30
7062	Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma. <i>Journal of Immunology Research</i> , 2018, 2018, 1-12.	0.9	11
7063	Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastatic cutaneous malignant melanoma. <i>PLoS ONE</i> , 2018, 13, e0206942.	1.1	35
7064	The Role of Co-Stimulatory Molecules in Chagas Disease. <i>Cells</i> , 2018, 7, 200.	1.8	6
7065	Self-assembly of porphyrin-grafted lipid into nanoparticles encapsulating doxorubicin for synergistic chemo-photodynamic therapy and fluorescence imaging. <i>Theranostics</i> , 2018, 8, 5501-5518.	4.6	66

#	ARTICLE	IF	CITATIONS
7066	T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2018, 21, 406.	0.8	32
7067	Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky056.	1.4	71
7068	Transforming of the Tumor Microenvironment: Implications for TGF- β Inhibition in the Context of Immune-Checkpoint Therapy. <i>Journal of Oncology</i> , 2018, 2018, 1-9.	0.6	35
7069	A multi-omics approach for identifying important pathways and genes in human cancer. <i>BMC Bioinformatics</i> , 2018, 19, 479.	1.2	15
7070	Improvement of cancer subtype prediction by incorporating transcriptome expression data and heterogeneous biological networks. <i>BMC Medical Genomics</i> , 2018, 11, 119.	0.7	10
7071	Analysis of PD-1 related immune transcriptional profile in different cancer types. <i>Cancer Cell International</i> , 2018, 18, 218.	1.8	15
7072	Tumor suppressor RARRES1- A novel regulator of fatty acid metabolism in epithelial cells. <i>PLoS ONE</i> , 2018, 13, e0208756.	1.1	21
7073	PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis. <i>Journal of Breast Cancer</i> , 2018, 21, 382.	0.8	14
7074	T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. <i>Theranostics</i> , 2018, 8, 6070-6087.	4.6	28
7075	Metastatic lobular breast carcinoma to the pancreas: a case report. <i>Journal of Surgical Case Reports</i> , 2018, 2018, rjy111.	0.2	2
7076	Radiotherapy and immune response: the systemic effects of a local treatment. <i>Clinics</i> , 2018, 73, e557s.	0.6	154
7077	Secretory High-Mobility Group Box 1 Protein Affects Regulatory T Cell Differentiation in Neuroblastoma Microenvironment <i>In Vitro</i> . <i>Journal of Oncology</i> , 2018, 2018, 1-12.	0.6	14
7078	Total HLA Class I Antigen Loss with the Downregulation of Antigen-Processing Machinery Components in Two Newly Established Sarcomatoid Hepatocellular Carcinoma Cell Lines. <i>Journal of Immunology Research</i> , 2018, 2018, 1-12.	0.9	4
7079	Effects of mir-128a on the invasion and proliferation of glioma U251 cells. <i>Oncology Letters</i> , 2018, 17, 891-896.	0.8	3
7080	Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. <i>Oncology Reports</i> , 2019, 41, 801-810.	1.2	76
7081	GSAE: an autoencoder with embedded gene-set nodes for genomics functional characterization. <i>BMC Systems Biology</i> , 2018, 12, 142.	3.0	52
7082	A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. , 2018, 6, 156.		58
7083	New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. <i>Oncotarget</i> , 2018, 9, 10635-10649.	0.8	41

#	ARTICLE	IF	CITATIONS
7102	Patient-derived xenograft mouse models: A high fidelity tool for individualized medicine (Review). <i>Oncology Letters</i> , 2019, 17, 3-10.	0.8	49
7103	Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. <i>Theranostics</i> , 2018, 8, 5690-5702.	4.6	45
7104	Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. <i>Nature Communications</i> , 2018, 9, 5361.	5.8	294
7105	Current Options and Future Directions in Immune Therapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2018, 8, 578.	1.3	21
7106	Immune Gene Signature Delineates a Subclass of Papillary Thyroid Cancer with Unfavorable Clinical Outcomes. <i>Cancers</i> , 2018, 10, 494.	1.7	68
7107	Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. , 2018, 6, 152.		53
7108	Comparative Transcriptomics Unravels Prodigiosin's Potential Cancer-Specific Activity Between Human Small Airway Epithelial Cells and Lung Adenocarcinoma Cells. <i>Frontiers in Oncology</i> , 2018, 8, 573.	1.3	11
7109	Isolated adrenocorticotrophic hormone deficiency potentially induced by nivolumab following pseudo-progression in clear cell renal cell carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 10, 304-308.	0.4	10
7110	Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. <i>Nature Communications</i> , 2018, 9, 5426.	5.8	11
7111	Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. <i>Nature Communications</i> , 2018, 9, 5450.	5.8	157
7112	Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 40.	2.3	36
7113	Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591881628.	1.4	56
7114	A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. <i>BMC Cancer</i> , 2018, 18, 1274.	1.1	31
7115	The clinical promise of immunotherapy in triple-negative breast cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 6823-6833.	0.9	113
7116	Local ablative therapy with or without chemotherapy for non-small-cell lung cancer patients with postoperative oligometastases. <i>Cancer Management and Research</i> , 2018, Volume 10, 6421-6429.	0.9	3
7117	Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8565-8573.	1.0	8
7118	Artificial T Cell Mimetics to Combat Melanoma Tumor Growth. <i>American Journal of Advanced Drug Delivery</i> , 2018, 06, .	0.1	2
7119	CBP ^{Δ2} -Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer. <i>Cancers</i> , 2018, 10, 525.	1.7	36

#	ARTICLE	IF	CITATIONS
7120	Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2018, 8, 17812.	1.6	39
7121	The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters. <i>Mediators of Inflammation</i> , 2018, 2018, 1-12.	1.4	23
7122	An innovative anti-cancer Chinese herbal formula exhibited multi-targeted efficacies in metastatic breast cancer mouse model. <i>Chinese Medicine</i> , 2018, 13, 64.	1.6	24
7123	Classification of triple-negative breast cancers based on Immunogenomic profiling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 327.	3.5	329
7124	Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. <i>Oncotarget</i> , 2018, 9, 36238-36249.	0.8	28
7125	Analysis of long non-coding RNAs in glioblastoma for prognosis prediction using weighted gene co-expression network analysis, Cox regression, and L1-LASSO penalization. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 157-168.	1.0	55
7126	The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1430.	1.6	88
7127	Two-Round Mixed Lymphocyte Reaction for Evaluation of the Functional Activities of Anti-PD-1 and Immunomodulators. <i>Immune Network</i> , 2018, 18, e45.	1.6	10
7128	Immunotherapy and molecular role of T-cell in PD-1 antibody treated resectable lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018, 10, 4682-4685.	0.6	5
7129	Neoadjuvant PD-1 blockade in lung cancer: weâ€™re not in Kansas anymore. <i>Journal of Thoracic Disease</i> , 2018, 10, 4686-4688.	0.6	0
7130	Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. <i>Cancers</i> , 2018, 10, 514.	1.7	141
7131	USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors. <i>Molecular Cell</i> , 2018, 72, 925-941.e4.	4.5	99
7132	CD36 plays a critical role in proliferation, migration and tamoxifen-inhibited growth of ER-positive breast cancer cells. <i>Oncogenesis</i> , 2018, 7, 98.	2.1	82
7133	The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice. <i>Cellular and Molecular Biology Letters</i> , 2018, 23, 58.	2.7	18
7134	CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers. <i>Breast Cancer Research</i> , 2018, 20, 154.	2.2	80
7135	Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 6457-6468.	0.9	23
7136	The Era of Immune Checkpoint Therapy: From Cancer to Viral Infectionâ€”A Mini Comment on the 2018 Medicine Nobel Prize. <i>Virologica Sinica</i> , 2018, 33, 467-471.	1.2	9
7137	Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas. <i>Nature Communications</i> , 2018, 9, 5330.	5.8	174

#	ARTICLE	IF	CITATIONS
7138	1-Pyrroline-5-carboxylate released by prostate Cancer cell inhibit T cell proliferation and function by targeting SHP1/cytochrome c oxidoreductase/ROS Axis. , 2018, 6, 148.		26
7139	The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. Biomedicines, 2018, 6, 114.	1.4	28
7140	Immunotherapy Advances in Urothelial Carcinoma. Current Treatment Options in Oncology, 2018, 19, 79.	1.3	5
7141	Implementing a comprehensive translational oncology platform: from molecular testing to actionability. Journal of Translational Medicine, 2018, 16, 358.	1.8	35
7142	Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry. Pharmaceutics, 2018, 10, 260.	2.0	6
7143	Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881559.	1.4	38
7144	CCL1 is a major regulatory T cell attracting factor in human breast cancer. BMC Cancer, 2018, 18, 1278.	1.1	52
7145	Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. Journal of Hematology and Oncology, 2018, 11, 142.	6.9	95
7146	Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. , 2018, 6, 155.		82
7147	Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. Journal of Immunology Research, 2018, 2018, 1-9.	0.9	75
7148	CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881834.	1.4	33
7149	PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells. International Journal of Nanomedicine, 2019, Volume 14, 17-32.	3.3	72
7150	CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. Frontiers in Oncology, 2018, 8, 608.	1.3	160
7151	Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 4689-4693.	0.6	57
7152	Organoid Modeling of the Tumor Immune Microenvironment. Cell, 2018, 175, 1972-1988.e16.	13.5	870
7153	Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment—are we barking up the wrong tree?. Translational Lung Cancer Research, 2018, 7, S275-S279.	1.3	36
7154	Immune checkpoint inhibitors in cancer therapy. Journal of Biomedical Research, 2018, 32, 317.	0.7	101
7155	Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. Oncotarget, 2018, 9, 35439-35447.	0.8	2

#	ARTICLE	IF	CITATIONS
7156	Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 563.	1.3	35
7157	Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, e116-e136.	2.5	49
7158	Common Mechanisms Linking Chronic Obstructive Pulmonary Disease and Lung Cancer. <i>Annals of the American Thoracic Society</i> , 2018, 15, S273-S277.	1.5	13
7159	Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 7684-7699.	0.8	62
7160	Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. <i>Cancers</i> , 2018, 10, 506.	1.7	40
7161	Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3924.	1.8	41
7162	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. <i>Journal of Clinical Medicine</i> , 2018, 7, 542.	1.0	64
7163	Immune checkpoint inhibitors in the onset of myasthenia gravis with hyper<sc>CK</sc>emia. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1421-1427.	1.7	31
7164	2018 Nobel Prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade â€“ A personal account. <i>Genes and Diseases</i> , 2018, 5, 302-303.	1.5	32
7165	Oncolytic virus immunotherapy: future prospects for oncology. , 2018, 6, 140.		197
7166	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
7167	Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3. <i>Cancers</i> , 2018, 10, 478.	1.7	30
7168	Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. <i>Nature Communications</i> , 2018, 9, 5200.	5.8	71
7169	Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival. <i>Genome Medicine</i> , 2018, 10, 94.	3.6	100
7170	Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitorâ€“induced colitis: a multi-center study. , 2018, 6, 142.		146
7171	The Multifarious Role of Microglia in Brain Metastasis. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 414.	1.8	25
7172	PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine. <i>Journal of Cancer</i> , 2018, 9, 4374-4381.	1.2	5
7173	Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma. <i>Journal of Cancer</i> , 2018, 9, 4287-4293.	1.2	34

#	ARTICLE	IF	CITATIONS
7174	The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer. <i>Journal of Cancer</i> , 2018, 9, 4325-4333.	1.2	16
7175	Disease networks identify specific conditions and pleiotropy influencing multimorbidity in the general population. <i>Scientific Reports</i> , 2018, 8, 15970.	1.6	22
7176	Biological subtypes and survival outcomes in breast cancer patients with brain metastases in the targeted therapy era. <i>Neuro-Oncology Practice</i> , 2018, 5, 161-169.	1.0	6
7177	Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set. <i>PLoS ONE</i> , 2018, 13, e0208459.	1.1	19
7178	High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. <i>Nature Communications</i> , 2018, 9, 5079.	5.8	91
7179	Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?. <i>Vaccines</i> , 2018, 6, 79.	2.1	7
7180	Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 655-663.	2.7	18
7181	Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 900.	1.1	15
7182	Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma. , 2018, 6, 130.		10
7183	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. <i>Oncotarget</i> , 2018, 9, 20617-20630.	0.8	36
7184	Immunological targets for cancer therapy: new recognition. <i>ImmunoTargets and Therapy</i> , 2018, Volume 7, 83-85.	2.7	13
7185	Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 2878.	2.2	4
7186	Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 108-114.	0.8	25
7187	Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. <i>Genome Medicine</i> , 2018, 10, 86.	3.6	14
7188	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. <i>Genome Medicine</i> , 2018, 10, 93.	3.6	121
7189	MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors. <i>PLoS ONE</i> , 2018, 13, e0207255.	1.1	65
7190	Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3793.	1.8	54
7191	Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases. <i>Case Reports in Oncology</i> , 2018, 11, 648-653.	0.3	24

#	ARTICLE	IF	CITATIONS
7192	Soluble immune checkpoints in cancer: production, function and biological significance. , 2018, 6, 132.		169
7193	Sepsis-Induced Immunosuppression in Neonates. <i>Frontiers in Pediatrics</i> , 2018, 6, 357.	0.9	43
7194	Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. <i>Nature Communications</i> , 2018, 9, 5150.	5.8	496
7195	Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. <i>Nature Communications</i> , 2018, 9, 5097.	5.8	21
7196	The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. <i>Cancer Immunology Research</i> , 2018, 6, 1445-1452.	1.6	132
7197	Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression. <i>Case Reports in Oncology</i> , 2018, 11, 688-692.	0.3	7
7198	Imitating Pathologist Based Assessment With Interpretable and Context Based Neural Network Modeling of Histology Images. <i>Biomedical Informatics Insights</i> , 2018, 10, 117822261880748.	4.6	6
7199	Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients. <i>BMC Cancer</i> , 2018, 18, 1202.	1.1	46
7200	Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. , 2018, 6, 131.		35
7201	Subgrouping breast cancer patients based on immune evasion mechanisms unravels a high involvement of transforming growth factor-beta and decoy receptor 3. <i>PLoS ONE</i> , 2018, 13, e0207799.	1.1	21
7202	Identification and Characterization of MicroRNAs Associated with Somatic Copy Number Alterations in Cancer. <i>Cancers</i> , 2018, 10, 475.	1.7	6
7203	Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. <i>Cancer Management and Research</i> , 2018, Volume 10, 5537-5544.	0.9	1
7204	Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. <i>Frontiers in Oncology</i> , 2018, 8, 532.	1.3	27
7205	Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. <i>Frontiers in Oncology</i> , 2018, 8, 609.	1.3	17
7206	Incidence and Survival Outcomes of Breast Cancer with Synchronous Hepatic Metastases: A Population-Based Study. <i>Journal of Cancer</i> , 2018, 9, 4306-4313.	1.2	5
7207	PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer. <i>Targeted Oncology</i> , 2018, 13, 769-777.	1.7	10
7208	Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: An observational study. <i>Molecular and Clinical Oncology</i> , 2018, 10, 137-143.	0.4	39
7209	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN- γ and IL-12. <i>Immunity</i> , 2018, 49, 1148-1161.e7.	6.6	639

#	ARTICLE	IF	CITATIONS
7210	Targeting tumor cells with antibodies enhances anti-tumor immunity. <i>Biophysics Reports</i> , 2018, 4, 243-253.	0.2	17
7211	Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report. <i>Frontiers in Immunology</i> , 2018, 9, 2145.	2.2	37
7212	Checkpoint Inhibition in Myeloma: Opportunities and Challenges. <i>Frontiers in Immunology</i> , 2018, 9, 2204.	2.2	45
7213	Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. <i>Cancer</i> , 2018, 124, 3693-3705.	2.0	26
7214	Who guards the guardian? Mechanisms that restrain APC/C during the cell cycle. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2018, 1865, 1924-1933.	1.9	44
7215	The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. <i>Journal of Translational Medicine</i> , 2018, 16, 273.	1.8	73
7216	Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5865-5872.	1.0	6
7217	Distribution of CD4 ⁺ and CD8 ⁺ exhausted tumor-infiltrating lymphocytes in molecular subtypes of Chinese breast cancer patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6139-6145.	1.0	6
7218	Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6189-6196.	1.0	47
7219	EGFR may participate in immune evasion through regulation of B7-H5 expression in non-small cell lung carcinoma. <i>Molecular Medicine Reports</i> , 2018, 18, 3769-3779.	1.1	10
7220	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	15.2	592
7221	A review of guidelines for lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S1556-S1563.	0.6	64
7222	Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2140.	2.2	92
7223	Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects. <i>Frontiers in Immunology</i> , 2018, 9, 2170.	2.2	48
7224	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer. <i>Chest</i> , 2018, 154, 1416-1423.	0.4	230
7225	Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. <i>Journal of Experimental Medicine</i> , 2018, 215, 2748-2759.	4.2	34
7226	Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. <i>Thoracic Cancer</i> , 2018, 9, 1522-1524.	0.8	9
7227	Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors. <i>Thoracic Cancer</i> , 2018, 9, 1500-1508.	0.8	18

#	ARTICLE	IF	CITATIONS
7228	Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs. <i>Cancer Research</i> , 2018, 78, 6413-6423.	0.4	33
7229	Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661880116.	1.0	5
7230	Activation of viral defense signaling in cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879310.	1.4	14
7231	Integrative pathway-based survival prediction utilizing the interaction between gene expression and DNA methylation in breast cancer. <i>BMC Medical Genomics</i> , 2018, 11, 68.	0.7	18
7232	The role of radiology in the evaluation of the immunotherapy efficacy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1438-S1446.	0.6	22
7233	Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2028.	2.2	36
7234	The Unfolded Protein Response in Breast Cancer. <i>Cancers</i> , 2018, 10, 344.	1.7	62
7235	Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2879.	1.8	151
7236	Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2890.	1.8	44
7237	Importance of the Keap1-Nrf2 pathway in NSCLC: Is it a possible biomarker? (Review). <i>Biomedical Reports</i> , 2018, 9, 375-382.	0.9	26
7238	The role of cancer stem cells in the modulation of anti-tumor immune responses. <i>Seminars in Cancer Biology</i> , 2018, 53, 189-200.	4.3	80
7239	Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. , 2018, 6, 93.		59
7240	Response to PD1 inhibition in conventional chondrosarcoma. , 2018, 6, 94.		26
7241	A neoepitope derived from a novel human germline APC gene mutation in familial adenomatous polyposis shows selective immunogenicity. <i>PLoS ONE</i> , 2018, 13, e0203845.	1.1	4
7242	IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma. <i>Internal Medicine</i> , 2018, 57, 1259-1263.	0.3	53
7243	Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis. <i>Frontiers in Immunology</i> , 2018, 9, 2077.	2.2	36
7244	The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 367.	1.3	140
7245	Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma. <i>EBioMedicine</i> , 2018, 36, 196-208.	2.7	17

#	ARTICLE	IF	CITATIONS
7246	KDM4B-regulated unfolded protein response as a therapeutic vulnerability in <i>PTEN</i> -deficient breast cancer. <i>Journal of Experimental Medicine</i> , 2018, 215, 2833-2849.	4.2	33
7247	Immunosenescence and lymphomagenesis. <i>Immunity and Ageing</i> , 2018, 15, 22.	1.8	30
7248	CD38 is methylated in prostate cancer and regulates extracellular NAD ⁺ . <i>Cancer & Metabolism</i> , 2018, 6, 13.	2.4	28
7249	New opportunities for nanoparticles in cancer immunotherapy. <i>Biomaterials Research</i> , 2018, 22, 24.	3.2	137
7250	Prognostic impact of programmed cell death ligand 1 expression on long-term oncologic outcomes in colorectal cancer. <i>Oncology Letters</i> , 2018, 16, 5214-5222.	0.8	10
7251	Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2018, 8, 351.	1.3	71
7252	MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers. <i>Frontiers in Oncology</i> , 2018, 8, 352.	1.3	13
7253	Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 994-1002.	0.9	29
7254	Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study. <i>Targeted Oncology</i> , 2018, 13, 611-619.	1.7	3
7255	Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9640-E9648.	3.3	116
7256	Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. <i>Gastroenterology Research</i> , 2018, 11, 264-273.	0.4	294
7257	Not All Immune Checkpoints Are Created Equal. <i>Frontiers in Immunology</i> , 2018, 9, 1909.	2.2	114
7258	Turn Back the TIME: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 1977.	2.2	123
7259	Oxygen Saturation on Admission Is a Predictive Biomarker for PD-L1 Expression on Circulating Monocytes and Impaired Immune Response in Patients With Sepsis. <i>Frontiers in Immunology</i> , 2018, 9, 2008.	2.2	18
7260	The $\text{C}^{\ast}3279\text{C}$ and $\text{G}^{\ast}924\text{A}$ polymorphisms in the FOXP3 Gene Are Associated With Viral Load and Liver Enzyme Levels in Patients With Chronic Viral Liver Diseases. <i>Frontiers in Immunology</i> , 2018, 9, 2014.	2.2	9
7261	Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas. <i>Cancers</i> , 2018, 10, 339.	1.7	13
7262	Impact of phosphorylated insulin-like growth factor-1 receptor on the outcome of breast cancer patients and the prognostic value of its alteration during neoadjuvant chemotherapy. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 2949-2959.	0.8	3
7263	Thyroid disorders induced by checkpoint inhibitors. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 325-333.	2.6	87

#	ARTICLE	IF	CITATIONS
7264	Immunotherapy for Merkel Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 57.	1.3	12
7265	Stochastic modeling of tumor progression and immune evasion. <i>Journal of Theoretical Biology</i> , 2018, 458, 148-155.	0.8	15
7266	Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 911.	1.1	25
7267	Checkpoint molecule PD-1-assisted CD8 ⁺ T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. <i>Cancer Management and Research</i> , 2018, Volume 10, 3419-3431.	0.9	47
7268	Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2857-2873.	2.0	10
7269	Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5601-5605.	1.0	7
7270	CD8+ T cells modulate autosomal dominant polycystic kidney disease progression. <i>Kidney International</i> , 2018, 94, 1127-1140.	2.6	54
7271	Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma. <i>Scientific Reports</i> , 2018, 8, 14216.	1.6	25
7272	Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells. <i>Genome Medicine</i> , 2018, 10, 71.	3.6	30
7273	Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer. <i>Cancers</i> , 2018, 10, 342.	1.7	109
7274	Drug resistance and new therapies in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 3834-3848.	1.4	406
7275	Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases. <i>Nature Communications</i> , 2018, 9, 3953.	5.8	45
7276	Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study). <i>Thoracic Cancer</i> , 2018, 9, 1795-1800.	0.8	3
7277	NKX2-1-AS1 negatively regulates CD274/PD-L1, cell-cell interaction genes, and limits human lung carcinoma cell migration. <i>Scientific Reports</i> , 2018, 8, 14418.	1.6	44
7278	The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2018, 2018, 1-13.	0.9	17
7279	Advanced pancreatic cancer: The standard of care and new opportunities. <i>Oncology Reviews</i> , 2018, 12, 370.	0.8	10
7280	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. <i>Trends in Biochemical Sciences</i> , 2018, 43, 1014-1032.	3.7	151
7281	Roles of the immune system in cancer: from tumor initiation to metastatic progression. <i>Genes and Development</i> , 2018, 32, 1267-1284.	2.7	1,326

#	ARTICLE	IF	CITATIONS
7282	Distribution and prognostic value of tumor-infiltrating T cells in breast cancer. <i>Molecular Medicine Reports</i> , 2018, 18, 4247-4258.	1.1	18
7283	EF Hand Domain Family Member D2 Is Required for T Cell Cytotoxicity. <i>Journal of Immunology</i> , 2018, 201, 2824-2831.	0.4	13
7284	RNAi-Mediated β -Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade. <i>Molecular Therapy</i> , 2018, 26, 2567-2579.	3.7	79
7285	Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	7
7286	Condition-adaptive fused graphical lasso (CFGL): An adaptive procedure for inferring condition-specific gene co-expression network. <i>PLoS Computational Biology</i> , 2018, 14, e1006436.	1.5	17
7287	Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study. <i>PLoS ONE</i> , 2018, 13, e0204729.	1.1	83
7288	PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5973-5989.	1.0	94
7289	Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues. <i>Medical Oncology</i> , 2018, 35, 149.	1.2	12
7290	Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment. <i>British Journal of Cancer</i> , 2018, 119, 572-579.	2.9	12
7291	Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor. <i>Scientific Reports</i> , 2018, 8, 14576.	1.6	55
7292	Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin. <i>Scientific Reports</i> , 2018, 8, 14654.	1.6	5
7293	Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment. <i>Thoracic Cancer</i> , 2018, 9, 1770-1773.	0.8	17
7294	Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. <i>BMJ Open</i> , 2018, 8, e017240.	0.8	20
7295	A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies. <i>Journal of Clinical Pathology</i> , 2018, 71, 1078-1083.	1.0	33
7296	Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 6049-6058.	3.3	404
7297	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. <i>Frontiers in Pharmacology</i> , 2018, 9, 1050.	1.6	48
7298	The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge. <i>Journal of Breast Cancer</i> , 2018, 21, 233.	0.8	59
7299	A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. <i>Cell</i> , 2018, 175, 313-326.	13.5	985

#	ARTICLE	IF	CITATIONS
7300	Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences. <i>British Journal of Cancer</i> , 2018, 119, 832-839.	2.9	15
7301	The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer. <i>BMC Cancer</i> , 2018, 18, 938.	1.1	94
7302	Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. , 2018, 6, 102.		141
7303	Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients. , 2018, 6, 101.		31
7304	Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond. <i>Journal of the Endocrine Society</i> , 2018, 2, 1109-1130.	0.1	26
7305	PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2018, 15, 116.	1.4	52
7306	Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). <i>BMC Cancer</i> , 2018, 18, 946.	1.1	32
7307	PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?. <i>BMC Cancer</i> , 2018, 18, 945.	1.1	19
7308	Cell adhesion-related gene somatic mutations are enriched in aggressive papillary thyroid microcarcinomas. <i>Journal of Translational Medicine</i> , 2018, 16, 269.	1.8	16
7309	Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. <i>Breast Cancer Research</i> , 2018, 20, 115.	2.2	63
7310	BHLHE40 confers a pro-survival and pro-metastatic phenotype to breast cancer cells by modulating HBEGF secretion. <i>Breast Cancer Research</i> , 2018, 20, 117.	2.2	43
7311	Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. , 2018, 6, 97.		19
7312	A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy. , 2018, 6, 100.		53
7313	Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. <i>Nature Communications</i> , 2018, 9, 3868.	5.8	211
7314	Financial toxicity and implications for cancer care in the era of molecular and immune therapies. <i>Annals of Translational Medicine</i> , 2018, 6, 166-166.	0.7	126
7315	Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2021.	2.2	29
7316	Improved Cancer Immunotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents. <i>Molecular Pharmaceutics</i> , 2018, 15, 5162-5173.	2.3	20
7317	RNA editing derived epitopes function as cancer antigens to elicit immune responses. <i>Nature Communications</i> , 2018, 9, 3919.	5.8	120

#	ARTICLE	IF	CITATIONS
7318	Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy. <i>ESMO Open</i> , 2018, 3, e000305.	2.0	34
7319	T Cell Calcium Signaling Regulation by the Co-Receptor CD5. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1295.	1.8	20
7320	The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. <i>Current Oncology Reports</i> , 2018, 20, 87.	1.8	119
7321	Biosynthetic energy cost for amino acids decreases in cancer evolution. <i>Nature Communications</i> , 2018, 9, 4124.	5.8	27
7322	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). <i>Science Signaling</i> , 2018, 11, .	1.6	53
7323	Key questions about the checkpoint blockade-are microRNAs an answer?. <i>Cancer Biology and Medicine</i> , 2018, 15, 103.	1.4	36
7324	Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	1
7325	Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity. <i>Neoplasia</i> , 2018, 20, 1150-1160.	2.3	14
7326	Typing tumors using pathways selected by somatic evolution. <i>Nature Communications</i> , 2018, 9, 4159.	5.8	19
7327	Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10119-E10126.	3.3	180
7328	PHLI-seq: constructing and visualizing cancer genomic maps in 3D by phenotype-based high-throughput laser-aided isolation and sequencing. <i>Genome Biology</i> , 2018, 19, 158.	3.8	18
7329	On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 2182.	2.2	15
7330	Lymph Node Cellular Dynamics in Cancer and HIV: What Can We Learn for the Follicular CD4 (Tfh) Cells?. <i>Frontiers in Immunology</i> , 2018, 9, 2233.	2.2	10
7331	Checkpoint Blockade Reverses Energy in IL-13R [±] 2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 20-38.	2.0	123
7332	Regulatory T cells in the treatment of disease. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 823-844.	21.5	224
7333	Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota. <i>Cell Death and Disease</i> , 2018, 9, 1039.	2.7	68
7334	Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. <i>Science</i> , 2018, 362, .	6.0	1,575
7335	Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy. <i>Respiratory Research</i> , 2018, 19, 197.	1.4	9

#	ARTICLE	IF	CITATIONS
7336	A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5879-5883.	1.0	10
7337	Î³ T cell-mediated individualized immunotherapy for hepatocellular carcinoma considering clinicopathological characteristics and immunosuppressive factors. <i>Oncology Letters</i> , 2018, 15, 5433-5442.	0.8	4
7338	NCI 8628: A randomized phase 2 study of zivâ€afibercept and highâ€dose interleukin 2 or highâ€dose interleukin 2 alone for inoperable stage III or IV melanoma. <i>Cancer</i> , 2018, 124, 4332-4341.	2.0	15
7340	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Targeted Oncology</i> , 2018, 13, 795-800.	1.7	15
7341	Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage IIâ€III colorectal cancer. <i>Scientific Reports</i> , 2018, 8, 15658.	1.6	49
7342	Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma. <i>Scientific Reports</i> , 2018, 8, 15732.	1.6	23
7343	New Insights into the Role of Exercise in Inhibiting mTOR Signaling in Triple-Negative Breast Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-19.	1.9	33
7344	Distinct esophageal adenocarcinoma molecular subtype has subtype-specific gene expression and mutation patterns. <i>BMC Genomics</i> , 2018, 19, 769.	1.2	8
7345	Diagnostic value of PD-1 mRNA expression combined with breast ultrasound in breast cancer patients. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1527-1535.	0.9	3
7346	The Hierarchical Modular Structure of HER2+ Breast Cancer Network. <i>Frontiers in Physiology</i> , 2018, 9, 1423.	1.3	40
7347	DNA Methylation Predicts the Response of Triple-Negative Breast Cancers to All-Trans Retinoic Acid. <i>Cancers</i> , 2018, 10, 397.	1.7	22
7348	Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. <i>Gynecologic Oncology</i> , 2018, 151, 407-413.	0.6	17
7349	Personalized vaccination against ovarian cancer: what are the possibilities?. <i>Expert Review of Vaccines</i> , 2018, 17, 955-958.	2.0	7
7350	Molecular Mechanisms Directing Migration and Retention of Natural Killer Cells in Human Tissues. <i>Frontiers in Immunology</i> , 2018, 9, 2324.	2.2	96
7351	Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology. <i>Frontiers in Immunology</i> , 2018, 9, 2582.	2.2	47
7353	Collagen prolyl 4-hydroxylase 1 is essential for HIF-1Î± stabilization and TNBC chemoresistance. <i>Nature Communications</i> , 2018, 9, 4456.	5.8	170
7354	A severe case of neuro-SjÃ¶grenâ€™s syndrome induced by pembrolizumab. , 2018, 6, 110.		40
7355	Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens. <i>PLoS ONE</i> , 2018, 13, e0204745.	1.1	20

#	ARTICLE	IF	CITATIONS
7356	Receptor-Targeted Glial Brain Tumor Therapies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3326.	1.8	34
7357	Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 114.	0.7	17
7358	Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer (Review). <i>Oncology Letters</i> , 2018, 16, 4984-4996.	0.8	27
7359	Effect of anesthetic methods on postoperative CD3+, CD4+ and CD4+CD25+ in patients with lung cancer undergoing radical operation. <i>Oncology Letters</i> , 2018, 16, 6547-6551.	0.8	5
7360	Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine. <i>Cancer Discovery</i> , 2018, 8, 1352-1354.	7.7	7
7361	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. <i>Genome Medicine</i> , 2018, 10, 79.	3.6	36
7362	Cardiac morbidity in HIV infection is associated with checkpoint inhibitor LAG-3 on CD4 T cells. <i>PLoS ONE</i> , 2018, 13, e0206256.	1.1	10
7363	Toxicity of radiation and immunotherapy combinations. <i>Advances in Radiation Oncology</i> , 2018, 3, 506-511.	0.6	42
7364	Role of the immunosuppressive microenvironment in immunotherapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 520-526.	0.6	107
7365	Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation. <i>Advances in Radiation Oncology</i> , 2018, 3, 486-493.	0.6	48
7366	A novel ternary heterostructure with dramatic SERS activity for evaluation of PD-L1 expression at the single-cell level. <i>Science Advances</i> , 2018, 4, eaau3494.	4.7	63
7367	Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis. <i>PLoS Computational Biology</i> , 2018, 14, e1006520.	1.5	13
7368	Next generation immune-checkpoints for cancer therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1581-S1601.	0.6	50
7369	Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma—Bench-to-Bedside Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3378.	1.8	20
7370	T Regulatory Cell Subpopulations Associated with Recent Ultraviolet Radiation Exposure in a Skin Cancer Screening Cohort. <i>Journal of Immunology</i> , 2018, 201, 3269-3281.	0.4	14
7371	Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. <i>PLoS ONE</i> , 2018, 13, e0206223.	1.1	149
7372	Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 2374.	2.2	150
7373	Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining. <i>Cancers</i> , 2018, 10, 415.	1.7	19

#	ARTICLE	IF	CITATIONS
7374	Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. <i>Diagnostics</i> , 2018, 8, 76.	1.3	23
7375	The Optimal Radiation Dose to Induce Robust Systemic Anti-Tumor Immunity. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3377.	1.8	45
7376	Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities. <i>Drugs</i> , 2018, 78, 1717-1740.	4.9	62
7377	mRNA-seq whole transcriptome profiling of fresh frozen versus archived fixed tissues. <i>BMC Genomics</i> , 2018, 19, 419.	1.2	38
7378	Is monitoring mean platelet volume necessary in breast cancer patients?. <i>Open Medicine (Poland)</i> , 2018, 13, 450-455.	0.6	3
7379	mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3396.	1.8	35
7380	Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors. , 2018, 22, 17-149.		11
7381	2018 Nobel Prize in physiology or medicine. <i>Clinical and Translational Immunology</i> , 2018, 7, e1041.	1.7	41
7382	Role of noninvasive molecular imaging in determining response. <i>Advances in Radiation Oncology</i> , 2018, 3, 534-547.	0.6	25
7383	Harnessing the immune system in glioblastoma. <i>British Journal of Cancer</i> , 2018, 119, 1171-1181.	2.9	138
7384	Targeting IFN γ to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. <i>Nature Communications</i> , 2018, 9, 4586.	5.8	60
7385	A Festschrift in Honor of Edward M. Messing, MD, FACS. <i>Bladder Cancer</i> , 2018, 4, S1-S43.	0.2	0
7386	MUC1 Mucin: A Putative Regulatory (Checkpoint) Molecule of T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2391.	2.2	25
7387	Developing a Bright NIR λ Fluorophore with Fast Renal Excretion and Its Application in Molecular Imaging of Immune Checkpoint PD λ L1. <i>Advanced Functional Materials</i> , 2018, 28, 1804956.	7.8	85
7389	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV λ or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018, 104, 137-144.	1.3	97
7390	Synthetic immunology: T-cell engineering and adoptive immunotherapy. <i>Synthetic and Systems Biotechnology</i> , 2018, 3, 179-185.	1.8	23
7391	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. <i>British Journal of Cancer</i> , 2018, 119, 1383-1391.	2.9	54
7392	Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	16

#	ARTICLE	IF	CITATIONS
7393	Durvalumab in NSCLC: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880415.	1.4	22
7394	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. , 2018, 6, 108.		16
7395	Predictive biomarkers for tumor immune checkpoint blockade. <i>Cancer Management and Research</i> , 2018, Volume 10, 4501-4507.	0.9	18
7396	Exploration of genetics commonness between bladder cancer and breast cancer based on a silico analysis on disease subtypes. <i>Technology and Health Care</i> , 2018, 26, 361-377.	0.5	3
7397	UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cells. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 3921-3928.	0.8	6
7398	Somatic mutation profiling of liver and biliary cancer by targeted next generation sequencing. <i>Oncology Letters</i> , 2018, 16, 6003-6012.	0.8	8
7399	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1733-1742.	0.5	120
7400	Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1884-1896.	0.5	78
7401	BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10642-E10651.	3.3	75
7402	Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10702-E10711.	3.3	50
7403	Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. , 2018, 6, 111.		122
7404	Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. <i>Cancer Management and Research</i> , 2018, Volume 10, 4333-4347.	0.9	37
7405	Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients. <i>International Journal of COPD</i> , 2018, Volume 13, 3191-3202.	0.9	23
7406	Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study. <i>In Vivo</i> , 2018, 32, 1541-1550.	0.6	4
7407	Targeting macrophages: therapeutic approaches in cancer. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 887-904.	21.5	1,246
7408	Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. <i>ESMO Open</i> , 2018, 3, e000406.	2.0	84
7409	The Protein Expression of PDL1 Is Highly Correlated with Those of eIF2 α and ATF4 in Lung Cancer. <i>Disease Markers</i> , 2018, 2018, 1-9.	0.6	13
7410	Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 4037-4046.	0.7	34

#	ARTICLE	IF	CITATIONS
7411	Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy. <i>Frontiers in Oncology</i> , 2018, 8, 405.	1.3	14
7412	Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609). <i>Journal of Hematology and Oncology</i> , 2018, 11, 124.	6.9	17
7413	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. , 2018, 6, 106.		138
7414	Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. <i>PLoS ONE</i> , 2018, 13, e0204513.	1.1	34
7415	Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6287-6294.	1.0	17
7416	Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. <i>Journal of Cancer</i> , 2018, 9, 3640-3646.	1.2	19
7417	Tumor Type-Agnostic Treatment and the Future of Cancer Therapy. <i>Targeted Oncology</i> , 2018, 13, 541-544.	1.7	7
7418	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. <i>British Journal of Cancer</i> , 2018, 119, 1200-1207.	2.9	83
7419	Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre. <i>British Journal of Cancer</i> , 2018, 119, 922-927.	2.9	3
7420	Adoptive cell transfer: new perspective treatment in veterinary oncology. <i>Acta Veterinaria Scandinavica</i> , 2018, 60, 60.	0.5	11
7421	Checkpoint-inhibition in ovarian cancer: rising star or just a dream?. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e93.	1.0	37
7422	Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms. <i>Journal of Cancer</i> , 2018, 9, 3489-3499.	1.2	12
7423	Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease. <i>Frontiers in Oncology</i> , 2018, 8, 414.	1.3	65
7424	Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered T cells in a phase I clinical trial: A case report. <i>Oncology Letters</i> , 2018, 16, 6998-7007.	0.8	29
7425	Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2018, 119, 950-960.	2.9	133
7426	Fasting and cancer: molecular mechanisms and clinical application. <i>Nature Reviews Cancer</i> , 2018, 18, 707-719.	12.8	324
7427	Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field. <i>Breast Care</i> , 2018, 13, 251-262.	0.8	4
7429	An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules. <i>PLoS ONE</i> , 2018, 13, e0205491.	1.1	53

#	ARTICLE	IF	CITATIONS
7430	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2018, 9, 8706-8715.	0.8	75
7431	Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6505-6524.	1.0	47
7432	Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature. <i>Frontiers in Medicine</i> , 2018, 5, 268.	1.2	49
7433	Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6525-6537.	1.0	10
7436	Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 911-912.	2.9	6
7437	Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. <i>Nature Communications</i> , 2018, 9, 4181.	5.8	77
7438	Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series. <i>Thoracic Cancer</i> , 2018, 9, 1782-1787.	0.8	23
7439	Pan-cancer analysis of tumor metabolic landscape associated with genomic alterations. <i>Molecular Cancer</i> , 2018, 17, 150.	7.9	21
7440	Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer. <i>PLoS ONE</i> , 2018, 13, e0204880.	1.1	10
7441	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. <i>Frontiers in Immunology</i> , 2018, 9, 2265.	2.2	107
7442	Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2018, 9, 1118.	1.6	126
7443	The DNA damage response in immunotherapy and radiation. <i>Advances in Radiation Oncology</i> , 2018, 3, 527-533.	0.6	24
7444	An assessment of prognostic immunity markers in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 35.	2.3	41
7445	Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 261.	3.5	112
7446	Network integration of multi-tumour omics data suggests novel targeting strategies. <i>Nature Communications</i> , 2018, 9, 4514.	5.8	33
7447	PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , 2018, 128, 580-588.	3.9	388
7448	Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	102
7449	Computational discovery of dynamic cell line specific Boolean networks from multiplex time-course data. <i>PLoS Computational Biology</i> , 2018, 14, e1006538.	1.5	25

#	ARTICLE	IF	CITATIONS
7450	MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer. <i>Oncotarget</i> , 2018, 9, 33577-33588.	0.8	15
7451	Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations. <i>Frontiers in Oncology</i> , 2018, 8, 425.	1.3	16
7452	Acute Myeloid Leukemia and the Bone Marrow Niche—Take a Closer Look. <i>Frontiers in Oncology</i> , 2018, 8, 444.	1.3	66
7453	Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. <i>Scientific Reports</i> , 2018, 8, 16008.	1.6	20
7454	IFN β -activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. <i>Journal of Experimental Medicine</i> , 2018, 215, 3057-3074.	4.2	134
7455	Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy094.	0.2	23
7456	Stereotactic Body Radiation Therapy for Spinal Malignancies. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880230.	0.8	24
7457	Predominance of triple wild-type and IGF2R mutations in mucosal melanomas. <i>BMC Cancer</i> , 2018, 18, 1054.	1.1	15
7458	Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. <i>Genome Medicine</i> , 2018, 10, 81.	3.6	72
7459	Oncolytic Viruses for Canine Cancer Treatment. <i>Cancers</i> , 2018, 10, 404.	1.7	31
7460	An update: emerging drugs to treat squamous cell carcinomas of the head and neck. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 283-299.	1.0	44
7461	Maftools: efficient and comprehensive analysis of somatic variants in cancer. <i>Genome Research</i> , 2018, 28, 1747-1756.	2.4	2,614
7462	STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 5948-5962.	3.2	59
7463	The IFN β /PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. <i>Journal of Neuroinflammation</i> , 2018, 15, 290.	3.1	177
7464	Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. , 2018, 6, 107.		52
7465	Association Analysis of Somatic Copy Number Alteration Burden With Breast Cancer Survival. <i>Frontiers in Genetics</i> , 2018, 9, 421.	1.1	38
7467	Characterization of the Neuroendocrine Tumor Immune Microenvironment. <i>Pancreas</i> , 2018, 47, 1123-1129.	0.5	63
7468	Combination therapy to checkmate Glioblastoma: clinical challenges and advances. <i>Clinical and Translational Medicine</i> , 2018, 7, 33.	1.7	148

#	ARTICLE	IF	CITATIONS
7469	Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers. <i>PLoS ONE</i> , 2018, 13, e0206008.	1.1	41
7470	Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. <i>Cancer Immunology Research</i> , 2018, 6, 1561-1577.	1.6	151
7471	LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications. <i>Scientific Reports</i> , 2018, 8, 15572.	1.6	26
7472	Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880690.	0.8	11
7473	Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. <i>Journal of Translational Medicine</i> , 2018, 16, 286.	1.8	24
7474	Neurological complications of immune checkpoint inhibitors: what happens when you “take the brakes off” the immune system. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641879986.	1.5	136
7475	An Update on Breast Cancer Multigene Prognostic Tests—Emergent Clinical Biomarkers. <i>Frontiers in Medicine</i> , 2018, 5, 248.	1.2	139
7476	A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1853-1862.	2.0	21
7478	Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1476-1482.	0.8	9
7479	PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma. <i>Frontiers in Immunology</i> , 2018, 9, 1955.	2.2	24
7480	Detection of copy number variants and loss of heterozygosity from impure tumor samples using whole exome sequencing data. <i>Oncology Letters</i> , 2018, 16, 4713-4720.	0.8	2
7481	Designing cancer immunotherapy trials with random treatment time-lag effect. <i>Statistics in Medicine</i> , 2018, 37, 4589-4609.	0.8	18
7482	Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. <i>Gynecologic Oncology</i> , 2018, 151, 381-389.	0.6	99
7483	Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. <i>Molecular Therapy</i> , 2018, 26, 2553-2566.	3.7	20
7484	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661879413.	1.0	35
7485	Organoid technology and applications in cancer research. <i>Journal of Hematology and Oncology</i> , 2018, 11, 116.	6.9	196
7486	Profile of abemaciclib and its potential in the treatment of breast cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5253-5259.	1.0	28
7487	Alterations of Signaling Pathways Related to the Immune System in Breast Cancer: New Perspectives in Patient Management. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2733.	1.8	9

#	ARTICLE	IF	CITATIONS
7488	Targeted Genomic Screen Reveals Focal Long Non-Coding RNA Copy Number Alterations in Cancer Cell Lines. <i>Non-coding RNA</i> , 2018, 4, 21.	1.3	5
7489	The precision prevention and therapy of <sc>HPV</sc>-related cervical cancer: new concepts and clinical implications. <i>Cancer Medicine</i> , 2018, 7, 5217-5236.	1.3	194
7490	Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 689-702.	1.1	32
7491	Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. <i>Antibody Therapeutics</i> , 2018, 1, 13-17.	1.2	81
7492	Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation. <i>BMC Cancer</i> , 2018, 18, 895.	1.1	17
7493	Native-mimicking in vitro microenvironment: an elusive and seductive future for tumor modeling and tissue engineering. <i>Journal of Biological Engineering</i> , 2018, 12, 20.	2.0	59
7494	Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 262.	0.4	44
7495	Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an Aescape lesion mimic. , 2018, 6, 89.		10
7496	Diurnal Cortisol Concentrations and Growth Indexes of 12- to 48-Month-Old Children From Mexico City. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3386-3393.	1.8	0
7497	Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients. <i>PLoS ONE</i> , 2018, 13, e0203495.	1.1	30
7498	Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence. <i>Cancer Management and Research</i> , 2018, Volume 10, 3083-3099.	0.9	21
7499	miR-376a inhibits breast cancer cell progression by targeting neuropilin-1 NR. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5293-5302.	1.0	26
7500	Apatinib mesylate tablet in the treatment of advanced malignant melanoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5333-5338.	1.0	9
7501	A Comprehensive Survey of Immune Cytolytic Activity-Associated Gene Co-Expression Networks across 17 Tumor and Normal Tissue Types. <i>Cancers</i> , 2018, 10, 307.	1.7	4
7502	Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma. <i>Cancers</i> , 2018, 10, 326.	1.7	23
7503	Efficacy and safety of Nivolumab in non-small cell lung cancer patients in Tel Aviv tertiary medical center: Facing the reality. <i>Molecular and Clinical Oncology</i> , 2018, 9, 419-422.	0.4	7
7504	Molecular mechanism of activated T cells in breast cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5015-5024.	1.0	11
7505	B cells and antibody production in melanoma. <i>Mammalian Genome</i> , 2018, 29, 790-805.	1.0	19

#	ARTICLE	IF	CITATIONS
7506	Roles of cytotoxic and helper innate lymphoid cells in cancer. <i>Mammalian Genome</i> , 2018, 29, 777-789.	1.0	15
7507	A machine learning approach for somatic mutation discovery. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	80
7508	T Cellâ€“Inflamed versus Non-T Cellâ€“Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. <i>Cancer Immunology Research</i> , 2018, 6, 990-1000.	1.6	297
7509	Discovering lncRNA mediated sponge interactions in breast cancer molecular subtypes. <i>BMC Genomics</i> , 2018, 19, 650.	1.2	41
7510	The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. <i>BMC Gastroenterology</i> , 2018, 18, 135.	0.8	44
7511	Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 101.	2.2	44
7512	Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. , 2018, 6, 82.		30
7513	The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations. <i>Frontiers in Medicine</i> , 2018, 5, 220.	1.2	147
7514	Hyperprogressive Disease in Patients With Advanced Nonâ€“Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	3.4	567
7515	<scp>AMPK</scp> promotes the survival of colorectal cancer stem cells. <i>Animal Models and Experimental Medicine</i> , 2018, 1, 134-142.	1.3	19
7516	Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1833-1844.	2.0	52
7517	A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. <i>Cell</i> , 2018, 174, 1373-1387.e19.	13.5	729
7518	Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab. <i>Blood Advances</i> , 2018, 2, 1865-1868.	2.5	18
7519	Activation of pro-survival metabolic networks by 1,25(OH)2D3 does not hamper the sensitivity of breast cancer cells to chemotherapeutics. <i>Cancer & Metabolism</i> , 2018, 6, 11.	2.4	12
7520	Immune checkpoint inhibitors for urothelial carcinoma. <i>Investigative and Clinical Urology</i> , 2018, 59, 285.	1.0	94
7521	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. <i>Drugs</i> , 2018, 78, 1443-1457.	4.9	70
7522	New drugs in thoracic oncology: needs and knowledge â€“ an online ERS Lung Cancer Assembly survey. <i>ERJ Open Research</i> , 2018, 4, 00040-2018.	1.1	2
7523	Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. <i>Breast Cancer Research</i> , 2018, 20, 108.	2.2	81

#	ARTICLE	IF	CITATIONS
7524	Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma?. <i>Yonsei Medical Journal</i> , 2018, 59, 912.	0.9	14
7525	TSNadb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis. <i>Genomics, Proteomics and Bioinformatics</i> , 2018, 16, 276-282.	3.0	97
7526	Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 527-535.	0.4	47
7527	Targeting Toll-Like Receptors for Cancer Therapy. <i>Targeted Oncology</i> , 2018, 13, 583-598.	1.7	88
7528	A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers. <i>Cell Reports</i> , 2018, 24, 3353-3366.e5.	2.9	80
7529	Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer. <i>ACS Nano</i> , 2018, 12, 9881-9893.	7.3	58
7530	Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. <i>Nature Communications</i> , 2018, 9, 3815.	5.8	137
7531	Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. <i>Nature Communications</i> , 2018, 9, 3787.	5.8	112
7532	Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular stress. <i>Scientific Reports</i> , 2018, 8, 13904.	1.6	25
7533	ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells. <i>International Journal of Molecular Medicine</i> , 2018, 42, 2343-2352.	1.8	14
7534	Clinical Relevance of Genomic Changes in Recurrent Pediatric Solid Tumors. <i>Translational Oncology</i> , 2018, 11, 1390-1397.	1.7	6
7535	A Preclinical Assessment of ⁸⁹ Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with ⁸⁹ Zr-C4. <i>Bioconjugate Chemistry</i> , 2018, 29, 3476-3482.	1.8	37
7536	Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3. <i>Journal of Human Genetics</i> , 2018, 63, 1197-1210.	1.1	41
7537	PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer. <i>Breast Journal</i> , 2018, 24, 911-919.	0.4	65
7538	Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology. <i>Integrative Cancer Therapies</i> , 2018, 17, 1012-1015.	0.8	4
7539	A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. , 2018, 6, 90.		32
7540	Circulating HLA-DR+CD4+ effector memory T cells resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis. <i>PLoS Pathogens</i> , 2018, 14, e1007289.	2.1	34
7541	The development of CAR design for tumor CAR-T cell therapy. <i>Oncotarget</i> , 2018, 9, 13991-14004.	0.8	31

#	ARTICLE	IF	CITATIONS
7542	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. <i>British Journal of Cancer</i> , 2018, 119, 670-674.	2.9	114
7543	BSA-bioinspired gold nanorods loaded with immunoadjuvant for the treatment of melanoma by combined photothermal therapy and immunotherapy. <i>Nanoscale</i> , 2018, 10, 21640-21647.	2.8	118
7544	Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. <i>MAbs</i> , 2018, 10, 1301-1311.	2.6	57
7545	Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 362, k3529.	2.4	354
7546	New developments in immunotherapy for lymphoma. <i>Cancer Biology and Medicine</i> , 2018, 15, 189.	1.4	24
7547	Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression. <i>Frontiers in Endocrinology</i> , 2018, 9, 483.	1.5	114
7548	Breast Cancer Incidence and Risk Reduction in the Hispanic Population. <i>Cureus</i> , 2018, 10, e2235.	0.2	36
7549	Comparison of PI3K Pathway in HPV-associated Oropharyngeal Cancer With and Without Tobacco Exposure. <i>Laryngoscope Investigative Otolaryngology</i> , 2018, 3, 283-289.	0.6	7
7550	Prognostic modeling of the immune-centric transcriptome reveals interleukin signaling candidates contributing to differential patient outcomes. <i>Carcinogenesis</i> , 2018, 39, 1447-1454.	1.3	4
7551	Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis. <i>Breast Cancer Research</i> , 2018, 20, 41.	2.2	15
7552	Genetic contribution to mesenchymal stem cell dysfunction in systemic lupus erythematosus. <i>Stem Cell Research and Therapy</i> , 2018, 9, 149.	2.4	30
7553	PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. <i>Oncotarget</i> , 2018, 9, 8584-8596.	0.8	53
7554	Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK. <i>Melanoma Management</i> , 2018, 5, MMT05.	0.1	25
7555	Combined radiotherapy with nivolumab for extracranial metastatic malignant melanoma. <i>Japanese Journal of Radiology</i> , 2018, 36, 712-718.	1.0	3
7556	A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer. <i>Nature Communications</i> , 2018, 9, 3726.	5.8	53
7557	Elucidating the Underlying Functional Mechanisms of Breast Cancer Susceptibility Through Post-GWAS Analyses. <i>Frontiers in Genetics</i> , 2018, 9, 280.	1.1	11
7558	Molecular Diagnostics in Clinical Oncology. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 76.	1.6	93
7559	Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2653.	1.8	32

#	ARTICLE	IF	CITATIONS
7560	Roles of intestinal microbiota in response to cancer immunotherapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2235-2240.	1.3	13
7561	Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 31.	2.3	23
7562	Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer. <i>Onc Immunology</i> , 2018, 7, e1500107.	2.1	66
7563	Deconvolution and phylogeny inference of structural variations in tumor genomic samples. <i>Bioinformatics</i> , 2018, 34, i357-i365.	1.8	40
7564	Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. <i>RMD Open</i> , 2018, 4, e000714.	1.8	65
7565	Obesity promotes the expansion of metastasis-initiating cells in breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 104.	2.2	68
7566	Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. <i>PLoS Genetics</i> , 2018, 14, e1007589.	1.5	56
7567	Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	77
7568	Genetic Alterations of TRAF Proteins in Human Cancers. <i>Frontiers in Immunology</i> , 2018, 9, 2111.	2.2	67
7569	POLE gene hotspot mutations in advanced pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2161-2166.	1.2	15
7570	Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Current Rheumatology Reports</i> , 2018, 20, 65.	2.1	39
7571	Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway. <i>Oncotarget</i> , 2018, 9, 14803-14814.	0.8	46
7572	Expression of the Vesicular Monoamine Transporter Gene Solute Carrier Family 18 Member 1 (<i>SLC18A1</i>) in Lung Cancer. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 387-393.	1.0	4
7573	SEG - A Software Program for Finding Somatic Copy Number Alterations in Whole Genome Sequencing Data of Cancer. <i>Computational and Structural Biotechnology Journal</i> , 2018, 16, 335-341.	1.9	7
7574	The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells. <i>Translational Oncology</i> , 2018, 11, 1343-1349.	1.7	25
7575	BAP1 links metabolic regulation of ferroptosis to tumour suppression. <i>Nature Cell Biology</i> , 2018, 20, 1181-1192.	4.6	565
7576	Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2. <i>Integrative Cancer Therapies</i> , 2018, 17, 1297-1303.	0.8	27
7577	Stromal versus tumoral inflammation differentially contribute to metastasis and poor survival in laryngeal squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 8415-8426.	0.8	31

#	ARTICLE	IF	CITATIONS
7578	Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2041.	2.2	93
7579	Current therapeutic landscape for advanced gastroesophageal cancers. <i>Annals of Translational Medicine</i> , 2018, 6, 78-78.	0.7	7
7580	Peripheral inflammation/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1423-1432.	1.0	34
7581	MEK inhibitors for the treatment of NRAS mutant melanoma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2553-2565.	2.0	37
7582	Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study. <i>In Vivo</i> , 2018, 32, 1155-1160.	0.6	5
7583	Immune Checkpoint Inhibition in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 310.	1.3	103
7584	Targeting IKK β in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKK β Inhibitors. <i>Cells</i> , 2018, 7, 115.	1.8	91
7585	DNA Methylation Profiling of Breast Cancer Cell Lines along the Epithelial Mesenchymal Spectrum—Implications for the Choice of Circulating Tumour DNA Methylation Markers. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2553.	1.8	15
7586	Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without <i>EGFR</i> Mutations or <i>ALK</i> Fusion. <i>Journal of Cancer</i> , 2018, 9, 1096-1105.	1.2	6
7587	Characterization of genomic alterations in primary central nervous system lymphomas. <i>Journal of Neuro-Oncology</i> , 2018, 140, 509-517.	1.4	23
7588	A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1284-1293.	0.5	30
7589	ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2462-2472.	1.9	59
7590	Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers. <i>Diagnostic Pathology</i> , 2018, 13, 66.	0.9	33
7591	Tumor–Stroma interactions differentially alter drug sensitivity based on the origin of stromal cells. <i>Molecular Systems Biology</i> , 2018, 14, e8322.	3.2	25
7592	Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 139-154.	0.7	13
7593	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. <i>Frontiers in Immunology</i> , 2018, 9, 1878.	2.2	127
7594	Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance. <i>Frontiers in Oncology</i> , 2018, 8, 322.	1.3	137
7595	Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 196-207.	0.6	18

#	ARTICLE	IF	CITATIONS
7596	Tissue-Resident Lymphocytes Across Innate and Adaptive Lineages. <i>Frontiers in Immunology</i> , 2018, 9, 2104.	2.2	38

7597

#	ARTICLE	IF	CITATIONS
7614	In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. <i>Nature Communications</i> , 2018, 9, 3501.	5.8	45
7615	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. <i>Nature Communications</i> , 2018, 9, 3503.	5.8	224
7616	SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. <i>Cancer Discovery</i> , 2018, 8, 1250-1257.	7.7	244
7617	Use of checkpoint inhibitors in liver transplant recipients. <i>United European Gastroenterology Journal</i> , 2018, 6, 970-973.	1.6	81
7618	Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study. <i>PLoS ONE</i> , 2018, 13, e0203070.	1.1	7
7619	<scp>CEP</scp> 55 is a determinant of cell fate during perturbed mitosis in breast cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	59
7620	Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 209-215.	2.0	29
7621	T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1767-1776.	2.0	51
7622	Identifying neoantigens for use in immunotherapy. <i>Mammalian Genome</i> , 2018, 29, 714-730.	1.0	28
7623	Strategies for Predicting Response to Checkpoint Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 383-395.	1.2	23
7624	Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity. <i>Cancer Cell</i> , 2018, 34, 466-482.e6.	7.7	111
7625	A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. <i>Journal of Autoimmunity</i> , 2018, 95, 77-99.	3.0	141
7626	Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1560-1568.	0.5	158
7627	Prolyl isomerase Pin1: a promoter of cancer and a target for therapy. <i>Cell Death and Disease</i> , 2018, 9, 883.	2.7	101
7628	CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair. <i>Cell Death and Disease</i> , 2018, 9, 887.	2.7	29
7629	Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. <i>Nature Communications</i> , 2018, 9, 3533.	5.8	92
7630	NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 29.	2.3	42
7631	Nomogram based on albumin and neutrophil-to-lymphocyte ratio for predicting the prognosis of patients with oral cavity squamous cell carcinoma. <i>Scientific Reports</i> , 2018, 8, 13081.	1.6	50

#	ARTICLE	IF	CITATIONS
7632	Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy. Bioscience Reports, 2018, 38, .	1.1	28
7633	Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thoracic Cancer, 2018, 9, 1519-1521.	0.8	17
7634	Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus. BioMed Research International, 2018, 2018, 1-8.	0.9	9
7635	Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of Immunology Research, 2018, 2018, 1-17.	0.9	147
7636	Immune characterization of breast cancer metastases: prognostic implications. Breast Cancer Research, 2018, 20, 62.	2.2	54
7637	Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. , 2018, 6, 84.		83
7638	Application of dynamic modeling for survival estimation in advanced renal cell carcinoma. PLoS ONE, 2018, 13, e0203406.	1.1	1
7639	Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis. ACG Case Reports Journal, 2018, 5, e17.	0.2	30
7640	Variability of PD-L1 expression in mastocytosis. Blood Advances, 2018, 2, 189-199.	2.5	10
7641	Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses. Porto Biomedical Journal, 2018, 3, e7.	0.4	8
7642	Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy. Cureus, 2018, 10, e3700.	0.2	25
7643	Novel immunotherapy approaches to follicular lymphoma. Hematology American Society of Hematology Education Program, 2018, 2018, 194-199.	0.9	8
7644	Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. Journal of Thoracic Disease, 2018, 10, 6636-6652.	0.6	33
7645	Extracellular vesicles in oral squamous carcinoma carry oncogenic miRNA profile and reprogram monocytes via NF- κ B pathway. Oncotarget, 2018, 9, 34838-34854.	0.8	50
7646	Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Advances, 2018, 2, 821-824.	2.5	8
7647	Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia. Blood Advances, 2018, 2, 1187-1190.	2.5	8
7648	Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. Blood Advances, 2018, 2, 2052-2062.	2.5	24
7649	Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. CNS Drugs, 2018, 32, 527-542.	2.7	10

#	ARTICLE	IF	CITATIONS
7650	MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. <i>Cell Research</i> , 2018, 28, 719-729.	5.7	105
7651	Multidisciplinary therapy for metastatic primary malignant melanoma of the esophagus: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 8, 528-532.	0.4	22
7652	Tight correlation between FoxM1 and FoxP3+ Tregs in gastric cancer and their clinical significance. <i>Clinical and Experimental Medicine</i> , 2018, 18, 413-420.	1.9	12
7653	Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 227-236.	0.6	28
7654	Checkpoint blockade in the treatment of breast cancer: current status and future directions. <i>British Journal of Cancer</i> , 2018, 119, 4-11.	2.9	82
7655	A case of drug-induced Graves's™ Orbitopathy after combination therapy with Tremelimumab and Durvalumab. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 877-878.	1.8	11
7656	Constrained Combinatorial Libraries of Gp2 Proteins Enhance Discovery of PD-L1 Binders. <i>ACS Combinatorial Science</i> , 2018, 20, 423-435.	3.8	16
7657	Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients. <i>Nature Communications</i> , 2018, 9, 2054.	5.8	68
7658	The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung. <i>Scientific Reports</i> , 2018, 8, 8135.	1.6	27
7659	Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation. <i>Scientific Reports</i> , 2018, 8, 8216.	1.6	27
7660	Interferon-gamma drives programmed death-ligand 1 expression on islet β^2 cells to limit T cell function during autoimmune diabetes. <i>Scientific Reports</i> , 2018, 8, 8295.	1.6	100
7661	Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer. <i>Cancer Research</i> , 2018, 78, 4282-4291.	0.4	83
7662	Feasibility of reâ€biopsy and <i>EGFR</i> mutation analysis in patients with nonâ€small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 856-864.	0.8	21
7663	FGFR1 and HER1 or HER2 coâ€amplification in breast cancer indicate poor prognosis. <i>Oncology Letters</i> , 2018, 15, 8206-8214.	0.8	13
7664	Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. <i>Clinical and Translational Oncology</i> , 2018, 20, 1548-1556.	1.2	10
7665	STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. <i>Nature Communications</i> , 2018, 9, 1908.	5.8	282
7666	PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF. <i>Molecular Cancer Research</i> , 2018, 16, 1241-1254.	1.5	20
7667	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	7.7	1,108

#	ARTICLE	IF	CITATIONS
7668	Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2323-2331.	0.7	107
7669	Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. <i>Oncogene</i> , 2018, 37, 4941-4954.	2.6	83
7670	Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. <i>Clinical Cancer Research</i> , 2018, 24, 5735-5743.	3.2	48
7671	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2018, 39, 624-631.	2.9	153
7672	Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. <i>Thoracic Cancer</i> , 2018, 9, 847-855.	0.8	103
7673	Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 5673-5684.	3.2	92
7674	Mechanisms for enhanced antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein. <i>Oncology Letters</i> , 2018, 15, 8505-8515.	0.8	6
7675	Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer. <i>Targeted Oncology</i> , 2018, 13, 399-407.	1.7	16
7676	Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy. <i>Journal of Immunotherapy</i> , 2018, 41, 336-339.	1.2	7
7677	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4380-4387.	3.2	49
7678	ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory cell-mediated immunosuppression. <i>Immunology</i> , 2018, 155, 238-250.	2.0	8
7679	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	2.0	42
7680	In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma. <i>Molecular Pharmaceutics</i> , 2018, 15, 3700-3716.	2.3	79
7681	BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 708-719.	1.5	9
7682	Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877281.	1.4	18
7683	Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune Checkpoint Inhibitors for Cancer Treatment. <i>Oncologist</i> , 2018, 23, 1236-1241.	1.9	20
7684	Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis. <i>Internal Medicine</i> , 2018, 57, 2217-2221.	0.3	34
7685	The era of immunogenomics/immunopharmacogenomics. <i>Journal of Human Genetics</i> , 2018, 63, 865-875.	1.1	15

#	ARTICLE	IF	CITATIONS
7686	Factor XIII α 2 expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking. <i>Nature Communications</i> , 2018, 9, 1988.	5.8	69
7687	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. <i>Oncologist</i> , 2018, 23, 1171-1177.	1.9	29
7688	Retrospective study of nivolumab for patients with recurrent high grade gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 139, 625-631.	1.4	25
7689	Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Oncologist</i> , 2018, 23, 879-886.	1.9	207
7690	MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells. <i>Oncology Letters</i> , 2018, 15, 9934-9940.	0.8	14
7691	Cutaneous toxicities of new treatments for melanoma. <i>Clinical and Translational Oncology</i> , 2018, 20, 1373-1384.	1.2	24
7692	Menace Elbow: Disseminated Nocardiosis. <i>American Journal of Medicine</i> , 2018, 131, 1307-1309.	0.6	3
7693	An androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancer. <i>Cell Death and Differentiation</i> , 2018, 25, 2209-2220.	5.0	94
7694	Enhanced ZnR/GPR39 Activity in Breast Cancer, an Alternative Trigger of Signaling Leading to Cell Growth. <i>Scientific Reports</i> , 2018, 8, 8119.	1.6	18
7695	Immuntherapie – Die neue Ära in der Onkologie. <i>Laryngo- Rhino- Otologie</i> , 2018, 97, S3-S47.	0.2	1
7696	HPV – Das andere Kopf-Hals-Karzinom. <i>Laryngo- Rhino- Otologie</i> , 2018, 97, S48-S113.	0.2	35
7697	Perspective: Biophysical regulation of cancerous and normal blood cell lineages in hematopoietic malignancies. <i>APL Bioengineering</i> , 2018, 2, 031802.	3.3	12
7698	Regulation of innate and adaptive antitumor immunity by IAP antagonists. <i>Immunotherapy</i> , 2018, 10, 787-796.	1.0	51
7699	Heterochromatin-Encoded Satellite RNAs Induce Breast Cancer. <i>Molecular Cell</i> , 2018, 70, 842-853.e7.	4.5	96
7700	Das Mikrobiom – die unplanbare Gräfinne zukünftiger Therapien. <i>Laryngo- Rhino- Otologie</i> , 2018, 97, S279-S311.	0.2	4
7701	Helicase-Driven Activation of NF κ B-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment. <i>Cancer Research</i> , 2018, 78, 4292-4302.	0.4	30
7702	Melanoma antigen family A4 protein produced by transgenic silkworms induces antitumor immune responses. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 2512-2518.	0.8	6
7703	Current perspectives of SA-4-1BBL in immune modulation during cancer (Review). <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 2699-2702.	0.8	1

#	ARTICLE	IF	CITATIONS
7704	A graph-embedded deep feedforward network for disease outcome classification and feature selection using gene expression data. <i>Bioinformatics</i> , 2018, 34, 3727-3737.	1.8	105
7705	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	3.2	89
7706	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. <i>World Journal of Urology</i> , 2018, 36, 1727-1740.	1.2	75
7707	Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1601-1611.	1.2	8
7708	Surface-Modified Macrophages Facilitate Tracking of Breast Cancer-Immune Interactions. <i>ACS Chemical Biology</i> , 2018, 13, 2339-2346.	1.6	11
7709	Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3979-3986.	1.6	38
7710	The combined presence of CD20+ B cells and PD-L1+ tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 273-282.	1.1	65
7711	Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 399-404.	0.6	22
7712	A Convergence-Based Framework for Cancer Drug Resistance. <i>Cancer Cell</i> , 2018, 33, 801-815.	7.7	181
7713	Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. <i>Nature Communications</i> , 2018, 9, 1866.	5.8	102
7714	Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. <i>Journal of Immunotherapy</i> , 2018, 41, 399-405.	1.2	32
7715	Expression of the DNA-Binding Factor TOX Promotes the Encephalitogenic Potential of Microbe-Induced Autoreactive CD8+ T Cells. <i>Immunity</i> , 2018, 48, 937-950.e8.	6.6	60
7716	The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation. <i>Oncogene</i> , 2018, 37, 4750-4768.	2.6	111
7717	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. <i>Oncogene</i> , 2018, 37, 4639-4661.	2.6	219
7718	Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. <i>Nature Communications</i> , 2018, 9, 1894.	5.8	65
7719	Temporal changes in immune cell composition and cytokines in response to chemoradiation in rectal cancer. <i>Scientific Reports</i> , 2018, 8, 7565.	1.6	14
7720	A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression. <i>Journal of Immunology</i> , 2018, 201, 782-791.	0.4	101
7721	Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. <i>Genes and Diseases</i> , 2018, 5, 77-106.	1.5	714

#	ARTICLE	IF	CITATIONS
7722	Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells. <i>Cell Death and Disease</i> , 2018, 9, 621.	2.7	23
7723	Genome-scale identification of transcription factors that mediate an inflammatory network during breast cellular transformation. <i>Nature Communications</i> , 2018, 9, 2068.	5.8	24
7724	PD-L1 Expression and CD8 ⁺ T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	54
7725	Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy. <i>Case Reports in Immunology</i> , 2018, 2018, 1-8.	0.2	5
7726	Synthetic Immunotherapeutics against Gram-negative Pathogens. <i>Cell Chemical Biology</i> , 2018, 25, 1185-1194.e5.	2.5	29
7727	Nivolumab-induced systemic vasculitis. <i>JAAD Case Reports</i> , 2018, 4, 606-608.	0.4	19
7728	Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1026-1033.	1.4	6
7729	Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. <i>Oncogene</i> , 2018, 37, 5682-5693.	2.6	29
7730	Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy. <i>British Journal of Cancer</i> , 2018, 119, 193-199.	2.9	21
7731	MiR-133b targets Sox9 to control pathogenesis and metastasis of breast cancer. <i>Cell Death and Disease</i> , 2018, 9, 752.	2.7	63
7732	Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis. <i>Journal of Immunology Research</i> , 2018, 2018, 1-9.	0.9	40
7733	Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2498-2499.	0.7	5
7734	PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3 ⁺ and CD8 ⁺ infiltrating lymphocytes. <i>PLoS ONE</i> , 2018, 13, e0194594.	1.1	19
7735	Development of a novel immunoproteasome digestion assay for synthetic long peptide vaccine design. <i>PLoS ONE</i> , 2018, 13, e0199249.	1.1	4
7736	Targeting tumor-associated acidity in cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1331-1348.	2.0	55
7737	Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	23
7738	Combination Immunotherapy Approaches for Pancreatic Cancer Treatment. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-7.	0.8	16
7739	An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-5.	0.2	4

#	ARTICLE	IF	CITATIONS
7740	Receptors That Inhibit Macrophage Activation: Mechanisms and Signals of Regulation and Tolerance. <i>Journal of Immunology Research</i> , 2018, 2018, 1-14.	0.9	21
7741	PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	12
7742	Novel tumour antigens and the development of optimal vaccine design. , 2018, 6, 31-47.	1.4	11
7743	Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. <i>Oncologist</i> , 2018, 23, 1358-1365.	1.9	196
7744	Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade. <i>ELife</i> , 2018, 7, .	2.8	98
7745	Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>Current Oncology Reports</i> , 2018, 20, 66.	1.8	7
7746	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 635-643.	3.7	60
7747	Exploring drivers of gene expression in the Cancer Genome Atlas. <i>Bioinformatics</i> , 2019, 35, 62-68.	1.8	21
7748	Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-4.	0.2	6
7749	Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	24
7750	Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-3.	0.2	26
7751	CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. <i>Clinical Cancer Research</i> , 2018, 24, 4976-4987.	3.2	79
7752	Repeated in-field radiosurgery for locally recurrent brain metastases: Feasibility, results and survival in a heavily treated patient cohort. <i>PLoS ONE</i> , 2018, 13, e0198692.	1.1	47
7753	Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGF β 2 mediated pathway. <i>PLoS ONE</i> , 2018, 13, e0200079.	1.1	24
7754	CUP Syndrome. <i>Deutsches A&#x0308;rztblatt International</i> , 2018, 115, 157-162.	0.6	25
7755	Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000375.	2.0	43
7756	Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer. <i>PLoS ONE</i> , 2018, 13, e0198634.	1.1	25
7757	Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody. <i>Internal Medicine</i> , 2018, 57, 2029-2034.	0.3	35

#	ARTICLE	IF	CITATIONS
7758	Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review. <i>Melanoma Management</i> , 2018, 5, MMT01.	0.1	11
7759	The revival of CpG oligonucleotide-based cancer immunotherapies. <i>Wspolczesna Onkologia</i> , 2018, 2018, 56-60.	0.7	61
7760	Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. <i>Immunity</i> , 2018, 49, 178-193.e7.	6.6	502
7761	Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer. <i>Scientific Reports</i> , 2018, 8, 9686.	1.6	5
7762	The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent. <i>International Journal of Breast Cancer</i> , 2018, 2018, 1-7.	0.6	12
7763	Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. <i>PLoS ONE</i> , 2018, 13, e0195945.	1.1	46
7764	T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model. <i>PLoS ONE</i> , 2018, 13, e0196033.	1.1	19
7765	miR-96 promotes invasion and metastasis by targeting GPC3 in non-small cell lung cancer cells. <i>Oncology Letters</i> , 2018, 15, 9081-9086.	0.8	23
7766	Immunotherapy for pancreatic cancer: Barriers and breakthroughs. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 274-281.	1.2	119
7767	Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 353-360.	1.1	15
7768	Seeking Convergence and Cure with New Myeloma Therapies. <i>Trends in Cancer</i> , 2018, 4, 567-582.	3.8	8
7769	Identification of epigenetic modulators in human breast cancer by integrated analysis of DNA methylation and RNA-Seq data. <i>Epigenetics</i> , 2018, 13, 473-489.	1.3	7
7770	Imaging and the completion of the omics paradigm in breast cancer. <i>Der Radiologe</i> , 2018, 58, 7-13.	1.7	14
7771	Imaging for the diagnosis and response assessment of renal tumours. <i>World Journal of Urology</i> , 2018, 36, 1927-1942.	1.2	59
7772	Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction. <i>Investigational New Drugs</i> , 2018, 36, 1138-1142.	1.2	13
7773	Pediatric Cancer Immunotherapy: Opportunities and Challenges. <i>Paediatric Drugs</i> , 2018, 20, 395-408.	1.3	76
7774	Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	60
7775	Immune Checkpoint Inhibitors to Treat Malignant Lymphomas. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	15

#	ARTICLE	IF	CITATIONS
7776	Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab. <i>In Vivo</i> , 2018, 32, 887-891.	0.6	11
7777	Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine. <i>Current Treatment Options in Oncology</i> , 2018, 19, 43.	1.3	10
7778	Diagnosis and Management of Acral Lentiginous Melanoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 42.	1.3	44
7779	Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity. <i>Molecular Therapy - Oncolytics</i> , 2018, 9, 51-63.	2.0	22
7780	S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. <i>British Journal of Cancer</i> , 2018, 119, 339-346.	2.9	83
7781	TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases. <i>Npj Breast Cancer</i> , 2018, 4, 13.	2.3	18
7782	A new method for constructing tumor specific gene co-expression networks based on samples with tumor purity heterogeneity. <i>Bioinformatics</i> , 2018, 34, i528-i536.	1.8	23
7783	Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 258-273.	1.0	41
7784	Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 123, 91-98.	0.9	35
7785	Role of RNF20 in cancer development and progression – a comprehensive review. <i>Bioscience Reports</i> , 2018, 38, .	1.1	34
7786	Precision Medicine for Breast Cancer: The Paths to Truly Individualized Diagnosis and Treatment. <i>International Journal of Breast Cancer</i> , 2018, 2018, 1-8.	0.6	27
7787	CXCR4/CXCL12 Signaling and Protumor Macrophages in Primary Tumors and Sentinel Lymph Nodes Are Involved in Luminal B Breast Cancer Progression. <i>Disease Markers</i> , 2018, 2018, 1-9.	0.6	10
7788	Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. <i>Stem Cells International</i> , 2018, 2018, 1-16.	1.2	593
7789	Lipid Accumulation in Peripheral Blood Dendritic Cells and Anticancer Immunity in Patients with Lung Cancer. <i>Journal of Immunology Research</i> , 2018, 2018, 1-8.	0.9	24
7790	Immunotherapies: Exploiting the Immune System for Cancer Treatment. <i>Journal of Immunology Research</i> , 2018, 2018, 1-16.	0.9	89
7791	Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management. <i>Journal of Skin Cancer</i> , 2018, 2018, 1-13.	0.5	21
7792	Similarities and differences between helminth parasites and cancer cell lines in shaping human monocytes: Insights into parallel mechanisms of immune evasion. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006404.	1.3	18
7793	Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 9-18.	0.2	18

#	ARTICLE	IF	CITATIONS
7794	The cJUN NH2-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation. <i>ELife</i> , 2018, 7, .	2.8	28
7795	Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity. <i>Journal of Cellular Physiology</i> , 2018, 233, 9136-9144.	2.0	80
7796	Novel application of normalized pointwise mutual information (NPMI) to mine biomedical literature for gene sets associated with disease: Use case in breast carcinogenesis. <i>Computational Toxicology</i> , 2018, 7, 46-57.	1.8	9
7797	Classifying tumors by supervised network propagation. <i>Bioinformatics</i> , 2018, 34, i484-i493.	1.8	34
7798	Anti-PD-1 Therapy-Associated Perforating Colitis. <i>Case Reports in Gastrointestinal Medicine</i> , 2018, 2018, 1-3.	0.2	24
7799	Merkel Cell Carcinoma Masquerading As Cellulitis: A Case Report and Review of the Literature. <i>Current Oncology</i> , 2018, 25, 106-112.	0.9	1
7800	Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms. <i>Mammalian Genome</i> , 2018, 29, 866-878.	1.0	10
7801	Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. <i>Current Urology Reports</i> , 2018, 19, 68.	1.0	12
7802	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159.	2.9	329
7803	Chimeric Antigen Receptor Therapy. <i>New England Journal of Medicine</i> , 2018, 379, 64-73.	13.9	1,488
7804	PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of <i>Toxoplasma gondii</i> . <i>Infection and Immunity</i> , 2018, 86, .	1.0	14
7805	DCE-MRI Pharmacokinetic-Based Phenotyping of Invasive Ductal Carcinoma: A Radiomic Study for Prediction of Histological Outcomes. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-11.	0.4	41
7806	Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2039-2052.	3.0	121
7807	EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells. <i>Cell Cycle</i> , 2018, 17, 1457-1470.	1.3	42
7808	Antiphospholipid Antibody Induced by Nivolumab. <i>Case Reports in Hematology</i> , 2018, 2018, 1-3.	0.3	6
7809	The Effect of Anesthesia on the Immune System in Colorectal Cancer Patients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-8.	0.8	34
7810	The Differential Expression of Core Genes in Nucleotide Excision Repair Pathway Indicates Colorectal Carcinogenesis and Prognosis. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	11
7811	New developments in brain metastases. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641878550.	1.5	25

#	ARTICLE	IF	CITATIONS
7812	Two critical positions in zinc finger domains are heavily mutated in three human cancer types. <i>PLoS Computational Biology</i> , 2018, 14, e1006290.	1.5	31
7813	Expression and clinical significance of PD-1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD-1 monoclonal antibody. <i>International Journal of Oncology</i> , 2018, 52, 2079-2092.	1.4	10
7814	Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1305-1315.	2.0	93
7815	The Progress of T Cell Immunity Related to Prognosis in Gastric Cancer. <i>BioMed Research International</i> , 2018, 2018, 1-6.	0.9	32
7816	A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors. <i>JAMA Network Open</i> , 2018, 1, e180416.	2.8	45
7817	Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Oncology</i> , 2018, 4, 1583.	3.4	84
7818	DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 901-903.	0.8	3
7819	Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas. <i>PLoS ONE</i> , 2018, 13, e0195958.	1.1	51
7820	Identification of DNA methylation prognostic signature of acute myelocytic leukemia. <i>PLoS ONE</i> , 2018, 13, e0199689.	1.1	8
7821	Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells. <i>Journal of Immunology</i> , 2018, 201, 971-981.	0.4	50
7822	Clinical and molecular aspects of breast cancer: Targets and therapies. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 14-34.	2.5	49
7823	A Severe Case of Ipilimumab-Induced Ileocolitis Refractory to Glucocorticosteroids and Infliximab. <i>Case Reports in Gastrointestinal Medicine</i> , 2018, 2018, 1-3.	0.2	0
7824	Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure. <i>Translational Oncology</i> , 2018, 11, 1155-1159.	1.7	8
7825	Minimal change disease associated with anti-PD1 immunotherapy: a case report. <i>BMC Nephrology</i> , 2018, 19, 156.	0.8	24
7826	Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. <i>Breast Cancer Research</i> , 2018, 20, 42.	2.2	48
7827	NDRG1 regulates neutral lipid metabolism in breast cancer cells. <i>Breast Cancer Research</i> , 2018, 20, 55.	2.2	64
7828	Latest development of liquid biopsy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1645-S1651.	0.6	62
7829	Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2269-2275.	1.0	32

#	ARTICLE	IF	CITATIONS
7830	Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 321-330.	2.0	92
7831	Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 278.	1.3	15
7832	Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs. <i>Vaccines</i> , 2018, 6, 42.	2.1	8
7833	Current Landscape of Immunotherapy for the Treatment of Metastatic Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 94-102.	0.9	39
7834	Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 68-76.	0.9	11
7835	Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2018, 81, 29.	0.7	24
7836	The role of proteomics in the age of immunotherapies. <i>Mammalian Genome</i> , 2018, 29, 757-769.	1.0	12
7837	Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer. <i>Translational Oncology</i> , 2018, 11, 1171-1187.	1.7	94
7838	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky021.	1.4	92
7839	PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study. <i>BMC Cancer</i> , 2018, 18, 652.	1.1	13
7840	Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study. <i>BMC Cancer</i> , 2018, 18, 768.	1.1	18
7841	Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 269.	1.3	106
7842	Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. <i>Cancers</i> , 2018, 10, 245.	1.7	34
7843	Immunotherapy for esophageal squamous cell carcinoma: a review. <i>Fukushima Journal of Medical Sciences</i> , 2018, 64, 46-53.	0.1	36
7844	Activation of phagocytosis by immune checkpoint blockade. <i>Frontiers of Medicine</i> , 2018, 12, 473-480.	1.5	15
7845	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2365-2376.	0.3	59
7846	Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. <i>Npj Breast Cancer</i> , 2018, 4, 19.	2.3	19
7847	Explaining cancer type specific mutations with transcriptomic and epigenomic features in normal tissues. <i>Scientific Reports</i> , 2018, 8, 11456.	1.6	11

#	ARTICLE	IF	CITATIONS
7848	RECK isoforms have opposing effects on cell migration. <i>Molecular Biology of the Cell</i> , 2018, 29, 1825-1838.	0.9	20
7849	A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy. <i>BMC Cancer</i> , 2018, 18, 620.	1.1	8
7850	Cytokeratin 5/6 and cytokeratin 8/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population. <i>BMC Research Notes</i> , 2018, 11, 372.	0.6	19
7851	Immune oncology, immune responsiveness and the theory of everything. , 2018, 6, 50.		58
7852	Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1645-1657.	2.0	19
7853	Triple-negative and HER2-overexpressing breast cancer cell sialylation impacts tumor microenvironment T-lymphocyte subset recruitment: a possible mechanism of tumor escape. <i>Cancer Management and Research</i> , 2018, Volume 10, 1051-1059.	0.9	8
7854	Are ovarian cancer stem cells the target for innovative immunotherapy?. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2615-2626.	1.0	12
7855	Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells. <i>Anticancer Research</i> , 2018, 38, 4435-4441.	0.5	29
7856	Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 429-440.	0.2	5
7857	The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4+Foxp3+ Regulatory T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 1556.	2.2	33
7858	Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line. <i>Frontiers in Immunology</i> , 2018, 9, 1609.	2.2	30
7859	Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts. <i>Frontiers in Immunology</i> , 2018, 9, 1614.	2.2	23
7860	Notch Signaling as a Regulator of the Tumor Immune Response: To Target or Not To Target?. <i>Frontiers in Immunology</i> , 2018, 9, 1649.	2.2	85
7861	Role of Tissue-Resident Memory in Intra-Tumor Heterogeneity and Response to Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2018, 9, 1655.	2.2	16
7862	Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 1786.	2.2	29
7863	Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers. <i>Oncology Letters</i> , 2018, 15, 4988-4996.	0.8	12
7864	Mechanisms of sepsis-induced immunosuppression and immunological modification therapies for sepsis. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 351-358.	1.2	56
7865	Immune Checkpoint Inhibitor Toxicity. <i>Current Oncology Reports</i> , 2018, 20, 72.	1.8	91

#	ARTICLE	IF	CITATIONS
7866	Programmed cell death protein-1 inhibitor-induced granuloma annulare and hypertrophic lichen planus masquerading as squamous cell carcinoma. <i>JAAD Case Reports</i> , 2018, 4, 636-639.	0.4	17
7867	Sno-derived RNAs are prevalent molecular markers of cancer immunity. <i>Oncogene</i> , 2018, 37, 6442-6462.	2.6	28
7868	Mutational landscape and clonal diversity of pulmonary adenoid cystic carcinoma. <i>Cancer Biology and Therapy</i> , 2018, 19, 898-903.	1.5	14
7869	Genome Plasticity of <i>agr</i> -Defective <i>Staphylococcus aureus</i> during Clinical Infection. <i>Infection and Immunity</i> , 2018, 86, .	1.0	50
7870	TGF β ² -Induced Lung Cancer Cell Migration Is NR4A1-Dependent. <i>Molecular Cancer Research</i> , 2018, 16, 1991-2002.	1.5	27
7871	Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma. <i>BMC Endocrine Disorders</i> , 2018, 18, 36.	0.9	12
7872	Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. , 2018, 6, 35.		172
7873	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
7874	Vinorelbine-induced regression of a choroidal metastasis from primary breast carcinoma. <i>International Journal of Retina and Vitreous</i> , 2018, 4, 17.	0.9	2
7875	Imaging Phenotypes in Women at High Risk for Breast Cancer on Mammography, Ultrasound, and Magnetic Resonance Imaging Using the Fifth Edition of the Breast Imaging Reporting and Data System. <i>European Journal of Radiology</i> , 2018, 106, 150-159.	1.2	28
7876	Extracellular vesicles: important collaborators in cancer progression. <i>Essays in Biochemistry</i> , 2018, 62, 149-163.	2.1	55
7877	Mutational Analysis of Oncogenic AKT1 Gene Associated with Breast Cancer Risk in the High Altitude Ecuadorian Mestizo Population. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	28
7878	Alternative empirical Bayes models for adjusting for batch effects in genomic studies. <i>BMC Bioinformatics</i> , 2018, 19, 262.	1.2	47
7879	A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 37.	1.5	5
7880	Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages. <i>Breast Cancer Research</i> , 2018, 20, 59.	2.2	38
7881	Nuclear factor- κ B p65 regulates glutaminase 1 expression in human hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3721-3729.	1.0	13
7882	The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features. <i>Internal Medicine</i> , 2018, 57, 1773-1777.	0.3	6
7883	First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?. <i>Current Gene Therapy</i> , 2018, 17, 309-319.	0.9	66

#	ARTICLE	IF	CITATIONS
7884	Checkpoint Blockade Rescues the Repressive Effect of Histone Deacetylases Inhibitors on $\hat{\beta}$ T Cell Function. <i>Frontiers in Immunology</i> , 2018, 9, 1615.	2.2	21
7885	CSF1R-Expressing Tumor-Associated Macrophages, Smoking and Survival in Lung Adenocarcinoma: Analyses Using Quantitative Phosphor-Integrated Dot Staining. <i>Cancers</i> , 2018, 10, 252.	1.7	20
7886	Targeting Macrophages as a Potential Therapeutic Intervention: Impact on Inflammatory Diseases and Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1953.	1.8	117
7887	Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. <i>Current Oncology</i> , 2018, 25, 18-27.	0.9	96
7888	Harmonization of PD-L1 Testing in Oncology: A Canadian Pathology Perspective. <i>Current Oncology</i> , 2018, 25, 209-216.	0.9	34
7889	Expression of V α domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer. <i>Oncology Letters</i> , 2018, 16, 3465-3472.	0.8	31
7890	Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 140, 317-328.	1.4	107
7891	Association between CTLA-4 +49A and G and C/T single-nucleotide polymorphisms and susceptibility to thyroid neoplasm. <i>Endocrine</i> , 2018, 62, 159-165.	1.1	6
7892	Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 1047-1052.	0.6	95
7893	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. <i>Nature Communications</i> , 2018, 9, 3114.	5.8	122
7894	Treg Fragility: A Prerequisite for Effective Antitumor Immunity?. <i>Cancer Immunology Research</i> , 2018, 6, 882-887.	1.6	64
7895	Mechanisms of immune evasion in breast cancer. <i>BMC Cancer</i> , 2018, 18, 556.	1.1	180
7896	Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab. <i>Journal of Clinical Medicine</i> , 2018, 7, 10.	1.0	41
7897	Targeting the cell cycle in breast cancer: towards the next phase. <i>Cell Cycle</i> , 2018, 17, 1871-1885.	1.3	108
7898	KDM5 histone demethylases repress immune response via suppression of STING. <i>PLoS Biology</i> , 2018, 16, e2006134.	2.6	106
7899	Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2018, 23, 1494-1499.	1.9	15
7900	From Chemotherapy to Combined Targeted Therapeutics: In Vitro and in Vivo Models to Decipher Intra-tumor Heterogeneity. <i>Frontiers in Pharmacology</i> , 2018, 9, 77.	1.6	21
7901	Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 158.	1.6	21

#	ARTICLE	IF	CITATIONS
7902	Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion. <i>Frontiers in Pharmacology</i> , 2018, 9, 536.	1.6	160
7903	The Function and Mechanism of Long Non-coding RNA-ATB in Cancers. <i>Frontiers in Physiology</i> , 2018, 9, 321.	1.3	48
7904	Technical Feasibility of Tissue Microarray (TMA) Analysis of Tumor-Associated Immune Response in Prostate Cancer. <i>Journal of Cancer</i> , 2018, 9, 2191-2202.	1.2	2
7905	The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel. <i>Journal of Cancer</i> , 2018, 9, 2302-2307.	1.2	23
7906	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. <i>Journal of Cancer</i> , 2018, 9, 1813-1820.	1.2	41
7907	Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis. <i>Journal of Cancer</i> , 2018, 9, 2525-2531.	1.2	46
7908	Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. <i>Theranostics</i> , 2018, 8, 3559-3570.	4.6	85
7909	Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 873-875.	1.0	11
7910	Two HLA Class II Gene Variants Are Independently Associated with Pediatric Osteosarcoma Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1151-1158.	1.1	4
7911	Effect of Propofol on breast Cancer cell, the immune system, and patient outcome. <i>BMC Anesthesiology</i> , 2018, 18, 77.	0.7	66
7913	ALK Inhibitors, Resistance Development, Clinical Trials. <i>Current Oncology</i> , 2018, 25, 59-67.	0.9	35
7914	Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer. <i>Oncology Letters</i> , 2018, 15, 5093-5097.	0.8	12
7915	A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer. <i>Journal of Cancer</i> , 2018, 9, 1200-1206.	1.2	31
7916	Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing. <i>Journal of Cancer</i> , 2018, 9, 219-231.	1.2	21
7917	Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer. <i>Journal of Cancer</i> , 2018, 9, 1145-1151.	1.2	19
7918	Molecular Regulation of Carcinogenesis: Friend and Foe. <i>Toxicological Sciences</i> , 2018, 165, 277-283.	1.4	34
7919	Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma. <i>International Journal of Immunopathology and Pharmacology</i> , 2018, 32, 205873841879031.	1.0	29
7920	Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. <i>Diagnostic Pathology</i> , 2018, 13, 47.	0.9	29

#	ARTICLE	IF	CITATIONS
7921	Tumor-infiltrating lymphocyte as a prognostic biomarker in stage IV colorectal cancer should take into account the metastatic status and operation modality. <i>Cancer Management and Research</i> , 2018, Volume 10, 1365-1375.	0.9	17
7922	Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 931-940.	0.9	10
7923	Coregulation of alternative splicing by hnRNPM and ESRP1 during EMT. <i>Rna</i> , 2018, 24, 1326-1338.	1.6	53
7924	Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 23-29.	1.0	15
7925	NF κ B in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12. <i>Gastroenterology</i> , 2018, 155, 880-891.e8.	0.6	111
7926	MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-20.	0.8	13
7927	A Coclinal Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. <i>Clinical Cancer Research</i> , 2018, 24, 6288-6299.	3.2	74
7928	Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter. <i>Molecular Cancer</i> , 2018, 17, 106.	7.9	46
7929	Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report. , 2018, 6, 53.		2
7930	A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. , 2018, 6, 76.		14
7931	Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1019-1040.	0.9	55
7932	Immuno-Oncology: Emerging Targets and Combination Therapies. <i>Frontiers in Oncology</i> , 2018, 8, 315.	1.3	244
7933	Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties. <i>Cancer Letters</i> , 2018, 434, 144-151.	3.2	25
7934	Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. <i>Nature Communications</i> , 2018, 9, 2897.	5.8	293
7935	Engineering cell heterogeneity into organs-on-a-chip. <i>Lab on A Chip</i> , 2018, 18, 2378-2395.	3.1	23
7936	Regulatory Role of CD4 ⁺ T Cells in Myocarditis. <i>Journal of Immunology Research</i> , 2018, 2018, 1-11.	0.9	44
7937	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878622.	1.4	5
7938	HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data. <i>BMC Bioinformatics</i> , 2018, 19, 271.	1.2	14

#	ARTICLE	IF	CITATIONS
7939	MICMIC: identification of DNA methylation of distal regulatory regions with causal effects on tumorigenesis. <i>Genome Biology</i> , 2018, 19, 73.	3.8	22
7940	Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma. , 2018, 6, 58.		48
7941	Angiogenic role of miR-20a in breast cancer. <i>PLoS ONE</i> , 2018, 13, e0194638.	1.1	58
7942	Biomarkers for Immune Checkpoint Inhibitors in Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 270.	1.3	47
7943	Construction of an anti- $\text{CD}28$ programmed death-1 ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells. <i>Oncology Letters</i> , 2018, 16, 157-166.	0.8	9
7944	AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer. <i>Theranostics</i> , 2018, 8, 676-692.	4.6	69
7945	Intracellular and extracellular TGF- β signaling in cancer: some recent topics. <i>Frontiers of Medicine</i> , 2018, 12, 387-411.	1.5	108
7946	Melanoma treatment in review. <i>ImmunoTargets and Therapy</i> , 2018, Volume 7, 35-49.	2.7	483
7947	New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4051-4064.	1.0	15
7948	Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma. <i>Molecular and Clinical Oncology</i> , 2018, 9, 75-81.	0.4	12
7949	Alternative splicing events implicated in carcinogenesis and prognosis of colorectal cancer. <i>Journal of Cancer</i> , 2018, 9, 1754-1764.	1.2	64
7950	Future perspectives: cancer metastases. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 559-561.	1.7	2
7951	Overview of precision oncology trials: challenges and opportunities. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 797-804.	1.3	31
7952	Analysis of the Cancer Genome Atlas Data Reveals Novel Putative ncRNAs Targets in Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	16
7953	SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. <i>Cancer Discovery</i> , 2018, 8, 1237-1249.	7.7	216
7954	Discovering mutated driver genes through a robust and sparse co-regularized matrix factorization framework with prior information from mRNA expression patterns and interaction network. <i>BMC Bioinformatics</i> , 2018, 19, 214.	1.2	24
7955	Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 168.	3.5	72
7956	Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0199575.	1.1	9

#	ARTICLE	IF	CITATIONS
7957	The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy. <i>Cancers</i> , 2018, 10, 242.	1.7	97
7958	PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma. <i>Journal of Cancer</i> , 2018, 9, 2224-2231.	1.2	17
7959	Characterizing functional consequences of DNA copy number alterations in breast and ovarian tumors by spaceMap. <i>Journal of Genetics and Genomics</i> , 2018, 45, 361-371.	1.7	1
7960	<i>Listeria monocytogenes</i> as a Vector for Cancer Immunotherapy: Current Understanding and Progress. <i>Vaccines</i> , 2018, 6, 48.	2.1	81
7961	Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs (Review). <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 2183-2192.	0.8	14
7962	A Review of FOXI3 Regulation of Development and Possible Roles in Cancer Progression and Metastasis. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 69.	1.8	12
7963	Targeted Next-Generation Sequencing Identifies Actionable Targets in Estrogen Receptor Positive and Estrogen Receptor Negative Endometrioid Endometrial Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 750.	1.6	3
7964	Current views on molecularly targeted therapy for lung cancer – a review of literature from the last five years. <i>Kardiochirurgia I Torakochirurgia Polska</i> , 2018, 15, 119-124.	0.1	6
7965	Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. <i>Journal of Cancer</i> , 2018, 9, 205-212.	1.2	9
7966	Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer?. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 313-318.	1.2	17
7967	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. <i>Targeted Oncology</i> , 2018, 13, 567-582.	1.7	12
7968	Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 63.	2.0	88
7969	Autoantigen-Harboring Apoptotic Cells Hijack the Coinhibitory Pathway of T Cell Activation. <i>Scientific Reports</i> , 2018, 8, 10533.	1.6	5
7970	Efficient homology-directed gene editing by CRISPR/Cas9 in human stem and primary cells using tube electroporation. <i>Scientific Reports</i> , 2018, 8, 11649.	1.6	53
7971	Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma. <i>Case Reports in Neurological Medicine</i> , 2018, 2018, 1-4.	0.3	34
7972	Atezolizumab-related encephalitis in the intensive care unit: Case report and review of the literature. <i>SAGE Open Medical Case Reports</i> , 2018, 6, 2050313X1879242.	0.2	26
7973	A powerful nonparametric method for detecting differentially co-expressed genes: distance correlation screening and edge-count test. <i>BMC Systems Biology</i> , 2018, 12, 58.	3.0	7
7974	Increased <i>AURKA</i> Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma. <i>Journal of Cancer</i> , 2018, 9, 1267-1276.	1.2	7

#	ARTICLE	IF	CITATIONS
7975	Cardiotoxicity of Anticancer Therapeutics. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 9.	1.1	68
7976	The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies. <i>Frontiers in Endocrinology</i> , 2018, 9, 297.	1.5	17
7977	Deep Sequencing Revealed a CpG Methylation Pattern Associated With ALDH1L1 Suppression in Breast Cancer. <i>Frontiers in Genetics</i> , 2018, 9, 169.	1.1	11
7978	A Leveraged Signal-to-Noise Ratio (LSTNR) Method to Extract Differentially Expressed Genes and Multivariate Patterns of Expression From Noisy and Low-Replication RNAseq Data. <i>Frontiers in Genetics</i> , 2018, 9, 176.	1.1	13
7979	AIMp1 Potentiates TH1 Polarization and Is Critical for Effective Antitumor and Antiviral Immunity. <i>Frontiers in Immunology</i> , 2017, 8, 1801.	2.2	28
7980	Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas. <i>Frontiers in Immunology</i> , 2017, 8, 1899.	2.2	18
7981	Acute Pharmacologic Degradation of a Stable Antigen Enhances Its Direct Presentation on MHC Class I Molecules. <i>Frontiers in Immunology</i> , 2017, 8, 1920.	2.2	32
7982	Combining Adoptive Cell Therapy with Cytomegalovirus-Based Vaccine Is Protective against Solid Skin Tumors. <i>Frontiers in Immunology</i> , 2018, 8, 1993.	2.2	22
7983	Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice. <i>Frontiers in Immunology</i> , 2018, 9, 7.	2.2	33
7984	Prior to Peripheral Tolerance, Newly Generated CD4 T Cells Maintain Dangerous Autoimmune Potential: Fas- and Perforin-Independent Autoimmunity Controlled by Programmed Death-1. <i>Frontiers in Immunology</i> , 2018, 9, 12.	2.2	17
7985	Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 14.	2.2	356
7986	Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 19.	2.2	20
7987	Modeling Human Antitumor Responses In Vivo Using Umbilical Cord Blood-Engrafted Mice. <i>Frontiers in Immunology</i> , 2018, 9, 54.	2.2	11
7988	Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. <i>Frontiers in Immunology</i> , 2018, 9, 70.	2.2	120
7989	Immunotherapy for Dogs: Running Behind Humans. <i>Frontiers in Immunology</i> , 2018, 9, 133.	2.2	39
7990	An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 150.	2.2	25
7991	The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 151.	2.2	245
7992	Unique Immune Gene Expression Patterns in Bronchoalveolar Lavage and Tumor Adjacent Non-Neoplastic Lung Tissue in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 232.	2.2	10

#	ARTICLE	IF	CITATIONS
7993	How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive. <i>Frontiers in Immunology</i> , 2018, 9, 262.	2.2	91
7994	Checks and Balances in Autoimmune Vasculitis. <i>Frontiers in Immunology</i> , 2018, 9, 315.	2.2	31
7995	Optimizing Tumor Microenvironment for Cancer Immunotherapy: β -Glucan-Based Nanoparticles. <i>Frontiers in Immunology</i> , 2018, 9, 341.	2.2	76
7996	Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 374.	2.2	51
7997	Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells. <i>Frontiers in Immunology</i> , 2018, 9, 385.	2.2	144
7998	Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 394.	2.2	84
7999	Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional <i>Bacillus Calmette-Guérin</i> followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 411.	2.2	49
8000	Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model. <i>Frontiers in Immunology</i> , 2018, 9, 416.	2.2	91
8001	Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. <i>Frontiers in Immunology</i> , 2018, 9, 444.	2.2	139
8002	Exhaustion of the CD8+ T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta. <i>Frontiers in Immunology</i> , 2018, 9, 446.	2.2	52
8003	New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms. <i>Frontiers in Immunology</i> , 2018, 9, 470.	2.2	84
8004	Tailoring Immune Responses toward Autoimmunity: Transcriptional Regulators That Drive the Creation and Collusion of Autoreactive Lymphocytes. <i>Frontiers in Immunology</i> , 2018, 9, 482.	2.2	7
8005	Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a <i>Mycoplasma fermentans</i> Lipopeptide. <i>Frontiers in Immunology</i> , 2018, 9, 496.	2.2	16
8006	Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 552.	2.2	74
8007	Human Endothelial Cells Modulate CD4+ T Cell Populations and Enhance Regulatory T Cell Suppressive Capacity. <i>Frontiers in Immunology</i> , 2018, 9, 565.	2.2	39
8008	Combination Immunotherapy: Taking Cancer Vaccines to the Next Level. <i>Frontiers in Immunology</i> , 2018, 9, 610.	2.2	46
8009	Debunking the Myth of Exercise-Induced Immune Suppression: Redefining the Impact of Exercise on Immunological Health Across the Lifespan. <i>Frontiers in Immunology</i> , 2018, 9, 648.	2.2	409
8010	Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination. <i>Frontiers in Immunology</i> , 2018, 9, 650.	2.2	31

#	ARTICLE	IF	CITATIONS
8011	Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. <i>Frontiers in Immunology</i> , 2018, 9, 727.	2.2	55
8012	Real-Time Tracking of Ex Vivo-Expanded Natural Killer Cells Toward Human Triple-Negative Breast Cancers. <i>Frontiers in Immunology</i> , 2018, 9, 825.	2.2	24
8013	Approaches to Improve Chemically Defined Synthetic Peptide Vaccines. <i>Frontiers in Immunology</i> , 2018, 9, 884.	2.2	54
8014	Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 946.	2.2	19
8015	Immune Microenvironment in Glioblastoma Subtypes. <i>Frontiers in Immunology</i> , 2018, 9, 1004.	2.2	291
8016	Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2018, 9, 1044.	2.2	107
8017	Antitumor Immunity Is Controlled by Tetraspanin Proteins. <i>Frontiers in Immunology</i> , 2018, 9, 1185.	2.2	29
8018	High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 1209.	2.2	114
8019	The Confluence of Sex Hormones and Aging on Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 1269.	2.2	178
8020	Immune Targeting of Tetraspanins Involved in Cell Invasion and Metastasis. <i>Frontiers in Immunology</i> , 2018, 9, 1277.	2.2	43
8021	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2018, 9, 1310.	2.2	404
8022	Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptorsâ€™Human Leukocyte Antigen Ligand Mismatch and Activation Receptorâ€™Ligand Interactions. <i>Frontiers in Immunology</i> , 2018, 9, 1345.	2.2	52
8023	Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 1370.	2.2	49
8024	Î³Î´ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion. <i>Frontiers in Immunology</i> , 2018, 9, 1395.	2.2	76
8025	Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG. <i>Frontiers in Immunology</i> , 2018, 9, 1412.	2.2	40
8026	Interferon Signaling Is Frequently Downregulated in Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 1414.	2.2	28
8027	Dendritic Cells Actively Limit Interleukin-10 Production Under Inflammatory Conditions via DC-SCRIPT and Dual-Specificity Phosphatase 4. <i>Frontiers in Immunology</i> , 2018, 9, 1420.	2.2	16
8028	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatmentâ€™A Review From the Melanoma Perspective and Beyond. <i>Frontiers in Immunology</i> , 2018, 9, 1474.	2.2	174

#	ARTICLE	IF	CITATIONS
8029	VÎ ³ 9VÎ ² T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression. <i>Frontiers in Immunology</i> , 2018, 9, 1492.	2.2	21
8030	<i>Echinococcus granulosus</i> : Cure for Cancer Revisited. <i>Frontiers in Medicine</i> , 2018, 5, 60.	1.2	16
8031	Overview on Clinical Relevance of Intra-Tumor Heterogeneity. <i>Frontiers in Medicine</i> , 2018, 5, 85.	1.2	182
8032	Association Between Programed Cell Death-1 and CD4+ T Cell Alterations in Different Phases of Ischemic Stroke Patients. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 170.	1.8	7
8033	The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 82.	1.4	61
8034	Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02). <i>Frontiers in Oncology</i> , 2017, 7, 329.	1.3	11
8035	Improvement of Antitumor Therapies Based on Vaccines and Immune-Checkpoint Inhibitors by Counteracting Tumor-Immunostimulation. <i>Frontiers in Oncology</i> , 2018, 8, 6.	1.3	5
8036	Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. <i>Frontiers in Oncology</i> , 2018, 8, 18.	1.3	34
8037	The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis. <i>Frontiers in Oncology</i> , 2018, 8, 27.	1.3	71
8038	Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis. <i>Frontiers in Oncology</i> , 2018, 8, 31.	1.3	115
8039	Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy. <i>Frontiers in Oncology</i> , 2018, 8, 39.	1.3	104
8040	Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells. <i>Frontiers in Oncology</i> , 2018, 8, 54.	1.3	62
8041	Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma. <i>Frontiers in Oncology</i> , 2018, 8, 71.	1.3	22
8042	Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice. <i>Frontiers in Oncology</i> , 2018, 8, 80.	1.3	40
8043	Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 85.	1.3	83
8044	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. <i>Frontiers in Oncology</i> , 2018, 8, 86.	1.3	926
8045	Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. <i>Frontiers in Oncology</i> , 2018, 8, 107.	1.3	24
8046	The Role of Epsteinâ€Barr Virus in Cervical Cancer: A Brief Update. <i>Frontiers in Oncology</i> , 2018, 8, 113.	1.3	28

#	ARTICLE	IF	CITATIONS
8047	Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack. <i>Frontiers in Oncology</i> , 2018, 8, 143.	1.3	7
8048	Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions. <i>Frontiers in Oncology</i> , 2018, 8, 152.	1.3	30
8049	Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 160.	1.3	283
8050	Mechanisms and Therapy for Cancer Metastasis to the Brain. <i>Frontiers in Oncology</i> , 2018, 8, 161.	1.3	123
8051	Melanoma Immunotherapy: Next-Generation Biomarkers. <i>Frontiers in Oncology</i> , 2018, 8, 178.	1.3	53
8052	The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors. <i>Frontiers in Oncology</i> , 2018, 8, 181.	1.3	19
8053	Expression of the Circadian Clock Gene BMAL1 Positively Correlates With Antitumor Immunity and Patient Survival in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 185.	1.3	60
8054	Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. <i>Frontiers in Oncology</i> , 2018, 8, 202.	1.3	35
8055	Recent Advances in the Treatment of Breast Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 227.	1.3	263
8056	Editorial: Controversies in the Local Management of Lung Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 233.	1.3	1
8057	Active Role of the Necrotic Zone in Desensitization of Hypoxic Macrophages and Regulation of CSC-Fate: A hypothesis. <i>Frontiers in Oncology</i> , 2018, 8, 235.	1.3	24
8058	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
8059	Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges. <i>Biomedicines</i> , 2018, 6, 76.	1.4	10
8060	Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners. <i>Cancers</i> , 2018, 10, 51.	1.7	21
8061	Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2000.	1.8	33
8062	DNA Tumor Virus Regulation of Host DNA Methylation and Its Implications for Immune Evasion and Oncogenesis. <i>Viruses</i> , 2018, 10, 82.	1.5	82
8063	Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 289-303.	1.2	35
8064	Optimization of combination therapy for chronic myeloid leukemia with dosing constraints. <i>Journal of Mathematical Biology</i> , 2018, 77, 1533-1561.	0.8	7

#	ARTICLE	IF	CITATIONS
8065	Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries. <i>Targeted Oncology</i> , 2018, 13, 509-515.	1.7	30
8066	Chromoanasythesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples. <i>BMC Cancer</i> , 2018, 18, 738.	1.1	13
8067	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. <i>BMC Cancer</i> , 2018, 18, 726.	1.1	77
8068	Immunotherapeutic interventions of Triple Negative Breast Cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 147.	1.8	100
8069	The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. <i>Breast Cancer Research</i> , 2018, 20, 71.	2.2	55
8070	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46.		135
8071	Immune Landscape of Breast Cancers. <i>Biomedicines</i> , 2018, 6, 20.	1.4	81
8072	The Peripheral and Intratumoral Immune Cell Landscape in Cancer Patients: A Proxy for Tumor Biology and a Tool for Outcome Prediction. <i>Biomedicines</i> , 2018, 6, 25.	1.4	19
8073	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. <i>Biomedicines</i> , 2018, 6, 26.	1.4	16
8074	Current Strategies to Enhance Anti-Tumour Immunity. <i>Biomedicines</i> , 2018, 6, 37.	1.4	11
8075	Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. <i>Brain Sciences</i> , 2018, 8, 15.	1.1	104
8076	Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy. <i>Cancers</i> , 2018, 10, 6.	1.7	158
8077	Current Advances in Aptamers for Cancer Diagnosis and Therapy. <i>Cancers</i> , 2018, 10, 9.	1.7	139
8078	Colorectal Cancers: An Update on Their Molecular Pathology. <i>Cancers</i> , 2018, 10, 26.	1.7	128
8079	Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. <i>Cancers</i> , 2018, 10, 32.	1.7	54
8080	Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. <i>Cancers</i> , 2018, 10, 39.	1.7	44
8081	Update on Immunohistochemistry for the Diagnosis of Lung Cancer. <i>Cancers</i> , 2018, 10, 72.	1.7	94
8082	Role of Pattern Recognition Receptors in KSHV Infection. <i>Cancers</i> , 2018, 10, 85.	1.7	14

#	ARTICLE	IF	CITATIONS
8083	The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome. <i>Cancers</i> , 2018, 10, 134.	1.7	18
8084	Clinical Importance of Epstein-Barr Virus-Associated Gastric Cancer. <i>Cancers</i> , 2018, 10, 167.	1.7	63
8085	Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses. <i>Cancers</i> , 2018, 10, 171.	1.7	11
8086	The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. <i>Cancers</i> , 2018, 10, 204.	1.7	37
8087	Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer. <i>Cancers</i> , 2018, 10, 205.	1.7	49
8088	Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities. <i>Cancers</i> , 2018, 10, 207.	1.7	150
8089	Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach. <i>Cancers</i> , 2018, 10, 212.	1.7	17
8090	MiRNAs at the Crossroads between Innate Immunity and Cancer: Focus on Macrophages. <i>Cells</i> , 2018, 7, 12.	1.8	38
8091	Perspective on Cancer Therapeutics Utilizing Analysis of Circulating Tumor Cells. <i>Diagnostics</i> , 2018, 8, 23.	1.3	10
8092	The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. <i>Genes</i> , 2018, 9, 29.	1.0	21
8093	lncRNA Gene Signatures for Prediction of Breast Cancer Intrinsic Subtypes and Prognosis. <i>Genes</i> , 2018, 9, 65.	1.0	31
8094	Applying Expression Profile Similarity for Discovery of Patient-Specific Functional Mutations. <i>High-Throughput</i> , 2018, 7, 6.	4.4	3
8095	Cezanne/OTUD7B is a cell cycle-regulated deubiquitinase that antagonizes the degradation of APC/IC substrates. <i>EMBO Journal</i> , 2018, 37, .	3.5	60
8096	Well-controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report. <i>Thoracic Cancer</i> , 2018, 9, 1190-1193.	0.8	13
8097	PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters. <i>PLoS ONE</i> , 2018, 13, e0196464.	1.1	20
8098	Immunotherapy of melanoma. <i>Wspolczesna Onkologia</i> , 2018, 2018, 61-67.	0.7	78
8099	Validation Strategy for Ultrasensitive Mutation Detection. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 603-611.	1.6	0
8100	Progress in targeted therapy for breast cancer. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 164-175.	0.9	31

#	ARTICLE	IF	CITATIONS
8101	CCL5-deficiency enhances intratumoral infiltration of CD8+ T cells in colorectal cancer. <i>Cell Death and Disease</i> , 2018, 9, 766.	2.7	51
8102	Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma. <i>Internal Medicine</i> , 2018, 57, 1789-1792.	0.3	26
8103	Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas. <i>International Journal of Molecular Sciences</i> , 2018, 19, 394.	1.8	78
8104	Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice. <i>International Journal of Molecular Sciences</i> , 2018, 19, 563.	1.8	44
8105	The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting. <i>International Journal of Molecular Sciences</i> , 2018, 19, 609.	1.8	21
8106	The Role of the Estrogen Pathway in the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2018, 19, 611.	1.8	145
8107	A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response. <i>International Journal of Molecular Sciences</i> , 2018, 19, 617.	1.8	31
8108	The Complex Subtype-Dependent Role of Connexin 43 (GJA1) in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 693.	1.8	30
8109	Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas. <i>International Journal of Molecular Sciences</i> , 2018, 19, 739.	1.8	44
8110	Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs™ Revolution for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 799.	1.8	33
8111	In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 910.	1.8	11
8112	Protein Expression in Tonsillar and Base of Tongue Cancer and in Relation to Human Papillomavirus (HPV) and Clinical Outcome. <i>International Journal of Molecular Sciences</i> , 2018, 19, 978.	1.8	13
8113	The Costimulatory Pathways and T Regulatory Cells in Ischemia-Reperfusion Injury: A Strong Arm in the Inflammatory Response?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1283.	1.8	6
8114	Mechanisms of Intrinsic Tumor Resistance to Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1340.	1.8	61
8115	Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1389.	1.8	77
8116	Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1421.	1.8	46
8117	Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1512.	1.8	16
8118	Effects of PTEN Loss and Activated KRAS Overexpression on Mechanical Properties of Breast Epithelial Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1613.	1.8	7

#	ARTICLE	IF	CITATIONS
8119	PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1984.	1.8	31
8120	Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?. <i>Journal of Clinical Medicine</i> , 2018, 7, 144.	1.0	54
8121	Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. <i>Journal of Clinical Medicine</i> , 2018, 7, 151.	1.0	11
8122	An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2018, 7, 153.	1.0	47
8123	Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Invasive and Personalised Medicine. <i>Journal of Clinical Medicine</i> , 2018, 7, 163.	1.0	50
8124	Structural Analysis and Epitope Prediction of MHC Class-1-Chain Related Protein-A for Cancer Vaccine Development. <i>Vaccines</i> , 2018, 6, 1.	2.1	26
8125	Advances in cancer immunotherapy for gastroenterological malignancy. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 244-245.	1.2	19
8126	Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 1338-1341.	0.2	8
8127	An Adaptive Dose-Finding Design Based on Both Safety and Immunologic Responses in Cancer Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2018, 10, 185-195.	0.6	11
8128	Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma. <i>BMC Cancer</i> , 2018, 18, 705.	1.1	23
8129	Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer. <i>BMC Cancer</i> , 2018, 18, 700.	1.1	37
8130	The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma. <i>Molecular Cancer</i> , 2018, 17, 95.	7.9	67
8131	Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients. <i>Journal of Translational Medicine</i> , 2018, 16, 195.	1.8	13
8132	Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer. <i>Clinical Epigenetics</i> , 2018, 10, 88.	1.8	49
8133	Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. , 2018, 6, 42.		15
8134	Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma. <i>Radiation Research</i> , 2018, 190, 322.	0.7	36
8135	Immune Checkpoint Inhibitor Therapy: A Boon to Elderly Patients with Advanced Melanoma?. <i>Internal Medicine</i> , 2018, 57, 2287-2288.	0.3	0
8136	Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma. <i>Immunotherapy</i> , 2018, 10, 779-786.	1.0	58

#	ARTICLE	IF	CITATIONS
8137	Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer. <i>Frontiers in Endocrinology</i> , 2018, 9, 277.	1.5	48
8138	Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. <i>Cancers</i> , 2018, 10, 62.	1.7	73
8139	Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. <i>Cancers</i> , 2018, 10, 193.	1.7	16
8140	Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis. <i>Oncology Letters</i> , 2018, 15, 5671-5679.	0.8	4
8141	Buparlisib is a brain penetrable pan-PI3K inhibitor. <i>Scientific Reports</i> , 2018, 8, 10784.	1.6	52
8142	Keap1-Nrf2 pathway: a lid on lung cancer: the Keap1-Nrf2 pathway. <i>Cell Cycle</i> , 2018, 17, 1696-1707.	1.3	39
8143	IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer. <i>Cancer Research</i> , 2018, 78, 5243-5258.	0.4	119
8144	Therapeutic landscape in mutational triple negative breast cancer. <i>Molecular Cancer</i> , 2018, 17, 99.	7.9	70
8145	Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome. <i>Genome Biology</i> , 2018, 19, 67.	3.8	81
8146	Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). , 2018, 6, 39.		329
8147	Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. <i>Acta Neuropathologica Communications</i> , 2018, 6, 51.	2.4	115
8148	Differential Characterization of Temozolomide-Resistant Human Glioma Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 127.	1.8	28
8149	Expected advances in human fertility treatments and their likely translational consequences. <i>Journal of Translational Medicine</i> , 2018, 16, 149.	1.8	8
8150	DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. <i>Clinical Epigenetics</i> , 2018, 10, 78.	1.8	103
8151	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). , 2018, 6, 75.		188
8152	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. , 2018, 6, 74.		292
8153	Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. , 2018, 6, 73.		46
8154	ER-positive breast cancer cells are poised for RET-mediated endocrine resistance. <i>PLoS ONE</i> , 2018, 13, e0194023.	1.1	19

#	ARTICLE	IF	CITATIONS
8155	A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management. <i>Oncologist</i> , 2018, 23, 1119-1126.	1.9	72
8156	Autoantibodies as Potential Biomarkers in Breast Cancer. <i>Biosensors</i> , 2018, 8, 67.	2.3	36
8157	Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review. <i>Obstetrics and Gynecology Science</i> , 2018, 61, 524.	0.6	9
8158	Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy. <i>JAMA Dermatology</i> , 2018, 154, 1057.	2.0	86
8159	Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 112-115.	0.3	2
8160	Management of adverse events related to checkpoint inhibition therapy. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 132-137.	0.3	22
8161	Patterns of genomic evolution in advanced melanoma. <i>Nature Communications</i> , 2018, 9, 2665.	5.8	62
8162	Is this really just "fatigue"? A case series of immune-related central adrenal insufficiency secondary to immune checkpoint inhibitors. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 1278-1281.	0.2	9
8163	Personalizing Radiation Treatment Delivery in the Management of Breast Cancer. <i>International Journal of Breast Cancer</i> , 2018, 2018, 1-8.	0.6	10
8164	Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. <i>ELife</i> , 2018, 7, .	2.8	474
8165	Cancer initiation and progression within the cancer microenvironment. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 361-367.	1.7	30
8166	Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment. <i>Radiology Case Reports</i> , 2018, 13, 882-885.	0.2	14
8167	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1693-1698.	2.8	39
8168	Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. <i>MAbs</i> , 2018, 10, 1-13.	2.6	31
8169	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. <i>Cancer Immunology Research</i> , 2018, 6, 1039-1045.	1.6	60
8170	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877742.	1.4	7
8171	Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer). <i>The Cochrane Library</i> , 2018, 7, CD012556.	1.5	13
8172	Microbial biomarkers for immune checkpoint blockade therapy against cancer. <i>Journal of Gastroenterology</i> , 2018, 53, 999-1005.	2.3	15

#	ARTICLE	IF	CITATIONS
8173	Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1851-1859.	1.2	55
8174	Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 503-520.	1.7	9
8175	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5250-5260.	3.2	116
8176	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2087.	1.8	14
8177	Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice. <i>European Journal of Immunology</i> , 2018, 48, 1728-1738.	1.6	13
8178	Novel frontiers in detecting cancer metastasis. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 403-412.	1.7	8
8179	Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis. <i>Cancer Research</i> , 2018, 78, 5038-5049.	0.4	64
8180	Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878665.	1.4	105
8181	Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors. <i>Diagnostic Pathology</i> , 2018, 13, 30.	0.9	43
8182	Immunotherapy-induced pneumonitis: cases report. <i>Einstein (Sao Paulo, Brazil)</i> , 2018, 16, eRC4030.	0.3	9
8183	Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2085-2096.	2.0	38
8184	Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses. <i>Frontiers in Oncology</i> , 2018, 8, 81.	1.3	86
8185	Association of the characteristics of B and T cell repertoires with papillary thyroid carcinoma. <i>Oncology Letters</i> , 2018, 16, 1584-1592.	0.8	8
8186	Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes. <i>International Journal of Biological Sciences</i> , 2018, 14, 204-216.	2.6	75
8187	Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. <i>Frontiers in Pharmacology</i> , 2018, 9, 185.	1.6	277
8188	Advances in the Systemic Treatment of Triple-Negative Breast Cancer. <i>Current Oncology</i> , 2018, 25, 142-150.	0.9	241
8189	Novel Systemic Therapies for Advanced Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2018, 18, 1.	0.9	33
8190	Immunotherapy in Advanced Gastric Cancer: An Overview of the Emerging Strategies. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-8.	0.8	15

#	ARTICLE	IF	CITATIONS
8191	Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival. <i>BMC Cancer</i> , 2018, 18, 750.	1.1	13
8192	Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 171.	0.4	25
8193	PD-L1 ⁺ tumor-associated macrophages and PD-1 ⁺ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. <i>Haematologica</i> , 2018, 103, 1908-1914.	1.7	64
8194	Aging Mouse Models Reveal Complex Tumor-Microenvironment Interactions in Cancer Progression. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 35.	1.8	5
8195	Predictors of breast cancer cell types and their prognostic power in breast cancer patients. <i>BMC Genomics</i> , 2018, 19, 137.	1.2	14
8196	ATF-3/miR-590/GOLPH3 signaling pathway regulates proliferation of breast cancer. <i>BMC Cancer</i> , 2018, 18, 255.	1.1	22
8197	CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer. <i>BMC Cancer</i> , 2018, 18, 462.	1.1	68
8198	Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the "panacea" for all patients?. <i>BMC Medicine</i> , 2018, 16, 24.	2.3	11
8199	Identifying statistically significant combinatorial markers for survival analysis. <i>BMC Medical Genomics</i> , 2018, 11, 31.	0.7	11
8200	Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. <i>Molecular Cancer</i> , 2018, 17, 59.	7.9	63
8201	Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients. <i>Diagnostic Pathology</i> , 2018, 13, 13.	0.9	37
8202	Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 44.	3.5	87
8203	Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. , 2018, 6, 22.		45
8204	Microsatellite instability in prostate cancer by PCR or next-generation sequencing. , 2018, 6, 29.		96
8205	Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma. <i>Inflammation and Regeneration</i> , 2018, 38, 3.	1.5	35
8206	The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer. <i>Hormones and Cancer</i> , 2018, 9, 215-228.	4.9	36
8207	Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN γ secretion. <i>Cancer Letters</i> , 2018, 430, 47-56.	3.2	117
8208	A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. <i>Npj Breast Cancer</i> , 2018, 4, 9.	2.3	32

#	ARTICLE	IF	CITATIONS
8209	Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5534-5539.	3.3	73
8210	Applications of RNA Indexes for Precision Oncology in Breast Cancer. Genomics, Proteomics and Bioinformatics, 2018, 16, 108-119.	3.0	16
8211	Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. British Journal of Cancer, 2018, 119, 538-545.	2.9	111
8212	PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 1059-1066.	2.1	79
8213	Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review). Oncology Letters, 2018, 15, 7497-7505.	0.8	50
8214	Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. Molecular Cancer Therapeutics, 2018, 17, 1739-1751.	1.9	87
8215	Combination of anti-PD-1 therapy and stereotactic radiosurgery for a gastric cancer patient with brain metastasis: a case report. BMC Cancer, 2018, 18, 173.	1.1	10
8216	Readministration of Nivolumab after Persistent Immune-related Colitis in a Patient with Recurrent Melanoma. Internal Medicine, 2018, 57, 1173-1176.	0.3	10
8217	Immune checkpoint receptors: homeostatic regulators of immunity. Hepatology International, 2018, 12, 223-236.	1.9	43
8218	Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nature Communications, 2018, 9, 1849.	5.8	310
8219	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nature Communications, 2018, 9, 1816.	5.8	105
8220	Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. Npj Breast Cancer, 2018, 4, 10.	2.3	95
8221	Immune-related Adverse Events in Cancer Patients. Academic Emergency Medicine, 2018, 25, 819-827.	0.8	18
8222	Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. BMC Cancer, 2018, 18, 87.	1.1	33
8223	Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer, 2018, 18, 4.	1.1	85
8224	Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC Cancer, 2018, 18, 56.	1.1	63
8225	Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data. BMC Cancer, 2018, 18, 145.	1.1	16
8226	Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells. BMC Cancer, 2018, 18, 149.	1.1	36

#	ARTICLE	IF	CITATIONS
8227	PD-L1 expression in malignant salivary gland tumors. BMC Cancer, 2018, 18, 156.	1.1	38
8228	Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer. BMC Cancer, 2018, 18, 320.	1.1	22
8229	VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer, 2018, 18, 511.	1.1	66
8230	High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review. BMC Pulmonary Medicine, 2018, 18, 23.	0.8	21
8231	Liquid biomarkers in melanoma: detection and discovery. Molecular Cancer, 2018, 17, 8.	7.9	74
8232	Physical basis of the "magnification rule"™ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer. Diagnostic Pathology, 2018, 13, 19.	0.9	15
8233	Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study. Radiation Oncology, 2018, 13, 10.	1.2	29
8234	Precision therapy for acute myeloid leukemia. Journal of Hematology and Oncology, 2018, 11, 3.	6.9	95
8235	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. Journal of Hematology and Oncology, 2018, 11, 15.	6.9	155
8236	PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. Journal of Hematology and Oncology, 2018, 11, 16.	6.9	96
8237	HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors. Breast Cancer Research, 2018, 20, 8.	2.2	44
8238	Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer. Breast Cancer Research, 2018, 20, 22.	2.2	15
8239	Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape. Breast Cancer Research, 2018, 20, 39.	2.2	38
8240	Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports. , 2018, 6, 2.		11
8241	Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. , 2018, 6, 4.		118
8242	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
8244	Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis. , 2018, 6, 20.		82
8245	Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. , 2018, 6, 18.		153

#	ARTICLE	IF	CITATIONS
8246	Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition. , 2018, 6, 25.		26
8247	Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer, 2018, 18, 265.	1.1	84
8248	Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. BMC Cancer, 2018, 18, 239.	1.1	38
8249	Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice “ results from the ElderTac study. BMC Cancer, 2018, 18, 333.	1.1	10
8250	Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. BMC Cancer, 2018, 18, 490.	1.1	73
8251	Molecular subtyping of nasopharyngeal carcinoma (NPC) and a microRNA-based prognostic model for distant metastasis. Journal of Biomedical Science, 2018, 25, 16.	2.6	38
8252	New therapeutic strategies to treat human cancers expressing mutant p53 proteins. Journal of Experimental and Clinical Cancer Research, 2018, 37, 30.	3.5	160
8253	Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. , 2018, 6, 19.		45
8254	Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. , 2018, 6, 24.		13
8255	New insights from the widening homogeneity perspective to target intratumor heterogeneity. Cancer Communications, 2018, 38, 1-7.	3.7	9
8256	Immunotherapy in Breast Cancer: the New Frontier. Current Breast Cancer Reports, 2018, 10, 35-40.	0.5	19
8257	Clinico-pathological Features of PIK3CA Mutation in HER2-Positive Breast Cancer of Indian Population. Indian Journal of Surgical Oncology, 2018, 9, 381-386.	0.3	3
8258	Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective. Acta Pharmaceutica Sinica B, 2018, 8, 530-538.	5.7	43
8259	Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncology, 2018, 4, e180798.	3.4	86
8260	Egr2-independent, Klf1-mediated induction of PD-L1 in CD4+ T cells. Scientific Reports, 2018, 8, 7021.	1.6	10
8261	Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy. Scientific Reports, 2018, 8, 7485.	1.6	19
8262	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocrine Connections, 2018, 7, R196-R211.	0.8	10
8263	Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. Aids, 2018, 32, 1491-1497.	1.0	136

#	ARTICLE	IF	CITATIONS
8264	Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4. <i>Molecular Oncology</i> , 2018, 12, 1540-1558.	2.1	30
8265	Anticalin® Proteins as Therapeutic Agents in Human Diseases. <i>BioDrugs</i> , 2018, 32, 233-243.	2.2	78
8266	Pathway-based dissection of the genomic heterogeneity of cancer hallmarks' acquisition with SLAPenrich. <i>Scientific Reports</i> , 2018, 8, 6713.	1.6	24
8267	Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. <i>Scientific Reports</i> , 2018, 8, 7205.	1.6	71
8268	Thresher: determining the number of clusters while removing outliers. <i>BMC Bioinformatics</i> , 2018, 19, 9.	1.2	45
8269	The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). <i>BMC Cancer</i> , 2018, 18, 552.	1.1	14
8270	Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. <i>Experimental Hematology and Oncology</i> , 2018, 7, 11.	2.0	38
8271	Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. , 2018, 6, 32.		111
8272	Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. , 2018, 6, 37.		174
8273	Identification of potential crucial genes and construction of microRNA-mRNA negative regulatory networks in osteosarcoma. <i>Hereditas</i> , 2018, 155, 21.	0.5	32
8274	Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 653-664.	1.4	26
8275	Combination Immunotherapy in Non-small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2018, 20, 55.	1.8	25
8276	Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial. <i>Clinical and Translational Oncology</i> , 2018, 20, 1474-1483.	1.2	20
8277	Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers. <i>Translational Oncology</i> , 2018, 11, 825-835.	1.7	45
8278	Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with pembrolizumab. <i>Medicine (United States)</i> , 2018, 97, e0718.	0.4	6
8279	CIMT 2018: Pushing frontiers in cancer immunotherapy " Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2864-2873.	1.4	1
8280	Unique, dual-indexed sequencing adapters with UMIs effectively eliminate index cross-talk and significantly improve sensitivity of massively parallel sequencing. <i>BMC Genomics</i> , 2018, 19, 30.	1.2	157
8281	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 104.	6.9	303

#	ARTICLE	IF	CITATIONS
8282	Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies. <i>Research Involvement and Engagement</i> , 2018, 4, 22.	1.1	3
8283	Therapeutic Vaccines for Genitourinary Malignancies. <i>Vaccines</i> , 2018, 6, 55.	2.1	9
8284	Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors. <i>Journal of Oncology</i> , 2018, 2018, 1-13.	0.6	3
8285	The role of Hippo signal pathway in breast cancer metastasis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2185-2193.	1.0	63
8286	New Directions in the Study and Treatment of Metastatic Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 258.	1.3	14
8287	Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions. <i>Biology</i> , 2018, 7, 5.	1.3	3
8288	Human cancer evolution in the context of a human immune system in mice. <i>Molecular Oncology</i> , 2018, 12, 1797-1810.	2.1	11
8289	Management of Brain Metastases in the New Era of Checkpoint Inhibition. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 70.	2.0	25
8290	Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks. <i>Current Oncology Reports</i> , 2018, 20, 75.	1.8	55
8291	Fluorescence detection of DNA mismatch repair in human cells. <i>Scientific Reports</i> , 2018, 8, 12181.	1.6	5
8292	Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. <i>Current Oncology Reports</i> , 2018, 20, 76.	1.8	72
8293	Contribution of excision repair cross-complementing group 1 genotypes to triple negative breast cancer risk. <i>PLoS ONE</i> , 2018, 13, e0202112.	1.1	8
8294	Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer. <i>Oncotarget</i> , 2018, 9, 7672-7683.	0.8	14
8295	Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 16512-16520.	0.8	71
8296	Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). <i>Annals of Translational Medicine</i> , 2018, 6, 144-144.	0.7	19
8297	Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2018, 21, 124.	0.8	54
8298	Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review. <i>Internal Medicine</i> , 2018, 57, 527-535.	0.3	40
8299	Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience. <i>Journal of Cancer</i> , 2018, 9, 182-188.	1.2	42

#	ARTICLE	IF	CITATIONS
8300	New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. <i>Precision Clinical Medicine</i> , 2018, 1, 21-28.	1.3	16
8301	Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 59, 723-732.	1.4	37
8302	Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. <i>Cancer Management and Research</i> , 2018, Volume 10, 91-103.	0.9	53
8303	<i>Trichinella spiralis</i> Infection Mitigates Collagen-Induced Arthritis via Programmed Death 1-Mediated Immunomodulation. <i>Frontiers in Immunology</i> , 2018, 9, 1566.	2.2	29
8304	Diagnostic value of peripheral blood immune profiling in colorectal cancer. <i>Annals of Surgical Treatment and Research</i> , 2018, 94, 312.	0.4	26
8305	Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 577-582.	1.4	14
8306	Immune Checkpoint Inhibitor-related Pneumonitis. Incidence, Risk Factors, and Clinical and Radiographic Features. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 951-953.	2.5	8
8307	CNS cancer immunity cycle and strategies to target this for glioblastoma. <i>Oncotarget</i> , 2018, 9, 22802-22816.	0.8	11
8308	Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. <i>Oncotarget</i> , 2018, 9, 29007-29017.	0.8	73
8309	The Emerging Role of CD8+ Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin. <i>Frontiers in Immunology</i> , 2018, 9, 1904.	2.2	100
8310	Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets. <i>Biomedicines</i> , 2018, 6, 32.	1.4	41
8311	A proteomic analysis of chemoresistance development via sequential treatment with doxorubicin reveals novel players in MCF7 breast cancer cells. <i>International Journal of Molecular Medicine</i> , 2018, 42, 1987-1997.	1.8	7
8312	Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells. <i>Journal of Cancer</i> , 2018, 9, 129-134.	1.2	11
8313	Complex interplay between tumor microenvironment and cancer therapy. <i>Frontiers of Medicine</i> , 2018, 12, 426-439.	1.5	37
8314	Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. <i>Drugs</i> , 2018, 78, 1197-1209.	4.9	34
8315	Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. <i>Nature Biotechnology</i> , 2018, 36, 847-856.	9.4	564
8316	A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. <i>Nature Communications</i> , 2018, 9, 3196.	5.8	145
8317	Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. <i>Nature Medicine</i> , 2018, 24, 1459-1468.	15.2	437

#	ARTICLE	IF	CITATIONS
8318	Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. <i>ESMO Open</i> , 2018, 3, e000332.	2.0	55
8319	Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i>		
8320	A Novel Approach for Identifying Relevant Genes for Breast Cancer Survivability on Specific Therapies. <i>Evolutionary Bioinformatics</i> , 2018, 14, 117693431879026.	0.6	13
8321	Predicting Antigen Presentationâ€”What Could We Learn From a Million Peptides?. <i>Frontiers in Immunology</i> , 2018, 9, 1716.	2.2	159
8322	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 1739.	2.2	174
8323	Targeting the Microenvironment in High Grade Serous Ovarian Cancer. <i>Cancers</i> , 2018, 10, 266.	1.7	30
8324	Next Generation Cancer Vaccinesâ€”Make It Personal!. <i>Vaccines</i> , 2018, 6, 52.	2.1	20
8325	Algorithm for the Treatment of Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer: An Evidence-Based Overview. <i>Current Oncology</i> , 2018, 25, 77-85.	0.9	9
8326	Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma. <i>Neoplasia</i> , 2018, 20, 883-893.	2.3	12
8327	Is there a role for immunotherapy in HER2-positive breast cancer?. <i>Npj Breast Cancer</i> , 2018, 4, 21.	2.3	19
8328	Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 545-551.	0.5	6
8329	Design considerations for early-phase clinical trials of immune-oncology agents. , 2018, 6, 81.		44
8330	Bacillus Calmette–Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2891-2899.	1.0	45
8331	Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer. <i>Internal Medicine</i> , 2018, 57, 1269-1272.	0.3	27
8332	DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer. <i>Cancers</i> , 2018, 10, 279.	1.7	15
8333	Implementation of cellâ€free tumor DNA sequencing from the cerebrospinal fluid to guide treatment in a patient with primary leptomeningeal melanoma: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 9, 58-61.	0.4	8
8334	The age of enlightenment in melanoma immunotherapy. , 2018, 6, 80.		25
8335	Role of mTOR Signaling in Tumor Microenvironment: An Overview. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2453.	1.8	109

#	ARTICLE	IF	CITATIONS
8336	Epigenetic mechanisms of tumor resistance to immunotherapy. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 4163-4176.	2.4	27
8337	Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes. <i>Nature Communications</i> , 2018, 9, 3417.	5.8	87
8338	Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. <i>Molecular Cancer</i> , 2018, 17, 129.	7.9	536
8339	Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0202725.	1.1	15
8340	Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease. <i>Research and Reports in Urology</i> , 2018, Volume 10, 7-16.	0.6	22
8341	Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. <i>Methods in Molecular Biology</i> , 2018, 1845, 241-257.	0.4	18
8342	An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer. <i>Drugs</i> , 2018, 78, 1353-1362.	4.9	6
8343	Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. <i>Lung Cancer</i> , 2018, 125, 273-281.	0.9	69
8344	Optic Neuritis Possibly Induced by Anti-PD-L1 Antibody Treatment in a Patient with Non-Small Cell Lung Carcinoma. <i>Case Reports in Ophthalmology</i> , 2018, 9, 348-356.	0.3	25
8345	Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 324-334.	0.9	56
8346	The role of automated cytometry in the new era of cancer immunotherapy (Review). <i>Molecular and Clinical Oncology</i> , 2018, 9, 355-361.	0.4	12
8347	Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review). <i>Oncology Letters</i> , 2018, 16, 4105-4113.	0.8	58
8348	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018, 50, 1271-1281.	9.4	438
8349	Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8698-E8706.	3.3	77
8350	Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2030.	2.2	77
8351	High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors. <i>Journal of Experimental Medicine</i> , 2018, 215, 2520-2535.	4.2	250
8352	Mouse models in the era of large human tumour sequencing studies. <i>Open Biology</i> , 2018, 8, .	1.5	7
8353	Molecular Magnetic Resonance Imaging of Endothelial Activation in the Central Nervous System. <i>Theranostics</i> , 2018, 8, 1195-1212.	4.6	55

#	ARTICLE	IF	CITATIONS
8354	Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 46.	1.3	16
8355	FACER: comprehensive molecular and functional characterization of epigenetic chromatin regulators. <i>Nucleic Acids Research</i> , 2018, 46, 10019-10033.	6.5	66
8356	Dendritic cell vaccines for high-grade gliomas. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1299-1313.	0.9	42
8357	Long non-coding RNA BRAF-regulated lncRNA 1 promotes lymph node invasion, metastasis and proliferation, and predicts poor prognosis in breast cancer. <i>Oncology Letters</i> , 2018, 15, 9543-9552.	0.8	13
8358	Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment. <i>Journal of Cancer</i> , 2018, 9, 1614-1622.	1.2	17
8359	The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer. <i>Drugs and Aging</i> , 2018, 35, 819-834.	1.3	16
8360	A cancer vaccine approach for personalized treatment of Lynch Syndrome. <i>Scientific Reports</i> , 2018, 8, 12122.	1.6	25
8361	Germline and Somatic <i>NF1</i> Alterations Are Linked to Increased HER2 Expression in Breast Cancer. <i>Cancer Prevention Research</i> , 2018, 11, 655-664.	0.7	4
8362	CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors. <i>Annals of Translational Medicine</i> , 2018, 6, 54-54.	0.7	36
8363	Review of checkpoint immunotherapy for the management of non-small cell lung cancer. <i>ImmunoTargets and Therapy</i> , 2018, Volume 7, 63-75.	2.7	48
8364	Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report. <i>Frontiers in Immunology</i> , 2018, 9, 1769.	2.2	15
8365	Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1774.	2.2	125
8366	New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. <i>Biomedicines</i> , 2018, 6, 87.	1.4	8
8367	Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 22.	2.3	30
8368	Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity. <i>Journal of Translational Medicine</i> , 2018, 16, 227.	1.8	18
8369	Global Inequities in Precision Medicine and Molecular Cancer Research. <i>Frontiers in Oncology</i> , 2018, 8, 346.	1.3	44
8370	Regulation of T cell immunity by cellular metabolism. <i>Frontiers of Medicine</i> , 2018, 12, 463-472.	1.5	33
8371	Checkpoint inhibitor-associated cutaneous small vessel vasculitis. <i>JAAD Case Reports</i> , 2018, 4, 675-677.	0.4	23

#	ARTICLE	IF	CITATIONS
8372	Role of regulatory T _H 1/2 cells and CD8 ⁺ T lymphocytes in the dissemination of circulating tumor cells in primary invasive breast cancer. <i>Oncology Letters</i> , 2018, 16, 3045-3053.	0.8	19
8373	Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy. <i>International Journal of Biological Sciences</i> , 2018, 14, 331-340.	2.6	57
8374	Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations. <i>Npj Breast Cancer</i> , 2018, 4, 23.	2.3	26
8375	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. <i>Nature</i> , 2018, 560, 382-386.	13.7	1,836
8376	Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis. <i>Scientific Reports</i> , 2018, 8, 11738.	1.6	21
8377	Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor. <i>Molecular Cancer Research</i> , 2018, 16, 1952-1964.	1.5	48
8378	Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 1713-1723.	1.5	14
8379	BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i> -Mutant Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 1234-1245.	1.6	80
8380	Approved checkpoint inhibitors in bladder cancer: which drug should be used when?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878831.	1.4	49
8381	Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?. <i>Journal of Translational Medicine</i> , 2018, 16, 219.	1.8	96
8382	DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. <i>Clinical Epigenetics</i> , 2018, 10, 104.	1.8	68
8383	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. <i>Oncologist</i> , 2018, 23, 1319-1327.	1.9	131
8384	Developing a Case-Based Blended Learning Ecosystem to Optimize Precision Medicine: Reducing Overdiagnosis and Overtreatment. <i>Healthcare (Switzerland)</i> , 2018, 6, 78.	1.0	3
8385	Systematic identification of non-coding pharmacogenomic landscape in cancer. <i>Nature Communications</i> , 2018, 9, 3192.	5.8	73
8386	Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer. <i>Scientific Reports</i> , 2018, 8, 11807.	1.6	43
8387	The Antitumor Effect of Xihuang Pill on Treg Cells Decreased in Tumor Microenvironment of 4T1 Breast Tumor-Bearing Mice by PI3K/AKT-AP-1 Signaling Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-13.	0.5	7
8388	Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 88.	2.2	53
8389	Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer. <i>PLoS Genetics</i> , 2018, 14, e1007571.	1.5	33

#	ARTICLE	IF	CITATIONS
8390	Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. <i>Annals of Translational Medicine</i> , 2018, 6, 163-163.	0.7	86
8391	Overexpression of Romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4233-4246.	1.0	17
8392	The Cancer Omics Atlas: an integrative resource for cancer omics annotations. <i>BMC Medical Genomics</i> , 2018, 11, 63.	0.7	20
8393	Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy. <i>World Journal of Clinical Oncology</i> , 2018, 9, 33-41.	0.9	23
8394	Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization. <i>Drug Delivery and Translational Research</i> , 2018, 8, 1508-1526.	3.0	28
8395	Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. <i>Cancer Management and Research</i> , 2018, Volume 10, 2475-2488.	0.9	22
8396	The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 981-986.	2.0	27
8397	Effective nivolumab sequential thoracic radiotherapy in elderly patients with advanced squamous cell lung cancer: did radiation therapy play a role? A case report. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4621-4629.	1.0	6
8398	Patient performance status and cancer immunotherapy efficacy: a meta-analysis. <i>Medical Oncology</i> , 2018, 35, 132.	1.2	52
8399	Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 947-957.	1.4	46
8400	Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1291-1299.	0.8	47
8401	CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-10.	0.6	20
8402	Dynamic Macrophages: Understanding Mechanisms of Activation as Guide to Therapy for Atherosclerotic Vascular Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 97.	1.1	21
8403	Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 1613.	2.2	83
8404	Personalized cancer neoantigen vaccines come of age. <i>Theranostics</i> , 2018, 8, 4238-4246.	4.6	51
8405	Notch3 inhibits epithelial-mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression. <i>Oncogenesis</i> , 2018, 7, 59.	2.1	31
8406	Rat models of 17 β -estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention. <i>Physiological Genomics</i> , 2018, 50, 215-234.	1.0	33
8407	PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin – case report. <i>BMC Nephrology</i> , 2018, 19, 210.	0.8	30

#	ARTICLE	IF	CITATIONS
8408	Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. <i>Journal of Ovarian Research</i> , 2018, 11, 43.	1.3	60
8409	Multi-drug therapy in breast cancer: are there any alternatives?. <i>Annals of Translational Medicine</i> , 2018, 6, 221-221.	0.7	0
8410	The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses. <i>Oncolytic Virotherapy</i> , 2017, Volume 7, 25-35.	6.0	7
8411	Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance. <i>Cancers</i> , 2018, 10, 274.	1.7	83
8412	Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site. <i>Cells</i> , 2018, 7, 108.	1.8	23
8413	Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300-mediated NF- κ B signaling. <i>International Journal of Oncology</i> , 2018, 53, 1469-1480.	1.4	63
8414	Molecular imaging of T cell co-regulator factor B7-H3 with ^{89}Zr -DS-5573a. <i>Theranostics</i> , 2018, 8, 4199-4209.	4.6	32
8415	Immune checkpoint therapy in liver cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 110.	3.5	255
8416	Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. <i>Oncologist</i> , 2018, 23, 991-997.	1.9	86
8417	Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1231-1238.	2.0	23
8418	Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 1741-1748.	1.2	13
8419	Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. <i>Nature Medicine</i> , 2018, 24, 724-730.	15.2	637
8420	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	15.2	900
8421	PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5766-E5775.	3.3	17
8422	RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2261-2270.	0.7	45
8423	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). <i>Oncologist</i> , 2018, 23, 1407-e136.	1.9	127
8424	DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. <i>Anti-Cancer Drugs</i> , 2018, 29, 774-785.	0.7	12
8425	Clinical significance of androgen receptor expression in triple negative breast cancer—an immunohistochemistry study. <i>Oncology Letters</i> , 2018, 15, 10008-10016.	0.8	26

#	ARTICLE	IF	CITATIONS
8426	Tissue-specific DNA methylation loss during ageing and carcinogenesis is linked to chromosome structure, replication timing and cell division rates. <i>Nucleic Acids Research</i> , 2018, 46, 7022-7039.	6.5	33
8427	Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. <i>Genome Research</i> , 2018, 28, 1217-1227.	2.4	172
8428	Low Levels of T Cell Exhaustion in Tuberculous Lung Granulomas. <i>Infection and Immunity</i> , 2018, 86, .	1.0	34
8429	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018, 24, 5347-5356.	3.2	253
8430	Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. <i>Cancer Discovery</i> , 2018, 8, 935-943.	7.7	130
8431	Association of <i>ERBB</i> Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1189.	3.4	53
8432	Prevalence of <i>PDL1</i> Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. <i>JAMA Oncology</i> , 2018, 4, 1237.	3.4	214
8433	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1335.	3.4	36
8434	The promise and challenges of immune agonist antibody development in cancer. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 509-527.	21.5	270
8435	Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 205-213.	0.4	7
8436	Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. <i>Nature Communications</i> , 2018, 9, 2351.	5.8	253
8437	Precision Medicine in Head and Neck Cancer: Myth or Reality?. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491877958.	0.6	18
8438	The role of abemaciclib in treatment of advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	14
8439	Cancer epigenetics: Moving forward. <i>PLoS Genetics</i> , 2018, 14, e1007362.	1.5	364
8440	Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma. <i>Internal Medicine</i> , 2018, 57, 3149-3152.	0.3	1
8441	Breast Cancer Immunotherapy: An Update. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341877480.	0.6	37
8442	Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers. <i>Scientific Reports</i> , 2018, 8, 8990.	1.6	31
8443	Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. <i>PLoS ONE</i> , 2018, 13, e0190058.	1.1	37

#	ARTICLE	IF	CITATIONS
8444	Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial. <i>PLoS ONE</i> , 2018, 13, e0192227.	1.1	78
8445	The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. <i>PLoS ONE</i> , 2018, 13, e0193018.	1.1	64
8446	Methods for improving the immunogenicity and efficacy of cancer vaccines. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 765-784.	1.4	13
8447	Cancer immunotherapy: broadening the scope of targetable tumours. <i>Open Biology</i> , 2018, 8, .	1.5	162
8448	Current state of therapeutic development for rare cancers in Japan, and proposals for improvement. <i>Cancer Science</i> , 2018, 109, 1731-1737.	1.7	11
8449	Macrophages Promote Circulating Tumor Cell-Mediated Local Recurrence following Radiotherapy in Immunosuppressed Patients. <i>Cancer Research</i> , 2018, 78, 4241-4252.	0.4	36
8450	Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring. <i>Internal Medicine</i> , 2018, 57, 3157-3162.	0.3	31
8451	The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. <i>Scientific Reports</i> , 2018, 8, 8703.	1.6	43
8452	Risk, Prediction and Prevention of Hereditary Breast Cancer – Large-Scale Genomic Studies in Times of Big and Smart Data. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 481-492.	0.8	38
8453	Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. <i>Nature Communications</i> , 2018, 9, 2237.	5.8	329
8454	Non-conventional Inhibitory CD4+Foxp3 ^{hi} PD-1 ^{hi} T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018, 33, 1017-1032.e7.	7.7	112
8455	Harnessing Tumor Evolution to Circumvent Resistance. <i>Trends in Genetics</i> , 2018, 34, 639-651.	2.9	49
8456	TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 4126-4137.	0.4	109
8457	The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4763-4770.	3.2	30
8458	Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. <i>Cancer Discovery</i> , 2018, 8, 944-957.	7.7	313
8459	Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples. <i>Npj Genomic Medicine</i> , 2018, 3, 14.	1.7	33
8460	Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies. <i>Scientific Reports</i> , 2018, 8, 8810.	1.6	13
8461	The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature. <i>Internal Medicine</i> , 2018, 57, 3135-3139.	0.3	23

#	ARTICLE	IF	CITATIONS
8462	The complex ecosystem in non small cell lung cancer invasion. PLoS Computational Biology, 2018, 14, e1006131.	1.5	7
8463	PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease. PLoS Medicine, 2018, 15, e1002497.	3.9	49
8464	Telomerase reverse transcriptase coordinates with the epithelial-to-mesenchymal transition through a feedback loop to define properties of breast cancer stem cells. Biology Open, 2018, 7, .	0.6	25
8465	Observational study of chemotherapy-induced Clostridium difficile infection in patients with lung cancer. International Journal of Clinical Oncology, 2018, 23, 1046-1051.	1.0	2
8466	Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. Journal of Neuro-Oncology, 2018, 140, 55-62.	1.4	25
8467	Pruritus Associated with Targeted Anticancer Therapies and Their Management. Dermatologic Clinics, 2018, 36, 315-324.	1.0	28
8468	EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. Developmental Cell, 2018, 45, 681-695.e4.	3.1	497
8469	Immunogenic effects of chemotherapy-induced tumor cell death. Genes and Diseases, 2018, 5, 194-203.	1.5	219
8470	CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis. PLoS ONE, 2018, 13, e0190158.	1.1	33
8471	Expression of multiple immune checkpoint molecules on T _H 1/2 cells in malignant ascites from epithelial ovarian carcinoma. Oncology Letters, 2018, 15, 6457-6468.	0.8	37
8472	Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. International Journal of Clinical Oncology, 2018, 23, 1052-1059.	1.0	27
8473	Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report. Gynecologic Oncology Reports, 2018, 25, 74-77.	0.3	42
8474	Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer. Scientific Reports, 2018, 8, 8960.	1.6	14
8475	Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities. Journal of Cell Biology, 2018, 217, 2951-2974.	2.3	35
8476	Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment. Precision Clinical Medicine, 2018, 1, 29-48.	1.3	79
8477	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer, 2018, 7, 235-260.	4.2	426
8478	Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer. PLoS Computational Biology, 2018, 14, e1006192.	1.5	26
8479	AR negative triple negative or "quadruple negative" breast cancers in African American women have an enriched basal and immune signature. PLoS ONE, 2018, 13, e0196909.	1.1	47

#	ARTICLE	IF	CITATIONS
8480	Profiles of brain metastases: Prioritization of therapeutic targets. <i>International Journal of Cancer</i> , 2018, 143, 3019-3026.	2.3	31
8481	Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. <i>Gastric Cancer</i> , 2018, 21, 1064-1070.	2.7	25
8482	Targeting EGFR in Lung Cancer: Current Standards and Developments. <i>Drugs</i> , 2018, 78, 893-911.	4.9	61
8483	Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. <i>Oncogene</i> , 2018, 37, 5701-5718.	2.6	24
8484	Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 180-188.	3.0	74
8485	The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. <i>Clinical and Translational Oncology</i> , 2019, 21, 206-212.	1.2	59
8486	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. <i>Liver Cancer</i> , 2019, 8, 110-120.	4.2	46
8487	New horizons in breast cancer: the promise of immunotherapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 117-125.	1.2	21
8488	Nanotechnology approaches to eradicating HIV reservoirs. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 138, 48-63.	2.0	35
8489	AhR ligand aminoflavone suppresses β -integrin Src Akt signaling to attenuate tamoxifen resistance in breast cancer cells. <i>Journal of Cellular Physiology</i> , 2019, 234, 108-121.	2.0	31
8491	Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. <i>Oncogene</i> , 2019, 38, 47-59.	2.6	20
8492	Quantifying heterogeneity of expression data based on principal components. <i>Bioinformatics</i> , 2019, 35, 553-559.	1.8	1
8493	Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application. <i>Briefings in Bioinformatics</i> , 2019, 20, 1795-1811.	3.2	112
8494	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 1063-1069.	3.2	257
8495	A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 486-495.	2.3	23
8496	Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England. <i>PharmacoEconomics - Open</i> , 2019, 3, 43-54.	0.9	15
8497	Functional genomics: paving the way for more successful cancer immunotherapy. <i>Briefings in Functional Genomics</i> , 2019, 18, 86-98.	1.3	6
8498	Immunotherapy in CNS cancers: the role of immune cell trafficking. <i>Neuro-Oncology</i> , 2019, 21, 37-46.	0.6	76

#	ARTICLE	IF	CITATIONS
8499	Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 69-77.	3.0	60
8500	New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. <i>Gastric Cancer</i> , 2019, 22, 77-90.	2.7	41
8501	Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 147-154.	2.7	16
8502	Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 69-76.	2.7	45
8503	Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada. <i>Supportive Care in Cancer</i> , 2019, 27, 219-227.	1.0	5
8504	Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 155-171.	4.2	25
8505	Acquired resistance to cancer immunotherapy. <i>Seminars in Immunopathology</i> , 2019, 41, 31-40.	2.8	34
8506	The T-win® technology: immune-modulating vaccines. <i>Seminars in Immunopathology</i> , 2019, 41, 87-95.	2.8	19
8507	Immune checkpoints and cancer in the immunogenomics era. <i>Briefings in Functional Genomics</i> , 2019, 18, 133-139.	1.3	19
8508	Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer. <i>Targeted Oncology</i> , 2019, 14, 1-12.	1.7	12
8509	Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. <i>Clinical and Translational Oncology</i> , 2019, 21, 363-372.	1.2	57
8510	Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer. <i>Oncogene</i> , 2019, 38, 360-374.	2.6	39
8511	Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015. <i>Investigational New Drugs</i> , 2019, 37, 166-174.	1.2	4
8512	Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 86-95.	1.9	11
8513	Relationships Between Human-Extracted MRI Tumor Phenotypes of Breast Cancer and Clinical Prognostic Indicators Including Receptor Status and Molecular Subtype. <i>Current Problems in Diagnostic Radiology</i> , 2019, 48, 467-472.	0.6	11
8514	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019, 21, 26-36.	0.6	114
8515	A comparison of mechanistic signaling pathway activity analysis methods. <i>Briefings in Bioinformatics</i> , 2019, 20, 1655-1668.	3.2	33
8516	The role of PIP5K1 β /pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1 β inhibitor. <i>Oncogene</i> , 2019, 38, 375-389.	2.6	29

#	ARTICLE	IF	CITATIONS
8517	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. <i>Oncogene</i> , 2019, 38, 390-405.	2.6	149
8518	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. <i>Oncologist</i> , 2019, 24, 319-326.	1.9	29
8519	Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer. <i>Briefings in Functional Genomics</i> , 2019, 18, 119-128.	1.3	4
8520	Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. <i>Cellular and Molecular Immunology</i> , 2019, 16, 28-39.	4.8	57
8521	Does patient age influence anti-cancer immunity?. <i>Seminars in Immunopathology</i> , 2019, 41, 125-131.	2.8	60
8522	Essential preanalytics in <sc>PD</sc>-1 immunocytochemistry. <i>Histopathology</i> , 2019, 74, 362-364.	1.6	6
8523	Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy. <i>Science Advances</i> , 2019, 5, eaaw6081.	4.7	58
8524	Exercise Behaviors and Fatigue in Patients Receiving Immunotherapy for Advanced Melanoma: A Cross-Sectional Survey via Social Media. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541986443.	0.8	14
8525	Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID ^h mice. <i>Oncology Letters</i> , 2019, 18, 1539-1547.	0.8	6
8526	Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. <i>Oncology Letters</i> , 2019, 18, 2140-2147.	0.8	35
8527	Genomic landscape of ductal carcinoma in situ and association with progression. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 307-316.	1.1	17
8528	Functional and Phenotypic Characterization of Tumor-Infiltrating Leukocyte Subsets and Their Contribution to the Pathogenesis of Hepatocellular Carcinoma and Cholangiocarcinoma. <i>Translational Oncology</i> , 2019, 12, 1468-1479.	1.7	9
8529	Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16987-16996.	3.3	14
8530	Glycosylation and its implications in breast cancer. <i>Expert Review of Proteomics</i> , 2019, 16, 665-680.	1.3	60
8531	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. <i>Radiology</i> , 2019, 293, 15-29.	3.6	45
8532	Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	15
8533	A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-6.	0.2	8
8534	Uveal Melanoma Metastatic to the Liver: Treatment Trends and Outcomes. <i>Ocular Oncology and Pathology</i> , 2019, 5, 323-332.	0.5	15

#	ARTICLE	IF	CITATIONS
8535	Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers. <i>Breast Cancer Research</i> , 2019, 21, 87.	2.2	26
8536	DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade. <i>Frontiers in Genetics</i> , 2019, 10, 724.	1.1	12
8537	TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2. <i>Frontiers in Immunology</i> , 2019, 10, 1644.	2.2	24
8538	Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma. <i>Frontiers in Immunology</i> , 2019, 10, 1756.	2.2	35
8539	Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies. <i>Frontiers in Medicine</i> , 2019, 6, 174.	1.2	49
8540	Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. <i>Frontiers in Oncology</i> , 2019, 9, 618.	1.3	9
8541	Designing gene panels for tumor mutational burden estimation: the need to shift from "correlation" to "accuracy"., 2019, 7, 206.		37
8542	A case of checkpoint inhibitor-induced celiac disease. , 2019, 7, 203.		25
8543	Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. <i>Cell</i> , 2019, 178, 933-948.e14.	13.5	301
8544	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Molecular Sciences</i> , 2019, 20, 3821.	1.8	116
8545	Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis. <i>Aging</i> , 2019, 11, 501-522.	1.4	25
8546	Extensive exploration of T cell heterogeneity in cancers by single cell sequencing. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 410-418.	0.7	3
8547	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. <i>Radiation Oncology</i> , 2019, 14, 141.	1.2	285
8548	Immune signature profiling identified prognostic factors for gastric cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 463-470.	0.7	56
8549	Different Features of Tumor-Associated NK Cells in Patients With Low-Grade or High-Grade Peritoneal Carcinomatosis. <i>Frontiers in Immunology</i> , 2019, 10, 1963.	2.2	21
8550	Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. <i>Frontiers in Oncology</i> , 2019, 9, 666.	1.3	113
8551	The Role of Exosomal MicroRNAs in the Tumor Microenvironment of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3884.	1.8	74
8552	Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1183.	1.0	38

#	ARTICLE	IF	CITATIONS
8553	Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-13.	3.2	194
8554	Immunogenicity of pembrolizumab in patients with advanced tumors. , 2019, 7, 212.		27
8555	<p>Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 199-219.	0.7	1
8556	Pneumonitis as a complication of immune system targeting drugs?â€”a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. <i>Journal of Thoracic Disease</i> , 2019, 11, 521-534.	0.6	16
8557	The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatmentâ€”Review. <i>Frontiers in Immunology</i> , 2019, 10, 2043.	2.2	7
8558	Sonographic Findings in Inflammatory Arthritis Secondary to Immune Checkpoint Inhibition: A Case Series. <i>ACR Open Rheumatology</i> , 2019, 1, 303-307.	0.9	30
8559	Delayed nivolumabâ€”induced hepatotoxicity during pazopanib treatment for metastatic renal cell carcinoma: An autopsy case. <i>IJU Case Reports</i> , 2019, 2, 272-275.	0.1	5
8560	Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. <i>MAbs</i> , 2019, 11, 1443-1451.	2.6	97
8561	A plea for taking all available clinical information into account when assessing the predictive value of omics data. <i>BMC Medical Research Methodology</i> , 2019, 19, 162.	1.4	10
8562	Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers. <i>Breast Cancer Research</i> , 2019, 21, 85.	2.2	18
8563	The genomic landscape of estrogen receptor β binding sites in mouse mammary gland. <i>PLoS ONE</i> , 2019, 14, e0220311.	1.1	25
8564	Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986190.	1.4	31
8565	Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody. <i>BMC Cancer</i> , 2019, 19, 805.	1.1	9
8566	Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib. <i>Journal of Thoracic Disease</i> , 2019, 11, 2664-2668.	0.6	3
8567	Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 652-662.	0.6	106
8568	Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice. <i>Translational Lung Cancer Research</i> , 2019, 8, 202-207.	1.3	12
8569	Low Photosensitizer Dose and Early Radiotherapy Enhance Antitumor Immune Response of Photodynamic Therapy-Based Dendritic Cell Vaccination. <i>Frontiers in Oncology</i> , 2019, 9, 811.	1.3	47
8570	Tumor mutation burden: from comprehensive mutational screening to the clinic. <i>Cancer Cell International</i> , 2019, 19, 209.	1.8	116

#	ARTICLE	IF	CITATIONS
8571	Tuning the Tumor Myeloid Microenvironment to Fight Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1611.	2.2	96
8572	Mechanistic Studies of Idiosyncratic DILI: Clinical Implications. <i>Frontiers in Pharmacology</i> , 2019, 10, 837.	1.6	61
8573	The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3934.	1.8	69
8574	Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. <i>Theranostics</i> , 2019, 9, 5085-5104.	4.6	29
8575	The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 709-725.	1.4	14
8576	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. <i>Advances in Therapy</i> , 2019, 36, 2638-2678.	1.3	145
8577	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 480-490.	4.2	57
8578	Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition. , 2019, 7, 216.		56
8579	Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/ β -catenin inhibitor-treated livers. <i>Oncotarget</i> , 2019, 10, 3013-3026.	0.8	13
8580	PD-L1 Distribution and Perspective for Cancer Immunotherapyâ€”Blockade, Knockdown, or Inhibition. <i>Frontiers in Immunology</i> , 2019, 10, 2022.	2.2	270
8581	Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression. <i>Tuberculosis and Respiratory Diseases</i> , 2019, 82, 227.	0.7	9
8582	Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy. , 2019, 7, 251513551986223.	1.4	28
8583	PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors. , 2019, 7, 217.		47
8584	Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer. , 2019, 7, 218.		64
8585	Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models. <i>Cells</i> , 2019, 8, 889.	1.8	151
8586	Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. <i>PLoS ONE</i> , 2019, 14, e0221301.	1.1	16
8587	Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention. <i>EMBO Journal</i> , 2019, 38, e100852.	3.5	69
8588	Examining Peripheral and Tumor Cellular Immune in Patients With Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1767.	2.2	44

#	ARTICLE	IF	CITATIONS
8589	Development of a Human Cytomegalovirus (HCMV)-Based Therapeutic Cancer Vaccine Uncovers a Previously Unsuspected Viral Block of MHC Class I Antigen Presentation. <i>Frontiers in Immunology</i> , 2019, 10, 1776.	2.2	15
8590	Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. <i>Frontiers in Immunology</i> , 2019, 10, 1848.	2.2	56
8591	The Tumor Microenvironment in Colorectal Cancer Therapy. <i>Cancers</i> , 2019, 11, 1172.	1.7	52
8592	Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1395-1408.	5.1	247
8593	Pentaerythritol-based lipid A bolsters the antitumor efficacy of a polyanhydride particle-based cancer vaccine. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 21, 102055.	1.7	11
8594	Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer. <i>Neoplasia</i> , 2019, 21, 932-944.	2.3	59
8595	Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer. <i>Translational Oncology</i> , 2019, 12, 1453-1460.	1.7	6
8596	Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. <i>Nature Reviews Cancer</i> , 2019, 19, 495-509.	12.8	573
8597	Engineering universal cells that evade immune detection. <i>Nature Reviews Immunology</i> , 2019, 19, 723-733.	10.6	123
8598	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkr049.	1.4	11
8599	The Goldilocks Window of Personalized Chemotherapy: Getting the Immune Response Just Right. <i>Cancer Research</i> , 2019, 79, 5302-5315.	0.4	38
8600	The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer. <i>Cancers</i> , 2019, 11, 1205.	1.7	57
8601	A Review of Immune-Mediated Adverse Events in Melanoma. <i>Oncology and Therapy</i> , 2019, 7, 101-120.	1.0	23
8602	Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?. <i>Journal of Global Oncology</i> , 2019, 5, 1-5.	0.5	36
8603	Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. <i>PLoS ONE</i> , 2019, 14, e0220570.	1.1	20
8604	Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. <i>Translational Lung Cancer Research</i> , 2019, 8, 302-316.	1.3	91
8605	Lactate Induces Pro-tumor Reprogramming in Intratumoral Plasmacytoid Dendritic Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1878.	2.2	85
8606	Regulation of Immunity in Breast Cancer. <i>Cancers</i> , 2019, 11, 1080.	1.7	43

#	ARTICLE	IF	CITATIONS
8607	Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. <i>Theranostics</i> , 2019, 9, 4678-4687.	4.6	61
8608	The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 1835.	2.2	440
8609	Clinical Implications of Chromosomal Instability (CIN) and Kinetochores Abnormalities in Breast Cancers. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 707-721.	1.6	14
8610	A tumor-targeted immune checkpoint blocker. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15889-15894.	3.3	21
8611	Every which way? On predicting tumor evolution using cancer progression models. <i>PLoS Computational Biology</i> , 2019, 15, e1007246.	1.5	27
8612	Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study. <i>Translational Lung Cancer Research</i> , 2019, 8, 258-267.	1.3	17
8613	Clinical implications of mismatch repair deficiency in prostate cancer. <i>Future Oncology</i> , 2019, 15, 2395-2411.	1.1	29
8614	Human Tumor-Infiltrating Dendritic Cells: From in Situ Visualization to High-Dimensional Analyses. <i>Cancers</i> , 2019, 11, 1082.	1.7	36
8615	Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC. <i>Cells</i> , 2019, 8, 809.	1.8	76
8616	Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 83.	1.3	21
8617	Neutralizing monoclonal antibody against Dickkopf2 impairs lung cancer progression via activating NK cells. <i>Cell Death Discovery</i> , 2019, 5, 123.	2.0	13
8618	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 617-630.	8.2	132
8619	Mechanisms of immunotherapy resistance: lessons from glioblastoma. <i>Nature Immunology</i> , 2019, 20, 1100-1109.	7.0	421
8620	Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics. <i>Leukemia and Lymphoma</i> , 2019, 60, 3350-3362.	0.6	1
8621	Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 663-677.	1.4	3
8622	Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases. <i>ESMO Open</i> , 2019, 4, e000464.	2.0	21
8623	Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. , 2019, 7, 196.		62
8624	Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies. <i>Frontiers in Immunology</i> , 2019, 10, 1791.	2.2	19

#	ARTICLE	IF	CITATIONS
8625	CA-170 â€œ A Potent Small-Molecule PD-L1 Inhibitor or Not?. <i>Molecules</i> , 2019, 24, 2804.	1.7	103
8626	The Spatial and Genomic Hierarchy of Tumor Ecosystems Revealed by Single-Cell Technologies. <i>Trends in Cancer</i> , 2019, 5, 411-425.	3.8	44
8627	The impact of DNA methylation on the cancer proteome. <i>PLoS Computational Biology</i> , 2019, 15, e1007245.	1.5	9
8628	Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 2208-2211.	0.6	13
8629	<p>Evaluating the prognostic significance of tumor-infiltrating lymphocytes in solid tumor: practice of a standardized method from the International Immuno-Oncology Biomarkers Working Group</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 6815-6827.	0.9	14
8630	Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review. <i>Diagnostics</i> , 2019, 9, 87.	1.3	94
8631	Whole Grain Consumption for the Prevention and Treatment of Breast Cancer. <i>Nutrients</i> , 2019, 11, 1769.	1.7	43
8632	Realâ€world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced nonâ€small cell lung cancer. <i>Cancer</i> , 2019, 125, 4019-4032.	2.0	115
8633	Does Industryâ€Conducted Allâ€Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?. <i>Clinical and Translational Science</i> , 2019, 12, 505-512.	1.5	4
8634	Upregulation of PDâ€1 follows tumour development in the AOM/DSS model of inflammationâ€induced colorectal cancer in mice. <i>Immunology</i> , 2019, 158, 35-46.	2.0	32
8635	RF_Purify: a novel tool for comprehensive analysis of tumor-purity in methylation array data based on random forest regression. <i>BMC Bioinformatics</i> , 2019, 20, 428.	1.2	36
8636	Comparison of tumor cell numbers and 22C3 PD-L1 expression between cryobiopsy and transbronchial biopsy with endobronchial ultrasonography-guide sheath for lung cancer. <i>Respiratory Research</i> , 2019, 20, 185.	1.4	21
8637	Identification of Potential Crucial Genes and Key Pathways in Breast Cancer Using Bioinformatic Analysis. <i>Frontiers in Genetics</i> , 2019, 10, 695.	1.1	161
8638	Expression of the immune checkpoint receptor TIGIT in seminoma. <i>Oncology Letters</i> , 2019, 18, 1497-1502.	0.8	7
8639	Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus. <i>Oncology Letters</i> , 2019, 18, 1872-1880.	0.8	12
8640	Programmed Death-1 Restrains the Germinal Center in Type 1 Diabetes. <i>Journal of Immunology</i> , 2019, 203, 844-852.	0.4	15
8641	Efficacy and Safety of Baviximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. <i>Targeted Oncology</i> , 2019, 14, 541-550.	1.7	18
8642	Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine. <i>JCI Insight</i> , 2019, 4, .	2.3	28

#	ARTICLE	IF	CITATIONS
8643	Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 364.	3.5	63
8644	Expression of PD-L1 in primary breast carcinoma and lymph node metastases. <i>Surgical and Experimental Pathology</i> , 2019, 2, .	0.2	14
8645	A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229). <i>Oncologist</i> , 2019, 24, 1439-1445.	1.9	40
8646	<p>Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7707-7719.	0.9	45
8647	Mutation-Derived Neoantigens for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1856.	2.2	78
8648	Reactive Oxygen Species in the Tumor Microenvironment: An Overview. <i>Cancers</i> , 2019, 11, 1191.	1.7	288
8649	Circulating DNAâ€Based Sequencing Guided Anlotinib Therapy in Nonâ€Small Cell Lung Cancer. <i>Advanced Science</i> , 2019, 6, 1900721.	5.6	30
8650	Systematic Immunotherapy Target Discovery Using Genome-Scale InÂVivo CRISPR Screens in CD8ÂT Cells. <i>Cell</i> , 2019, 178, 1189-1204.e23.	13.5	189
8651	Depletion of the Transcriptional Coactivator Amplified in Breast Cancer 1 (AIB1) Uncovers Functionally Distinct Subpopulations in Triple-Negative Breast Cancer. <i>Neoplasia</i> , 2019, 21, 963-973.	2.3	2
8652	Modular fabrication of intelligent material-tissue interfaces for bioinspired and biomimetic devices. <i>Progress in Materials Science</i> , 2019, 106, 100589.	16.0	72
8653	Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100879.	0.2	6
8654	A probabilistic multi-omics data matching method for detecting sample errors in integrative analysis. <i>GigaScience</i> , 2019, 8, .	3.3	9
8655	Phase II study of nedaplatin and amrubicin as firstâ€line treatment for advanced squamous cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1764-1769.	0.8	3
8656	Hyperprogression after immunotherapy in patients with malignant tumors of digestive system. <i>BMC Cancer</i> , 2019, 19, 705.	1.1	27
8657	GENT2: an updated gene expression database for normal and tumor tissues. <i>BMC Medical Genomics</i> , 2019, 12, 101.	0.7	236
8658	Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. , 2019, 7, 183.		231
8659	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
8660	Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. <i>Frontiers in Pharmacology</i> , 2019, 10, 726.	1.6	20

#	ARTICLE	IF	CITATIONS
8661	Vaccinations for Colorectal Cancer: Progress, Strategies, and Novel Adjuvants. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3403.	1.8	20
8662	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. <i>Journal of Clinical Medicine</i> , 2019, 8, 998.	1.0	28
8663	Novel Delivery Systems for Checkpoint Inhibitors. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 74.	0.7	24
8664	The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy. <i>Journal of Cancer</i> , 2019, 10, 3102-3111.	1.2	27
8665	A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma. <i>ELife</i> , 2019, 8, .	2.8	69
8666	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. <i>Cancer Cell</i> , 2019, 36, 168-178.e4.	7.7	240
8667	Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2019, 8, 214-226.	1.3	66
8668	<p>Clinical genetic features and related survival implications in patients with surgically resected&Arlarge-cell lung cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5489-5499.	0.9	5
8669	<p>Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4605-4620.	1.0	22
8670	<p>Monoclonal antibody AC10364 inhibits cell proliferation in 5-fluorouracil resistant hepatocellular carcinoma via apoptotic pathways</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5053-5067.	1.0	6
8671	Fluid shear stress stimulates breast cancer cells to display invasive and chemoresistant phenotypes while upregulating <i>PLAU</i> in a 3D bioreactor. <i>Biotechnology and Bioengineering</i> , 2019, 116, 3084-3097.	1.7	44
8672	Cancer and heart disease: associations and relations. <i>European Journal of Heart Failure</i> , 2019, 21, 1515-1525.	2.9	120
8673	Factors related to the quality of life in patients with bone metastases. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 441-448.	1.7	19
8674	Quantitation of Super Basic Peptides in Biological Matrices by a Generic Perfluoropentanoic Acid-Based Liquid Chromatography&Ae“Mass Spectrometry Method. <i>Journal of the American Society for Mass Spectrometry</i> , 2019, 30, 1779-1789.	1.2	3
8675	Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. , 2019, 7, 189.		41
8676	<p>Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5293-5298.	1.0	20
8677	Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1171-1181.	1.0	42
8678	Oncolytic Viruses: Priming Time for Cancer Immunotherapy. <i>BioDrugs</i> , 2019, 33, 485-501.	2.2	90

#	ARTICLE	IF	CITATIONS
8679	Disseminated blastomycosis in a patient on pembrolizumab for metastatic melanoma. <i>JAAD Case Reports</i> , 2019, 5, 580-581.	0.4	4
8680	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. <i>Npj Precision Oncology</i> , 2019, 3, 18.	2.3	25
8681	Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. <i>Cancers</i> , 2019, 11, 995.	1.7	53
8682	Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival. <i>Cancers</i> , 2019, 11, 996.	1.7	28
8683	Kidney Complications of Immune Checkpoint Inhibitors: A Review. <i>American Journal of Kidney Diseases</i> , 2019, 74, 529-537.	2.1	55
8684	Role of tumor gene mutations in treatment response to immune checkpoint blockades. <i>Precision Clinical Medicine</i> , 2019, 2, 100-109.	1.3	11
8685	MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-9.	1.9	17
8686	Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-10.	0.4	21
8687	Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy. <i>Case Reports in Obstetrics and Gynecology</i> , 2019, 2019, 1-8.	0.2	3
8688	Smoking history influences the prognostic value of peripheral naïve CD4+ T cells in advanced non-small cell lung cancer. <i>Cancer Cell International</i> , 2019, 19, 176.	1.8	8
8689	Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma. <i>Experimental Hematology and Oncology</i> , 2019, 8, 14.	2.0	10
8690	Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study. <i>PLoS ONE</i> , 2019, 14, e0218434.	1.1	18
8691	Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 1919-1928.	0.6	13
8692	Tertiary Lymphoid Organs in Cancer Immunology: Mechanisms and the New Strategy for Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1398.	2.2	45
8693	Tetramethylpyrazine Enhances the Antitumor Effect of Paclitaxel by Inhibiting Angiogenesis and Inducing Apoptosis. <i>Frontiers in Pharmacology</i> , 2019, 10, 707.	1.6	25
8694	RELB: A novel prognostic marker for glioblastoma as identified by population-based analysis. <i>Oncology Letters</i> , 2019, 18, 386-394.	0.8	7
8695	Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. <i>Oncology Letters</i> , 2019, 18, 161-168.	0.8	2
8696	Inhibition of insulin-like growth factor 1 signaling synergistically enhances the tumor suppressive role of triptolide in triple-negative breast cancer cells. <i>Oncology Letters</i> , 2019, 18, 822-829.	0.8	5

#	ARTICLE	IF	CITATIONS
8697	A long way to the battlefield: CAR T cell therapy against solid cancers. <i>Journal of Cancer</i> , 2019, 10, 3112-3123.	1.2	26
8698	Lymphocytic subsets play distinct roles in heart diseases. <i>Theranostics</i> , 2019, 9, 4030-4046.	4.6	17
8699	Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors. , 2019, 7, 172.		26
8700	Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. , 2019, 7, 173.		76
8701	Predicting drug activity against cancer cells by random forest models based on minimal genomic information and chemical properties. <i>PLoS ONE</i> , 2019, 14, e0219774.	1.1	75
8702	Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. <i>Journal of Clinical Medicine</i> , 2019, 8, 1014.	1.0	41
8703	Ellagic acid exerts antitumor effects via the PI3K signaling pathway in endometrial cancer. <i>Journal of Cancer</i> , 2019, 10, 3303-3314.	1.2	33
8704	Immune response profile of primary tumour, sentinel and non-sentinel axillary lymph nodes related to metastasis in breast cancer: an immunohistochemical point of view. <i>Histochemistry and Cell Biology</i> , 2019, 152, 177-193.	0.8	13
8705	Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. , 2019, 7, 177.		32
8706	CONFIGURE: A pipeline for identifying context specific regulatory modules from gene expression data and its application to breast cancer. <i>BMC Medical Genomics</i> , 2019, 12, 97.	0.7	5
8707	Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 75.	6.9	84
8708	Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. , 2019, 7, 182.		29
8709	Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy. , 2019, 7, 181.		15
8710	Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study. , 2019, 7, 180.		137
8711	A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an <i>EGFR</i> Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages. <i>Internal Medicine</i> , 2019, 58, 3033-3037.	0.3	7
8712	Immune-Related Adverse Events: A Case-Based Approach. <i>Frontiers in Oncology</i> , 2019, 9, 530.	1.3	31
8713	Personalized medicine: From diagnostic to adaptive. <i>Biomedical Journal</i> , 2022, 45, 132-142.	1.4	8
8714	Inflammation and Cancer: Triggers, Mechanisms, and Consequences. <i>Immunity</i> , 2019, 51, 27-41.	6.6	1,946

#	ARTICLE	IF	CITATIONS
8715	HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 5482-5489.	0.4	86
8716	<p></p>A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4955-4973.	1.0	9
8717	Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer. <i>BioMed Research International</i> , 2019, 2019, 1-10.	0.9	23
8718	Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1654.	2.2	101
8719	Possible Biomarkers for Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 935.	1.7	35
8720	Considering B7-CD28 as a family through sequence and structure. <i>Experimental Biology and Medicine</i> , 2019, 244, 1577-1583.	1.1	7
8721	Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression. <i>Oncogene</i> , 2019, 38, 5942-5958.	2.6	10
8722	Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. <i>Oncogene</i> , 2019, 38, 6159-6171.	2.6	45
8723	Human regulatory T cells (Treg) and their response to cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 215-228.	0.4	9
8724	Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. , 2019, 7, 165.		135
8725	Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2019, 10, 4018-4025.	0.8	118
8726	Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Nonâ€“Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e196879.	2.8	161
8727	Systemic immuneâ€“inflammation index, neutrophilâ€“lymphocyte ratio, plateletâ€“lymphocyte ratio can predict clinical outcomes in patients with metastatic nonâ€“smallâ€“cell lung cancer treated with nivolumab. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22964.	0.9	171
8728	Challenges for realâ€“time intraoperative diagnosis of high risk histology in lung adenocarcinoma: A necessity for sublobar resection. <i>Thoracic Cancer</i> , 2019, 10, 1663-1668.	0.8	23
8729	Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series. , 2019, 7, 170.		36
8730	<p></p>Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 6397-6410.	0.9	13
8731	Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e56.	1.0	19
8732	Pseudoprogression presenting as intestinal perforation in nonâ€“small cell lung cancer treated with antiâ€“PDâ€“1: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 132-134.	0.4	9

#	ARTICLE	IF	CITATIONS
8733	Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer. <i>Oncology Letters</i> , 2019, 18, 449-455.	0.8	13
8734	Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. <i>Journal of Cancer</i> , 2019, 10, 3070-3078.	1.2	10
8735	Checkpoint inhibitors in ovarian cancer: A review of preclinical data. <i>Gynecologic Oncology Reports</i> , 2019, 29, 48-54.	0.3	47
8736	NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. <i>Nature Communications</i> , 2019, 10, 3251.	5.8	55
8737	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. , 2019, 7, 192.		60
8738	Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 813.e1-813.e9.	0.8	16
8739	Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1798-1804.	0.8	37
8740	Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. <i>Frontiers in Immunology</i> , 2019, 10, 1505.	2.2	34
8741	Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 1009.	1.7	2
8742	Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract. <i>Marine Drugs</i> , 2019, 17, 421.	2.2	13
8743	Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology. <i>Journal of Cancer</i> , 2019, 10, 3717-3727.	1.2	46
8744	Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression. <i>Cancer Immunology Research</i> , 2019, 7, 1497-1510.	1.6	98
8745	Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2019, 26, 300-308.	0.9	4
8746	Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer. <i>JAMA Network Open</i> , 2019, 2, e197621.	2.8	25
8747	Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 1020-1030.	1.9	86
8748	Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. , 2019, 7, 194.		47
8749	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019, 11, 1033.	1.7	160
8750	CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1359-1368.	2.0	23

#	ARTICLE	IF	CITATIONS
8751	Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM). <i>Scientific Reports</i> , 2019, 9, 10173.	1.6	6
8752	First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. , 2019, 7, 195.		32
8753	Consensus Guidelines on Genetic Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. <i>Annals of Surgical Oncology</i> , 2019, 26, 3025-3031.	0.7	184
8754	A 23 gene-based molecular prognostic score precisely predicts overall survival of breast cancer patients. <i>EBioMedicine</i> , 2019, 46, 150-159.	2.7	64
8755	Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents. <i>ACS Omega</i> , 2019, 4, 12584-12597.	1.6	19
8756	The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression. <i>Npj Breast Cancer</i> , 2019, 5, 22.	2.3	19
8757	AP-1 Transcription Factors as Regulators of Immune Responses in Cancer. <i>Cancers</i> , 2019, 11, 1037.	1.7	166
8758	Clinical Trajectories and Causes of Death in Septic Patients with a Low APACHE II Score. <i>Journal of Clinical Medicine</i> , 2019, 8, 1064.	1.0	12
8759	The biological functions and clinical applications of exosomes in lung cancer. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4613-4633.	2.4	90
8760	Computational approaches for characterizing the tumor immune microenvironment. <i>Immunology</i> , 2019, 158, 70-84.	2.0	30
8761	Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer. , 2019, 7, 198.		28
8762	Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer. <i>PLoS ONE</i> , 2019, 14, e0220306.	1.1	21
8763	Immunotherapies for the Treatment of Uveal Melanoma—History and Future. <i>Cancers</i> , 2019, 11, 1048.	1.7	56
8764	PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer. <i>Cancers</i> , 2019, 11, 1050.	1.7	50
8765	Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with ²¹³ Bismuth and ¹⁷⁷ Lutetium. <i>Pharmaceutics</i> , 2019, 11, 348.	2.0	18
8766	The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. <i>Current Oncology Reports</i> , 2019, 21, 76.	1.8	18
8767	T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation. <i>Immuno-Oncology Technology</i> , 2019, 2, 1-10.	0.2	18
8768	Structural insights and binding analysis for determining the molecular bases for programmed cell death protein ligand-1 inhibition. <i>MedChemComm</i> , 2019, 10, 1810-1818.	3.5	5

#	ARTICLE	IF	CITATIONS
8769	CAR T cells for brain tumors: Lessons learned and road ahead. <i>Immunological Reviews</i> , 2019, 290, 60-84.	2.8	151
8770	T Cell Dysfunction in Cancer Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1719.	2.2	219
8771	The Statistical Evaluation of Treatment and Outcomes in Head and Neck Squamous Cell Carcinoma Clinical Trials. <i>Frontiers in Oncology</i> , 2019, 9, 634.	1.3	3
8772	Clinical utility of ramucirumab in non-small-cell lung cancer. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 133-137.	3.0	6
8773	Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5389-5393.	1.0	10
8774	Estradiol promotes the progression of ER+ breast cancer through methylation-mediated RSK4 inactivation. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5907-5916.	1.0	10
8775	Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer. <i>Bladder Cancer</i> , 2019, 5, 131-145.	0.2	11
8776	Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?. <i>Cancers</i> , 2019, 11, 1055.	1.7	40
8777	Downregulation of STAT3, β -Catenin, and Notch-1 by Single and Combinations of siRNA Treatment Enhance Chemosensitivity of Wild Type and Doxorubicin Resistant MCF7 Breast Cancer Cells to Doxorubicin. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3696.	1.8	26
8778	Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine. <i>EPMA Journal</i> , 2019, 10, 291-305.	3.3	14
8779	Characterizing Thermal Transitions of IgG with Mass Spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2019, 30, 2438-2445.	1.2	18
8780	Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer. <i>Genome Research</i> , 2019, 29, 1429-1441.	2.4	27
8781	The influence of microenvironment on tumor immunotherapy. <i>FEBS Journal</i> , 2019, 286, 4160-4175.	2.2	64
8782	An Atypical Presentation of Lichen Planus-Like Reaction from Pembrolizumab. <i>Case Reports in Dermatological Medicine</i> , 2019, 2019, 1-5.	0.1	7
8783	MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer. <i>Cancer Research</i> , 2019, 79, 5812-5825.	0.4	6
8784	Characterization and Comparison of GTR Expression in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6501-6510.	3.2	37
8785	Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. <i>Oncologist</i> , 2019, 24, e1197-e1211.	1.9	15
8786	The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1940.	2.2	66

#	ARTICLE	IF	CITATIONS
8787	Rescue of DNA damage after constricted migration reveals a mechano-regulated threshold for cell cycle. <i>Journal of Cell Biology</i> , 2019, 218, 2545-2563.	2.3	76
8788	TuBA: Tunable biclustering algorithm reveals clinically relevant tumor transcriptional profiles in breast cancer. <i>GigaScience</i> , 2019, 8, .	3.3	6
8789	Acute Interstitial Nephritis With Karyomegalic Epithelial Cells After Nivolumab Treatment—Two Case Reports. <i>Clinical Medicine Insights: Case Reports</i> , 2019, 12, 117954761985364.	0.3	11
8790	A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. <i>AAPS Journal</i> , 2019, 21, 79.	2.2	53
8791	<p>Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer</p>. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 47-56.	1.3	12
8792	PD-1 Blockade During Post-partum Involution Reactivates the Anti-tumor Response and Reduces Lymphatic Vessel Density. <i>Frontiers in Immunology</i> , 2019, 10, 1313.	2.2	15
8793	Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1325.	2.2	55
8794	Granulomatosis With Polyangiitis in a Patient on Programmed Death-1 Inhibitor for Advanced Non-small-cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 478.	1.3	15
8795	Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. <i>Cancers</i> , 2019, 11, 872.	1.7	50
8796	DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 877.	1.7	151
8797	Nivolumab treatment beyond RECISTâ€defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019, 125, 3208-3218.	2.0	64
8798	Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5561-5571.	3.2	64
8799	IL-9 Exerts Antitumor Effects in Colon Cancer and Transforms the Tumor Microenvironment <i>In Vivo</i>. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381985773.	0.8	29
8800	Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. <i>Oncotarget</i> , 2019, 10, 3835-3839.	0.8	8
8801	Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population. <i>Melanoma Management</i> , 2019, 6, MMT13.	0.1	13
8802	Downregulated expression of human leukocyte antigen class I heavy chain is associated with poor prognosis in nonâ€smallâ€cell lung cancer. <i>Oncology Letters</i> , 2019, 18, 117-126.	0.8	10
8803	LILRB1 Blockade Enhances Bispecific T Cell Engager Antibodyâ€Induced Tumor Cell Killing by Effector CD8+ T Cells. <i>Journal of Immunology</i> , 2019, 203, 1076-1087.	0.4	35
8804	Emerging Role of Genomics and Cell-Free DNA in Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 68.	1.3	9

#	ARTICLE	IF	CITATIONS
8805	Advances in Targeted Therapies for Triple-Negative Breast Cancer. <i>Drugs</i> , 2019, 79, 1217-1230.	4.9	71
8806	Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma. <i>Journal of Bone Oncology</i> , 2019, 17, 100245.	1.0	17
8807	Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer. <i>BMC Cancer</i> , 2019, 19, 615.	1.1	7
8808	Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 67.	6.9	54
8809	Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. <i>Clinical Drug Investigation</i> , 2019, 39, 931-938.	1.1	27
8810	Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 507-520.	1.6	39
8811	LobSig is a multigene predictor of outcome in invasive lobular carcinoma. <i>Npj Breast Cancer</i> , 2019, 5, 18.	2.3	28
8812	Case report: mutation analysis of primary pulmonary lymphoepithelioma-like carcinoma via whole-exome sequencing. <i>Diagnostic Pathology</i> , 2019, 14, 67.	0.9	3
8813	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. <i>Frontiers in Immunology</i> , 2019, 10, 1337.	2.2	85
8814	Molecular background of skin melanoma development and progression: therapeutic implications. <i>Postepy Dermatologii i Alergologii</i> , 2019, 36, 129-138.	0.4	22
8815	Modifiable Host Factors in Melanoma: Emerging Evidence for Obesity, Diet, Exercise, and the Microbiome. <i>Current Oncology Reports</i> , 2019, 21, 72.	1.8	29
8816	Next-generation sequencing and biomarkers for gastric cancer: what is the future?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984818.	1.4	9
8817	Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 673.	1.6	52
8818	Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study. <i>Radiotherapy and Oncology</i> , 2019, 138, 114-120.	0.3	11
8819	Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. <i>Gynecologic Oncology</i> , 2019, 154, 461-466.	0.6	27
8820	TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. <i>Nature</i> , 2019, 571, 211-218.	13.7	934
8821	T Regulatory CD4+CD25+FoxP3+ Lymphocytes in the Peripheral Blood of Left-Sided Colorectal Cancer Patients. <i>Medicina (Lithuania)</i> , 2019, 55, 307.	0.8	7
8822	Blocking the PD-1/PD-L1 axis in dendritic cell-stimulated Cytokine-Induced Killer Cells with pembrolizumab enhances their therapeutic effects against hepatocellular carcinoma. <i>Journal of Cancer</i> , 2019, 10, 2578-2587.	1.2	22

#	ARTICLE	IF	CITATIONS
8823	Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGF β ² and focal adhesion kinase (FAK) signaling. <i>Cell Death Discovery</i> , 2019, 5, 109.	2.0	63
8824	Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines. <i>BMC Medical Genomics</i> , 2019, 12, 92.	0.7	29
8825	The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 207.	1.8	194
8826	Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation. <i>Cancers</i> , 2019, 11, 911.	1.7	40
8827	Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2051-2059.	1.2	30
8828	Immunotherapy in Ovarian Cancer. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 447-464.	0.6	27
8829	Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. <i>Cancers</i> , 2019, 11, 920.	1.7	10
8830	ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer. <i>Cells</i> , 2019, 8, 678.	1.8	73
8831	<i>In Vitro</i> Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1187-1192.	1.3	22
8832	PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. <i>Modern Pathology</i> , 2019, 32, 1734-1743.	2.9	38
8833	The macrophage checkpoint CD47 : SIRP α for recognition of "self" cells: from clinical trials of blocking antibodies to mechanobiological fundamentals. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2019, 374, 20180217.	1.8	32
8834	Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature. <i>Journal of Diabetes and Metabolic Disorders</i> , 2019, 18, 267-272.	0.8	19
8836	TP53 Mutations Promote Immunogenic Activity in Breast Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-19.	0.6	51
8837	Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 2215-2234.	2.0	20
8838	Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1401.	2.2	71
8839	Mouse CD8+NKT-like cells exert dual cytotoxicity against mouse tumor cells and myeloid-derived suppressor cells. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1303-1315.	2.0	27
8840	Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome. <i>International Journal of Clinical Oncology</i> , 2019, 24, 999-1011.	1.0	57
8841	Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion. <i>BMC Biotechnology</i> , 2019, 19, 67.	1.7	15

#	ARTICLE	IF	CITATIONS
8842	Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer. <i>Journal of Nanobiotechnology</i> , 2019, 17, 110.	4.2	37
8843	DNA methylation exploration for ARDS: a multi-omics and multi-microarray interrelated analysis. <i>Journal of Translational Medicine</i> , 2019, 17, 345.	1.8	20
8844	Tumour heterogeneity revealed by unsupervised decomposition of dynamic contrast-enhanced magnetic resonance imaging is associated with underlying gene expression patterns and poor survival in breast cancer patients. <i>Breast Cancer Research</i> , 2019, 21, 112.	2.2	21
8845	Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses. <i>Genome Biology</i> , 2019, 20, 210.	3.8	171
8846	Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 1489.	1.7	37
8847	Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5129.	1.8	19
8848	Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5138.	1.8	14
8849	Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer. <i>Immuno-Oncology Technology</i> , 2019, 3, 1-7.	0.2	20
8850	SiCloneFit: Bayesian inference of population structure, genotype, and phylogeny of tumor clones from single-cell genome sequencing data. <i>Genome Research</i> , 2019, 29, 1847-1859.	2.4	97
8851	Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. , 2019, 7, 267.		156
8852	Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	52
8853	SWOG S1400C (NCT02154490)â€”A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alterationâ€”Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1853-1859.	0.5	58
8854	CD137 ligand feedback upregulates PDâ€”1 expression on lung cancer via T cell production of IFNâ€”Î³. <i>Thoracic Cancer</i> , 2019, 10, 2225-2235.	0.8	9
8855	Challenges and Opportunities for Childhood Cancer Drug Development. <i>Pharmacological Reviews</i> , 2019, 71, 671-697.	7.1	13
8856	Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. <i>ESMO Open</i> , 2019, 4, e000531.	2.0	60
8857	Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. <i>Future Science OA</i> , 2019, 5, FSO421.	0.9	26
8858	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3021-3036.	1.2	20
8859	CEACAM1 structure and function in immunity and its therapeutic implications. <i>Seminars in Immunology</i> , 2019, 42, 101296.	2.7	62

#	ARTICLE	IF	CITATIONS
8860	Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 1083-1091.	0.6	32
8861	<p></p>PD-1 inhibitors dependent CD8⁺ T cells inhibit mouse colon cancer cell metastasis</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6961-6971.	1.0	11
8862	NK Cell-Fc Receptors Advance Tumor Immunotherapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1667.	1.0	17
8863	Emergent Nanotechnological Strategies for Systemic Chemotherapy against Melanoma. <i>Nanomaterials</i> , 2019, 9, 1455.	1.9	34
8864	Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. <i>Nature Communications</i> , 2019, 10, 4706.	5.8	460
8865	Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 962.	1.6	29
8866	Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment. <i>Biomedicines</i> , 2019, 7, 80.	1.4	0
8867	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. <i>Cancers</i> , 2019, 11, 1554.	1.7	73
8868	Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells. <i>Vaccines</i> , 2019, 7, 149.	2.1	63
8869	Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors. <i>Postepy Dermatologii I Alergologii</i> , 2019, 36, 382-391.	0.4	24
8870	CAR-T cell therapy: a potential new strategy against prostate cancer. , 2019, 7, 258.		61
8871	One man's trash-another man's treasure: fecal transplantation. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 623-625.	0.7	0
8872	<p></p>Recent advances and application of PD-1 blockade in sarcoma</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6887-6896.	1.0	17
8873	The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 897.	1.3	29
8874	Integrated Transcriptome and Pathway Analyses Revealed Multiple Activated Pathways in Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 910.	1.3	44
8875	PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer. <i>Cancers</i> , 2019, 11, 1566.	1.7	7
8876	Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and Therapeutic Opportunities. <i>Cancers</i> , 2019, 11, 1569.	1.7	121
8877	Programmed death ligand¹/programmed death¹ inhibition therapy and programmed death ligand¹ expression in urothelial bladder carcinoma. <i>Chronic Diseases and Translational Medicine</i> , 2019, 5, 170-177.	0.9	3

#	ARTICLE	IF	CITATIONS
8878	Preparation of Immunotherapy Liposomal-Loaded Thermal-Responsive Hydrogel Carrier in the Local Treatment of Breast Cancer. <i>Polymers</i> , 2019, 11, 1592.	2.0	14
8879	Targeting AKT for cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 977-988.	1.9	150
8880	miR-149-3p reverses CD8 ⁺ T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells. <i>Open Biology</i> , 2019, 9, 190061.	1.5	43
8881	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987554.	1.4	21
8882	Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4931.	1.8	44
8883	Cyclin D1 is Associated with Radiosensitivity of Triple-Negative Breast Cancer Cells to Proton Beam Irradiation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4943.	1.8	17
8884	Rebalancing Immune Homeostasis to Treat Autoimmune Diseases. <i>Trends in Immunology</i> , 2019, 40, 888-908.	2.9	83
8885	Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. <i>Journal of Translational Medicine</i> , 2019, 17, 338.	1.8	16
8886	Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. <i>Genome Medicine</i> , 2019, 11, 61.	3.6	134
8887	Nectin-4 Expression Is an Independent Prognostic Biomarker and Associated With Better Survival in Triple-Negative Breast Cancer. <i>Frontiers in Medicine</i> , 2019, 6, 200.	1.2	22
8888	Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 972.	1.3	17
8889	Monoclonal Antibodies in Dermatocology—State of the Art and Future Perspectives. <i>Cancers</i> , 2019, 11, 1420.	1.7	9
8890	The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus. <i>Cells</i> , 2019, 8, 1213.	1.8	14
8891	Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2019, 22, 341.	0.8	39
8892	The Role of Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio in Predicting Neoadjuvant Chemotherapy Response in Breast Cancer. <i>Journal of Breast Cancer</i> , 2019, 22, 425.	0.8	27
8893	WNT/ β -Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 2293.	2.2	165
8894	Tumor Endothelial Heterogeneity in Cancer Progression. <i>Cancers</i> , 2019, 11, 1511.	1.7	66
8895	Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review. <i>Oncology Reviews</i> , 2019, 13, 425.	0.8	14

#	ARTICLE	IF	CITATIONS
8896	Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1747-1757.	2.0	16
8897	Immunomodulatory aspects in the progression and treatment of oral malignancy. <i>Japanese Dental Science Review</i> , 2019, 55, 113-120.	2.0	33
8898	Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. <i>Seminars in Immunology</i> , 2019, 42, 101305.	2.7	189
8899	Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?. <i>Current Urology Reports</i> , 2019, 20, 68.	1.0	27
8900	TGF β 2 and activin A in the tumor microenvironment in colorectal cancer. <i>Gene Reports</i> , 2019, 17, 100501.	0.4	7
8901	Ipilimumab-induced renal granulomatous arteritis: a case report. <i>BMC Nephrology</i> , 2019, 20, 366.	0.8	11
8902	Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?. <i>Mediastinum</i> , 2019, 3, 35-35.	0.6	38
8903	Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma. <i>Current Drug Safety</i> , 2019, 14, 225-229.	0.3	5
8904	Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma. <i>Melanoma Management</i> , 2019, 6, MMT20.	0.1	9
8905	Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis. <i>Frontiers in Oncology</i> , 2019, 9, 944.	1.3	17
8906	The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2019, 10, 1063.	1.6	7
8907	Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	9
8908	Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	0.6	6
8909	Ovarian cancer: Current status and strategies for improving therapeutic outcomes. <i>Cancer Medicine</i> , 2019, 8, 7018-7031.	1.3	197
8910	Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 . <i>Medicine Research</i> , 2019, 11, 225-236.	0.6	133
8911	NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. <i>Annals of Translational Medicine</i> , 2019, 7, 105-105.	0.7	143
8912	Intermittent hypoxia enhances the tumor programmed death ligand 1 expression in a mouse model of sleep apnea. <i>Annals of Translational Medicine</i> , 2019, 7, 97-97.	0.7	18
8913	Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 3794-3807.	0.6	3

#	ARTICLE	IF	CITATIONS
8914	Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation. <i>Communications Biology</i> , 2019, 2, 392.	2.0	39
8915	Lynch syndrome-associated ultra-hypermuted pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003863.	0.5	21
8916	Gastric Cancer in the Era of Immune Checkpoint Blockade. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	0.6	23
8917	A hierarchical integration deep flexible neural forest framework for cancer subtype classification by integrating multi-omics data. <i>BMC Bioinformatics</i> , 2019, 20, 527.	1.2	69
8918	Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. <i>Journal of Translational Medicine</i> , 2019, 17, 355.	1.8	150
8919	Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. <i>Journal of Hematology and Oncology</i> , 2019, 12, 111.	6.9	93
8920	Recent advances in nanotheranostics for triple negative breast cancer treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 430.	3.5	121
8921	pTuneos: prioritizing tumor neoantigens from next-generation sequencing data. <i>Genome Medicine</i> , 2019, 11, 67.	3.6	53
8922	<p>Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 151-166.	1.8	25
8923	The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 577-582.	1.0	52
8924	Artificial Intelligence in Lung Cancer Pathology Image Analysis. <i>Cancers</i> , 2019, 11, 1673.	1.7	152
8925	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenable Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019, 11, 1689.	1.7	44
8926	PD-L1/PD-1 Axis in Glioblastoma Multiforme. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5347.	1.8	115
8927	Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation. <i>Journal of Cancer</i> , 2019, 10, 5549-5556.	1.2	4
8928	Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1. <i>Current Breast Cancer Reports</i> , 2019, 11, 217-227.	0.5	7
8929	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. <i>Nature Communications</i> , 2019, 10, 5114.	5.8	64
8930	Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. <i>Nucleic Acids Research</i> , 2020, 48, D1031-D1041.	6.5	488
8931	ER-Negative Breast Cancer Is Highly Responsive to Cholesterol Metabolite Signalling. <i>Nutrients</i> , 2019, 11, 2618.	1.7	14

#	ARTICLE	IF	CITATIONS
8932	Reactive versus Constitutive: Reconcile the Controversial Results about the Prognostic Value of PD-L1 Expression in cancer. <i>International Journal of Biological Sciences</i> , 2019, 15, 1933-1941.	2.6	2
8933	Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor. <i>Theranostics</i> , 2019, 9, 5542-5557.	4.6	54
8934	Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment. <i>Theranostics</i> , 2019, 9, 7648-7665.	4.6	106
8935	Peptide-based materials for cancer immunotherapy. <i>Theranostics</i> , 2019, 9, 7807-7825.	4.6	77
8936	Integrin $\alpha_3\beta_1$ -targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy. <i>Theranostics</i> , 2019, 9, 7948-7960.	4.6	64
8937	Surgery for Metastatic Melanoma: an Evolving Concept. <i>Current Oncology Reports</i> , 2019, 21, 98.	1.8	11
8938	Immune regulation and cytotoxic T cell activation of IL-10 agonists â€“ Preclinical and clinical experience. <i>Seminars in Immunology</i> , 2019, 44, 101325.	2.7	30
8939	Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. <i>Molecular Cancer</i> , 2019, 18, 155.	7.9	723
8940	Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. , 2019, 7, 286.		92
8941	Signaling Complexity Measured by Shannon Entropy and Its Application in Personalized Medicine. <i>Frontiers in Genetics</i> , 2019, 10, 930.	1.1	22
8942	Deconvolution of the Genomic and Epigenomic Interaction Landscape of Triple-Negative Breast Cancer. <i>Cancers</i> , 2019, 11, 1692.	1.7	8
8943	Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1699.	1.7	81
8944	Balancing STAT Activity as a Therapeutic Strategy. <i>Cancers</i> , 2019, 11, 1716.	1.7	18
8945	The Prognostic Role of CD8+ T Lymphocytes in Childhood Adrenocortical Carcinomas Compared to Ki-67, PD-1, PD-L1, and the Weiss Score. <i>Cancers</i> , 2019, 11, 1730.	1.7	25
8946	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5452.	1.8	53
8947	Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1864.	1.0	13
8948	Advances in Engineering Cells for Cancer Immunotherapy. <i>Theranostics</i> , 2019, 9, 7889-7905.	4.6	44
8949	CXCR3: Here to stay to enhance cancer immunotherapy?. <i>EBioMedicine</i> , 2019, 49, 11-12.	2.7	3

#	ARTICLE	IF	CITATIONS
8950	Aptamers as Modular Components of Therapeutic Nucleic Acid Nanotechnology. ACS Nano, 2019, 13, 12301-12321.	7.3	102
8951	New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?. Annals of Translational Medicine, 2019, 7, S135-S135.	0.7	13
8952	Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 1033.	1.3	15
8953	If we build it they will come: targeting the immune response to breast cancer. Npj Breast Cancer, 2019, 5, 37.	2.3	132
8954	Overexpression of MiR-146a-5p Upregulates lncRNA HOTAIR in Triple-Negative Breast Cancer Cells and Predicts Poor Prognosis. Technology in Cancer Research and Treatment, 2019, 18, 153303381988294.	0.8	20
8955	Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment. Frontiers in Oncology, 2019, 9, 1104.	1.3	69
8956	Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target. Cancers, 2019, 11, 1683.	1.7	38
8957	PRODIGY: personalized prioritization of driver genes. Bioinformatics, 2020, 36, 1831-1839.	1.8	32
8958	Radium-223 mechanism of action: implications for use in treatment combinations. Nature Reviews Urology, 2019, 16, 745-756.	1.9	71
8959	Topology Consistency of Disease-specific Differential Co-regulatory Networks. BMC Bioinformatics, 2019, 20, 550.	1.2	4
8960	Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer. Respiratory Research, 2019, 20, 248.	1.4	12
8961	Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status. , 2019, 7, 297.		24
8962	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. Journal of Oncology Practice, 2019, 15, e825-e834.	2.5	37
8963	Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer?. Translational Lung Cancer Research, 2019, 8, 559-574.	1.3	5
8964	Insights Into Mechanisms of Tumor and Immune System Interaction: Association With Wound Healing. Frontiers in Oncology, 2019, 9, 1115.	1.3	21
8965	Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics, 2019, 9, 7906-7923.	4.6	100
8966	New formulation of the Gompertz equation to describe the kinetics of untreated tumors. PLoS ONE, 2019, 14, e0224978.	1.1	6
8967	Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients. Frontiers in Oncology, 2019, 9, 1111.	1.3	15

#	ARTICLE	IF	CITATIONS
8968	Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1254.	1.6	21
8969	The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 1260.	1.6	18
8970	Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 462.	3.5	41
8971	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. <i>Cancer Cell</i> , 2019, 36, 471-482.	7.7	280
8972	B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. <i>Cell</i> , 2019, 179, 1191-1206.e21.	13.5	291
8973	Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival. <i>Gynecologic Oncology</i> , 2019, 155, 483-488.	0.6	10
8974	Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. <i>BMC Cancer</i> , 2019, 19, 1019.	1.1	48
8975	Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. <i>Frontiers in Immunology</i> , 2019, 10, 2664.	2.2	214
8976	Evolution and Impact of Subclonal Mutations in Papillary Thyroid Cancer. <i>American Journal of Human Genetics</i> , 2019, 105, 959-973.	2.6	22
8977	Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. <i>Cancer Cell</i> , 2019, 36, 483-497.e15.	7.7	247
8978	Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. <i>EBioMedicine</i> , 2019, 48, 178-190.	2.7	66
8979	The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis. <i>IScience</i> , 2019, 21, 249-260.	1.9	39
8980	Increased Incidence of Colon Tumors in AOM-Treated Apc1638N/+ Mice Reveals Higher Frequency of Tumor Associated Neutrophils in Colon Than Small Intestine. <i>Frontiers in Oncology</i> , 2019, 9, 1001.	1.3	9
8981	Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1040.	1.3	38
8982	EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies. <i>Frontiers in Oncology</i> , 2019, 9, 1044.	1.3	146
8983	Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 1055.	1.3	18
8984	Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 1173.	1.6	35
8985	The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2019, 11, 1713.	1.7	56

#	ARTICLE	IF	CITATIONS
8986	Novel Targets for the Treatment of Melanoma. <i>Current Oncology Reports</i> , 2019, 21, 97.	1.8	15
8987	Novel Immunotherapy Combinations. <i>Current Oncology Reports</i> , 2019, 21, 96.	1.8	12
8988	Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3K $\hat{\pm}$ inhibitors. <i>Science</i> , 2019, 366, 714-723.	6.0	185
8989	IFN- $\hat{\beta}$ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer. <i>BMC Cancer</i> , 2019, 19, 1053.	1.1	37
8990	The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. <i>Journal of Translational Medicine</i> , 2019, 17, 357.	1.8	88
8991	Prediction of PD-L1 inhibition effects for HIV-infected individuals. <i>PLoS Computational Biology</i> , 2019, 15, e1007401.	1.5	10
8992	Comprehensive Outline of Whole Exome Sequencing Data Analysis Tools Available in Clinical Oncology. <i>Cancers</i> , 2019, 11, 1725.	1.7	27
8993	PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms. <i>Journal of Clinical Medicine</i> , 2019, 8, 1833.	1.0	19
8994	Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer. <i>Medicina (Lithuania)</i> , 2019, 55, 723.	0.8	18
8995	Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies. <i>Frontiers in Pharmacology</i> , 2019, 10, 1453.	1.6	24
8996	Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 23714-23723.	3.3	101
8997	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. , 2019, 7, 302.		72
8998	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. , 2019, 7, 299.		108
8999	Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 962-970.	1.3	17
9001	SpliceHetero: An information theoretic approach for measuring spliceomic intratumor heterogeneity from bulk tumor RNA-seq. <i>PLoS ONE</i> , 2019, 14, e0223520.	1.1	11
9002	Ligand Binding Induces Agonistic-Like Conformational Adaptations in Helix 12 of Progesterone Receptor Ligand Binding Domain. <i>Frontiers in Chemistry</i> , 2019, 7, 315.	1.8	7
9003	A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2514.	2.2	7
9004	Identification of Single Nucleotide Polymorphism in Red Clover (<i>Trifolium pratense</i> L.) Using Targeted Genomic Amplicon Sequencing and RNA-seq. <i>Frontiers in Plant Science</i> , 2019, 10, 1257.	1.7	8

#	ARTICLE	IF	CITATIONS
9005	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. <i>Antibodies</i> , 2019, 8, 51.	1.2	32
9006	Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. <i>Cancers</i> , 2019, 11, 1597.	1.7	77
9007	Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma. <i>Cancer</i> , 2019, 125, 4148-4157.	2.0	21
9008	The role and therapeutic implications of T cells in cancer of the lung. <i>Clinical and Translational Immunology</i> , 2019, 8, e1076.	1.7	25
9009	Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2084-2096.	0.5	48
9010	Engineering of a novel subnanomolar affinity fibronectin III domain binder targeting human programmed death-ligand 1. <i>Protein Engineering, Design and Selection</i> , 2019, 32, 231-240.	1.0	6
9011	Monitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis. <i>Thoracic Cancer</i> , 2019, 10, 2183-2187.	0.8	12
9012	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.	3.2	50
9013	Targeted and novel therapy in advanced gastric cancer. <i>Experimental Hematology and Oncology</i> , 2019, 8, 25.	2.0	53
9014	The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. , 2019, 7, 278.		586
9015	Molecular subtyping of mammary Paget's disease using immunohistochemistry. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2019, 40, 440-446.	0.5	8
9016	KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score $\geq 49\%$. <i>Journal of Thoracic Disease</i> , 2019, 11, S1963-S1965.	0.6	6
9017	Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab. <i>Journal of Thoracic Disease</i> , 2019, 11, 3757-3768.	0.6	29
9018	<p><p>Indole-2-Carboxamide Derivative LG25 Inhibits Triple-Negative Breast Cancer Growth By Suppressing Akt/mTOR/NF-κB Signalling Pathway</p>. <i>Drug Design, Development and Therapy</i>, 2019, Volume 13, 3539-3550.</p>	2.0	7
9019	<p><p>An Immunoscore System Based On CD3⁺ And CD8⁺ Infiltrating Lymphocytes Densities To Predict The Outcome Of Patients With Colorectal Adenocarcinoma</p>. <i>OncoTargets and Therapy</i>, 2019, Volume 12, 8663-8673.</p>	1.0	24
9020	<p><p>Decreased IFIT2 Expression In Human Non-Small-Cell Lung Cancer Tissues Is Associated With Cancer Progression And Poor Survival Of The Patients</p>. <i>OncoTargets and Therapy</i>, 2019, Volume 12, 8139-8149.</p>	1.0	12
9021	<p><p>Application Of Adoptive Immunotherapy In Ovarian Cancer</p>. <i>OncoTargets and Therapy</i>, 2019, Volume 12, 7975-7991.</p>	1.0	4
9022	Myeloid-Derived Suppressor Cells and Pancreatic Cancer: Implications in Novel Therapeutic Approaches. <i>Cancers</i> , 2019, 11, 1627.	1.7	59

#	ARTICLE	IF	CITATIONS
9023	Present Scenario of Bioconjugates in Cancer Therapy: A Review. International Journal of Molecular Sciences, 2019, 20, 5243.	1.8	37
9024	Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors. Immuno-Oncology Technology, 2019, 3, 15-23.	0.2	14
9025	Î±vÎ²3-integrin regulates PD-L1 expression and is involved in cancer immune evasion. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20141-20150.	3.3	57
9026	Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22246-22251.	3.3	142
9027	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. JNCI Cancer Spectrum, 2019, 3, pkz071.	1.4	4
9028	An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy. Immunology, 2019, 158, 136-149.	2.0	10
9029	The Course of Immune Stimulation by Photodynamic Therapy: Bridging Fundamentals of Photochemically Induced Immunogenic Cell Death to the Enrichment of T-Cell Repertoire. Photochemistry and Photobiology, 2019, 95, 1288-1305.	1.3	96
9030	Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988042.	1.4	41
9031	Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer, 2019, 19, 974.	1.1	104
9032	Breast cancer histopathology image classification through assembling multiple compact CNNs. BMC Medical Informatics and Decision Making, 2019, 19, 198.	1.5	100
9033	Mapping genetic interactions in cancer: a road to rational combination therapies. Genome Medicine, 2019, 11, 62.	3.6	16
9034	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. , 2019, 7, 269.		94
9035	PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S139-S146.	1.3	11
9036	A "Crazy Paving" Pattern on CT Scan in a Patient Treated with Pembrolizumab. Current Drug Safety, 2019, 14, 242-245.	0.3	4
9037	Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet. Frontiers in Genetics, 2019, 10, 1125.	1.1	28
9038	Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors. Frontiers in Genetics, 2019, 10, 1141.	1.1	34
9039	DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity. Frontiers in Immunology, 2019, 10, 2559.	2.2	84
9040	The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab. Biomolecules, 2019, 9, 629.	1.8	10

#	ARTICLE	IF	CITATIONS
9041	Three discipline collaborative radiation therapy (3DCRT) special debate: The single most important factor in determining the future of SBRT is immune response. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 6-12.	0.8	1
9042	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019, 49, 1457-1973.	1.6	766
9043	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. <i>Cancer Control</i> , 2019, 26, 107327481987054.	0.7	16
9044	Evolution of the nonsense-mediated decay pathway is associated with decreased cytolytic immune infiltration. <i>PLoS Computational Biology</i> , 2019, 15, e1007467.	1.5	15
9045	Role of stanniocalcin-1 in breast cancer (Review). <i>Oncology Letters</i> , 2019, 18, 3946-3953.	0.8	20
9046	Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing. <i>Bioinformatics</i> , 2019, 35, 2818-2826.	1.8	36
9047	Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis. <i>BMC Cancer</i> , 2019, 19, 43.	1.1	31
9048	Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. <i>Molecular Cancer</i> , 2019, 18, 7.	7.9	48
9049	Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients. <i>Cancers</i> , 2019, 11, 1619.	1.7	9
9050	Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 158.	1.8	29
9051	Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook. <i>Journal of Clinical Medicine</i> , 2019, 8, 1777.	1.0	87
9052	Tumor Suppression of Ras GTPase-Activating Protein RASA5 through Antagonizing Ras Signaling Perturbation in Carcinomas. <i>IScience</i> , 2019, 21, 1-18.	1.9	12
9053	Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22699-22709.	3.3	226
9054	Sustained Response and Rationale of Programmed Cell Death-1-Targeting for Progressive Multifocal Leukoencephalopathy. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz374.	0.4	17
9055	High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 2006-2012.	0.8	52
9056	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 2117-2123.	0.8	9
9057	Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. <i>Clinical Cancer Research</i> , 2019, 25, 6801-6814.	3.2	27
9058	BC200 overexpression contributes to luminal and triple negative breast cancer pathogenesis. <i>BMC Cancer</i> , 2019, 19, 994.	1.1	14

#	ARTICLE	IF	CITATIONS
9059	Host immune response to anti-cancer camptothecin conjugated cyclodextrin-based polymers. <i>Journal of Biomedical Science</i> , 2019, 26, 85.	2.6	21
9060	The role of exosomal PD-L1 in tumor progression and immunotherapy. <i>Molecular Cancer</i> , 2019, 18, 146.	7.9	236
9061	Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy. , 2019, 7, 270.		74
9062	Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. , 2019, 7, 274.		26
9063	Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value. <i>Oncologist</i> , 2019, 24, e1055-e1069.	1.9	36
9064	The Tumor Microenvironment as a Regulator of Endocrine Resistance in Breast Cancer. <i>Frontiers in Endocrinology</i> , 2019, 10, 547.	1.5	26
9065	IL-36 β Promotes CD8+ T Cell Activation and Antitumor Immune Responses by Activating mTORC1. <i>Frontiers in Immunology</i> , 2019, 10, 1803.	2.2	23
9066	A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1832.	2.2	73
9067	Targeting Angiogenesis With Peptide Vaccines. <i>Frontiers in Immunology</i> , 2019, 10, 1924.	2.2	15
9068	Novel Biomarkers for Personalized Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1223.	1.7	36
9069	The Changing Therapeutic Landscape of Metastatic Renal Cancer. <i>Cancers</i> , 2019, 11, 1227.	1.7	49
9070	Association of miR-100 expression with clinicopathological features and prognosis of patients with lung cancer. <i>Oncology Letters</i> , 2019, 18, 1318-1322.	0.8	5
9071	Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491986848.	0.6	15
9072	Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?. <i>Frontiers in Immunology</i> , 2019, 10, 1816.	2.2	52
9073	Aryl Hydrocarbon Receptor Modulates Carcinogenesis and Maintenance of Skin Cancers. <i>Frontiers in Medicine</i> , 2019, 6, 194.	1.2	18
9074	Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line. <i>Frontiers in Oncology</i> , 2019, 9, 886.	1.3	20
9075	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. <i>Genes and Diseases</i> , 2019, 6, 232-246.	1.5	44
9076	Phagocytosis checkpoints as new targets for cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 568-586.	12.8	557

#	ARTICLE	IF	CITATIONS
9077	The Prognostic Landscape of Tumor-Infiltrating Immune Cells and Immune Checkpoints in Glioblastoma. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381986994.	0.8	29
9078	Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 815.	1.1	35
9079	Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1250.	1.7	18
9080	Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer. <i>Oncology Letters</i> , 2019, 18, 2427-2433.	0.8	10
9081	Expression of programmed cell deathâ€‘ligand 1 in primary testicular diffuse large B cell lymphoma: A retrospective study. <i>Oncology Letters</i> , 2019, 18, 2670-2676.	0.8	3
9082	High expression of CD47 in triple negative breast cancer is associated with epithelialâ€‘mesenchymal transition and poor prognosis. <i>Oncology Letters</i> , 2019, 18, 3249-3255.	0.8	42
9083	Long nonâ€‘coding RNA OECC promotes cell proliferation and metastasis through the PI3K/Akt/mTOR signaling pathway in human lung cancer. <i>Oncology Letters</i> , 2019, 18, 3017-3024.	0.8	7
9084	Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy. <i>Case Reports in Oncology</i> , 2019, 12, 548-553.	0.3	1
9085	Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. <i>Vaccines</i> , 2019, 7, 100.	2.1	30
9086	Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. <i>Oncology Reviews</i> , 2019, 13, 430.	0.8	9
9087	PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. , 2019, 7, 228.		26
9088	<p>Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6023-6032.	1.0	25
9089	Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1782.	2.2	45
9090	Translational AI and Deep Learning in Diagnostic Pathology. <i>Frontiers in Medicine</i> , 2019, 6, 185.	1.2	165
9091	Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 19.	0.9	17
9092	Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis. <i>EBioMedicine</i> , 2019, 47, 78-88.	2.7	24
9093	Antiâ€‘PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1. <i>Kidney International Reports</i> , 2019, 4, 1152-1160.	0.4	44
9094	High expression of the vacuole membrane protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer. <i>PLoS ONE</i> , 2019, 14, e0221413.	1.1	9

#	ARTICLE	IF	CITATIONS
9095	<p>Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma</p>. Cancer Management and Research, 2019, Volume 11, 7021-7030.	0.9	26
9096	Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response. Cancers, 2019, 11, 1217.	1.7	36
9097	ADAM17: An Emerging Therapeutic Target for Lung Cancer. Cancers, 2019, 11, 1218.	1.7	57
9098	Integrin-Mediated TGFβ ² Activation Modulates the Tumour Microenvironment. Cancers, 2019, 11, 1221.	1.7	62
9099	Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). Advances in Therapy, 2019, 36, 2600-2617.	1.3	80
9100	Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence. EJNMMI Research, 2019, 9, 78.	1.1	21
9101	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?. Annals of Intensive Care, 2019, 9, 25.	2.2	46
9102	Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity. Cancer Research, 2019, 79, 5394-5406.	0.4	55
9103	Inhibition of lung cancer cells and Ras/Raf/MEK/ERK signal transduction by ectonucleoside triphosphate phosphohydrolase-7 (ENTPD7). Respiratory Research, 2019, 20, 194.	1.4	12
9104	Neoantigen vaccine: an emerging tumor immunotherapy. Molecular Cancer, 2019, 18, 128.	7.9	398
9105	Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. , 2019, 7, 225.		16
9106	Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. , 2019, 7, 227.		58
9107	Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis. BioMed Research International, 2019, 2019, 1-9.	0.9	9
9108	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer, 2019, 19, 857.	1.1	88
9109	Treatment sequences for advanced renal cell carcinoma: A health economic assessment. PLoS ONE, 2019, 14, e0215761.	1.1	15
9110	Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response. Frontiers in Immunology, 2019, 10, 1939.	2.2	38
9111	Learning Domain-Invariant Representations of Histological Images. Frontiers in Medicine, 2019, 6, 162.	1.2	29
9112	Pembrolizumab in a Patient With a Metastatic CASTLE Tumor of the Parotid. Frontiers in Oncology, 2019, 9, 734.	1.3	15

#	ARTICLE	IF	CITATIONS
9113	Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes. <i>Frontiers in Oncology</i> , 2019, 9, 883.	1.3	40
9114	Hypoxic Regulation of Neutrophils in Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4189.	1.8	9
9115	Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis. <i>Balkan Medical Journal</i> , 2019, 36, 184-189.	0.3	7
9116	Liquid Biopsy in Oligometastatic Prostate Cancer—A Biologist's Point of View. <i>Frontiers in Oncology</i> , 2019, 9, 775.	1.3	21
9117	Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 417-430.	2.7	27
9118	Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization. <i>Current Urology Reports</i> , 2019, 20, 64.	1.0	21
9119	siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion. <i>Translational Research</i> , 2019, 214, 105-120.	2.2	48
9120	Are all cyclin-dependent kinases 4/6 inhibitors created equal?. <i>Npj Breast Cancer</i> , 2019, 5, 27.	2.3	85
9121	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 1574-1579.	1.6	33
9122	Clonality of circulating tumor cells in breast cancer brain metastasis patients. <i>Breast Cancer Research</i> , 2019, 21, 101.	2.2	54
9123	STAT3, a Master Regulator of Anti-Tumor Immune Response. <i>Cancers</i> , 2019, 11, 1280.	1.7	68
9124	Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4251.	1.8	29
9125	The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4263.	1.8	17
9126	MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4287.	1.8	28
9127	Towards Circulating-Tumor DNA-Based Precision Medicine. <i>Journal of Clinical Medicine</i> , 2019, 8, 1365.	1.0	8
9128	Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2019, 20, 3773-3781.	1.1	38
9129	The current status of the clinical utility of liquid biopsies in cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1031-1041.	1.5	27
9130	The Janus Face of Tumor Microenvironment Targeted by Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4320.	1.8	43

#	ARTICLE	IF	CITATIONS
9131	Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1501-1513.	2.0	39
9132	Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. <i>Journal of Translational Medicine</i> , 2019, 17, 303.	1.8	89
9133	Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. <i>Journal of Hematology and Oncology</i> , 2019, 12, 92.	6.9	485
9134	Tumor neoantigens: from basic research to clinical applications. <i>Journal of Hematology and Oncology</i> , 2019, 12, 93.	6.9	266
9135	Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 370-377.	0.7	4
9136	PD-1 expression and its significance in tumour microenvironment of hepatocellular carcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 51-51.	1.5	16
9137	Neutrophil Heterogeneity in Cancer: From Biology to Therapies. <i>Frontiers in Immunology</i> , 2019, 10, 2155.	2.2	110
9138	Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. <i>Npj Precision Oncology</i> , 2019, 3, 21.	2.3	23
9139	Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient with Metastatic Gastric Adenocarcinoma. <i>Clinical Drug Investigation</i> , 2019, 39, 1251-1254.	1.1	3
9140	BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response. <i>Cancer Letters</i> , 2019, 465, 45-58.	3.2	36
9141	Circulating biomarkers predictive of tumor response to cancer immunotherapy. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 895-904.	1.5	28
9142	Best practices for bioinformatic characterization of neoantigens for clinical utility. <i>Genome Medicine</i> , 2019, 11, 56.	3.6	146
9143	Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4233.	1.8	44
9144	Immunotherapy in inoperable stage III non-small cell lung cancer: a review. <i>Drugs in Context</i> , 2019, 8, 1-6.	1.0	9
9145	Looking beyond the hype: Applied AI and machine learning in translational medicine. <i>EBioMedicine</i> , 2019, 47, 607-615.	2.7	82
9146	Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. <i>Immunity</i> , 2019, 51, 548-560.e4.	6.6	88
9147	Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC. <i>Molecular Therapy</i> , 2019, 27, 1906-1918.	3.7	35
9148	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. <i>Journal of Clinical Investigation</i> , 2019, 129, 2056-2070.	3.9	159

#	ARTICLE	IF	CITATIONS
9149	WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. <i>Cell Communication and Signaling</i> , 2019, 17, 109.	2.7	45
9150	Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. <i>Experimental Hematology and Oncology</i> , 2019, 8, 19.	2.0	30
9151	New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota. <i>Clinical and Translational Medicine</i> , 2019, 8, 23.	1.7	20
9152	Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN- γ . <i>Frontiers in Pharmacology</i> , 2019, 10, 898.	1.6	17
9153	PD-L1 Induction by Cancer-Associated Fibroblast-Derived Factors in Lung Adenocarcinoma Cells. <i>Cancers</i> , 2019, 11, 1257.	1.7	52
9154	Glycan-Modified Melanoma-Derived Apoptotic Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination. <i>Cancers</i> , 2019, 11, 1266.	1.7	47
9155	Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing. <i>Cancers</i> , 2019, 11, 1268.	1.7	38
9156	Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?. <i>Cancers</i> , 2019, 11, 1269.	1.7	25
9157	In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. <i>Cancers</i> , 2019, 11, 1271.	1.7	27
9158	Quantifying Risk Pathway Crosstalk Mediated by miRNA to Screen Precision drugs for Breast Cancer Patients. <i>Genes</i> , 2019, 10, 657.	1.0	5
9159	Whole exome sequencing study of a Chinese concurrent cancer family. <i>Oncology Letters</i> , 2019, 18, 2619-2627.	0.8	0
9160	Cardiac troponin I autoantibody induces myocardial dysfunction by PTEN signaling activation. <i>EBioMedicine</i> , 2019, 47, 329-340.	2.7	12
9161	MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis. <i>Neoplasia</i> , 2019, 21, 1015-1035.	2.3	76
9162	Ductal carcinoma in situ of breast: update 2019. <i>Pathology</i> , 2019, 51, 563-569.	0.3	43
9163	Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC). <i>Translational Oncology</i> , 2019, 12, 1539-1548.	1.7	3
9164	The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 866.	1.3	25
9165	Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). <i>Cancers</i> , 2019, 11, 1297.	1.7	21
9166	Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. <i>Molecules</i> , 2019, 24, 3214.	1.7	106

#	ARTICLE	IF	CITATIONS
9167	Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling. <i>EBioMedicine</i> , 2019, 47, 65-77.	2.7	36
9168	The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. <i>BioMed Research International</i> , 2019, 2019, 1-7.	0.9	20
9169	The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987036.	1.4	45
9170	Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 858.	1.3	125
9171	Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma. <i>Journal of Neuro-Oncology</i> , 2019, 145, 399-402.	1.4	1
9172	TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma. <i>Cancer Immunology Research</i> , 2019, 7, 1672-1686.	1.6	85
9173	Transcriptome analyses of tumor-adjacent somatic tissues reveal genes co-expressed with transposable elements. <i>Mobile DNA</i> , 2019, 10, 39.	1.3	21
9174	<p>Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 1867-1877.	0.9	12
9175	Pathways to Endocrine Therapy Resistance in Breast Cancer. <i>Frontiers in Endocrinology</i> , 2019, 10, 573.	1.5	100
9176	Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies. <i>Journal of Cancer</i> , 2019, 10, 5504-5517.	1.2	60
9177	Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. <i>BMC Cancer</i> , 2019, 19, 902.	1.1	6
9178	Non-canonical Expression of Cardiac Troponin-T in Neuroendocrine Ethmoid Sinus Carcinoma Following Immune Checkpoint Blockade. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 124.	1.1	5
9179	Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. <i>Frontiers in Immunology</i> , 2019, 10, 2109.	2.2	32
9180	Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas. <i>Biomolecules</i> , 2019, 9, 456.	1.8	11
9181	Panoptic View of Prognostic Models for Personalized Breast Cancer Management. <i>Cancers</i> , 2019, 11, 1325.	1.7	7
9182	Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4413.	1.8	140
9183	Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy. <i>Cancer Immunology Research</i> , 2019, 7, 1824-1836.	1.6	40
9184	Multiple Omics Data Integration to Identify Long Noncoding RNA Responsible for Breast Cancer-Related Mortality. <i>Cancer Informatics</i> , 2019, 18, 117693511987193.	0.9	3

#	ARTICLE	IF	CITATIONS
9185	IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 397.	3.5	111
9186	Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. , 2019, 7, 249.		61
9187	Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. <i>Cancers</i> , 2019, 11, 1334.	1.7	150
9188	Investigation of the Effect of PD-L1 Blockade on Triple Negative Breast Cancer Cells Using Fourier Transform Infrared Spectroscopy. <i>Vaccines</i> , 2019, 7, 109.	2.1	10
9189	Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types. <i>BMC Medical Genomics</i> , 2019, 12, 131.	0.7	47
9190	Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. <i>Breast Cancer Research</i> , 2019, 21, 108.	2.2	21
9191	Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer. , 2019, 7, 252.		57
9192	Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. , 2019, 7, 254.		14
9193	<p>APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice</p>. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 249-259.	1.0	7
9194	<p>Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7123-7134.	0.9	26
9195	Strategies in Developing Immunotherapy for Pancreatic Cancer: Recognizing and Correcting Multiple Immune “Defects” in the Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2019, 8, 1472.	1.0	56
9196	Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non“Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911895.	2.8	55
9197	Incidence and risk of developing photosensitivity with targeted anticancer therapies. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1009-1011.	0.6	7
9198	Genetic determinants of cellular addiction to DNA polymerase theta. <i>Nature Communications</i> , 2019, 10, 4286.	5.8	106
9199	Evidence for Etiologic Subtypes of Breast Cancer in the Carolina Breast Cancer Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1784-1791.	1.1	5
9200	Automatic discovery of 100-miRNA signature for cancer classification using ensemble feature selection. <i>BMC Bioinformatics</i> , 2019, 20, 480.	1.2	54
9201	Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 857.	1.3	12
9202	Generation of in situ sequencing based OncoMaps to spatially resolve gene expression profiles of diagnostic and prognostic markers in breast cancer. <i>EBioMedicine</i> , 2019, 48, 212-223.	2.7	29

#	ARTICLE	IF	CITATIONS
9203	Transperineal abdominoperineal resection for anorectal melanoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2019, 61, 214-217.	0.2	1
9204	The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality. <i>Immunity</i> , 2019, 51, 491-507.e7.	6.6	148
9205	Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	0.6	19
9206	Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country. <i>Journal of Global Oncology</i> , 2019, 5, 1-9.	0.5	13
9207	Digitaldsorter: Deep-Learning on scRNA-Seq to Deconvolute Gene Expression Data. <i>Frontiers in Genetics</i> , 2019, 10, 978.	1.1	22
9208	The Immune Microenvironment of Breast Cancer Progression. <i>Cancers</i> , 2019, 11, 1375.	1.7	68
9209	Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. <i>Cells</i> , 2019, 8, 1083.	1.8	153
9210	Paradox-driven adventures in the development of cancer immunology and immunotherapy. <i>Genes and Diseases</i> , 2019, 6, 224-231.	1.5	3
9211	Germline genetic host factors as predictive biomarkers in immuno-oncology. <i>Immuno-Oncology Technology</i> , 2019, 2, 14-21.	0.2	2
9212	Immunotherapeutic Challenges for Pediatric Cancers. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 38-48.	2.0	26
9213	Moderate physical exercise improves lymphocyte function in melanoma-bearing mice on a high-fat diet. <i>Nutrition and Metabolism</i> , 2019, 16, 63.	1.3	13
9214	Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. , 2019, 7, 244.		125
9215	Niclosamide, an anthelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. , 2019, 7, 245.		66
9216	Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events. <i>Clinical Pediatric Endocrinology</i> , 2019, 28, 59-68.	0.4	15
9217	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e31-e43.	2.5	97
9218	Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 403.	3.5	95
9219	Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results. <i>Breast Cancer Research</i> , 2019, 21, 106.	2.2	81
9220	Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma. <i>Experimental Hematology and Oncology</i> , 2019, 8, 20.	2.0	4

#	ARTICLE	IF	CITATIONS
9221	Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251.		26
9222	Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients. <i>Cancer Biology and Medicine</i> , 2019, 16, 350.	1.4	13
9223	PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3055-3065.	1.2	24
9224	VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models. <i>Neoplasia</i> , 2019, 21, 1036-1050.	2.3	17
9225	Prospects for combining immune checkpoint blockade with PARP inhibition. <i>Journal of Hematology and Oncology</i> , 2019, 12, 98.	6.9	92
9226	TCR-like antibodies in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 99.	6.9	39
9227	Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. <i>Molecular Cancer</i> , 2019, 18, 139.	7.9	156
9228	The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 2298.	2.2	244
9229	Macrophage activation by a substituted pyrimido[5,4-b]indole increases anti-cancer activity. <i>Pharmacological Research</i> , 2019, 148, 104452.	3.1	19
9230	Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. <i>Nature Protocols</i> , 2019, 14, 2900-2930.	5.5	92
9231	Traditional Chinese Medicine and regulatory roles on epithelialâ€mesenchymal transitions. <i>Chinese Medicine</i> , 2019, 14, 34.	1.6	13
9232	Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 63-63.	1.5	12
9233	<p>Breast cancer risk in a rapidly aging population: advances and approaches to study the aging tissue microenvironment</p>. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 111-113.	1.0	3
9234	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1534.	1.0	41
9235	Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3105-3114.	1.2	63
9236	Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4794.	1.8	29
9237	Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1547.	1.0	30
9238	<p>Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8201-8207.	0.9	34

#	ARTICLE	IF	CITATIONS
9239	<p>Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer</p>. OncoTargets and Therapy, 2019, Volume 12, 7193-7201.	1.0	9
9240	<p>Durable Response After Combination Of Concurrent Chemoradiotherapy And Anti-PD-1 Therapy In HER2-Negative Advanced Gastric Adenocarcinoma: A Case Report</p>. OncoTargets and Therapy, 2019, Volume 12, 7691-7698.	1.0	5
9241	Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. Frontiers in Pharmacology, 2019, 10, 1184.	1.6	50
9242	Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use. Biomolecules, 2019, 9, 548.	1.8	43
9243	Current Perspectives in Cancer Immunotherapy. Cancers, 2019, 11, 1472.	1.7	149
9244	MicroRNAâ€192 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting caveolin 1. Oncology Reports, 2019, 42, 1667-1676.	1.2	12
9245	<p>A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors</p>. Lung Cancer: Targets and Therapy, 2019, Volume 10, 95-105.	1.3	3
9246	Immune Landscape of Invasive Ductal Carcinoma Tumor Microenvironment Identifies a Prognostic and Immunotherapeutically Relevant Gene Signature. Frontiers in Oncology, 2019, 9, 903.	1.3	35
9247	The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1621-1633.	2.0	38
9248	Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment. Cancer Immunology, Immunotherapy, 2019, 68, 1635-1648.	2.0	13
9249	Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and Autoimmunity. Cell Reports, 2019, 28, 3353-3366.e5.	2.9	40
9250	Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients. Frontiers in Oncology, 2019, 9, 835.	1.3	32
9251	Novel and Alternative Targets Against Breast Cancer Stemness to Combat Chemoresistance. Frontiers in Oncology, 2019, 9, 1003.	1.3	42
9252	Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice. Cancers, 2019, 11, 1399.	1.7	27
9253	Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives. Cancers, 2019, 11, 1401.	1.7	70
9254	Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2019, 20, 4705.	1.8	48
9255	Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression. International Journal of Molecular Sciences, 2019, 20, 4719.	1.8	48
9256	Viral Infections and Autoimmune Disease: Roles of LCMV in Delineating Mechanisms of Immune Tolerance. Viruses, 2019, 11, 885.	1.5	5

#	ARTICLE	IF	CITATIONS
9257	In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination. <i>Vaccines</i> , 2019, 7, 120.	2.1	9
9258	Measuring tumor mutation burden in cell-free DNA: advantages and limits. <i>Translational Lung Cancer Research</i> , 2019, 8, 553-555.	1.3	4
9259	Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report. <i>Frontiers in Oncology</i> , 2019, 9, 819.	1.3	12
9260	Stem Cells and Cellular Origins of Breast Cancer: Updates in the Rationale, Controversies, and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2019, 9, 820.	1.3	54
9261	Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting. <i>Frontiers in Oncology</i> , 2019, 9, 827.	1.3	126
9262	Association Between Circulating Lymphocyte Populations and Outcome After Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 896.	1.3	23
9263	New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness. <i>Frontiers in Oncology</i> , 2019, 9, 953.	1.3	97
9264	Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4654.	1.8	29
9265	Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.2	1
9266	The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 429-449.	1.3	54
9267	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 450-460.	1.3	18
9268	The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. <i>Translational Lung Cancer Research</i> , 2019, 8, 413-428.	1.3	95
9269	Regulatory T Cells Control the Switch From in situ to Invasive Breast Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1942.	2.2	31
9270	Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. <i>Cancers</i> , 2019, 11, 1419.	1.7	54
9271	Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma. <i>Oncology Letters</i> , 2019, 17, 4557-4565.	0.8	16
9272	Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. <i>Nature Communications</i> , 2019, 10, 4369.	5.8	18
9273	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 31.	2.3	31
9274	Past, Current, and Future of Immunotherapies for Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 884.	1.3	89

#	ARTICLE	IF	CITATIONS
9275	Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition. <i>Journal of Clinical Medicine</i> , 2019, 8, 1596.	1.0	15
9276	Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses. <i>Molecular Therapy</i> , 2019, 27, 1892-1905.	3.7	28
9277	Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-4.	0.2	9
9278	Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer. <i>PLoS ONE</i> , 2019, 14, e0223325.	1.1	32
9279	Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. <i>Cancer Microenvironment</i> , 2019, 12, 119-132.	3.1	46
9280	SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1839-1846.	0.5	53
9281	Unraveling the Heterogeneous Mutational Signature of Spontaneously Developing Tumors in MLH1 ^{-/-} Mice. <i>Cancers</i> , 2019, 11, 1485.	1.7	7
9282	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1566.	1.0	26
9283	Design and application of oral colon administration system. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 1590-1596.	2.5	18
9284	Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. <i>Genes and Development</i> , 2019, 33, 1295-1318.	2.7	203
9285	[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. <i>PLoS ONE</i> , 2019, 14, e0222280.	1.1	23
9286	High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma. <i>Journal of Immunology</i> , 2019, 203, 2577-2587.	0.4	21
9287	Sinonasal Melanoma: A Single Institutional Analysis and Future Directions. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2019, 80, 484-492.	0.4	6
9288	Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression. <i>Journal of Immunology</i> , 2019, 203, 1999-2010.	0.4	63
9289	Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1257-1267.	1.1	58
9290	In vivo CRISPR screening in CD8 T cells with AAV Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. <i>Nature Biotechnology</i> , 2019, 37, 1302-1313.	9.4	123
9291	Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4624.	1.8	5
9292	Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987091.	1.4	35

#	ARTICLE	IF	CITATIONS
9293	Cancer-Specific Thresholds Adjust for Whole Exome Sequencingâ€‘Based Tumor Mutational Burden Distribution. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	21
9294	OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. <i>Translational Lung Cancer Research</i> , 2019, 8, 352-366.	1.3	38
9295	<p>Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7329-7336.	1.0	19
9296	Bronchial inflammatory granulation after endobronchial ultrasound-guided transbronchial needle aspiration and immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1199-1200.	3.3	1
9297	Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases. <i>Frontiers of Medicine</i> , 2019, 13, 24-31.	1.5	4
9298	Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development. <i>Current Oncology Reports</i> , 2019, 21, 2.	1.8	42
9299	Designing highly crystalline multifunctional multicolor-luminescence nanosystem for tracking breast cancer heterogeneity. <i>Nanoscale Advances</i> , 2019, 1, 1021-1034.	2.2	6
9300	Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer. <i>Science Signaling</i> , 2019, 12, .	1.6	26
9301	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.	3.2	80
9302	Mouse PVRIg Has CD8+ T Cellâ€‘Specific Coinhibitory Functions and Dampens Antitumor Immunity. <i>Cancer Immunology Research</i> , 2019, 7, 244-256.	1.6	32
9303	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
9304	Long non-coding RNA MALAT1 regulates BLCAP mRNA expression through binding to miR-339-5p and promotes poor prognosis in breast cancer. <i>Bioscience Reports</i> , 2019, 39, .	1.1	48
9305	Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive. <i>Melanoma Research</i> , 2019, 29, 301-310.	0.6	7
9306	Questionnaire survey on patient awareness of invasive rebiopsy in advanced nonâ€‘small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 501-507.	0.8	6
9307	Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier. <i>Breast Cancer Research</i> , 2019, 21, 14.	2.2	5
9308	Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18.		72
9309	Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART. <i>PLoS ONE</i> , 2019, 14, e0211112.	1.1	16
9310	Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes. <i>Cancers</i> , 2019, 11, 138.	1.7	30

#	ARTICLE	IF	CITATIONS
9311	Rsu1-dependent control of PTEN expression is regulated via ATF2 and cJun. <i>Journal of Cell Communication and Signaling</i> , 2019, 13, 331-341.	1.8	5
9312	Programmed cell death protein receptor and ligands in haematological malignancies – Current status. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 47-58.	2.0	4
9313	Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. <i>Npj Breast Cancer</i> , 2019, 5, 6.	2.3	21
9314	A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 309-316.	2.0	15
9315	The evolving role of immunoncology for the treatment of head and neck cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 62-69.	0.6	3
9316	Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients. <i>Translational Oncology</i> , 2019, 12, 585-595.	1.7	36
9317	A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). , 2019, 7, 20.		68
9318	The Prognostic and Therapeutic Value of PD-L1 in Glioma. <i>Frontiers in Pharmacology</i> , 2018, 9, 1503.	1.6	85
9319	PD-1/PD-L1 Inhibitors in Cervical Cancer. <i>Frontiers in Pharmacology</i> , 2019, 10, 65.	1.6	108
9320	Stereotactic Radiotherapy for Oligometastasis. <i>Cancers</i> , 2019, 11, 133.	1.7	40
9321	Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 4558-4566.	3.3	274
9322	Treatment of Advanced Prostate Cancer. <i>Annual Review of Medicine</i> , 2019, 70, 479-499.	5.0	417
9323	Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. <i>Radiation Oncology</i> , 2019, 14, 18.	1.2	41
9324	Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 53-69.	1.0	63
9325	<p>MNX1-AS1 is a functional oncogene that induces EMT and activates the AKT/mTOR pathway and MNX1 in breast cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 803-812.	0.9	36
9326	Observational Study of PD-L1, TGF- β 2, and Immune Cell Infiltrates in Hepatocellular Carcinoma. <i>Frontiers in Medicine</i> , 2019, 6, 15.	1.2	21
9327	A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	96
9328	Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer. <i>Nano Research</i> , 2019, 12, 855-861.	5.8	39

#	ARTICLE	IF	CITATIONS
9329	Multifunctional polymeric micelle-based chemo-immunotherapy with immune checkpoint blockade for efficient treatment of orthotopic and metastatic breast cancer. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 819-831.	5.7	43
9330	Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). <i>Leukemia</i> , 2019, 33, 844-862.	3.3	131
9331	Prognostic Value of CD133 and SOX2 in Advanced Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	14
9332	The Therapeutic Strategies of Regulatory T Cells in Malignancies and Stem Cell Transplantations. <i>Journal of Oncology</i> , 2019, 2019, 1-6.	0.6	6
9333	Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 71.	2.2	123
9334	On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 50.	1.3	11
9335	An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings. <i>Journal of Cancer</i> , 2019, 10, 223-237.	1.2	39
9336	Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 513-524.	0.9	5
9337	<i>Pseudomonas</i> Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient&TM's Bedside to Evaluation in Preclinical Models. <i>Toxins</i> , 2019, 11, 20.	1.5	37
9338	Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression. <i>Journal of Cancer</i> , 2019, 10, 211-222.	1.2	29
9340	Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer. <i>Nature Communications</i> , 2019, 10, 397.	5.8	59
9341	Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. <i>Disease Markers</i> , 2019, 2019, 1-13.	0.6	47
9342	Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. <i>Cancer Research</i> , 2019, 79, 1113-1123.	0.4	45
9343	miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 26.	3.5	45
9344	A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity. , 2019, 7, 15.		17
9345	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, 393.	3.4	303
9346	Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 747-757.	1.2	8
9347	ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 765-774.	1.2	35

#	ARTICLE	IF	CITATIONS
9348	Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives. <i>Human Genetics</i> , 2019, 138, 109-124.	1.8	146
9349	Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 129-139.	1.1	14
9350	Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS. <i>Clinical Drug Investigation</i> , 2019, 39, 319-330.	1.1	78
9351	Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2640-2645.	3.3	22
9352	Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. <i>Neuro-Oncology</i> , 2019, 21, 730-741.	0.6	63
9353	Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. <i>Cancer Discovery</i> , 2019, 9, 176-198.	7.7	778
9354	Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491882131.	0.6	7
9355	Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model. <i>Breast Cancer Research</i> , 2019, 21, 9.	2.2	40
9356	Reining in the CD8+ T cell: Respiratory virus infection and PD-1-mediated T-cell impairment. <i>PLoS Pathogens</i> , 2019, 15, e1007387.	2.1	15
9357	The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1494.	1.6	24
9358	The functional roles of exosomal long non-coding RNAs in cancer. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 2059-2076.	2.4	100
9359	Targeted Therapy and Immunotherapy for Melanoma in Japan. <i>Current Treatment Options in Oncology</i> , 2019, 20, 7.	1.3	79
9360	PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer. <i>Scientific Reports</i> , 2019, 9, 566.	1.6	90
9361	Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas. <i>Scientific Reports</i> , 2019, 9, 358.	1.6	33
9362	Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 526-532.	0.8	13
9363	Splicing factor <i>ESRP1</i> controls ER ⁺ positive breast cancer by altering metabolic pathways. <i>EMBO Reports</i> , 2019, 20, .	2.0	48
9364	<p>Efficacy and safety of nivolumab for metastatic biliary tract cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 861-867.	1.0	31
9365	Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America. <i>Ecanermedalscience</i> , 2019, 13, 896.	0.6	8

#	ARTICLE	IF	CITATIONS
9366	Fragment-based screening of programmed death ligand 1 (PD-L1). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 786-790.	1.0	48
9367	Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8 ⁺ T cells. <i>Science Immunology</i> , 2019, 4, .	5.6	95
9368	Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. <i>Clinical Diabetes and Endocrinology</i> , 2019, 5, 1.	1.3	125
9369	Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy. <i>Frontiers of Medicine</i> , 2019, 13, 32-44.	1.5	25
9370	Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report. <i>Lung Cancer</i> , 2019, 129, 75-79.	0.9	113
9371	A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. <i>Breast Cancer Research</i> , 2019, 21, 18.	2.2	37
9372	Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. , 2019, 7, 24.		114
9373	Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting. <i>Molecules</i> , 2019, 24, 478.	1.7	17
9374	Dendritic Cell-Targeted pH-Responsive Extracellular Vesicles for Anticancer Vaccination. <i>Pharmaceutics</i> , 2019, 11, 54.	2.0	27
9375	Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. , 2019, 7, 27.		66
9376	GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 1111-1124.	2.3	42
9377	Clonal Deletion of Tumor-Specific T Cells by Interferon- γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. <i>Immunity</i> , 2019, 50, 477-492.e8.	6.6	93
9378	pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation. <i>Npj Breast Cancer</i> , 2019, 5, 7.	2.3	18
9379	Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3100-3105.	3.3	56
9380	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	1.8	311
9381	DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays. <i>Bioinformatics</i> , 2019, 35, 3055-3062.	1.8	496
9382	Identification of microRNA clusters cooperatively acting on epithelial to mesenchymal transition in triple negative breast cancer. <i>Nucleic Acids Research</i> , 2019, 47, 2205-2215.	6.5	65
9383	TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. <i>Cancer Immunology Research</i> , 2019, 7, 355-362.	1.6	82

#	ARTICLE	IF	CITATIONS
9384	Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 13.	1.8	13
9385	Pharmacological inhibition of USP7 promotes antitumor immunity and contributes to colon cancer therapy. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 609-617.	1.0	33
9386	<p></p>Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4297-4312.	0.9	47
9387	<p></p>Relationship between <i>Helicobacter pylori</i> and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3909-3919.	0.9	20
9388	<p></p>Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2943-2948.	1.0	3
9389	<p></p>Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 605-612.	0.9	2
9390	Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab. <i>Medicina (Lithuania)</i> , 2019, 55, 176.	0.8	11
9391	Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms. <i>Translational Oncology</i> , 2019, 12, 987-995.	1.7	32
9392	The prognostic value of tumor-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2019, 17, 85.	0.8	60
9393	Interaction of CD99 and its ligand upregulates IL-6 and TNF- α upon T cell activation. <i>PLoS ONE</i> , 2019, 14, e0217393.	1.1	17
9394	<p></p>Baseline platelet counts and derived inflammatory biomarkers: prognostic relevance in metastatic melanoma patients receiving Endostar plus dacarbazine and cisplatin</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3681-3690.	0.9	6
9395	Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails. <i>Frontiers in Pharmacology</i> , 2019, 10, 387.	1.6	15
9396	Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer. <i>European Journal of Radiology Open</i> , 2019, 6, 156-162.	0.7	12
9397	Lipoproteins modulate growth and P-glycoprotein expression in drug-resistant HER2-overexpressed breast cancer cells. <i>Heliyon</i> , 2019, 5, e01573.	1.4	8
9398	The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz027.	1.4	20
9399	The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. <i>Cancer Cell International</i> , 2019, 19, 141.	1.8	38
9400	Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. , 2019, 7, 133.		32
9401	<p></p>Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4171-4184.	0.9	31

#	ARTICLE	IF	CITATIONS
9402	<p><p>Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges</p>. Cancer Management and Research, 2019, Volume 11, 4541-4548.	0.9	23
9403	<p>Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis</p>. Cancer Management and Research, 2019, Volume 11, 3957-3969.	0.9	5
9404	<p>Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis</p>. OncoTargets and Therapy, 2019, Volume 12, 3671-3682.	1.0	40
9405	<p>Poor prognosis of pulmonary sarcomatoid carcinoma with KRAS mutation and ALK fusion</p>. OncoTargets and Therapy, 2019, Volume 12, 3321-3325.	1.0	4
9406	Quantifying Cancer Epithelial-Mesenchymal Plasticity and its Association with Stemness and Immune Response. Journal of Clinical Medicine, 2019, 8, 725.	1.0	63
9407	Liquid biopsy for lung cancer immunotherapy (Review). Oncology Letters, 2019, 17, 4751-4760.	0.8	14
9408	Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210. Cancer Biology and Medicine, 2019, 16, 173.	1.4	47
9409	The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer. Frontiers in Immunology, 2019, 10, 911.	2.2	90
9410	Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. Frontiers in Immunology, 2019, 10, 954.	2.2	89
9411	PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 67-76.	1.4	13
9412	PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1785-1794.	1.2	20
9413	<i>BRCA1/2</i> Functional Loss Defines a Targetable Subset in Leiomyosarcoma. Oncologist, 2019, 24, 973-979.	1.9	49
9414	<p>Personalized medicine in breast cancer: pharmacogenomics approaches</p>. Pharmacogenomics and Personalized Medicine, 2019, Volume 12, 59-73.	0.4	39
9415	Recent advances in the clinical development of immune checkpoint blockade therapy. Cellular Oncology (Dordrecht), 2019, 42, 609-626.	2.1	76
9416	Evaluating the effects of design parameters on the performances of phase I trial designs. Contemporary Clinical Trials Communications, 2019, 15, 100379.	0.5	8
9417	Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone. Journal of Immunology Research, 2019, 2019, 1-10.	0.9	4
9418	Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures. Journal of Experimental and Clinical Cancer Research, 2019, 38, 253.	3.5	58
9419	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. Frontiers in Immunology, 2019, 10, 1181.	2.2	20

#	ARTICLE	IF	CITATIONS
9420	Cardiotoxicities of Modern Treatments in Breast Cancer. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 34.	0.4	2
9421	CHASMaplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers. Cell Systems, 2019, 9, 9-23.e8.	2.9	83
9422	Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nature Reviews Cancer, 2019, 19, 377-391.	12.8	262
9423	Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma. Frontiers in Immunology, 2019, 10, 1336.	2.2	57
9424	Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer. American Journal of Transplantation, 2019, 19, 3223-3232.	2.6	31
9425	Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984887.	1.4	30
9426	Management of metastatic cutaneous melanoma: updates in clinical practice. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985166.	1.4	29
9427	Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response. BMC Cancer, 2019, 19, 601.	1.1	15
9428	A Model for Apoptotic-Cell-Mediated Adaptive Immune Evasion via CD80-CTLA-4 Signaling. Frontiers in Pharmacology, 2019, 10, 562.	1.6	1
9429	Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status. Journal of Cancer, 2019, 10, 1745-1754.	1.2	19
9430	Aging, Cancer and Immunity. Journal of Cancer, 2019, 10, 3021-3027.	1.2	48
9431	Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis. Advanced Science, 2019, 6, 1802281.	5.6	50
9432	Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential. Advances in Therapy, 2019, 36, 1826-1832.	1.3	21
9433	Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis. BioMed Research International, 2019, 1-13.	0.9	21
9434	Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer. Cancer Immunology Research, 2019, 7, 1230-1236.	1.6	59
9435	Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development. Cancer Immunology Research, 2019, 7, 1244-1257.	1.6	51
9436	A Holistic Evaluation of Articles on PD-1 and PD-L1 Published Between 1975 and 2017: A Bibliometric Analysis. Cancer Informatics, 2019, 18, 117693511985262.	0.9	2
9437	CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985319.	1.4	13

#	ARTICLE	IF	CITATIONS
9438	Advances in cancer immunotherapy 2019 – latest trends. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 268.	3.5	401
9439	PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. <i>Journal of Ovarian Research</i> , 2019, 12, 56.	1.3	30
9440	Treatment Outcomes of Immune-Related Cutaneous Adverse Events. <i>Journal of Clinical Oncology</i> , 2019, 37, 2746-2758.	0.8	160
9441	The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	8
9442	<p>Plausibility of trophoblastic-like regulation of cancer tissue</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5033-5046.	0.9	7
9443	Probiotics <i>Lactobacillus reuteri</i> Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1235.	2.2	83
9444	PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1242.	2.2	130
9445	Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. <i>Frontiers in Oncology</i> , 2019, 9, 443.	1.3	25
9446	PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 806.	1.7	66
9447	Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?. <i>Cancers</i> , 2019, 11, 834.	1.7	41
9448	Immunopotentiator Aikejia improves the therapeutic efficacy of PD-1/PD-L1 immunosuppressive pathway in CT26.WT cancer cell. <i>Journal of Cancer</i> , 2019, 10, 3472-3480.	1.2	4
9449	The Rationale for Immunotherapy in Myeloproliferative Neoplasms. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 310-327.	1.2	21
9450	Evolutionary Underpinnings of Innate-Like T Cell Interactions with Cancer. <i>Immunological Investigations</i> , 2019, 48, 737-758.	1.0	6
9451	Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 569-587.	1.1	21
9452	Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 2128-2149.	4.2	160
9453	Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. <i>Genome Medicine</i> , 2019, 11, 40.	3.6	179
9454	Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. <i>Cancers</i> , 2019, 11, 835.	1.7	109
9455	Analysis of the transcriptomic features of microsatellite instability subtype colon cancer. <i>BMC Cancer</i> , 2019, 19, 605.	1.1	10

#	ARTICLE	IF	CITATIONS
9456	PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 207.	1.8	13
9457	Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. <i>Diagnostic Pathology</i> , 2019, 14, 62.	0.9	4
9458	Checkpoint Inhibitors. <i>Deutsches A&#x0308;rzteblatt International</i> , 2019, 116, 119-126.	0.6	83
9459	Loss of Human Leukocyte Antigen Class I Expression Is Associated with Poor Prognosis in Patients with Advanced Breast Cancer. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 75-85.	0.4	27
9460	Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies. <i>Current Treatment Options in Oncology</i> , 2019, 20, 62.	1.3	26
9461	Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 167-173.	0.9	9
9462	MetaGxData: Clinically Annotated Breast, Ovarian and Pancreatic Cancer Datasets and their Use in Generating a Multi-Cancer Gene Signature. <i>Scientific Reports</i> , 2019, 9, 8770.	1.6	29
9463	Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) â€“ Recommendations for Daily Routine Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 605-617.	0.8	28
9464	Determinants for Neoantigen Identification. <i>Frontiers in Immunology</i> , 2019, 10, 1392.	2.2	99
9465	An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More. <i>Frontiers in Immunology</i> , 2019, 10, 1415.	2.2	57
9466	Magnetic iron oxide nanoparticles for disease detection and therapy. <i>Materials Today</i> , 2019, 31, 86-99.	8.3	114
9467	DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. <i>Journal of Oncology</i> , 2019, 1-14.	0.6	18
9468	IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell. <i>Cancer Immunology Research</i> , 2019, 7, 1258-1266.	1.6	56
9469	Assessing the performance of in silico methods for predicting the pathogenicity of variants in the gene CHEK2, among Hispanic females with breast cancer. <i>Human Mutation</i> , 2019, 40, 1612-1622.	1.1	8
9470	Stability and survival analysis of elderly patients with osteolytic spinal bone metastases after palliative radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 1074-1085.	1.0	10
9471	Assessing the interactions between radiotherapy and antitumour immunity. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 729-745.	12.5	183
9472	Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. <i>MAbs</i> , 2019, 11, 1139-1148.	2.6	74
9473	The immune microenvironment and expression of PDâ€1, PRAME and MHC I in salivary duct carcinoma. <i>Histopathology</i> , 2019, 75, 672-682.	1.6	43

#	ARTICLE	IF	CITATIONS
9474	<i>EN1 Is a Transcriptional Dependency in Triple-Negative Breast Cancer Associated with Brain Metastasis.</i> Cancer Research, 2019, 79, 4173-4183.	0.4	47
9475	Refinement of breast cancer molecular classification by miRNA expression profiles. BMC Genomics, 2019, 20, 503.	1.2	75
9476	Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. , 2019, 7, 160.		132
9477	Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. Cancers, 2019, 11, 874.	1.7	85
9478	Salivary Extracellular Vesicle-Associated exRNA as Cancer Biomarker. Cancers, 2019, 11, 891.	1.7	37
9479	A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma. International Journal of Cancer, 2019, 145, 2535-2546.	2.3	48
9480	Updates on Management of Adult Medulloblastoma. Current Treatment Options in Oncology, 2019, 20, 64.	1.3	44
9481	Adjuvant Therapy for Melanoma. Current Treatment Options in Oncology, 2019, 20, 63.	1.3	38
9482	RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science, 2019, 364, .	6.0	369
9483	Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor. GE Portuguese Journal of Gastroenterology, 2019, 26, 268-274.	0.3	17
9484	Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing. Journal of Translational Medicine, 2019, 17, 189.	1.8	80
9485	Molecular profile of non-small cell lung cancer in northeastern Brazil. Jornal Brasileiro De Pneumologia, 2019, 45, e20180181.	0.4	12
9486	Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. Frontiers in Immunology, 2019, 10, 1113.	2.2	128
9487	When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?. Current Treatment Options in Oncology, 2019, 20, 60.	1.3	30
9488	Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer. BMC Cancer, 2019, 19, 541.	1.1	16
9489	Optimizing the Method of Cell Separation from Bile of Patients with Cholangiocarcinoma for Flow Cytometry. Gastroenterology Research and Practice, 2019, 2019, 1-8.	0.7	2
9490	Nivolumab-Associated Acute Demyelinating Encephalitis: A Case Report and Literature Review. Clinical Medicine and Research, 2019, 17, 29-33.	0.4	31
9491	Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships. Clinical Pharmacokinetics, 2019, 58, 1393-1405.	1.6	24

#	ARTICLE	IF	CITATIONS
9492	High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 5301-5314.	3.2	11
9493	A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer. <i>BMC Cancer</i> , 2019, 19, 546.	1.1	30
9494	Regulatory T cells and M2 macrophages present diverse prognostic value in gastric cancer patients with different clinicopathologic characteristics and chemotherapy strategies. <i>Journal of Translational Medicine</i> , 2019, 17, 192.	1.8	39
9495	DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes. , 2019, 7, 148.		67
9496	Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III&IV melanoma. , 2019, 7, 145.		261
9497	A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. <i>Frontiers in Pharmacology</i> , 2019, 10, 609.	1.6	60
9498	Interleukin-35 as an Emerging Player in Tumor Microenvironment. <i>Journal of Cancer</i> , 2019, 10, 2074-2082.	1.2	28
9499	Pembrolizumab as first-line treatment for metastatic uveal melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1179-1185.	2.0	60
9500	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. <i>Cancer Cell</i> , 2019, 35, 885-900.e10.	7.7	475
9501	The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1046-1060.	0.5	52
9502	mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo. <i>Molecular Therapy</i> , 2019, 27, 1415-1423.	3.7	125
9503	CD45RA+CCR7 ^{hi} CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab. , 2019, 7, 149.		44
9504	Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients. <i>Cardiac Failure Review</i> , 2019, 5, 112-118.	1.2	39
9505	Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene. <i>PeerJ</i> , 2019, 7, e6501.	0.9	18
9506	The Pregnancy Pickle: Evolved Immune Compensation Due to Pregnancy Underlies Sex Differences in Human Diseases. <i>Trends in Genetics</i> , 2019, 35, 478-488.	2.9	85
9507	Strategies based on metal-based nanoparticles for hypoxic-tumor radiotherapy. <i>Chemical Science</i> , 2019, 10, 6932-6943.	3.7	111
9508	Microenvironment and tumor inflammatory features improve prognostic prediction in gastro&entero&pancreatic neuroendocrine neoplasms. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 217-226.	1.3	29
9509	Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1121-1132.	2.0	13

#	ARTICLE	IF	CITATIONS
9510	Immunosuppressive Tumor Microenvironment Status and Histological Grading of Endometrial Carcinoma. <i>Cancer Microenvironment</i> , 2019, 12, 169-179.	3.1	21
9511	COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer. <i>Cancer Letters</i> , 2019, 458, 56-65.	3.2	121
9512	Application of PD-1 Blockade in Cancer Immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 661-674.	1.9	333
9513	Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets. <i>Vaccine</i> , 2019, 37, 3552-3561.	1.7	14
9514	An Oncolytic Adenovirus Targeting Transforming Growth Factor β^2 Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy. <i>Human Gene Therapy</i> , 2019, 30, 1117-1132.	1.4	36
9515	Pancreatic cancer microenvironment: a current dilemma. <i>Clinical and Translational Medicine</i> , 2019, 8, 2.	1.7	72
9516	Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 835.	2.2	25
9517	Chemerin Suppresses Breast Cancer Growth by Recruiting Immune Effector Cells Into the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 983.	2.2	50
9518	Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 990.	2.2	86
9519	Breast Cancer Subtypes Present a Differential Production of Reactive Oxygen Species (ROS) and Susceptibility to Antioxidant Treatment. <i>Frontiers in Oncology</i> , 2019, 9, 480.	1.3	95
9520	c-Cbl: An Important Regulator and a Target in Angiogenesis and Tumorigenesis. <i>Cells</i> , 2019, 8, 498.	1.8	41
9521	Early blood rise in autoantibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. <i>Molecular and Clinical Oncology</i> , 2019, 11, 81-90.	0.4	41
9522	MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 5193-5200.	0.8	14
9523	Metal-Organic Framework Nanoparticle-Based Biomineralization: A New Strategy toward Cancer Treatment. <i>Theranostics</i> , 2019, 9, 3134-3149.	4.6	82
9524	PD-1 high expression predicts lower local disease control in stage IV MO nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2019, 19, 503.	1.1	18
9525	Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFN γ signaling in non-small cell lung cancer. <i>PLoS ONE</i> , 2019, 14, e0216864.	1.1	11
9526	<p>High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer</p><p>Cancer Management and Research, 2019, Volume 11, 2987-2995.	0.9	28
9527	Precise cell behaviors manipulation through light-responsive nano-regulators: recent advance and perspective. <i>Theranostics</i> , 2019, 9, 3308-3340.	4.6	34

#	ARTICLE	IF	CITATIONS
9528	Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1193-1200.	0.8	6
9529	Identifying Epistasis in Cancer Genomes: A Delicate Affair. <i>Cell</i> , 2019, 177, 1375-1383.	13.5	81
9530	The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy. <i>Cancer Research</i> , 2019, 79, 5022-5033.	0.4	37
9531	Serine/Arginine-Rich Splicing Factor 3 Modulates the Alternative Splicing of Cytoplasmic Polyadenylation Element Binding Protein 2. <i>Molecular Cancer Research</i> , 2019, 17, 1920-1930.	1.5	8
9532	Prognostic value of TIM-1 expression in human non-small-cell lung cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 178.	1.8	16
9533	Editorial: Cancer Plasticity and the Microenvironment: Implications for Immunity and Therapy Response. <i>Frontiers in Oncology</i> , 2019, 9, 276.	1.3	6
9534	Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. <i>Cancers</i> , 2019, 11, 714.	1.7	79
9535	ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. <i>Cancers</i> , 2019, 11, 718.	1.7	9
9536	Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 743.	1.0	29
9537	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. <i>Intensive Care Medicine</i> , 2019, 45, 988-997.	3.9	18
9538	Superparamagnetic iron oxide nanoparticles (SPIONs) as a multifunctional tool in various cancer therapies. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019, 24, 307-314.	0.3	39
9539	<i>In silico</i> simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model. <i>Royal Society Open Science</i> , 2019, 6, 190366.	1.1	54
9540	An Ad Hoc Random Initialization Deep Neural Network Architecture for Discriminating Malignant Breast Cancer Lesions in Mammographic Images. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-9.	0.4	18
9541	PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma. , 2019, 60, 2388.		30
9542	Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC. <i>Radiation Oncology</i> , 2019, 14, 86.	1.2	30
9543	Immune cell therapy for hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 52.	6.9	90
9544	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. , 2019, 7, 142.		31
9545	Long-Term Outcomes of Carbon-Ion Radiotherapy for Malignant Gynecological Melanoma. <i>Cancers</i> , 2019, 11, 482.	1.7	13

#	ARTICLE	IF	CITATIONS
9546	Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. <i>Cancers</i> , 2019, 11, 754.	1.7	21
9547	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2560.	1.8	72
9548	MALDI Mass Spectrometry Imaging Linked with Top-Down Proteomics as a Tool to Study the Non-Small-Cell Lung Cancer Tumor Microenvironment. <i>Methods and Protocols</i> , 2019, 2, 44.	0.9	19
9549	Organizing pneumonia after thoracic radiotherapy followed by anti-PD-1 antibody treatment for patients with lung cancer: Three case reports. <i>Thoracic Cancer</i> , 2019, 10, 1503-1507.	0.8	2
9550	Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE). <i>Journal of Clinical Oncology</i> , 2019, 37, 2511-2513.	0.8	22
9551	A survivin-responsive, conditionally replicating adenovirus induces potent cytotoxic effects in adult T-cell leukemia/lymphoma. <i>BMC Cancer</i> , 2019, 19, 516.	1.1	6
9552	Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer. <i>Cancer Cell International</i> , 2019, 19, 146.	1.8	39
9553	Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?. <i>Cancers</i> , 2019, 7, 141.		14
9554	Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date. <i>Cancer Management and Research</i> , 2019, Volume 11, 4893-4904.	0.9	10
9555	Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies. <i>Journal of Clinical Medicine</i> , 2019, 8, 762.	1.0	53
9556	Differences in immune contexts among different molecular subtypes of gastric cancer and their prognostic impact. <i>Gastric Cancer</i> , 2019, 22, 1164-1175.	2.7	28
9557	Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer. <i>BMC Cancer</i> , 2019, 19, 521.	1.1	10
9558	From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2511-2513.	0.8	22
9559	Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-1 Treatment Assessment. <i>Cells</i> , 2019, 8, 526.	1.8	14
9560	Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1897-1905.	1.2	4
9561	Gene editing for immune cell therapies. <i>Nature Biotechnology</i> , 2019, 37, 1425-1434.	9.4	147
9562	Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles. <i>Molecules</i> , 2019, 24, 2071.	1.7	106
9563	Triptolide reverses helper T cell inhibition and down-regulates IFN- γ induced PD-L1 expression in glioma cell lines. <i>Journal of Neuro-Oncology</i> , 2019, 143, 429-436.	1.4	25

#	ARTICLE	IF	CITATIONS
9564	Solid Tumors Challenges and New Insights of CAR T Cell Engineering. <i>Stem Cell Reviews and Reports</i> , 2019, 15, 619-636.	1.7	71
9565	IL-27 promotes the expansion of self-renewing CD8+ T cells in persistent viral infection. <i>Journal of Experimental Medicine</i> , 2019, 216, 1791-1808.	4.2	45
9566	Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 54.	6.9	416
9567	PD-L1 and PD-L2 expression correlated genes in non-small cell lung cancer. <i>Cancer Communications</i> , 2019, 39, 1-14.	3.7	66
9568	Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma. <i>PLoS ONE</i> , 2019, 14, e0217762.	1.1	18
9569	Phase II study of avelumab in multiple relapsed/refractory germ cell cancer. <i>Investigational New Drugs</i> , 2019, 37, 748-754.	1.2	48
9570	Pathogenesis of fulminant type 1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patient-derived induced pluripotent stem cells for future research. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1158-1164.	1.1	30
9571	The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. <i>Journal of Oncology</i> , 2019, 2019, 1-13.	0.6	21
9572	Inhibition of the Nkp44-PCNA Immune Checkpoint Using a mAb to PCNA. <i>Cancer Immunology Research</i> , 2019, 7, 1120-1134.	1.6	26
9573	Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019, 11, 762.	1.7	5
9574	Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection. <i>BJS Open</i> , 2019, 3, 500-508.	0.7	40
9575	Radiation myelitis after durvalumab administration following chemoradiotherapy for locally advanced non-small cell lung cancer: an illustrative case report and review of the literature. <i>International Cancer Conference Journal</i> , 2019, 8, 118-121.	0.2	12
9576	Salvage treatment with anlotinib for advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1590-1596.	0.8	25
9577	Identification of CTRP1 as a Prognostic Biomarker and Oncogene in Human Glioblastoma. <i>BioMed Research International</i> , 2019, 2019, 1-11.	0.9	12
9578	Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Journal of Oncology</i> , 2019, 2019, 1-17.	0.6	55
9579	Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5351-5363.	3.2	57
9580	β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1124-1141.	7.7	498
9581	An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. <i>Cancer Immunology Research</i> , 2019, 7, 1267-1279.	1.6	92

#	ARTICLE	IF	CITATIONS
9582	Immune checkpoint inhibitors in the treatment of virus-associated cancers. <i>Journal of Hematology and Oncology</i> , 2019, 12, 58.	6.9	43
9583	Pathway-specific protein domains are predictive for human diseases. <i>PLoS Computational Biology</i> , 2019, 15, e1007052.	1.5	8
9584	Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay. <i>Oncologist</i> , 2019, 24, e1401-e1408.	1.9	9
9585	Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?. <i>Annals of Translational Medicine</i> , 2019, 7, S7-S7.	0.7	20
9586	Hyperprogression under Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2674.	1.8	96
9587	The Evolving Role of CD8+CD28 ^{hi} Immunosenescent T Cells in Cancer Immunology. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2810.	1.8	105
9588	Modeling Breast Cancer via an Intraductal Injection of Cre-expressing Adenovirus into the Mouse Mammary Gland. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	2
9589	The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer. <i>International Journal of Biological Sciences</i> , 2019, 15, 919-928.	2.6	21
9590	Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer. <i>Disease Markers</i> , 2019, 2019, 1-10.	0.6	7
9591	Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1374-1385.	1.9	26
9592	Tumor Lymphatic Function Regulates Tumor Inflammatory and Immunosuppressive Microenvironments. <i>Cancer Immunology Research</i> , 2019, 7, 1345-1358.	1.6	31
9593	Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. <i>BMC Cancer</i> , 2019, 19, 558.	1.1	106
9594	Intratatumoral Estrogen Receptor Heterogeneity of Expression in Human Epidermal Growth Factor Receptor 2 ⁺ Positive Breast Cancer as Evaluated by a Brightfield Multiplex Assay. <i>Journal of Histochemistry and Cytochemistry</i> , 2019, 67, 563-574.	1.3	5
9595	Combination treatment with nivolumab and Rigrivir of a progressive stage IIC skin melanoma patient. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1191-1196.	0.2	1
9596	Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 4619-4630.	0.9	5
9597	TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas. <i>Cancer Management and Research</i> , 2019, Volume 11, 4743-4756.	0.9	9
9598	Long non-coding RNA H19 promotes the proliferation and invasion of lung cancer cells and regulates the expression of E-cadherin, N-cadherin, and vimentin. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4099-4107.	1.0	32
9599	The Treatment of Refractory Pituitary Adenomas. <i>Frontiers in Endocrinology</i> , 2019, 10, 334.	1.5	26

#	ARTICLE	IF	CITATIONS
9600	Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles. <i>Frontiers in Medicine</i> , 2019, 6, 113.	1.2	25
9601	Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and SÃ©zary Syndrome. <i>Frontiers in Medicine</i> , 2019, 6, 116.	1.2	28
9602	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. <i>Frontiers in Medicine</i> , 2019, 6, 119.	1.2	145
9603	HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2754.	1.8	43
9604	Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100866.	0.2	6
9605	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 255.	3.5	577
9606	Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 412-420.	0.6	6
9607	Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 690.	1.7	57
9608	Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 627-644.	2.1	29
9609	Computer-assisted image analysis of the tumor microenvironment on an oral tongue squamous cell carcinoma tissue microarray. <i>Clinical and Translational Radiation Oncology</i> , 2019, 17, 32-39.	0.9	14
9610	Pan-cancer analysis connects tumor matrisome to immune response. <i>Npj Precision Oncology</i> , 2019, 3, 15.	2.3	58
9611	Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1131-1141.	3.0	116
9612	The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma. <i>British Journal of Radiology</i> , 2019, 92, 20181031.	1.0	20
9613	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 305-343.	157.7	203
9614	New Insights into Molecular Oncogenesis and Therapy of Uveal Melanoma. <i>Cancers</i> , 2019, 11, 694.	1.7	23
9615	PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2019, 11, 695.	1.7	12
9616	Actin Cytoskeleton Straddling the Immunological Synapse between Cytotoxic Lymphocytes and Cancer Cells. <i>Cells</i> , 2019, 8, 463.	1.8	41
9617	Modelâ€­Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Nonâ€­Small Cell Lung Cancer. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1415-1424.	1.0	12

#	ARTICLE	IF	CITATIONS
9618	TAAR1 levels and sub-cellular distribution are cell line but not breast cancer subtype specific. <i>Histochemistry and Cell Biology</i> , 2019, 152, 155-166.	0.8	12
9619	Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review. <i>Current Rheumatology Reports</i> , 2019, 21, 28.	2.1	22
9620	Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway. <i>Journal of Experimental Medicine</i> , 2019, 216, 1525-1541.	4.2	23
9621	MEXPRESS update 2019. <i>Nucleic Acids Research</i> , 2019, 47, W561-W565.	6.5	179
9622	Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer. <i>BMC Cancer</i> , 2019, 19, 465.	1.1	13
9623	Turning the Tide Against Regulatory T Cells. <i>Frontiers in Oncology</i> , 2019, 9, 279.	1.3	47
9624	Development of immune checkpoint therapy for cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 1244-1254.	4.2	125
9625	Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity?. <i>Cancer Research</i> , 2019, 79, 2447-2456.	0.4	41
9626	Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy. <i>Cancer Research</i> , 2019, 79, 3455-3465.	0.4	60
9627	Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. , 2019, 7, 121.		71
9628	PD1 pathway in immune-mediated myopathies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e558.	3.1	42
9629	Somatic mutations render human exome and pathogen DNA more similar. <i>PLoS ONE</i> , 2019, 14, e0197949.	1.1	0
9630	Immune checkpoint inhibitors in malignancy. <i>Australian Prescriber</i> , 2019, 42, 62.	0.5	24
9631	Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1061-1068.	1.0	26
9632	Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke. <i>Oncology and Therapy</i> , 2019, 7, 83-91.	1.0	5
9633	Dilated cardiomyopathy. <i>Nature Reviews Disease Primers</i> , 2019, 5, 32.	18.1	347
9634	Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984346.	1.4	19
9635	Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates. , 2019, 7, 123.		2

#	ARTICLE	IF	CITATIONS
9636	Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. <i>Genetics and Molecular Biology</i> , 2019, 42, 215-231.	0.6	14
9637	Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2258.	1.8	31
9638	T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 569-577.	1.1	18
9639	Emerging Role of SOX Proteins in Breast Cancer Development and Maintenance. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019, 24, 213-230.	1.0	24
9640	The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes. <i>Targeted Oncology</i> , 2019, 14, 247-252.	1.7	17
9641	Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. , 2019, 7, 128.		27
9642	Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis. <i>Oncologist</i> , 2019, 24, 829-835.	1.9	8
9643	Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors. <i>Journal of Thoracic Disease</i> , 2019, 11, 1117-1123.	0.6	46
9644	Myocarditis in Humans and in Experimental Animal Models. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 64.	1.1	99
9645	Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. <i>Frontiers in Immunology</i> , 2019, 10, 1205.	2.2	292
9646	The Role of CDK4/6 Inhibitors in Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 52.	1.3	39
9647	Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. <i>Clinical Neurophysiology</i> , 2019, 130, 1440-1445.	0.7	44
9648	Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 268-280.	0.8	21
9649	Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications. <i>Breast Cancer Research</i> , 2019, 21, 65.	2.2	78
9650	<p>Expression of PD-L1 in cervical carcinoma and its impact on survival associated with T-cell infiltration and FoxP3 expression<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4597-4605.	0.9	10
9651	Immunoprofiling of Breast Cancer Antigens Using Antibodies Derived from Local Lymph Nodes. <i>Cancers</i> , 2019, 11, 682.	1.7	10
9652	Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors. <i>Journal of Clinical Medicine</i> , 2019, 8, 695.	1.0	48
9653	Estrogen receptor signaling is reprogrammed during breast tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11437-11443.	3.3	55

#	ARTICLE	IF	CITATIONS
9654	Cytoplasmic HAX1 Is an Independent Risk Factor for Breast Cancer Metastasis. <i>Journal of Oncology</i> , 2019, 2019, 1-13.	0.6	8
9655	Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 640-647.	1.9	32
9656	Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 804.	2.2	65
9657	Pembrolizumab for the Treatment of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 143-154.	4.2	25
9658	Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. <i>BMC Cancer</i> , 2019, 19, 415.	1.1	49
9659	Proteins with Evolutionarily Hypervariable Domains are Associated with Immune Response and Better Survival of Basal-like Breast Cancer Patients. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 430-440.	1.9	27
9660	Adaptive immune cells in calcific aortic valve disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 317, H141-H155.	1.5	47
9661	Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	34
9662	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. , 2019, 7, 119.		35
9663	Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 93-106.	2.0	107
9664	Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity. <i>Immunology</i> , 2019, 157, 232-247.	2.0	79
9665	USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability. <i>Science Advances</i> , 2019, 5, eaav3235.	4.7	79
9666	Programming Structured DNA Assemblies to Probe Biophysical Processes. <i>Annual Review of Biophysics</i> , 2019, 48, 395-419.	4.5	56
9667	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. <i>Cancer Immunology Research</i> , 2019, 7, 1214-1220.	1.6	44
9668	Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma. <i>Frontiers in Medicine</i> , 2019, 6, 86.	1.2	18
9669	Identifying the Antiproliferative Effect of Astragalus Polysaccharides on Breast Cancer: Coupling Network Pharmacology With Targetable Screening From the Cancer Genome Atlas. <i>Frontiers in Oncology</i> , 2019, 9, 368.	1.3	27
9670	Antitumor activity of ginsenoside Rg3 in melanoma through downregulation of the ERK and Akt pathways. <i>International Journal of Oncology</i> , 2019, 54, 2069-2079.	1.4	27
9672	Tertiary lymphoid structures in the era of cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 307-325.	12.8	879

#	ARTICLE	IF	CITATIONS
9673	Tensor clustering with algebraic constraints gives interpretable groups of crosstalk mechanisms in breast cancer. <i>Journal of the Royal Society Interface</i> , 2019, 16, 20180661.	1.5	3
9674	CD91 on dendritic cells governs immunosurveillance of nascent, emerging tumors. <i>JCI Insight</i> , 2019, 4, .	2.3	17
9675	Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report. <i>Lung Cancer Management</i> , 2019, 8, LMT10.	1.5	5
9676	Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition. <i>Frontiers in Immunology</i> , 2019, 10, 867.	2.2	36
9677	Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer. <i>Cancers</i> , 2019, 11, 646.	1.7	37
9678	Treatment of Metastatic Disease through Natural Killer Cell Modulation by Infected Cell Vaccines. <i>Viruses</i> , 2019, 11, 434.	1.5	4
9679	Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1087-1094.	2.0	22
9680	Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 1443-1450.	1.8	40
9681	A Ca ²⁺ -ATPase Regulates E-cadherin Biogenesis and Epithelialâ€“Mesenchymal Transition in Breast Cancer Cells. <i>Molecular Cancer Research</i> , 2019, 17, 1735-1747.	1.5	24
9682	Recent advances in triple negative breast cancer: the immunotherapy era. <i>BMC Medicine</i> , 2019, 17, 90.	2.3	267
9683	Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2241.	1.8	93
9684	Decoding the link between WWOX and p53 in aggressive breast cancer. <i>Cell Cycle</i> , 2019, 18, 1177-1186.	1.3	18
9685	Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 187.	3.5	16
9686	Human transposons are an abundant supply of transcription factor binding sites and promoter activities in breast cancer cell lines. <i>Mobile DNA</i> , 2019, 10, 16.	1.3	21
9687	Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors. <i>Lung Cancer Management</i> , 2019, 8, LMT11.	1.5	58
9688	AVAILABLE NIS â€“ AVASTINÂ® in lung cancer treatment in routine oncology practice in Germany. <i>BMC Cancer</i> , 2019, 19, 433.	1.1	9
9689	Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. <i>Immunity</i> , 2019, 50, 1498-1512.e5.	6.6	406
9690	Abscopal Effects in Radio-Immunotherapyâ€“Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition. <i>Frontiers in Pharmacology</i> , 2019, 10, 511.	1.6	56

#	ARTICLE	IF	CITATIONS
9691	Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. <i>Cancers</i> , 2019, 11, 624.	1.7	32
9692	Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells. <i>Journal of Clinical Medicine</i> , 2019, 8, 642.	1.0	47
9693	Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer. <i>International Journal of Oncology</i> , 2019, 54, 2030-2038.	1.4	34
9694	High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC. <i>Molecular Medicine Reports</i> , 2019, 19, 4881-4889.	1.1	9
9695	Low frequency of mismatch repair deficiency in gallbladder cancer. <i>Diagnostic Pathology</i> , 2019, 14, 36.	0.9	19
9696	PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 193.	3.5	61
9697	Clinical and Pathological Aspects of Silent Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2473-2489.	1.8	120
9698	Local and systemic delivery of mRNA encoding survivin-T34A by lipoplex for efficient colon cancer gene therapy. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 2733-2751.	3.3	41
9699	Breast Cancer Tumor Stroma: Cellular Components, Phenotypic Heterogeneity, Intercellular Communication, Prognostic Implications and Therapeutic Opportunities. <i>Cancers</i> , 2019, 11, 664.	1.7	67
9700	A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. <i>Cancers</i> , 2019, 11, 665.	1.7	25
9701	Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. <i>Oncology Letters</i> , 2019, 17, 2647-2656.	0.8	56
9702	Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor. <i>ACS Nano</i> , 2019, 13, 6477-6490.	7.3	36
9703	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. <i>BioMed Research International</i> , 2019, 2019, 1-15.	0.9	37
9704	Portrait of a cancer: mutational signature analyses for cancer diagnostics. <i>BMC Cancer</i> , 2019, 19, 457.	1.1	84
9705	Genomic Profiling of the Steroidogenic Acute Regulatory Protein in Breast Cancer: In Silico Assessments and a Mechanistic Perspective. <i>Cancers</i> , 2019, 11, 623.	1.7	10
9706	Unleashing Tumour-Dendritic Cells to Fight Cancer by Tackling Their Three AAs: Abundance, Activation and Antigen-Delivery. <i>Cancers</i> , 2019, 11, 670.	1.7	15
9707	Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. <i>Journal of Pathology</i> , 2019, 249, 151-165.	2.1	80
9708	Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCR β diversity. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1095-1106.	2.0	5

#	ARTICLE	IF	CITATIONS
9709	Efficient development and expression of scFv recombinant proteins against PD-L1 surface domain and potency in cancer therapy. <i>Cytotechnology</i> , 2019, 71, 705-722.	0.7	7
9710	Computational analysis of hot spots and binding mechanism in the PD-1/PD-L1 interaction. <i>RSC Advances</i> , 2019, 9, 14944-14956.	1.7	23
9711	Nivolumab and immune-mediated colitis. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 644-647.	0.2	3
9712	The Discovery of Biomarkers in Cancer Immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 484-497.	1.9	31
9713	Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature. <i>Respiratory Medicine Case Reports</i> , 2019, 27, 100834.	0.2	25
9714	The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival. <i>Communications Biology</i> , 2019, 2, 135.	2.0	49
9715	Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges. <i>Precision Clinical Medicine</i> , 2019, 2, 57-70.	1.3	24
9716	Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients. <i>Thoracic Cancer</i> , 2019, 10, 1303-1309.	0.8	12
9717	Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper. <i>Radiology</i> , 2019, 292, 25-34.	3.6	57
9718	Unlike PD-L1, PD-1 Is Downregulated on Partial Immune Cells in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-8.	1.0	16
9719	Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721983928.	0.9	13
9720	Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients. <i>Cancer Cell International</i> , 2019, 19, 101.	1.8	49
9721	The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination. <i>Journal of Thoracic Disease</i> , 2019, 11, S347-S351.	0.6	6
9722	Gene Expression Profiling for Diagnosis of Triple-Negative Breast Cancer: A Multicenter, Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2019, 9, 354.	1.3	29
9723	The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer—Ways of Enhancing Immunotherapy Action. <i>Cancers</i> , 2019, 11, 533.	1.7	37
9724	Immunophenotype of T Cells Expressing Programmed Death-1 and Cytotoxic T Cell Antigen-4 in Early Lung Cancer: Local vs. Systemic Immune Response. <i>Cancers</i> , 2019, 11, 567.	1.7	17
9725	A four-gene signature for prognosis in breast cancer patients with hypermethylated IL15RA. <i>Oncology Letters</i> , 2019, 17, 4245-4254.	0.8	11
9726	A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 351-358.	1.1	8

#	ARTICLE	IF	CITATIONS
9727	Deep learning and manual assessment show that the absolute mitotic count does not contain prognostic information in triple negative breast cancer. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 555-569.	2.1	16
9728	Managing cardiotoxicity associated with immune checkpoint inhibitors. <i>Chronic Diseases and Translational Medicine</i> , 2019, 5, 6-14.	0.9	52
9729	Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation. <i>Npj Breast Cancer</i> , 2019, 5, 14.	2.3	38
9730	VIGLA-M: visual gene expression data analytics. <i>BMC Bioinformatics</i> , 2019, 20, 150.	1.2	8
9731	Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. , 2019, 7, 106.		203
9732	LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1874.	1.8	39
9733	Immunometabolism: A new target for improving cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 195-253.	1.9	30
9734	Conjunctival Melanoma in Childhood and Adolescence: A Systematic Review. <i>Ocular Oncology and Pathology</i> , 2019, 5, 387-395.	0.5	6
9735	Treatment of malignant pleural effusions: the case for localized immunotherapy. , 2019, 7, 110.		34
9736	Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	192
9737	Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. <i>Cancer Immunology Research</i> , 2019, 7, 866-873.	1.6	23
9738	Understanding the mechanisms of immune-evasion by lung cancer in the context of chronic inflammation in emphysema. <i>Journal of Thoracic Disease</i> , 2019, 11, 382-385.	0.6	2
9739	The Double-Edged Swordâ€™How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 653.	2.2	37
9740	Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 264.	1.3	87
9741	PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity. <i>Frontiers in Oncology</i> , 2019, 9, 343.	1.3	47
9742	Flavonoids: New Frontier for Immuno-Regulation and Breast Cancer Control. <i>Antioxidants</i> , 2019, 8, 103.	2.2	64
9743	CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1903.	1.8	15
9744	Beyond PD-L1 Markers for Lung Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1915.	1.8	61

#	ARTICLE	IF	CITATIONS
9745	In silico markers: an evolutionary and statistical approach to select informative genes of human breast cancer subtypes. <i>Genes and Genomics</i> , 2019, 41, 1371-1382.	0.5	3
9746	A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors. <i>Oncologist</i> , 2019, 24, 891-e431.	1.9	25
9747	Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2173.	1.8	68
9748	Lazarus-Type Tumour Response to Therapy with Nivolumab for Sarcomatoid Carcinomas of the Lung. <i>Current Oncology</i> , 2019, 26, 270-273.	0.9	17
9749	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. <i>Science</i> , 2019, 364, 485-491.	6.0	395
9750	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1025-1035.	1.6	70
9751	The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984159.	1.1	23
9752	Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study. <i>Journal of Ovarian Research</i> , 2019, 12, 37.	1.3	31
9753	Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. <i>Genome Medicine</i> , 2019, 11, 28.	3.6	107
9754	Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2505-2512.	1.0	17
9755	Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2513-2518.	1.0	25
9756	Immune check-point in endometrial cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 910-916.	1.0	34
9757	Synthesis and initial evaluation of radioactive 5-I ¹²⁵ -methyl-tryptophan: a Trp based agent targeting IDO-1. <i>MedChemComm</i> , 2019, 10, 814-816.	3.5	2
9758	Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations. <i>Cancer Immunology Research</i> , 2019, 7, 910-922.	1.6	68
9759	Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIA non-small-cell lung cancer (NSCLC): the NEOMUN trial. <i>BMC Cancer</i> , 2019, 19, 413.	1.1	57
9760	Emerging therapies for small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 47.	6.9	273
9761	A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology. <i>Current Oncology</i> , 2019, 26, 241-254.	0.9	34
9762	Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response. <i>Journal of Immunology</i> , 2019, 202, 3524-3536.	0.4	34

#	ARTICLE	IF	CITATIONS
9763	Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2019, 2, e193433.	2.8	8
9764	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. <i>International Journal of Clinical Oncology</i> , 2019, 24, 731-770.	1.0	100
9765	Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG. <i>Frontiers in Immunology</i> , 2019, 10, 704.	2.2	95
9766	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 303.	1.3	8
9767	A Network Approach to Developing Immuno-Oncology Combinations in Canada. <i>Current Oncology</i> , 2019, 26, 73-79.	0.9	1
9768	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	3.4	526
9769	The Need to Prioritize and Re-prioritize Palliative Care Options: Smoking Cessation as a Case-in-Point. <i>Current Treatment Options in Oncology</i> , 2019, 20, 33.	1.3	0
9771	Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform. <i>MAbs</i> , 2019, 11, 666-680.	2.6	25
9772	Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1474-1483.	1.9	38
9773	Clinicopathologic characteristics, tumor infiltrating lymphocytes and programmed cell death ligand-1 expression in 162 endometrial carcinomas with deficient mismatch repair function. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 113-118.	1.2	8
9774	Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541984637.	0.8	48
9775	BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer. <i>BMC Cancer</i> , 2019, 19, 387.	1.1	17
9776	Complicated prognostic values of CCL28 in breast cancer by subtype. <i>Journal of Thoracic Disease</i> , 2019, 11, 777-787.	0.6	9
9777	Role of Hedgehog Signaling in Breast Cancer: Pathogenesis and Therapeutics. <i>Cells</i> , 2019, 8, 375.	1.8	79
9778	Rational design of anti-GITR-based combination immunotherapy. <i>Nature Medicine</i> , 2019, 25, 759-766.	15.2	180
9779	ROS Reduction Does Not Decrease the Anticancer Efficacy of X-Ray in Two Breast Cancer Cell Lines. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-12.	1.9	12
9780	Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 50.	1.8	139
9781	Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 434-454.	3.3	131

#	ARTICLE	IF	CITATIONS
9782	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. <i>Trends in Immunology</i> , 2019, 40, 511-523.	2.9	180
9783	PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. <i>Molecular Cell</i> , 2019, 74, 1215-1226.e4.	4.5	144
9784	Regulation of regulatory T cells in cancer. <i>Immunology</i> , 2019, 157, 219-231.	2.0	45
9785	Introduction to Mathematical Oncology. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-4.	1.0	23
9786	Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 757.	2.2	119
9787	The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations. <i>Molecular and Clinical Oncology</i> , 2019, 10, 610-614.	0.4	4
9788	The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer. <i>Journal of Gastroenterology</i> , 2019, 54, 1019-1028.	2.3	6
9789	ClinOmicsTrailbc: a visual analytics tool for breast cancer treatment stratification. <i>Bioinformatics</i> , 2019, 35, 5171-5181.	1.8	11
9790	Implications of Immunotherapy in Hepatobiliary Tumors. <i>Visceral Medicine</i> , 2019, 35, 18-26.	0.5	6
9791	The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 54.	2.2	57
9792	rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2082.	1.8	6
9793	Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 88.		51
9794	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. <i>Journal of Clinical Oncology</i> , 2019, 37, 72-80.	0.8	17
9795	Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?. <i>Stem Cell Investigation</i> , 2019, 6, 4-4.	1.3	1
9796	CD8+ T cell exhaustion. <i>Seminars in Immunopathology</i> , 2019, 41, 327-337.	2.8	169
9797	A Human Organotypic Microfluidic Tumor Model Permits Investigation of the Interplay between Patient-Derived Fibroblasts and Breast Cancer Cells. <i>Cancer Research</i> , 2019, 79, 3139-3151.	0.4	88
9798	Engineering Multidimensional Evolutionary Forces to Combat Cancer. <i>Cancer Discovery</i> , 2019, 9, 587-604.	7.7	13
9799	Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis. <i>BMC Cancer</i> , 2019, 19, 353.	1.1	27

#	ARTICLE	IF	CITATIONS
9800	Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 162.	3.5	116
9801	Age Is Important for the Early-Stage Detection of Breast Cancer on Both Transcriptomic and Methyloomic Biomarkers. <i>Frontiers in Genetics</i> , 2019, 10, 212.	1.1	11
9802	Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. <i>Cancers</i> , 2019, 11, 462.	1.7	20
9803	PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1631.	1.8	59
9804	Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1692.	1.8	61
9805	Polyphenols as Immunomodulatory Compounds in the Tumor Microenvironment: Friends or Foes?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1714.	1.8	54
9806	Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 415-427.	1.3	53
9807	Co-stimulatory and co-inhibitory pathways in cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 145-194.	1.9	53
9808	Impact of the microbiome on cancer progression and response to anti-cancer therapies. <i>Advances in Cancer Research</i> , 2019, 143, 255-294.	1.9	23
9809	Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. <i>Oncolmmunology</i> , 2019, 8, e1570778.	2.1	19
9810	Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer. <i>Oncolmmunology</i> , 2019, 8, e1586042.	2.1	16
9811	TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1202-1215.	3.0	39
9812	Dual TGF β /BMP Pathway Inhibition Enables Expansion and Characterization of Multiple Epithelial Cell Types of the Normal and Cancerous Breast. <i>Molecular Cancer Research</i> , 2019, 17, 1556-1570.	1.5	16
9813	Highly efficient hypothesis testing methods for regression-type tests with correlated observations and heterogeneous variance structure. <i>BMC Bioinformatics</i> , 2019, 20, 185.	1.2	3
9814	Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. <i>BMC Cancer</i> , 2019, 19, 298.	1.1	24
9815	Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 360.	1.1	52
9816	The role of photodynamic therapy on multidrug resistant breast cancer. <i>Cancer Cell International</i> , 2019, 19, 91.	1.8	70
9817	Complementing the Cancer-Immunity Cycle. <i>Frontiers in Immunology</i> , 2019, 10, 774.	2.2	136

#	ARTICLE	IF	CITATIONS
9818	Protein interaction disruption in cancer. <i>BMC Cancer</i> , 2019, 19, 370.	1.1	7
9819	Advanced assessment of migration and invasion of cancer cells in response to mifepristone therapy using double fluorescence cytochemical labeling. <i>BMC Cancer</i> , 2019, 19, 376.	1.1	44
9820	Multiple antigen-engineered DC vaccines with or without IFN γ to promote antitumor immunity in melanoma. , 2019, 7, 113.		31
9821	Increased RNA Expression of von Willebrand Factor Gene Is Associated With Infiltrating Lobular Breast Cancer and Normal PAM50 Subtype. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 147-153.	1.0	11
9822	Proteasome 26S Subunit, non-ATPase 3 (PSMD3) Regulates Breast Cancer by Stabilizing HER2 from Degradation. <i>Cancers</i> , 2019, 11, 527.	1.7	29
9823	An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1822.	1.8	66
9824	Cell Reprogramming in Tumorigenesis and Its Therapeutic Implications for Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1827.	1.8	14
9825	Can Tumor-Infiltrating Lymphocytes (TILs) Be a Predictive Factor for Lymph Nodes Status in Both Early Stage and Locally Advanced Breast Cancer?. <i>Journal of Clinical Medicine</i> , 2019, 8, 545.	1.0	8
9826	Cystine α -glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9533-9542.	3.3	108
9827	PD-1 ^{hi} regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9999-10008.	3.3	655
9828	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 42.	6.9	58
9829	Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. <i>PLoS ONE</i> , 2019, 14, e0215381.	1.1	73
9830	Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 195-206.	1.0	13
9831	Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 221-228.	1.0	24
9832	Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers. <i>JAMA Network Open</i> , 2019, 2, e192906.	2.8	36
9833	Lymph α circulating tumor cells show distinct properties to blood α circulating tumor cells and are efficient metastatic precursors. <i>Molecular Oncology</i> , 2019, 13, 1400-1418.	2.1	19
9834	Nivolumab-induced myocardial necrosis in a patient with lung cancer: A case report. <i>Respiratory Medicine Case Reports</i> , 2019, 27, 100839.	0.2	8
9835	Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983992.	1.4	48

#	ARTICLE	IF	CITATIONS
9836	Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials. <i>BMC Cancer</i> , 2019, 19, 392.	1.1	7
9837	Case report: reinitiating pembrolizumab treatment after small bowel perforation. <i>BMC Cancer</i> , 2019, 19, 379.	1.1	14
9838	Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells. <i>Journal of Hematology and Oncology</i> , 2019, 12, 46.	6.9	23
9839	Emerging therapies for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 45.	6.9	111
9840	KEYNOTE-024: goodbye to chemotherapy?. <i>Journal of Thoracic Disease</i> , 2019, 11, S428-S432.	0.6	3
9841	Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 52.	1.8	222
9842	Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. <i>Frontiers in Immunology</i> , 2019, 10, 496.	2.2	69
9843	Next-Generation Cancer Immunotherapy Targeting Glypican-3. <i>Frontiers in Oncology</i> , 2019, 9, 248.	1.3	86
9844	Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity—From Case Report to Mouse Model Validation. <i>Cancers</i> , 2019, 11, 580.	1.7	28
9845	The Role of the Immune System in Cutaneous Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2009.	1.8	81
9846	Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations. <i>Cancer Cytopathology</i> , 2019, 127, 447-457.	1.4	12
9847	Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. <i>Medical Oncology</i> , 2019, 36, 49.	1.2	16
9848	Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 393-404.	1.1	26
9849	Inhibition of EphB4–Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers. <i>Cancer Research</i> , 2019, 79, 2722-2735.	0.4	36
9850	MGSEA – a multivariate Gene set enrichment analysis. <i>BMC Bioinformatics</i> , 2019, 20, 145.	1.2	11
9851	Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 156.	1.3	119
9852	Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product. <i>Molecules</i> , 2019, 24, 1059.	1.7	14
9853	Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. <i>British Journal of Surgery</i> , 2019, 106, 519-522.	0.1	35

#	ARTICLE	IF	CITATIONS
9854	Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1341-1349.	1.2	19
9855	Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000591.	1.2	137
9856	Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. , 2019, 7, 80.		65
9857	<p>Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1631-1640.	0.9	9
9858	Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets. <i>Cancers</i> , 2019, 11, 380.	1.7	33
9859	Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 385.	1.0	21
9860	Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. , 2019, 7, 82.		76
9861	The Ins and Outs of Chemokine-Mediated Immune Cell Trafficking in Skin Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 386.	2.2	11
9862	Antigen Targets for the Development of Immunotherapies in Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1397.	1.8	10
9863	PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1405.	1.8	36
9864	Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 89-99.	0.7	8
9865	Induction/reversal of drug resistance in gastric cancer by non-coding RNAs (Review). <i>International Journal of Oncology</i> , 2019, 54, 1511-1524.	1.4	21
9866	Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets. <i>Current Oncology Reports</i> , 2019, 21, 37.	1.8	72
9867	Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 1464-1471.	1.2	1
9868	Propofol Reduced Mammosphere Formation of Breast Cancer Stem Cells via PD-L1/Nanog In Vitro. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-9.	1.9	20
9869	Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. <i>Cancer Immunology Research</i> , 2019, 7, 805-812.	1.6	22
9870	Site-Specific Immuno-PET Tracer to Image PD-L1. <i>Molecular Pharmaceutics</i> , 2019, 16, 2028-2036.	2.3	41
9871	Granulomatosis with polyangiitis in a patient with biopsy-proven IgG4-related pulmonary disease and coincident small cell lung cancer. <i>BMJ Case Reports</i> , 2019, 12, e226280.	0.2	17

#	ARTICLE	IF	CITATIONS
9872	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019, 21, 39.	2.2	17
9873	<p>A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1791-1801.	1.0	20
9874	Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?. <i>Frontiers in Oncology</i> , 2019, 9, 166.	1.3	61
9875	Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1283.	1.8	296
9876	Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies. <i>Viruses</i> , 2019, 11, 269.	1.5	26
9877	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. <i>Medical Oncology</i> , 2019, 36, 35.	1.2	4
9878	Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. <i>Cancer Cell</i> , 2019, 35, 347-367.	7.7	533
9879	Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. <i>EBioMedicine</i> , 2019, 42, 281-295.	2.7	94
9880	Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. <i>EBioMedicine</i> , 2019, 42, 363-374.	2.7	257
9881	Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment. <i>Journal of Thoracic Oncology</i> , 2019, 14, 914-923.	0.5	66
9882	Immunotherapy in colorectal cancer: rationale, challenges and potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 361-375.	8.2	1,039
9883	PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1111-1122.	1.4	297
9884	MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-7.	0.7	21
9885	CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 131.	3.5	21
9886	Branched clonal evolution: nodal follicular lymphoma and primary diffuse large B-cell lymphoma of the central nervous system. <i>Haematologica</i> , 2019, 104, e326-e329.	1.7	1
9887	Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer Physiopathology. <i>Frontiers in Immunology</i> , 2019, 10, 348.	2.2	89
9888	Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report. <i>Oncology Letters</i> , 2019, 17, 4011-4015.	0.8	8
9889	Implementation of Mass Cytometry for Immunoprofiling of Patients with Solid Tumors. <i>Journal of Immunology Research</i> , 2019, 2019, 1-10.	0.9	3

#	ARTICLE	IF	CITATIONS
9890	Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. <i>EJNMMI Research</i> , 2019, 9, 8.	1.1	121
9891	Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 47.	1.3	52
9892	Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1349-1361.	0.3	23
9893	Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer. <i>Visceral Medicine</i> , 2019, 35, 28-37.	0.5	7
9894	Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 84.	1.3	18
9895	MicroRNA-Mediated Suppression of the TGF- β 2 Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. <i>Cell Reports</i> , 2019, 26, 2667-2680.e7.	2.9	101
9896	Genomic correlates of response to immune checkpoint blockade. <i>Nature Medicine</i> , 2019, 25, 389-402.	15.2	346
9897	HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503. <i>Scientific Reports</i> , 2019, 9, 3352.	1.6	15
9898	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591982771.	1.4	38
9899	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. <i>BMC Cancer</i> , 2019, 19, 196.	1.1	126
9900	The neoepitope landscape of breast cancer: implications for immunotherapy. <i>BMC Cancer</i> , 2019, 19, 200.	1.1	68
9901	Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 70.	1.8	162
9902	\pm -PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by \pm -TGF β 2 antibody to promote durable rejection and immunity in squamous cell carcinomas. , 2019, 7, 62.		121
9903	Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. <i>CNS Oncology</i> , 2019, 8, CNS28.	1.2	169
9904	Identification of the Germline Mutation Profile in Esophageal Squamous Cell Carcinoma by Whole Exome Sequencing. <i>Frontiers in Genetics</i> , 2019, 10, 47.	1.1	14
9905	Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer. <i>Cancers</i> , 2019, 11, 298.	1.7	10
9906	Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 918-927.	1.1	26
9907	Identifying genes with tri-modal association with survival and tumor grade in cancer patients. <i>BMC Bioinformatics</i> , 2019, 20, 13.	1.2	3

#	ARTICLE	IF	CITATIONS
9908	I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms. <i>Genome Biology</i> , 2019, 20, 52.	3.8	7
9909	Radiotherapy enhances responses of lung cancer to CTLA-4 blockade. , 2019, 7, 64.		16
9910	A data-driven interactome of synergistic genes improves network-based cancer outcome prediction. <i>PLoS Computational Biology</i> , 2019, 15, e1006657.	1.5	13
9911	A new computational drug repurposing method using established disease-drug pair knowledge. <i>Bioinformatics</i> , 2019, 35, 3672-3678.	1.8	33
9912	GSK3 β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 37.	2.2	102
9913	Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. <i>Cancers</i> , 2019, 11, 305.	1.7	51
9914	Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. <i>International Journal of Clinical Oncology</i> , 2019, 24, 461-467.	1.0	7
9915	Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2019, 21, 34.	1.8	37
9916	Surrogate minimal depth as an importance measure for variables in random forests. <i>Bioinformatics</i> , 2019, 35, 3663-3671.	1.8	26
9917	EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene-negative. <i>Thoracic Cancer</i> , 2019, 10, 1256-1259.	0.8	5
9918	Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 4592-4602.	3.2	447
9919	Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth. <i>Clinical Cancer Research</i> , 2019, 25, 3643-3657.	3.2	128
9920	Progression after Immunotherapy for Fibrolamellar Carcinoma. <i>Visceral Medicine</i> , 2019, 35, 39-42.	0.5	19
9921	The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours. <i>Breast Cancer Research</i> , 2019, 21, 34.	2.2	48
9922	Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report. , 2019, 7, 59.		9
9923	A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine. , 2019, 7, 60.		33
9924	Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. <i>PLoS ONE</i> , 2019, 14, e0212513.	1.1	294
9925	Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the <i>Kras</i> G12D+; <i>p53</i> fl/fl; myristolated <i>p110</i> fl/fl <i>ROSA</i> -gfp mouse. <i>PLoS ONE</i> , 2019, 14, e0212930.	1.1	12

#	ARTICLE	IF	CITATIONS
9926	Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China. <i>Oncologist</i> , 2019, 24, S11-S20.	1.9	2
9927	<p>Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1433-1442.	0.9	32
9928	Primary Immunodeficiency and Cancer Predisposition Revisited: Embedding Two Closely Related Concepts Into an Integrative Conceptual Framework. <i>Frontiers in Immunology</i> , 2018, 9, 3136.	2.2	47
9929	Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?. <i>Frontiers in Immunology</i> , 2019, 10, 9.	2.2	126
9930	Molecular mechanism of tripleâ€negative breast cancerâ€associated BRCA1 and the identification of signaling pathways. <i>Oncology Letters</i> , 2019, 17, 2905-2914.	0.8	22
9931	The Continuing Evolution of Precision Health in Type 2 Diabetes: Achievements and Challenges. <i>Current Diabetes Reports</i> , 2019, 19, 16.	1.7	2
9932	Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. <i>Medical Oncology</i> , 2019, 36, 33.	1.2	66
9933	Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 3235.	1.6	60
9934	DECO: decompose heterogeneous population cohorts for patient stratification and discovery of sample biomarkers using omic data profiling. <i>Bioinformatics</i> , 2019, 35, 3651-3662.	1.8	7
9935	Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma. <i>Clinical and Experimental Immunology</i> , 2019, 197, 74-82.	1.1	32
9936	Divergent <sc>SATB</sc> 1 expression across human life span and tissue compartments. <i>Immunology and Cell Biology</i> , 2019, 97, 498-511.	1.0	20
9937	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. <i>Oncologist</i> , 2019, 24, S3-S10.	1.9	108
9938	The Role of Radiation Oncology in Immuno-Oncology. <i>Oncologist</i> , 2019, 24, S42-S52.	1.9	23
9939	PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. <i>Oncologist</i> , 2019, 24, S31-S41.	1.9	239
9940	Turning â€Coldâ€ Into â€Hotâ€ Tumorsâ€ Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers. <i>Frontiers in Oncology</i> , 2019, 9, 163.	1.3	85
9941	The Contribution of the Immune System in Bone Metastasis Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 999.	1.8	67
9942	PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. <i>Frontiers of Medicine</i> , 2019, 13, 438-450.	1.5	32
9943	Depletion of PD-1-positive cells ameliorates autoimmune disease. <i>Nature Biomedical Engineering</i> , 2019, 3, 292-305.	11.6	48

#	ARTICLE	IF	CITATIONS
9944	The Immune Subtypes and Landscape of Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 3528-3537.	3.2	136
9945	Towards multiscale modeling of the CD8 ⁺ T cell response to viral infections. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2019, 11, e1446.	6.6	16
9946	Immunotherapy: Current Status and Future Perspectives. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1030-1040.	1.1	24
9947	KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 35, 559-572.e7.	7.7	353
9948	Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. <i>Cancer Treatment Reviews</i> , 2019, 75, 27-38.	3.4	32
9949	Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. <i>Immunity</i> , 2019, 50, 1084-1098.e10.	6.6	75
9950	CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes. <i>Journal of Experimental Medicine</i> , 2019, 216, 1170-1181.	4.2	145
9951	Efficacy of subsequent docetaxel +/â€² ramucirumab and Sâ€1 after nivolumab for patients with advanced nonâ€small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1141-1148.	0.8	11
9952	Immunotherapy-related hepatitis: real-world experience from a tertiary centre. <i>Frontline Gastroenterology</i> , 2019, 10, 364-371.	0.9	65
9953	Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4363-4374.	3.2	60
9954	Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 122.	1.3	63
9955	Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK Cell-Mediated Killing in Melanoma. <i>Cancers</i> , 2019, 11, 356.	1.7	37
9956	Tumor infiltrating lymphocytes: The regulator of melanoma evolution (Review). <i>Oncology Letters</i> , 2019, 17, 4155-4161.	0.8	66
9957	Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1613-1623.	1.2	66
9958	Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 1-6.	2.0	26
9959	Immunotherapy of Melanoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 5191-5201.	3.2	181
9960	Effector Functions of CD4 ⁺ T Cells at the Site of Local Autoimmune Inflammationâ€Lessons From Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2019, 10, 353.	2.2	144
9961	PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation. <i>Frontiers in Immunology</i> , 2019, 10, 630.	2.2	112

#	ARTICLE	IF	CITATIONS
9962	Integrating Germline and Somatic Mutation Information for the Discovery of Biomarkers in Triple-Negative Breast Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1055.	1.2	14
9963	Checkpoint Blockade Strategies in the Treatment of Breast Cancer: <i>Where We Are and Where We Are Heading</i> . <i>Current Treatment Options in Oncology</i> , 2019, 20, 35.	1.3	44
9964	Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment. <i>EBioMedicine</i> , 2019, 42, 431-442.	2.7	111
9965	The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. <i>Nature Communications</i> , 2019, 10, 1125.	5.8	131
9966	Separation of breast cancer and organ microenvironment transcriptomes in metastases. <i>Breast Cancer Research</i> , 2019, 21, 36.	2.2	36
9967	A clinical decision support system learned from data to personalize treatment recommendations towards preventing breast cancer metastasis. <i>PLoS ONE</i> , 2019, 14, e0213292.	1.1	32
9968	Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 355-363.	1.7	21
9969	KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. <i>EBioMedicine</i> , 2019, 41, 711-716.	2.7	142
9970	Nivolumab-induced interstitial lung disease in a patient with gastric cancer. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz007.	0.2	3
9971	Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes. <i>BMC Cancer</i> , 2019, 19, 215.	1.1	10
9972	Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo. <i>BMC Cancer</i> , 2019, 19, 211.	1.1	39
9973	Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). , 2019, 7, 65.		108
9974	Memory stem T cells generated by Wnt signaling from blood of human renal clear cell carcinoma patients. <i>Cancer Biology and Medicine</i> , 2019, 16, 109.	1.4	15
9975	RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade. <i>EBioMedicine</i> , 2019, 41, 146-155.	2.7	31
9976	Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer. <i>Scientific Reports</i> , 2019, 9, 3461.	1.6	11
9977	From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	12
9978	Pan-cancer association of a centrosome amplification gene expression signature with genomic alterations and clinical outcome. <i>PLoS Computational Biology</i> , 2019, 15, e1006832.	1.5	35
9979	Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 8, 656.	1.3	32

#	ARTICLE	IF	CITATIONS
9980	Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. <i>Frontiers in Oncology</i> , 2019, 9, 179.	1.3	34
9981	FOXM1 Deubiquitination by USP21 Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer. <i>Cell Reports</i> , 2019, 26, 3076-3086.e6.	2.9	60
9982	Intratumoral expression of FoxP3-positive regulatory T-cells in T-cell lymphoma: no correlation with survival. <i>Uppsala Journal of Medical Sciences</i> , 2019, 124, 105-110.	0.4	2
9983	Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2019, 26, 81-93.	0.9	38
9984	Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 2946-2952.	0.8	82
9985	Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors. <i>Oncology Letters</i> , 2019, 17, 2960-2968.	0.8	32
9986	The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery. <i>Molecular Oncology</i> , 2019, 13, 1166-1179.	2.1	57
9987	Renal toxicities associated with pembrolizumab. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 81-88.	1.4	101
9988	Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma. <i>Histopathology</i> , 2019, 75, 139-145.	1.6	22
9989	FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. , 2019, 7, 23.		20
9990	Management of brain metastases: history and the present. <i>Chinese Neurosurgical Journal</i> , 2019, 5, 1.	0.3	40
9991	<p>The distinct clinicopathological and prognostic implications of PIK3CA mutations in breast cancer patients from Central China</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1473-1492.	0.9	10
9992	Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy"Focus on Fc³RIIB. <i>Frontiers in Immunology</i> , 2019, 10, 481.	2.2	33
9993	Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 196.	1.3	44
9994	A Case of Nivolumab-Induced Acute-Onset Type 1 Diabetes Mellitus in Melanoma. <i>Current Oncology</i> , 2019, 26, 115-118.	0.9	20
9995	Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors. <i>Current Oncology</i> , 2019, 26, 111-114.	0.9	23
9996	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 897-905.	2.0	38
9997	Non-murine models to investigate tumor-immune interactions in head and neck cancer. <i>Oncogene</i> , 2019, 38, 4902-4914.	2.6	12

#	ARTICLE	IF	CITATIONS
9998	Differential metabolic activity and discovery of therapeutic targets using summarized metabolic pathway models. <i>Npj Systems Biology and Applications</i> , 2019, 5, 7.	1.4	30
9999	A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. <i>Scientific Reports</i> , 2019, 9, 1225.	1.6	16
10000	Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas. <i>Scientific Reports</i> , 2019, 9, 3536.	1.6	11
10001	Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers. <i>BMC Cancer</i> , 2019, 19, 219.	1.1	90
10002	Varicella zoster virus productively infects human peripheral blood mononuclear cells to modulate expression of immunoinhibitory proteins and blocking PD-L1 enhances virus-specific CD8+ T cell effector function. <i>PLoS Pathogens</i> , 2019, 15, e1007650.	2.1	40
10003	<p>Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1623-1629.	0.9	19
10004	<p>Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1521-1538.	1.0	3
10005	<p>Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 293-302.	0.9	27
10006	CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival. <i>Frontiers in Immunology</i> , 2019, 10, 306.	2.2	15
10007	Role of miRNAs in Melanoma Metastasis. <i>Cancers</i> , 2019, 11, 326.	1.7	64
10008	Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD–L1 antibodies. <i>Molecular and Clinical Oncology</i> , 2019, 10, 391-396.	0.4	3
10009	Significance of PD–L1 in the diagnosis and treatment of B–cell malignant lymphoma. <i>Oncology Letters</i> , 2019, 17, 3382-3386.	0.8	4
10010	Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1043-1053.	1.2	43
10011	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1029-1043.	1.6	6
10012	The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses. <i>Cancers</i> , 2019, 11, 329.	1.7	37
10013	Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In–Vivo. <i>Cell Systems</i> , 2019, 8, 136-151.e7.	2.9	14
10014	Impressionist portraits of mitotic exit: APC/C, K11-linked ubiquitin chains and Cezanne. <i>Cell Cycle</i> , 2019, 18, 652-660.	1.3	14
10015	Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity. <i>Cancers</i> , 2019, 11, 363.	1.7	35

#	ARTICLE	IF	CITATIONS
10016	Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting. <i>Clinical and Experimental Immunology</i> , 2019, 197, 153-160.	1.1	48
10017	Changes in plasma EBV-DNA and immune status in patients with nasopharyngeal carcinoma after treatment with intensity-modulated radiotherapy. <i>Diagnostic Pathology</i> , 2019, 14, 23.	0.9	8
10018	Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs). <i>Clinical Sarcoma Research</i> , 2019, 9, 3.	2.3	26
10019	The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 139.	1.6	76
10020	Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico. <i>Oncology Letters</i> , 2019, 17, 3581-3588.	0.8	11
10021	NIR-Triggered Phototherapy and Immunotherapy via an Antigen-Capturing Nanoplatfrom for Metastatic Cancer Treatment. <i>Advanced Science</i> , 2019, 6, 1802157.	5.6	221
10022	SNP mutation-related genes in breast cancer for monitoring and prognosis of patients: A study based on the TCGA database. <i>Cancer Medicine</i> , 2019, 8, 2303-2312.	1.3	31
10023	A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-4.	0.2	2
10024	Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles. <i>BMC Cancer</i> , 2019, 19, 328.	1.1	6
10025	Expression of LDH and CEA in serum in the process of targeted therapy of lung adenocarcinoma and the association between them and prognosis. <i>Oncology Letters</i> , 2019, 17, 4550-4556.	0.8	7
10026	Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 146.	3.5	246
10027	First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. <i>Journal of Clinical Oncology</i> , 2019, 37, 992-1000.	0.8	457
10028	Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 2191-2199.	0.7	127
10029	NOJAH: NOT Just Another Heatmap for genome-wide cluster analysis. <i>PLoS ONE</i> , 2019, 14, e0204542.	1.1	9
10030	Ex vivo Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 454.	2.2	48
10031	The Role of ZNF143 in Breast Cancer Cell Survival Through the NAD(P)H Quinone Dehydrogenase 1-p53-Beclin1 Axis Under Metabolic Stress. <i>Cells</i> , 2019, 8, 296.	1.8	15
10032	Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy. <i>European Radiology</i> , 2019, 29, 5045-5051.	2.3	36
10033	The FG Loop of PD-1 Serves as a "Hotspot" for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy. <i>IScience</i> , 2019, 14, 113-124.	1.9	34

#	ARTICLE	IF	CITATIONS
10034	Combining activatable nanodelivery with immunotherapy in a murine breast cancer model. <i>Journal of Controlled Release</i> , 2019, 303, 42-54.	4.8	31
10035	Enhancement of Cytomegalovirus-Specific Cytokine Production after Modulation of the Costimulation in Kidney Transplant Patients. <i>Journal of Immunology Research</i> , 2019, 2019, 1-8.	0.9	5
10036	Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report. <i>Thoracic Cancer</i> , 2019, 10, 1276-1279.	0.8	11
10037	Radiotherapy for Melanoma: More than DNA Damage. <i>Dermatology Research and Practice</i> , 2019, 2019, 1-9.	0.3	18
10038	A secure SNP panel scheme using homomorphically encrypted K-mers without SNP calling on the user side. <i>BMC Genomics</i> , 2019, 20, 188.	1.2	1
10039	Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2019, 19, 71.	1.8	92
10040	NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment. <i>Frontiers in Immunology</i> , 2019, 10, 661.	2.2	65
10041	Microbiome and Cancers, With Focus on Genitourinary Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 178.	1.3	20
10042	Integrative Analysis Reveals Subtype-Specific Regulatory Determinants in Triple Negative Breast Cancer. <i>Cancers</i> , 2019, 11, 507.	1.7	10
10043	Extracellular Vesicle-Based Therapeutic Targeting of β -Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer. <i>Hepatology Communications</i> , 2019, 3, 525-541.	2.0	38
10044	Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma. <i>IJU Case Reports</i> , 2019, 2, 30-33.	0.1	8
10045	Dawn of precision medicine on gastric cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 779-788.	1.0	15
10046	Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 356-364.e3.	0.2	88
10047	Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 13, 359-370.	1.8	74
10048	Bowel obstruction caused by colonic metastasis of lung adenocarcinoma: a case report and literature review. <i>World Journal of Surgical Oncology</i> , 2019, 17, 63.	0.8	12
10049	Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 12.	0.6	31
10050	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. , 2019, 7, 99.		110
10051	Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. <i>Oncologist</i> , 2019, 24, 1270-1284.	1.9	21

#	ARTICLE	IF	CITATIONS
10052	Quantitative Prediction of the Landscape of T Cell Epitope Immunogenicity in Sequence Space. <i>Frontiers in Immunology</i> , 2019, 10, 827.	2.2	68
10053	The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1723.	1.8	192
10054	Vitamin A deficiency exacerbates Lewis lung carcinoma via induction of type 2 innate lymphoid cells and alternatively activates macrophages. <i>Food Science and Nutrition</i> , 2019, 7, 1288-1294.	1.5	12
10055	Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice. <i>Molecular Therapy</i> , 2019, 27, 960-973.	3.7	24
10056	Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials. <i>Thoracic Cancer</i> , 2019, 10, 1176-1181.	0.8	8
10057	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019, 4, e000457.	2.0	151
10058	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. <i>Case Reports in Oncology</i> , 2019, 12, 260-276.	0.3	63
10059	An integrative U method for joint analysis of multi-level omic data. <i>BMC Genetics</i> , 2019, 20, 40.	2.7	2
10060	Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 120.	1.8	22
10061	Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. <i>Journal of Hematology and Oncology</i> , 2019, 12, 38.	6.9	66
10062	Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations. <i>PLoS ONE</i> , 2019, 14, e0215292.	1.1	12
10063	An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma. <i>Oncotarget</i> , 2019, 10, 1840-1849.	0.8	19
10064	Update on systemic therapy for colorectal cancer: biologics take sides. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 9-9.	1.5	22
10065	Biochemical pathways mediated by KLK6 protease in breast cancer. <i>Molecular Oncology</i> , 2019, 13, 2329-2343.	2.1	12
10066	Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. <i>International Journal of Clinical Oncology</i> , 2019, 24, 608-613.	1.0	22
10067	A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). <i>Translational Oncology</i> , 2019, 12, 828-835.	1.7	90
10068	Combinatorial Detection of Conserved Alteration Patterns for Identifying Cancer Subnetworks. <i>GigaScience</i> , 2019, 8, .	3.3	9
10069	Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report. <i>Thoracic Cancer</i> , 2019, 10, 1285-1288.	0.8	58

#	ARTICLE	IF	CITATIONS
10070	Clinical development of targeted and immune based anti-cancer therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 156.	3.5	170
10071	PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival. <i>Frontiers in Oncology</i> , 2019, 9, 189.	1.3	21
10072	Glial Cell Expression of PD-L1. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1677.	1.8	21
10073	Mutational load in carotid body tumor. <i>BMC Medical Genomics</i> , 2019, 12, 39.	0.7	12
10074	Natural killer NKG2A and NKG2D in patients with colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 218-225.	0.6	6
10075	Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma. <i>Frontiers in Genetics</i> , 2019, 10, 278.	1.1	49
10076	Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function. <i>Frontiers in Immunology</i> , 2019, 10, 877.	2.2	81
10077	Current Landscape of Immunotherapy in Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1205.	3.4	260
10078	Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1651-1660.	1.2	31
10079	A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2019, 17, 99.	1.8	52
10080	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. , 2019, 7, 90.		80
10081	Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. , 2019, 7, 87.		60
10082	Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. <i>Molecules</i> , 2019, 24, 1190.	1.7	163
10083	Role of the tumor microenvironment in pancreatic cancer. <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 130-137.	1.2	114
10084	Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients. <i>Supportive Care in Cancer</i> , 2019, 27, 4535-4542.	1.0	10
10085	Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma. <i>Paediatric Drugs</i> , 2019, 21, 71-79.	1.3	4
10086	Isoflavone daidzein regulates immune responses in the B6C3F1 and non-obese diabetic (NOD) mice. <i>International Immunopharmacology</i> , 2019, 71, 277-284.	1.7	22
10087	Tumour-Associated Macrophages (TAMs) in Colon Cancer and How to Reeducate Them. <i>Journal of Immunology Research</i> , 2019, 2019, 1-9.	0.9	116

#	ARTICLE	IF	CITATIONS
10088	Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification. , 2019, 7, 86.		11
10089	Breast cancer histopathological image classification using convolutional neural networks with small SE-ResNet module. PLoS ONE, 2019, 14, e0214587.	1.1	205
10090	Chasing the FOXO3: Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape. Cancers, 2019, 11, 414.	1.7	19
10091	MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology, 2019, 156, 1849-1861.e13.	0.6	131
10092	First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers. BMC Cancer, 2019, 19, 279.	1.1	53
10093	MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells. Molecular Cancer, 2019, 18, 54.	7.9	65
10094	Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. , 2019, 7, 91.		24
10095	Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Communications, 2019, 39, 1-13.	3.7	169
10096	PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?. Cancers, 2019, 11, 435.	1.7	86
10097	Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. Cancers, 2019, 11, 441.	1.7	3
10098	Effects of dezocine and sufentanyl for postoperative analgesia on activity of NK, CD4+ and CD8+ cells in patients with breast cancer. Oncology Letters, 2019, 17, 3392-3398.	0.8	7
10099	PD-L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling. Oncology Reports, 2019, 41, 2833-2843.	1.2	15
10100	Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study. Clinical Breast Cancer, 2019, 19, 225-235.e2.	1.1	4
10101	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. Human Pathology, 2019, 88, 66-77.	1.1	38
10102	Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. Gastroenterology, 2019, 156, 2056-2072.	0.6	300
10103	Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7624-7631.	3.3	205
10104	Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. Cancer Biology and Therapy, 2019, 20, 1105-1112.	1.5	22
10105	Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer. Journal of Immunotherapy, 2019, 42, 23-28.	1.2	22

#	ARTICLE	IF	CITATIONS
10106	TAMing pancreatic cancer: combat with a double edged sword. <i>Molecular Cancer</i> , 2019, 18, 48.	7.9	61
10107	Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 407.	2.2	44
10108	The future of lung cancer therapy: Striding beyond conventional EGFR and ALK treatments. <i>Molecular and Clinical Oncology</i> , 2019, 10, 469-475.	0.4	3
10109	Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 310-314.	0.2	24
10110	The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 11.	0.6	51
10111	Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. <i>Frontiers in Medicine</i> , 2019, 6, 27.	1.2	54
10112	Expression patterns and the prognostic value of the SMYD family members in human breast carcinoma using integrative bioinformatics analysis. <i>Oncology Letters</i> , 2019, 17, 3851-3861.	0.8	18
10113	Prognostic impact of tumor-infiltrating CD276/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma. <i>Oncology Letters</i> , 2019, 17, 4004-4010.	0.8	5
10114	Resveratrol antagonizes thyroid hormone-induced expression of checkpoint and proliferative genes in oral cancer cells. <i>Journal of Dental Sciences</i> , 2019, 14, 255-262.	1.2	26
10115	Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy. <i>Thyroid</i> , 2019, 29, 979-992.	2.4	71
10116	A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features. <i>Histopathology</i> , 2019, 75, 282-286.	1.6	17
10117	Phenotype of POLE-mutated endometrial cancer. <i>PLoS ONE</i> , 2019, 14, e0214318.	1.1	53
10118	Hippo pathway as another oncogenic mediator to promote immune evasion by PD-L1 signaling. <i>Journal of Thoracic Disease</i> , 2019, 11, S318-S321.	0.6	4
10119	A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 491.	2.2	23
10120	Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 311-331.	1.6	123
10121	Could the menagerie of the gut microbiome really cure cancer? Hope or hype. , 2019, 7, 92.		16
10122	<p>Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 2653-2661.	0.9	20
10123	Immunological Agents Used in Cancer Treatment. <i>Eurasian Journal of Medicine</i> , 2019, 51, 90-94.	0.2	32

#	ARTICLE	IF	CITATIONS
10124	Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. <i>Journal of Gastric Cancer</i> , 2019, 19, 1.	0.9	328
10125	What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 303-311.	1.4	8
10126	Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation. <i>Journal of Controlled Release</i> , 2019, 302, 148-159.	4.8	41
10127	Prevalence and role of HER2 mutations in cancer. , 2019, 199, 188-196.		44
10128	Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity. <i>Structure</i> , 2019, 27, 829-836.e3.	1.6	13
10129	Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 481-489.	0.8	265
10130	Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors. <i>Journal of Clinical Oncology</i> , 2019, 37, 1148-1150.	0.8	17
10131	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. <i>Endocrine Connections</i> , 2019, 8, R10-R26.	0.8	33
10132	Can an amino acid-based oral rehydration solution be effective in managing immune therapy-induced diarrhea?. <i>Medical Hypotheses</i> , 2019, 127, 66-70.	0.8	5
10133	Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1158-1166.	0.8	17
10134	Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells. <i>Cancer Cell International</i> , 2019, 19, 68.	1.8	22
10135	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 559-569.	0.8	505
10136	Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 52-60.	0.8	218
10137	The Inhibitory T Cell Receptors PD1 and 2B4 Are Differentially Regulated on CD4 and CD8 T Cells in a Mouse Model of Non-alcoholic Steatohepatitis. <i>Frontiers in Pharmacology</i> , 2019, 10, 244.	1.6	6
10138	Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series. <i>Health Science Reports</i> , 2019, 2, e115.	0.6	29
10139	Splicing, genome stability and disease: splice like your genome depends on it!. <i>Current Genetics</i> , 2019, 65, 905-912.	0.8	10
10140	A plasma protein derived TGF β ² signature is a prognostic indicator in triple negative breast cancer. <i>Npj Precision Oncology</i> , 2019, 3, 10.	2.3	18
10141	Vitiligo-like hypopigmentation associated with pembrolizumab in metastatic head and neck cancer. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz016.	0.2	6

#	ARTICLE	IF	CITATIONS
10142	Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 128-140.	1.3	28
10143	Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. <i>World Neurosurgery</i> , 2019, 124, 397-409.	0.7	19
10144	The association of <i>FOXP3</i> gene polymorphisms with cancer susceptibility: a comprehensive systemic review and meta-analysis. <i>Bioscience Reports</i> , 2019, 39, .	1.1	5
10145	Measuring DNA Copy Number Variation Using High-Density Methylation Microarrays. <i>Journal of Computational Biology</i> , 2019, 26, 295-304.	0.8	12
10146	Self-antigen MASH2 combined with the AS15 immunostimulant induces tumor protection in colorectal cancer mouse models. <i>PLoS ONE</i> , 2019, 14, e0210261.	1.1	8
10147	Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer. <i>Oncologist</i> , 2019, 24, 305-312.	1.9	11
10148	Early Phase I Study of a ^{99m} Tc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1213-1220.	2.8	111
10149	Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 333.	2.2	234
10150	Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing. <i>Frontiers in Immunology</i> , 2019, 10, 456.	2.2	60
10151	Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics. <i>Current Oncology Reports</i> , 2019, 21, 19.	1.8	34
10152	Immune Check Point Inhibitor-Associated Glomerulonephritis. <i>Kidney International Reports</i> , 2019, 4, 355-359.	0.4	22
10153	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	2.9	52
10154	Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. <i>Scientific Reports</i> , 2019, 9, 2447.	1.6	116
10155	Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment. <i>Scientific Reports</i> , 2019, 9, 2636.	1.6	38
10156	Magnetic aerosol drug targeting in lung cancer therapy using permanent magnet. <i>Drug Delivery</i> , 2019, 26, 120-128.	2.5	37
10157	Non-invasive analysis of tumor mutation profiles and druggable mutations by sequencing of cell free DNA of Chinese metastatic breast cancer patients. <i>Thoracic Cancer</i> , 2019, 10, 807-814.	0.8	7
10158	Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma. <i>Case Reports in Oncology</i> , 2019, 12, 29-32.	0.3	9
10159	Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541982709.	0.8	2

#	ARTICLE	IF	CITATIONS
10160	Mouse-Derived Isograft (MDI) In Vivo Tumor Models I. Spontaneous sMDI Models: Characterization and Cancer Therapeutic Approaches. <i>Cancers</i> , 2019, 11, 244.	1.7	4
10161	Self-Assembly of Therapeutic Peptide into Stimuli-Responsive Clustered Nanohybrids for Cancer-Targeted Therapy. <i>Advanced Functional Materials</i> , 2019, 29, 1807736.	7.8	59
10162	Robust Photodynamic Therapy Using 5-ALA-Incorporated Nanocomplexes Cures Metastatic Melanoma through Priming of CD4 ⁺ CD8 ⁺ Double Positive T Cells. <i>Advanced Science</i> , 2019, 6, 1802057.	5.6	36
10163	Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. <i>Frontiers of Medicine</i> , 2019, 13, 12-23.	1.5	14
10164	Blocking of checkpoint receptor PD-L1 aggravates osteoarthritis in macrophage-dependent manner in the mice model. <i>International Journal of Immunopathology and Pharmacology</i> , 2019, 33, 205873841882076.	1.0	9
10165	Late-onset isolated adrenocorticotrophic hormone deficiency caused by nivolumab: a case report. <i>BMC Endocrine Disorders</i> , 2019, 19, 25.	0.9	27
10166	Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. , 2019, 7, 50.		44
10167	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
10168	Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer. <i>Oncotarget</i> , 2019, 10, 561-572.	0.8	15
10169	<p>Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 523-538.	2.0	23
10170	TCR Repertoire Analysis Reveals Mobilization of Novel CD8+ T Cell Clones Into the Cancer-Immunity Cycle Following Anti-CD4 Antibody Administration. <i>Frontiers in Immunology</i> , 2018, 9, 3185.	2.2	33
10171	Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer. <i>Cancers</i> , 2019, 11, 251.	1.7	150
10172	Emerging Nano-Microapproaches for Cancer Immunotherapy. <i>Advanced Science</i> , 2019, 6, 1801847.	5.6	136
10173	The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies. <i>Targeted Oncology</i> , 2019, 14, 115-123.	1.7	19
10174	Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. <i>Endocrine</i> , 2019, 64, 605-613.	1.1	46
10175	Drainage of Tumor-Derived DNA into Sentinel Lymph Nodes in Breast Cancer Patients. <i>Pathology and Oncology Research</i> , 2019, 25, 1635-1643.	0.9	3
10176	MiR-873/PD-L1 axis regulates the stemness of breast cancer cells. <i>EBioMedicine</i> , 2019, 41, 395-407.	2.7	114
10177	Quantifying Antigen-Specific T Cell Responses When Using Antigen-Agnostic Immunotherapies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 13, 154-166.	1.8	15

#	ARTICLE	IF	CITATIONS
10178	Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2019, 153, 217-222.	0.6	38
10179	Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 247-259.	1.1	43
10180	Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 269-276.	0.4	218
10181	Met inhibition revokes IFN γ -induction of PD-1 ligands in MET-amplified tumours. <i>British Journal of Cancer</i> , 2019, 120, 527-536.	2.9	34
10182	Mycobacterium tuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDL-1 signaling pathway. <i>Cell Death and Disease</i> , 2019, 10, 44.	2.7	27
10184	Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer. <i>BMC Cancer</i> , 2019, 19, 120.	1.1	37
10185	TNF- α enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways. , 2019, 7, 28.		47
10186	Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma. <i>Frontiers in Oncology</i> , 2019, 9, 69.	1.3	68
10187	Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 176.	1.7	18
10188	Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer. <i>Journal of Cancer</i> , 2019, 10, 697-707.	1.2	16
10189	Immunotherapeutic advances in gastrointestinal malignancies. <i>Npj Precision Oncology</i> , 2019, 3, 4.	2.3	16
10190	Choline acetyltransferase-expressing T cells are required to control chronic viral infection. <i>Science</i> , 2019, 363, 639-644.	6.0	90
10191	Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses. <i>Frontiers in Immunology</i> , 2019, 10, 8.	2.2	156
10192	Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. <i>Nature Communications</i> , 2019, 10, 620.	5.8	60
10193	CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1126-1132.	1.4	42
10194	T cell checkpoint regulators in the heart. <i>Cardiovascular Research</i> , 2019, 115, 869-877.	1.8	70
10195	Drug Delivery for Cancer Immunotherapy and Vaccines. <i>Pharmaceutical Nanotechnology</i> , 2019, 6, 232-244.	0.6	18
10196	Cardiac Complications in Immune Checkpoint Inhibition Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 3.	1.1	65

#	ARTICLE	IF	CITATIONS
10197	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 609-618.	2.0	21
10198	Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer. <i>Scientific Reports</i> , 2019, 9, 1583.	1.6	36
10199	A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses. <i>Scientific Reports</i> , 2019, 9, 1538.	1.6	46
10200	Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Thoracic Cancer</i> , 2019, 10, 607-623.	0.8	22
10201	Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 761-768.	0.8	63
10202	Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 510-525.	1.6	47
10203	Prognostic value of CD8+PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. , 2019, 7, 34.		75
10204	Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. , 2019, 7, 32.		92
10205	Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status. <i>PLoS ONE</i> , 2019, 14, e0211866.	1.1	16
10206	Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. <i>Haematologica</i> , 2019, 104, 1440-1450.	1.7	67
10207	Personalization of Logical Models With Multi-Omics Data Allows Clinical Stratification of Patients. <i>Frontiers in Physiology</i> , 2018, 9, 1965.	1.3	66
10208	Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment (Review). <i>Oncology Letters</i> , 2019, 17, 2583-2591.	0.8	16
10209	A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4+ T and Natural Killer Cells. <i>Cancer Research</i> , 2019, 79, 783-794.	0.4	14
10210	Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort. <i>BMC Cancer</i> , 2019, 19, 142.	1.1	24
10211	Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels. , 2019, 7, 43.		42
10212	Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. <i>Journal of Thoracic Disease</i> , 2019, 11, S89-S101.	0.6	52
10213	Unveiling the Link Between Inflammation and Adaptive Immunity in Breast Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 56.	2.2	9
10214	Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 193.	2.2	105

#	ARTICLE	IF	CITATIONS
10215	FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 292.	2.2	111
10216	Activation of CD8+ T Cell Responses after Melanoma Antigen Targeting to CD169+ Antigen Presenting Cells in Mice and Humans. <i>Cancers</i> , 2019, 11, 183.	1.7	21
10217	Role of Exosomes in the Regulation of T-cell Mediated Immune Responses and in Autoimmune Disease. <i>Cells</i> , 2019, 8, 154.	1.8	121
10218	Abnormal Expression of c-Myc Oncogene in NK Cells in Patients with Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 756.	1.8	14
10219	Do PD-1 and PD-L2 expression have prognostic impact in hematologic malignancies?. <i>Turkish Journal of Medical Sciences</i> , 2019, 49, 265-271.	0.4	4
10220	The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis. <i>Scientific Reports</i> , 2019, 9, 2038.	1.6	25
10221	Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 553-563.	1.5	28
10222	Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. <i>Journal of Oncology</i> , 2019, 2019, 1-18.	0.6	76
10223	Insulin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells. <i>BMC Cancer</i> , 2019, 19, 153.	1.1	35
10224	Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. <i>Clinical and Translational Oncology</i> , 2019, 21, 1270-1279.	1.2	38
10225	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. <i>Cancers</i> , 2019, 11, 223.	1.7	18
10226	Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 824.	1.8	129
10227	Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin. <i>Digestive Diseases and Sciences</i> , 2019, 64, 685-688.	1.1	1
10228	A mathematical solution to Peto's paradox using Polya's urn model: implications for the aetiology of cancer in general. <i>Theory in Biosciences</i> , 2019, 138, 241-250.	0.6	3
10229	Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects. <i>Clinical Drug Investigation</i> , 2019, 39, 341-353.	1.1	28
10230	Advances in immune checkpoint inhibitors for bone sarcoma therapy. <i>Journal of Bone Oncology</i> , 2019, 15, 100221.	1.0	122
10231	Perspectives in Radiomics for Personalized Medicine and Theranostics. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 164-166.	0.6	11
10232	Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 990-997.	0.6	130

#	ARTICLE	IF	CITATIONS
10233	Turning the corner on therapeutic cancer vaccines. <i>Npj Vaccines</i> , 2019, 4, 7.	2.9	490
10234	SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 14.	6.9	41
10235	Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. , 2019, 7, 37.		123
10236	Accumulation of exhausted CD8+ T cells in extramammary Paget's disease. <i>PLoS ONE</i> , 2019, 14, e0211135.	1.1	12
10237	Adjuvant Ipilimumab in High-Risk Uveal Melanoma. <i>Cancers</i> , 2019, 11, 152.	1.7	27
10238	Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study. <i>Clinical and Translational Oncology</i> , 2019, 21, 1093-1103.	1.2	7
10239	Impact of Immunotherapy after Resection of Pancreatic Cancer. <i>Journal of the American College of Surgeons</i> , 2019, 229, 19-27.e1.	0.2	11
10240	A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 223-226.	0.2	10
10241	Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer. <i>British Journal of Cancer</i> , 2019, 120, 547-554.	2.9	42
10242	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 133-150.	12.8	1,657
10243	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	15.2	932
10244	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. <i>Nature Medicine</i> , 2019, 25, 462-469.	15.2	569
10245	Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?. , 2019, 7, 39.		14
10246	Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. <i>Oncologist</i> , 2019, 24, 549-554.	1.9	105
10247	Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis. <i>Oncotarget</i> , 2019, 10, 209-215.	0.8	33
10248	Immune Cell Composition in Human Non-small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 3101.	2.2	202
10249	Therapeutic Cancer Vaccines's T Cell Responses and Epigenetic Modulation. <i>Frontiers in Immunology</i> , 2018, 9, 3109.	2.2	26
10250	LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers. <i>Frontiers in Immunology</i> , 2019, 10, 6.	2.2	280

#	ARTICLE	IF	CITATIONS
10251	Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. <i>Diagnostics</i> , 2019, 9, 13.	1.3	10
10252	The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 667.	1.8	19
10253	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. <i>Nature Medicine</i> , 2019, 25, 454-461.	15.2	466
10254	Using association signal annotations to boost similarity network fusion. <i>Bioinformatics</i> , 2019, 35, 3718-3726.	1.8	20
10255	The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer. <i>Disease Markers</i> , 2019, 2019, 1-8.	0.6	16
10256	Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. <i>Clinical Cancer Research</i> , 2019, 25, 4422-4430.	3.2	6
10257	Genome-Wide CRISPR Screening Identifies JAK1 Deficiency as a Mechanism of T-Cell Resistance. <i>Frontiers in Immunology</i> , 2019, 10, 251.	2.2	17
10258	Peptide Super-Agonist Enhances T-Cell Responses to Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 319.	2.2	18
10259	Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy. <i>JAMA Dermatology</i> , 2019, 155, 442.	2.0	27
10260	Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1235-1242.	1.2	14
10261	Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future. <i>Purinergic Signalling</i> , 2019, 15, 53-67.	1.1	10
10262	Correlation between apparent diffusion coefficient of magnetic resonance imaging and tumor-infiltrating lymphocytes in breast cancer. <i>Radiologia Medica</i> , 2019, 124, 581-587.	4.7	24
10263	Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma. <i>Current Oncology Reports</i> , 2019, 21, 24.	1.8	16
10264	The second genome: Effects of the mitochondrial genome on cancer progression. <i>Advances in Cancer Research</i> , 2019, 142, 63-105.	1.9	19
10265	Conventional transbronchial needle aspiration is promising for identifying EGFR mutations in lung adenocarcinoma. <i>Thoracic Cancer</i> , 2019, 10, 856-863.	0.8	1
10266	The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381983106.	0.8	116
10267	Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature. <i>Internal Medicine</i> , 2019, 58, 1747-1752.	0.3	23
10268	Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 56.	1.3	36

#	ARTICLE	IF	CITATIONS
10269	Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. <i>JAMA Oncology</i> , 2019, 5, 696.	3.4	380
10270	A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019, 24, 149-162.	1.0	8
10271	Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 343-356.	2.1	23
10272	Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies. <i>Dermatology and Therapy</i> , 2019, 9, 209-222.	1.4	54
10273	Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization. <i>Cell Death and Disease</i> , 2019, 10, 204.	2.7	16
10274	Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs. <i>Scientific Reports</i> , 2019, 9, 3172.	1.6	178
10275	Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. <i>Cellular and Molecular Immunology</i> , 2019, 16, 430-441.	4.8	327
10276	Tumour targeted contrast enhanced ultrasound imaging dual-modal microbubbles for diagnosis and treatment of triple negative breast cancer. <i>RSC Advances</i> , 2019, 9, 5682-5691.	1.7	16
10277	Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 25.	2.2	22
10278	Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. , 2019, 7, 41.		10
10279	Are there any theranostic biomarkers in small cell lung carcinoma?. <i>Journal of Thoracic Disease</i> , 2019, 11, S102-S112.	0.6	12
10280	PD-L1 expression patterns in tumour cells and their association with CD8 ⁺ tumour infiltrating lymphocytes in clear cell renal cell carcinoma. <i>Journal of Cancer</i> , 2019, 10, 1154-1161.	1.2	18
10281	Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 399-412.	1.9	9
10282	Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2019, 11, S71-S80.	0.6	71
10283	Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives. <i>Journal of Thoracic Disease</i> , 2019, 11, S113-S126.	0.6	45
10284	Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment. <i>Journal of Thoracic Disease</i> , 2019, 11, 35-38.	0.6	28
10285	Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. <i>Journal of Thoracic Disease</i> , 2019, 11, S25-S36.	0.6	51
10286	Update on emerging biomarkers in lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, S81-S88.	0.6	23

#	ARTICLE	IF	CITATIONS
10287	Non-thermal Plasma as a Unique Delivery System of Short-Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells. <i>Advanced Science</i> , 2019, 6, 1802062.	5.6	177
10288	A high-risk luminal A dominant breast cancer subtype with increased mobility. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 459-472.	1.1	26
10289	The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 21.	1.3	27
10290	Curative effect assessment of immunotherapy for non-small cell lung cancer: The "blind area" of Immune Response Evaluation Criteria in Solid Tumors (iRECIST). <i>Thoracic Cancer</i> , 2019, 10, 587-592.	0.8	14
10291	Acute Interstitial Nephritis in a Patient with Non-Small Cell Lung Cancer under Immunotherapy with Nivolumab. <i>Case Reports in Nephrology</i> , 2019, 2019, 1-5.	0.2	8
10292	Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 87.	3.5	213
10293	Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. <i>Breast Cancer Research</i> , 2019, 21, 28.	2.2	59
10294	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. , 2019, 7, 49.		102
10295	Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. , 2019, 7, 47.		22
10296	Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2019, 10, 108.	2.2	117
10297	Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 51.	1.3	117
10298	PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer. <i>Cancers</i> , 2019, 11, 232.	1.7	43
10299	Genetic Epidemiology of Breast Cancer in Latin America. <i>Genes</i> , 2019, 10, 153.	1.0	34
10300	Targeting Tumor Microenvironment for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 840.	1.8	822
10301	Immune Exhaustion: Past Lessons and New Insights from Lymphocytic Choriomeningitis Virus. <i>Viruses</i> , 2019, 11, 156.	1.5	32
10302	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 563-574.	2.0	51
10303	MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer. <i>British Journal of Cancer</i> , 2019, 120, 621-632.	2.9	29
10304	PD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimeozide. <i>Cell Death and Disease</i> , 2019, 10, 164.	2.7	52

#	ARTICLE	IF	CITATIONS
10305	Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells. <i>Cancer Immunology Research</i> , 2019, 7, 572-583.	1.6	47
10306	Prediction of lncRNA-disease associations by integrating diverse heterogeneous information sources with RWR algorithm and positive pointwise mutual information. <i>BMC Bioinformatics</i> , 2019, 20, 87.	1.2	49
10307	The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2019, 11, S57-S64.	0.6	40
10308	Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 352-361.	1.0	32
10309	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 421-432.	1.4	45
10310	Advances in immunotherapy delivery from implantable and injectable biomaterials. <i>Acta Biomaterialia</i> , 2019, 88, 15-31.	4.1	127
10311	Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases. <i>Modern Pathology</i> , 2019, 32, 929-942.	2.9	67
10312	Base excision repair regulates PD-L1 expression in cancer cells. <i>Oncogene</i> , 2019, 38, 4452-4466.	2.6	70
10313	Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers. <i>Thyroid</i> , 2019, 29, 523-529.	2.4	31
10314	Immunotherapy for skin cancer. <i>International Immunology</i> , 2019, 31, 465-475.	1.8	47
10315	Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	169
10316	The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway. <i>MDM Policy and Practice</i> , 2019, 4, 238146831882110.	0.5	30
10317	Immunotherapy in extensive small cell lung cancer. <i>Experimental Hematology and Oncology</i> , 2019, 8, 5.	2.0	32
10318	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.		42
10319	The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-12.	1.0	22
10320	Network-guided prediction of aromatase inhibitor response in breast cancer. <i>PLoS Computational Biology</i> , 2019, 15, e1006730.	1.5	5
10321	Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control. <i>Frontiers in Immunology</i> , 2019, 10, 294.	2.2	27
10322	The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancers</i> , 2019, 11, 201.	1.7	49

#	ARTICLE	IF	CITATIONS
10323	Myeloid disorders after autoimmune disease. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 74-88.	0.7	19
10324	Cancer Metabolism Drives a Stromal Regenerative Response. <i>Cell Metabolism</i> , 2019, 29, 576-591.	7.2	92
10325	DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. <i>Gastroenterology</i> , 2019, 156, 890-903.	0.6	48
10326	Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. <i>Endocrine</i> , 2019, 64, 122-129.	1.1	39
10327	Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting. <i>Molecular Pharmaceutics</i> , 2019, 16, 1694-1702.	2.3	26
10328	Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. <i>Nature Communications</i> , 2019, 10, 766.	5.8	99
10329	T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. <i>Nature Reviews Cardiology</i> , 2019, 16, 325-343.	6.1	65
10330	Time resolved gene expression analysis during tamoxifen adaption of MCF-7 cells identifies long non-coding RNAs with prognostic impact. <i>RNA Biology</i> , 2019, 16, 661-674.	1.5	8
10331	Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell. <i>Cardiovascular Research</i> , 2019, 115, 949-959.	1.8	38
10332	Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 815-822.	0.8	20
10333	PD-L1 expression levels on tumor cells affect their immunosuppressive activity. <i>Oncology Letters</i> , 2019, 18, 5399-5407.	0.8	54
10334	Blood tumor mutational burden: are we ready for clinical implementation?. <i>Journal of Thoracic Disease</i> , 2019, 11, S1906-S1908.	0.6	6
10335	The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 3347-3360.	3.9	82
10336	CTHRC1 and PD-L1/PD-L1 expression predicts tumor recurrence in prostate cancer. <i>Molecular Medicine Reports</i> , 2019, 20, 4244-4252.	1.1	11
10337	Acute kidney injury in the patient with cancer. <i>Kidney Research and Clinical Practice</i> , 2019, 38, 295-308.	0.9	41
10338	Radiomics analysis of MRI for predicting molecular subtypes of breast cancer in young women. , 2019, 10950, .		1
10339	CD163 and CCR7 as markers for macrophage polarisation in lung cancer microenvironment. <i>Central-European Journal of Immunology</i> , 2019, 44, 395-402.	0.4	42
10340	Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 347-353.	0.4	24

#	ARTICLE	IF	CITATIONS
10341	Genomics applied to the treatment of breast cancer. <i>Oncotarget</i> , 2019, 10, 4786-4801.	0.8	20
10342	Can tumor mutational burden determine the most effective treatment for lung cancer patients?. <i>Lung Cancer Management</i> , 2019, 8, LMT21.	1.5	3
10343	Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?. <i>Annals of Translational Medicine</i> , 2019, 7, S282-S282.	0.7	4
10344	Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock. <i>Translational Lung Cancer Research</i> , 2019, 8, S360-S363.	1.3	3
10345	Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?. <i>Translational Lung Cancer Research</i> , 2019, 8, S327-S330.	1.3	3
10346	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. <i>Oncologist</i> , 2019, 24, 1469-1478.	1.9	25
10347	Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, S323-S326.	1.3	6
10348	Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. <i>Oncologist</i> , 2019, 24, e1228-e1231.	1.9	30
10349	Utilization of combined PD-L1 expression and neutrophil-to-lymphocyte ratio prior to surgery as a prognostic factor in non-small cell lung cancer with brain metastasis. <i>Translational Cancer Research</i> , 2019, 8, 2864-2877.	0.4	12
10350	Spontaneous Regression of Recurrent Undifferentiated Carcinoma of the Endometrium. <i>Internal Medicine</i> , 2019, 58, 1649-1653.	0.3	3
10351	Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer. <i>ESMO Open</i> , 2019, 4, e000474.	2.0	34
10352	Germline <i>POLE</i> mutation in a child with hypermutated medulloblastoma and features of constitutional mismatch repair deficiency. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004499.	0.5	19
10353	Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. <i>BioMed Research International</i> , 2019, 2019, 1-22.	0.9	9
10354	Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 1099-1109.	0.6	44
10355	Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy. <i>Journal of Breast Cancer</i> , 2019, 22, 497.	0.8	20
10356	Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-12.	0.8	43
10357	Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. <i>Translational Lung Cancer Research</i> , 2019, 8, 1078-1085.	1.3	34
10358	Cancer immunotherapy experience in the Integral Oncology Centre "Diana Laura Riojas de Colosio", MÃ©dica Sur Hospital. <i>Wspolczesna Onkologia</i> , 2019, 23, 239-246.	0.7	0

#	ARTICLE	IF	CITATIONS
10359	Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. <i>Oncologist</i> , 2019, 24, 791-797.	1.9	36
10360	Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 820-828.	1.9	87
10361	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019, 24, 1259-1269.	1.9	127
10362	<p>Thoracic Radiotherapy Benefits Elderly Extensive-Stage Small Cell Lung Cancer Patients with Distant Metastasis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10767-10775.	0.9	5
10363	PD-1 Inhibitors in the Advanced Esophageal Cancer. <i>Frontiers in Pharmacology</i> , 2019, 10, 1418.	1.6	22
10364	Knockdown of PTGS2 by CRISPR/CAS9 System Designates a New Potential Gene Target for Melanoma Treatment. <i>Frontiers in Pharmacology</i> , 2019, 10, 1456.	1.6	16
10365	<p>T-Regulatory Cells In Tumor Progression And Therapy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10731-10747.	0.9	57
10366	Current and Future Treatment Strategies for Rhabdomyosarcoma. <i>Frontiers in Oncology</i> , 2019, 9, 1458.	1.3	100
10367	Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval. <i>Oncologist</i> , 2019, 24, 648-656.	1.9	60
10368	Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy. <i>Translational Lung Cancer Research</i> , 2019, 8, 854-861.	1.3	31
10369	The Effects of AHCCÂ®, a Standardized Extract of Cultured <i>Lentinura edodes</i> Mycelia, on Natural Killer and T Cells in Health and Disease: Reviews on Human and Animal Studies. <i>Journal of Immunology Research</i> , 2019, 2019, 1-7.	0.9	18
10370	Toxicity of tumor immune checkpoint inhibitorsâ€”more attention should be paid. <i>Translational Lung Cancer Research</i> , 2019, 8, 1125-1133.	1.3	7
10371	Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 215-220.	1.2	47
10372	Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion. <i>Oncologist</i> , 2019, 24, 730-734.	1.9	9
10373	Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 604-614.	0.7	34
10374	Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-GuÃ©rin for patients with high-risk non-muscle invasive bladder cancer. <i>BMJ Open</i> , 2019, 9, e028287.	0.8	7
10375	MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. <i>Blood Advances</i> , 2019, 3, 375-383.	2.5	77
10376	Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study. <i>ESMO Open</i> , 2019, 4, e000536.	2.0	26

#	ARTICLE	IF	CITATIONS
10377	Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2019, 79, 6084-6100.	0.4	24
10378	A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 2047-2054.	1.1	11
10379	Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190024.	3.0	47
10380	PD-L1 and tumor-associated macrophages in de novo DLBCL. <i>Blood Advances</i> , 2019, 3, 531-540.	2.5	57
10381	The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 847-853.	1.3	52
10382	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. <i>Oncologist</i> , 2019, 24, e1165-e1171.	1.9	35
10383	Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. <i>Oncologist</i> , 2019, 24, 96-102.	1.9	35
10384	Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?. <i>Oncologist</i> , 2019, 24, e1190-e1196.	1.9	24
10385	Characterization of LAG-3, CTLA-4, and CD8+ TIL density and their joint influence on the prognosis of patients with esophageal squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, 776-776.	0.7	29
10386	Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 4982-4991.	0.6	33
10387	Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study. <i>BMJ Open</i> , 2019, 9, e027066.	0.8	3
10388	KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit. <i>Translational Lung Cancer Research</i> , 2019, 8, S403-S406.	1.3	2
10389	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. <i>Clinical Cancer Research</i> , 2019, 25, 7381-7387.	3.2	13
10390	Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy. <i>BJR Open</i> , 2019, 1, 20190029.	0.4	2
10391	Sequential treatment of metastatic renal cancer in a complex evolving landscape. <i>Annals of Translational Medicine</i> , 2019, 7, S272-S272.	0.7	6
10392	Impact of pretherapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific T cell therapy. <i>Clinical and Translational Immunology</i> , 2019, 8, e01088.	1.7	10
10393	A Hidden Epidemic of Intermediate Risk Oropharynx Cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 617-623.	0.6	11
10394	EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. <i>Molecular Cancer</i> , 2019, 18, 165.	7.9	160

#	ARTICLE	IF	CITATIONS
10395	Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response. <i>Genome Medicine</i> , 2019, 11, 71.	3.6	78
10396	Minimum environmental enrichment is effective in activating antitumor immunity to transplanted tumor cells in mice. <i>Experimental Animals</i> , 2019, 68, 569-576.	0.7	11
10397	Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 2007.	1.0	12
10398	Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy. <i>Medicina (Lithuania)</i> , 2019, 55, 743.	0.8	1
10399	Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice. <i>Targeted Oncology</i> , 2019, 14, 729-742.	1.7	18
10400	Management of V600E and V600K BRAF-Mutant Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 81.	1.3	28
10401	Chlorin e6-Conjugated and PEGylated Immune Checkpoint Inhibitor Nanocomposites for Pulmonary Metastatic Colorectal Cancer. <i>ACS Omega</i> , 2019, 4, 18593-18599.	1.6	7
10402	Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?. <i>Translational Lung Cancer Research</i> , 2019, 8, 710-714.	1.3	11
10403	Immunotherapy: A Challenge of Breast Cancer Treatment. <i>Cancers</i> , 2019, 11, 1822.	1.7	106
10404	Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy. <i>Theranostics</i> , 2019, 9, 8332-8343.	4.6	31
10405	Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2019, 11, 1753.	1.7	16
10406	Impaired B cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. <i>Immunological Reviews</i> , 2019, 292, 90-101.	2.8	86
10407	Mechanisms regulating PD-L1 expression on tumor and immune cells. , 2019, 7, 305.		291
10408	EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. , 2019, 7, 300.		114
10409	Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. , 2019, 7, 306.		642
10410	KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment. <i>Translational Lung Cancer Research</i> , 2019, 8, 706-709.	1.3	5
10411	Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage III Non-small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2019, 9, 1139.	1.3	28
10412	Immune checkpoint inhibitors win the 2018 Nobel Prize. <i>Biomedical Journal</i> , 2019, 42, 299-306.	1.4	62

#	ARTICLE	IF	CITATIONS
10413	Flip the coin: IL-7 and IL-7R in health and disease. <i>Nature Immunology</i> , 2019, 20, 1584-1593.	7.0	195
10414	<scp>CDK</scp> 12 drives breast tumor initiation and trastuzumab resistance via <scp>WNT</scp> and <scp>IRS</scp> 1â€rBâ€r<scp>PI</scp> 3K signaling. <i>EMBO Reports</i> , 2019, 20, e48058.	2.0	76
10415	KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?. <i>Translational Lung Cancer Research</i> , 2019, 8, 723-727.	1.3	4
10416	Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications. <i>Frontiers in Oncology</i> , 2019, 9, 1124.	1.3	52
10417	From Super-Enhancer Non-coding RNA to Immune Checkpoint: Frameworks to Functions. <i>Frontiers in Oncology</i> , 2019, 9, 1307.	1.3	29
10418	Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481988419.	1.4	62
10419	Breast Cancer in Young Women: Status Quo and Advanced Disease Management by a Predictive, Preventive, and Personalized Approach. <i>Cancers</i> , 2019, 11, 1791.	1.7	35
10420	Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1798.	1.7	99
10421	Melanoma and Vitiligo: In Good Company. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5731.	1.8	40
10422	Interleukin-18 Is a Prognostic Biomarker Correlated with CD8+ T Cell and Natural Killer Cell Infiltration in Skin Cutaneous Melanoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 1993.	1.0	31
10423	Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 180-187.	0.4	18
10424	Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC. <i>Targeted Oncology</i> , 2019, 14, 759-768.	1.7	21
10425	Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging. <i>ACS Nano</i> , 2019, 13, 13884-13898.	7.3	66
10426	Immune gene expression profiling reveals heterogeneity in luminal breast tumors. <i>Breast Cancer Research</i> , 2019, 21, 147.	2.2	43
10427	Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). <i>Trials</i> , 2019, 20, 753.	0.7	20
10428	Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade. <i>RSC Advances</i> , 2019, 9, 33903-33911.	1.7	17
10429	Immunotherapy-induced endocrinopathies: assessment, management and monitoring. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881989618.	1.4	29
10430	Classifying Stage IV Lung Cancer From Health Care Claims: A Comparison of Multiple Analytic Approaches. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-19.	1.0	8

#	ARTICLE	IF	CITATIONS
10431	Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	1.5	8
10432	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	58
10433	Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy. <i>Chronic Diseases and Translational Medicine</i> , 2019, 5, 155-169.	0.9	14
10434	Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response. <i>Immuno-Oncology Technology</i> , 2019, 4, 1-7.	0.2	2
10435	Tumour mutational burden: primary versus metastatic tissue creates systematic bias. <i>Immuno-Oncology Technology</i> , 2019, 4, 8-14.	0.2	26
10436	Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer. <i>JACC: CardioOncology</i> , 2019, 1, 182-192.	1.7	47
10437	What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 477-479.	1.2	5
10438	Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer. <i>Medicine (United States)</i> , 2019, 98, e18310.	0.4	2
10439	Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations. <i>Anti-Cancer Drugs</i> , 2019, 30, 873-878.	0.7	6
10440	Reliability of PD-L1 assays using small tissue samples compared with surgical specimens. <i>Medicine (United States)</i> , 2019, 98, e14972.	0.4	15
10441	Real-world experience with pembrolizumab in patients with advanced melanoma. <i>Medicine (United States)</i> , 2019, 98, e14972.	0.4	26
10442	Eliceptant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. <i>Breast Cancer Research</i> , 2019, 21, 146.	2.2	52
10443	Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. <i>Journal of Clinical Oncology</i> , 2019, 37, 353.		91
10444	A systematic flux analysis approach to identify metabolic vulnerabilities in human breast cancer cell lines. <i>Cancer & Metabolism</i> , 2019, 7, 12.	2.4	21
10445	Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6337.	1.8	23
10446	RNA-seq from archival FFPE breast cancer samples: molecular pathway fidelity and novel discovery. <i>BMC Medical Genomics</i> , 2019, 12, 195.	0.7	35
10447	Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4. <i>Genome Medicine</i> , 2019, 11, 87.	3.6	44
10448	The past, present, and future of costimulation blockade in organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 391-401.	0.8	36

#	ARTICLE	IF	CITATIONS
10449	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. , 2019, 7, 351.		39
10450	The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base. <i>Journal of Thoracic Disease</i> , 2019, 11, 4507-4515.	0.6	27
10451	The effect of PD-L1/PD-1 immunotherapy in the treatment of squamous non-small-cell lung cancer: a meta-analysis of randomized controlled clinical trials. <i>Journal of Thoracic Disease</i> , 2019, 11, 4453-4463.	0.6	5
10452	Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory. <i>Immunotherapy</i> , 2019, 11, 1293-1302.	1.0	55
10453	Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1256.	1.3	10
10454	Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. <i>Frontiers in Oncology</i> , 2019, 9, 1289.	1.3	10
10455	Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies. <i>Frontiers in Oncology</i> , 2019, 9, 1432.	1.3	27
10456	D-loop Mutations in Renal Cell Carcinoma Improve Predictive Accuracy for Cancer-Related Death by Integrating with Mutations in the NADH Dehydrogenase Subunit 1 Gene. <i>Genes</i> , 2019, 10, 998.	1.0	5
10457	Immune checkpoint inhibitors therapy in older patients (≥70 years) with metastatic melanoma: a multicentre study. <i>Postepy Dermatologii I Alergologii</i> , 2019, 36, 566-571.	0.4	13
10458	Efficacy of PI3K inhibitors in advanced breast cancer. <i>Annals of Oncology</i> , 2019, 30, x12-x20.	0.6	145
10459	Immunotherapy in Pediatric Solid Tumors—A Systematic Review. <i>Cancers</i> , 2019, 11, 2022.	1.7	13
10460	An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-7.	0.2	3
10461	Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses <i>In Vitro</i> . <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	0.9	12
10462	CD103 ⁺ tumor-infiltrating lymphocytes predict favorable prognosis in patients with esophageal squamous cell carcinoma. <i>Journal of Cancer</i> , 2019, 10, 5234-5243.	1.2	16
10463	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. <i>Nature Communications</i> , 2019, 10, 5386.	5.8	53
10464	Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6623-6632.	3.2	96
10465	Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment. <i>Journal of Hematology and Oncology</i> , 2019, 12, 125.	6.9	116
10466	Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 124.	6.9	95

#	ARTICLE	IF	CITATIONS
10467	Immune receptor repertoires in pediatric and adult acute myeloid leukemia. <i>Genome Medicine</i> , 2019, 11, 73.	3.6	38
10468	Gut microbiome and CAR-T therapy. <i>Experimental Hematology and Oncology</i> , 2019, 8, 31.	2.0	33
10469	MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. , 2019, 7, 327.		88
10470	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. , 2019, 7, 316.		102
10471	<p>Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10263-10273.	1.0	25
10472	<p>Blocking TGF-Î² Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9527-9538.	1.0	93
10473	Immune Checkpoints in Circulating and Tumor-Infiltrating CD4+ T Cell Subsets in Colorectal Cancer Patients. <i>Frontiers in Immunology</i> , 2019, 10, 2936.	2.2	97
10474	Is there an Exposureâ€“Response Relationship for Nivolumab in Real-World NSCLC Patients?. <i>Cancers</i> , 2019, 11, 1784.	1.7	28
10475	Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification. <i>Cancers</i> , 2019, 11, 1864.	1.7	5
10476	Significant prognostic values of differentially expressed-aberrantly methylated hub genes in breast cancer. <i>Journal of Cancer</i> , 2019, 10, 6618-6634.	1.2	47
10477	Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer. <i>Journal of Cancer</i> , 2019, 10, 6703-6710.	1.2	16
10478	Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Cancer</i> , 2019, 10, 6261-6268.	1.2	22
10479	Effects of Postoperative Radiotherapy in Early Breast Cancer Patients Older than 75 Years: A Propensity-Matched Analysis. <i>Journal of Cancer</i> , 2019, 10, 6225-6232.	1.2	3
10480	Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages. <i>Journal of Immunology Research</i> , 2019, 2019, 1-7.	0.9	93
10481	Prognostic factors and a new scoring system for survival of patients irradiated for bone metastases. <i>BMC Cancer</i> , 2019, 19, 1156.	1.1	10
10482	Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?. , 2019, 7, 325.		111
10483	Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. , 2019, 7, 329.		33
10484	Tumor PD-L1 Induction by Resveratrol/Piceatannol May Function as a Search, Enhance, and Engage (â€œSEEâ€) Signal to Facilitate the Elimination of â€œCold, Non-Responsiveâ€ Low PD-L1-Expressing Tumors by PD-L1 Blockade. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5969.	1.8	9

#	ARTICLE	IF	CITATIONS
10485	High hopes and high honours for cancer immunotherapy. <i>Biomedical Journal</i> , 2019, 42, 293-298.	1.4	2
10486	Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instabilityâ€“High Tumors. <i>Current Treatment Options in Oncology</i> , 2019, 20, 83.	1.3	11
10487	Immune-Mediated Colitis. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 506-523.	0.3	6
10488	Systematic profiling of alternative splicing signature reveals prognostic predictor for cervical cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 379.	1.8	23
10489	Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer. <i>Journal of the Endocrine Society</i> , 2019, 3, 2295-2304.	0.1	31
10490	Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, S339-S342.	1.3	13
10491	<p>The Prognosis Of Peroxiredoxin Family In Breast Cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 9685-9699.	0.9	24
10492	GATA Binding Protein 3 Boosts Extracellular ATP Hydrolysis and Inhibits Metastasis of Breast Cancer by Up-regulating Ectonucleoside Triphosphate Diphosphohydrolase 3. <i>International Journal of Biological Sciences</i> , 2019, 15, 2522-2537.	2.6	6
10493	The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 2472.	2.2	15
10494	Innate Immune Response Regulation by the Human RNASET2 Tumor Suppressor Gene. <i>Frontiers in Immunology</i> , 2019, 10, 2587.	2.2	22
10495	Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets. <i>Frontiers in Oncology</i> , 2019, 9, 1145.	1.3	36
10496	Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. <i>Frontiers in Oncology</i> , 2019, 9, 1148.	1.3	90
10497	The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1161.	1.3	96
10498	Targeted Therapies for Triple-Negative Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 82.	1.3	237
10499	Functional Enhancers Shape Extrachromosomal Oncogene Amplifications. <i>Cell</i> , 2019, 179, 1330-1341.e13.	13.5	206
10500	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2019, 25, 1916-1927.	15.2	541
10501	Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 128.	6.9	106
10502	Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy. <i>Frontiers in Medicine</i> , 2019, 6, 262.	1.2	19

#	ARTICLE	IF	CITATIONS
10503	Discovery of Small Molecules for the Reversal of T Cell Exhaustion. <i>Cell Reports</i> , 2019, 29, 3293-3302.e3.	2.9	34
10504	Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 201-213.	2.0	20
10505	Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient. , 2019, 7, 336.		21
10506	<p>The Exosome And Breast Cancer Cell Plasticity</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9817-9825.	1.0	10
10507	Harnessing NK Cells for Cancer Treatment. <i>Frontiers in Immunology</i> , 2019, 10, 2836.	2.2	66
10508	Comparative Approach to the Temporo-Spatial Organization of the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2019, 9, 1185.	1.3	9
10509	Association of Lymphopenia With Risk of Mortality Among Adults in the US General Population. <i>JAMA Network Open</i> , 2019, 2, e1916526.	2.8	77
10510	Reprioritizing Risk and Benefit: The Future of Study Design in Earlyâ€Phase Cancer Research. <i>Ethics & Human Research</i> , 2019, 41, 2-11.	0.5	8
10511	The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy. <i>Cancer Microenvironment</i> , 2019, 12, 133-148.	3.1	36
10512	APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells. <i>Neoplasia</i> , 2019, 21, 1143-1150.	2.3	47
10513	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988554.	1.4	25
10514	BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 386.	1.8	32
10515	Bioactive Compounds: Natural Defense Against Cancer?. <i>Biomolecules</i> , 2019, 9, 758.	1.8	98
10516	High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy. <i>Cancers</i> , 2019, 11, 1824.	1.7	36
10517	Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. <i>Cancers</i> , 2019, 11, 1826.	1.7	132
10518	Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma. <i>Journal of Cancer</i> , 2019, 10, 6114-6123.	1.2	3
10519	Clinical Implications of Tumor-Infiltrating Immune Cells in Breast Cancer. <i>Journal of Cancer</i> , 2019, 10, 6175-6184.	1.2	106
10520	The Evolution of Adjuvant Therapy for Melanoma. <i>Current Oncology Reports</i> , 2019, 21, 106.	1.8	23

#	ARTICLE	IF	CITATIONS
10521	Understanding and measuring human B cell tolerance and its breakdown in autoimmune disease. <i>Immunological Reviews</i> , 2019, 292, 76-89.	2.8	34
10522	Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients. <i>Respiratory Research</i> , 2019, 20, 263.	1.4	5
10523	Distinct functions of AKT isoforms in breast cancer: a comprehensive review. <i>Cell Communication and Signaling</i> , 2019, 17, 154.	2.7	192
10524	Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. <i>Clinical Epigenetics</i> , 2019, 11, 161.	1.8	49
10525	Cancer biomarkers for targeted therapy. <i>Biomarker Research</i> , 2019, 7, 25.	2.8	72
10526	Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. , 2019, 7, 314.		30
10527	Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. , 2019, 7, 322.		122
10528	Targeting DNA methylation for treating triple-negative breast cancer. <i>Pharmacogenomics</i> , 2019, 20, 1151-1157.	0.6	21
10529	Current Progress in CAR-T Cell Therapy for Solid Tumors. <i>International Journal of Biological Sciences</i> , 2019, 15, 2548-2560.	2.6	252
10530	CD4 ⁺ and CD8a ⁺ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models. <i>Theranostics</i> , 2019, 9, 8221-8238.	4.6	59
10531	Differential Functions of Splicing Factors in Mammary Transformation and Breast Cancer Metastasis. <i>Cell Reports</i> , 2019, 29, 2672-2688.e7.	2.9	70
10532	Cancer Cell Membrane-Coated Nanoparticles for Cancer Management. <i>Cancers</i> , 2019, 11, 1836.	1.7	149
10533	Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2019, 21, 108.	1.8	46
10534	A view on drug resistance in cancer. <i>Nature</i> , 2019, 575, 299-309.	13.7	1,391
10535	Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53. <i>Communications Biology</i> , 2019, 2, 436.	2.0	8
10536	Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-2.	0.2	11
10537	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , 2019, 2019, 1-10.	1.4	39
10538	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2019, 26, 96.	2.6	26

#	ARTICLE	IF	CITATIONS
10539	Role of the microbiome in occurrence, development and treatment of pancreatic cancer. <i>Molecular Cancer</i> , 2019, 18, 173.	7.9	67
10540	Identification of Breast Cancer Subtype Specific MicroRNAs Using Survival Analysis to Find Their Role in Transcriptomic Regulation. <i>Frontiers in Genetics</i> , 2019, 10, 1047.	1.1	16
10541	Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma. <i>Biomedicines</i> , 2019, 7, 91.	1.4	21
10542	Evaluation of the Reactivity and Receptor Competition of HLA-G Isoforms toward Available Antibodies: Implications of Structural Characteristics of HLA-G Isoforms. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5947.	1.8	12
10543	Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. , 2019, 7, 339.		65
10544	XIAOPI Formula Inhibits Breast Cancer Stem Cells via Suppressing Tumor-Associated Macrophages/C-X-C Motif Chemokine Ligand 1 Pathway. <i>Frontiers in Pharmacology</i> , 2019, 10, 1371.	1.6	19
10545	Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2019, 42, 221-227.	1.2	20
10546	Melanoma vaccines: clinical status and immune endpoints. <i>Melanoma Research</i> , 2019, 29, 109-118.	0.6	19
10547	Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer. <i>Medicine (United States)</i> , 2019, 98, e15201.	0.4	28
10548	The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients. <i>Medicine (United States)</i> , 2019, 98, e16439.	0.4	1
10549	Primary tumor resection for initially staged IV breast cancer. <i>Medicine (United States)</i> , 2019, 98, e16773.	0.4	7
10550	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 5961-5971.	3.2	118
10551	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. <i>Cancer Immunology Research</i> , 2019, 7, 1903-1909.	1.6	86
10552	Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort. <i>Journal of Thoracic Disease</i> , 2019, 11, 4591-4601.	0.6	35
10553	Biomarker for personalized immunotherapy. <i>Translational Lung Cancer Research</i> , 2019, 8, S308-S317.	1.3	7
10554	Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S265-S279.	1.3	17
10555	Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. <i>Melanoma Management</i> , 2019, 6, MMT30.	0.1	19
10556	Neoantigen Fitness Model Predicts Lower Immune Recognition of Cutaneous Squamous Cell Carcinomas Than Actinic Keratoses. <i>Frontiers in Immunology</i> , 2019, 10, 2799.	2.2	9

#	ARTICLE	IF	CITATIONS
10557	JAK Inhibitors and Oxidative Stress Control. <i>Frontiers in Immunology</i> , 2019, 10, 2814.	2.2	36
10558	Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. <i>Frontiers in Immunology</i> , 2019, 10, 2876.	2.2	60
10559	New Frontiers for Molecular Pathology. <i>Frontiers in Medicine</i> , 2019, 6, 284.	1.2	21
10560	Targeting of the Eukaryotic Translation Initiation Factor 4A Against Breast Cancer Stemness. <i>Frontiers in Oncology</i> , 2019, 9, 1311.	1.3	34
10561	Genetic Variation in CCL5 Signaling Genes and Triple Negative Breast Cancer: Susceptibility and Prognosis Implications. <i>Frontiers in Oncology</i> , 2019, 9, 1328.	1.3	13
10562	Lung Cancer Heterogeneity in Modulation of Th17/IL17A Responses. <i>Frontiers in Oncology</i> , 2019, 9, 1384.	1.3	7
10563	Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study. <i>Frontiers in Oncology</i> , 2019, 9, 1394.	1.3	35
10564	Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2019, 9, 1437.	1.3	13
10565	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1350.	1.6	75
10566	A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma. <i>Cancers</i> , 2019, 11, 2041.	1.7	17
10567	Spatial Organization of the Gene Regulatory Program: An Information Theoretical Approach to Breast Cancer Transcriptomics. <i>Entropy</i> , 2019, 21, 195.	1.1	25
10568	Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions. <i>Oncology Reviews</i> , 2019, 13, 433.	0.8	9
10569	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989160.	1.4	3
10570	Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. <i>BMC Endocrine Disorders</i> , 2019, 19, 144.	0.9	24
10571	Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. <i>Journal of Translational Medicine</i> , 2019, 17, 376.	1.8	20
10572	Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers. <i>Breast Cancer Research</i> , 2019, 21, 150.	2.2	14
10573	S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis. <i>Breast Cancer Research</i> , 2019, 21, 152.	2.2	4
10574	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182

#	ARTICLE	IF	CITATIONS
10575	Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug. PLoS ONE, 2019, 14, e0226869.	1.1	12
10576	Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. Liver Cancer, 2019, 8, 413-426.	4.2	40
10577	The prognostic role of circulating CD8+ T cell proliferation in patients with untreated extensive stage small cell lung cancer. Journal of Translational Medicine, 2019, 17, 402.	1.8	25
10578	An update on adjuvant systemic therapies in melanoma. Melanoma Management, 2019, 6, MMT28.	0.1	10
10580	Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Expert Review of Endocrinology and Metabolism, 2019, 14, 381-398.	1.2	54
10581	Postoperative adjuvant therapy for resectable esophageal cancer. Medicine (United States), 2019, 98, e15485.	0.4	6
10582	Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer. Medicine (United States), 2019, 98, e17257.	0.4	38
10583	PGR Gene Fusions Identify a Molecular Subset of Uterine Epithelioid Leiomyosarcoma With Rhabdoid Features. American Journal of Surgical Pathology, 2019, 43, 810-818.	2.1	28
10584	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. European Respiratory Review, 2019, 28, 190058.	3.0	73
10585	A systematic analysis of immune genes and overall survival in cancer patients. BMC Cancer, 2019, 19, 1225.	1.1	30
10586	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Research, 2019, 21, 142.	2.2	21
10587	Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1. Biomarker Research, 2019, 7, 28.	2.8	22
10588	Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. Nature Communications, 2019, 10, 5546.	5.8	98
10589	Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer. Integrative Cancer Therapies, 2019, 18, 153473541989002.	0.8	33
10590	The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Molecular Cancer, 2019, 18, 184.	7.9	54
10591	PI3K Inhibitors in Breast Cancer Therapy. Current Oncology Reports, 2019, 21, 110.	1.8	120
10592	Genetic determinants of the molecular portraits of epithelial cancers. Nature Communications, 2019, 10, 5666.	5.8	21
10593	Vulvar malignancies: an interdisciplinary perspective. JDDG - Journal of the German Society of Dermatology, 2019, 17, 1257-1276.	0.4	28

#	ARTICLE	IF	CITATIONS
10594	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. <i>Gastrointestinal Tumors</i> , 2019, 6, 71-80.	0.3	4
10595	Genetic instability as a driver for immune surveillance. , 2019, 7, 345.		9
10596	The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?. <i>Translational Lung Cancer Research</i> , 2019, 8, 731-737.	1.3	1
10597	The Intriguing History of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2965.	2.2	240
10598	Prognostic Immune Cell Profiling of Malignant Pleural Effusion Patients by Computerized Immunohistochemical and Transcriptional Analysis. <i>Cancers</i> , 2019, 11, 1953.	1.7	8
10599	CBNA: A control theory based method for identifying coding and non-coding cancer drivers. <i>PLoS Computational Biology</i> , 2019, 15, e1007538.	1.5	22
10600	Fast approximate inference for variable selection in Dirichlet process mixtures, with an application to pan-cancer proteomics. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2019, 18, .	0.2	6
10601	Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2019, 9, 1287.	1.3	22
10602	MHC-II neoantigens shape tumour immunity and response to immunotherapy. <i>Nature</i> , 2019, 574, 696-701.	13.7	563
10603	In vivo molecular imaging for immunotherapy using ultra-bright near-infrared-IIb rare-earth nanoparticles. <i>Nature Biotechnology</i> , 2019, 37, 1322-1331.	9.4	398
10604	The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy. <i>Nature Genetics</i> , 2019, 51, 1645-1651.	9.4	171
10605	Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. <i>Nature Immunology</i> , 2019, 20, 1494-1505.	7.0	83
10606	Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. <i>Nature Immunology</i> , 2019, 20, 1425-1434.	7.0	336
10607	Tumour flare reaction in cancer treatments. <i>Anti-Cancer Drugs</i> , 2019, 30, 953-958.	0.7	17
10608	Systematic analysis of breast atypical hyperplasia-associated hub genes and pathways based on text mining. <i>European Journal of Cancer Prevention</i> , 2019, 28, 507-514.	0.6	4
10609	Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. <i>Melanoma Research</i> , 2019, 29, 453-464.	0.6	26
10610	Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma. <i>Medicine (United States)</i> , 2019, 98, e15449.	0.4	41
10611	Pneumonitis and concomitant bacterial pneumonia in patients receiving pembrolizumab treatment. <i>Medicine (United States)</i> , 2019, 98, e16158.	0.4	8

#	ARTICLE	IF	CITATIONS
10612	Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer. <i>Medicine (United States)</i> , 2019, 98, e16324.	0.4	2
10613	Real-world treatment patterns and clinical outcomes among patients with advanced melanoma. <i>Medicine (United States)</i> , 2019, 98, e16328.	0.4	30
10614	Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. <i>Medicine (United States)</i> , 2019, 98, e16417.	0.4	28
10615	Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis. <i>Medicine (United States)</i> , 2019, 98, e17832.	0.4	37
10616	Enforcing the checkpoints. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 213-218.	1.2	25
10617	Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgery</i> , 2021, 274, e150-e159.	2.1	5
10618	A Celiac Disease Phenotype After Checkpoint Inhibitor Exposure: An Example of Immune Dysregulation After Immunotherapy. <i>ACG Case Reports Journal</i> , 2019, 6, e00158.	0.2	12
10619	Dysphagia predict the response to second cycle neoadjuvant chemotherapy in first cycle no response esophageal carcinoma. <i>Journal of Thoracic Disease</i> , 2019, 11, 4135-4143.	0.6	3
10620	<p>Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8595-8600.	1.0	23
10621	Multiple Targets of the Canonical WNT/ β -Catenin Signaling in Cancers. <i>Frontiers in Oncology</i> , 2019, 9, 1248.	1.3	135
10622	Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. <i>Cancers</i> , 2019, 11, 1940.	1.7	29
10623	An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	4
10624	The tumor microenvironment in renal cell cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 194-199.	1.1	36
10625	Impact of initial stage on metastatic melanoma survival. <i>Melanoma Research</i> , 2019, 29, 281-288.	0.6	12
10626	A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma. <i>Melanoma Research</i> , 2019, 29, 635-642.	0.6	4
10627	Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis. <i>Medicine (United States)</i> , 2019, 98, e14663.	0.4	21
10628	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 699-714.	0.6	36
10629	¹¹ C-Labeled Pictilisib (GDC-0941) as a Molecular Tracer Targeting Phosphatidylinositol 3-Kinase (PI3K) for Breast Cancer Imaging. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-11.	0.4	8

#	ARTICLE	IF	CITATIONS
10630	DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1961-1972.	1.9	14
10631	Pancytopenia And Limbic Encephalopathy Complicating Immunotherapy For Clear Cell Endometrial Cancer With Microsatellite Instability-High (MSI-H). <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9965-9973.	1.0	3
10632	Pseudo-Progression and the Neutrophil-to-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Case-Control Study. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10559-10568.	1.0	15
10633	Identifying successful biomarkers for patients with non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2019, 8, LMT17.	1.5	7
10634	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. <i>Cancers</i> , 2019, 11, 1926.	1.7	27
10635	Immunotherapy – Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites. <i>Cureus</i> , 2019, 11, e5938.	0.2	9
10636	Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. <i>Rheumatology</i> , 2019, 58, vii59-vii67.	0.9	137
10637	Management of rheumatic complications of ICI therapy: a rheumatology viewpoint. <i>Rheumatology</i> , 2019, 58, vii49-vii58.	0.9	24
10638	Toxicities associated with checkpoint inhibitors – an overview. <i>Rheumatology</i> , 2019, 58, vii7-vii16.	0.9	80
10639	BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes. , 2019, 7, 313.		67
10640	Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 131-149.	1.3	31
10641	Immune-Mediated Antitumor Effect By VEGFR2 Selective Inhibitor For Gastric Cancer. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9757-9765.	1.0	10
10642	A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 9469-9481.	0.9	1
10643	EPSILON: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. <i>Cancers</i> , 2019, 11, 1954.	1.7	57
10644	Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease. <i>Current Oncology</i> , 2019, 26, 24-32.	0.9	11
10645	Setting the scene – a future “epidemic” of immune-related adverse events in association with checkpoint inhibitor therapy. <i>Rheumatology</i> , 2019, 58, vii1-vii6.	0.9	3
10646	Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective. <i>Rheumatology</i> , 2019, 58, vii29-vii39.	0.9	22
10647	CTCs Expression Profiling for Advanced Breast Cancer Monitoring. <i>Cancers</i> , 2019, 11, 1941.	1.7	16

#	ARTICLE	IF	CITATIONS
10648	NF-kappa B Signaling-Related Signatures Are Connected with the Mesenchymal Phenotype of Circulating Tumor Cells in Non-Metastatic Breast Cancer. <i>Cancers</i> , 2019, 11, 1961.	1.7	18
10649	Somatic Mutation of PIK3CA (H1047R) Is a Common Driver Mutation Hotspot in Canine Mammary Tumors as Well as Human Breast Cancers. <i>Cancers</i> , 2019, 11, 2006.	1.7	35
10650	Basis of PD1/PD-L1 Therapies. <i>Journal of Clinical Medicine</i> , 2019, 8, 2168.	1.0	85
10651	Mechanistic Understanding of Curcumin's Therapeutic Effects in Lung Cancer. <i>Nutrients</i> , 2019, 11, 2989.	1.7	88
10652	Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10043-10055.	1.0	18
10653	The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 879.	1.3	6
10654	Immunotherapies for pediatric cancer: current landscape and future perspectives. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 573-594.	2.7	20
10655	MRI of Cardiotoxicity. <i>Cardiology Clinics</i> , 2019, 37, 429-439.	0.9	7
10656	Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 1715-1720.	15.2	194
10657	Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. <i>Journal of Clinical Investigation</i> , 2019, 129, 343.		56
10658	Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma. <i>Internal Medicine</i> , 2019, 58, 3283-3287.	0.3	17
10659	Latin American Study of Hereditary Breast and Ovarian Cancer LACAM: A Genomic Epidemiology Approach. <i>Frontiers in Oncology</i> , 2019, 9, 1429.	1.3	24
10660	Hypoxia-activated NIR photosensitizer anchoring in the mitochondria for photodynamic therapy. <i>Chemical Science</i> , 2019, 10, 10586-10594.	3.7	151
10661	Synergistic association of FOXP3+ tumor infiltrating lymphocytes with CCL20 expressions with poor prognosis of primary breast cancer. <i>Medicine (United States)</i> , 2019, 98, e18403.	0.4	8
10662	Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.2	6
10663	Development and Validation of Nomograms for Predicting the Prognosis of Triple-Negative Breast Cancer Patients Based on 379 Chinese Patients. <i>Cancer Management and Research</i> , 2019, Volume 11, 10827-10839.	0.9	16
10664	Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 11541-11547.	1.0	13
10665	Impact of the Gut Microbiome on Immune Checkpoint Inhibitor Efficacy: A Systematic Review. <i>Current Oncology</i> , 2019, 26, 395-403.	0.9	44

#	ARTICLE	IF	CITATIONS
10666	Innovation in Oncology Drug Development. <i>Journal of Oncology</i> , 2019, 2019, 1-16.	0.6	10
10667	Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma. <i>Oncologist</i> , 2019, 24, 1076-1088.	1.9	18
10668	Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1453-1461.	1.9	75
10669	High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation. , 2019, 7, 357.		52
10670	Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	26
10671	An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies. <i>Oncologist</i> , 2019, 24, e1294-e1302.	1.9	67
10672	In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1). <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 436.	1.8	7
10673	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. <i>Modern Pathology</i> , 2019, 32, 81-87.	2.9	10
10674	Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. <i>Veterinary and Comparative Oncology</i> , 2019, 17, 49-60.	0.8	33
10675	Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. <i>International Journal of Clinical Oncology</i> , 2019, 24, 41-45.	1.0	5
10676	Brain-Resident T Cells Following Viral Infection. <i>Viral Immunology</i> , 2019, 32, 48-54.	0.6	26
10677	T Cells and Regulated Cell Death. <i>International Review of Cell and Molecular Biology</i> , 2019, 342, 27-71.	1.6	27
10678	Principles of adoptive T cell therapy in cancer. <i>Seminars in Immunopathology</i> , 2019, 41, 49-58.	2.8	141
10679	SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 304-315.	5.7	129
10680	Mixed graphical models for integrative causal analysis with application to chronic lung disease diagnosis and prognosis. <i>Bioinformatics</i> , 2019, 35, 1204-1212.	1.8	63
10681	Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade. <i>Neurosurgery</i> , 2019, 84, 945-953.	0.6	24
10682	Lobular Carcinomas <i>In Situ</i> Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 674-686.	3.2	44
10683	HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. <i>Liver Cancer</i> , 2019, 8, 41-65.	4.2	38

#	ARTICLE	IF	CITATIONS
10684	Cancer immunophenotyping by seven-colour multispectral imaging without tyramide signal amplification. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 3-11.	1.3	33
10685	Improving efficacy of cancer immunotherapy through targeting of macrophages. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 189-192.	1.4	10
10686	Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression. <i>Human Pathology</i> , 2019, 83, 115-123.	1.1	19
10687	TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells. <i>Oncogene</i> , 2019, 38, 852-867.	2.6	43
10688	Progress in adjuvant systemic therapy for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 27-44.	12.5	175
10689	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 74.	3.4	557
10690	A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 15-19.	0.4	4
10691	Bugs in the system: bringing the human microbiome to bear in cancer immunotherapy. <i>Gut Microbes</i> , 2019, 10, 109-112.	4.3	15
10692	Disruption of sialic acid metabolism drives tumor growth by augmenting CD8 ⁺ T cell apoptosis. <i>International Journal of Cancer</i> , 2019, 144, 2290-2302.	2.3	34
10693	Combined γ -programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma. <i>Cancer Biology and Therapy</i> , 2019, 20, 666-679.	1.5	6
10694	Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 24.	1.8	100
10695	Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy. <i>Theranostics</i> , 2019, 9, 126-151.	4.6	128
10696	Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. <i>British Journal of Cancer</i> , 2019, 120, 346-355.	2.9	16
10697	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 471.	3.4	426
10698	Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 376.	3.4	235
10699	Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers. <i>JAMA Oncology</i> , 2019, 5, 529.	3.4	192
10700	Melanoma tumour vasculature heterogeneity: from mice models to human. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 589-597.	1.2	9
10701	Remodeling the Microenvironment before Occurrence and Metastasis of Cancer. <i>International Journal of Biological Sciences</i> , 2019, 15, 105-113.	2.6	15

#	ARTICLE	IF	CITATIONS
10702	Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. <i>Drugs</i> , 2019, 79, 21-42.	4.9	54
10703	Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma. <i>Translational Oncology</i> , 2019, 12, 350-360.	1.7	27
10704	Autoimmunity and Cancer, the Paradox Comorbidities Challenging Therapy in the Context of Preexisting Autoimmunity. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 72-84.	0.5	31
10705	Rational combination of cancer immunotherapy in melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 433-447.	1.4	7
10706	SMYD3 promotes the epithelialâ€mesenchymal transition in breast cancer. <i>Nucleic Acids Research</i> , 2019, 47, 1278-1293.	6.5	63
10707	Biomarkers for Programmed Deathâ€1 Inhibition in Prostate Cancer. <i>Oncologist</i> , 2019, 24, 444-448.	1.9	18
10708	KLP-PI: a new prognostic index for luminal B HER-2-negative breast cancer. <i>Human Cell</i> , 2019, 32, 172-184.	1.2	2
10709	Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. <i>Nature Biotechnology</i> , 2019, 37, 55-63.	9.4	203
10710	Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 156, 510-524.	0.6	179
10711	Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 517-527.	2.0	39
10712	Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 821-828.	1.2	4
10713	Oxidative stress generated by irradiation of a zinc(II) phthalocyanine induces a dual apoptotic and necrotic response in melanoma cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2019, 24, 119-134.	2.2	16
10714	Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer. <i>Drugs</i> , 2019, 79, 1-10.	4.9	18
10715	Cancer Stem Cells: The Architects of the Tumor Ecosystem. <i>Cell Stem Cell</i> , 2019, 24, 41-53.	5.2	407
10716	Ushering in Integrated T Cell Repertoire Profiling in Cancer. <i>Trends in Cancer</i> , 2019, 5, 85-94.	3.8	19
10717	KrÃ4ppel like factor 6 splice variant 1 (KLF6-SV1) overexpression recruits macrophages to participate in lung cancer metastasis by up-regulating TWIST1. <i>Cancer Biology and Therapy</i> , 2019, 20, 680-691.	1.5	13
10718	An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019, 34, 147-159.	0.7	20
10719	PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 798-806.	1.1	26

#	ARTICLE	IF	CITATIONS
10720	A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis. <i>Internal Medicine</i> , 2019, 58, 921-927.	0.3	18
10721	Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody. <i>In Vivo</i> , 2019, 33, 213-220.	0.6	15
10722	PDL1 Fusion Protein Protects Against Experimental Cerebral Malaria via Repressing Over-Reactive CD8+ T Cell Responses. <i>Frontiers in Immunology</i> , 2019, 9, 3157.	2.2	11
10723	Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: A radio-pathologic correlation. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 168-170.	0.2	8
10724	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. <i>JAMA Oncology</i> , 2019, 5, 546.	3.4	366
10725	Identification and characterization of an alternative cancer-derived PD-L1 splice variant. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 407-420.	2.0	53
10726	Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 933-938.	1.2	19
10727	Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. <i>Cell</i> , 2019, 176, 334-347.e12.	13.5	553
10728	Impact of tumor infiltrating lymphocytes and lymphoid follicle formation on patient survival following surgery for lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2019, 10, 219-225.	0.8	7
10729	Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers. <i>Laryngoscope</i> , 2019, 129, 1836-1843.	1.1	21
10730	TriPOINT: a software tool to prioritize important genes in pathways and their non-coding regulators. <i>Bioinformatics</i> , 2019, 35, 2686-2689.	1.8	0
10731	The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis. <i>Clinical and Translational Oncology</i> , 2019, 21, 674-686.	1.2	13
10732	PD-L1 Expression on Lung Cancer Stem Cells in Metastatic Lymph Nodes Aspirates. <i>Stem Cell Reviews and Reports</i> , 2019, 15, 324-330.	5.6	19
10733	Nondestructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy. <i>Laboratory Investigation</i> , 2019, 99, 1400-1413.	1.7	18
10734	T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. <i>Modern Pathology</i> , 2019, 32, 576-584.	2.9	29
10735	Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. <i>International Journal of Cancer</i> , 2019, 145, 1179-1188.	2.3	199
10736	Evaluation of tumor-infiltrating lymphocytes in osteosarcomas of the jaws: a multicenter study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 201-207.	1.4	15
10737	Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 276-287.	0.5	92

#	ARTICLE	IF	CITATIONS
10738	Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. <i>Breast Care</i> , 2019, 14, 53-59.	0.8	13
10739	Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?. <i>Drugs and Aging</i> , 2019, 36, 1-11.	1.3	10
10740	Product review: avelumab, an anti-PD-L1 antibody. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 891-908.	1.4	50
10741	PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1. <i>Thoracic Cancer</i> , 2019, 10, 103-110.	0.8	36
10742	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. <i>Cancer Discovery</i> , 2019, 9, 370-383.	7.7	380
10743	The Reciprocity between Radiotherapy and Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1709-1717.	3.2	95
10744	¹⁸ F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 335-341.	2.8	123
10745	Class II MHC antigen processing in immune tolerance and inflammation. <i>Immunogenetics</i> , 2019, 71, 171-187.	1.2	77
10746	Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. <i>Cancer Immunology Research</i> , 2019, 7, 86-99.	1.6	27
10747	Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 18, 326-335.	1.7	14
10748	The expression signature of cancer-associated KRAB-ZNF factors identified in TCGA pan-cancer transcriptomic data. <i>Molecular Oncology</i> , 2019, 13, 701-724.	2.1	51
10749	Increased Expression of GARP in Papillary Thyroid Carcinoma. <i>Endocrine Pathology</i> , 2019, 30, 1-7.	5.2	10
10750	Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer. <i>Medical Oncology</i> , 2019, 36, 4.	1.2	11
10751	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 3-17.	1.2	110
10752	Cancer immunotherapy of patients with HIV infection. <i>Clinical and Translational Oncology</i> , 2019, 21, 713-720.	1.2	22
10753	PHA eludes macrophage suppression to activate CD8+ T cells. <i>Immunobiology</i> , 2019, 224, 94-101.	0.8	8
10754	Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 17-22.	0.2	21
10755	The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 543-555.	0.8	21

#	ARTICLE	IF	CITATIONS
10756	Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. <i>Gynecologic Oncology</i> , 2019, 152, 11-19.	0.6	66
10757	Current status of immunotherapy in metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2019, 34, 13-25.	1.0	106
10758	Vaccine strain <i>Listeria monocytogenes</i> bacteremia occurring 31 months after immunization. <i>Infection</i> , 2019, 47, 489-492.	2.3	14
10759	Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what) Tj ETQq1 1 0.784314 1.85 BT /Overlock 107	1.85	51
10760	MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 257-269.	1.1	9
10761	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. <i>Gynecologic Oncology</i> , 2019, 152, 251-258.	0.6	33
10762	Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. <i>Advances in Radiation Oncology</i> , 2019, 4, 268-282.	0.6	13
10763	Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer. <i>Molecular Oncology</i> , 2019, 13, 376-391.	2.1	28
10764	Incorporating Biomarkers to Improve Statistical Power of Immunotherapeutic Neoadjuvant Clinical Trials in Patients with Triple-Negative Breast Cancer. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 210-219.	0.6	0
10765	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. <i>Radiology</i> , 2019, 290, 9-22.	3.6	147
10766	Biological Consequences of MHC-II Expression by Tumor Cells in Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2392-2402.	3.2	282
10767	Oncogenic activity of poly (ADP-ribose) glycohydrolase. <i>Oncogene</i> , 2019, 38, 2177-2191.	2.6	21
10768	Current and Emerging Targets in Immunotherapy for Osteosarcoma. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	79
10769	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 1272-1279.	3.2	57
10770	WNT/ β -catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 3074-3083.	3.2	435
10771	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. <i>Clinical Cancer Research</i> , 2019, 25, 2166-2173.	3.2	67
10772	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 2442-2449.	3.2	106
10773	Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. <i>Clinical Cancer Research</i> , 2019, 25, 2725-2736.	3.2	50

#	ARTICLE	IF	CITATIONS
10774	A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity. <i>Cancer Immunology Research</i> , 2019, 7, 428-442.	1.6	92
10775	Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma. <i>Cancer Immunology Research</i> , 2019, 7, 458-465.	1.6	43
10776	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. <i>BMC Cancer</i> , 2019, 19, 19.	1.1	66
10777	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. <i>Journal of Hematology and Oncology</i> , 2019, 12, 7.	6.9	113
10778	Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study. <i>Human Genomics</i> , 2019, 13, 4.	1.4	10
10779	Genetic variants in <i>RUNX3</i> , <i>AMD1</i> and <i>MSRA</i> in the methionine metabolic pathway and survival in nonsmall cell lung cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 621-631.	2.3	21
10780	The rise of the distributions: why non-normality is important for understanding the transcriptome and beyond. <i>Biophysical Reviews</i> , 2019, 11, 89-94.	1.5	39
10781	Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. <i>Drug Safety</i> , 2019, 42, 281-294.	1.4	69
10782	Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model. <i>Oncogene</i> , 2019, 38, 3535-3550.	2.6	15
10783	Nivolumab to pembrolizumab switch induced a durable melanoma response. <i>Medicine (United States)</i> , 2019, 98, e13804.	0.4	14
10784	Clinical target sequencing for precision medicine of breast cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 131-140.	1.0	14
10785	Liver damage related to immune checkpoint inhibitors. <i>Hepatology International</i> , 2019, 13, 248-252.	1.9	36
10786	PET imaging in patients with brain metastasis—report of the RANO/PET group. <i>Neuro-Oncology</i> , 2019, 21, 585-595.	0.6	139
10787	Coevolution of the coagulation and immune systems. <i>Inflammation Research</i> , 2019, 68, 117-123.	1.6	20
10788	A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 605-613.	1.1	14
10789	Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors. <i>Carcinogenesis</i> , 2019, 40, 998-1009.	1.3	20
10790	Efficacy of pembrolizumab for patients with both high PD-L1 expression and an <i>MET</i> exon 14 skipping mutation: A case report. <i>Thoracic Cancer</i> , 2019, 10, 369-372.	0.8	12
10791	Single Cell Omics of Breast Cancer: An Update on Characterization and Diagnosis. <i>Indian Journal of Clinical Biochemistry</i> , 2019, 34, 3-18.	0.9	14

#	ARTICLE	IF	CITATIONS
10792	Delivery technologies for cancer immunotherapy. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 175-196.	21.5	1,562
10793	Pembrolizumab for non-small cell lung cancer with central nervous system metastases: A case report. <i>Thoracic Cancer</i> , 2019, 10, 381-385.	0.8	6
10794	IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer. <i>Cancers</i> , 2019, 11, 36.	1.7	17
10795	Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies. <i>BMC Cancer</i> , 2019, 19, 72.	1.1	32
10796	Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma. <i>BMC Cancer</i> , 2019, 19, 68.	1.1	44
10797	Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-IL27 and anti-PD1 antibodies. , 2019, 7, 1.		143
10798	The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development. <i>Immunotherapy</i> , 2019, 11, 155-159.	1.0	12
10799	Deregulation of VEGFR-2 and PDGFR Expression and Microvascular Density in a Triple-Negative Model of Canine Malignant Mammary Tumors with Lymph Node or Lung Metastasis. <i>Veterinary Sciences</i> , 2019, 6, 3.	0.6	14
10800	The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 14, 301-317.	2.3	24
10801	Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 12.		67
10802	Differential modulation and prognostic values of immune-escape genes in uveal melanoma. <i>PLoS ONE</i> , 2019, 14, e0210276.	1.1	45
10803	Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study. <i>PLoS ONE</i> , 2019, 14, e0210372.	1.1	12
10804	Roles, function and relevance of LAG3 in HIV infection. <i>PLoS Pathogens</i> , 2019, 15, e1007429.	2.1	27
10805	Survival after a cancer diagnosis among solid organ transplant recipients in the United States. <i>Cancer</i> , 2019, 125, 933-942.	2.0	67
10806	The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 455-466.	2.0	31
10807	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 429-443.	1.2	13
10808	Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 785-792.	2.7	50
10809	Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 793-802.	2.7	124

#	ARTICLE	IF	CITATIONS
10810	Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas. <i>Cancer Causes and Control</i> , 2019, 30, 31-39.	0.8	14
10811	Optical Imaging of Triple-Negative Breast Cancer Cells in Xenograft Athymic Mice Using an ICAM-1-Targeting Small-Molecule Probe. <i>Molecular Imaging and Biology</i> , 2019, 21, 835-841.	1.3	7
10812	Synthesis and Immunomodulatory Activity of Fluorine-Containing Bisphosphonates. <i>ChemMedChem</i> , 2019, 14, 462-468.	1.6	7
10813	Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. <i>Journal of Pathology</i> , 2019, 247, 615-628.	2.1	70
10814	Time for radioimmunotherapy: an overview to bring improvements in clinical practice. <i>Clinical and Translational Oncology</i> , 2019, 21, 992-1004.	1.2	13
10815	HTiP: High-Throughput Immunomodulator Phenotypic Screening Platform to Reveal IAP Antagonists as Anti-cancer Immune Enhancers. <i>Cell Chemical Biology</i> , 2019, 26, 331-339.e3.	2.5	33
10816	Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review. <i>ENeurologicalSci</i> , 2019, 14, 49-50.	0.5	22
10817	Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. <i>Lung Cancer</i> , 2019, 127, 25-33.	0.9	13
10818	Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers. <i>Oncogene</i> , 2019, 38, 3261-3273.	2.6	41
10819	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
10820	Translation control of the immune checkpoint in cancer and its therapeutic targeting. <i>Nature Medicine</i> , 2019, 25, 301-311.	15.2	184
10821	Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab. <i>European Radiology</i> , 2019, 29, 3183-3191.	2.3	36
10822	The role of immunotherapy in small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 961-976.	1.2	81
10823	Vaccine protection against SIVmac239 acquisition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1739-1744.	3.3	15
10824	Improved indel detection in DNA and RNA via realignment with ABRA2. <i>Bioinformatics</i> , 2019, 35, 2966-2973.	1.8	55
10825	Correlate tumor mutation burden with immune signatures in human cancers. <i>BMC Immunology</i> , 2019, 20, 4.	0.9	149
10826	Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 49.	1.1	21
10827	Clinical and positron emission tomography responses to long-term high-dose interferon- β treatment among patients with Erdheim-Chester disease. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 11.	1.2	17

#	ARTICLE	IF	CITATIONS
10828	Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 16.	3.5	27
10829	Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy. <i>AAPS Journal</i> , 2019, 21, 18.	2.2	8
10830	Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice. <i>PLoS ONE</i> , 2019, 14, e0210225.	1.1	19
10831	Adverse events associated with immune checkpoint inhibitor treatment for cancer. <i>Cmaj</i> , 2019, 191, E40-E46.	0.9	36
10832	Transcriptional regulation of normal human mammary cell heterogeneity and its perturbation in breast cancer. <i>EMBO Journal</i> , 2019, 38, e100330.	3.5	35
10833	Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction. <i>Frontiers in Immunology</i> , 2019, 10, 86.	2.2	45
10834	The intimate relationship between gut microbiota and cancer immunotherapy. <i>Gut Microbes</i> , 2019, 10, 424-428.	4.3	98
10835	The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 175-188.	2.0	25
10836	Drug-Induced Liver Injury: Highlights of the Recent Literature. <i>Drug Safety</i> , 2019, 42, 365-387.	1.4	82
10837	Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up. <i>JAMA Oncology</i> , 2019, 5, 334.	3.4	206
10838	PD-1 methylation regulates PD-1 expression and is associated with melanoma survival. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 435-440.	1.5	54
10839	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	3.4	295
10840	RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 95-102.	1.4	5
10841	Engineering Precision Medicine. <i>Advanced Science</i> , 2019, 6, 1801039.	5.6	55
10842	FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 65-76.	1.2	18
10843	A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 799-809.	1.2	4
10844	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. <i>Endocrine Reviews</i> , 2019, 40, 17-65.	8.9	349
10845	Cancer diagnosis and immunotherapy in the age of CRISPR. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 233-243.	1.5	4

#	ARTICLE	IF	CITATIONS
10846	A prognostic index for colorectal cancer based on preoperative absolute lymphocyte, monocyte, and neutrophil counts. <i>Surgery Today</i> , 2019, 49, 245-253.	0.7	20
10847	Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 667-677.	1.1	19
10848	Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era. <i>American Journal of Pathology</i> , 2019, 189, 956-965.	1.9	15
10849	Aldehyde dehydrogenase in regulatory T cell development, immunity and cancer. <i>Immunology</i> , 2019, 156, 47-55.	2.0	38
10850	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF mutated melanoma and other advanced malignancies. <i>Cancer</i> , 2019, 125, 463-472.	2.0	10
10851	Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2019, 141, 1-12.	1.4	30
10852	A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues. <i>Clinical Cancer Research</i> , 2019, 25, 1774-1785.	3.2	30
10853	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 2116-2126.	3.2	390
10854	Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis. <i>Clinical Cancer Research</i> , 2019, 25, 1462-1471.	3.2	271
10855	Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. <i>Seminars in Immunopathology</i> , 2019, 41, 21-30.	2.8	49
10856	Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. <i>World Journal of Urology</i> , 2019, 37, 1773-1784.	1.2	22
10857	Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 253-259.	1.2	44
10858	Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS). <i>Clinical and Translational Oncology</i> , 2019, 21, 721-728.	1.2	32
10859	TPMCalculator: one-step software to quantify mRNA abundance of genomic features. <i>Bioinformatics</i> , 2019, 35, 1960-1962.	1.8	149
10860	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1 Low/Negative Recurrent or Metastatic HNSCC. <i>JAMA Oncology</i> , 2019, 5, 195.	3.4	235
10861	Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. <i>Clinical and Translational Oncology</i> , 2019, 21, 702-712.	1.2	38
10862	Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells. <i>Journal of the National Cancer Institute</i> , 2019, 111, 42-51.	3.0	30
10863	A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 204-212.	1.9	17

#	ARTICLE	IF	CITATIONS
10864	Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?. Journal of the National Cancer Institute, 2019, 111, 339-341.	3.0	11
10865	Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade. Cancer Immunology, Immunotherapy, 2019, 68, 163-174.	2.0	58
10866	The Impact of Early-Phase Trial Design in the Drug Development Process. Clinical Cancer Research, 2019, 25, 819-827.	3.2	38
10867	The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. Clinical Cancer Research, 2019, 25, 1196-1205.	3.2	85
10868	Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment. Molecular Cancer Therapeutics, 2019, 18, 213-226.	1.9	33
10869	Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care. Cancer Biology and Therapy, 2019, 20, 6-7.	1.5	7
10870	The lung microenvironment: an important regulator of tumour growth and metastasis. Nature Reviews Cancer, 2019, 19, 9-31.	12.8	692
10871	Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect. European Radiology, 2019, 29, 4294-4302.	2.3	28
10872	Clinical significance of $\geq 50\%$ PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients. Thoracic Cancer, 2019, 10, 175-182.	0.8	4
10873	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Research, 2019, 79, 1214-1225.	0.4	226
10874	Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations. International Journal of Cancer, 2019, 144, 3023-3030.	2.3	16
10875	Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 511-521.	1.2	153
10876	Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer. Pharmacoeconomics, 2019, 37, 105-116.	1.7	13
10877	Blocking IL-1 β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1361-1369.	3.3	302
10878	Evolving and Expanding the Roles of Mitophagy as a Homeostatic and Pathogenic Process. Physiological Reviews, 2019, 99, 853-892.	13.1	145
10879	Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy. Molecular Therapy, 2019, 27, 244-260.	3.7	67
10880	Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. Oncogene, 2019, 38, 2814-2829.	2.6	85
10881	Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases. Clinical and Experimental Metastasis, 2019, 36, 29-37.	1.7	47

#	ARTICLE	IF	CITATIONS
10882	Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles. <i>Biomaterials Science</i> , 2019, 7, 113-124.	2.6	67
10883	RUNX1-dependent mechanisms in biological control and dysregulation in cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 8597-8609.	2.0	48
10884	Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. <i>Gastric Cancer</i> , 2019, 22, 817-827.	2.7	42
10885	Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF- κ B Activation and PD-L1 Expression. <i>Molecular Cell</i> , 2019, 73, 22-35.e6.	4.5	174
10886	Cancer immunoediting and resistance to T cell-based immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 151-167.	12.5	1,093
10887	Pembrolizumab-related renal toxicities: diagnosis first, treatment later. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 78-80.	1.4	7
10888	Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. <i>Cancer</i> , 2019, 125, 884-891.	2.0	43
10889	Discovery of common and rare genetic risk variants for colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 76-87.	9.4	377
10890	Tipping the balance: inhibitory checkpoints in intestinal homeostasis. <i>Mucosal Immunology</i> , 2019, 12, 21-35.	2.7	13
10891	ANXA2 expression in African American triple-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 113-120.	1.1	16
10892	Potential protein markers for breast cancer recurrence: a retrospective cohort study. <i>Cancer Causes and Control</i> , 2019, 30, 41-51.	0.8	3
10893	Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 1-13.	1.1	21
10894	IL-10 producing CD8+ CD122+ PD-1+ regulatory T cells are expanded by dendritic cells silenced for Allograft Inflammatory Factor-1. <i>Journal of Leukocyte Biology</i> , 2018, 105, 123-130.	1.5	26
10895	A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 143-155.	1.1	18
10896	Metastatic prostate cancer remains incurable, why?. <i>Asian Journal of Urology</i> , 2019, 6, 26-41.	0.5	103
10897	Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. <i>Journal of Gastroenterology</i> , 2019, 54, 281-290.	2.3	25
10898	MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1. <i>Cancer Biology and Therapy</i> , 2019, 20, 31-41.	1.5	32
10899	Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis. <i>Clinical Cancer Research</i> , 2019, 25, 125-133.	3.2	57

#	ARTICLE	IF	CITATIONS
10900	The prognostic value of tumourâ€‘stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 55-64.	1.1	66
10901	Immune biomarkers for predicting response to adoptive cell transfer as cancer treatment. <i>Immunogenetics</i> , 2019, 71, 71-86.	1.2	7
10902	Revealing tumor heterogeneity of breast cancer by utilizing the linkage between somatic and germline mutations. <i>Briefings in Bioinformatics</i> , 2019, 20, 2306-2315.	3.2	4
10903	T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. <i>Haematologica</i> , 2019, 104, 338-346.	1.7	38
10904	PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2019, 25, 1-9.	0.3	69
10905	FDG PET/CT for assessing tumour response to immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 238-250.	3.3	194
10906	EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions. <i>Gastric Cancer</i> , 2019, 22, 486-496.	2.7	72
10907	Mechanisms of Resistance to Immune Checkpoint Blockade. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 41-54.	3.3	83
10908	Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 53-62.	1.3	7
10909	Breast cancer metastasis to gynaecological organs: a clinicoâ€‘pathological and molecular profiling study. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 25-39.	1.3	31
10910	Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ. <i>American Journal of Pathology</i> , 2019, 189, 966-974.	1.9	11
10911	The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. <i>European Urology</i> , 2019, 75, 435-444.	0.9	97
10912	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 95-105.	0.6	100
10913	Proteomics and phosphoproteomics in precision medicine: applications and challenges. <i>Briefings in Bioinformatics</i> , 2019, 20, 767-777.	3.2	34
10914	Evaluation of variable selection methods for random forests and omics data sets. <i>Briefings in Bioinformatics</i> , 2019, 20, 492-503.	3.2	342
10915	Tumor Infiltrating Lymphocytes in Breast Cancer Patients with Progressive Disease during Neoadjuvant Chemotherapy. <i>Pathology and Oncology Research</i> , 2019, 25, 1341-1347.	0.9	0
10916	Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2. <i>Pathology and Oncology Research</i> , 2019, 25, 319-325.	0.9	2
10917	Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. <i>Pathology and Oncology Research</i> , 2019, 25, 513-520.	0.9	5

#	ARTICLE	IF	CITATIONS
10918	Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 92-100.	0.6	144
10919	Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?. <i>European Heart Journal</i> , 2019, 40, 1764-1770.	1.0	21
10920	Semi-supervised identification of cancer subgroups using survival outcomes and overlapping grouping information. <i>Statistical Methods in Medical Research</i> , 2019, 28, 2137-2149.	0.7	5
10921	Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1508-1514.	1.0	13
10922	Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2019, 16, 401-409.	4.8	105
10923	Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies. <i>Wiener Medizinische Wochenschrift</i> , 2019, 169, 314-322.	0.5	5
10924	From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 2110-2153.	2.5	96
10925	Role of the DNA damage response in prostate cancer formation, progression and treatment. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 24-37.	2.0	37
10926	An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 561-570.	1.0	43
10927	HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases. <i>Cancer Gene Therapy</i> , 2020, 27, 341-355.	2.2	61
10928	Innate B Cells: the Archetype of Protective Immune Cells. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 58, 92-106.	2.9	30
10929	Managing Lung Cancer with Comorbid Interstitial Pneumonia. <i>Internal Medicine</i> , 2020, 59, 163-167.	0.3	14
10930	The emerging role of epigenetic therapeutics in immuno-oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 75-90.	12.5	260
10931	The Immune Microenvironment and Cancer Metastasis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037424.	2.9	57
10932	ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. <i>Oncogene</i> , 2020, 39, 487-502.	2.6	72
10933	C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. <i>International Journal of Clinical Oncology</i> , 2020, 25, 135-144.	1.0	38
10934	¹⁸ F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 178-184.	3.3	11
10935	NExUS: Bayesian simultaneous network estimation across unequal sample sizes. <i>Bioinformatics</i> , 2020, 36, 798-804.	1.8	2

#	ARTICLE	IF	CITATIONS
10936	Albuminâ€“globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 74-81.	1.0	25
10937	Subtype-specific transcriptional regulators in breast tumors subjected to genetic and epigenetic alterations. <i>Bioinformatics</i> , 2020, 36, 994-999.	1.8	6
10938	Use of Immunotherapy and Radiation Treatment in the Management of Metastatic Melanoma With Rhabdomyosarcomatous Differentiation. <i>Advances in Radiation Oncology</i> , 2020, 5, 134-139.	0.6	6
10939	Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 358-373.	5.7	61
10940	Treating Cancer as an Invasive Species. <i>Molecular Cancer Research</i> , 2020, 18, 20-26.	1.5	6
10941	First-in-Humans Imaging with ⁸⁹ Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. <i>Journal of Nuclear Medicine</i> , 2020, 61, 512-519.	2.8	170
10942	Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong. <i>Pharmacoeconomics - Open</i> , 2020, 4, 235-247.	0.9	19
10943	Giant cell myocarditis with central diabetes insipidus: A case report. <i>Journal of Cardiology Cases</i> , 2020, 21, 8-11.	0.2	2
10944	Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 723-733.	5.7	102
10945	Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies. <i>Modern Pathology</i> , 2020, 33, 518-530.	2.9	61
10946	Histologic patterns of liver injury induced by anti-PD-1 therapy. <i>Gastroenterology Report</i> , 2020, 8, 50-55.	0.6	24
10947	Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer. <i>Pharmacogenomics Journal</i> , 2020, 20, 136-158.	0.9	15
10948	Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 970-977.	3.2	200
10949	High-Intensity Focused Ultrasound (HIFU) Triggers Immune Sensitization of Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 1152-1161.	3.2	94
10950	Targeting DNA repair in cancer: current state and novel approaches. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 677-703.	2.4	65
10951	Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1-12.	4.8	273
10952	Unexpected Response to Nivolumab in a â€œFast Progressorâ€“Head and Neck Cancer Patient. <i>Case Reports in Oncology</i> , 2020, 12, 709-714.	0.3	3
10953	Immune Activation in Mismatch Repairâ€“Deficient Carcinogenesis: More Than Just Mutational Rate. <i>Clinical Cancer Research</i> , 2020, 26, 11-17.	3.2	61

#	ARTICLE	IF	CITATIONS
10954	Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 261-271.	1.4	15
10955	Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. <i>Modern Pathology</i> , 2020, 33, 4-17.	2.9	135
10956	The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population. <i>Modern Pathology</i> , 2020, 33, 109-117.	2.9	40
10957	Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases. <i>Modern Pathology</i> , 2020, 33, 138-152.	2.9	12
10958	ncRNA-eQTL: a database to systematically evaluate the effects of SNPs on non-coding RNA expression across cancer types. <i>Nucleic Acids Research</i> , 2020, 48, D956-D963.	6.5	56
10959	Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. <i>Laboratory Investigation</i> , 2020, 100, 4-15.	1.7	52
10960	Biomarker-guided therapy for colorectal cancer: strength in complexity. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 11-32.	12.5	195
10961	Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 497-509.	2.4	31
10962	Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC. <i>International Journal of Clinical Oncology</i> , 2020, 25, 67-73.	1.0	6
10963	Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 95-104.	2.7	78
10964	Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. <i>Oncogene</i> , 2020, 39, 187-203.	2.6	34
10965	Large miRNA survival analysis reveals a prognostic four-biomarker signature for triple negative breast cancer. <i>Genetics and Molecular Biology</i> , 2020, 43, e20180269.	0.6	16
10966	Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non-small-cell Lung Cancer. <i>Translational Oncology</i> , 2020, 13, 17-24.	1.7	23
10967	A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung. <i>Modern Pathology</i> , 2020, 33, 626-638.	2.9	38
10968	The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy. <i>Journal of Pharmacy Practice</i> , 2020, 33, 338-349.	0.5	9
10969	Platinum complexes of curcumin delivered by dual-responsive polymeric nanoparticles improve chemotherapeutic efficacy based on the enhanced anti-metastasis activity and reduce side effects. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1106-1121.	5.7	58
10970	First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or PD-L1-expressing metastatic non-small-cell lung cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 441-448.	1.2	8
10971	Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 349-357.	1.1	18

#	ARTICLE	IF	CITATIONS
10972	Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. <i>Journal of Cancer</i> , 2020, 11, 41-50.	1.2	3
10973	Long-Lasting Response after Pembrolizumab in a Patient with Metastatic Triple-Negative Breast Cancer. <i>Breast Care</i> , 2020, 15, 428-432.	0.8	0
10974	The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease. <i>International Journal of Clinical Oncology</i> , 2020, 25, 282-291.	1.0	17
10975	New Approaches on Cancer Immunotherapy. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036863.	2.9	17
10976	Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2 ⁺ Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 566-580.	3.2	125
10977	Zoledronate rescues immunosuppressed monocytes in sepsis patients. <i>Immunology</i> , 2020, 159, 88-95.	2.0	10
10978	Health care utilization and steroidâ€refractory toxicities from immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 322-328.	2.0	13
10979	Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in nonâ€small cell lung cancer. <i>Journal of Pathology</i> , 2020, 250, 19-29.	2.1	92
10980	Establishment and characterization of novel patient-derived extraskeletal osteosarcoma cell line NCC-ESOS1-C1. <i>Human Cell</i> , 2020, 33, 283-290.	1.2	5
10981	The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review. <i>International Journal of Cancer</i> , 2020, 146, 1479-1489.	2.3	20
10982	CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness. <i>Journal of Pathology</i> , 2020, 250, 205-216.	2.1	34
10983	Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization. <i>Oncogene</i> , 2020, 39, 1429-1444.	2.6	52
10984	Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy. <i>Cancers</i> , 2020, 12, 109.	1.7	26
10985	High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 217.	1.8	33
10986	<p>Immunotherapy for the Treatment of Breast Cancer: Emerging New Data</p>. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 321-328.	1.0	25
10987	PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis. <i>Cancers</i> , 2020, 12, 93.	1.7	57
10988	Current issues and perspectives in PD-1 blockade cancer immunotherapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 790-800.	1.0	120
10989	Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy. <i>Oncology and Therapy</i> , 2020, 8, 1-11.	1.0	37

#	ARTICLE	IF	CITATIONS
10990	Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma. American Journal of Surgical Pathology, 2020, 44, 657-664.	2.1	21
10991	Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis. Cancer Discovery, 2020, 10, 422-439.	7.7	223
10992	Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2020, 9, 102.	1.0	42
10993	AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer. BMC Cancer, 2020, 20, 18.	1.1	19
10994	Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science, 2020, 27, 1.	2.6	1,277
10995	iRECIST: how to do it. Cancer Imaging, 2020, 20, 2.	1.2	41
10996	Considering adjuvant therapy for stage II melanoma. Cancer, 2020, 126, 1166-1174.	2.0	32
10997	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥75 years) with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 457-466.	1.2	21
10998	Imaging findings in hypophysitis: a review. Radiologia Medica, 2020, 125, 319-328.	4.7	48
10999	Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report. Respiratory Medicine Case Reports, 2020, 29, 100976.	0.2	2
11000	Genetic Profiling of Breast Cancer with and Without Preexisting Metabolic Disease. Translational Oncology, 2020, 13, 245-253.	1.7	5
11001	Bone Metastasis: Current State of Play. Translational Oncology, 2020, 13, 308-320.	1.7	30
11002	Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients. Translational Oncology, 2020, 13, 186-192.	1.7	6
11003	Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma. Translational Oncology, 2020, 13, 336-345.	1.7	52
11004	Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy. Translational Oncology, 2020, 13, 262-274.	1.7	49
11005	Combination of C-reactive Protein and Monocyte Count Is a Useful Prognostic Indicator for Patients With Colorectal Cancer. In Vivo, 2020, 34, 299-305.	0.6	7
11006	Immune Therapy for Liver Cancers. Cancers, 2020, 12, 77.	1.7	49
11007	Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade. Journal of Immunotherapy, 2020, 43, 57-66.	1.2	36

#	ARTICLE	IF	CITATIONS
11008	Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 26-35.	0.9	69
11009	Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2020, 17, 27-35.	4.8	168
11010	Engineering strategies to overcome the current roadblocks in CAR T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 147-167.	12.5	786
11011	Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. <i>International Journal of Clinical Oncology</i> , 2020, 25, 165-174.	1.0	27
11012	High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities. <i>Targeted Oncology</i> , 2020, 15, 127-138.	1.7	23
11013	Targeting the interleukin-17 immune axis for cancer immunotherapy. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	105
11014	Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. <i>Journal of Virology</i> , 2020, 94, .	1.5	54
11015	Multifunctional phototheranostic nanomedicine for cancer imaging and treatment. <i>Materials Today Bio</i> , 2020, 5, 100035.	2.6	167
11016	Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOc patients treated with buparlisib and olaparib. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 503-514.	1.2	5
11017	Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. <i>Nature Cancer</i> , 2020, 1, 86-98.	5.7	140
11018	Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	58
11019	Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 108-119.	1.6	187
11020	Molecular Profiles of Matched Primary and Metastatic Tumor Samples Support a Linear Evolutionary Model of Breast Cancer. <i>Cancer Research</i> , 2020, 80, 170-174.	0.4	12
11021	<i>In Vivo</i> Epigenetic CRISPR Screen Identifies <i>Asf1a</i> as an Immunotherapeutic Target in <i>Kras</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2020, 10, 270-287.	7.7	129
11022	Harnessing big "omics" data and AI for drug discovery in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 238-251.	8.2	90
11023	Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis. <i>Medicine (United States)</i> , 2020, 99, e18445.	0.4	19
11024	Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. <i>BMC Genomics</i> , 2020, 21, 2.	1.2	124
11025	Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling. <i>BMC Cancer</i> , 2020, 20, 4.	1.1	23

#	ARTICLE	IF	CITATIONS
11026	Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. <i>Translational Oncology</i> , 2020, 13, 410-422.	1.7	52
11027	A Bis-Indoleâ€Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity. <i>Cancer Research</i> , 2020, 80, 1011-1023.	0.4	25
11028	Molecular Characterization of a Rare Dedifferentiated Liposarcoma With Rhabdomyosarcomatous Differentiation in a 24 Year Old. <i>International Journal of Surgical Pathology</i> , 2020, 28, 454-463.	0.4	1
11029	Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 43-55.	2.0	56
11030	Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 3441-3452.	2.4	22
11031	Mechanisms of immune evasion in bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 3-14.	2.0	127
11032	PAK4 inhibition improves PD-1 blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 46-58.	5.7	85
11033	Targeting innate sensing in the tumor microenvironment to improve immunotherapy. <i>Cellular and Molecular Immunology</i> , 2020, 17, 13-26.	4.8	76
11034	An intrinsic role of IL-33 in Treg cellâ€mediated tumor immunoevasion. <i>Nature Immunology</i> , 2020, 21, 75-85.	7.0	82
11035	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2111-2123.	3.2	91
11036	The Cytosolic DNA-Sensing cGASâ€STING Pathway in Cancer. <i>Cancer Discovery</i> , 2020, 10, 26-39.	7.7	558
11037	CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 569-576.	1.4	19
11038	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 555-563.	2.9	59
11039	Kinetic volume analysis on dynamic contrast-enhanced MRI of triple-negative breast cancer: associations with survival outcomes. <i>British Journal of Radiology</i> , 2020, 93, 20190712.	1.0	6
11040	Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 94-107.	1.6	24
11041	Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 48-63.	0.6	27
11042	Checkpoint inhibitors in AML: are we there yet?. <i>British Journal of Haematology</i> , 2020, 188, 159-167.	1.2	31
11043	Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 80-95.	1.9	15

#	ARTICLE	IF	CITATIONS
11044	Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. <i>British Journal of Cancer</i> , 2020, 122, 94-101.	2.9	35
11045	High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer. <i>British Journal of Cancer</i> , 2020, 122, 245-257.	2.9	27
11046	Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors. <i>Melanoma Research</i> , 2020, 30, 219-222.	0.6	3
11047	Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study. <i>Shock</i> , 2020, 53, 686-694.	1.0	27
11048	<scp>PTPN</scp> 2 phosphatase deletion in T cells promotes anti-tumour immunity and <scp>CAR</scp> T cell efficacy in solid tumours. <i>EMBO Journal</i> , 2020, 39, e103637.	3.5	79
11049	Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 137-152.	1.2	17
11050	Adjuvant regional nodal irradiation did not improve outcomes in T1-2N1 breast cancer after breast-conserving surgery: A propensity score matching analysis of BIG02/98 and BCIRG005 trials. <i>Breast</i> , 2020, 49, 165-170.	0.9	6
11051	Deep learning of pharmacogenomics resources: moving towards precision oncology. <i>Briefings in Bioinformatics</i> , 2020, 21, 2066-2083.	3.2	43
11052	PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 74-85.	0.9	10
11053	Nivolumab-induced small bowel obstruction and perforation: a rare but life-threatening side effect of immunotherapy. <i>Emergency Radiology</i> , 2020, 27, 107-110.	1.0	8
11054	Challenges in assessing solid tumor responses to immunotherapy. <i>Cancer Gene Therapy</i> , 2020, 27, 528-538.	2.2	36
11055	Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report. <i>Case Reports in Oncology</i> , 2020, 12, 866-871.	0.3	7
11056	Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. <i>Oncogene</i> , 2020, 39, 2040-2054.	2.6	141
11057	Brain immunology and immunotherapy in brain tumours. <i>Nature Reviews Cancer</i> , 2020, 20, 12-25.	12.8	389
11058	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	0.8	135
11059	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. <i>Journal of Thoracic Oncology</i> , 2020, 15, 231-247.	0.5	172
11060	Targeting Tumor Microenvironment by Small-Molecule Inhibitors. <i>Translational Oncology</i> , 2020, 13, 57-69.	1.7	82
11061	Immune-Related Pancytopenia Induced by Anti-PD-1 Therapy – “Interrupt or Continue Treatment” – The Role of Immunohistochemical Examination. <i>Case Reports in Oncology</i> , 2020, 12, 820-828.	0.3	4

#	ARTICLE	IF	CITATIONS
11062	Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells. <i>Journal of Cancer</i> , 2020, 11, 25-40.	1.2	13
11063	High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome. <i>International Journal of Cancer</i> , 2020, 146, 2007-2018.	2.3	38
11064	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. <i>Targeted Oncology</i> , 2020, 15, 11-24.	1.7	65
11065	Tumor immune microenvironment is associated with the growth of intracranial germinomas. <i>Journal of Neuro-Oncology</i> , 2020, 146, 139-146.	1.4	6
11066	Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158. <i>Journal of Structural Biology: X</i> , 2020, 4, 100014.	0.7	20
11067	Evaluation of the Metastatic Spine Disease Multidisciplinary Working Group Algorithms as Part of a Multidisciplinary Spine Tumor Conference. <i>Global Spine Journal</i> , 2020, 10, 888-895.	1.2	1
11068	PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 428-435.	0.9	14
11069	TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development. <i>Genes and Development</i> , 2020, 34, 179-193.	2.7	35
11070	Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the Netherlands. <i>European Journal of Cancer Care</i> , 2020, 29, e13210.	0.7	3
11071	Sustained Coevolution in a Stochastic Model of Cancer-Immune Interaction. <i>Cancer Research</i> , 2020, 80, 811-819.	0.4	11
11072	Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma. <i>Internal Medicine</i> , 2020, 59, 977-981.	0.3	14
11073	Platinum Derivatives Effects on Anticancer Immune Response. <i>Biomolecules</i> , 2020, 10, 13.	1.8	55
11074	Structure and Optimization of Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 38.	1.7	37
11075	Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 67.	1.7	39
11076	Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives. <i>Cells</i> , 2020, 9, 19.	1.8	23
11077	The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy. <i>Cells</i> , 2020, 9, 26.	1.8	29
11078	Fibronectin in Cancer: Friend or Foe. <i>Cells</i> , 2020, 9, 27.	1.8	108
11079	Hadrontherapy Interactions in Molecular and Cellular Biology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 133.	1.8	16

#	ARTICLE	IF	CITATIONS
11080	Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response. <i>International Journal of Molecular Sciences</i> , 2020, 21, 157.	1.8	136
11081	Microalgae with Immunomodulatory Activities. <i>Marine Drugs</i> , 2020, 18, 2.	2.2	91
11082	Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2020, 11, 741-749.	1.2	21
11083	Benign lymph node microenvironment is associated with response to immunotherapy. <i>Precision Clinical Medicine</i> , 2020, 3, 44-53.	1.3	10
11084	The effect of Tai Chi practice on immunological function in cancer survivors. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 58)</i> , 2020, 99, 1041-1048.	0.4	1
11085	Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy. <i>Science Advances</i> , 2020, 6, .	4.7	49
11086	Critical roles of super-enhancers in the pathogenesis of autoimmune diseases. <i>Inflammation and Regeneration</i> , 2020, 40, 16.	1.5	12
11087	GeTallele: A Method for Analysis of DNA and RNA Allele Frequency Distributions. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 1021.	2.0	2
11088	Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 573599.	1.8	26
11089	Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade. <i>Frontiers in Oncology</i> , 2020, 10, 1727.	1.3	97
11090	Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population. <i>Frontiers in Oncology</i> , 2020, 10, 1752.	1.3	10
11091	Blood-Brain Barrier Disruption in Neuro-Oncology: Strategies, Failures, and Challenges to Overcome. <i>Frontiers in Oncology</i> , 2020, 10, 563840.	1.3	38
11092	Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2020, 10, 573141.	1.3	63
11093	Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8+ T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 582863.	1.3	41
11094	Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma. <i>Cancers</i> , 2020, 12, 2761.	1.7	24
11095	A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine. <i>Cancers</i> , 2020, 12, 2811.	1.7	0
11096	Functional Transcription Factor Target Networks Illuminate Control of Epithelial Remodelling. <i>Cancers</i> , 2020, 12, 2823.	1.7	5
11097	Transcriptome Profiling Reveals New Insights into the Immune Microenvironment and Upregulation of Novel Biomarkers in Metastatic Uveal Melanoma. <i>Cancers</i> , 2020, 12, 2832.	1.7	27

#	ARTICLE	IF	CITATIONS
11098	Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. <i>Cancers</i> , 2020, 12, 2859.	1.7	92
11099	Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2969.	1.0	24
11100	8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3079.	1.0	16
11101	The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. <i>Life</i> , 2020, 10, 219.	1.1	11
11102	The Pathogenesis of Tuberculosis—The Koch Phenomenon Reinstated. <i>Pathogens</i> , 2020, 9, 813.	1.2	40
11103	Mitoxantrone-Loaded Nanoparticles for Magnetically Controlled Tumor Therapy—Induction of Tumor Cell Death, Release of Danger Signals and Activation of Immune Cells. <i>Pharmaceutics</i> , 2020, 12, 923.	2.0	6
11104	Resident Memory T Cells and Their Effect on Cancer. <i>Vaccines</i> , 2020, 8, 562.	2.1	13
11105	Breast cancer risk (un)awareness among women suffering from neurofibromatosis type 1 in Poland. <i>Wspolczesna Onkologia</i> , 2020, 24, 140-144.	0.7	1
11106	The Immune Microenvironment in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7307.	1.8	133
11107	Real-world treatment practice in patients with advanced melanoma. <i>Wspolczesna Onkologia</i> , 2020, 24, 118-124.	0.7	6
11108	Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study. <i>Oncologist</i> , 2020, 25, e1532-e1540.	1.9	13
11109	Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1649.	1.3	32
11110	A defucosylated anti-PD-L1 monoclonal antibody 13-mG2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. <i>Biochemistry and Biophysics Reports</i> , 2020, 24, 100801.	0.7	15
11111	TRIM27 Functions as a Novel Oncogene in Non-Triple-Negative Breast Cancer by Blocking Cellular Senescence through p21 Ubiquitination. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 910-923.	2.3	27
11112	Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. <i>Nature Communications</i> , 2020, 11, 5156.	5.8	12
11113	<p></p>Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9375-9387.	0.9	16
11114	<p></p>Application and Prospects of Molecular Imaging in Immunotherapy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9389-9403.	0.9	8
11115	A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 559896.	1.3	10

#	ARTICLE	IF	CITATIONS
11116	Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design. <i>Cancers</i> , 2020, 12, 2908.	1.7	8
11117	Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. <i>Cancers</i> , 2020, 12, 2947.	1.7	4
11118	From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy. <i>Cancers</i> , 2020, 12, 2974.	1.7	18
11119	Positron Emission Tomography for Response Evaluation in Microenvironment-Targeted Anti-Cancer Therapy. <i>Biomedicines</i> , 2020, 8, 371.	1.4	11
11120	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. <i>Cancers</i> , 2020, 12, 2658.	1.7	10
11121	Immunotherapies in ovarian cancer. <i>European Journal of Cancer, Supplement</i> , 2020, 15, 87-95.	2.2	7
11122	Therapy of Primary Liver Cancer. <i>Innovation(China)</i> , 2020, 1, 100032.	5.2	46
11123	<i>Cordyceps militaris</i> Induces Immunogenic Cell Death and Enhances Antitumor Immunogenic Response in Breast Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-11.	0.5	6
11124	Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093608.	1.4	19
11125	Tumor suppressive function of Matr3 in the basal-like breast cancer. <i>Biological Research</i> , 2020, 53, 42.	1.5	12
11126	Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. <i>PLoS ONE</i> , 2020, 15, e0237802.	1.1	223
11127	PD-L1 as a prognostic biomarker in surgically resectable non- small cell lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2020, 9, 1343-1360.	1.3	22
11128	A CT-derived deep neural network predicts for programmed death ligand-1 expression status in advanced lung adenocarcinomas. <i>Annals of Translational Medicine</i> , 2020, 8, 930-930.	0.7	13
11129	Reply to Comment on Āiljkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and ChallengesĀ. <i>Cancers</i> 2019, 11, 1554. <i>Cancers</i> , 2020, 12, 2673.	1.7	4
11130	Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model. <i>Frontiers in Oncology</i> , 2020, 10, 1771.	1.3	7
11131	PD1 blockade enhances K ⁺ channel activity, Ca ²⁺ signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer. , 2020, 8, e000844.		21
11132	<p>Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10411-10421.	0.9	14
11133	From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. <i>Cancers</i> , 2020, 12, 3057.	1.7	50

#	ARTICLE	IF	CITATIONS
11134	Immune contexture analysis in immuno-oncology: applications and challenges of multiplex fluorescent immunohistochemistry. <i>Clinical and Translational Immunology</i> , 2020, 9, e1183.	1.7	27
11135	Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis. <i>JACC: CardioOncology</i> , 2020, 2, 599-610.	1.7	69
11136	Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101236.	0.2	1
11137	TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice. <i>Scientific Reports</i> , 2020, 10, 17284.	1.6	13
11138	Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells. <i>Inflammation and Regeneration</i> , 2020, 40, 25.	1.5	4
11139	<p>Management of Immune Checkpoint Inhibitor Toxicities</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9139-9158.	0.9	18
11140	<p>Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9551-9561.	0.9	21
11141	Advances in Natural or Synthetic Nanoparticles for Metastatic Melanoma Therapy and Diagnosis. <i>Cancers</i> , 2020, 12, 2893.	1.7	14
11142	High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy. <i>Cancers</i> , 2020, 12, 2966.	1.7	16
11143	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. <i>Cancers</i> , 2020, 12, 3025.	1.7	55
11144	The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3334.	1.0	22
11145	Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles. <i>Advanced Materials</i> , 2020, 32, e2004853.	11.1	146
11146	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
11147	The genomic landscape of metastatic histologic special types of invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 53.	2.3	27
11148	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. <i>Npj Breast Cancer</i> , 2020, 6, 54.	2.3	181
11149	The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients. <i>Medicine (United States)</i> , 2020, 99, e22555.	0.4	2
11150	Risk of non-infectious uveitis or myasthenia gravis in patients on checkpoint inhibitors in a large healthcare claims database. <i>British Journal of Ophthalmology</i> , 2022, 106, 87-90.	2.1	7
11151	Heat Shock Protein 90 Family Isoforms as Prognostic Biomarkers and Their Correlations with Immune Infiltration in Breast Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-15.	0.9	15

#	ARTICLE	IF	CITATIONS
11152	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. <i>Liver Cancer</i> , 2020, 9, 596-612.	4.2	10
11153	The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. <i>Cancers</i> , 2020, 12, 2983.	1.7	56
11154	Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 3038.	1.7	66
11155	Role of Nurr1 in Carcinogenesis and Tumor Immunology: A State of the Art Review. <i>Cancers</i> , 2020, 12, 3044.	1.7	8
11156	Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens. <i>Cancers</i> , 2020, 12, 3045.	1.7	9
11157	Long non-coding RNA-based signatures to improve prognostic prediction of breast cancer. <i>Medicine (United States)</i> , 2020, 99, e22203.	0.4	5
11158	Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalanâ€™Long-Term Overall Survival Negatively Correlates with Tumor Burden. <i>Radiology Research and Practice</i> , 2020, 2020, 1-7.	0.6	9
11159	Understanding PD-L1 Testing in Breast Cancer: A Practical Approach. <i>Breast Care</i> , 2020, 15, 481-490.	0.8	34
11160	A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74â€™years old and patients with PS 0 or 1 from 75â€™years: NEJ039A.1.1 (trial in progress). <i>BMC Cancer</i> , 2020, 20, 961.		3
11161	The Application of Next-Generation Sequencing to Define Factors Related to Oral Cancer and Discover Novel Biomarkers. <i>Life</i> , 2020, 10, 228.	1.1	21
11162	Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. <i>Vaccines</i> , 2020, 8, 578.	2.1	16
11163	Identification of CTLA-4 associated with tumor microenvironment and competing interactions in triple negative breast cancer by co-expression network analysis. <i>Journal of Cancer</i> , 2020, 11, 6365-6375.	1.2	26
11164	The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients. <i>Medicine (United States)</i> , 2020, 99, e22567.	0.4	5
11165	The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and CD8+ T cell in an immunocompetent mouse model of colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 803-811.	0.6	3
11166	Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 572853.	1.3	15
11167	Systematic analysis of the transcriptome in smallâ€™cell carcinoma of the oesophagus reveals its immune microenvironment. <i>Clinical and Translational Immunology</i> , 2020, 9, e1173.	1.7	2
11168	The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 34-40.	0.9	11
11169	Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-small-Cell Lung Cancer Patients: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 558454.	1.3	14

#	ARTICLE	IF	CITATIONS
11170	Main Strategies for the Identification of Neoantigens. <i>Cancers</i> , 2020, 12, 2879.	1.7	32
11171	Sarcomatoid renal cell carcinoma: biology, natural history and management. <i>Nature Reviews Urology</i> , 2020, 17, 659-678.	1.9	76
11172	Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1787.	1.3	25
11173	The Resistance Mechanisms of Lung Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 568059.	1.3	47
11174	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020, 26, 1845-1851.	15.2	193
11175	Analysis of candidate genes expected to be essential for melanoma surviving. <i>Cancer Cell International</i> , 2020, 20, 488.	1.8	3
11176	Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 1050-1050.	0.7	31
11177	The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2020, 9, 811-815.	1.3	3
11178	Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight With Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 566297.	1.3	39
11179	Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. <i>Cancers</i> , 2020, 12, 2870.	1.7	64
11180	YAP increases response to Trastuzumab in HER2-positive Breast Cancer by enhancing P73-induced apoptosis. <i>Journal of Cancer</i> , 2020, 11, 6748-6759.	1.2	5
11181	inCNV: An Integrated Analysis Tool for Copy Number Variation on Whole Exome Sequencing. <i>Evolutionary Bioinformatics</i> , 2020, 16, 117693432095657.	0.6	3
11182	Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation. <i>Frontiers in Oncology</i> , 2020, 10, 1785.	1.3	35
11183	Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host's Innate Antiviral Immunity to Attack Tumor Cells. <i>Molecular Therapy - Oncolytics</i> , 2020, 19, 33-46.	2.0	13
11184	Human T Cells Expressing a CD19 CAR-T Receptor Provide Insights into Mechanisms of Human CD19-Positive \hat{I}^2 Cell Destruction. <i>Cell Reports Medicine</i> , 2020, 1, 100097.	3.3	16
11185	PD-1 Expression by Lymph Node and Intratumoral Regulatory T Cells Is Associated with Lymph Node Metastasis in Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 2756.	1.7	15
11186	ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 2758.	1.7	33
11187	Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade. <i>Cancers</i> , 2020, 12, 2762.	1.7	41

#	ARTICLE	IF	CITATIONS
11188	p.P476S mutation of RBPJL inhibits the efficacy of anti-PD-1 therapy in oesophageal squamous cell carcinoma by blunting T cell responses. <i>Clinical and Translational Immunology</i> , 2020, 9, e1172.	1.7	1
11189	Intratumoral administration of the Toll-like receptor 7/8 agonist 3M052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer. <i>Clinical and Translational Immunology</i> , 2020, 9, e1177.	1.7	22
11192	Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 298-309.	2.3	181
11193	CUE: CpG impUtation ensemble for DNA methylation levels across the human methylation450 (HM450) and EPIC (HM850) BeadChip platforms. <i>Epigenetics</i> , 2021, 16, 851-861.	1.3	1
11194	Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells. <i>Gastroenterology Report</i> , 2020, 8, 390-398.	0.6	25
11195	Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 1706-1721.	7.7	35
11196	Metastatic pulmonary adenocarcinoma to the nasopharynx at first clinical presentation: A case report and review of literature. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2093982.	0.2	4
11197	The correlation and role analysis of KCNK2/4/5/15 in Human Papillary Thyroid Carcinoma microenvironment. <i>Journal of Cancer</i> , 2020, 11, 5162-5176.	1.2	12
11198	Chemotherapy but Not the Tumor Draining Lymph Nodes Determine the Immunotherapy Response in Secondary Tumors. <i>IScience</i> , 2020, 23, 101056.	1.9	15
11199	Nerve growth factor and its receptor tyrosine kinase TrkA are overexpressed in cervical squamous cell carcinoma. <i>FASEB BioAdvances</i> , 2020, 2, 398-408.	1.3	12
11200	Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types. <i>Journal of Clinical Pathology</i> , 2020, 73, 656-664.	1.0	37
11201	Delineation of the Germline and Somatic Mutation Interaction Landscape in Triple-Negative and Non-Triple-Negative Breast Cancer. <i>International Journal of Genomics</i> , 2020, 2020, 1-16.	0.8	1
11202	Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. <i>Nature Immunology</i> , 2020, 21, 1010-1021.	7.0	85
11203	Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. <i>Melanoma Research</i> , 2020, 30, 364-375.	0.6	42
11204	Detection of response to tumor microenvironment-targeted cellular immunotherapy using nano-radiomics. <i>Science Advances</i> , 2020, 6, eaba6156.	4.7	27
11205	RNF181 modulates Hippo signaling and triple negative breast cancer progression. <i>Cancer Cell International</i> , 2020, 20, 291.	1.8	13
11206	High PKC β expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients. <i>PLoS ONE</i> , 2020, 15, e0235747.	1.1	8
11207	Bronchoscopic tissue yield for advanced molecular testing: are we getting enough?. <i>Journal of Thoracic Disease</i> , 2020, 12, 3287-3295.	0.6	9

#	ARTICLE	IF	CITATIONS
11208	Immune reaction and regulation in transplantation based on pluripotent stem cell technology. <i>Inflammation and Regeneration</i> , 2020, 40, 12.	1.5	20
11209	Characterization of Neoantigen Load Subgroups in Gynecologic and Breast Cancers. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 702.	2.0	8
11210	Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. <i>Cancers</i> , 2020, 12, 1872.	1.7	18
11211	Nanobodies as non-invasive imaging tools. <i>Immuno-Oncology Technology</i> , 2020, 7, 2-14.	0.2	26
11212	Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093790.	1.4	49
11213	Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093688.	1.4	17
11214	A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 76.	2.2	41
11215	Increased number of subclones in lung squamous cell carcinoma elicits overexpression of immune related genes. <i>Translational Lung Cancer Research</i> , 2020, 9, 659-669.	1.3	5
11216	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. <i>Translational Lung Cancer Research</i> , 2020, 9, 617-628.	1.3	8
11217	Molecular gene mutation profiles, TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2020, 9, 629-638.	1.3	10
11218	Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 761-767.	1.3	7
11219	Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2020, 9, 824-827.	1.3	0
11220	Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies. <i>Translational Lung Cancer Research</i> , 2020, 9, 906-916.	1.3	3
11221	Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1098.	1.3	29
11222	Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. <i>Pharmaceutics</i> , 2020, 12, 663.	2.0	24
11223	A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma. <i>Translational Lung Cancer Research</i> , 2020, 9, 833-836.	1.3	0
11224	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 109-116.	0.8	17
11225	Implementation of PD-L1 22C3 IHC pharmDx™;TM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of Cytolyt® Prefixation. <i>Acta Cytologica</i> , 2020, 64, 577-587.	0.7	14

#	ARTICLE	IF	CITATIONS
11226	Tumor immune microenvironment and mutational analysis of tracheal adenoid cystic carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 750-750.	0.7	13
11227	Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 2706-2712.	0.6	10
11228	Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 369-378.	1.2	10
11229	An extremely rare case of nivolumab-associated macroscopic duodenitis with spontaneous regression. <i>Respirology Case Reports</i> , 2020, 8, e00582.	0.3	0
11230	The Role of Biomarkers in Cardio-Oncology. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 431-450.	1.1	92
11231	Can Vitamins, as Epigenetic Modifiers, Enhance Immunity in COVID-19 Patients with Non-communicable Disease?. <i>Current Nutrition Reports</i> , 2020, 9, 202-209.	2.1	17
11232	High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples. <i>Translational Cancer Research</i> , 2020, 9, 5819-5828.	0.4	6
11233	Thioguanine Induces Apoptosis in Triple-Negative Breast Cancer by Regulating PI3K-AKT Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 524922.	1.3	10
11234	Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 568279.	1.3	11
11235	Targeting the Deterministic Evolutionary Trajectories of Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 3300.	1.7	6
11236	Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 3314.	1.7	5
11237	Immunomodulation in Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 3340.	1.7	12
11238	Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC). <i>Cancers</i> , 2020, 12, 3342.	1.7	62
11239	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
11240	Effect of age and sex on immune checkpoint expression and kinetics in human T cells. <i>Immunity and Ageing</i> , 2020, 17, 32.	1.8	8
11241	<p>The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 11351-11358.	0.9	3
11242	Complement and Cancer—A Dysfunctional Relationship?. <i>Antibodies</i> , 2020, 9, 61.	1.2	10
11243	Cardiomyopathies and Arrhythmias Induced by Cancer Therapies. <i>Biomedicines</i> , 2020, 8, 496.	1.4	10

#	ARTICLE	IF	CITATIONS
11244	Oncolytic Adenovirus in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 3354.	1.7	29
11245	The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions. <i>Pharmaceuticals</i> , 2020, 13, 389.	1.7	36
11246	Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma. <i>IJU Case Reports</i> , 2020, 3, 287-290.	0.1	6
11247	Two-step protocol for regeneration of immunocompetent T cells from mouse pluripotent stem cells. <i>Blood Science</i> , 2020, 2, 79-88.	0.4	3
11248	Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives. <i>International Journal of Breast Cancer</i> , 2020, 2020, 1-9.	0.6	7
11249	Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?. <i>Journal of Thoracic Disease</i> , 2020, 12, 6070-6089.	0.6	4
11250	Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2120-2136.	1.3	16
11251	<p>A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11499-11504.	1.0	6
11252	The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes. <i>Cancers</i> , 2020, 12, 3369.	1.7	15
11253	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. <i>Cancers</i> , 2020, 12, 3374.	1.7	27
11254	Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 3377.	1.7	35
11255	Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?. <i>Cancers</i> , 2020, 12, 3392.	1.7	5
11256	Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 3446.	1.7	19
11257	A prognostic risk model based on immune-related genes predicts overall survival of patients with hepatocellular carcinoma. <i>Health Science Reports</i> , 2020, 3, e202.	0.6	2
11258	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1188-1203.	5.7	114
11259	Quadruple-negative breast cancer: novel implications for a new disease. <i>Breast Cancer Research</i> , 2020, 22, 127.	2.2	17
11260	<p>PD-L1 Expression is Highly Associated with Tumor-Associated Macrophage Infiltration in Nasopharyngeal Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 11585-11596.	0.9	17
11261	The Non-Coding Landscape of Cutaneous Malignant Melanoma: A Possible Route to Efficient Targeted Therapy. <i>Cancers</i> , 2020, 12, 3378.	1.7	15

#	ARTICLE	IF	CITATIONS
11262	Modelling the structural and reactivity landscapes of tucatinib with special reference to its wavefunction-dependent properties and screening for potential antiviral activity. <i>Journal of Molecular Modeling</i> , 2020, 26, 341.	0.8	35
11263	Using Machine Learning Modeling to Explore New Immune-Related Prognostic Markers in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 550002.	1.3	10
11264	Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact. <i>Cancers</i> , 2020, 12, 3382.	1.7	16
11265	Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. <i>Nature Cancer</i> , 2020, 1, 1167-1175.	5.7	22
11266	FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression. <i>Translational Lung Cancer Research</i> , 2020, 9, 2165-2172.	1.3	0
11267	Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2059-2073.	1.3	9
11268	Molecular Immunotherapy: Promising Approach to Treat Metastatic Colorectal Cancer by Targeting Resistant Cancer Cells or Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2020, 10, 569017.	1.3	21
11269	Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors. <i>Antibodies</i> , 2020, 9, 65.	1.2	13
11270	Durvalumab-associated vasculitis presenting as "the blue toe syndrome". <i>BMJ Case Reports</i> , 2020, 13, e235886.	0.2	9
11271	Patient-derived cell line, xenograft and organoid models in lung cancer therapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2214-2232.	1.3	51
11272	<p></p>Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 273-288.	2.7	9
11273	Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival. <i>Frontiers in Oncology</i> , 2020, 10, 571545.	1.3	12
11274	Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment. <i>Cancers</i> , 2020, 12, 3448.	1.7	12
11275	Prognostic significance of the primary tumor site and immune indexes in patients with estrogen receptor-positive, human epidermal growth factor receptor-2-negative breast cancer. <i>Gland Surgery</i> , 2020, 9, 1450-1468.	0.5	2
11276	Prognostic Value of the Pretreatment Systemic Immune-Inflammation Index in Patients with Colorectal Cancer. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-8.	0.7	5
11277	Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1193-1193.	0.7	25
11278	Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis. <i>Annals of Translational Medicine</i> , 2020, 8, 1172-1172.	0.7	8
11279	A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient. <i>Translational Lung Cancer Research</i> , 2020, 9, 2157-2160.	1.3	5

#	ARTICLE	IF	CITATIONS
11280	Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 570654.	1.3	16
11281	Identification of Metabolism-Associated Prostate Cancer Subtypes and Construction of a Prognostic Risk Model. <i>Frontiers in Oncology</i> , 2020, 10, 598801.	1.3	16
11282	Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. <i>Cancers</i> , 2020, 12, 3486.	1.7	10
11283	Development and validation of a prognostic and immunotherapeutically relevant model in hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1177-1177.	0.7	8
11284	Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]. <i>Oncoimmunology</i> , 2020, 9, 1838189.	2.1	8
11285	<p>Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 11965-11971.	0.9	7
11286	<p>Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12003-12013.	1.0	29
11287	Pediatric onco-nephrology: time to spread the word. <i>Pediatric Nephrology</i> , 2021, 36, 2227-2255.	0.9	3
11288	Biomarkers in Her2- Positive Disease. <i>Breast Care</i> , 2020, 15, 586-593.	0.8	8
11289	The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center. <i>Annals of Translational Medicine</i> , 2020, 8, 1311-1311.	0.7	1
11290	The evolving landscape of predictive biomarkers in immuno–oncology with a focus on spatial technologies. <i>Clinical and Translational Immunology</i> , 2020, 9, e1215.	1.7	23
11291	Long noncoding RNA CASC11 promotes hepatocarcinogenesis and HCC progression through EIF4A3–mediated E2F1 activation. <i>Clinical and Translational Medicine</i> , 2020, 10, e220.	1.7	54
11292	Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine. <i>Bioconjugate Chemistry</i> , 2020, 31, 2668-2678.	1.8	13
11293	Unique genomic features and prognostic value of COSMIC mutational signature 4 in lung adenocarcinoma and lung squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1176-1176.	0.7	8
11294	<p>Circ_0002232 Acts as a Potential Biomarker for AML and Reveals a Potential ceRNA Network of Circ_0002232/miR-92a-3p/PTEN</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 11871-11881.	0.9	6
11295	Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model. <i>Vaccines</i> , 2020, 8, 703.	2.1	8
11296	Structural and conformational changes induced by missense variants in the zinc finger domains of GATA3 involved in breast cancer. <i>RSC Advances</i> , 2020, 10, 39640-39653.	1.7	8
11297	TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas. <i>Annals of Translational Medicine</i> , 2020, 8, 1218-1218.	0.7	7

#	ARTICLE	IF	CITATIONS
11298	The Landscape of Immune Cells Infiltrating in Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 517637.	1.3	63
11299	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. <i>Frontiers in Oncology</i> , 2020, 10, 590058.	1.3	5
11300	Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. <i>Cancers</i> , 2020, 12, 3317.	1.7	19
11301	Optimal Clinical Management and the Molecular Biology of Angiosarcomas. <i>Cancers</i> , 2020, 12, 3321.	1.7	15
11302	Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11. <i>Medicine (United States)</i> , 2020, 99, e22323.	0.4	12
11303	Characterizing heterogeneity of non-small cell lung tumour microenvironment to identify signature prognostic genes. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 14608-14618.	1.6	10
11304	Immune-Related Gene-Based Novel Subtypes to Establish a Model Predicting the Risk of Prostate Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 595657.	1.1	14
11305	PD-1 Regulates GABAergic Neurotransmission and GABA-Mediated Analgesia and Anesthesia. <i>IScience</i> , 2020, 23, 101570.	1.9	23
11306	Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy. <i>Medicine (United States)</i> , 2020, 99, e22933.	0.4	3
11307	PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 575978.	1.3	7
11308	Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers. <i>Innovation(China)</i> , 2020, 1, 100041.	5.2	31
11309	Recognition of Immune Microenvironment Landscape and Immune-Related Prognostic Genes in Breast Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-16.	0.9	6
11310	Case Report: Ipilimumab-Induced Panhypophysitis: An Infrequent Occurrence and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 582394.	1.3	17
11311	Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 596493.	1.3	24
11312	Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy. <i>Seminars in Cancer Biology</i> , 2022, 84, 310-328.	4.3	34
11313	Viroimmunotherapy for breast cancer: promises, problems and future directions. <i>Cancer Gene Therapy</i> , 2021, 28, 757-768.	2.2	13
11314	Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden. <i>Computational and Mathematical Methods in Medicine</i> , 2020, 2020, 1-14.	0.7	4
11315	BDCA1 ⁺ cDC2s, BDCA2 ⁺ pDCs and BDCA3 ⁺ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients. <i>Clinical and Translational Immunology</i> , 2020, 9, e1190.	1.7	16

#	ARTICLE	IF	CITATIONS
11316	TGF- β 2 is a Prognostic Biomarker Correlated with Immune Cell Infiltration in Colorectal Cancer. <i>Medicine (United States)</i> , 2020, 99, e23024.	0.4	8
11317	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20
11318	PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097421.	1.4	5
11319	Analysis of Immune Microenvironment by Multiplex Immunohistochemistry Staining in Different Oral Diseases and Oral Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 555757.	1.3	12
11320	Global Trends in Immunotherapy Research on Breast Cancer over the Past 10 Years. <i>Journal of Oncology</i> , 2020, 2020, 1-7.	0.6	16
11321	<p>Association Between Intermediate-Acting Neuromuscular-Blocking Agents and Short-Term Postoperative Outcomes in Patients with Gastric Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 11391-11402.	0.9	1
11322	Recent Advances on Rare Earth Upconversion Nanomaterials for Combined Tumor Near-Infrared Photoimmunotherapy. <i>Frontiers in Chemistry</i> , 2020, 8, 596658.	1.8	11
11323	Nicotinamide N-Methyltransferase Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 580299.	1.1	11
11324	Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study. <i>Frontiers in Oncology</i> , 2020, 10, 580241.	1.3	31
11325	Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses. <i>Biomedicines</i> , 2020, 8, 474.	1.4	24
11326	Breast Cancer Heterogeneity and Response to Novel Therapeutics. <i>Cancers</i> , 2020, 12, 3271.	1.7	40
11327	Causal Inference between Rheumatoid Arthritis and Breast Cancer in East Asian and European Population: A Two-Sample Mendelian Randomization. <i>Cancers</i> , 2020, 12, 3272.	1.7	5
11328	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. <i>Cancers</i> , 2020, 12, 3285.	1.7	85
11329	First line Immunotherapy for Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 373.	1.7	49
11330	Regulatory T Cells in Angiogenesis. <i>Journal of Immunology</i> , 2020, 205, 2557-2565.	0.4	39
11331	Cancer Extracellular Matrix Proteins Regulate Tumour Immunity. <i>Cancers</i> , 2020, 12, 3331.	1.7	60
11332	Cardiotoxicity of Contemporary Anticancer Immunotherapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 62.	0.4	34
11333	Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097004.	1.4	22

#	ARTICLE	IF	CITATIONS
11334	Triple-Negative Breast Cancer Comparison With Canine Mammary Tumors From Light Microscopy to Molecular Pathology. <i>Frontiers in Oncology</i> , 2020, 10, 563779.	1.3	13
11335	Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes. <i>Biomedicines</i> , 2020, 8, 484.	1.4	28
11336	Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. <i>Vaccines</i> , 2020, 8, 670.	2.1	17
11337	Immune Cell Infiltration and the Expression of PD-1 and PD-L1 in Primary PDGFRA-Mutant Gastrointestinal Stromal Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2091-2100.	0.9	10
11338	CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095299.	1.4	23
11339	<p>Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review</p>. <i>International Journal of General Medicine</i> , 2020, Volume 13, 1003-1009.	0.8	21
11340	Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 566511.	1.3	202
11341	Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 570080.	1.3	5
11342	Response of Pembrolizumab Alone for Non-small Cell Lung Cancer With Brain Metastasis: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 577159.	1.3	1
11343	Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2020, 11, 7137-7145.	1.2	14
11344	Metastatic Merkel Cell Carcinoma Masquerading as Multiple Immune-Related Adverse Events. <i>Case Reports in Dermatological Medicine</i> , 2020, 2020, 1-7.	0.1	2
11345	Site-Specific DNA Demethylation as a Potential Target for Cancer Epigenetic Therapy. <i>Epigenetics Insights</i> , 2020, 13, 251686572096480.	0.6	9
11346	Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity. <i>Frontiers in Oncology</i> , 2020, 10, 1289.	1.3	4
11347	Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer. <i>Translational Cancer Research</i> , 2020, 9, 2434-2448.	0.4	2
11348	<p>Nanotechnology-Based Targeting of mTOR Signaling in Cancer</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5767-5781.	3.3	12
11349	<p>Tumor-Associated CD163<sup>+</sup> M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5831-5843.	0.9	8
11350	<p>Predicting Individual Prognosis and Grade of Patients with Glioma Based on Preoperative Eosinophil and Neutrophil-to-Lymphocyte Ratio</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5793-5802.	0.9	9
11351	Limited Practical Utility of Liquid Biopsy in the Treated Patients with Advanced Breast Cancer. <i>Diagnostics</i> , 2020, 10, 523.	1.3	2

#	ARTICLE	IF	CITATIONS
11352	Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists. <i>Journal of Cancer</i> , 2020, 11, 5056-5068.	1.2	6
11353	Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel. <i>Nature Biomedical Engineering</i> , 2020, 4, 1090-1101.	11.6	168
11354	Discovery through clinical sequencing in oncology. <i>Nature Cancer</i> , 2020, 1, 774-783.	5.7	29
11355	Atezolizumab in a Cohort of pretreated, advanced, non-small cell lung cancer patients with rare Histological Subtypes (CHANCE trial). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091598.	1.4	5
11356	Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094092.	1.4	11
11357	Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094093.	1.4	55
11358	Past, Present, and Future of Anticancer Nanomedicine. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5719-5743.	3.3	23
11359	Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma. <i>Cancer Management and Research</i> , 2020, Volume 12, 5893-5902.	0.9	13
11360	NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score. <i>Cancer Management and Research</i> , 2020, Volume 12, 5975-5985.	0.9	7
11361	Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent. <i>Cancers</i> , 2020, 12, 2178.	1.7	25
11362	Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	18
11363	Esophageal Microenvironment: From Precursor Microenvironment to Premetastatic Niche. <i>Cancer Management and Research</i> , 2020, Volume 12, 5857-5879.	0.9	16
11364	The Ways of Isolating Neoantigen-Specific T Cells. <i>Frontiers in Oncology</i> , 2020, 10, 1347.	1.3	19
11365	Complete response to immunotherapy in a nonagenarian patient with metastatic melanoma. <i>BMJ Case Reports</i> , 2020, 13, e235472.	0.2	0
11366	Monoclonal Antibodies in Cancer Therapy. <i>Antibodies</i> , 2020, 9, 34.	1.2	325
11367	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 672.	1.8	205
11368	Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. <i>Cancers</i> , 2020, 12, 2012.	1.7	13
11369	Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	0.6	6

#	ARTICLE	IF	CITATIONS
11370	Identification of Prognostic Immune-Related Genes by Integrating mRNA Expression and Methylation in Lung Adenocarcinoma. <i>International Journal of Genomics</i> , 2020, 2020, 1-20.	0.8	11
11371	Clinical <i>BRCA1/2</i> Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance. <i>Cancer Discovery</i> , 2020, 10, 1475-1488.	7.7	109
11372	Nivolumab-Induced Autoimmune-Like Cholestatic Hepatitis in a Liver Transplant Recipient. <i>ACG Case Reports Journal</i> , 2020, 7, e00416.	0.2	17
11373	Interactive Effects of PD-L1 Expression in Tumor and Immune Cells on Prognosis of Esophageal Squamous Cell Carcinoma: A One-Center Retrospective Cohort Study. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6565-6572.	1.0	4
11374	Identification and Validation of an Immunological Expression-Based Prognostic Signature in Breast Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 912.	1.1	7
11375	Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. <i>British Journal of Cancer</i> , 2020, 123, 874-884.	2.9	15
11376	Optimizing Tissue Use: A Step-wise Approach to Diagnosing Squamous Cell Lung Carcinoma on Small Biopsies. <i>BMC Clinical Pathology</i> , 2020, 13, 2632010X2092187.	0.7	0
11377	Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC). <i>Frontiers in Oncology</i> , 2020, 10, 1074.	1.3	81
11378	Comprehensive Analysis of the Immune Implication of ACK1 Gene in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1132.	1.3	20
11379	The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice. <i>Frontiers in Oncology</i> , 2020, 10, 1143.	1.3	25
11380	Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?. <i>Frontiers in Oncology</i> , 2020, 10, 1193.	1.3	13
11381	Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 1197.	1.3	30
11382	Exploration the Significance of a Novel Immune-Related Gene Signature in Prognosis and Immune Microenvironment of Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1211.	1.3	17
11383	Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?. <i>Cancers</i> , 2020, 12, 1995.	1.7	8
11384	Patient-Derived Tumor Xenograft Models: Toward the Establishment of Precision Cancer Medicine. <i>Journal of Personalized Medicine</i> , 2020, 10, 64.	1.1	31
11385	Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 550.	1.8	14
11386	Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model. <i>Frontiers in Oncology</i> , 2020, 10, 1195.	1.3	94
11387	Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma. <i>Heliyon</i> , 2020, 6, e04117.	1.4	5

#	ARTICLE	IF	CITATIONS
11388	Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives. <i>British Journal of Cancer</i> , 2020, 123, 885-897.	2.9	22
11389	Pan-cancer image-based detection of clinically actionable genetic alterations. <i>Nature Cancer</i> , 2020, 1, 789-799.	5.7	343
11390	Novel cucurmosinâ€based immunotoxin targeting programmed cell death 1â€ligand 1 with high potency against human tumor in vitro and in vivo. <i>Cancer Science</i> , 2020, 111, 3184-3194.	1.7	10
11391	Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines. <i>BioMed Research International</i> , 2020, 2020, 1-14.	0.9	12
11392	The Better Survival of MSI Subtype Is Associated With the Oxidative Stress Related Pathways in Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1269.	1.3	24
11393	Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality. <i>Frontiers in Oncology</i> , 2020, 10, 1321.	1.3	22
11394	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. <i>Cancers</i> , 2020, 12, 1727.	1.7	36
11395	Prognostic Value of Immune Environment Analysis in Small Bowel Adenocarcinomas with Verified Mutational Landscape and Predisposing Conditions. <i>Cancers</i> , 2020, 12, 2018.	1.7	5
11396	The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies. <i>Cancers</i> , 2020, 12, 2030.	1.7	19
11397	Silence of Hippo Pathway Associates with Pro-Tumoral Immunosuppression: Potential Therapeutic Target of Glioblastomas. <i>Cells</i> , 2020, 9, 1761.	1.8	7
11398	ECG Changes in Melanoma Patients Undergoing Cancer Therapyâ€Data from the ECoR Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 2060.	1.0	6
11399	Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses. <i>Vaccines</i> , 2020, 8, 403.	2.1	2
11400	Inflammatory Manifestations of Systemic Diseases in the Central Nervous System. <i>Current Treatment Options in Neurology</i> , 2020, 22, 26.	0.7	12
11401	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093761.	1.4	78
11402	Progress in Neoantigen Targeted Cancer Immunotherapies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 728.	1.8	28
11403	Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature. <i>Frontiers in Medicine</i> , 2020, 7, 366.	1.2	7
11404	The Potential of Five Immune-Related Prognostic Genes to Predict Survival and Response to Immune Checkpoint Inhibitors for Soft Tissue Sarcomas Based on Multi-Omic Study. <i>Frontiers in Oncology</i> , 2020, 10, 1317.	1.3	18
11405	Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions. <i>Cancers</i> , 2020, 12, 2057.	1.7	48

#	ARTICLE	IF	CITATIONS
11406	Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and \pm PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4670-4681.	3.2	31
11407	Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1. <i>Frontiers in Oncology</i> , 2020, 10, 1090.	1.3	20
11408	The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 2081.	1.7	71
11409	High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors. <i>American Journal of Ophthalmology</i> , 2020, 220, 128-139.	1.7	8
11410	Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis. <i>Cancers</i> , 2020, 12, 2085.	1.7	17
11411	Considerations in treating patients with advance lung cancer during the epidemic outbreak of novel coronavirus (SARS-CoV-2). <i>Medical Oncology</i> , 2020, 37, 78.	1.2	4
11412	Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI). <i>European Journal of Cancer</i> , 2020, 137, 30-39.	1.3	4
11413	Characterization of the role of Samsn1 loss in multiple myeloma development. <i>FASEB BioAdvances</i> , 2020, 2, 554-572.	1.3	3
11414	Clinicopathologic significance of nuclear HER4 and phospho-YAP(S ¹²⁷) in human breast cancers and matching brain metastases. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094625.	1.4	11
11415	Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2020, 8, 778-778.	0.7	1
11416	The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 3804-3818.	0.4	7
11417	<p>Absolute Counts of Peripheral Lymphocyte Subsets Correlate with the Progression-Free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumour Patients</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6727-6737.	0.9	7
11418	Comprehensive Cohort Analysis of Mutational Spectrum in Early Onset Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 2089.	1.7	9
11419	Identification of the key genes and characterizations of Tumor Immune Microenvironment in Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC). <i>Journal of Cancer</i> , 2020, 11, 4965-4979.	1.2	27
11420	A brief review concerning Chimeric Antigen Receptors T cell therapy. <i>Journal of Cancer</i> , 2020, 11, 5424-5431.	1.2	4
11421	The role of gut microbiota in cancer treatment: friend or foe?. <i>Gut</i> , 2020, 69, 1867-1876.	6.1	189
11422	Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review. <i>Cancers</i> , 2020, 12, 2104.	1.7	50
11423	Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy. <i>Cancers</i> , 2020, 12, 2121.	1.7	26

#	ARTICLE	IF	CITATIONS
11424	Effects of Cancer Stem Cells in Triple-Negative Breast Cancer and Brain Metastasis: Challenges and Solutions. <i>Cancers</i> , 2020, 12, 2122.	1.7	18
11425	Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma. <i>Journal of Controlled Release</i> , 2020, 327, 266-283.	4.8	9
11426	The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. <i>Cancers</i> , 2020, 12, 1945.	1.7	49
11427	Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment. <i>Cancers</i> , 2020, 12, 1960.	1.7	20
11428	Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors. <i>Medicine (United States)</i> , 2020, 99, e21613.	0.4	0
11429	Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	117
11430	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. <i>Experimental Hematology and Oncology</i> , 2020, 9, 17.	2.0	21
11431	Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment. <i>Cancers</i> , 2020, 12, 2119.	1.7	7
11432	Endocrine-Resistant Breast Cancer: Mechanisms and Treatment. <i>Breast Care</i> , 2020, 15, 347-354.	0.8	46
11433	Investigating the Role of the N-Terminal Loop of PD-1 in Binding Process Between PD-1 and Nivolumab via Molecular Dynamics Simulation. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 574759.	1.6	6
11434	Understanding the Role of Innate Immune Cells and Identifying Genes in Breast Cancer Microenvironment. <i>Cancers</i> , 2020, 12, 2226.	1.7	21
11435	An integrative deep learning framework for classifying molecular subtypes of breast cancer. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 2185-2199.	1.9	40
11436	Novel targeted therapies for metastatic breast cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 907-907.	0.7	10
11437	Mechanisms of Cancer Resistance to Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 1290.	1.3	159
11438	Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells. <i>Cancers</i> , 2020, 12, 2204.	1.7	12
11439	Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies. <i>Cells</i> , 2020, 9, 1855.	1.8	20
11440	Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. <i>Advanced Science</i> , 2020, 7, 2001447.	5.6	30
11441	<p>Research Progress and Existing Problems for Abscopal Effect</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6695-6706.	0.9	8

#	ARTICLE	IF	CITATIONS
11442	Immune Cytolytic Activity as an Indicator of Immune Checkpoint Inhibitors Treatment for Prostate Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 930.	2.0	17
11443	Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm. <i>Frontiers in Oncology</i> , 2020, 10, 1369.	1.3	13
11444	Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?. <i>Biomedicines</i> , 2020, 8, 281.	1.4	26
11445	Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 583314.	1.3	7
11446	Heterogeneity of Tumors in Breast Cancer: Implications and Prospects for Prognosis and Therapeutics. <i>Scientifica</i> , 2020, 2020, 1-11.	0.6	19
11447	Hyperprogressive disease in advanced cancer patients with liver metastasis treated with PD-1 inhibitors: two case reports. <i>Annals of Translational Medicine</i> , 2020, 8, 1100-1100.	0.7	4
11448	Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. <i>Annals of Translational Medicine</i> , 2020, 8, 1187-1187.	0.7	31
11449	<p></p>Toll-Like Receptor 9 Agonists in Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10039-10061.	1.0	74
11450	Therapeutic Time-restricted Feeding Reduces Renal Tumor Bioluminescence in Mice but Fails to Improve Anti-CTLA-4 Efficacy. <i>Anticancer Research</i> , 2020, 40, 5445-5456.	0.5	10
11451	First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress. <i>Frontiers in Pharmacology</i> , 2020, 11, 578091.	1.6	51
11452	Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer. <i>Frontiers in Physiology</i> , 2020, 11, 583333.	1.3	42
11453	The UPR Transducer IRE1 Promotes Breast Cancer Malignancy by Degrading Tumor Suppressor microRNAs. <i>IScience</i> , 2020, 23, 101503.	1.9	25
11454	Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, e1753-e1762.	1.9	6
11455	<p></p>Therapeutic Vaccines for HPV-Associated Malignancies</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 167-200.	2.7	66
11456	Stemness Related Genes Revealed by Network Analysis Associated With Tumor Immune Microenvironment and the Clinical Outcome in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 549213.	1.1	47
11457	DNA Repair and Signaling in Immune-Related Cancer Therapy. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 205.	1.6	20
11458	On the Role of the Objective in the Optimization of Compartmental Models for Biomedical Therapies. <i>Journal of Optimization Theory and Applications</i> , 2020, 187, 305-335.	0.8	11
11459	Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma. <i>Journal of Bone Oncology</i> , 2020, 25, 100332.	1.0	19

#	ARTICLE	IF	CITATIONS
11460	A Phase 2 Study of Nivolumab Using a Fixed Dose of 40mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma. <i>HemaSphere</i> , 2020, 4, e480.	1.2	19
11461	Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	16
11462	Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic. <i>Pharmaceutics</i> , 2020, 12, 996.	2.0	6
11463	Increased SNX20 and PD-L1 Levels Can Predict the Clinical Response to PD-1 Inhibitors in Lung Adenocarcinoma. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10075-10085.	1.0	6
11464	Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 556275.	1.3	6
11465	Programmed cell death-ligand 1 expression in stromal immune cells is a marker of breast cancer outcome. <i>Journal of Cancer</i> , 2020, 11, 7246-7252.	1.2	7
11466	Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study. <i>Cancer Management and Research</i> , 2020, Volume 12, 10333-10340.	0.9	12
11467	The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. <i>Frontiers in Oncology</i> , 2020, 10, 546604.	1.3	15
11468	Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy. <i>Frontiers in Oncology</i> , 2020, 10, 568939.	1.3	15
11469	Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3112.	1.7	23
11470	The Immune Phenotype of Isolated Lymphoid Structures in Non-Tumorous Colon Mucosa Encrypts the Information on Pathobiology of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3117.	1.7	7
11471	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1952.	3.4	241
11472	Anti-PD-1 antibody therapy for epithelial skin malignancies. <i>Medicine (United States)</i> , 2020, 99, e22913.	0.4	6
11473	Novel Prognostic Model Based on Immune Signature for Head and Neck Squamous Cell Carcinoma. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	7
11474	Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility. <i>Breast Cancer: Targets and Therapy</i> , 2020, Volume 12, 153-163.	1.0	5
11475	CBX3 Promotes Gastric Cancer Progression and Affects Factors Related to Immunotherapeutic Responses. <i>Cancer Management and Research</i> , 2020, Volume 12, 10113-10125.	0.9	23
11476	Tumor-Infiltrating Lymphocyte-Based Risk Score for Predicting Prognosis in Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 522015.	1.3	8
11477	The Double-Edge Sword of Autophagy in Cancer: From Tumor Suppression to Pro-tumor Activity. <i>Frontiers in Oncology</i> , 2020, 10, 578418.	1.3	151

#	ARTICLE	IF	CITATIONS
11478	The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?. <i>Cancers</i> , 2020, 12, 3129.	1.7	29
11479	Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models. <i>Journal of Personalized Medicine</i> , 2020, 10, 179.	1.1	41
11481	Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. <i>Cancers</i> , 2020, 12, 3169.	1.7	10
11482	Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients. <i>Journal of Cancer</i> , 2020, 11, 7001-7008.	1.2	17
11483	Comprehensive analysis of gene regulation network and immune signatures of prognostic biomarker YAP1 in pancreatic cancer. <i>Journal of Cancer</i> , 2020, 11, 6960-6969.	1.2	7
11484	Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. <i>Nature Communications</i> , 2020, 11, 5488.	5.8	25
11485	Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues. <i>Scientific Reports</i> , 2020, 10, 18336.	1.6	6
11486	CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28960-28970.	3.3	150
11487	ACSL3â€“PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression. <i>Science Advances</i> , 2020, 6, .	4.7	27
11488	Three-Dimensional Models as a New Frontier for Studying the Role of Proteoglycans in the Normal and Malignant Breast Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 569454.	1.8	10
11489	Carbon Ion Radiobiology. <i>Cancers</i> , 2020, 12, 3022.	1.7	104
11490	Selecting Target Antigens for Cancer Vaccine Development. <i>Vaccines</i> , 2020, 8, 615.	2.1	59
11491	Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 5040-5049.	2.0	12
11492	Mutation position is an important determinant for predicting cancer neoantigens. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	73
11493	Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma. <i>Melanoma Research</i> , 2020, 30, 492-499.	0.6	3
11494	Immunotherapy via PD-L1â€“presenting biomaterials leads to long-term islet graft survival. <i>Science Advances</i> , 2020, 6, eaba5573.	4.7	54
11495	Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. <i>Biomarker Research</i> , 2020, 8, 34.	2.8	266
11496	Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. <i>Biomarker Research</i> , 2020, 8, 35.	2.8	122

#	ARTICLE	IF	CITATIONS
11497	microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers Is Mainly Dependent on HER2 Status—A Pilot Study. <i>Diagnostics</i> , 2020, 10, 617.	1.3	7
11498	Addition of Radiotherapy to Immunotherapy: Effects on Outcome of Different Subgroups Using a Propensity Score Matching. <i>Cancers</i> , 2020, 12, 2429.	1.7	5
11499	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6119-6128.	1.0	20
11500	Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer. <i>Npj Precision Oncology</i> , 2020, 4, 24.	2.3	86
11501	Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1147-1158.	1.3	8
11502	Checkpoint inhibitors and myeloma: promises, deadlocks and new directions. <i>Annals of Translational Medicine</i> , 2020, 8, 777-777.	0.7	3
11503	Editorial: Perspectives in Mammary Gland Development and Breast Cancer Research. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 719.	1.8	2
11504	Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 1625.	1.3	12
11505	Classical and Non-Classical Progesterone Signaling in Breast Cancers. <i>Cancers</i> , 2020, 12, 2440.	1.7	26
11506	iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery. <i>Polymers</i> , 2020, 12, 1906.	2.0	45
11507	Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 689-698.	1.1	4
11508	A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 861-872.	1.1	8
11509	Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1550-1563.	3.2	99
11510	Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 6350-6361.	3.2	35
11511	Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1404.	1.3	8
11512	Cancer-Specific Immune Prognostic Signature in Solid Tumors and Its Relation to Immune Checkpoint Therapies. <i>Cancers</i> , 2020, 12, 2476.	1.7	39
11513	Low ARID1A Expression is Associated with Poor Prognosis in Hepatocellular Carcinoma. <i>Cells</i> , 2020, 9, 2002.	1.8	25
11514	Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2775.	1.0	10

#	ARTICLE	IF	CITATIONS
11515	The application of artificial intelligence and radiomics in lung cancer. <i>Precision Clinical Medicine</i> , 2020, 3, 214-227.	1.3	25
11516	CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2020, 10, 1912-1933.	7.7	71
11517	Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094092.	1.4	86
11518	<p><p>Immune Checkpoint Inhibitor Therapy Achieved Complete Response for Drug-Sensitive EGFR/ALK Mutation-Negative Metastatic Pulmonary Large-Cell Neuroendocrine Carcinoma with High Tumor Mutation Burden: A Case Report</p>. <i>OncoTargets and Therapy</i>, 2020, Volume 13, 8245-8250.</p>	1.0	10
11519	Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. <i>Cancers</i> , 2020, 12, 2447.	1.7	70
11520	Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility â€œ a prospective, translational study. <i>Molecular Oncology</i> , 2020, 14, 2727-2743.	2.1	14
11521	A tumor-to-lymph procedure navigated versatile gel system for combinatorial therapy against tumor recurrence and metastasis. <i>Science Advances</i> , 2020, 6, .	4.7	95
11522	Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment. <i>Cancers</i> , 2020, 12, 2465.	1.7	90
11523	Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis. <i>Translational Lung Cancer Research</i> , 2020, 9, 1302-1323.	1.3	16
11524	G-CSF and G-CSFR Modulate CD4 and CD8 T Cell Responses to Promote Colon Tumor Growth and Are Potential Therapeutic Targets. <i>Frontiers in Immunology</i> , 2020, 11, 1885.	2.2	21
11525	Basis for Immunotherapy for Treatment of Meningiomas. <i>Frontiers in Neurology</i> , 2020, 11, 945.	1.1	27
11526	Genomic Signatures in Luminal Breast Cancer. <i>Breast Care</i> , 2020, 15, 355-365.	0.8	20
11527	Molecular differences across invasive lung adenocarcinoma morphological subgroups. <i>Translational Lung Cancer Research</i> , 2020, 9, 1029-1040.	1.3	3
11528	A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians. <i>Translational Lung Cancer Research</i> , 2020, 9, 1124-1137.	1.3	6
11529	Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling. <i>Frontiers in Oncology</i> , 2020, 10, 1429.	1.3	16
11530	Mutational Landscape of Esophageal Squamous Cell Carcinoma in an Indian Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 1457.	1.3	21
11531	Metabolic and epigenetic regulation of T-cell exhaustion. <i>Nature Metabolism</i> , 2020, 2, 1001-1012.	5.1	167
11532	Immunotherapy in prostate cancer: current state and future perspectives. <i>Therapeutic Advances in Urology</i> , 2020, 12, 175628722095140.	0.9	24

#	ARTICLE	IF	CITATIONS
11533	Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2020, 9, 1053-1066.	1.3	7
11534	Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 1015-1028.	1.3	15
11535	A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1335.	1.3	2
11536	Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC. <i>Cancers</i> , 2020, 12, 2657.	1.7	4
11537	Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2662.	1.7	31
11538	Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study. <i>Diagnostics</i> , 2020, 10, 704.	1.3	54
11539	Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation. <i>Medicine (United States)</i> , 2020, 99, e22312.	0.4	5
11540	Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 576314.	1.3	17
11541	Comment on: Jilkova, Z.M.; et al. "Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" <i>Cancers</i> 2019, 11, 1554. <i>Cancers</i> , 2020, 12, 2670.	1.7	0
11542	Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. <i>Nature Communications</i> , 2020, 11, 4858.	5.8	124
11543	Innovative approaches to immunotherapy in breast cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 4536-4540.	0.6	4
11544	Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy. <i>Frontiers in Microbiology</i> , 2020, 11, 575072.	1.5	40
11545	Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2967.	1.0	23
11546	CD8 ⁺ tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous <i>de novo</i> metastatic colorectal carcinoma do not track with survival. <i>Clinical and Translational Immunology</i> , 2020, 9, e1155.	1.7	8
11547	Design for immuno-oncology clinical trials enrolling both responders and nonresponders. <i>Statistics in Medicine</i> , 2020, 39, 3914-3936.	0.8	2
11548	Discovery of a Secalonic Acid Derivative from <i>Aspergillus aculeatus</i> , an Endophyte of <i>Rosa damascena</i> Mill., Triggers Apoptosis in MDA-MB-231 Triple Negative Breast Cancer Cells. <i>ACS Omega</i> , 2020, 5, 24296-24310.	1.6	27
11549	Illuminating the noncoding genome in cancer. <i>Nature Cancer</i> , 2020, 1, 864-872.	5.7	37
11550	Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2022, 83, 001-010.	0.4	4

#	ARTICLE	IF	CITATIONS
11551	KRAS ^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020, 383, 1207-1217.	13.9	1,049
11552	Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2. <i>Genes and Development</i> , 2020, 34, 1310-1315.	2.7	47
11553	CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. <i>Cancer Research</i> , 2020, 80, 5063-5075.	0.4	21
11554	Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ. <i>Frontiers in Oncology</i> , 2020, 10, 1486.	1.3	12
11555	Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment. <i>Cancers</i> , 2020, 12, 2634.	1.7	7
11556	Treatment of Advanced Melanoma: Past, Present and Future. <i>Life</i> , 2020, 10, 208.	1.1	18
11557	The value of red blood cell distribution width, neutrophil-to-lymphocyte ratio, and hemoglobin-to-red blood cell distribution width ratio in the progression of non-small cell lung cancer. <i>PLoS ONE</i> , 2020, 15, e0237947.	1.1	24
11558	High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8273-8285.	1.0	19
11559	Immune-based therapies in the management of multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 84.	2.8	38
11560	Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis—Similarities and Differences. <i>Current Rheumatology Reports</i> , 2020, 22, 68.	2.1	56
11561	Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3535-3545.	2.0	11
11562	Investigation of the SPAG5 gene expression and amplification related to the NuMA mRNA levels in breast ductal carcinoma. <i>World Journal of Surgical Oncology</i> , 2020, 18, 225.	0.8	5
11563	Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 172.	1.6	25
11564	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. <i>Nature Communications</i> , 2020, 11, 4324.	5.8	75
11565	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. <i>Cancers</i> , 2020, 12, 2392.	1.7	171
11566	Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study. <i>Cancers</i> , 2020, 12, 2422.	1.7	5
11567	Oral and Fecal Microbiota in Lynch Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 2735.	1.0	10
11568	Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma. <i>Biomedicines</i> , 2020, 8, 327.	1.4	9

#	ARTICLE	IF	CITATIONS
11569	<p>Moxibustion Enhances Chemotherapy of Breast Cancer by Affecting Tumor Microenvironment</p>. Cancer Management and Research, 2020, Volume 12, 8015-8022.	0.9	9
11570	Pathomechanisms and Clinical Implications of Myasthenic Syndromes Exacerbated and Induced by Medical Treatments. Frontiers in Molecular Neuroscience, 2020, 13, 156.	1.4	16
11571	Evolutionary dynamics of neoantigens in growing tumors. Nature Genetics, 2020, 52, 1057-1066.	9.4	68
11572	Anti-tumor immunity influences cancer cell reliance upon ATG7. OncoImmunology, 2020, 9, 1800162.	2.1	15
11573	<p>Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression</p>. OncoTargets and Therapy, 2020, Volume 13, 8901-8905.	1.0	7
11575	ctDNA Concentration, MIK167 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC. Frontiers in Oncology, 2020, 10, 1706.	1.3	17
11576	Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma. Cancers, 2020, 12, 2591.	1.7	8
11577	The Origin and Immune Recognition of Tumor-Specific Antigens. Cancers, 2020, 12, 2607.	1.7	30
11578	Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer. Molecular Cancer Research, 2020, 18, 1685-1698.	1.5	3
11579	Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms. Cancers, 2020, 12, 2592.	1.7	8
11580	Revisiting the PD-1 pathway. Science Advances, 2020, 6, .	4.7	277
11581	Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review. Gut Pathogens, 2020, 12, 43.	1.6	43
11582	VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer. In Vivo, 2020, 34, 2641-2646.	0.6	15
11583	Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 554313.	1.3	32
11584	Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab. IJU Case Reports, 2020, 3, 252-256.	0.1	5
11585	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Supportive Care in Cancer, 2020, 28, 6145-6157.	1.0	14
11586	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. Clinical Medicine Insights: Oncology, 2020, 14, 117955492095135.	0.6	24
11587	Hepatocellular CarcinomaâCirculating Tumor Cells Expressing PDâL1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors. Hepatology Communications, 2020, 4, 1527-1540.	2.0	60

#	ARTICLE	IF	CITATIONS
11588	Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1167.	1.3	8
11589	Palliative Radiofrequency Ablation Accelerates the Residual Tumor Progression Through Increasing Tumor-Infiltrating MDSCs and Reducing T-Cell-Mediated Anti-Tumor Immune Responses in Animal Model. <i>Frontiers in Oncology</i> , 2020, 10, 1308.	1.3	17
11590	Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma. <i>Frontiers in Oncology</i> , 2020, 10, 1361.	1.3	13
11591	Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. <i>Frontiers in Oncology</i> , 2020, 10, 1677.	1.3	32
11592	Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response. <i>Clinical and Translational Medicine</i> , 2020, 10, e118.	1.7	15
11593	Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 40.	2.3	27
11594	Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1644.	1.3	48
11595	Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2495.	1.7	12
11596	Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2020, 12, 2497.	1.7	17
11597	Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. <i>Nature Communications</i> , 2020, 11, 4520.	5.8	218
11598	Transcriptional signatures in histologic structures within glioblastoma tumors may predict personalized drug sensitivity and survival. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa093.	0.4	5
11599	Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	20
11600	Establishment of a 5-gene risk model related to regulatory T cells for predicting gastric cancer prognosis. <i>Cancer Cell International</i> , 2020, 20, 433.	1.8	12
11601	Treatment and Prevention of Lung Cancer Using a Virus-Infected Reprogrammed Somatic Cell-Derived Tumor Cell Vaccination (VIReST) Regime. <i>Frontiers in Immunology</i> , 2020, 11, 1996.	2.2	5
11602	Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2020, 11, 1213.	1.6	28
11603	Immunotherapy and NSCLC: The Long and Winding Road. <i>Cancers</i> , 2020, 12, 2512.	1.7	6
11604	Immunotherapy in Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 2522.	1.7	60
11605	Selective inhibition of TGF- β 1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer. <i>Nature Communications</i> , 2020, 11, 4545.	5.8	94

#	ARTICLE	IF	CITATIONS
11606	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3672-3684.	0.8	78
11607	Humanized Rodent Models for Cancer Research. <i>Frontiers in Oncology</i> , 2020, 10, 1696.	1.3	68
11608	ReactomeGSA - Efficient Multi-Omics Comparative Pathway Analysis. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 2115-2125.	2.5	145
11609	Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1637-1659.	0.4	17
11610	<p></p>PD-L1 in Lung Adenocarcinoma: Insights into the Role of ¹⁸F-FDG PET/CT</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6385-6395.	0.9	11
11611	<p></p>A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6493-6509.	0.9	19
11612	Genomic Mapping Identifies Mutations in RYR2 and AHNK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1. <i>Cancers</i> , 2020, 12, 2243.	1.7	22
11613	Development of Mannose-Modified Carboxylated Curdlan-Coated Liposomes for Antigen Presenting Cell Targeted Antigen Delivery. <i>Pharmaceutics</i> , 2020, 12, 754.	2.0	12
11614	Interface of cancer stem cells and cancer immunity. <i>Annals of Translational Medicine</i> , 2020, 8, 810-810.	0.7	0
11615	Differences in molecular epidemiology of lung cancer among ethnicities (Asian vs. Caucasian). <i>Journal of Thoracic Disease</i> , 2020, 12, 3776-3784.	0.6	24
11616	Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. <i>Pharmaceutics</i> , 2020, 12, 758.	2.0	6
11617	<p></p>Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5279-5288.	3.3	18
11618	<p></p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7229-7241.	1.0	12
11619	An Immunosuppressive Effect of Melanoma-derived Exosomes on NY-ESO-1 Antigen-specific Human CD8+ T Cells is Dependent on IL-10 and Independent of BRAFV600E Mutation in Melanoma Cell Lines. <i>Immunological Investigations</i> , 2020, 49, 744-757.	1.0	13
11620	Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells. <i>Prostate Cancer</i> , 2020, 2020, 1-12.	0.4	10
11621	A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer. <i>Cancer Research</i> , 2020, 80, 4754-4767.	0.4	37
11622	Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?. <i>Journal of Thoracic Disease</i> , 2020, 12, 3796-3803.	0.6	19
11623	A Global Gene Body Methylation Measure Correlates Independently with Overall Survival in Solid Cancer Types. <i>Cancers</i> , 2020, 12, 2257.	1.7	1

#	ARTICLE	IF	CITATIONS
11624	STAT3 and GR Cooperate to Drive Gene Expression and Growth of Basal-Like Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2020, 80, 4355-4370.	0.4	17
11625	Overhauling CAR T Cells to Improve Efficacy, Safety and Cost. <i>Cancers</i> , 2020, 12, 2360.	1.7	9
11626	Association of an anaplastic lymphoma kinase pathway signature with cell dedifferentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer. <i>Cancer Communications</i> , 2020, 40, 422-434.	3.7	6
11627	T-Cell Immunity in Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 1014-1023.	0.5	23
11628	The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1400.	1.3	11
11629	Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile. <i>Melanoma Management</i> , 2020, 7, MMT43.	0.1	7
11630	Mechanisms of T-Cell Exhaustion in Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 2274.	1.7	71
11631	Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review. <i>Cancers</i> , 2020, 12, 2314.	1.7	13
11632	Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. <i>Cancers</i> , 2020, 12, 2317.	1.7	37
11633	C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. <i>Cancers</i> , 2020, 12, 2319.	1.7	52
11634	Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction. <i>Cancers</i> , 2020, 12, 2326.	1.7	6
11635	Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 2329.	1.7	45
11636	Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016. <i>Cancers</i> , 2020, 12, 2354.	1.7	8
11637	TILs Immunophenotype in Breast Cancer Predicts Local Failure and Overall Survival: Analysis in a Large Radiotherapy Trial with Long-Term Follow-Up. <i>Cancers</i> , 2020, 12, 2365.	1.7	18
11638	Lipidomic-Based Advances in Diagnosis and Modulation of Immune Response to Cancer. <i>Metabolites</i> , 2020, 10, 332.	1.3	12
11639	The updated landscape of tumor microenvironment and drug repurposing. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 166.	7.1	563
11640	CD8+ T Cell Co-Expressed Genes Correlate With Clinical Phenotype and Microenvironments of Urothelial Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 553399.	1.3	26
11641	Non-epigenetic induction of HEXIM1 by DNMT1 inhibitors and functional relevance. <i>Scientific Reports</i> , 2020, 10, 21015.	1.6	2

#	ARTICLE	IF	CITATIONS
11642	Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data. <i>Frontiers in Immunology</i> , 2020, 11, 558757.	2.2	16
11643	Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey. <i>Cancer Control</i> , 2020, 27, 107327482097720.	0.7	5
11644	PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	1.4	13
11645	Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096723.	1.4	13
11646	Gastrointestinal side effects of cancer treatments. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232097035.	1.1	41
11647	PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 598205.	1.8	23
11648	Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. <i>Nature Communications</i> , 2020, 11, 6410.	5.8	66
11649	Iron Supplementation Interferes With Immune Therapy of Murine Mammary Carcinoma by Inhibiting Anti-Tumor T Cell Function. <i>Frontiers in Oncology</i> , 2020, 10, 584477.	1.3	10
11650	T-regulatory cell/T helper 17 cell imbalance functions as prognostic biomarker of oral squamous cell carcinoma " CONSORT. <i>Medicine (United States)</i> , 2020, 99, e23145.	0.4	13
11651	Clinical significance of LSEctin and its association with PVR in non-small-cell lung cancer patients. <i>Annals of Translational Medicine</i> , 2020, 8, 1393-1393.	0.7	1
11652	Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP). <i>Frontiers in Oncology</i> , 2020, 10, 588932.	1.3	4
11653	The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. <i>Disease Markers</i> , 2020, 2020, 1-14.	0.6	13
11654	The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2020, 12, 6426-6434.	0.6	30
11655	Deep learning-based cross-classifications reveal conserved spatial behaviors within tumor histological images. <i>Nature Communications</i> , 2020, 11, 6367.	5.8	108
11656	Understanding the Targeting Mechanisms of Multi-Specific Biologics in Immunotherapy with Multiscale Modeling. <i>IScience</i> , 2020, 23, 101835.	1.9	6
11657	Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100006.	0.6	8
11658	Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIRO2-Lung Trial. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100068.	0.6	10
11659	Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib. <i>JGH Open</i> , 2020, 4, 1183-1190.	0.7	6

#	ARTICLE	IF	CITATIONS
11660	Regulatory T Cells Support Breast Cancer Progression by Opposing IFN- γ -Dependent Functional Reprogramming of Myeloid Cells. <i>Cell Reports</i> , 2020, 33, 108482.	2.9	28
11661	Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 821-825.	1.2	18
11662	Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection. <i>Gastroenterology Report</i> , 2021, 9, 443-450.	0.6	3
11663	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. <i>Science</i> , 2020, 370, 1328-1334.	6.0	273
11664	Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095480.	1.4	9
11665	Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097535.	1.4	18
11666	Recent updates on Sintilimab in solid tumor immunotherapy. <i>Biomarker Research</i> , 2020, 8, 69.	2.8	26
11667	Changing paradigm in advanced and metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 6992-7001.	0.6	3
11668	Radiation and immunotherapy: emerging mechanisms of synergy. <i>Journal of Thoracic Disease</i> , 2020, 12, 7011-7023.	0.6	28
11669	<p>Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data</p>. <i>Breast Cancer: Targets and Therapy</i> , 2020, Volume 12, 251-258.	1.0	10
11670	<p><p>Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12301-12316.	1.0	22
11671	Systematic Analysis of Expression Profiles and Prognostic Significance for FAM83 Family in Non-small-Cell Lung Cancer. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 572406.	1.6	13
11672	The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study. <i>Frontiers in Oncology</i> , 2020, 10, 594125.	1.3	23
11673	â€œGiant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanomaâ€. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 20, 100891.	0.4	14
11674	Extended transcriptome analysis reveals genome-wide lncRNA-mediated epigenetic dysregulation in colorectal cancer. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 3507-3517.	1.9	2
11675	Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA. <i>Cell Death and Disease</i> , 2020, 11, 1052.	2.7	11
11676	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2020, 12, CD013257.	1.5	30
11677	Nâ€glycosylation of PDâ€1 promotes binding of camrelizumab. <i>EMBO Reports</i> , 2020, 21, e51444.	2.0	47

#	ARTICLE	IF	CITATIONS
11678	Female Malignancies and Immunotherapy: What's New?. <i>Cancers</i> , 2020, 12, 2909.	1.7	1
11679	Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells. <i>Cancers</i> , 2020, 12, 3181.	1.7	9
11680	Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up. <i>Journal of Clinical Medicine</i> , 2020, 9, 3280.	1.0	27
11681	Multi-Omics Analysis Detects Novel Prognostic Subgroups of Breast Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 574661.	1.1	18
11682	TMEM205 Is an Independent Prognostic Factor and Is Associated With Immune Cell Infiltrates in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 575776.	1.1	15
11683	Immune-Activated Regional Lymph Nodes Predict Favorable Survival in Early-Stage Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 570981.	1.3	7
11684	Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 571135.	1.3	2
11685	Liposome-Based Drug Delivery Systems in Cancer Immunotherapy. <i>Pharmaceutics</i> , 2020, 12, 1054.	2.0	77
11686	PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC. <i>Analytical Cellular Pathology</i> , 2020, 2020, 1-7.	0.7	3
11687	Co-inhibitory Receptor Signaling in T-Cell-Mediated Autoimmune Glomerulonephritis. <i>Frontiers in Medicine</i> , 2020, 7, 584382.	1.2	3
11688	Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8229.	1.8	7
11689	Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma. <i>Medicine (United States)</i> , 2020, 99, e23172.	0.4	15
11690	TFE3&PD&L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 14441-14452.	1.6	7
11691	iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti"PD-1 therapy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	133
11692	Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. <i>Journal of Thoracic Disease</i> , 2020, 12, 5096-5103.	0.6	0
11693	Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care. <i>Translational Lung Cancer Research</i> , 2020, 9, 1736-1748.	1.3	9
11694	Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 582370.	1.8	48
11695	Physical Activity and Breast Cancer Prevention: Possible Role of Immune Mediators. <i>Frontiers in Nutrition</i> , 2020, 7, 557997.	1.6	17

#	ARTICLE	IF	CITATIONS
11696	Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 558572.	1.3	12
11697	ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth. <i>Cancer Research</i> , 2021, 81, 174-186.	0.4	12
11698	Immune Responses and Risk of Triple-negative Breast Cancer: Implications for Higher Rates among African American Women. <i>Cancer Prevention Research</i> , 2020, 13, 901-910.	0.7	10
11699	Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies. <i>Breast Care</i> , 2020, 15, 470-480.	0.8	11
11700	Profiling chromatin regulatory landscape: insights into the development of ChIP-seq and ATAC-seq. <i>Molecular Biomedicine</i> , 2020, 1, 9.	1.7	34
11701	Prognostic nomogram on clinicopathologic features and serum indicators for advanced non-small cell lung cancer patients treated with anti-PD-1 inhibitors. <i>Annals of Translational Medicine</i> , 2020, 8, 1078-1078.	0.7	9
11702	Biomarkers in immunotherapy: literature review and future directions. <i>Journal of Thoracic Disease</i> , 2020, 12, 5119-5127.	0.6	7
11703	Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival. <i>Journal of Thoracic Disease</i> , 2020, 12, 5086-5095.	0.6	29
11704	<p>Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10615-10629.	0.9	11
11705	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. <i>Cancer Discovery</i> , 2020, 10, 1808-1825.	7.7	388
11706	Radiomics of ¹⁸ F Fluorodeoxyglucose PET/CT Images Predicts Severe Immune-related Adverse Events in Patients with NSCLC. <i>Radiology: Artificial Intelligence</i> , 2020, 2, e190063.	3.0	24
11707	Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric Adenocarcinoma. <i>In Vivo</i> , 2020, 34, 3171-3180.	0.6	12
11708	Genetic Co-Administration of Soluble PD-1 Ectodomains Modifies Immune Responses against Influenza A Virus Induced by DNA Vaccination. <i>Vaccines</i> , 2020, 8, 570.	2.1	5
11709	Therapeutic Vaccines and Cancer Immunotherapy. <i>Vaccines</i> , 2020, 8, 596.	2.1	6
11710	Clinical Data on Immunotherapy in Breast Cancer. <i>Breast Care</i> , 2020, 15, 450-469.	0.8	12
11711	Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. <i>Annals of Translational Medicine</i> , 2020, 8, 1095-1095.	0.7	27
11712	Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 569219.	1.8	59
11713	Molecular Profiling-Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges. <i>Frontiers in Oncology</i> , 2020, 10, 532403.	1.3	20

#	ARTICLE	IF	CITATIONS
11714	Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041). <i>Cancers</i> , 2020, 12, 3188.	1.7	8
11715	Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 3234.	1.7	39
11716	Analysis of the Gene Expression Profile of Stromal Pro-Tumor Factors in Cancer-Associated Fibroblasts from Luminal Breast Carcinomas. <i>Diagnostics</i> , 2020, 10, 865.	1.3	7
11717	Alternative Checkpoints as Targets for Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 126.	1.8	12
11718	Recurrent copy number gains drive PKC \hat{I}^1 expression and PKC \hat{I}^1 -dependent oncogenic signaling in human cancers. <i>Advances in Biological Regulation</i> , 2020, 78, 100754.	1.4	5
11719	Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation. <i>OncoImmunology</i> , 2020, 9, 1737385.	2.1	23
11720	Metagenomic characterization of lysine acetyltransferases in human cancer and their association with clinicopathologic features. <i>Cancer Science</i> , 2020, 111, 1829-1839.	1.7	15
11721	A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies. <i>Dermatopathology (Basel, Switzerland)</i> , 2019, 6, 255-259.	0.7	9
11722	Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 338-357.	4.2	96
11723	Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report. <i>Annals of Translational Medicine</i> , 2020, 8, 402-402.	0.7	8
11724	Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?. <i>Cancers</i> , 2020, 12, 1101.	1.7	9
11725	CD8+ Tumour-Infiltrating Lymphocytes and Tumour Microenvironment Immune Types as Biomarkers for Immunotherapy in Sinonasal Intestinal-Type Adenocarcinoma. <i>Vaccines</i> , 2020, 8, 202.	2.1	15
11726	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020, 8, 203.	2.1	38
11727	Harnessing the potential of multimodal radiotherapy in prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 321-338.	1.9	15
11728	Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. <i>Science Advances</i> , 2020, 6, eaay6298.	4.7	41
11729	Analysis of Lung Adenocarcinoma Subtypes Based on Immune Signatures Identifies Clinical Implications for Cancer Therapy. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 241-249.	2.0	60
11730	Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types. <i>Modern Pathology</i> , 2020, 33, 1753-1763.	2.9	25
11731	PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. <i>Nature Communications</i> , 2020, 11, 2135.	5.8	114

#	ARTICLE	IF	CITATIONS
11732	Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations. <i>Thyroid</i> , 2020, 30, 1440-1450.	2.4	53
11733	Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy. <i>Science Advances</i> , 2020, 6, eaaz8985.	4.7	93
11734	Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer. <i>European Thyroid Journal</i> , 2020, 9, 157-161.	1.2	4
11735	In vivo Imaging Technologies to Monitor the Immune System. <i>Frontiers in Immunology</i> , 2020, 11, 1067.	2.2	45
11736	Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database. <i>Frontiers in Pharmacology</i> , 2020, 11, 557.	1.6	87
11737	Tumor-Infiltrating CD8 T Cells Predict Clinical Breast Cancer Outcomes in Young Women. <i>Cancers</i> , 2020, 12, 1076.	1.7	31
11738	Differences of the Immune Phenotype of Breast Cancer Cells after Ex Vivo Hyperthermia by Warm-Water or Microwave Radiation in a Closed-Loop System Alone or in Combination with Radiotherapy. <i>Cancers</i> , 2020, 12, 1082.	1.7	23
11739	The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 1108.	1.7	13
11740	ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. <i>Oncotarget</i> , 2020, 9, 1744980.	2.1	77
11741	Doxorubicin pretreatment enhances FAP ⁺ /survivin co-targeting DNA vaccine anti-tumor activity primarily through decreasing peripheral MDSCs in the 4T1 murine breast cancer model. <i>Oncotarget</i> , 2020, 9, 1747350.	2.1	22
11742	Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. <i>Clinical Cancer Research</i> , 2020, 26, 1141-1151.	3.2	43
11743	Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 1133.	1.7	14
11744	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. <i>Annals of Oncology</i> , 2020, 31, 1075-1082.	0.6	62
11745	Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1130-1143.	0.6	89
11746	Stereotactic body radiation therapy (SBRT) in the management of pulmonary spindle cell carcinoma. <i>BMJ Case Reports</i> , 2020, 13, e234779.	0.2	3
11747	Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition. <i>Annals of Translational Medicine</i> , 2020, 8, 555-555.	0.7	8
11748	Comprehensive Analysis of the Expression and Prognosis for TDO2 in Breast Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 153-168.	2.0	36
11749	Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1769-1777.	1.1	25

#	ARTICLE	IF	CITATIONS
11750	circRNA-miRNA-mRNA regulatory network in human lung cancer: an update. <i>Cancer Cell International</i> , 2020, 20, 173.	1.8	136
11751	Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review. <i>Translational Lung Cancer Research</i> , 2020, 9, 379-388.	1.3	4
11752	Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer. <i>Lung Cancer Management</i> , 2020, 9, LMT31.	1.5	19
11753	Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. <i>Human Cell</i> , 2020, 33, 1099-1111.	1.2	9
11754	RADIANCE â€“ Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 43-49.	0.9	16
11755	Circular RNA ABCB10 promotes non-small cell lung cancer progression by increasing E2F5 expression through sponging miR-584-5p. <i>Cell Cycle</i> , 2020, 19, 1611-1620.	1.3	24
11756	Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092203.	1.4	26
11757	Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2020, 9, 401-405.	1.3	1
11758	Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. <i>Western Journal of Emergency Medicine</i> , 2020, 21, 566-580.	0.6	13
11759	Intervention strategies for microbial therapeutics in cancer immunotherapy. <i>Immuno-Oncology Technology</i> , 2020, 6, 9-17.	0.2	8
11760	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	10.6	2,160
11761	Expression and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder squamous cell carcinoma. <i>Translational Andrology and Urology</i> , 2020, 9, 428-436.	0.6	6
11762	The KEY for chemo-immunotherapy combination: taking NOTEs from squamous cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 410-413.	1.3	0
11763	PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors. <i>Cancers</i> , 2020, 12, 1257.	1.7	8
11764	Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. <i>Diagnostics</i> , 2020, 10, 310.	1.3	38
11765	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , 2020, 12, 1125.	1.7	43
11766	Predictive value of hypoxia, metabolism and immune factors for prognosis in hepatocellular carcinoma: a retrospective analysis and multicenter validation study. <i>Journal of Cancer</i> , 2020, 11, 4145-4156.	1.2	4
11767	Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 2827-2837.	3.2	86

#	ARTICLE	IF	CITATIONS
11768	Surgery for Unresectable Stage IIIc and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176.	1.7	11
11769	Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. <i>British Journal of Cancer</i> , 2020, 123, 92-100.	2.9	10
11770	Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. <i>Oncologist</i> , 2020, 25, 696-701.	1.9	73
11771	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. <i>Oncologist</i> , 2020, 25, 702-711.	1.9	17
11772	Cellular Plasticity in Breast Cancer Progression and Therapy. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 72.	1.6	37
11773	Tumor Necrosis Factor $\hat{\pm}$ Blockade: An Opportunity to Tackle Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 584.	1.3	96
11774	Permissive State of EMT: The Role of Immune Cell Compartment. <i>Frontiers in Oncology</i> , 2020, 10, 587.	1.3	19
11775	A Novel 4-gene Score to Predict Survival, Distant Metastasis and Response to Neoadjuvant Therapy in Breast Cancer. <i>Cancers</i> , 2020, 12, 1148.	1.7	46
11776	Hormone Receptor-Status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape. <i>Cancers</i> , 2020, 12, 1165.	1.7	4
11777	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1362.	1.0	102
11778	Rational Design of Polyglutamic Acid Delivering an Optimized Combination of Drugs Targeting Mutated BRAF and MEK in Melanoma. <i>Advanced Therapeutics</i> , 2020, 3, 2000028.	1.6	9
11779	High-dimensional analyses reveal a distinct role of T _H 17 cell subsets in the immune microenvironment of gastric cancer. <i>Clinical and Translational Immunology</i> , 2020, 9, e1127.	1.7	21
11781	Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. , 2020, 8, e000146.		49
11782	Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. <i>EMBO Molecular Medicine</i> , 2020, 12, e11571.	3.3	40
11783	Keynote 42: Pembrolizumab, PD-L1, and where to draw the line. <i>Annals of Translational Medicine</i> , 2020, 8, 517-517.	0.7	2
11784	Identification of a six-gene signature associated with tumor mutation burden for predicting prognosis in patients with invasive breast carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 453-453.	0.7	20
11785	The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab. <i>Journal of Thoracic Disease</i> , 2020, 12, 1520-1528.	0.6	52
11786	Opportunities for Conventional and In Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. <i>Cancers</i> , 2020, 12, 1121.	1.7	31

#	ARTICLE	IF	CITATIONS
11787	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 45.	2.2	175
11788	Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer. <i>PLoS ONE</i> , 2020, 15, e0233037.	1.1	17
11789	Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort. <i>Annals of Translational Medicine</i> , 2020, 8, 446-446.	0.7	16
11790	Breast Cancer Health Disparities in Hispanics/Latinas. <i>Current Breast Cancer Reports</i> , 2020, 12, 175-184.	0.5	10
11791	FOXC1-induced LINC01123 acts as a mediator in triple negative breast cancer. <i>Cancer Cell International</i> , 2020, 20, 199.	1.8	6
11792	LncRNA H19 promotes triple-negative breast cancer cells invasion and metastasis through the p53/TNFAIP8 pathway. <i>Cancer Cell International</i> , 2020, 20, 200.	1.8	40
11793	ETS1 Suppresses Tumorigenesis of Human Breast Cancer via Trans-Activation of Canonical Tumor Suppressor Genes. <i>Frontiers in Oncology</i> , 2020, 10, 642.	1.3	15
11794	PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake. <i>Frontiers in Pharmacology</i> , 2020, 11, 722.	1.6	65
11795	Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes. <i>Cancers</i> , 2020, 12, 1386.	1.7	29
11796	SAP interacts with CD28 to inhibit PD-1 signaling in T lymphocytes. <i>Clinical Immunology</i> , 2020, 217, 108485.	1.4	9
11797	Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer. <i>Medicine (United Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50</i>	0.4	6
11798	Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 611.	1.3	6
11799	Acquired Resistance to Immune Checkpoint Blockade Therapies. <i>Cancers</i> , 2020, 12, 1161.	1.7	9
11800	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , 2020, 12, 1196.	1.7	65
11801	The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors. <i>PLoS ONE</i> , 2020, 15, e0231999.	1.1	36
11802	Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant. <i>PLoS ONE</i> , 2020, 15, e0232545.	1.1	19
11803	Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. <i>Oncologist</i> , 2020, 25, e1481-e1491.	1.9	92
11804	<p>Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3319-3324.	1.0	15

#	ARTICLE	IF	CITATIONS
11805	Identification and Analysis of Dysfunctional Genes and Pathways in CD8+ T Cells of Non-Small Cell Lung Cancer Based on RNA Sequencing. <i>Frontiers in Genetics</i> , 2020, 11, 352.	1.1	6
11806	Measuring Efficiency of Semi-automated Brain Tumor Segmentation by Simulating User Interaction. <i>Frontiers in Computational Neuroscience</i> , 2020, 14, 32.	1.2	6
11807	Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 507.	1.3	6
11808	Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses. <i>Frontiers in Oncology</i> , 2020, 10, 515.	1.3	20
11809	Tumor-infiltrating Leukocytes Suppress Local Inflammation Via Interleukin-1 Receptor Antagonist in a Syngeneic Prostate Cancer Model. <i>Biology</i> , 2020, 9, 67.	1.3	2
11810	Evaluation of Anti-Tumor Effects of Whole-Body Low-Dose Irradiation in Metastatic Mouse Models. <i>Cancers</i> , 2020, 12, 1126.	1.7	4
11811	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. <i>Cancers</i> , 2020, 12, 1153.	1.7	4
11812	HIP1R Expression and Its Association with PD-1 Pathway Blockade Response in Refractory Advanced NonSmall Cell Lung Cancer: A Gene Set Enrichment Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1425.	1.0	6
11813	The Prognostic Value of Neutrophil-to-lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Metastatic Gastric Cancer Treated with Systemic Chemotherapy. <i>Journal of Cancer</i> , 2020, 11, 4205-4212.	1.2	25
11814	Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2198-2207.	2.9	21
11815	18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. <i>Cancer Imaging</i> , 2020, 20, 36.	1.2	46
11816	The neutrophil-to-lymphocyte ratio is a predictive factor for the survival of patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <i>Annals of Translational Medicine</i> , 2020, 8, 541-541.	0.7	18
11817	Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis. <i>Frontiers in Medicine</i> , 2020, 7, 144.	1.2	15
11818	Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 603.	1.3	26
11819	Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization. <i>Cancers</i> , 2020, 12, 1114.	1.7	34
11820	Molecular imaging for cancer immunotherapy. <i>Immuno-Oncology Technology</i> , 2020, 5, 10-21.	0.2	15
11821	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
11822	Relationship between IL-10 and PD-L1 in esophageal carcinoma tissues and IL-10 down-regulates PD-L1 expression via Met signaling pathway. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 337-355.	0.6	9

#	ARTICLE	IF	CITATIONS
11823	PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 1385-1392.	0.6	12
11824	Immune checkpoint inhibitor-related dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1255-1268.	0.6	221
11825	An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-4.	0.2	3
11826	A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092202.	1.4	8
11827	Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 214.	1.8	23
11828	Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma. <i>Experimental Hematology and Oncology</i> , 2020, 9, 10.	2.0	48
11829	Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies. <i>Cancers</i> , 2020, 12, 1364.	1.7	19
11830	Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters. <i>Cancers</i> , 2020, 12, 1373.	1.7	24
11831	Regulation of sister chromatid cohesion by nuclear PD-L1. <i>Cell Research</i> , 2020, 30, 590-601.	5.7	58
11832	Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. , 2020, 8, e000898.		3
11833	The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	8
11834	<p>Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3547-3560.	0.9	13
11835	Squamous cell anal cancer: Management and therapeutic options. <i>Annals of Medicine and Surgery</i> , 2020, 55, 36-46.	0.5	30
11836	Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 895-901.	2.8	18
11837	Nanomedicine-based immunotherapy for central nervous system disorders. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 936-953.	2.8	38
11838	Discovery of the PTEN Tumor Suppressor and Its Connection to the PI3K and AKT Oncogenes. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036129.	2.9	30
11839	Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	64
11840	A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab. , 2020, 8, e000380.		9

#	ARTICLE	IF	CITATIONS
11841	The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea. <i>BMC Public Health</i> , 2020, 20, 797.	1.2	4
11842	Patient-derived xenografts as compatible models for precision oncology. <i>Laboratory Animal Research</i> , 2020, 36, 14.	1.1	34
11843	The genomic landscape of metastasis in treatment-naïve breast cancer models. <i>PLoS Genetics</i> , 2020, 16, e1008743.	1.5	17
11844	Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 570.	1.3	127
11845	Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience. <i>Cancers</i> , 2020, 12, 1306.	1.7	0
11846	Relapse-Free Survival and PD-L1 Expression in First High- and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo- and Immunotherapy. <i>Cancers</i> , 2020, 12, 1316.	1.7	4
11847	Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer. <i>Cancers</i> , 2020, 12, 1317.	1.7	11
11848	PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity. <i>Bone Marrow Transplantation</i> , 2020, 55, 2308-2318.	1.3	12
11849	A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092682.	1.4	28
11850	The expression profiles and prognostic values of HSPs family members in Head and neck cancer. <i>Cancer Cell International</i> , 2020, 20, 220.	1.8	40
11851	Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 74.	6.9	17
11852	Triple-negative breast cancer molecular subtyping and treatment progress. <i>Breast Cancer Research</i> , 2020, 22, 61.	2.2	1,022
11853	Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 63.	2.2	8
11854	<p><p>Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3477-3487.	0.9	40
11855	Identification of Potential Key Genes Associated With the Pathogenesis, Metastasis, and Prognosis of Triple-Negative Breast Cancer on the Basis of Integrated Bioinformatics Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 856.	1.3	5
11856	Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers. <i>Frontiers in Veterinary Science</i> , 2020, 7, 330.	0.9	13
11857	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. <i>Cancers</i> , 2020, 12, 1502.	1.7	145
11858	Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer. <i>Pharmaceutics</i> , 2020, 12, 524.	2.0	22

#	ARTICLE	IF	CITATIONS
11859	Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma. <i>Case Reports in Oncology</i> , 2020, 13, 508-514.	0.3	15
11860	Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells. <i>PLoS ONE</i> , 2020, 15, e0234146.	1.1	5
11861	Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 85-88.	0.9	21
11862	PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. <i>Nature Cancer</i> , 2020, 1, 681-691.	5.7	240
11863	Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093033.	1.4	25
11864	Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date. <i>Cancer Management and Research</i> , 2020, Volume 12, 4871-4881.	0.9	29
11865	Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5887-5899.	1.0	16
11866	Real-world outcomes of advanced melanoma patients not represented in phase III trials. <i>International Journal of Cancer</i> , 2020, 147, 3461-3470.	2.3	27
11867	PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3013-3023.	1.2	4
11868	Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092203.	1.4	42
11869	Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections. <i>Cancer Cell International</i> , 2020, 20, 186.	1.8	24
11870	TRPM4 is overexpressed in breast cancer associated with estrogen response and epithelial-mesenchymal transition gene sets. <i>PLoS ONE</i> , 2020, 15, e0233884.	1.1	25
11871	Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review. <i>Diagnostics</i> , 2020, 10, 359.	1.3	51
11872	High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma. <i>Journal of Cancer</i> , 2020, 11, 4442-4452.	1.2	18
11873	Downexpression of HSD17B6 correlates with clinical prognosis and tumor immune infiltrates in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2020, 20, 210.	1.8	17
11874	Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1. <i>Journal of Translational Medicine</i> , 2020, 18, 220.	1.8	20
11875	Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics. <i>Investigational New Drugs</i> , 2020, 38, 1717-1729.	1.2	1
11876	Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. <i>Modern Pathology</i> , 2020, 33, 2473-2482.	2.9	29

#	ARTICLE	IF	CITATIONS
11877	Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex. <i>PLoS ONE</i> , 2020, 15, e0233578.	1.1	23
11878	<p>The Association Between Immune Characteristic and Clinical Pathology in Chinese Patients with Adenocarcinoma of Esophagogastric Junction</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3259-3269.	0.9	7
11879	Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 763.	1.3	32
11880	<p>Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4021-4034.	1.0	5
11881	Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients. <i>Medicine (United States)</i> , 2020, 99, e20545.	0.4	18
11882	Physical activity delays accumulation of immunosuppressive myeloid-derived suppressor cells. <i>PLoS ONE</i> , 2020, 15, e0234548.	1.1	20
11883	Finding the hot spot: identifying immune sensitive gastrointestinal tumors. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 48-48.	1.5	6
11884	Neutrophil Extracellular Traps (NETs) Promote Pro-Metastatic Phenotype in Human Breast Cancer Cells through Epithelialâ€Mesenchymal Transition. <i>Cancers</i> , 2020, 12, 1542.	1.7	77
11885	Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1769.	1.0	25
11886	Surface-Enhanced Raman Spectroscopy for Cancer Immunotherapy Applications: Opportunities, Challenges, and Current Progress in Nanomaterial Strategies. <i>Nanomaterials</i> , 2020, 10, 1145.	1.9	21
11887	Immune microenvironment composition in nonâ€small cell lung cancer and its association with survival. <i>Clinical and Translational Immunology</i> , 2020, 9, e1142.	1.7	119
11888	Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. <i>Kidney International Reports</i> , 2020, 5, 1139-1148.	0.4	71
11889	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	3.2	43
11890	Nonâ€Small Cell Lung Cancer Patient Preferences for First-Line Treatment: A Discrete Choice Experiment. <i>MDM Policy and Practice</i> , 2020, 5, 238146832092220.	0.5	2
11891	Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4325.	1.8	84
11892	Non-Invasive Assessment of Breast Cancer Molecular Subtypes with Multiparametric Magnetic Resonance Imaging Radiomics. <i>Journal of Clinical Medicine</i> , 2020, 9, 1853.	1.0	57
11893	Radiation Dose Escalation Is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance Local and Distant Antitumor Effect in Murine Osteosarcoma. <i>Cancers</i> , 2020, 12, 1546.	1.7	12
11894	Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 1559.	1.7	13

#	ARTICLE	IF	CITATIONS
11895	Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma. <i>Diagnostics</i> , 2020, 10, 394.	1.3	4
11896	A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer. <i>ERJ Open Research</i> , 2020, 6, 00174-2019.	1.1	3
11897	Near Infrared Light Triggered Photo/Immuno-Therapy Toward Cancers. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 488.	2.0	54
11898	Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 1414.	1.7	15
11899	PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 83-87.	0.9	7
11900	Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. , 2020, 8, e000451.		39
11901	Immunecheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-5.	0.2	3
11902	<p>Î²-Element Enhances the Chemotherapeutic Effect of 5-Fluorouracil in Triple-Negative Breast Cancer via PI3K/AKT, RAF-MEK-Erk, and NF-ÎB Signaling Pathways<p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5207-5222.	1.0	23
11903	Melanoma brain metastases: review of histopathological features and immune-molecular aspects. <i>Melanoma Management</i> , 2020, 7, MMT44.	0.1	8
11904	The Cancer-Immune Set Point in Oesophageal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 891.	1.3	15
11905	Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1721.	1.0	43
11906	Integrating Biology and Access to Care in Addressing Breast Cancer Disparities: 25 Yearsâ€™ Research Experience in the Carolina Breast Cancer Study. <i>Current Breast Cancer Reports</i> , 2020, 12, 149-160.	0.5	4
11907	Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 14331-14341.	3.3	55
11908	Reprogramming of tumor-associated macrophages by targeting Î²-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer. <i>Science Advances</i> , 2020, 6, eaaz6105.	4.7	110
11909	Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features. <i>Breast Care</i> , 2020, 15, 208-216.	0.8	6
11910	Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 280.	1.8	28
11911	Beyond the Variants: Mutational Patterns in Next-Generation Sequencing Data for Cancer Precision Medicine. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 370.	1.8	6
11912	The top 100 cited articles in lung cancer â€™ a bibliometric analysis. <i>Wspolczesna Onkologia</i> , 2020, 24, 17-28.	0.7	7

#	ARTICLE	IF	CITATIONS
11913	The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 1226-1239.	7.7	32
11914	ALDH1+ stem cells demonstrate more stem cell-like characteristics than CD44+/CD24 ^{low} stem cells in different molecular subtypes of breast cancer. <i>Translational Cancer Research</i> , 2020, 9, 1652-1659.	0.4	2
11915	Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 402.	1.8	67
11916	Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 689.	1.3	2
11917	Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients. <i>Frontiers in Oncology</i> , 2020, 10, 749.	1.3	11
11918	Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 757.	1.3	11
11919	Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28. <i>Frontiers in Oncology</i> , 2020, 10, 760.	1.3	33
11920	Dysregulated m6A-Related Regulators Are Associated With Tumor Metastasis and Poor Prognosis in Osteosarcoma. <i>Frontiers in Oncology</i> , 2020, 10, 769.	1.3	61
11921	Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma. <i>Frontiers in Oncology</i> , 2020, 10, 777.	1.3	6
11922	Development and Validation of a 12-Gene Immune Relevant Prognostic Signature for Lung Adenocarcinoma Through Machine Learning Strategies. <i>Frontiers in Oncology</i> , 2020, 10, 835.	1.3	14
11923	Multi-Omic Regulation of the PAM50 Gene Signature in Breast Cancer Molecular Subtypes. <i>Frontiers in Oncology</i> , 2020, 10, 845.	1.3	15
11924	Targeting Autophagy Facilitates T Lymphocyte Migration by Inducing the Expression of CXCL10 in Gastric Cancer Cell Lines. <i>Frontiers in Oncology</i> , 2020, 10, 886.	1.3	4
11925	The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 899.	1.3	44
11926	Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan. <i>Frontiers in Oncology</i> , 2020, 10, 905.	1.3	14
11927	Insights into the Role of Estrogen Receptor β in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 1477.	1.7	33
11928	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1039.	3.4	70
11929	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 47-68.	3.1	93
11930	Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. <i>Cancer Cell</i> , 2020, 38, 79-96.e11.	7.7	389

#	ARTICLE	IF	CITATIONS
11931	Noncoding RNAs: the shot callers in tumor immune escape. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 102.	7.1	37
11932	Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Thoracic Disease</i> , 2020, 12, 2859-2876.	0.6	11
11933	RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells. <i>Journal of Cellular Physiology</i> , 2020, 235, 7261-7272.	2.0	34
11934	The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. <i>British Journal of Cancer</i> , 2020, 122, 1496-1506.	2.9	26
11935	A mixed-model approach for powerful testing of genetic associations with cancer risk incorporating tumor characteristics. <i>Biostatistics</i> , 2020, 22, 772-788.	0.9	11
11936	The different benefits and side effects of nivolumab combined with ipilimumab in diverse cancer. <i>Medicine (United States)</i> , 2020, 99, e19367.	0.4	4
11937	MSIsensor-pro: Fast, Accurate, and Matched-normal-sample-free Detection of Microsatellite Instability. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 65-71.	3.0	53
11938	Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. <i>Nature Reviews Urology</i> , 2020, 17, 271-291.	1.9	32
11939	Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System. <i>Frontiers in Oncology</i> , 2020, 10, 132.	1.3	19
11940	The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 261.	1.3	11
11941	Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 666.	1.7	24
11942	Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer. <i>Medical Oncology</i> , 2020, 37, 30.	1.2	11
11943	Human T cell glycosylation and implications on immune therapy for cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2374-2388.	1.4	22
11944	Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1446-1461.	0.6	25
11945	The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology. <i>BMC Biology</i> , 2020, 18, 29.	1.7	6
11946	CANcer bioMarker Prediction Pipeline (CAMPP) – A standardized framework for the analysis of quantitative biological data. <i>PLoS Computational Biology</i> , 2020, 16, e1007665.	1.5	10
11947	Clinical implications of APOBEC3A and 3B expression in patients with breast cancer. <i>PLoS ONE</i> , 2020, 15, e0230261.	1.1	10
11948	Impaired Anti-Tumor T cell Response in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 627.	1.7	22

#	ARTICLE	IF	CITATIONS
11949	Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells. <i>Cancers</i> , 2020, 12, 673.	1.7	24
11950	Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours. <i>Cancers</i> , 2020, 12, 683.	1.7	34
11951	The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1960.	1.8	270
11952	12—Chemokine signature, a predictor of tumor recurrence in colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 532-541.	2.3	39
11953	Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. <i>BMC Cancer</i> , 2020, 20, 230.	1.1	24
11954	Viral Vector-Based Melanoma Gene Therapy. <i>Biomedicines</i> , 2020, 8, 60.	1.4	16
11955	Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. <i>Biomedicines</i> , 2020, 8, 61.	1.4	36
11956	Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	10
11957	—The same old story—: thoughts on authorized doses of anticancer drugs. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090541.	1.4	5
11958	Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 13-24.	0.7	11
11959	Integrative analysis of mRNA, miRNA and lncRNA profiles reveals the commonness between bladder cancer and breast cancer. <i>Translational Cancer Research</i> , 2020, 9, 1070-1090.	0.4	2
11960	Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method. <i>Translational Lung Cancer Research</i> , 2020, 9, 71-81.	1.3	9
11961	Calcium Homeostasis: A Potential Vicious Cycle of Bone Metastasis in Breast Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 293.	1.3	25
11962	Immunotherapy, Inflammation and Colorectal Cancer. <i>Cells</i> , 2020, 9, 618.	1.8	167
11963	Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 168.	1.3	22
11964	Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	46
11965	Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 155.	1.8	32
11966	Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6640-6650.	3.3	141

#	ARTICLE	IF	CITATIONS
11967	Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor. <i>Medicine (United States)</i> , 2020, 99, e19440.	0.4	3
11968	<p>High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1757-1765.	1.0	8
11969	<p>Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1751-1756.	1.0	9
11970	Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. <i>Pharmaceutical Medicine</i> , 2020, 34, 83-91.	1.0	9
11971	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β 2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222.	0.5	119
11972	Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients. <i>Leukemia</i> , 2020, 34, 2607-2620.	3.3	31
11973	Neurologic complications of immune checkpoint inhibitors. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 479-488.	1.0	82
11974	AXL as a Target in Breast Cancer Therapy. <i>Journal of Oncology</i> , 2020, 2020, 1-15.	0.6	55
11975	Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors. <i>PLoS ONE</i> , 2020, 15, e0229206.	1.1	21
11976	The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review. <i>Cancers</i> , 2020, 12, 586.	1.7	48
11977	Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1658.	1.8	22
11978	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	1.0	57
11979	Pulmonary Administration: Strengthening the Value of Therapeutic Proximity. <i>Frontiers in Medicine</i> , 2020, 7, 50.	1.2	11
11980	Primary pulmonary lymphoepithelioma-like carcinoma. <i>Medical Oncology</i> , 2020, 37, 20.	1.2	7
11981	Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. <i>Genes and Diseases</i> , 2020, 7, 359-369.	1.5	40
11982	4D blood flow model for dose calculation to circulating blood and lymphocytes. <i>Physics in Medicine and Biology</i> , 2020, 65, 055008.	1.6	25
11983	Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database. <i>Frontiers in Medicine</i> , 2020, 7, 64.	1.2	53
11984	Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 197.	1.3	9

#	ARTICLE	IF	CITATIONS
11985	Emerging Role of Circulating Tumor Cells in Gastric Cancer. <i>Cancers</i> , 2020, 12, 695.	1.7	30
11986	MicroRNAs in Cancer Treatment-Induced Cardiotoxicity. <i>Cancers</i> , 2020, 12, 704.	1.7	26
11987	Primary CNS lymphoma commonly expresses immune response biomarkers. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa018.	0.4	24
11988	A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 55-60.	1.3	18
11989	NK cells mediate clearance of CD8 ⁺ T cell-resistant tumors in response to STING agonists. <i>Science Immunology</i> , 2020, 5, .	5.6	128
11990	Case of small bowel perforation secondary to nivolumab and ipilimumab related tumour regression. <i>BMJ Case Reports</i> , 2020, 13, e232304.	0.2	4
11991	Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. <i>Frontiers in Medicine</i> , 2020, 7, 90.	1.2	31
11992	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 111-138.	1.3	27
11993	KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 148-153.	1.3	5
11994	Liver Transplantation for Pediatric Liver Cancer. <i>Cancers</i> , 2020, 12, 720.	1.7	22
11995	The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells. <i>Cancers</i> , 2020, 12, 727.	1.7	52
11996	DNA Repair Biomarker for Lung Cancer Risk and its Correlation With Airway Cells Gene Expression. <i>JNCI Cancer Spectrum</i> , 2020, 4, plz067.	1.4	10
11997	Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. <i>Current Oncology Reports</i> , 2020, 22, 39.	1.8	199
11998	Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. <i>Journal of Pancreatic Cancer</i> , 2020, 6, 21-31.	1.6	31
11999	Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-6.	0.2	8
12000	Immunotherapy: Newer Therapeutic Armamentarium against Cancer Stem Cells. <i>Journal of Oncology</i> , 2020, 2020, 1-15.	0.6	11
12001	Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090909.	1.4	14
12002	Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3. <i>Annals of Translational Medicine</i> , 2020, 8, 172-172.	0.7	8

#	ARTICLE	IF	CITATIONS
12003	<p></p>Novel Alternatively Spliced Variants of Smad4 Expressed in TGF-β2-Induced EMT Regulating Proliferation and Migration of A549 Cells<p></p>. OncoTargets and Therapy, 2020, Volume 13, 2203-2213.	1.0	10
12004	A New World of Biomarkers and Therapeutics for Female Reproductive System and Breast Cancers: Circular RNAs. Frontiers in Cell and Developmental Biology, 2020, 8, 50.	1.8	48
12005	Pre-existing heterologous T cell immunity and neoantigen immunogenicity. Clinical and Translational Immunology, 2020, 9, e01111.	1.7	26
12006	Suppression of age-related salivary gland autoimmunity by glycosylation-dependent galectin-1-driven immune inhibitory circuits. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6630-6639.	3.3	37
12007	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Medical Sciences (Basel, Switzerland), 2020, 8, 18.	1.3	72
12008	Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. Genes and Diseases, 2020, 7, 320-327.	1.5	10
12009	<p></p>Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma<p></p>. OncoTargets and Therapy, 2020, Volume 13, 2289-2298.	1.0	21
12010	Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. Cancers, 2020, 12, 767.	1.7	2
12011	<p></p>A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia<p></p>. Drug Design, Development and Therapy, 2020, Volume 14, 1177-1189.	2.0	21
12012	T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?. Frontiers in Oncology, 2020, 10, 382.	1.3	22
12013	Intra-Tumoral Delivery of IL-27 Using Adeno-Associated Virus Stimulates Anti-tumor Immunity and Enhances the Efficacy of Immunotherapy. Frontiers in Cell and Developmental Biology, 2020, 8, 210.	1.8	16
12014	Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nature Reviews Cardiology, 2020, 17, 474-502.	6.1	332
12015	Bilateral murine tumor models for characterizing the response to immune checkpoint blockade. Nature Protocols, 2020, 15, 1628-1648.	5.5	19
12016	Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. Immune Network, 2020, 20, e9.	1.6	143
12017	A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol. BMC Cancer, 2020, 20, 198.	1.1	25
12018	Mutational landscape differences between young-onset and older-onset breast cancer patients. BMC Cancer, 2020, 20, 212.	1.1	11
12019	Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors. BMC Cancer, 2020, 20, 207.	1.1	26
12020	<p></p>Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors<p></p>. OncoTargets and Therapy, 2020, Volume 13, 719-731.	1.0	11

#	ARTICLE	IF	CITATIONS
12021	Ductal Carcinoma In Situ of the Breast: An Update with Emphasis on Radiological and Morphological Features as Predictive Prognostic Factors. <i>Cancers</i> , 2020, 12, 609.	1.7	28
12022	Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models. <i>Cancers</i> , 2020, 12, 636.	1.7	40
12023	Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. <i>Diagnostics</i> , 2020, 10, 146.	1.3	56
12024	Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 725.	1.0	46
12025	Unanticipated Myocarditis in a Surgical Patient Treated With Pembrolizumab: A Case Report. <i>A&A Practice</i> , 2020, 14, e01177.	0.2	8
12026	Tumor-Associated Macrophages: Recent Insights and Therapies. <i>Frontiers in Oncology</i> , 2020, 10, 188.	1.3	401
12027	The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 300.	1.3	26
12028	Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report. <i>Case Reports in Oncology</i> , 2020, 13, 43-48.	0.3	7
12029	Rapidly Progressive Acute Kidney Injury Associated with Nivolumab Treatment. <i>Case Reports in Oncology</i> , 2020, 13, 85-90.	0.3	9
12030	A Pan-Cancer and Polygenic Bayesian Hierarchical Model for the Effect of Somatic Mutations on Survival. <i>Cancer Informatics</i> , 2020, 19, 117693512090739.	0.9	2
12031	<p></p>FTO Facilitates Lung Adenocarcinoma Cell Progression by Activating Cell Migration Through mRNA Demethylation</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1461-1470.	1.0	41
12032	<p></p>Demethylation of the Cosmc Promoter Alleviates the Progression of Breast Cancer Through Downregulation of the Tn and Sialyl-Tn Antigens</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1017-1027.	0.9	8
12033	PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old. <i>In Vivo</i> , 2020, 34, 639-647.	0.6	18
12034	Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 141.	2.0	35
12035	Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study. <i>Frontiers in Oncology</i> , 2020, 10, 70.	1.3	28
12036	Targeting Metabolic Deregulation Landscapes in Breast Cancer Subtypes. <i>Frontiers in Oncology</i> , 2020, 10, 97.	1.3	20
12037	Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 142.	1.3	37
12038	Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 268.	1.3	68

#	ARTICLE	IF	CITATIONS
12039	Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 40.	1.6	31
12040	MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma. <i>Cancers</i> , 2020, 12, 540.	1.7	55
12041	Determinants of Resistance to Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1594.	1.8	39
12042	Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review. <i>Pharmaceutics</i> , 2020, 12, 153.	2.0	4
12043	Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to MDA-MB231 cells. <i>Turkish Journal of Biology</i> , 2020, 44, 15-23.	2.1	10
12044	The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age. <i>Seminars in Nephrology</i> , 2020, 40, 28-41.	0.6	42
12045	Cardiovascular immune-related adverse events: Evaluation, diagnosis and management. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 232-240.	0.7	16
12046	Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. <i>Science Advances</i> , 2020, 6, eaaz4204.	4.7	136
12047	Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2020, 20, 179.	1.1	119
12048	Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications. <i>Frontiers in Oncology</i> , 2020, 10, 137.	1.3	53
12049	A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5129-5139.	3.2	67
12050	<p>Analysis of Patient Preferences in Lung Cancer â€“ Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 927-937.	0.8	39
12051	Effects of CORO2A on Cell Migration and Proliferation and Its Potential Regulatory Network in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 916.	1.3	9
12052	Good Cop, Bad Cop: Defining the Roles of p53 in Cancer and Aging. <i>Cancers</i> , 2020, 12, 1659.	1.7	22
12053	Gastric Cancer Tumor Microenvironment Characterization Reveals Stromal-Related Gene Signatures Associated With Macrophage Infiltration. <i>Frontiers in Genetics</i> , 2020, 11, 663.	1.1	31
12054	Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 913.	1.3	29
12055	Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1023.	1.3	22
12056	Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 1685.	1.7	10

#	ARTICLE	IF	CITATIONS
12057	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2221-2232.	2.9	23
12058	The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. <i>Experimental Hematology and Oncology</i> , 2020, 9, 9.	2.0	9
12059	Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers. <i>JCO Precision Oncology</i> , 2020, 4, 767-779.	1.5	23
12060	Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 592.	2.0	23
12061	Expression of ncRNAs on the DLK1-DIO3 Locus Is Associated With Basal and Mesenchymal Phenotype in Breast Epithelial Progenitor Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 461.	1.8	14
12062	Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 951.	1.3	35
12063	Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥ 2.0 and an Average HER2 Gene Copy Number ≤ 4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event. <i>Frontiers in Oncology</i> , 2020, 10, 985.	1.3	3
12064	Metabolic Adaptations in Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2020, 10, 1010.	1.3	100
12065	PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1015.	1.3	48
12066	Toward Systems Biomarkers of Response to Immune Checkpoint Blockers. <i>Frontiers in Oncology</i> , 2020, 10, 1027.	1.3	16
12067	Integrative Network Fusion: A Multi-Omics Approach in Molecular Profiling. <i>Frontiers in Oncology</i> , 2020, 10, 1065.	1.3	30
12068	Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092958.	1.4	1
12069	Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration. <i>Breast Cancer Research</i> , 2020, 22, 73.	2.2	29
12070	Role of DNA repair defects in predicting immunotherapy response. <i>Biomarker Research</i> , 2020, 8, 23.	2.8	47
12071	Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review. <i>Cancer Management and Research</i> , 2020, Volume 12, 4503-4518.	0.9	5
12072	Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges. <i>Cancers</i> , 2020, 12, 1699.	1.7	27
12073	Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020. <i>Kidney360</i> , 2020, 1, 130-140.	0.9	62
12074	Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers. <i>Modern Pathology</i> , 2020, 33, 2422-2436.	2.9	15

#	ARTICLE	IF	CITATIONS
12075	Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 2896-2909.	0.6	5
12076	The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 3231-3241.	0.4	5
12077	<p>Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6109-6129.	1.0	54
12078	<p>Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5191-5198.	1.0	3
12079	Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. <i>Nanomaterials</i> , 2020, 10, 1274.	1.9	26
12080	CMV coinfection in treatment refractory immune checkpoint inhibitor colitis. <i>BMJ Case Reports</i> , 2020, 13, e233519.	0.2	4
12081	Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoing 18F-FDG-PET/CT: a comparison with serologic markers of tumor burden and inflammation. <i>Cancer Imaging</i> , 2020, 20, 44.	1.2	13
12082	Plasma Level of Circular RNA hsa_circ_0000190 Correlates with Tumor Progression and Poor Treatment Response in Advanced Lung Cancers. <i>Cancers</i> , 2020, 12, 1740.	1.7	45
12083	Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1761.	1.7	8
12084	Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1763.	1.7	17
12085	Immunotherapy in Prostate Cancer. <i>Cancers</i> , 2020, 12, 1752.	1.7	58
12086	Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer. <i>Cancers</i> , 2020, 12, 1755.	1.7	37
12087	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 1757.	1.7	17
12088	Coronavirus infection and immune system: An insight of COVID-19 in cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103059.	2.0	29
12089	Immunotherapy discontinuation â€” how, and when? Data from melanoma as a paradigm. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 707-715.	12.5	57
12090	Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model. <i>Neuro-Oncology Advances</i> , 2020, 2, vdz058.	0.4	12
12091	Insights Into the Albinism Mechanism for Two Distinct Color Morphs of Northern Snakehead, <i>Channa argus</i> Through Histological and Transcriptome Analyses. <i>Frontiers in Genetics</i> , 2020, 11, 830.	1.1	3
12092	Harnessing NK Cell Checkpoint-Modulating Immunotherapies. <i>Cancers</i> , 2020, 12, 1807.	1.7	17

#	ARTICLE	IF	CITATIONS
12093	Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. <i>Immune Network</i> , 2020, 20, e10.	1.6	86
12094	Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location. <i>Oncology and Therapy</i> , 2020, 8, 59-66.	1.0	4
12095	Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy. <i>Cancers</i> , 2020, 12, 1609.	1.7	27
12096	PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer. <i>Vaccines</i> , 2020, 8, 317.	2.1	17
12097	High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. <i>Science Advances</i> , 2020, 6, eaba5542.	4.7	48
12098	MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy. , 2020, 8, e000328.		25
12099	Fluoropyrimidine Modulation of the Anti-Tumor Immune Response—Prospects for Improved Colorectal Cancer Treatment. <i>Cancers</i> , 2020, 12, 1641.	1.7	22
12100	Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process. <i>Cancers</i> , 2020, 12, 1660.	1.7	29
12101	<p>Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4161-4168.	0.9	17
12102	How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 972.	1.6	26
12103	Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1663.	1.7	112
12104	Anti-PDL1 effect in squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 406-409.	1.3	2
12105	Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. <i>Hepatic Oncology</i> , 2020, 7, HEP20.	4.2	30
12106	Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets. <i>Cancers</i> , 2020, 12, 1826.	1.7	46
12107	Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis. <i>Cancers</i> , 2020, 12, 1828.	1.7	1
12108	Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry. <i>Immuno-Oncology Technology</i> , 2020, 6, 2-8.	0.2	26
12109	Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100017.	0.6	0
12110	PD-1 IC Inhibition Synergistically Improves Influenza A Virus-Mediated Oncolysis of Metastatic Pulmonary Melanoma. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 190-204.	2.0	7

#	ARTICLE	IF	CITATIONS
12111	Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response. <i>Clinical and Translational Immunology</i> , 2020, 9, e1145.	1.7	7
12112	Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 532-557.	1.8	67
12113	Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF-V600</i> mutations. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092521.	1.4	31
12114	<p>PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4999-5008.	0.9	7
12115	Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy. <i>Immune Network</i> , 2020, 20, e4.	1.6	75
12116	ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 269.	1.8	26
12117	Is there hope in improving 5-year overall survival?â€”review of 5-year overall survival data from KEYNOTE-001. <i>Annals of Translational Medicine</i> , 2020, 8, 728-728.	0.7	0
12118	Matching cell lines with cancer type and subtype of origin via mutational, epigenomic, and transcriptomic patterns. <i>Science Advances</i> , 2020, 6, .	4.7	53
12119	Evaluation of Gene Expression Data From Cybrids and Tumours Highlights Elevated NDRG1-Driven Proliferation in Triple-Negative Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2020, 14, 117822342093444.	0.6	5
12120	Transgenic T-cell receptor immunotherapy for cancer: building on clinical success. , 2020, 8, 251513552093350.	1.4	10
12121	<p>Peripartum Blood Transfusions are Associated with Increased Risk of Cancer: A National Retrospective Cohort Study</p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 659-666.	1.5	2
12122	A DNA Methylation-Based Panel for the Prognosis and Diagnosis of Patients With Breast Cancer and Its Mechanisms. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 118.	1.6	11
12123	Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record. <i>Cancers</i> , 2020, 12, 1800.	1.7	12
12124	Acute Kidney Injury in Oncology Patients. <i>Journal of Cancer</i> , 2020, 11, 4700-4708.	1.2	6
12125	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa011.	0.4	22
12126	Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989575.	1.4	8
12127	<p>BTLA Expression in Stage Iâ€”III Nonâ€”Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 215-224.	1.0	38
12128	<p>Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 615-621.	1.0	7

#	ARTICLE	IF	CITATIONS
12129	Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 689-702.	2.0	16
12130	KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. <i>Cancer Treatment Reviews</i> , 2020, 85, 101978.	3.4	85
12131	A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with $\hat{\pm}$ Particle-Emitting Ultrasmall Silica Nanoparticles. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 459-473.	0.7	13
12132	Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. <i>Neuro-Oncology</i> , 2020, 22, 1359-1367.	0.6	49
12133	Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF- $\hat{\pm}$ B inhibitor for antitumor immunotherapy. <i>Science Advances</i> , 2020, 6, eaay7785.	4.7	95
12134	Improving prediction performance of colon cancer prognosis based on the integration of clinical and multi-omics data. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 22.	1.5	20
12135	Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. <i>Cancers</i> , 2020, 12, 344.	1.7	60
12136	Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. <i>Cancers</i> , 2020, 12, 361.	1.7	19
12137	Testing Differential Gene Networks under Nonparanormal Graphical Models with False Discovery Rate Control. <i>Genes</i> , 2020, 11, 167.	1.0	3
12138	Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. <i>Nature Cancer</i> , 2020, 1, 210-221.	5.7	138
12139	Integrative Transcriptomic Analysis Reveals a Multiphasic Epithelial $\hat{\pm}$ “Mesenchymal Spectrum in Cancer and Non-tumorigenic Cells. <i>Frontiers in Oncology</i> , 2019, 9, 1479.	1.3	28
12140	Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans. <i>Frontiers in Oncology</i> , 2019, 9, 1493.	1.3	51
12141	Reverting Immune Suppression to Enhance Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 1554.	1.3	49
12142	Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes. <i>BMC Cancer</i> , 2020, 20, 141.	1.1	18
12143	Cell Tracking in Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2020, 7, 34.	1.2	52
12144	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473.	1.7	72
12145	Combination Immune Checkpoint Blockade to Reverse HIV Latency. <i>Journal of Immunology</i> , 2020, 204, 1242-1254.	0.4	38
12146	Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 462.	1.7	57

#	ARTICLE	IF	CITATIONS
12147	Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer. <i>Advanced Science</i> , 2020, 7, 1903332.	5.6	66
12148	Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression. <i>BMC Cancer</i> , 2020, 20, 148.	1.1	5
12149	<p><p>Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer<p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 667-683.	1.0	24
12150	<p>Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non“Small Cell Lung Cancer: Emerging Mechanisms and Perspectives</p>. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 10, 161-170.	1.3	7
12151	Current Advances in the Treatment of BRAF-Mutant Melanoma. <i>Cancers</i> , 2020, 12, 482.	1.7	112
12152	PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1461.	1.8	25
12153	The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 519.	1.0	26
12154	Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1043-1056.	2.0	10
12155	Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. <i>Annals of Oncology</i> , 2020, 31, 599-608.	0.6	183
12156	Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens. <i>Communications Biology</i> , 2020, 3, 85.	2.0	36
12157	Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes. <i>PLoS Computational Biology</i> , 2020, 16, e1007701.	1.5	32
12158	Recent Progress of Potentiating Immune Checkpoint Blockade with External Stimuli“an Industry Perspective. <i>Advanced Science</i> , 2020, 7, 1903394.	5.6	40
12159	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 181-193.	1.0	2
12160	The Impact of Normalization Approaches to Automatically Detect Radiogenomic Phenotypes Characterizing Breast Cancer Receptors Status. <i>Cancers</i> , 2020, 12, 518.	1.7	38
12161	Pembrolizumab–axitinib–induced tumor lysis syndrome in a patient with metastatic renal cancer. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 704-708.	0.2	5
12162	Pembrolizumab for a patient with metastatic castration–resistant prostate cancer with microsatellite instability–high. <i>IJU Case Reports</i> , 2020, 3, 62-64.	0.1	5
12163	The promise of immunotherapy in the treatment of young adults with oral tongue cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2020, 5, 235-242.	0.6	4
12164	Modeling clear cell renal cell carcinoma and therapeutic implications. <i>Oncogene</i> , 2020, 39, 3413-3426.	2.6	86

#	ARTICLE	IF	CITATIONS
12165	Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. <i>OncolImmunology</i> , 2020, 9, 1708065.	2.1	41
12166	Oncolytic poxvirus CF33-hNIS- β 14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model. <i>OncolImmunology</i> , 2020, 9, 1729300.	2.1	29
12167	Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. <i>Medicine (United States)</i> , 2020, 99, e19059.	0.4	30
12168	Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 323-331.	1.9	12
12169	MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis. <i>Pharmacological Research</i> , 2020, 155, 104695.	3.1	29
12170	Revisiting Immunotherapy: A Focus on Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 1615-1623.	0.4	120
12171	EFMviz: A COBRA Toolbox Extension to Visualize Elementary Flux Modes in Genome-Scale Metabolic Models. <i>Metabolites</i> , 2020, 10, 66.	1.3	7
12172	Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression $\geq 50\%$. <i>Annals of Oncology</i> , 2020, 31, 404-411.	0.6	79
12173	Interfering MSN-NONO complex-activated CREB signaling serves as a therapeutic strategy for triple-negative breast cancer. <i>Science Advances</i> , 2020, 6, eaaw9960.	4.7	26
12174	PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas. <i>BMC Cancer</i> , 2020, 20, 127.	1.1	24
12175	Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. <i>Frontiers in Molecular Biosciences</i> , 2019, 6, 160.	1.6	596
12176	VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or Tj ETQq1 1 0.784314 rgrBT /Over	0.7	13
12177	Pediatric primary diffuse leptomenigeal melanomatosis. <i>Medicine (United States)</i> , 2020, 99, e19178.	0.4	11
12178	Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2020, 8, 506-517.	1.6	23
12179	Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation-Positive Lung Adenocarcinoma. <i>Tuberculosis and Respiratory Diseases</i> , 2020, 83, 51.	0.7	13
12180	Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 59-65.	0.4	13
12181	The clinical potential of gene editing as a tool to engineer cell-based therapeutics. <i>Clinical and Translational Medicine</i> , 2020, 9, 15.	1.7	56
12182	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. <i>Gastroenterology Report</i> , 2020, 8, 11-24.	0.6	68

#	ARTICLE	IF	CITATIONS
12183	HLA class I restricted epitopes prediction of common tumor antigens in white and East Asian populations: Implication on antigen selection for cancer vaccine design. <i>PLoS ONE</i> , 2020, 15, e0229327.	1.1	4
12184	<p>Activated Hepatic Stellate Cells (HSCs) Exert Immunosuppressive Effects in Hepatocellular Carcinoma by Producing Complement C3<p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1497-1505.	1.0	25
12185	Successful Conversion Surgery Following Chylous Ascites After Nivolumab for Advanced Gastric Cancer. <i>In Vivo</i> , 2020, 34, 583-585.	0.6	12
12186	Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 91.	1.3	112
12187	A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1047-1060.	5.7	50
12188	Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 717-730.	2.0	18
12189	BMP9 signaling promotes the normalization of tumor blood vessels. <i>Oncogene</i> , 2020, 39, 2996-3014.	2.6	27
12190	The Anticancer Effects of Atractylenolide III Associate With the Downregulation of Jak3/Stat3-Dependent IDO Expression. <i>Frontiers in Pharmacology</i> , 2019, 10, 1505.	1.6	15
12191	Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications. <i>Cancers</i> , 2020, 12, 371.	1.7	49
12192	Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer. <i>Cancers</i> , 2020, 12, 376.	1.7	52
12193	Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report. <i>Internal Medicine</i> , 2020, 59, 1105-1109.	0.3	6
12194	â€ˆOmics Approaches to Explore the Breast Cancer Landscape. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 395.	1.8	39
12195	Novel Immunomodulatory Proteins Generated via Directed Evolution of Variant IgSF Domains. <i>Frontiers in Immunology</i> , 2019, 10, 3086.	2.2	9
12196	Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies. <i>Cancers</i> , 2020, 12, 392.	1.7	47
12197	Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block. <i>Case Reports in Cardiology</i> , 2020, 2020, 1-5.	0.1	6
12198	Inhibition Mechanism of Indoleamine 2, 3-Dioxygenase 1 (IDO1) by Amidoxime Derivatives and Its Revelation in Drug Design: Comparative Molecular Dynamics Simulations. <i>Frontiers in Molecular Biosciences</i> , 2019, 6, 164.	1.6	5
12199	Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients. <i>The Journal of Breast Health</i> , 2020, 16, 39-43.	0.4	23
12200	Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer. <i>Medicine (United States)</i> , 2020, 99, e18332.	0.4	1

#	ARTICLE	IF	CITATIONS
12201	Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 676.	3.4	419
12202	Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer. <i>Targeted Oncology</i> , 2020, 15, 93-100.	1.7	27
12203	Worse survival of invasive melanoma patients in men and <i>de novo</i> lesions. <i>Anais Brasileiros De Dermatologia</i> , 2020, 95, 158-164.	0.5	5
12204	Tracking the evolution of circulating exosomal PD-L1 to monitor melanoma patients. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1710899.	5.5	175
12205	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 332-338.	0.5	140
12206	Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. <i>BMC Cancer</i> , 2020, 20, 25.	1.1	75
12207	Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer. <i>International Journal of Medical Sciences</i> , 2020, 17, 89-96.	1.1	37
12208	Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 978-985.	2.0	52
12209	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
12210	C3a-C3aR signaling promotes breast cancer lung metastasis via modulating carcinoma associated fibroblasts. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 11.	3.5	35
12211	Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 211-233.	2.7	42
12212	Peptide-based targeting of immunosuppressive cells in cancer. <i>Bioactive Materials</i> , 2020, 5, 92-101.	8.6	41
12213	Physiology and pathology of T-cell aging. <i>International Immunology</i> , 2020, 32, 223-231.	1.8	68
12214	Directing Traffic: How to Effectively Drive T Cells into Tumors. <i>Cancer Discovery</i> , 2020, 10, 185-197.	7.7	68
12215	Immune Suppression Mediated by STAT4 Deficiency Promotes Lymphatic Metastasis in HNSCC. <i>Frontiers in Immunology</i> , 2019, 10, 3095.	2.2	22
12216	Cancer Nano-Immunotherapy from the Injection to the Target: The Role of Protein Corona. <i>International Journal of Molecular Sciences</i> , 2020, 21, 519.	1.8	19
12217	Germline Variants in Driver Genes of Breast Cancer and Their Association with Familial and Early-Onset Breast Cancer Risk in a Chilean Population. <i>Cancers</i> , 2020, 12, 249.	1.7	4
12218	Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. <i>International Journal of Molecular Sciences</i> , 2020, 21, 597.	1.8	58

#	ARTICLE	IF	CITATIONS
12219	Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes. <i>Apmis</i> , 2020, 128, 298-307.	0.9	7
12220	Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials. <i>PLoS ONE</i> , 2020, 15, e0227344.	1.1	26
12221	VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance. <i>Science</i> , 2020, 367, .	6.0	156
12222	Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study. <i>World Journal of Surgical Oncology</i> , 2020, 18, 11.	0.8	19
12223	Photochemical Internalization: Light Paves Way for New Cancer Chemotherapies and Vaccines. <i>Cancers</i> , 2020, 12, 165.	1.7	29
12224	Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 448.	1.8	6
12225	Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 223.	1.0	95
12226	Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients. <i>Melanoma Research</i> , 2020, 30, 52-61.	0.6	2
12227	Immune-related gene signature for predicting the prognosis of head and neck squamous cell carcinoma. <i>Cancer Cell International</i> , 2020, 20, 22.	1.8	58
12228	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. <i>Oncologist</i> , 2020, 25, e460-e468.	1.9	29
12229	Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review. <i>Cancers</i> , 2020, 12, 192.	1.7	30
12230	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 556.	1.8	21
12231	Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 147.	1.0	14
12232	Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer. <i>Molecules</i> , 2020, 25, 252.	1.7	47
12233	Integration of Omics Data Sources to Inform Mechanistic Modeling of Immune—Oncology Therapies: A Tutorial for Clinical Pharmacologists. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 858-870.	2.3	24
12234	Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 356-367.	1.0	8
12235	PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 83-91.	1.4	41
12236	A Multi-Omics Analysis of Bone Morphogenetic Protein 5 (BMP5) mRNA Expression and Clinical Prognostic Outcomes in Different Cancers Using Bioinformatics Approaches. <i>Biomedicines</i> , 2020, 8, 19.	1.4	23

#	ARTICLE	IF	CITATIONS
12237	Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?. <i>Cancers</i> , 2020, 12, 230.	1.7	9
12238	Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma. <i>BMC Cancer</i> , 2020, 20, 58.	1.1	25
12239	Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies. <i>Cancers</i> , 2020, 12, 284.	1.7	9
12240	NK Cell-Based Immunotherapy in Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 316.	1.7	20
12241	Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging. <i>Immunity and Ageing</i> , 2020, 17, 2.	1.8	211
12242	Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. <i>Diagnostic Pathology</i> , 2020, 15, 6.	0.9	55
12243	Bone decalcification to assess programmed cell death ligand 1 expression in bone metastases of non-small cell lung cancers. <i>Journal of Bone Oncology</i> , 2020, 21, 100275.	1.0	8
12244	Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9 ⁺ T cells. <i>Science Advances</i> , 2020, 6, eaax4690.	4.7	51
12245	Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis. <i>BMC Cancer</i> , 2020, 20, 59.	1.1	8
12246	Recalling the Biological Significance of Immune Checkpoints on NK Cells: A Chance to Overcome LAG3, PD1, and CTLA4 Inhibitory Pathways by Adoptive NK Cell Transfer?. <i>Frontiers in Immunology</i> , 2019, 10, 3010.	2.2	48
12247	Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment. <i>Cancers</i> , 2020, 12, 125.	1.7	50
12248	Modulation of Vaccine-Induced HIV-1-Specific Immune Responses by Co-Electroporation of PD-L1 Encoding DNA. <i>Vaccines</i> , 2020, 8, 27.	2.1	11
12249	An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients. <i>Journal of Cancer</i> , 2020, 11, 883-892.	1.2	5
12250	Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study. <i>Journal of Cancer</i> , 2020, 11, 974-982.	1.2	10
12251	The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life. <i>Journal of Cancer Survivorship</i> , 2020, 14, 363-376.	1.5	22
12252	Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 15.	0.8	58
12253	Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 182.	1.7	74
12254	<p></p>Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle<p></p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 83-94.	1.0	27

#	ARTICLE	IF	CITATIONS
12255	XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2019, 9, 1459.	1.3	38
12256	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. <i>Journal of Clinical Medicine</i> , 2020, 9, 286.	1.0	50
12257	Novel Reporter System Monitoring IL-18 Specific Signaling Can Be Applied to High-Throughput Screening. <i>Marine Drugs</i> , 2020, 18, 60.	2.2	2
12258	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. <i>JAMA Oncology</i> , 2020, 6, 402.	3.4	125
12259	Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report. <i>Clinical Diabetes and Endocrinology</i> , 2020, 6, 1.	1.3	18
12260	Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. <i>Cancer Cell</i> , 2020, 37, 85-103.e9.	7.7	91
12261	Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma. <i>Pediatric Surgery International</i> , 2020, 36, 137-143.	0.6	14
12262	Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 351-360.e3.	0.9	14
12263	Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 137-145.	1.1	16
12264	Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis. <i>Medicine (United States)</i> , 2020, 99, e18701.	0.4	1
12265	Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. <i>BioMed Research International</i> , 2020, 2020, 1-24.	0.9	38
12266	Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer. <i>Medicine (United States)</i> , 2020, 99, e19013.	0.4	64
12267	Genomic subtyping of liver cancers with prognostic application. <i>BMC Cancer</i> , 2020, 20, 84.	1.1	6
12268	Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in China. <i>BMC Cancer</i> , 2020, 20, 86.	1.1	13
12269	Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 1486.	1.3	20
12270	Comprehensive Survey of Clinical Trials Registration for Melanoma Immunotherapy in the ClinicalTrials.gov. <i>Frontiers in Pharmacology</i> , 2019, 10, 1539.	1.6	5
12271	Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update. <i>Pharmaceutics</i> , 2020, 12, 92.	2.0	46
12272	Multi-omics Data Integration, Interpretation, and Its Application. <i>Bioinformatics and Biology Insights</i> , 2020, 14, 117793221989905.	1.0	642

#	ARTICLE	IF	CITATIONS
12273	<p>Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer</p>. Cancer Management and Research, 2020, Volume 12, 841-854.	0.9	26
12274	Integrative pathway enrichment analysis of multivariate omics data. Nature Communications, 2020, 11, 735.	5.8	125
12275	Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. Medicine (United States), 2020, 99, e18726.	0.4	23
12276	Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab. BMC Cancer, 2020, 20, 93.	1.1	15
12277	Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. Cancers, 2020, 12, 305.	1.7	56
12278	Rosemary Extract Inhibits Proliferation, Survival, Akt, and mTOR Signaling in Triple-Negative Breast Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 810.	1.8	28
12279	CDK1 serves as a potential prognostic biomarker and target for lung cancer. Journal of International Medical Research, 2020, 48, 030006051989750.	0.4	46
12280	Anti-cancer effect of gallic acid in presence of low level laser irradiation: ROS production and induction of apoptosis and ferroptosis. Cancer Cell International, 2020, 20, 18.	1.8	77
12281	Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. Journal of Experimental and Clinical Cancer Research, 2020, 39, 29.	3.5	45
12282	Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment. Frontiers in Oncology, 2020, 10, 48.	1.3	63
12283	Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation. Chonnam Medical Journal, 2020, 56, 6.	0.5	1
12284	Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer. Journal of Cancer, 2020, 11, 551-558.	1.2	7
12285	TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Therapy, 2020, 27, 841-853.	2.2	94
12286	Impact of Immunometabolism on Cancer Metastasis: A Focus on T Cells and Macrophages. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a037044.	2.9	10
12287	Efficient and Precise Secure Generalized Edit Distance and Beyond. IEEE Transactions on Dependable and Secure Computing, 2022, 19, 579-590.	3.7	4
12288	Optimal PD-L1â€“high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy. PLoS ONE, 2020, 15, e0231936.	1.1	16
12289	Longâ€“term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. Cancer Science, 2020, 111, 1676-1684.	1.7	21
12290	Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways. Frontiers in Oncology, 2020, 10, 562.	1.3	136

#	ARTICLE	IF	CITATIONS
12291	Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 18, 100691.	0.4	9
12292	Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2020, 9, LMT26.	1.5	9
12293	Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells. <i>Frontiers in Genetics</i> , 2020, 11, 312.	1.1	27
12294	5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 492.	1.3	33
12295	HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2020, 12, 1060.	1.7	40
12296	Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1089.	1.7	119
12297	Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder. <i>Journal of Clinical Medicine</i> , 2020, 9, 1265.	1.0	18
12298	The diverse roles of SPOP in prostate cancer and kidney cancer. <i>Nature Reviews Urology</i> , 2020, 17, 339-350.	1.9	62
12299	Cutaneous side effects of the potential COVID-19 drugs. <i>Dermatologic Therapy</i> , 2020, 33, e13476.	0.8	55
12300	Identification of the immune checkpoint signature of multiple myeloma using mass cytometry-based single-cell analysis. <i>Clinical and Translational Immunology</i> , 2020, 9, e01132.	1.7	14
12301	eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. <i>Nature Cancer</i> , 2020, 1, 533-545.	5.7	73
12302	Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer. <i>Cancer Cell International</i> , 2020, 20, 92.	1.8	38
12303	Intratumor Heterogeneity in Early Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 349.	1.3	41
12304	Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities. <i>Frontiers in Oncology</i> , 2020, 10, 636.	1.3	24
12305	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. <i>Cancers</i> , 2020, 12, 738.	1.7	826
12306	The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response. <i>Cancers</i> , 2020, 12, 742.	1.7	38
12307	Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives. <i>Cancers</i> , 2020, 12, 751.	1.7	66
12308	The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma. <i>Journal of Advanced Research</i> , 2020, 24, 139-148.	4.4	50

#	ARTICLE	IF	CITATIONS
12309	The Landscape of Targeted Therapies in TNBC. <i>Cancers</i> , 2020, 12, 916.	1.7	232
12310	Retrospective analysis of the prognostic value of PD-L1 expression and 18F-FDG PET/CT metabolic parameters in colorectal cancer. <i>Journal of Cancer</i> , 2020, 11, 2864-2873.	1.2	15
12311	Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma. <i>JAMA Network Open</i> , 2020, 3, e201611.	2.8	70
12313	Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment. <i>International Journal of Clinical Oncology</i> , 2020, 25, 801-809.	1.0	115
12314	Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 402-416.	1.1	16
12315	Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. <i>European Journal of Cancer</i> , 2020, 131, 40-50.	1.3	143
12316	Association of mutation and low expression of the CTCF gene with breast cancer progression. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 607-614.	1.2	8
12317	Temporal activation of WNT/ β -catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth. <i>Oncogene</i> , 2020, 39, 4132-4154.	2.6	23
12318	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 122, 1630-1637.	2.9	472
12319	Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+ tumour-infiltrating lymphocytes in oral squamous cell carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1686-1694.	2.9	38
12320	Multimodal preclinical platform predicts clinical response of melanoma to immunotherapy. <i>Nature Medicine</i> , 2020, 26, 781-791.	15.2	75
12321	Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials. , 2020, 8, e000492.		55
12322	Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised. <i>Frontiers in Medicine</i> , 2020, 7, 91.	1.2	2
12323	Endometrial Cancer Immune Escape Mechanisms: Let Us Learn From the Fetalâ€“Maternal Interface. <i>Frontiers in Oncology</i> , 2020, 10, 156.	1.3	24
12324	Metabolic Reprogramming in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 428.	1.3	137
12325	TCMIO: A Comprehensive Database of Traditional Chinese Medicine on Immuno-Oncology. <i>Frontiers in Pharmacology</i> , 2020, 11, 439.	1.6	34
12326	PD-L1â€“PD-1 Pathway in the Pathophysiology of Multiple Myeloma. <i>Cancers</i> , 2020, 12, 924.	1.7	41
12327	Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy. <i>Diagnostics</i> , 2020, 10, 216.	1.3	13

#	ARTICLE	IF	CITATIONS
12328	Dendritic Cells Pre-Pulsed with Wilmsâ€™ Tumor 1 in Optimized Culture for Cancer Vaccination. <i>Pharmaceutics</i> , 2020, 12, 305.	2.0	7
12329	Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 3596-3603.	1.2	17
12330	A_{2A}R Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model. <i>Journal of Cancer</i> , 2020, 11, 3685-3692.	1.2	12
12331	Reprogramming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma. <i>Cancer Science</i> , 2020, 111, 1899-1909.	1.7	54
12332	A Case of Isolated Adrenocorticotrophic Hormone Deficiency Caused by Pembrolizumab. <i>Case Reports in Oncology</i> , 2020, 13, 200-206.	0.3	15
12333	Anti-cancer Activity of Centipeda minima Extract in Triple Negative Breast Cancer via Inhibition of AKT, NF-Î²B, and STAT3 Signaling Pathways. <i>Frontiers in Oncology</i> , 2020, 10, 491.	1.3	26
12334	Contribution of Macrophages and T Cells in Skeletal Metastasis. <i>Cancers</i> , 2020, 12, 1014.	1.7	19
12335	Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2020, 15, 53-58.	1.0	23
12336	Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 321-321.	0.7	7
12337	Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients. <i>Cancers</i> , 2020, 12, 1008.	1.7	3
12338	Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy. <i>Cancers</i> , 2020, 12, 1025.	1.7	30
12339	Primary Resistance to PD-1-Based Immunotherapyâ€™ A Study in 319 Patients with Stage IV Melanoma. <i>Cancers</i> , 2020, 12, 1027.	1.7	17
12340	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. <i>Vaccines</i> , 2020, 8, 191.	2.1	10
12341	Improved Prognostic Prediction of Glioblastoma using a PAS Detected from Single-cell RNA-seq. <i>Journal of Cancer</i> , 2020, 11, 3751-3761.	1.2	1
12342	Comprehensive Analysis of the Tumor Microenvironment in Cutaneous Melanoma associated with Immune Infiltration. <i>Journal of Cancer</i> , 2020, 11, 3858-3870.	1.2	22
12343	Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. , 2020, 8, e000261.		53
12344	EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in nonâ€™small cell lung cancer. <i>Journal of the American Society of Cytopathology</i> , 2020, 9, 485-493.	0.2	9
12345	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. <i>Oncolimmunology</i> , 2020, 9, 1744947.	2.1	26

#	ARTICLE	IF	CITATIONS
12346	A 17-gene expression-based prognostic signature associated with the prognosis of patients with breast cancer. <i>Medicine (United States)</i> , 2020, 99, e19255.	0.4	4
12347	Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2020, 9, 66.	2.5	16
12348	Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients. <i>PLoS ONE</i> , 2020, 15, e0231038.	1.1	3
12349	<p>Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3085-3091.	1.0	25
12350	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 314.	1.3	62
12351	A Common Pituitary Autoantibody in Two Patients with Immune Checkpoint Inhibitor-Mediated Hypophysitis: ZCCHC8. <i>AACE Clinical Case Reports</i> , 2020, 6, e151-e160.	0.4	8
12352	Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer. <i>PLoS ONE</i> , 2020, 15, e0231786.	1.1	15
12353	Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. <i>Frontiers in Pharmacology</i> , 2020, 11, 441.	1.6	48
12354	The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients. <i>Translational Andrology and Urology</i> , 2020, 9, 367-381.	0.6	8
12355	<p>Ultrasound-Mediated Co-Delivery of miR-34a and sPD-1 Complexed with Microbubbles for Synergistic Cancer Therapy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2459-2469.	0.9	16
12356	Modeling Basins of Attraction for Breast Cancer Using Hopfield Networks. <i>Frontiers in Genetics</i> , 2020, 11, 314.	1.1	14
12357	How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies. <i>Frontiers in Physiology</i> , 2020, 11, 154.	1.3	27
12358	Non-Coding RNAs in Lung Tumor Initiation and Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2774.	1.8	27
12359	Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2020, 6, 865.	3.4	295
12360	Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. <i>Cancer Communications</i> , 2020, 40, 135-153.	3.7	339
12361	Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1627-1637.	2.0	16
12362	The Complexity of Targeting Chemokines to Promote a Tumor Immune Response. <i>Inflammation</i> , 2020, 43, 1201-1208.	1.7	17
12363	Targeted next generation sequencing identifies somatic mutations in a cohort of Egyptian breast cancer patients. <i>Journal of Advanced Research</i> , 2020, 24, 149-157.	4.4	13

#	ARTICLE	IF	CITATIONS
12364	Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100020.	0.6	23
12365	Default polyfunctional T helper 1 response to ample signal 1 alone. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1809-1822.	4.8	3
12366	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	13.7	374
12367	SNP2APA: a database for evaluating effects of genetic variants on alternative polyadenylation in human cancers. <i>Nucleic Acids Research</i> , 2020, 48, D226-D232.	6.5	37
12368	Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. <i>Neurosurgery</i> , 2020, 87, E281-E288.	0.6	22
12369	A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. <i>Medicine (United States)</i> , 2020, 99, e19741.	0.4	19
12370	Epigenetic Mechanisms in Leukemias and Lymphomas. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a034959.	2.9	14
12371	Sporadic activation of an oxidative stress-dependent NRF2-p53 signaling network in breast epithelial spheroids and premalignancies. <i>Science Signaling</i> , 2020, 13, .	1.6	25
12372	Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. <i>Clinical Cancer Research</i> , 2020, 26, 71-81.	3.2	109
12373	SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 883-894.	1.6	48
12374	PathME: pathway based multi-modal sparse autoencoders for clustering of patient-level multi-omics data. <i>BMC Bioinformatics</i> , 2020, 21, 146.	1.2	38
12375	Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes. <i>PLoS ONE</i> , 2020, 15, e0222551.	1.1	26
12376	Molecular subtypes and precision treatment of triple-negative breast cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 499-499.	0.7	64
12377	<p></p>Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2657-2666.	1.0	9
12378	Current Approaches for Personalized Therapy of Soft Tissue Sarcomas. <i>Sarcoma</i> , 2020, 2020, 1-15.	0.7	7
12379	Critical Care Admission of an HIV Patient with Diabetic Ketoacidosis Secondary to Pembrolizumab. <i>Case Reports in Critical Care</i> , 2020, 2020, 1-3.	0.2	6
12380	Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy. <i>Cancer Research</i> , 2020, 80, 3101-3115.	0.4	77
12381	Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells. <i>Clinical Cancer Research</i> , 2020, 26, 3384-3396.	3.2	24

#	ARTICLE	IF	CITATIONS
12382	A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. <i>Liver Cancer</i> , 2020, 9, 119-137.	4.2	45
12383	Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. <i>Breast Cancer Research</i> , 2020, 22, 32.	2.2	34
12384	Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. <i>Breast Cancer Research</i> , 2020, 22, 33.	2.2	26
12385	Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 4035-4043.	0.7	7
12386	Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival. <i>PLoS ONE</i> , 2020, 15, e0231003.	1.1	33
12387	Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles. <i>PLoS ONE</i> , 2020, 15, e0231227.	1.1	43
12388	<p>Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3047-3059.	1.0	25
12389	Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 162.	1.8	21
12390	Alterations in Immune-Related Genes as Potential Marker of Prognosis in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 333.	1.3	24
12391	Molecular Trajectory of BRCA1 and BRCA2 Mutations. <i>Frontiers in Oncology</i> , 2020, 10, 361.	1.3	31
12392	Hyperprogression Under Immune Checkpoint-Based Immunotherapyâ€”Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model. <i>Cancers</i> , 2020, 12, 804.	1.7	19
12393	An Organotypic Microcosm for the Pancreatic Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 811.	1.7	7
12394	The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma: The Role of Exosomal microRNAs and Their Clinical Implications. <i>Cancers</i> , 2020, 12, 823.	1.7	40
12395	BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 828.	1.7	27
12396	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. <i>Cancers</i> , 2020, 12, 832.	1.7	27
12397	Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. <i>Cancers</i> , 2020, 12, 848.	1.7	14
12398	Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients. <i>Cancers</i> , 2020, 12, 863.	1.7	18
12399	Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?. <i>Cancers</i> , 2020, 12, 889.	1.7	20

#	ARTICLE	IF	CITATIONS
12400	Mechanisms of Resistance to NK Cell Immunotherapy. <i>Cancers</i> , 2020, 12, 893.	1.7	34
12401	Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2078.	1.2	163
12402	Caffeine and Cisplatin Effectively Targets the Metabolism of a Triple-Negative Breast Cancer Cell Line Assessed via Phasor-FLIM. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2443.	1.8	13
12403	Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status. <i>Journal of Clinical Medicine</i> , 2020, 9, 940.	1.0	79
12404	RAD51Bme Levels as a Potential Predictive Biomarker for PD-1 Blockade Response in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 1000.	1.0	6
12405	Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics. <i>International Journal of Surgery Oncology</i> , 2017, 2, e43-e43.	0.2	5
12406	A review of glioblastoma immunotherapy. <i>Journal of Neuro-Oncology</i> , 2021, 151, 41-53.	1.4	159
12407	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.5	153
12408	Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 171-178.	2.8	29
12409	Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 418-423.	1.2	31
12410	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a038240.	2.9	34
12411	PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 546-553.	1.4	49
12412	Integrating Multidimensional Data for Clustering Analysis With Applications to Cancer Patient Data. <i>Journal of the American Statistical Association</i> , 2021, 116, 14-26.	1.8	7
12413	Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation. <i>International Journal of Surgery Oncology</i> , 2021, 2, 49.	0.2	4
12414	Current developments of targeting the p53 signaling pathway for cancer treatment. , 2021, 220, 107720.		70
12415	<scp><i>CDKN1B</i></scp> mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer. <i>Journal of Pathology</i> , 2021, 253, 234-245.	2.1	12
12416	Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 871-875.	0.6	5
12417	Immunotherapeutic strategies in breast cancer: A clinical update. <i>Journal of Surgical Oncology</i> , 2021, 123, 710-717.	0.8	4

#	ARTICLE	IF	CITATIONS
12418	Prognostic and predictive parameters in breast pathology: a pathologist's primer. <i>Modern Pathology</i> , 2021, 34, 94-106.	2.9	14
12419	Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1777-1780.	2.0	8
12420	Metabolic interventions: A new insight into the cancer immunotherapy. <i>Archives of Biochemistry and Biophysics</i> , 2021, 697, 108659.	1.4	8
12421	Evaluation of Intra-Lesional Interleukin 2 for the Treatment of In-Transit Melanoma Disease: L'Évaluation de l'interleukine-2 intralésionnelle pour traiter les mélanomes en transit. <i>Plastic Surgery</i> , 2021, 29, 4-9.	0.4	0
12422	A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 134-144.	0.4	61
12423	Calreticulin and cancer. <i>Cell Research</i> , 2021, 31, 5-16.	5.7	174
12424	Recent advances on microneedle arrays-mediated technology in cancer diagnosis and therapy. <i>Drug Delivery and Translational Research</i> , 2021, 11, 788-816.	3.0	32
12425	TGF β 2 biology in cancer progression and immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 9-34.	12.5	420
12426	Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. <i>Cell Research</i> , 2021, 31, 178-186.	5.7	146
12427	Classification of T-cell activation via autofluorescence lifetime imaging. <i>Nature Biomedical Engineering</i> , 2021, 5, 77-88.	11.6	92
12428	Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 582-590.	1.2	5
12429	Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 140-149.	2.0	15
12430	Association Between the Size and 3D CT-Based Radiomic Features of Breast Cancer Hepatic Metastasis. <i>Academic Radiology</i> , 2021, 28, e93-e100.	1.3	5
12431	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. <i>European Radiology</i> , 2021, 31, 1853-1862.	2.3	10
12432	Immune microenvironment in different molecular subtypes of ductal breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 261-279.	1.1	30
12433	IntAPT: integrated assembly of phenotype-specific transcripts from multiple RNA-seq profiles. <i>Bioinformatics</i> , 2021, 37, 650-658.	1.8	1
12434	Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 884-890.	1.4	13
12435	Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. <i>European Journal of Immunology</i> , 2021, 51, 331-341.	1.6	13

#	ARTICLE	IF	CITATIONS
12436	The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure. <i>Bioactive Materials</i> , 2021, 6, 697-711.	8.6	10
12437	Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases. <i>Journal of Neuro-Oncology</i> , 2021, 152, 15-25.	1.4	15
12438	Age-related DNA methylation in paired normal and tumour breast tissue in Chinese breast cancer patients. <i>Epigenetics</i> , 2021, 16, 677-691.	1.3	9
12439	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. <i>Blood</i> , 2021, 137, 216-231.	0.6	40
12440	Conferring receptors on recipient cells with extracellular vesicles for targeted drug delivery. <i>Bioactive Materials</i> , 2021, 6, 749-756.	8.6	22
12441	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. <i>Modern Pathology</i> , 2021, 34, 823-833.	2.9	6
12442	The <scp>BioGRID</scp> database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions. <i>Protein Science</i> , 2021, 30, 187-200.	3.1	769
12443	High intratumoral CD8⁺ Tâ€cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy. <i>Prostate</i> , 2021, 81, 20-28.	1.2	43
12444	PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective. <i>Cancer Research</i> , 2021, 81, 237-247.	0.4	26
12445	Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial. <i>Annals of Oncology</i> , 2021, 32, 58-65.	0.6	14
12446	Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. <i>Blood</i> , 2021, 137, 1777-1791.	0.6	25
12447	T cell regeneration after immunological injury. <i>Nature Reviews Immunology</i> , 2021, 21, 277-291.	10.6	99
12448	Stroma-derived ANGPTL2 establishes an anti-tumor microenvironment during intestinal tumorigenesis. <i>Oncogene</i> , 2021, 40, 55-67.	2.6	9
12449	Immunotherapy in gastroesophageal cancers: Current state and future directions. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 395-404.	0.5	2
12450	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. <i>Nature Reviews Cardiology</i> , 2021, 18, 169-193.	6.1	589
12451	Dicarbonyl Electrophiles Mediate Inflammation-Induced Gastrointestinal Carcinogenesis. <i>Gastroenterology</i> , 2021, 160, 1256-1268.e9.	0.6	17
12452	Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 919-935.	4.8	11
12453	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Antiâ€PD-(L)1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 1019-1028.	3.2	58

#	ARTICLE	IF	CITATIONS
12454	Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. <i>Blood</i> , 2021, 137, 2463-2480.	0.6	35
12455	Bioengineering of nano metal-organic frameworks for cancer immunotherapy. <i>Nano Research</i> , 2021, 14, 1244-1259.	5.8	37
12456	Tumor microenvironment as a therapeutic target in cancer. , 2021, 221, 107753.		567
12457	Recent Progress in the Synergistic Combination of Nanoparticle-Mediated Hyperthermia and Immunotherapy for Treatment of Cancer. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001415.	3.9	37
12458	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. <i>Cancer Discovery</i> , 2021, 11, 614-625.	7.7	145
12459	Neoantigen prediction in human breast cancer using RNA sequencing data. <i>Cancer Science</i> , 2021, 112, 465-475.	1.7	13
12460	Advances in bladder cancer biology and therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 104-121.	12.8	320
12461	SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). <i>Clinical Lung Cancer</i> , 2021, 22, 178-186.	1.1	6
12462	The emerging role of immunotherapy for the treatment of sarcoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 730-738.	0.8	16
12463	Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets. <i>Molecular Oncology</i> , 2021, 15, 364-380.	2.1	4
12464	Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N-SAS-BC01 trial and CUBC trial). <i>Breast Cancer Research and Treatment</i> , 2021, 186, 135-147.	1.1	1
12465	Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications. <i>Arthritis and Rheumatology</i> , 2021, 73, 553-565.	2.9	21
12466	Advanced Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 111-128.	0.9	5
12467	Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling. <i>Molecular Cancer Research</i> , 2021, 19, 329-345.	1.5	13
12468	Immune checkpoint inhibitor use, multimorbidity and healthcare expenditures among older adults with late-stage melanoma. <i>Immunotherapy</i> , 2021, 13, 103-112.	1.0	1
12469	Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 1287-1295.	3.2	2
12470	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory FoRECATT study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1583-1592.	2.0	12
12471	Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. <i>Supportive Care in Cancer</i> , 2021, 29, 2821-2840.	1.0	65

#	ARTICLE	IF	CITATIONS
12472	Altered gene expression in glycolysis–cholesterol synthesis axis correlates with outcome of triple-negative breast cancer. <i>Experimental Biology and Medicine</i> , 2021, 246, 560-571.	1.1	8
12473	Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1789-1796.	2.0	16
12474	The cutting-edge progress of immune-checkpoint blockade in lung cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 279-293.	4.8	102
12475	Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Thoracic Cancer</i> , 2021, 12, 153-164.	0.8	28
12476	Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 131-140.	3.2	93
12477	Bioengineering tools for probing intracellular events in T lymphocytes. <i>WIREs Mechanisms of Disease</i> , 2021, 13, e1510.	1.5	0
12478	microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1541-1555.	2.0	4
12479	Immune microenvironment features and efficacy of <i>PD-1/PD-L1</i> blockade in non-small cell lung cancer patients with <i>EGFR</i> or <i>HER2</i> exon 20 insertions. <i>Thoracic Cancer</i> , 2021, 12, 218-226.	0.8	44
12480	Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases. <i>Nature Biomedical Engineering</i> , 2021, 5, 441-454.	11.6	57
12481	An evaluation of palbociclib as a breast cancer treatment option: a current update. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 281-290.	0.9	3
12482	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. <i>Oncologist</i> , 2021, 26, e270-e278.	1.9	33
12483	Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. <i>Cancer Science</i> , 2021, 112, 305-313.	1.7	62
12484	Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy. <i>Trends in Cancer</i> , 2021, 7, 226-239.	3.8	34
12485	Lower Airway Dysbiosis Affects Lung Cancer Progression. <i>Cancer Discovery</i> , 2021, 11, 293-307.	7.7	139
12486	Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors. <i>Journal of Controlled Release</i> , 2021, 330, 1095-1105.	4.8	34
12487	MEScan: a powerful statistical framework for genome-scale mutual exclusivity analysis of cancer mutations. <i>Bioinformatics</i> , 2021, 37, 1189-1197.	1.8	7
12488	Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer. <i>Cancer Science</i> , 2021, 112, 178-193.	1.7	24
12489	Comprehensive genomic and immunophenotypic analysis of CD4 T cell infiltrating human triple-negative breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1649-1665.	2.0	11

#	ARTICLE	IF	CITATIONS
12490	Peptides that immunoactivate the tumor microenvironment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188486.	3.3	20
12491	COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. <i>International Immunopharmacology</i> , 2021, 90, 107247.	1.7	87
12492	A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 419-427.	0.5	33
12493	Parallels Between the Antiviral State and the Irradiated State. <i>Journal of the National Cancer Institute</i> , 2021, 113, 969-979.	3.0	4
12494	The Multifaceted Role of Regulatory T Cells in Breast Cancer. <i>Annual Review of Cancer Biology</i> , 2021, 5, 291-310.	2.3	24
12495	Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1105-1118.	3.2	24
12496	SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer. <i>Laboratory Investigation</i> , 2021, 101, 463-476.	1.7	16
12497	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1134-1143.	1.3	17
12498	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1667-1678.	2.0	27
12499	MR cell size imaging with temporal diffusion spectroscopy. <i>Magnetic Resonance Imaging</i> , 2021, 77, 109-123.	1.0	9
12500	Considerations when treating high-grade pediatric glioma patients with immunotherapy. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 205-219.	1.4	5
12501	Anti- γ pyroptotic function of TGF β ² is suppressed by a synthetic dsRNA analogue in triple negative breast cancer cells. <i>Molecular Oncology</i> , 2021, 15, 1289-1307.	2.1	14
12502	A Positive Feedback Loop Between TGF β ² and Androgen Receptor Supports Triple-negative Breast Cancer Anoikis Resistance. <i>Endocrinology</i> , 2021, 162, .	1.4	13
12503	Institutional-Level Differences in Quality and Outcomes of Lung Cancer Resections in the United States. <i>Chest</i> , 2021, 159, 1630-1641.	0.4	10
12504	Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 580045.	1.3	2
12505	A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. <i>Kidney International Reports</i> , 2021, 6, 66-77.	0.4	84
12506	The miR-5694/AF9/Snail Axis Provides Metastatic Advantages and a Therapeutic Target in Basal-like Breast Cancer. <i>Molecular Therapy</i> , 2021, 29, 1239-1257.	3.7	10
12507	Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. <i>Cell Death and Differentiation</i> , 2021, 28, 1773-1789.	5.0	80

#	ARTICLE	IF	CITATIONS
12508	FMSâ€like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 314-322.	1.7	8
12509	CD24, not CD47, negatively impacts upon response to PDâ€1/L1 inhibitors in nonâ€smallâ€cell lung cancer with PDâ€1 tumor proportion score<A<A50. <i>Cancer Science</i> , 2021, 112, 72-80.	1.7	9
12510	Hemagglutinating virus of Japanâ€envelope containing programmed cell deathâ€ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma. <i>Cancer Science</i> , 2021, 112, 81-90.	1.7	9
12511	Expression of human leukocyte antigen class I and Î²2â€microglobulin in colorectal cancer and its prognostic impact. <i>Cancer Science</i> , 2021, 112, 91-100.	1.7	8
12512	Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANGâ€TR). <i>Cancer Science</i> , 2021, 112, 388-396.	1.7	16
12513	The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. <i>Cancer Cell</i> , 2021, 39, 154-173.	7.7	491
12514	<i>SMARCA4</i> mutations in <i>KRAS</i>â€mutant lung adenocarcinoma: a multiâ€cohort analysis. <i>Molecular Oncology</i> , 2021, 15, 462-472.	2.1	29
12515	PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1049-1062.	2.0	17
12516	A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2021, 26, 99-e217.	1.9	49
12517	A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival. <i>British Journal of Cancer</i> , 2021, 124, 760-769.	2.9	13
12518	Tumor-infiltrating lymphocytes in the immunotherapy era. <i>Cellular and Molecular Immunology</i> , 2021, 18, 842-859.	4.8	403
12519	Triple-negative breast cancer: new treatment strategies in the era of precision medicine. <i>Science China Life Sciences</i> , 2021, 64, 372-388.	2.3	26
12520	Network-based survival analysis to discover target genes for developing cancer immunotherapies and predicting patient survival. <i>Journal of Applied Statistics</i> , 2021, 48, 1352-1373.	0.6	3
12521	Human immunology and immunotherapy: main achievements and challenges. <i>Cellular and Molecular Immunology</i> , 2021, 18, 805-828.	4.8	96
12522	Organized immune cell interactions within tumors sustain a productive T-cell response. <i>International Immunology</i> , 2021, 33, 27-37.	1.8	8
12523	Prevalence and clinical relevance of tumor-associated tissue eosinophilia (TATE) in breast cancer. <i>Surgery</i> , 2021, 169, 1234-1239.	1.0	19
12524	Association of <i>GATA3</i> Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021, 113, 408-417.	3.0	16
12525	Current status and future perspectives of immunotherapy in bladder cancer treatment. <i>Science China Life Sciences</i> , 2021, 64, 512-533.	2.3	21

#	ARTICLE	IF	CITATIONS
12526	Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). <i>Investigational New Drugs</i> , 2021, 39, 182-192.	1.2	8
12527	A Review of Imputation Strategies for Isobaric Labeling-Based Shotgun Proteomics. <i>Journal of Proteome Research</i> , 2021, 20, 1-13.	1.8	26
12528	⁸⁹ Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression. <i>Journal of Nuclear Medicine</i> , 2021, 62, 656-664.	2.8	22
12529	Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint. <i>Oncotarget</i> , 0, 7, 41274-41284.	0.8	32
12530	PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy. <i>Onc Immunology</i> , 2021, 10, 1912892.	2.1	25
12531	Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors. <i>Clinical and Translational Immunology</i> , 2021, 10, e1267.	1.7	4
12532	Research advances and new challenges in overcoming triple-negative breast cancer. , 2021, 4, 517-542.		11
12533	Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer. <i>In Vivo</i> , 2021, 35, 1865-1875.	0.6	4
12534	Bioinformatics Analysis of Potential Therapeutic Targets and Prognostic Biomarkers amid CXC Chemokines in Ovarian Carcinoma Microenvironment. <i>Journal of Oncology</i> , 2021, 2021, 1-18.	0.6	11
12535	First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center. <i>Breast Care</i> , 2021, 16, 129-134.	0.8	3
12536	B cell infiltration is highly associated with prognosis and an immune-infiltrated tumor microenvironment in neuroblastoma. , 2021, 7, .		10
12537	Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	48
12538	“Triple-Negative Breast Cancer Central Nervous System Metastases From the Laboratory to the Clinic” <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 76-82.	1.0	4
12539	Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function. <i>Journal of Immunotherapy</i> , 2021, 44, 63-70.	1.2	22
12540	Epithelial p53 Status Modifies Stromal-Epithelial Interactions During Basal-Like Breast Carcinogenesis. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2021, 26, 89-99.	1.0	1
12541	DNA-Damage-Induced Alternative Splicing of p53. <i>Cancers</i> , 2021, 13, 251.	1.7	10
12542	Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. <i>Investigational New Drugs</i> , 2021, 39, 785-795.	1.2	9
12543	Identification of significant genes and therapeutic agents for breast cancer by integrated genomics. <i>Bioengineered</i> , 2021, 12, 2140-2154.	1.4	4

#	ARTICLE	IF	CITATIONS
12544	Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors. <i>Investigational New Drugs</i> , 2021, 39, 891-898.	1.2	7
12545	Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges. <i>Journal of the National Cancer Institute</i> , 2021, 113, 823-832.	3.0	31
12546	Phosphorylation of PKC δ by FER tips the balance from EGFR degradation to recycling. <i>Journal of Cell Biology</i> , 2021, 220, .	2.3	14
12547	Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100136.	2.5	19
12548	Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. <i>Science Advances</i> , 2021, 7, .	4.7	38
12549	Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. <i>Cell</i> , 2021, 184, 384-403.e21.	13.5	94
12550	Recent advances and discoveries in the mechanisms and functions of CAR T cells. <i>Nature Reviews Cancer</i> , 2021, 21, 145-161.	12.8	436
12551	Large-scale tumor-associated collagen signatures identify high-risk breast cancer patients. <i>Theranostics</i> , 2021, 11, 3229-3243.	4.6	60
12552	Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 215-229.	12.5	486
12553	Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab012.	1.4	16
12554	Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer. <i>Oncimmunology</i> , 2021, 10, 1873607.	2.1	20
12555	Dendritic cell-based immunotherapies and their potential use in colorectal cancer immunotherapy. <i>Journal of Microscopy and Ultrastructure</i> , 2022, 10, 107.	0.1	4
12556	Long Non-coding RNA BTG3-7:1 and JUND Co-regulate C21ORF91 to Promote Triple-Negative Breast Cancer Progress. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 605623.	1.6	0
12557	Prognostic Factors Associated with Curing in Patients with Breast Cancer: A Joint Frailty Model. <i>International Journal of Preventive Medicine</i> , 2021, 12, 9.	0.2	0
12558	The prognostic and predictive value of the 8th American Joint Committee on Cancer (AJCC) staging system among early breast cancer patients aged <50 years. <i>Gland Surgery</i> , 2021, 10, 233-241.	0.5	2
12559	MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer. <i>International Journal of Biological Sciences</i> , 2021, 17, 1671-1681.	2.6	8
12560	Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. <i>Journal of Thoracic Disease</i> , 2021, 13, 220-231.	0.6	9
12561	An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers. <i>Cancer Control</i> , 2021, 28, 107327482110171.	0.7	3

#	ARTICLE	IF	CITATIONS
12562	Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy. <i>EClinicalMedicine</i> , 2021, 31, 100673.	3.2	23
12563	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. <i>Translational Lung Cancer Research</i> , 2021, 10, 202-220.	1.3	29
12564	Targeting TGF β 2 signal transduction for cancer therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 8.	7.1	186
12565	Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100126.	2.0	2
12566	Bioinformatic analysis of PLOD family member expression and prognostic value in non-small cell lung cancer. <i>Translational Cancer Research</i> , 2021, 10, 2707-2724.	0.4	7
12567	Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110044.	0.6	13
12568	Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 506.	1.7	9
12569	Neutrophil-Lymphocyte Ratio as a Prognostic Parameter in NSCLC Patients Receiving EGFR-TKIs: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	0.6	11
12570	Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing. <i>Annals of Translational Medicine</i> , 2021, 9, 140-140.	0.7	4
12571	Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1. <i>Oncolmmunology</i> , 2021, 10, 1957603.	2.1	10
12572	Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1036-1043.	3.0	50
12573	Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. , 2021, 9, e001731.		45
12574	Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2179-2195.	2.0	22
12575	Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2020, 10, 574752.	1.3	11
12576	Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 227.	5.8	76
12577	Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2389-2400.	2.0	11
12578	Identification of chemical compounds regulating PD-1 by introducing HiBiT-tagged cells. <i>FEBS Letters</i> , 2021, 595, 563-576.	1.3	8
12579	Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress. <i>Nature Communications</i> , 2021, 12, 145.	5.8	131

#	ARTICLE	IF	CITATIONS
12580	The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review. <i>Cancer Control</i> , 2021, 28, 107327482199743.	0.7	30
12581	Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. <i>Current Cardiology Reports</i> , 2021, 23, 11.	1.3	35
12582	Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1555-1567.	1.4	17
12583	Whole-Lesion Histogram Analysis of the Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker for Assessing the Level of Tumor-Infiltrating Lymphocytes: Value in Molecular Subtypes of Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 611571.	1.3	16
12584	Prognostic value of LRRC4C in Colon and Gastric Cancers correlates with Tumour Microenvironment Immunity. <i>International Journal of Biological Sciences</i> , 2021, 17, 1413-1427.	2.6	6
12585	Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. <i>Oncolimmunology</i> , 2021, 10, 1901434.	2.1	34
12586	Immune Checkpoint Inhibitors in Special Populations. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110365.	0.8	4
12587	H2O2-Inactivated Salmonella typhimurium RE88 Strain as a New Cancer Vaccine Carrier: Evaluation in a Mouse Model of Cancer. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 209-222.	2.0	4
12588	Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	0
12589	Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2021, 11, 2514.	1.6	17
12590	The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 131-131.	0.7	18
12591	Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. <i>Journal of Neuro-Oncology</i> , 2021, 152, 125-134.	1.4	7
12592	The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). <i>Cell Reports Medicine</i> , 2021, 2, 100186.	3.3	90
12593	Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape. <i>Current Research in Immunology</i> , 2021, 2, 132-141.	1.2	27
12594	New approaches to first-line treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110347.	1.4	25
12595	Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma. <i>Oncolimmunology</i> , 2021, 10, 1956173.	2.1	15
12596	Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician. <i>JCO Precision Oncology</i> , 2021, 5, 317-324.	1.5	9
12597	Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 4.	7.1	51

#	ARTICLE	IF	CITATIONS
12598	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , 2021, 9, 33-33.	0.7	16
12599	Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system. <i>Translational Lung Cancer Research</i> , 2021, 10, 2614-2624.	1.3	11
12600	High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2021, 10, 304-313.	1.3	23
12601	S100A8/S100A9 cytokine acts as a transcriptional coactivator during breast cellular transformation. <i>Science Advances</i> , 2021, 7, .	4.7	29
12602	Transcriptomic and Network Analysis of Minor Salivary Glands of Patients With Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 606268.	2.2	21
12603	Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 582185.	1.3	5
12604	Flow cytometry detection of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens. <i>Heliyon</i> , 2021, 7, e05880.	1.4	3
12605	Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	1.4	9
12606	Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110069.	1.2	13
12607	B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1910-1922.	1.4	9
12608	TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110384.	1.4	15
12609	Targeting myeloid-derived suppressor cells for cancer therapy. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	12
12610	The advance of adjuvant treatment for triple-negative breast cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	11
12611	Turning cold tumors into hot tumors by improving T-cell infiltration. <i>Theranostics</i> , 2021, 11, 5365-5386.	4.6	324
12612	Pan-Cancer Molecular Characterization of m6A Regulators and Immunogenomic Perspective on the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 618374.	1.3	28
12613	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 1.	2.3	331
12614	Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Immunology</i> , 2020, 11, 613815.	2.2	26
12615	Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. <i>Oncolmmunology</i> , 2021, 10, 1909296.	2.1	13

#	ARTICLE	IF	CITATIONS
12616	Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon. <i>SAGE Open Medicine</i> , 2021, 9, 205031212110437.	0.7	1
12617	Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2021, 44, 132-139.	1.2	19
12618	Postmastectomy radiation therapy can improve survival for breast cancer patients with 1â€³ positive axillary lymph nodes: a retrospective cohort study using the SEER database. <i>Translational Cancer Research</i> , 2021, 10, 1984-2001.	0.4	0
12619	Recent applications and strategies in nanotechnology for lung diseases. <i>Nano Research</i> , 2021, 14, 2067-2089.	5.8	49
12620	Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer. <i>Nanoscale Horizons</i> , 2021, 6, 319-329.	4.1	39
12621	Prognostic significance of preoperative serum inflammation markers in patients with male breast cancer. <i>Translational Cancer Research</i> , 2021, 10, 4002-4008.	0.4	1
12622	Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer. <i>Breast Care</i> , 2021, 16, 101-107.	0.8	2
12623	Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592198899.	1.4	17
12624	Geographic heterogeneity in the outcomes of patients receiving immune checkpoint inhibitors for advanced solid tumors: a meta-analysis. <i>Translational Cancer Research</i> , 2021, 10, 310-326.	0.4	1
12625	Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer. <i>Science China Life Sciences</i> , 2021, 64, 1590-1601.	2.3	9
12626	KCTD12 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration. <i>Translational Cancer Research</i> , 2021, 10, 261-272.	0.4	1
12627	Magnetic Forces Enable Control of Biological Processes In Vivo. <i>Journal of Applied Mechanics, Transactions ASME</i> , 2021, 88, 030801.	1.1	2
12628	Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 18.	0.7	3
12629	ImmunoPET of CD146 in Orthotopic and Metastatic Breast Cancer Models. <i>Bioconjugate Chemistry</i> , 2021, 32, 1306-1314.	1.8	13
12631	Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis. <i>Oncolmmunology</i> , 2021, 10, 1938476.	2.1	14
12632	Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer. <i>Molecular Omics</i> , 2021, 17, 677-691.	1.4	9
12633	Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab. <i>Translational Lung Cancer Research</i> , 2021, 10, 355-367.	1.3	26
12634	Functional Hierarchy and Cooperation of EMT Master Transcription Factors in Breast Cancer Metastasis. <i>Molecular Cancer Research</i> , 2021, 19, 784-798.	1.5	24

#	ARTICLE	IF	CITATIONS
12635	Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 563-580.	1.3	14
12636	Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1721-1733.	2.0	41
12637	Integrin $\alpha 6 \beta 1$ -TGF β 1-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer. <i>Cancer Cell</i> , 2021, 39, 54-67.e9.	7.7	99
12638	Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry. <i>Theranostics</i> , 2021, 11, 8771-8796.	4.6	50
12639	Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. <i>Investigational New Drugs</i> , 2021, 39, 860-870.	1.2	12
12640	Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor. <i>Annals of Translational Medicine</i> , 2021, 9, 129-129.	0.7	24
12641	Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations. <i>Current Treatment Options in Oncology</i> , 2021, 22, 13.	1.3	12
12642	Toll-like receptor 7 deficiency suppresses type 1 diabetes development by modulating B-cell differentiation and function. <i>Cellular and Molecular Immunology</i> , 2021, 18, 328-338.	4.8	13
12643	TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. <i>Oncolimmunology</i> , 2021, 10, 1889822.	2.1	21
12644	Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110066.	1.4	7
12645	Predictive factors for dental inflammation with exacerbation during cancer therapy with FDG-PET/CT imaging. <i>Supportive Care in Cancer</i> , 2021, 29, 4277-4284.	1.0	0
12646	Inhibition of Transforming Growth Factor Beta and Immune Checkpoints Induces a Distinctly Distributed, Severe Bullous Pemphigoid. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00489.	0.6	2
12647	Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 221-232.	1.3	7
12648	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. <i>Current Oncology Reports</i> , 2021, 23, 13.	1.8	38
12649	NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 574937.	1.3	29
12650	Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study. <i>Investigational New Drugs</i> , 2021, 39, 853-859.	1.2	4
12651	Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing. <i>Cancer Research and Treatment</i> , 2021, 53, 973-982.	1.3	6
12652	PLEKHA4 Promotes Wnt/ β -Catenin Signaling-Mediated G1/S Transition and Proliferation in Melanoma. <i>Cancer Research</i> , 2021, 81, 2029-2043.	0.4	13

#	ARTICLE	IF	CITATIONS
12653	Research Interest and Public Interest in Melanoma: A Bibliometric and Google Trends Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 629687.	1.3	15
12654	Actinidia eriantha Polysaccharide and PD1-Antibody Combination Therapy Enhances Antitumor Efficacy in Colorectal Cancerâ€“Xenograft Mice. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1239-1248.	1.0	4
12655	A prognostic model for stratification of stage IB/IIA esophageal squamous cell carcinoma: a retrospective study. <i>BMC Gastroenterology</i> , 2021, 21, 59.	0.8	4
12656	The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures. <i>Frontiers in Oncology</i> , 2021, 11, 567978.	1.3	6
12657	KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (â‰¥50%) lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 737-752.	1.3	28
12658	A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 544339.	1.3	18
12659	Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 112-120.	0.6	14
12660	Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2497-2502.	2.0	7
12661	Tailoring Materials for Modulation of Macrophage Fate. <i>Advanced Materials</i> , 2021, 33, e2004172.	11.1	141
12662	Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. <i>Cancer</i> , 2021, 127, 1553-1567.	2.0	33
12663	Tumor and Systemic Immunomodulatory Effects of MEK Inhibition. <i>Current Oncology Reports</i> , 2021, 23, 23.	1.8	6
12664	Ratio of the interferon-Î³ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. <i>Npj Genomic Medicine</i> , 2021, 6, 7.	1.7	41
12665	Intratumoral heterogeneity in cancer progression and response to immunotherapy. <i>Nature Medicine</i> , 2021, 27, 212-224.	15.2	376
12666	Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 832.	5.8	248
12667	Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2648-2662.	3.2	4
12668	Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Antiâ€“PD-1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 2481-2493.	3.2	33
12669	Tumor immunogenomic signatures improve a prognostic model of melanoma survival. <i>Journal of Translational Medicine</i> , 2021, 19, 78.	1.8	4
12670	Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 965-980.	1.3	12

#	ARTICLE	IF	CITATIONS
12671	Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells. <i>Cancer Immunology Research</i> , 2021, 9, 583-597.	1.6	9
12672	Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 776-789.	1.3	6
12673	Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 583-590.	1.1	4
12674	Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. <i>Cancer Discovery</i> , 2021, 11, 1454-1467.	7.7	19
12675	Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3896-3904.	3.2	36
12676	Socioeconomic and Surgical Disparities are Associated with Rapid Relapse in Patients with Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6500-6509.	0.7	16
12677	Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Thoracic Cancer</i> , 2021, 12, 1058-1066.	0.8	18
12678	Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor. <i>International Cancer Conference Journal</i> , 2021, 10, 112-115.	0.2	9
12679	Delivery of gefitinib with an immunostimulatory nanocarrier improves therapeutic efficacy in lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 926-935.	1.3	5
12680	Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 618215.	1.3	15
12681	The evolving landscape of immunotherapy in solid tumors. <i>Journal of Surgical Oncology</i> , 2021, 123, 798-806.	0.8	17
12682	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. <i>Seminars in Cancer Biology</i> , 2022, 84, 89-102.	4.3	21
12683	Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 845-855.	1.0	5
12684	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1005-1016.	3.0	171
12685	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. <i>Blood Advances</i> , 2021, 5, 1069-1080.	2.5	20
12686	FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review. <i>Clinical Cancer Research</i> , 2021, 27, 3522-3527.	3.2	32
12687	Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma. <i>Journal of Oncology</i> , 2021, 2021, 1-9.	0.6	7
12688	Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and \pm -PD-1. <i>British Journal of Cancer</i> , 2021, 124, 1275-1285.	2.9	5

#	ARTICLE	IF	CITATIONS
12689	Systemic Immune-Inflammation Index Is a Prognostic Predictor in Patients with Intrahepatic Cholangiocarcinoma Undergoing Liver Transplantation. <i>Mediators of Inflammation</i> , 2021, 2021, 1-7.	1.4	11
12690	Concordance of PD-L1 Status Between Image-Guided Percutaneous Biopsies and Matched Surgical Specimen in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 551367.	1.3	4
12691	The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 1029-1038.	1.3	12
12692	Applying artificial intelligence for cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3393-3405.	5.7	33
12693	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 435-453.	12.5	31
12694	Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells. <i>Cancer Research</i> , 2021, 81, 2457-2469.	0.4	31
12695	Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. , 2021, 9, e002015.		23
12696	Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 575457.	1.3	5
12697	A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targeting. <i>Science Advances</i> , 2021, 7, .	4.7	81
12698	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
12699	Harnessing non-destructive 3D pathology. <i>Nature Biomedical Engineering</i> , 2021, 5, 203-218.	11.6	74
12700	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2021, 11, 1524-1541.	7.7	103
12701	Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients. <i>Nature Communications</i> , 2021, 12, 1119.	5.8	26
12702	Protein-based immune profiles of basal-like vs. luminal breast cancers. <i>Laboratory Investigation</i> , 2021, 101, 785-793.	1.7	9
12703	Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1377-1385.	1.0	11
12704	Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 595650.	1.3	19
12705	Defining and Targeting BRAF Mutations in Solid Tumors. <i>Current Treatment Options in Oncology</i> , 2021, 22, 30.	1.3	25
12706	Advances in Human Immune System Mouse Models for Studying Human Hematopoiesis and Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 619236.	2.2	23

#	ARTICLE	IF	CITATIONS
12707	PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2577-2587.	2.0	14
12708	Advanced Approaches to Breast Cancer Classification and Diagnosis. <i>Frontiers in Pharmacology</i> , 2020, 11, 632079.	1.6	86
12709	Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 980-988.	3.0	25
12710	Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting. <i>Cell Reports Medicine</i> , 2021, 2, 100194.	3.3	77
12711	Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. <i>Cancer Cell</i> , 2021, 39, 193-208.e10.	7.7	157
12712	Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 623424.	1.1	20
12713	Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 9.	2.3	35
12714	The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1-10.	0.6	65
12715	Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses. <i>Frontiers in Oncology</i> , 2020, 10, 610513.	1.3	17
12716	The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis. <i>Cancer Management and Research</i> , 2021, Volume 13, 1383-1393.	0.9	5
12717	Syngeneic tobacco carcinogen-induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden. <i>JCI Insight</i> , 2021, 6, .	2.3	13
12718	Integrative clustering methods for multi-omics data. <i>Wiley Interdisciplinary Reviews: Computational Statistics</i> , 2022, 14, e1553.	2.1	7
12719	FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. <i>Breast Cancer Research</i> , 2021, 23, 21.	2.2	22
12720	Mutational signatures in squamous cell carcinoma of the lung. <i>Journal of Thoracic Disease</i> , 2021, 13, 1075-1082.	0.6	4
12721	Longitudinal Immune Profiling Reveals Unique Myeloid and T-cell Phenotypes Associated with Spontaneous Immunoediting in a Prostate Tumor Model. <i>Cancer Immunology Research</i> , 2021, 9, 529-541.	1.6	11
12722	PD-L1 in Breast Cancer: The Road to the Perfect Biomarker Is Fraught With Uncertainty. <i>Journal of the National Cancer Institute</i> , 2021, 113, 951-952.	3.0	3
12723	Development and Characterization of a Modular CRISPR and RNA Aptamer Mediated Base Editing System. <i>CRISPR Journal</i> , 2021, 4, 58-68.	1.4	9
12724	Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation. <i>Scientific Reports</i> , 2021, 11, 3750.	1.6	22

#	ARTICLE	IF	CITATIONS
12725	Comprehensive Analysis of CDCAs Methylation and Immune Infiltrates in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 566183.	1.3	8
12726	Targeted drug delivery strategies for precision medicines. <i>Nature Reviews Materials</i> , 2021, 6, 351-370.	23.3	388
12727	Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies. <i>Cancer Reports</i> , 2021, 4, e1340.	0.6	13
12728	ITM2A as a Tumor Suppressor and Its Correlation With PD-L1 in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 581733.	1.3	7
12729	Identifying key questions in the ecology and evolution of cancer. <i>Evolutionary Applications</i> , 2021, 14, 877-892.	1.5	58
12730	Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. <i>Science</i> , 2021, 371, 595-602.	6.0	746
12731	Immune checkpoint blockade in renal cell carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 739-750.	0.8	13
12732	CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2353-2365.	2.0	13
12733	Pan-Cancer Drivers Are Recurrent Transcriptional Regulatory Heterogeneities in Early-Stage Luminal Breast Cancer. <i>Cancer Research</i> , 2021, 81, 1840-1852.	0.4	10
12734	Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma. <i>Annals of Translational Medicine</i> , 2021, 9, 339-339.	0.7	12
12735	Genetic engineering of T cells for immunotherapy. <i>Nature Reviews Genetics</i> , 2021, 22, 427-447.	7.7	63
12736	The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2021, 23, 1261-1272.	0.6	28
12737	Changing Trends in Melanoma Incidence and Decreasing Melanoma Mortality in Hungary Between 2011 and 2019: A Nationwide Epidemiological Study. <i>Frontiers in Oncology</i> , 2020, 10, 612459.	1.3	14
12738	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab010.	1.4	21
12739	Dampening antiviral immunity can protect the host. <i>FEBS Journal</i> , 2022, 289, 634-646.	2.2	5
12740	Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100140.	0.6	11
12741	The Reproducibility of Histopathologic Assessments of Programmed Cell Death-Ligand 1 Using Companion Diagnostics in NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100102.	0.6	2
12742	Rare deleterious germline variants and risk of lung cancer. <i>Npj Precision Oncology</i> , 2021, 5, 12.	2.3	19

#	ARTICLE	IF	CITATIONS
12743	Treatment personalization in gastrointestinal neuroendocrine tumors. <i>Current Treatment Options in Oncology</i> , 2021, 22, 29.	1.3	10
12744	The Impact of Preoperative Radiomics Signature on the Survival of Breast Cancer Patients With Residual Tumors After NAC. <i>Frontiers in Oncology</i> , 2020, 10, 523327.	1.3	5
12745	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. <i>Cell</i> , 2021, 184, 596-614.e14.	13.5	485
12746	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). <i>Journal of Clinical Oncology</i> , 2021, 39, 619-630.	0.8	317
12747	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 72.	7.1	191
12748	Random Forest Modelling of High-Dimensional Mixed-Type Data for Breast Cancer Classification. <i>Cancers</i> , 2021, 13, 991.	1.7	21
12749	Dynamics of thymus function and T cell receptor repertoire breadth in health and disease. <i>Seminars in Immunopathology</i> , 2021, 43, 119-134.	2.8	29
12750	Non-canonical PD-1 signaling in cancer and its potential implications in clinic. , 2021, 9, e001230.		15
12751	High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability. <i>BMC Cancer</i> , 2021, 21, 186.	1.1	16
12752	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 558-e1098.	1.9	18
12753	Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. <i>Annals of Translational Medicine</i> , 2021, 9, 513-513.	0.7	4
12754	Effect of prior therapy on tumor mutational burden in NSCLC. <i>Translational Lung Cancer Research</i> , 2021, 10, 1231-1238.	1.3	2
12755	HER2 transmembrane domain mutation: comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 1383-1396.	1.3	2
12756	BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 603223.	1.3	9
12757	Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review. <i>Breast Care</i> , 2022, 17, 63-70.	0.8	6
12758	Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 640690.	1.3	6
12759	Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1142-1155.	0.8	8
12760	Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 501-509.	1.5	4

#	ARTICLE	IF	CITATIONS
12761	Rare Breast Cancer Subtypes. <i>Current Oncology Reports</i> , 2021, 23, 54.	1.8	15
12762	New immunological potential markers for triple negative breast cancer: IL18R1, CD53, TRIM, Jaw1, LTB, PTPRCAP. <i>Discover Oncology</i> , 2021, 12, 6.	0.8	10
12763	Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100142.	0.6	1
12764	Association of Matrix Metalloproteinase-2 mRNA Expression with Subtypes of Pediatric Cholesteatoma. <i>BioMed Research International</i> , 2021, 2021, 1-8.	0.9	4
12765	An emerging role for cellular crosstalk in the cancer stem cell niche. <i>Journal of Pathology</i> , 2021, 254, 384-394.	2.1	31
12766	^{99m} Tc-Radiolabeled Silica Nanocarriers for Targeted Detection and Treatment of HER2-Positive Breast Cancer. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 1943-1960.	3.3	14
12767	PD-1 Blockade Modulates Functional Activities of Exhausted-Like T Cell in Patients With Cutaneous Leishmaniasis. <i>Frontiers in Immunology</i> , 2021, 12, 632667.	2.2	16
12768	Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies. <i>Clinical Cancer Research</i> , 2021, 27, 3825-3833.	3.2	8
12769	Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2177-2183.	1.0	5
12770	Identification of Stemness Characteristics Associated With the Immune Microenvironment and Prognosis in Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 626961.	1.3	18
12771	The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 975-985.	1.9	79
12772	Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. <i>Nature Cancer</i> , 2021, 2, 300-311.	5.7	70
12773	Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer. <i>International Journal of Cancer</i> , 2021, 149, 169-176.	2.3	24
12774	PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3975-3989.	3.3	25
12775	Quantitative Image Analysis for Tissue Biomarker Use: A White Paper From the Digital Pathology Association. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 479-493.	0.6	28
12776	Phenotypic and Functional Analyses Guiding Combination Immune Checkpoint Immunotherapeutic Strategies in HTLV-1 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 608890.	2.2	8
12777	Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway. <i>BioMed Research International</i> , 2021, 2021, 1-6.	0.9	4
12778	Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1085-1095.	4.8	74

#	ARTICLE	IF	CITATIONS
12779	Higher CD1a Levels Correlate with PD-L1 Expression and Predict Worse Overall Survival in Triple-Negative Breast Carcinoma. <i>Breast Care</i> , 2022, 17, 31-39.	0.8	1
12780	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1128-1155.	1.1	4
12781	A case of multiple synchronously diagnosed brain metastases from alveolar soft part sarcoma without concurrent lung involvement. , 2021, 12, 111.		2
12782	Neoadjuvant vascular-targeted photodynamic therapy improves survival and reduces recurrence and progression in a mouse model of urothelial cancer. <i>Scientific Reports</i> , 2021, 11, 4842.	1.6	4
12783	Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 642883.	1.3	21
12784	Tumor immune microenvironment in brain metastases from gynecologic malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2951-2960.	2.0	9
12785	Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. <i>Frontiers in Oncology</i> , 2021, 11, 639947.	1.3	24
12786	Ribosomal RNA Transcription Regulation in Breast Cancer. <i>Genes</i> , 2021, 12, 502.	1.0	22
12787	BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer. <i>Oncogene</i> , 2021, 40, 2982-2997.	2.6	21
12788	Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy. <i>Molecular Therapy</i> , 2021, 29, 908-919.	3.7	58
12789	Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component. <i>Translational Lung Cancer Research</i> , 2021, 10, 1292-1304.	1.3	7
12790	âœœSkin rashesâ€and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management. <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-8.	1.4	5
12791	Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	1
12792	Identification ACTA2 and KDR as key proteins for prognosis of PDâ€1/PDâ€1 blockade therapy in melanoma. <i>Animal Models and Experimental Medicine</i> , 2021, 4, 138-150.	1.3	4
12793	Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 1889-1899.	3.3	28
12794	Dual role of endothelial <i>Myct1</i> in tumor angiogenesis and tumor immunity. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	35
12795	Single-Cell Deconvolution of Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1230.	1.7	26
12796	TNF in the era of immune checkpoint inhibitors: friend or foe?. <i>Nature Reviews Rheumatology</i> , 2021, 17, 213-223.	3.5	77

#	ARTICLE	IF	CITATIONS
12797	PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway. <i>Annals of Translational Medicine</i> , 2021, 9, 410-410.	0.7	37
12798	Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 2107-2121.	3.3	30
12799	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 1759-1776.	2.9	113
12800	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.	0.8	329
12801	Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. <i>Nature Reviews Cancer</i> , 2021, 21, 298-312.	12.8	553
12802	STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data. <i>Future Science OA</i> , 2021, 7, FSO661.	0.9	3
12803	Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. <i>Nature Communications</i> , 2021, 12, 1439.	5.8	39
12804	Single-Cell RNA-seq Reveals Characteristics of Malignant Cells and Immune Microenvironment in Subcutaneous Panniculitis-Like T-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 611580.	1.3	7
12805	Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients. <i>Annals of Translational Medicine</i> , 2021, 9, 397-397.	0.7	0
12806	First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion. <i>IJU Case Reports</i> , 2021, 4, 176-179.	0.1	2
12807	Primary malignant melanoma of uterine cervix treated with pembrolizumab as adjuvant immunotherapy. <i>International Cancer Conference Journal</i> , 2021, 10, 254-258.	0.2	3
12808	Recent advances in preclinical models for lung squamous cell carcinoma. <i>Oncogene</i> , 2021, 40, 2817-2829.	2.6	26
12809	Identification of Hub Genes and Pathways of Triple Negative Breast Cancer by Expression Profiles Analysis. <i>Cancer Management and Research</i> , 2021, Volume 13, 2095-2104.	0.9	6
12810	Distinct genomic features across cytolytic subgroups in skin melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3137-3154.	2.0	12
12811	Ocular Toxicity of Targeted Anticancer Agents. <i>Drugs</i> , 2021, 81, 771-823.	4.9	22
12812	Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy. <i>Clinical Epigenetics</i> , 2021, 13, 63.	1.8	34
12813	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. <i>Clinical Cancer Research</i> , 2021, 27, 2920-2927.	3.2	42
12814	The role of opioids in cancer response to immunotherapy. <i>Journal of Translational Medicine</i> , 2021, 19, 119.	1.8	24

#	ARTICLE	IF	CITATIONS
12815	Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients. <i>Frontiers in Oncology</i> , 2021, 11, 570623.	1.3	29
12816	Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis. <i>Journal of Immunotherapy</i> , 2021, 44, 224-233.	1.2	3
12817	Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2021, 13, 1760-1768.	0.6	36
12818	Targeting loss of heterozygosity for cancer-specific immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	39
12819	Sex- and Gender-Based Pharmacological Response to Drugs. <i>Pharmacological Reviews</i> , 2021, 73, 730-762.	7.1	80
12820	Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	84
12821	An expanded universe of cancer targets. <i>Cell</i> , 2021, 184, 1142-1155.	13.5	135
12822	Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. <i>Frontiers in Immunology</i> , 2021, 12, 636568.	2.2	394
12823	CD8+ T Lymphocyte Coexpression Genes Correlate with Immune Microenvironment and Overall Survival in Breast Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-13.	0.6	0
12824	PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 1581-1591.	2.9	12
12825	Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. <i>Cancer Biology and Therapy</i> , 2021, 22, 175-183.	1.5	13
12826	DNA-methylation for the detection and distinction of 19 human malignancies. <i>Epigenetics</i> , 2022, 17, 191-201.	1.3	7
12827	Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. <i>Science Advances</i> , 2021, 7, .	4.7	10
12828	Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review. <i>Bone Marrow Transplantation</i> , 2021, 56, 1784-1793.	1.3	5
12829	Group phenotypic composition in cancer. <i>ELife</i> , 2021, 10, .	2.8	18
12830	Protocol for proteogenomic dissection of intronic splicing enhancer interactome for prediction of individualized cancer prognosis. <i>STAR Protocols</i> , 2021, 2, 100338.	0.5	1
12831	A signature of estimate-stromal-immune score-based genes associated with the prognosis of lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 1484-1500.	1.3	22
12832	Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 609054.	1.3	23

#	ARTICLE	IF	CITATIONS
12833	Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. <i>ENeurologicalSci</i> , 2021, 22, 100324.	0.5	9
12834	Immune Checkpoint Inhibition as a Strategy in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 86-104.	0.6	0
12835	Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint. <i>Molecular Diversity</i> , 2022, 26, 245-264.	2.1	9
12836	Aging, cancer, and antitumor immunity. <i>International Journal of Clinical Oncology</i> , 2022, 27, 316-322.	1.0	29
12837	Granzyme B PET Imaging of Combined Chemotherapy and Immune Checkpoint Inhibitor Therapy in Colon Cancer. <i>Molecular Imaging and Biology</i> , 2021, 23, 714-723.	1.3	16
12838	MIG-6 is essential for promoting glucose metabolic reprogramming and tumor growth in triple-negative breast cancer. <i>EMBO Reports</i> , 2021, 22, e50781.	2.0	8
12839	An unexpected role for p53 in regulating cancer cell-intrinsic PD-1 by acetylation. <i>Science Advances</i> , 2021, 7, .	4.7	32
12840	PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2301-2309.	1.0	6
12841	A single-cell atlas of the healthy breast tissues reveals clinically relevant clusters of breast epithelial cells. <i>Cell Reports Medicine</i> , 2021, 2, 100219.	3.3	48
12842	FOXQ1 is Differentially Expressed Across Breast Cancer Subtypes with Low Expression Associated with Poor Overall Survival. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 171-188.	1.0	5
12843	Pyroptosis: mechanisms and diseases. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 128.	7.1	821
12844	Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies. <i>Health Services Research</i> , 2021, 56, 486-496.	1.0	3
12845	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3123-3135.	2.0	6
12846	Long non-coding RNA ROR recruits histone methylase MLL1 to up-regulate TIMP3 expression and promote breast cancer progression. <i>Journal of Translational Medicine</i> , 2021, 19, 95.	1.8	18
12847	Model-based feature selection and clustering of RNA-seq data for unsupervised subtype discovery. <i>Annals of Applied Statistics</i> , 2021, 15, 481-508.	0.5	6
12848	KRAS G12C inhibition and innate immune targeting. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 1-8.	1.5	6
12849	Environmental triggers of dermatomyositis: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 434-434.	0.7	22
12850	Deep sequencing reveals the genomic characteristics of lung adenocarcinoma presenting as ground-glass nodules (GGNs). <i>Translational Lung Cancer Research</i> , 2021, 10, 1239-1255.	1.3	4

#	ARTICLE	IF	CITATIONS
12851	Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3243-3252.	3.2	14
12852	Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 628124.	1.3	39
12853	Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Clinical Science</i> , 2021, 135, 703-724.	1.8	18
12854	Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 657615.	1.3	29
12855	Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 630136.	1.3	17
12856	<i>BRAF</i> V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1072-1079.	1.9	6
12857	Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). , 2021, 9, e001504.		72
12858	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 899-919.	21.5	208
12859	Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches. <i>Cancer Discovery</i> , 2021, 11, 1024-1039.	7.7	56
12860	Dermatologic infections in cancer patients treated with checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1528-1536.	0.6	3
12861	Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function. <i>JCI Insight</i> , 2021, 6, .	2.3	47
12862	Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2~ Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). <i>Clinical Cancer Research</i> , 2021, 27, 4177-4185.	3.2	47
12863	Functional Assessment of Four Novel Immune-Related Biomarkers in the Pathogenesis of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 621618.	1.8	7
12864	The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2021, 2021, 1-13.	0.9	15
12865	Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series. <i>Frontiers in Oncology</i> , 2021, 11, 633522.	1.3	8
12866	Sinonasal mucosal melanoma: treatment strategies and survival rates for a rare disease entity. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1137-1147.	1.0	8
12867	High CD8/CD33 ratio in peritoneal metastatic lesions is associated with favorable prognosis in gastric cancer. <i>Cancer Reports</i> , 2021, 4, e1389.	0.6	2
12868	Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings. <i>Frontiers in Oral Health</i> , 2021, 2, 653104.	1.2	2

#	ARTICLE	IF	CITATIONS
12869	Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study. <i>Translational Lung Cancer Research</i> , 2021, 10, 1594-1607.	1.3	17
12870	Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. <i>Gynecologic Oncology</i> , 2021, 161, 113-121.	0.6	42
12871	Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors. <i>Endocrinology and Metabolism</i> , 2021, 36, 312-321.	1.3	15
12872	The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 429-445.	2.8	5
12873	Imaging Biomarkers to Assess Response to Immune Checkpoint Inhibitors in Solid Tumors to Tailor Therapy. <i>Radiology</i> , 2021, 299, 120-121.	3.6	0
12874	Solid Organ Transplantation and Survival among Individuals with a History of Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1312-1319.	1.1	5
12875	A GATA6-centred gene regulatory network involving HNFs and \hat{I}^m Np63 controls plasticity and immune escape in pancreatic cancer. <i>Gut</i> , 2022, 71, 766-777.	6.1	38
12876	Exploration of the Associations of lncRNA Expression Patterns with Tumor Mutation Burden and Prognosis in Colon Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2893-2909.	1.0	13
12877	Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights. <i>Drug Discovery Today</i> , 2021, 26, 951-967.	3.2	25
12878	Vascular normalisation as the stepping stone into tumour microenvironment transformation. <i>British Journal of Cancer</i> , 2021, 125, 324-336.	2.9	44
12879	Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 645699.	2.2	18
12880	How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 697-717.	2.0	93
12881	Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors. <i>Endocrinology and Metabolism</i> , 2021, 36, 413-423.	1.3	24
12882	Cervical Cancer Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2021, 27, 4953-4973.	3.2	129
12883	Development and Validation of a Robust Immune-Related Prognostic Signature for Gastric Cancer. <i>Journal of Immunology Research</i> , 2021, 2021, 1-24.	0.9	8
12884	Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 572740.	1.3	4
12885	Overcoming therapy resistance in EGFR-mutant lung cancer. <i>Nature Cancer</i> , 2021, 2, 377-391.	5.7	198
12886	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 562315.	1.3	38

#	ARTICLE	IF	CITATIONS
12887	COBRAC: a fast implementation of convex biclustering with compression. <i>Bioinformatics</i> , 2021, 37, 3667-3669.	1.8	4
12888	PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	40
12889	Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 666691.	1.3	2
12890	Trials and tribulations of pancreatic cancer immunotherapy. <i>Cancer Letters</i> , 2021, 504, 1-14.	3.2	37
12891	Anti-angiogenic agents “overcoming tumour endothelial cell energy and improving immunotherapy outcomes. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 527-540.	12.5	162
12892	Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy. <i>Seminars in Cancer Biology</i> , 2022, 85, 246-252.	4.3	38
12893	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	7.7	130
12894	ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2617-2625.	1.4	11
12895	A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. <i>Journal of Medical Toxicology</i> , 2021, 17, 411-424.	0.8	54
12896	Systemic immunity in cancer. <i>Nature Reviews Cancer</i> , 2021, 21, 345-359.	12.8	605
12897	An Immune-Related Gene Pairs Signature Predicts Prognosis and Immune Heterogeneity in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 592211.	1.3	1
12898	Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	0.6	13
12899	Targeting regulatory T cells for immunotherapy in melanoma. <i>Molecular Biomedicine</i> , 2021, 2, 11.	1.7	22
12900	Expression and Prognosis of Sperm-Associated Antigen 1 in Human Breast Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2689-2698.	1.0	3
12901	Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 172-179.	0.7	23
12902	Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3295-3308.	0.4	51
12903	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 686-696.	0.5	13
12904	Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects. <i>Frontiers in Medicine</i> , 2021, 8, 642380.	1.2	28

#	ARTICLE	IF	CITATIONS
12905	Tumor resident regulatory T cells. <i>Seminars in Immunology</i> , 2021, 52, 101476.	2.7	18
12906	CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway. <i>Neurotherapeutics</i> , 2021, 18, 1980-1994.	2.1	6
12907	The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 654877.	2.2	19
12908	CD8+ T cells inhibit metastasis and CXCL4 regulates its function. <i>British Journal of Cancer</i> , 2021, 125, 176-189.	2.9	21
12909	Emerging Role of PD-1 in the Central Nervous System and Brain Diseases. <i>Neuroscience Bulletin</i> , 2021, 37, 1188-1202.	1.5	30
12910	Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. <i>Nature Cancer</i> , 2021, 2, 400-413.	5.7	41
12911	Use of amantadine in the evaluation of response to chemotherapy in lung cancer: a pilot study. <i>Future Science OA</i> , 2021, 7, FSO679.	0.9	3
12912	Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines. <i>Cancer Gene Therapy</i> , 2021, 28, 935-946.	2.2	10
12913	Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. <i>Frontiers in Oncology</i> , 2021, 11, 628456.	1.3	14
12914	Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. <i>British Journal of Cancer</i> , 2021, 125, 164-175.	2.9	177
12915	Therapeutic cancer vaccines. <i>Nature Reviews Cancer</i> , 2021, 21, 360-378.	12.8	630
12916	Metabolic barriers to cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2021, 21, 785-797.	10.6	245
12917	Construction of miRNA-mRNA Regulatory Network and Prognostic Signature in Endometrial Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2363-2378.	1.0	7
12918	Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. <i>Frontiers in Immunology</i> , 2021, 12, 643310.	2.2	27
12919	Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. <i>JCO Precision Oncology</i> , 2021, 5, 432-441.	1.5	16
12920	A Network Pharmacology Study Based on the Mechanism of Citri Reticulatae Pericarpium-Pinelliae Rhizoma in the Treatment of Gastric Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-17.	0.5	8
12921	Gastrointestinal disorders as immune-related adverse events. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	2
12922	Up to your NEK2 in CIN. <i>Oncotarget</i> , 2021, 12, 723-725.	0.8	0

#	ARTICLE	IF	CITATIONS
12923	Personal and Prognostic: Tissue and Liquid Biomarkers of Radiotherapeutic Response in Non-Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 149-154.	1.0	1
12924	Abnormal spindle-like microcephaly-associated protein enhances cell invasion through Wnt/ β -catenin-dependent regulation of epithelial-mesenchymal transition in non-small cell lung cancer cells. <i>Journal of Thoracic Disease</i> , 2021, 13, 2460-2474.	0.6	5
12925	IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3557-3571.	2.0	11
12926	Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1922-1935.	0.6	33
12927	Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade. <i>Cancer Research</i> , 2021, 81, 3693-3705.	0.4	15
12928	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2021, 2021, CD013257.	1.5	35
12929	Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs. <i>Cancers</i> , 2021, 13, 1674.	1.7	9
12930	The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients. <i>Cancer Research and Treatment</i> , 2021, 53, 339-354.	1.3	63
12931	Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels. <i>Molecular Therapy</i> , 2021, 29, 1512-1528.	3.7	73
12932	Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. <i>Brain</i> , 2021, 144, 1046-1066.	3.7	24
12933	Endocrine toxicities of immune checkpoint inhibitors. <i>Nature Reviews Endocrinology</i> , 2021, 17, 389-399.	4.3	162
12934	Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 618767.	1.3	12
12935	Integrated Profiling Identifies CCNA2 as a Potential Biomarker of Immunotherapy in Breast Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2433-2448.	1.0	12
12936	Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 705-705.	0.7	6
12937	The roles of the cell division cycle-associated gene family in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 781-794.	0.6	2
12938	Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study. <i>Annals of Translational Medicine</i> , 2021, 9, 685-685.	0.7	10
12939	Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3313-3322.	2.0	17
12940	Tumour neoantigen mimicry by microbial species in cancer immunotherapy. <i>British Journal of Cancer</i> , 2021, 125, 313-323.	2.9	29

#	ARTICLE	IF	CITATIONS
12941	Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment. <i>Gland Surgery</i> , 2021, 10, 1300-1314.	0.5	4
12942	Computing the Role of Alternative Splicing in Cancer. <i>Trends in Cancer</i> , 2021, 7, 347-358.	3.8	19
12943	Optimizing the diagnosis and management of ductal prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 337-358.	1.9	21
12944	Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies. <i>Biomolecules</i> , 2021, 11, 582.	1.8	11
12945	Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model. <i>Molecular Cancer Research</i> , 2021, 19, 1422-1436.	1.5	3
12946	Overview of Ocular Side Effects of Selinexor. <i>Oncologist</i> , 2021, 26, 619-623.	1.9	5
12947	Evolutionary genetic algorithm identifies <i>IL2RB</i> as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer. <i>NAR Genomics and Bioinformatics</i> , 2021, 3, lqab016.	1.5	10
12948	Factors affecting survival after palliative radiotherapy in patients with lung cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 674-682.	0.3	0
12949	Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1634-1647.	3.0	28
12950	Feasibility of semiquantitative ¹⁸ F-fluorodeoxyglucose PET/computed tomography in patients with advanced lung cancer for interim treatment evaluation of combining immunotherapy and chemotherapy. <i>Nuclear Medicine Communications</i> , 2021, 42, 1017-1023.	0.5	3
12951	MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells. <i>Cancer Cell International</i> , 2021, 21, 213.	1.8	26
12952	Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3489-3499.	2.0	5
12953	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 650292.	1.3	22
12954	The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer. <i>Nutrients</i> , 2021, 13, 1212.	1.7	27
12955	Association of Body Mass Index With Somatic Mutations in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 613933.	1.3	1
12956	The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer. <i>British Journal of Cancer</i> , 2021, 125, 240-246.	2.9	8
12957	Cellular networks controlling T cell persistence in adoptive cell therapy. <i>Nature Reviews Immunology</i> , 2021, 21, 769-784.	10.6	83
12958	Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients. <i>Cancer Management and Research</i> , 2021, Volume 13, 3055-3065.	0.9	3

#	ARTICLE	IF	CITATIONS
12959	Prognostic Significance and Tumor Immune Microenvironment Heterogeneity of m5C RNA Methylation Regulators in Triple-Negative Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 657547.	1.8	57
12960	Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events. <i>Kidney International Reports</i> , 2021, 6, 1022-1031.	0.4	54
12961	Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC. <i>Frontiers in Oncology</i> , 2021, 11, 671228.	1.3	13
12962	Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 646883.	1.3	7
12963	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. , 2021, 9, e002478.		59
12964	Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. <i>Nature Biomedical Engineering</i> , 2021, 5, 1038-1047.	11.6	164
12965	Primary vaginal malignant melanoma. <i>Medicine (United States)</i> , 2021, 100, e25691.	0.4	8
12966	Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines. <i>Current Opinion in Immunology</i> , 2021, 69, 65-71.	2.4	14
12967	IFN γ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity. <i>Cancer Discovery</i> , 2021, 11, 2248-2265.	7.7	86
12968	Evaluating the transcriptional fidelity of cancer models. <i>Genome Medicine</i> , 2021, 13, 73.	3.6	26
12969	Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis. <i>Journal of Thoracic Disease</i> , 2021, 13, 2959-2967.	0.6	2
12970	Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 618570.	1.3	12
12971	Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study. <i>Molecular Oncology</i> , 2022, 16, 206-218.	2.1	7
12972	YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 607224.	1.3	64
12973	Post-transcriptional control of T cell cytokine production: Implications for cancer therapy. <i>Immunology</i> , 2021, 164, 57-72.	2.0	3
12974	In-transit metastatic cutaneous melanoma: current management and future directions. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 201-211.	1.7	6
12975	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2021, 23, 79.	1.8	85
12976	Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 663406.	1.3	14

#	ARTICLE	IF	CITATIONS
12977	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. <i>Neuro-Oncology</i> , 2022, 24, 101-113.	0.6	38
12978	Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. <i>Nutrients</i> , 2021, 13, 1718.	1.7	10
12979	A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. <i>Nature Medicine</i> , 2021, 27, 820-832.	15.2	330
12980	Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. <i>Gut</i> , 2022, 71, 734-745.	6.1	177
12981	Inpatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 667-673.	0.6	11
12982	Adamantyl Isothiocyanates as Mutant p53 Rescuing Agents and Their Structure-Activity Relationships. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6621-6633.	2.9	11
12983	Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. <i>Cell Reports</i> , 2021, 35, 109120.	2.9	60
12984	A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types. <i>Nature Cancer</i> , 2021, 2, 563-574.	5.7	38
12985	Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release. , 2021, 9, e002222.		24
12986	Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 172.	3.5	104
12987	Soluble cytotoxic T-lymphocyte-associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma. <i>BMC Immunology</i> , 2021, 22, 33.	0.9	9
12988	Genomic characterization of small cell carcinomas of the uterine cervix. <i>Molecular Oncology</i> , 2022, 16, 833-845.	2.1	14
12989	Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2+, PIK3CA-Mutated Breast Cancer. <i>Oncologist</i> , 2021, 26, e1133-e1142.	1.9	17
12990	A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer. <i>Npj Precision Oncology</i> , 2021, 5, 36.	2.3	20
12991	Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	17
12992	Emerging concepts in PD-1 checkpoint biology. <i>Seminars in Immunology</i> , 2021, 52, 101480.	2.7	84
12993	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12
12994	NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells. <i>Cell Reports Medicine</i> , 2021, 2, 100279.	3.3	7

#	ARTICLE	IF	CITATIONS
12995	The Role of Programmed Death-1 in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 20.	1.7	11
12996	Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5207.	1.8	20
12997	Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer. <i>Oncology Letters</i> , 2021, 22, 540.	0.8	8
12998	PUM1 is upregulated by DNA methylation to suppress antitumor immunity and results in poor prognosis in pancreatic cancer. <i>Translational Cancer Research</i> , 2021, 10, 2153-2168.	0.4	8
12999	Immunotherapy and radiation for high-grade glioma: a narrative review. <i>Translational Cancer Research</i> , 2021, 10, 2537-2570.	0.4	6
13000	Immu-Mela: An open resource for exploring immunotherapy-related multidimensional genomic profiles in melanoma. <i>Journal of Genetics and Genomics</i> , 2021, 48, 361-368.	1.7	3
13001	PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR. <i>Cell Reports</i> , 2021, 35, 109181.	2.9	27
13002	Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[18F]FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4054-4066.	3.3	8
13003	The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 669839.	1.3	4
13004	Cancer microenvironment and genomics: evolution in process. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 85-99.	1.7	11
13005	Intracranial complete response for non-small cell lung cancer patient with negative PD-L1 expression of the lung using nivolumab. <i>Cancer Reports</i> , 2021, , e1460.	0.6	3
13006	PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma. <i>Cell Death and Differentiation</i> , 2021, 28, 2745-2764.	5.0	52
13007	Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 625-633.	1.1	8
13008	A six-gene signature related with tumor mutation burden for predicting lymph node metastasis in breast cancer. <i>Translational Cancer Research</i> , 2021, 10, 2229-2246.	0.4	3
13009	The application of artificial intelligence in lung cancer: a narrative review. <i>Translational Cancer Research</i> , 2021, 10, 2478-2487.	0.4	7
13010	Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 4233-4240.	0.9	17
13011	Comparative Characterization of Lymphoid Infiltration in Different Molecular-Biological Subtypes of Invasive Breast Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2021, 171, 62-67.	0.3	0
13012	The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 663612.	1.3	8

#	ARTICLE	IF	CITATIONS
13013	Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors. <i>Journal of Oncology</i> , 2021, 2021, 1-15.	0.6	8
13014	Phenotypic Heterogeneity of Triple-Negative Breast Cancer Mediated by Epithelial-Mesenchymal Plasticity. <i>Cancers</i> , 2021, 13, 2188.	1.7	35
13015	Imaging of T-cell Responses in the Context of Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 490-502.	1.6	8
13016	Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 191-207.	3.0	5
13017	ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer. <i>Nature Cancer</i> , 2021, 2, 503-514.	5.7	72
13018	Age-Associated Changes in Adverse Events Arising From Anti-PD-(L)1 Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 619385.	1.3	12
13019	Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2953-2965.	1.0	6
13020	High endothelial venules (HEVs) in immunity, inflammation and cancer. <i>Angiogenesis</i> , 2021, 24, 719-753.	3.7	64
13021	Progesterone promotes immunomodulation and tumor development in the murine mammary gland. , 2021, 9, e001710.		12
13022	Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. <i>Clinical and Translational Oncology</i> , 2021, 23, 2237-2252.	1.2	7
13023	CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function. <i>Immunology</i> , 2021, 163, 512-520.	2.0	46
13024	Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2103-2117.	1.3	12
13025	Experiences of cancer immunotherapy with immune checkpoint inhibitors (ExCIIm)-insights of people affected by cancer and healthcare professionals: a qualitative study protocol. <i>BMJ Open</i> , 2021, 11, e043750.	0.8	3
13026	The utilization of immunotherapy with radiation therapy in lung cancer: a narrative review. <i>Translational Cancer Research</i> , 2021, 10, 2596-2608.	0.4	8
13027	Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells. <i>Science Advances</i> , 2021, 7, .	4.7	53
13028	Melanoma models for the next generation of therapies. <i>Cancer Cell</i> , 2021, 39, 610-631.	7.7	90
13029	Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e352-e359.	0.9	0
13030	Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review. <i>JCO Precision Oncology</i> , 2021, 5, 953-973.	1.5	31

#	ARTICLE	IF	CITATIONS
13031	Gingival Leukoplakia: Hyperkeratosis with Epithelial Atrophy Is A Frequent Histopathologic Finding. <i>Head and Neck Pathology</i> , 2021, 15, 1235-1245.	1.3	4
13032	Data-Driven Mathematical Model of Osteosarcoma. <i>Cancers</i> , 2021, 13, 2367.	1.7	20
13033	The Multifaceted Effects of Breast Cancer on Tumor-Draining Lymph Nodes. <i>American Journal of Pathology</i> , 2021, 191, 1353-1363.	1.9	15
13034	Near infrared photoimmunotherapy of cancer; possible clinical applications. <i>Nanophotonics</i> , 2021, 10, 3135-3151.	2.9	19
13035	Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. <i>Endocrine</i> , 2021, 74, 172-179.	1.1	19
13036	Metastasis is altered through multiple processes regulated by the E2F1 transcription factor. <i>Scientific Reports</i> , 2021, 11, 9502.	1.6	3
13037	Immune Cells and Immunotherapy for Cardiac Injury and Repair. <i>Circulation Research</i> , 2021, 128, 1766-1779.	2.0	93
13038	STING Agonists as Cancer Therapeutics. <i>Cancers</i> , 2021, 13, 2695.	1.7	181
13039	Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3669-3677.	2.0	39
13040	Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 519-536.	2.7	56
13041	Chromatin accessibility governs the differential response of cancer and T _H cells to arginine starvation. <i>Cell Reports</i> , 2021, 35, 109101.	2.9	20
13042	Role of immunotherapy in oligometastatic nonsmall cell lung cancer. <i>BMJ Case Reports</i> , 2021, 14, e241070.	0.2	1
13043	Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis. <i>Journal of Oncology</i> , 2021, 2021, 1-13.	0.6	6
13044	Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, .	0.5	1
13045	Sarcoid-like reaction: a unique response to immunotherapy in malignant melanoma. <i>BMJ Case Reports</i> , 2021, 14, e243723.	0.2	0
13046	Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662392.	1.3	3
13047	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.	0.9	20
13048	Precision and Immunoprevention Strategies for Tobacco-Related Head and Neck Cancer Chemoprevention. <i>Current Treatment Options in Oncology</i> , 2021, 22, 52.	1.3	1

#	ARTICLE	IF	CITATIONS
13049	Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4379-4396.	3.2	30
13050	Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100147.	0.6	3
13051	Antibody-based cancer therapy. <i>Oncogene</i> , 2021, 40, 3655-3664.	2.6	42
13052	Development and Validation of a Hypoxia-Related Signature for Predicting Survival Outcomes in Patients With Bladder Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 670384.	1.1	15
13053	Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancers. <i>Science Advances</i> , 2021, 7, .	4.7	12
13054	Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review). <i>Pharmaceuticals</i> , 2021, 14, 447.	1.7	32
13055	Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 25-38.	2.0	15
13056	Evolution of delayed resistance to immunotherapy in a melanoma responder. <i>Nature Medicine</i> , 2021, 27, 985-992.	15.2	67
13057	Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO. <i>Neuro-Oncology</i> , 2021, 23, 1750-1764.	0.6	28
13058	Epigenetic dysregulation of immune-related pathways in cancer: bioinformatics tools and visualization. <i>Experimental and Molecular Medicine</i> , 2021, 53, 761-771.	3.2	8
13059	Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. <i>Cell Reports</i> , 2021, 35, 109071.	2.9	35
13060	Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older. <i>Cancer Reports</i> , 2021, 4, e1405.	0.6	8
13061	Genome profiling of mismatch repair genes in eight types of tumors. <i>Cell Cycle</i> , 2021, 20, 1-16.	1.3	0
13062	Identification of genetic variations associated with drug resistance in non-small cell lung cancer patients undergoing systemic treatment. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	7
13063	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. <i>Oncologist</i> , 2021, 26, e1226-e1239.	1.9	17
13064	Clinical and Hematological Predictors of High-Grade Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 268-275.	0.6	7
13065	Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection. <i>Npj Breast Cancer</i> , 2021, 7, 59.	2.3	5
13066	Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition. <i>Frontiers in Oncology</i> , 2021, 11, 664848.	1.3	10

#	ARTICLE	IF	CITATIONS
13067	Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2021, 13, 216-226.	0.5	5
13068	The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review. <i>Clinical Otolaryngology</i> , 2021, 46, 919-934.	0.6	17
13069	PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 111-120.	2.0	11
13070	Identification of KIF4A as a pan-cancer diagnostic and prognostic biomarker via bioinformatics analysis and validation in osteosarcoma cell lines. <i>PeerJ</i> , 2021, 9, e11455.	0.9	4
13071	Role of the ABL tyrosine kinases in the epithelial-mesenchymal transition and the metastatic cascade. <i>Cell Communication and Signaling</i> , 2021, 19, 59.	2.7	17
13072	Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 645245.	1.3	9
13073	Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators. <i>Frontiers in Oncology</i> , 2021, 11, 659754.	1.3	6
13074	M5C regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 2172-2192.	1.3	15
13075	Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2021, 13, 2824-2832.	0.6	9
13076	Bioinformatic analysis of the expression and prognosis of ZNF589 in human breast cancer. <i>Translational Cancer Research</i> , 2021, 10, 2286-2304.	0.4	2
13077	Automated Identification of Patients With Immune-Related Adverse Events From Clinical Notes Using Word Embedding and Machine Learning. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 541-549.	1.0	8
13078	Sex as an important factor in nanomedicine. <i>Nature Communications</i> , 2021, 12, 2984.	5.8	47
13079	Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab048.	1.4	23
13080	Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4435-4448.	3.2	35
13081	FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. <i>Npj Breast Cancer</i> , 2021, 7, 51.	2.3	11
13082	Penalized estimation of the Gaussian graphical model from data with replicates. <i>Statistics in Medicine</i> , 2021, 40, 4279-4293.	0.8	5
13083	Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review. <i>Cancer Medicine</i> , 2021, 10, 5031-5040.	1.3	5
13084	Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. , 2021, 9, e002345.		7

#	ARTICLE	IF	CITATIONS
13085	Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 517-527.	1.3	6
13086	Nanotechnology synergized immunoengineering for cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 163, 72-101.	2.0	8
13087	N ⁶ -methyladenosine (m ⁶ A) RNA modification of G protein-coupled receptor 133 increases proliferation of lung adenocarcinoma. <i>FEBS Open Bio</i> , 2021, , .	1.0	3
13088	A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression. <i>Liver Cancer</i> , 2021, 10, 500-509.	4.2	9
13089	Prostate Cancer Immunotherapy—Finally in From the Cold?. <i>Current Oncology Reports</i> , 2021, 23, 88.	1.8	21
13090	The clinical and molecular significance associated with STING signaling in breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 81.	2.3	21
13091	Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies. <i>Drug Delivery and Translational Research</i> , 2021, 11, 2394-2413.	3.0	9
13092	Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab100.	0.1	9
13093	netgsa: Fast computation and interactive visualization for topology-based pathway enrichment analysis. <i>PLoS Computational Biology</i> , 2021, 17, e1008979.	1.5	8
13094	Identification of G-protein signaling modulator 2 as a diagnostic and prognostic biomarker of pancreatic adenocarcinoma: an exploration of its regulatory mechanisms. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1164-1179.	0.6	3
13095	Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1117-1131.	0.6	7
13096	Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab. <i>Translational Lung Cancer Research</i> , 2021, 10, 2509-2522.	1.3	13
13097	Correlation Between 18F-FDG Uptake and Immune Cell Infiltration in Metastatic Brain Lesions. <i>Frontiers in Oncology</i> , 2021, 11, 618705.	1.3	5
13098	Hepatectomy and immune checkpoint inhibitor treatment for liver metastasis originating from non-cutaneous melanoma: a report of three cases. <i>International Cancer Conference Journal</i> , 2021, 10, 274-279.	0.2	2
13099	Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response. <i>Disease Markers</i> , 2021, 1-15.	0.6	25
13100	Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). <i>Clinical Cancer Research</i> , 2021, 27, 5828-5837.	3.2	18
13101	Immune-related cutaneous adverse events due to checkpoint inhibitors. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 613-622.	0.5	12
13102	The landscape of PD-L1 expression and somatic mutations in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1132-1140.	0.6	5

#	ARTICLE	IF	CITATIONS
13103	Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than PD-L1/PD-L2 alterations. <i>Blood</i> , 2021, 138, 1194-1197.	0.6	5
13104	Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 202.	3.5	14
13105	Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1619-1627.	1.0	6
13106	Imaging Assessment of Tumor Response in the Era of Immunotherapy. <i>Diagnostics</i> , 2021, 11, 1041.	1.3	3
13107	A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics. <i>Gastric Cancer</i> , 2021, 24, 1227-1241.	2.7	21
13108	Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 631037.	1.3	10
13109	Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy. <i>Cancer Gene Therapy</i> , 2022, 29, 647-660.	2.2	40
13110	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4883-4897.	3.2	11
13111	Challenges targeting cancer neoantigens in 2021: a systematic literature review. <i>Expert Review of Vaccines</i> , 2021, 20, 827-837.	2.0	13
13112	Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade. <i>Journal of Immunotherapy</i> , 2021, 44, 283-291.	1.2	6
13113	Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 639-651.	3.3	15
13114	Correlations Between the Characteristics of Alternative Splicing Events, Prognosis, and the Immune Microenvironment in Breast Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 686298.	1.1	3
13115	Immunotherapy in oncogene addicted non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2736-2751.	1.3	7
13116	PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2441-2451.	1.3	19
13117	The dark side of immunotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1041-1041.	0.7	12
13118	Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistent. <i>Cancer Medicine</i> , 2021, 10, 5712-5720.	1.3	5
13119	Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2021, 27, 4557-4565.	3.2	61
13120	ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4898-4909.	3.2	66

#	ARTICLE	IF	CITATIONS
13121	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. <i>Science</i> , 2021, 372, .	6.0	114
13122	Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1038-1049.	2.3	5
13123	FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-“High Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4685-4689.	3.2	216
13124	Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation. <i>New England Journal of Medicine</i> , 2021, 384, 2371-2381.	13.9	833
13125	PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 648068.	1.3	13
13126	CD8 ⁺ T cell immunity blocks the metastasis of carcinogen-exposed breast cancer. <i>Science Advances</i> , 2021, 7, .	4.7	24
13127	The Impact of Nrf2 Silencing on Nrf2-PD-L1 Axis to Overcome Oxaliplatin Resistance and Migration in Colon Cancer Cells. <i>Avicenna Journal of Medical Biotechnology</i> , 2021, 13, 116-122.	0.2	9
13128	Not-so-opposite ends of the spectrum: CD8 ⁺ T cell dysfunction across chronic infection, cancer and autoimmunity. <i>Nature Immunology</i> , 2021, 22, 809-819.	7.0	113
13129	Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer. <i>Cancer Medicine</i> , 2021, 10, 5375-5391.	1.3	6
13130	Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment. <i>Vaccines</i> , 2021, 9, 634.	2.1	8
13131	E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion. <i>Oncogene</i> , 2021, 40, 5567-5578.	2.6	3
13132	Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 107-134.	5.7	70
13133	Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 189-201.	2.0	3
13134	TIRR inhibits the 53BP1-p53 complex to alter cell-fate programs. <i>Molecular Cell</i> , 2021, 81, 2583-2595.e6.	4.5	16
13135	Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 537-547.	2.7	58
13136	The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index. <i>Frontiers in Oncology</i> , 2021, 11, 690093.	1.3	5
13137	Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR ⁺ /HER2 ⁻ advanced breast cancer. <i>Investigational New Drugs</i> , 2021, 39, 1549-1558.	1.2	2
13138	Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 634920.	1.3	7

#	ARTICLE	IF	CITATIONS
13139	IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. <i>Annals of Oncology</i> , 2021, 32, 736-745.	0.6	23
13140	In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response. <i>Advanced Materials</i> , 2021, 33, e2100628.	11.1	34
13141	The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 639745.	1.3	9
13142	Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 $\geq 50\%$: Results of a Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 691519.	1.3	4
13143	Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2937-2954.	1.3	19
13144	Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. <i>Annals of Translational Medicine</i> , 2021, 9, 1033-1033.	0.7	23
13145	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. <i>Npj Breast Cancer</i> , 2021, 7, 73.	2.3	2
13146	Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming. <i>Cancer Immunology Research</i> , 2021, 9, 877-890.	1.6	14
13147	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 4859-4869.	3.2	33
13148	Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III-IV Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 693655.	1.3	16
13149	Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 267-276.	2.0	2
13150	Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy. <i>Molecular Oncology</i> , 2022, 16, 885-903.	2.1	11
13151	Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 752-758.	0.5	3
13152	T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 102.	6.9	64
13153	Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications. <i>Cancer Medicine</i> , 2021, 10, 5358-5374.	1.3	3
13154	Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2923-2933.	1.2	7
13155	Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 205.	1.5	15
13156	Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance. <i>Drug Safety</i> , 2021, 44, 957-971.	1.4	38

#	ARTICLE	IF	CITATIONS
13157	The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types. <i>Frontiers in Oncology</i> , 2021, 11, 645159.	1.3	10
13158	Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 277-287.	2.0	27
13159	Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2021, 10, 2842-2857.	1.3	28
13160	Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. <i>Translational Lung Cancer Research</i> , 2021, 10, 2955-2969.	1.3	2
13161	The Biological Basis for Enhanced Effects of Proton Radiation Therapy Relative to Photon Radiation Therapy for Head and Neck Squamous Cell Carcinoma. <i>International Journal of Particle Therapy</i> , 2021, 8, 3-13.	0.9	10
13162	Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy. <i>Npj Precision Oncology</i> , 2021, 5, 52.	2.3	24
13163	Cancer immunotherapy: it's time to better predict patients' response. <i>British Journal of Cancer</i> , 2021, 125, 927-938.	2.9	63
13164	Prognostic Impact of Memory CD8(+) T Cells on Immunotherapy in Human Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 698076.	1.3	9
13165	First-Line Treatment Options for PD-L1-Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 657545.	1.3	6
13166	Analyzing the influence of IL18 in regulation of YAP1 in breast oncogenesis using cBioportal. <i>Cancer Reports</i> , 2022, 5, e1484.	0.6	2
13167	Metabolic disease and adverse events from immune checkpoint inhibitors. <i>European Journal of Endocrinology</i> , 2021, 184, 857-865.	1.9	12
13168	CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4025-4035.	3.2	51
13169	A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4746-4756.	3.2	22
13170	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. <i>Clinical Cancer Research</i> , 2021, 27, 4836-4847.	3.2	20
13171	Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARCB1) genes. <i>Modern Pathology</i> , 2021, 34, 1850-1859.	2.9	3
13172	Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. <i>Science Advances</i> , 2021, 7, .	4.7	56
13173	Pan-cancer network disorders revealed by overall and local signaling entropy. <i>Journal of Molecular Cell Biology</i> , 2021, 13, 622-635.	1.5	2
13174	E2A Modulates Stemness, Metastasis, and Therapeutic Resistance of Breast Cancer. <i>Cancer Research</i> , 2021, 81, 4529-4544.	0.4	18

#	ARTICLE	IF	CITATIONS
13175	Clonal fitness inferred from time-series modelling of single-cell cancer genomes. <i>Nature</i> , 2021, 595, 585-590.	13.7	71
13176	Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 184.	3.5	204
13177	Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1159-1169.	1.2	13
13178	Biomarkers of therapeutic response with immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2021, 9, 1040-1040.	0.7	3
13179	First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2917-2936.	1.3	18
13180	Holding our breath: the promise of tissue-resident memory T cells in lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2819-2829.	1.3	6
13181	Challenges and Opportunities in the Statistical Analysis of Multiplex Immunofluorescence Data. <i>Cancers</i> , 2021, 13, 3031.	1.7	21
13182	ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 219-228.	2.0	5
13183	Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer. <i>Disease Markers</i> , 2021, 2021, 1-10.	0.6	13
13184	Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 638154.	1.3	4
13185	Immune System Effects on Breast Cancer. <i>Cellular and Molecular Bioengineering</i> , 2021, 14, 279-292.	1.0	9
13186	Development and validation of an individualized immune prognostic model in stage III lung squamous cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 12727.	1.6	12
13187	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 630-638.	0.5	23
13188	Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 813-819.	0.5	23
13189	Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 3530.	5.8	68
13190	PFKFB4 Overexpression Facilitates Proliferation by Promoting the G1/S Transition and Is Associated with a Poor Prognosis in Triple-Negative Breast Cancer. <i>Disease Markers</i> , 2021, 2021, 1-10.	0.6	9
13191	Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662731.	1.3	10
13192	Serum IL-5 and IFN- γ Are Novel Predictive Biomarkers for Anti-PD-1 Treatment in NSCLC and GC Patients. <i>Disease Markers</i> , 2021, 2021, 1-7.	0.6	9

#	ARTICLE	IF	CITATIONS
13193	HER2-antigen-specific humoral immune response in breast cancer lymphocytes transplanted in hu-PBL hIL-4 NOG mice. <i>Scientific Reports</i> , 2021, 11, 12798.	1.6	4
13194	SOX factors as cell-state regulators in the mammary gland and breast cancer. <i>Seminars in Cell and Developmental Biology</i> , 2021, 114, 126-133.	2.3	14
13195	KCNN4 is a potential prognostic marker and critical factor affecting the immune status of the tumor microenvironment in kidney renal clear cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 2454-2470.	0.6	15
13196	The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 702924.	1.3	6
13197	A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 679331.	1.3	4
13198	T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study. <i>British Journal of Cancer</i> , 2021, 125, 717-724.	2.9	12
13199	Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. <i>Nature Reviews Urology</i> , 2021, 18, 543-555.	1.9	20
13200	Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2890-2916.	1.3	21
13201	Harnessing the power of antibodies to fight bone metastasis. <i>Science Advances</i> , 2021, 7, .	4.7	18
13202	Physio-pathological effects of m6A modification and its potential contribution to melanoma. <i>Clinical and Translational Oncology</i> , 2021, 23, 2269-2279.	1.2	12
13203	Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5628-5637.	3.2	32
13204	G-CSF in tumors: Aggressiveness, tumor micro-environment and immune cell regulation. <i>Cytokine</i> , 2021, 142, 155479.	1.4	44
13205	Stromal hyaluronan accumulation is associated with low immune response and poor prognosis in pancreatic cancer. <i>Scientific Reports</i> , 2021, 11, 12216.	1.6	26
13206	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
13207	Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 981-993.	1.6	22
13208	Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer. <i>Aging</i> , 2021, 13, 17177-17189.	1.4	25
13209	Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 658690.	1.3	15
13210	T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 339-352.	2.0	2

#	ARTICLE	IF	CITATIONS
13211	Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors. <i>Cells</i> , 2021, 10, 1429.	1.8	5
13212	Tumor Microenvironment Subtypes and Immune-Related Signatures for the Prognosis of Breast Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-12.	0.9	2
13213	Inhibition of host Ogr1 enhances effector CD8+ T-cell function by modulating acidic microenvironment. <i>Cancer Gene Therapy</i> , 2021, 28, 1213-1224.	2.2	13
13214	Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer. <i>Cell Reports</i> , 2021, 35, 109285.	2.9	38
13215	Thromboembolic risk in patients with lung cancer receiving systemic therapy. <i>British Journal of Haematology</i> , 2021, 194, 179-190.	1.2	9
13216	Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. <i>Journal of Clinical Oncology</i> , 2021, 39, 2005-2015.	0.8	23
13217	A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics. <i>Clinical and Translational Oncology</i> , 2021, 23, 2415-2430.	1.2	8
13218	Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 668610.	1.3	4
13219	The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2539-2550.	1.3	6
13220	Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation. <i>Translational Lung Cancer Research</i> , 2021, 10, 2858-2864.	1.3	12
13221	Exploring the immune-checkpoint inhibitors™ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease. <i>Translational Lung Cancer Research</i> , 2021, 10, 2876-2889.	1.3	2
13222	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
13223	An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5557-5565.	3.2	26
13224	Interleukins in cancer: from biology to therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 481-499.	12.8	318
13225	Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 4290-4304.	0.4	40
13226	Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies. <i>Seminars in Cancer Biology</i> , 2022, 82, 3-10.	4.3	23
13227	Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1. <i>Hepatology Communications</i> , 2022, 6, 178-193.	2.0	16
13228	A System for the Evolution of Protein-Protein Interaction Inducers. <i>ACS Synthetic Biology</i> , 2021, 10, 2096-2110.	1.9	5

#	ARTICLE	IF	CITATIONS
13229	Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	30
13230	Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling. Clinical Cancer Research, 2021, 27, 4781-4793.	3.2	14
13231	Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. Journal of the National Cancer Institute, 2022, 114, 664-675.	3.0	31
13232	Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment. Nature Cancer, 2021, 2, 680-692.	5.7	56
13233	Imaging in Tumor Immunology. Nuclear Medicine and Molecular Imaging, 2021, 55, 225-236.	0.6	2
13234	Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers. Frontiers in Oncology, 2021, 11, 625668.	1.3	9
13235	Mutational status of main driver genes influences the prognosis of stage III lung adenocarcinoma patients underwent radical surgery. Translational Cancer Research, 2021, 10, 3286-3298.	0.4	4
13236	PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis. Journal of Thoracic Disease, 2021, 13, 4360-4370.	0.6	3
13237	The incidence of gastrointestinal adverse events in patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1 inhibitors: a meta-analysis. Translational Cancer Research, 2021, 10, 3389-3403.	0.4	1
13238	Intrapulmonic Cavity or Necrosis on Baseline CT Scan Serves as an Efficacy Predictor of Anti-PD-(L)1 Inhibitor in Advanced Lung Squamous Cell Carcinoma. Cancer Management and Research, 2021, Volume 13, 5931-5939.	0.9	2
13239	Investigational Drug Treatments for Triple-Negative Breast Cancer. Journal of Personalized Medicine, 2021, 11, 652.	1.1	8
13240	Crosstalk between Tumor-Infiltrating Immune Cells and Cancer-Associated Fibroblasts in Tumor Growth and Immunosuppression of Breast Cancer. Journal of Immunology Research, 2021, 2021, 1-15.	0.9	15
13241	Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. Human Vaccines and Immunotherapeutics, 2022, 18, 1-9.	1.4	3
13242	A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. Investigational New Drugs, 2021, 39, 1624-1632.	1.2	0
13243	miRNome and Functional Network Analysis of PGRMC1 Regulated miRNA Target Genes Identify Pathways and Biological Functions Associated With Triple Negative Breast Cancer. Frontiers in Oncology, 2021, 11, 710337.	1.3	3
13244	Novel strategies for immuno-oncology breakthroughs with cell therapy. Biomarker Research, 2021, 9, 62.	2.8	18
13245	Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid-Coated Superparamagnetic Iron Oxide. International Journal of Nanomedicine, 2021, Volume 16, 5233-5246.	3.3	5
13246	Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 659380.	1.3	10

#	ARTICLE	IF	CITATIONS
13247	Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. , 2021, 9, e002703.		9
13248	Prognostic Significance of Gene Signature of Tertiary Lymphoid Structures in Patients With Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 693234.	1.3	18
13249	A chemokine regulatory loop induces cholesterol synthesis in lung-colonizing triple-negative breast cancer cells to fuel metastatic growth. <i>Molecular Therapy</i> , 2022, 30, 672-687.	3.7	11
13250	Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity. <i>Nature Cancer</i> , 2021, 2, 950-961.	5.7	13
13251	RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway. <i>Advanced Science</i> , 2021, 8, e2100881.	5.6	54
13252	Determining breast cancer biomarker status and associated morphological features using deep learning. <i>Communications Medicine</i> , 2021, 1, .	1.9	53
13253	Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Targeted Oncology</i> , 2021, 16, 553-568.	1.7	13
13254	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	15.2	216
13255	CX-072 (pacmilimab), a Probody[®] PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. , 2021, 9, e002447.		26
13256	Down-regulation of A20 promotes immune escape of lung adenocarcinomas. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	10
13257	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 495-508.	21.5	120
13258	Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST. <i>Japanese Journal of Radiology</i> , 2022, 40, 75-85.	1.0	12
13259	Identification of Prognostic miRNAs Associated With Immune Cell Tumor Infiltration Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 705869.	1.3	4
13260	RBM10 Deficiency Is Associated With Increased Immune Activity in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 677826.	1.3	7
13261	CPT1A and fatty acid β -oxidation are essential for tumor cell growth and survival in hormone receptor-positive breast cancer. <i>NAR Cancer</i> , 2021, 3, zcab035.	1.6	19
13262	Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression. <i>Molecular Oncology</i> , 2022, 16, 88-103.	2.1	18
13263	Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. <i>Molecular Therapy</i> , 2021, 29, 2321-2334.	3.7	48
13264	Synergies between therapeutic ultrasound, gene therapy and immunotherapy in cancer treatment. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113906.	6.6	20

#	ARTICLE	IF	CITATIONS
13265	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. <i>Translational Lung Cancer Research</i> , 2021, 10, 3093-3105.	1.3	23
13266	Hyperprogression under immunotherapy: a new form of immunotherapy response?â€”a narrative literature review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3276-3291.	1.3	15
13267	Applications and analytical tools of cell communication based on ligand-receptor interactions at single cell level. <i>Cell and Bioscience</i> , 2021, 11, 121.	2.1	21
13268	Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy. <i>Bioactive Materials</i> , 2022, 9, 251-265.	8.6	30
13269	3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity. <i>Communications Biology</i> , 2021, 4, 893.	2.0	38
13270	Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab. <i>Oncologist</i> , 2021, 26, e1599-e1608.	1.9	18
13271	Oncolytic Viruses for Malignant Glioma: On the Verge of Success?. <i>Viruses</i> , 2021, 13, 1294.	1.5	28
13272	CD8+ T cell differentiation and dysfunction in cancer. <i>Nature Reviews Immunology</i> , 2022, 22, 209-223.	10.6	345
13273	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5365-5375.	3.2	29
13274	Targeting the spectrum of immune checkpoints in prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1253-1266.	1.3	13
13275	<i>In silico</i> model for miRNA-mediated regulatory network in cancer. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	7
13276	The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 701636.	2.2	6
13277	Integrated Chromatin Accessibility and Transcriptome Landscapes of Doxorubicin-Resistant Breast Cancer Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 708066.	1.8	17
13278	Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics elio Tissue Complete Kitted Solution. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1324-1333.	1.2	9
13279	Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA. <i>Communications Biology</i> , 2021, 4, 906.	2.0	12
13280	Multi-resolution characterization of molecular taxonomies in bulk and single-cell transcriptomics data. <i>Nucleic Acids Research</i> , 2021, 49, e98-e98.	6.5	4
13281	Immunotherapy in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2115-2127.	0.8	33
13282	The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury. <i>Cell Communication and Signaling</i> , 2021, 19, 76.	2.7	14

#	ARTICLE	IF	CITATIONS
13283	The Molecular Signature of High-intensity Training in the Human Body. <i>International Journal of Sports Medicine</i> , 2022, 43, 195-205.	0.8	7
13284	Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies. <i>Cancers</i> , 2021, 13, 3566.	1.7	6
13285	Neoantigen Controversies. <i>Annual Review of Biomedical Data Science</i> , 2021, 4, 227-253.	2.8	9
13286	Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 39-47.	0.1	3
13287	The mechanisms of action of Plasmodium infection against cancer. <i>Cell Communication and Signaling</i> , 2021, 19, 74.	2.7	7
13288	Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. <i>Leukemia</i> , 2022, 36, 138-154.	3.3	28
13289	Cell Fate Reprogramming in the Era of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 714822.	2.2	27
13290	Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis. <i>Molecular Oncology</i> , 2022, 16, 1493-1507.	2.1	17
13291	First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 536-542.	2.8	56
13292	Analysis of Prostate Cancer Tumor Microenvironment Identifies Reduced Stromal CD4 Effector T-cell Infiltration in Tumors with Pelvic Nodal Metastasis. <i>European Urology Open Science</i> , 2021, 29, 19-29.	0.2	6
13293	Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. <i>British Journal of Anaesthesia</i> , 2021, 127, 75-84.	1.5	33
13294	Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. <i>Endocrine-Related Cancer</i> , 2021, 28, 419-431.	1.6	29
13295	Oncolytic HSV: Underpinnings of Tumor Susceptibility. <i>Viruses</i> , 2021, 13, 1408.	1.5	6
13296	Expression of 5-methylcytosine regulators is highly associated with the clinical phenotypes of prostate cancer and DNMTs expression predicts biochemical recurrence. <i>Cancer Medicine</i> , 2021, 10, 5681-5695.	1.3	4
13297	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100187.	0.6	11
13298	Comprehensive Analysis of Peritoneal Metastasis Sequencing Data to Identify LINC00924 as a Prognostic Biomarker in Gastric Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 5599-5611.	0.9	29
13299	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. , 2021, 9, e002742.		16
13300	KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 659200.	1.3	9

#	ARTICLE	IF	CITATIONS
13301	Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 565-578.	2.0	7
13302	Ubiquitin ligases in cancer: Functions and clinical potentials. <i>Cell Chemical Biology</i> , 2021, 28, 918-933.	2.5	36
13303	Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer. <i>Gland Surgery</i> , 2021, 10, 2159-2169.	0.5	4
13304	The Expression of PD-L1 and B7-H4 in Thymic Epithelial Tumor and Its Relationship With Tumor Immune-Infiltrating Cells. <i>Frontiers in Oncology</i> , 2021, 11, 662010.	1.3	4
13305	Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 692-707.	5.7	37
13306	Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison. <i>Frontiers in Oncology</i> , 2021, 11, 693542.	1.3	4
13307	Landmark trials in the medical oncology management of metastatic breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 246-258.	0.8	4
13308	Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab. <i>Translational Lung Cancer Research</i> , 2021, 10, 3071-3078.	1.3	11
13309	Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression. <i>Cancer Discovery</i> , 2021, 11, 3178-3197.	7.7	7
13310	Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12120.	5.5	55
13311	Myelocytomatosis- ϵ Protein Arginine N ϵ Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 1932-1951.	3.6	28
13312	Inflammation and tumor progression: signaling pathways and targeted intervention. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 263.	7.1	739
13313	Multi-Omics Data Integration Analysis of an Immune-Related Gene Signature in LGG Patients With Epilepsy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 686909.	1.8	18
13314	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. <i>Nature Medicine</i> , 2021, 27, 1250-1261.	15.2	159
13315	Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo. <i>Journal of Surgical Research</i> , 2021, 263, 44-52.	0.8	3
13316	The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis. <i>Journal of Thoracic Disease</i> , 2021, 13, 4301-4310.	0.6	6
13317	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 417-431.	2.0	6
13318	Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy. <i>BMC Medicine</i> , 2021, 19, 154.	2.3	32

#	ARTICLE	IF	CITATIONS
13319	Astragalus IV Undermines Multi-Drug Resistance and Glycolysis of MDA-MB-231/ADR Cell Line by Depressing hsa_circ_0001982-miR-206/miR-613 Axis. <i>Cancer Management and Research</i> , 2021, Volume 13, 5821-5833.	0.9	5
13320	Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. <i>Annals of Translational Medicine</i> , 2021, 9, 1189-1189.	0.7	8
13321	Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. <i>Translational Lung Cancer Research</i> , 2021, 10, 3191-3202.	1.3	10
13322	Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 797-804.	2.3	11
13323	Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5131-5140.	3.2	40
13324	Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 720125.	1.3	18
13325	The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 667650.	1.3	8
13326	Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias. <i>JCO Precision Oncology</i> , 2021, 5, 1147-1150.	1.5	4
13327	Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice. <i>Nuclear Medicine and Biology</i> , 2021, 98-99, 8-17.	0.3	2
13328	A Problematic Biomarker Trial Design. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	8
13329	Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study. , 2021, 9, e002197.		44
13330	The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3656.	1.7	8
13331	A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab. <i>Cancer Medicine</i> , 2021, 10, 6218-6226.	1.3	2
13332	Intratumor microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. <i>European Journal of Cancer</i> , 2021, 151, 25-34.	1.3	59
13333	Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study. <i>Clinical Cancer Research</i> , 2021, 27, 5141-5150.	3.2	33
13334	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. <i>Modern Pathology</i> , 2021, 34, 2130-2140.	2.9	14
13335	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. <i>Clinical Cancer Research</i> , 2021, 27, 5280-5288.	3.2	21
13336	Bidirectional Regulatory Cross-Talk between Cell Context and Genomic Aberrations Shapes Breast Tumorigenesis. <i>Molecular Cancer Research</i> , 2021, 19, 1802-1817.	1.5	6

#	ARTICLE	IF	CITATIONS
13337	Protean role of epigenetic mechanisms and their impact in regulating the Tregs in TME. <i>Cancer Gene Therapy</i> , 2022, 29, 661-664.	2.2	3
13338	CDK4: A Novel Therapeutic Target for Extramammary Paget's Disease. <i>Frontiers in Oncology</i> , 2021, 11, 710378.	1.3	4
13339	Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 658564.	1.3	5
13340	Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication. <i>Npj Breast Cancer</i> , 2021, 7, 86.	2.3	9
13341	Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 3394.	1.7	9
13342	Pulsed focused ultrasound can improve the anti-cancer effects of immune checkpoint inhibitors in murine pancreatic cancer. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20210266.	1.5	25
13343	Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. <i>Nature Communications</i> , 2021, 12, 4172.	5.8	16
13344	Global mapping of cancers: The Cancer Genome Atlas and beyond. <i>Molecular Oncology</i> , 2021, 15, 2823-2840.	2.1	55
13345	Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution. <i>Cancer Reports</i> , 2021, , e1465.	0.6	1
13346	Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Cancer Research and Treatment</i> , 2022, 54, 424-433.	1.3	11
13347	Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 698551.	1.3	9
13348	Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. <i>Current Problems in Surgery</i> , 2022, 59, 101030.	0.6	4
13349	Photothermal Therapy Combined with Neoantigen Cancer Vaccination for Effective Immunotherapy against Large Established Tumors and Distant Metastasis. <i>Advanced Therapeutics</i> , 2021, 4, 2100093.	1.6	20
13350	Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression. <i>Nature Cancer</i> , 2021, 2, 803-818.	5.7	54
13351	Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. <i>Pharmacogenomics</i> , 2021, 22, 703-726.	0.6	3
13352	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. <i>Kidney International</i> , 2021, 100, 196-205.	2.6	95
13353	The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy. <i>Cancer Letters</i> , 2021, 510, 67-78.	3.2	60
13354	Emerging Technologies for Non-invasive Monitoring of Treatment Response to Immunotherapy for Brain Tumors. <i>NeuroMolecular Medicine</i> , 2022, 24, 74-87.	1.8	3

#	ARTICLE	IF	CITATIONS
13355	Effects of Inflammation on the Immune Microenvironment in Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 690298.	1.3	13
13356	Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER+ Breast Cancers. <i>Cancers</i> , 2021, 13, 3725.	1.7	7
13357	CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study. <i>Journal of Digital Imaging</i> , 2021, 34, 1073-1085.	1.6	17
13358	Genotoxic Treatment Enhances Immune Response in a Genetic Model of Lung Cancer. <i>Cancers</i> , 2021, 13, 3595.	1.7	1
13359	Horizon Scanning in Cancer Genomics: How Advances in Genomic Medicine Will Change Cancer Care Over the Next Decade. <i>Current Genetic Medicine Reports</i> , 2021, 9, 37-46.	1.9	1
13360	Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease. <i>Translational Lung Cancer Research</i> , 2021, 10, 3132-3143.	1.3	1
13361	Molecular Imaging, How Close to Clinical Precision Medicine in Lung, Brain, Prostate and Breast Cancers. <i>Molecular Imaging and Biology</i> , 2022, 24, 8-22.	1.3	7
13362	Update on recent key publications in lung oncology: picking up speed. <i>European Respiratory Review</i> , 2021, 30, 200300.	3.0	1
13363	Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 579-588.	2.0	27
13364	MRI and PET of Brain Tumor Neuroinflammation in the Era of Immunotherapy, From the <i>AJR</i> Special Series on Inflammation. <i>American Journal of Roentgenology</i> , 2022, 218, 582-596.	1.0	4
13365	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. <i>EClinicalMedicine</i> , 2021, 37, 100940.	3.2	11
13366	Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1739.	3.3	19
13367	Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2021, 26, e1812-e1821.	1.9	15
13368	Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	2.7	72
13369	Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 632357.	1.3	14
13370	Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis. <i>JCO Precision Oncology</i> , 2021, 5, 1151-1159.	1.5	16
13371	Nuclear Aurora kinase A triggers programmed death ligand 1-mediated immune suppression by activating MYC transcription in triple-negative breast cancer. <i>Cancer Communications</i> , 2021, 41, 851-866.	3.7	12
13372	Detection of Immune Checkpoint Receptors—A Current Challenge in Clinical Flow Cytometry. <i>Frontiers in Immunology</i> , 2021, 12, 694055.	2.2	22

#	ARTICLE	IF	CITATIONS
13373	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5299-5306.	3.2	39
13374	Chitosan-Poly(Acrylic Acid) Nanoparticles Loaded with R848 and MnCl ₂ Inhibit Melanoma via Regulating Macrophage Polarization and Dendritic Cell Maturation. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 5675-5692.	3.3	10
13375	Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. <i>Current Oncology</i> , 2021, 28, 3227-3239.	0.9	2
13376	Exploring the Pharmacological Mechanisms of <i>Tripterygium wilfordii</i> Hook F against Cardiovascular Disease Using Network Pharmacology and Molecular Docking. <i>BioMed Research International</i> , 2021, 2021, 1-11.	0.9	3
13377	Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4217-4228.	1.6	20
13378	Roles of Neutrophils in Glioma and Brain Metastases. <i>Frontiers in Immunology</i> , 2021, 12, 701383.	2.2	41
13379	Plasmonic gold nanostars for synergistic photoimmunotherapy to treat cancer. <i>Nanophotonics</i> , 2021, 10, 3295-3302.	2.9	8
13380	Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. <i>Cancer Cell</i> , 2021, 39, 1099-1114.e8.	7.7	45
13381	Tislelizumab combined with apatinib in the treatment of advanced renal clear cell carcinoma: a case report. <i>Anti-Cancer Drugs</i> , 2022, 33, e834-e839.	0.7	2
13382	FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. <i>Frontiers in Endocrinology</i> , 2021, 12, 712107.	1.5	16
13383	Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates. <i>Journal of Translational Medicine</i> , 2021, 19, 371.	1.8	9
13384	Immune Checkpoint Inhibitors in the Aged. <i>Current Oncology Reports</i> , 2021, 23, 115.	1.8	3
13385	Identification of a Five-Gene Prognostic Signature Related to B Cells Infiltration in Pancreatic Adenocarcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5051-5068.	0.8	6
13386	Use and Toxicity of Checkpoint Inhibitors for Solid Tumor Treatment in a Veteran Population. , 2021, 38, S46-S51.		0
13387	The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 38, 100990.	3.2	34
13388	An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma. <i>Clinical and Translational Science</i> , 2021, 14, 2300-2313.	1.5	9
13389	Which factors matter the most? Revisiting and dissecting antibody therapeutic doses. <i>Drug Discovery Today</i> , 2021, 26, 1980-1990.	3.2	3
13390	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5993-6000.	3.2	70

#	ARTICLE	IF	CITATIONS
13391	Activation or exhaustion of CD8+ T cells in patients with COVID-19. Cellular and Molecular Immunology, 2021, 18, 2325-2333.	4.8	106
13392	The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer. Annals of Translational Medicine, 2021, 9, 1332-1332.	0.7	3
13393	Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. Journal of Clinical Oncology, 2021, 39, 3199-3206.	0.8	5
13394	The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3,) Tj ETQq1 1 0.784314 rg3T 1.8 36	1.8	36
13395	Cutting both ways: the innate immune response to oncolytic virotherapy. Cancer Gene Therapy, 2022, 29, 629-646.	2.2	5
13396	CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of ⁸⁹ Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody. Journal of Nuclear Medicine, 2021, , jnumed.121.262485.	2.8	49
13397	Immune-Related Genes Are Prognostic Markers for Prostate Cancer Recurrence. Frontiers in Genetics, 2021, 12, 639642.	1.1	11
13398	Entinostat induces antitumor immune responses through immune editing of tumor neoantigens. Journal of Clinical Investigation, 2021, 131, .	3.9	43
13399	Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti- PD-L1 Therapy via IRF8 Expression. Journal of Immunology, 2021, 207, 1298-1309.	0.4	8
13400	CDKN1C as a prognostic biomarker correlated with immune infiltrates and therapeutic responses in breast cancer patients. Journal of Cellular and Molecular Medicine, 2021, 25, 9390-9401.	1.6	10
13401	Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium. Molecular Therapy, 2022, 30, 662-671.	3.7	25
13402	Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). International Journal of Oncology, 2021, 59, .	1.4	17
13403	Protein detection in blood with single-molecule imaging. Science Advances, 2021, 7, .	4.7	15
13404	Toward personalized treatment approaches for non-small-cell lung cancer. Nature Medicine, 2021, 27, 1345-1356.	15.2	338
13405	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	5.8	54
13406	Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features. Frontiers in Oncology, 2021, 11, 620246.	1.3	38
13407	PD-1 preferentially inhibits the activation of low-affinity T cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	9
13408	Interpretable systems biomarkers predict response to immune-checkpoint inhibitors. Patterns, 2021, 2, 100293.	3.1	47

#	ARTICLE	IF	CITATIONS
13409	Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 703210.	1.1	3
13410	Multifunctional Nanocarriers-Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2100010.	1.7	5
13411	Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. <i>International Journal of Oral Science</i> , 2021, 13, 24.	3.6	107
13412	Immunotherapy Treatment for Triple Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 763.	1.7	30
13413	Cellular based immunotherapy for primary liver cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 250.	3.5	12
13414	Targeting the DNA damage response in immuno-oncology: developments and opportunities. <i>Nature Reviews Cancer</i> , 2021, 21, 701-717.	12.8	150
13415	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
13416	Predicting Molecular Phenotypes from Histopathology Images: A Transcriptome-Wide Expression-Morphology Analysis in Breast Cancer. <i>Cancer Research</i> , 2021, 81, 5115-5126.	0.4	32
13417	Multi-omics data integration by generative adversarial network. <i>Bioinformatics</i> , 2021, 38, 179-186.	1.8	25
13418	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. <i>Scientific Reports</i> , 2021, 11, 17324.	1.6	24
13419	Mapping lung squamous cell carcinoma pathogenesis through in vitro and in vivo models. <i>Communications Biology</i> , 2021, 4, 937.	2.0	6
13420	The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models. <i>Cancer Management and Research</i> , 2021, Volume 13, 6045-6053.	0.9	8
13421	HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 329-341.	3.0	5
13422	The somatic molecular evolution of cancer: Mutation, selection, and epistasis. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 165, 56-65.	1.4	11
13423	Use of Antibiotics during Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 606-614.	4.2	30
13424	Toward reproducible, scalable, and robust data analysis across multiplex tissue imaging platforms. <i>Cell Reports Methods</i> , 2021, 1, 100053.	1.4	22
13425	Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	11
13426	Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses. <i>Cancer Immunology Research</i> , 2021, 9, 1158-1174.	1.6	28

#	ARTICLE	IF	CITATIONS
13427	Modeling the effects of EMT-immune dynamics on carcinoma disease progression. <i>Communications Biology</i> , 2021, 4, 983.	2.0	3
13428	Multi-Parametric MRI-Based Radiomics Models for Predicting Molecular Subtype and Androgen Receptor Expression in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 706733.	1.3	39
13429	Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer. <i>Current Oncology</i> , 2021, 28, 3139-3149.	0.9	7
13430	Two Similar Signatures for Predicting the Prognosis and Immunotherapy Efficacy of Stomach Adenocarcinoma Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 704242.	1.8	5
13431	Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms. <i>Clinical Cancer Research</i> , 2021, 27, 4265-4276.	3.2	23
13432	Intestinal Regulatory T Cells as Specialized Tissue-Restricted Immune Cells in Intestinal Immune Homeostasis and Disease. <i>Frontiers in Immunology</i> , 2021, 12, 716499.	2.2	34
13433	Repurposing RNA sequencing for discovery of RNA modifications in clinical cohorts. <i>Science Advances</i> , 2021, 7, .	4.7	12
13434	PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain. <i>Nature Communications</i> , 2021, 12, 5106.	5.8	38
13435	BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 313.	7.1	16
13436	Characterizing Trends in Cancer Patients' Survival Using the JPSurv Software. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2001-2009.	1.1	9
13437	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. <i>Npj Breast Cancer</i> , 2021, 7, 110.	2.3	20
13438	No evidence that HLA genotype influences the driver mutations that occur in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 819-827.	2.0	3
13439	Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications. <i>Frontiers in Immunology</i> , 2021, 12, 705999.	2.2	24
13440	Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma. <i>Haematologica</i> , 2022, 107, 1619-1632.	1.7	9
13441	Protein Complex Organization Imposes Constraints on Proteome Dysregulation in Cancer. <i>Frontiers in Bioinformatics</i> , 2021, 1, .	1.0	3
13442	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 1202-1213.	1.6	71
13443	Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	1
13444	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100831.	0.3	4

#	ARTICLE	IF	CITATIONS
13445	JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. <i>Carcinogenesis</i> , 2021, 42, 1411-1419.	1.3	30
13446	Activated B Cells and Plasma Cells Are Resistant to Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 514-528.	0.4	11
13447	Immune-related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell carcinoma with stasis dermatitis. <i>IJU Case Reports</i> , 2021, 4, 386-390.	0.1	0
13448	Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy. <i>Cancer Research and Treatment</i> , 2022, 54, 362-374.	1.3	5
13449	A novel lncRNA derived from an ultraconserved region: lnc-uc.147, a potential biomarker in luminal A breast cancer. <i>RNA Biology</i> , 2021, , 1-14.	1.5	9
13450	Survival benefit of immune checkpoint inhibitor monotherapy in patients with non-small cell lung cancer recurrence after completely pulmonary resection. <i>Annals of Translational Medicine</i> , 2021, 9, 1225-1225.	0.7	2
13451	The calcium-binding protein S100B reduces IL6 production in malignant melanoma via inhibition of RSK cellular signaling. <i>PLoS ONE</i> , 2021, 16, e0256238.	1.1	1
13452	Predictive Models for HCC Prognosis, Recurrence Risk, and Immune Infiltration Based on Two Exosomal Genes: MYL6B and THOC2. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4089-4109.	1.6	14
13453	Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis. <i>EMBO Molecular Medicine</i> , 2021, 13, e13929.	3.3	6
13454	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. <i>Nature Cancer</i> , 2021, 2, 794-802.	5.7	173
13455	Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100208.	0.6	0
13456	IL-36 and IL-36Ra Reciprocally Regulate NSCLC Progression by Modulating GSH Homeostasis and Oxidative Stress-Induced Cell Death. <i>Advanced Science</i> , 2021, 8, e2101501.	5.6	10
13457	Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. <i>Cancer Discovery</i> , 2022, 12, 47-61.	7.7	58
13458	Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1388-1398.	2.9	11
13459	Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	3
13460	Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement. <i>Nature Communications</i> , 2021, 12, 5138.	5.8	28
13461	Radiomics Analysis Based on Automatic Image Segmentation of DCE-MRI for Predicting Triple-Negative and Nontriple-Negative Breast Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-7.	0.7	16
13462	Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small cell lung cancer with high-level PD-L1 expression in China. <i>Cancer Medicine</i> , 2021, 10, 6344-6353.	1.3	9

#	ARTICLE	IF	CITATIONS
13463	Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune-related lncRNA. <i>Cancer Medicine</i> , 2021, 10, 6561-6575.	1.3	8
13464	PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies. <i>Cancer Medicine</i> , 2021, 10, 6384-6401.	1.3	10
13465	An analysis of the immunological tumor microenvironment of primary tumors and regional lymph nodes in squamous cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 3520-3537.	1.3	3
13466	Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells. <i>Molecular Oncology</i> , 2022, 16, 148-165.	2.1	14
13467	Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. <i>Nature Communications</i> , 2021, 12, 5053.	5.8	14
13468	Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2021, 39, 1429-1442.	1.7	10
13469	Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	2
13470	Predictors of Rheumatic <sc>Immune-Related</sc> Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer. <i>Arthritis and Rheumatology</i> , 2022, 74, 527-540.	2.9	21
13471	Breast Cancer in Jamaica: Stage, Grade and Molecular Subtype Distributions Across Age Blocks, the Implications for Screening and Treatment. <i>World Journal of Oncology</i> , 2021, 12, 93-103.	0.6	10
13472	N6-Methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 718644.	1.3	15
13473	Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3659-3670.	1.3	7
13474	Identification of Key Genes Mutations Associated With the Radiosensitivity by Whole Exome Sequencing in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 697308.	1.3	4
13475	Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. <i>British Journal of Cancer</i> , 2022, 126, 401-408.	2.9	18
13476	Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition â€œ Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry. <i>Frontiers in Oncology</i> , 2021, 11, 725549.	1.3	6
13477	Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models. <i>FEBS Open Bio</i> , 2021, 11, 2586-2599.	1.0	16
13478	Systematic functional interrogation of human pseudogenes using CRISPRi. <i>Genome Biology</i> , 2021, 22, 240.	3.8	13
13479	High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer. <i>Breast Cancer</i> , 2022, 29, 103-113.	1.3	5
13480	A systematic review of datasets that can help elucidate relationships among gene expression, race, and immunohistochemistry-defined subtypes in breast cancer. <i>Cancer Biology and Therapy</i> , 2021, 22, 1-13.	1.5	2

#	ARTICLE	IF	CITATIONS
13481	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)., 2021, 9, e002973.		26
13482	MERTK on mononuclear phagocytes regulates T cell antigen recognition at autoimmune and tumor sites. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	15
13483	Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 6291-6303.	1.3	11
13484	Identification of a novel 10 immune-related genes signature as a prognostic biomarker panel for gastric cancer. <i>Cancer Medicine</i> , 2021, 10, 6546-6560.	1.3	9
13485	The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2018-2027.e4.	0.3	8
13487	Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100205.	0.6	32
13488	Immune Checkpoint Inhibitors and Neurotoxicity. <i>Current Neuropharmacology</i> , 2021, 19, 1246-1263.	1.4	10
13489	Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study. <i>Cancer Medicine</i> , 2021, 10, 6705-6713.	1.3	13
13490	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. <i>Cancer Cell</i> , 2021, 39, 1342-1360.e14.	7.7	119
13491	Novel and Promising Systemic Treatment Approaches in Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 89.	1.3	2
13492	Chemotherapy is a risk factor of lymphopenia before adjuvant radiotherapy in breast cancer. <i>Cancer Reports</i> , 2021, , e1525.	0.6	4
13493	Caloric Restriction Impairs Regulatory T cells Within the Tumor Microenvironment After Radiation and Primes Effector T cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1341-1349.	0.4	19
13494	Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 721333.	1.1	14
13495	Identification of a Costimulatory Molecule Gene Signature to Predict Survival and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 695533.	1.8	12
13496	Combining an Alarmin HMGN1 Peptide with PD-L1 Blockade Results in Robust Antitumor Effects with a Concomitant Increase of Stem-Like/Progenitor Exhausted CD8+ T Cells. <i>Cancer Immunology Research</i> , 2021, 9, 1214-1228.	1.6	12
13497	Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 703143.	1.3	23
13498	Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1752.	3.3	13
13499	Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3582-3593.	1.3	12

#	ARTICLE	IF	CITATIONS
13500	Reverting to single-cell biology: The predictions of the atavism theory of cancer. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 165, 49-55.	1.4	12
13501	Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibitionâ€œoverall survival modeling framework. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1171-1182.	1.3	15
13502	A systematic comparison of data- and knowledge-driven approaches to disease subtype discovery. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	3
13503	Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. <i>British Journal of Cancer</i> , 2021, , .	2.9	12
13504	Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 312.	7.1	50
13505	Acral lentiginous melanomaâ€œPopulation, treatment, and survival using the NCDB from 2004 to 2015. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 1049-1061.	1.5	8
13506	Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 851-863.	2.0	6
13507	Immunotherapy in Hepatocellular Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 87.	1.3	25
13508	Association Between Body Mass Index and Survival Outcomes In Patients Treated With Immune Checkpoint Inhibitors: Meta-analyses of Individual Patient Data. <i>Journal of Immunotherapy</i> , 2021, 44, 371-375.	1.2	13
13509	A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	12
13510	Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. <i>Dermatology and Therapy</i> , 2021, 11, 1481-1496.	1.4	12
13511	Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). <i>Journal of Clinical Oncology</i> , 2021, 39, 3671-3681.	0.8	84
13512	Proteogenomic characterization of pancreatic ductal adenocarcinoma. <i>Cell</i> , 2021, 184, 5031-5052.e26.	13.5	236
13513	Loss of cancer cell STAT1 improves response to radiation therapy and promotes T cell activation in head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	4
13514	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. <i>Cancer Discovery</i> , 2022, 12, 108-133.	7.7	165
13515	A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 7131-7137.	0.9	7
13516	Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy. <i>Cancers</i> , 2021, 13, 4462.	1.7	2
13517	HSP70iQ435A to subdue autoimmunity and support anti-tumor responses. <i>Cell Stress and Chaperones</i> , 2021, 26, 845-857.	1.2	2

#	ARTICLE	IF	CITATIONS
13518	Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4795-4807.	1.6	16
13519	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2914-2925.	0.8	55
13520	The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2021, 11, 732214.	1.3	11
13521	Molecular Alterations in Lung Adenocarcinoma With Ground-Glass Nodules: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 724692.	1.3	2
13522	Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target. <i>Frontiers in Immunology</i> , 2021, 12, 670309.	2.2	11
13523	Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma. , 2021, 38, 287-295.		6
13524	Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-6.	0.7	13
13525	Cellâ€™s intrinsic and â€™s extrinsic roles of miRNAs in regulating T cell immunity. <i>Immunological Reviews</i> , 2021, 304, 126-140.	2.8	11
13526	Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer. <i>Nature Cancer</i> , 2021, 2, 919-931.	5.7	26
13527	Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 708195.	1.3	16
13528	Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block. <i>Translational Lung Cancer Research</i> , 2021, 10, 3850-3854.	1.3	1
13529	YAP1/MMP7/CXCL16 axis affects efficacy of neoadjuvant chemotherapy via tumor environment immunosuppression in triple-negative breast cancer. <i>Gland Surgery</i> , 2021, 10, 2799-2814.	0.5	3
13530	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. <i>Nature Communications</i> , 2021, 12, 5668.	5.8	91
13531	Expression, prognostic significance and therapeutic implications of PDâ€™L1 in gliomas. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	8
13532	A Tumor-Infiltration CD8+ T Cell-Based Gene Signature for Facilitating the Prognosis and Estimation of Immunization Responses in HPV+ Head and Neck Squamous Cell Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 749398.	1.3	7
13533	A mouse model for the study of anti-tumor Tâ€™cell responses in Kras-driven lung adenocarcinoma. <i>Cell Reports Methods</i> , 2021, 1, 100080.	1.4	13
13534	Pathogenic roles of long noncoding RNAs in melanoma: Implications in diagnosis and therapies. <i>Genes and Diseases</i> , 2023, 10, 113-125.	1.5	1
13535	Interferon alpha-inducible protein 27 (IFI27) is a prognostic marker for pancreatic cancer based on comprehensive bioinformatics analysis. <i>Bioengineered</i> , 2021, 12, 8515-8528.	1.4	14

#	ARTICLE	IF	CITATIONS
13536	Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	2
13537	Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2648-2660.	1.1	20
13538	Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	29
13539	The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges. <i>Targeted Oncology</i> , 2021, 16, 537-552.	1.7	20
13540	Efficacy and Safety of Actively Personalized Neoantigen Vaccination in the Management of Newly Diagnosed Glioblastoma: A Systematic Review. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5209-5220.	0.8	4
13541	Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor. <i>Molecular Oncology</i> , 2021, 15, 2958-2968.	2.1	5
13542	The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 737311.	2.2	28
13543	A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma. <i>Lung Cancer Management</i> , 2021, 10, LMT47.	1.5	1
13544	Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy. <i>Kidney Diseases (Basel, Switzerland)</i> , 2022, 8, 26-43.	1.2	16
13545	A Novel Prognostic Biomarker LPAR6 in Hepatocellular Carcinoma via Associating with Immune Infiltrates. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 90-103.	0.7	9
13546	Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors. <i>British Journal of Radiology</i> , 2021, 94, 20210228.	1.0	2
13547	Emerging therapeutic opportunities for integrin inhibitors. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 60-78.	21.5	191
13548	Transcription factor KLF2 enhances the sensitivity of breast cancer cells to cisplatin by suppressing kinase WEE1. <i>Cancer Biology and Therapy</i> , 2021, 22, 465-477.	1.5	6
13549	Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 599-606.	1.1	11
13550	Characterization of m6A-Related Genes Landscape in Skin Cutaneous Melanoma to Aid Immunotherapy and Assess Prognosis. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5345-5361.	0.8	7
13551	Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 10-28.	1.8	48
13552	Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3651-3655.	0.8	8
13553	Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	13

#	ARTICLE	IF	CITATIONS
13554	Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. <i>Cell Chemical Biology</i> , 2022, 29, 358-372.e5.	2.5	10
13555	Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials. <i>Current Treatment Options in Oncology</i> , 2021, 22, 100.	1.3	11
13556	Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer. <i>Molecular Therapy</i> , 2021, 29, 2723-2736.	3.7	85
13557	Single-cell profiling defines the prognostic benefit of CD39 ^{high} tissue resident memory CD8 ⁺ T cells in luminal-like breast cancer. <i>Communications Biology</i> , 2021, 4, 1117.	2.0	11
13558	Differential effects of CD20 ⁺ B cells and PD-L1 ⁺ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 477-489.	1.1	6
13559	Characterization of the tumor immune microenvironment of sinonasal squamous cell carcinoma. <i>International Forum of Allergy and Rhinology</i> , 2021, , .	1.5	5
13560	Case Report: Long Progression-Free Survival of Immunotherapy for Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutation. <i>Frontiers in Oncology</i> , 2021, 11, 731429.	1.3	5
13561	Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers. <i>Frontiers in Oncology</i> , 2021, 11, 753788.	1.3	4
13562	Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene signatures. <i>Immunity, Inflammation and Disease</i> , 2022, 10, 43-59.	1.3	4
13563	Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2021, 27, 6662-6665.	3.2	11
13564	Chromatin accessibility associates with protein-RNA correlation in human cancer. <i>Nature Communications</i> , 2021, 12, 5732.	5.8	18
13565	Genomic and evolutionary classification of lung cancer in never smokers. <i>Nature Genetics</i> , 2021, 53, 1348-1359.	9.4	81
13566	Immune PET Imaging. <i>Radiologic Clinics of North America</i> , 2021, 59, 875-886.	0.9	2
13567	Breast cancer immunotherapy: Current biomarkers and the potential of in vitro assays. <i>Current Opinion in Biomedical Engineering</i> , 2022, 21, 100348.	1.8	2
13568	Chaperone-assisted E3 ligase CHIP: A double agent in cancer. <i>Genes and Diseases</i> , 2022, 9, 1521-1555.	1.5	15
13569	Spherical Nucleic Acid Vaccine Structure Markedly Influences Adaptive Immune Responses of Clinically Utilized Prostate Cancer Targets. <i>Advanced Healthcare Materials</i> , 2021, 10, e2101262.	3.9	16
13570	¹⁸ F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 899-905.	2.8	36
13571	Current Immunotherapeutic Strategies for the Treatment of Glioblastoma. <i>Cancers</i> , 2021, 13, 4548.	1.7	16

#	ARTICLE	IF	CITATIONS
13572	Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle. <i>Frontiers in Immunology</i> , 2021, 12, 731947.	2.2	43
13573	MLL3 is a de novo cause of endocrine therapy resistance. <i>Cancer Medicine</i> , 2021, 10, 7692-7711.	1.3	6
13574	Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing. <i>Annals of Translational Medicine</i> , 2021, 9, 1437-1437.	0.7	8
13575	The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 744951.	1.3	9
13576	Positron Emission Tomography-Computed Tomography Parameters Predict Efficacy of Immunotherapy in Head and Neck Squamous Cell Carcinomas. <i>Frontiers in Oncology</i> , 2021, 11, 728040.	1.3	4
13577	PD-1 inhibition in advanced myeloproliferative neoplasms. <i>Blood Advances</i> , 2021, 5, 5086-5097.	2.5	16
13578	Glial and myeloid heterogeneity in the brain tumour microenvironment. <i>Nature Reviews Cancer</i> , 2021, 21, 786-802.	12.8	83
13579	A Radiomic Approach to Assess Tumor Immune Status by CD8+TRMs on Surgically Resected Non-Small-Cell Lung Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4921-4931.	1.0	4
13580	Whole-body PET Imaging of T-cell Response to Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 6445-6456.	3.2	10
13581	Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?. <i>Liver Cancer</i> , 2021, 10, 545-560.	4.2	22
13582	Molecular Pathology of Breast Tumors. <i>Surgical Pathology Clinics</i> , 2021, 14, 455-471.	0.7	2
13583	Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions. <i>Molecular Neurobiology</i> , 2021, 58, 6249-6271.	1.9	15
13584	Immunosuppressive Roles of Galectin-1 in the Tumor Microenvironment. <i>Biomolecules</i> , 2021, 11, 1398.	1.8	19
13585	A Novel Tool for the Risk Assessment and Personalized Chemo-/Immunotherapy Response Prediction of Adenocarcinoma and Squamous Cell Carcinoma Lung Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5771-5785.	0.8	2
13586	An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 698199.	1.3	5
13587	Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma. <i>Quality of Life Research</i> , 2022, 31, 937-950.	1.5	1
13588	Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis. <i>JTCVS Open</i> , 2021, , .	0.2	2
13589	Transgenic mouse models of breast cancer. <i>Cancer Letters</i> , 2021, 516, 73-83.	3.2	7

#	ARTICLE	IF	CITATIONS
13590	Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics. <i>Advanced Science</i> , 2021, 8, e2100460.	5.6	34
13591	A late endosome signaling hub that couples PI3K β and WNT/ β -catenin signaling in breast cancer. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1954470.	0.3	0
13592	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 5563.	5.8	19
13593	Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 741993.	1.3	9
13594	The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1041-1053.	5.7	27
13595	A new approach to produce IgG4-like bispecific antibodies. <i>Scientific Reports</i> , 2021, 11, 18630.	1.6	2
13596	InÂvivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. <i>Cell</i> , 2021, 184, 5357-5374.e22.	13.5	79
13597	CALD1 promotes the expression of PD-L1 in bladder cancer via the JAK/STAT signaling pathway. <i>Annals of Translational Medicine</i> , 2021, 9, 1441-1441.	0.7	13
13598	Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China. <i>Annals of Translational Medicine</i> , 2021, 9, 1480-1480.	0.7	7
13599	Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 662-676.	3.2	38
13600	Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics. <i>Oncogene</i> , 2021, 40, 6059-6070.	2.6	13
13601	Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	0.6	10
13602	A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance. <i>Anti-Cancer Drugs</i> , 2022, 33, e76-e83.	0.7	9
13603	The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events. <i>Frontiers in Oncology</i> , 2021, 11, 704475.	1.3	7
13604	Development and validation of a <i>PBRM1</i> -associated immune prognostic model for clear cell renal cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 6590-6609.	1.3	6
13605	HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. <i>Trends in Cancer</i> , 2021, 7, 1089-1101.	3.8	32
13606	Development and Validation of a Novel Model for Predicting Prognosis of Non-PCR Patients After Neoadjuvant Therapy for Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 675533.	1.3	5
13607	The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 691002.	1.3	6

#	ARTICLE	IF	CITATIONS
13608	Deep learning-based prediction of the T cell receptorâ€™ antigen binding specificity. <i>Nature Machine Intelligence</i> , 2021, 3, 864-875.	8.3	99
13609	ImmunoPET: harnessing antibodies for imaging immune cells. <i>Molecular Imaging and Biology</i> , 2022, 24, 181-197.	1.3	15
13610	Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden. <i>Pathology and Oncology Research</i> , 2021, 27, 1609852.	0.9	10
13611	White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer. <i>Lung</i> , 2021, 199, 549-557.	1.4	6
13612	Comprehensive Analysis of the Prognostic Value and Immune Function of Immune Checkpoints in Stomach Adenocarcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5807-5824.	0.8	7
13613	A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases. <i>Npj Breast Cancer</i> , 2021, 7, 121.	2.3	6
13614	Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy. <i>Heliyon</i> , 2021, 7, e07916.	1.4	4
13615	Imaging CAR T-cell kinetics in solid tumors: Translational implications. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 355-367.	2.0	20
13616	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. <i>Cell</i> , 2021, 184, 4753-4771.e27.	13.5	99
13617	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
13618	Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1054-1067.	5.7	16
13619	Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities. <i>Genes and Diseases</i> , 2022, 9, 1181-1193.	1.5	8
13620	Mouse resources at the RIKEN BioResource Research Center and the National BioResource Project core facility in Japan. <i>Mammalian Genome</i> , 2021, , 1.	1.0	2
13621	PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies. <i>Medicine and Pharmacy Reports</i> , 0, , .	0.2	10
13622	Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy. <i>World Journal of Surgical Oncology</i> , 2021, 19, 264.	0.8	21
13623	Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 953-966.	2.0	8
13624	Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment. <i>Oral Oncology</i> , 2021, 120, 105420.	0.8	20
13625	The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 723609.	2.2	17

#	ARTICLE	IF	CITATIONS
13626	MRTF-A-NF- κ B/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF- β ² . <i>Experimental and Molecular Medicine</i> , 2021, 53, 1366-1378.	3.2	22
13627	DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. <i>Nature Communications</i> , 2021, 12, 5406.	5.8	29
13628	Clinical translation of immunomodulatory therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113896.	6.6	8
13629	Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 757804.	2.2	31
13630	Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. <i>Cell Reports Medicine</i> , 2021, 2, 100383.	3.3	49
13631	Immune checkpoint inhibitor associated ocular hypertension (from presumed trabeculitis). <i>American Journal of Ophthalmology Case Reports</i> , 2021, 23, 101125.	0.4	2
13632	Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100230.	0.6	8
13633	Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1475-1475.	0.7	3
13634	Using DNA sequencing data to quantify T cell fraction and therapy response. <i>Nature</i> , 2021, 597, 555-560.	13.7	36
13635	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 37-50.	12.5	350
13636	Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2695-2709.	5.7	31
13637	Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). <i>Clinical and Translational Science</i> , 2022, 15, 141-157.	1.5	13
13638	The promise and perils of immunotherapy. <i>Blood Advances</i> , 2021, 5, 3709-3725.	2.5	23
13639	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2991-3001.	0.8	257
13640	Antimelanoma Effects of Concomitant Inhibition of SIRT1 and SIRT3 in Braf/Pten Mice. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1145-1157.e7.	0.3	5
13641	Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors. <i>Molecular Oncology</i> , 2021, 15, 2910-2922.	2.1	23
13642	Integrated analysis reveals distinct molecular, clinical, and immunological features of <i>B7β</i> in acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 7831-7846.	1.3	9
13643	Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients. <i>Cancers</i> , 2021, 13, 4861.	1.7	5

#	ARTICLE	IF	CITATIONS
13644	Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	21
13645	Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Reports, 2021, 36, 109699.	2.9	37
13646	Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab. Molecular Oncology, 2021, 15, 2923-2940.	2.1	17
13647	Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations. British Journal of Clinical Pharmacology, 2021, , .	1.1	5
13648	Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study. JTO Clinical and Research Reports, 2021, 2, 100234.	0.6	10
13649	Systemic inhibition of PTPN22 augments anticancer immunity. Journal of Clinical Investigation, 2021, 131, .	3.9	24
13650	Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-small Cell Lung Cancer. JAMA Oncology, 2021, 7, 1351.	3.4	113
13651	Multi-omic molecular profiling guide™s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial. Molecular Oncology, 2022, 16, 104-115.	2.1	6
13652	Engineered in vitro tumor models for cell-based immunotherapy. Acta Biomaterialia, 2021, 132, 345-359.	4.1	13
13653	Aging preclinical models in oncology field: from cells to aging. Aging Clinical and Experimental Research, 2021, , 1.	1.4	1
13654	Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists. Modern Pathology, 2022, 35, 142-151.	2.9	7
13655	PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer. Molecular Therapy, 2022, 30, 621-631.	3.7	17
13656	Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis. European Journal of Hospital Pharmacy, 2023, 30, 3-8.	0.5	9
13657	Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice. International Journal of Cancer, 2022, 150, 317-326.	2.3	12
13658	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nature Communications, 2021, 12, 5606.	5.8	76
13659	Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 6761-6771.	3.2	33
13660	Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series. Journal of Critical Care, 2021, 65, 126-132.	1.0	6
13661	caAtlas: An immunopeptidome atlas of human cancer. IScience, 2021, 24, 103107.	1.9	23

#	ARTICLE	IF	CITATIONS
13662	Immunotherapy for HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 361-370.	1.0	5
13663	Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy. <i>Tissue Engineering and Regenerative Medicine</i> , 2022, 19, 263-280.	1.6	11
13664	Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8 ⁺ T cell clone size and cytotoxicity. <i>Science Immunology</i> , 2021, 6, eabj8825.	5.6	41
13665	A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 434-446.	0.9	16
13666	A reservoir of stem-like CD8 ⁺ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. <i>Science Immunology</i> , 2021, 6, eabg7836.	5.6	123
13667	Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study. <i>Surgery Open Science</i> , 2021, 6, 10-14.	0.5	4
13668	miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer. <i>Cancer Letters</i> , 2021, 518, 115-126.	3.2	34
13669	A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. <i>Science</i> , 2021, 374, eabf2911.	6.0	37
13670	A protein interaction landscape of breast cancer. <i>Science</i> , 2021, 374, eabf3066.	6.0	66
13671	Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 2620.	1.8	10
13672	Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. <i>Journal of Bone Oncology</i> , 2021, 30, 100391.	1.0	8
13673	Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. <i>Trends in Cancer</i> , 2021, 7, 958-970.	3.8	18
13674	First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 57-70.	3.2	30
13675	The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6343-6358.	0.8	4
13676	Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. <i>Lung Cancer</i> , 2021, 161, 34-41.	0.9	7
13677	Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. <i>Lung Cancer</i> , 2021, 161, 60-67.	0.9	2
13678	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021, 157, 391-402.	1.3	13
13679	New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188624.	3.3	29

#	ARTICLE	IF	CITATIONS
13680	The estrogen receptor/GATA3/FOXA1 transcriptional network: lessons learned from breast cancer. <i>Current Opinion in Structural Biology</i> , 2021, 71, 65-70.	2.6	14
13681	Atezolizumab-induced bilateral anterior uveitis: A case report. <i>American Journal of Ophthalmology Case Reports</i> , 2021, 24, 101205.	0.4	2
13682	Immunotherapy in non-small cell lung cancer: update and new insights. <i>Journal of Clinical and Translational Research</i> , 0, .	0.3	23
13683	Laser nanobubbles induce immunogenic cell death in breast cancer. <i>Nanoscale</i> , 2021, 13, 3644-3653.	2.8	7
13684	Immunotyping and Quantification of Melanoma Tumorâ€“Infiltrating Lymphocytes. <i>Methods in Molecular Biology</i> , 2021, 2265, 515-528.	0.4	2
13685	Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 542140.	1.3	21
13686	Proteomic approaches to investigate gammaherpesvirus biology and associated tumorigenesis. <i>Advances in Virus Research</i> , 2021, 109, 201-254.	0.9	0
13687	CTD: An information-theoretic algorithm to interpret sets of metabolomic and transcriptomic perturbations in the context of graphical models. <i>PLoS Computational Biology</i> , 2021, 17, e1008550.	1.5	8
13688	PD-1 Expression and its Correlation With Prognosis in Clear Cell Renal Cell Carcinoma. <i>In Vivo</i> , 2021, 35, 1549-1553.	0.6	4
13689	Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry. <i>Clinical Cancer Research</i> , 2021, 27, 1987-1996.	3.2	38
13690	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199299.	1.4	20
13691	Gender-related disparities in the frequencies of PD-1 and PD-L1 positive peripheral blood T and B lymphocytes in patients with alcohol-related liver disease: a single center pilot study. <i>PeerJ</i> , 2021, 9, e10518.	0.9	6
13692	Synthesis and Preclinical Evaluation of a ⁶⁸ Ga-Labeled Adnectin, ⁶⁸ Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1228-1234.	2.8	21
13693	Multifaceted roles of CCL20 (C-C motif chemokine ligand 20): mechanisms and communication networks in breast cancer progression. <i>Bioengineered</i> , 2021, 12, 6923-6934.	1.4	14
13694	Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 593.	1.8	35
13695	Targeting metastatic cancer. <i>Nature Medicine</i> , 2021, 27, 34-44.	15.2	447
13696	Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 26.	7.1	112
13697	Antitumour immunity regulated by aberrant ERBB family signalling. <i>Nature Reviews Cancer</i> , 2021, 21, 181-197.	12.8	141

#	ARTICLE	IF	CITATIONS
13698	Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis. <i>Cancer Research and Treatment</i> , 2021, 53, 77-86.	1.3	8
13699	Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 555-562.	0.7	8
13700	A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. <i>Nature Biomedical Engineering</i> , 2021, 5, 297-308.	11.6	28
13701	Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00377.	0.6	26
13702	Efficacy and safety of immunological checkpoint inhibitors combined with anti-angiogenic drugs in first-line treatment of metastatic renal cell carcinoma: a systematic review and meta-analysis. <i>Translational Andrology and Urology</i> , 2021, 10, 300-309.	0.6	4
13703	The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study. <i>Clinical and Translational Immunology</i> , 2021, 10, e1257.	1.7	4
13704	Landscape of cell heterogeneity and evolutionary trajectory in ulcerative colitis-associated colon cancer revealed by single-cell RNA sequencing. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 271-288.	0.7	14
13705	A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation. <i>Translational Cancer Research</i> , 2021, 10, 3963-3978.	0.4	4
13706	Residue substitution enhances the immunogenicity of neoepitopes from gastric cancers. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	1
13707	Antigen Delivery to DEC205 ⁺ Dendritic Cells Induces Immunological Memory and Protective Therapeutic Effects against HPV-Associated Tumors at Different Anatomical Sites. <i>International Journal of Biological Sciences</i> , 2021, 17, 2944-2956.	2.6	11
13708	Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry. <i>Oncolmmunology</i> , 2021, 10, 1954761.	2.1	28
13709	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. <i>Clinical Cancer Research</i> , 2021, 27, 2226-2235.	3.2	25
13710	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). <i>Clinical Cancer Research</i> , 2021, 27, 5038-5048.	3.2	13
13711	Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 2-7.	1.0	13
13712	Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1681-1694.	3.2	33
13713	The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine. <i>Oncolmmunology</i> , 2021, 10, 1924492.	2.1	8
13714	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) $\geq 50\%$: real-world data. <i>Oncolmmunology</i> , 2021, 10, 1865653.	2.1	24
13715	Immune regulation in renal inflammation. <i>Cell and Tissue Research</i> , 2021, 385, 305-322.	1.5	7

#	ARTICLE	IF	CITATIONS
13716	Ral GTPases promote breast cancer metastasis by controlling biogenesis and organ targeting of exosomes. <i>ELife</i> , 2021, 10, .	2.8	70
13717	The association of transcription factor Prox1 with the proliferation, migration, and invasion of lung cancer. <i>Open Life Sciences</i> , 2021, 16, 602-610.	0.6	2
13718	ImmuCellAI: A Unique Method for Comprehensive Tâ€Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy. <i>Advanced Science</i> , 2020, 7, 1902880.	5.6	558
13719	Hyperprogression: A novel response pattern under immunotherapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e167.	1.7	22
13720	Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 58-66.	1.3	195
13721	Statistical and Bioinformatics Analysis of Data from Bulk and Single-Cell RNA Sequencing Experiments. <i>Methods in Molecular Biology</i> , 2021, 2194, 143-175.	0.4	12
13722	Taking Bioinformatics to Systems Medicine. <i>Methods in Molecular Biology</i> , 2016, 1386, 17-41.	0.4	9
13723	Pharmacokinetics and Pharmacodynamics in Breast Cancer Animal Models. <i>Methods in Molecular Biology</i> , 2016, 1406, 271-287.	0.4	3
13724	The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier. <i>Cancer Treatment and Research</i> , 2020, 180, 173-195.	0.2	48
13725	Immune-Related Adverse Events: Pneumonitis. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 255-269.	0.8	38
13726	Modeling Prolactin Actions in Breast Cancer In Vivo: Insights from the NRL-PRL Mouse. <i>Advances in Experimental Medicine and Biology</i> , 2015, 846, 201-220.	0.8	21
13727	Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 771-777.	2.0	70
13728	High PD-1 expression level is associated with an unfavorable prognosis in patients with cervical adenocarcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 209-218.	0.8	12
13729	Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 467-474.	1.0	8
13730	Phase III trial comparing UFTÂ+ÂPSK to UFTÂ+ÂLV in stage IIB, III colorectal cancer (MCSGO-CCTG). <i>Surgery Today</i> , 2018, 48, 66-72.	0.7	19
13731	The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. <i>BioDrugs</i> , 2020, 34, 495-503.	2.2	15
13732	Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. <i>British Journal of Anaesthesia</i> , 2020, 124, 251-260.	1.5	35
13733	Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. <i>Cancer Cell</i> , 2020, 37, 639-654.e6.	7.7	151

#	ARTICLE	IF	CITATIONS
13734	Tumor microenvironment pathways: Cross regulation in breast cancer metastasis. <i>Genes and Diseases</i> , 2022, 9, 310-324.	1.5	15
13735	Immune checkpoint inhibitors to treat cutaneous malignancies. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1239-1253.	0.6	56
13736	Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. <i>JAAD Case Reports</i> , 2017, 3, 412-415.	0.4	40
13737	CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities. , 2018, 191, 65-73.		50
13738	RUNX1 prevents oestrogen-mediated AXIN1 suppression and β -catenin activation in ER-positive breast cancer. <i>Nature Communications</i> , 2016, 7, 10751.	5.8	61
13739	Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 81-95.	8.2	62
13740	Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis. <i>Oncogene</i> , 2017, 36, 6863-6872.	2.6	53
13741	Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. <i>Oncogene</i> , 2018, 37, 439-449.	2.6	29
13742	Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 80-88.	2.9	74
13743	Translating current basic research into future therapies for neurofibromatosis type 1. <i>British Journal of Cancer</i> , 2020, 123, 178-186.	2.9	17
13744	The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. <i>Nature Communications</i> , 2020, 11, 6433.	5.8	37
13745	Dramatic enhancement of the detection limits of bioassays via ultrafast deposition of polydopamine. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	93
13746	Immune crosstalk in cancer progression and metastatic spread: a complex conversation. <i>Nature Reviews Immunology</i> , 2020, 20, 483-497.	10.6	241
13747	Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies. <i>Scientific Reports</i> , 2020, 10, 21985.	1.6	9
13748	c-Rel is a myeloid checkpoint for cancer immunotherapy. <i>Nature Cancer</i> , 2020, 1, 507-517.	5.7	63
13749	The T cell differentiation landscape is shaped by tumour mutations in lung cancer. <i>Nature Cancer</i> , 2020, 1, 546-561.	5.7	74
13750	P63 modulates the expression of the WDFY2 gene which is implicated in cancer regulation and limb development. <i>Bioscience Reports</i> , 2019, 39, .	1.1	5
13751	The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 775-784.	1.1	268

#	ARTICLE	IF	CITATIONS
13752	Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. <i>MABs</i> , 2019, 11, 681-690.	2.6	30
13753	Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. <i>Onc Immunology</i> , 2020, 9, 1684714.	2.1	12
13754	Common risk factors for heart failure and cancer. <i>Cardiovascular Research</i> , 2019, 115, 844-853.	1.8	175
13755	A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab). <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-6.	0.3	9
13756	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa115.	1.4	14
13757	An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa140.	0.4	6
13758	T cell regeneration: an update on progress and challenges. <i>Blood Science</i> , 2020, 2, 22-26.	0.4	4
13759	Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia. <i>Journal of Immunotherapy</i> , 2021, 44, 9-15.	1.2	10
13760	Nivolumab induced inflammation of seborrheic keratoses: a novel cutaneous manifestation in a metastatic melanoma patient. <i>Melanoma Research</i> , 2018, 28, 475-477.	0.6	14
13761	Clinical Characteristics and Treatment Response With Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina. <i>Journal of Lower Genital Tract Disease</i> , 2021, 25, 146-151.	0.9	12
13762	Ki67 Immunohistochemistry Quantification in Breast Carcinoma: A Comparison of Visual Estimation, Counting, and ImmunoRatio. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 105-111.	0.6	16
13763	Î”PK oncolytic activity includes modulation of the tumour cell milieu. <i>Journal of General Virology</i> , 2016, 97, 496-508.	1.3	29
13764	Aligner optimization increases accuracy and decreases compute times in multi-species sequence data. <i>Microbial Genomics</i> , 2017, 3, e000122.	1.0	13
13765	A survey of <i>Fusobacterium nucleatum</i> genes modulated by host cell infection. <i>Microbial Genomics</i> , 2020, 6, .	1.0	14
13766	CD20 ⁺ tumor-infiltrating immune cells and CD204 ⁺ M2 macrophages are associated with prognosis in thymic carcinoma. <i>Cancer Science</i> , 2020, 111, 1921-1932.	1.7	28
13767	Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer. <i>Cancer Science</i> , 2020, 111, 1933-1942.	1.7	13
13768	Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1969-1978.	1.7	13
13769	Proliferation-associated long noncoding RNA, <i>TMPOAS1</i> , is a potential therapeutic target for triple-negative breast cancer. <i>Cancer Science</i> , 2020, 111, 2440-2450.	1.7	26

#	ARTICLE	IF	CITATIONS
13770	Microsatellite instability and mismatch repair protein expressions in lymphocyteâ€predominant breast cancer. <i>Cancer Science</i> , 2020, 111, 2647-2654.	1.7	49
13771	Pan-Cancer Analyses of the Nuclear Receptor Superfamily. <i>Nuclear Receptor Research</i> , 2015, 2, .	2.5	40
13772	Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis. <i>Journal of Medical Imaging</i> , 2017, 5, 1.	0.8	18
13773	Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014208102.	0.2	38
13774	Ipilimumab-associated colitis or refractory <i>Clostridium difficile</i> infection?. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015211160.	0.2	10
13775	Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015213692.	0.2	14
13776	Immunotherapy in a rare case of primary pelvic retroperitoneal melanoma. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216450.	0.2	2
13777	Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217454.	0.2	56
13778	Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220415.	0.2	17
13779	Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-BarrÃ© syndrome. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-221318.	0.2	6
13780	Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-221801.	0.2	11
13781	Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224485.	0.2	6
13782	Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-13.	0.9	29
13783	Expression, Prognosis, and Immune Infiltrates Analyses of E2Fs in Human Brain and CNS Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-17.	0.9	13
13784	Aberrant Induction of a Mesenchymal/Stem Cell Program Engages Senescence in Normal Mammary Epithelial Cells. <i>Molecular Cancer Research</i> , 2021, 19, 651-666.	1.5	6
13785	Genomic Alterations during the <i>In Situ</i> to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System. <i>Molecular Cancer Research</i> , 2021, 19, 623-635.	1.5	24
13786	Breast Cancer beyond the Age of Mutation. <i>Gerontology</i> , 2016, 62, 434-442.	1.4	42
13787	The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis. <i>Case Reports in Oncology</i> , 2016, 9, 68-75.	0.3	6

#	ARTICLE	IF	CITATIONS
13788	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight, 2018, 3, .	2.3	128
13789	Endogenous retrovirus expression is associated with response to immune checkpoint pathway in clear cell renal cell carcinoma. JCI Insight, 2018, 3, .	2.3	128
13790	Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. JCI Insight, 2018, 3, .	2.3	120
13791	Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV. JCI Insight, 2018, 3, .	2.3	83
13792	Glucose metabolism controls disease-specific signatures of macrophage effector functions. JCI Insight, 2018, 3, .	2.3	60
13793	Targeting tumor-resident mast cells for effective anti-melanoma immune responses. JCI Insight, 2019, 4, .	2.3	36
13794	PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight, 2019, 4, .	2.3	64
13795	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight, 2019, 4, .	2.3	345
13796	An effective cell-penetrating antibody delivery platform. JCI Insight, 2019, 4, .	2.3	14
13797	Titin mutation associated with responsiveness to checkpoint blockades in solid tumors. JCI Insight, 2019, 4, .	2.3	104
13798	Eosinophils downregulate lung alloimmunity by decreasing TCR signal transduction. JCI Insight, 2019, 4, .	2.3	23
13799	Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. JCI Insight, 2019, 4, .	2.3	182
13800	Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients. JCI Insight, 2019, 4, .	2.3	83
13801	Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight, 2019, 4, .	2.3	113
13802	Multipanel mass cytometry reveals anti-PD-1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodes. JCI Insight, 2020, 5, .	2.3	17
13803	Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy. JCI Insight, 2020, 5, .	2.3	58
13804	MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC. JCI Insight, 2020, 5, .	2.3	22
13805	Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insight, 2020, 5, .	2.3	95

#	ARTICLE	IF	CITATIONS
13806	Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. JCI Insight, 2020, 5, .	2.3	22
13807	Clinical implications of monitoring nivolumab immunokinetics in nonâ€“small cell lung cancer patients. JCI Insight, 2018, 3, .	2.3	156
13808	Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight, 2016, 1, e85902.	2.3	179
13809	Deficiency of mitochondrial modulator MCJ promotes chemoresistance in breast cancer. JCI Insight, 2016, 1, .	2.3	16
13810	Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. JCI Insight, 2016, 1, .	2.3	41
13811	Lymphocyte activation gene 3 and coronary artery disease. JCI Insight, 2016, 1, e88628.	2.3	32
13812	Multiparametric profiling of nonâ€“small-cell lung cancers reveals distinct immunophenotypes. JCI Insight, 2016, 1, e89014.	2.3	110
13813	Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity. JCI Insight, 2016, 1, e89020.	2.3	17
13814	Physiologically activated mammary fibroblasts promote postpartum mammary cancer. JCI Insight, 2017, 2, e89206.	2.3	39
13815	C3d regulates immune checkpoint blockade and enhances antitumor immunity. JCI Insight, 2017, 2, .	2.3	23
13816	Loss of immune homeostasis dictates SHIV rebound after stem-cell transplantation. JCI Insight, 2017, 2, e91230.	2.3	24
13817	Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation. JCI Insight, 2017, 2, .	2.3	48
13818	microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer. JCI Insight, 2017, 2, .	2.3	22
13819	Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight, 2017, 2, .	2.3	62
13820	Human lung tumor FOXP+ Tregs upregulate four â€œTreg-lockingâ€“transcription factors. JCI Insight, 2017, 2, .	2.3	56
13821	Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. JCI Insight, 2017, 2, .	2.3	111
13822	CTLA4 methylation predicts response to antiâ€“PD-1 and antiâ€“CTLA-4 immunotherapy in melanoma patients. JCI Insight, 2018, 3, .	2.3	67
13823	IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma. JCI Insight, 2018, 3, .	2.3	18

#	ARTICLE	IF	CITATIONS
13824	CX3CR1 identifies PD-1 therapyâ€‘responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight, 2018, 3, .	2.3	106
13825	IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy. JCI Insight, 2018, 3, .	2.3	42
13826	Emerging strategies for combination checkpoint modulators in cancer immunotherapy. Journal of Clinical Investigation, 2018, 128, 3209-3218.	3.9	170
13827	DNA repair defects and implications for immunotherapy. Journal of Clinical Investigation, 2018, 128, 4236-4242.	3.9	59
13828	Peptide-based PET quantifies target engagement of PD-L1 therapeutics. Journal of Clinical Investigation, 2019, 129, 616-630.	3.9	94
13829	Oncolytic viruses: overcoming translational challenges. Journal of Clinical Investigation, 2019, 129, 1407-1418.	3.9	70
13830	An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. Journal of Clinical Investigation, 2018, 128, 5549-5560.	3.9	193
13831	Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor. Journal of Clinical Investigation, 2019, 129, 1863-1877.	3.9	56
13832	microRNA-142â€‘mediated repression of phosphodiesterase 3B critically regulates peripheral immune tolerance. Journal of Clinical Investigation, 2019, 129, 1257-1271.	3.9	45
13833	Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. Journal of Clinical Investigation, 2019, 129, 4708-4723.	3.9	41
13834	Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets. Journal of Clinical Investigation, 2019, 129, 2463-2479.	3.9	4
13835	Immunotherapy transforms cancer treatment. Journal of Clinical Investigation, 2018, 129, 46-47.	3.9	34
13836	Cellular therapy against public neoantigens. Journal of Clinical Investigation, 2019, 129, 506-508.	3.9	8
13837	Cancer neoantigens targeted by adoptive T cell transfer: private no more. Journal of Clinical Investigation, 2019, 129, 949-951.	3.9	5
13838	Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity. Journal of Clinical Investigation, 2019, 130, 231-246.	3.9	31
13839	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. Journal of Clinical Investigation, 2019, 130, 374-388.	3.9	43
13840	Adipocyte and lipid metabolism in cancer drug resistance. Journal of Clinical Investigation, 2019, 129, 3006-3017.	3.9	262
13841	cGAS/STING axis mediates a topoisomerase II inhibitorâ€‘induced tumor immunogenicity. Journal of Clinical Investigation, 2019, 129, 4850-4862.	3.9	136

#	ARTICLE	IF	CITATIONS
13842	Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. <i>Journal of Clinical Investigation</i> , 2019, 129, 4992-5004.	3.9	107
13843	Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. <i>Journal of Clinical Investigation</i> , 2019, 129, 5553-5567.	3.9	94
13844	Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. <i>Journal of Clinical Investigation</i> , 2020, 130, 4252-4265.	3.9	61
13845	Methylation of immune synapse genes modulates tumor immunogenicity. <i>Journal of Clinical Investigation</i> , 2020, 130, 974-980.	3.9	34
13846	PD-1 blockade inhibits osteoclast formation and murine bone cancer pain. <i>Journal of Clinical Investigation</i> , 2020, 130, 3603-3620.	3.9	90
13847	Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 1073-1083.	3.9	53
13848	S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion. <i>Journal of Clinical Investigation</i> , 2020, 130, 5461-5476.	3.9	48
13849	Maintenance DNA methylation is essential for regulatory T cell development and stability of suppressive function. <i>Journal of Clinical Investigation</i> , 2020, 130, 6571-6587.	3.9	51
13850	Activation and inhibition of lymphocytes by costimulation. <i>Journal of Clinical Investigation</i> , 2002, 109, 295-299.	3.9	140
13851	Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. <i>Journal of Clinical Investigation</i> , 2003, 111, 363-370.	3.9	164
13852	Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. <i>Journal of Clinical Investigation</i> , 2004, 113, 664-667.	3.9	47
13853	Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. <i>Journal of Clinical Investigation</i> , 2005, 115, 1903-1912.	3.9	126
13854	Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. <i>Journal of Clinical Investigation</i> , 2006, 116, 2543-51.	3.9	104
13855	Tregs and rethinking cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2007, 117, 1167-1174.	3.9	464
13856	Principles of adoptive T cell cancer therapy. <i>Journal of Clinical Investigation</i> , 2007, 117, 1204-1212.	3.9	217
13857	Harnessing the immune system to treat cancer. <i>Journal of Clinical Investigation</i> , 2007, 117, 1130-1136.	3.9	103
13858	Death-associated protein kinase 1 promotes growth of p53-mutant cancers. <i>Journal of Clinical Investigation</i> , 2015, 125, 2707-2720.	3.9	49
13859	Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2014, 124, 5145-5158.	3.9	105

#	ARTICLE	IF	CITATIONS
13860	Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. <i>Journal of Clinical Investigation</i> , 2014, 124, 5411-5423.	3.9	128
13861	RASAL2 activates RAC1 to promote triple-negative breast cancer progression. <i>Journal of Clinical Investigation</i> , 2014, 124, 5291-5304.	3.9	72
13862	Lymphatic vessels regulate immune microenvironments in human and murine melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3389-3402.	3.9	157
13863	CAR therapy: the CD19 paradigm. <i>Journal of Clinical Investigation</i> , 2015, 125, 3392-3400.	3.9	187
13864	Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2015, 125, 3377-3383.	3.9	146
13865	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 921-937.	3.9	71
13866	RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. <i>Journal of Clinical Investigation</i> , 2016, 126, 3739-3757.	3.9	107
13867	Sepsis-induced immune dysfunction: can immune therapies reduce mortality?. <i>Journal of Clinical Investigation</i> , 2016, 126, 23-31.	3.9	461
13868	Metabolic regulation of immune responses: therapeutic opportunities. <i>Journal of Clinical Investigation</i> , 2016, 126, 2031-2039.	3.9	78
13869	Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. <i>Journal of Clinical Investigation</i> , 2016, 126, 3130-3144.	3.9	773
13870	Targeting human melanoma neoantigens by T cell receptor gene therapy. <i>Journal of Clinical Investigation</i> , 2016, 126, 854-858.	3.9	52
13871	Thymic stromal lymphopoietin blocks early stages of breast carcinogenesis. <i>Journal of Clinical Investigation</i> , 2016, 126, 1458-1470.	3.9	62
13872	Hypoxia-inducible factors: a central link between inflammation and cancer. <i>Journal of Clinical Investigation</i> , 2016, 126, 3689-3698.	3.9	144
13873	Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. <i>Journal of Clinical Investigation</i> , 2016, 126, 2334-2340.	3.9	312
13874	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. <i>Journal of Clinical Investigation</i> , 2016, 126, 2642-2660.	3.9	81
13875	The host STING pathway at the interface of cancer and immunity. <i>Journal of Clinical Investigation</i> , 2016, 126, 2404-2411.	3.9	327
13876	NLR4 suppresses melanoma tumor progression independently of inflammasome activation. <i>Journal of Clinical Investigation</i> , 2016, 126, 3917-3928.	3.9	65
13877	Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. <i>Journal of Clinical Investigation</i> , 2018, 128, 2487-2499.	3.9	80

#	ARTICLE	IF	CITATIONS
13878	Role of steroid receptor and coregulator mutations in hormone-dependent cancers. <i>Journal of Clinical Investigation</i> , 2017, 127, 1126-1135.	3.9	42
13879	Overcoming therapeutic resistance in glioblastoma: the way forward. <i>Journal of Clinical Investigation</i> , 2017, 127, 415-426.	3.9	354
13880	Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. <i>Journal of Clinical Investigation</i> , 2017, 127, 2725-2738.	3.9	75
13881	Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma. <i>Journal of Clinical Investigation</i> , 2017, 128, 294-308.	3.9	55
13882	Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. <i>Journal of Clinical Investigation</i> , 2017, 127, 3039-3051.	3.9	124
13883	Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 1338-1354.	3.9	64
13884	Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment. <i>Journal of Clinical Investigation</i> , 2017, 127, 1218-1220.	3.9	15
13885	Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. <i>Journal of Clinical Investigation</i> , 2018, 128, 644-654.	3.9	144
13886	PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation. <i>Journal of Clinical Investigation</i> , 2018, 128, 4669-4681.	3.9	98
13887	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , 2018, 128, 805-815.	3.9	423
13888	Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 1371-1383.	3.9	126
13889	Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. <i>Journal of Clinical Investigation</i> , 2019, 129, 1785-1800.	3.9	266
13890	Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 2104-2115.	3.9	152
13891	CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2018, 128, 5465-5478.	3.9	37
13892	STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion. <i>Journal of Clinical Investigation</i> , 2018, 128, 1867-1872.	3.9	30
13893	Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. <i>Journal of Clinical Investigation</i> , 2018, 128, 2535-2550.	3.9	27
13894	Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. <i>Journal of Clinical Investigation</i> , 2018, 128, 4098-4114.	3.9	31
13895	Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. <i>Journal of Clinical Investigation</i> , 2018, 128, 2356-2369.	3.9	118

#	ARTICLE	IF	CITATIONS
13896	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. <i>Journal of Clinical Investigation</i> , 2019, 129, 1278-1294.	3.9	102
13897	PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 1413-1428.	3.9	111
13898	Imaging activated T cells predicts response to cancer vaccines. <i>Journal of Clinical Investigation</i> , 2018, 128, 2569-2580.	3.9	114
13899	Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 1563-1568.	3.9	93
13900	The host protecting the tumor from the host " targeting PD-L1 expressed by host cells. <i>Journal of Clinical Investigation</i> , 2018, 128, 570-572.	3.9	15
13901	Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 4654-4668.	3.9	591
13902	Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 4413-4428.	3.9	44
13903	PD-L1 monoclonal antibody-decorated nanoliposomes loaded with Paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers. <i>Nanoscale Research Letters</i> , 2020, 15, 59.	3.1	27
13904	Adipocytes promote tumor progression and induce PD-L1 expression via TNF- α /IL-6 signaling. <i>Cancer Cell International</i> , 2020, 20, 179.	1.8	21
13905	The immune system view of the coronavirus SARS-CoV-2. <i>Biology Direct</i> , 2020, 15, 30.	1.9	19
13907	Influence on [18F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor. <i>EJNMMI Research</i> , 2020, 10, 24.	1.1	10
13908	Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report. <i>Surgical Case Reports</i> , 2019, 5, 166.	0.2	6
13909	Multimodal therapy with surgery and adjuvant nivolumab for late-onset multiple liver metastases of choroidal malignant melanoma: a case report. <i>Surgical Case Reports</i> , 2020, 6, 187.	0.2	3
13910	Undifferentiated carcinoma of the transverse colon with rhabdoid features that developed during treatment of non-small cell lung carcinoma with pembrolizumab: a case report. <i>Surgical Case Reports</i> , 2020, 6, 196.	0.2	3
13911	The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 88.	0.9	19
13913	Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient. <i>American Journal of Case Reports</i> , 2016, 17, 880-882.	0.3	13
13914	Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes. <i>American Journal of Case Reports</i> , 2018, 19, 783-789.	0.3	3
13915	A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma. <i>American Journal of Case Reports</i> , 2019, 20, 106-110.	0.3	7

#	ARTICLE	IF	CITATIONS
13916	A Case Report of Atezolizumab Induced Tumor Lysis Syndrome. American Journal of Case Reports, 2019, 20, 785-789.	0.3	9
13917	Complete Response of Chemo-Refractory Metastatic Metaplastic Breast Cancer to Paclitaxel-Immunotherapy Combination. American Journal of Case Reports, 2019, 20, 1630-1635.	0.3	29
13918	Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models. Medical Science Monitor, 2017, 23, 3360-3366.	0.5	35
13919	Downregulation of TBC1 Domain Family Member 24 (BC1D24) Inhibits Breast Carcinoma Growth via IGF1R/PI3K/AKT Pathway. Medical Science Monitor, 2018, 24, 3987-3996.	0.5	6
13920	Relationship Between ADAMTS8, ADAMTS18, and ADAMTS20 (A Disintegrin and Metalloproteinase with) Tj ETQq0 0 0 rgBT /Overlock 1 Parameters, and Prognosis in Breast Invasive Ductal Carcinoma. Medical Science Monitor, 2018, 24, 3726-3735.	0.5	11
13921	Correlation of T Cell Immunoglobulin and ITIM Domain (TIGIT) and Programmed Death 1 (PD-1) with Clinicopathological Characteristics of Renal Cell Carcinoma May Indicate Potential Targets for Treatment. Medical Science Monitor, 2018, 24, 6861-6872.	0.5	20
13922	Bibliometric Analysis of Tumor Immunotherapy Studies. Medical Science Monitor, 2018, 24, 3405-3414.	0.5	34
13923	Expression of B7 Homolog 1 (B7H1) Is Associated with Clinicopathologic Features in Urothelial Bladder Cancer. Medical Science Monitor, 2018, 24, 7303-7308.	0.5	5
13924	LINC00922 Accelerates the Proliferation, Migration and Invasion of Lung Cancer Via the miRNA-204/CXCR4 Axis. Medical Science Monitor, 2019, 25, 5075-5086.	0.5	25
13925	New discoveries in the molecular landscape of bladder cancer. F1000Research, 2016, 5, 2875.	0.8	5
13926	Harnessing the immune response to target tumors. F1000Research, 2017, 6, 710.	0.8	2
13927	Recent advances in understanding the complexities of metastasis. F1000Research, 2018, 7, 1169.	0.8	45
13928	Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies. F1000Research, 2019, 8, 227.	0.8	20
13929	Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019. F1000Research, 2019, 8, 849.	0.8	50
13930	Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer. F1000Research, 2019, 8, 591.	0.8	15
13931	Triple-negative breast cancer: recent treatment advances. F1000Research, 2019, 8, 1342.	0.8	152
13932	Cancer immunosurveillance by CD8 T cells. F1000Research, 2020, 9, 80.	0.8	11
13933	Cancer Genomics. F1000Research, 2015, 4, 1162.	0.8	2

#	ARTICLE	IF	CITATIONS
13934	Signaling in T cells “ is anything the m(a)TOR with the picture(s)?. F1000Research, 2016, 5, 191.	0.8	6
13935	Concerning immune synapses: a spatiotemporal timeline. F1000Research, 2016, 5, 418.	0.8	35
13936	Recent advances in the management of renal cell carcinoma. F1000Research, 2016, 5, 391.	0.8	4
13937	Recent advances in molecular genetics of melanoma progression: implications for diagnosis and treatment. F1000Research, 2016, 5, 1529.	0.8	4
13938	Recent advances in T-cell engineering for use in immunotherapy. F1000Research, 2016, 5, 2344.	0.8	14
13939	Recent advances in understanding antitumor immunity. F1000Research, 2016, 5, 2545.	0.8	29
13940	Biomarkers for immune therapy in melanoma. Seminars in Cutaneous Medicine and Surgery, 2018, 37, 120-126.	1.6	2
13941	Primary malignant melanoma of the biliary tract: A case report and literature review. World Journal of Clinical Cases, 2019, 7, 2302-2308.	0.3	7
13942	Immune checkpoint inhibitor-induced colitis: A comprehensive review. World Journal of Clinical Cases, 2019, 7, 405-418.	0.3	171
13943	Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: A case report. World Journal of Clinical Cases, 2020, 8, 2833-2840.	0.3	3
13944	Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report. World Journal of Clinical Cases, 2020, 8, 2876-2884.	0.3	6
13945	Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report. World Journal of Clinical Cases, 2020, 8, 624-629.	0.3	8
13946	Optical clearing agent increases effectiveness of photodynamic therapy in a mouse model of cutaneous melanoma: an analysis by Raman microspectroscopy. Biomedical Optics Express, 2020, 11, 6516.	1.5	6
13947	ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells. PLoS Biology, 2015, 13, e1002330.	2.6	59
13948	Modeling Cellular Noise Underlying Heterogeneous Cell Responses in the Epidermal Growth Factor Signaling Pathway. PLoS Computational Biology, 2016, 12, e1005222.	1.5	25
13949	Contextual Refinement of Regulatory Targets Reveals Effects on Breast Cancer Prognosis of the Regulome. PLoS Computational Biology, 2017, 13, e1005340.	1.5	6
13950	Multiscale mutation clustering algorithm identifies pan-cancer mutational clusters associated with pathway-level changes in gene expression. PLoS Computational Biology, 2017, 13, e1005347.	1.5	14
13951	NetNorM: Capturing cancer-relevant information in somatic exome mutation data with gene networks for cancer stratification and prognosis. PLoS Computational Biology, 2017, 13, e1005573.	1.5	27

#	ARTICLE	IF	CITATIONS
13952	Learning causal networks with latent variables from multivariate information in genomic data. PLoS Computational Biology, 2017, 13, e1005662.	1.5	28
13953	Epigenetics in Cancer: A Hematological Perspective. PLoS Genetics, 2016, 12, e1006193.	1.5	77
13954	Somatic Mutation Patterns in Hemizygous Genomic Regions Unveil Purifying Selection during Tumor Evolution. PLoS Genetics, 2016, 12, e1006506.	1.5	24
13955	The INO80 chromatin remodeler sustains metabolic stability by promoting TOR signaling and regulating histone acetylation. PLoS Genetics, 2018, 14, e1007216.	1.5	23
13956	Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. PLoS Medicine, 2016, 13, e1002193.	3.9	75
13957	Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. PLoS Medicine, 2016, 13, e1002196.	3.9	21
13958	Precancerous Stem Cells Have the Potential for both Benign and Malignant Differentiation. PLoS ONE, 2007, 2, e293.	1.1	98
13959	Adoptive Immunotherapy of Cytokine-Induced Killer Cell Therapy in the Treatment of Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e112662.	1.1	28
13960	Characterization of Genomic Alterations in Radiation-Associated Breast Cancer among Childhood Cancer Survivors, Using Comparative Genomic Hybridization (CGH) Arrays. PLoS ONE, 2015, 10, e0116078.	1.1	10
13961	Location of Triple-Negative Breast Cancers: Comparison with Estrogen Receptor-Positive Breast Cancers on MR Imaging. PLoS ONE, 2015, 10, e0116344.	1.1	9
13962	LSD1 Overexpression Is Associated with Poor Prognosis in Basal-Like Breast Cancer, and Sensitivity to PARP Inhibition. PLoS ONE, 2015, 10, e0118002.	1.1	67
13963	Exome Analysis Reveals Differentially Mutated Gene Signatures of Stage, Grade and Subtype in Breast Cancers. PLoS ONE, 2015, 10, e0119383.	1.1	19
13964	The Identification of Specific Methylation Patterns across Different Cancers. PLoS ONE, 2015, 10, e0120361.	1.1	48
13965	Folate Receptor-1 (FOLR1) Expression and Function in Triple Negative Tumors. PLoS ONE, 2015, 10, e0122209.	1.1	103
13966	Transcriptome Analysis of Wnt3a-Treated Triple-Negative Breast Cancer Cells. PLoS ONE, 2015, 10, e0122333.	1.1	61
13967	Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153. PLoS ONE, 2015, 10, e0124059.	1.1	74
13968	Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection. PLoS ONE, 2015, 10, e0124590.	1.1	9
13969	Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. PLoS ONE, 2015, 10, e0125232.	1.1	27

#	ARTICLE	IF	CITATIONS
13970	Evaluation of Two Highly-Multiplexed Custom Panels for Massively Parallel Semiconductor Sequencing on Paraffin DNA. PLoS ONE, 2015, 10, e0128818.	1.1	13
13971	Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model. PLoS ONE, 2015, 10, e0129237.	1.1	17
13972	Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. PLoS ONE, 2015, 10, e0131177.	1.1	177
13973	PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS ONE, 2015, 10, e0131403.	1.1	288
13974	Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis. PLoS ONE, 2015, 10, e0131689.	1.1	75
13975	The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells. PLoS ONE, 2015, 10, e0134715.	1.1	83
13976	Identification of Gene-Expression Signatures and Protein Markers for Breast Cancer Grading and Staging. PLoS ONE, 2015, 10, e0138213.	1.1	30
13977	The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types. PLoS ONE, 2015, 10, e0138726.	1.1	24
13978	Semi-Supervised Projective Non-Negative Matrix Factorization for Cancer Classification. PLoS ONE, 2015, 10, e0138814.	1.1	18
13979	TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway. PLoS ONE, 2015, 10, e0140694.	1.1	58
13980	Multiplex Identification of Antigen-Specific T Cell Receptors Using a Combination of Immune Assays and Immune Receptor Sequencing. PLoS ONE, 2015, 10, e0141561.	1.1	111
13981	Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110. PLoS ONE, 2015, 10, e0141669.	1.1	19
13982	Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter. PLoS ONE, 2015, 10, e0142224.	1.1	20
13983	Bringing Down Cancer Aircraft: Searching for Essential Hypomutated Proteins in Skin Melanoma. PLoS ONE, 2015, 10, e0142819.	1.1	14
13984	The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients. PLoS ONE, 2015, 10, e0143061.	1.1	90
13985	Identifying Triple-Negative Breast Cancer Using Background Parenchymal Enhancement Heterogeneity on Dynamic Contrast-Enhanced MRI: A Pilot Radiomics Study. PLoS ONE, 2015, 10, e0143308.	1.1	110
13986	An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells. PLoS ONE, 2015, 10, e0144594.	1.1	13
13987	More Accurate Prediction of Metastatic Pancreatic Cancer Patients's Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. PLoS ONE, 2016, 11, e0145692.	1.1	14

#	ARTICLE	IF	CITATIONS
13988	Evaluation of Selected Immunomodulatory Glycoproteins as an Adjunct to Cancer Immunotherapy. PLoS ONE, 2016, 11, e0146881.	1.1	7
13989	A Feature Selection Algorithm to Compute Gene Centric Methylation from Probe Level Methylation Data. PLoS ONE, 2016, 11, e0148977.	1.1	25
13990	Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice. PLoS ONE, 2016, 11, e0150084.	1.1	35
13991	Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1 Protease-Sensitive Toxin Nanocapsules. PLoS ONE, 2016, 11, e0151572.	1.1	20
13992	Examining the Relationship between Pre-Malignant Breast Lesions, Carcinogenesis and Tumor Evolution in the Mammary Epithelium Using an Agent-Based Model. PLoS ONE, 2016, 11, e0152298.	1.1	4
13993	Estrogen Receptor Expression Is Associated with DNA Repair Capacity in Breast Cancer. PLoS ONE, 2016, 11, e0152422.	1.1	23
13994	The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0152500.	1.1	219
13995	Increased Soluble CD155 in the Serum of Cancer Patients. PLoS ONE, 2016, 11, e0152982.	1.1	83
13996	Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer. PLoS ONE, 2016, 11, e0155660.	1.1	107
13997	Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance. PLoS ONE, 2016, 11, e0155840.	1.1	20
13998	Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients. PLoS ONE, 2016, 11, e0156789.	1.1	30
13999	Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma. PLoS ONE, 2016, 11, e0157176.	1.1	92
14000	Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma. PLoS ONE, 2016, 11, e0157969.	1.1	54
14001	Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers. PLoS ONE, 2016, 11, e0158259.	1.1	16
14002	Abundant NDRG2 Expression Is Associated with Aggressiveness and Unfavorable Patients' Outcome in Basal-Like Breast Cancer. PLoS ONE, 2016, 11, e0159073.	1.1	12
14003	Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Colorectal Liver Metastasis: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0159447.	1.1	39
14004	Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. PLoS ONE, 2016, 11, e0160004.	1.1	33
14005	Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study. PLoS ONE, 2016, 11, e0162133.	1.1	17

#	ARTICLE	IF	CITATIONS
14006	PD-L1 Status in Refractory Lymphomas. PLoS ONE, 2016, 11, e0166266.	1.1	47
14007	RAS Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers. PLoS ONE, 2016, 11, e0166626.	1.1	140
14008	Mutant PIK3CA Induces EMT in a Cell Type Specific Manner. PLoS ONE, 2016, 11, e0167064.	1.1	5
14009	Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women. PLoS ONE, 2016, 11, e0168090.	1.1	17
14010	Claudin-Low Breast Cancer; Clinical & Pathological Characteristics. PLoS ONE, 2017, 12, e0168669.	1.1	111
14011	Identification of Post-Transcriptional Modulators of Breast Cancer Transcription Factor Activity Using MINDy. PLoS ONE, 2016, 11, e0168770.	1.1	4
14012	The Prognostic and Clinicopathological Significance of Tumor-Associated Macrophages in Patients with Gastric Cancer: A Meta-Analysis. PLoS ONE, 2017, 12, e0170042.	1.1	84
14013	P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis. PLoS ONE, 2017, 12, e0170302.	1.1	5
14014	Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy. PLoS ONE, 2017, 12, e0171460.	1.1	18
14015	An integrative study on the impact of highly differentially methylated genes on expression and cancer etiology. PLoS ONE, 2017, 12, e0171694.	1.1	1
14016	Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability. PLoS ONE, 2017, 12, e0174863.	1.1	23
14017	Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors. PLoS ONE, 2017, 12, e0175128.	1.1	28
14018	Genetic profiling of putative breast cancer stem cells from malignant pleural effusions. PLoS ONE, 2017, 12, e0175223.	1.1	6
14019	Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. PLoS ONE, 2017, 12, e0176167.	1.1	27
14020	Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis. PLoS ONE, 2017, 12, e0176822.	1.1	64
14021	ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1). PLoS ONE, 2017, 12, e0177919.	1.1	8
14022	Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics. PLoS ONE, 2017, 12, e0178296.	1.1	25
14023	A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy. PLoS ONE, 2017, 12, e0179170.	1.1	9

#	ARTICLE	IF	CITATIONS
14024	Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0179536.	1.1	34
14025	Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. PLoS ONE, 2017, 12, e0179726.	1.1	216
14026	Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients. PLoS ONE, 2017, 12, e0179744.	1.1	33
14027	A longitudinal MRI study on lymph nodes histiocytosis of a xenograft cancer model. PLoS ONE, 2017, 12, e0181043.	1.1	6
14028	High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals. PLoS ONE, 2017, 12, e0181464.	1.1	10
14029	PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients. PLoS ONE, 2017, 12, e0184254.	1.1	17
14030	Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of ¹⁸ F-deoxyglucose levels on positron emission tomography for breast cancers. PLoS ONE, 2017, 12, e0184508.	1.1	6
14031	Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors. PLoS ONE, 2017, 12, e0186190.	1.1	24
14032	A comprehensive analysis of breast cancer microbiota and host gene expression. PLoS ONE, 2017, 12, e0188873.	1.1	111
14033	FGMD: A novel approach for functional gene module detection in cancer. PLoS ONE, 2017, 12, e0188900.	1.1	5
14034	Safety and antitumor activity of the anti- α PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS ONE, 2017, 12, e0189848.	1.1	190
14035	High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism. PLoS ONE, 2018, 13, e0190619.	1.1	69
14036	Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model. PLoS ONE, 2018, 13, e0192449.	1.1	48
14037	In vitro immunotherapy potency assays using real-time cell analysis. PLoS ONE, 2018, 13, e0193498.	1.1	76
14038	Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells. PLoS ONE, 2018, 13, e0194913.	1.1	9
14039	Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures. PLoS ONE, 2020, 15, e0239197.	1.1	13
14040	Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses. PLoS ONE, 2020, 15, e0239369.	1.1	14
14041	HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT). PLoS Pathogens, 2016, 12, e1005372.	2.1	67

#	ARTICLE	IF	CITATIONS
14042	The Future of Combining Carbon-Ion Radiotherapy with Immunotherapy: Evidence and Progress in Mouse Models. <i>International Journal of Particle Therapy</i> , 2016, 3, 61-70.	0.9	37
14043	TrkB Promotes Breast Cancer Metastasis via Suppression of Runx3 and Keap1 Expression. <i>Molecules and Cells</i> , 2016, 39, 258-265.	1.0	35
14044	RUNX1 Dosage in Development and Cancer. <i>Molecules and Cells</i> , 2020, 43, 126-138.	1.0	16
14045	Molecular subtypes and imaging phenotypes of breast cancer. <i>Ultrasonography</i> , 2016, 35, 281-288.	1.0	88
14046	A Case of Acute Heart Failure due to Immune Checkpoint Blocker Nivolumab. <i>Cardiology Research</i> , 2019, 10, 120-123.	0.5	11
14047	An Unusual Case of Gastritis in One Patient Receiving PD-1 Blocking Therapy: Coexisting Immune-Related Gastritis and Cytomegaloviral Infection. <i>Gastroenterology Research</i> , 2018, 11, 383-387.	0.4	19
14048	Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 63-75.	0.6	49
14049	Isolated Adrenocorticotrophic Hormone Deficiency and Severe Hypercalcemia After Destructive Thyroiditis in a Patient on Nivolumab Therapy With a Malignant Melanoma. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 358-362.	0.6	23
14050	Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer. <i>World Journal of Oncology</i> , 2020, 11, 9-22.	0.6	36
14051	Dendritic Cell Targeting Vaccine for HPV-Associated Cancer. <i>Cancer Cell & Microenvironment</i> , 0, , .	0.8	8
14052	Efferocytosis Creates a Tumor Microenvironment Supportive of Tumor Survival and Metastasis. <i>Cancer Cell & Microenvironment</i> , 2015, 2, .	0.8	22
14053	PD-1 pathway-mediated regulation of islet-specific CD4+ T cell subsets in autoimmune diabetes. <i>Immunoendocrinology (Houston, Tex)</i> , 2016, 3, .	1.0	14
14054	IL-10: Expanding the Immune Oncology Horizon. <i>Receptors & Clinical Investigation</i> , 0, , .	0.9	4
14055	Urgent need to define Pretreatment predictors of immune check point inhibitors related endocrinopathies: A case report and review of literature. <i>Journal of Translational Internal Medicine</i> , 2017, 5, 235-239.	1.0	1
14056	Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma. <i>Open Medicine (Poland)</i> , 2020, 15, 292-301.	0.6	7
14057	Current Biochemical Applications and Future Prospects of Chlorotoxinin Cancer Diagnostics and Therapeutics. <i>Advanced Pharmaceutical Bulletin</i> , 2019, 9, 510-520.	0.6	9
14058	A cancer vaccine with dendritic cells differentiated with GM-CSF and IFN γ and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model. <i>Biolmpacts</i> , 2018, 8, 211-221.	0.7	23
14059	Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities. <i>Biolmpacts</i> , 2019, 9, 1-3.	0.7	7

#	ARTICLE	IF	CITATIONS
14060	Combined targeting of G protein-coupled receptor and <sc>EGF</sc> receptor signaling overcomes resistance to <sc>PI</sc> 3K pathway inhibitors in <sc>PTEN</sc> -null triple negative breast cancer. EMBO Molecular Medicine, 2020, 12, e11987.	3.3	17
14061	Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer. Endocrine Connections, 2019, 8, 1040-1051.	0.8	23
14062	POLE and POLD1 pathogenic variants in the proofreading domain in papillary thyroid cancer. Endocrine Connections, 2020, 9, 923-932.	0.8	7
14063	A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 140092.	0.2	27
14064	Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, .	0.2	60
14065	Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.2	26
14066	New-onset insulin-dependent diabetes due to nivolumab. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.2	14
14067	Low PR in ER(+)/HER2(âˆ“) breast cancer: high rates of TP53 mutation and high SUV. Endocrine-Related Cancer, 2019, 26, 177-185.	1.6	15
14068	French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocrine-Related Cancer, 2019, 26, G1-G18.	1.6	95
14069	The molecular genetic make-up of male breast cancer. Endocrine-Related Cancer, 2019, 26, 779-794.	1.6	27
14070	Impact of Diet and Nutrition on Cancer Hallmarks. Journal of Cancer Prevention & Current Research, 2017, 7, .	0.1	4
14071	Identification of Biomarkers for Breast Cancer Using Databases. Journal of Cancer Prevention, 2016, 21, 235-242.	0.8	22
14072	Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?. Journal of Kidney Cancer and VHL, 2014, 1, 74-83.	0.2	25
14073	Present and future perspectives on immunotherapy for advanced renal cell carcinoma: Going to the core or beating around the bush?. Journal of Kidney Cancer and VHL, 2015, 2, 55-63.	0.2	3
14074	Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives. Journal of Kidney Cancer and VHL, 2018, 5, 15-18.	0.2	20
14075	T lymphocytes against solid malignancies: winning ways to defeat tumours. Cell Stress, 2018, 2, 200-212.	1.4	22
14076	Immunosurveillance of cancer cell stress. Cell Stress, 2019, 3, 295-309.	1.4	10
14077	Inflammation induced PD-L1-specific T cells. Cell Stress, 2019, 3, 319-327.	1.4	13

#	ARTICLE	IF	CITATIONS
14078	Role of tumor microenvironment in the efficacy of BCG therapy. Trends in Research, 2020, 3, .	0.2	8
14079	A genetic variant in microRNA-146a is associated with sporadic breast cancer in a Southern Brazilian Population. Genetics and Molecular Biology, 2019, 42, e20190278.	0.6	7
14080	Liquid Biopsies for Assessing Metastatic Melanoma Progression. Critical Reviews in Oncogenesis, 2016, 21, 141-154.	0.2	15
14081	Immunology Comes Full Circle in Melanoma While Specific Immunity Is Unleashed to Eliminate Metastatic Disease, Inflammatory Products of Innate Immunity Promote Resistance. Critical Reviews in Oncogenesis, 2016, 21, 57-63.	0.2	2
14082	Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes. Critical Reviews in Oncogenesis, 2016, 21, 333-351.	0.2	44
14083	Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy. Critical Reviews in Oncogenesis, 2019, 24, 105-118.	0.2	8
14084	Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come. Critical Reviews in Oncogenesis, 2015, 20, 339-347.	0.2	6
14085	Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. Oncologist, 2019, 24, 1534-1542.	1.9	15
14086	Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations. Radiation Research, 2020, 194, 688-697.	0.7	29
14087	Avelumab inducing hypothyroidism and hypoadrenalism: A case report and review of literature. EXCLI Journal, 2018, 17, 526-530.	0.5	6
14088	Prognostic role of immune cells in hepatocellular carcinoma. EXCLI Journal, 2020, 19, 718-733.	0.5	21
14089	Tumor suppressor maspin as a modulator of host immune response to cancer. Bosnian Journal of Basic Medical Sciences, 2015, 15, 1-6.	0.6	19
14090	Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer. Bosnian Journal of Basic Medical Sciences, 2019, 19, 227-233.	0.6	76
14091	Are Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer?. Iranian Journal of Cancer Prevention, 2016, 9, e6565.	0.7	11
14092	Mechanistic roles of epithelial and immune cell signaling during the development of colitis-associated cancer. Cancer Research Frontiers, 2016, 2, 1-21.	0.2	24
14093	Immune mechanisms of idiosyncratic drug-induced liver injury. Journal of Clinical and Translational Research, 2017, , .	0.3	11
14094	Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: The Rationale for Combination Therapies. Medical Research Archives, 2015, 3, .	0.1	15
14095	The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy. Sultan Qaboos University Medical Journal, 2019, 19, 277.	0.3	3

#	ARTICLE	IF	CITATIONS
14096	Aging is associated with an expansion of CD49 ^{hi} mammary stem cells that show a decline in function and increased transformation potential. <i>Aging</i> , 2016, 8, 2754-2776.	1.4	15
14097	Transcriptome-wide association study of inflammatory biologic age. <i>Aging</i> , 2017, 9, 2288-2301.	1.4	12
14098	FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC. <i>Aging</i> , 2019, 11, 6069-6088.	1.4	48
14099	A disparate role of RP11-424C20.2/UHRF1 axis through control of tumor immune escape in liver hepatocellular carcinoma and thymoma. <i>Aging</i> , 2019, 11, 6422-6439.	1.4	31
14100	JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer. <i>Aging</i> , 2019, 11, 11124-11135.	1.4	41
14101	Prognostic value of immune-related genes in clear cell renal cell carcinoma. <i>Aging</i> , 2019, 11, 11474-11489.	1.4	56
14102	Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer. <i>Aging</i> , 2019, 11, 12270-12277.	1.4	11
14103	Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes. <i>Genes and Cancer</i> , 2016, 7, 218-228.	0.6	5
14104	Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. <i>Genes and Cancer</i> , 2016, 7, 301-308.	0.6	15
14105	A tumor specific antibody to aid breast cancer screening in women with dense breast tissue. <i>Genes and Cancer</i> , 2017, 8, 536-549.	0.6	28
14106	Identification of candidate genes associated with triple negative breast cancer. <i>Genes and Cancer</i> , 2017, 8, 659-672.	0.6	19
14107	Robust genomic copy number predictor of pan cancer metastasis. <i>Genes and Cancer</i> , 2018, 9, 66-77.	0.6	7
14108	Immuno-stimulatory/regulatory gene expression patterns in advanced ovarian cancer. <i>Genes and Cancer</i> , 2015, 6, 399-407.	0.6	4
14109	Multiple myeloma cell lines and primary tumors proteome: protein biosynthesis and Immune system as potential therapeutic targets. <i>Genes and Cancer</i> , 2015, 6, 462-471.	0.6	16
14110	Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies. <i>Oncoscience</i> , 2015, 2, 81-90.	0.9	27
14111	Targeting the tumor-stromal-immune cell axis. <i>Oncoscience</i> , 2015, 2, 743-744.	0.9	1
14112	Elafin: a double agent in breast and ovarian cancer. <i>Oncoscience</i> , 2015, 2, 793-794.	0.9	1
14113	Conserved E2F mediated metastasis in mouse models of breast cancer and HER2 positive patients. <i>Oncoscience</i> , 2015, 2, 867-871.	0.9	16

#	ARTICLE	IF	CITATIONS
14114	Genetic biomarkers for PD-1/PD-L1 blockade therapy. <i>Oncoscience</i> , 2016, 3, 311-312.	0.9	9
14115	Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans. <i>Oncoscience</i> , 2014, 1, 272-282.	0.9	47
14116	Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer. <i>Oncoscience</i> , 2014, 1, 709-724.	0.9	44
14117	TGF- β 1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment. <i>Oncotarget</i> , 2016, 7, 44534-44544.	0.8	40
14118	Network-based identification of microRNAs as potential pharmacogenomic biomarkers for anticancer drugs. <i>Oncotarget</i> , 2016, 7, 45584-45596.	0.8	85
14119	Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 44395-44405.	0.8	25
14120	Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 47252-47264.	0.8	79
14121	Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 48206-48219.	0.8	32
14122	Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 47565-47575.	0.8	40
14123	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. <i>Oncotarget</i> , 2017, 8, 35656-35668.	0.8	44
14124	T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells. <i>Oncotarget</i> , 2019, 10, 6006-6020.	0.8	14
14125	Epigenetic activation of <i>MGAT3</i> and corresponding bisecting GlcNAc shortens the survival of cancer patients. <i>Oncotarget</i> , 2016, 7, 51674-51686.	0.8	33
14126	Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens. <i>Oncotarget</i> , 2016, 7, 56584-56597.	0.8	8
14127	Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response. <i>Oncotarget</i> , 2016, 7, 56619-56627.	0.8	16
14128	A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. <i>Oncotarget</i> , 2016, 7, 52166-52178.	0.8	9
14129	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. <i>Oncotarget</i> , 2016, 7, 56295-56308.	0.8	83
14130	Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers. <i>Oncotarget</i> , 2016, 7, 52849-52861.	0.8	33
14131	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mTOR pathway. <i>Oncotarget</i> , 2016, 7, 60712-60722.	0.8	103

#	ARTICLE	IF	CITATIONS
14132	Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer. <i>Oncotarget</i> , 2016, 7, 56864-56875.	0.8	53
14133	Endoplasmic reticulum stress induces secretion of high-mobility group proteins and is associated with tumor-infiltrating lymphocytes in triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 59957-59964.	0.8	19
14134	EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. <i>Oncotarget</i> , 2016, 7, 54137-54156.	0.8	27
14135	PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. <i>Oncotarget</i> , 2016, 7, 59976-59986.	0.8	56
14136	NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling. <i>Oncotarget</i> , 2016, 7, 61036-61053.	0.8	58
14137	Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. <i>Oncotarget</i> , 2016, 7, 64967-64976.	0.8	42
14138	Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?. <i>Oncotarget</i> , 2016, 7, 60752-60774.	0.8	56
14139	Association mining of mutated cancer genes in different clinical stages across 11 cancer types. <i>Oncotarget</i> , 2016, 7, 68270-68277.	0.8	9
14140	Identification of breast cancer cell subtypes sensitive to ATG4B inhibition. <i>Oncotarget</i> , 2016, 7, 66970-66988.	0.8	58
14141	CD73 is associated with poor prognosis in HNSCC. <i>Oncotarget</i> , 2016, 7, 61690-61702.	0.8	57
14142	Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer. <i>Oncotarget</i> , 2016, 7, 67071-67086.	0.8	20
14143	Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. <i>Oncotarget</i> , 2016, 7, 63424-63436.	0.8	12
14144	Identification of breast cancer recurrence risk factors based on functional pathways in tumor and normal tissues. <i>Oncotarget</i> , 2017, 8, 20679-20694.	0.8	12
14145	TP53 mutation hits energy metabolism and increases glycolysis in breast cancer. <i>Oncotarget</i> , 2016, 7, 67183-67195.	0.8	46
14146	Expression of immune checkpoints in T cells of esophageal cancer patients. <i>Oncotarget</i> , 2016, 7, 63669-63678.	0.8	35
14147	GBM-associated mutations and altered protein expression are more common in young patients. <i>Oncotarget</i> , 2016, 7, 69466-69478.	0.8	27
14148	T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy. <i>Oncotarget</i> , 2016, 7, 64543-64559.	0.8	6
14149	Prognostic value of <i>PDL1</i> expression in pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 71198-71210.	0.8	81

#	ARTICLE	IF	CITATIONS
14150	Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. <i>Oncotarget</i> , 2016, 7, 64300-64308.	0.8	44
14151	Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis. <i>Oncotarget</i> , 2016, 7, 84142-84154.	0.8	5
14152	<i>ERBB2</i> mutations associated with solid variant of high-grade invasive lobular breast carcinomas. <i>Oncotarget</i> , 2016, 7, 73337-73346.	0.8	34
14153	CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. <i>Oncotarget</i> , 2016, 7, 70223-70231.	0.8	33
14154	Addressing intra-tumoral heterogeneity and therapy resistance. <i>Oncotarget</i> , 2016, 7, 72322-72342.	0.8	67
14155	Role of <i>TP53</i> mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. <i>Oncotarget</i> , 2016, 7, 67686-67698.	0.8	50
14156	Programmed death-ligand 1 is upregulated in intrahepatic lymphoepithelioma-like cholangiocarcinoma. <i>Oncotarget</i> , 2016, 7, 69749-69759.	0.8	20
14157	A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. <i>Oncotarget</i> , 2016, 7, 68012-68022.	0.8	110
14158	High-throughput proteomics integrated with gene microarray for discovery of colorectal cancer potential biomarkers. <i>Oncotarget</i> , 2016, 7, 75279-75292.	0.8	29
14159	PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. <i>Oncotarget</i> , 2016, 7, 72961-72977.	0.8	258
14160	B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. <i>Oncotarget</i> , 2016, 7, 67901-67918.	0.8	21
14161	CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3NOMO stage esophageal squamous cell cancer. <i>Oncotarget</i> , 2016, 7, 71455-71465.	0.8	42
14162	Somatic alterations of targetable oncogenes are frequently observed in <i>BRCA1/2</i> mutation negative male breast cancers. <i>Oncotarget</i> , 2016, 7, 74097-74106.	0.8	8
14163	Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data. <i>Oncotarget</i> , 2016, 7, 71620-71634.	0.8	12
14164	T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. <i>Oncotarget</i> , 2016, 7, 76902-76919.	0.8	131
14165	FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. <i>Oncotarget</i> , 2016, 7, 75729-75738.	0.8	10
14166	Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer. <i>Oncotarget</i> , 2016, 7, 75763-75773.	0.8	116
14167	Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. <i>Oncotarget</i> , 2017, 8, 8807-8817.	0.8	68

#	ARTICLE	IF	CITATIONS
14168	Detection of cellular senescence within human invasive breast carcinomas distinguishes different breast tumor subtypes. <i>Oncotarget</i> , 2016, 7, 74846-74859.	0.8	16
14169	Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth. <i>Oncotarget</i> , 2016, 7, 75940-75953.	0.8	6
14170	Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group. <i>Oncotarget</i> , 2016, 7, 80426-80434.	0.8	42
14171	Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis. <i>Oncotarget</i> , 2016, 7, 80855-80871.	0.8	2
14172	Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. <i>Oncotarget</i> , 2016, 7, 82504-82510.	0.8	64
14173	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. <i>Oncotarget</i> , 2016, 7, 79428-79441.	0.8	11
14174	Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. <i>Oncotarget</i> , 2016, 7, 76891-76901.	0.8	9
14175	PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials. <i>Oncotarget</i> , 2016, 7, 77010-77020.	0.8	44
14176	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016, 7, 76604-76612.	0.8	93
14177	ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells. <i>Oncotarget</i> , 2017, 8, 5823-5833.	0.8	17
14178	The nuclear corepressor 1 and the thyroid hormone receptor β^2 suppress breast tumor lymphangiogenesis. <i>Oncotarget</i> , 2016, 7, 78971-78984.	0.8	15
14179	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. <i>Oncotarget</i> , 2016, 7, 76362-76373.	0.8	22
14180	Differentially expressed miRNAs in triple negative breast cancer between African-American and non-Hispanic white women. <i>Oncotarget</i> , 2016, 7, 79274-79291.	0.8	43
14181	Peripheral blood lymphocyte subset levels differ in patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 77558-77564.	0.8	21
14182	SCIB1, a hulgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. <i>Oncotarget</i> , 2016, 7, 83088-83100.	0.8	16
14183	IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). <i>Oncotarget</i> , 2017, 8, 2731-2744.	0.8	21
14184	A functional variant rs4442975 modulating FOXA1-binding affinity does not influence the risk or progression of breast cancer in Chinese Han population. <i>Oncotarget</i> , 2016, 7, 81691-81697.	0.8	3
14185	Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 81750-81756.	0.8	22

#	ARTICLE	IF	CITATIONS
14186	The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis. <i>Oncotarget</i> , 2016, 7, 81493-81511.	0.8	14
14187	KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 82104-82111.	0.8	30
14188	Genomic and transcriptomic characterization of skull base chordoma. <i>Oncotarget</i> , 2017, 8, 1321-1328.	0.8	17
14189	DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival. <i>Oncotarget</i> , 2017, 8, 1074-1082.	0.8	16
14190	IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination. <i>Oncotarget</i> , 2017, 8, 2659-2671.	0.8	41
14191	The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. <i>Oncotarget</i> , 2017, 8, 7598-7613.	0.8	79
14192	Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. <i>Oncotarget</i> , 2017, 8, 7614-7624.	0.8	46
14193	The role of tumor microenvironment in therapeutic resistance. <i>Oncotarget</i> , 2017, 8, 3933-3945.	0.8	189
14194	Autologous reconstitution of human cancer and immune system <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 2053-2068.	0.8	20
14195	Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 9354-9365.	0.8	32
14196	High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes. <i>Oncotarget</i> , 2017, 8, 5160-5178.	0.8	66
14197	Independent prognostic role of PD-L1 expression in patients with esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 8315-8329.	0.8	19
14198	Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes. <i>Oncotarget</i> , 2017, 8, 10171-10184.	0.8	27
14199	Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. <i>Oncotarget</i> , 2017, 8, 17313-17327.	0.8	31
14200	Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer. <i>Oncotarget</i> , 2017, 8, 13099-13115.	0.8	19
14201	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. <i>Oncotarget</i> , 2017, 8, 13320-13328.	0.8	60
14202	Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 13762-13769.	0.8	68
14203	The EMSY threonine 207 phospho-site is required for EMSY-driven suppression of DNA damage repair. <i>Oncotarget</i> , 2017, 8, 13792-13804.	0.8	12

#	ARTICLE	IF	CITATIONS
14204	The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 15584-15592.	0.8	101
14205	Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. <i>Oncotarget</i> , 2017, 8, 22218-22234.	0.8	46
14206	Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma. <i>Oncotarget</i> , 2017, 8, 14759-14769.	0.8	39
14207	Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer. <i>Oncotarget</i> , 2017, 8, 15610-15620.	0.8	21
14208	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. <i>Oncotarget</i> , 2017, 8, 14416-14427.	0.8	70
14209	Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. <i>Oncotarget</i> , 2017, 8, 10845-10857.	0.8	14
14210	A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens. <i>Oncotarget</i> , 2017, 8, 43915-43924.	0.8	12
14211	Cancer-associated oxidoreductase ERO1- β promotes immune escape through up-regulation of PD-L1 in human breast cancer. <i>Oncotarget</i> , 2017, 8, 24706-24718.	0.8	52
14212	PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. <i>Oncotarget</i> , 2017, 8, 50782-50791.	0.8	10
14213	Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response. <i>Oncotarget</i> , 2017, 8, 19803-19813.	0.8	30
14214	TNBC invasion: downstream of STAT3. <i>Oncotarget</i> , 2017, 8, 20517-20518.	0.8	5
14215	Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition. <i>Oncotarget</i> , 2017, 8, 17610-17627.	0.8	53
14216	Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. <i>Oncotarget</i> , 2017, 8, 26356-26367.	0.8	54
14217	Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 21177-21186.	0.8	20
14218	The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 23177-23187.	0.8	58
14219	Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 30175-30189.	0.8	69
14220	The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC. <i>Oncotarget</i> , 2017, 8, 23517-23528.	0.8	26
14221	Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis. <i>Oncotarget</i> , 2017, 8, 30621-30643.	0.8	80

#	ARTICLE	IF	CITATIONS
14222	Gene regulatory pattern analysis reveals essential role of core transcriptional factors's activation in triple-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 21938-21953.	0.8	13
14223	Immunotherapeutic target expression on breast tumors can be amplified by hormone receptor antagonism: a novel strategy for enhancing efficacy of targeted immunotherapy. <i>Oncotarget</i> , 2017, 8, 32536-32549.	0.8	10
14224	The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. <i>Oncotarget</i> , 2017, 8, 26789-26801.	0.8	64
14225	PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC). <i>Oncotarget</i> , 2017, 8, 26845-26857.	0.8	55
14226	Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma. <i>Oncotarget</i> , 2017, 8, 23760-23774.	0.8	18
14227	Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes. <i>Oncotarget</i> , 2017, 8, 27997-28007.	0.8	23
14228	High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 28101-28115.	0.8	23
14229	MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma. <i>Oncotarget</i> , 2017, 8, 28125-28134.	0.8	49
14230	Gene-based comparative analysis of tools for estimating copy number alterations using whole-exome sequencing data. <i>Oncotarget</i> , 2017, 8, 27277-27285.	0.8	19
14231	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model. <i>Oncotarget</i> , 2017, 8, 28312-28327.	0.8	29
14232	The antitumor activity and preliminary modeling on the potential mechanism of action of human peroxiredoxin-5. <i>Oncotarget</i> , 2017, 8, 27189-27198.	0.8	5
14233	Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody. <i>Oncotarget</i> , 2017, 8, 20558-20571.	0.8	49
14234	Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 36857-36868.	0.8	50
14235	Survival differences of CIMP subtypes integrated with CNA information in human breast cancer. <i>Oncotarget</i> , 2017, 8, 48807-48819.	0.8	3
14236	Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 32722-32730.	0.8	73
14237	Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. <i>Oncotarget</i> , 2017, 8, 38706-38716.	0.8	31
14238	Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. <i>Oncotarget</i> , 2017, 8, 30276-30287.	0.8	69
14239	Identification of driver modules in pan-cancer via coordinating coverage and exclusivity. <i>Oncotarget</i> , 2017, 8, 36115-36126.	0.8	19

#	ARTICLE	IF	CITATIONS
14240	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. <i>Oncotarget</i> , 2017, 8, 32918-32929.	0.8	46
14241	Long non-coding RNAs in cutaneous melanoma: clinical perspectives. <i>Oncotarget</i> , 2017, 8, 43470-43480.	0.8	35
14242	TIPE3 protein promotes breast cancer metastasis through activating AKT and NF- κ B signaling pathways. <i>Oncotarget</i> , 2017, 8, 48889-48904.	0.8	19
14243	Elevated heparanase expression is associated with poor prognosis in breast cancer: a study based on systematic review and TCGA data. <i>Oncotarget</i> , 2017, 8, 43521-43535.	0.8	42
14244	Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity. <i>Oncotarget</i> , 2017, 8, 39117-39130.	0.8	21
14245	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. <i>Oncotarget</i> , 2017, 8, 43555-43570.	0.8	10
14246	The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma. <i>Oncotarget</i> , 2017, 8, 36279-36288.	0.8	24
14247	Multi-omics study revealing the complexity and spatial heterogeneity of tumor-infiltrating lymphocytes in primary liver carcinoma. <i>Oncotarget</i> , 2017, 8, 34844-34857.	0.8	31
14248	Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice. <i>Oncotarget</i> , 2017, 8, 48959-48971.	0.8	5
14249	Increased risk of brain metastases in women with breast cancer and p16 expression in metastatic lymph-nodes. <i>Oncotarget</i> , 2017, 8, 37332-37341.	0.8	9
14250	RNA sequencing-based cell proliferation analysis across 19 cancers identifies a subset of proliferation-informative cancers with a common survival signature. <i>Oncotarget</i> , 2017, 8, 38668-38681.	0.8	29
14251	Phase I study of nivolumab combined with IFN- γ for patients with advanced melanoma. <i>Oncotarget</i> , 2017, 8, 71181-71187.	0.8	21
14252	Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. <i>Oncotarget</i> , 2017, 8, 41227-41241.	0.8	16
14253	Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. <i>Oncotarget</i> , 2017, 8, 41242-41255.	0.8	89
14254	Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. <i>Oncotarget</i> , 2017, 8, 42487-42494.	0.8	10
14255	Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review. <i>Oncotarget</i> , 2017, 8, 51779-51785.	0.8	13
14256	<i>PDCD1</i> (<i>PD-1</i>) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 41011-41020.	0.8	38
14257	Driving better and safer HER2-specific CARs for cancer therapy. <i>Oncotarget</i> , 2017, 8, 62730-62741.	0.8	46

#	ARTICLE	IF	CITATIONS
14258	Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model. <i>Oncotarget</i> , 2017, 8, 45415-45431.	0.8	47
14259	Biological and clinical evidence for somatic mutations in <i>BRCA1</i> and <i>BRCA2</i> as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. <i>Oncotarget</i> , 2017, 8, 43653-43661.	0.8	85
14260	Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response. <i>Oncotarget</i> , 2017, 8, 47400-47411.	0.8	21
14261	5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy. <i>Oncotarget</i> , 2017, 8, 47474-47489.	0.8	25
14262	Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the <i>JAK2</i> gene in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 60975-60986.	0.8	15
14263	Tumor-infiltrating FoxP3+ Tregs predict favorable outcome in colorectal cancer patients: A meta-analysis. <i>Oncotarget</i> , 2017, 8, 75361-75371.	0.8	40
14264	Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer. <i>Oncotarget</i> , 2017, 8, 81967-81977.	0.8	43
14265	Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor. <i>Oncotarget</i> , 2017, 8, 71709-71724.	0.8	27
14266	Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 44418-44433.	0.8	95
14267	Strategies targeting angiogenesis in advanced non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 53854-53872.	0.8	57
14268	PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. <i>Oncotarget</i> , 2017, 8, 54722-54734.	0.8	39
14269	Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 57386-57398.	0.8	78
14270	Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. <i>Oncotarget</i> , 2017, 8, 53068-53083.	0.8	19
14271	Cancer and the kidney: dangereux liaisons or price paid for the progress in medicine?. <i>Oncotarget</i> , 2017, 8, 66601-66619.	0.8	22
14272	Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway. <i>Oncotarget</i> , 2017, 8, 47916-47930.	0.8	23
14273	Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. <i>Oncotarget</i> , 2017, 8, 73947-73963.	0.8	33
14274	Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 51630-51640.	0.8	54
14275	The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. <i>Oncotarget</i> , 2017, 8, 95083-95094.	0.8	15

#	ARTICLE	IF	CITATIONS
14276	Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients. <i>Oncotarget</i> , 2017, 8, 75914-75923.	0.8	5
14277	Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. <i>Oncotarget</i> , 2017, 8, 97671-97682.	0.8	254
14278	Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 59901-59914.	0.8	64
14279	Ccr4</i>-deficient T cells are less susceptible to PD-L1-mediated inhibition. <i>Oncotarget</i> , 2017, 8, 41841-41853.	0.8	19
14280	Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review. <i>Oncotarget</i> , 2017, 8, 57889-57897.	0.8	26
14281	Identification of a novel p53 target, COL17A1, that inhibits breast cancer cell migration and invasion. <i>Oncotarget</i> , 2017, 8, 55790-55803.	0.8	58
14282	Tumor reductive therapies and antitumor immunity. <i>Oncotarget</i> , 2017, 8, 55736-55749.	0.8	11
14283	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 97920-97927.	0.8	69
14284	SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 53518-53530.	0.8	33
14285	Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. <i>Oncotarget</i> , 2017, 8, 76029-76043.	0.8	7
14286	Association of breast carcinoma growth with a non-canonical axis of IFN γ /IDO1/TSP1. <i>Oncotarget</i> , 2017, 8, 85024-85039.	0.8	14
14287	Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers. <i>Oncotarget</i> , 2017, 8, 62029-62038.	0.8	28
14288	Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. <i>Oncotarget</i> , 2017, 8, 67782-67789.	0.8	18
14289	Multicomponent analysis of the tumour microenvironment reveals low CD8 T cell number, low stromal caveolin-1 and high tenascin-C and their combination as significant prognostic markers in non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 1760-1771.	0.8	16
14290	Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation. <i>Oncotarget</i> , 2017, 8, 82123-82143.	0.8	29
14291	Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. <i>Oncotarget</i> , 2017, 8, 57121-57133.	0.8	31
14292	A Bayesian pick-the-winner design in a randomized phase II clinical trial. <i>Oncotarget</i> , 2017, 8, 88376-88385.	0.8	6
14293	Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review. <i>Oncotarget</i> , 2017, 8, 96453-96459.	0.8	8

#	ARTICLE	IF	CITATIONS
14294	Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc- γ 3 receptor engagement. <i>Oncotarget</i> , 2017, 8, 52045-52060.	0.8	25
14295	Overexpression of the E2F target gene <i>CENPI</i> promotes chromosome instability and predicts poor prognosis in estrogen receptor-positive breast cancer. <i>Oncotarget</i> , 2017, 8, 62167-62182.	0.8	38
14296	Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 59086-59102.	0.8	35
14297	Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. <i>Oncotarget</i> , 2017, 8, 91841-91859.	0.8	28
14298	PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. <i>Oncotarget</i> , 2017, 8, 64066-64082.	0.8	62
14299	Peripheral CD4+ na \tilde{A} ve/memory ratio is an independent predictor of survival in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 83650-83659.	0.8	16
14300	Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection. <i>Oncotarget</i> , 2017, 8, 82399-82414.	0.8	19
14301	The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. <i>Oncotarget</i> , 2017, 8, 58122-58132.	0.8	13
14302	Secreted protein acidic and rich in cysteine (SPARC) induces cell migration and epithelial mesenchymal transition through WNK1/snail in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 63691-63702.	0.8	52
14303	Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence. <i>Oncotarget</i> , 2017, 8, 69934-69944.	0.8	100
14304	Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. <i>Oncotarget</i> , 2017, 8, 60257-60269.	0.8	12
14305	PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration. <i>Oncotarget</i> , 2017, 8, 58948-58963.	0.8	35
14306	PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment. <i>Oncotarget</i> , 2017, 8, 59677-59689.	0.8	7
14307	Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. <i>Oncotarget</i> , 2017, 8, 70481-70495.	0.8	14
14308	Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes. <i>Oncotarget</i> , 2017, 8, 64283-64293.	0.8	9
14309	IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model. <i>Oncotarget</i> , 2017, 8, 68571-68582.	0.8	51
14310	Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 66178-66194.	0.8	50
14311	Concurrent somatic mutations in driver genes were significantly correlated with lymph node metastasis and pathological types in solid tumors. <i>Oncotarget</i> , 2017, 8, 68746-68757.	0.8	6

#	ARTICLE	IF	CITATIONS
14312	Development of mesenchymal subtype gene signature for clinical application in gastric cancer. <i>Oncotarget</i> , 2017, 8, 66305-66315.	0.8	23
14313	Dynamic circulating tumor DNA quantification for the individualization of non-small-cell lung cancer patients treatment. <i>Oncotarget</i> , 2017, 8, 60291-60298.	0.8	22
14314	Excellent response to chemotherapy post immunotherapy. <i>Oncotarget</i> , 2017, 8, 91795-91802.	0.8	51
14315	Prognostic role of long non-coding RNA TUG1 expression in various cancers: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 100499-100507.	0.8	12
14316	Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA <i>in situ</i> hybridization. <i>Oncotarget</i> , 2017, 8, 87234-87243.	0.8	17
14317	The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 76974-76986.	0.8	34
14318	Transcriptome analysis of human colorectal cancer biopsies reveals extensive expression correlations among genes related to cell proliferation, lipid metabolism, immune response and collagen catabolism. <i>Oncotarget</i> , 2017, 8, 74703-74719.	0.8	26
14319	Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors. <i>Oncotarget</i> , 2017, 8, 72755-72772.	0.8	43
14320	Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractionated cisplatin and metronomic etoposide and bevacizumab (mPEBev). <i>Oncotarget</i> , 2017, 8, 75904-75913.	0.8	23
14321	Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems. <i>Oncotarget</i> , 2017, 8, 80804-80819.	0.8	24
14322	Matrix metalloproteinase-1 expression in breast carcinoma: a marker for unfavorable prognosis. <i>Oncotarget</i> , 2017, 8, 91379-91390.	0.8	18
14323	Analyses of functions of an anti-PD-L1/TGF β 2R2 bispecific fusion protein (M7824). <i>Oncotarget</i> , 2017, 8, 75217-75231.	0.8	44
14324	Parity improves anti-tumor immunity in breast cancer patients. <i>Oncotarget</i> , 2017, 8, 104981-104991.	0.8	4
14325	Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma. <i>Oncotarget</i> , 2017, 8, 89391-89405.	0.8	25
14326	Advances in lung cancer. <i>Oncotarget</i> , 2017, 8, 78247-78248.	0.8	2
14327	PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 89903-89912.	0.8	31
14328	PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors. <i>Oncotarget</i> , 2017, 8, 89465-89474.	0.8	13
14329	The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China. <i>Oncotarget</i> , 2017, 8, 87442-87454.	0.8	6

#	ARTICLE	IF	CITATIONS
14330	Prostaglandin E2 and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment. <i>Oncotarget</i> , 2017, 8, 89802-89810.	0.8	54
14331	PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance. <i>Oncotarget</i> , 2017, 8, 101535-101544.	0.8	42
14332	Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 103117-103128.	0.8	84
14333	Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology. <i>Oncotarget</i> , 2017, 8, 92890-92903.	0.8	38
14334	RNAscope <i>in situ</i> hybridization confirms mRNA integrity in formalin-fixed, paraffin-embedded cancer tissue samples. <i>Oncotarget</i> , 2017, 8, 93392-93403.	0.8	41
14335	An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 101795-101807.	0.8	31
14336	Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 101994-102005.	0.8	72
14337	Radiotherapy: the key to immunotherapy ignition?. <i>Oncotarget</i> , 2017, 8, 93307-93308.	0.8	3
14338	Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma <i>in situ</i> and minimally invasive adenocarcinoma of lung. <i>Oncotarget</i> , 2017, 8, 97801-97810.	0.8	7
14339	Studies of lncRNAs in DNA double strand break repair: what is new?. <i>Oncotarget</i> , 2017, 8, 102690-102704.	0.8	9
14340	Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer. <i>Oncotarget</i> , 2017, 8, 103671-103681.	0.8	76
14341	Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. <i>Oncotarget</i> , 2017, 8, 108786-108801.	0.8	22
14342	Immunological landscape of consensus clusters in colorectal cancer. <i>Oncotarget</i> , 2017, 8, 105299-105311.	0.8	55
14343	Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent. <i>Oncotarget</i> , 2017, 8, 104303-104314.	0.8	12
14344	A core program of gene expression characterizes cancer metastases. <i>Oncotarget</i> , 2017, 8, 102161-102175.	0.8	19
14345	The sexist behaviour of immune checkpoint inhibitors in cancer therapy?. <i>Oncotarget</i> , 2017, 8, 99336-99346.	0.8	76
14346	PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 112584-112597.	0.8	37
14347	Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology. <i>Oncotarget</i> , 2017, 8, 106167-106168.	0.8	25

#	ARTICLE	IF	CITATIONS
14348	TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC). <i>Oncotarget</i> , 2017, 8, 107621-107629.	0.8	19
14349	Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 107630-107639.	0.8	16
14350	The relative change in regulatory T cells / T helper lymphocytes ratio as parameter for prediction of therapy efficacy in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2017, 8, 109079-109093.	0.8	13
14351	Protein methyltransferases and demethylases dictate CD8+ T-cell exclusion in squamous cell carcinoma of the head and neck. <i>Oncotarget</i> , 2017, 8, 112797-112808.	0.8	9
14352	Domain retention in transcription factor fusion genes and its biological and clinical implications: a pan-cancer study. <i>Oncotarget</i> , 2017, 8, 110103-110117.	0.8	15
14353	Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 111130-111143.	0.8	34
14354	Inhibition of PI4K III β radiosensitizes in human tumor xenograft and immune-competent syngeneic murine tumor model. <i>Oncotarget</i> , 2017, 8, 110392-110405.	0.8	17
14355	Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 113807-113816.	0.8	8
14356	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 10284-10293.	0.8	44
14357	Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. <i>Oncotarget</i> , 2017, 8, 111836-111846.	0.8	44
14358	Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors. <i>Oncotarget</i> , 2017, 8, 115114-115127.	0.8	1
14359	Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance. <i>Oncotarget</i> , 2017, 8, 113287-113293.	0.8	3
14360	YAP regulates PD-L1 expression in human NSCLC cells. <i>Oncotarget</i> , 2017, 8, 114576-114587.	0.8	96
14361	Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients. <i>Oncotarget</i> , 2018, 9, 982-994.	0.8	12
14362	Mitochondrial dysfunction activates lysosomal-dependent mitophagy selectively in cancer cells. <i>Oncotarget</i> , 2018, 9, 995-1011.	0.8	31
14363	Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 114268-114280.	0.8	169
14364	Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. <i>Oncotarget</i> , 2018, 9, 4375-4384.	0.8	26
14365	The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. <i>Oncotarget</i> , 2018, 9, 3815-3829.	0.8	17

#	ARTICLE	IF	CITATIONS
14366	Implications of KRAS mutations in acquired resistance to treatment in NSCLC. <i>Oncotarget</i> , 2018, 9, 6630-6643.	0.8	42
14367	Targeted drugs for systemic therapy of lung cancer with brain metastases. <i>Oncotarget</i> , 2018, 9, 5459-5472.	0.8	47
14368	Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer. <i>Oncotarget</i> , 2018, 9, 4061-4073.	0.8	14
14369	Germline polymorphism of interferon-lambda3 is clinically associated with progression of renal cell carcinoma. <i>Oncotarget</i> , 2018, 9, 4188-4199.	0.8	1
14370	The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease. <i>Oncotarget</i> , 2018, 9, 6201-6212.	0.8	33
14371	Current status and perspectives in immunotherapy for metastatic melanoma. <i>Oncotarget</i> , 2018, 9, 12452-12470.	0.8	73
14372	Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature. <i>Oncotarget</i> , 2018, 9, 8801-8809.	0.8	25
14373	Gene aberration profile of tumors of adolescent and young adult females. <i>Oncotarget</i> , 2018, 9, 6228-6237.	0.8	7
14374	Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. <i>Oncotarget</i> , 2018, 9, 5652-5664.	0.8	105
14375	Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 13920-13933.	0.8	60
14376	T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. <i>Oncotarget</i> , 2018, 9, 6536-6549.	0.8	37
14377	Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples. <i>Oncotarget</i> , 2018, 9, 6841-6851.	0.8	17
14378	Metformin and erlotinib synergize to inhibit basal breast cancer. <i>Oncotarget</i> , 2014, 5, 10503-10517.	0.8	44
14379	Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients. <i>Oncotarget</i> , 2018, 9, 6320-6335.	0.8	10
14380	Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients. <i>Oncotarget</i> , 2018, 9, 12164-12173.	0.8	16
14381	A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. <i>Oncotarget</i> , 2018, 9, 6993-7009.	0.8	31
14382	Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2018, 9, 11846-11857.	0.8	2
14383	MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment. <i>Oncotarget</i> , 2018, 9, 8042-8053.	0.8	3

#	ARTICLE	IF	CITATIONS
14384	Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 12400-12407.	0.8	13
14385	Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype. <i>Oncotarget</i> , 2018, 9, 11126-11144.	0.8	11
14386	Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy. <i>Oncotarget</i> , 2018, 9, 13301-13312.	0.8	24
14387	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 14268-14284.	0.8	12
14388	Molecular and clinical features of the <i>TP53</i> signature gene expression profile in early-stage breast cancer. <i>Oncotarget</i> , 2018, 9, 14193-14206.	0.8	11
14389	Correlation of <i>MET</i> gene amplification and <i>TP53</i> mutation with PD-L1 expression in non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 13682-13693.	0.8	39
14390	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018, 9, 14922-14938.	0.8	29
14391	Dynamic changes during the treatment of pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 14764-14790.	0.8	21
14392	Affinity-purified DNA-based mutation profiles of endometriosis-related ovarian neoplasms in Japanese patients. <i>Oncotarget</i> , 2018, 9, 14754-14763.	0.8	19
14393	Potential therapeutic targets of <i>TP53</i> gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. <i>Oncotarget</i> , 2018, 9, 16234-16247.	0.8	24
14394	A myriad of roles of miR-25 in health and disease. <i>Oncotarget</i> , 2018, 9, 21580-21612.	0.8	77
14395	¹⁸ F-FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients. <i>Oncotarget</i> , 2018, 9, 16343-16353.	0.8	15
14396	Effect of postmastectomy radiotherapy on triple-negative breast cancer with T1-2 and 1-3 positive axillary lymph nodes: a population-based study using the SEER 18 database. <i>Oncotarget</i> , 2019, 10, 5245-5252.	0.8	6
14397	Immunotherapy in mucosal melanoma: a case report and review of the literature. <i>Oncotarget</i> , 2018, 9, 17971-17977.	0.8	19
14398	<i>PIK3CA</i> mutation, reduced AKT serine 473 phosphorylation, and increased ER α serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive early breast cancer. <i>Oncotarget</i> , 2018, 9, 17711-17724.	0.8	10
14399	A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. <i>Oncotarget</i> , 2018, 9, 18985-18996.	0.8	83
14400	PD-L1 expression in medulloblastoma: an evaluation by subgroup. <i>Oncotarget</i> , 2018, 9, 19177-19191.	0.8	45
14401	Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of <i>EGFR</i> or <i>HER2</i> . <i>Oncotarget</i> , 2018, 9, 21132-21140.	0.8	24

#	ARTICLE	IF	CITATIONS
14402	Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2018, 9, 20034-20047.	0.8	32
14403	Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma. <i>Oncotarget</i> , 2018, 9, 20681-20697.	0.8	63
14404	Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma. <i>Oncotarget</i> , 2018, 9, 20769-20780.	0.8	20
14405	Functional significance of co-occurring mutations in <i>PIK3CA</i> and <i>MAP3K1</i> in breast cancer. <i>Oncotarget</i> , 2018, 9, 21444-21458.	0.8	39
14406	Somatic mutations in early onset luminal breast cancer. <i>Oncotarget</i> , 2018, 9, 22460-22479.	0.8	25
14407	A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma. <i>Oncotarget</i> , 2018, 9, 21569-21579.	0.8	20
14408	Association of increased primary breast tumor AGR2 with decreased disease-specific survival. <i>Oncotarget</i> , 2018, 9, 23114-23125.	0.8	11
14409	Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma. <i>Oncotarget</i> , 2018, 9, 22741-22748.	0.8	8
14410	Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer. <i>Oncotarget</i> , 2018, 9, 23482-23493.	0.8	17
14411	Stromal cells in breast cancer as a potential therapeutic target. <i>Oncotarget</i> , 2018, 9, 23761-23779.	0.8	30
14412	Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients. <i>Oncotarget</i> , 2018, 9, 23173-23182.	0.8	4
14413	Aberration hubs in protein interaction networks highlight actionable targets in cancer. <i>Oncotarget</i> , 2018, 9, 25166-25180.	0.8	6
14414	VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells. <i>Oncotarget</i> , 2018, 9, 25833-25841.	0.8	36
14415	Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 25586-25596.	0.8	66
14416	Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile. <i>Oncotarget</i> , 2018, 9, 25216-25224.	0.8	26
14417	Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. <i>Oncotarget</i> , 2018, 9, 25265-25276.	0.8	46
14418	PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. <i>Oncotarget</i> , 2018, 9, 27460-27470.	0.8	53
14419	APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer. <i>Oncotarget</i> , 2018, 9, 30513-30526.	0.8	6

#	ARTICLE	IF	CITATIONS
14420	Global metabolite profiling analysis of lipotoxicity in HER2/neu-positive breast cancer cells. <i>Oncotarget</i> , 2018, 9, 27133-27150.	0.8	8
14421	Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients. <i>Oncotarget</i> , 2018, 9, 27171-27196.	0.8	7
14422	Activating HER3 mutations in breast cancer. <i>Oncotarget</i> , 2018, 9, 27773-27788.	0.8	23
14423	Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 27789-27796.	0.8	9
14424	Role for the transcriptional activator ZRF1 in early metastatic events in breast cancer progression and endocrine resistance. <i>Oncotarget</i> , 2018, 9, 28666-28690.	0.8	7
14425	Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. <i>Oncotarget</i> , 2018, 9, 28702-28716.	0.8	27
14426	Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients. <i>Oncotarget</i> , 2018, 9, 28903-28909.	0.8	37
14427	Regulation of the interferon-gamma (IFN- γ) pathway by p63 and β 133p53 isoform in different breast cancer subtypes. <i>Oncotarget</i> , 2018, 9, 29146-29161.	0.8	16
14428	Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy. <i>Oncotarget</i> , 2018, 9, 29985-30004.	0.8	11
14429	Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity. <i>Oncotarget</i> , 2018, 9, 30115-30127.	0.8	25
14430	Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. <i>Oncotarget</i> , 2018, 9, 30587-30593.	0.8	18
14431	Intratumoral immune-biomarkers and mismatch repair status in leiomyosarcoma -potential predictive markers for adjuvant treatment: a pilot study. <i>Oncotarget</i> , 2018, 9, 30847-30854.	0.8	11
14432	PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. <i>Oncotarget</i> , 2018, 9, 30465-30471.	0.8	26
14433	The vulnerability of RB loss in breast cancer: Targeting a void in cell cycle control. <i>Oncotarget</i> , 2018, 9, 30940-30941.	0.8	14
14434	Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 31448-31458.	0.8	3
14435	A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. <i>Oncotarget</i> , 2018, 9, 31709-31718.	0.8	32
14436	A potential novel option for cancer immunotherapy - TLR7 stimulation inhibits malignant melanoma bone invasion. <i>Oncotarget</i> , 2018, 9, 31792-31792.	0.8	2
14437	PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients. <i>Oncotarget</i> , 2018, 9, 32024-32035.	0.8	25

#	ARTICLE	IF	CITATIONS
14438	Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 32298-32304.	0.8	53
14439	Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles. <i>Oncotarget</i> , 2018, 9, 34229-34239.	0.8	2
14440	Autotaxin-1 ² interaction with the cell surface via syndecan-4 impacts on cancer cell proliferation and metastasis. <i>Oncotarget</i> , 2018, 9, 33170-33185.	0.8	24
14441	Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling. <i>Oncotarget</i> , 2018, 9, 33348-33359.	0.8	13
14442	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. <i>Oncotarget</i> , 2018, 9, 33232-33243.	0.8	26
14443	Genomic mechanisms of immune evasion in colorectal cancer: from discovery to clinical practice. <i>Oncotarget</i> , 2018, 9, 33743-33744.	0.8	3
14444	Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling. <i>Oncotarget</i> , 2018, 9, 34554-34566.	0.8	13
14445	Anti-PD-1 therapy for clinical treatment of lymphoma: a single-arm meta-analysis. <i>Oncotarget</i> , 2018, 9, 35343-35355.	0.8	7
14446	A recessive variant of <i>XRCC4</i> predisposes to non- <i>BRCA1/2</i> breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization. <i>Oncotarget</i> , 2014, 5, 12218-12232.	0.8	5
14447	Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides. <i>Oncotarget</i> , 2018, 9, 36029-36038.	0.8	15
14448	Glyoxalase 1 gene is highly expressed in basal-like human breast cancers and contributes to survival of ALDH1-positive breast cancer stem cells. <i>Oncotarget</i> , 2018, 9, 36515-36529.	0.8	32
14449	Co-treatment of tumor cells with hyaluronan plus doxorubicin affects endothelial cell behavior independently of VEGF expression. <i>Oncotarget</i> , 2018, 9, 36585-36602.	0.8	16
14450	Epstein-Barr virus: From kisses to cancer, an ingenious immune evader. <i>Oncotarget</i> , 2018, 9, 36411-36412.	0.8	8
14451	STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNF α mediated immune responses in a model of NSCLC. <i>Oncotarget</i> , 2018, 9, 37157-37172.	0.8	10
14452	Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer. <i>Oncotarget</i> , 2018, 9, 37216-37228.	0.8	24
14453	Pan-cancer analysis of intratumor heterogeneity associated with patient prognosis using multidimensional measures. <i>Oncotarget</i> , 2018, 9, 37689-37699.	0.8	7
14454	Carbon ion irradiation enhances the antitumor efficacy of dual immune checkpoint blockade therapy both for local and distant sites in murine osteosarcoma. <i>Oncotarget</i> , 2019, 10, 633-646.	0.8	52
14455	Emerging approaches to study cell-cell interactions in tumor microenvironment. <i>Oncotarget</i> , 2019, 10, 785-797.	0.8	51

#	ARTICLE	IF	CITATIONS
14456	Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. <i>Oncotarget</i> , 2019, 10, 942-952.	0.8	11
14457	Immunonutritional consequences of different serine-type protease inhibitors in a C57BL/6 hepatocarcinoma model. <i>Oncotarget</i> , 2019, 10, 760-772.	0.8	13
14458	Immune response characterization of endometrial cancer. <i>Oncotarget</i> , 2019, 10, 982-992.	0.8	13
14459	Application of cell-free DNA for genomic tumor profiling: a feasibility study. <i>Oncotarget</i> , 2019, 10, 1388-1398.	0.8	13
14460	Modes of immunosuppression in glioblastoma microenvironment. <i>Oncotarget</i> , 2019, 10, 920-921.	0.8	5
14461	Reliable evaluation of tumor-infiltrating lymphocytes in pancreatic cancer tissue biopsies. <i>Oncotarget</i> , 2019, 10, 1149-1159.	0.8	10
14462	Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models. <i>Oncotarget</i> , 2019, 10, 1399-1406.	0.8	35
14463	POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2019, 10, 1572-1588.	0.8	22
14464	Specific allelic variants of SNPs in the <i>MDM2</i> and <i>MDMX</i> genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients. <i>Oncotarget</i> , 2019, 10, 1975-1992.	0.8	7
14465	Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer. <i>Oncotarget</i> , 2019, 10, 2012-2021.	0.8	3
14466	A global immune gene expression signature for human cancers. <i>Oncotarget</i> , 2019, 10, 1993-2005.	0.8	9
14467	PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models. <i>Oncotarget</i> , 2019, 10, 2252-2269.	0.8	10
14468	Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer. <i>Oncotarget</i> , 2019, 10, 2947-2958.	0.8	27
14469	Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab. <i>Oncotarget</i> , 2019, 10, 3302-3311.	0.8	6
14470	A DNA telomerase vaccine for canine cancer immunotherapy. <i>Oncotarget</i> , 2019, 10, 3361-3372.	0.8	14
14471	Melanoma patients with additional primary cancers: a single-center retrospective analysis. <i>Oncotarget</i> , 2019, 10, 3373-3384.	0.8	4
14472	PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer. <i>Oncotarget</i> , 2019, 10, 3667-3680.	0.8	6
14473	The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment. <i>Oncotarget</i> , 2019, 10, 4532-4545.	0.8	8

#	ARTICLE	IF	CITATIONS
14474	Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma. <i>Oncotarget</i> , 2019, 10, 4546-4555.	0.8	11
14475	The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer. <i>Oncotarget</i> , 2019, 10, 4907-4918.	0.8	20
14476	Differential gene expression analysis of HNSCC tumors deciphered tobacco dependent and independent molecular signatures. <i>Oncotarget</i> , 2019, 10, 6168-6183.	0.8	18
14477	Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment. <i>Oncotarget</i> , 2019, 10, 6546-6560.	0.8	2
14478	Tumor mutational burden in lung cancer: a systematic literature review. <i>Oncotarget</i> , 2019, 10, 6604-6622.	0.8	72
14479	SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection. <i>Oncotarget</i> , 2019, 10, 6494-6508.	0.8	19
14480	A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host. <i>Oncotarget</i> , 2019, 10, 6845-6854.	0.8	11
14481	Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade. <i>Oncotarget</i> , 2019, 10, 6678-6690.	0.8	8
14482	The impact of systemic precision medicine and immunotherapy treatments on brain metastases. <i>Oncotarget</i> , 2019, 10, 6739-6753.	0.8	13
14483	Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2020, 11, 1618-1628.	0.8	18
14484	Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. <i>Oncotarget</i> , 2020, 11, 2092-2105.	0.8	64
14485	BCATc modulates crosstalk between the PI3K/Akt and the Ras/ERK pathway regulating proliferation in triple negative breast cancer. <i>Oncotarget</i> , 2020, 11, 1971-1987.	0.8	10
14486	miR-708-5p targets oncogenic prostaglandin E2 production to suppress a pro-tumorigenic phenotype in lung cancer cells. <i>Oncotarget</i> , 2020, 11, 2464-2483.	0.8	14
14487	Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases. <i>Oncotarget</i> , 2020, 11, 3118-3128.	0.8	18
14488	A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties <i>in vivo</i> . <i>Oncotarget</i> , 2020, 11, 3698-3711.	0.8	8
14489	A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?. <i>Oncotarget</i> , 2020, 11, 3489-3501.	0.8	30
14490	CD80-CD28 signaling controls the progression of inflammatory colorectal carcinogenesis. <i>Oncotarget</i> , 2015, 6, 20058-20069.	0.8	24
14491	MicroRNA-based regulation of Aurora A kinase in breast cancer. <i>Oncotarget</i> , 2020, 11, 4306-4324.	0.8	11

#	ARTICLE	IF	CITATIONS
14492	Population analysis of microsatellite genotypes reveals a signature associated with ovarian cancer. <i>Oncotarget</i> , 2015, 6, 11407-11420.	0.8	3
14493	Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. <i>Oncotarget</i> , 2015, 6, 2466-2482.	0.8	128
14494	PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma. <i>Oncotarget</i> , 2015, 6, 3479-3492.	0.8	146
14495	Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. <i>Oncotarget</i> , 2015, 6, 2623-2640.	0.8	55
14496	Genomic differences between pure ductal carcinoma <i>in situ</i> and synchronous ductal carcinoma <i>in situ</i> with invasive breast cancer. <i>Oncotarget</i> , 2015, 6, 7597-7607.	0.8	67
14497	Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies. <i>Oncotarget</i> , 2015, 6, 5041-5058.	0.8	24
14498	Split anergized natural killer cells halt inflammation by inducing stem cell differentiation, resistance to NK cell cytotoxicity and prevention of cytokine and chemokine secretion. <i>Oncotarget</i> , 2015, 6, 8947-8959.	0.8	45
14499	Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. <i>Oncotarget</i> , 2015, 6, 9612-9626.	0.8	166
14500	Cell type of origin as well as genetic alterations contribute to breast cancer phenotypes. <i>Oncotarget</i> , 2015, 6, 9018-9030.	0.8	19
14501	Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion. <i>Oncotarget</i> , 2015, 6, 10473-10486.	0.8	58
14502	Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 6029-6039.	0.8	29
14503	Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. <i>Oncotarget</i> , 2015, 6, 11139-11149.	0.8	89
14504	Low spinophilin expression enhances aggressive biological behavior of breast cancer. <i>Oncotarget</i> , 2015, 6, 11191-11202.	0.8	10
14505	HGFL supports mammary tumorigenesis by enhancing tumor cell intrinsic survival and influencing macrophage and T-cell responses. <i>Oncotarget</i> , 2015, 6, 17445-17461.	0.8	15
14506	Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas. <i>Oncotarget</i> , 2015, 6, 39127-39139.	0.8	14
14507	Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. <i>Oncotarget</i> , 2015, 6, 20902-20920.	0.8	96
14508	CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. <i>Oncotarget</i> , 2015, 6, 17462-17478.	0.8	168
14509	Identification and evaluation of network modules for the prognosis of basal-like breast cancer. <i>Oncotarget</i> , 2015, 6, 17713-17724.	0.8	3

#	ARTICLE	IF	CITATIONS
14510	Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers. <i>Oncotarget</i> , 2015, 6, 18641-18652.	0.8	20
14511	Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. <i>Oncotarget</i> , 2015, 6, 20592-20603.	0.8	61
14512	â€˜Cut from the same clothâ€™: Shared microsatellite variants among cancers link to ectodermal tissues-neural tube and crest cells. <i>Oncotarget</i> , 2015, 6, 22038-22047.	0.8	7
14513	The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study. <i>Oncotarget</i> , 2015, 6, 29254-29267.	0.8	77
14514	The pioneer factor PBX1 is a novel driver of metastatic progression in ER \pm -positive breast cancer. <i>Oncotarget</i> , 2015, 6, 21878-21891.	0.8	45
14515	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. <i>Oncotarget</i> , 2015, 6, 22348-22360.	0.8	12
14516	Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. <i>Oncotarget</i> , 2015, 6, 19819-19825.	0.8	80
14517	<i>SERPINA1</i> is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients. <i>Oncotarget</i> , 2015, 6, 25815-25827.	0.8	58
14518	Genomic amplification of 9p24.1 targeting <i>JAK2</i> , <i>PD-L1</i> , and <i>PD-L2</i> is enriched in high-risk triple negative breast cancer. <i>Oncotarget</i> , 2015, 6, 26483-26493.	0.8	118
14519	Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. <i>Oncotarget</i> , 2015, 6, 24990-25002.	0.8	49
14520	Analysis of SDHD promoter mutations in various types of melanoma. <i>Oncotarget</i> , 2015, 6, 25868-25882.	0.8	9
14521	Dissecting tRNA-derived fragment complexities using personalized transcriptomes reveals novel fragment classes and unexpected dependencies. <i>Oncotarget</i> , 2015, 6, 24797-24822.	0.8	146
14522	Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer. <i>Oncotarget</i> , 2015, 6, 27923-27937.	0.8	24
14523	A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. <i>Oncotarget</i> , 2015, 6, 28999-29015.	0.8	53
14524	Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. <i>Oncotarget</i> , 2015, 6, 29143-29160.	0.8	44
14525	PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. <i>Oncotarget</i> , 2015, 6, 33019-33032.	0.8	69
14526	Multistep, effective drug distribution within solid tumors. <i>Oncotarget</i> , 2015, 6, 39564-39577.	0.8	22
14527	Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome. <i>Oncotarget</i> , 2015, 6, 33191-33205.	0.8	3

#	ARTICLE	IF	CITATIONS
14528	mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. <i>Oncotarget</i> , 2015, 6, 36400-36417.	0.8	43
14529	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. <i>Oncotarget</i> , 2015, 6, 30306-30316.	0.8	14
14530	The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. <i>Oncotarget</i> , 2015, 6, 19393-19404.	0.8	61
14531	Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer. <i>Oncotarget</i> , 2015, 6, 32027-32038.	0.8	36
14532	The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015, 6, 33358-33368.	0.8	24
14533	The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. <i>Oncotarget</i> , 2015, 6, 34910-34923.	0.8	52
14534	Vesicular stomatitis virus expressing interferon- β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 33165-33177.	0.8	87
14535	First description of a sporadic breast cancer in a woman with BRCA1 germline mutation. <i>Oncotarget</i> , 2015, 6, 35616-35624.	0.8	9
14536	Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors. <i>Oncotarget</i> , 2015, 6, 34892-34909.	0.8	27
14537	A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 41339-41349.	0.8	79
14538	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. <i>Oncotarget</i> , 2015, 6, 37269-37280.	0.8	135
14539	Genome and transcriptome delineation of two major oncogenic pathways governing invasive ductal breast cancer development. <i>Oncotarget</i> , 2015, 6, 36652-36674.	0.8	24
14540	miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers. <i>Oncotarget</i> , 2015, 6, 32115-32137.	0.8	20
14541	TGF- β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner. <i>Oncotarget</i> , 2015, 6, 43005-43015.	0.8	68
14542	Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. <i>Oncotarget</i> , 2015, 6, 35770-35781.	0.8	37
14543	Increased metastasis with loss of <i>E2F2</i> in <i>Myc</i> -driven tumors. <i>Oncotarget</i> , 2015, 6, 38210-38224.	0.8	27
14544	Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. <i>Oncotarget</i> , 2015, 6, 40836-40849.	0.8	106
14545	Auranofin is a potent suppressor of osteosarcoma metastasis. <i>Oncotarget</i> , 2016, 7, 831-844.	0.8	38

#	ARTICLE	IF	CITATIONS
14546	The predictive value of centre tumour CD8+ T cells in patients with hepatocellular carcinoma: comparison with Immunoscore. <i>Oncotarget</i> , 2015, 6, 35602-35615.	0.8	60
14547	Epigenetic silencing of miR-145-5p contributes to brain metastasis. <i>Oncotarget</i> , 2015, 6, 35183-35201.	0.8	75
14548	Mutational profiling of colorectal cancers with microsatellite instability. <i>Oncotarget</i> , 2015, 6, 42334-42344.	0.8	69
14549	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , 2015, 6, 42773-42780.	0.8	14
14550	βKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers. <i>Oncotarget</i> , 2016, 7, 2611-2628.	0.8	17
14551	Chromosomal instability triggers cell death via local signalling through the innate immune receptor Toll. <i>Oncotarget</i> , 2015, 6, 38552-38565.	0.8	18
14552	Effects of a novel Nodal-targeting monoclonal antibody in melanoma. <i>Oncotarget</i> , 2015, 6, 34071-34086.	0.8	24
14553	Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. <i>Oncotarget</i> , 2015, 6, 41600-41619.	0.8	102
14554	The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence. <i>Oncotarget</i> , 2015, 6, 35231-35246.	0.8	26
14555	Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. <i>Oncotarget</i> , 2015, 6, 43731-43742.	0.8	63
14556	CCN: core regulatory proteins in the microenvironment that affect the metastasis of hepatocellular carcinoma?. <i>Oncotarget</i> , 2016, 7, 1203-1214.	0.8	42
14557	Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. <i>Oncotarget</i> , 2016, 7, 5074-5087.	0.8	54
14558	A novel gammaretroviral shuttle vector insertional mutagenesis screen identifies SHARPIN as a breast cancer metastasis gene and prognostic biomarker. <i>Oncotarget</i> , 2015, 6, 39507-39520.	0.8	25
14559	Sense-antisense gene-pairs in breast cancer and associated pathological pathways. <i>Oncotarget</i> , 2015, 6, 42197-42221.	0.8	20
14560	Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. <i>Oncotarget</i> , 2016, 7, 255-265.	0.8	39
14561	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. <i>Oncotarget</i> , 2016, 7, 1486-1499.	0.8	212
14562	FGFR1 is an adverse outcome indicator for luminal A breast cancers. <i>Oncotarget</i> , 2016, 7, 5063-5073.	0.8	24
14563	Identification of TIM3 2-Fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 4522-4530.	0.8	44

#	ARTICLE	IF	CITATIONS
14564	Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice. <i>Oncotarget</i> , 2015, 6, 44134-44150.	0.8	26
14565	Interferon- β -induced p27KIP1 binds to and targets MYC for proteasome-mediated degradation. <i>Oncotarget</i> , 2016, 7, 2837-2854.	0.8	12
14566	Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. <i>Oncotarget</i> , 2016, 7, 8944-8955.	0.8	60
14567	Gene copy number variations in the leukocyte genome of hepatocellular carcinoma patients with integrated hepatitis B virus DNA. <i>Oncotarget</i> , 2016, 7, 8006-8018.	0.8	2
14568	Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 7227-7240.	0.8	38
14569	Common and distinct features of mammary tumors driven by Pten-deletion or activating Pik3ca mutation. <i>Oncotarget</i> , 2016, 7, 9060-9068.	0.8	11
14570	Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. <i>Oncotarget</i> , 2016, 7, 64431-64446.	0.8	161
14571	Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells. <i>Oncotarget</i> , 2016, 7, 12806-12822.	0.8	10
14572	Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. <i>Oncotarget</i> , 2016, 7, 13587-13598.	0.8	485
14573	Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 13765-13781.	0.8	155
14574	ER β decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function. <i>Oncotarget</i> , 2016, 7, 13599-13611.	0.8	39
14575	Cross-platform comparison of independent datasets identifies an immune signature associated with improved survival in metastatic melanoma. <i>Oncotarget</i> , 2016, 7, 14415-14428.	0.8	13
14576	Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 13060-13068.	0.8	80
14577	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 15901-15914.	0.8	125
14578	The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. <i>Oncotarget</i> , 2016, 7, 13106-13121.	0.8	63
14579	loncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment. <i>Oncotarget</i> , 2016, 7, 13236-13247.	0.8	23
14580	Drug resistance in cancer: molecular evolution and compensatory proliferation. <i>Oncotarget</i> , 2016, 7, 11746-11755.	0.8	60
14581	“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944.	0.8	33

#	ARTICLE	IF	CITATIONS
14582	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , 2016, 7, 19738-19747.	0.8	134
14583	The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures. <i>Oncotarget</i> , 2016, 7, 15033-15046.	0.8	24
14584	<i>CD274/PD-L1</i> gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. <i>Oncotarget</i> , 2016, 7, 12024-12034.	0.8	141
14585	Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. <i>Oncotarget</i> , 2016, 7, 18508-18520.	0.8	75
14586	The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutic drugs may finally work through immune response. <i>Oncotarget</i> , 2016, 7, 29794-29803.	0.8	48
14587	ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells. <i>Oncotarget</i> , 2016, 7, 19897-19909.	0.8	39
14588	FOXO1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorigenesis of human triple negative breast cancer cells. <i>Oncotarget</i> , 2016, 7, 16619-16635.	0.8	84
14589	Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2016, 7, 50963-50971.	0.8	71
14590	MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating <i>BRCA1</i> expression. <i>Oncotarget</i> , 2016, 7, 20068-20079.	0.8	42
14591	CD40-activated B cells induce anti-tumor immunity <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 27740-27753.	0.8	43
14592	Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. <i>Oncotarget</i> , 2016, 7, 21556-21569.	0.8	24
14593	Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. <i>Oncotarget</i> , 2016, 7, 25050-25063.	0.8	6
14594	Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. <i>Oncotarget</i> , 2016, 7, 25087-25102.	0.8	60
14595	A BRCA1 deficient, NF- κ B driven immune signal predicts good outcome in triple negative breast cancer. <i>Oncotarget</i> , 2016, 7, 19884-19896.	0.8	30
14596	Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects. <i>Oncotarget</i> , 2016, 7, 20532-20548.	0.8	49
14597	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. <i>Oncotarget</i> , 2016, 7, 22543-22555.	0.8	11
14598	Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers. <i>Oncotarget</i> , 2016, 7, 20773-20787.	0.8	36
14599	Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. <i>Oncotarget</i> , 2016, 7, 23581-23593.	0.8	35

#	ARTICLE	IF	CITATIONS
14600	Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition. <i>Oncotarget</i> , 2016, 7, 23757-23771.	0.8	46
14601	Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts. <i>Oncotarget</i> , 2016, 7, 23801-23811.	0.8	13
14602	Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations. <i>Oncotarget</i> , 2016, 7, 23825-23836.	0.8	10
14603	Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. <i>Oncotarget</i> , 2016, 7, 17301-17313.	0.8	22
14604	Prognostic implications of PIK3CA amplification in curatively resected liposarcoma. <i>Oncotarget</i> , 2016, 7, 24549-24558.	0.8	7
14605	NF- κ B functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. <i>Oncotarget</i> , 2016, 7, 23395-23415.	0.8	12
14606	Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. <i>Oncotarget</i> , 0, 7, 42698-42715.	0.8	34
14607	Comparative genomic analysis of primary tumors and metastases in breast cancer. <i>Oncotarget</i> , 2016, 7, 27208-27219.	0.8	69
14608	Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?. <i>Oncotarget</i> , 2016, 7, 26454-26464.	0.8	11
14609	CD74 and intratumoral immune response in breast cancer. <i>Oncotarget</i> , 2017, 8, 12664-12674.	0.8	115
14610	ProNGF is a potential diagnostic biomarker for thyroid cancer. <i>Oncotarget</i> , 2016, 7, 28488-28497.	0.8	24
14611	Changing perspective on oncometabolites: from metabolic signature of cancer to tumorigenic and immunosuppressive agents. <i>Oncotarget</i> , 2016, 7, 46692-46706.	0.8	25
14612	Emerging therapeutic targets in esophageal adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 48644-48655.	0.8	13
14613	B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy. <i>Oncotarget</i> , 2016, 7, 29480-29491.	0.8	49
14614	Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 36198-36206.	0.8	30
14615	Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 30772-30780.	0.8	93
14616	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. <i>Oncotarget</i> , 2016, 7, 33350-33362.	0.8	56
14617	Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis. <i>Oncotarget</i> , 2016, 7, 36065-36073.	0.8	41

#	ARTICLE	IF	CITATIONS
14618	Identification of breast cancer candidate genes using gene co-expression and protein-protein interaction information. <i>Oncotarget</i> , 2016, 7, 36092-36100.	0.8	19
14619	Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. <i>Oncotarget</i> , 2016, 7, 36138-36153.	0.8	6
14620	Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA <i>in situ</i> hybridization and its clinical significance. <i>Oncotarget</i> , 2016, 7, 39671-39679.	0.8	37
14621	Targeting tumor-associated macrophages to combat pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 50735-50754.	0.8	73
14622	Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. <i>Oncotarget</i> , 2016, 7, 52442-52449.	0.8	6
14623	Using lymph node swelling as a potential biomarker for successful vaccination. <i>Oncotarget</i> , 2016, 7, 35655-35669.	0.8	11
14624	Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. <i>Oncotarget</i> , 2016, 7, 40252-40265.	0.8	35
14625	Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1. <i>Oncotarget</i> , 2016, 7, 44096-44112.	0.8	26
14626	Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients. <i>Oncotarget</i> , 2016, 7, 43604-43615.	0.8	45
14627	Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer. <i>Oncotarget</i> , 0, 7, 42385-42392.	0.8	16
14628	Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. <i>Oncotarget</i> , 2016, 7, 43039-43051.	0.8	62
14629	Impact of autoimmune diseases on outcome of patients with early breast cancer. <i>Oncotarget</i> , 2016, 7, 51184-51192.	0.8	10
14630	Medical management of malignant melanoma. <i>Australian Prescriber</i> , 2015, 38, 74-78.	0.5	24
14631	New drugs: Pembrolizumab. <i>Australian Prescriber</i> , 2015, 38, 180-182.	0.5	2
14632	Refractory hypotension due to Nivolumab-induced adrenal insufficiency. <i>Nagoya Journal of Medical Science</i> , 2018, 80, 285-288.	0.6	9
14633	Costimulation and Pancreatic Autoimmunity: The PD-1/PD-L Conundrum. <i>Review of Diabetic Studies</i> , 2006, 3, 6-6.	0.5	10
14634	Nrf2 Deficiency Promotes Melanoma Growth and Lung Metastasis. , 2016, 2, 308-314.		11
14635	<i>ESR1</i> alterations and metastasis in estrogen receptor positive breast cancer. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	62

#	ARTICLE	IF	CITATIONS
14636	Cellular plasticity and metastasis in breast cancer: a pre- and post-malignant problem. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	11
14637	Pharmacogenetics of anticancer monoclonal antibodies. , 2019, 2, 69-81.		3
14638	MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression. , 2020, 3, 603-612.		15
14639	New insights into acquired endocrine resistance of breast cancer. , 2019, 2, 198-209.		32
14640	The role of exosomal microRNAs; focus on clinical applications in breast cancer. , 2019, 2, 847-861.		3
14641	Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors. , 2019, 2, 744-761.		3
14642	Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies. , 2019, 2, 980-993.		9
14643	The role of exosomal long non-coding RNAs in cancer drug resistance. , 2019, 2, 1178-1192.		25
14644	Cell-mediated immune resistance in cancer. , 2020, 3, 232-251.		9
14645	Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy. , 2020, 3, 356-370.		15
14646	Resistance to chemoimmunotherapy in non-small-cell lung cancer. , 2020, 3, 445-453.		3
14647	A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. , 2020, 3, 252-275.		18
14648	The dark side of immunotherapy: pancreatic cancer. , 2020, 3, 491-520.		15
14649	Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?. , 2020, 3, 276-286.		3
14650	Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7
14651	Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. , 2020, 3, 726-741.		6
14652	Next-generation sequencing and its clinical application. <i>Cancer Biology and Medicine</i> , 2019, 16, 4-10.	1.4	105
14653	Current applications and future prospects of nanotechnology in cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2019, 16, 487-497.	1.4	40

#	ARTICLE	IF	CITATIONS
14654	From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers. <i>Cancer Biology and Medicine</i> , 2019, 16, 435-461.	1.4	15
14655	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. <i>Cancer Biology and Medicine</i> , 2019, 16, 655-670.	1.4	95
14656	Tobacco, air pollution, environmental carcinogenesis, and thoughts on conquering strategies of lung cancer. <i>Cancer Biology and Medicine</i> , 2019, 16, 700-713.	1.4	33
14657	The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series. <i>Cancer Biology and Medicine</i> , 2019, 16, 811-821.	1.4	14
14658	T Cell Metabolism in Cancer Immunotherapy. <i>Immunometabolism</i> , 2020, 2, .	0.7	16
14659	Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1603-1603.	0.7	8
14660	Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk. <i>Annals of Translational Medicine</i> , 2020, 8, 1417-1417.	0.7	7
14661	Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations. <i>Annals of Translational Medicine</i> , 2020, 8, 1297-1297.	0.7	8
14662	Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1478-1478.	0.7	17
14663	What does the future hold for immunotherapy in cancer?. <i>Annals of Translational Medicine</i> , 2016, 4, 177-177.	0.7	9
14664	Revisiting of cancer vaccine?â€”Specific immunotherapy comes to field with the biomarker. <i>Annals of Translational Medicine</i> , 2016, 4, 179-179.	0.7	1
14665	Uveal melanoma as a target for immune-therapy. <i>Annals of Translational Medicine</i> , 2016, 4, 172-172.	0.7	63
14666	Nivolumab for advanced non-small cell lung cancer: an immunologically-mediated tumor checkout. <i>Annals of Translational Medicine</i> , 2016, 4, 201-201.	0.7	5
14667	The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. <i>Annals of Translational Medicine</i> , 2016, 4, 267-267.	0.7	17
14668	Immunobiology and immunotherapy in genitourinary malignancies. <i>Annals of Translational Medicine</i> , 2016, 4, 270-270.	0.7	14
14669	Melanoma immunotherapy dominates the field. <i>Annals of Translational Medicine</i> , 2016, 4, 269-269.	0.7	19
14670	Towards tumor immunodiagnostics. <i>Annals of Translational Medicine</i> , 2016, 4, 263-263.	0.7	11
14671	DNA damage, tumor mutational load and their impact on immune responses against cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 264-264.	0.7	35

#	ARTICLE	IF	CITATIONS
14672	Immunotherapy in small-cell lung cancer: at what point are we?. <i>Annals of Translational Medicine</i> , 2016, 4, S5-S5.	0.7	3
14673	Tumor vaccines and cellular immunotherapies. <i>Annals of Translational Medicine</i> , 2016, 4, S24-S24.	0.7	3
14674	CK1 β : a pharmacologically tractable Achilles $\text{\textcircled{R}}$ heel of Wnt-driven cancers?. <i>Annals of Translational Medicine</i> , 2016, 4, 433-433.	0.7	5
14675	Acquired resistance mechanisms to immunotherapy. <i>Annals of Translational Medicine</i> , 2016, 4, 547-547.	0.7	2
14676	Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies. <i>Annals of Translational Medicine</i> , 2016, 4, 529-529.	0.7	11
14677	The KEY to the end of chemotherapy in non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2017, 5, 166-166.	0.7	4
14678	Novel immunotherapy clinical trials in malignant pleural mesothelioma. <i>Annals of Translational Medicine</i> , 2017, 5, 245-245.	0.7	6
14679	Atezolizumab in non-small cell lung cancer: the era of precision immuno-oncology. <i>Annals of Translational Medicine</i> , 2017, 5, 265-265.	0.7	5
14680	Neopterin as a biomarker of immune response in cancer patients. <i>Annals of Translational Medicine</i> , 2017, 5, 280-280.	0.7	42
14681	Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2017, 5, 376-376.	0.7	79
14682	Relevance of genetic alterations in squamous and small cell lung cancer. <i>Annals of Translational Medicine</i> , 2017, 5, 373-373.	0.7	9
14683	Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance. <i>Annals of Translational Medicine</i> , 2017, 5, 377-377.	0.7	15
14684	PD-L1 as a biomarker in NSCLC: challenges and future directions. <i>Annals of Translational Medicine</i> , 2017, 5, 375-375.	0.7	35
14685	Predictive factors of response to immunotherapy—a review from the Spanish Melanoma Group (GEM). <i>Annals of Translational Medicine</i> , 2017, 5, 389-389.	0.7	26
14686	EGFR mutation positive non-small cell lung cancer: can we identify predictors of benefit from immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2017, 5, 424-424.	0.7	5
14687	New trends in antitumor vaccines in melanoma. <i>Annals of Translational Medicine</i> , 2017, 5, 384-384.	0.7	16
14688	Immune checkpoint pathways in non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 88-88.	0.7	13
14689	Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4—a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2017, 5, 467-467.	0.7	12

#	ARTICLE	IF	CITATIONS
14690	The emerging treatment landscape of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 138-138.	0.7	29
14691	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. <i>Annals of Translational Medicine</i> , 2018, 6, 143-143.	0.7	13
14692	Which criteria should we use to evaluate the efficacy of immune-checkpoint inhibitors?. <i>Annals of Translational Medicine</i> , 2018, 6, 222-222.	0.7	19
14693	Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. <i>Annals of Translational Medicine</i> , 2018, 6, 160-160.	0.7	22
14694	Emerging biomarkers and targeted therapies in urothelial carcinoma. <i>Annals of Translational Medicine</i> , 2018, 6, 250-250.	0.7	33
14695	Surrogate study endpoints in the era of cancer immunotherapy. <i>Annals of Translational Medicine</i> , 2018, 6, S27-S27.	0.7	18
14696	Non-invasive assessment of tumor PD-L1 status with circulating tumor cells. <i>Annals of Translational Medicine</i> , 2018, 6, S48-S48.	0.7	10
14697	Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach. <i>Annals of Translational Medicine</i> , 2019, 7, 14-14.	0.7	11
14698	Is the onset of adverse effects of immunotherapy always bad news for the patientsâ€ ?â€”certainly not!. <i>Annals of Translational Medicine</i> , 2019, 7, S5-S5.	0.7	5
14699	Is an immune checkpoint inhibitor really a hopeless therapeutic choice for EGFR-mutant non-small cell lung cancer (NSCLC) patients?. <i>Annals of Translational Medicine</i> , 2019, 7, S32-S32.	0.7	1
14700	Systemic therapy of elderly patients with advanced non-small cell lung cancerâ€”individualized treatment is key. <i>Annals of Translational Medicine</i> , 2019, 7, S48-S48.	0.7	3
14701	The role of endobronchial ultrasound transbronchial needle aspiration for programmed death ligand 1 testing and next generation sequencing in advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 351-351.	0.7	14
14702	Immunotherapy for head and neck cancer: where are we now and where are we going?. <i>Annals of Translational Medicine</i> , 2019, 7, S75-S75.	0.7	35
14703	Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?. <i>Annals of Translational Medicine</i> , 2019, 7, S76-S76.	0.7	5
14704	SF3B1 mutation predicts unfavorable treatment-free survival in Chinese chronic lymphocytic leukemia patients. <i>Annals of Translational Medicine</i> , 2019, 7, 176-176.	0.7	9
14705	Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts. <i>Annals of Translational Medicine</i> , 2019, 7, 179-179.	0.7	56
14706	Immunity in cancer and atherosclerosis. <i>Annals of Translational Medicine</i> , 2019, 7, 204-204.	0.7	11
14707	Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?. <i>Annals of Translational Medicine</i> , 2019, 7, S95-S95.	0.7	2

#	ARTICLE	IF	CITATIONS
14708	Immunotherapy for mucosal melanoma. <i>Annals of Translational Medicine</i> , 2019, 7, S118-S118.	0.7	23
14709	The PD-1/PD-L1 pathway in advanced prostate cancer—have we milked this cow?. <i>Annals of Translational Medicine</i> , 2019, 7, 346-346.	0.7	7
14710	Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?. <i>Annals of Translational Medicine</i> , 2019, 7, S140-S140.	0.7	11
14711	Are we facing a cure in lung cancer?—KEYNOTE-001 insights. <i>Annals of Translational Medicine</i> , 2019, 7, S215-S215.	0.7	7
14712	JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial. <i>Annals of Translational Medicine</i> , 2019, 7, 435-435.	0.7	17
14713	Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 572-572.	0.7	28
14714	Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. <i>Annals of Translational Medicine</i> , 2019, 7, 640-640.	0.7	103
14715	PD-L1 assessment in urothelial carcinoma: a practical approach. <i>Annals of Translational Medicine</i> , 2019, 7, 690-690.	0.7	77
14716	Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma. <i>Chinese Clinical Oncology</i> , 2017, 6, 31-31.	0.4	12
14717	Immunotherapy in patients with autoimmune disease. <i>Journal of Thoracic Disease</i> , 2020, 12, 7032-7038.	0.6	13
14718	Challenges of PD-L1 testing in non-small cell lung cancer and beyond. <i>Journal of Thoracic Disease</i> , 2020, 12, 4541-4548.	0.6	13
14719	High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2018, 10, 4741-4750.	0.6	20
14720	Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort. <i>Journal of Thoracic Disease</i> , 2019, 11, 4972-4981.	0.6	35
14721	Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses. <i>Journal of Thoracic Disease</i> , 2020, 12, 4504-4509.	0.6	3
14722	Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy. <i>Translational Cancer Research</i> , 2017, 6, S652-S654.	0.4	8
14723	Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. <i>Translational Cancer Research</i> , 2018, 7, S16-S20.	0.4	4
14724	Gut microbes modulate host response to immune checkpoint inhibitor cancer immunotherapy. <i>Translational Cancer Research</i> , 2018, 7, S608-S610.	0.4	5
14725	Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy. <i>Translational Cancer Research</i> , 2019, 8, 59-65.	0.4	11

#	ARTICLE	IF	CITATIONS
14726	Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer. <i>Translational Cancer Research</i> , 2019, 8, 111-119.	0.4	9
14727	Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial. <i>Translational Cancer Research</i> , 2019, 8, S404-S420.	0.4	5
14728	Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2367-2367.	1.3	20
14729	Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2391-2400.	1.3	19
14730	Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2656-2673.	1.3	16
14731	Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer? a literature review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2674-2685.	1.3	2
14732	Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2696-2715.	1.3	43
14733	Harnessing the potential synergy of combining radiation therapy and immunotherapy for thoracic malignancies. <i>Translational Lung Cancer Research</i> , 2007, 6, 109-112.	1.3	10
14734	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	1.3	7
14735	Characterization of PD-L1 protein expression and CD8+ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 748-759.	1.3	22
14736	T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 895-906.	1.3	29
14737	Challenges of evaluating immunotherapy efficacy in solid tumors. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 853-861.	0.7	8
14738	Advances and challenges in immunotherapy of small cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 115-128.	0.7	19
14739	Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 287-302.	0.7	20
14740	Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 448-466.	0.7	6
14741	Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers. <i>Future Science OA</i> , 2020, 6, FSO616.	0.9	10
14742	<p>Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 241-252.	0.7	4
14743	<p>Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway) Tj ETQq1 1 0,784314,rgBT /Over 645-656.	0.7	5

#	ARTICLE	IF	CITATIONS
14744	<p><p>Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant</p>. Journal of Hepatocellular Carcinoma, 2020, Volume 7, 385-401.</p>	1.8	8
14745	<p><p>Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells</p>. OncoTargets and Therapy, 2019, Volume 12, 11033-11044.</p>	1.0	9
14746	<p><p>Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib</p>. OncoTargets and Therapy, 2020, Volume 13, 9305-9321.</p>	1.0	16
14747	<p><p>PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases</p>. OncoTargets and Therapy, 2020, Volume 13, 12777-12786.</p>	1.0	7
14748	Osteoclast-like Giant Cell-type Pancreatic Anaplastic Carcinoma Presenting with a Duodenal Polypoid Lesion. Internal Medicine, 2019, 58, 3545-3550.	0.3	5
14749	Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy. Current Medicinal Chemistry, 2019, 26, 3026-3041.	1.2	142
14750	Inflammation Fuels Tumor Progress and Metastasis. Current Pharmaceutical Design, 2015, 21, 3032-3040.	0.9	69
14751	Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. Current Drug Targets, 2017, 18, 315-331.	1.0	39
14752	Towards Breast Cancer Vaccines, Progress and Challenges. Current Drug Discovery Technologies, 2019, 16, 251-258.	0.6	21
14753	Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2012, 12, 224-235.	0.5	45
14754	Producing Capabilities of Interferon-gamma and Interleukin-10 in Peripheral Blood from Oral Squamous Cell Carcinoma Patients. Open Dentistry Journal, 2015, 9, 120-124.	0.2	6
14755	Perspectives of Immune Suppression in the Tumor Microenvironment Promoting Oral Malignancy. Open Dentistry Journal, 2018, 12, 455-465.	0.2	9
14756	DNA Methylation in Breast Tumor from High-risk Women in the Breast Cancer Family Registry. Anticancer Research, 2017, 37, 659-664.	0.5	7
14757	Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution. Anticancer Research, 2019, 39, 781-790.	0.5	25
14758	Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. Cancer Genomics and Proteomics, 2017, 14, 181-195.	1.0	30
14759	Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises. Cancer Genomics and Proteomics, 2017, 14, 299-313.	1.0	46
14760	Screening for Multiple Autoantibodies in Plasma of Patients with Breast Cancer. Cancer Genomics and Proteomics, 2017, 14, 427-435.	1.0	11
14761	Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures. In Vivo, 2017, 31, 475-479.	0.6	7

#	ARTICLE	IF	CITATIONS
14762	The Positive Relationship Between γ H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. <i>In Vivo</i> , 2018, 32, 171-177.	0.6	10
14763	Thyrototoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma. <i>In Vivo</i> , 2018, 32, 345-351.	0.6	19
14764	Mobile Phone App-Based Pulmonary Rehabilitation for Chemotherapy-Treated Patients With Advanced Lung Cancer: Pilot Study. <i>JMIR MHealth and UHealth</i> , 2019, 7, e11094.	1.8	37
14765	Detecting and Filtering Immune-Related Adverse Events Signal Based on Text Mining and Observational Health Data Sciences and Informatics Common Data Model: Framework Development Study. <i>JMIR Medical Informatics</i> , 2020, 8, e17353.	1.3	6
14766	Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study. <i>JMIR Formative Research</i> , 2020, 4, e17898.	0.7	17
14767	Photoaging Mobile Apps as a Novel Opportunity for Melanoma Prevention: Pilot Study. <i>JMIR MHealth and UHealth</i> , 2017, 5, e101.	1.8	29
14768	A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol. <i>JMIR Research Protocols</i> , 2016, 5, e167.	0.5	6
14769	Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility. <i>JMIR Research Protocols</i> , 2017, 6, e45.	0.5	6
14770	Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol. <i>JMIR Research Protocols</i> , 2017, 6, e195.	0.5	5
14771	PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 57-64.	0.5	8
14772	Tumor-Associated Neutrophils in Breast Cancer Subtypes. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 2689-2693.	0.5	31
14773	Programmed Death-Ligand 1 (PD-L1) Expression Associated with a High Neutrophil/Lymphocyte Ratio in Cholangiocarcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 1671-1674.	0.5	20
14774	Increased Tumour Infiltration of CD4+ and CD8+ T-Lymphocytes in Patients with Triple Negative Breast Cancer Suggests Susceptibility to Immune Therapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 1827-1832.	0.5	10
14775	BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 2209-2213.	0.5	16
14776	An Altered Ratio of CD4+ And CD8+ T Lymphocytes in Cervical Cancer Tissues and Peripheral Blood – A Prognostic Clue?. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 471-478.	0.5	20
14777	Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy. <i>Diabetes Care</i> , 2015, 38, e55-e57.	4.3	278
14778	Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy. <i>Acta Dermato-Venereologica</i> , 2020, 100, 1-2.	0.6	7
14779	Patient Preferences in Adjuvant and Palliative Treatment of Advanced Melanoma: A Discrete Choice Experiment. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00083-9.	0.6	17

#	ARTICLE	IF	CITATIONS
14780	A Systematic Review of Drug-Induced Pemphigoid. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00224.	0.6	71
14781	Increasing Costs of Skin Cancer due to Increasing Incidence and Introduction of Pharmaceuticals, 2007-2017. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00147.	0.6	15
14782	Uridine Cytidine Kinase Like-1 Enhances Tumor Cell Proliferation and Mediates Protection from Natural Killer-Mediated Killing. <i>International Journal of Immunology and Immunotherapy</i> , 2016, 3, .	0.2	2
14783	Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. <i>Journal of Medical Biochemistry</i> , 2019, 38, 332-341.	0.7	21
14784	Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. <i>Radiology and Oncology</i> , 2018, 52, 281-288.	0.6	22
14785	NF- κ B Inhibition Suppresses Experimental Melanoma Lung Metastasis. <i>Journal of Cancer Science and Clinical Therapeutics</i> , 2020, 04, 256-265.	0.2	8
14786	LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state. <i>Life Science Alliance</i> , 2018, 1, e201800171.	1.3	26
14787	Tumor-intrinsic response to IFN γ shapes the tumor microenvironment and anti-PD-1 response in NSCLC. <i>Life Science Alliance</i> , 2019, 2, e201900328.	1.3	38
14789	The immunomodulating roles of glycoproteins in epithelial ovarian cancer. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 631.	0.9	4
14790	Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2016, 13, 87-100.	1.4	21
14791	Mediator kinase module and human tumorigenesis. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2015, 50, 393-426.	2.3	88
14792	Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 239.	0.3	2
14793	Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 355.	0.3	6
14794	Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer. <i>Ochsner Journal</i> , 2019, 19, 138-151.	0.5	26
14795	Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast Cancers. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 3341-3351.	0.5	8
14796	Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 2951-2957.	0.5	8
14797	Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 3421-3427.	0.5	7
14798	Observational Molecular Case-Control Study of Genetic Polymorphisms 1 in Programmed Cell Death Protein-1 in Patients with Oral Lichen Planus. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 421-424.	0.5	3

#	ARTICLE	IF	CITATIONS
14799	Immunohistochemical Expression of Programmed Death Ligand-1 (PDL-1) in Colorectal carcinoma and Its Correlation with Stromal Tumor Infiltrating Lymphocytes. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 225-232.	0.5	9
14800	The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction. <i>Deutsches A&#x0308;rzteblatt International</i> , 2019, 116, 497-504.	0.6	15
14801	Nanoparticles for Effective Combination Therapy of Cancer. <i>International Journal of Nanotechnology and Nanomedicine</i> , 2016, 1, .	1.0	11
14802	Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review. <i>Croatian Medical Journal</i> , 2020, 61, 326-332.	0.2	4
14803	Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes. <i>Journal of Korean Neurosurgical Society</i> , 2018, 61, 319-332.	0.5	30
14804	Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy. <i>Journal of Korean Medical Science</i> , 2019, 34, e186.	1.1	8
14805	Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies. <i>Yonsei Medical Journal</i> , 2020, 61, 844.	0.9	7
14806	The mutational landscape of hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 220.	4.5	108
14807	Identification of an Immune-Related Prognostic Signature Associated With Immune Infiltration in Melanoma. <i>Frontiers in Genetics</i> , 2020, 11, 1002.	1.1	16
14808	Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 3023.	2.2	45
14809	PCOLCE Is Potent Prognostic Biomarker and Associates With Immune Infiltration in Gastric Cancer. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 544895.	1.6	16
14810	Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 263.	1.3	62
14811	Overexpression of B7-H3 in \pm -SMA-Positive Fibroblasts Is Associated With Cancer Progression and Survival in Gastric Adenocarcinomas. <i>Frontiers in Oncology</i> , 2019, 9, 1466.	1.3	39
14812	High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 1483.	1.3	10
14813	CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 697.	1.3	129
14814	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.	1.2	14
14815	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
14816	Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy Response. <i>Cancers</i> , 2020, 12, 2835.	1.7	8

#	ARTICLE	IF	CITATIONS
14817	The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options. <i>Cancers</i> , 2015, 7, 1154-1177.	1.7	20
14818	Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?. <i>Cancers</i> , 2015, 7, 1925-1958.	1.7	51
14819	Revealing the Complexity of Breast Cancer by Next Generation Sequencing. <i>Cancers</i> , 2015, 7, 2183-2200.	1.7	28
14820	The Role of Immune Checkpoint Blockade in Uveal Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 879.	1.8	57
14821	The impact of tumour pH on cancer progression: strategies for clinical intervention. , 2020, 1, 71-100.		60
14822	Role of liquid biopsy for thoracic cancers immunotherapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, 183-199.	0.5	5
14823	An overview of immune checkpoint inhibitors in breast cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, .	0.5	4
14824	Perspectives on Treatment Advances for Stage III Locally Advanced Unresectable Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2019, 26, 37-42.	0.9	56
14825	Depletion of CD4+CD25+ regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma. <i>World Journal of Gastroenterology</i> , 2008, 14, 5797.	1.4	31
14826	B7molecule mRNA expression in colorectal carcinoma. <i>World Journal of Gastroenterology</i> , 2005, 11, 5655.	1.4	11
14827	Ipilimumab associated colitis: An IpiColitis case series at MedStar Georgetown University Hospital. <i>World Journal of Gastroenterology</i> , 2015, 21, 4373.	1.4	24
14828	Perspectives in the treatment of pancreatic adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 9297.	1.4	124
14829	Potentiality of immunotherapy against hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 10314.	1.4	32
14830	Prognostic significance of plasma interleukin-6/8 in pancreatic cancer patients receiving chemoimmunotherapy. <i>World Journal of Gastroenterology</i> , 2015, 21, 11168.	1.4	20
14831	Promises and paradoxes of regulatory T cells in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11236.	1.4	48
14832	Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 4446.	1.4	13
14833	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 748.	1.4	16
14834	Immunotherapy in human colorectal cancer: Challenges and prospective. <i>World Journal of Gastroenterology</i> , 2016, 22, 6362.	1.4	41

#	ARTICLE	IF	CITATIONS
14835	Progress in systemic therapy of advanced hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 6582.	1.4	43
14836	Personalized medicine in gastric cancer: Where are we and where are we going?. World Journal of Gastroenterology, 2016, 22, 1160.	1.4	37
14837	Changing strategies for target therapy in gastric cancer. World Journal of Gastroenterology, 2016, 22, 1179.	1.4	32
14838	Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World Journal of Gastroenterology, 2016, 22, 7080.	1.4	10
14839	Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World Journal of Gastroenterology, 2016, 22, 7440.	1.4	15
14840	Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World Journal of Gastroenterology, 2016, 22, 1393.	1.4	24
14841	Role of Tim-3 in hepatitis B virus infection: An overview. World Journal of Gastroenterology, 2016, 22, 2294-2303.	1.4	33
14842	Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World Journal of Gastroenterology, 2016, 22, 2678.	1.4	177
14843	Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality. World Journal of Gastroenterology, 2017, 23, 3017.	1.4	9
14844	Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. World Journal of Gastroenterology, 2018, 24, 1839-1858.	1.4	30
14845	Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?. World Journal of Gastroenterology, 2018, 24, 2137-2151.	1.4	99
14846	Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. World Journal of Gastroenterology, 2018, 24, 2686-2697.	1.4	23
14847	Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line. World Journal of Gastroenterology, 2018, 24, 3749-3759.	1.4	11
14848	Biomarkers for hepatocellular carcinoma: What's new on the horizon?. World Journal of Gastroenterology, 2018, 24, 3974-3979.	1.4	34
14849	Establishment, functional and genetic characterization of three novel patient-derived rectal cancer cell lines. World Journal of Gastroenterology, 2018, 24, 4880-4892.	1.4	7
14850	Checkpoint inhibitors: What gastroenterologists need to know. World Journal of Gastroenterology, 2018, 24, 5433-5438.	1.4	14
14851	Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World Journal of Gastroenterology, 2019, 25, 1684-1696.	1.4	29
14852	Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 3870-3896.	1.4	70

#	ARTICLE	IF	CITATIONS
14853	Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance. <i>World Journal of Gastroenterology</i> , 2019, 25, 4383-4404.	1.4	160
14854	Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment. <i>World Journal of Gastroenterology</i> , 2020, 26, 134-153.	1.4	36
14855	Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. <i>World Journal of Gastroenterology</i> , 2020, 26, 353-365.	1.4	54
14861	Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e94.	1.0	29
14862	Radiotherapy and immune checkpoint blockades: a snapshot in 2016. <i>Radiation Oncology Journal</i> , 2016, 34, 250-259.	0.7	26
14863	Novel biological strategies to enhance the radiation therapeutic ratio. <i>Radiation Oncology Journal</i> , 2018, 36, 172-181.	0.7	8
14864	Local ablative radiotherapy for oligometastatic non-small cell lung cancer. <i>Radiation Oncology Journal</i> , 2019, 37, 149-155.	0.7	12
14865	The emerging role of myeloid-derived suppressor cells in radiotherapy. <i>Radiation Oncology Journal</i> , 2020, 38, 1-10.	0.7	36
14866	Reader-free ELISPOT assay for immune monitoring in peptide-based cancer vaccine immunotherapy. <i>Biomedical Reports</i> , 2020, 12, 244-250.	0.9	5
14867	Prognostic and therapeutic value of CD103 cells in renal cell carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 4979-4986.	0.8	11
14868	M2 tumor-associated macrophages promote tumor progression in non-small cell lung cancer. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 4490-4498.	0.8	83
14869	Downregulation of PD-L1 via amide analogues of brefelamide: Alternatives to antibody-based cancer immunotherapy. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 3150-3158.	0.8	5
14870	Ephrin-B2 inhibits cell proliferation and motility <i>in vitro</i> and predicts longer metastasis-free survival in breast cancer. <i>International Journal of Oncology</i> , 2019, 55, 1275-1286.	1.4	8
14871	Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature. <i>Molecular and Clinical Oncology</i> , 2019, 11, 439-446.	0.4	16
14872	Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer. <i>Molecular and Clinical Oncology</i> , 2020, 12, 415-420.	0.4	4
14873	Circulating tumor cells and breast cancer-specific mutations in primary breast cancer. <i>Molecular and Clinical Oncology</i> , 2020, 12, 565-573.	0.4	4
14874	Guillain-Barre syndrome induced by pembrolizumab and sunitinib: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 13, 38-42.	0.4	8
14875	Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 13, 43-47.	0.4	12

#	ARTICLE	IF	CITATIONS
14876	Predicting therapeutic efficacy of endocrine therapy for stageÂIV breast cancer by tumorâ€infiltrating lymphocytes. <i>Molecular and Clinical Oncology</i> , 2020, 13, 195-202.	0.4	3
14877	Value of TTFâ€1 expression in nonâ€squamous nonâ€smallâ€cell lung cancer for assessing docetaxel monotherapy after chemotherapy failure. <i>Molecular and Clinical Oncology</i> , 2020, 13, 9.	0.4	6
14878	HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation. <i>Oncology Letters</i> , 2017, 14, 4415-4427.	0.8	60
14879	Imbalance in circulatory iNKT, Th17 and T regulatory cell frequencies in patients with B-cell non-Hodgkin's lymphoma. <i>Oncology Letters</i> , 2017, 14, 7957-7964.	0.8	12
14880	CARâ€T 19 combined with reducedâ€dose PDâ€1 blockade therapy for treatment of refractory follicular lymphoma: A case report. <i>Oncology Letters</i> , 2019, 18, 4415-4420.	0.8	24
14881	Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy (Review). <i>Oncology Letters</i> , 2019, 18, 5011-5021.	0.8	11
14882	Identification of key genes and evaluation of clinical outcomes in lung squamous cell carcinoma using integrated bioinformatics analysis. <i>Oncology Letters</i> , 2019, 18, 5859-5870.	0.8	13
14883	Use of immunotherapy in the treatment of gastric cancer (Review). <i>Oncology Letters</i> , 2019, 18, 5681-5690.	0.8	31
14884	A subset of patients with MSS/MSIâ€lowâ€colorectal cancer showed increased CD8(+) TILs together with upâ€regulated IFNâ€Î³. <i>Oncology Letters</i> , 2019, 18, 5977-5985.	0.8	33
14885	Accelerated elimination of human cancer cells by a CD40 agonist antibody combined with a PDâ€1 antagonist in CD4â€depleted mice. <i>Oncology Letters</i> , 2019, 18, 5889-5896.	0.8	2
14886	Methylselenol producing selenocompounds enhances the efficiency of mammaglobinâ€A peptide vaccination against breast cancer cells. <i>Oncology Letters</i> , 2019, 18, 6891-6898.	0.8	7
14887	Significant function and research progress of biomarkers in gastric cancer (Review). <i>Oncology Letters</i> , 2020, 19, 17-29.	0.8	26
14888	Nomogram construction for predicting survival of patients with nonâ€small cell lung cancer with malignant pleural or pericardial effusion based on SEER analysis of 10,268ÿ½patients. <i>Oncology Letters</i> , 2020, 19, 449-459.	0.8	8
14889	Threeâ€microRNA expression signature predicts survival in tripleâ€negative breast cancer. <i>Oncology Letters</i> , 2020, 19, 301-308.	0.8	21
14890	POLR1B is upregulated and promotes cell proliferation in nonâ€small cell lung cancer. <i>Oncology Letters</i> , 2020, 19, 671-680.	0.8	11
14891	Bioinformatics analysis of the expression of HOXC13 and its role in the prognosis of breast cancer. <i>Oncology Letters</i> , 2020, 19, 899-907.	0.8	13
14892	Radiomics predicts survival of patients with advanced nonâ€small cell lung cancer undergoing PDâ€1 blockade using Nivolumab. <i>Oncology Letters</i> , 2020, 19, 1559-1566.	0.8	46
14893	PDâ€L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer. <i>Oncology Letters</i> , 2020, 19, 1223-1234.	0.8	12

#	ARTICLE	IF	CITATIONS
14894	Cardamonin as a potential treatment for melanoma induces human melanoma cell apoptosis. <i>Oncology Letters</i> , 2020, 19, 1393-1399.	0.8	10
14895	Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers. <i>Oncology Letters</i> , 2020, 19, 1673-1682.	0.8	25
14896	Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer. <i>Oncology Letters</i> , 2020, 19, 1842-1848.	0.8	32
14897	Breast cancer stem cell RNA-pulsed dendritic cells enhance tumor cell killing by effector T _H 1/2 cells. <i>Oncology Letters</i> , 2020, 19, 2422-2430.	0.8	8
14898	ZW10 interacting kinetochore protein may serve as a prognostic biomarker for human breast cancer: An integrated bioinformatics analysis. <i>Oncology Letters</i> , 2020, 19, 2163-2174.	0.8	12
14899	Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape (Review). <i>Oncology Letters</i> , 2020, 19, 2595-2601.	0.8	14
14900	Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 19, 2739-2748.	0.8	16
14901	Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors. <i>Oncology Letters</i> , 2020, 19, 2817-2824.	0.8	13
14902	Comprehensive genomic profile of cholangiocarcinomas in China. <i>Oncology Letters</i> , 2020, 19, 3101-3110.	0.8	18
14903	The roles of curcumin in regulating the tumor immunosuppressive microenvironment (Review). <i>Oncology Letters</i> , 2020, 19, 3059-3070.	0.8	21
14904	The daily practice reality of PD-L1 (CD274) evaluation in non-small cell lung cancer: A retrospective study. <i>Oncology Letters</i> , 2020, 19, 3400-3410.	0.8	6
14905	Gene silencing of indoleamine 2,3-dioxygenase 1 inhibits lung cancer growth by suppressing T cell exhaustion. <i>Oncology Letters</i> , 2020, 19, 3827-3838.	0.8	7
14906	Clinical significance of CD38 and CD101 expression in PD-L1+CD8+ T cells in patients with epithelial ovarian cancer. <i>Oncology Letters</i> , 2020, 20, 724-732.	0.8	10
14907	Analysis of immune-related signatures of colorectal cancer identifying two different immune phenotypes: Evidence for immune checkpoint inhibitor therapy. <i>Oncology Letters</i> , 2020, 20, 517-524.	0.8	12
14908	Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2020, 20, 611-622.	0.8	34
14909	Mining the prognostic significance of the GINS2 gene in human breast cancer using bioinformatics analysis. <i>Oncology Letters</i> , 2020, 20, 1300-1310.	0.8	5
14910	Prognostic value of immune cell infiltration in bladder cancer: A gene expression-based study. <i>Oncology Letters</i> , 2020, 20, 1677-1684.	0.8	6
14911	Interferon- γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer. <i>Oncology Letters</i> , 2020, 20, 2161-2168.	0.8	28

#	ARTICLE	IF	CITATIONS
14912	miR129â€¹ regulates protein phosphatase 1D protein expression under hypoxic conditions in nonâ€¹small cell lung cancer cells harboring a TP53 mutation. <i>Oncology Letters</i> , 2020, 20, 2239-2247.	0.8	3
14913	Early response of bone metastases can predict tumor response in patients with nonâ€¹smallâ€¹cell lung cancer with bone metastases in the treatment with nivolumab. <i>Oncology Letters</i> , 2020, 20, 2977-2986.	0.8	11
14914	Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies. <i>Oncology Letters</i> , 2020, 20, 14.	0.8	10
14915	Biomarkers of immunotherapy in nonâ€¹small cell lung cancer (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	8
14916	Immunotyping of tumorâ€¹infiltrating lymphocytes in tripleâ€¹negative breast cancer and genetic characterization. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	12
14917	Progress of immune checkpoint LAGâ€¹3 in immunotherapy (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	41
14918	Circulating microRNAs and their role in the immune response in tripleâ€¹negative breast cancer (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	13
14919	CXCL5 expression in tumor tissues is associated with poor prognosis in patients with pancreatic cancer. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	5
14920	MUC1â€¹induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	11
14921	Mechanism of intrinsic resistance of lung squamous cell carcinoma to epithelial growth factor receptorâ€¹tyrosine kinase inhibitors revealed by highâ€¹throughput RNA interference screening. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	3
14922	Mass spectrum analysis of membrane proteins reveals that CASK, CD36 and EPB42 are differentially expressed in pancreatic adenocarcinoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	10
14923	Early palliative care of non-small cell lung cancer in the context of immunotherapy. <i>Oncology Letters</i> , 2020, 20, 396.	0.8	1
14924	Plasma plastinâ€¹3: A tumor marker in patients with nonâ€¹smallâ€¹cell lung cancer treated with nivolumab. <i>Oncology Letters</i> , 2020, 21, 1-1.	0.8	4
14925	Expression levels of FBXW7 and MDM2 E3 ubiquitin ligases and their câ€¹Myc and p53 substrates in patients with dysplastic nevi or melanoma. <i>Oncology Letters</i> , 2020, 21, 1-1.	0.8	2
14926	HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma. <i>Oncology Reports</i> , 2019, 42, 2309-2322.	1.2	14
14927	Highly sensitive detection of sentinel lymph node metastasis of breast cancer by digital PCR for RASSF1A methylation. <i>Oncology Reports</i> , 2019, 42, 2382-2389.	1.2	7
14928	Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 50-59.	0.7	14
14929	Rheumatic complications in cancer patients treated with immune checkpoint inhibitors. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1197-1209.	0.7	11

#	ARTICLE	IF	CITATIONS
14930	Drug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis. <i>AIMS Microbiology</i> , 2018, 4, 642-654.	1.0	26
14931	The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2015, 27, 128-37.	0.7	12
14932	Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2015, 27, 376-91.	0.7	16
14933	Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. <i>Journal of Thoracic Disease</i> , 2015, 7, 455-61.	0.6	29
14934	Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. <i>Journal of Thoracic Disease</i> , 2015, 7, 462-70.	0.6	106
14935	Impact of the immune system and immunotherapy in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 208-23.	0.6	142
14936	Current status of novel agents in advanced gastroesophageal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 60-74.	0.6	19
14937	Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 561-9.	0.6	61
14938	Duodenal and gallbladder metastasis of regressive melanoma: a case report and review of the literature. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, E77-81.	0.6	14
14939	Immune targeting of cancer stem cells in gastrointestinal oncology. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, S1-S10.	0.6	12
14940	New therapeutic strategies for BRAF mutant colorectal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 650-9.	0.6	21
14941	Immunotherapy in lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 2-14.	1.3	53
14942	Immunotherapy prospects in the treatment of lung cancer and mesothelioma. <i>Translational Lung Cancer Research</i> , 2014, 3, 34-45.	1.3	22
14943	A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors. <i>Translational Lung Cancer Research</i> , 2014, 3, 406-7.	1.3	19
14944	Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 403-5.	1.3	21
14945	A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736. <i>Translational Lung Cancer Research</i> , 2014, 3, 408-10.	1.3	19
14946	The past, present and future of immunotherapy against tumor. <i>Translational Lung Cancer Research</i> , 2015, 4, 253-64.	1.3	34
14947	The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. <i>Translational Lung Cancer Research</i> , 2015, 4, 177-90.	1.3	73

#	ARTICLE	IF	CITATIONS
14948	First-line nivolumab (anti-PD-1) monotherapy in advanced NSCLC: the story of immune checkpoint inhibitors and "the sorcerers apprentice". <i>Translational Lung Cancer Research</i> , 2015, 4, 215-6.	1.3	16
14949	Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?. <i>Translational Lung Cancer Research</i> , 2015, 4, 804-8.	1.3	15
14950	Lung cancer biomarkers, targeted therapies and clinical assays. <i>Translational Lung Cancer Research</i> , 2015, 4, 503-14.	1.3	23
14951	New strategies in immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 553-9.	1.3	35
14952	Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. <i>Translational Lung Cancer Research</i> , 2015, 4, 560-75.	1.3	303
14953	Treatment of advanced squamous cell carcinoma of the lung: a review. <i>Translational Lung Cancer Research</i> , 2015, 4, 524-32.	1.3	74
14954	Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. <i>Translational Lung Cancer Research</i> , 2015, 4, 545-52.	1.3	70
14955	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. <i>Translational Lung Cancer Research</i> , 2015, 4, 721-7.	1.3	26
14956	Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. <i>Translational Lung Cancer Research</i> , 2015, 4, 728-42.	1.3	48
14957	Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 756-62.	1.3	8
14958	Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 743-51.	1.3	31
14959	Cancer stem cells and immunoresistance: clinical implications and solutions. <i>Translational Lung Cancer Research</i> , 2015, 4, 689-703.	1.3	91
14960	Cellular and molecular biology of small cell lung cancer: an overview. <i>Translational Lung Cancer Research</i> , 2016, 5, 2-15.	1.3	52
14961	Novel non-AR therapeutic targets in castrate resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2013, 2, 265-77.	0.6	4
14962	Bacille-Calmette-Guerin non-responders: how to manage. <i>Translational Andrology and Urology</i> , 2015, 4, 244-53.	0.6	5
14963	Genotyping of cutaneous melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 27.	0.4	17
14964	The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). <i>Annals of Translational Medicine</i> , 2015, 3, 96.	0.7	20
14965	Predictive factors for immunotherapy in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 208.	0.7	27

#	ARTICLE	IF	CITATIONS
14966	Melanoma: oncogenic drivers and the immune system. <i>Annals of Translational Medicine</i> , 2015, 3, 265.	0.7	19
14967	Immune checkpoint inhibitors: therapeutic advances in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 267.	0.7	47
14968	Immunological interactions in radiotherapy-opening a new window of opportunity. <i>Annals of Translational Medicine</i> , 2016, 4, 51.	0.7	7
14969	Pembrolizumab-Induced Myasthenic Crisis with HyperCKemia in a Patient with Thymoma. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
14984	Antibody-supervised deep learning for quantification of tumor-infiltrating immune cells in hematoxylin and eosin stained breast cancer samples. <i>Journal of Pathology Informatics</i> , 2016, 7, 38.	0.8	78
14985	Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 270.	0.8	15
14986	Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review. <i>Avicenna Journal of Medicine</i> , 2018, 8, 34-36.	0.3	18
14987	Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region. <i>Annals of Thoracic Medicine</i> , 2019, 14, 173.	0.7	8
14988	Saudi lung cancer management guidelines 2017. <i>Annals of Thoracic Medicine</i> , 2017, 12, 221.	0.7	16
14989	Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens. <i>CytoJournal</i> , 2018, 15, 29.	0.8	14
14990	Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma. <i>International Journal of Critical Illness and Injury Science</i> , 2017, 7, 177.	0.2	13
14991	Nivolumab – Pearls of evidence. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2017, 38, 520.	0.1	7
14992	Immune Checkpoint Blockers and Ovarian Cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2017, 38, 182-189.	0.1	4
14993	Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma. <i>Indian Journal of Medical Research</i> , 2019, 150, 376.	0.4	5
14994	Immune checkpoint inhibitors (Nivolumab)-induced enterocolitis demonstrated on ¹⁸ F-fluorine-fluorodeoxyglucose positron emission tomography-computed tomography. <i>Indian Journal of Nuclear Medicine</i> , 2019, 34, 173.	0.1	1
14995	Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance. <i>Indian Journal of Ophthalmology</i> , 2019, 67, 1983.	0.5	10
14996	Immunotherapy in breast cancer. <i>Journal of Carcinogenesis</i> , 2019, 18, 2.	2.5	56
14997	Programmed death-ligand 1 signaling pathway involves in bladder cancer growth and progression. <i>Journal of Carcinogenesis</i> , 2019, 18, 3.	2.5	2
14998	Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting. <i>Journal of Family Medicine and Primary Care</i> , 2020, 9, 4086.	0.3	2
14999	An agent-based model for investigating the effect of myeloid-derived suppressor cells and its depletion on tumor immune surveillance. <i>Journal of Medical Signals and Sensors</i> , 2019, 9, 15.	0.5	13
15000	Immunotherapy in oral cancer. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2019, 11, 107.	0.2	37
15001	Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images. <i>Journal of Pathology Informatics</i> , 2019, 10, 24.	0.8	70

#	ARTICLE	IF	CITATIONS
15002	A methodology for texture feature-based quality assessment in nucleus segmentation of histopathology image. <i>Journal of Pathology Informatics</i> , 2017, 8, 38.	0.8	12
15003	Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer. <i>Lung India</i> , 2020, 37, 145.	0.3	7
15004	Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy. <i>South Asian Journal of Cancer</i> , 2019, 08, 65-68.	0.2	4
15005	Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update. <i>South Asian Journal of Cancer</i> , 2019, 08, 01-17.	0.2	8
15006	Immune checkpoint inhibitors: Advances and impact in neuro-oncology. , 2019, 10, 9.		18
15007	Bilateral anterior uveitis after immunotherapy for malignant melanoma. <i>Taiwan Journal of Ophthalmology</i> , 2018, 8, 173.	0.3	13
15008	NK Cell-Based Immunotherapies in Cancer. <i>Immune Network</i> , 2020, 20, e14.	1.6	79
15009	Re-defining T-Cell Exhaustion: Subset, Function, and Regulation. <i>Immune Network</i> , 2020, 20, e2.	1.6	33
15010	Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors. <i>Immune Network</i> , 2020, 20, e27.	1.6	36
15011	Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. <i>Journal of Pathology and Translational Medicine</i> , 2015, 49, 355-363.	0.4	41
15012	Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 1-9.	0.4	21
15013	Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma. <i>Journal of Pathology and Translational Medicine</i> , 2018, 52, 9-13.	0.4	16
15014	PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 199-206.	0.4	51
15015	Tumor immune response and immunotherapy in gastric cancer. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 20-33.	0.4	59
15016	Immune landscape and biomarkers for immuno-oncology in colorectal cancers. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 351-360.	0.4	9
15017	Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. <i>Translational Oncogenomics</i> , 2015, Suppl. 1, 1-11.	1.7	19
15018	The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus. <i>Translational Oncogenomics</i> , 2016, Suppl. 1, 1-7.	1.7	2
15019	Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2016, 48, 527-536.	1.3	104

#	ARTICLE	IF	CITATIONS
15020	Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. <i>Cancer Research and Treatment</i> , 2017, 49, 246-254.	1.3	158
15021	Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)â€Positive Breast Cancers. <i>Cancer Research and Treatment</i> , 2017, 49, 313-321.	1.3	11
15022	Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 399-407.	1.3	97
15023	Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 95-102.	1.3	22
15024	BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database. <i>Cancer Research and Treatment</i> , 2018, 50, 658-669.	1.3	14
15025	Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers. <i>Cancer Research and Treatment</i> , 2019, 51, 80-89.	1.3	22
15026	EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 493-501.	1.3	30
15027	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 211-222.	1.3	12
15028	Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 649-663.	1.3	48
15029	Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology. <i>Cancer Research and Treatment</i> , 2019, 51, 832-840.	1.3	11
15030	Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. <i>Cancer Research and Treatment</i> , 2019, 51, 819-831.	1.3	10
15031	Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance. <i>Cancer Research and Treatment</i> , 2019, 51, 737-747.	1.3	53
15032	Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study. <i>Cancer Research and Treatment</i> , 2019, 51, 1336-1346.	1.3	11
15033	Higher Age Puts Lung Cancer Patients at Risk for Not Receiving Anti-cancer Treatment. <i>Cancer Research and Treatment</i> , 2019, 51, 1241-1248.	1.3	7
15034	Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1086-1097.	1.3	59
15035	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1527-1539.	1.3	5
15036	High-Throughput Multiplex Immunohistochemical Imaging of the Tumor and Its Microenvironment. <i>Cancer Research and Treatment</i> , 2020, 52, 98-108.	1.3	18
15037	A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset. <i>Cancer Research and Treatment</i> , 2020, 52, 530-542.	1.3	13

#	ARTICLE	IF	CITATIONS
15038	Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer. <i>Annals of Surgical Treatment and Research</i> , 2020, 98, 291.	0.4	8
15039	Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer. <i>Epidemiology and Health</i> , 2018, 40, e2018040.	0.8	7
15040	Clinical Significance of PD-L1 Expression in Parathyroid Cancer. <i>Acta Endocrinologica</i> , 2016, 12, 383-386.	0.1	3
15041	Identification of genomic features associated with immunotherapy response in gastrointestinal cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 270-280.	0.8	8
15042	Precision medicine for gastrointestinal cancer: Recent progress and future perspective. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 12, 1-20.	0.8	31
15043	Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 173-181.	0.8	172
15044	Immune cell interplay in colorectal cancer prognosis. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 221.	0.8	27
15045	Novel therapy for advanced gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 263.	0.8	6
15046	Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 338.	0.8	41
15047	Targeted therapy for advanced gastric cancer: A review of current status and future prospects. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 401.	0.8	23
15048	Anti program death-1/anti program death-ligand 1 in digestive cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 95.	0.8	53
15049	Is metastatic pancreatic cancer an untargetable malignancy?. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 297.	0.8	8
15050	Molecular classifications of gastric cancers: Novel insights and possible future applications. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 194.	0.8	46
15051	Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 293.	0.8	48
15052	Retinoblastoma tumor suppressor functions shared by stem cell and cancer cell strategies. <i>World Journal of Stem Cells</i> , 2016, 8, 170.	1.3	14
15053	Current systemic treatment of hepatocellular carcinoma: A review of the literature. <i>World Journal of Hepatology</i> , 2015, 7, 1412.	0.8	50
15054	Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. <i>World Journal of Hepatology</i> , 2015, 7, 649.	0.8	29
15055	Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. <i>World Journal of Hepatology</i> , 2015, 7, 980.	0.8	35

#	ARTICLE	IF	CITATIONS
15056	Chimeric Antigen Receptor T Cell (Car T Cell) Therapy In Hematology. Turkish Journal of Haematology, 2015, 32, 285-294.	0.2	8
15057	Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World Journal of Gastrointestinal Pathophysiology, 2019, 10, 17-28.	0.5	26
15058	Immunobiology of hepatocarcinogenesis: Ways to go or almost there?. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 242.	0.5	12
15059	Immune checkpoint inhibitors in patients with pretreated Hodgkin's lymphoma: a Korean single-center, retrospective study. Blood Research, 2020, 55, 85-90.	0.5	3
15060	Novel therapies for advanced skin carcinomas. Postepy Dermatologii I Alergologii, 2020, 37, 660-670.	0.4	3
15061	Expression of pendrin and NIS iodide transporters in human breast tumor and peri-tumoral tissue. Archives of Medical Science, 2019, , .	0.4	2
15062	Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients. The Journal of Breast Health, 2019, 15, 235-241.	0.4	17
15063	Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma. European Journal of Rheumatology, 2019, 6, 153-154.	1.3	6
15064	Immune Checkpoint Inhibitors in Advanced-Stage Non-small Cell Lung Cancer. Turkish Thoracic Journal, 2017, 18, 101-107.	0.2	2
15065	Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. Journal of Gastric Cancer, 2019, 19, 375.	0.9	11
15066	Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report. World Journal of Clinical Oncology, 2019, 10, 247-255.	0.9	6
15067	Objective response rate assessment in oncology: Current situation and future expectations. World Journal of Clinical Oncology, 2020, 11, 53-73.	0.9	49
15068	Immunotherapy " new perspective in lung cancer. World Journal of Clinical Oncology, 2020, 11, 250-259.	0.9	10
15069	Progress in immunotherapy for small cell lung cancer. World Journal of Clinical Oncology, 2020, 11, 370-377.	0.9	6
15070	Why natural killer cells in triple negative breast cancer?. World Journal of Clinical Oncology, 2020, 11, 464-476.	0.9	33
15071	Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants. World Journal of Clinical Oncology, 2014, 5, 806.	0.9	22
15072	Neoadjuvant treatment for resectable pancreatic adenocarcinoma. World Journal of Clinical Oncology, 2016, 7, 1.	0.9	11
15073	Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches. World Journal of Clinical Oncology, 2016, 7, 15.	0.9	14

#	ARTICLE	IF	CITATIONS
15074	Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. <i>World Journal of Clinical Oncology</i> , 2016, 7, 387.	0.9	42
15075	Immunotherapies in sarcoma: Updates and future perspectives. <i>World Journal of Clinical Oncology</i> , 2017, 8, 145.	0.9	10
15076	Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. <i>World Journal of Clinical Oncology</i> , 2017, 8, 230.	0.9	52
15077	Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>World Journal of Clinical Oncology</i> , 2017, 8, 320.	0.9	8
15078	Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer. <i>World Journal of Clinical Oncology</i> , 2018, 9, 172-179.	0.9	9
15079	Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 346-356.	0.6	11
15080	Zinc finger protein 143 expression is closely related to tumor malignancy via regulating cell motility in breast cancer. <i>BMB Reports</i> , 2017, 50, 621-627.	1.1	15
15081	Enhanced anticancer effects of a methylation inhibitor by inhibiting a novel DNMT1 target, CEP 131, in cervical cancer. <i>BMB Reports</i> , 2019, 52, 342-347.	1.1	7
15082	A primer on tumour immunology and prostate cancer immunotherapy. <i>Canadian Urological Association Journal</i> , 2016, 10, 60.	0.3	10
15083	Immune profiling and cancer post transplantation. <i>World Journal of Nephrology</i> , 2015, 4, 41.	0.8	10
15084	Classification of Genes Based on Age-Related Differential Expression in Breast Cancer. <i>Genomics and Informatics</i> , 2017, 15, 156-161.	0.4	16
15085	Manipulation of Regulatory Cells's™ Responses to Treatments for Chronic Hepatitis B Virus Infection. <i>Hepatitis Monthly</i> , 2016, 16, e37927.	0.1	11
15086	Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2014, 5, 418-31.	0.2	48
15087	Pembrolizumab: First in Class for Treatment of Metastatic Melanoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2015, 6, 234-8.	0.2	3
15088	Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 58-72.	0.2	7
15089	Clinical Management of Pneumonitis in Patients Receiving Anti-“PD-1/PD-L1 Therapy. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, .	0.2	5
15090	PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. <i>Clinics</i> , 2012, 67, 1285-1290.	0.6	45
15091	Increased Tim-3 expression on TILs during treatment with the Anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer. <i>Journal of Cancer</i> , 2020, 11, 648-656.	1.2	25

#	ARTICLE	IF	CITATIONS
15092	Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. <i>Cancer Biology and Medicine</i> , 2014, 11, 237-46.	1.4	64
15093	Assays for predicting and monitoring responses to lung cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2015, 12, 87-95.	1.4	35
15094	Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. <i>Cancer Biology and Medicine</i> , 2015, 12, 79-86.	1.4	28
15095	Epigenetic modification of the PD-1 (Pdccl1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy. <i>ELife</i> , 2014, 3, .	2.8	52
15096	Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state. <i>ELife</i> , 2014, 3, e03915.	2.8	88
15097	The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium. <i>ELife</i> , 2016, 5, e12034.	2.8	19
15098	CD301b+ dendritic cells suppress T follicular helper cells and antibody responses to protein antigens. <i>ELife</i> , 2016, 5, .	2.8	40
15099	Macrophage PPAR α inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone. <i>ELife</i> , 2016, 5, .	2.8	41
15100	Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. <i>ELife</i> , 2017, 6, .	2.8	66
15101	Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. <i>ELife</i> , 2019, 8, .	2.8	214
15102	Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. <i>Drugs in Context</i> , 2020, 9, 1-11.	1.0	34
15103	Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. <i>Drugs in Context</i> , 2015, 4, 1-7.	1.0	32
15104	Second-line treatment options in hepatocellular carcinoma. <i>Drugs in Context</i> , 2019, 8, 1-13.	1.0	32
15105	ZFPM2-AS1 promotes the proliferation, migration, and invasion of human non-small cell lung cancer cells involving the JAK-STAT and AKT pathways. <i>PeerJ</i> , 2020, 8, e10225.	0.9	10
15106	Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling. <i>PeerJ</i> , 2020, 8, e10414.	0.9	12
15107	BMP2/BMPRI1A is linked to tumour progression in dedifferentiated liposarcomas. <i>PeerJ</i> , 2016, 4, e1957.	0.9	7
15108	Formal modeling and analysis of ER α -associated Biological Regulatory Network in breast cancer. <i>PeerJ</i> , 2016, 4, e2542.	0.9	6
15109	CTLA-4 polymorphisms associate with breast cancer susceptibility in Asians: a meta-analysis. <i>PeerJ</i> , 2017, 5, e2815.	0.9	15

#	ARTICLE	IF	CITATIONS
15110	Clinical significance of circulating immune cells in left- and right-sided colon cancer. PeerJ, 2017, 5, e4153.	0.9	6
15111	Robust and accurate quantification of biomarkers of immune cells in lung cancer micro-environment using deep convolutional neural networks. PeerJ, 2019, 7, e6335.	0.9	24
15112	Characterization of bidirectional gene pairs in The Cancer Genome Atlas (TCGA) dataset. PeerJ, 2019, 7, e7107.	0.9	8
15113	Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ, 2019, 7, e7132.	0.9	70
15114	Long non-coding RNA, LINC01614 as a potential biomarker for prognostic prediction in breast cancer. PeerJ, 2019, 7, e7976.	0.9	27
15115	Reduced GRAMD1C expression correlates to poor prognosis and immune infiltrates in kidney renal clear cell carcinoma. PeerJ, 2019, 7, e8205.	0.9	16
15116	Bioinformatics profiling identifies seven immune-related risk signatures for hepatocellular carcinoma. PeerJ, 2020, 8, e8301.	0.9	9
15117	Identification and validation of HELLS (Helicase, Lymphoid-Specific) and ICAM1 (Intercellular adhesion) Tj ETQq1 1 0.784314 IgBT /Over	0.9	17
15118	CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients. PeerJ, 2020, 8, e9536.	0.9	19
15119	Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases. Cureus, 2020, 12, e11150.	0.2	16
15120	The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors. Cureus, 2017, 9, e1774.	0.2	17
15121	Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma. Cureus, 2017, 9, e1943.	0.2	8
15122	Novel Immunotherapeutics for the Treatment of Glioblastoma: The Last Decade of Research. Cureus, 2018, 10, e2130.	0.2	4
15123	The Concept of Hormesis in Cancer Therapy “Is Less More?”. Cureus, 2015, 7, e261.	0.2	12
15124	Case Reports of Pembrolizumab-induced Acute Inflammatory Demyelinating Polyneuropathy. Cureus, 2018, 10, e3371.	0.2	18
15125	Radiation Therapy and its Effects Beyond the Primary Target: An Abscopal Effect. Cureus, 2019, 11, e4100.	0.2	12
15126	Prognostic Significance of the Dynamic Change of Programmed Death-ligand 1 Expression in Patients with Multiple Myeloma. Cureus, 2019, 11, e4401.	0.2	5
15127	Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis. Cureus, 2019, 11, e5997.	0.2	5

#	ARTICLE	IF	CITATIONS
15128	Immune-mediated Colitis from Dual Checkpoint Inhibitors. <i>Cureus</i> , 2019, 11, e6233.	0.2	2
15129	Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab. <i>Cureus</i> , 2016, 8, e631.	0.2	20
15130	Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More. <i>Cureus</i> , 2020, 12, e6935.	0.2	11
15131	Immune Checkpoint Inhibitor-induced Fanconi Syndrome. <i>Cureus</i> , 2020, 12, e7686.	0.2	9
15132	Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies. <i>Cureus</i> , 2020, 12, e8095.	0.2	19
15133	A Rare Case of Immune-Mediated Primary Adrenal Insufficiency With Cytotoxic T-Lymphocyte Antigen-4 Inhibitor Ipilimumab in Metastatic Melanoma of Lung and Neck of Unknown Primary. <i>Cureus</i> , 2020, 12, e8602.	0.2	6
15134	The Association of Radiation Dose-Fractionation and Immunotherapy Use With Overall Survival in Metastatic Melanoma Patients. <i>Cureus</i> , 2020, 12, e8767.	0.2	7
15135	Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. <i>Cureus</i> , 2016, 8, e924.	0.2	59
15136	Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report. , 2015, 19, 41-46.		10
15137	Breast Cancer Incidence and Mortality by Molecular Subtype: Statewide Age and Racial/Ethnic Disparities in New Jersey. <i>Cancer Health Disparities</i> , 2019, 3, e1-e17.	0.5	15
15138	Targeting PD-L1 (Programmed death-ligand 1) and inhibiting the expression of IGF2BP2 (Insulin-like) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 carcinoma cells. <i>Bioengineered</i> , 2021, 12, 7755-7764.	1.4	10
15139	A narrative review of prognosis prediction models for non-small cell lung cancer: what kind of predictors should be selected and how to improve models?. <i>Annals of Translational Medicine</i> , 2021, 9, 1597-1597.	0.7	2
15140	Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110458.	0.8	2
15141	Construction of a competing endogenous RNA network related to the prognosis of cholangiocarcinoma and comprehensive analysis of the immunological correlation. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2287-2309.	0.6	3
15142	Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1568-1568.	0.7	5
15143	The "œImmunescore" in rectal cancer: could we search quality beyond quantity of life?. <i>Oncotarget</i> , 2022, 13, 18-31.	0.8	3
15144	Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. <i>RSC Chemical Biology</i> , 2022, 3, 140-169.	2.0	5
15145	Molecular characterization of squamous cell carcinoma of the anal canal. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2423-2437.	0.6	7

#	ARTICLE	IF	CITATIONS
15146	The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection. <i>Translational Lung Cancer Research</i> , 2021, 10, 3929-3942.	1.3	6
15147	SHP-1 acts as a tumor suppressor by interacting with EGFR and predicts the prognosis of human breast cancer. <i>Cancer Biology and Medicine</i> , 2021, 19, 468-485.	1.4	6
15148	The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma – systematic review and discussion of current therapeutic options. <i>Wspolczesna Onkologia</i> , 2021, 25, 213-223.	0.7	7
15149	COL6A6 inhibits the proliferation and metastasis of non-small cell lung cancer through the JAK signalling pathway. <i>Translational Cancer Research</i> , 2021, 10, 4514-4522.	0.4	6
15150	Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model. <i>Cancer Gene Therapy</i> , 2022, 29, 456-465.	2.2	35
15151	Centrosome Aberrations as Drivers of Chromosomal Instability in Breast Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	8
15152	Digital pathology and artificial intelligence in translational medicine and clinical practice. <i>Modern Pathology</i> , 2022, 35, 23-32.	2.9	179
15153	NR4A1 regulates expression of immediate early genes, suppressing replication stress in cancer. <i>Molecular Cell</i> , 2021, 81, 4041-4058.e15.	4.5	16
15154	The efficacy of immune checkpoint inhibitors in thoracic malignancies. <i>European Respiratory Review</i> , 2021, 30, 200387.	3.0	5
15155	A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment. <i>Cells</i> , 2021, 10, 2700.	1.8	25
15156	Ferroptosis Patterns Correlate with Immune Microenvironment Characterization in Gastric Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6573-6586.	0.8	3
15157	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. , 2021, 9, e003066.		34
15158	Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect. <i>Toxins</i> , 2021, 13, 719.	1.5	11
15159	Low expression of endoplasmic reticulum stress-related gene SERP1 is associated with poor prognosis and immune infiltration in skin cutaneous melanoma. <i>Agıng</i> , 2021, 13, 23036-23071.	1.4	3
15160	Integrated analysis of tumor-associated macrophage infiltration and prognosis in ovarian cancer. <i>Agıng</i> , 2021, 13, 23210-23232.	1.4	22
15161	Establishment of a novel ferroptosis-related lncRNA pair prognostic model in colon adenocarcinoma. <i>Agıng</i> , 2021, 13, 23072-23095.	1.4	18
15162	The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas. <i>Frontiers in Endocrinology</i> , 2021, 12, 726448.	1.5	11
15163	Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11038.	1.2	3

#	ARTICLE	IF	CITATIONS
15164	Effect of p53 and its N-terminally truncated isoform, $\Delta 40$ p53, on breast cancer migration and invasion. <i>Molecular Oncology</i> , 2022, 16, 447-465.	2.1	15
15165	Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-24.	1.9	93
15166	Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts. <i>Oncogene</i> , 2022, 41, 112-124.	2.6	6
15167	MYTH: An algorithm to score intratumour heterogeneity based on alterations of DNA methylation profiles. <i>Clinical and Translational Medicine</i> , 2021, 11, e611.	1.7	3
15168	Improved Immunotherapy Efficacy by Vascular Modulation. <i>Cancers</i> , 2021, 13, 5207.	1.7	12
15169	Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. <i>Cancer Prevention Research</i> , 2022, 15, 3-10.	0.7	7
15170	Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials. <i>Cancer Research and Treatment</i> , 2022, 54, 803-816.	1.3	5
15171	Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. <i>Journal of Immunotherapy</i> , 2021, 9, e003499.		23
15172	Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. <i>Thorax</i> , 2022, 77, 304-311.	2.7	44
15173	IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2457-2468.	1.9	2
15174	PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. <i>Journal of Immunotherapy</i> , 2021, 9, e002179.		6
15175	Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. <i>Journal of Molecular Medicine</i> , 2021, 99, 1691-1710.	1.7	40
15176	Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Cells</i> , 2021, 10, 2823.	1.8	7
15177	Identification of Cell Surface Molecules That Determine the Macrophage Activation Threshold Associated With an Early Stage of Malignant Transformation. <i>Frontiers in Immunology</i> , 2021, 12, 749597.	2.2	1
15178	Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice. <i>Science Translational Medicine</i> , 2021, 13, eaba6006.	5.8	33
15179	The miRNA Profile of Inflammatory Colorectal Tumors Identify TGF- $\beta 2$ as a Companion Target for Checkpoint Blockade Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 754507.	1.8	3
15180	A Mathematical Model of Breast Tumor Progression Based on Immune Infiltration. <i>Journal of Personalized Medicine</i> , 2021, 11, 1031.	1.1	18
15181	Solid tumor size for prediction of recurrence in large and giant non-functioning pituitary adenomas. <i>Neurosurgical Review</i> , 2022, 45, 1401-1411.	1.2	6

#	ARTICLE	IF	CITATIONS
15182	The Effect of miR-520b on Macrophage Polarization and T Cell Immunity by Targeting PTEN in Breast Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-19.	0.6	5
15183	Dissecting the Role of N6-Methyladenosine-Related Long Non-coding RNAs Signature in Prognosis and Immune Microenvironment of Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 711859.	1.8	8
15184	Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. <i>BMC Medicine</i> , 2021, 19, 239.	2.3	11
15185	Alloantigen-activated (AAA) CD4+ T cells reinvigorate host endogenous T cell immunity to eliminate pre-established tumors in mice. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 314.	3.5	1
15186	Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 360-367.	3.2	14
15187	Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 651553.	1.3	3
15188	MS4A1 as a Potential Independent Prognostic Factor of Breast Cancer Related to Lipid Metabolism and Immune Microenvironment Based on TCGA Database Analysis. <i>Medical Science Monitor</i> , 2022, 27, e934597.	0.5	5
15189	KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. <i>Nature</i> , 2021, 598, 682-687.	13.7	117
15190	REHE: Fast variance components estimation for linear mixed models. <i>Genetic Epidemiology</i> , 2021, 45, 891-905.	0.6	1
15191	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. <i>Nature Communications</i> , 2021, 12, 6023.	5.8	21
15192	Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10327-10348.	1.6	19
15193	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. <i>Nature Communications</i> , 2021, 12, 6071.	5.8	44
15194	Exosomes loaded with programmed death ligand-1 promote tumor growth by immunosuppression in osteosarcoma. <i>Bioengineered</i> , 2021, 12, 9520-9530.	1.4	8
15195	A Research Agenda for Precision Medicine in Sepsis and Acute Respiratory Distress Syndrome: An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 891-901.	2.5	38
15196	Multiplexed imaging reveals an IFN- γ -driven inflammatory state in nivolumab-associated gastritis. <i>Cell Reports Medicine</i> , 2021, 2, 100419.	3.3	9
15197	Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 734872.	1.3	9
15198	Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 740890.	2.2	15
15199	CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma. <i>Nano Research</i> , 2022, 15, 2300-2314.	5.8	12

#	ARTICLE	IF	CITATIONS
15200	The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1233-1245.	2.0	9
15201	Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy. <i>Cancer Research</i> , 2021, 81, 5745-5755.	0.4	13
15202	Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	40
15203	Metabolic regulation of the cancer-immunity cycle. <i>Trends in Immunology</i> , 2021, 42, 975-993.	2.9	28
15204	Targeted Anti-CTLA-4 Tumor Immunotherapy Using Tumor Infiltrating Cells. <i>Advanced Science</i> , 2021, 8, e2101672.	5.6	36
15205	Assessment of programmed death-ligand 1 receptor immunohistochemical expression and its association with tumor-infiltrating lymphocytes and p53 status in triple-negative breast cancer. <i>Romanian Journal of Morphology and Embryology</i> , 2021, 62, 63-71.	0.4	1
15206	Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 739263.	1.3	8
15207	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <i>Cell</i> , 2021, 184, 5309-5337.	13.5	588
15208	Nanomedicines in B cell-targeting therapies. <i>Acta Biomaterialia</i> , 2022, 137, 1-19.	4.1	9
15209	Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes. <i>Archives of Dermatological Research</i> , 2021, , 1.	1.1	3
15210	Novel classes of immunotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 15-29.	1.1	8
15211	Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma. <i>Nature Biomedical Engineering</i> , 2021, 5, 1274-1287.	11.6	33
15212	Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2021, 9, 1465-1475.	1.6	8
15213	Progress of Phototherapy Applications in the Treatment of Bone Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11354.	1.8	30
15214	Recent advances in primary resistance mechanisms against immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2022, 34, 95-106.	1.1	9
15215	DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. <i>Clinical Epigenetics</i> , 2021, 13, 184.	1.8	2
15216	Hematologic complications of immune checkpoint inhibitors. <i>Blood</i> , 2022, 139, 3594-3604.	0.6	30
15217	Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 326.	3.5	19

#	ARTICLE	IF	CITATIONS
15218	High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. <i>Genes</i> , 2021, 12, 1629.	1.0	8
15219	Editorial: Genetic and Epigenetic Control of Immune Responses. <i>Frontiers in Immunology</i> , 2021, 12, 775101.	2.2	2
15220	The Frequency of DNA Mismatch Repair Deficiency Is Very Low in Surgically Resected Lung Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 752005.	1.3	9
15221	Biomarkers of immunotherapy response in breast cancer beyond PD-L1. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 39-49.	1.1	11
15222	Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective. <i>Nanomaterials</i> , 2021, 11, 2792.	1.9	8
15223	Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study. <i>BMJ Open</i> , 2021, 11, e053397.	0.8	1
15224	Neoadjuvant <i>In Situ</i> Immunomodulation Enhances Systemic Antitumor Immunity against Highly Metastatic Tumors. <i>Cancer Research</i> , 2021, 81, 6183-6195.	0.4	9
15225	Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2021, 12, 754436.	2.2	21
15226	Engineered Cell Membrane-Derived Nanoparticles in Immune Modulation. <i>Advanced Science</i> , 2021, 8, e2102330.	5.6	31
15227	The gold complex auranofin: new perspectives for cancer therapy. <i>Discover Oncology</i> , 2021, 12, 42.	0.8	48
15228	Gene editing to enhance the efficacy of cancer cell therapies. <i>Molecular Therapy</i> , 2021, 29, 3153-3162.	3.7	5
15229	Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2021, 10, 8272-8287.	1.3	5
15230	Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 781872.	2.2	3
15231	Immunotherapy in Cancer Management: A Literature Review of Clinical Efficacy of Pembrolizumab in the Non-small Cell Lung Cancer Treatment. <i>Advanced Pharmaceutical Bulletin</i> , 2021, , .	0.6	3
15232	Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. <i>Cell Reports Medicine</i> , 2021, 2, 100411.	3.3	18
15233	Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 747914.	2.2	17
15234	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 765608.	1.3	10
15235	VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment. <i>JCI Insight</i> , 2021, 6, .	2.3	22

#	ARTICLE	IF	CITATIONS
15236	Haploinsufficient tumor suppressor PRP4K is negatively regulated during epithelial-to-mesenchymal transition. <i>FASEB Journal</i> , 2021, 35, e22001.	0.2	3
15237	CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 20059.	1.6	53
15238	Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. <i>Nature Communications</i> , 2021, 12, 5906.	5.8	36
15239	Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment. <i>JGH Open</i> , 2021, 5, 1266-1274.	0.7	9
15240	Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 532-540.	1.0	14
15241	Nanotechnology-enhanced immunotherapy for metastatic cancer. <i>Innovation(China)</i> , 2021, 2, 100174.	5.2	29
15242	Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 355.	7.1	45
15243	PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	1
15244	Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1530-1540.	5.1	130
15245	Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells. <i>Journal of Immunology</i> , 2021, 207, 2598-2607.	0.4	10
15246	miR-424/503 modulates Wnt/ β -catenin signaling in the mammary epithelium by targeting LRP6. <i>EMBO Reports</i> , 2021, 22, e53201.	2.0	2
15247	Uncovering the Immunoregulatory Function and Therapeutic Potential of the PD-1/PD-L1 Axis in Cancer. <i>Cancer Research</i> , 2021, 81, 5141-5143.	0.4	8
15248	Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. <i>Nature Communications</i> , 2021, 12, 5955.	5.8	25
15249	Fluid flow exposure promotes epithelial-to-mesenchymal transition and adhesion of breast cancer cells to endothelial cells. <i>Breast Cancer Research</i> , 2021, 23, 97.	2.2	8
15250	Is there a role for neoadjuvant anti-PD-1 therapies in glioma?. <i>Current Opinion in Neurology</i> , 2021, Publish Ahead of Print, 834-839.	1.8	0
15251	Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents. <i>Cancer Immunology Research</i> , 2021, 9, 1451-1464.	1.6	15
15252	PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. <i>Molecular Therapy</i> , 2022, 30, 579-592.	3.7	29
15253	Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition. <i>Nature Communications</i> , 2021, 12, 6201.	5.8	57

#	ARTICLE	IF	CITATIONS
15254	Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-CD30 programmed cell death-1 therapies for melanoma: A cross-sectional study. <i>JAAD International</i> , 2021, 5, 112-120.	1.1	10
15255	Drug-eluting immune checkpoint blockade antibody-nanoparticle conjugate enhances locoregional and systemic combination cancer immunotherapy through T lymphocyte targeting. <i>Biomaterials</i> , 2021, 279, 121184.	5.7	10
15256	CallSim: Evaluation of Base Calls Using Sequencing Simulation. , 2012, 2012, 1-10.		0
15257	An update on current management of advanced renal cell cancer, biomarkers, and future directions. <i>Journal of Cancer Therapeutics & Research</i> , 2014, 3, 8.	1.2	4
15258	A New Approach for Identification of Cancer-related Pathways using Protein Networks and Genomic Data. <i>Cancer Informatics</i> , 2015, 14s5, CIN.S30800.	0.9	1
15259	Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies. <i>AIMS Public Health</i> , 2015, 2, 86-114.	1.1	1
15260	Molecular subtypes and prognosis in RCC. <i>Aging</i> , 2015, 7, 219-220.	1.4	0
15261	Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. <i>Oncotarget</i> , 2015, 6, 34573-34591.	0.8	3
15262	Fast-track drug approval in inflammatory bowel diseases. <i>Annals of Gastroenterology</i> , 2016, 29, 439-444.	0.4	4
15263	LongoVital- An Imminent Therapeutic Modality: An Unseen Drug Review with Advanced Features and Hypothesis. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016, 10, ZE04-7.	0.8	1
15264	Perianal melanoma with a BRAF gene mutation in a young Portuguese Roma native. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015212772.	0.2	3
15265	Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes. <i>Oncotarget</i> , 2016, 7, 21686-21698.	0.8	2
15266	Nivolumab in Metastatic Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, .	0.2	0
15267	Author reply: The neutrophil-to-lymphocyte ratio in clinical practice. <i>Canadian Urological Association Journal</i> , 2016, 10, 141.	0.3	1
15268	TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2016, 4, 185-185.	0.7	0
15269	Moving molecular subtypes to the clinic in gastric cancer. <i>Translational Cancer Research</i> , 2016, 5, S25-S30.	0.4	1
15270	2015 Review of Newly Approved Oncologic Therapies. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 268-270.	0.2	0
15271	Evolving Paradigms in Melanoma Therapy. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 291-294.	0.2	1

#	ARTICLE	IF	CITATIONS
15272	LIGHTing tumor up for checkpoint blockade. <i>Oncotarget</i> , 2016, 7, 48857-48858.	0.8	0
15273	Advances in lung cancer with a focus on ATS 2016 updates. <i>Journal of Thoracic Disease</i> , 2016, 8, S566-S568.	0.6	0
15275	Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 514-524.	0.2	1
15276	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, .	0.2	3
15277	Actionable intelligence provided by pancreatic cancer genomic landscape: are targets for curative therapy on the map?. <i>Translational Cancer Research</i> , 2016, 5, S243-S247.	0.4	1
15278	Programmed cell death 1 correlates with the occurrence and development of MG63 osteosarcoma. <i>Oncology Letters</i> , 2016, 12, 5199-5204.	0.8	2
15279	Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors. <i>Methods in Molecular Biology</i> , 2017, 1554, 253-262.	0.4	2
15280	Saudi lung cancer management guidelines 2017: Improving lung cancer care in Saudi region. <i>Annals of Thoracic Medicine</i> , 2017, 12, 219.	0.7	0
15281	What Can We Save for the First-Line Treatment of NSCLC in 2016?. <i>World Journal of Oncology</i> , 2017, 8, 31-33.	0.6	4
15282	Correct information to patients undergoing breast-conserving surgery: the medicolegal significance. <i>Giornale Di Chirurgia</i> , 2017, 38, 61.	0.5	0
15283	Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. <i>Translational Cancer Research</i> , 2017, 6, S151-S157.	0.4	2
15284	A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy. <i>SOJ Immunology</i> , 2017, 5, 1-5.	0.2	0
15285	Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 138-145.	0.2	3
15286	Management of Patients With Skin Cancers: Basal Cell Carcinoma and Melanoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 244-248.	0.2	0
15287	Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG. <i>Oncotarget</i> , 2017, 8, 44447-44464.	0.8	1
15288	Acute Inflammatory Demyelinating Polyneuroradiculopathy with Ipilimumab in Metastatic Melanoma: A Case Report and Review of Literature. <i>Cureus</i> , 2017, 9, e1310.	0.2	3
15289	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. <i>Oncotarget</i> , 2017, 8, 87163-87173.	0.8	0
15290	Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival. <i>Turkish Journal of Urology</i> , 2017, 43, 273-278.	1.3	3

#	ARTICLE	IF	CITATIONS
15291	Co-inhibitory receptor programmed cell death protein 1 targets co-stimulatory CD28. <i>Translational Cancer Research</i> , 2017, 6, S1080-S1083.	0.4	2
15292	Metastatic HER2+ Breast Cancer: A Potentially Curable Disease?. <i>Cureus</i> , 2017, 9, e1654.	0.2	2
15293	Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options. <i>American Journal of Case Reports</i> , 2017, 18, 1099-1109.	0.3	2
15294	Single subject transcriptome analysis to identify functionally signed gene set or pathway activity. , 2018, , .		0
15295	Multifactorial regulators of tumor programmed death-ligand 1 (PD-L1) response. <i>Translational Cancer Research</i> , 2017, 6, S1451-S1454.	0.4	1
15296	Cytokine Syntheses by T-Cell Subsets From Chronic Myeloid Leukemia Patients: Relationship Between Pre-Treatment Levels and Response to Imatinib Therapy. <i>Journal of Hematology (Brossard, Quebec)</i> , 2018, 7, 96-106.	0.4	2
15297	Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma. <i>Oncology & Hematology Review</i> , 2018, 14, 82.	0.2	1
15298	A novel isolation method for cancer prognostic factors via the p53 pathway by a combination of in vitro and in silico analyses. <i>Oncoscience</i> , 2018, 5, 88-98.	0.9	0
15299	Implications of the HDAC6-ERK1 feed forward loop in immunotherapy. <i>Journal of Immunological Sciences</i> , 2018, 2, 59-68.	0.5	2
15300	Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of <i>PIK3CA</i> mutations. <i>Oncotarget</i> , 2018, 9, 27380-27396.	0.8	6
15301	GIFT: Guided and Interpretable Factorization for Tensors with an application to large-scale multi-platform cancer analysis. <i>Bioinformatics</i> , 2018, 34, 4151-4158.	1.8	8
15302	Ipilimumab: A tale of twists and turns. <i>South Asian Journal of Cancer</i> , 2018, 07, 193-194.	0.2	3
15303	Are lung adenocarcinoma mutations shaping the immune microenvironment?. <i>Translational Cancer Research</i> , 2018, 7, S740-S742.	0.4	2
15304	Gut Microbiome and the Response to Immunotherapy in Cancer. <i>Discoveries</i> , 2018, 6, e84.	1.5	4
15305	Systemic Treatments for Lung Cancer Patients Receiving Hemodialysis. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, .	0.2	1
15306	Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer. <i>Oncotarget</i> , 2018, 9, 36547-36548.	0.8	0
15307	A repository of microbial marker genes related to human health and diseases for host phenotype prediction using microbiome data. , 2018, , .		2
15308	Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma. <i>Cureus</i> , 2018, 10, e3748.	0.2	0

#	ARTICLE	IF	CITATIONS
15309	Spotlight on tumor mutational burden in patients with non-small cell lung carcinoma. <i>Translational Lung Cancer Research</i> , 2018, 7, 614-615.	1.3	1
15310	Immunotherapy with subcutaneous injection of immunomodulatory agent (OK-432) elicits durable response in locally advanced or relapsed cervical cancer. <i>Gynecology and Minimally Invasive Therapy</i> , 2019, 8, 80.	0.2	2
15311	Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab. <i>JMA Journal</i> , 2019, 3, 58-66.	0.6	13
15312	Targeting the "undruggable" RAS - new strategies - new hope?. , 2019, 2, 813-826.		2
15313	Insights into breast cancer phenotyping through molecular omics approaches and therapy response. , 2019, 2, 527-538.		2
15314	Mechanism of resistance to immune checkpoint inhibitors. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 178-188.	0.9	3
15315	Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 86-93.	0.4	3
15316	Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S42-S42.	0.7	3
15317	A Case Report of the Clinico-radiologic Challenges of Assessing Treatment Response after Stereotactic Radiation of Oligometastases Preceded by Immunotherapy: Pseudoprogression, Mixed Response Patterns, and Opportunities for Precision Radiation. <i>Cureus</i> , 2019, 11, e4264.	0.2	2
15318	Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 37-46.	0.2	5
15319	Extracranial Abscopal Responses after Radiation Therapy for Intracranial Metastases: A Review of the Clinical Literature and Commentary on Mechanism. <i>Cureus</i> , 2019, 11, e4207.	0.2	7
15320	Signal removal methods for highly multiplexed immunofluorescent staining using antibody conjugated oligonucleotides. , 2019, 10881, .		1
15321	An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S53-S53.	0.7	5
15322	Immunotherapy-induced interstitial lung disease: Cases report. <i>South Asian Journal of Cancer</i> , 2019, 08, 079-101.	0.2	1
15323	Efficacy of Pembrolizumab and Nivolumab in Crossing the Blood Brain Barrier. <i>Cureus</i> , 2019, 11, e4446.	0.2	9
15324	MetaMSD: meta analysis for mass spectrometry data. <i>PeerJ</i> , 2019, 7, e6699.	0.9	2
15325	Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab. <i>Cureus</i> , 2019, 11, e4862.	0.2	3
15326	Clinical Behavior of Triple Negative Breast Cancer in a Cohort of Latin American Women  . <i>Cureus</i> , 2019, 11, e4963.	0.2	6

#	ARTICLE	IF	CITATIONS
15327	Programmed death ligand 1 (PD-L1) expression in parathyroid tumors. <i>Endocrine Connections</i> , 2019, 8, 887-897.	0.8	7
15328	Chronic nicotine exposure affects programmed death-ligand 1 expression and sensitivity to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. <i>Translational Cancer Research</i> , 2019, 8, S378-S388.	0.4	3
15329	Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 $\geq 50\%$, but unanswered questions remain. <i>Annals of Translational Medicine</i> , 2019, 7, S127-S127.	0.7	7
15330	Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis. <i>Oncotarget</i> , 2019, 10, 5007-5010.	0.8	2
15331	Changes in immune markers in tumor-free lymph node and peripheral blood of malignant head and neck cancer patients. <i>Translational Cancer Research</i> , 2019, 8, 1523-1530.	0.4	0
15332	Combined Immunotherapy in Metastatic Melanoma with Unknown Primary. <i>Cureus</i> , 2019, 11, e5324.	0.2	1
15333	Patterns of Radiotherapy Utilization for Lung Cancer Patients with Brain Metastases: A Population-based Analysis. <i>Cureus</i> , 2019, 11, e5591.	0.2	1
15334	Toward precision medicine in inflammatory breast cancer. <i>Translational Cancer Research</i> , 2019, 8, S469-S478.	0.4	4
15335	Clinicopathological correlation of immune response in human cancers. <i>Oncotarget</i> , 2019, 10, 5859-5870.	0.8	0
15336	Droplet digital polymerase chain reaction offers an improvisation over conventional immunohistochemistry and fluorescent in situ hybridization for ascertaining Her2 status of breast cancer. <i>South Asian Journal of Cancer</i> , 2019, 08, 203-210.	0.2	0
15337	Impact of antiretroviral drugs on PD-L1 expression and copy number gains with clinical outcomes in HIV-positive and -negative locally advanced cervical cancers. <i>Oncology Letters</i> , 2019, 18, 5747-5758.	0.8	5
15338	Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety. <i>AIMS Genetics</i> , 2019, 06, 064-066.	1.9	0
15339	Investigating the duality of Inpp4b function in the cellular transformation of mouse fibroblasts. <i>Oncotarget</i> , 2019, 10, 6378-6390.	0.8	3
15340	T1N1M0 triple-negative breast cancer patients from the SEER database showed potential benefit from post-mastectomy radiotherapy. <i>Oncology Letters</i> , 2020, 19, 735-744.	0.8	5
15341	RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer. <i>Oncology Letters</i> , 2020, 19, 52-60.	0.8	5
15342	Downregulation of LINC01140 is associated with adverse features of breast cancer. <i>Oncology Letters</i> , 2020, 19, 1157-1164.	0.8	13
15343	The role of immune checkpoint inhibitors (ICI) in the treatment of metastatic non-small cell lung carcinoma in the elderly. <i>Annals of Translational Medicine</i> , 2019, 7, S383-S383.	0.7	2
15344	Clinical Impact of Next-generation Sequencing in Pediatric Neuro-Oncology Patients: A Single-institutional Experience. <i>Cureus</i> , 2019, 11, e6281.	0.2	3

#	ARTICLE	IF	CITATIONS
15345	Manipulation of the immune system by non-small cell lung cancer and possible therapeutic interference. , 2020, 3, 710-725.		2
15346	Analysis of Circulating Tumor DNA to Predict Neoadjuvant Therapy Effectiveness and Breast Cancer Recurrence. <i>Journal of Breast Cancer</i> , 2020, 23, 373.	0.8	1
15347	Combination of pembrolizumab and 125I attenuates the aggressiveness of non-small cell lung cancer. <i>Oncology Letters</i> , 2020, 19, 4142-4150.	0.8	1
15348	Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer. <i>World Journal of Clinical Oncology</i> , 2020, 11, 169-179.	0.9	1
15349	Metallothionein 1M (MT1M) inhibits lung adenocarcinoma cell viability, migration, and expression of cell mobility-related proteins through MDM2/p53/MT1M signaling. <i>Translational Cancer Research</i> , 2020, 9, 2710-2720.	0.4	6
15350	Increased frequency of ESR1 mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor. <i>Oncology Letters</i> , 2020, 20, 1231-1238.	0.8	1
15351	Computational disease progression modeling can provide insights into cancer evolution. <i>Oncoscience</i> , 2020, 7, 21-22.	0.9	1
15352	Lymph nodes may be a source for immunotherapy in gastric cancer. <i>Oncotarget</i> , 2020, 11, 1729-1736.	0.8	1
15353	<p>>Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes</p></p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3145-3153.	0.9	2
15354	Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gall Bladder With a Mass. <i>Cureus</i> , 2020, 12, e8786.	0.2	0
15355	Molecular analysis of circulating tumor DNA from breast cancer patients before and after surgery and following adjuvant chemotherapy. <i>Molecular and Clinical Oncology</i> , 2020, 13, 26.	0.4	1
15356	Cellular heterogeneity map of diverse immune and stromal phenotypes within breast tumor microenvironment. <i>PeerJ</i> , 2020, 8, e9478.	0.9	5
15357	Prognostic values of EDNRB in triple-negative breast cancer. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	6
15358	Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 121-127.	0.6	1
15359	Prognostic Factors and Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer. <i>The Journal of Breast Health</i> , 2020, 16, 276-281.	0.4	5
15360	Novel temporal and spatial patterns of metastatic colonization from breast cancer rapid-autopsy tumor biopsies. <i>Genome Medicine</i> , 2021, 13, 170.	3.6	5
15361	Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2021, 23, 99.	2.2	23
15362	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5471.	1.7	18

#	ARTICLE	IF	CITATIONS
15363	Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity. , 2021, 9, e003036.		12
15364	Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?. Journal of Clinical Medicine, 2021, 10, 5124.	1.0	10
15365	Analysis of Sociodemographic, Clinical, and Genomic Factors Associated With Breast Cancer Mortality in the Linked Surveillance, Epidemiology, and End Results and Medicare Database. JAMA Network Open, 2021, 4, e2131020.	2.8	4
15366	4-(N)-Docosahexaenoyl 2â€™™, 2â€™™-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent. Cancer Chemotherapy and Pharmacology, 2022, 89, 59-69.	1.1	3
15367	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11.	7.7	126
15368	Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation. Scientific Reports, 2021, 11, 21072.	1.6	9
15369	<scp>NKG2A</scp> is a late immune checkpoint on <scp>CD8</scp> T cells and marks repeated stimulation and cell division. International Journal of Cancer, 2022, 150, 688-704.	2.3	22
15370	Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 731148.	1.3	5
15371	Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer. Breast Cancer Research and Treatment, 2022, 191, 229-241.	1.1	12
15372	Fluid Flow Stimulation Modulates Expression of S100 Genes in Normal Breast Epithelium and Breast Cancer. Cellular and Molecular Bioengineering, 2022, 15, 115-127.	1.0	1
15373	Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermuted cancers. Science Translational Medicine, 2021, 13, eabe6201.	5.8	19
15374	The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10â€™™IL-10R Pathways in Acute Myeloid Leukemia. Pharmaceuticals, 2021, 14, 1105.	1.7	6
15375	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers, 2021, 13, 5415.	1.7	13
15376	Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy. Nature Communications, 2021, 12, 6218.	5.8	58
15377	Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2â€™™ Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies. Cancers, 2021, 13, 5397.	1.7	7
15378	The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens. Immuno-Oncology Technology, 2021, 11, 100043.	0.2	9
15379	Clinical determinants of long-term survival in metastatic uveal melanoma. Cancer Immunology, Immunotherapy, 2022, 71, 1467-1477.	2.0	10
15380	Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model. European Radiology, 2022, 32, 2437-2447.	2.3	9

#	ARTICLE	IF	CITATIONS
15381	Heterogeneity of Circulating Tumor Cellâ€“Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response. <i>Cancer Research</i> , 2021, 81, 6196-6206.	0.4	5
15382	Longâ€“term outcomes in patients with advanced and/or metastatic nonâ€“small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, realâ€“world data (KCSG LU20â€“11). <i>Cancer</i> , 2022, 128, 778-787.	2.0	23
15383	Canonical and Non-Canonical Roles of PFKFB3 in Brain Tumors. <i>Cells</i> , 2021, 10, 2913.	1.8	8
15384	Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1718-1724.	0.4	16
15385	Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy. <i>Disease Markers</i> , 2021, 2021, 1-10.	0.6	2
15386	Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma. <i>Cancers</i> , 2021, 13, 5367.	1.7	10
15387	A mixture model for signature discovery from sparse mutation data. <i>Genome Medicine</i> , 2021, 13, 173.	3.6	8
15388	Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 8241-8255.	0.9	11
15389	Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. <i>Frontiers in Immunology</i> , 2021, 12, 782775.	2.2	23
15390	Prognostic value of preoperative soluble interleukin 2 receptor $\hat{\pm}$ as a novel immune biomarker in epithelial ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1519-1530.	2.0	1
15391	TCF-1+ PD-1+ CD8+T cells are associated with the response to PD-1 blockade in non-small cell lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2653-2660.	1.2	4
15392	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	9.4	110
15393	Synergy between <i>Toxoplasma gondii</i> type I $\hat{\pm}$ GRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors. , 2021, 9, e002970.		19
15394	Prognostic Implications of Intratumoral and Peritumoral Infiltrating Lymphocytes in Pancreatic Ductal Adenocarcinoma. <i>Current Oncology</i> , 2021, 28, 4367-4376.	0.9	5
15395	Immune-related Adverse Effects Associated with Programmed Death-1 Inhibitor Therapy in the Treatment of Non-Small Cell Lung Cancer: Incidence, Management, and Effect on Outcomes. , 2021, 25, 1-1.		4
15396	Yonsei Criteria, a Potential Linkage to Intratumoral Foxp3+/CD8+ Ratio for the Prediction of Oncologic Outcomes in Resected Left-Sided Pancreatic Cancer. <i>Yonsei Medical Journal</i> , 2020, 61, 291.	0.9	2
15397	Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer. <i>World Journal of Oncology</i> , 2020, 11, 216-222.	0.6	7
15398	<p>Screening and Identifying Cisplatin-Related Gene Mutations in Lung Squamous Cell Carcinoma</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 757-766.	0.4	1

#	ARTICLE	IF	CITATIONS
15399	Prognostic value of programmed cell death ligand-1 expression in breast cancer. <i>Medicine (United States)</i> , 2020, 99, e23537.	0.4	5
15400	Platinum versus immunotherapy for unresectable esophageal cancer. <i>Medicine (United States)</i> , 2020, 99, e23537.	0.4	0
15401	Gene modification strategies using AAV-mediated exon skipping and CRISPR/Cas9 as potential therapies for Duchenne muscular dystrophy patients. <i>Engineering Biology</i> , 2020, 4, 37-42.	0.8	0
15402	Is hyperprogressive disease a specific phenomenon of immunotherapy?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, .	0.5	1
15403	Response evaluation after immunotherapy in NSCLC. <i>Medicine (United States)</i> , 2020, 99, e23815.	0.4	8
15404	Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	8
15405	Mutational Characterization and Potential Prognostic Biomarkers of Chinese Patients with Esophageal Squamous Cell Carcinoma. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12797-12809.	1.0	20
15406	The expression of programmed death-ligand 1 in patients with invasive breast cancer. <i>Gland Surgery</i> , 2020, 9, 2106-2115.	0.5	2
15407	Fighting microbial pathogens by integrating host ecosystem interactions and evolution. <i>BioEssays</i> , 2021, 43, 2000272.	1.2	5
15408	Tumor immune microenvironment lncRNAs. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	77
15409	The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma. <i>Internal Medicine</i> , 2022, 61, 1485-1490.	0.3	3
15410	Cancer Treatment Response to Checkpoint Inhibitors Is Associated with Cytomegalovirus Infection. <i>Cureus</i> , 2020, 12, e6670.	0.2	3
15411	The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study. <i>European Clinical Respiratory Journal</i> , 2021, 8, 1984375.	0.7	0
15412	Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. <i>Oncotarget</i> , 2019, 10, 6297-6307.	0.8	1
15413	Conversion therapy from N3 unresectable lung adenocarcinoma to radical surgery: a case report. <i>Annals of Translational Medicine</i> , 2019, 7, 590-590.	0.7	3
15414	Understanding the etiopathogenesis and diagnosis of malignancy in the framework of Ayurveda: A review based on experience of working in an institute of oncology. <i>AYU: an International Quarterly Journal of Research in Ayurveda</i> , 2020, 41, 58.	0.3	1
15415	A comparative analysis of body mass index with estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in pre- and postmenopausal breast cancer patients. <i>Journal of Mid-Life Health</i> , 2020, 11, 210.	0.4	2
15416	Correlation between MR Image-Based Radiomics Features and Risk Scores Associated with Gene Expression Profiles in Breast Cancer. <i>Journal of the Korean Society of Radiology</i> , 2020, 81, 632.	0.1	0

#	ARTICLE	IF	CITATIONS
15417	PD-L1 expression in malignant melanomas of the skin and gastrointestinal tract. <i>Oncology Letters</i> , 2020, 19, 2481-2488.	0.8	4
15418	Histo- and clinico-pathological analysis of a large series of triple-negative breast cancer in a single center in China: Evidences on necessity of histological subtyping and grading. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 580-595.	0.7	5
15419	Tumor Microenvironment in Penile Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 291-307.	0.8	0
15420	Current Status and Future Perspectives of Immunotherapy in Middle-Income Countries: A Single-Center Early Experience. <i>World Journal of Oncology</i> , 2020, 11, 150-157.	0.6	3
15421	APOBEC3B expression and its prognostic potential in breast cancer. <i>Oncology Letters</i> , 2020, 19, 3205-3214.	0.8	7
15422	Application of a Biphasic Mathematical Model of Cancer Cell Drug Response for Formulating Potent and Synergistic Targeted Drug Combinations to Triple Negative Breast Cancer Cells. <i>Cancers</i> , 2020, 12, 1087.	1.7	5
15423	Ultrasonography Combined With Contrast-enhanced Ultrasonography Can Predict Lymphocyte-predominant Breast Cancer. <i>Cancer Diagnosis & Prognosis</i> , 2021, 1, 309-316.	0.3	2
15424	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	15
15425	Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2103-2119.	5.7	24
15426	Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting. <i>Prostate</i> , 2021, .	1.2	2
15427	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 5501.	1.7	10
15428	Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 21992.	1.6	5
15429	Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1549-1567.	2.0	20
15430	PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors. <i>Clinical and Translational Oncology</i> , 2022, 24, 586-596.	1.2	1
15431	Nonnegative matrix factorization-based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner sub-consensuses of lung adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 9058-9077.	1.3	7
15432	Galectins in Glioma: Current Roles in Cancer Progression and Future Directions for Improving Treatment. <i>Cancers</i> , 2021, 13, 5533.	1.7	3
15433	TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 124-131.	1.1	2
15434	Large-scale genomic sequencing reveals adaptive opportunity of targeting mutated PI3K in early and advanced HER2-positive breast cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e589.	1.7	6

#	ARTICLE	IF	CITATIONS
15435	Myeloid antigen-presenting cell niches sustain antitumor T ^A cells and license PD-1 blockade via CD28 costimulation. <i>Cancer Cell</i> , 2021, 39, 1623-1642.e20.	7.7	64
15436	ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target. <i>Frontiers in Oncology</i> , 2021, 11, 759577.	1.3	14
15437	Immunotherapy in the First-Line Setting in Wild-Type NSCLC. <i>Current Oncology</i> , 2021, 28, 4457-4470.	0.9	10
15438	Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 761110.	1.3	5
15439	The Role of Immune Checkpoint Inhibitors in Leptomeningeal Disease: A Systematic Review. <i>Anticancer Research</i> , 2021, 41, 5333-5342.	0.5	10
15440	Advances in Pancreatic Ductal Adenocarcinoma Treatment. <i>Cancers</i> , 2021, 13, 5510.	1.7	28
15441	Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. <i>Genome Medicine</i> , 2021, 13, 175.	3.6	12
15442	Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 636716.	1.3	5
15443	Cancer cell-derived exosomal circUSP7 induces CD8 ⁺ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC. <i>Molecular Cancer</i> , 2021, 20, 144.	7.9	92
15444	Interleukin 2-Based Fusion Proteins for the Treatment of Cancer. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	0.9	12
15445	Bioinformatic Analysis of Immune Significance of RYR2 Mutation in Breast Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-12.	0.9	12
15446	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 53-81.	1.3	6
15447	Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. <i>Frontiers in Endocrinology</i> , 2021, 12, 764138.	1.5	22
15448	Secreted indicators of androgen receptor activity in breast cancer pre-clinical models. <i>Breast Cancer Research</i> , 2021, 23, 102.	2.2	7
15449	Comparison of programmed death ligand 1 immunostaining for pancreatic ductal adenocarcinoma between paired cytological and surgical samples. <i>CytoJournal</i> , 2021, 18, 28.	0.8	1
15450	Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy. <i>BMC Cancer</i> , 2021, 21, 1187.	1.1	6
15451	Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways. <i>Pharmaceuticals</i> , 2021, 14, 1122.	1.7	5
15452	CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients. <i>International Journal of General Medicine</i> , 2021, Volume 14, 7647-7657.	0.8	16

#	ARTICLE	IF	CITATIONS
15453	Tumor immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. <i>Journal of Pathology</i> , 2022, 256, 282-296.	2.1	11
15454	The role of ferroptosis-related genes for overall survival prediction in breast cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e24094.	0.9	9
15455	AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 749135.	1.3	6
15456	Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11941.	1.8	27
15457	Multiplexed immunofluorescence identifies high stromal CD68+PD-L1+ macrophages as a predictor of improved survival in triple negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 21608.	1.6	16
15458	Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients. <i>Current Oncology Reports</i> , 2021, 23, 138.	1.8	11
15459	Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 6375.	5.8	22
15460	PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NF κ B pathway. <i>Science Advances</i> , 2021, 7, eabh2148.	4.7	18
15461	Prognostic Value and Clinical Significance of LIPH in Breast Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 7613-7623.	0.8	3
15462	Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 93-103.	1.1	12
15463	CCR4 as a Therapeutic Target for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 5542.	1.7	47
15464	Discovery of a novel potentially transforming somatic mutation in <i>CSF2RB</i> gene in breast cancer. <i>Cancer Medicine</i> , 2021, 10, 8138-8150.	1.3	6
15465	In Vivo and In Vitro Models of Hepatocellular Carcinoma: Current Strategies for Translational Modeling. <i>Cancers</i> , 2021, 13, 5583.	1.7	18
15466	The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer. <i>Current Oncology</i> , 2021, 28, 4392-4407.	0.9	4
15467	SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis. <i>Cancer Research</i> , 2021, 81, 6131-6141.	0.4	31
15468	Cell Survival and Cell Death at the Intersection of Autophagy and Apoptosis: Implications for Current and Future Cancer Therapeutics. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1728-1746.	2.5	19
15469	NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 159, 113-124.	1.3	13
15470	Involvement of MM cell-derived exosomes in T lymphocytes immune responses. <i>Oncology Letters</i> , 2020, 20, 31.	0.8	9

#	ARTICLE	IF	CITATIONS
15471	Risk of colitis in immune checkpoint inhibitors and in chemotherapy/placebo for solid tumors: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 4173-4187.	0.4	2
15472	Association of histologic subtypes with genetic alteration and PD-L1 expression in pulmonary adenocarcinoma. <i>Molecular and Clinical Oncology</i> , 2020, 13, 12.	0.4	1
15473	Directionally dependent multi-view clustering using copula model. <i>PLoS ONE</i> , 2020, 15, e0238996.	1.1	0
15474	Pseudoprogression in lung cancer: a case report. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, .	0.5	0
15475	Peritumoral immune infiltrates in primary tumours are not associated with the presence of axillary lymph node metastasis in breast cancer: a retrospective cohort study. <i>PeerJ</i> , 2020, 8, e9779.	0.9	2
15476	MLLT6 maintains PD-L1 expression and mediates tumor immune resistance. <i>EMBO Reports</i> , 2020, 21, e50155.	2.0	13
15477	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. <i>Melanoma Research</i> , 2021, 31, 58-66.	0.6	6
15478	Immunotherapy Use in Patients With Lung Cancer and Comorbidities. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 525-536.	1.0	12
15479	Advances in Molecular and Immunohistochemical Detection of Prognostic and Therapeutic Markers in Breast Cancer. , 0, , .		1
15480	Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. <i>Translational Lung Cancer Research</i> , 2015, 4, 678-88.	1.3	16
15482	OUP accepted manuscript. <i>Japanese Journal of Clinical Oncology</i> , 2021, , .	0.6	1
15483	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110396.	0.8	4
15484	Disparities in Tumor Mutational Burden, Immunotherapy Use, and Outcomes Based on Genomic Ancestry in Non-Small-Cell Lung Cancer. <i>JCO Global Oncology</i> , 2021, 7, 1537-1546.	0.8	8
15485	Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6716-6725.	3.2	12
15486	High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer. , 2021, 9, e003353.		14
15487	When Should Neuroendovascular Care for Patients With Acute Stroke Be Palliative?. <i>AMA Journal of Ethics</i> , 2021, 23, E783-793.	0.4	7
15488	Endocrinopathies in Inborn Errors of Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 786241.	2.2	3
15489	The Effect of Albumin-Binding Moiety on Tumor Targeting and Biodistribution Properties of ⁶⁷ Ga-Labeled Albumin Binder-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 47-55.	0.7	1

#	ARTICLE	IF	CITATIONS
15490	Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype. <i>PLoS Genetics</i> , 2021, 17, e1009876.	1.5	14
15491	Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL. <i>Cancers</i> , 2021, 13, 6003.	1.7	6
15492	Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden. <i>Current Oncology</i> , 2021, 28, 4587-4596.	0.9	4
15493	Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 603-615.	1.0	0
15494	Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 736769.	1.3	17
15495	Prediction of Survival Outcome in Lower-Grade Glioma Using a Prognostic Signature with 33 Immune-Related Gene Pairs. <i>International Journal of General Medicine</i> , 2021, Volume 14, 8149-8160.	0.8	7
15496	Identification of the Upregulation of MRPL13 as a Novel Prognostic Marker Associated with Overall Survival Time and Immunotherapy Response in Breast Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-14.	0.7	9
15497	Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5856.	1.7	39
15498	RDAClone: Deciphering Tumor Heterozygosity through Single-Cell Genomics Data Analysis with Robust Deep Autoencoder. <i>Genes</i> , 2021, 12, 1847.	1.0	2
15499	Cancer metabolism and tumor microenvironment: fostering each other?. <i>Science China Life Sciences</i> , 2022, 65, 236-279.	2.3	68
15500	Deciphering cell lineage specification of human lung adenocarcinoma with single-cell RNA sequencing. <i>Nature Communications</i> , 2021, 12, 6500.	5.8	53
15501	The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed. <i>Frontiers in Immunology</i> , 2021, 12, 764596.	2.2	31
15502	HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers. <i>Frontiers in Immunology</i> , 2021, 12, 791535.	2.2	7
15503	Deregulation of AKT/mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma. <i>Molecular Cancer Research</i> , 2022, 20, 425-433.	1.5	3
15504	Study on Horizon Scanning by Citation Network Analysis and Text Mining: A Focus on Drug Development Related to T Cell Immune Response. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, , 1.	0.8	3
15505	The Effect of miR-138 on the Function of Follicular Helper T Cells and the Differentiation of B Cells in Osteosarcoma. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-11.	0.7	7
15506	A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 769272.	1.3	23
15507	Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 8293-8299.	0.8	4

#	ARTICLE	IF	CITATIONS
15508	The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors. <i>Cancer Research and Treatment</i> , 2022, 54, 1017-1029.	1.3	7
15509	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12330.	1.8	16
15510	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables. <i>Cells</i> , 2021, 10, 3166.	1.8	20
15511	Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. , 2021, 9, e003675.		24
15512	CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer. <i>Scientific Reports</i> , 2021, 11, 22495.	1.6	10
15513	New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2021, 12, 983-999.	0.9	2
15514	Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 771335.	1.3	15
15515	Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy. <i>Cells</i> , 2021, 10, 3313.	1.8	24
15516	Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma. <i>Archives of Dermatological Research</i> , 2021, , 1.	1.1	1
15517	Identification of an Innate Immune-Related Prognostic Signature in Early-Stage Lung Squamous Cell Carcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9007-9022.	0.8	2
15518	Pan-cancer analyses reveal that increased Hedgehog activity correlates with tumor immunosuppression and resistance to immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2021, , .	1.3	10
15519	Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5645.	1.7	6
15520	Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategies. <i>EPMA Journal</i> , 2021, 12, 629-645.	3.3	0
15521	Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity. <i>Frontiers in Oncology</i> , 2021, 11, 778989.	1.3	18
15522	Pro- and Anti- Effects of Immunoglobulin A- Producing B Cell in Tumors and Its Triggers. <i>Frontiers in Immunology</i> , 2021, 12, 765044.	2.2	10
15523	The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 5789.	1.7	2
15524	The Chicken Embryo Model: A Novel and Relevant Model for Immune-Based Studies. <i>Frontiers in Immunology</i> , 2021, 12, 791081.	2.2	37
15525	Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response. , 2021, 9, e003550.		8

#	ARTICLE	IF	CITATIONS
15526	Neoantigen-driven B cell and CD4 ⁺ follicular helper cell collaboration promotes anti-tumor CD8 T _H cell responses. <i>Cell</i> , 2021, 184, 6101-6118.e13.	13.5	192
15527	The New Old CD8 ⁺ T Cells in the Immune Paradox of Pregnancy. <i>Frontiers in Immunology</i> , 2021, 12, 765730.	2.2	13
15528	Transplantable programmed death ligand 1 expressing gastroids from gastric cancer prone Nfkb1 ^{+/+} mice. <i>Cell Death and Disease</i> , 2021, 12, 1091.	2.7	2
15529	A high OXPPOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	37
15530	Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. <i>Advanced Drug Delivery Reviews</i> , 2022, 181, 114033.	6.6	5
15531	Treatment landscape of triple-negative breast cancer – expanded options, evolving needs. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 91-113.	12.5	414
15532	Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells. <i>Cancer Communications</i> , 2021, 41, 1275-1313.	3.7	51
15533	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. <i>MedComm</i> , 2021, 2, 514-530.	3.1	12
15534	Evaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma. <i>Scientific Reports</i> , 2021, 11, 22478.	1.6	8
15535	The SETDB1 ⁺ TRIM28 Complex Suppresses Antitumor Immunity. <i>Cancer Immunology Research</i> , 2021, 9, 1413-1424.	1.6	24
15536	Directing the Future Breakthroughs in Immunotherapy: The Importance of a Holistic Approach to the Tumour Microenvironment. <i>Cancers</i> , 2021, 13, 5911.	1.7	1
15537	Effector memory cytotoxic CD3 ⁺ /CD8 ⁺ /CD45RO ⁺ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. <i>Modern Pathology</i> , 2022, 35, 601-608.	2.9	10
15538	Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. <i>Cancers</i> , 2021, 13, 5999.	1.7	6
15539	BIPSE: A biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint. <i>Statistics in Medicine</i> , 2022, 41, 1205-1224.	0.8	4
15540	Development and Verification of an Immune-Based Gene Signature for Risk Stratification and Immunotherapeutic Efficacy Assessment in Gastric Cancer. <i>Disease Markers</i> , 2021, 2021, 1-41.	0.6	1
15541	Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 759217.	2.2	18
15542	Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients. <i>BMC Cancer</i> , 2021, 21, 1225.	1.1	0
15543	The Potential Prognostic Role of Oligosaccharide-Binding Fold-Containing Protein 2A (OBFC2A) in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 751430.	1.3	3

#	ARTICLE	IF	CITATIONS
15544	Lipid Nanoparticleâ€mRNA Formulations for Therapeutic Applications. <i>Accounts of Chemical Research</i> , 2021, 54, 4283-4293.	7.6	87
15545	Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 766248.	1.3	7
15546	The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 1703-1703.	0.7	9
15547	PlntMF: Penalized Integrative Matrix Factorization method for multi-omics data. <i>Bioinformatics</i> , 2022, 38, 900-907.	1.8	5
15548	Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 26-42.	2.0	26
15549	Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 782106.	2.2	0
15550	Prognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in Resected Pancreatic Adenocarcinoma. , 2021, , .		2
15551	Drug eruptions with novel targeted therapies â€ immune checkpoint and EGFR inhibitors. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1621-1643.	0.4	6
15552	Development and validation of a supervised deep learning algorithm for automated wholeâ€slide programmed deathâ€ligand 1 tumour proportion score assessment in nonâ€small cell lung cancer. <i>Histopathology</i> , 2022, 80, 635-647.	1.6	21
15553	Sudden and severe cardiotoxicity induced with pembrolizumab, its clinical course, therapeutic intervention, and outcome. <i>International Cancer Conference Journal</i> , 2022, 11, 81-86.	0.2	2
15554	Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. <i>Cancers</i> , 2021, 13, 5847.	1.7	16
15555	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinicâ€Pathologic Correlations. <i>Cells</i> , 2021, 10, 3165.	1.8	9
15556	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models). <i>International Journal of Molecular Sciences</i> , 2021, 22, 12297.	1.8	10
15557	Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma. <i>Stem Cell Investigation</i> , 2021, 8, 22-22.	1.3	1
15558	A Novel Strategy Conjugating PD-L1 Polypeptide With Doxorubicin Alleviates Chemotherapeutic Resistance and Enhances Immune Response in Colon Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 737323.	1.3	2
15559	Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2022, 27, 59-71.	1.0	19
15560	Metabolic characterization and metabolism-score of tumor to predict the prognosis in prostate cancer. <i>Scientific Reports</i> , 2021, 11, 22486.	1.6	6
15561	The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 759497.	1.3	4

#	ARTICLE	IF	CITATIONS
15562	TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. , 2022, 9, e003134.		32
15563	Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. <i>Cancer Cell</i> , 2021, 39, 1594-1609.e12.	7.7	151
15564	Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 5773.	1.7	0
15565	Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110596.	0.4	7
15566	Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma. <i>Melanoma Research</i> , 2022, 32, 241-248.	0.6	9
15567	Progress in Nanocarriers Codelivery System to Enhance the Anticancer Effect of Photodynamic Therapy. <i>Pharmaceutics</i> , 2021, 13, 1951.	2.0	15
15568	Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines. <i>Biomaterials</i> , 2022, 280, 121297.	5.7	27
15569	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. <i>Cell Communication and Signaling</i> , 2021, 19, 117.	2.7	25
15570	Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden. <i>Respiratory Research</i> , 2021, 22, 302.	1.4	5
15571	Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1777-1787.	1.5	5
15572	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. <i>Cells</i> , 2021, 10, 3231.	1.8	18
15573	BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment. <i>Cancer Research</i> , 2022, 82, 264-277.	0.4	8
15574	Clinico-pathological relationship between androgen receptor and tumour infiltrating lymphocytes in triple negative breast cancer. <i>Ecancermedicalsecience</i> , 2021, 15, 1317.	0.6	2
15575	Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms. <i>JCI Insight</i> , 2021, 6, .	2.3	11
15576	DI-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling. <i>Cancer Management and Research</i> , 2021, Volume 13, 8513-8524.	0.9	3
15577	DNA Methylation Modification Regulator-Mediated Molecular Clusters and Tumor Metabolic Characterization in Prostate Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-19.	0.6	1
15578	Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review. <i>Frontiers in Immunology</i> , 2021, 12, 771201.	2.2	14
15579	Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 747012.	1.3	3

#	ARTICLE	IF	CITATIONS
15580	Expression and associated epigenetic mechanisms of the Ca ²⁺ -signaling genes in breast cancer subtypes and epithelial-to-mesenchymal transition. <i>Journal of Cell Communication and Signaling</i> , 2022, 16, 461-474.	1.8	3
15581	S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 758004.	2.2	18
15582	Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 790674.	2.2	14
15583	Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints. <i>Frontiers in Oncology</i> , 2021, 11, 759015.	1.3	13
15584	Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 764618.	1.3	17
15585	Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12126.	1.8	8
15586	Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation. <i>Frontiers in Oncology</i> , 2021, 11, 739090.	1.3	19
15587	Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram. <i>Frontiers in Oncology</i> , 2021, 11, 718531.	1.3	7
15588	The Leptin Axis and Its Association With the Adaptive Immune System in Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 784823.	2.2	10
15589	Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response. <i>BMC Cancer</i> , 2021, 21, 1222.	1.1	28
15590	The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2021, 21, 1220.	1.1	8
15591	Complete and durable response of pulmonary large-cell neuroendocrine carcinoma to pembrolizumab. <i>Cancer Reports</i> , 2022, 5, e1589.	0.6	5
15592	Therapeutic vaccines for breast cancer: Has the time finally come?. <i>European Journal of Cancer</i> , 2022, 160, 150-174.	1.3	49
15593	<i>Fusobacterium nucleatum</i> enhances the efficacy of PD-L1 blockade in colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 398.	7.1	84
15594	Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma. <i>International Journal of Clinical Oncology</i> , 2022, 27, 626-632.	1.0	6
15595	APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2022, 10, 70-86.	1.6	20
15596	Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. <i>Nature Communications</i> , 2021, 12, 6742.	5.8	45
15597	B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression. <i>Oncogene</i> , 2022, 41, 704-717.	2.6	15

#	ARTICLE	IF	CITATIONS
15598	Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination. <i>Frontiers in Immunology</i> , 2021, 12, 786286.	2.2	8
15599	For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. , 2021, 9, e003679.		11
15600	Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 786046.	2.2	17
15601	Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance. <i>Frontiers in Veterinary Science</i> , 2021, 8, 771737.	0.9	1
15602	The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors. <i>Nanomaterials</i> , 2021, 11, 3018.	1.9	8
15603	Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1253-1261.	1.2	11
15604	T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. <i>Pharmaceuticals</i> , 2021, 14, 1172.	1.7	13
15605	Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 773420.	1.3	10
15606	LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2-FLIP-NF- κ B signaling axis. <i>Nature Cancer</i> , 2021, 2, 1170-1184.	5.7	23
15607	MKL1 is a key biomarker correlated with immune infiltrates and chemosensitivity in breast cancer. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, , .	0.6	0
15608	Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 785400.	2.2	5
15609	The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1693-1703.	2.0	18
15610	The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance. <i>Cancers</i> , 2021, 13, 6012.	1.7	26
15611	Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24141.	0.9	12
15612	Single-Cell RNA Sequencing Reveals Multiple Pathways and the Tumor Microenvironment Could Lead to Chemotherapy Resistance in Cervical Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 753386.	1.3	9
15613	Propensity for Early Metastatic Spread in Breast Cancer: Role of Tumor Vascularization Features and Tumor Immune Infiltrate. <i>Cancers</i> , 2021, 13, 5917.	1.7	4
15614	Single-cell transcriptome identifies molecular subtype of autism spectrum disorder impacted by de novo loss-of-function variants regulating glial cells. <i>Human Genomics</i> , 2021, 15, 68.	1.4	20
15615	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. <i>JCO Precision Oncology</i> , 2021, 5, 1768-1776.	1.5	12

#	ARTICLE	IF	CITATIONS
15616	Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups. , 2021, 9, e003683.		9
15617	lncRNA prostate cancer-associated transcript 18 upregulates activating transcription factor 7 to prevent metastasis of triple-negative breast cancer via sponging miR-103a-3p. Bioengineered, 2021, 12, 12070-12086.	1.4	5
15618	Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. Frontiers in Immunology, 2021, 12, 777073.	2.2	5
15619	Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. Frontiers in Oncology, 2021, 11, 749064.	1.3	17
15620	Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nature Communications, 2021, 12, 6726.	5.8	101
15621	CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities. Life, 2021, 11, 1282.	1.1	18
15622	The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis. Molecular Cancer, 2021, 20, 145.	7.9	33
15623	PD-1 Inhibitor Maintenance Therapy Combined Iodine-125 Seed Implantation Successfully Salvage Recurrent Cervical Cancer after CCRT: A Case Report. Current Oncology, 2021, 28, 4577-4586.	0.9	2
15624	Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. Npj Breast Cancer, 2021, 7, 142.	2.3	13
15625	Adjuvant Pembrolizumab versus IFN±2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discovery, 2022, 12, 644-653.	7.7	32
15626	Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nature Biotechnology, 2022, 40, 527-538.	9.4	128
15627	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1. International Journal of Molecular Sciences, 2021, 22, 12314.	1.8	6
15628	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nature Communications, 2021, 12, 6655.	5.8	24
15629	Pre-treatment neutrophil-to-lymphocyte ratio is an independent prognostic factor in head and neck squamous cell carcinoma: Meta-analysis and trial sequential analysis. Journal of Oral Pathology and Medicine, 2022, 51, 39-51.	1.4	23
15630	Development of a Flow Cytometry Assay to Predict Immune Checkpoint Blockade-Related Complications. Frontiers in Immunology, 2021, 12, 765644.	2.2	5
15631	Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. Cell Reports, 2021, 37, 110021.	2.9	21
15632	Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy. Annals of Translational Medicine, 2021, 9, 1639-1639.	0.7	4
15633	Correlation between aryl hydrocarbon receptor and IL17 + and Foxp3 + T cell infiltration in bladder cancer. International Journal of Experimental Pathology, 2021, 102, 249-259.	0.6	5

#	ARTICLE	IF	CITATIONS
15634	Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study. <i>Annals of Translational Medicine</i> , 2021, 9, 1661-1661.	0.7	11
15635	<scp>MammaPrint</scp> and <scp>BluePrint</scp> comprehensively capture the cancer hallmarks in early-stage breast cancer patients. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 148-160.	1.5	11
15636	Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 5967.	1.7	11
15637	Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. <i>Journal of Immunology Research</i> , 2021, 2021, 1-18.	0.9	21
15638	A scoring model based on ferroptosis genes for prognosis and immunotherapy response prediction and tumor microenvironment evaluation in liver hepatocellular carcinoma. <i>Ageing</i> , 2021, 13, 24866-24881.	1.4	4
15639	Metformin inhibits human non-small cell lung cancer by regulating AMPK—CEBPB—PDL1 signaling pathway. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1733-1746.	2.0	23
15640	Effect of targeted therapy and immunotherapy on advanced non-small cell lung cancer outcomes in the real world. <i>Cancer Medicine</i> , 2022, 11, 86-93.	1.3	19
15641	<i>TP53</i> mutations are associated with primary endocrine resistance in luminal early breast cancer. <i>Cancer Medicine</i> , 2021, 10, 8581-8594.	1.3	14
15642	What is beyond LncRNAs in breast cancer: A special focus on colon cancer-associated Transcript-1 (CCAT-1). <i>Non-coding RNA Research</i> , 2021, 6, 174-186.	2.4	14
15643	The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 792340.	1.3	3
15644	The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 792691.	2.2	39
15645	Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2021, 10, 4106-4119.	1.3	4
15646	Bioinformatic Analysis of Prognostic Value, Genetic Interaction, and Immune Infiltration of Chromobox Family Proteins in Breast Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9181-9191.	0.8	4
15647	Pan-cancer analysis of the effect of biopsy site on tumor mutational burden observations. <i>Communications Medicine</i> , 2021, 1, .	1.9	1
15648	High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy. <i>Japanese Journal of Radiology</i> , 2022, 40, 534-541.	1.0	4
15649	Dual inhibition of TGF β 2 and PD-L1: a novel approach to cancer treatment. <i>Molecular Oncology</i> , 2022, 16, 2117-2134.	2.1	53
15650	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	2.3	112
15651	A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2021, , .	1.3	5

#	ARTICLE	IF	CITATIONS
15652	Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 7005.	5.8	66
15653	T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy. <i>Cancers</i> , 2021, 13, 6067.	1.7	9
15654	Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1013-1026.	3.2	19
15655	An adaptive method of defining negative mutation status for multi-sample comparison using next-generation sequencing. <i>BMC Medical Genomics</i> , 2021, 14, 32.	0.7	0
15656	Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. <i>Clinical Cancer Research</i> , 2022, 28, 697-707.	3.2	17
15657	Association of <i>PTPRT</i> mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer. <i>Cancer Medicine</i> , 2022, 11, 676-691.	1.3	18
15658	Tumor metastasis: Mechanistic insights and therapeutic interventions. <i>MedComm</i> , 2021, 2, 587-617.	3.1	42
15659	Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection. <i>Translational Research</i> , 2022, 241, 83-95.	2.2	12
15660	A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 760737.	2.2	8
15661	Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. <i>Immunity</i> , 2021, 54, 2812-2824.e4.	6.6	99
15662	Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology. <i>Cancers</i> , 2021, 13, 6052.	1.7	15
15663	Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness. <i>Medicinal Research Reviews</i> , 2022, 42, 1111-1146.	5.0	36
15664	A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer. <i>Translational Cancer Research</i> , 2021, 11, 0-0.	0.4	3
15665	The miR-345-3p/PPP2CA signaling axis promotes proliferation and invasion of breast cancer cells. <i>Carcinogenesis</i> , 2022, 43, 150-159.	1.3	7
15666	Predictive role of the monocyte-to-lymphocyte ratio in advanced hepatocellular carcinoma patients receiving anti-PD-1 therapy. <i>Translational Cancer Research</i> , 2021, 11, 0-0.	0.4	5
15667	Agonistic nanobodies and antibodies to human VISTA. <i>MAbs</i> , 2021, 13, 2003281.	2.6	5
15668	Landscape of Immunotherapy in Genitourinary Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 143-192.	0.8	2
15669	Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 81-111.	0.8	7

#	ARTICLE	IF	CITATIONS
15670	Immune System in Action. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 1-43.	0.8	0
15671	Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110521.	0.8	5
15672	An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 273-295.	0.8	1
15673	Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients. <i>Annals of Translational Medicine</i> , 2021, 10, 0-0.	0.7	1
15674	Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2021, 4, 1061-1071.	0.9	2
15675	Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110623.	0.8	11
15676	Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110565.	1.0	5
15677	Hepatobiliary and Pancreatic Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 339-355.	0.8	6
15678	Prognostic value of tumor mutation burden and the relationship between tumor mutation burden and immune infiltration in HER2+ breast cancer: a gene expression-based study. <i>Gland Surgery</i> , 2022, 11, 100-114.	0.5	4
15679	Pulmonary Toxicities of Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 357-375.	0.8	4
15680	Resistance to Immunotherapy: Mechanisms and Means for Overcoming. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 45-80.	0.8	2
15681	Immuno-Oncology for Gynecologic Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 193-232.	0.8	1
15682	Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1350, 123-143.	0.8	0
15683	Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 113-142.	0.8	5
15684	A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 426-437.	0.6	7
15685	A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot Study. <i>Journal of Pathology Informatics</i> , 2021, 12, 45.	0.8	17
15686	Engineering of a trispesific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade. <i>Oncolmunology</i> , 2021, 10, .	2.1	14
15687	A Darwinian perspective on tumor immune evasion. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188671.	3.3	6

#	ARTICLE	IF	CITATIONS
15688	Loss of function of GATA3 induces basal-like mammary tumors. <i>Theranostics</i> , 2022, 12, 720-733.	4.6	8
15689	A Pan-Cancer Analysis of Tumor-Infiltrating B Cell Repertoires. <i>Frontiers in Immunology</i> , 2021, 12, 790119.	2.2	7
15690	Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. <i>Oncologist</i> , 2022, 27, e463-e470.	1.9	7
15691	Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 800951.	2.2	11
15692	Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma. <i>Oncologist</i> , 2022, 27, e18-e28.	1.9	41
15693	Control of Tumors by Antigen-Specific CD8+ T Cells through PDL1-Targeted Delivery of Antigenic Peptide. <i>Journal of Immunology Research</i> , 2022, 2022, 1-8.	0.9	0
15694	The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer. <i>Cancer Management and Research</i> , 2022, Volume 14, 1-17.	0.9	38
15695	The cGAS/STING Pathway: A Novel Target for Cancer Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 795401.	2.2	37
15696	Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1897-1908.	2.0	12
15697	Clinical Reliability of Genomic Data Obtained from Spinal Metastatic Tumor Samples. <i>Neuro-Oncology</i> , 2022, , .	0.6	0
15698	Cancer Stem Cells and the Tumor Microenvironment in Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 803974.	1.3	20
15699	On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. <i>Molecular Cancer</i> , 2022, 21, 4.	7.9	28
15700	Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma. <i>International Journal of Biological Sciences</i> , 2022, 18, 995-1007.	2.6	16
15701	Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise. <i>Diagnostics</i> , 2022, 12, 124.	1.3	12
15702	Immune-related lncRNA pairs as novel signature to predict prognosis and immune landscape in melanoma patients. <i>Medicine (United States)</i> , 2022, 101, e28531.	0.4	2
15703	Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women. <i>Journal of Clinical Medicine</i> , 2022, 11, 283.	1.0	2
15704	Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced esophageal squamous cell cancer: A case report. <i>Thoracic Cancer</i> , 2022, , .	0.8	2
15705	Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy. <i>BMC Cancer</i> , 2022, 22, 46.	1.1	6

#	ARTICLE	IF	CITATIONS
15706	Immunotherapy toxicity: identification and management. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 1-17.	1.1	24
15707	Accounting for B-cell Behavior and Sampling Bias Predicts Anti-PD-L1 Response in Bladder Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 343-353.	1.6	9
15708	MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade. <i>Nature Communications</i> , 2022, 13, 245.	5.8	17
15709	Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model. <i>PLoS ONE</i> , 2022, 17, e0262453.	1.1	8
15710	A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 688679.	1.3	13
15711	Anticancer Applications and Pharmacological Properties of Piperidine and Piperine: A Comprehensive Review on Molecular Mechanisms and Therapeutic Perspectives. <i>Frontiers in Pharmacology</i> , 2021, 12, 772418.	1.6	37
15712	PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF- κ B/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 802795.	2.2	14
15713	Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 752-761.	0.8	189
15714	Association between immune-related adverse event timing and treatment outcomes. <i>Oncolimmunology</i> , 2022, 11, 2017162.	2.1	33
15715	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. <i>Nature Medicine</i> , 2022, 28, 125-135.	15.2	53
15716	Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy. <i>Cancers</i> , 2022, 14, 279.	1.7	12
15717	OUP accepted manuscript. <i>Briefings in Bioinformatics</i> , 2022, , .	3.2	0
15718	Enhancing the HSV-1-mediated antitumor immune response by suppressing Bach1. <i>Cellular and Molecular Immunology</i> , 2022, 19, 516-526.	4.8	4
15719	Biomarkers for predicting the efficacy of immune checkpoint inhibitors. <i>Journal of Cancer</i> , 2022, 13, 481-495.	1.2	12
15720	Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 55-63.	0.3	2
15721	Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy. <i>Molecular Cancer</i> , 2022, 21, 2.	7.9	14
15722	Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. <i>Clinical Cancer Research</i> , 2022, 28, 1107-1116.	3.2	7
15723	Immunotherapy for prostate cancer: Requirements for a successful regime transfer. <i>Investigative and Clinical Urology</i> , 2022, 63, 3.	1.0	8

#	ARTICLE	IF	CITATIONS
15724	Age influences on the molecular presentation of tumours. <i>Nature Communications</i> , 2022, 13, 208.	5.8	26
15725	Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. <i>JCI Insight</i> , 2022, 7, .	2.3	20
15726	Antitumor Peptide-Based Vaccine in the Limelight. <i>Vaccines</i> , 2022, 10, 70.	2.1	10
15727	Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group â€œ ESOI Joint Paper. <i>Frontiers in Oncology</i> , 2021, 11, 800547.	1.3	10
15728	Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 810388.	2.2	9
15729	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. <i>Nature Medicine</i> , 2022, 28, 144-153.	15.2	102
15730	Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations. <i>Journal of Medical Internet Research</i> , 2022, 24, e25792.	2.1	0
15731	Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments. , 2022, 10, e003735.		14
15732	PBX3-activated DLG1-AS1 can promote the proliferation, invasion, and migration of TNBC cells by sponging miR-16-5p. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 201-210.	2.0	1
15733	Prognostic value of immune related genes in lung adenocarcinoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	5
15734	Impact of physical activity and energy restriction on immune regulation of cancer. <i>Translational Cancer Research</i> , 2020, 9, 5700-5731.	0.4	5
15735	Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 5437-5449.	0.4	4
15736	Association between clinicopathological features and prognosis significance of PD-L1 expression in small cell lung cancer patients: a systemic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 5508-5516.	0.4	2
15737	Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	5
15738	On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1712-1719.	1.3	2
15739	FOXP3 expression in FOXP3+ tumor cells promotes hepatocellular cells metastasis. <i>Translational Cancer Research</i> , 2020, 9, 5868-5881.	0.4	4
15740	CD204â€™positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed deathâ€™1 expression. <i>Oncology Letters</i> , 2020, 21, 1-1.	0.8	5
15741	Fibroblast growth factor receptor 4 as a prognostic indicator in triple-negative breast cancer. <i>Translational Cancer Research</i> , 2020, 9, 6881-6888.	0.4	5

#	ARTICLE	IF	CITATIONS
15742	Novel emerging biomarkers to immunotherapy in kidney cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110593.	1.4	12
15743	Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110646.	1.4	14
15744	Immunotherapy for Neuro-oncology. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 233-258.	0.8	4
15745	Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 683502.	1.3	21
15746	Complete Pathologic Response to Pembrolizumab and Axitinib in a Patient With Sarcomatoid RCC and Ocrelizumab-Treated Multiple Sclerosis. <i>Urology</i> , 2022, 164, 50-54.	0.5	1
15747	Immunotherapy of cancer in the era of checkpoint inhibitor. <i>Clinical and Experimental Metastasis</i> , 2021, 39, 231.	1.7	1
15748	Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib. <i>Thoracic Cancer</i> , 2022, 13, 394-403.	0.8	7
15749	Emerging Therapeutic Agents for Colorectal Cancer. <i>Molecules</i> , 2021, 26, 7463.	1.7	14
15750	Signal pathways of melanoma and targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 424.	7.1	115
15751	Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2127-2139.	2.0	11
15752	Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. <i>Cell</i> , 2022, 185, 299-310.e18.	13.5	161
15753	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. <i>Cells</i> , 2022, 11, 320.	1.8	43
15754	Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis. <i>BMC Cancer</i> , 2022, 22, 80.	1.1	6
15755	Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups. <i>Immunologic Research</i> , 2022, 70, 256-268.	1.3	4
15756	Eosinophils and melanoma: Implications for immunotherapy. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 192-202.	1.5	5
15757	Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1119.	1.8	10
15758	Clinical research in oncology: in memory of Professor Gordon McVie. <i>Ecancermedalscience</i> , 2022, 16, 1340.	0.6	1
15759	An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer. <i>BMC Cancer</i> , 2022, 22, 62.	1.1	5

#	ARTICLE	IF	CITATIONS
15760	Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses. <i>World Journal of Surgical Oncology</i> , 2022, 20, 16.	0.8	12
15761	Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer. <i>Scientific Reports</i> , 2022, 12, 626.	1.6	14
15762	Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance. <i>Haematologica</i> , 2022, 107, 1880-1890.	1.7	6
15763	KDM6A Depletion in Breast Epithelial Cells Leads to Reduced Sensitivity to Anticancer Agents and Increased TGF β 2 Activity. <i>Molecular Cancer Research</i> , 2022, 20, 637-649.	1.5	4
15764	Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer. <i>Scientific Reports</i> , 2022, 12, 1470.	1.6	10
15765	ALME: Autoencoder-based integrative multi-omics data embedding that allows for confounder adjustments. <i>PLoS Computational Biology</i> , 2022, 18, e1009826.	1.5	11
15766	Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	33
15767	Prognostic Value of Metabolic, Volumetric and Textural Parameters of Baseline [18F]FDG PET/CT in Early Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 637.	1.7	17
15768	Human Microbiota and Immunotherapy in Breast Cancer - A Review of Recent Developments. <i>Frontiers in Oncology</i> , 2021, 11, 815772.	1.3	17
15769	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. <i>Cancers</i> , 2022, 14, 682.	1.7	6
15770	Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 131-142.	0.5	0
15771	CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1565.	1.8	7
15772	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. <i>Journal of Hematology and Oncology</i> , 2022, 15, 6.	6.9	17
15773	The Fairy Chemical Imidazole-4-carboxamide Inhibits the Expression of Axl, PD-L1, and PD-L2 and Improves Response to Cisplatin in Melanoma. <i>Cells</i> , 2022, 11, 374.	1.8	7
15774	Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	26
15775	Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <i>BRCA1/2</i> -Mutated Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1383-1390.	3.2	12
15776	Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells. <i>Frontiers in Immunology</i> , 2021, 12, 812171.	2.2	3
15777	Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	1

#	ARTICLE	IF	CITATIONS
15778	Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors. <i>Cell Reports</i> , 2022, 38, 110278.	2.9	14
15779	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes. <i>Biomedicines</i> , 2022, 10, 236.	1.4	13
15780	Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group. <i>British Journal of Cancer</i> , 2022, 126, 1589-1594.	2.9	22
15781	Applications of Antibody-Based Antigen Delivery Targeted to Dendritic Cells In Vivo. <i>Antibodies</i> , 2022, 11, 8.	1.2	8
15782	PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 453-464.	1.4	2
15783	Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors. <i>Health Economics Review</i> , 2022, 12, 8.	0.8	1
15784	Regulation of activated T cell survival in rheumatic autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 232-244.	3.5	21
15785	Vitamin D can reduce severity in COVID-19 through regulation of PD-L1. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 487-494.	1.4	9
15786	Immunotherapeutic Strategies in Cancer and Atherosclerosis – Two Sides of the Same Coin. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 812702.	1.1	2
15787	The co-mutation of EGFR and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2022, 14, 185-193.	0.6	7
15788	Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity. <i>Clinical Cancer Research</i> , 2022, 28, 2038-2049.	3.2	16
15789	Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. , 2022, 10, e003087.		31
15790	XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	16
15791	Identification of potential key molecular biomarkers in lung adenocarcinoma by bioinformatics analysis. <i>Translational Cancer Research</i> , 2022, 11, 227-241.	0.4	0
15792	Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. <i>Theranostics</i> , 2022, 12, 747-766.	4.6	28
15793	Pathophysiological Integration of Metabolic Reprogramming in Breast Cancer. <i>Cancers</i> , 2022, 14, 322.	1.7	9
15794	Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer. <i>Current Oncology</i> , 2022, 29, 283-293.	0.9	1
15795	Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity. <i>Cancers</i> , 2022, 14, 285.	1.7	12

#	ARTICLE	IF	CITATIONS
15796	In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-1/PD-L1 interaction. <i>Scientific Reports</i> , 2022, 12, 303.	1.6	6
15797	A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer. <i>Oncolimmunology</i> , 2022, 11, 2028962.	2.1	26
15798	<i>In vivo</i> genome editing screen identifies tumor suppressor genes that cooperate with <i>Trp53</i> loss during mammary tumorigenesis. <i>Molecular Oncology</i> , 2022, 16, 1119-1131.	2.1	6
15799	PET/CT Imaging of Activated Cancer-Associated Fibroblasts Predict Response to PD-1 Blockade in Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 802257.	1.3	9
15800	PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. <i>Cancers</i> , 2022, 14, 599.	1.7	8
15801	Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets. <i>BMC Cancer</i> , 2022, 22, 13.	1.1	15
15802	OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, e244-e250.	1.9	1
15803	Identification of a Novel Epithelial-Mesenchymal Transition-Related Gene Signature for Endometrial Carcinoma Prognosis. <i>Genes</i> , 2022, 13, 216.	1.0	8
15804	Bystander CD4 ⁺ T cells infiltrate human tumors and are phenotypically distinct. <i>Oncolimmunology</i> , 2022, 11, .	2.1	13
15805	Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. <i>Cancers</i> , 2022, 14, 621.	1.7	34
15806	Mapping Intellectual Structures and Research Hotspots of Triple Negative Breast Cancer: A Bibliometric Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 689553.	1.3	17
15807	High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study. <i>Frontiers in Immunology</i> , 2021, 12, 779248.	2.2	3
15808	Perspectives of future lung toxicology studies using human pluripotent stem cells. <i>Archives of Toxicology</i> , 2022, 96, 389-402.	1.9	8
15809	Harnessing big data to characterize immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 269-280.	12.5	41
15810	Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 794615.	1.3	2
15811	CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival. <i>Cancers</i> , 2022, 14, 353.	1.7	0
15812	Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 163-173.	1.1	6
15813	Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. <i>Frontiers in Immunology</i> , 2021, 12, 730666.	2.2	31

#	ARTICLE	IF	CITATIONS
15814	T Cell Memory in Infection, Cancer, and Autoimmunity. <i>Frontiers in Immunology</i> , 2021, 12, 811968.	2.2	9
15815	T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. <i>Nature Medicine</i> , 2022, 28, 353-362.	15.2	132
15816	Comprehensive analysis of a TNF family based-signature in diffuse gliomas with regard to prognosis and immune significance. <i>Cell Communication and Signaling</i> , 2022, 20, 6.	2.7	15
15817	CpG Island Methylator Phenotype—A Hope for the Future or a Road to Nowhere?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 830.	1.8	8
15818	Prevalence and Spectrum of Predisposition Genes With Germline Mutations Among Chinese Patients With Bowel Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 755629.	1.1	1
15819	Evaluation of exosomal non-coding RNAs in cancer using high-throughput sequencing. <i>Journal of Translational Medicine</i> , 2022, 20, 30.	1.8	22
15820	Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. , 2022, 10, e004008.		28
15821	Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies. <i>Oncologist</i> , 2022, 27, 30-39.	1.9	10
15822	The correlation and role analysis of SLC30A1 and SLC30A10 in cervical carcinoma. <i>Journal of Cancer</i> , 2022, 13, 1031-1047.	1.2	6
15823	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. <i>Molecular Cancer</i> , 2022, 21, 28.	7.9	393
15824	NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-L1 therapy. <i>Cancer Science</i> , 2021, , .	1.7	7
15825	Comparative analysis of protein-protein interaction networks in metastatic breast cancer. <i>PLoS ONE</i> , 2022, 17, e0260584.	1.1	12
15826	Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 793992.	2.2	14
15827	Epigenetic Therapies and Biomarkers in Breast Cancer. <i>Cancers</i> , 2022, 14, 474.	1.7	16
15828	Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors. <i>Molecular and Cellular Biology</i> , 2022, 42, MCB0044921.	1.1	8
15829	Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1923-1935.	2.0	19
15830	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	0.7	21
15831	Variegated Outcomes of T Cell Activation by Dendritic Cells in the Steady State. <i>Journal of Immunology</i> , 2022, 208, 539-547.	0.4	8

#	ARTICLE	IF	CITATIONS
15832	Endocrine and Neuroendocrine Tumors Special Issueâ€”Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?. <i>Cancers</i> , 2022, 14, 467.	1.7	18
15833	Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactions. <i>Cell Reports Methods</i> , 2022, 2, 100153.	1.4	9
15834	Anti-Programmed Death Ligand-1 Induced Acute Vision Loss in a Patient With Cancer-Associated Retinopathy. <i>Cureus</i> , 2022, 14, e21709.	0.2	2
15835	Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy. <i>JCI Insight</i> , 2022, 7, .	2.3	10
15836	Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications. <i>Frontiers in Oncology</i> , 2022, 12, 809179.	1.3	2
15837	Exploring the Interobserver Agreement in Computer-Aided Radiologic Tumor Measurement and Evaluation of Tumor Response. <i>Frontiers in Oncology</i> , 2021, 11, 691638.	1.3	0
15838	Blocking the inhibitory receptor programmed cell death 1 prevents allergic immune response and anaphylaxis in mice. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 178-191.e9.	1.5	5
15839	Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2321-2328.	3.2	7
15840	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. <i>New England Journal of Medicine</i> , 2022, 386, 24-34.	13.9	766
15841	Breast Cancer Vaccines: Disappointing or Promising?. <i>Frontiers in Immunology</i> , 2022, 13, 828386.	2.2	30
15842	Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 806963.	1.3	14
15843	Role of the Mediator Complex and MicroRNAs in Breast Cancer Etiology. <i>Genes</i> , 2022, 13, 234.	1.0	6
15844	Exosome application in tumorigenesis: diagnosis and treatment of melanoma. <i>Medical Oncology</i> , 2022, 39, 19.	1.2	7
15845	Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. <i>BMC Cancer</i> , 2022, 22, 22.	1.1	6
15846	Identification and validation of a novel signature for prediction the prognosis and immunotherapy benefit in bladder cancer. <i>PeerJ</i> , 2022, 10, e12843.	0.9	8
15847	Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. <i>Cancer Cell International</i> , 2022, 22, 2.	1.8	83
15848	Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists. <i>Frontiers in Oncology</i> , 2021, 11, 773366.	1.3	5
15849	Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer. <i>PLoS ONE</i> , 2022, 17, e0262455.	1.1	12

#	ARTICLE	IF	CITATIONS
15850	Celecoxib-Induced Modulation of Colon Cancer CD133 Expression Occurs through AKT Inhibition and Is Monitored by ⁸⁹ Zr Immuno-PET. <i>Molecular Imaging</i> , 2022, 2022, 4906934.	0.7	6
15851	OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, 245-250.	1.9	1
15852	GBE1 Is an Independent Prognostic Marker and Associated With CD163+ Tumor-Associated Macrophage Infiltration in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 781344.	1.3	4
15853	CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism. <i>Theranostics</i> , 2022, 12, 1486-1499.	4.6	8
15854	The Clinical, Pathological, and Prognostic Value of High PD-1 Expression and the Presence of Epstein-Barr Virus Reactivation in Patients with Laryngeal Cancer. <i>Cancers</i> , 2022, 14, 480.	1.7	2
15855	PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 257-267.	1.3	9
15856	A review of prognostic and predictive biomarkers in breast cancer. <i>Clinical and Experimental Medicine</i> , 2022, , 1.	1.9	33
15857	Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma. <i>Annals of Hematology</i> , 2022, 101, 799.	0.8	2
15858	Identification of long non-coding RNAs and RNA binding proteins in breast cancer subtypes. <i>Scientific Reports</i> , 2022, 12, 693.	1.6	14
15859	Retinoblastoma protein regulates carcinogen susceptibility at heterochromatic cancer driver loci. <i>Life Science Alliance</i> , 2022, 5, e202101134.	1.3	4
15860	Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 796197.	1.3	11
15861	The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 802049.	2.2	6
15862	Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 624-630.	0.8	9
15863	Efficient gradient boosting for prognostic biomarker discovery. <i>Bioinformatics</i> , 2022, 38, 1631-1638.	1.8	13
15864	Prognostic and Predictive Value of BGN in Colon Cancer Outcomes and Response to Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 761030.	1.3	6
15865	Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. , 2022, 10, e003392.		34
15866	Applications of Extracellular Vesicles in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 451.	1.7	14
15867	Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2339-2348.	3.2	20

#	ARTICLE	IF	CITATIONS
15868	A Case of Bilateral Inflammatory Breast Cancer that Developed Two Years after Treatment for Triple-negative Breast Cancer¹. <i>Internal Medicine</i> , 2022, , .	0.3	0
15869	Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. <i>Nature Biomedical Engineering</i> , 2022, 6, 232-245.	11.6	56
15870	PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2067-2075.	2.0	24
15871	The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 811434.	1.3	6
15872	Expression of Immunomodulatory Checkpoint Molecules in Drug-Resistant Neuroblastoma: An Exploratory Study. <i>Cancers</i> , 2022, 14, 751.	1.7	5
15873	A Novel Prognostic Signature for Survival Prediction and Immune Implication Based on SARS-CoV-2â€“Related Genes in Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 744659.	2.0	8
15874	Research progress on dendritic cell vaccines in cancer immunotherapy. <i>Experimental Hematology and Oncology</i> , 2022, 11, 3.	2.0	61
15875	Exosomes in cancer immunoediting and immunotherapy. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 193-205.	4.3	21
15876	T cell subtype profiling measures exhaustion and predicts anti-PD-1 response. <i>Scientific Reports</i> , 2022, 12, 1342.	1.6	7
15877	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
15878	Development and Validation of a Prognostic Index Based on Genes Participating in Autophagy in Patients With Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 799759.	1.3	8
15879	Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. , 2022, 10, e003747.		23
15880	Targeting NF-Î²B Signaling in Cancer Stem Cells: A Narrative Review. <i>Biomedicines</i> , 2022, 10, 261.	1.4	11
15881	Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy. <i>Biomedicines</i> , 2022, 10, 284.	1.4	2
15882	Peripheral Blood Transcriptome in Breast Cancer Patients as a Source of Less Invasive Immune Biomarkers for Personalized Medicine, and Implications for Triple Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 591.	1.7	7
15883	Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	8
15884	Antitumorigenic Effect of Tramadol and Synergistic Effect With Doxorubicin in Human Breast Cancer Cells. <i>Frontiers in Oncology</i> , 2022, 12, 811716.	1.3	5
15885	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. <i>Genome Medicine</i> , 2022, 14, 1.	3.6	68

#	ARTICLE	IF	CITATIONS
15886	CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoin blockade. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 998-1009.	2.3	10
15887	The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression. <i>Frontiers in Oncology</i> , 2021, 11, 706606.	1.3	9
15888	Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study. <i>Oncotarget</i> , 2022, 13, 257-270.	0.8	0
15889	Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 798474.	2.2	10
15890	GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models. <i>Nature Communications</i> , 2022, 13, 97.	5.8	15
15891	Immune-Related lncRNA Pairs as Prognostic Signature and Immune-Landscape Predictor in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 673567.	1.3	2
15892	The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer. <i>Scientific Reports</i> , 2022, 12, 293.	1.6	6
15893	Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 806324.	2.2	6
15894	Recent advances in systemic therapy for hepatocellular carcinoma. <i>Biomarker Research</i> , 2022, 10, 3.	2.8	94
15895	Pembrolizumab-induced Focal Pancreatitis Diagnosed by Endoscopic Ultrasound-guided Fine-needle Aspiration. <i>Internal Medicine</i> , 2022, 61, 2463-2469.	0.3	4
15896	Network models of prostate cancer immune microenvironments identify ROMO1 as heterogeneity and prognostic marker. <i>Scientific Reports</i> , 2022, 12, 192.	1.6	8
15897	Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 832942.	2.2	18
15898	Pioneer Role of Extracellular Vesicles as Modulators of Cancer Initiation in Progression, Drug Therapy, and Vaccine Prospects. <i>Cells</i> , 2022, 11, 490.	1.8	21
15899	Immune escape mechanism behind resistance to anti-PD-1 therapy in gastrointestinal tract metastasis in malignant melanoma patients with multiple metastases. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2293-2300.	2.0	6
15900	Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. <i>Frontiers in Immunology</i> , 2022, 13, 815575.	2.2	63
15901	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	2.2	15
15902	Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias. <i>Cells</i> , 2022, 11, 139.	1.8	6
15903	Cancer cell-expressed BTLN2 facilitates tumour immune escape via engagement with IL-17A-producing $\hat{3}1^+$ T cells. <i>Nature Communications</i> , 2022, 13, 231.	5.8	14

#	ARTICLE	IF	CITATIONS
15904	Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. <i>Blood Advances</i> , 2022, 6, 1143-1151.	2.5	21
15905	Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis. <i>Thoracic Cancer</i> , 2022, 13, 724-731.	0.8	10
15906	Tumor-Infiltrating Lymphocytes (TILs) as a Biomarker of Abscopal Effect of Cryoablation in Breast Cancer: A Pilot Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 2914-2925.	0.7	16
15907	Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2022, 28, 368-377.	3.2	40
15908	Single-Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment. <i>Clinical Cancer Research</i> , 2022, 28, 2069-2081.	3.2	9
15909	Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes. <i>Oncologist</i> , 2022, 27, e313-e327.	1.9	14
15910	The benefits of trastuzumab in the treatment of HER2+ breast cancer as a function of exposure time. <i>Ecanermedicalscience</i> , 2022, 16, 1347.	0.6	2
15911	A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24232.	0.9	3
15912	Single-Cell RNA Sequencing in Lung Cancer: Revealing Phenotype Shaping of Stromal Cells in the Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 802080.	2.2	19
15913	Therapeutic Perspectives in the Systemic Treatment of Kaposi's Sarcoma. <i>Cancers</i> , 2022, 14, 484.	1.7	5
15914	Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma. <i>Cancer Research</i> , 2022, 82, 929-942.	0.4	13
15915	Redox Metabolism-Associated Molecular Classification of Clear Cell Renal Cell Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-19.	1.9	4
15916	Pathogenesis of Triple-Negative Breast Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 181-204.	9.6	132
15917	TCR-T Immunotherapy: The Challenges and Solutions. <i>Frontiers in Oncology</i> , 2021, 11, 794183.	1.3	36
15918	Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer. <i>PLoS ONE</i> , 2022, 17, e0262650.	1.1	7
15919	Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma. <i>PeerJ</i> , 2022, 10, e12646.	0.9	1
15920	Perspectives on the role of breast cancer susceptibility gene in breast cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 495-511.	1.0	1
15921	Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance. <i>Cells</i> , 2022, 11, 410.	1.8	9

#	ARTICLE	IF	CITATIONS
15922	Immunotherapy for glioblastoma: the promise of combination strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 35.	3.5	85
15923	Immune Microenvironment Characteristics of Urachal Carcinoma and Its Implications for Prognosis and Immunotherapy. <i>Cancers</i> , 2022, 14, 615.	1.7	7
15924	Keep a Little Fire Burning—The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1289.	1.8	2
15925	Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead. <i>Frontiers in Oncology</i> , 2022, 12, 789728.	1.3	2
15926	Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers. <i>Nanoscale</i> , 2022, 14, 1144-1159.	2.8	11
15927	Endoplasmic reticulum stress promotes the release of exosomal PD-L1 from head and neck cancer cells and facilitates M2 macrophage polarization. <i>Cell Communication and Signaling</i> , 2022, 20, 12.	2.7	28
15928	SEC61G regulates breast cancer cell proliferation and metastasis by affecting the Epithelial-Mesenchymal Transition. <i>Journal of Cancer</i> , 2022, 13, 831-846.	1.2	6
15929	Identification of tumor microenvironment-based genes associated with acquired resistance to EGFR Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. <i>Journal of Cancer</i> , 2022, 13, 877-889.	1.2	1
15930	Immune-checkpoint inhibitors: long-term implications of toxicity. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 254-267.	12.5	360
15931	Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 268-278.	1.3	12
15932	Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report. <i>Cureus</i> , 2022, 14, e21770.	0.2	5
15933	Pan-Cancer Study on Protein Kinase C Family as a Potential Biomarker for the Tumors Immune Landscape and the Response to Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 798319.	1.8	7
15934	Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2022, 10, e003091.		67
15935	New Therapeutic Approaches for Conjunctival Melanoma—What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1478.	1.8	4
15936	Two cell line models to study multiorgan metastasis and immunotherapy in lung squamous cell carcinoma. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	5
15937	Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity. <i>Medicina (Lithuania)</i> , 2022, 58, 209.	0.8	6
15938	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. <i>Oncologist</i> , 2022, 27, e273-e285.	1.9	22
15939	Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. <i>Radiation Oncology</i> , 2022, 17, 7.	1.2	20

#	ARTICLE	IF	CITATIONS
15940	Hypophosphorylated pRb knockâ€in mice exhibit hallmarks of aging and vitamin Câ€preventable diabetes. <i>EMBO Journal</i> , 2022, 41, e106825.	3.5	13
15941	Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors. <i>Translational Cancer Research</i> , 2022, 11, 252-261.	0.4	6
15942	Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice. <i>Hepatology</i> , 2022, 76, 630-645.	3.6	13
15943	Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3KÎ±/Î²/Î³ treatment. <i>Nature Communications</i> , 2022, 13, 182.	5.8	40
15944	Predicting treatment outcomes using ¹⁸ F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110687.	1.4	7
15945	Emerging Roles for LGR4 in Organ Development, Energy Metabolism and Carcinogenesis. <i>Frontiers in Genetics</i> , 2021, 12, 728827.	1.1	7
15946	Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience. <i>Current Oncology</i> , 2022, 29, 221-230.	0.9	2
15947	Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab. <i>Journal of Immunotherapy</i> , 2022, 45, 167-179.	1.2	7
15948	Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 3947-3956.	0.8	4
15949	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 198-209.	1.9	18
15950	Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings. <i>Oncologist</i> , 2022, 27, 175-182.	1.9	12
15951	Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma. <i>Endocrine Connections</i> , 2022, 11, .	0.8	4
15952	The current landscape of immunotherapy for pediatric brain tumors. <i>Nature Cancer</i> , 2022, 3, 11-24.	5.7	21
15953	Local consolidative therapy for synchronous oligometastatic nonâ€small cell lung cancer treated with firstâ€line pembrolizumab: A retrospective observational study. <i>Thoracic Cancer</i> , 2022, , .	0.8	6
15954	Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors. <i>Frontiers in Immunology</i> , 2021, 12, 811726.	2.2	24
15955	<scp>PDâ€1</scp> overexpression correlates with <scp>i>JAK2</i>â€V617F</scp> mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2022, 97, 390-400.	2.0	8
15956	Metabolic Implications of Immune Checkpoint Proteins in Cancer. <i>Cells</i> , 2022, 11, 179.	1.8	15
15957	Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382110689.	0.8	12

#	ARTICLE	IF	CITATIONS
15958	The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1823-1835.	2.0	9
15959	Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy. <i>Cancer Reports</i> , 2022, 5, e1578.	0.6	8
15960	Precision Medicine in Low- and Middle-Income Countries. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 387-402.	9.6	11
15961	Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy. <i>Biomaterials</i> , 2022, 280, 121315.	5.7	46
15962	A comprehensive profiling of soluble immune checkpoints from the sera of patients with non-small cell lung cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24224.	0.9	13
15963	Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 836417.	1.6	107
15964	Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?. <i>Cancers</i> , 2022, 14, 482.	1.7	21
15965	Novel Mouse Models for Cancer Immunology. <i>Annual Review of Cancer Biology</i> , 2022, 6, 269-291.	2.3	9
15966	TGF- β -mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. <i>Immunity</i> , 2022, 55, 115-128.e9.	6.6	62
15967	The Role of miRNA in Tumor Immune Escape and miRNA-Based Therapeutic Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 807895.	2.2	20
15968	Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 791411.	1.3	2
15969	CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor. <i>Scientific Reports</i> , 2022, 12, 1100.	1.6	7
15970	Pan-cancer analysis identifies RNA helicase DDX1 as a prognostic marker. <i>Phenomics</i> , 2022, 2, 33.	0.9	5
15971	Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. <i>Frontiers in Immunology</i> , 2021, 12, 806043.	2.2	7
15972	A Case of Acquired Factor V Inhibitor Following Nivolumab Administration. <i>Cureus</i> , 2022, 14, e21670.	0.2	2
15973	Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer. <i>Journal of Ovarian Research</i> , 2022, 15, 18.	1.3	7
15974	Identification of solute carrier family genes related to the prognosis and tumor-infiltrating immune cells of pancreatic ductal adenocarcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 57-57.	0.7	3
15975	Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 803355.	2.2	33

#	ARTICLE	IF	CITATIONS
15976	Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. <i>Journal of Personalized Medicine</i> , 2022, 12, 149.	1.1	14
15977	TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma. <i>Cancers</i> , 2022, 14, 579.	1.7	4
15978	Identification and Characterization of Immunogene-Related Alternative Splicing Patterns and Tumor Microenvironment Infiltration Patterns in Breast Cancer. <i>Cancers</i> , 2022, 14, 595.	1.7	2
15979	New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond. <i>Cells</i> , 2022, 11, 357.	1.8	16
15980	Integrative Modeling of Multiomics Data for Predicting Tumor Mutation Burden in Patients with Lung Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-14.	0.9	7
15981	Vectorized Treg-depleting $\hat{\pm}$ CTLA-4 elicits antigen cross-presentation and CD8 ⁺ T cell immunity to reject "cold" tumors. , 2022, 10, e003488.		14
15982	Checkpoint blockade-induced CD8 ⁺ T cell differentiation in head and neck cancer responders. , 2022, 10, e004034.		14
15983	Bioactive compounds of pequi pulp and oil extracts modulate antioxidant activity and antiproliferative activity in cocultured blood mononuclear cells and breast cancer cells. <i>Food and Nutrition Research</i> , 2022, 66, .	1.2	2
15984	Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	11
15985	Role of Exosomes in Immune Microenvironment of Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	16
15986	GATA3 Truncation Mutants Alter EMT Related Gene Expression via Partial Motif Recognition in Luminal Breast Cancer Cells. <i>Frontiers in Genetics</i> , 2022, 13, 820532.	1.1	6
15987	Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 638.	1.7	16
15988	Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment. <i>Cancers</i> , 2022, 14, 631.	1.7	19
15989	The Hypoxia-Related Gene COL5A1 Is a Prognostic and Immunological Biomarker for Multiple Human Tumors. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-42.	1.9	10
15990	FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer. <i>Pharmaceutics</i> , 2022, 14, 242.	2.0	4
15991	Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. <i>Science Advances</i> , 2022, 8, eabj3671.	4.7	38
15992	Expression Profiles and Prognostic Value of Multiple Inhibitory Checkpoints in Head and Neck Lymphoepithelioma-Like Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 818411.	2.2	1
15993	Transcribed Ultraconserved Regions Are Associated with Clinicopathological Features in Breast Cancer. <i>Biomolecules</i> , 2022, 12, 214.	1.8	3

#	ARTICLE	IF	CITATIONS
15994	Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542110731.	0.8	3
15995	Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. <i>Journal of Clinical Oncology</i> , 2022, , JCO2102054.	0.8	14
15996	Breast cancer recurrence: factors impacting occurrence and survival. <i>Irish Journal of Medical Science</i> , 2022, 191, 2501-2510.	0.8	12
15997	Dual-Sensitive Gold-Nanocubes Platform with Synergistic Immunotherapy for Inducing Immune Cycle Using NIR-Mediated PTT/NO/IDO. <i>Pharmaceuticals</i> , 2022, 15, 138.	1.7	5
15998	Immunomagnetic microscopy of tumor tissues using quantum sensors in diamond. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	17
15999	Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures. <i>Frontiers in Immunology</i> , 2022, 13, 805184.	2.2	6
16000	Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors. <i>Frontiers in Immunology</i> , 2022, 13, 811131.	2.2	6
16001	Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience. <i>Journal of Personalized Medicine</i> , 2022, 12, 195.	1.1	1
16002	GNIFdb: a neoantigen intrinsic feature database for glioma. <i>Database: the Journal of Biological Databases and Curation</i> , 2022, 2022, .	1.4	5
16003	Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 702.	1.7	3
16004	Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review. <i>Current Oncology</i> , 2022, 29, 479-489.	0.9	6
16005	Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancer Management and Research</i> , 2022, Volume 14, 427-435.	0.9	6
16006	Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study. <i>Frontiers in Immunology</i> , 2022, 13, 809971.	2.2	6
16007	MoGCN: A Multi-Omics Integration Method Based on Graph Convolutional Network for Cancer Subtype Analysis. <i>Frontiers in Genetics</i> , 2022, 13, 806842.	1.1	29
16008	Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	33
16009	PD-L1+CD8+ TÂcells enrichment in lung cancer exerted regulatory function and tumor-promoting tolerance. <i>IScience</i> , 2022, 25, 103785.	1.9	19
16010	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2022, , 1.	1.6	2
16011	Biomarkers and risk factors for the early prediction of immune-related adverse events: a review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	11

#	ARTICLE	IF	CITATIONS
16012	<sc>Fusion-associated</sc> carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 261-273.	1.5	10
16013	Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents. <i>Journal of Nanobiotechnology</i> , 2022, 20, 64.	4.2	5
16014	Immune checkpoint blockade in HIV. <i>EBioMedicine</i> , 2022, 76, 103840.	2.7	15
16015	Engineered implantable vaccine platform for continuous antigen-specific immunomodulation. <i>Biomaterials</i> , 2022, 281, 121374.	5.7	7
16016	Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes. <i>Journal of Clinical Oncology</i> , 2022, 40, 1741-1754.	0.8	65
16017	Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition. <i>Journal of Biological Chemistry</i> , 2022, 298, 101525.	1.6	9
16018	A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer. <i>Medical Oncology</i> , 2022, 39, 49.	1.2	5
16019	Identification of neoantigens for individualized therapeutic cancer vaccines. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 261-282.	21.5	173
16020	Mechanisms of immune activation and regulation: lessons from melanoma. <i>Nature Reviews Cancer</i> , 2022, 22, 195-207.	12.8	101
16021	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). , 2022, 10, e004025.		22
16022	Outcome Prediction at Patient Level Derived from Pre-Treatment 18F-FDG PET Due to Machine Learning in Metastatic Melanoma Treated with Anti-PD1 Treatment. <i>Diagnostics</i> , 2022, 12, 388.	1.3	9
16023	Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. <i>Cancer Treatment Reviews</i> , 2022, 103, 102333.	3.4	21
16024	Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	14
16025	Fibroblast-derived LPP as a biomarker for treatment response and therapeutic target in gastric cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 547-560.	2.0	5
16026	Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100267.	1.5	28
16027	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	38
16028	Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis. <i>Biomedicines</i> , 2022, 10, 360.	1.4	17
16029	Dextran-Mimetic Quantum Dots for Multimodal Macrophage Imaging <i>In Vivo</i> , <i>Ex Vivo</i> , and <i>In Situ</i> . <i>ACS Nano</i> , 2022, 16, 1999-2012.	7.3	17

#	ARTICLE	IF	CITATIONS
16030	Transcriptional determinants of cancer immunotherapy response and resistance. <i>Trends in Cancer</i> , 2022, 8, 404-415.	3.8	9
16031	A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100265.	0.6	15
16032	HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glematumumab vedotin. <i>Oncogene</i> , 2022, 41, 1701-1717.	2.6	8
16033	Engineering CAR T cells for enhanced efficacy and safety. <i>APL Bioengineering</i> , 2022, 6, 011502.	3.3	14
16034	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
16035	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. <i>Cancer Treatment Reviews</i> , 2022, 104, 102337.	3.4	6
16036	Immune priming using DC- and T _H 1-cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 429-442.	2.0	9
16037	Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host. <i>International Immunopharmacology</i> , 2022, 105, 108531.	1.7	1
16038	Metformin bicarbonate-mediated efficient RNAi for precise targeting of TP53 deficiency in colon and rectal cancers. <i>Nano Today</i> , 2022, 43, 101406.	6.2	8
16039	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111.		25
16040	Immunotherapy resistance of lung cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 114-128.	0.9	0
16041	Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor. <i>Acta Histochemica Et Cytochemica</i> , 2022, 55, 25-35.	0.8	4
16042	Depth normalization of small RNA sequencing: using data and biology to select a suitable method. <i>Nucleic Acids Research</i> , 2022, 50, e56-e56.	6.5	4
16043	Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 147-164.	0.9	5
16044	Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death. <i>Theranostics</i> , 2022, 12, 1999-2014.	4.6	53
16045	Monitoring tumor growth rate to predict immune checkpoint inhibitors TM treatment outcome in advanced NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110583.	1.4	2
16046	Current Immunotherapeutic Approaches for Malignant Gliomas. <i>Brain Tumor Research and Treatment</i> , 2022, 10, 1.	0.4	5
16047	Association of Personal Characteristics and Effectiveness of Immunotherapy in Late-Stage Non-Small Cell Lung Cancer: A Systematic Review. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	1

#	ARTICLE	IF	CITATIONS
16048	Ferroptosis-associated molecular classification characterized by distinct tumor microenvironment profiles in colorectal cancer. <i>International Journal of Biological Sciences</i> , 2022, 18, 1773-1794.	2.6	12
16049	Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. , 2022, 10, e003427.		11
16050	Anti- α PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC. <i>JCI Insight</i> , 2022, 7, .	2.3	42
16051	Emerging drug targets for colon cancer: A preclinical assessment. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 207-216.	1.5	4
16052	CD8 ⁺ PD-1 ⁺ to CD4 ⁺ PD-1 ⁺ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers. , 2022, 10, e004012.		16
16053	The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment. <i>Frontiers in Immunology</i> , 2022, 13, 851004.	2.2	12
16054	Methylation of Immune-Related Genes in Peripheral Blood Leukocytes and Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 817565.	1.3	2
16055	Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade. <i>Life</i> , 2022, 12, 229.	1.1	15
16056	Exploration of Prognostic Immune-Related Genes and lncRNAs Biomarkers in Kidney Renal Clear Cell Carcinoma and Its Crosstalk with Acute Kidney Injury. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	1
16057	Unraveling the Expression Patterns of Immune Checkpoints Identifies New Subtypes and Emerging Therapeutic Indicators in Lung Adenocarcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-19.	1.9	8
16058	CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	68
16059	<i>cfTrack</i> : A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution. <i>Clinical Cancer Research</i> , 2022, 28, 1841-1853.	3.2	4
16060	Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment. <i>Frontiers in Immunology</i> , 2022, 13, 830292.	2.2	24
16061	Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. <i>Leukemia</i> , 2022, 36, 1324-1335.	3.3	9
16062	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 981-996.	4.3	15
16063	Knockout of high-mobility group box 1 in B16F10 melanoma cells induced host immunity-mediated suppression of in vivo tumor growth. <i>Medical Oncology</i> , 2022, 39, 58.	1.2	6
16064	Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial. <i>Trials</i> , 2022, 23, 137.	0.7	10
16065	⁸⁹ Zr Immuno-PET Imaging of Tumor PD-1 Reveals That PMA Upregulates Lymphoma PD-1 through NF- κ B and JNK Signaling. <i>Molecular Imaging</i> , 2022, 2022, 5916692.	0.7	4

#	ARTICLE	IF	CITATIONS
16066	Histological Features of Celiac-Disease-like Conditions Related to Immune Checkpoint Inhibitors Therapy: A Signal to Keep in Mind for Pathologists. <i>Diagnostics</i> , 2022, 12, 395.	1.3	2
16067	A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre. <i>Current Oncology</i> , 2022, 29, 869-880.	0.9	2
16068	A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 826302.	1.6	10
16069	First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. <i>BioDrugs</i> , 2022, 36, 137-151.	2.2	6
16070	Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 287-305.	12.5	155
16071	Understanding the Critical Role of Glycolysis-Related lncRNAs in Lung Adenocarcinoma Based on Three Molecular Subtypes. <i>BioMed Research International</i> , 2022, 2022, 1-36.	0.9	3
16072	Emerging new therapeutic antibody derivatives for cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 39.	7.1	158
16073	Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. , 2022, 10, e003625.		16
16074	From Mouse to Human: Cellular Morphometric Subtype Learned From Mouse Mammary Tumors Provides Prognostic Value in Human Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 819565.	1.3	5
16075	Tertiary lymphoid structure and decreased CD8+ T cell infiltration in minimally invasive adenocarcinoma. <i>IScience</i> , 2022, 25, 103883.	1.9	3
16076	T Lymphocyte Infiltration in Association with IDO1 Expression in Resected Lung Adenocarcinoma and Normal Adjacent Lung Tissues. <i>BioMed Research International</i> , 2022, 2022, 1-9.	0.9	1
16077	Immune checkpoint inhibitors for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 563-576.	1.4	10
16078	Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?. <i>Nature Reviews Neurology</i> , 2022, 18, 173-185.	4.9	31
16079	Integrated Analysis of MATH-Based Subtypes Reveals a Novel Screening Strategy for Early-Stage Lung Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 769711.	1.8	1
16080	Links Between N6-Methyladenosine and Tumor Microenvironments in Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 807129.	1.8	4
16081	Epigenetic state determines inflammatory sensing in neuroblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	21
16082	Mesenchymal stromal cells equipped by IFN γ empower T cells with potent anti-tumor immunity. <i>Oncogene</i> , 2022, 41, 1866-1881.	2.6	9
16083	Integration of multiple lineage measurements from the same cell reconstructs parallel tumor evolution. <i>Cell Genomics</i> , 2022, 2, 100096.	3.0	13

#	ARTICLE	IF	CITATIONS
16084	System Analysis of Adaptor-Related Protein Complex 1 Subunit Mu 2 (AP1M2) on Malignant Tumors: A Pan-Cancer Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	3
16085	Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 809304.	1.3	23
16086	NK cells require immune checkpoint receptor LILRB4/gp49B to control neurotropic Zika virus infections in mice. <i>JCI Insight</i> , 2022, 7, .	2.3	5
16087	T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 833017.	2.2	13
16088	Bibliometric analysis of the 100 top-cited articles on immunotherapy of urological cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-8.	1.4	11
16089	An Asia-specific variant of human IgG1 represses colorectal tumorigenesis by shaping the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	14
16090	PD-L1 signaling in reactive astrocytes counteracts neuroinflammation and ameliorates neuronal damage after traumatic brain injury. <i>Journal of Neuroinflammation</i> , 2022, 19, 43.	3.1	21
16091	Immune ULBP1 is Elevated in Colon Adenocarcinoma and Predicts Prognosis. <i>Frontiers in Genetics</i> , 2022, 13, 762514.	1.1	7
16092	Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases. <i>Cancers</i> , 2022, 14, 792.	1.7	8
16093	Cilengitide, an α ν β 3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model. <i>Bioengineered</i> , 2022, 13, 4557-4572.	1.4	6
16094	The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 827788.	2.2	15
16095	PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity. <i>Nature Immunology</i> , 2022, 23, 399-410.	7.0	36
16096	Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment. <i>Journal of Cellular and Molecular Medicine</i> , 2022, , .	1.6	6
16097	The Potential Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Journal of Clinical Medicine</i> , 2022, 11, 865.	1.0	8
16098	ERAP2 Inhibition Induces Cell-Surface Presentation by MOLT-4 Leukemia Cancer Cells of Many Novel and Potentially Antigenic Peptides. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1913.	1.8	5
16099	Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 840313.	2.2	19
16100	Checkpoint: Inspecting the barriers in glioblastoma immunotherapies. <i>Seminars in Cancer Biology</i> , 2022, 86, 473-481.	4.3	9
16101	Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non-small cell lung cancer. <i>Cancer Medicine</i> , 2022, , .	1.3	5

#	ARTICLE	IF	CITATIONS
16102	Tegaserod Maleate Inhibits Breast Cancer Progression and Enhances the Sensitivity of Immunotherapy. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	1
16103	Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage ^I non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 947-955.	0.8	8
16104	Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC. <i>Frontiers in Oncology</i> , 2022, 12, 769124.	1.3	20
16105	Immunotherapy in Lung Cancer: Current Landscape and Future Directions. <i>Frontiers in Immunology</i> , 2022, 13, 823618.	2.2	105
16106	PD-L1 Expression Correlated with Clinicopathological Factors and Akt/Stat3 Pathway in Oral SCC. <i>Life</i> , 2022, 12, 238.	1.1	3
16107	Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India. <i>South Asian Journal of Cancer</i> , 0, , .	0.2	0
16108	Managing Metastatic Melanoma in 2022: A Clinical Review. <i>JCO Oncology Practice</i> , 2022, 18, 335-351.	1.4	91
16109	Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	12
16110	Functional and molecular characterization of PD1⁺ tumor-infiltrating lymphocytes from lung cancer patients. <i>Oncolimmunology</i> , 2022, 11, 2019466.	2.1	4
16111	Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer. <i>BMC Cancer</i> , 2022, 22, 154.	1.1	1
16112	Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis. <i>Frontiers in Genetics</i> , 2022, 13, 820135.	1.1	6
16113	Effective Identification of Maternal Malignancies in Pregnancies Undergoing Noninvasive Prenatal Testing. <i>Frontiers in Genetics</i> , 2022, 13, 802865.	1.1	5
16114	Metabolic Biomarkers in B-Cell Lymphomas for Early Diagnosis and Prediction, as Well as Their Influence on Prognosis and Treatment. <i>Diagnostics</i> , 2022, 12, 394.	1.3	4
16115	Intestinal <i>Akkermansia muciniphila</i> predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. <i>Nature Medicine</i> , 2022, 28, 315-324.	15.2	225
16116	Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 795933.	1.3	4
16117	Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 824.	1.7	2
16118	Targeting KDM4C enhances CD8⁺ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer. , 2022, 10, e003716.		24
16119	C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients. <i>Frontiers in Immunology</i> , 2022, 13, 808101.	2.2	19

#	ARTICLE	IF	CITATIONS
16120	Potentials of Non-Invasive 18F-FDG PET/CT in Immunotherapy Prediction for Non-Small Cell Lung Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 810011.	1.1	10
16121	Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer: A Proposal for Combining Immunohistochemistry and Gene Expression Analysis to Refine Scoring. <i>Frontiers in Immunology</i> , 2022, 13, 794175.	2.2	13
16122	Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0263629.	1.1	11
16123	Development of Gene Expression-Based Random Forest Model for Predicting Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 881.	1.7	5
16124	Colorectal cancer development is affected by the ECM molecule EMILIN-2 hinging on macrophage polarization via the TLR-4/MyD88 pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 60.	3.5	9
16125	The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner. <i>Clinical Cancer Research</i> , 2022, 28, 3387-3399.	3.2	24
16126	Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men. <i>Oncology and Therapy</i> , 2022, 10, 185-193.	1.0	1
16127	CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients. <i>Breast Cancer</i> , 2022, 29, 618-635.	1.3	2
16128	Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 783495.	2.2	13
16129	Current therapy and development of therapeutic agents for lung cancer. , 2022, 1, 100015.		8
16130	The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 2871-2881.	0.7	5
16131	cPLA2 blockade attenuates S100A7-mediated breast tumorigenicity by inhibiting the immunosuppressive tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 54.	3.5	23
16132	In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy. <i>Scientific Reports</i> , 2022, 12, 2132.	1.6	8
16133	Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 56.	3.5	20
16134	Recent insights into the use of immune checkpoint inhibitors in gastric cancer. <i>Porto Biomedical Journal</i> , 2022, 7, e162.	0.4	3
16135	FOXP3/HAT1 Axis Controls Treg Infiltration in the Tumor Microenvironment by Inducing CCR4 Expression in Breast Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 740588.	2.2	23
16136	Natural Killer Cell-Mediated Immunotherapy for Leukemia. <i>Cancers</i> , 2022, 14, 843.	1.7	16
16137	Impact of Tumor Mutational Burden and Gene Alterations Associated with Radiation-Response on Outcomes of Post-Operative Radiation Therapy in Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	8

#	ARTICLE	IF	CITATIONS
16138	Intron-Retention Neoantigen Load Predicts Favorable Prognosis in Pancreatic Cancer. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100124.	1.0	6
16139	Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications. <i>Journal of the American College of Cardiology</i> , 2022, 79, 577-593.	1.2	34
16140	Use of an antagonist of HMGB1 in mice affected by malignant mesothelioma: a preliminary ultrasound and optical imaging study. <i>European Radiology Experimental</i> , 2022, 6, 7.	1.7	2
16141	Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker spatial heterogeneity within breast cancer subtypes. <i>Breast Cancer Research</i> , 2021, 23, 114.	2.2	3
16142	Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 3553.	1.8	5
16143	Cardiotoxicity and Chemotherapy—The Role of Precision Medicine. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 90.	1.0	3
16144	Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia. <i>Cancers</i> , 2021, 13, 6188.	1.7	12
16145	B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?. <i>Clinical Cancer Research</i> , 2022, 28, 1751-1758.	3.2	39
16146	T cell receptor (TCR) signaling in health and disease. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 412.	7.1	127
16147	Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 422.	7.1	57
16148	A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. <i>Nature Medicine</i> , 2021, 27, 2212-2223.	15.2	88
16149	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. <i>Nature Medicine</i> , 2021, 27, 2200-2211.	15.2	65
16150	Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. <i>Nature Cancer</i> , 2022, 3, 108-121.	5.7	150
16151	Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis. <i>Thoracic Cancer</i> , 2022, 13, 322-337.	0.8	13
16152	A Randomized Phase II Study Comparing Nivolumab with Carboplatin+Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). <i>Clinical Cancer Research</i> , 2022, 28, 893-902.	3.2	35
16154	Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. <i>Blood Advances</i> , 2022, 6, 1152-1161.	2.5	13
16155	Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells. <i>Stem Cell Research and Therapy</i> , 2021, 12, 598.	2.4	21
16156	Deciphering functional tumor states at single-cell resolution. <i>EMBO Journal</i> , 2022, 41, e109221.	3.5	23

#	ARTICLE	IF	CITATIONS
16157	ASSOCIATION OF MTHFR A1298C POLYMORPHISM WITH BREAST CANCER AND/OR OVARIAN CANCER RISK: AN UPDATED META-ANALYSIS. Tropical Journal of Obstetrics and Gynaecology, 2016, 13, 72-86.	0.3	8
16158	Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. Frontiers in Immunology, 2021, 12, 800879.	2.2	54
16159	Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 793808.	1.3	2
16160	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy. Journal of Personalized Medicine, 2021, 11, 1312.	1.1	6
16163	Immuno-PET imaging of PD-L1 expression in patient-derived lung cancer xenografts with [68Ga]Ga-NOTA-Nb109. Quantitative Imaging in Medicine and Surgery, 2022, 12, 3300-3313.	1.1	5
16164	ECSIT inhibits cell death to increase tumor progression and metastasis via p53 in human breast cancer. Translational Cancer Research, 2021, 11, 0-0.	0.4	4
16165	Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer. Annals of Translational Medicine, 2022, 10, 441-441.	0.7	11
16166	The treatment of resectable gastric cancer: a literature review of an evolving landscape. Journal of Gastrointestinal Oncology, 2022, 13, 871-884.	0.6	3
16167	A clinical case of diagnosis of breast cancer in patients with family history of BRCA mutations 1. Reports of Practical Oncology and Radiotherapy, 2021, 26, 463-469.	0.3	0
16168	Adoptive T-cell Immunotherapy: Perfecting Self-Defenses. Experientia Supplementum (2012), 2022, 113, 253-294.	0.5	1
16169	Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression. Experientia Supplementum (2012), 2022, 113, 89-106.	0.5	4
16170	The Use of Targeted Agents in the Treatment of Gynecologic Cancers. Current Treatment Options in Oncology, 2022, 23, 15-28.	1.3	3
16171	Overall Survival Prediction of Docetaxel-based Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis. Oman Medical Journal, 2022, 37, e419-e419.	0.3	2
16172	Emerging mechanisms of immunotherapy resistance in sarcomas. Cancer Drug Resistance (Alhambra), Tj ETQq1 1 0,784314 rgBT /Overl	0.9	1
16173	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune Network, 2022, 22, e2.	1.6	53
16174	Research progress in immunotherapy of NSCLC with EGFR sensitive mutations. Oncology Research, 2022, , .	0.6	0
16175	Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer. NAR Cancer, 2022, 4, zcac008.	1.6	6
16176	Effects of PD-1 Signaling on Immunometabolic Reprogramming. Immunometabolism, 2022, 4, .	0.7	10

#	ARTICLE	IF	CITATIONS
16177	Simultaneous Pseudoprogression and an Immune-related Adverse Event of Pulmonary Pleomorphic Carcinoma after Combined Therapy with Cytotoxic Anticancer Agents and Immune Checkpoint Inhibitor. <i>Internal Medicine</i> , 2022, , .	0.3	1
16178	Estrogen-Related Receptors Gene Expression and Copy Number Alteration Association With the Clinicopathologic Characteristics of Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2022, 16, 117822342210867.	0.6	1
16179	Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors. <i>Experientia Supplementum (2012)</i> , 2022, 113, 1-57.	0.5	8
16180	Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer. <i>Antibody Therapeutics</i> , 2022, 5, 73-83.	1.2	5
16181	CDPA: Common and distinctive pattern analysis between high-dimensional datasets. <i>Electronic Journal of Statistics</i> , 2022, 16, .	0.4	0
16182	BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC. <i>Journal of Cancer</i> , 2022, 13, 2126-2137.	1.2	15
16183	Recent advances in noble metal complex based photodynamic therapy. <i>Chemical Science</i> , 2022, 13, 5085-5106.	3.7	62
16184	Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma. <i>Journal of Applied Oral Science</i> , 2022, 30, e20210344.	0.7	1
16185	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker. <i>Biomarker Insights</i> , 2022, 17, 117727192210787.	1.0	11
16186	Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210830.	1.4	13
16187	Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratification and frontline therapies in pancreatic cancer. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1154-1167.	1.9	12
16188	Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer. <i>Cancer Informatics</i> , 2022, 21, 117693512210870.	0.9	3
16189	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. <i>Experientia Supplementum (2012)</i> , 2022, 113, 295-350.	0.5	3
16190	Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody. <i>Internal Medicine</i> , 2022, 61, 2973-2979.	0.3	7
16191	Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy. <i>Immune Network</i> , 2022, 22, e3.	1.6	11
16192	Utilization of metal or non-metal-based functional materials as efficient composites in cancer therapies. <i>RSC Advances</i> , 2022, 12, 6540-6551.	1.7	2
16193	Emerging treatment strategies for metastatic triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210869.	1.4	15
16194	Co-Relation of Hormonal Profile and BRCA1 in Sporadic Breast Carcinoma: A Single Institutional Experience of 303 Patients. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2210763.	0.7	1

#	ARTICLE	IF	CITATIONS
16195	Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210753.	0.6	1
16196	Melanoma therapeutics: a literature review. <i>Journal of Biomedical Research</i> , 2022, 36, 77.	0.7	16
16197	Immunogenetics of Lupus Erythematosus. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1367, 213-257.	0.8	1
16198	The Immunogenetics of Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1367, 383-396.	0.8	0
16199	Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer. <i>Cancer Control</i> , 2022, 29, 107327482210766.	0.7	11
16200	CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application. <i>International Journal of Biological Sciences</i> , 2022, 18, 2609-2626.	2.6	40
16201	PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202210784.	1.0	9
16202	Comprehensive analysis of expression signature and immune microenvironment signature of biomarker Endothelin Receptor Type A in stomach adenocarcinoma. <i>Journal of Cancer</i> , 2022, 13, 2086-2104.	1.2	1
16203	MGP promotes CD8 ⁺ T cell exhaustion by activating the NF- κ B pathway leading to liver metastasis of colorectal cancer. <i>International Journal of Biological Sciences</i> , 2022, 18, 2345-2361.	2.6	22
16204	Teaching cancer imaging in the era of precision medicine: Looking at the big picture. <i>European Journal of Radiology Open</i> , 2022, 9, 100414.	0.7	3
16205	Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment. <i>Frontiers in Immunology</i> , 2022, 13, 845923.	2.2	11
16206	Regulatory networks and 5â€² partner usage of miRNA host gene fusions in breast cancer. <i>International Journal of Cancer</i> , 2022, 151, 95-106.	2.3	5
16207	Etiological roles of core promoter variation in triple-negative breast cancer. <i>Genes and Diseases</i> , 2023, 10, 228-238.	1.5	1
16208	Development and verification of a microsatellite instability-related risk signature for predicting survival and therapy effectiveness in gastric cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 84-101.	0.6	3
16209	Immunomodulatory Properties of Masticadienonic Acid and 3 β -Hydroxy Masticadienoic Acid in Dendritic Cells. <i>Molecules</i> , 2022, 27, 1451.	1.7	4
16210	Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	7
16211	Biomarkers of response to PD-1 pathway blockade. <i>British Journal of Cancer</i> , 2022, 126, 1663-1675.	2.9	52
16212	Prognostic Value of Tumor Infiltrating Lymphocytes in Locally Advanced HER2 Enriched Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 553-560.	0.5	1

#	ARTICLE	IF	CITATIONS
16213	Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment. <i>Pathology and Oncology Research</i> , 2022, 28, 1610196.	0.9	1
16214	Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature. <i>Frontiers in Pharmacology</i> , 2022, 13, 774170.	1.6	15
16215	Polymeric Systems for Cancer Immunotherapy: A Review. <i>Frontiers in Immunology</i> , 2022, 13, 826876.	2.2	12
16216	LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer. <i>Oncogene</i> , 2022, 41, 2054-2068.	2.6	7
16217	Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies. <i>Current Oncology</i> , 2022, 29, 1390-1407.	0.9	11
16218	Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. <i>Frontiers in Oncology</i> , 2022, 10, e003302.		16
16219	Identification of the Crucial Role of CCL22 in F. nucleatum-Related Colorectal Tumorigenesis that Correlates With Tumor Microenvironment and Immune Checkpoint Therapy. <i>Frontiers in Genetics</i> , 2022, 13, 811900.	1.1	12
16220	Early Breast Cancer Evolution by Autosomal Broad Copy Number Alterations. <i>International Journal of Genomics</i> , 2022, 2022, 1-17.	0.8	1
16221	Immunotherapy Outcomes in Individuals With Non-Small Cell Lung Cancer and Poor Performance Status. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	2
16222	The Impact of Obesity, Adipose Tissue, and Tumor Microenvironment on Macrophage Polarization and Metastasis. <i>Biology</i> , 2022, 11, 339.	1.3	16
16223	Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours. <i>Cancers</i> , 2022, 14, 978.	1.7	12
16224	Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo. <i>Molecules</i> , 2022, 27, 1482.	1.7	8
16225	Immune Checkpoint Inhibitors as a Threat to the Hypothalamus-Pituitary Axis: A Completed Puzzle. <i>Cancers</i> , 2022, 14, 1057.	1.7	4
16226	Comprehensive Analysis of Potential Correlation Between Solute Carrier 1A (SLC1A) Family and Lung Adenocarcinoma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 2101-2117.	0.8	1
16227	Cost-Effectiveness of PET/CT Surveillance Schedules to Detect Distant Recurrence of Resected Stage III Melanoma. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2331.	1.2	1
16228	Imaging Kv1.3 Expressing Memory T Cells as a Marker of Immunotherapy Response. <i>Cancers</i> , 2022, 14, 1217.	1.7	7
16229	Differential Effects on the Translation of Immune-Related Alternatively Polyadenylated mRNAs in Melanoma and T Cells by eIF4A Inhibition. <i>Cancers</i> , 2022, 14, 1177.	1.7	5
16230	Cytokine Profiles of Head and Neck Squamous Cell Carcinoma Undergoing Dual Immunotherapy With Cetuximab and Pembrolizumab Identify Interferon Gamma-Induced Protein 10 as Novel Biomarker. <i>Frontiers in Oncology</i> , 2022, 12, 795277.	1.3	3

#	ARTICLE	IF	CITATIONS
16231	METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer. <i>Molecular Cancer</i> , 2022, 21, 60.	7.9	135
16232	Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age. <i>World Journal of Surgical Oncology</i> , 2022, 20, 38.	0.8	5
16233	Emerging strategies for engineering <i>Escherichia coli</i> Nissle 1917-based therapeutics. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 772-786.	4.0	41
16234	Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. <i>Australasian Journal of Dermatology</i> , 2022, 63, .	0.4	1
16235	The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy. <i>Journal of Biomedical Science</i> , 2022, 29, 12.	2.6	27
16236	Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 1184.	1.7	16
16237	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. <i>Cell Reports Medicine</i> , 2022, 3, 100500.	3.3	13
16238	Identification and validation of a twelve immune infiltration-related lncRNA prognostic signature for bladder cancer. <i>Aging</i> , 2022, 14, 1492-1507.	1.4	12
16239	Visualization of the Effect of Assay Size on the Error Profile of Tumor Mutational Burden Measurement. <i>Genes</i> , 2022, 13, 432.	1.0	0
16240	Bystander T cells in cancer immunology and therapy. <i>Nature Cancer</i> , 2022, 3, 143-155.	5.7	47
16241	Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors. <i>Frontiers in Immunology</i> , 2022, 13, 799988.	2.2	7
16242	A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen. <i>Frontiers in Medicine</i> , 2022, 9, 712466.	1.2	2
16243	Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2022, 10, 420-436.	1.6	17
16244	<i>NOTCH1</i> PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model. <i>Oncotarget</i> , 2022, 13, 373-386.	0.8	1
16245	D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	66
16246	Multiomics Topic Modeling for Breast Cancer Classification. <i>Cancers</i> , 2022, 14, 1150.	1.7	4
16247	Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice. <i>Neurological Sciences</i> , 2022, 43, 2339-2361.	0.9	16
16248	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38

#	ARTICLE	IF	CITATIONS
16249	Cell membrane coated-nanoparticles for cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3233-3254.	5.7	61
16250	Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. <i>Cancers</i> , 2022, 14, 1253.	1.7	69
16251	Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 201-212.	1.3	10
16252	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. <i>International Journal of Clinical Oncology</i> , 2022, 27, 695-706.	1.0	11
16253	A comprehensive analysis of the diagnostic and prognostic value associated with the SLC7A family members in breast cancer. <i>Gland Surgery</i> , 2022, 11, 389-411.	0.5	6
16254	Molecular profiles and circulating tumor-DNA detected in Chinese early stage breast cancer. <i>Gland Surgery</i> , 2022, 11, 319-329.	0.5	3
16255	Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment. <i>Scientific Reports</i> , 2022, 12, 3278.	1.6	25
16256	Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 62.	3.5	44
16257	Predicting Mutational Status of Driver and Suppressor Genes Directly from Histopathology With Deep Learning: A Systematic Study Across 23 Solid Tumor Types. <i>Frontiers in Genetics</i> , 2021, 12, 806386.	1.1	14
16258	DNA Methylation in Lung Cancer: Mechanisms and Associations with Histological Subtypes, Molecular Alterations, and Major Epidemiological Factors. <i>Cancers</i> , 2022, 14, 961.	1.7	24
16259	Tumor Microenvironment and Hydrogel-Based 3D Cancer Models for In Vitro Testing Immunotherapies. <i>Cancers</i> , 2022, 14, 1013.	1.7	17
16260	Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?. <i>Journal of Clinical Medicine</i> , 2022, 11, 1019.	1.0	5
16261	PD-L1 mediates lung fibroblast to myofibroblast transition through Smad3 and β -catenin signaling pathways. <i>Scientific Reports</i> , 2022, 12, 3053.	1.6	23
16262	The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond. <i>Vaccines</i> , 2022, 10, 304.	2.1	2
16263	Data-driven design of targeted gene panels for estimating immunotherapy biomarkers. <i>Communications Biology</i> , 2022, 5, 156.	2.0	1
16264	RAS pathway regulation in melanoma. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	11
16265	Identification of the Expression Patterns and Potential Prognostic Role of 5-Methylcytosine Regulators in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 842220.	1.8	8
16266	Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. <i>Cancers</i> , 2022, 14, 955.	1.7	9

#	ARTICLE	IF	CITATIONS
16267	What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?. <i>Current Oncology Reports</i> , 2022, 24, 451-461.	1.8	1
16268	Machine learning and bioinformatics analysis revealed classification and potential treatment strategy in stage 3â€“4 NSCLC patients. <i>BMC Medical Genomics</i> , 2022, 15, 33.	0.7	3
16269	ERK1/2â€™s regulation of oestrogen homeostasis. <i>FEBS Journal</i> , 2022, , .	2.2	2
16270	Role of Hypoxia in the Interferon Response. <i>Frontiers in Immunology</i> , 2022, 13, 821816.	2.2	5
16271	Frequency of Expression of PD-1 and PD-L1 In Head And Neck Squamous Cell Carcinoma And their Association With Nodal Metastasis: A Cross-Sectional Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 467-473.	0.5	2
16272	Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 164-170.	1.3	10
16273	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
16274	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. <i>Nature Communications</i> , 2022, 13, 896.	5.8	46
16275	Evolution of Immunotherapy for Ovarian Cancer from a Birdâ€™s-Eye Perspective: A Text-Mining Analysis of Publication Trends and Topics. <i>Frontiers in Oncology</i> , 2022, 12, 795129.	1.3	5
16276	High farnesoid X receptor expression predicts favorable clinical outcomes in PDâ€™L1^{low/negative} nonâ€™small cell lung cancer patients receiving antiâ€™PDâ€™1â€™based chemoâ€™immunotherapy. <i>International Journal of Oncology</i> , 2022, 60, .	1.4	2
16277	Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 847350.	1.3	6
16278	New Immunometabolic Strategy Based on Cell Type-Specific Metabolic Reprogramming in the Tumor Immune Microenvironment. <i>Cells</i> , 2022, 11, 768.	1.8	14
16279	Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?. <i>Cancers</i> , 2022, 14, 1101.	1.7	8
16280	Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes. <i>Cancers</i> , 2022, 14, 1042.	1.7	7
16281	Detection of genetic mutations in patients with breast cancer from Saudi Arabia using Ion AmpliSeqâ„¢ Cancer Hotspot Panel v.2.0. <i>Biomedical Reports</i> , 2022, 16, 26.	0.9	5
16282	Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective. <i>Current Treatment Options in Oncology</i> , 2022, 23, 268-294.	1.3	8
16283	Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 804466.	1.3	6
16284	Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. <i>Biomedicines</i> , 2022, 10, 537.	1.4	9

#	ARTICLE	IF	CITATIONS
16285	Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2022, 15, 17.	6.9	46
16286	A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. <i>Genome Medicine</i> , 2022, 14, 20.	3.6	26
16287	Expression of immune checkpoint molecules programmed death protein 1, programmed death ligand 1 and inducible T cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome*. <i>British Journal of Dermatology</i> , 2022, 187, 234-243.	1.4	8
16288	¹⁸ F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 483-494.	0.9	11
16289	Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis. <i>Cell Reports Medicine</i> , 2022, 3, 100526.	3.3	7
16290	Multi-Level Analysis and Identification of Tumor Mutational Burden Genes across Cancer Types. <i>Genes</i> , 2022, 13, 365.	1.0	3
16291	A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer. <i>Scientific Reports</i> , 2022, 12, 2478.	1.6	2
16292	Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. , 2022, 10, e003776.		79
16293	The New Era of Immunotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 1054.	1.7	68
16294	An artificial intelligence method to assess the tumor microenvironment with treatment outcomes for gastric cancer patients after gastrectomy. <i>Journal of Translational Medicine</i> , 2022, 20, 100.	1.8	8
16295	Nanoscale Drug Delivery Systems in Glioblastoma. <i>Nanoscale Research Letters</i> , 2022, 17, 27.	3.1	19
16296	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. <i>Molecular Cancer</i> , 2022, 21, 61.	7.9	6
16297	Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2594.	1.8	14
16298	In silico recognition of a prognostic signature in basal-like breast cancer patients. <i>PLoS ONE</i> , 2022, 17, e0264024.	1.1	5
16299	The Landscape of Nanovectors for Modulation in Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 397.	2.0	4
16300	Nivolumab-DTPA-Based PD-1 Imaging Reveals Structural and Pathological Changes in Colorectal Carcinoma. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 839756.	2.0	2
16301	Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC. , 2022, 10, e004064.		10
16302	Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3139-3155.	5.7	13

#	ARTICLE	IF	CITATIONS
16303	TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 833-840.	1.2	6
16304	Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1238.	1.7	7
16305	STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1154.	1.7	11
16306	Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma. <i>Antibodies</i> , 2022, 11, 15.	1.2	3
16307	Cell-type heterogeneity: Why we should adjust for it in epigenome and biomarker studies. <i>Clinical Epigenetics</i> , 2022, 14, 31.	1.8	18
16308	Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses. <i>Cancers</i> , 2022, 14, 997.	1.7	2
16309	Soluble Immune Checkpoints Are Dysregulated in COVID-19 and Heavy Alcohol Users With HIV Infection. <i>Frontiers in Immunology</i> , 2022, 13, 833310.	2.2	10
16310	Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2405-2420.	2.0	10
16311	Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 810269.	1.3	14
16312	Characterisation of the Stromal Microenvironment in Lobular Breast Cancer. <i>Cancers</i> , 2022, 14, 904.	1.7	13
16313	Differential expression of PD-L1 and PD-L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non-small cell lung cancer. <i>Oncology Reports</i> , 2022, 47, .	1.2	9
16314	Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer. <i>Pharmaceutics</i> , 2022, 14, 505.	2.0	7
16315	Navigational bronchoscopy specimens and PD-L1 expression: a retrospective study. <i>Journal of Thoracic Disease</i> , 2022, 14, 295-305.	0.6	0
16316	Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number. <i>Biology Direct</i> , 2022, 17, 5.	1.9	1
16317	Analysis of Gene Co-Expression Network to Identify the Role of CD8 + T Cell Infiltration-Related Biomarkers in High-Grade Glioma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 1879-1890.	0.8	4
16318	Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2381-2389.	2.0	2
16319	Oncolytic viruses in melanoma. <i>Frontiers in Bioscience</i> , 2022, 27, 063.	0.8	12
16320	HAUS5 Is A Potential Prognostic Biomarker With Functional Significance in Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 829777.	1.3	6

#	ARTICLE	IF	CITATIONS
16321	Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches. <i>Biomedicines</i> , 2022, 10, 543.	1.4	14
16322	CD84 is a Suppressor of T and B Cell Activation during <i>Mycobacterium tuberculosis</i> Pathogenesis. <i>Microbiology Spectrum</i> , 2022, 10, e0155721.	1.2	3
16323	Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in <i>KRAS</i> -mutated non-small cell lung cancer with <i>STK11</i> , <i>KEAP1</i> or <i>TP53</i> comutations: subgroup results from the phase III IMpower150 trial. , 2022, 10, e003027.		45
16324	Immunotherapy in Advanced Prostate Cancer—Light at the End of the Tunnel?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2569.	1.8	11
16325	A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1104-1119.	0.7	5
16326	An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, 839901.	2.2	1
16327	VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?. <i>Cancers</i> , 2022, 14, 1006.	1.7	2
16328	G-Quadruplex Matters in Tissue-Specific Tumorigenesis by <i>BRCA1</i> Deficiency. <i>Genes</i> , 2022, 13, 391.	1.0	5
16329	QuantISH: RNA in situ hybridization image analysis framework for quantifying cell type-specific target RNA expression and variability. <i>Laboratory Investigation</i> , 2022, 102, 753-761.	1.7	3
16330	Comprehensive Analysis of an Individualized Immune-Related lncRNA Pair Signature in Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 805623.	1.8	3
16331	Role of Base Excision Repair in Innate Immune Cells and Its Relevance for Cancer Therapy. <i>Biomedicines</i> , 2022, 10, 557.	1.4	1
16332	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. , 2022, 10, e004036.		24
16333	Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3K ^{Î³} inhibitor can enhance immunogenicity and eradicate tumors. , 2022, 10, e003564.		6
16334	Palliative Systemic Therapy Given near the End of Life for Metastatic Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 1316-1325.	0.9	3
16335	Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment. <i>Cancers</i> , 2022, 14, 985.	1.7	25
16336	Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma. <i>Cancers</i> , 2022, 14, 1248.	1.7	3
16337	Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 896.	1.7	36
16338	Comparison of Immune Checkpoint Molecules PD-1 and PD-L1 in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence. <i>Brain Sciences</i> , 2022, 12, 266.	1.1	0

#	ARTICLE	IF	CITATIONS
16339	Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2022.	1.8	13
16340	Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers. <i>Cancers</i> , 2022, 14, 1028.	1.7	24
16341	Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas. <i>World Journal of Clinical Oncology</i> , 2022, 13, 135-146.	0.9	1
16342	Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 847901.	2.0	13
16343	PTPN2 elicits cell autonomous and non-cell autonomous effects on antitumor immunity in triple-negative breast cancer. <i>Science Advances</i> , 2022, 8, eabk3338.	4.7	22
16344	Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 820408.	1.3	1
16345	The Unfolded Protein Response at the Tumor-Immune Interface. <i>Frontiers in Immunology</i> , 2022, 13, 823157.	2.2	11
16346	Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 807575.	2.2	4
16347	An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. <i>Cell Reports Medicine</i> , 2022, 3, 100525.	3.3	22
16348	Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential. <i>British Journal of Cancer</i> , 2022, , .	2.9	2
16349	Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens. , 2022, 10, e003572.		9
16350	Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 43.	1.6	4
16351	A Prognostic Model for Predicting Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Bladder Urothelial Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 708003.	1.1	2
16352	Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics. <i>Cancer Research</i> , 2022, 82, 1174-1192.	0.4	21
16353	Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 1087.	1.7	7
16354	Overexpression of Programmed Cell Death 1 Prevents Doxorubicin-Induced Apoptosis Through Autophagy Induction in H9c2 Cardiomyocytes. <i>Cardiovascular Toxicology</i> , 2022, 22, 462-476.	1.1	7
16355	Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 331-338.	3.3	16
16356	Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Medicine</i> , 2022, 9, 860733.	1.2	2

#	ARTICLE	IF	CITATIONS
16357	Expression of PD-L1 in Early-Stage Invasive Breast Carcinoma and Its Relation to Tumor-Infiltrating Lymphocytes. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 1091-1102.	0.5	0
16358	Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. <i>Life Science Alliance</i> , 2022, 5, e202101230.	1.3	16
16359	LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma. <i>Hereditas</i> , 2022, 159, 16.	0.5	1
16360	DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1137-1150.	1.5	8
16361	Single-Cell Multiomics Reveals Clonal T-Cell Expansions and Exhaustion in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Frontiers in Immunology</i> , 2022, 13, 809414.	2.2	6
16362	Alternative Splicing in Cancer and Immune Cells. <i>Cancers</i> , 2022, 14, 1726.	1.7	15
16363	Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2631-2643.	2.0	23
16364	A Gene Panel for Early Identification of Future Responders to Immune Checkpoint Blockade. <i>Frontiers in Genetics</i> , 2022, 13, 706468.	1.1	0
16365	Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. <i>Gut</i> , 2022, 71, 1412-1425.	6.1	79
16366	Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2022, 8, 462.	3.4	22
16367	PD-L1 and PD-1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor. <i>Apmis</i> , 2022, 130, 276-283.	0.9	3
16368	Treatment of Metastatic Melanoma in the Elderly. <i>Current Oncology Reports</i> , 2022, 24, 825-833.	1.8	5
16369	Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4. <i>Pharmaceuticals</i> , 2022, 15, 335.	1.7	35
16370	Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. <i>Frontiers in Oncology</i> , 2022, 12, 802579.	1.3	5
16371	Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer. <i>Science Translational Medicine</i> , 2022, 14, eabe8195.	5.8	16
16372	Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?. <i>Cancers</i> , 2022, 14, 1710.	1.7	13
16373	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. <i>Journal of Hematology and Oncology</i> , 2022, 15, 24.	6.9	136
16374	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514.	1.1	7

#	ARTICLE	IF	CITATIONS
16375	Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society. <i>Breast Cancer Research</i> , 2022, 24, 22.	2.2	80
16376	Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12209.	5.5	18
16377	Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance. <i>Frontiers in Oncology</i> , 2022, 12, 856974.	1.3	35
16378	High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers. <i>Journal of Clinical Medicine</i> , 2022, 11, 1605.	1.0	2
16379	The Transcriptomic Portrait of Locally Advanced Breast Cancer and Its Prognostic Value in a Multi-Country Cohort of Latin American Patients. <i>Frontiers in Oncology</i> , 2022, 12, 835626.	1.3	1
16380	A Necroptosis-Related lncRNA-Based Signature to Predict Prognosis and Probe Molecular Characteristics of Stomach Adenocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 833928.	1.1	34
16381	Pretreatment DCE-MRI-Based Deep Learning Outperforms Radiomics Analysis in Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 846775.	1.3	12
16382	Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)â€”Their Incidence, Management, Multiorgan irAEs, and Rechallenge. <i>Biomedicines</i> , 2022, 10, 790.	1.4	17
16383	Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3548-3566.	5.7	11
16384	Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 841977.	1.3	10
16385	Construction of a Novel Immune-Related mRNA Signature to Predict the Prognosis and Immune Characteristics of Human Colorectal Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 851373.	1.1	2
16386	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 440-462.	21.5	58
16387	An Oxidative Stress-Related Genes Signature for Predicting Survival in Bladder Cancer: Based on TCGA Database and Bioinformatics. <i>International Journal of General Medicine</i> , 2022, Volume 15, 2645-2667.	0.8	9
16388	Strategies for Manipulating T Cells in Cancer Immunotherapy. <i>Biomolecules and Therapeutics</i> , 2022, , .	1.1	0
16389	The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 635-647.	0.4	11
16390	An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response. <i>STAR Protocols</i> , 2022, 3, 101198.	0.5	2
16391	The Interplay between Tumour Microenvironment Components in Malignant Melanoma. <i>Medicina (Lithuania)</i> , 2022, 58, 365.	0.8	8
16392	Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 801909.	2.2	4

#	ARTICLE	IF	CITATIONS
16393	A text-based computational framework for patient -specific modeling for classification of cancers. IScience, 2022, 25, 103944.	1.9	7
16394	Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1103-1113.	1.2	1
16395	The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients. Cancers, 2022, 14, 1569.	1.7	4
16396	Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions. Biomedicines, 2022, 10, 821.	1.4	5
16397	TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer. Frontiers in Immunology, 2022, 13, 832230.	2.2	13
16398	Brain Vascular Microenvironments in Cancer Metastasis. Biomolecules, 2022, 12, 401.	1.8	7
16399	Immune-related gene signature predicts clinical outcomes and immunotherapy response in acute myeloid leukemia. Cancer Medicine, 2022, 11, 3364-3380.	1.3	3
16400	Prognostic value of CD155/TIGIT expression in patients with colorectal cancer. PLoS ONE, 2022, 17, e0265908.	1.1	11
16401	Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report. Frontiers in Endocrinology, 2022, 13, 810747.	1.5	4
16402	N6-methyladenosine-related lncRNAs is a potential marker for predicting prognosis and immunotherapy in ovarian cancer. Hereditas, 2022, 159, 17.	0.5	4
16403	Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment. International Journal of Molecular Sciences, 2022, 23, 2847.	1.8	19
16404	Identification of the Tumor Immune Microenvironment and Therapeutic Biomarkers by a Novel Molecular Subtype Based on Aging-Related Genes in Hepatocellular Carcinoma. Frontiers in Surgery, 2022, 9, 836080.	0.6	7
16405	The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma. Biomedicines, 2022, 10, 822.	1.4	18
16406	The Role of Circulating Tumor Cells in the Prognosis of Metastatic Triple-Negative Breast Cancers: A Systematic Review of the Literature. Biomedicines, 2022, 10, 769.	1.4	3
16407	Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1-Resistant Melanoma. Cancer Immunology Research, 2022, 10, 612-625.	1.6	12
16408	Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study. Annals of Translational Medicine, 2022, 10, 251-251.	0.7	14
16409	Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights. Cancer Management and Research, 2022, Volume 14, 1043-1061.	0.9	6
16410	Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis. World Journal of Surgical Oncology, 2022, 20, 93.	0.8	20

#	ARTICLE	IF	CITATIONS
16411	MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. , 2022, 10, e004241.		11
16412	TGF- β 2 1-Mediated PD-L1 Glycosylation Contributes to Immune Escape via c-Jun/STT3A Pathway in Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 815437.	1.3	6
16413	Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 749461.	2.2	11
16414	Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. <i>Experimental Hematology and Oncology</i> , 2022, 11, 11.	2.0	35
16415	Interpretation of 2-[18F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors. <i>European Radiology</i> , 2022, , 1.	2.3	2
16416	FAT10 is a Prognostic Biomarker and Correlated With Immune Infiltrates in Skin Cutaneous Melanoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 805887.	1.6	1
16417	Development of Tumor Mutation Burden-Related Prognostic Model and Novel Biomarker Identification in Stomach Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 790920.	1.8	10
16418	MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcoma. <i>Cell Death Discovery</i> , 2022, 8, 117.	2.0	13
16419	Downregulation of TPX2 impairs the antitumor activity of CD8+ T cells in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 223.	2.7	11
16420	Neutrophil Extracellular Traps in Cancer Therapy Resistance. <i>Cancers</i> , 2022, 14, 1359.	1.7	30
16421	SIRP β 3-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	20
16422	Integrative Analysis of Gene Expression and DNA Methylation Depicting the Impact of Obesity on Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818082.	1.8	3
16423	MicroRNA Dysregulation in Prostate Cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2022, Volume 15, 177-193.	0.4	4
16424	The immune microenvironment in gastric adenocarcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 451-467.	8.2	47
16425	A Bayesian Network Meta-Analysis of First-Line Treatments for Non-Small Cell Lung Cancer with High Programmed Death Ligand-1 Expression. <i>Journal of Clinical Medicine</i> , 2022, 11, 1492.	1.0	3
16426	Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database. <i>Frontiers in Pharmacology</i> , 2022, 13, 803706.	1.6	6
16427	Anti-PD-1: When to Stop Treatment. <i>Current Oncology Reports</i> , 2022, 24, 905-915.	1.8	5
16428	Pan-cancer predictions of transcription factors mediating aberrant DNA methylation. <i>Epigenetics and Chromatin</i> , 2022, 15, 10.	1.8	10

#	ARTICLE	IF	CITATIONS
16429	Basic cancer immunology for radiation oncologists. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 508-518.	0.9	2
16430	Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon γ -mediated suppression of immune checkpoint receptor expression. <i>OncImmunology</i> , 2022, 11, 2054758.	2.1	7
16431	Selective Photo-Assisted Eradication of Triple-Negative Breast Cancer Cells through Aptamer Decoration of Doped Conjugated Polymer Nanoparticles. <i>Pharmaceutics</i> , 2022, 14, 626.	2.0	24
16432	A Novel Ferroptosis-Related lncRNAs Signature Predicts Clinical Prognosis and Is Associated With Immune Landscape in Pancreatic Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 786689.	1.1	15
16433	Comprehensive analysis of the correlations of S100B with hypoxia response and immune infiltration in hepatocellular carcinoma. <i>PeerJ</i> , 2022, 10, e13201.	0.9	4
16434	Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis. <i>Clinical Cancer Research</i> , 2022, 28, 1180-1191.	3.2	30
16435	Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression. <i>Cancer Immunology Research</i> , 2022, 10, 581-596.	1.6	24
16436	Association between clinical outcomes and local treatment in stage \geq IV non-small cell lung cancer patients with single extrathoracic metastasis. <i>Thoracic Cancer</i> , 2022, 13, 1349-1360.	0.8	4
16437	CD8+ T-cell exhaustion in the tumor microenvironment of head and neck squamous cell carcinoma determines poor prognosis. <i>Annals of Translational Medicine</i> , 2022, 10, 273-273.	0.7	8
16438	Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics. <i>Frontiers in Pharmacology</i> , 2022, 13, 836925.	1.6	4
16439	CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-35.	1.9	15
16440	Extrachromosomal DNA formation enables tumor immune escape potentially through regulating antigen presentation gene expression. <i>Scientific Reports</i> , 2022, 12, 3590.	1.6	14
16441	Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. <i>Cancers</i> , 2022, 14, 1735.	1.7	6
16442	Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma. <i>Blood Advances</i> , 2022, 6, 5659-5667.	2.5	3
16443	Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis. <i>Cancers</i> , 2022, 14, 1682.	1.7	2
16444	Development of a Model System to Study Expression Profile of RAC2 Gene in Breast Cancer MDA-MB-231 Cell Line. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-8.	0.5	2
16445	Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2022, 14, 1327.	1.7	9
16446	Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans. <i>Cell Death and Disease</i> , 2022, 13, 274.	2.7	11

#	ARTICLE	IF	CITATIONS
16447	A Bâ€cell or a key player? The different roles of Bâ€cells and antibodies in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 303-319.	1.5	5
16448	A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. <i>Nature Immunology</i> , 2022, 23, 660-670.	7.0	191
16449	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 827921.	2.2	43
16450	Pinpointing Cancer Sub-Type Specific Metabolic Tasks Facilitates Identification of Anti-cancer Targets. <i>Frontiers in Medicine</i> , 2022, 9, 872024.	1.2	1
16451	Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity. <i>Frontiers in Immunology</i> , 2022, 13, 812774.	2.2	157
16452	Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors. <i>Life</i> , 2022, 12, 409.	1.1	8
16453	N6-methyladenosine (m6A) RNA modification in tumor immunity. <i>Cancer Biology and Medicine</i> , 2022, 19, .	1.4	6
16454	Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. <i>Genome Medicine</i> , 2022, 14, 35.	3.6	29
16455	Identification of New m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Landscape that Predict Clinical Outcomes for Papillary Renal Cell Carcinoma Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818194.	1.8	1
16456	Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 21-35.	1.1	4
16457	Current Clinical Trial Landscape of OX40 Agonists. <i>Current Oncology Reports</i> , 2022, 24, 951-960.	1.8	15
16458	Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Antiâ€Programmed Cell Death 1 Immunotherapy. <i>JAMA Network Open</i> , 2022, 5, e220587.	2.8	23
16459	Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 95.	3.5	21
16460	Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Based on Cytolytic Activity in Skin Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2022, 12, 844666.	1.3	2
16461	A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies. <i>Cell Death Discovery</i> , 2022, 8, 106.	2.0	10
16462	Generalizable design parameters for soluble T cell receptor-based T cell engagers. , 2022, 10, e004281.		1
16463	Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening. <i>Frontiers in Oncology</i> , 2022, 12, 755053.	1.3	12
16464	Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. <i>British Journal of Cancer</i> , 2022, 127, 383-393.	2.9	36

#	ARTICLE	IF	CITATIONS
16465	Identify a DNA Damage Repair Gene Signature for Predicting Prognosis and Immunotherapy Response in Cervical Squamous Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	3
16466	Emerging Novel Combined CAR-T Cell Therapies. <i>Cancers</i> , 2022, 14, 1403.	1.7	9
16467	NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic Neoantigens. <i>Journal of Immunology</i> , 2022, 208, 1813-1827.	0.4	4
16468	Harnessing the chemokine system to home CAR-T cells into solid tumors. <i>Cell Reports Medicine</i> , 2022, 3, 100543.	3.3	24
16469	Comprehensive Analysis of the Immune and Prognostic Implication of TRIM8 in Breast Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 835540.	1.1	1
16470	The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer. <i>Biomarker Research</i> , 2022, 10, 9.	2.8	28
16471	Global analysis of miRNA-mRNA regulation pair in bladder cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, 66.	0.8	3
16472	A Pan-Cancer Analysis on the Systematic Correlation of MutS Homolog 2 (MSH2) to a Malignant Tumor. <i>Journal of Oncology</i> , 2022, 2022, 1-22.	0.6	0
16473	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	2.2	27
16474	The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, 748674.	1.6	27
16475	vWCluster: Vector-valued optimal transport for network based clustering using multi-omics data in breast cancer. <i>PLoS ONE</i> , 2022, 17, e0265150.	1.1	5
16476	The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3324.	1.8	4
16477	MD2 Is a Potential Biomarker Associated with Immune Cell Infiltration in Gliomas. <i>Frontiers in Oncology</i> , 2022, 12, 854598.	1.3	3
16478	Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1627.	1.0	14
16479	Cluster analyses of the TCGA and a TMA dataset using the coexpression of HSP27 and CRYAB improves alignment with clinical-pathological parameters of breast cancer and suggests different epichaperome influences for each sHSP. <i>Cell Stress and Chaperones</i> , 2022, 27, 177-188.	1.2	1
16480	Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment. <i>Molecular Oncology</i> , 2022, 16, 2153-2173.	2.1	13
16481	Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 515-527.	1.1	7
16482	Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives. <i>Frontiers in Oncology</i> , 2022, 12, 836891.	1.3	5

#	ARTICLE	IF	CITATIONS
16483	Pan-Cancer Analyses Confirmed the Ferroptosis-Related Gene SLC7A11 as a Prognostic Biomarker for Cancer. <i>International Journal of General Medicine</i> , 2022, Volume 15, 2501-2513.	0.8	10
16484	Identification of Biomarkers Related to Regulatory T Cell Infiltration in Oral Squamous Cell Carcinoma Based on Integrated Bioinformatics Analysis. <i>International Journal of General Medicine</i> , 2022, Volume 15, 2361-2376.	0.8	3
16485	Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2022, 24, 17.	2.2	45
16486	Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 848327.	2.2	11
16487	A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 851032.	1.8	14
16488	Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 440-451.	1.3	12
16489	Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. , 2022, 10, e003532.		8
16490	CMTM6 as a master regulator of PD-L1. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2325-2340.	2.0	7
16491	Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818453.	1.8	14
16492	Identification and Validation of N6-Methyladenosine-Related Biomarkers for Bladder Cancer: Implications for Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 820242.	1.3	5
16493	PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. <i>Cell Reports</i> , 2022, 38, 110582.	2.9	24
16494	Brain Metastases among Cancer Patients Diagnosed from 2010â€“2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence. <i>Current Oncology</i> , 2022, 29, 2091-2105.	0.9	4
16495	Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 536-545.	0.9	5
16496	Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. <i>Nature Reviews Urology</i> , 2022, 19, 305-320.	1.9	9
16497	Inhibiting ERK5 Overcomes Breast Cancer Resistance to Anti-HER2 Therapy By Targeting the G1â€“S Cell-Cycle Transition. <i>Cancer Research Communications</i> , 2022, 2, 131-145.	0.7	3
16498	Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 727487.	1.1	18
16499	Associations of Clinical and Molecular Characteristics with the Response to Immune Checkpoint Blockade in Advanced Gastric Cancers. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	0
16500	Cardiotoxicity risk factors with immune checkpoint inhibitors. <i>Cardio-Oncology</i> , 2022, 8, 3.	0.8	12

#	ARTICLE	IF	CITATIONS
16501	Identification of a Mitochondria-Related Gene Signature to Predict the Prognosis in AML. <i>Frontiers in Oncology</i> , 2022, 12, 823831.	1.3	9
16502	Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention. <i>Cancers</i> , 2022, 14, 1367.	1.7	10
16503	Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future. <i>Cancers</i> , 2022, 14, 1406.	1.7	13
16504	Benefits of Targeted Molecular Therapy to Immune Infiltration and Immune-Related Genes Predicting Signature in Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 824166.	1.3	2
16505	Predicting exon criticality from protein sequence. <i>Nucleic Acids Research</i> , 2022, 50, 3128-3141.	6.5	1
16506	Correlation Between Immune Cell Infiltration and PD-L1 Expression and Immune-Related lncRNA Determination in Triple-Negative Breast Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 878658.	1.1	3
16507	The spectrum of renal diseases with lupus-like features: a single-center study. <i>Renal Failure</i> , 2022, 44, 581-593.	0.8	1
16508	Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors. <i>Journal of Immunotherapy</i> , 2022, 45, 210-216.	1.2	15
16509	Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy. <i>Translational Lung Cancer Research</i> , 2022, 11, 452-461.	1.3	10
16510	Comprehensive Analysis of R-Spondin Fusions and <i>RNF43</i> Mutations Implicate Novel Therapeutic Options in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1863-1870.	3.2	16
16511	Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression. , 2022, 10, e003923.		13
16512	Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 839136.	1.8	6
16513	Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor. <i>Frontiers in Oncology</i> , 2022, 12, 789228.	1.3	3
16514	Nanoliposome C6â€Ceramide in combination with antiâ€CTLA4 antibody improves antiâ€tumor immunity in hepatocellular cancer. <i>FASEB Journal</i> , 2022, 36, e22250.	0.2	10
16515	Correlations between Circulating and Tumor-Infiltrating CD4+ T Cell Subsets with Immune Checkpoints in Colorectal Cancer. <i>Vaccines</i> , 2022, 10, 538.	2.1	2
16516	Tumor immune cell clustering and its association with survival in African American women with ovarian cancer. <i>PLoS Computational Biology</i> , 2022, 18, e1009900.	1.5	8
16517	ExhauFS: exhaustive search-based feature selection for classification and survival regression. <i>PeerJ</i> , 2022, 10, e13200.	0.9	7
16518	AXL inhibition improves BRAF-targeted treatment in melanoma. <i>Scientific Reports</i> , 2022, 12, 5076.	1.6	14

#	ARTICLE	IF	CITATIONS
16519	Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1855.	1.0	11
16520	Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update. <i>Frontiers in Oncology</i> , 2022, 12, 859152.	1.3	15
16521	Discovery of efficacy biomarkers for non-small cell lung cancer with first-line anti-PD-1 immunotherapy by data-independent acquisition mass spectrometry. <i>Clinical and Experimental Immunology</i> , 2022, , .	1.1	1
16522	Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma. <i>Biomedicines</i> , 2022, 10, 673.	1.4	4
16523	Integrative Analysis of Multi-Omics Data-Identified Key Genes With KLRC3 as the Core in a Gene Regulatory Network Related to Immune Phenotypes in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 810193.	1.1	1
16524	Tim-3 mediates T cell trogocytosis to limit antitumor immunity. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	25
16525	Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response. <i>Frontiers in Immunology</i> , 2022, 13, 833792.	2.2	5
16526	Analysis of Stemness and Prognosis of Subtypes in Breast Cancer Using the Transcriptome Sequencing Data. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	1
16527	An Integrative Pan-Cancer Analysis of Kinesin Family Member C1 (KIFC1) in Human Tumors. <i>Biomedicines</i> , 2022, 10, 637.	1.4	2
16528	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. <i>Cancer Discovery</i> , 2022, 12, 654-669.	7.7	34
16529	Nomograms for Predicting Specific Distant Metastatic Sites and Overall Survival of Breast Invasive Ductal Carcinoma Patients After Surgery: A Large Population-Based Study. <i>Frontiers in Surgery</i> , 2022, 9, 779220.	0.6	1
16530	Reduced CCR2 Can Improve the Prognosis of Sarcoma by Remodeling the Tumor Microenvironment. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3043-3053.	0.8	4
16531	Prognostic Implications and Immune Infiltration Characteristics of Chromosomal Instability-Related Dysregulated CeRNA in Lung Adenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 843640.	1.6	3
16532	Artificial Intelligence-based Radiomics in the Era of Immuno-oncology. <i>Oncologist</i> , 2022, 27, e471-e483.	1.9	15
16533	Boosting antitumor response with PSMA-targeted immunomodulatory VLPs, harboring costimulatory TNFSF ligands and GM-CSF cytokine. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 650-662.	2.0	2
16534	TcellInflamedDetector: an R package to distinguish T cell inflamed tumor types from non-T cell inflamed tumor types. <i>Genomics and Informatics</i> , 2022, 20, e13.	0.4	0
16535	Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments. <i>Biomedicines</i> , 2022, 10, 650.	1.4	24
16536	MiR-206 conjugated gold nanoparticle based targeted therapy in breast cancer cells. <i>Scientific Reports</i> , 2022, 12, 4713.	1.6	17

#	ARTICLE	IF	CITATIONS
16537	TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types. <i>Aging</i> , 2022, 14, 2868-2879.	1.4	0
16538	Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment. <i>Journal of Immunology Research</i> , 2022, 2022, 1-9.	0.9	20
16539	Phospholipid Scramblases: Role in Cancer Progression and Anticancer Therapeutics. <i>Frontiers in Genetics</i> , 2022, 13, 875894.	1.1	5
16540	Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 798401.	1.3	4
16541	Heterogeneity induced GZMA-F2R communication inefficient impairs antitumor immunotherapy of PD-1 mAb through JAK2/STAT1 signal suppression in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 213.	2.7	18
16542	The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	0.6	3
16543	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2361-2374.	0.8	45
16544	Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults. <i>JAMA Network Open</i> , 2022, 5, e223461.	2.8	16
16545	TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression. <i>Oncogene</i> , 2022, 41, 2357-2371.	2.6	4
16546	MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy. <i>Cancers</i> , 2022, 14, 1579.	1.7	6
16547	Quantifying the contribution of transcription factor activity, mutations and microRNAs to CD274 expression in cancer patients. <i>Scientific Reports</i> , 2022, 12, 4374.	1.6	6
16548	Hallmarks of Resistance to Immune-Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2022, 10, 372-383.	1.6	36
16549	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 826045.	2.2	13
16550	A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets. <i>Frontiers in Oncology</i> , 2022, 12, 786438.	1.3	6
16551	Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer. , 2022, 10, e003821.		12
16552	Development of Peptide-Based Vaccines for Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	32
16553	Melanoma and Nanotechnology-Based Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 858185.	1.3	12
16554	Bidimensional linked matrix factorization for pan-omics pan-cancer analysis. <i>Annals of Applied Statistics</i> , 2022, 16, 193-215.	0.5	9

#	ARTICLE	IF	CITATIONS
16555	Polymerase Epsilon-Associated Ultramutagenesis in Cancer. <i>Cancers</i> , 2022, 14, 1467.	1.7	9
16556	The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	0
16557	Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy. <i>Cancers</i> , 2022, 14, 1331.	1.7	2
16558	Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	6
16559	Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer. <i>Cells</i> , 2022, 11, 1015.	1.8	7
16560	HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2925.	1.8	19
16561	Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. <i>Cancer Science</i> , 2022, , .	1.7	3
16562	Tumor-Mediated Neutrophil Polarization and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3218.	1.8	20
16563	Diagnosis and prognosis of breast cancer by high-performance serum metabolic fingerprints. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2122245119.	3.3	53
16564	Characterization of aging tumor microenvironment with drawing implications in predicting the prognosis and immunotherapy response in low-grade gliomas. <i>Scientific Reports</i> , 2022, 12, 5457.	1.6	3
16565	Comprehensive Analysis of Colorectal Cancer Immunity and Identification of Immune-Related Prognostic Targets. <i>Disease Markers</i> , 2022, 2022, 1-13.	0.6	3
16566	Serum exosomal miR-16 functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression. <i>Cancer Medicine</i> , 2022, 11, 2627-2643.	1.3	9
16567	Transmembrane Protein-Based Risk Model and H3K4me3 Modification Characteristics in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 828814.	1.3	6
16568	Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 831101.	2.2	7
16569	Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents. <i>Oncologist</i> , 2022, 27, 352-362.	1.9	6
16570	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. <i>Nature Communications</i> , 2022, 13, 1325.	5.8	31
16571	Functions of non-coding RNAs in regulating cancer drug targets. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 279-291.	0.9	5
16572	Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. <i>Molecular Biomedicine</i> , 2022, 3, 8.	1.7	38

#	ARTICLE	IF	CITATIONS
16573	N6-Methyladenine-Related Signature for Immune Microenvironment and Response to Immunotherapy in Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3525-3540.	0.8	5
16574	Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient. <i>Frontiers in Pharmacology</i> , 2022, 13, 817265.	1.6	5
16575	CirITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. , 2022, 10, e004029.		44
16576	Immunotherapy of glioblastoma: Recent advances and future prospects. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-16.	1.4	29
16577	Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. <i>Frontiers in Oncology</i> , 2022, 12, 836859.	1.3	25
16578	Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. <i>Molecular Cancer</i> , 2022, 21, 64.	7.9	45
16579	Biomimetic radiosensitizers unlock radiogenetics for local interstitial radiotherapy to activate systematic immune responses and resist tumor metastasis. <i>Journal of Nanobiotechnology</i> , 2022, 20, 103.	4.2	25
16580	Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation. <i>Australasian Journal of Dermatology</i> , 2022, 63, 217-221.	0.4	6
16581	Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. , 2022, 10, e003569.		10
16582	Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma. <i>Frontiers in Endocrinology</i> , 2022, 13, 829175.	1.5	14
16583	Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?. <i>World Journal of Nuclear Medicine</i> , 2022, 21, 34-43.	0.3	0
16584	Minimally Invasive Preclinical Monitoring of the Peritoneal Cavity Tumor Microenvironment. <i>Cancers</i> , 2022, 14, 1775.	1.7	2
16585	First-line $PD-1$ inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials. <i>Cancer Medicine</i> , 2022, 11, 2043-2055.	1.3	5
16586	Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers. <i>Cancers</i> , 2022, 14, 1681.	1.7	64
16587	Lipid Metabolism Regulation Based on Nanotechnology for Enhancement of Tumor Immunity. <i>Frontiers in Pharmacology</i> , 2022, 13, 840440.	1.6	6
16588	Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study. <i>BMJ Open</i> , 2022, 12, e056424.	0.8	5
16589	5-methylcytosine RNA methylation regulators affect prognosis and tumor microenvironment in lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 259-259.	0.7	15
16590	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. <i>Cell Reports Medicine</i> , 2022, 3, 100554.	3.3	29

#	ARTICLE	IF	CITATIONS
16591	High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 49-63.	1.1	8
16592	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928.	0.8	94
16593	Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors. <i>Nature Biomedical Engineering</i> , 2022, 6, 310-324.	11.6	16
16594	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1323.	1.7	4
16595	Case Report: Outcome and Adverse Events of Anti-PD-1 Antibody Plus Chidamide for Relapsed/Refractory Scleroderma Syndrome: Case Series and A Literature Review. <i>Frontiers in Oncology</i> , 2022, 12, 842123.	1.3	1
16596	Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1500.	1.0	3
16597	It's Not Always SIAD: Immunotherapy-Triggered Endocrinopathies Enter the Field of Cancer-Related Hyponatremia. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac036.	0.1	4
16598	CAR-NK cells for cancer immunotherapy: from bench to bedside. <i>Biomarker Research</i> , 2022, 10, 12.	2.8	65
16599	Efficacy and Prognostic Factors for Response to PD-1 Inhibitors in Advanced Cervical Carcinoma: A Retrospective Study. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 887-897.	2.0	6
16600	Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients. <i>Scientific Reports</i> , 2022, 12, 5448.	1.6	5
16601	Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. <i>Vaccines</i> , 2022, 10, 540.	2.1	8
16602	Local Ablative Therapy Associated with Immunotherapy in Locally Advanced Pancreatic Cancer: A Solution to Overcome the Double Trouble? A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1948.	1.0	7
16603	Checkpoint Inhibitors and Induction of Celiac Disease-like Condition. <i>Biomedicines</i> , 2022, 10, 609.	1.4	5
16604	Management Strategies for Hyperglycemia Associated with the Î±-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. <i>Cancers</i> , 2022, 14, 1598.	1.7	16
16605	Regulation of a Novel Splice Variant of Early Growth Response 4 (EGR4-S) by HER+ Signalling and HSF1 in Breast Cancer. <i>Cancers</i> , 2022, 14, 1567.	1.7	0
16606	The Expression Pattern of Ferroptosis-Related Genes in Colon Adenocarcinoma: Highly Correlated to Tumor Microenvironment Characteristics. <i>Frontiers in Genetics</i> , 2022, 13, 837941.	1.1	0
16607	Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions. <i>Seminars in Cancer Biology</i> , 2022, 86, 532-541.	4.3	14
16608	Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?. <i>Frontiers in Oncology</i> , 2022, 12, 798517.	1.3	9

#	ARTICLE	IF	CITATIONS
16609	Updated Prognostic Factors in Localized NSCLC. <i>Cancers</i> , 2022, 14, 1400.	1.7	28
16610	Integrative Pan-Cancer Analysis of KIF15 Reveals Its Diagnosis and Prognosis Value in Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 772816.	1.3	6
16611	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. <i>Diagnostics</i> , 2022, 12, 685.	1.3	1
16612	The emergence of nanoporous materials in lung cancer therapy. <i>Science and Technology of Advanced Materials</i> , 2022, 23, 225-274.	2.8	15
16613	A Novel Prognostic Ferroptosis-Related lncRNA Signature Associated with Immune Landscape in Invasive Breast Cancer. <i>Disease Markers</i> , 2022, 2022, 1-25.	0.6	4
16614	Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3207.	1.8	7
16615	Comprehensive analysis of pyroptosis regulation patterns and their influence on tumor immune microenvironment and patient prognosis in glioma. <i>Discover Oncology</i> , 2022, 13, 13.	0.8	3
16616	The clinical and prognostic significance of CMTM6/PD-L1 in oncology. <i>Clinical and Translational Oncology</i> , 2022, 24, 1478-1491.	1.2	2
16617	Relationship between Cigarette Smoking and Cancer Characteristics and Survival among Breast Cancer Patients. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4084.	1.2	3
16618	Targeting HIF-1 α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	42
16619	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. <i>BMC Medicine</i> , 2022, 20, 105.	2.3	60
16620	PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases. <i>Frontiers in Pharmacology</i> , 2022, 13, 854967.	1.6	10
16621	Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti-PD-1 Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2022, 28, 1192-1202.	3.2	24
16622	Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases. <i>Frontiers in Immunology</i> , 2022, 13, 852811.	2.2	6
16623	Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival. <i>Frontiers in Oncology</i> , 2022, 12, 847917.	1.3	12
16624	eEF2K promotes PD-L1 stabilization through inactivating GSK3 β in melanoma. , 2022, 10, e004026.		11
16625	Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor. <i>Cancer Discovery</i> , 2022, 12, 1482-1499.	7.7	48
16626	Immunomodulatory Treatment Strategies Targeting B Cells for Heart Failure. <i>Frontiers in Pharmacology</i> , 2022, 13, 854592.	1.6	3

#	ARTICLE	IF	CITATIONS
16627	Identification of molecular subtypes premised on the characteristics of immune infiltration of endometrial cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 337-337.	0.7	4
16628	Immunotherapy-Associated Hypothyroidism: Comparison of the Pre-Existing With De-Novo Hypothyroidism. <i>Frontiers in Endocrinology</i> , 2022, 13, 798253.	1.5	3
16629	T lymphocytes as dynamic regulators of glioma pathobiology. <i>Neuro-Oncology</i> , 2022, 24, 1647-1657.	0.6	18
16630	Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	1.2	2
16631	Secondary Adrenal Insufficiency in a Patient with Metastatic Melanoma Treated with Nivolumab. <i>Case Reports in Dermatology</i> , 2022, 14, 55-60.	0.3	1
16632	Cervical cancer "times" they are a changing: A report from the Society of Gynecologic Oncology journal club. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100949.	0.3	0
16633	In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4077.	1.8	4
16634	"Know thyself"™ " host factors influencing cancer response to immune checkpoint inhibitors. <i>Journal of Pathology</i> , 2022, 257, 513-525.	2.1	8
16635	Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2022, 165, 664-670.	0.6	7
16636	Extracellular Vesicle-Mediated Mitochondrial Reprogramming in Cancer. <i>Cancers</i> , 2022, 14, 1865.	1.7	6
16637	CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 834002.	1.3	8
16638	Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target. , 2022, 10, e004302.		20
16639	Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100307.	0.6	9
16640	Tyrosinase suppresses vasculogenic mimicry in human melanoma cells. <i>Oncology Letters</i> , 2022, 23, 169.	0.8	6
16641	Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function. <i>Frontiers in Immunology</i> , 2022, 13, 845499.	2.2	8
16642	Identification of RNA Methylation-Related lncRNAs Signature for Predicting Hot and Cold Tumors and Prognosis in Colon Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 870945.	1.1	10
16643	Multiplexed single-cell analysis reveals prognostic and nonprognostic T cell types in human colorectal cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	24
16644	Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors. <i>Breast Cancer Research</i> , 2022, 24, 23.	2.2	5

#	ARTICLE	IF	CITATIONS
16645	Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2587-2597.	3.2	16
16646	Efficacy of Cytokine-Induced Killer Cell Immunotherapy for Patients With Pathologically Pure Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 851628.	1.3	4
16647	BRCA testing and testing results among women 18–65 years old. <i>Preventive Medicine Reports</i> , 2022, 26, 101738.	0.8	3
16648	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. <i>Journal of Translational Medicine</i> , 2022, 20, 159.	1.8	12
16649	High Expression of RAI14 in Triple-Negative Breast Cancer Participates in Immune Recruitment and Implies Poor Prognosis Through Bioinformatics Analyses. <i>Frontiers in Pharmacology</i> , 2022, 13, 809454.	1.6	1
16650	BAP1-deficient breast cancer in a patient with BAP1 cancer syndrome. <i>Breast Cancer</i> , 2022, 29, 921-927.	1.3	2
16651	Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents. <i>Healthcare (Switzerland)</i> , 2022, 10, 694.	1.0	4
16652	Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100309.	0.6	8
16653	Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 1813.	1.7	4
16654	Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 838966.	2.2	3
16655	Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2022, 13, 864739.	2.2	40
16656	The Role of NcrNAs to Regulate Immune Checkpoints in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 853480.	2.2	12
16657	High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer. <i>Journal of Pathology: Clinical Research</i> , 2022, , .	1.3	2
16658	Developing a translational murine canine pathway for an IL-2/agonist anti-CD40 antibody cancer immunotherapy. <i>Veterinary and Comparative Oncology</i> , 2022, 20, 602-612.	0.8	4
16659	CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3809-3826.	0.8	2
16660	UV-induced local immunosuppression in the tumour microenvironment of eccrine porocarcinoma and poroma. <i>Scientific Reports</i> , 2022, 12, 5529.	1.6	4
16661	Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2323-2341.	3.3	48
16662	Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 1689-1695.	0.8	4

#	ARTICLE	IF	CITATIONS
16663	TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. , 2022, 10, e004711.		69
16664	Somatic Mutations in Core Spliceosome Components Promote Tumorigenesis and Generate an Exploitable Vulnerability in Human Cancer. <i>Cancers</i> , 2022, 14, 1827.	1.7	8
16665	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. <i>Cell Communication and Signaling</i> , 2022, 20, 44.	2.7	109
16666	Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?. <i>Cancers</i> , 2022, 14, 1856.	1.7	12
16667	Agents of cancer immunosurveillance: HSPs and dsDNA. <i>Trends in Immunology</i> , 2022, 43, 404-413.	2.9	7
16668	Abemaciclib-loaded ethylcellulose based nanospheres for sustained cytotoxicity against MCF-7 and MDA-MB-231 human breast cancer cells lines. <i>Saudi Pharmaceutical Journal</i> , 2022, 30, 726-734.	1.2	11
16669	Elevated tumor markers for monitoring tumor response to immunotherapy. <i>EClinicalMedicine</i> , 2022, 46, 101381.	3.2	4
16670	Ubiquitin ligase STUB1 destabilizes IFN γ -receptor complex to suppress tumor IFN γ signaling. <i>Nature Communications</i> , 2022, 13, 1923.	5.8	18
16671	KRAS: A Druggable Target in Colon Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4120.	1.8	13
16672	Cardiac Magnetic Resonance Imaging in Immune Check-Point Inhibitor Myocarditis: A Systematic Review. <i>Journal of Imaging</i> , 2022, 8, 99.	1.7	4
16673	Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 872531.	1.3	16
16674	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 441-457.	12.5	176
16675	Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. <i>ESMO Open</i> , 2022, 7, 100419.	2.0	7
16676	Weighted Gene Coexpression Network Analysis Identifies TBC1D10C as a New Prognostic Biomarker for Breast Cancer. <i>Analytical Cellular Pathology</i> , 2022, 2022, 1-20.	0.7	1
16677	Enhanced T-Cell Priming and Improved Anti-Tumor Immunity through Lymphatic Delivery of Checkpoint Blockade Immunotherapy. <i>Cancers</i> , 2022, 14, 1823.	1.7	4
16678	Acute Kidney Injury Induced by Immune Checkpoint Inhibitors. <i>Kidney Diseases (Basel, Switzerland)</i> , 2022, 8, 190-201.	1.2	11
16679	The role of microRNA-4723-5p regulated by c-myc in triple-negative breast cancer. <i>Bioengineered</i> , 2022, 13, 9097-9105.	1.4	1
16680	Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. <i>Cancers</i> , 2022, 14, 1804.	1.7	4

#	ARTICLE	IF	CITATIONS
16681	Endothelial Cell Adhesion Molecules- (un)Attainable Targets for Nanomedicines. <i>Frontiers in Medical Technology</i> , 2022, 4, 846065.	1.3	7
16682	A Pyroptosis-Related Gene Signature Predicts Prognosis and Immune Microenvironment for Breast Cancer Based on Computational Biology Techniques. <i>Frontiers in Genetics</i> , 2022, 13, 801056.	1.1	9
16683	Comprehensive Analysis of Tumor Immune Microenvironment Characteristics for the Prognostic Prediction and Immunotherapy of Oral Squamous Cell Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 788580.	1.1	8
16684	Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 1479-1489.	0.8	6
16685	CAR-T Cells for the Treatment of Lung Cancer. <i>Life</i> , 2022, 12, 561.	1.1	8
16686	Predictive biomarkers for the efficacy of nivolumab as 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. <i>BMC Cancer</i> , 2022, 22, 378.	1.1	16
16687	Clinical trial data and emerging strategies: HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 281-291.	1.1	12
16688	Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing. <i>BioDrugs</i> , 2022, 36, 373-380.	2.2	2
16689	Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1893-1901.	1.2	8
16690	PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma. <i>Oncolmmunology</i> , 2022, 11, 2061396.	2.1	20
16691	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. <i>Frontiers in Immunology</i> , 2022, 13, 830631.	2.2	28
16692	TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 860563.	1.3	12
16693	Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management. <i>International Journal of Ophthalmology</i> , 2022, 15, 646-656.	0.5	12
16694	Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients. <i>BMC Endocrine Disorders</i> , 2022, 22, 89.	0.9	14
16695	Organoid Models for Precision Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 770465.	2.2	23
16696	Prediction of Survival Rate and Chemotherapy Effect by an Immune Score Model in Colorectal Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-13.	0.9	0
16697	Comprehensive Analysis of CDK1-Associated ceRNA Network Revealing the Key Pathways LINC00460/LINC00525-Hsa-Mir-338-FAM111/ZWINT as Prognostic Biomarkers in Lung Adenocarcinoma Combined with Experiments. <i>Cells</i> , 2022, 11, 1220.	1.8	5
16698	Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. <i>BMJ Open</i> , 2022, 12, e059779.	0.8	1

#	ARTICLE	IF	CITATIONS
16699	Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	5
16700	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. <i>Nature Communications</i> , 2022, 13, 1878.	5.8	3
16701	Imaging immunity in patients with cancer using positron emission tomography. <i>Npj Precision Oncology</i> , 2022, 6, 24.	2.3	13
16702	Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 2461-2473.	3.2	9
16703	New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis. , 2022, 10, e003765.		10
16704	Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally. <i>Clinical Cancer Research</i> , 2022, 28, 2994-3001.	3.2	15
16705	A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. <i>Cell Metabolism</i> , 2022, 34, 595-614.e14.	7.2	70
16706	Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 82-89.	0.6	2
16707	Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study. <i>Dermatologic Therapy</i> , 2022, 35, e15492.	0.8	3
16708	Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Quantum Leap in the Treatment of Advanced Breast Cancers. <i>Cureus</i> , 2022, 14, e23901.	0.2	1
16709	The role of tumor-infiltrating lymphocytes in cholangiocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 127.	3.5	39
16710	Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC. <i>Frontiers in Immunology</i> , 2022, 13, 828560.	2.2	18
16711	Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer. <i>ESMO Open</i> , 2022, 7, 100445.	2.0	26
16712	Enhancer RNA Transcription Is Essential for a Novel CSF1 Enhancer in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1852.	1.7	3
16713	Inhibition of renalase drives tumour rejection by promoting T cell activation. <i>European Journal of Cancer</i> , 2022, 165, 81-96.	1.3	2
16714	Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	21
16715	Bacteria as Nanoparticle Carriers for Immunotherapy in Oncology. <i>Pharmaceutics</i> , 2022, 14, 784.	2.0	3
16716	Immunogenic Cell Death-Relevant Damage-Associated Molecular Patterns and Sensing Receptors in Triple-Negative Breast Cancer Molecular Subtypes and Implications for Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 870914.	1.3	26

#	ARTICLE	IF	CITATIONS
16717	Cannabis suppresses antitumor immunity by inhibiting JAK/STAT signaling in T cells through CNR2. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 99.	7.1	18
16718	Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients. <i>International Immunopharmacology</i> , 2022, 106, 108628.	1.7	1
16719	Plasma secretome analyses identify IL-8 and nitrites as predictors of poor prognosis in nasopharyngeal carcinoma patients. <i>Cytokine</i> , 2022, 153, 155852.	1.4	1
16720	Genetics of cancer therapy-associated cardiotoxicity. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 167, 85-91.	0.9	10
16721	Multimodal predictors for precision immunotherapy. <i>Immuno-Oncology Technology</i> , 2022, 14, 100071.	0.2	4
16722	“The emerging role of capivasertib in breast cancer” <i>Breast</i> , 2022, 63, 157-167.	0.9	20
16723	Cytotoxicity, crosslinking and biological activity of three mitomycins. <i>Bioorganic Chemistry</i> , 2022, 123, 105744.	2.0	1
16724	Mature dendritic cell-derived dendrosomes swallow oxaliplatin-loaded nanoparticles to boost immunogenic chemotherapy and tumor antigen-specific immunotherapy. <i>Bioactive Materials</i> , 2022, 15, 15-28.	8.6	9
16725	Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy. <i>Bioactive Materials</i> , 2022, 16, 107-119.	8.6	24
16726	Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis. <i>Journal of Medical Internet Research</i> , 2022, 24, e32728.	2.1	7
16727	Development of a Prognostic Nomogram for Patients with Lung Adenocarcinoma in the Stages I, II, and III Based on Immune Scores. <i>International Journal of General Medicine</i> , 2021, Volume 14, 8677-8688.	0.8	4
16728	Old and New Players of Inflammation and Their Relationship With Cancer Development. <i>Frontiers in Oncology</i> , 2021, 11, 722999.	1.3	14
16729	Inhibition of triple-negative breast cancer proliferation and motility by reactivating p53 and inhibiting overactivated Akt. <i>Oncology Reports</i> , 2021, 47, .	1.2	8
16730	Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. , 2021, 9, e003439.		10
16731	Subclonal heterogeneity and evolution in breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 155.	2.3	23
16732	De novo individualized disease modules reveal the synthetic penetrance of genes and inform personalized treatment regimens. <i>Genome Research</i> , 2022, 32, 124-134.	2.4	4
16733	The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. <i>British Journal of Cancer</i> , 2022, 126, 1168-1177.	2.9	9
16734	Correlation-based and feature-driven mutation signature analyses to identify genetic features associated with DNA mutagenic processes in cancer genomes. <i>Genomics and Informatics</i> , 2021, 19, e40.	0.4	1

#	ARTICLE	IF	CITATIONS
16735	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13311.	1.8	54
16736	Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. <i>Nature Communications</i> , 2021, 12, 7041.	5.8	43
16737	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. <i>Clinical Cancer Research</i> , 2022, 28, 960-971.	3.2	4
16738	Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 427-439.	1.9	10
16739	Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset. <i>Nature Communications</i> , 2021, 12, 7304.	5.8	17
16740	Identification and Development of Subtypes with Poor Prognosis in Gastric Cancer Based on Both Hypoxia and Immune Cell Infiltration. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9379-9399.	0.8	6
16741	Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. , 2021, 9, e002780.		15
16742	Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. <i>Science Translational Medicine</i> , 2021, 13, eabf8495.	5.8	16
16743	ENTREP/FAM189A2 encodes a new ITCH ubiquitin ligase activator that is downregulated in breast cancer. <i>EMBO Reports</i> , 2022, 23, e51182.	2.0	8
16744	B7-1 and programmed cell death ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma. <i>Cancer Medicine</i> , 2022, 11, 479-491.	1.3	5
16745	WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	7
16746	Prognostic Model Construction and Immune Microenvironment Analysis of Breast Cancer Based on Ferroptosis-Related lncRNAs. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9817-9831.	0.8	7
16747	A Novel Kinase Inhibitor AX-0085 Inhibits Interferon- β -Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells. <i>Cells</i> , 2022, 11, 19.	1.8	3
16748	PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC: A Cost-Effectiveness Analysis in China. <i>Frontiers in Oncology</i> , 2021, 11, 745493.	1.3	2
16749	Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 794099.	2.2	34
16750	Polo-Like Kinase 1 (PLK1) Immunohistochemical Expression in Triple Negative Breast Carcinoma: A Probable Therapeutic Target. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 3921-3925.	0.5	3
16751	Current Advancements of Plant-Derived Agents for Triple-Negative Breast Cancer Therapy through Deregulating Cancer Cell Functions and Reprogramming Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13571.	1.8	8
16752	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. <i>Frontiers in Immunology</i> , 2021, 12, 773168.	2.2	18

#	ARTICLE	IF	CITATIONS
16753	Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 719140.	1.3	2
16754	IL-36 β promotes anti-tumor effects in CD8 $^+$ T cells by downregulating micro-RNA let-7c-5p. <i>Annals of Translational Medicine</i> , 2021, 9, 1734-1734.	0.7	2
16755	Anesthesia Techniques and Long-Term Oncological Outcomes. <i>Frontiers in Oncology</i> , 2021, 11, 788918.	1.3	10
16756	Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment. <i>Cancers</i> , 2021, 13, 6231.	1.7	13
16757	The Diverse Roles of β 1 T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma. <i>Cancers</i> , 2021, 13, 6212.	1.7	13
16758	Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer. <i>Aging</i> , 2021, 13, 25518-25549.	1.4	3
16759	Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 9411-9420.	0.9	0
16760	HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis. <i>Journal of Immunology Research</i> , 2021, 2021, 1-12.	0.9	13
16761	WNT11/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 395.	3.5	16
16762	Loss of myeloid cell-specific SIRP α , but not CD47, attenuates inflammation and suppresses atherosclerosis. <i>Cardiovascular Research</i> , 2022, 118, 3097-3111.	1.8	18
16763	Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers. <i>Cancer Research</i> , 2022, 82, 665-680.	0.4	5
16764	Integrative Molecular Analyses of an Individual Transcription Factor-Based Genomic Model for Lung Cancer Prognosis. <i>Disease Markers</i> , 2021, 2021, 1-18.	0.6	2
16765	microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1. <i>Bioengineered</i> , 2022, 13, 917-929.	1.4	15
16766	Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. <i>Frontiers in Immunology</i> , 2021, 12, 793831.	2.2	16
16767	Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. , 2021, 9, e003645.		23
16768	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. <i>Cancers</i> , 2022, 14, 109.	1.7	21
16769	Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response. <i>Nature Communications</i> , 2021, 12, 7297.	5.8	25
16770	Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD-L1. <i>Advanced Science</i> , 2022, 9, e2103245.	5.6	22

#	ARTICLE	IF	CITATIONS
16771	Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-10.	0.7	5
16772	Assessing PD-L1 Expression Status Using Radiomic Features from Contrast-Enhanced Breast MRI in Breast Cancer Patients: Initial Results. Cancers, 2021, 13, 6273.	1.7	9
16773	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm, 2021, 2, 692-729.	3.1	38
16775	Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics. Cancer Research Communications, 2021, 1, 178-193.	0.7	8
16776	Deep Learning to Predict EGFR Mutation and PD-L1 Expression Status in Non-Small-Cell Lung Cancer on Computed Tomography Images. Journal of Oncology, 2021, 2021, 1-11.	0.6	20
16777	Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review. Translational Cancer Research, 2021, 10, 5406-5429.	0.4	4
16778	Three-Dimensional Genome Organization in Breast and Gynecological Cancers: How Chromatin Folding Influences Tumorigenic Transcriptional Programs. Cells, 2022, 11, 75.	1.8	4
16779	A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 813331.	2.2	9
16780	Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers. Cancer Research and Treatment, 2022, 54, 1200-1208.	1.3	11
16781	Single-Cell Transcriptome Analysis Reveals RGS1 as a New Marker and Promoting Factor for T-Cell Exhaustion in Multiple Cancers. Frontiers in Immunology, 2021, 12, 767070.	2.2	29
16782	The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer. Cancer Research and Treatment, 2022, 54, 1111-1120.	1.3	1
16783	Management of acute kidney injury in gastrointestinal tumor: An overview. World Journal of Clinical Cases, 2021, 9, 10746-10764.	0.3	0
16784	Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer. Cancer Discovery, 2022, 12, 1022-1045.	7.7	43
16785	A Pan-Cancer Analysis of Predictive Methylation Signatures of Response to Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 796647.	2.2	16
16786	NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis. Cell Metabolism, 2021, 33, 2380-2397.e9.	7.2	73
16787	Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways. BMC Medical Genomics, 2021, 14, 295.	0.7	5
16788	In Vitro Antineoplastic and Antiviral Activity and In Vivo Toxicity of Geum urbanum L. Extracts. Molecules, 2022, 27, 245.	1.7	5
16789	Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. Journal of Advanced Research, 2022, 40, 109-124.	4.4	10

#	ARTICLE	IF	CITATIONS
16790	Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1801-1801.	0.7	11
16791	Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 797880.	2.2	35
16792	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 509-528.	21.5	201
16793	NKG7 Is a T-cellâ€™Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2022, 10, 162-181.	1.6	26
16794	Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 689076.	2.2	21
16795	Clinical Trials of Oncolytic Viruses in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 803050.	1.3	13
16796	Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update. <i>Breast</i> , 2022, 62, S29-S33.	0.9	7
16797	A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract. <i>Medical Science Monitor</i> , 2022, 28, e935348.	0.5	2
16798	Development of a nonhuman primate challenge model to evaluate CD8 ⁺ T cell responses to an adenovirus-based vaccine expressing SIV proteins upon repeat-dose treatment with checkpoint inhibitors. <i>MAbs</i> , 2022, 14, 1979447.	2.6	1
16799	Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience. <i>South Asian Journal of Cancer</i> , 2022, 11, 058-061.	0.2	1
16800	Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. <i>Nature Communications</i> , 2021, 12, 7280.	5.8	11
16801	Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 799428.	2.2	39
16802	Low Expression of PLAT in Breast Cancer Infers Poor Prognosis and High Immune Infiltrating Level. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10213-10224.	0.8	4
16803	Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis. <i>Diagnostics</i> , 2021, 11, 2370.	1.3	6
16804	Chamaejasmenin B, an Inhibitor for Metastatic Outgrowth, Reversed M2-Dominant Macrophage Polarization in Breast Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 774230.	2.2	1
16805	Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A realâ€™world study. <i>Cancer Medicine</i> , 2022, 11, 139-150.	1.3	6
16806	Prognostic significance of natural killer cell-associated markers in gastric cancer: quantitative analysis using multiplex immunohistochemistry. <i>Journal of Translational Medicine</i> , 2021, 19, 529.	1.8	8
16807	Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance. <i>Modern Pathology</i> , 2022, 35, 615-624.	2.9	7

#	ARTICLE	IF	CITATIONS
16808	Efficacy and Safety of Immune Checkpoint Blockades in the Treatment of Ocular Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 781162.	1.3	3
16809	Identification and Validation of the lncRNA BACE1-AS as Immune-Related Influencing Factor in Tumorigenesis following Pan-Carcinoma Analysis. <i>Journal of Immunology Research</i> , 2021, 2021, 1-21.	0.9	6
16810	Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy. <i>Cancers</i> , 2021, 13, 6352.	1.7	2
16811	Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 6246.	1.7	9
16812	Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	3
16813	Pathogenesis of Autoimmune Hepatitis—Cellular and Molecular Mechanisms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13578.	1.8	33
16814	<i>Cutibacterium acnes</i> Induces the Expression of Immunosuppressive Genes in Macrophages and is Associated with an Increase of Regulatory T-Cells in Prostate Cancer. <i>Microbiology Spectrum</i> , 2021, 9, e0149721.	1.2	10
16815	Magnetic nanoparticles in theranostics of malignant melanoma. <i>EJNMMI Research</i> , 2021, 11, 127.	1.1	9
16816	Circ_0014235 confers Gefitinib resistance and malignant behaviors in non-small cell lung cancer resistant to Gefitinib by governing the miR-146b-5p/YAP/PD-L1 pathway. <i>Cell Cycle</i> , 2022, 21, 86-100.	1.3	10
16817	Epstein-Barr Virus Epithelial Cancers—A Comprehensive Understanding to Drive Novel Therapies. <i>Frontiers in Immunology</i> , 2021, 12, 734293.	2.2	24
16818	Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines. <i>Methods in Molecular Biology</i> , 2022, 2410, 649-670.	0.4	11
16819	Not so “rare” an example of malignant melanoma in India: report from a tertiary cancer centre. <i>Ecanermedicalscience</i> , 2021, 15, 1335.	0.6	1
16820	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2022, 126, 889-898.	2.9	8
16821	Interleukin-8 in Melanoma Pathogenesis, Prognosis and Therapy—An Integrated View into Other Neoplasms and Chemokine Networks. <i>Cells</i> , 2022, 11, 120.	1.8	14
16822	Oncolytic virotherapy as immunotherapy. <i>Science</i> , 2021, 374, 1325-1326.	6.0	51
16823	Clinical and Prognostic Significance of Tumor-Infiltrating CD8+ T Cells and PD-L1 Expression in Primary Gastrointestinal Stromal Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 789915.	1.3	8
16824	Costimulation of $\hat{3}$ TCR and TLR7/8 promotes $\hat{2}$ T-cell antitumor activity by modulating mTOR pathway and APC function. , 2021, 9, e003339.		14
16825	A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2021, 10, 4511-4525.	1.3	6

#	ARTICLE	IF	CITATIONS
16826	Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment. <i>BMC Pulmonary Medicine</i> , 2021, 21, 420.	0.8	7
16827	Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient. <i>Thoracic Cancer</i> , 2022, 13, 510-513.	0.8	2
16828	The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 118.	2.2	5
16829	Tumor Endothelial Marker TEM7 is a Prognostic Biomarker and Correlating with Immune Infiltrates in Gastric Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10155-10171.	0.8	1
16830	Expression and Clinical Significance of Origin Recognition Complex Subunit 6 in Breast Cancer – A Comprehensive Bioinformatics Analysis. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9733-9745.	0.8	2
16831	Fecal Streptococcus Alteration Is Associated with Gastric Cancer Occurrence and Liver Metastasis. <i>MBio</i> , 2021, 12, e0299421.	1.8	25
16832	Pan-Cancer Analyses of the Tumor Microenvironment Reveal That Ubiquitin-Conjugating Enzyme E2C Might Be a Potential Immunotherapy Target. <i>Journal of Immunology Research</i> , 2021, 2021, 1-27.	0.9	5
16833	Immunotherapy Resistance in Glioblastoma. <i>Frontiers in Genetics</i> , 2021, 12, 750675.	1.1	13
16834	Can Systems Biology Advance Clinical Precision Oncology?. <i>Cancers</i> , 2021, 13, 6312.	1.7	10
16835	Joint and individual analysis of breast cancer histologic images and genomic covariates. <i>Annals of Applied Statistics</i> , 2021, 15, 1697-1722.	0.5	4
16836	pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition. <i>Frontiers in Immunology</i> , 2021, 12, 794226.	2.2	2
16837	FOLFIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial. <i>Frontiers in Oncology</i> , 2021, 11, 766500.	1.3	12
16838	Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset. <i>Bioengineered</i> , 2021, 12, 10366-10378.	1.4	3
16839	Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids. <i>Cancers</i> , 2021, 13, 6158.	1.7	17
16840	CRISPR Screens to Identify Regulators of Tumor Immunity. <i>Annual Review of Cancer Biology</i> , 2022, 6, 103-122.	2.3	5
16841	Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 629-636.	3.2	15
16842	C1632 suppresses the migration and proliferation of non-small cell lung cancer cells involving LIN28 and FGFR1 pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 422-435.	1.6	8
16843	Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. <i>Precision Clinical Medicine</i> , 2021, 4, 258-270.	1.3	18

#	ARTICLE	IF	CITATIONS
16844	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in <scp>China</scp>. <i>Thoracic Cancer</i> , 2022, 13, 412-422.	0.8	19
16845	Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by 18F-FDG PET/CT Radiomics and Clinicopathological Characteristics. <i>Frontiers in Oncology</i> , 2021, 11, 789014.	1.3	30
16846	Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. <i>Pharmaceutics</i> , 2022, 14, 41.	2.0	27
16847	Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment. <i>Nutrients</i> , 2022, 14, 79.	1.7	15
16848	Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. <i>Cancers</i> , 2021, 13, 6109.	1.7	9
16849	Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of ⁸⁹ Zr-Labeled Anti-PD-L1 Antibody Formats. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1259-1265.	2.8	11
16850	Emerging immunological strategies: recent advances and future directions. <i>Frontiers of Medicine</i> , 2021, 15, 805-828.	1.5	5
16851	Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. <i>Clinical Breast Cancer</i> , 2022, 22, 308-318.	1.1	2
16852	Adjunctive Probiotic <i>Lactobacillus rhamnosus</i> Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota. <i>Frontiers in Immunology</i> , 2021, 12, 772532.	2.2	47
16853	A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities. <i>Frontiers in Immunology</i> , 2021, 12, 778978.	2.2	20
16854	Characterization of m6A RNA Methylation Regulators Predicts Survival and Immunotherapy in Lung Adenocarcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 782551.	2.2	7
16855	Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy. <i>Pathology and Oncology Research</i> , 2021, 27, 1609972.	0.9	8
16856	Clinical and prognostic implications of an immune-related risk model based on <i>TP53</i> status in lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 436-448.	1.6	3
16857	Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy. <i>Frontiers in Oncology</i> , 2021, 11, 789078.	1.3	6
16858	ADAMTS8 Expression is a Potential Prognostic Biomarker for Postoperative Metastasis in Lymph Node-Negative Early-Stage Invasive Breast Carcinoma Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1701-1713.	0.4	0
16859	ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. <i>Cancer Medicine</i> , 2022, 11, 880-887.	1.3	5
16860	Molecular analysis of TCGA breast cancer histologic types. <i>Cell Genomics</i> , 2021, 1, 100067.	3.0	37
16861	Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2022, 82, 15-32.	4.9	3

#	ARTICLE	IF	CITATIONS
16862	Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion. <i>Frontiers in Immunology</i> , 2021, 12, 760683.	2.2	4
16863	Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. <i>Clinical Cancer Research</i> , 2022, 28, 1363-1371.	3.2	2
16864	Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. <i>The Cochrane Library</i> , 2021, 2021, CD011300.	1.5	8
16866	mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 774103.	2.2	57
16868	Galectins: An Ancient Family of Carbohydrate Binding Proteins with Modern Functions. <i>Methods in Molecular Biology</i> , 2022, 2442, 1-40.	0.4	21
16869	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	1.9	1
16870	Cardiac complications of cancer therapies. <i>Advances in Cancer Research</i> , 2022, , 167-214.	1.9	5
16871	Prediction of the Immune Phenotypes of Bladder Cancer Patients for Precision Oncology. <i>IEEE Open Journal of Engineering in Medicine and Biology</i> , 2022, 3, 47-57.	1.7	2
16872	Antitumor Effect and Induced Immune Response Following Exposure of Hexaminolevulinate and Blue Light in Combination with Checkpoint Inhibitor in an Orthotopic Model of Rat Bladder Cancer. <i>Biomedicines</i> , 2022, 10, 548.	1.4	4
16873	Understanding Drug Sensitivity and Tackling Resistance in Cancer. <i>Cancer Research</i> , 2022, 82, 1448-1460.	0.4	24
16874	Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers. <i>Cancers</i> , 2022, 14, 1627.	1.7	7
16875	Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients. <i>Frontiers in Immunology</i> , 2022, 13, 783695.	2.2	5
16876	Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2657-2668.	3.2	4
16877	CD155 expression and its clinical significance in non-small cell lung cancer. <i>Oncology Letters</i> , 2022, 23, 166.	0.8	7
16878	Challenges and Gaps in Clinical Trial Genomic Data Management. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100193.	1.0	0
16879	Immunotherapy in triple-negative breast cancer: A literature review and new advances. <i>World Journal of Clinical Oncology</i> , 2022, 13, 219-236.	0.9	16
16880	The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer. <i>Frontiers in Surgery</i> , 2022, 9, 895982.	0.6	1
16881	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. <i>Nature Communications</i> , 2022, 13, 1935.	5.8	37

#	ARTICLE	IF	CITATIONS
16882	PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. <i>Frontiers in Pharmacology</i> , 2022, 13, 835510.	1.6	10
16883	Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy. <i>Thoracic Cancer</i> , 2022, 13, 1631-1641.	0.8	8
16884	Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity. <i>MedComm</i> , 2022, 3, e137.	3.1	11
16885	Dissection of Immune Profiles in Microsatellite Stable and Low Microsatellite Instability Colon Adenocarcinoma by Multiomics Data Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	0
16886	Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA). <i>Oncolmmunology</i> , 2022, 11, 2066609.	2.1	13
16887	The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 1913.	1.7	7
16888	Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics™. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 783494.	1.6	6
16889	Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 837525.	1.3	6
16890	Construction and validation of a protein-associated prognostic model for gastrointestinal cancer. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, .	0.6	0
16891	Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article. <i>Current Oncology</i> , 2022, 29, 2871-2886.	0.9	24
16892	A loss-of-function polymorphism in <i>ATG16L1</i> compromises therapeutic outcome in head and neck carcinoma patients. <i>Oncolmmunology</i> , 2022, 11, 2059878.	2.1	3
16893	Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine. <i>Frontiers in Immunology</i> , 2022, 13, 826164.	2.2	8
16894	STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation. <i>Nano Research</i> , 2022, 15, 6328-6339.	5.8	13
16895	The ratio of CD8+ lymphocytes to tumor-infiltrating suppressive FOXP3+effector regulatory T cells is associated with treatment response in invasive breast cancer. <i>Discover Oncology</i> , 2022, 13, 27.	0.8	10
16896	Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 752-758.	0.4	5
16897	Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter. <i>Frontiers in Oncology</i> , 2022, 12, 880876.	1.3	21
16898	Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer. <i>Cancer Medicine</i> , 2022, 11, 3886-3901.	1.3	9
16899	Tumor Microenvironment Profiling Identifies Prognostic Signatures and Suggests Immunotherapeutic Benefits in Neuroblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 814836.	1.8	3

#	ARTICLE	IF	CITATIONS
16900	A Cancer Associated Fibroblasts-Related Six-Gene Panel for Anti-PD-1 Therapy in Melanoma Driven by Weighted Correlation Network Analysis and Supervised Machine Learning. <i>Frontiers in Medicine</i> , 2022, 9, 880326.	1.2	9
16901	Emerging therapies for glioblastoma: current state and future directions. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 142.	3.5	103
16902	Structural Requirements for the Binding of a Peptide to Prohibitins on the Cell Surface of Monocytes/Macrophages. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4282.	1.8	5
16903	Expression and Prognostic Implication of PD-L1 in Patients with Urothelial Carcinoma with Variant Histology (Squamous Differentiation or Micropapillary) Undergoing Radical Cystectomy. <i>Biomedicines</i> , 2022, 10, 910.	1.4	2
16904	Tumor-associated macrophages promote intratumoral conversion of conventional CD4 ⁺ T cells into regulatory T cells via PD-1 signalling. <i>Oncolmmunology</i> , 2022, 11, 2063225.	2.1	14
16905	Platycodon grandiflorum Triggers Antitumor Immunity by Restricting PD-1 Expression of CD8+ T Cells in Local Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 2022, 13, 774440.	1.6	5
16906	Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity. <i>Molecular Carcinogenesis</i> , 2022, 61, 664-676.	1.3	3
16907	The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2731-2742.	2.0	6
16908	The Give-and-Take Interaction Between the Tumor Microenvironment and Immune Cells Regulating Tumor Progression and Repression. <i>Frontiers in Immunology</i> , 2022, 13, 850856.	2.2	20
16909	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2547-2554.	3.2	32
16910	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. <i>Cancers</i> , 2022, 14, 2056.	1.7	24
16911	CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab. <i>BMC Cancer</i> , 2022, 22, 418.	1.1	3
16912	Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. <i>Advances in Therapy</i> , 2022, 39, 2831-2849.	1.3	5
16913	A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors. <i>Oncolmmunology</i> , 2022, 11, 2064958.	2.1	10
16914	T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity. <i>Cancers</i> , 2022, 14, 1998.	1.7	9
16915	Immune cell subsets in interface cutaneous immune-related adverse events associated with anti-PD therapy resemble acute graft versus host disease more than lichen planus. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 701-708.	0.7	4
16916	Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab. <i>International Journal of Cancer</i> , 2022, 151, 473-480.	2.3	24
16917	Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features. <i>Frontiers in Immunology</i> , 2022, 13, 875093.	2.2	10

#	ARTICLE	IF	CITATIONS
16918	Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge. <i>Molecular and Clinical Oncology</i> , 2022, 16, 104.	0.4	3
16919	Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2765-2776.	2.0	7
16920	Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review. <i>Journal of Neuro-Oncology</i> , 2022, 157, 533-550.	1.4	7
16921	The landscape of immune microenvironments in racially-diverse breast cancer patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , .	1.1	7
16922	Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy. <i>Immunotherapy</i> , 2022, 14, 593-598.	1.0	15
16923	Risk Analysis of Positive PD-L1 Expression and Clinicopathological Features and Survival Prognosis in Patients with Colorectal Cancer: Systematic Review and Meta-Analysis. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-8.	1.1	6
16924	The Landscape of Immunotherapy Resistance in NSCLC. <i>Frontiers in Oncology</i> , 2022, 12, 817548.	1.3	27
16925	Classification of colorectal carcinoma subtypes based on ferroptosis-associated molecular markers. <i>World Journal of Surgical Oncology</i> , 2022, 20, 117.	0.8	6
16926	The top 100 most cited articles on triple-negative breast cancer: a bibliometric analysis. <i>Clinical and Experimental Medicine</i> , 2022, , 1.	1.9	4
16927	Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 4446-4457.	5.7	15
16928	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 862084.	2.2	18
16929	Nuclear translocation of p85 ¹² promotes tumorigenesis of PIK3CA helical domain mutant cancer. <i>Nature Communications</i> , 2022, 13, 1974.	5.8	13
16930	Activation of T cell checkpoint pathways during Î² cell antigen presentation by engineered dendritic cells promotes protection from type 1 diabetes. <i>Immunology</i> , 2022, 166, 341-356.	2.0	2
16931	Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. <i>BioMed Research International</i> , 2022, 2022, 1-16.	0.9	156
16932	Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers. <i>Frontiers in Immunology</i> , 2022, 13, 810539.	2.2	4
16933	Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 837560.	1.3	2
16934	Pan-cancer analysis of mutations in open chromatin regions and their possible association with cancer pathogenesis. <i>Cancer Medicine</i> , 2022, , .	1.3	3
16935	EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives. <i>Biomarker Research</i> , 2022, 10, 21.	2.8	28

#	ARTICLE	IF	CITATIONS
16936	Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts. <i>Cancer Discovery</i> , 2022, 12, 1760-1781.	7.7	15
16937	Dissecting the Role of Immune Checkpoint Regulation Patterns in Tumor Microenvironment and Prognosis of Gastric Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 853648.	1.1	5
16938	Incidence of Elevated Aminotransferases With or Without Bilirubin Elevation During Treatment With Immune Checkpoint Inhibitors: A Retrospective Study of Patients From Community Oncology Clinics in the United States. <i>Cureus</i> , 2022, 14, e24053.	0.2	1
16939	Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 865656.	1.3	0
16940	Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2022, 15, 489.	1.7	6
16941	Endothelial Cells Activated by Extracellular Histones Promote Foxp3+ Suppressive Treg Cells In Vitro. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4527.	1.8	2
16942	Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer. <i>Cancers</i> , 2022, 14, 1924.	1.7	5
16943	Beyond the snapshot: optimizing prognostication and prediction by moving from fixed to functional multidimensional cancer pathology. <i>Journal of Pathology</i> , 2022, , .	2.1	1
16944	Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12187.	5.5	33
16945	SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 148.	3.5	10
16946	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 659-670.	5.1	282
16947	Caerin 1 Peptides, the Potential Jack-of-All-Trades for the Multiple Antibiotic-Resistant Bacterial Infection Treatment and Cancer Immunotherapy. <i>BioMed Research International</i> , 2022, 2022, 1-11.	0.9	2
16948	Mesenchymal tumor cells drive adaptive resistance of <i>Trp53</i> ^{+/+} breast tumor cells to inactivated mutant <i>Kras</i> . <i>Molecular Oncology</i> , 2022, 16, 3128-3145.	2.1	1
16949	Molecular Characteristics of m6A Regulators and Tumor Microenvironment Infiltration in Soft Tissue Sarcoma: A Gene-Based Study. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 846812.	2.0	2
16950	Frailty and checkpoint inhibitor toxicity in older patients with melanoma. <i>Cancer</i> , 2022, 128, 2746-2752.	2.0	12
16951	Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function. <i>Cancer Cell</i> , 2022, 40, 393-409.e9.	7.7	59
16952	Severe immune-related hepatitis and myocarditis caused by PD-1 inhibitors in the treatment of triple-negative breast cancer: a case report. <i>Annals of Translational Medicine</i> , 2022, 10, 424-424.	0.7	7
16953	Non-Coding RNAs Are Brokers in Breast Cancer Interactome Networks and Add Discrimination Power between Subtypes. <i>Journal of Clinical Medicine</i> , 2022, 11, 2103.	1.0	1

#	ARTICLE	IF	CITATIONS
16954	Functional Interaction Between the Oncogenic Kinase NEK2 and Sam68 Promotes a Splicing Program Involved in Migration and Invasion in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 880654.	1.3	7
16955	Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes. <i>Cancers</i> , 2022, 14, 1942.	1.7	2
16956	Pan-Immune-Inflammation Value: A New Prognostic Index in Operative Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 830138.	1.3	26
16957	LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance. <i>Frontiers in Oncology</i> , 2022, 12, 831407.	1.3	10
16958	The role of cellular proteostasis in antitumor immunity. <i>Journal of Biological Chemistry</i> , 2022, 298, 101930.	1.6	6
16959	Targeting the gut and tumor microbiota in cancer. <i>Nature Medicine</i> , 2022, 28, 690-703.	15.2	159
16960	Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 862527.	2.2	23
16961	PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy. <i>Current Oncology</i> , 2022, 29, 2895-2908.	0.9	7
16962	CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 842653.	2.2	7
16963	Immunotherapy of Neuroblastoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2022, 28, 3196-3206.	3.2	29
16964	Next-Generation CAR T-cell Therapies. <i>Cancer Discovery</i> , 2022, 12, 1625-1633.	7.7	53
16965	Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution. <i>Cancers</i> , 2022, 14, 1999.	1.7	5
16966	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events. <i>JAMA Network Open</i> , 2022, 5, e227722.	2.8	25
16967	Clinical Impact of 11q13.3 Amplification on Immune Cell Infiltration and Prognosis in Breast Cancer. <i>International Journal of General Medicine</i> , 2022, Volume 15, 4037-4052.	0.8	4
16968	Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2018.	1.7	15
16969	Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 878740.	2.2	19
16970	Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients. <i>Npj Breast Cancer</i> , 2022, 8, 52.	2.3	3
16971	PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. <i>Nature Communications</i> , 2022, 13, 2176.	5.8	18

#	ARTICLE	IF	CITATIONS
16972	Sintilimab for the treatment of non-small cell lung cancer. <i>Biomarker Research</i> , 2022, 10, 23.	2.8	16
16973	Soluble form of CTLA-4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients. <i>Cancer Medicine</i> , 2022, 11, 3786-3795.	1.3	5
16974	The Overexpression and Clinical Significance of AP1S1 in Breast Cancer. <i>Cancer Management and Research</i> , 2022, Volume 14, 1475-1492.	0.9	1
16975	Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 834564.	1.3	12
16976	Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2022, 22, 407.	1.1	9
16977	Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review. <i>Cancers</i> , 2022, 14, 1949.	1.7	2
16978	Breast tumor microenvironment structures are associated with genomic features and clinical outcome. <i>Nature Genetics</i> , 2022, 54, 660-669.	9.4	88
16979	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/â ² trastuzumab in patients with breast cancer brain metastases. <i>Npj Breast Cancer</i> , 2022, 8, 50.	2.3	17
16980	High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 866561.	2.2	15
16981	A Review of the Effects of Cervical Cancer Standard Treatment on Immune Parameters in Peripheral Blood, Tumor Draining Lymph Nodes, and Local Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2022, 11, 2277.	1.0	5
16982	Improving ovarian cancer treatment decision using a novel risk predictive tool. <i>Aging</i> , 2022, 14, 3464-3483.	1.4	4
16983	Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 793403.	1.6	4
16984	PD-1 cooperates with AIRE-mediated tolerance to prevent lethal autoimmune disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120149119.	3.3	8
16985	A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response. <i>Cell Reports Medicine</i> , 2022, 3, 100602.	3.3	1
16986	CXCL13 as a Novel Immune Checkpoint for Regulatory B Cells and Its Role in Tumor Metastasis. <i>Journal of Immunology</i> , 2022, 208, 2425-2435.	0.4	9
16987	AKT mutant allele-specific activation dictates pharmacologic sensitivities. <i>Nature Communications</i> , 2022, 13, 2111.	5.8	10
16988	Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings. <i>Healthcare (Switzerland)</i> , 2022, 10, 763.	1.0	8
16989	Bioorthogonal in situ assembly of nanomedicines as drug depots for extracellular drug delivery. <i>Nature Communications</i> , 2022, 13, 2038.	5.8	27

#	ARTICLE	IF	CITATIONS
16990	Pulmonary Lymphangitis Poses a Major Challenge for Radiologists in an Oncological Setting during the COVID-19 Pandemic. <i>Journal of Personalized Medicine</i> , 2022, 12, 624.	1.1	9
16991	Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. , 2022, 10, e004424.		54
16992	Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2022, 7, 100465.	2.0	17
17001	Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma.. <i>EXCLI Journal</i> , 2022, 21, 250-268.	0.5	10
17002	Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy. <i>Advanced Science</i> , 2022, 9, e2200999.	5.6	11
17003	Direct and indirect regulation of the tumor immune microenvironment by VEGF. <i>Journal of Leukocyte Biology</i> , 2022, 111, 1269-1286.	1.5	28
17004	Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 779-789.	1.2	10
17005	Serum soluble programmed death-1 levels predict the spontaneous HBeAg seroclearance in chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2022, 57, 423-432.	2.3	2
17006	A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. <i>Cancer Cell</i> , 2022, 40, 479-493.e6.	7.7	64
17007	Development of an immunohistochemical assay for Siglec-15. <i>Laboratory Investigation</i> , 2022, 102, 771-778.	1.7	8
17008	Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse. <i>Heredity</i> , 2022, 129, 64-74.	1.2	4
17009	Interferon- β increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer. <i>Scientific Reports</i> , 2022, 12, 6657.	1.6	8
17010	Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 2093-2106.	0.6	18
17011	Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 546-559.	0.9	5
17012	Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 560-574.	0.9	3
17013	Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors. <i>International Journal of Urology</i> , 2022, 29, 741-747.	0.5	6
17014	Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity. <i>Science Advances</i> , 2022, 8, eabj7002.	4.7	95
17015	Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. <i>Science Advances</i> , 2022, 8, eabl9171.	4.7	30

#	ARTICLE	IF	CITATIONS
17016	Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis. , 2022, 10, e004564.		7
17017	Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer. Disease Markers, 2022, 2022, 1-11.	0.6	16
17018	Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial. Clinical Cancer Research, 2022, 28, 2807-2817.	3.2	30
17019	Neoantigen Identification and Response to Adoptive Cell Transfer in Anti-“PD-1 Na~ve and Experienced Patients with Metastatic Melanoma. Clinical Cancer Research, 2022, 28, 3042-3052.	3.2	18
17020	Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer. Cancer Immunology Research, 2022, 10, 680-697.	1.6	12
17021	AKT1 and PIK3CA activating mutations in Moroccan bladder cancer patients’s biopsies and matched urine.. Pan African Medical Journal, 2022, 41, 59.	0.3	2
17022	Association between plasma somatic copy number variations and response to immunotherapy in patients with programmed death-ligand 1-negative non-small cell lung cancer. Journal of International Medical Research, 2022, 50, 030006052210932.	0.4	3
17023	Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma. BMC Endocrine Disorders, 2022, 22, 110.	0.9	7
17024	Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR. BMC Medicine, 2022, 20, 136.	2.3	7
17025	Squamous cell carcinoma of the lung presenting as a fungating ulcerated skin lesion: a case report. Journal of Medical Case Reports, 2022, 16, 172.	0.4	0
17028	Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: A concise review. Bosnian Journal of Basic Medical Sciences, 2022, , .	0.6	2
17029	Capture a live-photo of tumor infiltrating T cell landscape at single cell resolution. Cancer Biology and Medicine, 2019, 16, 619-622.	1.4	3
17030	miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy. Breast Cancer: Targets and Therapy, 2022, Volume 14, 25-39.	1.0	3
17033	Design of a new multi-epitope peptide vaccine for non-small cell Lung cancer via vaccinology methods: an study.. Molecular Biology Research Communications, 2022, 11, 55-66.	0.2	1
17034	Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task. Frontiers in Endocrinology, 2022, 13, 840971.	1.5	2
17035	OIP5 Is a Novel Prognostic Biomarker in Clear Cell Renal Cell Cancer Correlating With Immune Infiltrates. Frontiers in Immunology, 2022, 13, 805552.	2.2	7
17036	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. Frontiers in Oncology, 2021, 11, 672797.	1.3	8
17037	Tumor-Derived circRNAs as Circulating Biomarkers for Breast Cancer. Frontiers in Pharmacology, 2022, 13, 811856.	1.6	6

#	ARTICLE	IF	CITATIONS
17085	Interferon- γ stimulated gene 15 promotes progression of endometrial carcinoma and weakens antitumor immune response. <i>Oncology Reports</i> , 2022, 47, .	1.2	4
17098	The side effects of immune checkpoint inhibitor therapy on the endocrine system. <i>Indian Journal of Medical Research</i> , 2021, 154, 559.	0.4	7
17104	Association of <i>CD274</i> (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2022, 27, 732-739.	1.9	5
17105	Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases. <i>Oncologist</i> , 2022, 27, 538-547.	1.9	4
17106	Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects. <i>Theranostics</i> , 2022, 12, 3719-3746.	4.6	23
17107	Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. <i>International Journal of Biological Sciences</i> , 2022, 18, 3019-3033.	2.6	54
17108	Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer. <i>Theranostics</i> , 2022, 12, 3456-3473.	4.6	10
17109	Melanoma: An immunotherapy journey from bench to bedside. <i>Cancer Treatment and Research</i> , 2022, 183, 49-89.	0.2	0
17110	Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity. <i>Cancer Treatment and Research</i> , 2022, 183, 91-129.	0.2	1
17111	Identifying novel SMYD3 interactors on the trail of cancer hallmarks. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1860-1875.	1.9	6
17112	Review of Checkpoint Inhibitor Immunotherapy in Neuroendocrine Tumor of Prostate and Our Experience in 2 Cases. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2022, 10, 232470962210938.	0.3	3
17113	Combination of Photodynamic Therapy and Immune Checkpoint Blockade. <i>Methods in Molecular Biology</i> , 2022, 2451, 589-596.	0.4	0
17114	Heterogeneous data integration methods for patient similarity networks. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	12
17115	Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice. <i>Journal of Breast Cancer</i> , 0, 25, .	0.8	2
17116	Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210927.	0.6	1
17117	Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210968.	1.4	9
17118	Current status and advances of immunotherapy in nasopharyngeal carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210962.	1.4	23
17119	Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 117-130.	0.7	2

#	ARTICLE	IF	CITATIONS
17120	Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210962.	1.4	6
17121	The Single-Cell Level Perspective of the Tumor Microenvironment and Its Remodeling by CAR-T Cells. <i>Cancer Treatment and Research</i> , 2022, 183, 275-285.	0.2	1
17122	Development of Cancer Immunotherapies. <i>Cancer Treatment and Research</i> , 2022, 183, 1-48.	0.2	4
17123	Management of Acral and Mucosal Melanoma: Medical Oncology Perspective. <i>Oncologist</i> , 2022, 27, 703-710.	1.9	8
17124	HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab. <i>Pathology and Oncology Research</i> , 2022, 28, 1610297.	0.9	5
17125	High Dose Local Photon Irradiation Is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance the Abscopal Response in a Murine Pancreatic Carcinoma Model. <i>Cancers</i> , 2022, 14, 2087.	1.7	3
17126	Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer. <i>Cancers</i> , 2022, 14, 2140.	1.7	11
17127	BUBs Are New Biomarkers of Promoting Tumorigenesis and Affecting Prognosis in Breast Cancer. <i>Disease Markers</i> , 2022, 2022, 1-21.	0.6	3
17128	Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival. <i>Gastroenterology Research</i> , 2022, 15, 56-66.	0.4	2
17129	Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma. <i>Diagnostics</i> , 2022, 12, 1116.	1.3	7
17130	Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk. <i>Translational Lung Cancer Research</i> , 2022, 11, 670-685.	1.3	13
17131	<sc>PD</sc> <sc>PD</sc> co-localization: A novel biomarker for immunotherapy response in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, , .	0.8	0
17132	Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model. <i>Frontiers in Immunology</i> , 2022, 13, 829634.	2.2	7
17133	Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies. <i>Frontiers in Microbiology</i> , 2022, 13, 862270.	1.5	19
17134	Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2022, 15, 533.	1.7	5
17135	Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study. <i>Clinical Cancer Research</i> , 2022, 28, 2818-2829.	3.2	12
17136	Development of a Novel Reference Material for Tumor Mutational Burden Measurement Based on CRISPR/Cas9 Technology. <i>Frontiers in Oncology</i> , 2022, 12, 845636.	1.3	1
17137	Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. <i>Genome Medicine</i> , 2022, 14, 45.	3.6	73

#	ARTICLE	IF	CITATIONS
17138	A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study. <i>Frontiers in Immunology</i> , 2022, 13, 859323.	2.2	25
17139	Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma. <i>Frontiers in Pharmacology</i> , 2022, 13, 869488.	1.6	8
17140	Integrative Analysis Constructs an Extracellular Matrix-Associated Gene Signature for the Prediction of Survival and Tumor Immunity in Lung Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 835043.	1.8	4
17141	Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice. <i>Cancers</i> , 2022, 14, 2102.	1.7	12
17142	Advanced Immune Cell Profiling by Multiparameter Flow Cytometry in Humanized Patient-Derived Tumor Mice. <i>Cancers</i> , 2022, 14, 2214.	1.7	5
17143	Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment. <i>Cells</i> , 2022, 11, 1466.	1.8	6
17144	CHSY3 can be a Poor Prognostic Biomarker and Mediates Immune Evasion in Stomach Adenocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 876588.	1.1	0
17145	Dose Finding in Oncology: What is Impeding Coming of Age?. <i>Pharmaceutical Research</i> , 2022, , 1.	1.7	1
17146	Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1881-1887.	1.4	12
17147	Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit. <i>Scientific Reports</i> , 2022, 12, 7021.	1.6	8
17148	DNA Copy Number Aberrations and Expression of ABC Transporter Genes in Breast Tumour: Correlation with the Effect of Neoadjuvant Chemotherapy and Prognosis of the Disease. <i>Pharmaceutics</i> , 2022, 14, 948.	2.0	3
17149	Bioorthogonal Equipping CAR-T Cells with Hyaluronidase and Checkpoint Blocking Antibody for Enhanced Solid Tumor Immunotherapy. <i>ACS Central Science</i> , 2022, 8, 603-614.	5.3	24
17150	Role of CD47-SIRP α Checkpoint in Nanomedicine-Based Anti-Cancer Treatment. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 887463.	2.0	0
17151	Outcomes From Cytotoxic Chemotherapy Following Progression on Immunotherapy in Metastatic Melanoma: An Institutional Case-Series. <i>Frontiers in Oncology</i> , 2022, 12, 855782.	1.3	5
17152	Regulatory T Cells with Additional COX-2 Expression Are Independent Negative Prognosticators for Vulvar Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4662.	1.8	2
17153	Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward. <i>Medicina (Lithuania)</i> , 2022, 58, 600.	0.8	1
17154	Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection. <i>JGH Open</i> , 2022, 6, 309-316.	0.7	6
17155	PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives. <i>Cancers</i> , 2022, 14, 2161.	1.7	15

#	ARTICLE	IF	CITATIONS
17156	Identification of FOXM1 and CXCR4 as key genes in breast cancer prevention and prognosis after intermittent energy restriction through bioinformatics and functional analyses. <i>Adipocyte</i> , 2022, 11, 301-314.	1.3	1
17157	Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer. <i>Biomedicines</i> , 2022, 10, 1047.	1.4	3
17158	A Genomic Signature Reflecting Fibroblast Infiltration Into Gastric Cancer Is Associated With Prognosis and Treatment Outcomes of Immune Checkpoint Inhibitors. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 862294.	1.8	5
17159	Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	9
17160	DNA Hypermethylation-Regulated CX3CL1 Reducing T Cell Infiltration Indicates Poor Prognosis in Wilms Tumour. <i>Frontiers in Oncology</i> , 2022, 12, 882714.	1.3	7
17161	Identification of Novel Prognostic Biomarkers Relevant to Immune Infiltration in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 863796.	1.1	0
17162	In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	42
17163	Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC). <i>Pharmaceuticals</i> , 2022, 15, 542.	1.7	14
17164	Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancersâ€”A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference. <i>Current Oncology</i> , 2022, 29, 3160-3170.	0.9	0
17165	The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanomaâ€”A Retrospective, Real-World Cohort Study. <i>Cancers</i> , 2022, 14, 2082.	1.7	9
17166	Multilevel mechanism of immune checkpoint inhibitor action in solid tumors: History, present issues and future development (Review). <i>Oncology Letters</i> , 2022, 23, 190.	0.8	1
17167	Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial). <i>BMC Cancer</i> , 2022, 22, 462.	1.1	10
17168	PCMT1 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltrates in Breast Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-18.	0.9	7
17169	Immune Checkpoint Inhibitors in Cancer Therapy. <i>Current Oncology</i> , 2022, 29, 3044-3060.	0.9	239
17170	Nucleolin Overexpression Predicts Patient Prognosis While Providing a Framework for Targeted Therapeutic Intervention in Lung Cancer. <i>Cancers</i> , 2022, 14, 2217.	1.7	7
17171	Leveraging Deep Learning Techniques and Integrated Omics Data for Tailored Treatment of Breast Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 674.	1.1	6
17172	Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 860767.	1.3	6
17173	NR4A Family Genes: A Review of Comprehensive Prognostic and Gene Expression Profile Analysis in Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 777824.	1.3	6

#	ARTICLE	IF	CITATIONS
17174	Paradoxical Behavior of Oncogenes Undermines the Somatic Mutation Theory. <i>Biomolecules</i> , 2022, 12, 662.	1.8	9
17175	A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies. <i>Journal of Personalized Medicine</i> , 2022, 12, 669.	1.1	1
17176	Identification of Implications of Angiogenesis and m6A Modification on Immunosuppression and Therapeutic Sensitivity in Low-Grade Glioma by Network Computational Analysis of Subtypes and Signatures. <i>Frontiers in Immunology</i> , 2022, 13, 871564.	2.2	4
17177	Necroptosis-Associated lncRNA Prognostic Model and Clustering Analysis: Prognosis Prediction and Tumor-Infiltrating Lymphocytes in Breast Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-18.	0.6	12
17178	The cure from within? a review of the microbiome and diet in melanoma. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 261-280.	2.7	8
17179	Hypoxia and anaerobic metabolism relate with immunologically cold breast cancer and poor prognosis. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 13-23.	1.1	16
17180	Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back. <i>Frontiers in Immunology</i> , 2022, 13, 849515.	2.2	15
17181	Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma. <i>Frontiers in Endocrinology</i> , 2022, 13, 859013.	1.5	10
17182	Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis. <i>Cancer Gene Therapy</i> , 2022, 29, 1578-1589.	2.2	11
17183	Novel Al ¹⁸ F-NOTA-Conjugated Lactam-Cyclized \pm -Melanocyte-Stimulating Hormone Peptides with Enhanced Melanoma Uptake. <i>Bioconjugate Chemistry</i> , 2022, 33, 982-990.	1.8	1
17184	Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression. <i>Cancers</i> , 2022, 14, 2148.	1.7	22
17185	Novel ⁶⁴ Cu-Labeled NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptides with Enhanced Tumor to Kidney Uptake Ratios. <i>Molecular Pharmaceutics</i> , 2022, 19, 2535-2541.	2.3	6
17186	Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
17187	What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine. <i>Cancers</i> , 2022, 14, 2238.	1.7	6
17188	Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. <i>Cancers</i> , 2022, 14, 2241.	1.7	26
17189	COMMD2 Upregulation Mediated by an ncRNA Axis Correlates With an Unfavorable Prognosis and Tumor Immune Infiltration in Liver Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 853026.	1.3	1
17190	Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing. <i>Genes</i> , 2022, 13, 799.	1.0	4
17191	Pyroptosis-Related Patterns Predict Tumor Immune Landscape and Immunotherapy Response in Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 815290.	1.6	2

#	ARTICLE	IF	CITATIONS
17192	Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy. <i>Life</i> , 2022, 12, 659.	1.1	4
17193	TMPRSS2 Serves as a Prognostic Biomarker and Correlated With Immune Infiltrates in Breast Invasive Cancer and Lung Adenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 647826.	1.6	8
17194	Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 172-199.	0.5	6
17195	CSF2RB Is a Unique Biomarker and Correlated With Immune Infiltrates in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 822849.	1.3	7
17196	The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies. <i>Cancers</i> , 2022, 14, 2177.	1.7	2
17197	Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 679.	1.1	2
17198	Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias. <i>Frontiers in Oncology</i> , 2022, 12, 858426.	1.3	0
17199	The Effect of Intratumoral Interrelation among FOXP3+ Regulatory T Cells on Treatment Response and Survival in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2138.	1.7	4
17200	Tumor Microenvironment in Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: Interaction between Tumors and Immune Cells, and Potential Effects of Neuroendocrine Differentiation on the Tumor Microenvironment. <i>Cancers</i> , 2022, 14, 2152.	1.7	6
17201	Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 2157.	1.7	7
17202	MAPK signaling regulates the efficacy of chemoimmunotherapy. <i>Molecular and Cellular Oncology</i> , 2022, 9, 2054652.	0.3	0
17203	Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2749-2758.	2.8	16
17204	A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 607-616.	1.3	5
17205	Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications. <i>Antioxidants</i> , 2022, 11, 853.	2.2	10
17206	Distinct phenotypic states and spatial distribution of CD8+ TÂcell clonotypes in human brain metastases. <i>Cell Reports Medicine</i> , 2022, 3, 100620.	3.3	29
17207	PD-1/PD-L1 expression is frequent and correlated with lymphocyte density in Erdheim-Chester disease. <i>Haematologica</i> , 2022, , .	1.7	0
17208	Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival. <i>Cancers</i> , 2022, 14, 2090.	1.7	5
17209	Near-Complete Remission of Glioblastoma in a Patient Treated with an Allogenic Dendritic Cell-Based Vaccine: The Role of Tumor-Specific CD4+T-Cell Cytokine Secretion Pattern in Predicting Response and Recurrence. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5396.	1.8	4

#	ARTICLE	IF	CITATIONS
17210	Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma. <i>Oncolmmunology</i> , 2022, 11, 2073010.	2.1	6
17211	Captopril, a Renin-angiotensin System Inhibitor, Attenuates Tumour Progression in the Regenerating Liver Following Partial Hepatectomy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5281.	1.8	5
17212	Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cell-derived explants. <i>JCI Insight</i> , 2022, , .	2.3	5
17213	Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy. <i>Science Advances</i> , 2022, 8, eabi8075.	4.7	21
17214	Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. <i>BMC Medicine</i> , 2022, 20, 187.	2.3	28
17215	Prognostic Value and Therapeutic Perspectives of CXCR Members in the Glioma Microenvironment. <i>Frontiers in Genetics</i> , 2022, 13, 787141.	1.1	3
17216	Neuronal intermediate filament paraneoplastic autoimmunity complicating avelumab therapy of Merkel cell carcinoma. <i>Journal of Neuroimmunology</i> , 2022, 368, 577882.	1.1	6
17217	Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 57.	2.3	11
17218	ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors. <i>BMC Medicine</i> , 2022, 20, 170.	2.3	15
17219	LOXL2 small molecule inhibitor restrains malignant transformation of cervical cancer cells by repressing LOXL2-induced epithelial-mesenchymal transition (EMT). <i>Cell Cycle</i> , 2022, 21, 1827-1841.	1.3	5
17220	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3990-4002.	3.2	15
17221	Deciphering radiological stable disease to immune checkpoint inhibitors. <i>Annals of Oncology</i> , 2022, 33, 824-835.	0.6	21
17222	From Tumor Cells to Endothelium and Gut Microbiome: A Complex Interaction Favoring the Metastasis Cascade. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0
17223	Exosome-Derived Non-Coding RNAs in the Tumor Microenvironment of Colorectal Cancer: Possible Functions, Mechanisms and Clinical Applications. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
17224	NADPH Oxidase 4: A Potential Therapeutic Target of Malignancy. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	12
17225	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. <i>Npj Breast Cancer</i> , 2022, 8, 60.	2.3	11
17226	The Use of Bacteriophages in Biotechnology and Recent Insights into Proteomics. <i>Antibiotics</i> , 2022, 11, 653.	1.5	11
17227	HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	44

#	ARTICLE	IF	CITATIONS
17228	Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients. <i>Journal of Translational Medicine</i> , 2022, 20, 211.	1.8	8
17229	<scp>Realâ€World</scp> longitudinal practice patterns in the use of <scp>PD</scp> â€1 and <scp>PDâ€L1</scp> inhibitors as <scp>Firstâ€Line</scp> therapy in patients with <scp>Nonâ€Small</scp> cell lung cancer in the United States. <i>Cancer Medicine</i> , 2022, , .	1.3	2
17230	Association of the tissue infiltrated and peripheral blood immune cell subsets with response to radiotherapy for rectal cancer. <i>BMC Medical Genomics</i> , 2022, 15, 107.	0.7	5
17231	Multiparameter Longitudinal Imaging of Immune Cell Activity in Chimeric Antigen Receptor T Cell and Checkpoint Blockade Therapies. <i>ACS Central Science</i> , 2022, 8, 590-602.	5.3	15
17232	Effect of Concomitant Use of Analgesics on Prognosis in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	6
17233	A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2022, 9, 808378.	1.2	5
17234	Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability. <i>Frontiers in Medicine</i> , 2022, 9, 874213.	1.2	11
17235	Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study. <i>Cancers</i> , 2022, 14, 2276.	1.7	4
17236	Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	14
17237	The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 2133-2142.	0.8	4
17238	Identification of TRP-Related Subtypes, Development of a Prognostic Model, and Characterization of Tumor Microenvironment Infiltration in Lung Adenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	1
17239	Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 523-545.	3.3	2
17240	Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0
17241	Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma. <i>Cancer Medicine</i> , 2022, , .	1.3	2
17242	Spatial determinants of CD8+ T cell differentiation in cancer. <i>Trends in Cancer</i> , 2022, 8, 642-654.	3.8	8
17243	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 172.	3.5	2
17244	PD-L1 Inhibits T Cell-Induced Cytokines and Hyaluronan Expression via the CD40-CD40L Pathway in Orbital Fibroblasts From Patients With Thyroid Associated Ophthalmopathy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
17245	Application of lipid nanovesicle drug delivery system in cancer immunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, 214.	4.2	24

#	ARTICLE	IF	CITATIONS
17246	CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer. <i>Nature Communications</i> , 2022, 13, 2642.	5.8	15
17247	Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance. <i>Biomedicines</i> , 2022, 10, 1130.	1.4	11
17248	OX40 and 4-1BB delineate distinct immune profiles in sarcoma. <i>Oncolimmunology</i> , 2022, 11, 2066050.	2.1	6
17249	Prognostic significance of the expression levels of Tâ€cell immunoglobulin mucinâ€3 and its ligand galectinâ€9 for relapseâ€free survival in tripleâ€negative breast cancer. <i>Oncology Letters</i> , 2022, 23, 197.	0.8	5
17250	The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer. <i>Breast Care</i> , 2022, 17, 470-479.	0.8	2
17251	Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2405.	1.7	1
17252	Interpatient Heterogeneity in Drug Response and Protein Biomarker Expression of Recurrent Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2279.	1.7	5
17253	Development of a Clinically Oriented Model to Predict Antitumor Effects after PD-1/PD-L1 Inhibitor Therapy. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	2
17254	Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. <i>Cancers</i> , 2022, 14, 2300.	1.7	6
17255	Identification of a 5-gene-risk score model for predicting luminal A-invasive lobular breast cancer survival. <i>Genetica</i> , 2022, 150, 299-316.	0.5	3
17256	A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies. <i>Nature Communications</i> , 2022, 13, 2366.	5.8	26
17257	Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer. <i>Cells</i> , 2022, 11, 1550.	1.8	0
17258	CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	9
17259	Melanoma-specific antigen-associated antitumor antibody reactivity as an immune-related biomarker for targeted immunotherapies. <i>Communications Medicine</i> , 2022, 2, .	1.9	1
17260	Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 865975.	2.2	13
17261	Reverting TP53 Mutation in Breast Cancer Cells: Prime Editing Workflow and Technical Considerations. <i>Cells</i> , 2022, 11, 1612.	1.8	7
17262	Immunosuppressive Tumor Microenvironment and Immunotherapy of Epsteinâ€Barr Virus-Associated Malignancies. <i>Viruses</i> , 2022, 14, 1017.	1.5	11
17263	LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of Tâ€cells through dendritic cell activation. <i>Molecular Therapy</i> , 2022, 30, 2800-2816.	3.7	29

#	ARTICLE	IF	CITATIONS
17264	Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
17265	Pan-Cancer Analysis of the Characteristics of LY96 in Prognosis and Immunotherapy Across Human Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	10
17266	Clinical Significance of a CD3/CD8-Based Immunoscore in Neuroblastoma Patients Using Digital Pathology. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
17267	Recent Advances in Engineering Nanomedicines for Second Near-Infrared Photothermal-Combinational Immunotherapy. <i>Nanomaterials</i> , 2022, 12, 1656.	1.9	9
17268	Autoimmunity and Cancer—Two Sides of the Same Coin. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	16
17269	Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study. <i>Oncotarget</i> , 2022, 13, 686-693.	0.8	4
17270	Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , .	1.2	4
17271	Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1. <i>IScience</i> , 2022, 25, 104353.	1.9	3
17272	Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. <i>Cell</i> , 2022, 185, 1924-1942.e23.	13.5	111
17273	Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers. <i>Pharmaceuticals</i> , 2022, 15, 574.	1.7	9
17274	Hematological Prognostic Scoring System Can Predict Overall Survival and Can Indicate Response to Immunotherapy in Patients With Osteosarcoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3
17275	A hierarchical approach to combine histological grade and immunohistochemical factors to identify high-risk luminal breast cancers. <i>Ecancermedalscience</i> , 0, 16, .	0.6	0
17276	Multifunctional Nanosystems Powered Photodynamic Immunotherapy. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	11
17277	Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR. <i>Npj Breast Cancer</i> , 2022, 8, 58.	2.3	9
17278	Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. <i>Nature Reviews Urology</i> , 2022, 19, 391-418.	1.9	20
17279	Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression. <i>Frontiers in Immunology</i> , 2022, 13, 874589.	2.2	71
17280	Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3235-3241.	3.2	6
17281	A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 799-806.	2.4	4

#	ARTICLE	IF	CITATIONS
17282	Focal Adhesion-Related Signatures Predict the Treatment Efficacy of Chemotherapy and Prognosis in Patients with Gastric Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	4
17283	Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5097.	1.8	3
17284	Multi-Omic Data Improve Prediction of Personalized Tumor Suppressors and Oncogenes. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	1
17285	Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	31
17286	Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
17287	Identification of a Pyroptosis-Related Gene Signature for Predicting the Immune Status and Prognosis in Lung Adenocarcinoma. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, .	2.0	14
17288	Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma. <i>Cancer Cell International</i> , 2022, 22, 186.	1.8	4
17289	The characteristics and clinical significance of atypical mitosis in breast cancer. <i>Modern Pathology</i> , 2022, 35, 1341-1348.	2.9	9
17290	Therapeutic Effects of Cold Atmospheric Plasma on Solid Tumor. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	13
17291	Prognostic Risk Signature and Comprehensive Analyses of Endoplasmic Reticulum Stress-Related Genes in Lung Adenocarcinoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-39.	0.9	7
17292	Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature. <i>Journal of Clinical Medicine</i> , 2022, 11, 2629.	1.0	6
17293	Comparative characterization of 3D chromatin organization in triple-negative breast cancers. <i>Experimental and Molecular Medicine</i> , 2022, 54, 585-600.	3.2	12
17294	CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules. <i>Journal of Translational Medicine</i> , 2022, 20, 217.	1.8	9
17295	Deciphering the tumor microenvironment cellâ€infiltrating landscape reveals microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC. <i>JCI Insight</i> , 2022, 7, .	2.3	6
17296	Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0268288.	1.1	8
17297	Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development. <i>Frontiers in Immunology</i> , 2022, 13, 752065.	2.2	21
17298	CAD v1.0: Cancer Antigens Database Platform for Cancer Antigen Algorithm Development and Information Exploration. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, .	2.0	2
17299	TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	2

#	ARTICLE	IF	CITATIONS
17300	Deciphering Innate Immune Cell-Tumor Microenvironment Crosstalk at a Single-Cell Level. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
17301	Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer. <i>Cell Death and Differentiation</i> , 2022, 29, 2247-2261.	5.0	24
17302	A ROS-responsive synergistic delivery system for combined immunotherapy and chemotherapy. <i>Materials Today Bio</i> , 2022, 14, 100284.	2.6	11
17303	Potential clinical utility of liquid biopsies in ovarian cancer. <i>Molecular Cancer</i> , 2022, 21, 114.	7.9	51
17304	Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy. <i>Annals of Medicine</i> , 2022, 54, 1339-1349.	1.5	8
17305	Synergistic effect of IFN- γ and IL-1 β on PD-L1 expression in hepatocellular carcinoma. <i>Biochemistry and Biophysics Reports</i> , 2022, 30, 101270.	0.7	12
17306	Macrophage density is an adverse prognosticator for ipsilateral recurrence in ductal carcinoma in situ. <i>Breast</i> , 2022, 64, 35-40.	0.9	3
17307	Effects of heavy ions (12C6+) on malignant melanoma B16F10 cells. <i>Translational Cancer Research</i> , 2021, .	0.4	2
17308	Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 875764.	2.2	2
17309	OVOL1 inhibits breast cancer cell invasion by enhancing the degradation of TGF- β type I receptor. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 126.	7.1	15
17310	High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition. <i>Cancers</i> , 2022, 14, 2200.	1.7	1
17311	Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 876098.	1.3	2
17312	Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. <i>BMC Medicine</i> , 2022, 20, 142.	2.3	55
17313	High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. , 2022, 10, e004197.		5
17314	Non-canonical genomic driver mutations of urethane carcinogenesis. <i>PLoS ONE</i> , 2022, 17, e0267147.	1.1	0
17315	Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 113-123.	1.0	10
17316	Treatment of patients with cancer using PD-1/PD-L1 antibodies: Adverse effects and management strategies (Review). <i>International Journal of Oncology</i> , 2022, 60, .	1.4	9
17317	Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2022, 27, 101-131.	1.0	9

#	ARTICLE	IF	CITATIONS
17318	Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naïve, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00941.	1.1	1
17319	Characterization and clustering of kinase isoform expression in metastatic melanoma. <i>PLoS Computational Biology</i> , 2022, 18, e1010065.	1.5	4
17320	Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response. <i>Pharmaceuticals</i> , 2022, 15, 605.	1.7	0
17321	Peripheral Blood Mononuclear Cell Populations Correlate with Outcome in Patients with Metastatic Breast Cancer. <i>Cells</i> , 2022, 11, 1639.	1.8	8
17322	Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?. <i>Cancers</i> , 2022, 14, 2434.	1.7	7
17323	SLC2A1 plays a significant prognostic role in lung adenocarcinoma and is associated with tumor immunity based on bioinformatics analysis. <i>Annals of Translational Medicine</i> , 2022, 10, 519-519.	0.7	5
17324	Penile cancer: Updates in systemic therapy. <i>Asian Journal of Urology</i> , 2022, 9, 374-388.	0.5	6
17325	Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5999.	1.2	3
17326	Amino Acid Metabolism-Related lncRNA Signature Predicts the Prognosis of Breast Cancer. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	9
17327	Immune responses of patients without cancer recurrence after a cancer vaccine over a long term. <i>Molecular and Clinical Oncology</i> , 2022, 16, .	0.4	1
17328	Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT). <i>Oncology and Therapy</i> , 2022, , 1.	1.0	0
17329	Association of the gut microbiome with cancer immunotherapy. <i>International Journal of Clinical Oncology</i> , 2022, , 1.	1.0	0
17330	The breast cancer immune microenvironment is modified by neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2022, 12, 7981.	1.6	15
17331	Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3878-3891.	3.3	3
17332	FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma. <i>Applied Bionics and Biomechanics</i> , 2022, 2022, 1-11.	0.5	3
17333	Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 829-843.	1.6	12
17334	Characterization of Tumor Mutation Burden-Based Gene Signature and Molecular Subtypes to Assist Precision Treatment in Gastric Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-27.	0.9	6
17335	Tumor-Derived Lactate Creates a Favorable Niche for Tumor via Supplying Energy Source for Tumor and Modulating the Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	14

#	ARTICLE	IF	CITATIONS
17336	Enhancement of antitumor immunotherapy using mitochondria-targeted cancer cell membrane-biomimetic MOF-mediated sonodynamic therapy and checkpoint blockade immunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, 228.	4.2	37
17337	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. <i>ESMO Open</i> , 2022, 7, 100474.	2.0	3
17338	Integrated Analysis Reveals Critical Ferroptosis Regulators and FTL Contribute to Cancer Progression in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	9
17339	Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	4
17340	Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	3
17341	Cyclophilin a represses reactive oxygen species generation and death of hypoxic non-small-cell lung cancer cells by degrading thioredoxin-interacting protein. <i>Cell Cycle</i> , 2022, 21, 1996-2007.	1.3	1
17342	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-“Small-Cell Lung Cancer (NADIM phase II trial). <i>Journal of Clinical Oncology</i> , 2022, 40, 2924-2933.	0.8	127
17343	A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair-deficient/microsatellite instability-high metastatic colon cancer: A case report. <i>Oncology Letters</i> , 2022, 24, .	0.8	4
17344	The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	3
17345	Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review. <i>Cancer Reports</i> , 2022, 5, e1624.	0.6	7
17346	Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. <i>Cancers</i> , 2022, 14, 2460.	1.7	2
17347	Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	1
17348	Evolution of Medical Approaches and Prominent Therapies in Breast Cancer. <i>Cancers</i> , 2022, 14, 2450.	1.7	4
17349	Update in TIGIT Immune-Checkpoint Role in Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	19
17350	Regulation of protein complex partners as a compensatory mechanism in aneuploid tumors. <i>ELife</i> , 2022, 11, .	2.8	7
17351	Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors. <i>BMC Cancer</i> , 2022, 22, 551.	1.1	4
17352	PD-L1 Mediates IFN β -Regulation of Glucose but Not of Tryptophan Metabolism in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	6
17353	An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, 8230.	1.6	9

#	ARTICLE	IF	CITATIONS
17354	Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy. <i>BMJ Open</i> , 2022, 12, e050112.	0.8	6
17355	Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	7
17356	Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. <i>Laboratory Investigation</i> , 2022, 102, 1143-1149.	1.7	5
17357	Intra-tumoral angiogenesis correlates with immune features and prognosis in glioma. <i>Aging</i> , 2022, 14, 4402-4424.	1.4	1
17358	Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 1348-1361.	1.8	75
17359	A novel four-gene signature predicts immunotherapy response of patients with different cancers. <i>Journal of Clinical Laboratory Analysis</i> , 2022, , e24494.	0.9	2
17360	Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape. <i>Medical Oncology</i> , 2022, 39, 92.	1.2	0
17361	Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression. <i>Scientific Reports</i> , 2022, 12, 8098.	1.6	6
17362	Ex silico engineering of cystine-dense peptides yielding a potent bispecific T cell engager. <i>Science Translational Medicine</i> , 2022, 14, eabn0402.	5.8	3
17363	Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study. <i>BMJ Open</i> , 2022, 12, e054404.	0.8	4
17364	Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation. , 2022, 10, e003819.		13
17365	CD4 ⁺ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. , 2022, 10, e004022.		7
17366	Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. , 2022, 10, e004076.		30
17367	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329.		15
17368	Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. , 2022, 10, e004839.		4
17369	Cancer Immunoediting in the Era of Immuno-oncology. <i>Clinical Cancer Research</i> , 2022, 28, 3917-3928.	3.2	31
17370	The role of biomarkers in personalized immunotherapy. <i>Biomarker Research</i> , 2022, 10, 32.	2.8	27
17374	Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2211020.	0.7	2

#	ARTICLE	IF	CITATIONS
17375	Effectiveness of Rehabilitation for Cancer Patients with Bone Metastasis. <i>Progress in Rehabilitation Medicine</i> , 2022, 7, n/a.	0.3	0
17376	RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells. <i>Theranostics</i> , 2022, 12, 4348-4373.	4.6	3
17377	Circular RNAs modulate Hippo-YAP signaling: functional mechanisms in cancer. <i>Theranostics</i> , 2022, 12, 4269-4287.	4.6	10
17378	Molecular Classification of Gastric Cancer With Emphasis on PDL-1 Expression: The First Report From Iran. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2210963.	0.7	1
17379	Comprehensive Analysis of the Butyrate-Metabolism-Related Gene Signature in Tumor Microenvironment-Infiltrating Immune Cells in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	4
17380	Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance. <i>Journal of Dermatology</i> , 2022, 49, 862-871.	0.6	6
17381	Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials. <i>Genes and Diseases</i> , 2023, 10, 76-88.	1.5	34
17382	Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5731.	1.8	9
17383	A brain-enriched lncRNA shields cancer cells from immune-mediated killing for metastatic colonization in the brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	8
17384	Predicting Differences in Treatment Response and Survival Time of Lung Adenocarcinoma Patients Based on a Prognostic Risk Model of Glycolysis-Related Genes. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	1
17385	Epitope Mapping and Binding Assessment by Solid-State NMR Provide a Way for the Development of Biologics under the Quality by Design Paradigm. <i>Journal of the American Chemical Society</i> , 2022, 144, 10006-10016.	6.6	9
17386	PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
17387	Prognostic and Immunological Role of PPP1R14A as a Pan-Cancer Analysis Candidate. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	0
17388	Automated next-generation profiling of genomic alterations in human cancers. <i>Nature Communications</i> , 2022, 13, .	5.8	8
17389	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. <i>Biomedicines</i> , 2022, 10, 1181.	1.4	8
17390	Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer (Review). <i>Oncology Letters</i> , 2022, 24, .	0.8	4
17391	Using Single Cell Transcriptomics to Elucidate the Myeloid Compartment in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
17392	Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 3029-3042.	2.0	9

#	ARTICLE	IF	CITATIONS
17393	Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
17394	The AKT1E17K Allele Promotes Breast Cancer in Mice. <i>Cancers</i> , 2022, 14, 2645.	1.7	1
17395	Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study. <i>Cancers</i> , 2022, 14, 2615.	1.7	7
17396	Necroptosis is Related to Anti-PD-1 Treatment Response and Influences the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	2
17397	Analysis of Spatial Heterogeneity of Responses in Metastatic Sites in Renal Cell Carcinoma Patients Treated with Nivolumab. <i>Tomography</i> , 2022, 8, 1363-1373.	0.8	1
17398	The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	13
17399	High Expression of CKS2 Predicts Adverse Outcomes: A Potential Therapeutic Target for Glioma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	7
17400	Wnt Signaling in the Breast: From Development to Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	10
17401	Kindlin-2 promotes Src-mediated tyrosine phosphorylation of androgen receptor and contributes to breast cancer progression. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	3
17402	A human breast atlas integrating single-cell proteomics and transcriptomics. <i>Developmental Cell</i> , 2022, 57, 1400-1420.e7.	3.1	50
17403	Individualized Treatment for Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
17404	The Role of Cancer-Associated Fibroblasts in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2637.	1.7	23
17405	Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review. <i>Biomedicines</i> , 2022, 10, 1237.	1.4	7
17406	Immunoexpression of Programmed Death-1 Receptor (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Non-Small-Cell Lung Carcinoma and Its Correlation With Other Clinicopathological Parameters: A Cross-Sectional Study From North India. <i>Cureus</i> , 2022, , .	0.2	0
17407	Immune Related Adverse Events of the Thyroid – A Narrative Review. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	19
17408	A dual-responsive doxorubicin–indoximod conjugate for programmed chemoimmunotherapy. <i>RSC Chemical Biology</i> , 2022, 3, 853-858.	2.0	1
17409	Clinically approved combination immunotherapy: Current status, limitations, and future perspective. <i>Current Research in Immunology</i> , 2022, 3, 118-127.	1.2	20
17410	Comprehensive Analysis of the Function, Immune Profiles, and Clinical Implication of m1A Regulators in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
17411	Systematic Review of Available CAR-T Cell Trials around the World. <i>Cancers</i> , 2022, 14, 2667.	1.7	31
17412	Dihydroconiferyl Ferulate Isolated from <i>Dendropanax morbiferus</i> H.L.Ã©v. Suppresses Stemness of Breast Cancer Cells via Nuclear EGFR/c-Myc Signaling. <i>Pharmaceuticals</i> , 2022, 15, 664.	1.7	1
17413	High-throughput virtual screening of small-molecule inhibitors targeting immune cell checkpoints to discover new immunotherapeutics for human diseases. <i>Molecular Diversity</i> , 2023, 27, 729-751.	2.1	14
17414	Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
17415	Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. <i>Molecules</i> , 2022, 27, 3454.	1.7	5
17416	Identification of CD8+ T Cell Related Biomarkers in Ovarian Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
17417	Heritable genomic diversity in breast cancer driver genes and associations with risk in a Chilean population. <i>Biological Research</i> , 2022, 55, .	1.5	1
17418	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
17419	Exploration of Different Hypoxia Patterns and Construction of a Hypoxia-Related Gene Prognostic Index in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
17420	Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to Butylidenephthalide in a Recurrent GBM. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	1
17421	mRNA-based therapeutics: powerful and versatile tools to combat diseases. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	160
17422	Identification of lung cancer drivers by comparison of the observed and the expected numbers of missense and nonsense mutations in individual human genes. <i>Oncotarget</i> , 2022, 13, 756-767.	0.8	2
17423	Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
17424	Recent Applications of Artificial Intelligence from Histopathologic Image-Based Prediction of Microsatellite Instability in Solid Cancers: A Systematic Review. <i>Cancers</i> , 2022, 14, 2590.	1.7	17
17425	Immune-related conditions and cancer-specific mortality among older adults with cancer in the United States. <i>International Journal of Cancer</i> , 2022, 151, 1216-1227.	2.3	4
17426	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
17427	Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	9
17428	Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6

#	ARTICLE	IF	CITATIONS
17429	Frailty and risk of mortality in older cancer survivors and adults without a cancer history: Evidence from the National Health and Nutrition Examination Survey, 1999-2014. <i>Cancer</i> , 2022, 128, 2978-2987.	2.0	10
17430	Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
17431	The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	94
17432	<sc>NKG2A</sc>â€checkpoint inhibition and its blockade critically depends on peptides presented by its ligand <sc>HLAâ€E</sc>. <i>Immunology</i> , 2022, 166, 507-521.	2.0	15
17433	Multi-Omics Analysis of MCM2 as a Promising Biomarker in Pan-Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	8
17434	Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping. <i>Cancers</i> , 2022, 14, 2571.	1.7	2
17435	The paradox of immune checkpoint inhibition re-activating tuberculosis. <i>European Respiratory Journal</i> , 2022, 60, 2102512.	3.1	8
17436	Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
17437	Simple <sc>IHC</sc> reveals complex <sc>MMR</sc> alternations than <sc>PCR</sc> assays: Validation by <sc>LCM</sc> and nextâ€generation sequencing. <i>Cancer Medicine</i> , 2022, 11, 4479-4490.	1.3	6
17438	Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	7
17439	Evaluation PD-L1, CD8 and CD20 as early predictor and tracking markers for breast cancer (BC) in Egypt. <i>Heliyon</i> , 2022, 8, e09474.	1.4	1
17440	Platelets Increase the Expression of PD-L1 in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2498.	1.7	12
17441	The earlier, the better? A review of neoadjuvant immunotherapy in resectable nonâ€smallâ€cell lung cancer. <i>Chronic Diseases and Translational Medicine</i> , 2022, 8, 100-111.	0.9	0
17442	Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Nonâ€Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2022, 5, e2214046.	2.8	15
17443	Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy. <i>Cells</i> , 2022, 11, 1758.	1.8	3
17444	A novel <sc>DNA</sc> damage and repairâ€related gene signature to improve predictive capacity of overall survival for patients with gliomas. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 3736-3750.	1.6	7
17445	Identification and Validation of Novel Immune-Related Alternative Splicing Signatures as a Prognostic Model for Colon Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
17446	Antisense modulation of IL7R splicing to control sIL7R expression in human CD4⁺T cells. <i>Rna</i> , 2022, 28, 1058-1073.	1.6	1

#	ARTICLE	IF	CITATIONS
17447	Identification of a seven-gene signature predicting clinical outcome of liver cancer based on tumor mutational burden. <i>Human Cell</i> , 2022, 35, 1192-1206.	1.2	6
17448	Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma. , 2022, 10, e004297.		41
17449	Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC. <i>Cancers</i> , 2022, 14, 2626.	1.7	7
17450	MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy. <i>Oncolmmunology</i> , 2022, 11, .	2.1	8
17451	Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	4
17452	Characterization of the Immune Cell Infiltration Landscape Uncovers Prognostic and Immunogenic Characteristics in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
17453	High levels of blood circulating immune checkpoint molecules in children with new-onset type 1 diabetes are associated with the risk of developing an additional autoimmune disease. <i>Diabetologia</i> , 2022, 65, 1390-1397.	2.9	2
17454	Real-world outcomes of pembrolizumab monotherapy in <sc>non-small</sc> cell lung cancer in Japan: A post-marketing surveillance. <i>Cancer Science</i> , 2022, 113, 3110-3119.	1.7	5
17455	Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC). <i>Cancers</i> , 2022, 14, 2695.	1.7	3
17456	Pan-cancer analysis identifies <sc>CD300</sc> molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia. <i>Cancer Medicine</i> , 2023, 12, 789-807.	1.3	5
17457	Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis. <i>Disease Markers</i> , 2022, 2022, 1-27.	0.6	3
17458	Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. <i>Leukemia</i> , 2022, 36, 1887-1897.	3.3	23
17459	Antibody Recognition of Cancer Cells via Glycan Surface Engineering. <i>ChemBioChem</i> , 0, , .	1.3	1
17460	PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 825-837.	2.5	3
17461	Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity. <i>Nature Cancer</i> , 2022, 3, 734-752.	5.7	12
17462	A Novel lncRNA Panel for Risk Stratification and Immune Landscape in Breast Cancer Patients. <i>International Journal of General Medicine</i> , 0, Volume 15, 5253-5272.	0.8	0
17463	Classification of <sc>PD-L1</sc> expression in various cancers and macrophages based on immunohistocytological analysis. <i>Cancer Science</i> , 2022, 113, 3255-3266.	1.7	8
17464	Classification of Muscle Invasive Bladder Cancer to Predict Prognosis of Patients Treated with Immunotherapy. <i>Journal of Immunology Research</i> , 2022, 2022, 1-15.	0.9	1

#	ARTICLE	IF	CITATIONS
17465	Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
17466	Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	7
17467	Prosaposin, tumor-secreted protein, promotes pancreatic cancer progression by decreasing tumor-infiltrating lymphocytes. <i>Cancer Science</i> , 2022, 113, 2548-2559.	1.7	7
17468	Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model. <i>Cancers</i> , 2022, 14, 2692.	1.7	11
17469	Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	2
17470	The risk of PD-L1 expression misclassification in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	1
17471	<sc>TIGIT</sc> / <sc>CD47</sc> dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 0, , .	0.8	4
17472	PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5837.	1.8	7
17473	Genetic Variation of PD-L1 Gene Affects its Expression and Is Related to Clinical Outcome in Epithelial Ovarian Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	1
17474	Development of Two Diagnostic Prediction Models for Leptomeningeal Metastasis in Patients With Solid Tumors. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	0
17475	mTOR pathway gene expression in association with race and clinicopathological characteristics in Black and White breast cancer patients. <i>Discover Oncology</i> , 2022, 13, .	0.8	4
17476	Cytokeratins 5 and 17 Maintain an Aggressive Epithelial State in Basal-Like Breast Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1443-1455.	1.5	1
17477	Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 231-241.	1.1	20
17478	A local human V α 1 T cell population is associated with survival in nonsmall-cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 696-709.	5.7	39
17479	Binding and Efficacy of Anti-Robo4 CAR-T Cells against Solid Tumors. <i>Biomedicines</i> , 2022, 10, 1273.	1.4	1
17480	Mechanisms of miR-3189-3p-mediated inhibition of c-MYC translation in triple negative breast cancer. <i>Cancer Cell International</i> , 2022, 22, .	1.8	1
17481	Prediction of Tumor Mutation Load in Colorectal Cancer Histopathological Images Based on Deep Learning. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
17482	The Chemokines Initiating and Maintaining Immune Hot Phenotype Are Prognostic in ICB of HNSCC. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	0

#	ARTICLE	IF	CITATIONS
17483	Dysregulation and therapeutic targeting of RNA splicing in cancer. <i>Nature Cancer</i> , 2022, 3, 536-546.	5.7	65
17484	Evaluating the tumor immune profile based on a three-gene prognostic risk model in HER2 positive breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
17485	Bidirectional effects of intestinal microbiota and antibiotics: a new strategy for colorectal cancer treatment and prevention. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2387-2404.	1.2	6
17486	Case Report: First-Line Immune Checkpoint Inhibitor Plus Chemotherapy for Oral Metastasis in a Patient with Ultra High-Risk Gestational Choriocarcinoma. <i>Cancer Management and Research</i> , 0, Volume 14, 1867-1875.	0.9	2
17487	Associations of different immune checkpoints-expressing CD4+ Treg/ T cell subsets with disease-free survival in colorectal cancer patients. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
17488	ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
17489	Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 3071-3085.	2.0	5
17490	Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors. <i>Biomarker Research</i> , 2022, 10, .	2.8	0
17491	Characterization of m6A Methylation Modification Patterns in Colorectal Cancer Determines Prognosis and Tumor Microenvironment Infiltration. <i>Journal of Immunology Research</i> , 2022, 2022, 1-17.	0.9	1
17492	Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein. <i>Biomedicines</i> , 2022, 10, 1313.	1.4	9
17493	SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	17
17494	Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors. <i>Science Advances</i> , 2022, 8, .	4.7	31
17495	Integrated pan-cancer analysis reveals distinct clinical, genomic and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia. <i>Molecular Therapy - Oncolytics</i> , 2022, , .	2.0	2
17496	The Prognostic Model and Drug Sensitivity of LKB1-Mutant Lung Adenocarcinoma Based on Immune Landscape. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	0
17497	Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	39
17498	Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
17499	Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
17500	Exhausted PD-1+ TOX+ CD8+ T Cells Arise Only in Long-Term Experimental <i>Trypanosoma cruzi</i> Infection. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4

#	ARTICLE	IF	CITATIONS
17501	Development and Verification of a Prognostic Ferroptosis-Related Gene Model in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
17502	Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. <i>British Journal of Cancer</i> , 2022, 127, 976-987.	2.9	26
17503	Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 851-864.	5.1	50
17504	Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC). <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	20
17505	Difference in immunohistochemical findings among anti-PD-L1 antibodies and their relationships with CD4+ and CD8+ T cells in Japanese melanoma patients. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1364-1371.	1.0	2
17506	Metastatic melanoma treated by immunotherapy: discovering prognostic markers from radiomics analysis of pretreatment CT with feature selection and classification. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2022, 17, 1867-1877.	1.7	2
17507	Cause of Death During Renal Cell Carcinoma Survivorship: A Contemporary, Population-Based Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
17508	Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines. <i>Current Oncology</i> , 2022, 29, 4020-4033.	0.9	0
17509	Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials. <i>Cancer Communications</i> , 2022, 42, 493-516.	3.7	14
17510	TERC suppresses PD-L1 expression by downregulating RNA binding protein HuR. <i>Science China Life Sciences</i> , 2022, 65, 2505-2516.	2.3	1
17511	Nanotechnology for Enhanced Cytoplasmic and Organelle Delivery of Bioactive Molecules to Immune Cells. <i>Pharmaceutical Research</i> , 2022, 39, 1065-1083.	1.7	3
17512	Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE). <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	21
17513	Immunotherapy and Antivascular Targeted Therapy in Patients' Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge. <i>Journal of Immunology Research</i> , 2022, 2022, 1-13.	0.9	0
17514	Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
17515	Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN). <i>Cancers</i> , 2022, 14, 2782.	1.7	11
17516	Bafetinib Suppresses the Transcription of PD-L1 Through c-Myc in Lung Cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
17517	A pro-metastatic tRNA fragment drives Nucleolin oligomerization and stabilization of its bound metabolic mRNAs. <i>Molecular Cell</i> , 2022, 82, 2604-2617.e8.	4.5	33
17518	5' isomiR-183-5p +2 elicits tumor suppressor activity in a negative feedback loop with E2F1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	2

#	ARTICLE	IF	CITATIONS
17519	Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (âˆ™) Breast Cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
17520	Profiling the Tumor-Infiltrating Lymphocytes in Gastric Cancer Reveals Its Implication in the Prognosis. <i>Genes</i> , 2022, 13, 1017.	1.0	2
17521	A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
17522	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. , 2022, 10, e004440.		49
17523	Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	7
17524	Estimating tumor mutational burden from RNA-sequencing without a matched-normal sample. <i>Nature Communications</i> , 2022, 13, .	5.8	4
17525	Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 2775.	1.7	5
17526	Conscription of Immune Cells by Lightâ€Activatable Silencing NKâ€Derived Exosome (LASNEO) for Synergetic Tumor Eradication. <i>Advanced Science</i> , 2022, 9, .	5.6	30
17527	Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
17528	Case Report: Extensive Tumor Profiling in Primary Neuroendocrine Breast Cancer Cases as a Role Model for Personalized Treatment in Rare and Aggressive Cancer Types. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	1
17529	New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Vaccines</i> , 2022, 10, 885.	2.1	2
17530	KCNN4 is a Potential Biomarker for Predicting Cancer Prognosis and an Essential Molecule that Remodels Various Components in the Tumor Microenvironment: A Pan-Cancer Study. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	7
17531	Multi-Omics Integrative Analysis of Lung Adenocarcinoma: An in silico Profiling for Precise Medicine. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
17532	Dose-Dependent Effect of Tumor Mutation Burden on Cancer Prognosis Following Immune Checkpoint Blockade: Causal Implications. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3
17533	Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 283-293.	1.4	3
17534	Beyond Genetics: Metastasis as an Adaptive Response in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6271.	1.8	9
17535	LINCO0892 Is an lncRNA Induced by T Cell Activation and Expressed by Follicular Lymphoma-Resident T Helper Cells. <i>Non-coding RNA</i> , 2022, 8, 40.	1.3	3
17536	Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	11

#	ARTICLE	IF	CITATIONS
17537	Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100355.	0.6	5
17538	Safety evaluation of fixed-dose nivolumab in patients with gastric cancer. <i>Health Science Reports</i> , 2022, 5, .	0.6	4
17539	Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. <i>Advanced Science</i> , 2022, 9, .	5.6	140
17540	Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer. <i>Translational Oncology</i> , 2022, 22, 101464.	1.7	3
17541	A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	1
17542	A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments. <i>Journal of Thoracic Disease</i> , 2022, 14, 2131-2146.	0.6	2
17543	Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration. <i>Translational Lung Cancer Research</i> , 2022, 11, 964-974.	1.3	9
17544	Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 464-476.	1.0	9
17545	Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 560-76.	0.9	3
17546	A Brief Introduction to Current Cancer Gene Therapy. <i>Methods in Molecular Biology</i> , 2022, , 1-21.	0.4	3
17547	Understanding the tumor microenvironment in head and neck squamous cell carcinoma. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	10
17548	Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210998.	0.6	10
17549	An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 472-486.	0.9	12
17550	Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression $\geq 50\%$. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211050.	1.4	1
17551	Imaging response assessment for oncology: An algorithmic approach. <i>European Journal of Radiology Open</i> , 2022, 9, 100426.	0.7	2
17552	Antitumor activity of recombinant oncolytic vaccinia virus with human IL2. <i>Open Medicine (Poland)</i> , 2022, 17, 1084-1091.	0.6	3
17553	VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment. <i>International Journal of Biological Sciences</i> , 2022, 18, 3845-3858.	2.6	64
17554	PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer. <i>Cancer Control</i> , 2022, 29, 107327482211075.	0.7	1

#	ARTICLE	IF	CITATIONS
17555	Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 691-702.	0.9	5
17556	Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity. <i>International Ophthalmology Clinics</i> , 2022, 62, 49-63.	0.3	6
17557	Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis. <i>World Journal of Otorhinolaryngology - Head and Neck Surgery</i> , 0, .	0.7	0
17558	A degranulation system targeting endogenous PD-1 inhibits the growth of tumor cells in mice. <i>NAR Cancer</i> , 2022, 4, .	1.6	4
17559	Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
17560	Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	15
17561	Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks. <i>Bioinformatics</i> , 2022, 38, 3462-3469.	1.8	9
17562	Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor. <i>Targeted Oncology</i> , 2022, 17, 329-341.	1.7	2
17563	Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. <i>Current Oncology Reports</i> , 2022, 24, 1273-1280.	1.8	5
17564	Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors. <i>PLoS Computational Biology</i> , 2022, 18, e1010109.	1.5	1
17565	Long noncoding RNA (lncRNA) metallothionein 1b, pseudogene (MT1JP) is downregulated in triple-negative breast cancer and upregulates microRNA-138 (miR-138) to downregulate hypoxia-inducible factor-1 α (HIF-1 α). <i>Bioengineered</i> , 2022, 13, 13718-13727.	1.4	6
17566	Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy. <i>ACS Central Science</i> , 2022, 8, 692-704.	5.3	9
17567	Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors. <i>Targeted Oncology</i> , 2022, 17, 355-368.	1.7	1
17568	When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents. <i>Targeted Oncology</i> , 2022, 17, 253-270.	1.7	5
17569	Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. , 2022, 10, e004762.		19
17570	Mapping Phenotypic Plasticity upon the Cancer Cell State Landscape Using Manifold Learning. <i>Cancer Discovery</i> , 2022, 12, 1847-1859.	7.7	26
17571	Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. <i>Current Oncology</i> , 2022, 29, 4185-4198.	0.9	12
17572	The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0

#	ARTICLE	IF	CITATIONS
17573	Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
17574	Recent Advances and Challenges in Uveal Melanoma Immunotherapy. <i>Cancers</i> , 2022, 14, 3094.	1.7	23
17575	Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with <i>nab</i> -paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031). <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	0
17576	Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	28
17577	Safety of sequential immune checkpoint inhibitors after prior immune therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2375-2382.	1.2	2
17578	Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
17579	Genomic Analysis of Waterpipe Smoke-Induced Lung Tumor Autophagy and Plasticity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6848.	1.8	3
17580	Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
17581	Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade. , 2022, 10, e004582.		16
17582	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. <i>Nature Communications</i> , 2022, 13, .	5.8	63
17583	Automated detection and segmentation of non-small cell lung cancer computed tomography images. <i>Nature Communications</i> , 2022, 13, .	5.8	44
17584	MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
17585	Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-stage small cell lung cancer. <i>Cancer Medicine</i> , 2023, 12, 73-83.	1.3	13
17586	Evaluation of cancer outcome assessment using MRI: A review of deep-learning methods. <i>BJR Open</i> , 2022, 4, .	0.4	0
17587	The risk variant rs11836367 contributes to breast cancer onset and metastasis by attenuating Wnt signaling via regulating <i>NTN4</i> expression. <i>Science Advances</i> , 2022, 8, .	4.7	1
17588	The Treatment of Advanced Melanoma: Therapeutic Update. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6388.	1.8	41
17589	Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
17590	APOBEC Alteration Contributes to Tumor Growth and Immune Escape in Pan-Cancer. <i>Cancers</i> , 2022, 14, 2827.	1.7	11

#	ARTICLE	IF	CITATIONS
17591	Current Status and Future Directions of Bacteria-Based Immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
17592	Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	22
17593	Radiopharmaceuticals as Novel Immune System Tracers. <i>Advances in Radiation Oncology</i> , 2022, , 100936.	0.6	1
17594	The Immune Cell Infiltration Patterns and Characterization Score in Bladder Cancer to Identify Prognosis. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
17595	Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy. <i>Cancers</i> , 2022, 14, 2992.	1.7	12
17596	Tripartite motif-containing 25 facilitates immunosuppression and inhibits apoptosis of glioma via activating NF- κ B. <i>Experimental Biology and Medicine</i> , 2022, 247, 1529-1541.	1.1	4
17597	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <i>Molecules</i> , 2022, 27, 3798.	1.7	29
17598	Pan-Cancer Pyroptosis Analyses Identified Novel Immunology and Chemotherapy-Related Prognostic Signatures in Cancer Subtypes. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	0
17599	Breast Cancer Genomics: Primary and Most Common Metastases. <i>Cancers</i> , 2022, 14, 3046.	1.7	3
17600	Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome. <i>British Journal of Cancer</i> , 2022, 127, 1162-1171.	2.9	3
17601	Clinical significance and molecular annotation of cellular morphometric subtypes in lower-grade gliomas discovered by machine learning. <i>Neuro-Oncology</i> , 2023, 25, 68-81.	0.6	18
17602	Virus-Based Immuno-Oncology Models. <i>Biomedicines</i> , 2022, 10, 1441.	1.4	4
17603	Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	0
17604	The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer. , 2022, 10, e004312.		5
17605	Classification of triple negative breast cancer by epithelial mesenchymal transition and the tumor immune microenvironment. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
17606	Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	11
17607	MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer. <i>Communications Biology</i> , 2022, 5, .	2.0	8
17608	Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma. <i>World Journal of Oncology</i> , 2022, 13, 126-135.	0.6	2

#	ARTICLE	IF	CITATIONS
17609	Breast carcinomas with osteoclast-like giant cells: a comprehensive clinico-pathological and molecular portrait and evidence of RANK-L expression. <i>Modern Pathology</i> , 2022, 35, 1624-1635.	2.9	3
17610	Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. , 2022, 10, e004771.		16
17611	Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) Tâ€cellular therapy development. <i>Clinical and Translational Science</i> , 2022, 15, 2057-2074.	1.5	9
17612	Analysis of Omics Data Reveals Nucleotide Excision Repair-Related Genes Signature in Highly-Grade Serous Ovarian Cancer to Predict Prognosis. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
17613	CD47-SIRPÎ± Controls ADCC Killing of Primary T Cells by PMN Through a Combination of Trogocytosis and NADPH Oxidase Activation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
17614	Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	1
17615	Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors. <i>BioMed Research International</i> , 2022, 2022, 1-9.	0.9	1
17616	Value of a Signature of Immune-Related Genes in Predicting the Prognosis of Melanoma and Its Responses to Immune Checkpoint Blocker Therapies. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-13.	0.7	3
17617	GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	12
17618	Vaccines for immunoprevention of DNA mismatch repair deficient cancers. , 2022, 10, e004416.		21
17619	Role of Adenoviruses in Cancer Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
17620	PD-1/PD-L Axis in Neuroinflammation: New Insights. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	16
17621	First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3452-3463.	3.2	21
17622	Differential Immune Checkpoint and Ig-like V-Type Receptor Profiles in COVID-19: Associations with Severity and Treatment. <i>Journal of Clinical Medicine</i> , 2022, 11, 3287.	1.0	1
17623	Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis. <i>Pharmaceuticals</i> , 2022, 15, 747.	1.7	18
17624	Integrated analysis reveals the pivotal interactions between immune cells in the melanoma tumor microenvironment. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
17625	Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment. <i>Cancer Research</i> , 2022, 82, 2593-2609.	0.4	5
17626	Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports. <i>Saudi Pharmaceutical Journal</i> , 2022, 30, 1193-1199.	1.2	1

#	ARTICLE	IF	CITATIONS
17627	Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6806.	1.8	74
17628	Metabolomic and Transcriptomic Profiling Identified Significant Genes in Thymic Epithelial Tumor. <i>Metabolites</i> , 2022, 12, 567.	1.3	6
17629	Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
17630	Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer. <i>Investigational New Drugs</i> , 2022, 40, 1066-1079.	1.2	9
17631	SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 3042.	1.7	1
17632	Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	5
17633	Current and Future Immunotherapy-Based Treatments for Oesophageal Cancers. <i>Cancers</i> , 2022, 14, 3104.	1.7	1
17634	Single B Cell Gene Co-Expression Networks Implicated in Prognosis, Proliferation, and Therapeutic Responses in Non-Small Cell Lung Cancer Bulk Tumors. <i>Cancers</i> , 2022, 14, 3123.	1.7	5
17635	The current state of molecular profiling in gastrointestinal malignancies. <i>Biology Direct</i> , 2022, 17, .	1.9	5
17636	Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2022, 9, 100103.	0.7	3
17637	Injectable DNA Hydrogel-Based Local Drug Delivery and Immunotherapy. <i>Gels</i> , 2022, 8, 400.	2.1	11
17638	Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma. <i>Oncologist</i> , 2022, 27, e703-e722.	1.9	2
17639	A digital assay for programmed death-ligand 1 (22C3) quantification combined with immune cell recognition algorithms in non-small cell lung cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
17640	High Expression of a Cancer Stemness-Related Gene, Chromobox 8 (CBX8), in Normal Tissue Adjacent to the Tumor (NAT) Is Associated with Poor Prognosis of Colorectal Cancer Patients. <i>Cells</i> , 2022, 11, 1852.	1.8	0
17641	PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	13
17642	NCAPH is a prognostic biomarker and associated with immune infiltrates in lung adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
17643	Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	32
17645	Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 3245.	1.0	8

#	ARTICLE	IF	CITATIONS
17646	Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors. <i>American Journal of Clinical Dermatology</i> , 0, , .	3.3	3
17647	Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
17648	A Highly Effective System for Predicting MHC-II Epitopes With Immunogenicity. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
17649	Mitochondrial Homeostasis-Related lncRNAs are Potential Biomarkers for Predicting Prognosis and Immune Response in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
17650	Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line. <i>Molecules</i> , 2022, 27, 3661.	1.7	10
17651	Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade. <i>Cancer Research</i> , 2022, 82, 2904-2917.	0.4	72
17652	Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. <i>JAMA Network Open</i> , 2022, 5, e2215589.	2.8	15
17653	Metabolism-Associated DNA Methylation Signature Stratifies Lower-Grade Glioma Patients and Predicts Response to Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
17654	Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials. <i>Cancers</i> , 2022, 14, 2867.	1.7	10
17655	RhoBTB3 Regulates Proliferation and Invasion of Breast Cancer Cells via Col1a1. <i>Molecules and Cells</i> , 2022, 45, 631-639.	1.0	6
17656	Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	1
17657	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	21.5	134
17658	Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1747-1754.	1.2	2
17659	PD-L2 Serves as a Potential Prognostic Biomarker That Correlates With Immune Infiltration and May Predict Therapeutic Sensitivity in Lower-Grade Gliomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
17660	Distinguishable Prognostic Signatures and Tumor Immunogenicity Between Pancreatic Head Cancer and Pancreatic Body/Tail Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
17661	Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
17662	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	1.6	18
17663	Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect. <i>Oncolimmunology</i> , 2022, 11, .	2.1	7

#	ARTICLE	IF	CITATIONS
17664	Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 2022, 10, 6110-6118.	0.3	3
17665	Clinical evidence for synergy between immunotherapy and radiotherapy (<scp>SITAR</scp>). <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 881-895.	0.9	9
17666	Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
17667	Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	19
17668	NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation. <i>Cancers</i> , 2022, 14, 2962.	1.7	10
17669	Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
17670	Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	13
17671	Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
17672	Blocking TIGIT/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	18
17673	Integrated multi-omic characterization of congenital heart disease. <i>Nature</i> , 2022, 608, 181-191.	13.7	37
17674	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	33
17675	Depletion of Mannose Receptorâ€“Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast Cancer Progression in Mice. <i>Cancer Research Communications</i> , 2022, 2, 533-551.	0.7	7
17676	Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	21
17677	Self-Sustained Regulation or Self-Perpetuating Dysregulation: ROS-dependent HIF-YAP-Notch Signaling as a Double-Edged Sword on Stem Cell Physiology and Tumorigenesis. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
17678	Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
17679	Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	1
17680	Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue. <i>Prostate Cancer</i> , 2022, 2022, 1-8.	0.4	1
17681	Deep reinforcement learning for personalized treatment recommendation. <i>Statistics in Medicine</i> , 2022, 41, 4034-4056.	0.8	13

#	ARTICLE	IF	CITATIONS
17682	Bifunctional scaffolds for tumor therapy and bone regeneration: Synergistic effect and interplay between therapeutic agents and scaffold materials. <i>Materials Today Bio</i> , 2022, 15, 100318.	2.6	8
17683	Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	21
17684	Reciprocal regulation of Daxx and PIK3CA promotes colorectal cancer cell growth. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	5
17685	Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses. <i>Onc Immunology</i> , 2022, 11, .	2.1	6
17686	Genomic Landscape of Metastatic Lymph Nodes and Primary Tumors in Non-Small-Cell Lung Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	5
17687	Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	6
17688	Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation. <i>Cancer Research and Treatment</i> , 2023, 55, 155-166.	1.3	1
17689	Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review. <i>Current Drug Metabolism</i> , 2022, 23, 781-799.	0.7	2
17690	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	9
17691	PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
17692	Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
17693	Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma. <i>Cancers</i> , 2022, 14, 2937.	1.7	9
17694	Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkinâ€™s Lymphoma. <i>Cancers</i> , 2022, 14, 2936.	1.7	4
17695	Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
17696	Two-year efficacy of <sc>SNK01</sc> plus pembrolizumab for non-small cell lung cancer: Expanded observations from a phase <sc>III</sc> randomized controlled trial. <i>Thoracic Cancer</i> , 0, , .	0.8	3
17697	Immune Checkpoint Proteins, Metabolism and Adhesion Molecules: Overlooked Determinants of CAR T-Cell Migration?. <i>Cells</i> , 2022, 11, 1854.	1.8	7
17698	Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
17699	Spontaneous xenogeneic <sc>GvHD</sc> in Wilms' tumor <sc>Patientâ€™Derived</sc> xenograft models and potential solutions. <i>Animal Models and Experimental Medicine</i> , 2022, 5, 389-396.	1.3	3

#	ARTICLE	IF	CITATIONS
17700	Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
17701	Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	15
17702	Activation Versus Inhibition of IGF1R: A Dual Role in Breast Tumorigenesis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
17703	Occupational Low-Dose Radiation Affects the Expression of Immune Checkpoint of Medical Radiologists. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7105.	1.2	0
17704	Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 941.	1.1	3
17705	Non-cytotoxic nanoparticles re-educating macrophages achieving both innate and adaptive immune responses for tumor therapy. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 557-570.	4.3	7
17706	Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women. <i>Genome Medicine</i> , 2022, 14, .	3.6	10
17707	Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 2816.	1.7	3
17708	BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma. , 2022, 10, e004133.		8
17709	Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside. <i>JPRAS Open</i> , 2022, 33, 155-160.	0.4	7
17710	Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
17711	Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
17712	Molecular and Clinical Characterization of CD80 Expression via Large-Scale Analysis in Breast Cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
17713	Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas. <i>Cancers</i> , 2022, 14, 3037.	1.7	6
17714	Mitochondrial genotype remodels the metabolic and microenvironmental landscape of H4rthle cell carcinoma. <i>Science Advances</i> , 2022, 8, .	4.7	15
17715	Drug Repurposing by Tumor Tissue Editing. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
17716	Plac1 Remodels the Tumor Immune Evasion Microenvironment and Predicts Therapeutic Response in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
17717	Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
17718	Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACTiVe-2 trial). <i>BMJ Open</i> , 2022, 12, e060431.	0.8	4
17719	Catalytical nano-immunocomplexes for remote-controlled sono-metabolic checkpoint trimodal cancer therapy. <i>Nature Communications</i> , 2022, 13, .	5.8	76
17720	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. <i>JAMA Oncology</i> , 2022, 8, 1160.	3.4	117
17721	Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
17722	A hierarchical spike-and-slab model for pan-cancer survival using pan-omic data. <i>BMC Bioinformatics</i> , 2022, 23, .	1.2	0
17723	Tumor Microenvironment—A Short Review of Cellular and Interaction Diversity. <i>Biology</i> , 2022, 11, 929.	1.3	22
17724	Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
17725	iRECIST and atypical patterns of response to immuno-oncology drugs. , 2022, 10, e004849.		12
17726	Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. <i>Gut</i> , 2023, 72, 325-337.	6.1	47
17727	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. <i>Nature Medicine</i> , 2022, 28, 1599-1611.	15.2	185
17728	CAR T Cell Locomotion in Solid Tumor Microenvironment. <i>Cells</i> , 2022, 11, 1974.	1.8	15
17729	Pembrolizumab-Induced Acute Skin Reaction: A Case Report and Review of Literature. <i>Cureus</i> , 2022, , .	0.2	1
17730	Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. <i>Cancers</i> , 2022, 14, 3003.	1.7	3
17731	Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates. <i>Cancer Management and Research</i> , 0, Volume 14, 2079-2090.	0.9	3
17732	ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
17733	Contribution of the Skin-Gut Axis to Immune-Related Adverse Events with Multi-System Involvement. <i>Cancers</i> , 2022, 14, 2995.	1.7	5
17734	Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis. <i>Biomedicines</i> , 2022, 10, 1334.	1.4	5
17735	Prognostic and Predictive Relevance of Tumor-Infiltrating Lymphocytes in Squamous Cell Head-Neck Cancer Patients Treated with Radical Radiotherapy/Chemo-Radiotherapy. <i>Current Oncology</i> , 2022, 29, 4274-4284.	0.9	9

#	ARTICLE	IF	CITATIONS
17736	Cytoplasmic p53 ^{Î²} Isoforms Are Associated with Worse Disease-Free Survival in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6670.	1.8	7
17737	Co-Inhibitory Molecules ‘‘ Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
17738	Immune Cell Networks Uncover Candidate Biomarkers of Melanoma Immunotherapy Response. <i>Journal of Personalized Medicine</i> , 2022, 12, 958.	1.1	0
17739	Excessive immunosuppression by regulatory T cells antagonizes T cell response to schistosome infection in PD-1-deficient mice. <i>PLoS Pathogens</i> , 2022, 18, e1010596.	2.1	7
17740	Replication Stress Defines Distinct Molecular Subtypes Across Cancers. <i>Cancer Research Communications</i> , 2022, 2, 503-517.	0.7	12
17741	Predicting Tumor Mutational Burden From Lung Adenocarcinoma Histopathological Images Using Deep Learning. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
17742	Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-Î² degradation. <i>Nature Communications</i> , 2022, 13, .	5.8	26
17743	A Framework to Predict the Molecular Classification and Prognosis of Breast Cancer Patients and Characterize the Landscape of Immune Cell Infiltration. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-23.	0.7	0
17744	Combined treatment with anti-PSMA CAR NK-Î² cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	18
17745	EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6489.	1.8	45
17746	Tumor-Associated Inflammation: The Tumor-Promoting Immunity in the Early Stages of Tumorigenesis. <i>Journal of Immunology Research</i> , 2022, 2022, 1-13.	0.9	7
17747	Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6547.	1.8	11
17748	Novel Hypoxia-Associated Gene Signature Depicts Tumor Immune Microenvironment and Predicts Prognosis of Colon Cancer Patients. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
17749	Prognostic utility of preoperative inflammatory markers in patients with intrahepatic cholangiocarcinoma after hepatic resection: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2023, 12, 99-110.	1.3	6
17750	Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	18
17751	An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy. <i>ESMO Open</i> , 2022, 7, 100502.	2.0	3
17752	Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. <i>Cancer Treatment Reviews</i> , 2022, 109, 102429.	3.4	30
17753	Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3449-3460.	1.9	3

#	ARTICLE	IF	CITATIONS
17754	Sensitivity and specificity of amide proton transfer-weighted imaging for assessing programmed death-ligand 1 status in non-small cell lung cancer: a comparative study with intravoxel incoherent motion and 18F-FDG PET. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 4474-4487.	1.1	5
17755	Pomegranate seed extract enhances the inhibitory effect of adipose- derived mesenchymal stem cells on breast cancer cell line in co-culture conditions. <i>Research in Pharmaceutical Sciences</i> , 2022, 17, 372.	0.6	4
17756	Nonsurgical Approach to Isolated Pancreatic Metastatic Malignant Melanoma: A Case Report and Review of the Literature. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2022, 10, 232470962211117.	0.3	0
17757	MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202211123.	1.0	0
17758	Trends and costs of stereotactic body radiation therapy in metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2022, .	0.6	4
17759	Crucial Roles of LncRNAs-Mediated Autophagy in Breast Cancer. <i>International Journal of Medical Sciences</i> , 2022, 19, 1082-1092.	1.1	7
17760	Chemical-induced lung tumor in Tg-rasH2 mice: a novel mouse tumor model to assess immune checkpoint inhibitors combined with a chemotherapy drug. <i>Journal of Toxicologic Pathology</i> , 2022, , .	0.3	0
17761	UBR5 promotes tumor immune evasion through enhancing IFN- β -induced <i>PDL1</i> transcription in triple negative breast cancer. <i>Theranostics</i> , 2022, 12, 5086-5102.	4.6	20
17762	Progress in advanced nanotherapeutics for enhanced photodynamic immunotherapy of tumor. <i>Theranostics</i> , 2022, 12, 5272-5298.	4.6	21
17763	Prognostic/predictive markers in systemic therapy resistance and metastasis in breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211126.	1.4	3
17764	Inflammation Markers Have Important Value in Predicting Relapse in Patients with papillary thyroid carcinoma: A Long-Term Follow-Up Retrospective Study. <i>Cancer Control</i> , 2022, 29, 107327482211152.	0.7	12
17765	Identification and verification of immune-related gene prognostic signature based on ssGSEA for breast cancer. <i>Central-European Journal of Immunology</i> , 2022, 47, 139-150.	0.4	1
17766	Bioinformatic analysis of the role of solute carrier-glutamine transporters in breast cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 777-777.	0.7	2
17767	Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma. <i>Genes and Development</i> , 2022, 36, 514-532.	2.7	11
17768	Dapl1 controls NFATc2 activation to regulate CD8+ T cell exhaustion and responses in chronic infection and cancer. <i>Nature Cell Biology</i> , 2022, 24, 1165-1176.	4.6	9
17769	Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report. <i>Cureus</i> , 2022, , .	0.2	1
17770	Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	21
17771	ICIs-Related Cardiotoxicity in Different Types of Cancer. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 203.	0.8	11

#	ARTICLE	IF	CITATIONS
17772	Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2946-2956.	0.8	46
17773	A combination of stromal PD-L1 and tumoral nuclear β -catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 458-469.	1.3	8
17774	Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2022, 140, 1507-1521.	0.6	2
17775	Network-based machine learning approach to predict immunotherapy response in cancer patients. <i>Nature Communications</i> , 2022, 13, .	5.8	56
17776	Tumor Microenvironment Heterogeneity-Based Score System Predicts Clinical Prognosis and Response to Immune Checkpoint Blockade in Multiple Colorectal Cancer Cohorts. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	4
17777	Synergistic antitumor effect of a penicillin derivative combined with thapsigargin in melanoma cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
17778	Immune checkpoint inhibitors combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	4
17779	Immunotherapy: an alternative promising therapeutic approach against cancers. <i>Molecular Biology Reports</i> , 2022, 49, 9903-9913.	1.0	17
17780	Successful electrochemotherapy treatment of a large bleeding lymph node melanoma metastasis. <i>Melanoma Management</i> , 2022, 9, .	0.1	1
17781	Real-world utilization of PD-L1 inhibitors with palliative radiotherapy in patients with metastatic non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2291-2300.	0.8	7
17782	Clinical significance and immunogenomic landscape analysis of glycolysis-associated prognostic model to guide clinical therapy in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1351-1366.	0.6	1
17783	Role of germline variants in the metastasis of breast carcinomas. <i>Oncotarget</i> , 2022, 13, 843-862.	0.8	0
17784	Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
17785	Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. <i>Journal of Hematology (Brossard, Quebec)</i> , 2022, 11, 113-120.	0.4	3
17786	Immune Infiltration Represents Potential Diagnostic and Prognostic Biomarkers for Esophageal Squamous Cell Carcinoma. <i>BioMed Research International</i> , 2022, 2022, 1-15.	0.9	0
17787	Prognostic significance of PD-L1 expression and CD8+ TILs density for disease-free survival in surgically resected lung squamous cell carcinoma: a retrospective study. <i>Journal of Thoracic Disease</i> , 2022, 14, 2224-2234.	0.6	3
17788	18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3190.	1.7	5
17789	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18

#	ARTICLE	IF	CITATIONS
17790	Relationship between PD-L1 expression and prognostic factors in high-risk cutaneous squamous and basal cell carcinoma. <i>Bosnian Journal of Basic Medical Sciences</i> , 2022, 22, 894-900.	0.6	2
17791	PD-L1 Up-Regulation in Prostate Cancer Cells by <i>Porphyromonas gingivalis</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	12
17792	Functional screening reveals <i>HORMAD1</i> -driven gene dependencies associated with translesion synthesis and replication stress tolerance. <i>Oncogene</i> , 2022, 41, 3969-3977.	2.6	6
17793	Identification of the Key miRNAs and Genes Associated with the Regulation of Non-Small Cell Lung Cancer: A Network-Based Approach. <i>Genes</i> , 2022, 13, 1174.	1.0	4
17794	Multiplex Immunofluorescence and the Digital Image Analysis Workflow for Evaluation of the Tumor Immune Environment in Translational Research. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
17795	Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	134
17796	Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. <i>Archives of Pharmacal Research</i> , 2022, 45, 401-416.	2.7	32
17797	Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer. <i>Cancers</i> , 2022, 14, 3159.	1.7	5
17798	Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 1038-1050.	1.3	4
17799	Precision Medicine in Solid Tumors: How Far We Traveled So Far?. <i>Cancers</i> , 2022, 14, 3202.	1.7	1
17800	Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. <i>Journal of Personalized Medicine</i> , 2022, 12, 1073.	1.1	36
17801	Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
17802	Ferroptosis in Glioma Immune Microenvironment: Opportunity and Challenge. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
17803	Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics. <i>Cancer Medicine</i> , 0, , .	1.3	1
17804	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. <i>Journal of Clinical Oncology</i> , 2022, 40, 3808-3816.	0.8	19
17805	Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 1344.	2.0	8
17806	Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
17807	Clinical Efficacy and Safety Analysis of PD-1/PD-L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2022, 2022, 1-9.	0.9	2

#	ARTICLE	IF	CITATIONS
17808	Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives. <i>Cancers</i> , 2022, 14, 3138.	1.7	0
17809	Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer. <i>Biomedicines</i> , 2022, 10, 1539.	1.4	2
17810	A Novel Defined Endoplasmic Reticulum Stress-Related lncRNA Signature for Prognosis Prediction and Immune Therapy in Glioma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
17811	Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1. <i>Pharmaceutics</i> , 2022, 14, 1381.	2.0	1
17812	Enhancement of antitumor immune response by radiation therapy combined with dual immune checkpoint inhibitor in a metastatic model of HER2-positive murine tumor. <i>Japanese Journal of Radiology</i> , 2022, 40, 1307-1315.	1.0	1
17813	Expression of PD-L1 in Locally Advanced Breast Cancer and Its Impact on Neoadjuvant Chemotherapy Response. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2095-2103.	0.5	0
17814	Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
17815	TNFRSF9 Suppressed the Progression of Breast Cancer via the p38MAPK/PAX6 Signaling Pathway. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	1
17816	Bacterial Cellulose as Drug Delivery System for Optimizing Release of Immune Checkpoint Blocking Antibodies. <i>Pharmaceutics</i> , 2022, 14, 1351.	2.0	8
17817	Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 969-978.	1.2	9
17818	From Intestinal Epithelial Homeostasis to Colorectal Cancer: Autophagy Regulation in Cellular Stress. <i>Antioxidants</i> , 2022, 11, 1308.	2.2	2
17819	Tumor Microenvironment Characterization in Breast Cancer and an Immune Cell Infiltration Score Development, Validation, and Application. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
17820	Research Progress of DUB Enzyme in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
17821	Oncolytic adenovirus <sc>H101</sc> ameliorate the efficacy of <sc>anti-EPD</sc>â€1 monotherapy in colorectal cancer. <i>Cancer Medicine</i> , 2022, 11, 4575-4587.	1.3	7
17822	Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1014-1031.	0.5	31
17823	A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
17824	The Role of the Immune System in the Development of Endometriosis. <i>Cells</i> , 2022, 11, 2028.	1.8	40
17825	Rationale for Combing Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors in Medically Inoperable Early-Stage Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3144.	1.7	4

#	ARTICLE	IF	CITATIONS
17826	Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab+Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	2
17827	Research progress on immunotherapy in triple-negative breast cancer (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	9
17828	Know thy cells: commonly used triple-negative human breast cancer cell lines carry mutations in RAS and effectors. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	8
17829	The obesity-breast cancer link: a multidisciplinary perspective. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 607-625.	2.7	36
17830	Immunological Landscape of HER-2 Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 3167.	1.7	3
17831	Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
17832	Sequence-specific 1H, 13C and 15N backbone NMR assignments for the N-terminal IgV-like domain (D1) and full extracellular region (D1D2) of PD-L1. <i>Biomolecular NMR Assignments</i> , 2022, 16, 281-288.	0.4	1
17833	Development and Characterization of a Nanobody against Human T-Cell Immunoglobulin and Mucin-3. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-8.	0.7	5
17834	A deep learning model to classify neoplastic state and tissue origin from transcriptomic data. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
17835	Role of tertiary lymphoid organs in the regulation of immune responses in the periphery. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	24
17836	Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden. <i>Cancer</i> , 0, , .	2.0	0
17837	Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma. <i>Aging</i> , 2022, 14, 5271-5291.	1.4	3
17838	Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-10.	0.9	4
17839	Therapeutic targeting of regulatory T cells in cancer. <i>Trends in Cancer</i> , 2022, 8, 944-961.	3.8	44
17840	Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
17841	Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
17842	Racial and Ethnic Trends and Disparities in NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100374.	0.6	1
17843	Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-7.	0.7	1

#	ARTICLE	IF	CITATIONS
17844	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. <i>Clinical Cancer Research</i> , 2022, 28, 3480-3488.	3.2	8
17845	In vivo multidimensional CRISPR screens identify <i>Lgals2</i> as an immunotherapy target in triple-negative breast cancer. <i>Science Advances</i> , 2022, 8, .	4.7	26
17846	Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors. , 2022, 10, e004325.		4
17847	TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, preventive, and personalized medicine. <i>EPMA Journal</i> , 2022, 13, 519-534.	3.3	4
17848	<i>ITCH</i> facilitates proteasomal degradation of <i>TXNIP</i> in hypoxia-induced lung cancer cells. <i>Thoracic Cancer</i> , 2022, 13, 2235-2247.	0.8	4
17849	Multi-modal molecular programs regulate melanoma cell state. <i>Nature Communications</i> , 2022, 13, .	5.8	9
17850	Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy. <i>Cancers</i> , 2022, 14, 3374.	1.7	2
17851	HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors. <i>Nature Communications</i> , 2022, 13, .	5.8	23
17852	Pretreatment Modified Albuminâ€“Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. <i>Current Oncology</i> , 2022, 29, 4799-4810.	0.9	8
17853	Self-Assembly of a Multifunction DNA Tetrahedron for Effective Delivery of Aptamer PL1 and <i>Pcsk9</i> siRNA Potentiate Immune Checkpoint Therapy for Colorectal Cancer. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 31634-31644.	4.0	23
17854	Dual-responsive nanovaccine for cytosolic delivery of antigens to boost cellular immune responses and cancer immunotherapy. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 583-595.	4.3	10
17855	Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 4119.	1.0	28
17856	Histological changes associated with laser interstitial thermal therapy for radiation necrosis: illustrative cases. <i>Journal of Neurosurgery Case Lessons</i> , 2022, 4, .	0.1	0
17857	HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3495.	1.7	6
17858	Necroptosis Identifies Novel Molecular Phenotypes and Influences Tumor Immune Microenvironment of Lung Adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
17859	The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
17860	Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
17861	mRNA vaccine development for cholangiocarcinoma: a precise pipeline. <i>Military Medical Research</i> , 2022, 9, .	1.9	6

#	ARTICLE	IF	CITATIONS
17862	IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy. <i>Biomarker Research</i> , 2022, 10, .	2.8	2
17863	SFRP4 Is a Potential Biomarker for the Prognosis and Immunotherapy for Gastric Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	2
17864	Radiomics model based on multi-sequence MR images for predicting preoperative immunoscore in rectal cancer. <i>Radiologia Medica</i> , 2022, 127, 702-713.	4.7	19
17865	CpG ODN (K3)â€”toll-like receptor 9 agonistâ€”induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
17866	Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7922.	1.8	2
17867	The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2346-2354.	0.8	5
17868	Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
17869	Immunotherapy approaches for malignant pleural mesothelioma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 573-584.	12.5	21
17870	Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3294.	1.7	4
17871	Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
17872	Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	27
17873	Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes. <i>BMC Women's Health</i> , 2022, 22, .	0.8	2
17874	Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	33
17875	CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
17876	Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Nonâ€”Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
17877	Deciphering Prognostic Value of TTN and Its Correlation With Immune Infiltration in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
17878	Immunohistochemical expression of PD-L1 and MDR1 in breast tumors: association with clinico-pathological parameters and treatment outcome. <i>Clinical and Experimental Medicine</i> , 2023, 23, 859-869.	1.9	2
17879	A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs. <i>Nature Biotechnology</i> , 2022, 40, 1823-1833.	9.4	17

#	ARTICLE	IF	CITATIONS
17880	PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas. <i>Biomedicines</i> , 2022, 10, 1587.	1.4	6
17881	Recurrent somatic mutations as predictors of immunotherapy response. <i>Nature Communications</i> , 2022, 13, .	5.8	12
17882	Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. <i>Cancer Communications</i> , 2022, 42, 689-715.	3.7	41
17883	Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 226-244.	2.0	4
17884	Clustering analysis and prognostic signature of lung adenocarcinoma based on the tumor microenvironment. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
17885	NAIRscore as a biomarker for the quality of immune response to neoantigens is related with an increased overall survival in multiple myeloma. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 285-295.	2.3	5
17886	Immunologic Strategies in Pancreatic Cancer: Making <i>Cold</i> Tumors <i>Hot</i>. <i>Journal of Clinical Oncology</i> , 2022, 40, 2789-2805.	0.8	69
17887	Advanced non-small-cell lung cancer: how to manage non-oncogene disease. <i>Drugs in Context</i> , 0, 11, 1-14.	1.0	2
17888	Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. <i>Molecular Carcinogenesis</i> , 0, , .	1.3	8
17889	Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-27.	0.6	5
17890	From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine. <i>Cancers</i> , 2022, 14, 3469.	1.7	5
17891	Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma. <i>Cancers</i> , 2022, 14, 3282.	1.7	4
17892	<sc>Non-small</sc> cell lung cancer with tumor proportion score >= 90% could increase the risk of severe <sc>immune-related</sc> adverse events in <sc>first-line</sc> treatments with immune checkpoint inhibitors: A retrospective <sc>single-center</sc> study. <i>Thoracic Cancer</i> , 2022, 13, 2450-2458.	0.8	4
17893	Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. <i>Modern Pathology</i> , 2022, 35, 1529-1539.	2.9	14
17894	Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	9
17895	Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
17896	SYK Is Associated With Malignant Phenotype and Immune Checkpoints in Diffuse Glioma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
17897	Ferroptosis-Related lncRNA Signature Correlates with the Prognosis, Tumor Microenvironment, and Therapeutic Sensitivity of Esophageal Squamous Cell Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-29.	1.9	8

#	ARTICLE	IF	CITATIONS
17898	CCDC69 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	6
17899	Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	3
17900	Stromal or intraepithelial tumor-infiltrating lymphocytes: which one has more prognostic significance in cervical cancer?. <i>Archives of Gynecology and Obstetrics</i> , 2023, 307, 969-980.	0.8	3
17901	Targeting CD47 as a Novel Immunotherapy for Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
17902	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. <i>JCO Precision Oncology</i> , 2022, , .	1.5	11
17903	<i>PAPPA2</i> mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer. <i>Cell Proliferation</i> , 2022, 55, .	2.4	5
17904	The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
17905	A Dramatic Response to Toripalimab With Chemotherapy and Antiangiogenic Agent Followed by Surgery in a Stage IIIB Lung Adenocarcinoma Patient With an Uncommon EGFR Mutation: A Case Report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
17906	The Road Less Taken: Less Appreciated Pathways for Manipulating CD8+ T Cell Exhaustion. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
17907	Differential Infiltration of Immune Cells Driven by Tumor Heterogeneity Reveals Two Immune Subtypes in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
17908	Application of ATAC-seq in tumor-specific T cell exhaustion. <i>Cancer Gene Therapy</i> , 2023, 30, 1-10.	2.2	4
17909	Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index. <i>Targeted Oncology</i> , 2022, 17, 453-465.	1.7	4
17910	Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. <i>Oncologist</i> , 2022, 27, 778-789.	1.9	2
17911	Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	11
17912	Immunotherapy-related renal toxicity causes reversible renal enlargement. <i>Abdominal Radiology</i> , 2022, 47, 3301-3307.	1.0	2
17913	Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
17914	DriverRWH: discovering cancer driver genes by random walk on a gene mutation hypergraph. <i>BMC Bioinformatics</i> , 2022, 23, .	1.2	7
17915	Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: A case report and literature review. <i>Thoracic Cancer</i> , 0, , .	0.8	4

#	ARTICLE	IF	CITATIONS
17916	High expression of fibroblast-activating protein is a prognostic marker in non-small cell lung carcinoma. <i>Thoracic Cancer</i> , 2022, 13, 2377-2384.	0.8	4
17917	Pharmacological Properties of 4,5,7-Trihydroxyflavone (Apigenin) and Its Impact on Cell Signaling Pathways. <i>Molecules</i> , 2022, 27, 4304.	1.7	20
17918	<i>Helicobacter pylori</i> serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. <i>Oncolimmunology</i> , 2022, 11, .	2.1	11
17919	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		6
17920	Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 4370-4384.	3.2	15
17921	MicroRNA-21 is immunosuppressive and pro-metastatic via separate mechanisms. <i>Oncogenesis</i> , 2022, 11, .	2.1	9
17922	Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance. <i>Genome Medicine</i> , 2022, 14, .	3.6	20
17923	The CD226/TIGIT axis is involved in T cell hypo-responsiveness appearance in long-term kidney transplant recipients. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
17924	Mechanisms of resistance to immune checkpoint inhibitors. <i>Cancer Science</i> , 2022, 113, 3303-3312.	1.7	12
17925	Comprehensive Analysis Identifies and Validates the Tumor Microenvironment Subtypes to Predict Anti-Tumor Therapy Efficacy in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
17926	Glioblastoma: Current Status, Emerging Targets, and Recent Advances. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8596-8685.	2.9	29
17927	Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3440.	1.7	1
17928	TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy. <i>Cancers</i> , 2022, 14, 3382.	1.7	4
17929	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7839.	1.8	13
17930	Immune-based therapies in penile cancer. <i>Nature Reviews Urology</i> , 2022, 19, 457-474.	1.9	14
17931	Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
17932	Noninvasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	14
17933	DOCK4 as a Potential Biomarker Associated with Immune Infiltration in Stomach Adenocarcinoma: A Database Analysis. <i>International Journal of General Medicine</i> , 0, Volume 15, 6127-6143.	0.8	1

#	ARTICLE	IF	CITATIONS
17934	Pan-cancer analysis of tumor mutation burden sensitive tumors reveals tumor-specific subtypes and hub genes related to immune infiltration. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, .	1.2	0
17935	Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	10
17936	Targeting the CD47-SIRP α Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils. <i>Cancers</i> , 2022, 14, 3366.	1.7	13
17937	Comparisons of Metastatic Patterns, Survival Outcomes and Tumor Immune Microenvironment Between Young and Non-Young Breast Cancer Patients. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	10
17938	Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort. <i>Discover Oncology</i> , 2022, 13, .	0.8	3
17939	Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
17940	T helper cell-mediated epitanscriptomic regulation via m6A RNA methylation bridges link between coronary artery disease and invasive ductal carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3421-3436.	1.2	6
17941	A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
17942	HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
17943	The Roles of ATP13A2 Gene Mutations Leading to Abnormal Aggregation of α -Synuclein in Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	1.8	7
17944	Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
17945	Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
17946	The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
17947	EBF1 promotes triple-negative breast cancer progression by surveillance of the HIF1 α pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	4
17948	Gut Microbiota and Immunotherapy. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	8
17949	The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction. <i>Updates in Surgery</i> , 2023, 75, 313-323.	0.9	8
17950	Management of cutaneous melanoma: radiologists challenging and risk assessment. <i>Radiologia Medica</i> , 2022, 127, 899-911.	4.7	20
17951	Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer. <i>Cureus</i> , 2022, , .	0.2	1

#	ARTICLE	IF	CITATIONS
17952	Comparative Analysis of Gene Correlation Networks of Breast Cancer Patients Based on Mutations in TP53. <i>Biomolecules</i> , 2022, 12, 979.	1.8	1
17953	Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 3305.	1.7	11
17954	Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma. <i>Thoracic Cancer</i> , 2022, 13, 2309-2317.	0.8	7
17955	Addition of Capecitabine to Adjuvant Chemotherapy May be the Most Effective Strategy for Patients With Early-Stage Triple-Negative Breast Cancer: A Network Meta-Analysis of 9 Randomized Controlled Trials. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
17956	LCOR Reverses Immune-Checkpoint Inhibitors Therapy Resistance Out of IFN Constraint in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
17957	ZNF750 facilitates carcinogenesis via promoting the expression of long non-coding RNA CYTOR and influences pharmacotherapy response in colon adenocarcinoma. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 587-596.	1.3	4
17958	Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
17959	Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 3473.	1.7	5
17960	A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
17962	Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
17963	Exploring immunotherapy in colorectal cancer. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	104
17964	Association of PD-1/PD-L1 expression and Epstein-Barr virus infection in patients with invasive breast cancer. <i>Diagnostic Pathology</i> , 2022, 17, .	0.9	7
17965	Identification and Verification of Potential Biomarkers in Gastric Cancer By Integrated Bioinformatic Analysis. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	7
17966	Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial. <i>Cancer Reports</i> , 2023, 6, .	0.6	6
17967	Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	13
17968	Identification and characterization of novel CD274 (PD-L1) regulating microRNAs and their functional relevance in melanoma. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	4
17969	Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 5013-5020.	3.2	8
17970	Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
17971	Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients Receiving Heat Shock Protein Peptide Complex 96 Vaccination. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
17972	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. <i>Nature Genetics</i> , 2022, 54, 996-1012.	9.4	30
17973	AP3S1 is a Novel Prognostic Biomarker and Correlated With an Immunosuppressive Tumor Microenvironment in Pan-Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
17974	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 3337.	1.7	21
17975	Near-Infrared Photoimmunotherapy for Thoracic Cancers: A Translational Perspective. <i>Biomedicines</i> , 2022, 10, 1662.	1.4	7
17976	CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. <i>Cancers</i> , 2022, 14, 3361.	1.7	6
17977	Paediatric pre-acute lymphoblastic leukaemia-derived exosomes regulate immune function in human T cells. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4566-4576.	1.6	6
17978	Smoking patients with laryngeal cancer screened with a novel immunogenomics-based prognostic signature. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
17979	Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer. <i>Oncolmmunology</i> , 2022, 11, .	2.1	16
17980	Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3618-3629.	3.2	12
17981	The role of interleukin-7 serum level as biological marker in breast cancer: a cross-sectional, observational, and analytical study. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	2
17982	Preparation and Evaluation of Animal Models of Cardiotoxicity in Antineoplastic Therapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-16.	1.9	4
17983	Molecular and Circulating Biomarkers in Patients with Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7474.	1.8	19
17984	POLE/POLD1 mutation and tumor immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	42
17985	Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism. <i>Genes</i> , 2022, 13, 1204.	1.0	7
17986	Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells. <i>PLoS ONE</i> , 2022, 17, e0270832.	1.1	4
17987	Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles. <i>Nature Communications</i> , 2022, 13, .	5.8	70
17988	Validation of the Optimum Timing of Assessment of Tumor Infiltrating Lymphocytes During Preoperative Chemotherapy for Breast Cancer. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 443-451.	0.3	0

#	ARTICLE	IF	CITATIONS
17989	PD-1 signaling facilitates activation of lymphoid tissue inducer cells by restraining fatty acid oxidation. <i>Nature Metabolism</i> , 2022, 4, 867-882.	5.1	17
17990	Generation, secretion and degradation of cancer immunotherapy target PD-L1. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	5
17991	A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	20
17992	Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	21
17993	Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. <i>Cancers</i> , 2022, 14, 3452.	1.7	6
17994	Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes. <i>Cancers</i> , 2022, 14, 3472.	1.7	1
17995	Educational Review: Neoadjuvant Approaches to Melanoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 8492-8500.	0.7	4
17996	Stromal and Immune Cell Dynamics in Tumor Associated Tertiary Lymphoid Structures and Anti-Tumor Immune Responses. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
17997	Ferroptosis Associates With Diagnosis and Prognosis by Promoting Antitumor Immune Response in Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	0
17998	Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population. <i>BMC Medical Genomics</i> , 2022, 15, .	0.7	4
17999	CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
18000	Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	15
18001	Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	4
18002	Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis. <i>Molecular Therapy</i> , 2022, 30, 3430-3449.	3.7	8
18003	Imaging Mass Cytometry Analysis of immune Checkpoint Inhibitor-Related Pneumonitis: A Case Report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
18004	Hypoxia induces HIF1 α -dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy. <i>Nature Communications</i> , 2022, 13, .	5.8	48
18005	PDL1Binder: Identifying programmed cell death ligand 1 binding peptides by incorporating next-generation phage display data and different peptide descriptors. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
18006	Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 398-409.	0.8	4

#	ARTICLE	IF	CITATIONS
18007	Delineating Molecular Subtypes through Gene Set Variation Analysis Confers Therapeutic and Prognostic Capability in Gastric Cancer. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-11.	0.8	0
18008	Gene-guided OX40L anchoring to tumor cells for synergetic tumor self-killing-immunotherapy. <i>Bioactive Materials</i> , 2023, 25, 689-700.	8.6	5
18009	Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell-Cell Interactions That Predict Immunotherapy Response. <i>Cancer Research</i> , 2022, 82, 3275-3290.	0.4	17
18010	Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	2
18011	Clinical trials of immunotherapy in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 1-15.	1.1	19
18012	Clinical significance and immune landscape of <i>KIR2DL4</i> and the senescence-based signature in cutaneous melanoma. <i>Cancer Science</i> , 2022, 113, 3947-3959.	1.7	3
18013	Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	2
18014	Rethinking the immunotherapy numbers game. , 2022, 10, e005107.		8
18015	TNF Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
18016	Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	58
18017	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. <i>Cancer Research Communications</i> , 2022, 2, 739-753.	0.7	2
18018	Breast Cancer Stem Cells: Signaling Pathways, Cellular Interactions, and Therapeutic Implications. <i>Cancers</i> , 2022, 14, 3287.	1.7	10
18019	Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy. <i>PLoS ONE</i> , 2022, 17, e0270950.	1.1	5
18020	Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
18021	Anticancer Activity of Bee Venom Components against Breast Cancer. <i>Toxins</i> , 2022, 14, 460.	1.5	13
18022	Unraveling the Immune Microenvironment of Thymic Epithelial Tumors: Implications for Autoimmunity and Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7864.	1.8	8
18023	Dostarlimab: A breakthrough in the field of oncology. <i>Annals of Medicine and Surgery</i> , 2022, 80, .	0.5	1
18024	Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels. <i>ESMO Open</i> , 2022, 7, 100540.	2.0	7

#	ARTICLE	IF	CITATIONS
18025	Irradiation combined with PD-L1 ^{hi} and autophagy inhibition enhances the antitumor effect of lung cancer via cGAS-STING-mediated T cell activation. <i>IScience</i> , 2022, 25, 104690.	1.9	8
18026	Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer. <i>IScience</i> , 2022, 25, 104702.	1.9	15
18027	Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology. <i>Advanced Drug Delivery Reviews</i> , 2022, 188, 114421.	6.6	18
18028	Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 7400-7406.	0.7	4
18029	Bacterial outer membrane vesicles-based therapeutic platform eradicates triple-negative breast tumor by combinational photodynamic/chemo-immunotherapy. <i>Bioactive Materials</i> , 2023, 20, 548-560.	8.6	21
18030	Carrier-free nanoprodruge for p53-mutated tumor therapy via concurrent delivery of zinc-manganese dual ions and ROS. <i>Bioactive Materials</i> , 2023, 20, 404-417.	8.6	11
18031	The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 347-366.	2.7	11
18032	Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNF α Receptors in Human Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 3513.	1.7	2
18033	Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
18034	Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1153-1168.	1.3	7
18035	A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
18036	Comprehensive Analysis of HMCN1 Somatic Mutation in Clear Cell Renal Cell Carcinoma. <i>Genes</i> , 2022, 13, 1282.	1.0	2
18037	ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics. , 2022, 10, e004825.		9
18038	A phase I/II study of triple-mutated oncolytic herpes virus G47 Δ in patients with progressive glioblastoma. <i>Nature Communications</i> , 2022, 13, .	5.8	72
18039	Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
18040	The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	9
18041	Association of Pathway Mutations With Survival in Taiwanese Breast Cancers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
18042	Intratumoral oncolytic herpes virus G47 Δ for residual or recurrent glioblastoma: a phase 2 trial. <i>Nature Medicine</i> , 2022, 28, 1630-1639.	15.2	157

#	ARTICLE	IF	CITATIONS
18043	Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
18044	Techniques for Profiling the Cellular Immune Response and Their Implications for Interventional Oncology. <i>Cancers</i> , 2022, 14, 3628.	1.7	4
18045	Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
18046	3D Bioprinting: An Enabling Technology to Understand Melanoma. <i>Cancers</i> , 2022, 14, 3535.	1.7	6
18047	A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma. <i>Bioscience Reports</i> , 2022, 42, .	1.1	7
18048	Immunotherapy-induced Hepatotoxicity: A Review. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
18049	Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment. , 2022, 10, e004695.		16
18050	Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy. , 2022, 10, e004831.		4
18051	Nomogram Prediction Model Analysis of Risk Factors for Conversion to Thoracotomy after Thoracoscopic Resection of Lung Cancer and Prognostic Value of Lung Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-10.	0.7	1
18052	Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
18053	Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 0, , .	2.9	0
18054	Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid”A Retrospective, Monocentric Study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
18055	Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
18056	Predicting cancer immunotherapy response from gut microbiomes using machine learning models. <i>Oncotarget</i> , 2022, 13, 876-889.	0.8	12
18057	Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	13
18058	Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma. <i>Cancers</i> , 2022, 14, 3587.	1.7	6
18059	Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments. <i>ELife</i> , 0, 11, .	2.8	10
18060	Potential association factors for developing effective peptide-based cancer vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1

#	ARTICLE	IF	CITATIONS
18061	Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy. <i>ESC Heart Failure</i> , 2022, 9, 3533-3542.	1.4	3
18062	The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
18063	Regulation of the TUG1/miRâ€¹45â€¹5p/SOX2 axis on the migratory and invasive capabilities of melanoma cells. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	0
18064	Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
18065	Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
18066	Interferon-Î³ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
18067	Multivalent, Bispecific Î±B7-H3-Î±CD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma. <i>ACS Nano</i> , 2022, 16, 12185-12201.	7.3	6
18068	Microsatellite Instabilityâ€“High Endometrial Cancers with <i><i>MLH1</i></i> Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles. <i>Clinical Cancer Research</i> , 2022, 28, 4302-4311.	3.2	14
18069	Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study. , 2022, 10, e004879.		14
18070	The Multi-Omics Landscape and Clinical Relevance of the Immunological Signature of Phagocytosis Regulators: Implications for Risk Classification and Frontline Therapies in Skin Cutaneous Melanoma. <i>Cancers</i> , 2022, 14, 3582.	1.7	0
18071	LncRNA profiles from Notch signaling: Implications for clinical management and tumor microenvironment of colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
18072	Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
18073	A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions. <i>Molecular Cancer</i> , 2022, 21, .	7.9	6
18074	Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	8
18075	Mutant p53-microRNA-200c-ZEB2-Axis-Induced CPT1C Elevation Contributes to Metabolic Reprogramming and Tumor Progression in Basal-Like Breast Cancers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
18076	Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma. <i>Blood Advances</i> , 0, , .	2.5	2
18077	Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry. , 2022, 10, e004638.		6
18078	The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer. <i>Biomedicines</i> , 2022, 10, 1778.	1.4	10

#	ARTICLE	IF	CITATIONS
18079	Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?. , 2022, 10, e004848.		14
18080	Mesenchymal Stem Cell-Derived Antimicrobial Peptides as Potential Anti-Neoplastic Agents: New Insight into Anticancer Mechanisms of Stem Cells and Exosomes. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	13
18081	Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
18082	Clinical Eosinophil-Associated Genes can Serve as a Reliable Predictor of Bladder Urothelial Cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	17
18083	Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes. <i>Frontiers in Oral Health</i> , 0, 3, .	1.2	3
18084	Electrochemotherapy of skin metastases from malignant melanoma: a PRISMA-compliant systematic review. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 743-755.	1.7	5
18085	Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines. <i>Oncolmmunology</i> , 2022, 11, .	2.1	9
18086	Real-world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: An All-cause postmarketing surveillance in Japan. <i>Journal of Dermatology</i> , 2022, 49, 1096-1105.	0.6	4
18087	The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
18088	A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4392-4401.	3.2	13
18089	Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access. <i>Cancer Research Communications</i> , 2022, 2, 806-813.	0.7	7
18090	Analysis of Genomic Alterations Associated with Recurrence in Early Stage HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 3650.	1.7	1
18091	Advances in Cutaneous Squamous Cell Carcinoma Management. <i>Cancers</i> , 2022, 14, 3653.	1.7	14
18092	PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 4893-4906.	3.2	18
18093	The role of obesity and bariatric surgery-induced weight loss in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 673-695.	2.7	7
18094	Immune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer Cells. <i>Annals of Surgical Oncology</i> , 2022, 29, 7423-7433.	0.7	4
18095	The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
18096	Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?. <i>Cancers</i> , 2022, 14, 3575.	1.7	18

#	ARTICLE	IF	CITATIONS
18097	Neurospora crassa is a potential source of anti-cancer agents against breast cancer. <i>Breast Cancer</i> , 2022, 29, 1032-1041.	1.3	2
18098	Positive Correlation of Peripheral CD8+ T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3568.	1.7	2
18099	Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	2
18100	NKG7 Enhances CD8+ T Cell Synapse Efficiency to Limit Inflammation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
18101	Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 8284-8290.	0.3	1
18102	Imaging features of toxicities associated with immune checkpoint inhibitors. <i>European Journal of Radiology Open</i> , 2022, 9, 100434.	0.7	6
18103	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists's Perspectives. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 244-253.	0.2	1
18104	Pozotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. <i>Cancer Research</i> , 2022, 82, 2928-2939.	0.4	7
18105	Immunology and immunotherapy in breast cancer. <i>Cancer Biology and Medicine</i> , 2022, 19, 609-618.	1.4	10
18106	The Generation of Dual-Targeting Fusion Protein PD-L1/CD47 for the Inhibition of Triple-Negative Breast Cancer. <i>Biomedicines</i> , 2022, 10, 1843.	1.4	2
18107	Boosting Antitumor Immunity with an Expanded Neoepitope Landscape. <i>Cancer Research</i> , 2022, 82, 3637-3649.	0.4	4
18108	Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres. <i>Life</i> , 2022, 12, 1149.	1.1	2
18109	Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer. <i>Genes</i> , 2022, 13, 1362.	1.0	1
18110	Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
18111	Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 4373.	1.0	1
18112	Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-11.	0.5	2
18113	Crosstalk Between Programmed Death Ligand 1, Ki-67 Labelling Index, and Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer and Clinicopathological Correlations in a Tertiary Care Center in Western India. <i>Iranian Journal of Pathology</i> , 2022, 17, 314-322.	0.2	1
18114	CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy. <i>International Immunology</i> , 2022, 34, 571-577.	1.8	7

#	ARTICLE	IF	CITATIONS
18115	Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary Cancers: A Review. <i>Cureus</i> , 2022, , .	0.2	0
18116	Editorial: Decoding checkpoint inhibitor-induced endocrinopathies. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
18117	Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	6
18118	A comprehensive study of alternative splicing in malignant pleural mesothelioma identifies potential therapeutic targets in a new cluster with poor survival. <i>Thoracic Cancer</i> , 2022, 13, 2318-2330.	0.8	1
18119	Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
18120	Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients â€”A retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
18121	Therapeutic KRAS ^{G12C} inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. <i>Science Advances</i> , 2022, 8, .	4.7	40
18122	Anti-PD-1 Monotherapy in Advanced Melanomaâ€”Real-World Data from a 77-Month-Long Retrospective Observational Study. <i>Biomedicines</i> , 2022, 10, 1737.	1.4	8
18123	Targeting Tumor Acidosis and Regulatory T Cells Unmasks Anti-Metastatic Potential of Local Tumor Ablation in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8479.	1.8	4
18124	A robust experimental and computational analysis framework at multiple resolutions, modalities and coverages. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
18125	Immature tertiary lymphoid structure formation was increased in the melanoma tumor microenvironment of IKZF1 transgenic mice. <i>Translational Cancer Research</i> , 2022, 11, 2388-2397.	0.4	1
18126	IL-6: The Link Between Inflammation, Immunity and Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	22
18127	Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. <i>Nature Communications</i> , 2022, 13, .	5.8	62
18128	Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
18129	Nanomedicine approaches for treatment of hematologic and oncologic malignancies. <i>World Journal of Clinical Oncology</i> , 2022, 13, 553-566.	0.9	2
18130	Identifying the Antitumor Effects of Curcumin on Lung Adenocarcinoma Using Comprehensive Bioinformatics Analysis. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 2365-2382.	2.0	4
18131	NPC1 Confers Metabolic Flexibility in Triple Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 3543.	1.7	7
18132	A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	7

#	ARTICLE	IF	CITATIONS
18133	A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
18134	8-Gene signature related to CD8+ T cell infiltration by integrating single-cell and bulk RNA-sequencing in head and neck squamous cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
18135	Tumor-Stroma Ratio and Programmed Cell Death Ligand 1 Expression in Preoperative Biopsy and Matched Laryngeal Carcinoma Surgical Specimen. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8053.	1.8	4
18136	Clinical M2 Macrophage-Related Genes Can Serve as a Reliable Predictor of Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
18137	Inhibition of stearyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β -catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody. , 2022, 10, e004616.		25
18138	The Long and Winding Road: An Overview of the Immunological Landscape of Intracranial Meningiomas. <i>Cancers</i> , 2022, 14, 3639.	1.7	7
18139	Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. <i>Cancers</i> , 2022, 14, 3695.	1.7	1
18140	<sc>Nanoalbuminâ€“prodrug</sc> conjugates prepared via a <sc>thiolationâ€“andâ€“conjugation</sc> method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting <sc>CD8</sc>⁺ Tâ€“cell infiltration. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	2
18141	Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 1420-1433.	1.3	7
18142	Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer. <i>Oncotarget</i> , 2022, 13, 907-917.	0.8	1
18143	Constitutive programmed death ligand 1 expression protects gastric Gâ€“cells from <i>Helicobacter pylori</i> â€“induced inflammation. <i>Helicobacter</i> , 0, , .	1.6	1
18144	A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 351-369.	2.0	6
18145	Pilot Study: Immune Checkpoints Polymorphisms in Greek Primary Breast Cancer Patients. <i>Biomedicines</i> , 2022, 10, 1827.	1.4	3
18146	Overexpression of 14-3-3 η primes disease recurrence, metastasis and resistance to chemotherapy by inducing epithelial-mesenchymal transition in NSCLC. <i>Aging</i> , 2022, 14, 5838-5854.	1.4	3
18147	Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor. <i>Cells</i> , 2022, 11, 2351.	1.8	29
18148	Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System. <i>Biomedicines</i> , 2022, 10, 1842.	1.4	5
18149	Hub genes associated with immune cell infiltration in breast cancer, identified through bioinformatic analyses of multiple datasets. <i>Cancer Biology and Medicine</i> , 0, , 1-28.	1.4	3
18150	Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses. <i>Science Advances</i> , 2022, 8, .	4.7	10

#	ARTICLE	IF	CITATIONS
18151	Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
18152	Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. , 2022, 10, e004803.		15
18153	Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
18154	Immune-Related Biomarkers Improve Performance of Risk Prediction Models for Survival in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
18155	Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis. <i>Intestinal Research</i> , 2023, 21, 126-136.	1.0	1
18156	Cultivating Clinical Clarity through Computer Vision: A Current Perspective on Whole Slide Imaging and Artificial Intelligence. <i>Diagnostics</i> , 2022, 12, 1778.	1.3	5
18157	A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: <sc>BiT</sc>â€œ1. <i>Cancer</i> , 2022, 128, 3523-3530.	2.0	22
18158	Construction and validation of a glioblastoma prognostic model based on immune-related genes. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	3
18159	Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend?. <i>Molecules</i> , 2022, 27, 4799.	1.7	9
18160	Emerging concepts regarding pro- and anti tumor properties of B cells in tumor immunity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
18161	The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	44
18162	Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients. <i>Biomarker Research</i> , 2022, 10, .	2.8	10
18163	Radiotherapy combined with immunotherapy: the dawn of cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	142
18164	Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. <i>Diagnostics</i> , 2022, 12, 1799.	1.3	7
18165	When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 1589.	2.0	10
18166	Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	31
18167	Blood Immune Cell Biomarkers in Lung Cancer Patients Undergoing Treatment with a Combination of Chemotherapy and Immune Checkpoint Blockade. <i>Cancers</i> , 2022, 14, 3690.	1.7	6
18168	Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0

#	ARTICLE	IF	CITATIONS
18169	Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
18170	Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything. <i>Cancers</i> , 2022, 14, 3729.	1.7	5
18171	Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 3720.	1.7	3
18172	Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
18173	Combined Blockade Of PD-1 and TIGIT is not Sufficient to Improve the Function Of CD8+ T-Cells in Chronic Lymphocytic Leukemia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2225-2231.	0.5	3
18174	PD-L1 and the Clinical Outcomes of Ovarian Cancer: Meta-Analysis and Bioinformatical Analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2285-2290.	0.5	0
18175	Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus. <i>Annals of Translational Medicine</i> , 2022, 10, 805-805.	0.7	2
18176	Glycoproteomics Identifies Plexin-B3 as a Targetable Cell Surface Protein Required for the Growth and Invasion of Triple-Negative Breast Cancer Cells. <i>Journal of Proteome Research</i> , 2022, 21, 2224-2236.	1.8	4
18177	N1-Methyladenosine-Related lncRNAs Are Potential Biomarkers for Predicting Prognosis and Immune Response in Uterine Corpus Endometrial Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 1-32.	1.9	5
18178	HOXA11-AS1 Promotes PD-L1-Mediated Immune Escape and Metastasis of Hypopharyngeal Carcinoma by Facilitating PTBP1 and FOSL1 Association. <i>Cancers</i> , 2022, 14, 3694.	1.7	4
18179	Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
18180	Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 3860.	1.7	11
18181	Grade 3-4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study. <i>Cancers</i> , 2022, 14, 3878.	1.7	7
18182	Editorial: Advancements in immunology and immunotherapy for breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
18183	Prospective Clinical Genomic Profiling of Ewing Sarcoma: <i>ERF</i> and <i>FGFR1</i> Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance. <i>JCO Precision Oncology</i> , 2022, , .	1.5	2
18184	Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>JCO Precision Oncology</i> , 2022, , .	1.5	26
18185	Multiple Myeloma Therapy: Emerging Trends and Challenges. <i>Cancers</i> , 2022, 14, 4082.	1.7	19
18186	The crucial roles of long noncoding RNA SNHG3 in lung cancer. <i>Clinical and Translational Oncology</i> , 2022, 24, 2272-2284.	1.2	2

#	ARTICLE	IF	CITATIONS
18187	Identification of the pyroptosis-related prognostic gene signature and characterization of tumor microenvironment infiltration in triple-negative breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
18188	Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 153-162.	1.1	8
18189	Immunization Combined with Ferroptosis Related Genes to Construct a New Prognostic Model for Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4099.	1.7	3
18190	Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
18191	Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling. <i>Cancer Gene Therapy</i> , 2022, 29, 1988-2000.	2.2	14
18192	Emerging Biomarkers and the Changing Landscape of Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3772.	1.7	11
18193	A pan-cancer analysis reveals the genetic alterations and immunotherapy of Piezo2 in human cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
18194	TIMM13 as a prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma (SKCM). <i>Frontiers in Surgery</i> , 0, 9, .	0.6	5
18195	Recent Advances and Challenges in Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 3972.	1.7	26
18196	A Targeted Proteomics Approach for Screening Serum Biomarkers Observed in the Early Stage of Type I Endometrial Cancer. <i>Biomedicines</i> , 2022, 10, 1857.	1.4	6
18197	PD-L1 rs2890658 Polymorphism Increases Risk for Non-Small-Cell Lung Cancer in Northern China Population Based on Experimental Data and Meta-Analysis. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-8.	0.4	2
18198	Bias and inconsistency in the estimation of tumour mutation burden. <i>BMC Cancer</i> , 2022, 22, .	1.1	8
18199	Internal checkpoint regulates T _H 1 cell neoantigen reactivity and susceptibility to PD1 blockade. <i>Med</i> , 2022, 3, 682-704.e8.	2.2	22
18200	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	32
18201	The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively. <i>Journal of Medical Ultrasonics (2001)</i> , 2022, 49, 709-717.	0.6	2
18202	Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions. <i>Cancers</i> , 2022, 14, 3774.	1.7	10
18203	Microwave ablation combined with anti-PD-1/CTLA-4 therapy induces an antitumor immune response to renal cell carcinoma in a murine model. <i>Cell Cycle</i> , 2023, 22, 242-254.	1.3	2
18204	TGF β ² signaling activation correlates with immune-inflamed tumor microenvironment across human cancers and predicts response to immunotherapy. <i>Cell Cycle</i> , 0, , 1-16.	1.3	2

#	ARTICLE	IF	CITATIONS
18205	Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
18206	NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	3
18207	Dermatological adverse events under programmed cell death inhibitors as a prognostic marker in metastatic melanoma. <i>Dermatologic Therapy</i> , 2022, 35, .	0.8	3
18208	Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8844.	1.8	4
18209	Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologists' Decision on Systemic Therapy in a Real-World Setting. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8716.	1.8	5
18210	Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	50
18211	PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
18212	A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORIG1630. <i>Clinical Cancer Research</i> , 2022, 28, 4402-4409.	3.2	11
18213	Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	5
18214	Lactate score predicts survival, immune cell infiltration and response to immunotherapy in breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
18215	Detection of Potential Mutated Genes Associated with Common Immunotherapy Biomarkers in Non-Small-Cell Lung Cancer Patients. <i>Current Oncology</i> , 2022, 29, 5715-5730.	0.9	0
18216	The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
18217	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
18218	Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	5
18219	Comprehensive characterization of clonality of driver genes revealing their clinical relevance in colorectal cancer. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	5
18220	Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy. <i>BMC Biotechnology</i> , 2022, 22, .	1.7	10
18221	The potential of gas plasma technology for targeting breast cancer. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	9
18222	Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2023, 41, 528-540.	0.8	62

#	ARTICLE	IF	CITATIONS
18223	BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
18224	Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. <i>Genes and Diseases</i> , 2023, 10, 1318-1350.	1.5	11
18225	A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
18226	The gamble between oncolytic virus therapy and IFN. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
18228	Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
18229	Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	5
18230	Relationship between metabolic reprogramming and drug resistance in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
18231	Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. <i>Nature Medicine</i> , 2022, 28, 1619-1629.	15.2	56
18232	Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment. <i>JAMA Network Open</i> , 2022, 5, e2227211.	2.8	8
18233	A Novel Ferroptosis-Related Gene Signature for Prognosis Prediction in Ewing Sarcoma. <i>Analytical Cellular Pathology</i> , 2022, 2022, 1-22.	0.7	3
18234	Tumour Derived Extracellular Vesicles: Challenging Target to Blunt Tumour Immune Evasion. <i>Cancers</i> , 2022, 14, 4020.	1.7	6
18235	Iodine-Rich Nanoadjuvants for CT Imagingâ€“Guided Photodynamic Immunotherapy of Breast Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	2
18236	Circular RNA circWWC3 augments breast cancer progression through promoting M2 macrophage polarization and tumor immune escape via regulating the expression and secretion of IL-4. <i>Cancer Cell International</i> , 2022, 22, .	1.8	15
18237	Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
18238	Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
18239	Network Pharmacology Analysis, Molecular Docking, and In Vitro Verification Reveal the Action Mechanism of <i>Prunella vulgaris</i> L. in Treating Breast Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-19.	0.5	4
18240	PD-L1 testing by immunohistochemistry in Immuno-Oncology. <i>Bosnian Journal of Basic Medical Sciences</i> , 0, , .	0.6	6
18241	Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease. <i>Biomedicines</i> , 2022, 10, 1872.	1.4	6

#	ARTICLE	IF	CITATIONS
18242	Lysosomal acid lipase, CSF1R, and PD-L1 determine functions of CD11c+ myeloid-derived suppressor cells. <i>JCI Insight</i> , 2022, 7, .	2.3	9
18243	Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 288-307.	2.8	14
18244	Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration-resistant prostate cancer. <i>IJU Case Reports</i> , 0, , .	0.1	0
18245	Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies. <i>Cancers</i> , 2022, 14, 3779.	1.7	18
18246	Flow-Cytometry Intracellular Detection and Quantification of HIV1 p24 Antigen and Immunocheckpoint Molecules in T Cells among HIV/AIDS Patients. <i>HIV/AIDS - Research and Palliative Care</i> , 0, Volume 14, 365-379.	0.4	0
18247	Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis. <i>Biologics: Targets and Therapy</i> , 0, Volume 16, 119-127.	3.0	1
18248	Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial. <i>Cancers</i> , 2022, 14, 3808.	1.7	2
18249	PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
18250	Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. <i>Life</i> , 2022, 12, 1229.	1.1	4
18251	Importance of the endometrial immune environment in endometrial cancer and associated therapies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
18252	Stocky/Packed Pancreas: A Case of Focal Drug-Induced Acute Pancreatitis Mimicking Cancer. <i>Tomography</i> , 2022, 8, 2073-2082.	0.8	1
18253	Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
18254	Breast Cancer-Delivered Exosomal miRNA as Liquid Biopsy Biomarkers for Metastasis Prediction: A Focus on Translational Research with Clinical Applicability. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9371.	1.8	16
18255	Total neoadjuvant therapy or standard chemoradiotherapy for locally advanced rectal cancer: A systematic review and meta-analysis. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	5
18256	Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies. <i>Pharmaceutics</i> , 2022, 14, 1762.	2.0	4
18257	Impact of microbiota-immunity axis in pancreatic cancer management. <i>World Journal of Gastroenterology</i> , 2022, 28, 4527-4539.	1.4	3
18258	The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	3
18259	Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer. <i>JAMA Oncology</i> , 2022, 8, 1456.	3.4	60

#	ARTICLE	IF	CITATIONS
18260	Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection. <i>BMC Genomic Data</i> , 2022, 23, .	0.7	1
18261	Computational identification of immune-related lncRNA signature for predicting the prognosis and immune landscape of human glioblastoma multiforme. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
18262	Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis. <i>BMC Bioinformatics</i> , 2022, 23, .	1.2	4
18263	Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
18264	PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
18265	PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer. <i>Cells</i> , 2022, 11, 2508.	1.8	42
18267	Expression of Programmed Death Ligand 1 in Breast Cancer in Mexican Women. <i>World Journal of Oncology</i> , 2022, 13, 185-189.	0.6	1
18268	Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 475-491.	2.0	15
18269	Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8707.	1.8	3
18270	Identification of a prognostic model based on costimulatory molecule-related subtypes and characterization of tumor microenvironment infiltration in acute myeloid leukemia. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
18272	Predicting the molecular subtypes of breast cancer using nomograms based on three-dimensional ultrasonography characteristics. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
18273	Exploring the pharmacological mechanism of compound kushen injection in the treatment of breast cancer using in vitro experiments: Coupling network pharmacology with GEO database. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
18274	Total mutational load and clinical features as predictors of the metastatic status in lung adenocarcinoma and squamous cell carcinoma patients. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	1
18275	HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer. <i>EBioMedicine</i> , 2022, 83, 104205.	2.7	8
18276	KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9391.	1.8	13
18277	Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
18278	Adverse Renal Effects of Anticancer Immunotherapy: A Review. <i>Cancers</i> , 2022, 14, 4086.	1.7	3
18279	A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2022, 41, 202-209.	0.8	5

#	ARTICLE	IF	CITATIONS
18280	A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 3862.	1.7	8
18281	MTUS1 is a promising diagnostic and prognostic biomarker for colorectal cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	4
18282	Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8878.	1.8	5
18283	The multifaceted mechanisms of malignant glioblastoma progression and clinical implications. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 871-898.	2.7	8
18284	From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
18285	Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
18286	Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis. <i>Molecular Diversity</i> , 0, , .	2.1	1
18287	Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3846.	1.7	15
18288	Sex-specific differences in immunogenomic features of response to immune checkpoint blockade. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
18289	Injectable Nanoparticle-Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies. <i>Advanced Science</i> , 2022, 9, .	5.6	11
18290	Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy. <i>Genome Medicine</i> , 2022, 14, .	3.6	6
18291	Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
18292	Perfecting antigen prediction. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	1
18293	Triple negative breast cancer: approved treatment options and their mechanisms of action. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3701-3719.	1.2	13
18294	Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. , 2022, 10, e004761.		15
18295	Immune Checkpoint Inhibitors-Associated Renal Toxicity: A Series of 12 Cases. <i>Journal of Clinical Medicine</i> , 2022, 11, 4786.	1.0	4
18296	Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
18297	Clever-1 positive macrophages in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 237-248.	1.1	2

#	ARTICLE	IF	CITATIONS
18298	Phosphofructokinase 1 platelet isoform induces PD-L1 expression to promote glioblastoma immune evasion. <i>Genes and Genomics</i> , 2022, 44, 1509-1517.	0.5	4
18299	Predicting the Prognostic Value of POLI Expression in Different Cancers via a Machine Learning Approach. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8571.	1.8	2
18300	Assessing the robustness of radiomics/deep learning approach in the identification of efficacy of anti-PD-1 treatment in advanced or metastatic non-small cell lung carcinoma patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
18301	Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	2
18302	Ordered and deterministic cancer genome evolution after p53 loss. <i>Nature</i> , 2022, 608, 795-802.	13.7	90
18303	Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy. <i>Nature Immunology</i> , 2022, 23, 1309-1316.	7.0	39
18304	The changes in peripheral blood Th17 and Treg ratios in Hashimoto's thyroiditis are accompanied by differential PD-1/PD-L1 expression. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
18305	Integration of miRNA:mRNA Co-Expression Revealed Crucial Mechanisms Modulated in Immunogenic Cancer Cell Death. <i>Biomedicines</i> , 2022, 10, 1896.	1.4	2
18306	Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. <i>Cancer Research Communications</i> , 2022, 2, 1293-1303.	0.7	2
18307	Machine learning-based screening of an epithelial-mesenchymal transition-related long non-coding RNA signature reveals lower-grade glioma prognosis and the tumor microenvironment and predicts antitumor therapy response. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	0
18308	Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
18309	Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	19
18310	Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
18311	Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
18312	The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
18313	Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
18314	PD-L1 Expression in Endometrial Cancer and Its Association with Clinicopathological Features: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 3911.	1.7	15
18315	Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9006.	1.8	9

#	ARTICLE	IF	CITATIONS
18316	The prognostic impact of B7-H3 and B7-H4 in head and neck squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
18317	Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
18318	Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer. <i>Oncology Research and Treatment</i> , 2022, 45, 681-692.	0.8	7
18319	Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
18320	Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
18321	Core immune cell infiltration signatures identify molecular subtypes and promote precise checkpoint immunotherapy in cutaneous melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
18322	The multifaceted role of STAT3 pathway and its implication as a potential therapeutic target in oral cancer. <i>Archives of Pharmacal Research</i> , 2022, 45, 507-534.	2.7	5
18323	A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review. <i>Cancer Cell International</i> , 2022, 22, .	1.8	3
18324	Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
18325	Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	13
18326	Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer. <i>Current Oncology</i> , 2022, 29, 6154-6166.	0.9	7
18327	Risk Stratification for Breast Cancer Patient by Simultaneous Learning of Molecular Subtype and Survival Outcome Using Genetic Algorithm-Based Gene Set Selection. <i>Cancers</i> , 2022, 14, 4120.	1.7	0
18328	Ocular Inflammation Induced by Immune Checkpoint Inhibitors. <i>Journal of Clinical Medicine</i> , 2022, 11, 4993.	1.0	12
18329	Development and validation of a robust necroptosis related classifier for colon adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
18330	The combined prognostic model of copper-dependent to predict the prognosis of pancreatic cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
18331	What is the status of immunotherapy in thyroid neoplasms?. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	12
18332	Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses' Health Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	1.1	0
18333	Identifying immune cells-related phenotype to predict immunotherapy and clinical outcome in gastric cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
18334	Tumor mutation burden-assisted risk stratification for papillary thyroid cancer. <i>Endocrine</i> , 2022, 78, 296-305.	1.1	3
18335	The epiphany derived from T-cell "inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
18336	Membrane-wrapped nanoparticles for photothermal cancer therapy. <i>Nano Convergence</i> , 2022, 9, .	6.3	13
18337	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
18338	Mining the multifunction of mucosal-associated invariant T cells in hematological malignancies and transplantation immunity: A promising hexagon soldier in immunomodulatory. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
18339	Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study. <i>Investigational New Drugs</i> , 2022, 40, 1282-1289.	1.2	7
18340	The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
18341	Comprehensive Analysis of the Prognostic Value and Immune Infiltration of Butyrophilin Subfamily 2/3 (BTN2/3) Members in Pan-Glioma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
18342	FN1 overexpression is correlated with unfavorable prognosis and immune infiltrates in breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	16
18343	Ovo Like Zinc Finger 2 (OVOL2) Suppresses Breast Cancer Stem Cell Traits and Correlates with Immune Cells Infiltration. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 211-227.	1.0	1
18344	Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
18345	Next Steps for Immunotherapy in Glioblastoma. <i>Cancers</i> , 2022, 14, 4023.	1.7	9
18346	Scleroderma-like Syndrome in the Setting of Pembrolizumab Therapy for Non-Small Cell Lung Cancer: Diagnosis and Dermatologic Management. <i>Case Reports in Dermatology</i> , 2022, 14, 225-229.	0.3	6
18347	An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	29
18348	The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	16
18349	Triple negative breast cancer: Pitfalls and progress. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	110
18350	Purinergic receptors are a key bottleneck in tumor metabolic reprogramming: The prime suspect in cancer therapeutic resistance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
18351	Identification of an immune-related gene signature as a prognostic target and the immune microenvironment for adrenocortical carcinoma. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	0

#	ARTICLE	IF	CITATIONS
18352	Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3469-3483.	1.2	9
18353	The pyroptosis-related gene signature predicts prognosis and reveals characterization of the tumor immune microenvironment in acute myeloid leukemia. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
18354	A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
18355	Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
18356	A benchmark study of deep learning-based multi-omics data fusion methods for cancer. <i>Genome Biology</i> , 2022, 23, .	3.8	42
18357	Activation Markers on B and T Cells and Immune Checkpoints in Autoimmune Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8656.	1.8	4
18358	Accurate determination of CRISPR-mediated gene fitness in transplantable tumours. <i>Nature Communications</i> , 2022, 13, .	5.8	1
18359	Breast cancer cell-derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	18
18360	Identification of Lethal Inhibitors and Inhibitor Combinations for Mono-Driver versus Multi-Driver Triple-Negative Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 4027.	1.7	4
18361	A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
18362	Clinical course and management of insidious adrenal crisis manifested initially as hyperpyrexia secondary to pembrolizumab: Case reports and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
18363	A Joint Model Considering Measurement Errors for Optimally Identifying Tumor Mutation Burden Threshold. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
18364	Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4859-4871.	1.6	4
18365	Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
18366	Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 $\geq 50\%$. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
18367	Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma. <i>Journal of Ophthalmic and Vision Research</i> , 0, , .	0.7	0
18368	STUB1 is an intracellular checkpoint for interferon gamma sensing. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
18369	The Role of Pathology-Based Methods in Qualitative and Quantitative Approaches to Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 3833.	1.7	4

#	ARTICLE	IF	CITATIONS
18370	A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. <i>Cancer Research</i> , 2022, 82, 3673-3686.	0.4	4
18371	Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy. <i>Cancer Research</i> , 2022, 82, 3532-3548.	0.4	14
18372	Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
18373	Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
18374	Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	17
18375	PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
18376	Whole blood transcriptome analysis in onchocerciasis. <i>Current Research in Parasitology and Vector-borne Diseases</i> , 2022, , 100100.	0.7	0
18377	Distinctive gene expression patterns in pregnancy-associated breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
18378	Connecting omics signatures and revealing biological mechanisms with iLINCS. <i>Nature Communications</i> , 2022, 13, .	5.8	24
18379	Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
18380	Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature. <i>Life</i> , 2022, 12, 1302.	1.1	5
18381	Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). , 2022, 10, e005332.		18
18382	Differential distribution and prognostic value of CD4+ T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
18383	Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 4101.	1.7	5
18384	Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
18385	Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma Growth <i>in Vivo</i> . <i>ACS Nano</i> , 2022, 16, 12695-12710.	7.3	11
18386	Self-Healing Injectable Hydrogels for Tissue Regeneration. <i>Chemical Reviews</i> , 2023, 123, 834-873.	23.0	190
18387	COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
18388	Solving the puzzle of what makes immunotherapies work. <i>Trends in Cancer</i> , 2022, 8, 890-900.	3.8	7
18389	Macrophages in melanoma: A double-edged sword and targeted therapy strategies (Review). <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	9
18390	Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067. <i>Pharmacoeconomics - Open</i> , 2022, 6, 697-710.	0.9	3
18391	Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1380-1391.	3.0	4
18392	Exome sequencing reveals a distinct somatic genomic landscape in breast cancer from women with germline PTEN variants. <i>American Journal of Human Genetics</i> , 2022, 109, 1520-1533.	2.6	2
18393	Bilateral corneal perforation in Ipilimumab/Nivolumab - associated peripheral ulcerative keratitis. <i>American Journal of Ophthalmology Case Reports</i> , 2022, 28, 101686.	0.4	2
18394	Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	1
18395	The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials. <i>Disease Markers</i> , 2022, 2022, 1-11.	0.6	3
18396	A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint blockade therapy of low-grade glioma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	12
18397	Single-cell analysis reveals clonally expanded tumor-associated CD57 ⁺ CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade. , 2022, 10, e004759.		11
18398	Temporally restricted activation of IFN γ signaling underlies response to immune checkpoint therapy in mice. <i>Nature Communications</i> , 2022, 13, .	5.8	12
18399	Cold Atmospheric Plasma Targeting Hematological Malignancies: Potentials and Problems of Clinical Translation. <i>Antioxidants</i> , 2022, 11, 1592.	2.2	9
18400	Subtype and cell type specific expression of lncRNAs provide insight into breast cancer. <i>Communications Biology</i> , 2022, 5, .	2.0	10
18401	Exosome-based strategies for diagnosis and therapy of glioma cancer. <i>Cancer Cell International</i> , 2022, 22, .	1.8	16
18402	Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-42.	1.9	1
18403	Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 561-578.	2.0	5
18404	Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the-Art. <i>Cancers</i> , 2022, 14, 4093.	1.7	7
18405	Schlafen family is a prognostic biomarker and corresponds with immune infiltration in gastric cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9

#	ARTICLE	IF	CITATIONS
18406	Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study. , 2022, 10, e005226.		17
18407	Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs. <i>Science Advances</i> , 2022, 8, .	4.7	16
18408	Computational design of PD-L1 small molecule inhibitors for cancer therapy. <i>Molecular Diversity</i> , 2023, 27, 1633-1644.	2.1	7
18409	Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors. <i>Cancer Discovery</i> , 2022, 12, 2606-2625.	7.7	69
18410	Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
18411	Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
18412	Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents. <i>Cancers</i> , 2022, 14, 4064.	1.7	11
18413	The Pyroptosis-Related Risk Genes APOBEC3D, TNFRSF14, and RAC2 Were Used to Evaluate Prognosis and as Tumor Suppressor Genes in Breast Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	3
18414	Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programmed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
18415	Construction of a prognostic model related to copper dependence in breast cancer by single-cell sequencing analysis. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
18416	Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
18417	Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade. <i>Nature Communications</i> , 2022, 13, .	5.8	24
18418	Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast. <i>Cancers</i> , 2022, 14, 3916.	1.7	2
18419	Fate decisions of breast cancer stem cells in cancer progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
18420	Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
18421	Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer – A Review of Molecular Characterisation, Therapeutic Targets and Future Trends. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
18422	CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
18423	Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	8

#	ARTICLE	IF	CITATIONS
18424	HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
18425	Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis. <i>Nature Communications</i> , 2022, 13, .	5.8	63
18426	Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
18427	Programmable Bispecific Nano-immunoengager That Captures T Cells and Reprograms Tumor Microenvironment. <i>Nano Letters</i> , 2022, 22, 6866-6876.	4.5	4
18428	Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
18429	Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2022, 27, 171-183.	1.0	9
18430	Deep learning reveals cuproptosis features assist in predict prognosis and guide immunotherapy in lung adenocarcinoma. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	8
18431	Development and validation of a novel fibroblast scoring model for lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
18432	BET inhibition triggers antitumor immunity by enhancing MHC class I expression in head and neck squamous cell carcinoma. <i>Molecular Therapy</i> , 2022, 30, 3394-3413.	3.7	6
18433	Triple-negative breast cancer influences a mixed M1/M2 macrophage phenotype associated with tumor aggressiveness. <i>PLoS ONE</i> , 2022, 17, e0273044.	1.1	13
18434	PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients with high PD-L1 expression: a meta-analysis of randomized controlled trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	3
18435	A deep learning approach with subregion partition in MRI image analysis for metastatic brain tumor. <i>Frontiers in Neuroinformatics</i> , 0, 16, .	1.3	3
18436	Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e058692.	0.8	3
18437	Supercharged chimeric antigen receptor T cells in solid tumors. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	6
18438	High IGC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9124.	1.8	7
18439	Association Between Adrenal-Restrictive <i>HSD3B1</i> Inheritance and Hormone-Independent Subtypes of Endometrial and Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	3
18440	Visceral Surgery Profoundly Affects the Cellular and Humoral Components of the Anti-Tumour Immune Response in a Murine Pancreatic Adenocarcinoma Model. <i>Cancers</i> , 2022, 14, 3850.	1.7	1
18441	PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?. <i>Clinics and Practice</i> , 2022, 12, 653-671.	0.6	8

#	ARTICLE	IF	CITATIONS
18442	Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer. <i>Archives of Pharmacal Research</i> , 2022, 45, 597-617.	2.7	6
18443	Noncanonical Wnt/Ror2 signaling regulates cellâ€“matrix adhesion to prompt directional tumor cell invasion in breast cancer. <i>Molecular Biology of the Cell</i> , 2022, 33, .	0.9	2
18444	Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	0
18445	TGF-Î² regulates the stem-like state of PD-1+ TCF-1+ virus-specific CD8 T cells during chronic infection. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	28
18446	X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
18447	Significant response to Pembrolizumab for metastatic cutaneous squamous cell carcinoma in patient with Netherton syndrome. <i>Annals of Medicine and Surgery</i> , 2022, 81, .	0.5	0
18448	Pneumocystis pneumonia in patient with lung adenocarcinoma: early side effects from pembrolizumab. <i>Radiology Case Reports</i> , 2022, 17, 3979-3981.	0.2	3
18449	Tumor Microenvironment Multiple Responsive Nanoparticles for Targeted Delivery of Doxorubicin and CpG Against Triple-Negative Breast Cancer. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 4401-4417.	3.3	3
18450	BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer. <i>Cell Reports</i> , 2022, 40, 111304.	2.9	1
18451	Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Cancers</i> , 2022, 14, 4494.	1.7	16
18452	On-demand integrated nano-engager converting cold tumors to hot via increased DNA damage and dual immune checkpoint inhibition. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1740-1754.	5.7	5
18453	Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
18454	Exploration of shared TF-miRNAâ€“mRNA and mRNA-RBP-pseudogene networks in type 2 diabetes mellitus and breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
18455	Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
18456	STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 45-56.	1.1	2
18457	Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models. <i>Cancers</i> , 2022, 14, 4669.	1.7	0
18458	CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	13
18459	Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma. , 2022, 10, e005328.		6

#	ARTICLE	IF	CITATIONS
18460	The Effect of PD-1 Inhibitor Combined with Chemotherapy on the Level of Peripheral Blood T Lymphocytes among Patients with Non-Small-Cell Lung Cancer and Its Relationship with Prognosis. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-7.	0.7	0
18461	Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 259-280.	1.0	3
18462	The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	21
18463	Finding the Right Heavy Chains for Immunostimulatory Antibodies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10367.	1.8	3
18464	Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity. <i>ELife</i> , 0, 11, .	2.8	10
18465	ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy in metastatic colorectal cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 1671-1683.	0.9	1
18466	Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study. <i>BMC Cancer</i> , 2022, 22, .	1.1	5
18467	Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indoleamine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors. <i>Diagnostic Pathology</i> , 2022, 17, .	0.9	1
18468	Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	5
18469	Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	3
18470	Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
18471	The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response. <i>Cells</i> , 2022, 11, 2866.	1.8	4
18472	Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
18473	<i>EGFR</i> Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil. <i>Oncologist</i> , 0, , .	1.9	1
18474	Association between germ-line HLA and immune-related adverse events. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
18475	MRI techniques for immunotherapy monitoring. , 2022, 10, e004708.		5
18476	PD-1 expression on mouse intratumoral NK cells and its effects on NK cell phenotype. <i>IScience</i> , 2022, 25, 105137.	1.9	6
18477	The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. <i>ESMO Open</i> , 2022, 7, 100577.	2.0	11

#	ARTICLE	IF	CITATIONS
18478	Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports. <i>World Journal of Clinical Cases</i> , 0, 10, 10550-10558.	0.3	1
18479	Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. <i>Seminars in Cancer Biology</i> , 2022, 86, 14-27.	4.3	21
18480	Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data. <i>Translational Oncology</i> , 2022, 25, 101526.	1.7	4
18481	A platinum@polymer-catechol nanobroker enables radio-immunotherapy for crippling melanoma tumorigenesis, angiogenesis, and radioresistance. <i>Bioactive Materials</i> , 2023, 22, 34-46.	8.6	7
18482	Pilot Study of Combination Gemogenovatucl-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211105.	0.6	4
18483	Microneedle Transdermal Drug Delivery Systems for Allergen-Specific Immunotherapy, Skin Disease Treatment, and Vaccine Development. <i>Yonsei Medical Journal</i> , 2022, 63, 881.	0.9	4
18484	Turning towards nonimmunoreactive tumors: Evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivity in pancreatic cancer. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3911-3923.	1.9	2
18485	Pyroptosis-related gene expression patterns and corresponding tumor microenvironment infiltration characterization in ovarian cancer. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 5440-5452.	1.9	6
18486	Lipid phosphate phosphatase-2 promotes tumor growth through increased c-Myc expression. <i>Theranostics</i> , 2022, 12, 5675-5690.	4.6	4
18487	Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211227.	1.4	0
18488	Polyglutamate-based nanoconjugates for image-guided surgery and post-operative melanoma metastases prevention. <i>Theranostics</i> , 2022, 12, 6339-6362.	4.6	0
18489	Multi-omics analysis to identify lung squamous carcinoma lactate metabolism-related subtypes and establish related index to predict prognosis and guide immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4756-4770.	1.9	2
18490	Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy. <i>Journal of Cancer</i> , 2022, 13, 3091-3102.	1.2	4
18491	Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 5150-5161.	1.9	5
18492	Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	7
18493	EZH2 inhibition activates dsRNA-interferon axis stress and promotes response to PD-1 checkpoint blockade in NSCLC. <i>Journal of Cancer</i> , 2022, 13, 2893-2904.	1.2	5
18494	Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma. <i>International Journal of Biological Sciences</i> , 2022, 18, 4884-4900.	2.6	22
18495	Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis. <i>Chemical Science</i> , 2022, 13, 10897-10903.	3.7	8

#	ARTICLE	IF	CITATIONS
18496	Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. <i>Theranostics</i> , 2022, 12, 6273-6290.	4.6	25
18497	Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211136.	1.4	34
18498	Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan. <i>Journal of Cancer</i> , 2022, 13, 2922-2932.	1.2	0
18499	Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody. <i>Cancer Control</i> , 2022, 29, 107327482211112.	0.7	17
18500	European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211188.	1.4	1
18501	Recognition of immune-related tumor antigens and immune subtypes for mRNA vaccine development in lung adenocarcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 5001-5013.	1.9	5
18502	Nuclear Receptors and Lipid Sensing. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 83-105.	0.8	2
18503	Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 171-194.	0.8	2
18504	Programmed death ligand 1 gene silencing in murine glioma models reveals cell line-specific modulation of tumor growth in vivo. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	0
18505	CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
18506	Clustering Molecular Subtypes in Breast Cancer, Immunohistochemical Parameters and Risk of Axillary Nodal Involvement. <i>Journal of Personalized Medicine</i> , 2022, 12, 1404.	1.1	2
18507	High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities. <i>Cancer Research</i> , 2022, 82, 3917-3931.	0.4	11
18508	Lidocaine promotes apoptosis in breast cancer cells by affecting VDAC1 expression. <i>BMC Anesthesiology</i> , 2022, 22, .	0.7	4
18509	Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	15
18510	Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	0.6	2
18511	Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 4220.	1.7	6
18512	Mechano-Sensing Channel PIEZO2 Enhances Invasive Phenotype in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9909.	1.8	8
18513	The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy. <i>Cancers</i> , 2022, 14, 4255.	1.7	3

#	ARTICLE	IF	CITATIONS
18514	T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer. <i>Cancers</i> , 2022, 14, 4246.	1.7	4
18515	CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment. <i>Onc Immunology</i> , 2022, 11, .	2.1	10
18516	Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
18517	Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy. <i>Diagnostics</i> , 2022, 12, 2091.	1.3	5
18518	Cuproptosis scoring model predicts overall survival and assists in immunotherapeutic decision making in pancreatic carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
18519	Systematic identification of cancer-associated-fibroblast-derived genes in patients with colorectal cancer based on single-cell sequencing and transcriptomics. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
18520	High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	7
18521	Recent advances in therapeutic strategies for triple-negative breast cancer. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	145
18522	Effect of Bevacizumab on a Human Breast Cancer Model that Exhibited Palbociclib-resistance by RB Knockout. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 533-541.	0.3	3
18523	Letter Regarding "Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma". <i>Liver Cancer</i> , 2023, 12, 85-86.	4.2	1
18524	LINC00511/hsa-miR-573 axis-mediated high expression of Gasdermin C associates with dismal prognosis and tumor immune infiltration of breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
18525	The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets. <i>Genes</i> , 2022, 13, 1555.	1.0	2
18526	Stromal Tumor Infiltrating Lymphocytes (sTILs) Were Associated with a Higher Grade and a Lower Stage of Indonesian Triple Negative Breast Cancers. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2749-2754.	0.5	0
18527	Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells. <i>Communications Biology</i> , 2022, 5, .	2.0	7
18528	Bioinformatics analysis of immune infiltrates and tripartite motif (TRIM) family genes in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1942-1958.	0.6	5
18529	Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2022, 11, 1555-1566.	1.3	8
18530	Cancer cell histone density links global histone acetylation, mitochondrial proteome and histone acetylase inhibitor sensitivity. <i>Communications Biology</i> , 2022, 5, .	2.0	4
18531	High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy. <i>Biomedicines</i> , 2022, 10, 2109.	1.4	0

#	ARTICLE	IF	CITATIONS
18532	Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy. <i>Molecules</i> , 2022, 27, 5607.	1.7	12
18533	Cost-Effectiveness of Pembrolizumab for the treatment of Non-Small-Cell lung cancer: A systematic review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
18534	CC Chemokine Ligand-2: A Promising Target for Overcoming Anticancer Drug Resistance. <i>Cancers</i> , 2022, 14, 4251.	1.7	4
18535	The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling. <i>Cancers</i> , 2022, 14, 4203.	1.7	5
18536	Endocrine therapy resistance: what we know and future directions. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 480-496.	0.5	5
18537	Prognostic and immune-related value of complement C1Q (C1QA, C1QB, and C1QC) in skin cutaneous melanoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	11
18538	Disrupting the Interplay between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic Acids in Treating Cancer. <i>ACS Central Science</i> , 2022, 8, 1299-1305.	5.3	8
18539	The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 817-826.	1.4	5
18540	Applying artificial intelligence technology to assist with breast cancer diagnosis and prognosis prediction. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
18541	Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 6260-6276.	0.9	6
18542	Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics. <i>Heliyon</i> , 2022, 8, e10450.	1.4	5
18543	Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report. <i>Current Oncology</i> , 2022, 29, 6203-6210.	0.9	1
18544	A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab. <i>Translational Lung Cancer Research</i> , 2022, 11, 1619-1630.	1.3	3
18545	Development of multivariable risk signature based on four immune-related RNA-binding proteins to predict survival and immune status in lung adenocarcinoma. <i>Translational Cancer Research</i> , 2022, 11, 2591-2606.	0.4	1
18546	Rational Approach to Finding Genes Encoding Molecular Biomarkers: Focus on Breast Cancer. <i>Genes</i> , 2022, 13, 1538.	1.0	0
18547	CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy. <i>Oncolimmunology</i> , 2022, 11, .	2.1	22
18548	Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 1151-1164.	5.7	79
18549	Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9394.	1.8	3

#	ARTICLE	IF	CITATIONS
18550	Pyroptosis-Related Gene Model Predicts Prognosis and Immune Microenvironment for Non-Small-Cell Lung Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-27.	1.9	3
18551	MS4A6A is a new prognostic biomarker produced by macrophages in glioma patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
18552	Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
18553	Photodynamic therapy of lung cancer, where are we?. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	13
18554	Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor. <i>Cancers</i> , 2022, 14, 4134.	1.7	9
18555	Tumor vessel co-option: The past & the future. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	17
18556	Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	25
18557	PD-L2 controls peripherally induced regulatory T cells by maintaining metabolic activity and Foxp3 stability. <i>Nature Communications</i> , 2022, 13, .	5.8	12
18558	Severe Immune-Related Adverse Events: A Case Series of Patients Needing Hospital Admission in a Spanish Oncology Referral Center and Review of the Literature. <i>Diagnostics</i> , 2022, 12, 2116.	1.3	1
18559	ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. <i>Cell Reports</i> , 2022, 40, 111268.	2.9	5
18560	The Microbiome-Immune Axis Therapeutic Effects in Cancer Treatments. <i>Journal of Microbiology and Biotechnology</i> , 2022, 32, 1086-1097.	0.9	2
18561	What does radiomics do in <sc>PD-1</sc> blockade therapy of <sc>NSCLC</sc> patients?. <i>Thoracic Cancer</i> , 2022, 13, 2669-2680.	0.8	2
18562	GPNMB: a potent inducer of immunosuppression in cancer. <i>Oncogene</i> , 2022, 41, 4573-4590.	2.6	11
18563	Recent Advances in DNA Vaccines against Lung Cancer: A Mini Review. <i>Vaccines</i> , 2022, 10, 1586.	2.1	4
18564	Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after α IFN- γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. <i>British Journal of Cancer</i> , 2023, 128, 461-467.	2.9	9
18565	Prostate Cancer Tumor Stroma: Responsibility in Tumor Biology, Diagnosis and Treatment. <i>Cancers</i> , 2022, 14, 4412.	1.7	4
18566	Comprehensive analysis of the prognostic implications and functional exploration of PAK gene family in human cancer. <i>Cancer Cell International</i> , 2022, 22, .	1.8	3
18567	The Tumor Microenvironment of Clear-Cell Ovarian Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 1326-1339.	1.6	12

#	ARTICLE	IF	CITATIONS
18568	The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy. <i>International Journal of Breast Cancer</i> , 2022, 2022, 1-10.	0.6	1
18569	VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6
18570	Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and promotes progression of tumor cells. <i>Cellular Oncology (Dordrecht)</i> , 0, , .	2.1	4
18571	Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgery via anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
18572	miR155 deficiency reduces breast tumor burden in the MMTV-PyMT mouse model. <i>Physiological Genomics</i> , 2022, 54, 433-442.	1.0	1
18573	Wnt2b and Wnt5a expression is highly associated with M2 TAMs in non-small cell lung cancer. <i>Oncology Reports</i> , 2022, 48, .	1.2	6
18574	Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy. <i>ELife</i> , 0, 11, .	2.8	23
18575	Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	97
18576	An acetonetic extract and secondary metabolites from the endolichenic fungus <i>Nemania</i> sp. ELO06872 exhibit immune checkpoint inhibitory activity in lung cancer cell. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
18577	Recent advancement of bioinspired nanomaterials and their applications: A review. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	5
18578	DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma. <i>Aging</i> , 2022, 14, 7824-7850.	1.4	1
18579	Immune status for monitoring and treatment of bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
18580	Correlations between Circulating and Tumor-Infiltrating CD4+ Treg Subsets with Immune Checkpoints in Colorectal Cancer Patients with Early and Advanced Stages. <i>Vaccines</i> , 2022, 10, 1471.	2.1	3
18581	Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	14
18582	First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
18583	Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
18584	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
18585	Tumor necrosis factor receptor regulation of peripheral node addressin biosynthetic components in tumor endothelial cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4

#	ARTICLE	IF	CITATIONS
18586	Analysis of Tumor-Infiltrating T-Cell Transcriptomes Reveal a Unique Genetic Signature across Different Types of Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11065.	1.8	4
18587	Upregulation of PD-L1 in Senescence and Aging. <i>Molecular and Cellular Biology</i> , 2022, 42, .	1.1	24
18588	Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
18589	Recent advances in CAR-T cells therapy for colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
18590	Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
18591	Echocardiography-Assessed Changes of Left and Right Ventricular Cardiac Function May Correlate with Progression of Advanced Lung Cancer—A Generating Hypothesis Study. <i>Cancers</i> , 2022, 14, 4770.	1.7	4
18592	MAP7D2 reduces CD8+ cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer. <i>Molecular Therapy</i> , 2023, 31, 90-104.	3.7	3
18593	Expression of immune checkpoints (PD-L1 and IDO) and tumour-infiltrating lymphocytes in breast cancer. <i>Heliyon</i> , 2022, 8, e10482.	1.4	2
18594	Biofabrication of 3D breast cancer models for dissecting the cytotoxic response of human T cells expressing engineered MAIT cell receptors. <i>Biofabrication</i> , 2022, 14, 044105.	3.7	14
18595	Transplant or dialysis: What's the better choice for RCC-induced ESRD patients? A 20-year analysis of OPTN/UNOS data. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
18596	Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks. <i>Clinical Cancer Research</i> , 2022, 28, 4968-4982.	3.2	16
18597	Roles of activator protein-2 gamma in breast cancer: A narrative review (SANRA). <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlo</i>	0.4	0
18598	The Novel Diagnostic Techniques and Biomarkers of Canine Mammary Tumors. <i>Veterinary Sciences</i> , 2022, 9, 526.	0.6	9
18599	The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review. , 2022, 39, .		6
18600	Induced CD45 Proximity Potentiates Natural Killer Cell Receptor Antagonism. <i>ACS Synthetic Biology</i> , 2022, 11, 3426-3439.	1.9	2
18601	Association of Oncologist Participation in Medicare's Oncology Care Model With Patient Receipt of Novel Cancer Therapies. <i>JAMA Network Open</i> , 2022, 5, e2234161.	2.8	0
18602	ICSBP-induced PD-L1 enhances osteosarcoma cell growth. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
18603	Optimisation of b-values for the accurate estimation of the apparent diffusion coefficient (ADC) in whole-body diffusion-weighted MRI in patients with metastatic melanoma. <i>European Radiology</i> , 2023, 33, 863-871.	2.3	2

#	ARTICLE	IF	CITATIONS
18604	Immune Effect of T Lymphocytes Infiltrated by Tumors on Non-Small-Cell Lung Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	0
18605	Genetics of Immune Dysregulation and Cancer Predisposition: Two Sides of the Same Coin. <i>Clinical and Experimental Immunology</i> , 0, , .	1.1	4
18606	Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. , 2022, 10, e004884.		15
18607	The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose. <i>Molecular Cancer Research</i> , 2022, 20, 1799-1810.	1.5	1
18608	omicsGAT: Graph Attention Network for Cancer Subtype Analyses. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10220.	1.8	1
18609	Utilization of cytologic cell blocks for targeted sequencing of solid tumors. <i>Cancer Medicine</i> , 2023, 12, 4042-4063.	1.3	3
18610	Establishing a Novel Gene Signature Related to Histone Modifications for Predicting Prognosis in Lung Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-19.	0.6	0
18611	Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research. <i>Targeted Oncology</i> , 2022, 17, 497-505.	1.7	3
18612	What is the optimal duration of immune checkpoint inhibitors in malignant tumors?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
18613	New methodology of TMB assessment from tissue and liquid biopsy in NSCLC. <i>PLoS ONE</i> , 2022, 17, e0275121.	1.1	0
18614	Positron Emission Tomography Probes for Imaging Cytotoxic Immune Cells. <i>Pharmaceutics</i> , 2022, 14, 2040.	2.0	1
18615	Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
18616	Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit. <i>Journal of Clinical Medicine</i> , 2022, 11, 5611.	1.0	5
18617	Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors. <i>Journal of Clinical Medicine</i> , 2022, 11, 5647.	1.0	3
18618	Transient Systemic Autophagy Inhibition Is Selectively and Irreversibly Deleterious to Lung Cancer. <i>Cancer Research</i> , 2022, 82, 4429-4443.	0.4	10
18619	Photothermal Nano-Vaccine Promoting Antigen Presentation and Dendritic Cells Infiltration for Enhanced Immunotherapy of Melanoma via Transdermal Microneedles Delivery. <i>Research</i> , 2022, 2022, .	2.8	6
18620	ELEVATE â€“ evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
18621	Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	35

#	ARTICLE	IF	CITATIONS
18622	Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96. <i>Biomedicines</i> , 2022, 10, 2146.	1.4	0
18623	Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
18624	Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression. <i>Biomaterials Research</i> , 2022, 26, .	3.2	18
18625	Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment. <i>Cells</i> , 2022, 11, 2793.	1.8	3
18626	Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
18627	Th17, Th22, and Myeloid-Derived Suppressor Cell Population Dynamics and Response to IL-6 in 4T1 Mammary Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10299.	1.8	2
18628	PIK3CA mutation status, progression and survival in advanced HR ⁺ /HER2 ⁻ breast cancer: a meta-analysis of published clinical trials. <i>BMC Cancer</i> , 2022, 22, .	1.1	9
18629	Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. <i>Cancers</i> , 2022, 14, 4562.	1.7	15
18630	BRCA1 transports the DNA damage signal for CDDP-induced centrosome amplification through the centrosomal Aurora A. <i>Cancer Science</i> , 2022, 113, 4230-4243.	1.7	2
18631	The expression pattern of immune-related genes and characterization of tumor immune microenvironment: predicting prognosis and immunotherapeutic effects in cutaneous melanoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
18632	Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis. , 2022, 10, e005490.		4
18633	Systemic Sclerosis Association with Malignancy. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 398-416.	2.9	7
18634	Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma. <i>Cancer Management and Research</i> , 0, Volume 14, 2723-2731.	0.9	2
18635	Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2022, 28, 4121-4130.	3.2	19
18636	Keratinocyte-derived cytokine TSLP promotes growth and metastasis of melanoma by regulating the tumor-associated immune microenvironment. <i>JCI Insight</i> , 2022, 7, .	2.3	5
18637	Advanced Research on Immune Checkpoint Inhibitor Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 5392.	1.0	0
18638	m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
18639	Single-cell transcriptome sequencing reveals potential novel combination of biomarkers for antibody-based cancer therapeutics in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0

#	ARTICLE	IF	CITATIONS
18640	The role of non-coding RNAs in myocarditis: a narrative review. <i>Annals of Translational Medicine</i> , 2022, 10, 1022-1022.	0.7	0
18641	Regulation of autoimmune disease progression by Pik3ip1 through metabolic reprogramming in T cells and therapeutic implications. <i>Science Advances</i> , 2022, 8, .	4.7	3
18642	Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 1796-1808.	1.3	1
18643	Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy—Resistant Early Breast Cancers. <i>Clinical Cancer Research</i> , 2022, 28, 4494-4508.	3.2	5
18644	Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. , 2022, 10, e005052.		9
18645	A Novel B7-H6—Targeted IgG-Like T Cell—Engaging Antibody for the Treatment of Gastrointestinal Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 5190-5201.	3.2	7
18646	Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. <i>Molecular Cancer</i> , 2022, 21, .	7.9	5
18647	Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. <i>Discover Oncology</i> , 2022, 13, .	0.8	6
18648	An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	9
18649	New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?. <i>Vaccines</i> , 2022, 10, 1607.	2.1	5
18650	AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11468.	1.8	0
18651	miR-acious new avenues for cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
18652	Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer. <i>Cells</i> , 2022, 11, 3028.	1.8	7
18653	Novel targets for immunotherapy associated with exhausted CD8+T cells in cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
18654	A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100416.	0.6	1
18655	USO1 expression is dysregulated in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 1877-1895.	1.3	1
18656	Primary melanoma of the bladder: case report and review of the literature. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
18657	Clinical predictive value of naïve and memory T cells in advanced NSCLC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13

#	ARTICLE	IF	CITATIONS
18658	Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 707-718.	2.0	3
18659	The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma. <i>Biomedicines</i> , 2022, 10, 2158.	1.4	5
18660	Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 3055-3070.	2.0	6
18661	The Immune Subtypes and Landscape of Advanced-Stage Ovarian Cancer. <i>Vaccines</i> , 2022, 10, 1451.	2.1	1
18662	Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms. <i>Vaccines</i> , 2022, 10, 1448.	2.1	3
18663	A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 827-840.	2.0	3
18664	Breast cancer: an up-to-date review and future perspectives. <i>Cancer Communications</i> , 2022, 42, 913-936.	3.7	70
18665	Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
18666	Combined Evaluation of mRNA and Protein Expression, Promoter Methylation, and Immune Infiltration of UBE2I in Pan-Digestive System Tumors. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-20.	1.9	1
18667	Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
18668	A prognostic signature of pyroptosis-related lncRNAs verified in gastric cancer samples to predict the immunotherapy and chemotherapy drug sensitivity. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
18669	Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
18670	Super-enhancer-controlled positive feedback loop BRD4/ERÎ±â€“RETâ€“ERÎ± promotes ERÎ±-positive breast cancer. <i>Nucleic Acids Research</i> , 2022, 50, 10230-10248.	6.5	10
18671	Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	28
18672	Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e29390.	0.4	0
18673	Recent advances in photothermal therapy-based multifunctional nanoplatforms for breast cancer. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	16
18674	Development and verification of an immune-related gene prognostic index for gastric cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
18675	Review: PDâ€“L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer. <i>Molecular Carcinogenesis</i> , 2023, 62, 52-61.	1.3	5

#	ARTICLE	IF	CITATIONS
18676	Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?. <i>Cancers</i> , 2022, 14, 4499.	1.7	17
18677	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10948.	1.8	8
18678	Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. <i>European Journal of Endocrinology</i> , 2022, 187, G1-G21.	1.9	35
18679	Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy. , 2022, 10, e005068.		6
18680	Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test. <i>Diagnostic Pathology</i> , 2022, 17, .	0.9	6
18681	Comprehensive analyses of a tumor-infiltrating lymphocytes-related gene signature regarding the prognosis and immunologic features for immunotherapy in bladder cancer on the basis of WGCNA. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
18682	Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
18683	Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
18684	Thyroid-related adverse events induced by immune checkpoint inhibitors. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
18685	Genomic mapping of copy number variations influencing immune response in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
18686	The immune landscape of hepatocellular carcinoma—where we are? (Review). <i>Oncology Letters</i> , 2022, 24, .	0.8	6
18687	Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas. <i>Human Cell</i> , 2022, 35, 1976-1992.	1.2	2
18688	Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade. <i>Cancer Discovery</i> , 2022, 12, 2774-2799.	7.7	22
18689	Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?. <i>Biomedicines</i> , 2022, 10, 2424.	1.4	4
18690	Critical evaluation of an autologous peripheral blood mononuclear cell-based humanized cancer model. <i>PLoS ONE</i> , 2022, 17, e0273076.	1.1	0
18691	Macrophages Upregulate Estrogen Receptor Expression in the Model of Obesity-Associated Breast Carcinoma. <i>Cells</i> , 2022, 11, 2844.	1.8	6
18692	The Role of Immunotherapy in Pancreatic Cancer. <i>Current Oncology</i> , 2022, 29, 6864-6892.	0.9	18
18693	Functional Downregulation of PD-L1 and PD-L2 by CpG and non-CpG Oligonucleotides in Melanoma Cells. <i>Cancers</i> , 2022, 14, 4698.	1.7	0

#	ARTICLE	IF	CITATIONS
18694	Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study. <i>Translational Lung Cancer Research</i> , 2022, 11, 1847-1857.	1.3	1
18695	A single-center analysis of 71 patients with thymic carcinoma: the chronological changes in the surgical procedure and prognosis. <i>Journal of Thoracic Disease</i> , 2022, 14, 3211-3220.	0.6	0
18696	Gut commensal bacteria enhance pathogenesis of a tumorigenic murine retrovirus. <i>Cell Reports</i> , 2022, 40, 111341.	2.9	2
18697	Thyroid Hormone Induces Oral Cancer Growth via the PD-L1-Dependent Signaling Pathway. <i>Cells</i> , 2022, 11, 3050.	1.8	2
18698	Expression, Localization and Prognosis Association of MEP50 in Breast Cancer. <i>Cancers</i> , 2022, 14, 4766.	1.7	2
18699	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)., 2022, 10, e005413.		6
18700	GraphBio: A shiny web app to easily perform popular visualization analysis for omics data. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	14
18701	Computational Biology Predicts the Efficacy of Tumor Immune Checkpoint Blockade. <i>BioMed Research International</i> , 2022, 2022, 1-9.	0.9	1
18702	Increased percentage of apoptotic and CTLA-4 (CD152) expressing cells in CD4+/CD8+ cells in COVID-19 patients. <i>Medicine (United States)</i> , 2022, 101, e30650.	0.4	2
18703	The therapeutic effect of an autologous and allogenic mixed glioma cell lysate vaccine in a rat model. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
18704	Sources of Cancer Neoantigens beyond Single-Nucleotide Variants. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10131.	1.8	16
18705	In vitro models as tools for screening treatment options of head and neck cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
18706	Comprehensive analysis for cellular senescence-related immunogenic characteristics and immunotherapy prediction of acute myeloid leukemia. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
18707	Towards an era of precise diagnosis and treatment: Role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
18708	Immune cells and their inflammatory mediators modify β 2 cells and cause checkpoint inhibitor-induced diabetes. <i>JCI Insight</i> , 2022, 7, .	2.3	17
18709	Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
18710	Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy. <i>Vaccines</i> , 2022, 10, 1552.	2.1	2
18711	A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma. <i>Current Oncology</i> , 2022, 29, 6445-6462.	0.9	6

#	ARTICLE	IF	CITATIONS
18712	Real-world data analysis of pembrolizumab monotherapy for non-small cell lung cancer utilizing Japanese post-marketing all-case surveillance data. <i>JTO Clinical and Research Reports</i> , 2022, , 100404.	0.6	0
18713	Manufacturingâ€dependent change in biological activity of the <scp>TLR4</scp> agonist <scp>GSK1795091</scp> and implications for lipid Aâ€analog development. <i>Clinical and Translational Science</i> , 2022, 15, 2625-2639.	1.5	6
18714	Network approaches for omics studies of neurodegenerative diseases. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
18715	Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
18716	Comprehensive analysis of LAMC1 expression and prognostic value in kidney renal papillary cell carcinoma and clear cell carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	5
18717	The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	31
18718	OncomiRs as noncoding RNAs having functions in cancer: Their role in immune suppression and clinical implications. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
18719	Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy. <i>Science Advances</i> , 2022, 8, .	4.7	23
18720	Changes in the Epidemiology of Hepatocellular Carcinoma in Asia. <i>Cancers</i> , 2022, 14, 4473.	1.7	20
18721	Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	19
18722	Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. <i>Cell Genomics</i> , 2022, 2, 100179.	3.0	74
18723	ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables <i>In Vivo</i> Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4907-4916.	3.2	7
18724	Deep Learning and Machine Learning with Grid Search to Predict Later Occurrence of Breast Cancer Metastasis Using Clinical Data. <i>Journal of Clinical Medicine</i> , 2022, 11, 5772.	1.0	23
18725	Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
18726	Advanced Acral Melanoma Therapies: Current Status and Future Directions. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1405-1427.	1.3	9
18727	Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment. <i>Pharmaceutics</i> , 2022, 14, 2076.	2.0	10
18728	Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. <i>Cancers</i> , 2022, 14, 4543.	1.7	9
18729	Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5

#	ARTICLE	IF	CITATIONS
18730	Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-“small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2951-2959.	0.8	2
18731	The role of polyamine metabolism in remodeling immune responses and blocking therapy within the tumor immune microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
18732	PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
18733	Signature based on RNA-binding protein-related genes for predicting prognosis and guiding therapy in non-small cell lung cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
18734	Myocarditis Induced by Immunotherapy in Metastatic Melanoma“Review of Literature and Current Guidelines. <i>Journal of Clinical Medicine</i> , 2022, 11, 5182.	1.0	2
18735	Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
18736	A Novel Prognosis Signature Based on Ferroptosis-Related Gene DNA Methylation Data for Lung Squamous Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	0
18737	TMBcat: A multi-endpoint p-value criterion on different discrepancy metrics for superiorly inferring tumor mutation burden thresholds. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
18738	Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 4481.	1.7	3
18739	Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
18740	Editorial: Tumor microenvironment signaling networks in pathophysiology and therapeutics. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
18741	Immune depletion of the methylated phenotype of colon cancer is closely related to resistance to immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
18742	MicroRNA-570 targets the HSP chaperone network, increases proteotoxic stress and inhibits mammary tumor cell migration. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
18743	Polycomb Directed Cell Fate Decisions in Development and Cancer. <i>Epigenomes</i> , 2022, 6, 28.	0.8	8
18744	Scarring Alopecia Under Immune Checkpoint Blockade: a Report of Three Cases. <i>Acta Dermato-Venereologica</i> , 0, 102, adv00792.	0.6	3
18745	A-to-I nonsynonymous RNA editing was significantly enriched in the ubiquitination site and correlated with clinical features and immune response. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
18746	PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity. <i>Biomolecules</i> , 2022, 12, 1226.	1.8	4
18747	INPP4B inhibits glioma cell proliferation and immune escape via inhibition of the PI3K/AKT signaling pathway. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6

#	ARTICLE	IF	CITATIONS
18748	Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2235-2242.	1.2	4
18749	Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	10
18750	The Interaction of the IFN γ /JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	1
18751	Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	2
18752	Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	10
18753	Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
18754	Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the "Real-Life" Setting. <i>Pharmaceuticals</i> , 2022, 15, 1154.	1.7	0
18755	Adjuvant atezolizumab in Japanese patients with resected stage <sc>IB&#IIA</sc> non&#small cell lung cancer (<sc>IMpower010</sc>). <i>Cancer Science</i> , 2022, 113, 4327-4338.	1.7	9
18756	Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
18757	Antifungal immunity mediated by C-type lectin receptors may be a novel target in immunotherapy for urothelial bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
18758	Upregulation of EMID1 Accelerates to a Favorable Prognosis and Immune Infiltration in Lung Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	3
18759	The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
18760	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	83
18761	Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 851-864.	2.0	6
18762	Association of adenosine signaling gene signature with estrogen receptor-positive breast and prostate cancer bone metastasis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
18763	Paving the road to make chimeric antigen receptor&#T&#cell therapy effective against solid tumors. <i>Cancer Science</i> , 2022, 113, 4020-4029.	1.7	2
18764	V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
18765	Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11

#	ARTICLE	IF	CITATIONS
18766	Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
18767	Gene signature of m6A-related targets to predict prognosis and immunotherapy response in ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 593-608.	1.2	6
18768	Label-free metabolic imaging for sensitive and robust monitoring of anti-CD47 immunotherapy response in triple-negative breast cancer. , 2022, 10, e005199.		5
18769	Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
18770	Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	2
18771	Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64). , 2022, 10, e005424.		7
18772	The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
18773	On-Target Side Effects of Targeted Therapeutics of Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	9
18774	Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis. , 2022, 19, 1153-1167.		6
18775	Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer. <i>Current Oncology</i> , 2022, 29, 6847-6863.	0.9	7
18776	Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy. <i>Military Medical Research</i> , 2022, 9, .	1.9	19
18777	Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	3
18778	Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 112-122.	1.9	3
18779	Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review. , 2022, 000, 000-000.		1
18780	A Bayesian phase I/II design to determine subgroup-specific optimal dose for immunotherapy sequentially combined with radiotherapy. <i>Pharmaceutical Statistics</i> , 2023, 22, 143-161.	0.7	2
18781	Identification and validation of ferroptosis-related lncRNA signatures as a novel prognostic model for glioma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
18782	Conductive target range of breast cancer: Hypoxic tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
18783	Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3

#	ARTICLE	IF	CITATIONS
18784	The DPY30-H3K4me3 Axis-Mediated PD-L1 Expression in Melanoma. <i>Journal of Inflammation Research</i> , 0, Volume 15, 5595-5609.	1.6	1
18785	Therapeutic strategies for gastric cancer targeting immune cells: Future directions. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
18786	Mechanism and strategies of immunotherapy resistance in colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
18787	Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 5136-5148.	3.2	8
18788	PAUF Induces Migration of Human Pancreatic Cancer Cells Exclusively via the TLR4/MyD88/NF- κ B Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11414.	1.8	3
18789	MXenes in Cancer Nanotheranostics. <i>Nanomaterials</i> , 2022, 12, 3360.	1.9	20
18790	Telomere-Associated Changes in Nuclear Architecture of Cancer-Associated Macrophage-like Cells in Liquid Biopsies from Melanoma Patients. <i>Biomedicines</i> , 2022, 10, 2391.	1.4	0
18791	Diagnostic Efficacy of CT Examination on Early Detection of Lung Cancer during Pandemic of COVID-19. <i>Diagnostics</i> , 2022, 12, 2317.	1.3	1
18792	Drug-related immune-mediated myelopathies. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1
18793	Bioinformatics Analysis of the Prognostic Significance of CAND1 in ER \pm -Positive Breast Cancer. <i>Diagnostics</i> , 2022, 12, 2327.	1.3	1
18794	Prognostic Relevance of Nuclear Receptors in Relation to Peritumoral Inflammation and Tumor Infiltration by Lymphocytes in Breast Cancer. <i>Cancers</i> , 2022, 14, 4561.	1.7	1
18795	Interpretation of the role of germline and somatic non-coding mutations in cancer: expression and chromatin conformation informed analysis. <i>Clinical Epigenetics</i> , 2022, 14, .	1.8	3
18796	Programmed Death-Ligand 1 Expression in Lung Cancer and Paired Brain Metastases—a Single-Center Study in 190 Patients. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100413.	0.6	1
18797	Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report. <i>Annals of Translational Medicine</i> , 2022, 10, 1028-1028.	0.7	1
18798	Durable melanoma control following disseminated talimogene laherparepvec herpetic infection. <i>JAAD Case Reports</i> , 2022, 29, 131-133.	0.4	4
18799	Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis. <i>JCI Insight</i> , 2022, 7, .	2.3	7
18800	Effect of Antigen Retrieval on Genomic DNA From Immunodissected Samples. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 643-658.	1.3	0
18801	An immunogold single extracellular vesicular RNA and protein (^{Au}SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patients. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	16

#	ARTICLE	IF	CITATIONS
18802	The Notch Signaling Pathway Contributes to Angiogenesis and Tumor Immunity in Breast Cancer. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 291-309.	1.0	4
18803	Effect of Previous Cancer History on Survival of Patients with Different Subtypes of Breast Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-15.	0.9	1
18804	PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond. <i>Cancers</i> , 2022, 14, 4332.	1.7	17
18805	Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
18806	Molecular characteristics, clinical significance, and cancer immune interactions of cuproptosis and ferroptosis-associated genes in colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	14
18807	NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9985.	1.8	11
18808	Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis. <i>British Journal of Cancer</i> , 0, , .	2.9	2
18809	PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment—A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters. <i>Journal of Clinical Medicine</i> , 2022, 11, 5524.	1.0	1
18810	Big data in basic and translational cancer research. <i>Nature Reviews Cancer</i> , 2022, 22, 625-639.	12.8	67
18811	Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene. <i>Targeted Oncology</i> , 2022, 17, 683-694.	1.7	1
18812	Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
18813	The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
18814	Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. <i>Nature Reviews Nephrology</i> , 2022, 18, 794-805.	4.1	20
18815	T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	18
18816	MCT4/Lactate Promotes PD-L1 Glycosylation in Triple-Negative Breast Cancer Cells. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	6
18817	Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. <i>Nature Medicine</i> , 2022, 28, 2155-2161.	15.2	93
18818	Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. <i>Oncolimmunology</i> , 2022, 11, .	2.1	28
18819	Neoantigens and their clinical applications in human gastrointestinal cancers. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1

#	ARTICLE	IF	CITATIONS
18820	Necroptosis-related lncRNA signature predicts prognosis and immune response for cervical squamous cell carcinoma and endocervical adenocarcinomas. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
18821	An Integrative Multi-Omics Analysis Based on Nomogram for Predicting Prostate Cancer Bone Metastasis Incidence. <i>Genetical Research</i> , 2022, 2022, 1-17.	0.3	1
18822	Synthesis, docking studies, biological activity of carbon monoxide release molecules based on coumarin derivatives. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	2
18823	Integrated bioinformatic analysis of potential biomarkers of poor prognosis in triple-negative breast cancer. <i>Translational Cancer Research</i> , 2022, 11, 3039-3049.	0.4	3
18824	Recent advances in bacterial therapeutics based on sense and response. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1014-1027.	5.7	4
18825	Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
18826	Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
18827	Anti-PD-1 immune checkpoint inhibitor inducing endocrine toxicity in a patient with advanced lung cancer: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	3
18828	Comprehensive analysis of ECHDC3 as a potential biomarker and therapeutic target for acute myeloid leukemia: Bioinformatic analysis and experimental verification. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
18829	Exploring the Surface of the Ectodomain of the PD-L1 Immune Checkpoint with Small-Molecule Fragments. <i>ACS Chemical Biology</i> , 2022, 17, 2655-2663.	1.6	8
18830	Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
18831	Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
18832	The Immune Landscape of Papillary Thyroid Cancer in the Context of Autoimmune Thyroiditis. <i>Cancers</i> , 2022, 14, 4287.	1.7	9
18833	Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
18834	Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy. <i>Pharmacological Reviews</i> , 2022, 74, 1146-1175.	7.1	8
18835	Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. <i>Biomedicines</i> , 2022, 10, 2211.	1.4	2
18836	High CENPA expression in papillary renal cell carcinoma tissues is associated with poor prognosis. <i>BMC Urology</i> , 2022, 22, .	0.6	1
18837	Impact of TP53 mutations in Triple Negative Breast Cancer. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	9

#	ARTICLE	IF	CITATIONS
18838	Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy. <i>Cells</i> , 2022, 11, 2802.	1.8	4
18839	Emerging Trends in Immunotherapy for Cancer. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 60.	1.0	17
18840	Exploring the oncogenic roles of LINC00857 in pan-cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
18841	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
18842	Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery. <i>Cancers</i> , 2022, 14, 4353.	1.7	3
18843	Poor prognosis, hypomethylation, and immune infiltrates are associated with downregulation of INMT in head and neck squamous cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
18844	Transcriptome analysis of <i>Homo sapiens</i> and <i>Mus musculus</i> reveals mechanisms of CD8+ T cell exhaustion caused by different factors. <i>PLoS ONE</i> , 2022, 17, e0274494.	1.1	3
18845	Inhibition of UBA6 by inosine augments tumour immunogenicity and responses. <i>Nature Communications</i> , 2022, 13, .	5.8	14
18846	The new progress in cancer immunotherapy. <i>Clinical and Experimental Medicine</i> , 2023, 23, 553-567.	1.9	6
18847	ATXN2-Mediated PI3K/AKT Activation Confers Gastric Cancer Chemoresistance and Attenuates CD8+ T Cell Cytotoxicity. <i>Journal of Immunology Research</i> , 2022, 2022, 1-16.	0.9	3
18848	Unraveling tumor microenvironment heterogeneity in malignant pleural mesothelioma identifies biologically distinct immune subtypes enabling prognosis determination. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
18849	Histone lysine methylation patterns in prostate cancer microenvironment infiltration: Integrated bioinformatic analysis and histological validation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
18850	CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab. <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	0.6	2
18851	Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 4616.	1.7	18
18852	Development and validation of a combined glycolysis and immune prognostic signature for lung squamous cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
18853	Targeting RNA N6-methyladenosine modification: a precise weapon in overcoming tumor immune escape. <i>Molecular Cancer</i> , 2022, 21, .	7.9	15
18854	Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
18855	Exploiting the Innate Plasticity of the Programmed Cell Death-1 (PD1) Receptor to Design Pembrolizumab H3 Loop Mimics**. <i>ChemBioChem</i> , 2022, 23, .	1.3	4

#	ARTICLE	IF	CITATIONS
18856	Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
18857	Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment. <i>Translational Lung Cancer Research</i> , 2022, 11, 1866-1876.	1.3	1
18858	Identification of Immuno-Targeted Combination Therapies Using Explanatory Subgroup Discovery for Cancer Patients with EGFR Wild-Type Gene. <i>Cancers</i> , 2022, 14, 4759.	1.7	1
18859	Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
18860	Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies. <i>Translational Lung Cancer Research</i> , 2022, 11, 1835-1846.	1.3	2
18861	Tumor microenvironment antigens. <i>Seminars in Immunopathology</i> , 2023, 45, 253-264.	2.8	21
18862	Bioinformatics analysis of prognostic value and immune cell infiltration of SERPINA1 gene in cutaneous melanoma. <i>Annals of Translational Medicine</i> , 2022, 10, 966-966.	0.7	0
18863	Investigation of the Role of PUFA Metabolism in Breast Cancer Using a Rank-Based Random Forest Algorithm. <i>Cancers</i> , 2022, 14, 4663.	1.7	3
18864	Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers. <i>Cells</i> , 2022, 11, 3033.	1.8	21
18865	In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. <i>Nature Immunology</i> , 2022, 23, 1495-1506.	7.0	57
18866	Protocol of the TREASURE study: Thoracic Radiotherapy with Atezolizumab in Small cell Lung cancer Extensive disease " a randomized, open-label, multicenter phase II trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
18867	A novel T-cell proliferation-associated regulator signature pre-operatively predicted the prognostic of bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
18868	A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers. <i>Scientific Data</i> , 2022, 9, .	2.4	6
18869	Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab. <i>Molecular Oncology</i> , 2023, 17, 792-809.	2.1	8
18870	Association of androgen receptor expression with glucose metabolic features in triple-negative breast cancer. <i>PLoS ONE</i> , 2022, 17, e0275279.	1.1	2
18871	Quantitative high-throughput analysis of tumor infiltrating lymphocytes in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
18872	Comprehensive analysis identifies as a critical prognostic prediction gene in breast cancer. <i>Chinese Medical Journal</i> , 2022, 135, 2218-2231.	0.9	1
18873	Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	5

#	ARTICLE	IF	CITATIONS
18874	Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10119.	1.8	2
18875	Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11046.	1.8	19
18876	A Therapy-Terminating Event: Programmed Death-1 Inhibitor-Induced Mucositis. <i>Cureus</i> , 2022, , .	0.2	0
18877	Protein Profiling of Breast Carcinomas Reveals Expression of Immune-Suppressive Factors and Signatures Relevant for Patient Outcome. <i>Cancers</i> , 2022, 14, 4542.	1.7	0
18878	Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate. <i>Molecular Diagnosis and Therapy</i> , 2022, 26, 679-688.	1.6	3
18879	Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 2219-2227.	1.1	3
18880	Clinical significance for diagnosis and prognosis of POP1 and its potential role in breast cancer: a comprehensive analysis based on multiple databases. <i>Aging</i> , 2022, 14, 6936-6956.	1.4	3
18881	Firstâ€inâ€human study of <scp>ONO</scp>â€4578, an antagonist of prostaglandin <scp>E</sub>2</sub></scp> receptor 4, alone and with nivolumab in solid tumors. <i>Cancer Science</i> , 2023, 114, 211-220.	1.7	4
18882	Pathogenesis of central nervous system germ cell tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
18883	Extracellular vesicle-based checkpoint regulation and immune state in cancer. , 2022, 39, .		10
18884	Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma. <i>Molecular Therapy</i> , 2023, 31, 119-133.	3.7	13
18885	Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
18886	Linc00996 is a favorable prognostic factor in LUAD: Results from bioinformatics analysis and experimental validation. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
18887	Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice. <i>Heliyon</i> , 2022, 8, e10775.	1.4	0
18888	Noninvasive assessment of breast cancer molecular subtypes on multiparametric <scp>MRI</scp> using convolutional neural network with transfer learning. <i>Thoracic Cancer</i> , 2022, 13, 3183-3191.	0.8	7
18889	Nanocarriers for cancer nano-immunotherapy. <i>Drug Delivery and Translational Research</i> , 2023, 13, 1936-1954.	3.0	17
18890	Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer. <i>Heliyon</i> , 2022, 8, e10932.	1.4	7
18891	Identification of fatty acid signature to predict prognosis and guide clinical therapy in patients with ovarian cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
18892	Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma. <i>Cancer Medicine</i> , 2023, 12, 4605-4615.	1.3	12
18893	DNA methylation regulator-mediated modification pattern defines tumor microenvironment immune infiltration landscape in colon cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
18894	Overview and clinical significance of multiple mutations in individual genes in hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
18895	Clinical neutrophil-associated genes as reliable predictors of hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
18896	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	33
18897	Emerging Targeted Therapies for Early Breast Cancer. <i>Drugs</i> , 2022, 82, 1437-1451.	4.9	5
18898	Monoclonal antibodies in cervical malignancy-related HPV. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
18899	Bibliometric analysis of research on immunogenic cell death in cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
18900	Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation. <i>Frontiers in Digital Health</i> , 0, 4, .	1.5	15
18901	Integrative genomic analysis facilitates precision strategies for glioblastoma treatment. <i>IScience</i> , 2022, 25, 105276.	1.9	0
18902	Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 323, C1475-C1495.	2.1	6
18903	MTAP deficiency contributes to immune landscape remodeling and tumor evasion. <i>Immunology</i> , 0, , .	2.0	1
18904	Immunotherapy in Biliary Tract Cancers: Where Are We?. <i>Current Oncology Reports</i> , 2022, 24, 1821-1828.	1.8	2
18905	The role of immune checkpoints in cardiovascular disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
18906	Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
18907	Computer classification and construction of a novel prognostic signature based on moonlighting genes in prostate cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
18908	Platelet membrane camouflaged AIEgen-mediated photodynamic therapy improves the effectiveness of anti-PD-L1 immunotherapy in large-burden tumors. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	8
18909	Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2

#	ARTICLE	IF	CITATIONS
18910	Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer. <i>Oncogene</i> , 2022, 41, 4905-4915.	2.6	9
18911	Technology meets TILs: Deciphering T cell function in the -omics era. <i>Cancer Cell</i> , 2023, 41, 41-57.	7.7	17
18912	The prognostic impact of the immune signature in head and neck squamous cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
18913	Prognosis of lasso-like penalized Cox models with tumor profiling improves prediction over clinical data alone and benefits from bi-dimensional pre-screening. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
18914	<i>Bifidobacterium breve</i> predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients. <i>Cancer Medicine</i> , 2023, 12, 6325-6336.	1.3	10
18915	Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2022, 27, 787-799.	2.2	4
18916	Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
18917	Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
18918	Lipid metabolic features of T cells in the Tumor Microenvironment. <i>Lipids in Health and Disease</i> , 2022, 21, .	1.2	2
18919	Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01). <i>Journal of Clinical Oncology</i> , 2023, 41, 651-663.	0.8	45
18920	Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization. , 2022, 10, e005103.		10
18921	Anlotinib Benefits the ±PDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-18.	1.9	3
18922	Deficiency of C-reactive protein or human C-reactive protein transgenic treatment aggravates influenza A infection in mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
18923	Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
18924	Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets. <i>Clinical Cancer Research</i> , 2022, 28, 4957-4967.	3.2	5
18925	Lung adenocarcinoma patients with malignant pleural effusions in hot adaptive immunity status have a longer overall survival. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
18926	Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 641-656.	3.5	37
18927	Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine. <i>IScience</i> , 2022, 25, 105081.	1.9	5

#	ARTICLE	IF	CITATIONS
18928	Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
18929	Metabolites of medicine food homology-derived endophytic fungi and their activities. <i>Current Research in Food Science</i> , 2022, 5, 1882-1896.	2.7	6
18930	Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. <i>Communications Biology</i> , 2022, 5, .	2.0	2
18931	A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
18932	Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma. <i>Heliyon</i> , 2022, 8, e10667.	1.4	2
18933	A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). <i>OncoImmunology</i> , 2022, 11, .	2.1	10
18934	From simplicity to complexity in current melanoma models. <i>Experimental Dermatology</i> , 2022, 31, 1818-1836.	1.4	3
18935	Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1788-1797.	1.9	0
18936	The Programmed Death-1 Signaling Axis Modulates Inflammation and LV Structure/Function in a Stress-Induced Cardiomyopathy Model. <i>JACC Basic To Translational Science</i> , 2022, 7, 1120-1139.	1.9	8
18937	Role of copper ionophore-induced death in immune microenvironment and clinical prognosis of ccRCC: An integrated analysis. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
18938	PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
18939	Identification of LAT/ZAP70 characterized immune subtypes of prostate cancer. <i>World Journal of Urology</i> , 2022, 40, 2817-2824.	1.2	1
18940	The multiple roles of LDH in cancer. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 749-762.	12.5	53
18941	Injectable versatile liquid-solid transformation implants alliance checkpoint blockade for magnetothermal dynamic-immunotherapy. <i>Materials Today Bio</i> , 2022, 16, 100442.	2.6	0
18942	Onco-biome in pharmacotherapy for lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2022, 11, 2332-2345.	1.3	1
18943	Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 2208-2215.	1.3	5
18944	Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer. <i>Journal of Cancer</i> , 2022, 13, 3434-3443.	1.2	16
18945	PTEN in Immunity. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 95-115.	0.7	0

#	ARTICLE	IF	CITATIONS
18946	Somatic Mutations of <i>TP53</i> Identified by Targeted Next-Generation Sequencing Are Poor Prognostic Factors for Primary Operable Breast Cancer: A Single-Center Study. <i>Journal of Breast Cancer</i> , 2022, 25, 379.	0.8	5
18947	Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 0, 5, 971-80.	0.9	9
18948	A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors. <i>Cancer Control</i> , 2022, 29, 107327482211305.	0.7	4
18949	Molecular Pathology of Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2022, 22, 264.	0.9	6
18950	NMR-Based Metabolomics to Evaluate Individual Response to Treatments. <i>Handbook of Experimental Pharmacology</i> , 2022, , 209-245.	0.9	4
18951	Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211338.	1.4	1
18952	Diabetes induced by checkpoint inhibition in nonobese ^Å diabetic mice can be prevented or reversed by a <i>JAK1/JAK2</i> inhibitor. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	6
18953	AKT Isoforms in the Immune Response in Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 349-366.	0.7	0
18954	Targeting Inflammation in the Diagnosis, Management, and Prevention of Cardiovascular Diseases. <i>Global Heart</i> , 2022, 17, .	0.9	5
18955	AKT Regulation of ORA1-Mediated Calcium Influx in Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 4794.	1.7	2
18956	The Use of Breath Analysis in the Management of Lung Cancer: Is It Ready for Primetime?. <i>Current Oncology</i> , 2022, 29, 7355-7378.	0.9	7
18957	UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress. <i>NAR Cancer</i> , 2022, 4, .	1.6	2
18958	Epitope Mapping of Therapeutic Antibodies Targeting Human LAG3. <i>Journal of Immunology</i> , 2022, 209, 1586-1594.	0.4	4
18959	Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 4796.	1.7	4
18960	Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	7
18961	Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. <i>Biology of Sex Differences</i> , 2022, 13, .	1.8	9
18962	Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
18963	Identification and validation of immunotherapy for four novel clusters of colorectal cancer based on the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9

#	ARTICLE	IF	CITATIONS
18964	MatchTope: A tool to predict the cross reactivity of peptides complexed with Major Histocompatibility Complex I. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
18965	Multiplexed imaging mass cytometry reveals distinct tumor-immune microenvironments linked to immunotherapy responses in melanoma. <i>Communications Medicine</i> , 2022, 2, .	1.9	6
18966	PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application. <i>Pathologica</i> , 2022, 114, 352-364.	1.3	13
18967	Age distribution and a multi-stage theory of carcinogenesis: 70 years on. <i>British Journal of Cancer</i> , 2023, 128, 404-406.	2.9	1
18968	Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma. <i>Current Oncology</i> , 2022, 29, 7718-7731.	0.9	3
18969	Nivolumab-induced radiation recall pneumonitis in non-small cell lung cancer patients with thoracic radiation therapy. <i>Cancer Science</i> , 0, , .	1.7	3
18970	Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1109-1125.	1.8	11
18971	An exploration of <sc>LAF–TMB</sc> as a predictor for the efficacy of immunotherapy combined with chemotherapy in <sc>non–small cell lung cancer</sc>. <i>Thoracic Cancer</i> , 0, , .	0.8	1
18972	Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management. <i>Cureus</i> , 2022, , .	0.2	1
18973	A genome-wide cell-free DNA methylation analysis identifies an episcapature associated with metastatic luminal B breast cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
18974	Spatial Transcriptomic Analysis of a Diverse Patient Cohort Reveals a Conserved Architecture in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2023, 83, 34-48.	0.4	9
18975	Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. <i>International Urology and Nephrology</i> , 2023, 55, 1025-1032.	0.6	3
18976	Engineered Oncolytic Adenoviruses: An Emerging Approach for Cancer Therapy. <i>Pathogens</i> , 2022, 11, 1146.	1.2	4
18977	Tumor response assessment on imaging following immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
18978	The gut microbiota modulates responses to anti-PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
18979	NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
18980	A predictive signature based on enhancer RNA associates with immune infiltration and aids treatment decision in clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
18981	AKT-mTORC1 reactivation is the dominant resistance driver for PI3K/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. <i>Oncogene</i> , 2022, 41, 5046-5060.	2.6	4

#	ARTICLE	IF	CITATIONS
18982	Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis. <i>Nature Communications</i> , 2022, 13, .	5.8	12
18983	Systemic therapy for early-stage breast cancer: learning from the past to build the future. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 763-774.	12.5	32
18984	The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100427.	0.6	3
18985	Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. <i>Oncologist</i> , 0, , .	1.9	1
18986	Decreased Tertiary Lymphoid Structures in Lung Adenocarcinomas with ALK Rearrangements. <i>Journal of Clinical Medicine</i> , 2022, 11, 5935.	1.0	1
18987	Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12067.	1.8	15
18988	Immunotherapy for bilateral multiple ground glass opacities: An exploratory study for synchronous multiple primary lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
18989	RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis. <i>Cell Communication and Signaling</i> , 2022, 20, .	2.7	6
18990	An Insight into Molecular Targets of Breast Cancer Brain Metastasis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11687.	1.8	5
18991	Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
18992	How Risk Factors Affect Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Immune Microenvironment (TIME): Their Influence on Immune Escape Mechanisms and Immunotherapy Strategy. <i>Biomedicines</i> , 2022, 10, 2498.	1.4	6
18993	Clinical Significance and Immune Infiltration Analyses of the Cuproptosis-Related Human Copper Proteome in Gastric Cancer. <i>Biomolecules</i> , 2022, 12, 1459.	1.8	9
18994	Trends in immune-related adverse events for colorectal cancer: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
18995	Current advances of CRISPR-Cas technology in cell therapy. , 2022, 1, 100067.		10
18996	Comprehensive analysis of prognostic significance of cadherin (CDH) gene family in breast cancer. <i>Aging</i> , 2022, , 8498-8567.	1.4	2
18997	MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	0
18998	Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors. , 2022, 10, e004781.		2
18999	Immune-infiltrating signature-based classification reveals CD103+CD39+ T cells associate with colorectal cancer prognosis and response to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
19000	Alterations in the p53 isoform ratio govern breast cancer cell fate in response to DNA damage. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	7
19001	Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2 ⁺ Negative Postmenopausal Breast Cancer Patients. <i>Cancers</i> , 2022, 14, 4844.	1.7	2
19002	High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	7
19003	Beyond the α 3 Ps α : A critical appraisal of the non-endocrine manifestations of multiple endocrine neoplasia type 1. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
19004	Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study. <i>BMJ Open</i> , 2022, 12, e055718.	0.8	12
19005	Influence of chemoradiation on the immune microenvironment of cervical cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2023, 199, 121-130.	1.0	7
19006	PD α L1 mediates triple α negative breast cancer evolution via the regulation of TAM/M2 polarization. <i>International Journal of Oncology</i> , 2022, 61, .	1.4	8
19007	Differential expansion of T peripheral helper cells in early rheumatoid arthritis and osteoarthritis synovium. <i>RMD Open</i> , 2022, 8, e002563.	1.8	2
19008	Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
19009	Targeting Both Autophagy and Immunotherapy in Breast Cancer Treatment. <i>Metabolites</i> , 2022, 12, 966.	1.3	2
19010	Evolutionary Origins of Metabolic Reprogramming in Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12063.	1.8	0
19011	CXCR5+CD8 T cells: Potential immunotherapy targets or drivers of immune-mediated adverse events?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
19012	Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
19013	Incidence and factors associated with cutaneous immune-related adverse events to immune checkpoint inhibitors: An ambispective cohort study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
19014	Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19. <i>Biomedicines</i> , 2022, 10, 2628.	1.4	1
19015	Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy. <i>Cancers</i> , 2022, 14, 5008.	1.7	5
19016	Insulin-like growth factor 2 receptor is a key immune-related gene that is correlated with a poor prognosis in patients with triple-negative breast cancer: A bioinformatics analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
19017	Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7

#	ARTICLE	IF	CITATIONS
19018	Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 5241.	1.7	1
19019	Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3—anti-PSMA bispecific 2.9 design. <i>British Journal of Cancer</i> , 2022, 127, 2186-2197.		3
19020	Metabolic communication in the tumour—immune microenvironment. <i>Nature Cell Biology</i> , 2022, 24, 1574-1583.	4.6	65
19021	Chimeric antigen receptor T cells applied to solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
19022	Subcellular location of source proteins improves prediction of neoantigens for immunotherapy. <i>EMBO Journal</i> , 2022, 41, .	3.5	2
19023	Case report: Reproductive organ preservation and subsequent pregnancy for an infertility patient with lynch syndrome-associated synchronous endometrial cancer and colon cancer after treatment with a PD-1 checkpoint inhibitor. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
19024	Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. <i>Nature Communications</i> , 2022, 13, .	5.8	28
19025	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
19026	The pivotal application of patient-derived organoid biobanks for personalized treatment of gastrointestinal cancers. <i>Biomarker Research</i> , 2022, 10, .	2.8	5
19027	Seq2Neo: A Comprehensive Pipeline for Cancer Neoantigen Immunogenicity Prediction. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11624.	1.8	11
19028	The Present and Future of Clinical Management in Metastatic Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 5891.	1.0	7
19029	lncRNAs AC156455.1 and AC104532.2 as Biomarkers for Diagnosis and Prognosis in Colorectal Cancer. <i>Disease Markers</i> , 2022, 2022, 1-13.	0.6	2
19030	STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. <i>Oncogene</i> , 2022, 41, 5214-5222.	2.6	3
19031	Cutaneous Melanoma versus Vulvovaginal Melanoma—Risk Factors, Pathogenesis and Comparison of Immunotherapy Efficacy. <i>Cancers</i> , 2022, 14, 5123.	1.7	7
19032	Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?. <i>Cells</i> , 2022, 11, 3280.	1.8	6
19033	Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	0
19034	Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
19036	Heart failure and cancer: From active exposure to passive adaption. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0

#	ARTICLE	IF	CITATIONS
19037	Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	2
19038	Efficient Minimum Flow Decomposition via Integer Linear Programming. <i>Journal of Computational Biology</i> , 2022, 29, 1252-1267.	0.8	4
19039	Oncogenic Role of HMGB1 as An Alarming in Robust Prediction of Immunotherapy Response in Colorectal Cancer. <i>Cancers</i> , 2022, 14, 4875.	1.7	8
19040	Infections simulating immune checkpoint inhibitor toxicities: Uncommon and deceptive. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	3
19041	Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers. <i>Cancers</i> , 2022, 14, 4985.	1.7	5
19042	Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. <i>Biomolecules</i> , 2022, 12, 1562.	1.8	5
19043	Immune checkpoint inhibitors in cervical cancer: Current status and research progress. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19044	Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. , 2022, 10, e005573.		11
19045	Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration. <i>JCI Insight</i> , 2022, 7, .	2.3	2
19046	Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision. <i>Cancers</i> , 2022, 14, 5074.	1.7	9
19047	Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. <i>Cancers</i> , 2022, 14, 5078.	1.7	9
19048	Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
19049	PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
19050	Oncolytic Virotherapy for Prostate Cancer: Lighting a Fire in Winter. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12647.	1.8	2
19051	Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway. , 2022, 39, .		12
19052	Novel Biomarkers and Therapeutic Targets for Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11656.	1.8	3
19053	Immunosenescence is a therapeutic target for frailty in older adults: a narrative review. <i>Annals of Translational Medicine</i> , 2022, 10, 1142-1142.	0.7	3
19054	Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function. <i>British Journal of Cancer</i> , 2022, 127, 2175-2185.	2.9	11

#	ARTICLE	IF	CITATIONS
19055	Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter study. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
19056	Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
19057	Sex difference in the expression of PD-1 of non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
19058	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13241.	1.8	9
19059	Review on Advanced Cancer Modeling for a Cancer Study. <i>Current Issues in Molecular Biology</i> , 2022, 44, 5352-5362.	1.0	0
19060	PD-L1 Expression in High-Risk Early-Stage Colorectal Cancer—Its Clinical and Biological Significance in Immune Microenvironment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13277.	1.8	3
19061	Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11968.	1.8	5
19062	Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
19063	PD-L1 Gene Polymorphisms rs822336 G>C and rs822337 T>A: Promising Prognostic Markers in Triple Negative Breast Cancer Patients. <i>Medicina (Lithuania)</i> , 2022, 58, 1399.	0.8	2
19064	A novel non-viral PDCD1 site-integrated CAR design: killing 2 birds with 1 stone. <i>Blood Science</i> , 2022, 4, 211-213.	0.4	0
19065	Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	4
19066	The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study. <i>Cancers</i> , 2022, 14, 5158.	1.7	3
19067	Immune-related histologic phenotype in pretreatment tumour biopsy predicts the efficacy of neoadjuvant anti-PD-1 treatment in squamous lung cancer. <i>BMC Medicine</i> , 2022, 20, .	2.3	0
19068	Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor. <i>Thoracic Cancer</i> , 2022, 13, 3420-3430.	0.8	5
19069	PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer. <i>Cancer Research</i> , 2022, 82, 4624-4640.	0.4	4
19070	Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. , 2022, 10, e005119.		8
19071	PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. , 2022, 10, e004590.		12
19072	Increased Aurora B expression reduces substrate phosphorylation and induces chromosomal instability. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3

#	ARTICLE	IF	CITATIONS
19073	Clinical cancer immunotherapy: Current progress and prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	39
19074	Machine learning and BP neural network revealed abnormal B cell infiltration predicts the survival of lung cancer patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19075	Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2022, 24, .	0.8	0
19076	Exosome-encapsulated ncRNAs: Emerging yin and yang of tumor hallmarks. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
19077	The intracellular cation channel TMEM176B as a dual immunoregulator. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
19078	Advances in the Management of Central Nervous System Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12525.	1.8	1
19079	Advanced MXene-Based Micro- and Nanosystems for Targeted Drug Delivery in Cancer Therapy. <i>Micromachines</i> , 2022, 13, 1773.	1.4	11
19080	Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	12
19081	A genomic and transcriptomic study toward breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
19082	Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer. <i>Cancers</i> , 2022, 14, 4885.	1.7	5
19083	Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. <i>Nature Medicine</i> , 2022, 28, 2364-2373.	15.2	45
19084	Characteristics, treatment, and outcome of diverticulitis after immune checkpoint inhibitor treatment in patients with malignancies. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
19085	Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	24
19086	The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology. <i>Animals</i> , 2022, 12, 2661.	1.0	2
19087	Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events. , 2022, 10, e005635.		11
19088	Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO. <i>Translational Lung Cancer Research</i> , 2022, 11, 2010-2021.	1.3	6
19089	Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study. <i>Journal of Thoracic Disease</i> , 2022, 14, 4125-4135.	0.6	3
19090	Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11

#	ARTICLE	IF	CITATIONS
19091	Clinical and Translational Advances in Glioma Immunotherapy. <i>Neurotherapeutics</i> , 2022, 19, 1799-1817.	2.1	14
19092	The maximum entropy principle for compositional data. <i>BMC Bioinformatics</i> , 2022, 23, .	1.2	4
19093	Single-cell genomic variation induced by mutational processes in cancer. <i>Nature</i> , 2022, 612, 106-115.	13.7	40
19094	Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1029-1045.	2.0	2
19095	Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor-infiltrating immunocytes. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 812-822.	1.3	3
19096	Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
19097	The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis. <i>Cancers</i> , 2022, 14, 5258.	1.7	1
19098	The Predictive and Prognostic Role of RASâ€“RAFâ€“MEKâ€“ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets. <i>Cancers</i> , 2022, 14, 5306.	1.7	12
19099	Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group. <i>Seminars in Arthritis and Rheumatism</i> , 2023, 58, 152110.	1.6	6
19100	PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative. <i>Journal of Personalized Medicine</i> , 2022, 12, 1793.	1.1	2
19101	Understanding the role of Toll-like receptors in lung cancer immunity and immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
19102	Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities. <i>Vaccines</i> , 2022, 10, 1673.	2.1	1
19103	Core promoter in TNBC is highly mutated with rich ethnic signature. <i>Briefings in Functional Genomics</i> , 0, , .	1.3	0
19104	Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?. <i>Pharmaceutics</i> , 2022, 14, 2326.	2.0	2
19105	Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints. <i>Cancers</i> , 2022, 14, 5332.	1.7	5
19106	The Lung Microbiota and Lung Cancer: A Growing Relationship. <i>Cancers</i> , 2022, 14, 4813.	1.7	6
19107	Spatial and Quantitative Analysis of Tumor-Associated Macrophages: Intratumoral CD163-/PD-L1+ TAMs as a Marker of Favorable Clinical Outcomes in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13235.	1.8	6
19108	Identification of miRNA biomarkers for breast cancer by combining ensemble regularized multinomial logistic regression and Cox regression. <i>BMC Bioinformatics</i> , 2022, 23, .	1.2	4

#	ARTICLE	IF	CITATIONS
19109	Granulocyte Apheresis: Can It Be Associated with Anti PD-1 Therapy for Melanoma?. <i>Medicina (Lithuania)</i> , 2022, 58, 1398.	0.8	1
19110	Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients. <i>Diagnostics</i> , 2022, 12, 2527.	1.3	2
19111	Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells. <i>Pharmaceutics</i> , 2022, 14, 2225.	2.0	15
19112	Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies. <i>Cancers</i> , 2022, 14, 5206.	1.7	14
19113	M1 Macrophage-Derived Sonoresponsive Nanoparticles for Sonodynamic Anticancer Therapy. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 4725-4741.	3.3	5
19114	Cell cycle associated miRNAs as target and therapeutics in lung cancer treatment. <i>Heliyon</i> , 2022, 8, e11081.	1.4	8
19115	Anti-Hormonal Therapy in Breast Cancer and Its Effect on the Blood-Brain Barrier. <i>Cancers</i> , 2022, 14, 5132.	1.7	2
19116	The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment. <i>Cancers</i> , 2022, 14, 5144.	1.7	8
19117	Immunophenotyping of pulmonary sarcomatoid carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
19118	Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2022, 127, 2227-2233.	2.9	1
19119	Identifying enhancer-driven subtype-specific prognostic markers in breast cancer based on multi-omics data. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
19120	Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients. <i>Current Oncology</i> , 2022, 29, 7953-7963.	0.9	10
19121	Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer. <i>Cells</i> , 2022, 11, 3226.	1.8	0
19122	Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity. <i>Cells</i> , 2022, 11, 3147.	1.8	3
19123	High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	13
19124	Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 623-637.	1.2	5
19125	CD8A as a Prognostic and Immunotherapy Predictive Biomarker Can Be Evaluated by MRI Radiomics Features in Bladder Cancer. <i>Cancers</i> , 2022, 14, 4866.	1.7	13
19126	Identification and verification of the prognostic value of CUL7 in colon adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0

#	ARTICLE	IF	CITATIONS
19127	Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients. <i>Expert Review of Clinical Pharmacology</i> , 0, , 1-10.	1.3	0
19128	Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacistsâ€™ Perspective. <i>Journal of Clinical Medicine</i> , 2022, 11, 6021.	1.0	2
19129	A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
19130	Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
19131	Changes in the Immune Cell Repertoire for the Treatment of Malignant Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12991.	1.8	3
19132	A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients. <i>Hereditas</i> , 2022, 159, .	0.5	1
19133	Long noncoding RNAâ€™mediated activation of PROTOR1/PRR5-AKT signaling shunt downstream of PI3K inâ€triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	7
19134	Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
19135	Monocyte programming by cancer therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	22
19136	Study of PD-L1 Expression with Association of Pathological Factors and Molecular Subtypes in Breast Carcinoma. <i>Journal of Laboratory Physicians</i> , 0, , .	0.4	1
19137	Hypophysitis induced by anti-programmed cell death protein 1 immunotherapy in non-small cell lung cancer: Three case reports. <i>World Journal of Clinical Cases</i> , 0, 10, 11049-11058.	0.3	3
19138	Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
19139	Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
19140	Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
19141	Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
19142	Bile acid distributions, sex-specificity, and prognosis in colorectal cancer. <i>Biology of Sex Differences</i> , 2022, 13, .	1.8	7
19143	Current landscape and future directions of bispecific antibodies in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	36
19144	Immunotherapy and Modern Radiotherapy Technique for Older Patients with Locally Advanced Head and Neck Cancer: A Proposed Paradigm by the International Geriatric Radiotherapy Group. <i>Cancers</i> , 2022, 14, 5285.	1.7	2

#	ARTICLE	IF	CITATIONS
19145	Integrating Genomic Information with Tumor-Immune Microenvironment in Triple-Negative Breast Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 13901.	1.2	1
19146	The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 2111-2124.	1.3	2
19147	Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. <i>Cancer Communications</i> , 2023, 43, 42-74.	3.7	9
19148	Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1. , 2022, 19, 1290-1301.		13
19149	The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. <i>Nature Communications</i> , 2022, 13, .	5.8	15
19150	Prognostic stratification based on the levels of tumor-infiltrating myeloid-derived suppressor cells and PD-1/PD-L1 axis in locally advanced rectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
19151	Enhanced antitumor immune responses via a new agent [131I]-labeled dual-target immunosuppressant. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 275-286.	3.3	6
19152	Tumor immune checkpoints and their associated inhibitors. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 823-843.	1.3	9
19153	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1003-1014.	2.0	4
19154	Effectiveness of immunological agents in non-small cell lung cancer. <i>Cancer Reports</i> , 2023, 6, .	0.6	3
19155	Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?. <i>Cancers</i> , 2022, 14, 5184.	1.7	7
19156	Diagnostic and therapeutic approach to pulmonary infiltrates in cancer patients receiving immune checkpoint inhibitors. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 67-73.	0.5	0
19157	Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
19158	Classification and Prognosis Analysis of Pancreatic Cancer Based on DNA Methylation Profile and Clinical Information. <i>Genes</i> , 2022, 13, 1913.	1.0	5
19159	Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	28
19160	Radioimmunotherapy study of 131I-labeled Atezolizumab in preclinical models of colorectal cancer. <i>EJNMMI Research</i> , 2022, 12, .	1.1	4
19161	Limitations of Immunotherapy in Cancer. <i>Cureus</i> , 2022, , .	0.2	2
19162	Integrative Genomic Tests in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13129.	1.8	8

#	ARTICLE	IF	CITATIONS
19163	A novel oxidative stress- and ferroptosis-related gene prognostic signature for distinguishing cold and hot tumors in colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
19164	K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer. <i>Cancers</i> , 2022, 14, 5322.	1.7	1
19165	Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	12
19166	KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China. <i>Translational Lung Cancer Research</i> , 2022, 11, 2136-2147.	1.3	4
19167	PD-L1 Activity Is Associated with Partial EMT and Metabolic Reprogramming in Carcinomas. <i>Current Oncology</i> , 2022, 29, 8285-8301.	0.9	12
19168	Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination. , 2022, 10, e005248.		8
19169	The genetics of myelodysplastic syndromes and the opportunities for tailored treatments. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
19170	Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
19171	Identification of a prognostic risk-scoring model and risk signatures based on glycosylation-associated cluster in breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
19172	Hsp90 α inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
19173	The prognostic significance of PD-L1 expression in patients with glioblastoma: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
19174	Molecular subtypes based on cuproptosis-related genes and immune profiles in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
19175	Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy. <i>Journal of Clinical Oncology</i> , 2023, 41, 170-172.	0.8	8
19176	SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
19177	Advances in immunotherapy for glioblastoma multiforme. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
19178	Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59. <i>Cells</i> , 2022, 11, 3365.	1.8	4
19179	Exploring Gut Microbiome in Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 5401.	1.7	7
19180	Exploiting DNA Replication Stress as a Therapeutic Strategy for Breast Cancer. <i>Biomedicines</i> , 2022, 10, 2775.	1.4	5

#	ARTICLE	IF	CITATIONS
19181	A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13322.	1.8	2
19182	Blocking PD-L1â€“PD-1 improves senescence surveillance and ageing phenotypes. <i>Nature</i> , 2022, 611, 358-364.	13.7	102
19183	Comprehensive analysis of chemokines family and related regulatory ceRNA network in lung adenocarcinoma. <i>Heliyon</i> , 2022, , e11399.	1.4	0
19184	Tbc1d10c is a selective, constitutive suppressor of the CD8 T-cell anti-tumor response. <i>Oncolmmunology</i> , 2022, 11, .	2.1	3
19185	The Role of miR-155 in Antitumor Immunity. <i>Cancers</i> , 2022, 14, 5414.	1.7	10
19186	Selection of a <scp>PD</scp>â€“ blocking antibody from a novel fully human phage display library. <i>Protein Science</i> , 2022, 31, .	3.1	7
19187	Immune Checkpoint Inhibitors Related to Cardiotoxicity. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 378.	0.8	3
19188	Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
19189	Cutting edges and therapeutic opportunities on tumor-associated macrophages in lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
19190	Overlap of diabetic ketoacidosis and hyperosmolar hyperglycemic state. <i>World Journal of Clinical Cases</i> , 0, 10, 11702-11711.	0.3	4
19191	SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
19192	A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19193	Prognostic signature of lipid metabolism associated LncRNAs predict prognosis and treatment of lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
19194	Genopathomic profiling identifies signatures for immunotherapy response of lung adenocarcinoma via confounder-aware representation learning. <i>IScience</i> , 2022, 25, 105382.	1.9	0
19195	Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptorâ€“Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 5066-5078.	3.2	5
19196	Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.4	1
19197	OncoTheradÂ® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5025-5036.	1.2	3
19198	Nociceptor neurons affect cancer immunosurveillance. <i>Nature</i> , 2022, 611, 405-412.	13.7	58

#	ARTICLE	IF	CITATIONS
19199	The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance. <i>Cancers</i> , 2022, 14, 5388.	1.7	10
19200	Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	13
19201	TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. <i>Nucleic Acids Research</i> , 2023, 51, D1425-D1431.	6.5	79
19202	Bidirectional crosstalk between epithelial and mesenchymal plasticity and IFN γ -induced PD-L1 expression promotes tumour progression. <i>Royal Society Open Science</i> , 2022, 9, .	1.1	7
19203	Identification of CKS1B as a prognostic indicator and a predictive marker for immunotherapy in pancreatic cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
19204	BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13424.	1.8	4
19205	Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5061-5070.	1.2	7
19206	Development and validation of blood tumor mutational burden reference standards. <i>Genes Chromosomes and Cancer</i> , 0, , .	1.5	1
19207	Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. <i>Cancers</i> , 2022, 14, 5403.	1.7	7
19208	Physiology of chemokines in the cancer microenvironment. <i>American Journal of Physiology - Cell Physiology</i> , 2023, 324, C167-C182.	2.1	10
19209	Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer. <i>Communications Medicine</i> , 2022, 2, .	1.9	5
19210	Omics analyses of a somatic $\text{Trp53}^{\text{R245W/+}}$ breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	7
19211	Enhancer decommissioning by MLL4 ablation elicits dsRNA-interferon signaling and GSDMD-mediated pyroptosis to potentiate anti-tumor immunity. <i>Nature Communications</i> , 2022, 13, .	5.8	14
19212	The Influence of the Gut Microbiome in Paediatric Cancer Origin and Treatment. <i>Antibiotics</i> , 2022, 11, 1521.	1.5	1
19213	Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study. <i>Clinical and Translational Radiation Oncology</i> , 2023, 38, 130-137.	0.9	7
19214	Implications and Emerging Therapeutic Avenues of Inflammatory Response in HPV+ Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 5406.	1.7	3
19215	A photodynamically sensitized dendritic cell vaccine that promotes the anti-tumor effects of anti-PD-L1 monoclonal antibody in a murine model of head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
19216	A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3

#	ARTICLE	IF	CITATIONS
19217	Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma. <i>Cancer Cell</i> , 2022, 40, 1324-1340.e8.	7.7	11
19218	Loss of LXN promotes macrophage M2 polarization and PD-L2 expression contributing cancer immune-escape in mice. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	2
19219	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. <i>PLoS ONE</i> , 2022, 17, e0272022.	1.1	4
19220	Vessel state and immune infiltration of the angiogenesis subgroup and construction of a prediction model in osteosarcoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
19221	MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. <i>Nature Communications</i> , 2022, 13, .	5.8	30
19222	Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. <i>Medicina (Lithuania)</i> , 2022, 58, 1572.	0.8	5
19223	The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
19224	Multiregional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos. <i>Cancer Research Communications</i> , 2022, 2, 1487-1496.	0.7	2
19225	Immune infiltration in aggressive papillary craniopharyngioma: High infiltration but low action. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
19226	Prognostic value of CD103+ tumor-infiltrating lymphocytes and programmed death ligand-1 (PD-L1) combined positive score in recurrent laryngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 135, 106226.	0.8	3
19227	CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial. <i>ESMO Open</i> , 2022, 7, 100594.	2.0	6
19228	The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance. <i>Cytokine</i> , 2023, 161, 156081.	1.4	3
19229	A Review of Immune Checkpoint Blockade for the General Surgeon. <i>Journal of Surgical Research</i> , 2023, 281, 289-298.	0.8	3
19230	Comprehensive landscape and future perspectives of long noncoding RNAs (lncRNAs) in colorectal cancer (CRC): Based on a bibliometric analysis. <i>Non-coding RNA Research</i> , 2023, 8, 33-52.	2.4	9
19231	Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape of prostate cancer. <i>Asian Journal of Andrology</i> , 2023, 25, 171.	0.8	3
19232	The PD-L1 Expression Among Triple-Negative Breast Cancer Patients in Universitas Sumatera Utara Teaching Hospital, Indonesia. <i>Acta Informatica Medica</i> , 2022, 30, 308.	0.5	0
19233	Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review. <i>Annals of Translational Medicine</i> , 2022, .	0.7	0
19234	Regulation of Immune Cells by microRNAs and microRNA-Based Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 75-108.	0.8	1

#	ARTICLE	IF	CITATIONS
19235	Hyponatraemia in patients on immune checkpoint inhibitors. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882211367.	1.4	1
19236	Myeloid checkpoints for cancer immunotherapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 460-482.	0.7	7
19237	Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational study. <i>PLoS ONE</i> , 2022, 17, e0275865.	1.1	4
19238	KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19239	Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2023, 14, 73-80.	0.8	3
19240	Development of Acute Adult T-cell Leukemia Following PD-1 Blockade Therapy for Lung Cancer. <i>Internal Medicine</i> , 2022, 61, 3421-3424.	0.3	2
19241	SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity. <i>International Journal of Cancer</i> , 2023, 152, 1243-1258.	2.3	12
19242	Efficacy and safety of adjuvant therapy with PD-1/PD-L1 inhibitors in cancer. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	1
19243	Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 5473.	1.7	4
19244	Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	6
19245	Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy. <i>Cancers</i> , 2022, 14, 5520.	1.7	10
19246	Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy. <i>Cancers</i> , 2022, 14, 5438.	1.7	8
19247	Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
19248	Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
19249	Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 5391-5411.	3.3	10
19250	The expression and prognostic value of transporter 1, ATP binding cassette subfamily B member in clear cell renal cell cancer with experimental validation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19251	Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19252	CXCL12, a potential modulator of tumor immune microenvironment (TIME) of bladder cancer: From a comprehensive analysis of TCGA database. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
19253	Biomolecule-mimetic nanomaterials for photothermal and photodynamic therapy of cancers: Bridging nanobiotechnology and biomedicine. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	21
19254	Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
19255	Regulatory T Cells in Ovarian Carcinogenesis and Future Therapeutic Opportunities. <i>Cancers</i> , 2022, 14, 5488.	1.7	3
19256	CD4+CD25+ T regulatory cells in renal transplantation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
19257	Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
19258	Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	12
19259	Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100431.	0.6	3
19260	Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
19261	PA-MSHA induces inflamed tumor microenvironment and sensitizes tumor to anti-PD-1 therapy. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	2
19262	Novel peripheral blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	3
19263	Promoter hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19264	Improving Infinium MethylationEPIC data processing: re-annotation of enhancers and long noncoding RNA genes and benchmarking of normalization methods. <i>Epigenetics</i> , 2022, 17, 2434-2454.	1.3	3
19265	Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects. , 2022, 10, e005401.		10
19266	Characterization of genomic alterations and neoantigens and analysis of immune infiltration identified therapeutic and prognostic biomarkers in adenocarcinoma at the gastroesophageal junction. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19267	Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration. <i>Disease Markers</i> , 2022, 2022, 1-15.	0.6	2
19268	A SERPINE1-Based Immune Gene Signature Predicts Prognosis and Immunotherapy Response in Gastric Cancer. <i>Pharmaceuticals</i> , 2022, 15, 1401.	1.7	2
19269	A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
19270	Voltage imaging reveals the dynamic electrical signatures of human breast cancer cells. <i>Communications Biology</i> , 2022, 5, .	2.0	12

#	ARTICLE	IF	CITATIONS
19271	SLC11A1 associated with tumor microenvironment is a potential biomarker of prognosis and immunotherapy efficacy for colorectal cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
19272	Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	0
19273	Combined mitoxantrone and anti-TGF β 2 treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	8
19274	Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma. <i>Cancers</i> , 2022, 14, 5618.	1.7	2
19275	Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
19276	Treatment beyond progression in non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19277	CD8+ T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
19278	Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	14
19279	Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19280	lncRNASNP v3: an updated database for functional variants in long non-coding RNAs. <i>Nucleic Acids Research</i> , 2023, 51, D192-D198.	6.5	16
19281	Molecular subtypes identified by pyroptosis-related genes are associated with tumor microenvironment cell infiltration in colon cancer. <i>Aging</i> , 0, , .	1.4	0
19282	Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing. <i>Cell Genomics</i> , 2023, 3, 100215.	3.0	4
19283	Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19284	Overlapping pathogenic de novo CNVs in neurodevelopmental disorders and congenital anomalies impacting constraint genes regulating early development. <i>Human Genetics</i> , 2023, 142, 1201-1213.	1.8	5
19285	Inhibition of the CD47-SIRP α axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
19286	Integrin β 6 signals through DNA damage response pathway to sensitize breast cancer cells to cisplatin. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
19287	Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). <i>Cancer Communications</i> , 2022, 42, 1314-1330.	3.7	14
19288	Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
19289	A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	3
19290	Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13696.	1.8	0
19291	Scope and Consistency of Cancer Outcomes Reported in Randomized Trials in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2023, 8, 274-281.	0.4	1
19292	External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 347-355.	1.4	3
19293	Tumor factors stimulate lysosomal degradation of tumor antigens and undermine their cross-presentation in lung cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	7
19294	Host Molecule Incorporation into HIV Virions, Potential Influences in HIV Pathogenesis. <i>Viruses</i> , 2022, 14, 2523.	1.5	1
19295	Ferroptosis: a double-edged sword mediating immune tolerance of cancer. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	20
19296	Development of a novel BRCAness score that predicts response to PARP inhibitors. <i>Biomarker Research</i> , 2022, 10, .	2.8	6
19297	Tumor suppressor DEAR1 regulates mammary epithelial cell fate and predicts early onset and metastasis in triple negative breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
19298	The radiological appearances of lung cancer treated with immunotherapy. <i>British Journal of Radiology</i> , 2023, 96, .	1.0	1
19299	A novel immune signature predicts immunotherapy responsiveness and reveals the landscape of the tumor immune microenvironment in head and neck squamous cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
19300	Diabetes insipidus: A rare endocrine complication of immune check point inhibitors: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2022, 25, .	0.8	3
19301	Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
19302	Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors. <i>Cells</i> , 2022, 11, 3626.	1.8	5
19303	Granulomatous interstitial nephritis with CTLA-4 haploinsufficiency: a case report. <i>BMC Nephrology</i> , 2022, 23, .	0.8	2
19304	Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 5209-5227.	3.3	5
19305	The prognostic impact of the immune microenvironment in small-cell neuroendocrine carcinoma of the uterine cervix: PD-L1 and immune cell subtypes. <i>Cancer Cell International</i> , 2022, 22, .	1.8	3
19306	Androgen receptor function and targeted therapeutics across breast cancer subtypes. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	19

#	ARTICLE	IF	CITATIONS
19307	The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
19308	AntiPD-L1 antibody conjugated Au-SPIOs nanoplatfom for enhancing radiosensitivity and triggering anti-tumor immune response. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
19309	Grace-AKO: a novel and stable knockoff filter for variable selection incorporating gene network structures. <i>BMC Bioinformatics</i> , 2022, 23, .	1.2	0
19310	Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma. <i>Discover Oncology</i> , 2022, 13, .	0.8	0
19311	Pan-cancer Analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma. <i>Respiratory Research</i> , 2022, 23, .	1.4	3
19312	Immunostimulatory oncolytic activity of coxsackievirus <scp>A11</scp> in human malignant pleural mesothelioma. <i>Cancer Science</i> , 2023, 114, 1095-1107.	1.7	2
19313	Antibody-dependent cellular cytotoxicity-null effector developed using mammalian and plant GlycoDelete platform. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
19314	Personalized genome assembly for accurate cancer somatic mutation discovery using tumor-normal paired reference samples. <i>Genome Biology</i> , 2022, 23, .	3.8	3
19315	Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 697-706.	1.4	2
19316	Self-Cooperative Prodrug Nanovesicles Migrate Immune Evasion to Potentiate Chemoradiotherapy in Head and Neck Cancer. <i>Advanced Science</i> , 2022, 9, .	5.6	5
19317	Low-dose nivolumab in advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	5
19318	Adjuvant therapy options in renal cell carcinoma " targeting the metastatic cascade. <i>Nature Reviews Urology</i> , 2023, 20, 179-193.	1.9	4
19319	The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction. <i>Nature Communications</i> , 2022, 13, .	5.8	32
19320	WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function. <i>Experimental and Molecular Medicine</i> , 2022, 54, 1913-1926.	3.2	0
19321	CAR T-cells for colorectal cancer immunotherapy: Ready to go?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
19322	Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	30
19323	MLSP: A bioinformatics tool for predicting molecular subtypes and prognosis in patients with breast cancer. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 6412-6426.	1.9	0
19324	Expression of plant-produced anti-PD-L1 antibody with anoikis sensitizing activity in human lung cancer cells via., suppression on epithelial-mesenchymal transition. <i>PLoS ONE</i> , 2022, 17, e0274737.	1.1	10

#	ARTICLE	IF	CITATIONS
19325	Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives. <i>Cancers</i> , 2022, 14, 5489.	1.7	4
19326	Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones. <i>Clinical Cancer Research</i> , 2023, 29, 505-507.	3.2	2
19327	Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
19328	Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14197.	1.8	8
19329	Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nursesâ€™ health study. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	2
19330	CNS and CNS diseases in relation to their immune system. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
19331	Identification of tumor antigens and immune subtypes in head and neck squamous cell carcinoma for mRNA vaccine development. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
19332	Estrogen-Inducible LncRNA BNAT1 Functions as a Modulator for Estrogen Receptor Signaling in Endocrine-Resistant Breast Cancer Cells. <i>Cells</i> , 2022, 11, 3610.	1.8	5
19333	Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
19334	Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	12
19335	Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion. <i>Biomedicines</i> , 2022, 10, 2809.	1.4	8
19336	DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response. <i>Nature Communications</i> , 2022, 13, .	5.8	6
19337	Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways. <i>Cell Reports Medicine</i> , 2022, 3, 100819.	3.3	15
19338	Human papillomavirus infection can alter the level of tumour stemness and T cell infiltration in patients with head and neck squamous cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
19339	Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19340	Abemaciclib in combination with pembrolizumab for HR+, HER2 ⁺ metastatic breast cancer: Phase 1b study. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	14
19341	Editorial: Impact of immunotherapy in lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
19342	Myeloid-derived suppressor cells and plasmacytoid dendritic cells are associated with oncogenesis of oral squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2023, 52, 9-19.	1.4	5

#	ARTICLE	IF	CITATIONS
19343	Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review. <i>BMC Medicine</i> , 2022, 20, .	2.3	8
19344	Endoplasmic reticulum stress targeted therapy for breast cancer. <i>Cell Communication and Signaling</i> , 2022, 20, .	2.7	15
19345	Spatial architecture of regulatory T-cells correlates with disease progression in patients with nasopharyngeal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
19346	Cuproptosis-related LncRNA signatures as a prognostic model for head and neck squamous cell carcinoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 0, , .	2.2	5
19347	Genetic Ancestry Inference from Cancer-Derived Molecular Data across Genomic and Transcriptomic Platforms. <i>Cancer Research</i> , 2023, 83, 49-58.	0.4	5
19348	Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. <i>World Journal of Gastroenterology</i> , 0, 28, 6034-6044.	1.4	6
19349	Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	4
19350	Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	0
19351	T cell receptor convergence is an indicator of antigen-specific T cell response in cancer immunotherapies. <i>ELife</i> , 0, 11, .	2.8	6
19352	Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
19353	Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab. <i>BMC Urology</i> , 2022, 22, .	0.6	0
19354	An Innovative PTD-IVT-mRNA Delivery Platform for CAR Immunotherapy of ErbB(+) Solid Tumor Neoplastic Cells. <i>Biomedicines</i> , 2022, 10, 2885.	1.4	3
19355	A mouse pancreatic organoid model to compare PD-L1 blocking antibodies. <i>MAbs</i> , 2022, 14, .	2.6	0
19356	Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer. <i>ESMO Open</i> , 2022, 7, 100631.	2.0	4
19357	Comparison of Survival Outcomes and Risk Factors Between Ductal Carcinoma of the Prostate and Acinar Adenocarcinoma of the Prostate: A Population-based Propensity Score“matching Study. <i>European Urology Open Science</i> , 2022, 46, 88-95.	0.2	2
19358	Utilization of macrocyclic peptides to target protein-protein interactions in cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19359	Gut microbiota diversity and composition in predicting immunotherapy response and immunotherapy-related colitis in melanoma patients: A systematic review. <i>World Journal of Clinical Oncology</i> , 0, 13, 929-942.	0.9	6
19360	Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis. <i>Cancer Cell International</i> , 2022, 22, .	1.8	5

#	ARTICLE	IF	CITATIONS
19361	The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2022, 22, .	1.1	11
19362	Fatty Acid Synthase Mutations Predict Favorable Immune Checkpoint Inhibitor Outcome and Response in Melanoma and Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 5638.	1.7	7
19363	Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy—A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study. <i>Cancers</i> , 2022, 14, 5635.	1.7	3
19364	Cancer Patients and the COVID-19 Vaccines: Considerations and Challenges. <i>Cancers</i> , 2022, 14, 5630.	1.7	4
19365	Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 0, 10, 12305-12312.	0.3	2
19366	Advances of Electroporation-Related Therapies and the Synergy with Immunotherapy in Cancer Treatment. <i>Vaccines</i> , 2022, 10, 1942.	2.1	7
19367	Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	4
19368	Intrinsic resistance and efficacy of immunotherapy in microsatellite instability-high colorectal cancer: A systematic review and meta-analysis. <i>Bosnian Journal of Basic Medical Sciences</i> , 2023, 23, .	0.6	5
19369	Identification of a novel oxidative stress-related prognostic model in lung adenocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
19370	NADPH Selective Depletion Nanomedicine-Mediated Radio-Immunometabolism Regulation for Strengthening Anti-PDL1 Therapy against TNBC. <i>Advanced Science</i> , 2023, 10, .	5.6	13
19371	REFINE (REduced Frequency ImmUNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers. <i>Contemporary Clinical Trials</i> , 2023, 124, 107030.	0.8	3
19372	Exosomes in Genitourinary Cancers: Emerging Mediators of Drug Resistance and Promising Biomarkers. <i>International Journal of Biological Sciences</i> , 2023, 19, 167-182.	2.6	3
19373	Number of FoxP3+ regulatory T-cells are associated with recurrence in vulvar squamous cell carcinoma. <i>Journal of Gynecologic Oncology</i> , 0, 34, .	1.0	1
19374	Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments. <i>Translational Cancer Research</i> , 2021, .	0.4	0
19375	The role of platelet-lymphocyte ratio in hepatocellular carcinoma: a valuable prognostic marker. <i>Translational Cancer Research</i> , 2022, 11, 4231-4234.	0.4	1
19376	Immunotherapy for the treatment of pediatric brain tumors: a narrative review. <i>Translational Pediatrics</i> , 2022, 11, 2040-2056.	0.5	2
19377	Screening for Physical Activity Levels in Non-Metastatic Breast Cancer Patients Undergoing Surgery: An Observational Study. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542211403.	0.8	0
19378	The prognostic importance of PD-L1, PTEN, PHH3, and KI-67 expressions in invasive breast carcinoma. <i>Revista Da Associação Médica Brasileira</i> , 2022, 68, 1638-1644.	0.3	0

#	ARTICLE	IF	CITATIONS
19379	An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870). <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211383.	1.4	2
19380	Antitumor efficacy of multi-target <i>in situ</i> vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamers. <i>Journal of Biomedical Research</i> , 2023, 37, 194.	0.7	1
19381	Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211417.	1.4	1
19382	Molecular typing and prognostic model of lung adenocarcinoma based on cuprotosis-related lncRNAs. <i>Journal of Thoracic Disease</i> , 2022, 14, 4828-4845.	0.6	2
19383	Effects of postoperative radiotherapy and docetaxel and PD-1 inhibitors on the survival and safety of glioblastoma patients: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2022, 10, 1326-1326.	0.7	1
19384	Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy. <i>Theranostics</i> , 2022, 12, 7821-7852.	4.6	12
19385	Eosinophilia in cancer and its regulation by sex hormones. <i>Trends in Endocrinology and Metabolism</i> , 2023, 34, 5-20.	3.1	6
19386	Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2023, 34, .	1.0	3
19387	Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review. <i>Current Research in Pharmacology and Drug Discovery</i> , 2023, 4, 100146.	1.7	1
19388	Polymeric microneedles enable simultaneous delivery of cancer immunomodulatory drugs and detection of skin biomarkers. <i>Theranostics</i> , 2023, 13, 1-15.	4.6	14
19389	Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases. <i>ESMO Open</i> , 2023, 8, 100741.	2.0	4
19390	Prognostic score and sex-specific nomograms to predict survival in resectable lung cancer: a French nationwide study from the Epithor cohort database. <i>Lancet Regional Health - Europe</i> , The, 2023, 26, 100566.	3.0	3
19391	Meta-analysis and Critical Review: Association Between Radio-induced Lymphopenia and Overall Survival in Solid Cancers. <i>Advances in Radiation Oncology</i> , 2023, 8, 101038.	0.6	4
19392	Effect of N6-methyladenosine (m6A) regulator-related immunogenes on the prognosis and immune microenvironment of breast cancer. <i>Translational Cancer Research</i> , 2021, .	0.4	0
19393	Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model. <i>Investigative and Clinical Urology</i> , 2023, 64, 74.	1.0	3
19394	A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy. <i>Cancer Informatics</i> , 2022, 21, 117693512211360.	0.9	1
19395	Clinicopathological and Prognostic Significance of Programmed Death Ligand-1 SP142 Expression in 132 Patients With Triple-negative Breast Cancer. <i>In Vivo</i> , 2022, 36, 2890-2898.	0.6	3
19396	Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211440.	1.4	7

#	ARTICLE	IF	CITATIONS
19397	The Tri-iodothyronine (T3) Level Is a Prognostic Factor for Patients With Advanced NSCLC: Receiving Immune Checkpoint Inhibitors and Is Associated With Liver Metastasis. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211395.	0.6	2
19398	PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study. <i>Asian Journal of Andrology</i> , 2022, .	0.8	1
19399	Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211396.	1.4	4
19400	Comprehensive analysis of the correlation between GSTM1 and tumor immunity in colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 3025-3037.	0.6	1
19401	Somatic Mutations in Breast Cancer: The Tip of the Iceberg. <i>Journal of Breast Cancer</i> , 0, 25, .	0.8	0
19402	RUNX Proteins as Epigenetic Modulators in Cancer. <i>Cells</i> , 2022, 11, 3687.	1.8	5
19403	Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy. <i>Seminars in Immunopathology</i> , 0, , .	2.8	2
19404	Preoperative Computed Tomography Radiomics Analysis for Predicting Receptors Status and Ki-67 Levels in Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 526-533.	0.6	5
19405	Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
19406	Immunological role and prognostic value of SPARCL1 in pan-cancer analysis. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	0
19407	Immune landscape and immunotherapy for penile cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
19408	The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment. <i>Cardio-Oncology</i> , 2022, 8, .	0.8	8
19409	Tumor immunomodulatory effects of polyphenols. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
19410	Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14534.	1.8	3
19411	Comparison of <i>PIK3CA</i> Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations. <i>JCO Precision Oncology</i> , 2022, , .	1.5	3
19412	Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
19413	Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. <i>Life</i> , 2022, 12, 1990.	1.1	3
19414	Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2022, 11, 2192-2207.	1.3	1

#	ARTICLE	IF	CITATIONS
19415	Gallium-68â€“labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics. <i>Clinical Cancer Research</i> , 2023, 29, 581-591.	3.2	8
19416	Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
19417	Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy. <i>Vaccines</i> , 2022, 10, 2049.	2.1	0
19418	Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies. <i>Cancers</i> , 2022, 14, 5858.	1.7	2
19419	Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 â€“ 2020 - A population-based registry study from Norway. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19420	Nanoparticle-Delivered Transforming Growth Factor-Î²1 siRNA Induces PD-1 against Gastric Cancer by Transforming the Phenotype of the Tumor Immune Microenvironment. <i>Pharmaceutics</i> , 2022, 15, 1487.	1.7	2
19421	Feasibility of Intratumoral Anti-PD1 as Treatment of Human Basal Cell Carcinoma: An Explorative Study with Adjuvant Ablative Fractional Laser. <i>Cancers</i> , 2022, 14, 5815.	1.7	2
19422	Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19423	Photodynamic Opening of the Bloodâ€“Brain Barrier and the Meningeal Lymphatic System: The New Niche in Immunotherapy for Brain Tumors. <i>Pharmaceutics</i> , 2022, 14, 2612.	2.0	12
19424	Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	6
19425	Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 2606.	2.0	2
19426	How to Manage a Patient with Ocular Metastases?. <i>Biomedicines</i> , 2022, 10, 3044.	1.4	2
19427	Predictive biomarkers of colon cancer immunotherapy: Present and future. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	30
19428	Design and reporting of phase III oncology trials with prospective biomarker validation. <i>Journal of the National Cancer Institute</i> , 0, , .	3.0	1
19429	Differential Immunomodulatory Effects of Head and Neck Cancer-Derived Exosomes on B Cells in the Presence of ATP. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14446.	1.8	1
19430	Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1285-1300.	2.0	8
19431	Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19432	CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24

#	ARTICLE	IF	CITATIONS
19433	Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Cancers</i> , 2022, 14, 5931.	1.7	6
19434	Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma. <i>Cancers</i> , 2022, 14, 5676.	1.7	3
19435	Gallic acid suppresses the progression of triple-negative breast cancer HCC1806 cells via modulating PI3K/AKT/EGFR and MAPK signaling pathways. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
19436	High SURF4 expression is associated with poor prognosis of breast cancer. <i>Aging</i> , 2022, 14, 9317-9337.	1.4	4
19437	Expression of immune checkpoint molecules on adult and neonatal T-cells. <i>Immunologic Research</i> , 2023, 71, 185-196.	1.3	3
19438	Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients. <i>Cancers</i> , 2022, 14, 5751.	1.7	0
19439	Understanding and harnessing triple-negative breast cancer-related microbiota in oncology. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
19440	Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term "One Stop Therapeutic Shop". <i>OncoTargets and Therapy</i> , 0, Volume 15, 1409-1415.	1.0	2
19441	Initial clinical and experimental analyses of ALDOA in gastric cancer, as a novel prognostic biomarker and potential therapeutic target. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	1
19442	An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
19443	The predictive ability of routinely collected laboratory markers for surgically treated spinal metastases: a retrospective single institution study. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
19444	Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
19445	Effectiveness of Adjuvant Chemotherapy for elderly Patients with Triple-Negative Breast Cancer. <i>Bosnian Journal of Basic Medical Sciences</i> , 0, , .	0.6	0
19446	Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis. , 2022, 10, e005132.		2
19447	Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
19448	Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. , 2022, 10, e005517.		5
19449	PVR "A Prognostic Biomarker Correlated with Immune Cell Infiltration in Hepatocellular Carcinoma. <i>Diagnostics</i> , 2022, 12, 2953.	1.3	1
19450	Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France. <i>Current Oncology</i> , 2022, 29, 9255-9270.	0.9	1

#	ARTICLE	IF	CITATIONS
19451	Comprehensive evaluation of breast cancer immunotherapy and tumor microenvironment characterization based on interleukin genes-related risk model. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
19452	Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14937.	1.8	21
19453	Comprehensive multi-omics analysis of the m7G in pan-cancer from the perspective of predictive, preventive, and personalized medicine. <i>EPMA Journal</i> , 2022, 13, 671-697.	3.3	11
19454	A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1405-1415.	2.0	4
19455	Single-Cell Analysis in Lung Adenocarcinoma Implicates RNA Editing in Cancer Innate Immunity and Patient Prognosis. <i>Cancer Research</i> , 2023, 83, 374-385.	0.4	7
19456	Evaluation of tumor-infiltrating lymphocytes (TILs) in molecular subtypes of an Indian cohort of breast cancer patients. <i>Diagnostic Pathology</i> , 2022, 17, .	0.9	1
19457	A Review of the Role of Stereotactic Radiosurgery and Immunotherapy in the Management of Primary Central Nervous System Tumors. <i>Biomedicines</i> , 2022, 10, 2977.	1.4	2
19458	Therapeutic Antibodies in Cancer Treatment in the UK. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14589.	1.8	1
19459	Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review. <i>Rheumatology International</i> , 2023, 43, 559-565.	1.5	1
19460	Role of Immunotherapy in the Treatment of Triple-Negative Breast Cancer: A Literature Review. <i>Cureus</i> , 2022, , .	0.2	1
19461	Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
19462	Advances in the Lung Cancer Immunotherapy Approaches. <i>Vaccines</i> , 2022, 10, 1963.	2.1	6
19463	Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. <i>Nature Reviews Urology</i> , 2023, 20, 133-157.	1.9	46
19464	Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis. <i>Current Oncology</i> , 2022, 29, 9046-9065.	0.9	6
19465	Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
19466	Regulatory T Cells but Not Tumour-Infiltrating Lymphocytes Correlate with Tumour Invasion Depth in Basal Cell Carcinoma. <i>Diagnostics</i> , 2022, 12, 2987.	1.3	2
19467	Experimental in vitro, ex vivo and in vivo models in prostate cancer research. <i>Nature Reviews Urology</i> , 2023, 20, 158-178.	1.9	11
19468	Glomerular diseases after immune checkpoint inhibitors use: What do We know so far?. <i>Renal Failure</i> , 2022, 44, 2058-2067.	0.8	1

#	ARTICLE	IF	CITATIONS
19469	A tumor vasculature-based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors. <i>Science Advances</i> , 2022, 8, .	4.7	6
19470	Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer. <i>Current Issues in Molecular Biology</i> , 2022, 44, 5848-5865.	1.0	4
19471	Staging Breast Cancer with MRI, the T. A Key Role in the Neoadjuvant Setting. <i>Cancers</i> , 2022, 14, 5786.	1.7	8
19472	Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 5727.	1.7	9
19473	KrÄppel-like factor 4 regulates the cytolytic effector function of exhausted CD8 T cells. <i>Science Advances</i> , 2022, 8, .	4.7	7
19474	Systematic analysis of the expression profile and prognostic significance of m6A regulators and PD-L1 in hepatocellular carcinoma. <i>Discover Oncology</i> , 2022, 13, .	0.8	4
19475	Treating Biliary Tract Cancers: New Targets and Therapies. <i>Drugs</i> , 2022, 82, 1629-1647.	4.9	2
19476	Radiotherapy of the Primary Disease for Synchronous Metastatic Cancer: A Systematic Review. <i>Cancers</i> , 2022, 14, 5929.	1.7	4
19477	<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response. <i>Onc Immunology</i> , 2022, 11, .	2.1	10
19478	Involvement in the tumor-infiltrating CD8+ T cell expression by the initial disease of remnant gastric cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	0
19479	PD-L1 is associated with the prognosis of penile cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19480	Development of therapeutic antibodies for the treatment of diseases. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	19
19481	Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15006.	1.8	4
19482	Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity. <i>Nature Communications</i> , 2022, 13, .	5.8	15
19483	Histology-Agnostic Drugs: A Paradigm ShiftA Narrative Review. <i>Advances in Therapy</i> , 2023, 40, 1379-1392.	1.3	3
19484	Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers. <i>Cells</i> , 2022, 11, 3769.	1.8	2
19485	Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
19486	Bronchoalveolar Lavage Fluid-Isolated Biomarkers for the Diagnostic and Prognostic Assessment of Lung Cancer. <i>Diagnostics</i> , 2022, 12, 2949.	1.3	4

#	ARTICLE	IF	CITATIONS
19487	Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19488	Pan-Cancer Analysis Identifies Tumor Cell Surface Targets for CAR-T Cell Therapies and Antibody Drug Conjugates. <i>Cancers</i> , 2022, 14, 5674.	1.7	2
19489	Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer. <i>Cancers</i> , 2022, 14, 5678.	1.7	1
19490	Inactivation of LATS1/2 drives luminal-basal plasticity to initiate basal-like mammary carcinomas. <i>Nature Communications</i> , 2022, 13, .	5.8	5
19491	Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14496.	1.8	13
19492	Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy. <i>Cells</i> , 2022, 11, 3717.	1.8	5
19493	Choice of High-Throughput Proteomics Method Affects Data Integration with Transcriptomics and the Potential Use in Biomarker Discovery. <i>Cancers</i> , 2022, 14, 5761.	1.7	1
19494	Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGF β 2 and PD-1/PD-L1. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1187-1202.	1.9	1
19495	Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model. <i>Science Advances</i> , 2022, 8, .	4.7	8
19496	PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19497	Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment. <i>Cells</i> , 2022, 11, 3672.	1.8	15
19498	Camptothecin Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy. <i>Molecular Pharmaceutics</i> , 2022, 19, 4665-4674.	2.3	4
19499	MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors. <i>Cell Reports</i> , 2022, 41, 111704.	2.9	19
19500	Prognostic and Immunological Roles of Cell Cycle Regulator CDCA5 in Human Solid Tumors. <i>International Journal of General Medicine</i> , 0, Volume 15, 8257-8274.	0.8	0
19501	<sc>RASAL3</sc> predicts overall survival and <sc>CD8</sc> + T lymphocyte infiltration in lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 6056-6065.	1.6	1
19502	Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADORE study. <i>Oncolimmunology</i> , 2022, 11, .	2.1	9
19503	Preclinical Assessment of Immunogenicity and Protectivity of Novel ROR1 Fusion Proteins in a Mouse Tumor Model. <i>Cancers</i> , 2022, 14, 5827.	1.7	3
19504	Membrane Applications in Autologous Cell Therapy. <i>Membranes</i> , 2022, 12, 1182.	1.4	0

#	ARTICLE	IF	CITATIONS
19505	Imaging endpoints for clinical trial use: a RECIST perspective. , 2022, 10, e005092.		2
19506	Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer. Translational Lung Cancer Research, 2022, 11, 2170-2174.	1.3	0
19507	ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nature Communications, 2022, 13, .	5.8	20
19508	Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer. Cells, 2022, 11, 3841.	1.8	3
19509	Vemurafenib inhibits immune escape biomarker BCL2A1 by targeting PI3K/AKT signaling pathway to suppress breast cancer. Frontiers in Oncology, 0, 12, .	1.3	1
19510	The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target. Life, 2022, 12, 1992.	1.1	18
19511	Genomic alteration profile and <scp>PD&L1</scp> expression among different breast cancer subtypes in Chinese population and their correlations. Cancer Medicine, 0, , .	1.3	1
19512	Nonsurgical Treatment Strategies for Elderly Head and Neck Cancer Patients: An Emerging Subject Worldwide. Cancers, 2022, 14, 5689.	1.7	0
19513	Identification of immune cell function in breast cancer by integrating multiple single-cell data. Frontiers in Immunology, 0, 13, .	2.2	1
19514	The Role of the Microbiome on the Pathogenesis and Treatment of Colorectal Cancer. Cancers, 2022, 14, 5685.	1.7	11
19515	SIEVE: joint inference of single-nucleotide variants and cell phylogeny from single-cell DNA sequencing data. Genome Biology, 2022, 23, .	3.8	9
19516	The role of YAP1 in survival prediction, immune modulation, and drug response: A pan-cancer perspective. Frontiers in Immunology, 0, 13, .	2.2	8
19517	Effects of BRAF V600E and NRAS mutational status on the progression&free survival and clinicopathological characteristics of patients with melanoma. Oncology Letters, 2022, 25, .	0.8	9
19518	Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies. Frontiers in Immunology, 0, 13, .	2.2	2
19519	Inflammatory Ratios as Predictors for Tumor Invasiveness, Metastasis, Resectability and Early Postoperative Evolution in Gastric Cancer. Current Oncology, 2022, 29, 9242-9254.	0.9	3
19520	Prognostic value and immunological role of FOXM1 in human solid tumors. Aging, 2022, 14, 9128-9148.	1.4	4
19521	Genomic profiling and network-level understanding uncover the potential genes and the pathways in hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	7
19522	Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report. Journal of Medical Case Reports, 2022, 16, .	0.4	2

#	ARTICLE	IF	CITATIONS
19523	A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. <i>Nature Communications</i> , 2022, 13, .	5.8	18
19524	A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma. <i>IJU Case Reports</i> , 0, , .	0.1	0
19525	The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy. <i>Cancers</i> , 2022, 14, 5845.	1.7	3
19526	A Comparison of Patientsâ€™ and Physiciansâ€™ Knowledge and Expectations Regarding Precision Oncology Tests. <i>Current Oncology</i> , 2022, 29, 9916-9927.	0.9	1
19527	A pan-cancer analysis of the FAT1 in human tumors. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
19528	Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
19529	Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation. , 2022, 10, e005615.		18
19530	Diaphanous-related formin subfamily: Novel prognostic biomarkers and tumor microenvironment regulators for pancreatic adenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	0
19531	Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
19532	The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	6
19533	Imaging of Activated T Cells. <i>Journal of Nuclear Medicine</i> , 2023, 64, 30-33.	2.8	1
19534	Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer. <i>British Journal of Cancer</i> , 0, , .	2.9	0
19535	Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
19536	Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	1
19537	Integrated investigation of the prognostic role of HLA LOH in advanced lung cancer patients with immunotherapy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
19538	Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
19539	SETD7 Expression Is Associated with Breast Cancer Survival Outcomes for Specific Molecular Subtypes: A Systematic Analysis of Publicly Available Datasets. <i>Cancers</i> , 2022, 14, 6029.	1.7	2
19540	Acetylcholine receptor binding antibodyâ€™ associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
19541	Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
19542	<i>ACTA2</i> Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1077-1085.	3.2	9
19543	Prognostic value of CD8 ⁺ tumor-infiltrating T cells in patients with breast cancer: A systematic review and meta-analysis. <i>Oncology Letters</i> , 2022, 25, .	0.8	7
19544	Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profiling. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
19545	3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15650.	1.8	4
19546	Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors. <i>Cancers</i> , 2022, 14, 6095.	1.7	8
19547	Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. <i>Nature Communications</i> , 2022, 13, .	5.8	5
19548	Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15720.	1.8	13
19549	A Novel Gene Signature Associated with Inflammatory Responses and Immune Status Assists in Prognosis and Intervention for Patients with HCC. <i>Journal of Inflammation Research</i> , 0, Volume 15, 6729-6743.	1.6	6
19550	Clinical Implications of APOBEC3-Mediated Mutagenesis in Breast Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1658-1669.	3.2	4
19551	The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients. <i>Diagnostics</i> , 2022, 12, 3042.	1.3	14
19552	PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
19553	Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors? A Systematic Review of the Literature. <i>Current Oncology</i> , 2022, 29, 9428-9436.	0.9	4
19554	Ethnic and racial-specific differences in levels of centrosome-associated mitotic kinases, proliferative and epithelial-to-mesenchymal markers in breast cancers. <i>Cell Division</i> , 2022, 17, .	1.1	0
19555	Reproducible and opposing gut microbiome signatures distinguish autoimmune diseases and cancers: a systematic review and meta-analysis. <i>Microbiome</i> , 2022, 10, .	4.9	8
19556	Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers. <i>Clinical Cancer Research</i> , 2023, 29, 921-929.	3.2	2
19557	Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19558	Study of epirubicin sustained-release chemoablation in tumor suppression and tumor microenvironment remodeling. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
19559	An Approach for Systems-Level Understanding of Prostate Cancer from High-Throughput Data Integration to Pathway Modeling and Simulation. <i>Cells</i> , 2022, 11, 4121.	1.8	7
19560	Prognostic value of TMEM59L and its genomic and immunological characteristics in cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
19561	Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. , 2022, 10, e005224.		3
19562	Checkpoint inhibitors are a basic scienceâ€based, transformative new treatment for lung cancer. <i>Respirology</i> , 2023, 28, 101-106.	1.3	2
19563	Transcriptomic panâ€cancer analysis using rankâ€based Bayesian inference. <i>Molecular Oncology</i> , 2023, 17, 548-563.	2.1	0
19564	Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	12
19565	Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer. , 2022, 10, e005436.		3
19566	MicroRNAs within the Basal-like signature of Quadruple Negative Breast Cancer impact overall survival in African Americans. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
19567	Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
19568	Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study. <i>MABs</i> , 2023, 15, .	2.6	1
19569	Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
19570	Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, Angiogenesis Inhibition, and Autophagy Modulation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16091.	1.8	21
19571	What Are the Roles of Proprotein Convertases in the Immune Escape of Tumors?. <i>Biomedicines</i> , 2022, 10, 3292.	1.4	5
19572	Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
19573	Manipulation of PDâ€L1 Endosomal Trafficking Promotes Anticancer Immunity. <i>Advanced Science</i> , 2023, 10, .	5.6	6
19574	Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
19575	Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. <i>Angiogenesis</i> , 2023, 26, 279-293.	3.7	12
19576	A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer. <i>European Radiology</i> , 2023, 33, 3918-3930.	2.3	6

#	ARTICLE	IF	CITATIONS
19577	A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
19578	Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
19579	Succinate at the Crossroad of Metabolism and Angiogenesis: Roles of SDH, HIF1 α and SUCNR1. <i>Biomedicines</i> , 2022, 10, 3089.	1.4	4
19580	The Interplay of Lung Cancer, COVID-19, and Vaccines. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15067.	1.8	2
19581	Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
19582	circAR-E2E4-miR-665-STAT3 axis is a potential regulatory network in triple-negative breast cancer. <i>Heliyon</i> , 2023, 9, e12654.	1.4	2
19583	Metformin Inducing the Change of Functional and Exhausted Phenotypic Tumor-Infiltrated Lymphocytes and the Correlation with JNK Signal Pathway in Triple-Negative Breast Cancer. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 391-403.	1.0	1
19584	TGF- β : A novel predictor and target for anti-PD-1/PD-L1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	22
19585	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. <i>International Journal of Molecular Sciences</i> , 2023, 24, 41.	1.8	6
19586	Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response. <i>Science Advances</i> , 2022, 8, .	4.7	3
19587	Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors. <i>Cancer Communications</i> , 2023, 43, 214-224.	3.7	5
19588	The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. <i>Cancer Discovery</i> , 2023, 13, 23-40.	7.7	35
19589	Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15384.	1.8	12
19590	Analysis of prognostic model based on immunotherapy related genes in lung adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
19591	NARF is a hypoxia-induced coactivator for OCT4-mediated breast cancer stem cell specification. <i>Science Advances</i> , 2022, 8, .	4.7	6
19592	CHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4/B7 axis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
19593	Racial/Ethnic Differences Among Tumor-Infiltrating Lymphocytes in Breast Cancer Tumors. <i>Oncologist</i> , 2023, 28, 116-122.	1.9	4
19594	Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
19595	Comprehensive analysis of alternative splicing signatures in pancreatic head cancer. <i>IET Systems Biology</i> , 0, .	0.8	1
19596	Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
19597	Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression. <i>Oncotarget</i> , 2022, 13, 1350-1358.	0.8	0
19598	HER3 Alterations in Cancer and Potential Clinical Implications. <i>Cancers</i> , 2022, 14, 6174.	1.7	4
19599	LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice. <i>JACC: CardioOncology</i> , 2022, 4, 635-645.	1.7	4
19600	Cancer Immunotherapy Beyond Checkpoint Blockade. <i>JACC: CardioOncology</i> , 2022, 4, 563-578.	1.7	1
19601	Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles. <i>Human Genomics</i> , 2022, 16, .	1.4	2
19602	Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19603	Immune Checkpoint Inhibitor Therapy in Oncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	1.7	25
19604	Artificial Intelligence and Advanced Melanoma: Treatment Management Implications. <i>Cells</i> , 2022, 11, 3965.	1.8	7
19605	Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. <i>Cancer Cell International</i> , 2022, 22, .	1.8	3
19606	A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 156.	1.8	4
19607	Local therapy treatment conditions for oligometastatic non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19608	Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society. <i>Endocrinology and Metabolism</i> , 2022, 37, 839-850.	1.3	3
19609	New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2023, 25, 1252-1267.	1.2	5
19610	HS3ST3A1 and CAPN8 Serve as Immune-Related Biomarkers for Predicting the Prognosis in Thyroid Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	2
19611	Fecal Microbiota Transplant in Immunotherapy-Resistant Melanoma: What Can We Expect in the Near Future?. <i>Cureus</i> , 2022, .	0.2	2
19612	Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2023, 14, 442-449.	0.8	5

#	ARTICLE	IF	CITATIONS
19613	Comprehensive analysis of cuproptosis-related long non-coding RNA signature and personalized therapeutic strategy of breast cancer patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
19614	EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. <i>Science Advances</i> , 2022, 8, .	4.7	14
19615	Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 746-762.	0.5	0
19616	SP140 inhibits STAT1 signaling, induces IFN- γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response. , 2022, 10, e005088.		2
19617	New Insights into the Phenotype Switching of Melanoma. <i>Cancers</i> , 2022, 14, 6118.	1.7	7
19618	Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
19619	Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer. <i>Cancers</i> , 2023, 15, 104.	1.7	14
19620	Early circulating tumor <scp>DNA</scp> dynamics as a panâ€tumor biomarker for longâ€term clinical outcome in patients treated with durvalumab and tremelimumab. <i>Molecular Oncology</i> , 2023, 17, 298-311.	2.1	7
19621	Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 7176.	1.0	0
19622	Tertiary Lymphoid Structures: A Potential Biomarker for Anti-Cancer Therapy. <i>Cancers</i> , 2022, 14, 5968.	1.7	3
19623	Network-based approaches for modeling disease regulation and progression. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 780-795.	1.9	10
19624	Nextâ€generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction. <i>Histopathology</i> , 2023, 82, 162-169.	1.6	2
19625	Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models. <i>Cancers</i> , 2022, 14, 6146.	1.7	3
19626	Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	3
19627	Integrated molecular analyses of an interferon- γ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification. <i>Heliyon</i> , 2022, 8, e12102.	1.4	0
19628	Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
19629	Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
19630	Primary esophageal malignant melanoma without recurrence after surgery and adjuvant therapy with nivolumab. <i>International Cancer Conference Journal</i> , 0, , .	0.2	1

#	ARTICLE	IF	CITATIONS
19631	Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1541-1551.	2.0	4
19632	In vivo genome-wide CRISPR screening identifies ZNF24 as a negative NF- κ B modulator in lung cancer. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	2
19633	The BRCAness Landscape of Cancer. <i>Cells</i> , 2022, 11, 3877.	1.8	5
19634	The Emerging Role of NK Cells in Immune Checkpoint Blockade. <i>Cancers</i> , 2022, 14, 6005.	1.7	1
19635	Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
19636	Disruption of CISH promotes the antitumor activity of human T \hat{A} cells and decreases PD-1 expression levels. <i>Molecular Therapy - Oncolytics</i> , 2023, 28, 46-58.	2.0	7
19637	Prognostic pyroptosis-related lncRNA signature predicts the efficacy of immunotherapy in hepatocellular carcinoma. <i>Biochemistry and Biophysics Reports</i> , 2022, 32, 101389.	0.7	2
19638	A Novel Cuproptosis-Related Prognostic Model and the Hub Gene FDX1 Predict the Prognosis and Correlate with Immune Infiltration in Clear Cell Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-19.	0.6	1
19639	A prognostic model and immune regulation analysis of uterine corpus endometrial carcinoma based on cellular senescence. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
19640	Exosomal LINC00460/miR-503-5p/ANLN positive feedback loop aggravates pancreatic cancer progression through regulating T cell-mediated cytotoxicity and PD-1 checkpoint. <i>Cancer Cell International</i> , 2022, 22, .	1.8	8
19641	Neoadjuvant immunotherapy for resectable esophageal cancer: A review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
19642	Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
19643	Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution. <i>Genome Medicine</i> , 2022, 14, .	3.6	15
19644	Genetic landscape and personalized tracking of tumor mutations in Vietnamese women with breast cancer. <i>Molecular Oncology</i> , 2023, 17, 598-610.	2.1	3
19645	CD5L-associated gene analyses highlight the dysregulations, prognostic effects, immune associations, and drug-sensitivity predicative potentials of LCAT and CDC20 in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2022, 22, .	1.8	4
19646	A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHolangiocarcinoma (NATCHO). <i>BMC Cancer</i> , 2022, 22, .	1.1	1
19647	Implications of Possible HBV-Driven Regulation of Gene Expression in Stem Cell-like Subpopulation of Huh-7 Hepatocellular Carcinoma Cell Line. <i>Journal of Personalized Medicine</i> , 2022, 12, 2065.	1.1	1
19648	Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of \hat{I}^3 H2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases. <i>BMC Cancer</i> , 2022, 22, .	1.1	1

#	ARTICLE	IF	CITATIONS
19649	Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Nonâ€“Small Cell Lung Cancer With High Tumor Mutation Burden. <i>JAMA Oncology</i> , 2023, 9, 344.	3.4	13
19650	Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC. <i>Molecular Cancer Research</i> , 2023, 21, 374-385.	1.5	0
19651	Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
19652	Protocol for mathematical prediction of patient response and survival to immune checkpoint inhibitor immunotherapy. <i>STAR Protocols</i> , 2022, 3, 101886.	0.5	0
19653	Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence. <i>Cell Reports</i> , 2022, 41, 111756.	2.9	3
19654	Identification of an Immune-Related Gene Signature Associated with Prognosis and Tumor Microenvironment in Esophageal Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-22.	0.9	3
19655	Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy. <i>Cancer Research Communications</i> , 2023, 3, 119-129.	0.7	3
19656	Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone. <i>Cancers</i> , 2023, 15, 48.	1.7	4
19657	Estimated Costs of the Ipilimumabâ€“Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. <i>Cancers</i> , 2023, 15, 31.	1.7	1
19658	Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics. <i>Cancers</i> , 2023, 15, 82.	1.7	5
19659	Chemotherapy: A partnership with immunotherapy in n<sc>onâ€“small</sc> cell lung cancer. <i>Thoracic Cancer</i> , 2023, 14, 437-441.	0.8	4
19660	Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes. <i>International Journal of Molecular Sciences</i> , 2023, 24, 207.	1.8	1
19661	Lasp1 Expression Is Implicated in Embryonic Development of Zebrafish. <i>Genes</i> , 2023, 14, 35.	1.0	2
19662	Lipid Metabolism Heterogeneity and Crosstalk with Mitochondria Functions Drive Breast Cancer Progression and Drug Resistance. <i>Cancers</i> , 2022, 14, 6267.	1.7	6
19663	Approach to the Patient With Immune Checkpoint Inhibitorâ€“Associated Endocrine Dysfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 1514-1525.	1.8	8
19664	Distinct niche structures and intrinsic programs of fallopian tube and ovarian surface epithelial cells. <i>IScience</i> , 2023, 26, 105861.	1.9	3
19665	Chimeric antigen receptor T-cell therapy for multiple myeloma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
19666	An integrated analysis of the cancer genome atlas data discovers a hierarchical association structure across thirty three cancer types. , 2022, 1, e0000151.		0

#	ARTICLE	IF	CITATIONS
19667	Somatic A-to-G RNA-edited RHOA isoform 2 specific C176G mutation promotes tumor progression in lung adenocarcinoma. <i>Molecular Carcinogenesis</i> , 0, , .	1.3	1
19668	The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	12
19669	Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
19670	Prediction of prognosis and immunotherapy response of amino acid metabolism genes in acute myeloid leukemia. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	3
19671	Multi-omics characteristics and immunotherapeutic potential of EZH2 in pan-cancer. <i>Bioscience Reports</i> , 0, , .	1.1	2
19672	Overexpression of HMGB3 and its prognostic value in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
19673	Immune-related adverse events: A bibliometric analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
19674	Sensitive and quantitative in vivo analysis of PD-L1 using magnetic particle imaging and imaging-guided immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1291-1305.	3.3	5
19675	Genetic variants in African-American and Hispanic patients with breast cancer. <i>Oncology Letters</i> , 2022, 25, .	0.8	0
19676	Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19677	Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 6034.	1.7	6
19678	The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. <i>Biomedicines</i> , 2022, 10, 3154.	1.4	4
19679	CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1479-1492.	2.0	9
19680	Behavioral factors to modulate immunotherapy efficacy in cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
19681	Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
19682	Hereditary Diffuse Gastric Cancer: A 2022 Update. <i>Journal of Personalized Medicine</i> , 2022, 12, 2032.	1.1	1
19683	The Microbiome in PDAC—Vantage Point for Future Therapies?. <i>Cancers</i> , 2022, 14, 5974.	1.7	5
19684	Notch signaling pathway: a comprehensive prognostic and gene expression profile analysis in breast cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	10

#	ARTICLE	IF	CITATIONS
19685	Multiparametric and accurate functional analysis of genetic sequence variants using CRISPR-Select. <i>Nature Genetics</i> , 2022, 54, 1983-1993.	9.4	7
19686	Prognostic significance of tumor-infiltrating lymphocytes in predicting outcome of distal cholangiocarcinoma in Thailand. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
19687	Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo. <i>Clinical and Translational Oncology</i> , 2023, 25, 1067-1079.	1.2	4
19688	AKTIP loss is enriched in ER \pm -positive breast cancer for tumorigenesis and confers endocrine resistance. <i>Cell Reports</i> , 2022, 41, 111821.	2.9	2
19689	Current status and challenges of immunotherapy in ALK rearranged NSCLC. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
19690	Case report: Eosinophilic fasciitis induced by pembrolizumab with high FDG uptake on 18F-FDG-PET/CT. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
19691	Circ_0000052/ \langle scp \rangle miR \langle /scp \rangle axis induces \langle scp \rangle PD \langle L1 \rangle / \langle /scp \rangle expression and regulates cell proliferation and immune evasion in head and neck squamous cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2023, 27, 113-126.	1.6	7
19692	Glucose metabolism and tumour microenvironment in pancreatic cancer: A key link in cancer progression. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
19693	Advances in Single-Cell Sequencing Technology and Its Applications in Triple-Negative Breast Cancer. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 465-474.	1.0	1
19694	Novel treatment paradigms for metastatic uveal melanoma. <i>Cancer Gene Therapy</i> , 2022, 29, 1807-1808.	2.2	0
19695	MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors. <i>ESMO Open</i> , 2022, 7, 100646.	2.0	7
19696	Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends. <i>Cancers</i> , 2023, 15, 51.	1.7	6
19697	Incorporating RNA-based Risk Scores for Genomic Instability to Predict Breast Cancer Recurrence and Immunogenicity in a Diverse Population. <i>Cancer Research Communications</i> , 2023, 3, 12-20.	0.7	1
19698	Artificial intelligence in breast cancer imaging: risk stratification, lesion detection and classification, treatment planning and prognosis—a narrative review. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 795-816.	0.5	4
19699	A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma. <i>Heliyon</i> , 2022, 8, e12648.	1.4	0
19700	Anti-TGF- β 2/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. , 2022, 10, e005543.		53
19701	Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-50.	1.9	9
19702	Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15163.	1.8	4

#	ARTICLE	IF	CITATIONS
19703	Post-Translational Modification of ZEB Family Members in Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15127.	1.8	6
19704	SPATA2 and CYLD inhibit T cell infiltration into colorectal cancer via regulation of IFN- γ /STAT1 axis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
19705	Increased expression of ECT2 predicts the poor prognosis of breast cancer patients. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	7
19706	HER2 classification in breast cancer cells: A new explainable machine learning application for immunohistochemistry. <i>Oncology Letters</i> , 2022, 25, .	0.8	3
19707	Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach. <i>Diagnostics</i> , 2022, 12, 3157.	1.3	6
19708	Development of ⁸⁹ Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration. , 2022, 10, e004877.		2
19709	Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. <i>Cell Reports Medicine</i> , 2023, 4, 100868.	3.3	16
19710	Monitoring PD-L1 Expression on Circulating Tumor-Associated Cells in Recurrent Metastatic Non-Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	10
19711	Klatskin Tumor: A Survival Analysis According to Tumor Characteristics and Inflammatory Ratios. <i>Medicina (Lithuania)</i> , 2022, 58, 1788.	0.8	0
19712	Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
19713	Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. <i>Cancers</i> , 2022, 14, 6145.	1.7	10
19714	Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade. <i>Cancers</i> , 2022, 14, 6150.	1.7	3
19715	Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. <i>JAMA Oncology</i> , 2023, 9, 102.	3.4	11
19716	Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors. <i>PeerJ</i> , 0, 10, e14566.	0.9	1
19717	Immune-based combination therapy for esophageal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
19718	Construction of novel hypoxia-related gene model for prognosis and tumor microenvironment in endometrial carcinoma. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
19719	Rhèndostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study. <i>Cancer Medicine</i> , 2023, 12, 7724-7733.	1.3	7
19720	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	46

#	ARTICLE	IF	CITATIONS
19721	Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes. <i>Biomedicines</i> , 2022, 10, 3196.	1.4	6
19722	Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. <i>British Journal of Cancer</i> , 2023, 128, 1196-1207.	2.9	28
19723	Gaseous nitric oxide tumor ablation induces an anti-tumor abscopal effect. <i>Cancer Cell International</i> , 2022, 22, .	1.8	1
19724	Cognitive assessment in patients treated by immunotherapy: the prospective Cog-Immuno trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
19725	High PPFIA1 expression promotes cancer survival by suppressing CD8+T cells in breast cancer: drug discovery and machine learning approach. <i>Breast Cancer</i> , 2023, 30, 259-270.	1.3	2
19726	Analysis of scRNA-seq and bulk RNA-seq demonstrates the effects of EVI2B or CD361 on CD8 ⁺ T cells in osteosarcoma. <i>Experimental Biology and Medicine</i> , 2023, 248, 130-145.	1.1	1
19727	Toward Establishing an Ideal Adjuvant for Non-Inflammatory Immune Enhancement. <i>Cells</i> , 2022, 11, 4006.	1.8	4
19728	Zinc-finger Protein CXXC5 Promotes Breast Carcinogenesis by Regulating the TSC1/mTOR Signaling Pathway. <i>Journal of Biological Chemistry</i> , 2022, , 102812.	1.6	0
19729	Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer. <i>MAbs</i> , 2023, 15, .	2.6	0
19730	Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
19731	Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives. <i>Molecular Biology Reports</i> , 0, , .	1.0	0
19732	Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	0
19733	PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	36
19734	Construction of a metabolism-related gene prognostic model to predict survival of pancreatic cancer patients. <i>Heliyon</i> , 2023, 9, e12378.	1.4	0
19735	Targeting the EGF receptor family in non-small cell lung cancerâ€”increased complexity and future perspectives. <i>Cancer Biology and Medicine</i> , 2022, 19, 1543-1564.	1.4	12
19736	Immune related biomarkers for cancer metastasis to the brain. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	0
19737	Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirusâ€”Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2023, 29, 560-570.	3.2	11
19738	Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. <i>Journal of Clinical Oncology</i> , 2023, 41, 2166-2180.	0.8	32

#	ARTICLE	IF	CITATIONS
19739	Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	1
19740	Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2023, 41, 1735-1746.	0.8	19
19741	Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019. <i>JAMA Network Open</i> , 2022, 5, e2245269.	2.8	19
19742	T-cell repertoire diversity: friend or foe for protective antitumor response?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	11
19743	Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
19744	Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations. <i>ESMO Open</i> , 2022, 7, 100641.	2.0	7
19745	ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	0
19746	The Effect of Oxidative Phosphorylation on Cancer Drug Resistance. <i>Cancers</i> , 2023, 15, 62.	1.7	17
19747	Impact of lymphopenia on efficacy of nivolumab in head and neck cancer patients. <i>European Archives of Oto-Rhino-Laryngology</i> , 2023, 280, 2453-2461.	0.8	3
19748	SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	0
19749	Blockade of store-operated calcium entry sensitizes breast cancer cells to cisplatin therapy via modulating inflammatory response. <i>Saudi Pharmaceutical Journal</i> , 2023, 31, 245-254.	1.2	3
19750	Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. <i>Cancer Cell</i> , 2022, 40, 1600-1618.e10.	7.7	40
19751	Definition of a novel breast tumor-specific classifier based on secretome analysis. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	2
19752	Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. <i>Nature Cancer</i> , 2022, 3, 1513-1533.	5.7	20
19753	In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
19754	VLA-4 suppression by senescence signals regulates meningeal immunity and leptomeningeal metastasis. <i>ELife</i> , 0, 11, .	2.8	1
19755	Melanogenesis and the Targeted Therapy of Melanoma. <i>Biomolecules</i> , 2022, 12, 1874.	1.8	9
19756	Regulatory Fibroblast-Like Synoviocytes Cell Membrane Coated Nanoparticles: A Novel Targeted Therapy for Rheumatoid Arthritis. <i>Advanced Science</i> , 2023, 10, .	5.6	11

#	ARTICLE	IF	CITATIONS
19757	The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study. <i>Cancers</i> , 2022, 14, 6184.	1.7	3
19758	CD73 Inhibits cGAS-“STING and Cooperates with CD39 to Promote Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2023, 11, 56-71.	1.6	20
19759	TYK2 correlates with immune infiltration: A prognostic marker for head and neck squamous cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
19760	Influences of intratumoral heterogeneity on assessment of tumor microenvironment in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 0, , .	1.7	1
19761	Viral delivery of a peptide-based immunomodulator enhances T cell priming during vaccination. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
19762	Tumor Cell-Intrinsic BTLA Receptor Inhibits the Proliferation of Tumor Cells via ERK1/2. <i>Cells</i> , 2022, 11, 4021.	1.8	5
19763	IMP1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
19764	Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of MSH6: A case report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
19765	Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer. <i>Biomedicines</i> , 2022, 10, 3262.	1.4	2
19766	A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma. <i>Medicina (Lithuania)</i> , 2023, 59, 23.	0.8	1
19767	Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 4269-4277.	2.0	4
19768	Design of a self-driven probiotic-CRISPR/Cas9 nanosystem for sono-immunometabolic cancer therapy. <i>Nature Communications</i> , 2022, 13, .	5.8	16
19769	Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5429-5436.	1.2	2
19770	A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. <i>ESMO Open</i> , 2022, 7, 100639.	2.0	21
19772	The FDA-Approved Drug Pyrvinium Selectively Targets ER+ Breast Cancer Cells with High INPP4B Expression. <i>Cancers</i> , 2023, 15, 135.	1.7	3
19773	Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	2
19774	Non-small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
19775	The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
19776	Genetic Engineering of Immune Evasive Stem Cell-Derived Islets. <i>Transplant International</i> , 0, 35, .	0.8	5
19777	Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	6
19779	Pancreatic Cancer Cells Undergo Immunogenic Cell Death upon Exposure to Gas Plasma-Oxidized Ringers Lactate. <i>Cancers</i> , 2023, 15, 319.	1.7	4
19780	Radiopharmaceuticals heat anti-tumor immunity. <i>Theranostics</i> , 2023, 13, 767-786.	4.6	4
19781	Current Targeted Therapy for Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1702.	1.8	22
19782	Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382211452.	0.8	6
19783	Coding roles of long non-coding RNAs in breast cancer: Emerging molecular diagnostic biomarkers and potential therapeutic targets with special reference to chemotherapy resistance. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
19784	Expression of Three Clones of PD-L1 in Lung Cancer: A Single-center Experience. <i>In Vivo</i> , 2023, 37, 233-241.	0.6	1
19785	Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens. <i>Nature Genetics</i> , 2023, 55, 19-25.	9.4	11
19786	Opportunities and Obstacles to the Development of Health Data Warehouses in Hospitals in France: The Recent Experience of Comprehensive Cancer Centers. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 1645.	1.2	0
19787	<i>P. gingivalis</i> Infection Upregulates PD-L1 Expression on Dendritic Cells, Suppresses CD8+ T-cell Responses, and Aggravates Oral Cancer. <i>Cancer Immunology Research</i> , 2023, 11, 290-305.	1.6	3
19788	Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
19789	Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19790	Advances in immunotherapy modalities for atherosclerosis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
19791	Novel immune-related prognostic model and nomogram for breast cancer based on ssGSEA. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
19792	Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood. <i>Immunotherapy Advances</i> , 2023, 3, .	1.2	3
19793	Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review. <i>Vaccines</i> , 2023, 11, 146.	2.1	14
19794	Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2023, .	0.6	1

#	ARTICLE	IF	CITATIONS
19795	Traditional Herbal Medicine: A Potential Therapeutic Approach for Adjuvant Treatment of Non-small Cell Lung Cancer in the Future. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542211443.	0.8	6
19796	Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination. , 2023, 11, e005463.		2
19797	Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. <i>Cell Research</i> , 2023, 33, 215-228.	5.7	14
19798	Breast cancer heterogeneity and its implication in personalized precision therapy. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	31
19799	Releasing the restraints of V β 9V γ 2 T-cells in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
19800	Immunotherapy Assessment: A New Paradigm for Radiologists. <i>Diagnostics</i> , 2023, 13, 302.	1.3	1
19801	Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
19802	Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
19803	⁶⁸ Ga-HBED-CC-WL-12 PET in Diagnosing and Differentiating Pancreatic Cancers in Murine Models. <i>Pharmaceuticals</i> , 2023, 16, 80.	1.7	3
19804	<scp>CD47</scp> and <scp>CD68</scp> expression in breast cancer is associated with tumorâ€infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis. <i>Journal of Pathology: Clinical Research</i> , 2023, 9, 151-164.	1.3	0
19805	Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus. <i>Journal of Virology</i> , 2023, 97, .	1.5	1
19806	PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent nonâ€muscleâ€invasive bladder cancer. <i>BJUI Compass</i> , 2023, 4, 322-330.	0.7	3
19807	Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	14
19808	Drastic transformation of visceral adipose tissue and peripheral CD4 T cells in obesity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
19809	Editorial: Modulation of the immune system by bacteria: From evasion to therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
19810	Effects of lymphopenia on survival in proton therapy with chemotherapy for non-small cell lung cancer. <i>Journal of Radiation Research</i> , 2023, 64, 438-447.	0.8	0
19811	Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers. <i>Cancers</i> , 2023, 15, 403.	1.7	3
19812	Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
19813	Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. <i>IScience</i> , 2023, 26, 105799.	1.9	12
19814	Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
19815	Association of <i>KMT2C/D</i> loss-of-function variants with response to immune checkpoint blockades in colorectal cancer. <i>Cancer Science</i> , 2023, 114, 1229-1239.	1.7	10
19816	Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1280.	1.8	5
19817	The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma. <i>Journal of Ovarian Research</i> , 2023, 16, .	1.3	1
19818	Harnessing the immune system in the treatment of cutaneous T cell lymphomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19819	PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	8
19820	Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1365-1379.	2.0	93
19821	Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy. <i>Biomedicines</i> , 2023, 11, 169.	1.4	0
19822	Pembrolizumab-induced encephalitis in a patient with renal cell carcinoma post nephrectomy: A case report. <i>SAGE Open Medical Case Reports</i> , 2023, 11, 2050313X2211498.	0.2	1
19823	Partners in crime: The feedback loop between metabolic reprogramming and immune checkpoints in the tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19824	IGF2: A Role in Metastasis and Tumor Evasion from Immune Surveillance?. <i>Biomedicines</i> , 2023, 11, 229.	1.4	10
19825	Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies. <i>Biomedicines</i> , 2023, 11, 238.	1.4	2
19826	Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer. <i>Cancers</i> , 2023, 15, 563.	1.7	2
19827	Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors. <i>Cell Reports Medicine</i> , 2023, 4, 100900.	3.3	10
19828	Neoadjuvant treatment for stage III and IV cutaneous melanoma. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	1
19829	Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. <i>Cancers</i> , 2023, 15, 543.	1.7	8
19830	<i>Poria cocos</i> polysaccharide-functionalized graphene oxide nanosheet induces efficient cancer immunotherapy in mice. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	1

#	ARTICLE	IF	CITATIONS
19831	PD-L1 expression and CD8 positive lymphocytes in human neoplasms: A tissue microarray study on 11,838 tumor samples. <i>Cancer Biomarkers</i> , 2023, 36, 177-191.	0.8	3
19832	The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study. <i>Annals of Translational Medicine</i> , 2023, 11, 45-45.	0.7	2
19833	Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
19834	Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
19835	Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	13
19836	Functional impact of multi-omic interactions in breast cancer subtypes. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
19837	The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
19838	Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	3
19839	Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
19840	Mining TCGA Database for Genes with Prognostic Value in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1622.	1.8	2
19841	Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. <i>Cancers</i> , 2023, 15, 321.	1.7	21
19842	Editorial: Impact of tumor microenvironment on lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
19843	Cannabinoid receptor 2 plays a pro-tumorigenic role in non-small cell lung cancer by limiting anti-tumor activity of CD8+ T and NK cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
19844	PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies. <i>Breast Cancer Research</i> , 2023, 25, .	2.2	4
19845	Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1671-1688.	3.3	2
19846	Progress in the application of hydrogels in immunotherapy of gastrointestinal tumors. <i>Drug Delivery</i> , 2023, 30, .	2.5	5
19847	Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. <i>Biomedicines</i> , 2023, 11, 109.	1.4	18
19848	Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patients with Locally Advanced Nonâ€“Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab. <i>JAMA Network Open</i> , 2023, 6, e2249591.	2.8	6

#	ARTICLE	IF	CITATIONS
19849	Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer. <i>Cureus</i> , 2023, , .	0.2	1
19850	Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies. <i>Frontiers in Veterinary Science</i> , 0, 9, .	0.9	4
19851	Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19852	A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancers</i> , 2023, 15, 329.	1.7	8
19853	Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma. <i>International Urology and Nephrology</i> , 2023, 55, 867-874.	0.6	1
19854	Study of the clinicopathological features of soluble PD-L1 in lung cancer patients. <i>Journal of Rural Medicine: JRM</i> , 2023, 18, 42-49.	0.2	0
19855	Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19856	The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1506.	1.8	2
19857	Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis. , 2023, 11, e005801.		10
19858	Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
19859	Immunohistochemical HER2 Recognition and Analysis of Breast Cancer Based on Deep Learning. <i>Diagnostics</i> , 2023, 13, 263.	1.3	3
19860	Caspase-8 contributes to an immuno-hot microenvironment by promoting phagocytosis via an ecto-calreticulin-dependent mechanism. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	0
19861	Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	13
19862	Aberrant promoter hypermethylation of miR-335 and miR-145 is involved in breast cancer PD-L1 overexpression. <i>Scientific Reports</i> , 2023, 13, .	1.6	7
19863	Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. <i>Cancer Cell International</i> , 2023, 23, .	1.8	5
19864	At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 143-159.	12.5	29
19865	Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
19866	Molecular Alterations and Putative Therapeutic Targeting of Planar Cell Polarity Proteins in Breast Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 411.	1.0	2

#	ARTICLE	IF	CITATIONS
19867	Identification of a tissue resident memory CD8 T cell-related risk score signature for colorectal cancer, the association with TME landscapes and therapeutic responses. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
19868	Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. <i>Cancer Discovery</i> , 2023, 13, 654-671.	7.7	15
19869	STARD3: A New Biomarker in HER2-Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 362.	1.7	5
19870	Comprehensive analysis of immune-related lncRNAs and their clinical relevance in gastric adenocarcinoma. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	2
19871	Advances in artificial intelligence to predict cancer immunotherapy efficacy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	23
19872	Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow-Derived Macrophages. <i>Cancer Research</i> , 2023, 83, 771-785.	0.4	6
19873	Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma. <i>Pharmaceuticals</i> , 2023, 16, 102.	1.7	0
19874	Cellular mitophagy: Mechanism, roles in diseases and small molecule pharmacological regulation. <i>Theranostics</i> , 2023, 13, 736-766.	4.6	43
19875	Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
19876	Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
19877	Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
19878	Research landscape and trends of melanoma immunotherapy: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
19879	Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1601.	1.8	13
19880	Narrative review: blood and tumor biomarker testing in non-small cell lung cancer without an oncogenic driver. <i>Translational Lung Cancer Research</i> , 2023, 12, 158-167.	1.3	2
19881	DNA methylation-based patterns for early diagnostic prediction and prognostic evaluation in colorectal cancer patients with high tumor mutation burden. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
19882	Mapping the interplay between NK cells and HIV: therapeutic implications. <i>Journal of Leukocyte Biology</i> , 2023, 113, 109-138.	1.5	1
19883	Extracellular Vesicles Are Important Mediators That Regulate Tumor Lymph Node Metastasis via the Immune System. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1362.	1.8	3
19884	Anti-colorectal cancer of <i>Ardisia gigantifolia</i> Stapf. and targets prediction via network pharmacology and molecular docking study. <i>BMC Complementary Medicine and Therapies</i> , 2023, 23, .	1.2	5

#	ARTICLE	IF	CITATIONS
19885	CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
19886	Identification of the diagnostic genes and immune cell infiltration characteristics of gastric cancer using bioinformatics analysis and machine learning. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
19887	Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
19888	Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression. <i>International Journal of Molecular Sciences</i> , 2023, 24, 818.	1.8	3
19889	The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
19890	Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1294.	1.8	6
19891	A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma. <i>BMC Medical Genomics</i> , 2023, 16, .	0.7	1
19892	The mutation in splicing factor genes correlates with unfavorable prognosis, genomic instability, anti-tumor immunosuppression and increased immunotherapy response in pan-cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	0
19893	Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	3
19894	Bioinformatics and In silico approaches to identify novel biomarkers and key pathways for cancers that are linked to the progression of female infertility: A comprehensive approach for drug discovery. <i>PLoS ONE</i> , 2023, 18, e0265746.	1.1	3
19895	CRISPR/Cas9 therapeutics: progress and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	73
19896	AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 1290-1303.	2.8	3
19897	Disproportionality analysis of acetaminophen-induced hepatic disorders with and without immune checkpoint inhibitors. <i>International Journal of Clinical Pharmacy</i> , 0, , .	1.0	0
19898	The FOXO1 inhibitor AS1842856 triggers apoptosis in glioblastoma multiforme and basal-like breast cancer cells. <i>FEBS Open Bio</i> , 2023, 13, 352-362.	1.0	4
19899	Molecular characterization based on tumor microenvironment-related signatures for guiding immunotherapy and therapeutic resistance in lung adenocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
19900	Case report: Identification of acute promyelocytic leukemia during osimertinib resistance followed by granulocyte colony-stimulating factor and pembrolizumab. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19901	Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer. <i>Oncolmmunology</i> , 2023, 12, .	2.1	7
19902	Identification and characterization of nucleotide metabolism and neuroendocrine regulation-associated modification patterns in stomach adenocarcinoma with auxiliary prognostic assessment and immunotherapy response prediction. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2

#	ARTICLE	IF	CITATIONS
19903	Upregulation of complement proteins in lung cancer cells mediates tumor progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
19904	Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19905	Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	8
19906	Quantities of CD3+, CD8+ and CD56+ lymphocytes decline in breast cancer recurrences while CD4+ remain similar. <i>Diagnostic Pathology</i> , 2023, 18, .	0.9	0
19907	Neoantigens: promising targets for cancer therapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	112
19908	Effect of metformin on outcomes of patients treated with immune checkpoint inhibitors: a retrospective cohort study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1951-1956.	2.0	6
19909	Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives. <i>Molecular Therapy - Oncolytics</i> , 2023, 28, 132-157.	2.0	15
19910	Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2023, 13, 167.	1.1	5
19911	On data normalization and batch-effect correction for tumor subtyping with microRNA data. <i>NAR Genomics and Bioinformatics</i> , 2023, 5, .	1.5	1
19912	From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	1
19913	Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
19914	Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity. <i>Nature Communications</i> , 2023, 14, .	5.8	20
19915	Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
19916	Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer. <i>Cells</i> , 2023, 12, 258.	1.8	10
19917	Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
19918	An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
19919	Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors. , 2023, 11, e006136.		9
19920	Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	2

#	ARTICLE	IF	CITATIONS
19921	PDJ amplicon in triple negative breast cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
19922	Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 974.	1.8	3
19923	PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
19924	The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2023, 14, 497-505.	0.8	1
19925	Identification of Key Biomarkers and Candidate Molecules in Non-Small-Cell Lung Cancer by Integrated Bioinformatics Analysis. <i>Genetical Research</i> , 2023, 2023, 1-19.	0.3	3
19926	The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma. <i>Esophagus</i> , 2023, 20, 524-532.	1.0	5
19927	Canine oral squamous cell carcinoma as a spontaneous, translational model for radiation and immunology research. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
19928	Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous Non-Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2023, , 100461.	0.6	0
19929	Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
19930	Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
19931	Recent advances in drug delivery systems for targeting brain tumors. <i>Drug Delivery</i> , 2023, 30, 1-18.	2.5	13
19932	MHC II immunogenicity shapes the neoepitope landscape in human tumors. <i>Nature Genetics</i> , 2023, 55, 221-231.	9.4	5
19933	Poison cassette exon splicing of <i>SRSF6</i> regulates nuclear speckle dispersal and the response to hypoxia. <i>Nucleic Acids Research</i> , 2023, 51, 870-890.	6.5	14
19934	An Aggrephagy-Related LncRNA Signature for the Prognosis of Pancreatic Adenocarcinoma. <i>Genes</i> , 2023, 14, 124.	1.0	14
19935	Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.1	1
19936	How Advanced are Cancer Immuno-Nanotherapeutics? A Comprehensive Review of the Literature. <i>International Journal of Nanomedicine</i> , 0, Volume 18, 35-48.	3.3	3
19937	Expression of PD-L1 through evolution phase from pre-invasive to invasive lung adenocarcinoma. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	2
19938	Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response. <i>BMC Medicine</i> , 2023, 21, .	2.3	0

#	ARTICLE	IF	CITATIONS
19939	Comprehensive analysis of alfa defensin expression and prognosis in human colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
19940	Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. <i>Biomedicines</i> , 2023, 11, 107.	1.4	4
19941	ProNGF Expression and Targeting in Glioblastoma Multiforme. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1616.	1.8	2
19942	S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas. <i>Neoplasia</i> , 2023, 36, 100874.	2.3	3
19943	Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis. <i>Clinical and Translational Radiation Oncology</i> , 2023, 39, 100573.	0.9	1
19944	Tumor-infiltrating lymphocyte: features and prognosis of lymphocytes infiltration on colorectal cancer. <i>Bioengineered</i> , 2022, 13, 14872-14888.	1.4	5
19945	PPP2R2D Suppresses Effector T Cell Exhaustion and Regulatory T Cell Expansion and Inhibits Tumor Growth in Melanoma. <i>Journal of Immunology</i> , 2022, 209, 621-628.	0.4	1
19946	Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer. <i>Chinese Medical Journal</i> , 2022, 135, 2436-2445.	0.9	6
19947	Immune checkpoint inhibitors in kidney transplantation. <i>Current Opinion in Organ Transplantation</i> , 2023, 28, 46-54.	0.8	4
19948	Differentiating Acute Interstitial Nephritis From Immune Checkpoint Inhibitors From Other Causes. <i>Kidney International Reports</i> , 2023, 8, 672-675.	0.4	1
19949	Present and Future Role of Immune Targets in Acute Myeloid Leukemia. <i>Cancers</i> , 2023, 15, 253.	1.7	2
19950	Implementation of microsatellite instability testing for the assessment of solid tumors in clinical practice. <i>Cancer Medicine</i> , 2023, 12, 7932-7940.	1.3	2
19951	The Prognostic and Predictive Value of Genomic Assays in Guiding Adjuvant Breast Radiation Therapy. <i>Biomedicines</i> , 2023, 11, 98.	1.4	2
19952	Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. <i>Targeted Oncology</i> , 0, , .	1.7	1
19953	Correlation of TROP-2 expression with clinical pathological characteristics and outcome in triple-negative breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
19954	Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses. <i>Cancers</i> , 2023, 15, 185.	1.7	0
19955	Long Non-Coding RNAs as Epigenetic Regulators of Immune Checkpoints in Cancer Immunity. <i>Cancers</i> , 2023, 15, 184.	1.7	3
19956	Intrinsic and Extrinsic Transcriptional Profiles That Affect the Clinical Response to PD-1 Inhibitors in Patients with Non-Small Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 197.	1.7	1

#	ARTICLE	IF	CITATIONS
19957	The exhaustion of lymphocytes is the main factor that decreases the sensitivity of QFT-GIT detection in silicosis. <i>BMC Immunology</i> , 2022, 23, .	0.9	0
19958	Advancements in Cancer Immunotherapies. <i>Vaccines</i> , 2023, 11, 59.	2.1	8
19959	Value of genomics- and radiomics-based machine learning models in the identification of breast cancer molecular subtypes: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2022, 10, 1394-1394.	0.7	8
19960	Identification and validation of endocrine resistance-related and immune-related long non-coding RNA (lncRNA) signatures for predicting endocrinotherapy response and prognosis in breast cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 1399-1399.	0.7	2
19961	RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 266.	1.8	4
19962	Atypical Response in Metastatic Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: Radiographic Patterns and Clinical Value of Local Therapy. <i>Cancers</i> , 2023, 15, 180.	1.7	0
19963	Stereotactic Body Radiotherapy and Immunotherapy for Older Patients with Oligometastases: A Proposed Paradigm by the International Geriatric Radiotherapy Group. <i>Cancers</i> , 2023, 15, 244.	1.7	3
19964	5-Methylcytosine (m5C) Modification Patterns and Tumor Immune Infiltration Characteristics in Clear Cell Renal Cell Carcinoma. <i>Current Oncology</i> , 2023, 30, 559-574.	0.9	2
19965	Penetrating Exploration of Prognostic Correlations of the FKBP Gene Family with Lung Adenocarcinoma. <i>Journal of Personalized Medicine</i> , 2023, 13, 49.	1.1	2
19966	DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 2539-2566.	1.3	0
19967	The Role of Immune Checkpoint Inhibitors in Cancer Therapy. <i>Clinics and Practice</i> , 2023, 13, 22-40.	0.6	14
19968	Advances in adoptive cellular therapy for colorectal cancer: a narrative review. <i>Annals of Translational Medicine</i> , 2022, 10, 1404-1404.	0.7	4
19969	Balancing the Risk of Adverse Events against the Efficacy of Immunotherapy in Advanced Thymic Epithelial Tumors. <i>Cancers</i> , 2023, 15, 289.	1.7	2
19970	Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario. <i>Cancers</i> , 2023, 15, 246.	1.7	8
19971	Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study. <i>Biomedicines</i> , 2023, 11, 83.	1.4	3
19972	Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. <i>Nature Cancer</i> , 0, , .	5.7	13
19973	RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	7
19974	CD3+ and CD8+ T-Cell-Based Immune Cell Score and PD-(L)1 Expression in Pulmonary Metastases of Microsatellite Stable Colorectal Cancer. <i>Cancers</i> , 2023, 15, 206.	1.7	4

#	ARTICLE	IF	CITATIONS
19975	Construction of an Immune Escape-Related Signature in Clear Cell Renal Cell Carcinoma and Identification of the Relationship between IFNAR1 and Immune Infiltration by Multiple Immunohistochemistry. <i>Cancers</i> , 2023, 15, 169.	1.7	1
19976	Tumor Microenvironment before and after Chemoradiation in Locally Advanced Rectal Cancer: Beyond PD-L1. <i>Cancers</i> , 2023, 15, 276.	1.7	4
19977	Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology. <i>Cancers</i> , 2023, 15, 257.	1.7	11
19978	Immunohistochemical Expression of PD-L1 and IDH1 with Detection of MGMT Promoter Methylation in Astrocytoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 4333-4338.	0.5	1
19979	SAMHD1 silencing cooperates with radiotherapy to enhance anti-tumor immunity through IFI16-STING pathway in lung adenocarcinoma. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
19980	An Overview of Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Canine Tumors: How Far Have We Come?. <i>Veterinary Sciences</i> , 2023, 10, 19.	0.6	4
19981	Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 599.	1.8	5
19982	Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors. <i>Cancers</i> , 2023, 15, 216.	1.7	6
19983	Firocoxib as a Potential Neoadjuvant Treatment in Canine Patients with Triple-Negative Mammary Gland Tumors. <i>Animals</i> , 2023, 13, 60.	1.0	1
19984	Rise of the natural red pigment "prodigiosin"™ as an immunomodulator in cancer. <i>Cancer Cell International</i> , 2022, 22, .	1.8	5
19985	Sarcopenia using pectoralis muscle area and lymphocyte-to-monocyte ratio (LMR) are independent prognostic factors in patients for nonmetastatic breast cancer. <i>Medicine (United States)</i> , 2022, 101, e32229.	0.4	3
19986	PD-L1 Expression is not a Predictive Factor for Recurrence in Resected Non-small Cell Lung Cancer. <i>Lung</i> , 2023, 201, 95-101.	1.4	1
19987	Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series. <i>Journal of Clinical Medicine</i> , 2023, 12, 130.	1.0	4
19988	Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma. <i>Biomolecules</i> , 2023, 13, 58.	1.8	4
19989	Establishment and validation of a nomogram for predicting immune-related prognostic features in trunk melanoma-specific death. <i>Annals of Translational Medicine</i> , 2022, 10, 1371-1371.	0.7	0
19990	Inflammatory Cell Infiltration Into Islets Without PD-L1 Expression Is Associated With the Development of Immune Checkpoint Inhibitor-Related Type 1 Diabetes in Genetically Susceptible Patients. <i>Diabetes</i> , 2023, 72, 511-519.	0.3	5
19991	Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors. <i>PLoS ONE</i> , 2023, 18, e0281143.	1.1	4
19992	IFN γ signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells. <i>Nature Communications</i> , 2023, 14, .	5.8	12

#	ARTICLE	IF	CITATIONS
19993	Gastric adenocarcinoma with high level microsatellite instability: A case report. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	0
19994	YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+ T cells. <i>Nature Immunology</i> , 2023, 24, 255-266.	7.0	31
19995	Mannosylated-serum albumin nanoparticle imaging to monitor tumor-associated macrophages under anti-PD1 treatment. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	2
19996	GRHL2 Regulation of Growth/Motility Balance in Luminal versus Basal Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2512.	1.8	3
19997	Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2505.	1.8	21
19998	Innate Immune Program in Formation of Tumor-Initiating Cells from Cells-of-Origin of Breast, Prostate, and Ovarian Cancers. <i>Cancers</i> , 2023, 15, 757.	1.7	1
19999	Hypoxia signaling in cancer: Implications for therapeutic interventions. <i>MedComm</i> , 2023, 4, .	3.1	16
20000	gC1qR: A New Target for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20001	Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
20002	Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor Positive (HR+)/HER2-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1719-1729.	3.2	12
20003	In-situ cryo-immune engineering of tumor microenvironment with cold-responsive nanotechnology for cancer immunotherapy. <i>Nature Communications</i> , 2023, 14, .	5.8	25
20004	Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382211505.	0.8	7
20005	New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors. , 2023, 11, e005977.		8
20006	Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
20007	Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
20008	Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. <i>Molecular Cell</i> , 2023, 83, 660-680.	4.5	10
20009	Elafin is related to immune infiltration and could predict the poor prognosis in ovarian cancer. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
20010	Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. , 2023, 11, e005924.		24

#	ARTICLE	IF	CITATIONS
20011	Manipulation of metabolic pathways to promote stem-like and memory T cell phenotypes for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
20012	Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy. <i>Biomolecules</i> , 2023, 13, 190.	1.8	4
20013	Malignant Melanoma Arising from Esophageal Melanosis and Synchronous with Esophageal Squamous Cell Carcinoma. <i>American Journal of Case Reports</i> , 0, 24, .	0.3	0
20014	Radiogenomic association of deep MR imaging features with genomic profiles and clinical characteristics in breast cancer. <i>Biomarker Research</i> , 2023, 11, .	2.8	1
20015	The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations. <i>Cancers</i> , 2023, 15, 808.	1.7	8
20016	PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells. <i>Journal of Personalized Medicine</i> , 2023, 13, 221.	1.1	8
20017	DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20018	Hyperpolarized 13C-Pyruvate to Assess Response to Anti-PD1 Immune Checkpoint Inhibition in YUMMER 1.7 Melanoma Xenografts. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2499.	1.8	2
20019	Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	2
20020	Recent Progress in Immunotherapy for Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2023, 23, 207.	0.9	7
20021	Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?. <i>Cancers</i> , 2023, 15, 689.	1.7	5
20022	An Immunogenic Cell Death-Related Gene Signature Reflects Immune Landscape and Predicts Prognosis in Melanoma Independently of BRAF V600E Status. <i>BioMed Research International</i> , 2023, 2023, 1-21.	0.9	2
20023	Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review. <i>Cancers</i> , 2023, 15, 682.	1.7	2
20024	Panâ€Cancer landscape of protein activities identifies drivers of signalling dysregulation and patient survival. <i>Molecular Systems Biology</i> , 2023, 19, .	3.2	10
20025	Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs. <i>Cancers</i> , 2023, 15, 648.	1.7	6
20026	The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2160.	1.8	2
20027	Nanobodies in cell-mediated immunotherapy: On the road to fight cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	12
20028	Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines. <i>Genes and Cancer</i> , 2023, 14, 3-11.	0.6	2

#	ARTICLE	IF	CITATIONS
20029	Distinct Prognostic and Immunological Roles of ETS1 and ETS2: A Pan-Cancer Analysis. <i>BioMed Research International</i> , 2023, 2023, 1-13.	0.9	2
20030	Data mining combines bioinformatics discover immunoinfiltration-related gene SERPINE1 as a biomarker for diagnosis and prognosis of stomach adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	7
20031	Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1381-1394.	2.0	3
20032	Confirmation of the Prognostic Value of Foxp3+ Cells in Canine Mammary Tumors. <i>Animals</i> , 2023, 13, 505.	1.0	0
20033	Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer. <i>Diagnostics</i> , 2023, 13, 470.	1.3	1
20034	Quality improvements in radiation oncology clinical trials. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
20035	Phytochemicals as Immunomodulatory Agents in Melanoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2657.	1.8	4
20036	Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. , 2023, 11, e005007.		3
20037	DNA methylation and transcriptome signatures of the PDCD1 gene in ankylosing spondylitis. <i>Genes and Immunity</i> , 2023, 24, 46-51.	2.2	2
20038	Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response. <i>Cancers</i> , 2023, 15, 597.	1.7	4
20039	Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
20040	Pyroptosis in urinary malignancies: a literature review. <i>Discover Oncology</i> , 2023, 14, .	0.8	1
20041	Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20042	Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2023, 23, .	1.1	3
20043	Nomograms for Predicting Disease-Free Survival Based on Core Needle Biopsy and Surgical Specimens in Female Breast Cancer Patients with Non-Pathological Complete Response to Neoadjuvant Chemotherapy. <i>Journal of Personalized Medicine</i> , 2023, 13, 249.	1.1	0
20044	Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment. <i>Breast Cancer Research</i> , 2023, 25, .	2.2	6
20045	Post-COVID Endocrine Disorders: Putative Role of Molecular Mimicry and Some Pathomorphological Correlates. <i>Diagnostics</i> , 2023, 13, 522.	1.3	2
20046	Understanding the squamous cell carcinoma immune microenvironment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7

#	ARTICLE	IF	CITATIONS
20047	Identification of a novel immune-related gene signature for prognosis and the tumor microenvironment in patients with uveal melanoma combining single-cell and bulk sequencing data. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20048	Whole-Transcriptome Sequencing Combined with High-Dimensional Proteomic Technologies Reveals the Potential Value of miR-135b-5p as a Biomarker for Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2023, 2023, 1-22.	0.9	0
20049	MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment. <i>Cancers</i> , 2023, 15, 824.	1.7	3
20050	Mechanisms driving the immunoregulatory function of cancer cells. <i>Nature Reviews Cancer</i> , 2023, 23, 193-215.	12.8	40
20051	Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. <i>Journal of Clinical Medicine</i> , 2023, 12, 953.	1.0	12
20052	ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors. <i>Cancers</i> , 2023, 15, 878.	1.7	6
20053	Construction and characterization of a cuproptosis- and immune checkpoint-based LncRNAs signature for breast cancer risk stratification. <i>Breast Cancer</i> , 0, , .	1.3	0
20054	Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211461.	1.4	5
20055	Potential Regulation of miRNA-29 and miRNA-9 by Estrogens in Neurodegenerative Disorders: An Insightful Perspective. <i>Brain Sciences</i> , 2023, 13, 243.	1.1	1
20056	Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data. <i>Cells</i> , 2023, 12, 367.	1.8	1
20057	ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
20058	A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
20059	Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti-PD-1 Antibody. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 499-510.	1.9	3
20060	An <i>in silico</i> model to study the impact of carbonic anhydrase IX expression on tumour growth and anti-PD-1 therapy. <i>Journal of the Royal Society Interface</i> , 2023, 20, .	1.5	2
20061	The application of patient-derived organoid in the research of lung cancer. <i>Cellular Oncology (Dordrecht)</i> , 2023, 46, 503-519.	2.1	9
20063	Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers. , 2023, 11, e003837.		2
20064	Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
20065	High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. <i>JCO Precision Oncology</i> , 2023, , .	1.5	6

#	ARTICLE	IF	CITATIONS
20066	Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy. <i>Current Opinion in Oncology</i> , 2023, 35, 94-99.	1.1	4
20067	Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET/CT radiomics. <i>EJNMMI Research</i> , 2023, 13, .	1.1	6
20068	Bibliometric Analysis of Hotspots and Frontiers of Immunotherapy in Pancreatic Cancer. <i>Healthcare (Switzerland)</i> , 2023, 11, 304.	1.0	5
20069	Base editing screens map mutations affecting interferon- β signaling in cancer. <i>Cancer Cell</i> , 2023, 41, 288-303.e6.	7.7	14
20070	Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211489.	1.4	2
20071	Artificial intelligence reveals features associated with breast cancer neoadjuvant chemotherapy responses from multi-stain histopathologic images. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	18
20072	T lymphocyte cell: A pivotal player in lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
20073	The prognostic values of FOXP3+ tumor-infiltrating T cells in breast cancer: a systematic review and meta-analysis. <i>Clinical and Translational Oncology</i> , 2023, 25, 1830-1843.	1.2	1
20074	Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2676.	1.8	6
20075	S100a9 deficiency accelerates MDS-associated tumor escape via PD-1/PD-L1 overexpression. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, 55, 194-201.	0.9	1
20076	HER2-driven breast cancer suppression by the JNK signaling pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	4
20077	Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment. <i>Molecular Cancer Research</i> , 0, , .	1.5	3
20078	Low pretreatment prognostic nutritional index predicts poor survival in breast cancer patients: A meta-analysis. <i>PLoS ONE</i> , 2023, 18, e0280669.	1.1	3
20079	Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
20080	Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy. , 2023, 11, e005902.		7
20081	Enhancer RNA-based modeling of adverse events and objective responses of cancer immunotherapy reveals associated key enhancers and target genes. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
20082	Targeting the Tumor Immune Microenvironment Could Become a Potential Therapeutic Modality for Aggressive Pituitary Adenoma. <i>Brain Sciences</i> , 2023, 13, 164.	1.1	2
20083	Associated Factors of Spontaneous Hemorrhage in Brain Metastases in Patients with Lung Adenocarcinoma. <i>Cancers</i> , 2023, 15, 619.	1.7	2

#	ARTICLE	IF	CITATIONS
20084	Epidemiology, management, and treatment outcomes of metastatic spinal melanoma. <i>World Neurosurgery: X</i> , 2023, 18, 100156.	0.6	1
20086	Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. , 2023, 11, e005809.		4
20087	Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 6171-6179.	1.2	3
20088	GRHL2-controlled gene expression networks in luminal breast cancer. <i>Cell Communication and Signaling</i> , 2023, 21, .	2.7	3
20089	Role of FABP5 in T Cell Lipid Metabolism and Function in the Tumor Microenvironment. <i>Cancers</i> , 2023, 15, 657.	1.7	2
20090	Immune-Related Adverse Events of the Gastrointestinal System. <i>Cancers</i> , 2023, 15, 691.	1.7	1
20091	Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy. <i>Journal of Personalized Medicine</i> , 2023, 13, 190.	1.1	0
20092	Minimally invasive versus open McKeown esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant PD-1 inhibitor plus chemotherapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
20093	Persistent mutation burden drives sustained anti-tumor immune responses. <i>Nature Medicine</i> , 2023, 29, 440-449.	15.2	35
20094	MiXcan: a framework for cell-type-aware transcriptome-wide association studies with an application to breast cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	5
20095	The Cell-Specific Role of SHP2 in Regulating Bone Homeostasis and Regeneration Niches. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2202.	1.8	0
20096	LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
20097	Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1789-1801.	2.0	2
20098	Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	9
20099	Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy. <i>Pharmaceutics</i> , 2023, 15, 452.	2.0	3
20100	Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders. <i>Molecules</i> , 2023, 28, 1283.	1.7	5
20101	Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma. <i>Cancers</i> , 2023, 15, 863.	1.7	6
20102	Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	3

#	ARTICLE	IF	CITATIONS
20103	Immunotherapies in rare cancers. <i>Molecular Cancer</i> , 2023, 22, .	7.9	15
20104	Low-dose X-ray radiodynamic therapy solely based on gold nanoclusters for efficient treatment of deep hypoxic solid tumors combined with enhanced antitumor immune response. <i>Theranostics</i> , 2023, 13, 1042-1058.	4.6	8
20105	Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens. <i>British Journal of Cancer</i> , 2023, 128, 1166-1175.	2.9	5
20106	Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer. <i>Cancers</i> , 2023, 15, 1087.	1.7	5
20107	Association between <sc>PD</sc> Æ inhibitorÆ related adverse events and frailty assessed by frailty index in lung cancer patients. <i>Cancer Medicine</i> , 0, , .	1.3	1
20108	Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	13
20109	Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
20110	Upregulated SSB Is Involved in Hepatocellular Carcinoma Progression and Metastasis through the Epithelial-Mesenchymal Transition, Antiapoptosis, and Altered ROS Level Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-16.	1.9	0
20112	Establishment and validation of a multigene model to predict the risk of relapse in hormone receptor-positive early-stage Chinese breast cancer patients. <i>Chinese Medical Journal</i> , 2023, 136, 184-193.	0.9	1
20113	The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 1041-1056.	1.5	3
20114	AlbuminÆ derived Neutrophil-to-Lymphocyte Ratio Score as a Marker of Nivolumab Treatment Sensitivity in Gastric Cancer: A Multicenter Study. <i>In Vivo</i> , 2023, 37, 818-824.	0.6	0
20115	Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis. <i>Open Medicine (Poland)</i> , 2023, 18, .	0.6	0
20116	Prognostic significance of lymph node dissection for lung cancer surgery: a narrative review. <i>Journal of Thoracic Disease</i> , 2023, 15, 2253-2260.	0.6	1
20117	Metabolic Regulation of T cell Activity: Implications for Metabolic-Based T-cell Therapies for Cancer. <i>Iranian Biomedical Journal</i> , 2023, 27, 1-14.	0.4	0
20118	A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 2536-2546.	1.9	4
20119	Pyroptosis-based risk score predicts prognosis and drug sensitivity in lung adenocarcinoma. <i>Open Medicine (Poland)</i> , 2023, 18, .	0.6	0
20120	Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311563.	1.4	1
20121	Neoadjuvant chemotherapy modulates exhaustion of T cells in breast cancer patients. <i>PLoS ONE</i> , 2023, 18, e0280851.	1.1	2

#	ARTICLE	IF	CITATIONS
20122	Editorial: Factors that impact the survival of non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
20123	Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4302.	1.8	0
20124	Immune-related thyroid dysfunction is associated with improved long-term prognosis in patients with non-small cell lung cancer treated with immunotherapy: a systematic review and meta-analysis. <i>Journal of Thoracic Disease</i> , 2023, 15, 690-700.	0.6	1
20125	Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	6
20126	Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	9
20127	Association of Computed Tomography Measures of Muscle and Adipose Tissue and Progressive Changes throughout Treatment with Clinical Endpoints in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2023, 15, 1382.	1.7	1
20128	Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known. <i>Hepatology Communications</i> , 2023, 7, e0063-e0063.	2.0	3
20129	Evidence of Flavonoids on Disease Prevention. <i>Antioxidants</i> , 2023, 12, 527.	2.2	28
20130	A Ribosome-Related Prognostic Signature of Breast Cancer Subtypes Based on Changes in Breast Cancer Patients's Immunological Activity. <i>Medicina (Lithuania)</i> , 2023, 59, 424.	0.8	0
20131	Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8+ tumor-infiltrating lymphocytes and patient prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 755-766.	1.4	3
20132	Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management. <i>Archives of Dermatological Research</i> , 2023, 315, 1697-1703.	1.1	1
20133	Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20134	Novel exosome-related risk signature as prognostic biomarkers in glioblastoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20135	Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
20136	Application of Novel Breast Biospecimen Cell-Type Adjustment Identifies Shared DNA Methylation Alterations in Breast Tissue and Milk with Breast Cancer Risk Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2023, 32, 550-560.	1.1	5
20137	The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. <i>Nature Communications</i> , 2023, 14, .	5.8	17
20138	Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 7925-7932.	1.2	2
20139	Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	5

#	ARTICLE	IF	CITATIONS
20140	Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	2
20141	PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma. <i>Journal of Biomedical Science</i> , 2023, 30, .	2.6	4
20142	Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6052.	1.8	2
20143	CRISPR screens identify gene targets at breast cancer risk loci. <i>Genome Biology</i> , 2023, 24, .	3.8	6
20144	CRS: a circadian rhythm score model for predicting prognosis and treatment response in cancer patients. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	4
20145	PD-L1-targeted magnetic fluorescent hybrid nanoparticles: Illuminating the path of image-guided cancer immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 2240-2243.	3.3	2
20146	Neopeptide load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
20147	Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis. <i>Current Oncology Reports</i> , 2023, 25, 743-751.	1.8	2
20148	Generation of peptides using phage display technology for cancer diagnosis and molecular imaging. <i>Molecular Biology Reports</i> , 2023, 50, 4653-4664.	1.0	5
20149	Combating pancreatic cancer with ovarian cancer cells. <i>Aging</i> , 2023, 15, 2189-2207.	1.4	0
20150	Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	5
20151	Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 617-631.	0.8	3
20152	Diagnosis and Management of Pembrolizumab-Associated Pericardial Effusion in a Non-small Cell Lung Cancer Patient. <i>Cureus</i> , 2023, , .	0.2	0
20153	Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center. <i>Immunotherapy</i> , 2023, 15, 417-428.	1.0	0
20154	FIPRESCI: droplet microfluidics based combinatorial indexing for massive-scale 5'-end single-cell RNA sequencing. <i>Genome Biology</i> , 2023, 24, .	3.8	4
20155	TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer. <i>Cancer Research</i> , 2023, 83, 1345-1360.	0.4	4
20157	Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	9
20158	Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 1017-1030.	0.6	3

#	ARTICLE	IF	CITATIONS
20159	Moving Spatially Resolved Multiplexed Protein Profiling toward Clinical Oncology. <i>Cancer Discovery</i> , 2023, 13, 824-828.	7.7	3
20160	A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?. <i>Translational Oncology</i> , 2023, 30, 101636.	1.7	2
20161	Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis. <i>Immunologic Research</i> , 2023, 71, 588-599.	1.3	21
20162	Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives. <i>Molecular Cancer</i> , 2023, 22, .	7.9	3
20163	Efficacy and safety of combined immunotherapy and stereotactic radiosurgery in NSCLCBM patients and a novel prognostic nomogram: A real-world study. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
20165	Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer. <i>Cellular and Molecular Biology Letters</i> , 2023, 28, .	2.7	6
20166	Long noncoding RNA HITT coordinates with RGS2 to inhibit PD-L1 translation in T cell immunity. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	7
20167	Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer. <i>Modern Pathology</i> , 2023, 36, 100128.	2.9	7
20168	Viral- and tumor-reactive natural killer cells. <i>Seminars in Immunology</i> , 2023, 67, 101749.	2.7	5
20169	Novel unconventional radiotherapy techniques: Current status and future perspectives – Report from the 2nd international radiation oncology online seminar. <i>Clinical and Translational Radiation Oncology</i> , 2023, 40, 100605.	0.9	0
20170	Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic. <i>Respiratory Medicine and Research</i> , 2023, 83, 101004.	0.4	0
20171	An exosome-related lncRNA signature correlates with prognosis, immune microenvironment, and therapeutic responses in hepatocellular carcinoma. <i>Translational Oncology</i> , 2023, 31, 101651.	1.7	8
20172	Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report. <i>Gynecologic Oncology Reports</i> , 2023, 47, 101174.	0.3	1
20173	Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer. <i>Breast</i> , 2023, 69, 330-341.	0.9	3
20174	Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy. <i>Bioactive Materials</i> , 2023, 26, 169-180.	8.6	3
20175	Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2023, 15, 2288.	1.7	2
20176	Familial CCM Genes Might Not Be Main Drivers for Pathogenesis of Sporadic CCMs-Genetic Similarity between Cancers and Vascular Malformations. <i>Journal of Personalized Medicine</i> , 2023, 13, 673.	1.1	3
20177	Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Oncology</i> , 2023, 9, 779.	3.4	18

#	ARTICLE	IF	CITATIONS
20178	Organoids as an Enabler of Precision Immuno-Oncology. <i>Cells</i> , 2023, 12, 1165.	1.8	2
20179	Next generation immuno-oncology tumor profiling using a rapid, non-invasive, computational biophysics biomarker in early-stage breast cancer. <i>Frontiers in Artificial Intelligence</i> , 0, 6, .	2.0	0
20180	Immunotherapy for recurrent hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 2261-2271.	1.4	1
20181	Syndecan-1 as an immunogene in Triple-negative breast cancer: regulation tumor-infiltrating lymphocyte in the tumor microenvironment and EMT by TGFb1/Smad pathway. <i>Cancer Cell International</i> , 2023, 23, .	1.8	0
20182	Single-cell transcriptome analysis revealed the immune profile of PD-1 blockade in gallbladder carcinoma liver metastasis. <i>Hepatology Communications</i> , 2023, 7, .	2.0	1
20183	Targeting polymerase δ , impairs tumorigenesis and enhances radiosensitivity in lung adenocarcinoma. <i>Cancer Science</i> , 2023, 114, 1943-1957.	1.7	4
20184	SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers. <i>IScience</i> , 2023, 26, 106027.	1.9	6
20185	Elevated PTTG1 predicts poor prognosis in kidney renal clear cell carcinoma and correlates with immunity. <i>Heliyon</i> , 2023, 9, e13201.	1.4	0
20186	ABC1 Amplicon Contains Cyclic AMP Response Element-Driven TRIP6 Gene in Taxane-Resistant MCF-7 Breast Cancer Sublines. <i>Genes</i> , 2023, 14, 296.	1.0	1
20187	Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
20188	Reversing T Cell Dysfunction to Boost Glioblastoma Immunotherapy by Paroxetine-Mediated GRK2 Inhibition and Blockade of Multiple Checkpoints through Biomimetic Nanoparticles. <i>Advanced Science</i> , 2023, 10, .	5.6	9
20189	Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment. <i>Cancers</i> , 2023, 15, 777.	1.7	3
20190	Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment. <i>Cancers</i> , 2023, 15, 767.	1.7	13
20191	Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy. <i>IScience</i> , 2023, 26, 106064.	1.9	0
20192	An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers. <i>EBioMedicine</i> , 2023, 88, 104452.	2.7	9
20193	Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol. <i>BMJ Open</i> , 2023, 13, e063500.	0.8	1
20194	Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. <i>Biology</i> , 2023, 12, 218.	1.3	27
20195	Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3

#	ARTICLE	IF	CITATIONS
20196	Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2769.	1.8	7
20197	DKK1-CKAP4 signal axis promotes hepatocellular carcinoma aggressiveness. <i>Cancer Science</i> , 2023, 114, 2063-2077.	1.7	2
20198	Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	4
20199	Comparison of the prognostic value of stromal tumor-infiltrating lymphocytes and CD3+T cells between schistosomal and non-schistosomal colorectal cancer. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	0
20200	Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals TP53 Aneuploidy-driven Metabolic Reprogramming. <i>Cancer Research Communications</i> , 2023, 3, 281-296.	0.7	0
20201	Pan-cancer molecular subtypes of metastasis reveal distinct and evolving transcriptional programs. <i>Cell Reports Medicine</i> , 2023, 4, 100932.	3.3	5
20202	Genetic differences between smokers and never-smokers with lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
20203	Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNIp-RCC trial. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1903-1915.	2.0	4
20204	Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1569-1581.	3.2	8
20205	The CTLA-4 immune checkpoint protein regulates PD-L1:PD interaction via transendocytosis of its ligand CD80. <i>EMBO Journal</i> , 2023, 42, .	3.5	7
20206	Helper Innate Lymphoid Cells- Unappreciated Players in Melanoma Therapy. <i>Cancers</i> , 2023, 15, 933.	1.7	1
20207	The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2805.	1.8	6
20208	Management of papillary thyroid cancer with tracheal invasion and lung cancer: A case report. <i>Oncology Letters</i> , 2023, 25, .	0.8	0
20209	2,2-Diphenethyl Isothiocyanate Enhances Topoisomerase Inhibitor-Induced Cell Death and Suppresses Multi-Drug Resistance 1 in Breast Cancer Cells. <i>Cancers</i> , 2023, 15, 928.	1.7	2
20210	Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
20211	Application of injectable hydrogels in cancer immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 11, .	2.0	2
20212	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes in Patients with Advanced Breast Cancer Treated with Primary Systemic Therapy. <i>World Journal of Surgery</i> , 2023, 47, 1238-1246.	0.8	1
20213	Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review. <i>Lung Cancer: Targets and Therapy</i> , 0, Volume 14, 11-25.	1.3	4

#	ARTICLE	IF	CITATIONS
20214	Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2975.	1.8	3
20215	Integrating multi-type aberrations from DNA and RNA through dynamic mapping gene space for subtype-specific breast cancer driver discovery. <i>PeerJ</i> , 0, 11, e14843.	0.9	2
20216	Immunotherapeutic Approaches in Ovarian Cancer. <i>Current Issues in Molecular Biology</i> , 2023, 45, 1233-1249.	1.0	5
20217	A narrative review of genetic biomarkers in non-small cell lung cancer: an update and future perspectives. <i>AME Medical Journal</i> , 0, 8, 6-6.	0.4	1
20218	Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance. <i>Cancers</i> , 2023, 15, 971.	1.7	3
20219	Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2023, 13, 1210-1229.	7.7	18
20220	Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	0
20221	Identify AGAP2 as prognostic biomarker in clear cell renal cell carcinoma based on bioinformatics and IHC staining. <i>Heliyon</i> , 2023, 9, e13543.	1.4	2
20222	A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 392-396.	0.4	1
20223	Modulation of oxidative phosphorylation and mitochondrial biogenesis by cigarette smoke influence the response to immune therapy in NSCLC patients. <i>Lung Cancer</i> , 2023, 178, 37-46.	0.9	0
20224	An IL-12-Based Nanocytokine Safely Potentiates Anticancer Immunity through Spatiotemporal Control of Inflammation to Eradicate Advanced Cold Tumors. <i>Advanced Science</i> , 2023, 10, .	5.6	9
20225	Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
20226	Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation. <i>Immunity</i> , 2023, 56, 289-306.e7.	6.6	22
20227	Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3151.	1.8	5
20228	The effects of traditional Chinese medicine and dietary compounds on digestive cancer immunotherapy and gut microbiota modulation: A review. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
20229	Regulation of immunological tolerance by the p53-inhibitor iASPP. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	3
20230	<sc>IL</sc>7 germline variant: setting the stage for immune-related adverse events. <i>Molecular Oncology</i> , 2023, 17, 384-386.	2.1	0
20231	Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3. <i>Cancers</i> , 2023, 15, 1031.	1.7	0

#	ARTICLE	IF	CITATIONS
20232	The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3226.	1.8	3
20233	Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2023, 18, e0281459.	1.1	6
20234	Targeting Cbl-b in cancer immunotherapy. , 2023, 11, e006007.		14
20235	A Rare Case of Pembrolizumab-Associated Gravesâ€™ Disease. <i>Cureus</i> , 2023, , .	0.2	1
20236	Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. <i>Communications Medicine</i> , 2023, 3, .	1.9	9
20237	Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20238	Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal â€“ U-PIK Project. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	0
20239	Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
20240	Tumor-infiltrating lymphocytes for melanoma immunotherapy. <i>Oncolimmunology</i> , 2023, 12, .	2.1	2
20241	FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects. <i>Cancers</i> , 2023, 15, 1063.	1.7	4
20242	Clinicopathological Features of Kidney Injury Related to Immune Checkpoint Inhibitors: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 1349.	1.0	1
20243	Prognostic role of immune environment in luminal B early breast cancer. <i>Cancer Medicine</i> , 0, , .	1.3	1
20244	Genomic features and its potential implication in bone oligometastatic NSCLC. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	0
20245	Characterization of the immune cell landscape in CRC: Clinical implications of tumour-infiltrating leukocytes in early- and late-stage CRC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
20246	AXL upregulates c-Myc expression through AKT and ERK signaling pathways in breast cancers. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	1
20247	Overview of Chemotherapy for Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 1336.	1.0	10
20248	Essential updates 2020/2021: Recent topics in surgery and perioperative therapy for esophageal cancer. <i>Annals of Gastroenterological Surgery</i> , 2023, 7, 346-357.	1.2	3
20249	Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. , 2023, 11, e005640.		11

#	ARTICLE	IF	CITATIONS
20250	A bibliometric analysis of 16,826 triple-negative breast cancer publications using multiple machine learning algorithms: Progress in the past 17 years. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
20251	Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. <i>Cancers</i> , 2023, 15, 1093.	1.7	4
20252	The oncogenic roles and clinical implications of YAP/TAZ in breast cancer. <i>British Journal of Cancer</i> , 2023, 128, 1611-1624.	2.9	13
20253	Combination IFN γ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity. <i>Cancer Immunology Research</i> , 2023, 11, 466-485.	1.6	1
20254	Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	6
20255	Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
20256	<scp>CD70</scp> and <scp>PD-L1</scp> (<scp>CD274</scp>) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma. <i>Journal of Pathology: Clinical Research</i> , 2023, 9, 195-207.	1.3	2
20257	Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 1076.	1.7	13
20258	Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
20259	GPR65 as a potential immune checkpoint regulates the immune microenvironment according to pan-cancer analysis. <i>Heliyon</i> , 2023, 9, e13617.	1.4	2
20260	Immunotherapy in Melanoma: Recent Advances and Future Directions. <i>Cancers</i> , 2023, 15, 1106.	1.7	39
20261	Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	3
20262	Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinoma. <i>Heliyon</i> , 2023, 9, e13629.	1.4	0
20263	Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis. <i>BMC Cancer</i> , 2023, 23, .	1.1	4
20264	The Prognostic Value and the Oncogenic and Immunological Roles of Vacuolar Protein Sorting Associated Protein 26 A in Pancreatic Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3486.	1.8	1
20265	Long-Term Response of Pembrolizumab in a Patient with Metastatic Squamous Non-Small Cell Lung Cancer on Hemodialysis: Case Report and Review of the Literature. <i>Medicina (Lithuania)</i> , 2023, 59, 325.	0.8	3
20266	Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. <i>Biomedicines</i> , 2023, 11, 508.	1.4	3
20267	Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model. <i>Scientific Reports</i> , 2023, 13, .	1.6	3

#	ARTICLE	IF	CITATIONS
20268	Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ER β and Mutant p53. <i>Oncologist</i> , 2023, 28, 358-363.	1.9	5
20269	The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance. <i>Oncogenesis</i> , 2023, 12, .	2.1	12
20270	Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100474.	0.6	0
20271	DNMT3a-dermatopontin axis suppresses breast cancer malignancy via inactivating YAP. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	8
20272	c-MYC-Induced AP4 Attenuates DREAM-Mediated Repression by p53. <i>Cancers</i> , 2023, 15, 1162.	1.7	1
20273	Paraneoplastic Neurologic Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2023, 23, 67-82.	2.0	6
20274	Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
20275	Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3704.	1.8	7
20276	Immunotherapy in breast cancer: an overview of current strategies and perspectives. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	63
20277	Prediction of CD3 T cells and CD8 T cells expression levels in non-small cell lung cancer based on radiomic features of CT images. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
20278	Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review. <i>Cancers</i> , 2023, 15, 1164.	1.7	4
20279	Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3618.	1.8	6
20280	Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment?. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 251-267.	0.8	6
20281	The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study. <i>Annals of Translational Medicine</i> , 2023, 11, 157-157.	0.7	2
20282	Post-Surgical Imaging Assessment in Rectal Cancer: Normal Findings and Complications. <i>Journal of Clinical Medicine</i> , 2023, 12, 1489.	1.0	1
20283	Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. <i>EMBO Molecular Medicine</i> , 2023, 15, .	3.3	5
20284	Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation. <i>Cell Reports Medicine</i> , 2023, 4, 100940.	3.3	4
20285	Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2

#	ARTICLE	IF	CITATIONS
20286	TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
20287	Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
20288	Impact of the immune molecular profile of the tumor microenvironment on the prognosis of NSCLC. <i>Oncology Letters</i> , 2023, 25, .	0.8	0
20289	<it>Salmonella typhimurium</it> may support cancer treatment: a review. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, 55, 331-342.	0.9	2
20290	The Gut Microbiome and Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2023, 12, 1502.	1.0	3
20292	Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
20293	Clinical application of immune repertoire sequencing in solid organ transplant. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
20294	ONEST (Observers Needed to Evaluate Subjective Tests) Analysis of Stromal Tumour-Infiltrating Lymphocytes (sTILs) in Breast Cancer and Its Limitations. <i>Cancers</i> , 2023, 15, 1199.	1.7	3
20295	Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: A retrospective study. <i>JGH Open</i> , 2023, 7, 87-97.	0.7	4
20296	Waking immune-resistant tumors with neddylation. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	2
20297	Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report. <i>World Journal of Clinical Cases</i> , 0, 11, 1165-1174.	0.3	1
20298	Life-threatening "hyper-progression" on immunotherapy revealed as pseudo-progression in DNA mismatch repair deficiency: a case report. <i>Journal of Gastrointestinal Oncology</i> , 2023, 14, 435-441.	0.6	0
20299	OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. <i>Cell Reports Medicine</i> , 2023, 4, 100939.	3.3	6
20300	Association between Tumor Mutational Burden, Stromal CD8+ Tumor-Infiltrating Lymphocytes, and Clinical Factors in Cervical Cancers Treated with Radiotherapy. <i>Cancers</i> , 2023, 15, 1210.	1.7	3
20301	Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	18
20302	Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab. <i>Cancer Medicine</i> , 0, , .	1.3	1
20303	Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches. <i>Journal of Personalized Medicine</i> , 2023, 13, 334.	1.1	13
20304	Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. <i>Current Oncology</i> , 2023, 30, 2366-2387.	0.9	5

#	ARTICLE	IF	CITATIONS
20305	Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	2
20306	The Prognostic Impact of Gender, Therapeutic Strategies, Molecular Background, and Tumor-Infiltrating Lymphocytes in Glioblastoma: A Still Unsolved Jigsaw. <i>Genes</i> , 2023, 14, 501.	1.0	5
20307	Unexpected curative effect of PD-1 inhibitor in gastric cancer with brain metastasis: A case report. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
20308	Revisiting the Role of the CXCL13/CXCR5-Associated Immune Axis in Melanoma: Potential Implications for Anti-PD-1-Related Biomarker Research. <i>Life</i> , 2023, 13, 553.	1.1	2
20309	ALK-positive lung cancer: a moving target. <i>Nature Cancer</i> , 2023, 4, 330-343.	5.7	24
20310	Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3971.	1.8	4
20311	Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity. <i>Cancer Medicine</i> , 2023, 12, 9373-9383.	1.3	7
20312	Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies. <i>Viruses</i> , 2023, 15, 547.	1.5	15
20313	CAR-T Therapy in GBM: Current Challenges and Avenues for Improvement. <i>Cancers</i> , 2023, 15, 1249.	1.7	8
20314	NKG2A Immune Checkpoint in V α 2 T Cells: Emerging Application in Cancer Immunotherapy. <i>Cancers</i> , 2023, 15, 1264.	1.7	3
20315	Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
20316	LncRNA and its role in gastric cancer immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	2
20317	Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	6
20318	Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives) Tj ETQq1 1 0.784314 rgB International Journal of Oncology, 2023, 62, .	1.4	7
20319	Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20320	Exosomal microRNAs in cancer: Potential biomarkers and immunotherapeutic targets for immune checkpoint molecules. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	6
20321	Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
20322	Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 6583-6599.	1.2	2

#	ARTICLE	IF	CITATIONS
20323	The past, present, and future of immunotherapy for colorectal cancer. , 2023, 40, .		3
20324	The role of immune checkpoint inhibitors in patients with intracranial metastatic disease. <i>Journal of Neuro-Oncology</i> , 2023, 161, 469-478.	1.4	0
20325	Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
20326	Risk score = LncRNAs associated with doxorubicin metabolism can be used as molecular markers for immune microenvironment and immunotherapy in non-small cell lung cancer. <i>Heliyon</i> , 2023, 9, e13811.	1.4	7
20327	Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies. <i>Cancers</i> , 2023, 15, 1297.	1.7	4
20328	Caspase-9-mediated cleavage of vimentin attenuates the aggressiveness of leukemic NB4 cells. <i>Molecular and Cellular Biochemistry</i> , 0, , .	1.4	0
20329	Dynamic network biomarker to determine the critical point of breast cancer stage progression. <i>Breast Cancer</i> , 2023, 30, 453-465.	1.3	1
20330	Downstream Targets of VHL/HIF-1 α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance. <i>Cancers</i> , 2023, 15, 1316.	1.7	11
20331	p53 mutation and deletion contribute to tumor immune evasion. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	2
20332	Targeted Therapy Development in Acute Myeloid Leukemia. <i>Biomedicines</i> , 2023, 11, 641.	1.4	7
20333	Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence. <i>Cancers</i> , 2023, 15, 1314.	1.7	2
20334	Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer. <i>BioImpacts</i> , 0, , .	0.7	0
20336	Prognostic significance of epidermal growth factor receptor and programmed cell death-ligand 1 co-expression in esophageal squamous cell carcinoma. <i>Aging</i> , 0, , .	1.4	0
20337	NLRC3 is a potential prognostic biomarker that is correlated with immune cell infiltration in lung adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
20338	Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer. <i>Cancers</i> , 2023, 15, 1320.	1.7	13
20339	Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment. <i>Diagnostics</i> , 2023, 13, 793.	1.3	1
20340	MMP2 is a immunotherapy related biomarker and correlated with cancer-associated fibroblasts infiltrate in melanoma. <i>Cancer Cell International</i> , 2023, 23, .	1.8	3
20341	VISTA expression and patient selection for immune-based anticancer therapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6

#	ARTICLE	IF	CITATIONS
20342	The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients. <i>European Journal of Medical Research</i> , 2023, 28, .	0.9	1
20343	Advances in antibody-based therapy in oncology. <i>Nature Cancer</i> , 2023, 4, 165-180.	5.7	32
20344	MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation. <i>Cell Discovery</i> , 2023, 9, .	3.1	5
20345	The role of LncRNAs in tumor immunotherapy. <i>Cancer Cell International</i> , 2023, 23, .	1.8	11
20346	Cutaneous manifestations associated with immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	12
20347	Using deep learning to predict tumor mutational burden from scans of H&E-stained multicenter slides of lung squamous cell carcinoma. <i>Journal of Medical Imaging</i> , 2023, 10, .	0.8	1
20348	Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
20349	Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. <i>Molecular Cancer</i> , 2023, 22, .	7.9	29
20350	Metastasis-Related Signature for Clinically Predicting Prognosis and Tumor Immune Microenvironment of Osteosarcoma Patients. <i>Molecular Biotechnology</i> , 0, , .	1.3	0
20351	Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	1
20352	Dishevelled 2 regulates cancer cell proliferation and T cell mediated immunity in HER2-positive breast cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
20353	Characteristics and Prognosis of 8p11.23-Amplified Squamous Lung Carcinomas. <i>Journal of Clinical Medicine</i> , 2023, 12, 1711.	1.0	1
20354	Lung cancer immunotherapy: progress, pitfalls, and promises. <i>Molecular Cancer</i> , 2023, 22, .	7.9	104
20355	Current Trends in Mucosal Melanomas: An Overview. <i>Cancers</i> , 2023, 15, 1356.	1.7	5
20356	Case series: Immune checkpoint inhibitor-induced transverse myelitis. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	1
20357	Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. <i>Cell Reports Medicine</i> , 2023, 4, 100947.	3.3	7
20359	Tailoring therapies to counter the divergent immune landscapes of breast cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	3
20360	Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab. <i>JAMA Network Open</i> , 2023, 6, e230400.	2.8	15

#	ARTICLE	IF	CITATIONS
20361	Microbiota, Oxidative Stress, and Skin Cancer: An Unexpected Triangle. <i>Antioxidants</i> , 2023, 12, 546.	2.2	5
20362	An immune-related prognostic signature associated with immune landscape and therapeutic responses in gastric cancer. <i>Aging</i> , 0, , .	1.4	0
20363	Acquired radioresistance in EMT6 mouse mammary carcinoma cell line is mediated by CTLA-4 and PD-1 through JAK/STAT/PI3K pathway. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
20364	Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment. <i>Oncogene</i> , 2023, 42, 1117-1131.	2.6	8
20365	Immunotherapy in malignant peritoneal mesothelioma (Review). <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	2
20366	Killer to cure: Expression and production costs calculation of tobacco plantâ€made cancerâ€immune checkpoint inhibitors. <i>Plant Biotechnology Journal</i> , 2023, 21, 1254-1269.	4.1	4
20367	Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution. <i>Cancers</i> , 2023, 15, 1385.	1.7	5
20368	Developing an m5C regulatorâ€mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
20369	Advances in immune checkpoint inhibitors induced-cardiotoxicity. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20370	Imaging assessment of toxicity related to immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
20371	Targeting pyroptosis in breast cancer: biological functions and therapeutic potentials on It. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	5
20372	Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. , 2023, 11, e006464.		4
20373	PD-L1, a Master Regulator of Immunity 2.0. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4385.	1.8	0
20374	Interferon Gamma-Inducible NAMPT in Melanoma Cells Serves as a Mechanism of Resistance to Enhance Tumor Growth. <i>Cancers</i> , 2023, 15, 1411.	1.7	2
20375	Three cases of immune-related hypopituitarism after atezolizumabâ€bevacizumab treatment for hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 422-431.	0.4	2
20376	An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
20377	Blockade of neutrophil recruitment to tumor sites based on sialic acid-modified nanoplateforms enhances the efficacy of checkpoint blockade immunotherapy. <i>Asian Journal of Pharmaceutical Sciences</i> , 2023, 18, 100784.	4.3	0
20378	Predictive and Prognostic Implications of Circulating CX3CR1+ CD8+ T Cells in Nonâ€Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy. <i>Cancer Research Communications</i> , 2023, 3, 510-520.	0.7	2

#	ARTICLE	IF	CITATIONS
20379	LINC01798/miR-17-5p axis regulates ITGA8 and causes changes in tumor microenvironment and stemness in lung adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
20380	Unobvious Neutrophil Extracellular Traps Signification in the Course of Oral Squamous Cell Carcinoma: Current Understanding and Future Perspectives. <i>Cancer Control</i> , 2023, 30, 107327482311593.	0.7	1
20381	RAGA prevents tumor immune evasion of LUAD by promoting CD47 lysosome degradation. <i>Communications Biology</i> , 2023, 6, .	2.0	3
20382	Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. <i>Cancer Immunology Research</i> , 2023, 11, 558-569.	1.6	2
20383	Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress. <i>Cancers</i> , 2023, 15, 1404.	1.7	0
20384	An angiogenesis-related three-long non-coding ribonucleic acid signature predicts the immune landscape and prognosis in hepatocellular carcinoma. <i>Heliyon</i> , 2023, 9, e13989.	1.4	5
20385	Leveraging Tumor Microenvironment Infiltration in Pancreatic Cancer to Identify Gene Signatures Related to Prognosis and Immunotherapy Response. <i>Cancers</i> , 2023, 15, 1442.	1.7	2
20386	Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. , 2023, 20, 318-340.		13
20387	Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	9
20388	Comprehensive Analysis of Prognosis and Immune Landscapes Based on Lipid-Metabolism- and Ferroptosis-Associated Signature in Uterine Corpus Endometrial Carcinoma. <i>Diagnostics</i> , 2023, 13, 870.	1.3	1
20389	Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, .	1.2	0
20390	Probabilistic Mixture Models Improve Calibration of Panel-derived Tumor Mutational Burden in the Context of both Tumor-normal and Tumor-only Sequencing. <i>Cancer Research Communications</i> , 2023, 3, 501-509.	0.7	1
20391	Cross-platform normalization enables machine learning model training on microarray and RNA-seq data simultaneously. <i>Communications Biology</i> , 2023, 6, .	2.0	8
20392	Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL). <i>JTO Clinical and Research Reports</i> , 2023, 4, 100484.	0.6	1
20393	Bronchiolitis obliterans syndrome associated with an immune checkpoint inhibitor in a patient with non-small cell lung cancer. <i>Respiratory Medicine Case Reports</i> , 2023, 42, 101824.	0.2	1
20394	Adhesion analysis via a tumor vasculature-like microfluidic device identifies CD8+ T cells with enhanced tumor homing to improve cell therapy. <i>Cell Reports</i> , 2023, 42, 112175.	2.9	3
20395	<sc>CD169</sc>+ sinus macrophages in regional lymph nodes do not predict mismatch repair status of patients with colorectal cancer. <i>Cancer Medicine</i> , 2023, 12, 10199-10211.	1.3	5
20396	Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer” current status and future directions. <i>Translational Lung Cancer Research</i> , 2023, 12, 322-336.	1.3	1

#	ARTICLE	IF	CITATIONS
20397	Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin?. <i>Journal of Personalized Medicine</i> , 2023, 13, 415.	1.1	2
20398	Variable Intrinsic Expression of Immunoregulatory Biomarkers in Breast Cancer Cell Lines, Mammospheres, and Co-Cultures. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4478.	1.8	2
20399	Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies. <i>Translational Pediatrics</i> , 2023, 12, 487-502.	0.5	2
20400	Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations. <i>Translational Lung Cancer Research</i> , 2023, 12, 219-229.	1.3	1
20401	SWI/SNF Complex Genomic Alterations as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Multiple Cancers. <i>Cancer Immunology Research</i> , 2023, 11, 646-656.	1.6	7
20402	Therapeutic Potential of Luteolin on Cancer. <i>Vaccines</i> , 2023, 11, 554.	2.1	21
20403	Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29). <i>Translational Lung Cancer Research</i> , 2023, 12, 266-276.	1.3	2
20404	KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions. <i>Cells</i> , 2023, 12, 749.	1.8	5
20405	Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	25
20406	Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 222-233.	0.8	0
20407	Myeloid cells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
20408	Pyodermitis during Nivolumab Treatment for Non-Small Cell Lung Cancer: A Case Report and Review of the Literature. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4580.	1.8	3
20409	Development and Validation of a Prognostic Risk Model Based on Nature Killer Cells for Serous Ovarian Cancer. <i>Journal of Personalized Medicine</i> , 2023, 13, 403.	1.1	1
20410	Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4522.	1.8	16
20411	Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study. <i>Translational Lung Cancer Research</i> , 2023, 12, 312-321.	1.3	1
20412	Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. <i>Lancet Oncology</i> , The, 2023, 24, e133-e143.	5.1	6
20413	Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 1833.	1.0	4
20414	Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody. , 2023, 11, e006234.		10

#	ARTICLE	IF	CITATIONS
20415	Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2023, 83, 1410-1425.	0.4	7
20416	CRISPR/Cas9 screen uncovers functional translation of cryptic lncRNA-encoded open reading frames in human cancer. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	10
20417	Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors. <i>ESMO Open</i> , 2023, 8, 100784.	2.0	1
20418	Contrast subgraphs allow comparing homogeneous and heterogeneous networks derived from omics data. <i>GigaScience</i> , 2022, 12, .	3.3	3
20419	3D Spheroid Configurations Are Possible Indicators for Evaluating the Pathophysiology of Melanoma Cell Lines. <i>Cells</i> , 2023, 12, 759.	1.8	8
20420	Biochemical Studies of Systemic Lupus Erythematosus-Associated Mutations in Nonreceptor Tyrosine Kinases Ack1 and Brk. <i>Biochemistry</i> , 2023, 62, 1124-1137.	1.2	0
20421	A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors. <i>Annals of Translational Medicine</i> , 2023, 11, 164-164.	0.7	0
20422	ANKLE1 cleaves mitochondrial DNA and contributes to cancer risk by promoting apoptosis resistance and metabolic dysregulation. <i>Communications Biology</i> , 2023, 6, .	2.0	1
20423	Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines. <i>Biomedicines</i> , 2023, 11, 735.	1.4	0
20424	The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4708.	1.8	2
20425	Tumor-specific memory CD8+ T cells are strictly resident in draining lymph nodes during tumorigenesis. , 2023, 20, 423-426.		1
20426	PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell lung cancer (NSCLC) by granzyme B secretion. <i>Clinical and Translational Oncology</i> , 2023, 25, 2373-2383.	1.2	3
20427	Construction of a prognostic risk assessment model for HER2+ breast cancer based on autophagy-related genes. <i>Breast Cancer</i> , 2023, 30, 478-488.	1.3	0
20428	Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	11
20429	Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer. <i>Cancers</i> , 2023, 15, 1532.	1.7	6
20430	Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2023, 13, 457.	1.1	2
20431	Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311568.	1.4	2
20432	Notch3 regulates Mybl2 via HeyL to limit proliferation and tumor initiation in breast cancer. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	1

#	ARTICLE	IF	CITATIONS
20433	Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 1985.	1.0	7
20434	β 3-adrenergic receptor on tumor-infiltrating lymphocytes sustains IFN- β -dependent PD-L1 expression and impairs anti-tumor immunity in neuroblastoma. <i>Cancer Gene Therapy</i> , 2023, 30, 890-904.	2.2	5
20435	Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	3
20436	A case of pembrolizumab-induced pigmented purpuric dermatosis. <i>JAAD Case Reports</i> , 2023, 34, 77-79.	0.4	1
20437	Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification. <i>Cell Death and Differentiation</i> , 2023, 30, 1305-1319.	5.0	4
20438	Supplementation with α -ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	7
20439	PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	1
20440	DNA methylation patterns associated with breast cancer prognosis that are specific to tumor subtype and menopausal status. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
20441	RTP4 silencing provokes tumor-intrinsic resistance to immune checkpoint blockade in colorectal cancer. <i>Journal of Gastroenterology</i> , 2023, 58, 540-553.	2.3	1
20442	Efficacy and Safety of Tyrosine Kinase Inhibitors Alone or Combination with Programmed Death-1 Inhibitors in Treating of Hepatitis C-Related Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 357-367.	1.8	2
20443	Chimeric antigen receptor T cells therapy in solid tumors. <i>Clinical and Translational Oncology</i> , 2023, 25, 2279-2296.	1.2	2
20444	CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy. <i>Biomolecules</i> , 2023, 13, 465.	1.8	8
20445	Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2217-2231.	2.0	2
20446	Dancing with the Surgeon: Neoadjuvant and Adjuvant Immunotherapies from the Medical Oncologist's Perspective. <i>Journal of Chest Surgery</i> , 2023, 56, 67-74.	0.2	2
20447	Characterization of a novel potency endpoint for the evaluation of immune checkpoint blockade in humanized mice. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
20448	Precision Surgery in NSCLC. <i>Cancers</i> , 2023, 15, 1571.	1.7	5
20449	Blocking of programmed cell death-ligand 1 (PD-L1) expressed on endothelial cells promoted the recruitment of CD8+IFN- β + T cells in atherosclerosis. <i>Inflammation Research</i> , 2023, 72, 783-796.	1.6	3
20450	Antitumor Therapy Targeting the Tumor Microenvironment. <i>Journal of Oncology</i> , 2023, 2023, 1-16.	0.6	4

#	ARTICLE	IF	CITATIONS
20451	Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4877.	1.8	5
20452	Opportunities and challenges related to ferroptosis in glioma and neuroblastoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
20453	Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the “NSCLC” of GI Oncology?. <i>Cancers</i> , 2023, 15, 1578.	1.7	8
20454	Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. <i>ESMO Open</i> , 2023, 8, 101160.	2.0	3
20455	Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?. <i>Pharmaceutics</i> , 2023, 15, 823.	2.0	1
20456	A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2023, 50, 147-172.	0.8	5
20457	ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors. <i>NAR Cancer</i> , 2023, 5, .	1.6	0
20458	CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. <i>Nature Communications</i> , 2023, 14, .	5.8	14
20459	Dynamic changes in circulating tumor <sc>DNA</sc> assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in <sc>NSCLC</sc>. <i>Molecular Oncology</i> , 2023, 17, 779-791.	2.1	0
20460	PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
20461	Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20462	T cell effects and mechanisms in immunotherapy of head and neck tumors. <i>Cell Communication and Signaling</i> , 2023, 21, .	2.7	4
20463	Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature. <i>Diagnostics</i> , 2023, 13, 987.	1.3	5
20464	HR+/HER2- de novo metastatic breast cancer: a true peculiar entity?. <i>Drugs in Context</i> , 0, 12, 1-19.	1.0	2
20465	[18F]FDG PET/CT in the Evaluation of Melanoma Patients Treated with Immunotherapy. <i>Diagnostics</i> , 2023, 13, 978.	1.3	4
20466	Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
20467	Progression in immunotherapy for advanced prostate cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
20468	Single-cell and bulk RNA sequencing identifies T cell marker genes score to predict the prognosis of pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	1

#	ARTICLE	IF	CITATIONS
20469	Eosinophil and IFN- γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
20470	Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
20472	Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5011.	1.8	1
20473	Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
20474	Current landscape and tailored management of immune-related adverse events. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
20475	Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
20476	Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs. <i>Cancers</i> , 2023, 15, 1582.	1.7	4
20477	The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer. <i>Cancers</i> , 2023, 15, 1597.	1.7	6
20478	Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. <i>Cancers</i> , 2023, 15, 1629.	1.7	9
20479	Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
20480	Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma. <i>Biomedicines</i> , 2023, 11, 801.	1.4	2
20481	Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME). <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
20482	Diversity of immune checkpoints in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	11
20483	Collectin-11 promotes cancer cell proliferation and tumor growth. <i>JCI Insight</i> , 2023, 8, .	2.3	4
20484	Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer. <i>Cell Communication and Signaling</i> , 2023, 21, .	2.7	5
20485	Emerging phagocytosis checkpoints in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	32
20486	Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. <i>Nature</i> , 2023, 615, 668-677.	13.7	129
20487	Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1

#	ARTICLE	IF	CITATIONS
20488	Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond. <i>Cancers</i> , 2023, 15, 1643.	1.7	1
20489	Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
20490	Acute myocarditis with transient myocardial thickening in two oncologic patients treated with anti-CD2 immunotherapy. <i>ESC Heart Failure</i> , 2023, 10, 2090-2093.	1.4	3
20491	Status and prognostic value of immunological biomarkers of breast cancer. <i>Oncology Letters</i> , 2023, 25, .	0.8	1
20492	Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity. , 2023, 11, e006462.		3
20493	Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer. <i>Endocrine Connections</i> , 2023, 12, .	0.8	3
20494	Blocking soluble TNF α sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. , 2023, 11, e005325.		6
20495	Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
20496	The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
20497	Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. <i>Nature</i> , 2023, 615, 697-704.	13.7	44
20498	Discontinuation of Immune Checkpoint Inhibitor due to irAEs in NSCLC Patients With EGFR Mutation. <i>Cancer Diagnosis & Prognosis</i> , 2023, 3, 244-250.	0.3	1
20499	Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity. <i>Science Advances</i> , 2023, 9, .	4.7	20
20500	MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
20501	Adaptive immune receptor features related to breast cancer tissue in Kenyan patients: high immunoglobulin gene expression and high levels of gamma-delta T-cells. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
20502	Intercellular hif1 α reprograms mammary progenitors and myeloid immune evasion to drive high-risk breast lesions. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	3
20503	Overexpression of CHAF1A is associated with poor prognosis, tumor immunosuppressive microenvironment and treatment resistance. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
20504	Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
20505	Comprehensive bioinformatic analysis constructs a CXCL model for predicting survival and immunotherapy effectiveness in ovarian cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1

#	ARTICLE	IF	CITATIONS
20506	Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy. <i>Vaccines</i> , 2023, 11, 614.	2.1	4
20507	Circulating Tumor Cells Predict Response of Neoadjuvant Chemotherapy in Patients with Bladder Cancer: A Preliminary Study. <i>Diagnostics</i> , 2023, 13, 1032.	1.3	0
20508	PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors'™ Response and Survival in Advanced Melanoma Patients in Brazil. <i>Diagnostics</i> , 2023, 13, 1041.	1.3	1
20509	Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
20510	Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
20511	Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies. <i>Cancers</i> , 2023, 15, 1679.	1.7	6
20512	Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients. <i>Molecular Oncology</i> , 2023, 17, 737-746.	2.1	3
20513	Impact of microbiota on breast cancer hormone therapy. <i>Cell Stress</i> , 2023, 7, 12-19.	1.4	1
20514	Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China. <i>PharmacoEconomics - Open</i> , 2023, 7, 273-284.	0.9	1
20515	Exosomal PD-L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B-cell lymphoma. <i>Oncology Reports</i> , 2023, 49, .	1.2	1
20516	Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5424.	1.8	2
20517	A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
20518	Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment. , 0, 3, .		0
20519	Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles. <i>Molecules</i> , 2023, 28, 2556.	1.7	5
20520	Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2023, 12, 2173.	1.0	6
20521	Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic Implications. <i>Cancers</i> , 2023, 15, 1728.	1.7	2
20522	Metastasis of breast cancer to bones alters the tumor immune microenvironment. <i>European Journal of Medical Research</i> , 2023, 28, .	0.9	4
20523	Anti-PD(L)1 therapy of non-small cell lung cancer—A summary of clinical trials and current progresses. <i>Heliyon</i> , 2023, 9, e14566.	1.4	2

#	ARTICLE	IF	CITATIONS
20524	Chromothripsis is correlated with reduced cytotoxic immune infiltration and diminished responsiveness to checkpoint blockade immunotherapy. <i>Theranostics</i> , 2023, 13, 1443-1453.	4.6	0
20525	Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. <i>Theranostics</i> , 2023, 13, 1520-1544.	4.6	19
20526	Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 \geq 50% in Patients Treated in Quebec's University Teaching Hospitals (DALP-First Study). <i>Current Oncology</i> , 2023, 30, 3251-3262.	0.9	0
20527	The role of Th-17 cells and IL-17 in the metastatic spread of breast cancer: As a means of prognosis and therapeutic target. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
20528	Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
20529	Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment. <i>Cancer Medicine</i> , 2023, 12, 10371-10384.	1.3	2
20530	Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 1748.	1.7	2
20531	Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355. <i>Cancer Medicine</i> , 2023, 12, 10280-10293.	1.3	5
20532	Turning a Tumor Microenvironment Pitfall into Opportunity: Discovery of Benzamidoxime as PD-L1 Ligand with pH-Dependent Potency. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5535.	1.8	3
20533	Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype. <i>Pharmaceutics</i> , 2023, 15, 938.	2.0	1
20534	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. , 2023, 11, e005921.		6
20535	Association of Glycosylation-Related Genes with Different Patterns of Immune Profiles and Prognosis in Cervical Cancer. <i>Journal of Personalized Medicine</i> , 2023, 13, 529.	1.1	1
20536	Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2023, 13, 526.	1.1	5
20537	Immunohistochemical profiling of the tumour microenvironment in borderline and malignant ovarian tumours in young women. <i>Oncology Letters</i> , 2023, 25, .	0.8	0
20538	SIRT7 orchestrates melanoma progression by simultaneously promoting cell survival and immune evasion via UPR activation. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	11
20539	Timed hazard networks: Incorporating temporal difference for oncogenetic analysis. <i>PLoS ONE</i> , 2023, 18, e0283004.	1.1	2
20540	Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	3
20541	Case report: POLE (P286R) mutation in a case of recurrent intestinal leakage and its treatment. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1

#	ARTICLE	IF	CITATIONS
20542	Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020. <i>JAMA Network Open</i> , 2023, 6, e232002.	2.8	7
20543	The current understanding of the immune landscape relative to radiotherapy across tumor types. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
20544	Characterization of pancreatic cancer with ultra-low tumor mutational burden. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
20545	Immunotherapy for HER-2 positive breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	8
20546	Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5643.	1.8	7
20547	Development and validation of a tumor immune cell infiltration-related gene signature for recurrence prediction by weighted gene co-expression network analysis in prostate cancer. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
20548	Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
20549	CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
20550	Functional and Phenotypic Characterisations of Common Syngeneic Tumour Cell Lines as Estrogen Receptor-Positive Breast Cancer Models. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5666.	1.8	0
20551	Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
20552	An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5648.	1.8	2
20553	Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
20554	Recent advances in immunotherapy and molecular targeted therapy for gastric cancer. <i>Future Science OA</i> , 2023, 9, .	0.9	2
20555	Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20556	The Potential Revolution of Cancer Treatment with CRISPR Technology. <i>Cancers</i> , 2023, 15, 1813.	1.7	7
20557	Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. <i>Nature Cancer</i> , 2023, 4, 516-534.	5.7	9
20558	Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
20559	Associations of immune checkpoint inhibitor therapy efficacy with clinical parameters and tumor-infiltrating CD68-positive cell counts in patients with EGFR-mutant non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	1

#	ARTICLE	IF	CITATIONS
20560	Immune microenvironment of medulloblastoma: The association between its molecular subgroups and potential targeted immunotherapeutic receptors. <i>World Journal of Clinical Oncology</i> , 0, 14, 117-130.	0.9	1
20561	Metal-Organic Frameworks Applications in Synergistic Cancer Photo-Immunotherapy. <i>Polymers</i> , 2023, 15, 1490.	2.0	7
20562	Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients. <i>Breast Cancer</i> , 0, , .	1.3	1
20563	Development and validation of prognostic index based on immunogenic cell death-related genes with melanoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
20564	Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy. <i>Journal of Immunology Research</i> , 2023, 2023, 1-13.	0.9	2
20565	H4-methylation regulators mediated epitranscriptome patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma. <i>Clinical Epigenetics</i> , 2023, 15, .	1.8	1
20566	Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311614.	1.4	8
20567	Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	4
20568	Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2023, 12, 10636-10646.	1.3	3
20569	Antitumor effect of neoantigen-reactive T cells combined with PD1 inhibitor therapy in mouse lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 7363-7378.	1.2	1
20570	Intratumoral heterogeneity, treatment response, and survival outcome of <sc>ER</sc> â€œpositive <sc>HER2</sc> â€œpositive breast cancer. <i>Cancer Medicine</i> , 0, , .	1.3	1
20571	Theranostic applications of selenium nanomedicines against lung cancer. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	10
20572	Propagated Circulating Tumor Cells Uncover the Potential Role of NFÎ²B, EMT, and TGFÎ² Signaling Pathways and COP1 in Metastasis. <i>Cancers</i> , 2023, 15, 1831.	1.7	3
20573	Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion. <i>Molecular Cell</i> , 2023, 83, 1216-1236.e12.	4.5	13
20575	11Î²-HSD1 inhibition does not affect murine tumour angiogenesis but may exert a selective effect on tumour growth by modulating inflammation and fibrosis. <i>PLoS ONE</i> , 2023, 18, e0255709.	1.1	0
20576	Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review. <i>Biology</i> , 2023, 12, 472.	1.3	2
20577	GE11-antigen-loaded hepatitis B virus core antigen virus-like particles efficiently bind to TNBC tumor. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
20578	Refractory right ventricular myocarditis induced by immune checkpoint inhibitor despite therapy cessation and immune suppression. <i>Cardio-Oncology</i> , 2023, 9, .	0.8	1

#	ARTICLE	IF	CITATIONS
20579	Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2023, .	1.3	1
20580	MiR-4521 perturbs FOXM1-mediated DNA damage response in breast cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	2
20581	Immunotherapies for advanced hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
20582	Non-Oncogene Addiction of KRAS-Mutant Cancers to IL-1 β via Versican and Mononuclear IKK β . <i>Cancers</i> , 2023, 15, 1866.	1.7	0
20583	The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
20584	Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5938.	1.8	9
20585	Interactive process mining of cancer treatment sequences with melanoma real-world data. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
20586	Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature. <i>Journal of Immunotherapy and Precision Oncology</i> , 2023, 6, 111-116.	0.6	2
20587	Definition of a Novel Immunogenic Cell Death-Relevant Gene Signature Associated with Immune Landscape in Gastric Cancer. <i>Biochemical Genetics</i> , 2023, 61, 2092-2115.	0.8	2
20588	Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	7
20589	Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study. <i>ESMO Open</i> , 2023, 8, 100877.	2.0	3
20590	CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies. <i>IScience</i> , 2023, 26, 106443.	1.9	2
20591	Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. <i>Molecular Cancer</i> , 2023, 22, .	7.9	32
20592	Ageing microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	5
20593	Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Oncology and Therapy</i> , 2023, 11, 185-198.	1.0	2
20594	FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 1901.	1.7	1
20595	Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 1909.	1.7	4
20596	Epigenetic state determines the in vivo efficacy of STING agonist therapy. <i>Nature Communications</i> , 2023, 14, .	5.8	12

#	ARTICLE	IF	CITATIONS
20597	DNA hypomethylation mediates immune response in pan-cancer. <i>Epigenetics</i> , 2023, 18, .	1.3	3
20598	Systematic pan-cancer analysis of the potential tumor diagnosis and prognosis biomarker P4HA3. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	2
20599	Myocarditis and myasthenia gravis induced by immune checkpoint inhibitor in a patient with relapsed thymoma: A case report. <i>Clinical Case Reports (discontinued)</i> , 2023, 11, .	0.2	1
20600	Genomics of Prostate Cancer: Clinical Utility and Challenges. <i>Acta Clinica Croatica</i> , 2022, , .	0.1	0
20601	Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
20602	Towards a consensus definition of immune exclusion in cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
20603	Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine. <i>Cancers</i> , 2023, 15, 1891.	1.7	2
20604	Immune microenvironment and clinical feature analyses based on a prognostic model in lymph node-positive breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
20605	Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
20606	Tumors evade immune cytotoxicity by altering the surface topology of NK cells. <i>Nature Immunology</i> , 2023, 24, 802-813.	7.0	17
20607	Tim3 and PD-1 as a therapeutic and prognostic targets in colorectal cancer: Relationship with sidedness, clinicopathological parameters, and survival. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
20608	Disparities in stage at diagnosis among breast cancer molecular subtypes in China. <i>Cancer Medicine</i> , 0, , .	1.3	1
20609	Performance of a PLK1-based immune risk model for prognosis and treatment response prediction in breast cancer. <i>Cancer Medicine</i> , 0, , .	1.3	1
20610	What Can Trigger Spontaneous Regression of Breast Cancer?. <i>Diagnostics</i> , 2023, 13, 1224.	1.3	1
20611	Recent Developments in Nanoparticle-Based Photoimmunotherapy for Cancer Treatment. <i>Small Methods</i> , 2023, 7, .	4.6	4
20612	Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	3
20613	Mitochondrial Signaling Pathways Associated with DNA Damage Responses. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6128.	1.8	5
20614	Antibody Surface Profiling Identifies Glycoforms in Multiple Myeloma as Targets for Immunotherapy: From Antibody Derivatives to Mimetic Peptides for Killing Tumor Cells. <i>Cancers</i> , 2023, 15, 1934.	1.7	0

#	ARTICLE	IF	CITATIONS
20615	Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer. <i>Cancers</i> , 2023, 15, 1936.	1.7	6
20616	Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
20617	Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20618	Arenaviruses: Old viruses present new solutions for cancer therapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
20619	Risk stratification based on DNA damage-repair-related signature reflects the microenvironmental feature, metabolic status and therapeutic response of breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20620	Application status and future prospects of the PDX model in lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
20621	Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine. <i>Nature Biomedical Engineering</i> , 2023, 7, 281-297.	11.6	28
20622	Microparticle Phosphatidylserine Mediates Coagulation: Involvement in Tumor Progression and Metastasis. <i>Cancers</i> , 2023, 15, 1957.	1.7	3
20623	S1P1 Threonine 236 Phosphorylation Mediates the Invasiveness of Triple-Negative Breast Cancer and Sensitivity to FTY720. <i>Cells</i> , 2023, 12, 980.	1.8	2
20624	URB2 as an important marker for glioma prognosis and immunotherapy. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
20625	Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	0
20626	Targeting adipocyte-immune cell crosstalk to control breast cancer progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
20627	The predictive value of <sc>PD</sc>L1 expression in patients with advanced hepatocellular carcinoma treated with <sc>PD</sc>L1 inhibitors: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2023, 12, 9282-9292.	1.3	8
20628	The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage III triple-negative breast cancer. <i>British Journal of Cancer</i> , 2023, 128, 2044-2053.	2.9	3
20629	Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance. <i>Cardio-Oncology</i> , 2023, 9, .	0.8	1
20630	Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. <i>Molecular Cancer</i> , 2023, 22, .	7.9	18
20631	Comprehensive analysis of cuproptosis-related long noncoding RNA for predicting prognostic and diagnostic value and immune landscape in colorectal adenocarcinoma. <i>Human Genomics</i> , 2023, 17, .	1.4	1
20632	PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy. <i>Scientific Reports</i> , 2023, 13, .	1.6	3

#	ARTICLE	IF	CITATIONS
20633	Correlation of androgen receptor with ultrasound, clinicopathological features and clinical outcomes in breast cancer. <i>Insights Into Imaging</i> , 2023, 14, .	1.6	2
20634	Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1971-1989.	2.0	5
20635	Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
20636	Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. <i>Nature Reviews Nephrology</i> , 2023, 19, 440-450.	4.1	4
20637	A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity. <i>Cancer Biology and Medicine</i> , 2023, 20, 218-228.	1.4	2
20638	Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms. <i>Biological Trace Element Research</i> , 2023, 201, 5692-5707.	1.9	5
20639	Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasis. <i>Nature Communications</i> , 2023, 14, .	5.8	9
20640	Quantification of spatial and phenotypic heterogeneity in an agent-based model of tumour-macrophage interactions. <i>PLoS Computational Biology</i> , 2023, 19, e1010994.	1.5	7
20641	Emerging Targeted Therapies for HER2-Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 1987.	1.7	18
20642	Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study. <i>Life</i> , 2023, 13, 877.	1.1	3
20643	Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas. <i>Cancers</i> , 2023, 15, 1989.	1.7	2
20644	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. <i>Biomedicines</i> , 2023, 11, 1020.	1.4	6
20645	Radiomics and Delta-Radiomics Signatures to Predict Response and Survival in Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2023, 15, 1968.	1.7	7
20646	Precision Oncology: Evolving Clinical Trials across Tumor Types. <i>Cancers</i> , 2023, 15, 1967.	1.7	9
20647	Low-Dose Immunotherapy: Is It Just an Illusion?. <i>Biomedicines</i> , 2023, 11, 1032.	1.4	1
20648	The efficacy and safety of first-line anti-PD-1/PD-L1 immunotherapy for gastric esophageal cancer: A systematic review and meta-analysis of phase III randomized controlled trials. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	0.8	0
20649	Therapeutic Cancer Vaccines for Nonmelanoma Skin Cancer. <i>Current Treatment Options in Oncology</i> , 2023, 24, 496-514.	1.3	1
20650	APC mutation correlated with poor response of immunotherapy in colon cancer. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	1

#	ARTICLE	IF	CITATIONS
20651	Aptamer-Based Strategies to Boost Immunotherapy in TNBC. <i>Cancers</i> , 2023, 15, 2010.	1.7	5
20652	Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner. <i>British Journal of Cancer</i> , 2023, 128, 2126-2139.	2.9	5
20653	Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis. <i>Cell Discovery</i> , 2023, 9, .	3.1	18
20654	The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events. <i>Cancers</i> , 2023, 15, 2016.	1.7	3
20655	Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
20656	LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2023, 12, 510-529.	1.3	2
20657	Oral Squamous Cell Carcinoma and Concomitant Primary Tumors, What Do We Know? A Review of the Literature. <i>Current Oncology</i> , 2023, 30, 3721-3734.	0.9	12
20658	Enhancement of immune surveillance in breast cancer by targeting hypoxic tumor endothelium: Can it be an immunological switch point?. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
20659	Correlating volumetric and linear measurements of brain metastases on MRI scans using intelligent automation software: a preliminary study. <i>Journal of Neuro-Oncology</i> , 2023, 162, 363-371.	1.4	1
20660	First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	3
20661	Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
20662	Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2023, 29, 1938-1951.	3.2	2
20663	Identifying novel biomarkers associated with bladder cancer treatment outcomes. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
20664	Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC. <i>Discover Oncology</i> , 2023, 14, .	0.8	2
20665	Molecular breast cancer subtype identification using photoacoustic spectral analysis and machine learning at the biomacromolecular level. <i>Photoacoustics</i> , 2023, 30, 100483.	4.4	7
20666	Exploring immune interactions in triple negative breast cancer: IL-1 β inhibition and its therapeutic potential. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	5
20668	An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
20669	The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications. <i>Molecular Diagnosis and Therapy</i> , 0, , .	1.6	2

#	ARTICLE	IF	CITATIONS
20670	Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens. <i>Cancers</i> , 2023, 15, 2029.	1.7	1
20671	Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
20672	Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
20673	Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	8
20674	A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
20675	GATA-3 expression in breast cancer is related to intratumoral M2 macrophage infiltration and tumor differentiation. <i>PLoS ONE</i> , 2023, 18, e0283003.	1.1	4
20676	LncRNA LITATS1 suppresses TGF β -induced EMT and cancer cell plasticity by potentiating T β RI degradation. <i>EMBO Journal</i> , 2023, 42, .	3.5	14
20677	Hyperprogressive disease after immune checkpoint inhibitor therapy in a patient with non-small cell lung cancer who harbors a TGFBR2 mutation: A case report. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	0.8	4
20678	RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
20679	Macrophages facilitate tumor cell PD-L1 expression via an IL-1 β -centered loop to attenuate immune checkpoint blockade. <i>MedComm</i> , 2023, 4, .	3.1	2
20680	Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	14
20681	Tumor Immunophenotyping-Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer. <i>Advanced Science</i> , 2023, 10, .	5.6	3
20682	Targeting the Molecular and Immunologic Features of Leiomyosarcoma. <i>Cancers</i> , 2023, 15, 2099.	1.7	5
20683	Upregulation of the ferroptosis-related STEAP3 gene is a specific predictor of poor triple-negative breast cancer patient outcomes. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	7
20684	The tumor-nerve circuit in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 543-574.	2.7	4
20685	Somatic Super-Enhancer Epigenetic Signature for Overall Survival Prediction in Patients with Breast Invasive Carcinoma. <i>Bioinformatics and Biology Insights</i> , 2023, 17, 117793222311627.	1.0	0
20686	Crosstalk between triple negative breast cancer and microenvironment. <i>Oncotarget</i> , 2023, 14, 284-293.	0.8	2
20687	A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1

#	ARTICLE	IF	CITATIONS
20688	The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions. <i>Cancers</i> , 2023, 15, 2101.	1.7	3
20689	The Blockade of Mitogen-Activated Protein Kinase 14 Activation by Marine Natural Product Crassolide Triggers ICD in Tumor Cells and Stimulates Anti-Tumor Immunity. <i>Marine Drugs</i> , 2023, 21, 225.	2.2	0
20690	Comprehensive analysis of glycolysis mediated pattern clusters and immune infiltration characterization of tumor microenvironment in triple-negative breast cancer. <i>Heliyon</i> , 2023, 9, e15175.	1.4	0
20691	Spending, Utilization, and Price Trends for Immune Checkpoint Inhibitors in US Medicaid Programs: An Empirical Analysis from 2011 to 2021. <i>Clinical Drug Investigation</i> , 2023, 43, 289-298.	1.1	5
20692	Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice. <i>Biomedicines</i> , 2023, 11, 1071.	1.4	27
20693	Integrative bioinformatics approaches to establish potential prognostic immune-related genes signature and drugs in the non-small cell lung cancer microenvironment. <i>Frontiers in Pharmacology</i> , 2023, 14, .	1.6	0
20694	Tumour Infiltrating Lymphocytes (TILs) and immune composition in breast cancer patients from Kenya: Spatial distributions and associations with risk factors and tumour characteristics. <i>Breast Cancer Research and Treatment</i> , 2023, .	1.1	0
20695	Ubiquitin-Specific Protease 43 Impacts Pancreatic Ductal Adenocarcinoma Prognosis by Altering Its Proliferation and Infiltration of Surrounding Immune Cells. <i>Journal of Immunology Research</i> , 2023, 2023, 1-13.	0.9	1
20696	CircPVT1 promotes ERα-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS. <i>EMBO Journal</i> , 2023, 42, .	3.5	17
20697	Kernelized multiview signed graph learning for single-cell RNA sequencing data. <i>BMC Bioinformatics</i> , 2023, 24, .	1.2	0
20698	Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311659.	1.4	0
20699	Newly developed 3D in vitro models to study tumor-immune interaction. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	11
20700	Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
20701	A2AR as a Prognostic Marker and a Potential Immunotherapy Target in Human Glioma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6688.	1.8	4
20702	Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors. <i>Molecular and Cellular Biochemistry</i> , 2024, 479, 127-170.	1.4	1
20703	Stemness-related lncRNAs signature as a biologic prognostic model for head and neck squamous cell carcinoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2023, .	2.2	1
20704	MLKL and other necroptosis-related genes promote the tumor immune cell infiltration, guiding for the administration of immunotherapy in bladder urothelial carcinoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2023, .	2.2	1
20705	The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma. <i>Pharmaceutics</i> , 2023, 15, 1134.	2.0	5

#	ARTICLE	IF	CITATIONS
20706	The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6710.	1.8	7
20707	Evolution-Informed Strategies for Combating Drug Resistance in Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6738.	1.8	5
20708	Prognostic value of various immune cells and Immunoscore in triple-negative breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
20709	The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
20710	Machine learning-based construction of immunogenic cell death-related score for improving prognosis and response to immunotherapy in melanoma. <i>Aging</i> , 2023, 15, 2667-2688.	1.4	2
20711	The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2483-2498.	2.0	1
20712	Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy. <i>Nature Communications</i> , 2023, 14, .	5.8	7
20714	Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
20715	Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
20716	Dietary tryptophan metabolite released by intratumoral <i>Lactobacillus reuteri</i> facilitates immune checkpoint inhibitor treatment. <i>Cell</i> , 2023, 186, 1846-1862.e26.	13.5	92
20717	Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. <i>Nature Genetics</i> , 2023, 55, 807-819.	9.4	18
20718	PATZ1 in Non-Small Cell Lung Cancer: A New Biomarker That Negatively Correlates with PD-L1 Expression and Suppresses the Malignant Phenotype. <i>Cancers</i> , 2023, 15, 2190.	1.7	3
20719	The influence of antibody CD166 on the treatment of tumor and the immunological mechanism in mice bearing oral squamous cell carcinoma. <i>Translational Cancer Research</i> , 2023, .	0.4	0
20720	The effects of KIR2DL4 stimulated NK-92 cells on the apoptotic pathways of HER2+HER-breast cancer cells. , 2023, 40, .		2
20721	Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors. <i>Immuno-Oncology Technology</i> , 2023, 18, 100384.	0.2	8
20722	Immunotherapeutic and their immunological aspects: Current treatment strategies and agents. <i>National Journal of Maxillofacial Surgery</i> , 2022, 13, 322.	0.1	1
20723	Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. <i>Cancers</i> , 2023, 15, 2204.	1.7	10
20724	Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6945.	1.8	7

#	ARTICLE	IF	CITATIONS
20725	Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. <i>Cancer Cell</i> , 2023, 41, 791-806.e4.	7.7	5
20726	Isolation of tumour-reactive lymphocytes from peripheral blood via microfluidic immunomagnetic cell sorting. <i>Nature Biomedical Engineering</i> , 2023, 7, 1188-1203.	11.6	9
20727	Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. <i>Healthcare (Switzerland)</i> , 2023, 11, 1073.	1.0	0
20728	Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer. <i>Current Oncology</i> , 2023, 30, 4094-4109.	0.9	0
20729	Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. <i>Cancer Cell International</i> , 2023, 23, .	1.8	24
20730	SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC. <i>Investigational New Drugs</i> , 0, , .	1.2	0
20731	Autoimmunity and Carcinogenesis: Their Relationship under the Umbrella of Autophagy. <i>Biomedicines</i> , 2023, 11, 1130.	1.4	3
20732	Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?. <i>Nature Reviews Clinical Oncology</i> , 0, , .	12.5	0
20733	Active recruitment of anti-“PD-1” conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy. <i>Science Advances</i> , 2023, 9, .	4.7	9
20735	The novel putative methyltransferase METTL7A as one prognostic biomarker potentially associated with immune infiltration in human renal cancer. <i>Heliyon</i> , 2023, 9, e15371.	1.4	1
20736	N-acetylcysteine overcomes NF1 loss-driven resistance to PI3K \pm inhibition in breast cancer. <i>Cell Reports Medicine</i> , 2023, 4, 101002.	3.3	3
20737	Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy. <i>Journal of Cancer</i> , 2023, 14, 850-873.	1.2	5
20738	Transformable prodrug nanoplatfom <i>via</i> tumor microenvironment modulation and immune checkpoint blockade potentiates immunogenic cell death mediated cancer immunotherapy. <i>Theranostics</i> , 2023, 13, 1906-1920.	4.6	2
20739	Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
20740	FAM72A promotes glioma progression by regulating mitophagy through the Pink1/Parkin signaling pathway. <i>Journal of Cancer</i> , 2023, 14, 903-915.	1.2	0
20741	Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials. <i>British Journal of Cancer</i> , 2023, 129, 185-203.	2.9	6
20742	Cuproptosis-related molecular subtypes direct T cell exhaustion phenotypes and therapeutic strategies for patients with lung adenocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
20743	Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer. <i>International Journal of Biological Sciences</i> , 2023, 19, 1731-1747.	2.6	2

#	ARTICLE	IF	CITATIONS
20744	Research Progress of Immunotherapy for Gastric Cancer. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382211505.	0.8	2
20745	Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. <i>Cancer Reports</i> , 2023, 6, .	0.6	4
20746	Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	5
20747	Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma. <i>Cell Communication and Signaling</i> , 2023, 21, .	2.7	7
20748	The Significance of SPP1 in Lung Cancers and Its Impact as a Marker for Protumor Tumor-Associated Macrophages. <i>Cancers</i> , 2023, 15, 2250.	1.7	17
20749	Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. <i>Investigational New Drugs</i> , 0, , .	1.2	0
20750	Flexible Monitoring, Diagnosis, and Therapy by Microneedles with Versatile Materials and Devices toward Multifunction Scope. <i>Research</i> , 2023, 6, .	2.8	6
20751	Comprehensive analysis of a novel RNA modifications-related model in the prognostic characterization, immune landscape and drug therapy of bladder cancer. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
20752	Molecular portraits of lung cancer evolution. <i>Nature</i> , 2023, 616, 435-436.	13.7	2
20753	Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	1
20754	A tumor microenvironment-based prognostic index for osteosarcoma. <i>Journal of Biomedical Science</i> , 2023, 30, .	2.6	6
20755	Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?. <i>Cancers</i> , 2023, 15, 2273.	1.7	2
20757	Inflammatory Cells Can Alter the Levels of H3K9ac and H2AX in Dysplastic Cells and Favor Tumor Phenotype. <i>Journal of Personalized Medicine</i> , 2023, 13, 662.	1.1	1
20758	Novel strategies for cancer immunotherapy: counter-immunoediting therapy. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	14
20759	Apoptosis: a Janus bifrons in T-cell immunotherapy. , 2023, 11, e005967.		3
20760	T Cell Based Immunotherapy for Cancer: Approaches and Strategies. <i>Vaccines</i> , 2023, 11, 835.	2.1	9
20761	Malignancy diseases and kidneys: A nephrologist prospect and updated review. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	0.4	2
20762	Unveiling DNA damage repair-based molecular subtypes, tumor microenvironment and pharmacogenomic landscape in gastric cancer. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	2

#	ARTICLE	IF	CITATIONS
20763	BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
20764	Intersections between innate immune response and gastric cancer development. <i>World Journal of Gastroenterology</i> , 0, 29, 2222-2240.	1.4	2
20765	Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
20766	Radiomics of Tumor Heterogeneity in 18F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 2297.	1.7	3
20767	Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy. <i>Cells</i> , 2023, 12, 1156.	1.8	7
20768	Camrelizumab for cancers in patients living with HIV: one-single center experience. <i>AIDS Research and Therapy</i> , 2023, 20, .	0.7	0
20769	Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. <i>Pharmaceutics</i> , 2023, 15, 1252.	2.0	7
20770	Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. , 2023, 20, 694-713.		8
20771	Immunotherapies against human bacterial and fungal infectious diseases: A review. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	6
20772	The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy. <i>Cancers</i> , 2023, 15, 2323.	1.7	14
20773	Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
20774	Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7312.	1.8	2
20775	C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2023, .	0.6	1
20776	Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial. <i>Clinical Cancer Research</i> , 2023, 29, 1783-1793.	3.2	2
20777	Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities. <i>Cancers</i> , 2023, 15, 2354.	1.7	2
20778	Ovarian cancer-associated immune exhaustion involves SPP1+ T cell and NKT cell, symbolizing more malignant progression. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
20779	PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	1
20780	Micro-abnormalities in the retina and choroid induced by anti-CTLA4 treatment. <i>Scientific Reports</i> , 2023, 13, .	1.6	0

#	ARTICLE	IF	CITATIONS
20781	Anti-PD-1 immunotherapy combined with stereotactic body radiation therapy and GM-CSF for the treatment of advanced malignant PEComa: A case report. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
20782	Prognostic Biomarker SLCO4A1 Is Correlated with Tumor Immune Infiltration in Colon Adenocarcinoma. <i>Mediators of Inflammation</i> , 2023, 2023, 1-13.	1.4	2
20784	Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
20785	Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	8
20786	COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	3
20787	Methods for assessment of the tumour microenvironment and immune interactions in non-small cell lung cancer. A narrative review. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
20788	Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma. <i>JAMA Network Open</i> , 2023, 6, e236356.	2.8	3
20789	Integrative learning in developing an immunologic lncRNA signature as a consensus risk-stratification tool for lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2023, .	0.6	0
20790	Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies. <i>Cancers</i> , 2023, 15, 2366.	1.7	3
20791	Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond. <i>Current Oncology</i> , 2023, 30, 4246-4256.	0.9	7
20792	A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
20793	Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
20794	Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring. <i>Diagnostic Pathology</i> , 2023, 18, .	0.9	3
20795	Drawbacks of immune checkpoint inhibition and rigorous management for immune-related adverse events along with a mathematical model to assess therapy success and optimum therapy duration and a strategy against tumor plasticity. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
20796	Correlation of preclinical and clinical biomarkers with efficacy and toxicity of cancer immunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311638.	1.4	0
20797	Role of the tumor microenvironment in malignant melanoma organoids during the development and metastasis of tumors. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	2
20798	Sema4D silencing increases the sensitivity of nivolumab to B16-F10 resistant melanoma via inhibiting the PI3K/AKT signaling pathway. <i>PeerJ</i> , 0, 11, e15172.	0.9	1
20799	Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center. <i>Journal of Endocrinological Investigation</i> , 2023, 46, 2399-2409.	1.8	2

#	ARTICLE	IF	CITATIONS
20800	CodeBreak 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code. Lung Cancer: Targets and Therapy, 0, Volume 14, 31-39.	1.3	0
20801	Immunotherapy in glioblastoma treatment: Current state and future prospects. World Journal of Clinical Oncology, 0, 14, 138-159.	0.9	13
20802	Early Changes of Serum Interleukin 14± Levels Predicts the Response to Anti-PD-1 Therapy in Cancer. Clinical Medicine Insights: Oncology, 2023, 17, 117955492311633.	0.6	0
20803	Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular Toxicities. Current Oncology Reports, 2023, 25, 753-763.	1.8	3
20805	A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011-2021. Frontiers in Endocrinology, 0, 14, .	1.5	0
20806	Novel tumor necrosis factor-related long non-coding RNAs signature for risk stratification and prognosis in glioblastoma. Frontiers in Neurology, 0, 14, .	1.1	0
20807	Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. International Journal of Molecular Sciences, 2023, 24, 7577.	1.8	2
20808	Regulation of early diagnosis and prognostic markers of lung adenocarcinoma in immunity and hypoxia. Scientific Reports, 2023, 13, .	1.6	1
20809	Recent advances in recurrent hepatocellular carcinoma therapy. World Journal of Hepatology, 0, 15, 460-476.	0.8	4
20810	Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals, 2023, 16, 614.	1.7	18
20811	Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 7640.	1.8	5
20812	spongEffects: ceRNA modules offer patient-specific insights into the miRNA regulatory landscape. Bioinformatics, 2023, 39, .	1.8	2
20813	Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer. Scientific Reports, 2023, 13, .	1.6	3
20814	Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type. International Journal of Molecular Sciences, 2023, 24, 7592.	1.8	1
20815	Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses. Cancers, 2023, 15, 2393.	1.7	2
20816	Tumor-infiltrating CD36+CD8+T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer. BMC Cancer, 2023, 23, .	1.1	2
20817	Comprehensive Analysis of NABP2 as a Prognostic Biomarker and Its Correlation with Immune Infiltration in Hepatocellular Carcinoma. Journal of Inflammation Research, 0, Volume 16, 1783-1804.	1.6	0
20818	PPP1R81 correlates with the survival and cell proliferation in lower-grade glioma. Bioscience Reports, 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
20819	Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 15, 281-294.	1.0	1
20820	Baseline neutrophil-to- ratio combined with the change during treatment provides risk stratification for metastatic malignant melanoma patients treated with PD-1 inhibitors in a Chinese population. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
20821	Late-stage MC38 tumours recapitulate features of human colorectal cancer – implications for appropriate timepoint selection in preclinical studies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
20822	Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
20823	The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma. <i>Journal of Neuro-Oncology</i> , 2023, 163, 1-14.	1.4	2
20824	Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?. <i>Journal of Clinical Medicine</i> , 2023, 12, 3014.	1.0	0
20825	Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work. <i>Quantitative Imaging in Medicine and Surgery</i> , 2023, .	1.1	1
20826	Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	15
20830	mRNA vaccination in breast cancer: current progress and future direction. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 9435-9450.	1.2	3
20859	Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 408-422.	12.5	9